Gene	Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
ABL1	ABL1 G250R ABL1 G251D	oral cavity cancer	no benefit	Nilotinib	Case Reports/Case Series	Actionable	In a clinical case study, Tasigna (nilotinib) treatment resulted in no benefit in a patient with oral cavity cancer harboring ABL1 G250R and G251D (PMID: 28514312).	28514312
ABL1	ABL1 R332W ABL1 T315I	lung adenocarcinoma	resistant	Dasatinib	Preclinical	Actionable	In a preclinical study, lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) and expressing ABL1 T315I demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 26758680).	26758680
ABL1	ABL1 R332W ABL1 T315I	lung adenocarcinoma	resistant	Imatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) and expressing ABL1 T315I demonstrated resistance to Gleevec (imatinib) in culture and in xenograft models (PMID: 26758680).	26758680
ABL1	ABL1 R332W	lung adenocarcinoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, treatment with Sprycel (dasatinib) in decreased CRKL phosphorylation and reduced viability of lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) in culture (PMID: 26758680).	26758680
ABL1	ABL1 R332W	lung adenocarcinoma	sensitive	Imatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gleevec (imatinib) inhibited growth of a lung adenocarcinoma cell line harboring ABL1 R332W (also reported as R351W) in culture, and inhibited tumor growth in xenograft models (PMID: 26758680).	26758680
ABL1	ABL1 G321L	lung adenocarcinoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, treatment with Sprycel (dasatinib) in decreased CRKL phosphorylation and reduced viability of lung adenocarcinoma cells harboring ABL1 G321L (also reported as G340L) in culture (PMID: 26758680).	26758680
ABL1	ABL1 G321L	lung adenocarcinoma	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) inhibited growth of a lung adenocarcinoma cell line harboring ABL1 G321L (also reported as G340L) in culture (PMID: 26758680).	26758680
AKT1	AKT1 W80A	breast cancer	resistant	MK2206	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing AKT1 W80A were resistant to MK2206 in culture, resulting in repression of induced cell death when compared to wild-type AKT1 (PMID: 25551293).	25551293
AKT1	AKT1 W80A	Advanced Solid Tumor	resistant	MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, transformed mouse adipocytes expressing human Akt1 W80A were resistant to the AKT inhibitor, MK-2206 (PMID: 25856301).	25856301
AKT1	AKT1 over exp PIK3CA H1047R	breast cancer	resistant	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).	27604488
AKT1	AKT1 over exp PIK3CA E545K	breast cancer	resistant	Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA E545K resulted in resistance to Pictilisib (GDC-0941) in culture (PMID: 27604488).	27604488
AKT1	AKT1 P68_C77dup	breast cancer	sensitive	Capivasertib	Preclinical - Cell culture	Actionable	In a preclinical study, breast epithelial cells expressing AKT1 P68_C77dup demonstrated sensitivity by AZD5363 in culture, resulting in decreased cell survival (PMID: 29247016).	29247016
AKT1	AKT1 E17K	estrogen-receptor positive breast cancer	predicted - sensitive	Capivasertib	Phase I	Actionable	In a Phase I trial, Capivasertib (AZD5363) treatment resulted in confirmed partial response in 20% (4/20) and unconfirmed partial response in 10% (2/20) of patients with ESR1-positive breast cancer harboring AKT1 E17K (PMID: 28489509; NCT01226316).	28489509
AKT1	AKT1 E17K	ovarian endometrial cancer	sensitive	Capivasertib	Phase I	Actionable	In a Phase I clinical study, a patient with endometrioid ovarian carcinoma harboring AKT1 E17K had a sustained partial response to AZD5363 for more than two years (PMID: 26351323).	26351323
AKT1	AKT1 E17K	triple-receptor negative breast cancer	predicted - sensitive	Capivasertib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with triple-receptor negative breast cancer harboring AKT1 E17K demonstrated a partial response when treated with Capivasertib (AZD5363) (PMID: 28489509; NCT01226316).	28489509
AKT1	AKT1 E17K	breast papillary carcinoma	sensitive	Capivasertib	Phase I	Actionable	In a Phase I clinical trial, a patient with ER-positive, ERBB2 (HER2)-negative papillary breast carcinoma harboring AKT1 E17K had a sustained partial response to AZD5363 (PMID: 26351323).	26351323
AKT1	AKT1 E17K	endometrial cancer	sensitive	ARQ 751	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an endometrial cell line xenograft model harboring AKT E17K was sensitive to ARQ 751, demonstrating inhibition of tumor growth (PMID: 26469692).	26469692
AKT1	AKT1 E17K	Advanced Solid Tumor	no benefit	BAY1125976	Phase I	Actionable	In a Phase I trial, BAY 1125976 treatment demonstrated safety and pharmacological inhibition of Akt signaling, but only resulted in partial response in 1% (1/78) and stable disease in 38% (30/78) of patients with advanced solid tumors, clinical benefit rate at recommended Phase II dose was 27.9% (12/43), and AKT1 E17K mutation status was not associated with response (AACR Annual Meeting 2019, Abstract CT015; NCT01915576).	detail...
AKT1	AKT1 E17K	melanoma	sensitive	Uprosertib	Preclinical - Cell culture	Actionable	In a preclinical study, Uprosertib (GSK2141795) inhibited the growth of melanoma cells harboring AKT1 E17K in culture (PMID: 24735930).	24735930
AKT1	AKT1 E17K	parotid gland cancer	predicted - sensitive	Capivasertib	Phase II	Actionable	In a Phase II (MATCH) trial, Capivasertib (AZD5363) treatment resulted in stable disease over 21 months in a patient with an oncocytic carcinoma of the parotid gland harboring AKT1 E17K mutation (PMID: 30429128; NCT02465060).	30429128
AKT1	AKT1 E17K	breast cancer	no benefit	MK2206	Phase II	Actionable	In a Phase II trial, MK2206 treatment resulted in no objective response in 4 patients with advanced breast cancer harboring AKT1 E17K (PMID: 31277699; NCT01277757).	31277699
AKT1	AKT1 E17K	cervical cancer	predicted - sensitive	Capivasertib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with cervical cancer harboring AKT1 E17K demonstrated a partial response when treated with Capivasertib (AZD5363) (PMID: 28489509; NCT01226316).	28489509
AKT1	AKT1 E17K	endometrial cancer	predicted - sensitive	Capivasertib	Case Reports/Case Series	Actionable	In a Phase I trial, two patients with endometrial cancer harboring AKT1 E17K demonstrated a partial response when treated with Capivasertib (AZD5363) (PMID: 28489509; NCT01226316).	28489509
AKT1	AKT1 E17K	uterus leiomyosarcoma	predicted - sensitive	Capivasertib	Phase II	Actionable	In a Phase II (MATCH) trial, Capivasertib (AZD5363) treatment resulted in partial response in a patient with uterus leiomyosarcoma harboring AKT1 E17K mutation (PMID: 30429128; NCT02465060).	30429128
AKT1	AKT1 E17K	cancer	sensitive	Uprosertib	Preclinical	Actionable	In a preclinical study, the pan AKT inhibitor GSK2141795 displayed similar levels of inhibition against ATK1 E17K (activating mutation) as ATK1 wild-type (PMID: 24978597).	24978597
AKT1	AKT1 E17K	Her2-receptor negative breast cancer	predicted - sensitive	Capivasertib	Phase II	Actionable	In a Phase II (MATCH) trial, Capivasertib (AZD5363) treatment resulted in partial response in 23% (8/35) of patients with advanced solid tumors harboring AKT1 E17K mutation, 6 of the patients achieved partial response had hormone receptor-positive, Erbb2 (Her2)-negative breast cancer (PMID: 30429128; NCT02465060).	30429128
AKT1	AKT1 E17K	breast cancer	sensitive	BAY1125976	Preclinical - Pdx	Actionable	In a preclinical study, BAY1125976 induced complete tumor regression in a patient-derived xenograft (PDX) model of breast cancer harboring AKT E17K (PMID: 27699769).	27699769
AKT1	AKT1 E17K	anal canal cancer	sensitive	BAY1125976	Preclinical - Pdx	Actionable	In a preclinical study, treatment with BAY1125976 reduced tumor growth and resulted in partial tumor regression or stable disease in anal cancer patient-derived xenograft (PDX) models harboring AKT1 E17K (PMID: 27699769).	27699769 detail...
AKT1	AKT1 E17K	meningothelial meningioma	predicted - sensitive	Capivasertib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with meningothelial meningioma harboring AKT1 E17K demonstrated stable disease and some tumor regression when treated with Capivasertib (AZD5363) (PMID: 28376212).	28376212
AKT1	AKT1 E17K	Her2-receptor negative breast cancer	sensitive	Ipatasertib	Phase I	Actionable	In a Phase I trial, a patient with ERBB2 (HER2)-receptor negative breast cancer harboring AKT1 E17K demonstrated a complete metabolic response when treated with Ipatasertib (GDC-0068) (PMID: 27872130).	27872130
AKT1	AKT1 E17K	Advanced Solid Tumor	sensitive	Capivasertib	Phase II	Actionable	In a Phase II (MATCH) trial, Capivasertib (AZD5363) treatment resulted in partial response in 23% (8/35) and stable disease in 46% (16/35) of patients with advanced solid tumors harboring AKT1 E17K mutation (PMID: 30429128; NCT02465060).	30429128
AKT1	AKT1 E17K	Advanced Solid Tumor	sensitive	Capivasertib	Phase I	Actionable	In a Phase I trial, Capivasertib (AZD5363) demonstrated safety and preliminary antitumor activity in patients with advanced solid tumors, resulted in stable disease in 27% (10/37) of patients and partial response in two patients, both of whom harbored an AKT1 E17K mutation (PMID: 26931343; NCT01353781).	26931343 detail...
AKT1	AKT1 E17K	ovarian carcinoma	predicted - sensitive	Miransertib	Case Reports/Case Series	Actionable	In a clinical case study, Miransertib (ARQ092) treatment resulted in complete tumor remission and improved quality of life in a patient harboring AKT1 E17K who had Proteus syndrome and developed ovarian carcinoma, and treatment was ongoing at 22 months (PMID: 31058421).	31058421
AKT1	AKT1 E17K	granulosa cell tumor	sensitive	Capivasertib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with ovarian granulosa cell tumor cancer harboring subclonal AKT E17K demonstrated an overall tumor regression of 24% when treated with AZD5363, which lasted 253 days (PMID: 28489509).	28489509
AKT1	AKT1 E17K	endometrial adenocarcinoma	predicted - sensitive	Capivasertib	Phase II	Actionable	In a Phase II (MATCH) trial, Capivasertib (AZD5363) treatment resulted in partial response in a patient with endometrioid adenocarcinoma harboring AKT1 E17K mutation (PMID: 30429128; NCT02465060).	30429128
AKT1	AKT1 E17K	lung adenocarcinoma	predicted - sensitive	Capivasertib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with lung adenocarcinoma harboring AKT1 E17K demonstrated a partial response when treated with Capivasertib (AZD5363) (PMID: 28489509; NCT01226316).	28489509
AKT1	AKT1 E17K	breast cancer	sensitive	Capivasertib	Preclinical	Actionable	In a preclinical study, Capivasertib (AZD5363) inhibited growth and colony formation of breast cancer cells expressing AKT E17K in cell culture and in xenografts as well as breast cancer explant models harboring AKT E17K (PMID: 26351323).	26351323
AKT1	AKT1 E17K	breast cancer	sensitive	Capivasertib	Case Reports/Case Series	Actionable	In a Phase I trial, four patients with ESR1-positive breast cancer harboring AKT1 E17K demonstrated a partial response when treated with Capivasertib (AZD5363) (PMID: 28489509; NCT01226316).	28489509
AKT1	AKT1 E17K	endometrial cancer	sensitive	Miransertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an endometrial cell line xenograft model harboring AKT E17K was sensitive to Miransertib (ARQ092), demonstrating inhibition of tumor growth (PMID: 26469692).	26469692
AKT1	AKT1 E17K FGFR3 Y373C	urinary bladder cancer	sensitive	AZD4547 + Capivasertib	Preclinical	Actionable	In a preclinical study, the combined therapy of AZD5363 and AZD4547 resulted in tumor regression in urinary bladder cancer xenograft models simultaneously harboring the mutations, AKT1 E17K and FGFR3 Y373C (PMID: 26351323).	26351323
AKT1	AKT1 E17K NRAS Q61R	bladder carcinoma	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited Akt activation and downstream signaling in bladder cancer cell lines carrying both Akt1 E17K and Nras Q61R mutations (AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3685).	detail...
AKT1	AKT1 E17K BRAF V600X PTEN pos	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).	24265152
AKT1	AKT1 E17K NRAS G12D	prostate cancer	sensitive	BAY1125976	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring AKT E17K and NRAS G12D in culture, and demonstrated antitumor activity in xenograft models (PMID: 27699769).	27699769
AKT1	AKT1 amp	Advanced Solid Tumor	predicted - sensitive	ONC201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ONC201 (TIC-10) inhibited Akt activation and induced apoptosis and tumor regression in a variety of cell line xenograft models (PMID: 23390247).	23390247
AKT1	AKT1 S266L FGFR1 amp	lung cancer	predicted - resistant	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cells harboring FGFR1 amplification demonstrated resistance to increasing concentrations of PD173074 in culture and was subsequently, found to have acquired AKT1 S266L (PMID: 30140389).	30140389
AKT1	AKT1 S266L FGFR1 amp	lung cancer	predicted - sensitive	Uprosertib	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cells harboring FGFR1 amplification and AKT1 S266L demonstrated sensitivity to Uprosertib (GSK2141795) in culture, showing decreased phosphorylation of Akt1 targets and reduced cell growth (PMID: 30140389).	30140389
AKT1	AKT1 act mut	lymphoma	no benefit	Sirolimus	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Rapamune (sirolimus) treatment did not improve survival in cell line xenograft animal models of lymphoma overexpressing constitutively active Akt (PMID: 18708578).	18708578
AKT1	AKT1 act mut	lymphoma	predicted - sensitive	Doxorubicin + Sirolimus	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Rapamune (sirolimus) and Adriamycin (doxorubicin) combination treatment resulted in improved survival and prolonged remission in cell line xenograft animal models of lymphoma overexpressing constitutively active Akt (PMID: 18708578).	18708578
AKT1	AKT1 act mut	lymphoma	decreased response	Doxorubicin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, lymphoma cells overexpressing constitutively active Akt demonstrated reduced sensitivity to Adriamycin (doxorubicin) treatment in cell line xenograft models (PMID: 18708578).	18708578
AKT1	AKT1 act mut	Advanced Solid Tumor	no benefit	Triciribine	Phase I	Actionable	In a Phase I trial, Triciribine (API-2) demonstrated safety, but lacked efficacy as a monotherapy in advanced solid tumor patients with activated Akt (PMID: 20644979).	20644979
AKT1	AKT1 wild-type	ovarian cancer	predicted - sensitive	Uprosertib	Phase I	Actionable	In a Phase I trial, GSK2141795 treatment resulted in Akt inhibition and clinical benefit in 27% (3/11) of ovarian cancer patients (PMID: 26429956).	26429956
AKT1	AKT1 wild-type	clear cell renal cell carcinoma	sensitive	Everolimus + RX-0201	Phase Ib/II	Actionable	In a Phase I/II trial, RX-0201 and Afinitor (everolimus) combination therapy resulted in stable disease in 40% (2/5) of patients with metastatic clear cell renal carcinoma (J Clin Oncol 34, 2016 (suppl 2S; abstr 550)).	detail...
AKT1	AKT1 wild-type	cancer	sensitive	Uprosertib	Preclinical	Actionable	In a preclinical study, GSK2141795 inhibited all isoforms of AKT in human cancer cell lines (PMID: 23795919).	23795919
AKT1	AKT1 wild-type PIK3CA wild-type PTEN wild-type	triple-receptor negative breast cancer	no benefit	Capivasertib + Paclitaxel	Phase II	Actionable	In a Phase II trial, Capivasertib (AZD5363) in combination with Taxol (paclitaxel) as first-line therapy resulted in improved median progression-free survival (9.3 vs 3.7 months, HR=0.30, p=0.01) compared to placebo in patients with metastatic triple-negative breast cancer harboring PIK3CA, AKT1, and/or PTEN mutations, but not in patients with wile-type PIK3CA, AKT1, and PTEN (5.3 vs 4.4 months, HR=1.13, p=0.61) (PMID: 30715161; NCT02423603).	30715161
AKT1	AKT1 positive	ovarian clear cell carcinoma	predicted - sensitive	Perifosine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Perifosine (KRX-0401) inhibited Akt1 signaling, inhibited proliferation, and induced apoptosis in human ovarian clear cell cancer cells with activated Akt1 in culture and inhibited tumor growth in cell line xenografts (PMID: 25519148).	25519148
AKT1	AKT1 positive	ovarian clear cell carcinoma	predicted - sensitive	Cisplatin + Perifosine	Preclinical - Cell culture	Actionable	In a preclinical study, Perifosine (KRX-0401) enhanced the sensitivity of human ovarian clear cell cancer cells with activated Akt1 to Platinol (cisplatin) treatment in culture (PMID: 25519148).	25519148
AKT1	AKT1 pos NRAS mut	melanoma	predicted - resistant	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, two of two NRAS-mutant melanoma cell lines with AKT1 expression demonstrated resistance to treatment with Ibrance (palbociclib) in culture (PMID: 30819666).	30819666
AKT1	AKT1 pos NRAS mut	melanoma	predicted - resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, one of two NRAS-mutant melanoma cell lines expressing AKT1 demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).	30819666
AKT1	AKT1 pos NRAS mut	melanoma	predicted - resistant	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, two of four NRAS-mutant melanoma cell lines expressing AKT1 were resistant to the combination treatment of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 30819666).	30819666
AKT1	AKT1 mutant	triple-receptor negative breast cancer	predicted - sensitive	Capivasertib + Paclitaxel	Phase II	Actionable	In a Phase II trial, Capivasertib (AZD5363) in combination with Taxol (paclitaxel) as first-line therapy resulted in improved median progression-free survival (9.3 vs 3.7 months, HR=0.30, p=0.01) compared to placebo in patients with metastatic triple-negative breast cancer harboring PIK3CA, AKT1, and/or PTEN mutations, but not in patients with wile-type PIK3CA, AKT1, and PTEN (5.3 vs 4.4 months, HR=1.13, p=0.61) (PMID: 30715161; NCT02423603).	30715161
AKT1	AKT1 mutant	triple-receptor negative breast cancer	predicted - sensitive	Ipatasertib + Paclitaxel	Phase II	Actionable	In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients harboring mutations in PIK3CA, AKT1, or PTEN (J Clin Oncol 35, 2017 (suppl; abstr 1009)).	detail...
AKT1	AKT1 mutant	invasive bladder transitional cell carcinoma	predicted - resistant	Cisplatin + Gemcitabine + Sorafenib	Phase II	Actionable	In a Phase II trial, AKT1 mutations were more frequent in muscle-invasive urothelial bladder cancer patients that did not respond to Nexavar (sorafenib), Platinol (cisplatin) and Gemzar (gemcitabine) combination therapy than those who did respond (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).	detail...
AKT1	AKT1 mutant	endometrial cancer	sensitive	GDC-0980	Phase II	Actionable	In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)).	detail...
AKT1	AKT1 mutant	endometrial cancer	predicted - sensitive	Temsirolimus	Phase II	Actionable	In a retrospective study of a Phase II trial, Torisel (temsirolimus) treatment resulted in an increased progression-free survival (HR 0.16) and response rate (response difference 0.83) in advanced endometrial cancer patients harboring AKT1 mutations (PMID: 27016228).	27016228
AKT1	AKT1 Q79K	ovarian cancer	predicted - sensitive	Capivasertib	Case Reports/Case Series	Actionable	In a Phase I trial, an ovarian cancer patient harboring AKT1 Q79K demonstrated tumor regression that lasted 14 months when treated with Capivasertib (AZD5363) (PMID: 28489509; NCT01226316).	28489509
AKT1	AKT1 Q79K BRAF V600X PTEN pos	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).	24265152
AKT1	AKT1 Q79K BRAF V600X PTEN pos	melanoma	sensitive	MK2206 + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited AKT activation and growth of PTEN-expressing BRAF V600-mutant melanoma cells expressing AKT1 Q79K in culture, with increased efficacy over either agent alone (PMID: 24265152).	24265152
ALK	ALK rearrange ALK L1198F ALK mut	lung non-small cell carcinoma	sensitive	Ceritinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, patients with ALK-rearrangement positive non-small cell lung cancer who acquired ALK drug resistance mutations following Xalkori (crizotinib) treatment had a median progression-free survival (mPFS) of 5.4 months on Zykadia (ceritinib), which was not significantly different than the mPFS of 6.5 months for patients without ALK mutations (PMID: 25724526).	25724526
ALK	ALK mut TP53 wild-type	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in patient-derived neuroblastoma cell lines harboring Alk mutations and functional TP53, resulting in growth inhibition in culture and tumor regression in animal models (PMID: 26438783).	26438783
ALK	ALK neg ROS1 pos	lung non-small cell carcinoma	sensitive	Crizotinib	Phase II	Actionable	In a Phase II trial, Xalkori (crizotinib) treatment resulted in an objective response rate of 69% (89/129), and a median duration of treatment of 7.8 months in ALK negative, ROS1 positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9022); NCT01945021).	detail...
ALK	ALK negative	anaplastic large cell lymphoma	predicted - sensitive	Brentuximab vedotin	Phase II	Actionable	In a Phase II trial (SGN-35), Adcetris (brentuximab vedotin) treatment resulted in complete remission in 57% (33/58), partial remission in 29% (17/58) of patients with relapsed or refractory systemic anaplastic large cell lymphoma, 72% (42/58) of the patients were ALK-negative (PMID: 22614995; NCT00866047).	22614995
ALK	ALK negative	colon carcinoma	resistant	CEP-28122	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CEP-28122 did not inhibit tumor growth in cell line xenograft models of ALK-negative colon carcinoma (PMID: 22203728).	22203728
ALK	ALK negative	lung non-small cell carcinoma	resistant	CEP-28122	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ALK negative non-small cell lung carcinoma cells were resistant to CEP-28122 in culture and in cell line xenograft models (PMID: 22203728).	22203728
ALK	ALK negative	leukemia	resistant	CEP-28122	Preclinical - Cell culture	Actionable	In a preclinical study, CEP-28122 did not inhibit growth of ALK-negative leukemia cells in culture (PMID: 22203728).	22203728
ALK	ALK negative	lymphoma	resistant	CEP-28122	Preclinical - Cell culture	Actionable	In a preclinical study, CEP-28122 did not inhibit growth of ALK-negative lymphoma cells in culture (PMID: 22203728).	22203728
ALK	ALK rearrange ALK I1171X	lung non-small cell carcinoma	predicted - resistant	Ceritinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK I1171X was identified in 24% (17/70) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received second-generation ALK TKI treatment, including Alecensa (alectinib) (n=46), Zykadia (ceritinib) (n=4), Alunbrig (brigatinib) (n=3), Ensartinib (X-396) (n=1), or more than 2 lines of TKIs (n=16) (PMID: 31358542).	31358542
ALK	ALK rearrange ALK I1171X	lung non-small cell carcinoma	predicted - resistant	Lorlatinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK I1171X was identified in 14% (4/29) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received Lorbrena (lorlatinib) treatment (PMID: 31358542).	31358542
ALK	ALK rearrange ALK I1171X	lung non-small cell carcinoma	predicted - resistant	Ensartinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK I1171X was identified in 24% (17/70) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received second-generation ALK TKI treatment, including Alecensa (alectinib) (n=46), Zykadia (ceritinib) (n=4), Alunbrig (brigatinib) (n=3), Ensartinib (X-396) (n=1), or more than 2 lines of TKIs (n=16) (PMID: 31358542).	31358542
ALK	ALK rearrange ALK I1171X	lung non-small cell carcinoma	predicted - resistant	Brigatinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK I1171X was identified in 24% (17/70) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received second-generation ALK TKI treatment, including Alecensa (alectinib) (n=46), Zykadia (ceritinib) (n=4), Alunbrig (brigatinib) (n=3), Ensartinib (X-396) (n=1), or more than 2 lines of TKIs (n=16) (PMID: 31358542).	31358542
ALK	ALK rearrange ALK I1171X	lung non-small cell carcinoma	predicted - resistant	Alectinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK I1171X was identified in 26% (12/46) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received Alecensa (alectinib) treatment (PMID: 31358542).	31358542
ALK	ALK wild-type	head and neck cancer	predicted - sensitive	Cisplatin + Dalantercept	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the addition of Dalantercept (ACE-041) to Platinol (cisplatin) treatment resulted in increased cytoxicity and decreased tumor growth in cell line xenograft models of head and neck cancer (PMID: 26373572).	26373572
ALK	ALK wild-type	neuroblastoma	resistant	CEP-28122	Preclinical - Cell culture	Actionable	In a preclinical study, CEP-28122 did not inhibit growth of ALK wild-type neuroblastoma cells in culture (PMID: 22203728).	22203728
ALK	ALK wild-type	breast cancer	predicted - sensitive	Cisplatin + Dalantercept	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Dalantercept (ACE-041) in combination with Platinol (cisplatin) resulted in decreased tumor growth in cell line xenograft models of breast cancer (PMID: 26373572).	26373572
ALK	ALK wild-type	melanoma	sensitive	Dalantercept + Doxorubicin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Dalantercept (ACE-041) in combination with Adria (doxorubicin) resulted in decreased tumor growth in cell line xenograft models of melanoma, with increased efficacy over either agent alone (PMID: 26373572).	26373572
ALK	ALK wild-type	endometrial cancer	no benefit	Dalantercept	Phase II	Actionable	In a Phase II clinical trial, treatment with Dalantercept (ACE-041) did not demonstrate activity as single agent in recurrent or persistent endometrial cancer, with a median progression-free survival (PFS) of 2.1 months, overall survival of 14.5 months, no objective responses, and stable disease in 57% (16/28) of patients (PMID: 25888978).	25888978
ALK	ALK wild-type	Advanced Solid Tumor	sensitive	Repotrectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Repotrectinib (TPX-0005) inhibited cell proliferation in transformed cell lines over expressing wild-type ALK in culture and suppressed tumor growth in xenograft models (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).	detail...
ALK	ALK wild-type	neuroblastoma	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) did not inhibit growth of ALK wild-type neuroblastoma cells in culture (PMID: 26554404).	26554404
ALK	ALK wild-type TP53 C176F	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 C176F in culture (PMID: 26438783).	26438783
ALK	ALK wild-type TP53 H168R	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Xalkori (crizotinib) did not improve the effect of Topotecan and Cytoxan (cyclophosphamide) on tumor growth suppression in xenograft models of a human neuroblastoma cell line harboring wild-type ALK and TP53 H168R (PMID: 26438783).	26438783
ALK	ALK wild-type TP53 P177T	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 P177T in culture (PMID: 26438783).	26438783
ALK	ALK wild-type TP53 mutant	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 mutations in culture (PMID: 26438783).	26438783
ALK	ALK wild-type TP53 wild-type	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and wild-type TP53 in culture (PMID: 26438783).	26438783
ALK	ALK wild-type EGFR wild-type	lung non-squamous non-small cell carcinoma	sensitive	Carboplatin + Pembrolizumab + Pemetrexed	FDA approved	Actionable	In a Phase III trial (KEYNOTE-189) that supported FDA approval, Keytruda (pembrolizumab) in combination with Alimta (pemetrexed), and a platinum therapy (cisplatin or carboplatin), resulted in improved overall survival rate at 12 months (69.2% vs 49.4%, HR=0.49, p<0.001) and median progression-free survival (8.8 vs 4.9 months, HR=0.52, p<0.001) compared to placebo in previously untreated metastatic nonsquamous non-small-cell lung cancer patients without EGFR or ALK mutations (PMID: 29658856; NCT02578680).	detail... 29658856
ALK	ALK wild-type EGFR wild-type	lung non-squamous non-small cell carcinoma	sensitive	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel	FDA approved	Actionable	In a Phase III trial (IMpower150) that supported FDA approval, Tecentriq (atezolizumab) in combination with bevacizumab, paclitaxel, and carboplatin resulted in significantly improved median progression-free survival (8.3 vs 6.8 months, HR=0.62, p<0.001) and median overall survival (19.2 vs 14.7 months, HR=0.78, p=0.02) compared to control in patients with metastatic nonsquamous non-small cell lung cancer, regardless of PD-L1 expression and EGFR or ALK mutation status (PMID: 29863955; NCT02366143).	29863955 detail...
ALK	ALK wild-type EGFR wild-type	lung non-squamous non-small cell carcinoma	sensitive	Cisplatin + Pembrolizumab + Pemetrexed	FDA approved	Actionable	In a Phase III trial (KEYNOTE-189) that supported FDA approval, Keytruda (pembrolizumab) in combination with Alimta (pemetrexed), and a platinum therapy (cisplatin or carboplatin), resulted in improved overall survival rate at 12 months (69.2% vs 49.4%, HR=0.49, p<0.001) and median progression-free survival (8.8 vs 4.9 months, HR=0.52, p<0.001) compared to placebo in previously untreated metastatic nonsquamous non-small cell lung cancer patients without EGFR or ALK mutations (PMID: 29658856; NCT02578680).	detail... 29658856
ALK	ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing ALK G1269A was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).	27049722
ALK	EML4-ALK ALK G1269A	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated moderate resistance to ASP3026 in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK G1269A	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK G1269A	lung non-small cell carcinoma	resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK demonstrated stable disease when treated with Xalkori (crizotinib), but then progressed, and was found to harbor a secondary resistance mutation, ALK G1269A (PMID: 22235099).	22235099
ALK	EML4-ALK ALK G1269A	lung non-small cell carcinoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human lung cancer cell lines expressing ALK G1269A in the context of EML4-ALK demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 24675041).	24675041
ALK	EML4-ALK ALK G1269A	lung non-small cell carcinoma	sensitive	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK fusion positive non-small cell lung cancer with ALK G1269A had a partial response to Alecensa (alectinib) treatment (PMID: 26849637).	26849637
ALK	EML4-ALK ALK G1269A	lung non-small cell carcinoma	sensitive	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited proliferation of a Xalkori (crizotinib)-resistant human non-small cell lung cancer cell line harboring an EML-ALK fusion with ALK G1269A in culture and induced tumor regression in cell line xenograft models (PMID: 26849637, PMID: 23344087).	26849637 23344087
ALK	EML4-ALK ALK G1269A	Advanced Solid Tumor	decreased response	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated a decreased response when treated with Rozlytrek (entrectinib) compared to cells expressing wild-type EML4-ALK (PMID: 26939704).	26939704
ALK	EML4-ALK ALK G1269A	lung non-small cell carcinoma	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, human lung cancer cell lines harboring EML4-ALK with ALK G1269A demonstrated sensitivity to Zykadia (ceritinib) in culture (PMID: 24675041).	24675041
ALK	EML4-ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated resistance to Alecensa (alectinib) in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) modestly inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture, and inhibited tumor growth in xenograft models (PMID: 24887559).	24887559
ALK	EML4-ALK ALK G1269A	lung non-small cell carcinoma	sensitive	Lorlatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and growth of non-small cell lung cancer (NSCLC) cells over expressing ALK G1269A in the context of EML4-ALK in culture and in cell line xenograft models, as well as inhibited growth of patient derived NSCLC cells harboring EML4-ALK ALK G1269A in culture (PMID: 26144315).	26144315
ALK	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK G1269A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK in the context of EML4-ALK were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK G1269A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK G1269A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1269A in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22235099).	22235099
ALK	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In preclinical studies, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859, PMID: 26698910).	26698910 27009859
ALK	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK G1269A	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK G1269A	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK G1269A	Advanced Solid Tumor	conflicting	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK G1269A	Advanced Solid Tumor	conflicting	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A demonstrated resistance to ASP3026 in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK G1269A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK G1269A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK G1269A	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK G1269A	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK G1269A	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A demonstrated resistance to Alecensa (alectinib) in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK G1269A	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1269A in the context of EML4-ALK were re-sensitized and became modestly sensitive to Xalkori (crizotinib) with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A and L1198F in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK G1269A ALK L1196M	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a patient with non-small cell lung cancer harboring EML4-ALK demonstrated a partial response when treated with Xalkori (crizotinib), however, after 6 months the patient progressed and was found to harbor two secondary resistance mutations, ALK G1269A and ALK L1196M (PMID: 23344087).	23344087
ALK	EML4-ALK ALK G1269A ALK L1196M	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1196M was identified as a compound mutation in transformed cells expressing ALK G1269A in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	ALK rearrange ALK T1151dup ALK G1269A	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring an ALK rearrangement demonstrated a partial response with Xalkori (crizotinib) treatment, but then progressed after 10.8 months, and was found to harbor secondary resistance mutations, ALK T1151dup and ALK G1269A (PMID: 25724526).	25724526
ALK	EML4-ALK ALK C1156Y ALK G1269A	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK G1269A was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	EML4-ALK ALK F1174C ALK G1269A	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK G1269A was identified as a compound mutation in transformed cells expressing ALK F1174C in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	EML4-ALK ALK G1269A ALK I1171T	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1171T was identified as a compound mutation in transformed cells expressing ALK G1269A in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	EML4-ALK ALK G1269A ALK I1171N	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1171N was identified as a compound mutation in transformed cells expressing ALK G1269A in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	ALK rearrange ALK G1202R ALK G1269A	lung non-small cell carcinoma	resistant	Lorlatinib	Case Reports/Case Series	Actionable	In a clinical study, an ALK-positive non-small cell lung cancer patient harboring ALK G1202R ALK G1269A developed resistance to Lorlatinib (PF-06463922) after initial response (PMID: 29650534).	29650534
ALK	ALK rearrange ALK G1202R ALK G1269A ALK L1204V	lung non-small cell carcinoma	resistant	Lorlatinib	Case Reports/Case Series	Actionable	In a clinical study, ALK G1269A and L1204V were identified as acquired mutations in an ALK-positive non-small cell lung cancer patient harboring ALK G1202R who developed resistance to Lorlatinib (PF-06463922) after initial response (PMID: 29650534).	29650534
ALK	ALK rearrange ALK E1210K ALK D1203N ALK G1269A	lung non-small cell carcinoma	resistant	Lorlatinib	Case Reports/Case Series	Actionable	In a clinical study, ALK G1269A was identified as an acquired mutation in an ALK-positive non-small cell lung cancer patient harboring ALK E1210K and D1203N, who developed resistance to Lorlatinib (PF-06463922) after initial response (PMID: 29650534).	29650534
ALK	EML4-ALK ALK F1174L ALK G1269A	lung adenocarcinoma	predicted - resistant	Belizatinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK F1174L and ALK G1269A were identified as newly acquired mutations in the pleural effusion from a patient with lung adenocarcinoma harboring an acquired EML4-ALK after his disease progressed on Belizatinib (TSR-011) treatment (PMID: 28434515).	28434515
ALK	EML4-ALK ALK F1174L ALK D1203N ALK G1269A	lung adenocarcinoma	predicted - resistant	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK D1203N were identified as a newly acquired mutation in the pleural effusion from a patient with lung adenocarcinoma after his disease progressed on Zykadia (ceritinib) treatment, in addition to the EML4-ALK, ALK F1174L, and ALK G1269A acquired after disease progression on Xalkori (crizotinib) and Belizatinib (TSR-011) sequentially (PMID: 28434515).	28434515
ALK	ALK F1245C	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK F1245C in culture (PMID: 26554404).	26554404
ALK	ALK F1245C	neuroblastoma	sensitive	Lorlatinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of neuroblastoma cells over expressing ALK F1245C in culture, and induced rapid and sustained complete tumor regression in patient-derived xenograft models harboring ALK F1245C (PMID: 26554404).	26554404
ALK	ALK F1245C	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing ALK F1245C was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).	27049722
ALK	ALK F1245C	neuroblastoma	resistant	Crizotinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK F1245C in culture, and only delayed tumor growth in patient-derived xenograft models harboring ALK F1245C (PMID: 26554404).	26554404
ALK	ALK F1245C TP53 wild-type	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Pdx	Actionable	In a preclinical study, Xalkori (crizotinib) worked synergistically with Topotecan and Cytoxan (cyclophosphamide), resulting in sustained tumor regression in crizotinib-resistant neuroblastoma PDX models harboring ALK F1245C and wild-type Tp53 (PMID: 26438783).	26438783
ALK	EML4-ALK ALK F1245C	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 demonstrated an initial response to treatment with Xalkori (crizotinib), but progressed after 27 months and was found to have acquired ALK F1245C (PMID: 26775591).	26775591
ALK	EML4-ALK ALK F1245C	lung non-small cell carcinoma	sensitive	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 that demonstrated resistance to treatment with Xalkori (crizotinib) after acquisition of ALK F1245C, achieved a complete radiographic response with no evidence of progression at 6 months following treatment with Zykadia (ceritinib) (PMID: 26775591).	26775591
ALK	ALK G1128A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing ALK G1128A was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).	27049722
ALK	EML4-ALK ALK G1202del	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated moderate resistance to treatment with Alecensa (alectinib) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK G1202del	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK G1202del	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK G1202del	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Alunbrig (brigatinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK G1202del	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK S1206F	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK S1206F in the context of EML4-ALK in culture (PMID: 27780853).	27780853
ALK	ALK L1196M	Advanced Solid Tumor	sensitive	Repotrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Repotrectinib (TPX-0005) inhibited cell proliferation in transformed cell lines over expressing ALK L1196M in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).	detail...
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1196M in the context of EML4-ALK were insensitive to Xalkori (crizotinib) as demonstrated by a lack of growth inhibition and Alk phosphorylation in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1196M in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).	22277784
ALK	EML4-ALK ALK L1196M	lung non-small cell carcinoma	sensitive	Ceritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited cell survival and PI3K/AKT, MEK/ERK, and mTOR signaling in two human non-small cell lung carcinoma cell lines harboring the Xalkori (crizotinib) resistance mutation EML4-ALK ALK L1196M in culture and inhibited tumor growth in xenograft models of one of those cell lines (PMID: 24675041).	24675041
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Repotrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Repotrectinib (TPX-0005) inhibited Alk activity and proliferation of transformed cells over expressing ALK L1196M in the context of EML4-ALK in culture (European Journal of Cancer , Volume 69, S32).	detail...
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK L1196M demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 26698910)	26698910
ALK	EML4-ALK ALK L1196M	lung non-small cell carcinoma	sensitive	Lorlatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and proliferation of non-small cell lung carcinoma cells over expressing ALK L1196M in the context of EML4-ALK in culture, and resulted in tumor regression in cell line xenograft models (PMID: 26144315).	26144315
ALK	EML4-ALK ALK L1196M	lung non-small cell carcinoma	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of non-small cell lung cancer cells expressing ALK L1196M in the context of EML4-ALK in culture (PMID: 21502504).	21502504
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	WX-0593	Preclinical - Cell culture	Actionable	In a preclinical study, WX-0593 inhibited growth of transformed cells expressing ALK L1196M in the context of EML4-ALK in culture (Cancer Res 2018;78(13 Suppl):Abstract nr 4794).	detail...
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ensartinib	Preclinical	Actionable	In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK ALK L1196M (PMID: 21613408).	21613408
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK L196M in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).	27780853
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated decreased sensitivity to Alecensa (alectinib) compared to cells expressing EML4-ALK with wild-type ALK, in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing an EML4-ALK fusion and ALK L1196M in culture and in cell line xenograft models (PMID: 21575866).	21575866
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 24887559).	24887559
ALK	EML4-ALK ALK L1196M	lung adenocarcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, EML4-ALK and ALK L1196M were identified as acquired mutations in the pleural effusion from a patient with lung adenocarcinoma after his disease progressed on Xalkori (crizotinib) treatment (PMID: 28434515).	28434515
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated moderate resistance to ASP3026 in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).	26698910 27432227
ALK	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were sensitive to Rozlytrek (entrectinib), resulting in anti-proliferative activity in culture (PMID: 26939704).	26939704
ALK	NPM1-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M demonstrated moderate resistance to Alunbrig (brigatinib) in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK L1196M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M demonstrated resistance to ASP3026 in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK L1196M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M demonstrated moderate resistance to Zykadia (ceritinib) in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK L1122V ALK L1196M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1122V ALK L1196M	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1122V ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1122V ALK L1196M	anaplastic large cell lymphoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1122V ALK L1196M	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	decreased response	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).	25421750
ALK	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, introduction of an additional ALK mutation L1198F in transformed cells expressing ALK L1196M in the context of EML4-ALK reduced resistance to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F were resistant to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK C1156Y ALK L1196M	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1196M was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	EML4-ALK ALK C1156Y ALK L1196M	lung adenocarcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EML4-ALK treated on a clinical trial achieved a partial response when treated with Xalkori (crizotinib), however, after 5 months, the patient progressed and was found to harbor secondary resistance mutations, ALK C1156Y and ALK L1196M (PMID: 20979473; NCT00585195).	20979473
ALK	ALK rearrange ALK L1196M	lung non-small cell carcinoma	resistant	Crizotinib	Case Reports/Case Series	Actionable	In a retrospective analysis, four non-small cell lung cancer patients harboring an ALK rearrangement responded to Xalkori (crizotinib) therapy, but then progressed, and were found to have acquired ALK L1196M (PMID: 25724526).	25724526
ALK	ALK rearrange ALK L1196M	lung non-small cell carcinoma	resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK L1196M was identified in biopsies from a non-small cell lung cancer patient harboring an ALK rearrangement who developed resistance to Xalkori (crizotinib) (PMID: 22277784).	22277784
ALK	ALK rearrange ALK L1196M	lung non-small cell carcinoma	predicted - resistant	Brigatinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK L1196M was identified in 17% (12/70) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received second-generation ALK TKI treatment, including Alecensa (alectinib) (n=46), Zykadia (ceritinib) (n=4), Alunbrig (brigatinib) (n=3), Ensartinib (X-396) (n=1), or more than 2 lines of TKIs (n=16) (PMID: 31358542).	31358542
ALK	ALK rearrange ALK L1196M	lung non-small cell carcinoma	predicted - resistant	Ceritinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK L1196M was identified in 17% (12/70) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received second-generation ALK TKI treatment, including Alecensa (alectinib) (n=46), Zykadia (ceritinib) (n=4), Alunbrig (brigatinib) (n=3), Ensartinib (X-396) (n=1), or more than 2 lines of TKIs (n=16) (PMID: 31358542).	31358542
ALK	ALK rearrange ALK L1196M	lung non-small cell carcinoma	predicted - resistant	Ensartinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK L1196M was identified in 17% (12/70) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received second-generation ALK TKI treatment, including Alecensa (alectinib) (n=46), Zykadia (ceritinib) (n=4), Alunbrig (brigatinib) (n=3), Ensartinib (X-396) (n=1), or more than 2 lines of TKIs (n=16) (PMID: 31358542).	31358542
ALK	ALK rearrange ALK L1196M	lung non-small cell carcinoma	predicted - resistant	Alectinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK L1196M was identified in 22% (10/46) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received Alecensa (alectinib) treatment (PMID: 31358542).	31358542
ALK	ALK rearrange ALK L1196M	lung non-small cell carcinoma	predicted - resistant	Lorlatinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK L1196M was identified in 38% (11/29) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received Lorbrena (lorlatinib) treatment (PMID: 31358542).	31358542
ALK	EML4-ALK ALK L1196M ALK I1171S	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1171S was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	EML4-ALK ALK L1196M ALK F1174C	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174C was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	EML4-ALK ALK L1196M ALK F1174L	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174L was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	EML4-ALK ALK L1196M ALK F1174V	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174V was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	EML4-ALK ALK L1196M ALK I1179V	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1179V was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	EML4-ALK ALK L1196M ALK L1256F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1256F was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	EML4-ALK ALK L1196M ALK G1202R	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1196M was identified as a compound mutation in transformed cells expressing ALK G1202R in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	ALK rearrange ALK G1202R ALK L1196M	lung non-small cell carcinoma	resistant	Lorlatinib	Case Reports/Case Series	Actionable	In a clinical study, an ALK-positive non-small cell lung cancer patient harboring ALK G1202R ALK L1196M developed resistance to Lorlatinib (PF-06463922) after initial response (PMID: 29650534).	29650534
ALK	ALK rearrange ALK V1180L ALK L1196M ALK G1202R	lung non-small cell carcinoma	predicted - resistant	Brigatinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK G1202R and ALK L1196M were identified at disease progression while on Alunbrig (brigatinib) treatment in liquid biopsy of a patient with ALK-positive non-small cell lung cancer also harboring an ALK V1180L (PMID: 29935304).	29935304
ALK	EML4-ALK ALK I1171S	Advanced Solid Tumor	conflicting	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alunbrig (brigatinib)-mediated growth inhibition in culture (PMID: 27009859), however, another study with comparable cells demonstrated sensitivity (PMID: 27432227).	27432227 27009859
ALK	EML4-ALK ALK I1171S	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK I1171S	Advanced Solid Tumor	resistant	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK I1171S	lung non-small cell carcinoma	predicted - resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer initially responded to Alecensa (alectinib), but progressed with the emergence of a secondary ALK I1171S mutation (PMID: 25393796).	25393796
ALK	EML4-ALK ALK I1171S	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171S demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK I1171S	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859), however, in another study comparable cells demonstrated sensitivity (PMID: 27432227).	27009859 27432227
ALK	EML4-ALK ALK I1171S	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK I1171S	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK I1171S	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1161S were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK I1171S	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK I1171S	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK I1171S	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK I1171S	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK I1171S	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK I1171S	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK F1174V ALK I1171S	lung non-small cell carcinoma	predicted - resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK and ALK F1174V initially responded to Alecensa (alectinib), but then demonstrated progression in one of two lung nodules, which was found to harbor a secondary resistance mutation, ALK I1171S, and upon resection of the nodule the patient continued Alecensa (alectinib) treatment and achieved complete remission (PMID: 26464158).	26464158
ALK	ALK D1091N	neuroblastoma	predicted - sensitive	Alectinib + Doxorubicin	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) treatment enhanced the cytotoxic effects of Adriamycin (doxorubicin) in a neuroblastoma cell line harboring ALK D1091N, demonstrating increased apoptotic activity and decreased cell viability in culture (PMID: 28455243).	28455243
ALK	ALK D1091N	neuroblastoma	sensitive	AZD3463 + Doxorubicin	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 treatment enhanced the cytotoxic effects of Adriamycin (doxorubicin) in a neuroblastoma cell line harboring ALK D1091N, demonstrating increased apoptotic activity and decreased cell viability in culture (PMID: 28455243).	28455243
ALK	ALK D1091N	neuroblastoma	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 treatment in a neuroblastoma cell line harboring ALK D1091N resulted in inhibition of colony formation, repression of Pi3k signaling, and induction of apoptosis in culture (PMID: 26786851).	26786851
ALK	ALK D1091N	neuroblastoma	predicted - sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) treatment in a neuroblastoma cell line harboring ALK D1091N resulted in decreased cell viability, inhibition of colony formation, and inhibition of Pi3k pathway signaling in culture (PMID: 28455243).	28455243
ALK	EML4-ALK ALK L1152R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1152R demonstrated resistance to Zykadia (ceritinib) in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK L1152R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1152R in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).	27780853
ALK	EML4-ALK ALK L1152R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1152R demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK L1152R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1152R in the context of EML4-ALK demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 21791641).	21791641
ALK	EML4-ALK ALK L1152R	lung non-small cell carcinoma	resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated a brief response to Xalkori (crizotinib) treatment, but after 3 months showed tumor progression, and was found to harbor the secondary resistance mutation, ALK L1152R (PMID: 21791641).	21791641
ALK	EML4-ALK ALK L1152R	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK L1152R in the context of EML4-ALK in culture (PMID: 26144315).	26144315
ALK	EML4-ALK ALK L1152R	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK L1152R in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK L1152R	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK L1152R in the context of EML4-ALK in culture (PMID: 27780853).	27780853
ALK	EML4-ALK ALK L1152R	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK L1152R in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK L1152R	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1152R demonstrated resistance to ASP3026 in culture (PMID: 25727400).	25727400
ALK	ALK rearrange ALK L1152R	lung adenocarcinoma	predicted - resistant	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with ALK-rearranged lung adenocarcinoma, which also harbored RB1 deletion and TP53 G154V and R158C mutations, demonstrated a partial response following treatment with Zykadia (ceritinib), however, progressed after 4 months and was found to have an acquired ALK L1152R mutation in a biopsy of a pleural nodule (PMID: 27091190).	27091190
ALK	ALK rearrange ALK L1152R	lung adenocarcinoma	predicted - sensitive	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with ALK-rearranged lung adenocarcinoma, which also harbored RB1 deletion and TP53 G154V and R158C mutations, was found to have an acquired ALK L1152R mutation in a biopsy of a pleural nodule following progression on Xalkori (crizotinib) and Zykadia (ceritinib), and was subsequently treated with Alecensa (alectinib), resulting in a partial response in all disease areas (PMID: 27091190).	27091190
ALK	NPM1-ALK ALK L1152R	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1152R demonstrated moderate resistance to Alecensa (alectinib) in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK L1152R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1152R demonstrated resistance to Zykadia (ceritinib) in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK L1152R	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK L1152R in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK L1152R	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1152R demonstrated resistance to ASP3026 in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK L1152R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1152R demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
ALK	ALK G1202R	Advanced Solid Tumor	sensitive	Repotrectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Repotrectinib (TPX-0005) inhibited ALK G1202R and suppressed tumor growth in cell line xenograft models with ALK G1202R (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).	detail...
ALK	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R demonstrated resistance to Zykadia (ceritinib) in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK G1202R	Advanced Solid Tumor	conflicting	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R demonstrated resistance to Alunbrig (brigatinib) in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK G1202R	Advanced Solid Tumor	conflicting	Brigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK G1202R in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).	27780853
ALK	EML4-ALK ALK G1202R	lung non-small cell carcinoma	predicted - resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK, who had developed resistance to Xalkori (crizotinib), was found to harbor ALK G1202R following treatment with Alecensa (alectinib) (PMID: 24736079).	24736079
ALK	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) did not effectively inhibit growth of transformed cells expressing EML4-ALK with ALK G1202R in culture, and did not inhibit tumor growth in xenograft models (PMID: 24887559).	24887559
ALK	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R demonstrated resistance to Alecensa (alectinib) in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1202R in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).	22277784
ALK	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK G1202R	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202R demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK G1202R	lung cancer	conflicting	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK G1202R	lung cancer	conflicting	Lorlatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis in transformed cells over expressing ALK G1202R in the context of EML4-ALK in culture and in cell line xenograft models (PMID: 26144315).	26144315
ALK	EML4-ALK ALK G1202R	Advanced Solid Tumor	sensitive	Repotrectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Repotrectinib (TPX-0005) inhibited Alk activity and proliferation of transformed cells expressing ALK G1201R in the context of EML4-ALK in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 30093503).	30093503 detail...
ALK	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R demonstrated resistance to ASP3026 in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK G1202R	lung non-small cell carcinoma	resistant	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK who acquired the secondary drug resistance mutation, ALK S1206Y, when treated with Xalkori (crizotinib) was subsequently treated with Zykadia (ceritinib), developed drug resistance, and was then found to have lost the ALK S1206Y mutation, but gained ALK G1202R (PMID: 24675041).	24675041
ALK	EML4-ALK ALK G1202R	lung non-small cell carcinoma	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were insensitive to Zykadia (ceritinib) in culture (PMID: 24675041).	24675041
ALK	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to Rozlytrek (entrectinib) in culture (PMID: 26939704).	26939704
ALK	ALK fusion ALK G1202R	lung non-small cell carcinoma	sensitive	Lorlatinib	Phase I	Actionable	In a Phase I trial, treatment with Lorlatinib (PF-06463922) demonstrated safety and resulted in durable responses in patients with ALK-positive non-small cell lung cancer, including patients harboring ALK G1202R (J Clin Oncol 34, 2016 (suppl; abstr 9009)).	detail...
ALK	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1202R in the context of EML4-ALK were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).	26698910
ALK	ALK rearrange ALK G1202R	lung non-small cell carcinoma	predicted - resistant	Brigatinib	Case Reports/Case Series	Actionable	In a clinical case study, Alunbrig (brigatinib) treatment resulted in progressive disease in a patient with ALK-rearranged non-small cell lung cancer refractory to Alecensa (alectinib) treatment, ALK G1202R was identified in post-brigatinib biopsy (PMID: 29935304).	29935304
ALK	ALK rearrange ALK G1202R	lung non-small cell carcinoma	predicted - resistant	Brigatinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK G1202R was identified in 33% (23/70) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received second-generation ALK TKI treatment, including Alecensa (alectinib) (n=46), Zykadia (ceritinib) (n=4), Alunbrig (brigatinib) (n=3), Ensartinib (X-396) (n=1), or more than 2 lines of TKIs (n=16) (PMID: 31358542).	31358542
ALK	ALK rearrange ALK G1202R	lung non-small cell carcinoma	predicted - resistant	Lorlatinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK G1202R was identified in 28% (8/29) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received Lorbrena (lorlatinib) treatment (PMID: 31358542).	31358542
ALK	ALK rearrange ALK G1202R	lung non-small cell carcinoma	predicted - resistant	Ceritinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK G1202R was identified in 33% (23/70) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received second-generation ALK TKI treatment, including Alecensa (alectinib) (n=46), Zykadia (ceritinib) (n=4), Alunbrig (brigatinib) (n=3), Ensartinib (X-396) (n=1), or more than 2 lines of TKIs (n=16) (PMID: 31358542).	31358542
ALK	ALK rearrange ALK G1202R	lung non-small cell carcinoma	predicted - resistant	Ensartinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK G1202R was identified in 33% (23/70) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received second-generation ALK TKI treatment, including Alecensa (alectinib) (n=46), Zykadia (ceritinib) (n=4), Alunbrig (brigatinib) (n=3), Ensartinib (X-396) (n=1), or more than 2 lines of TKIs (n=16) (PMID: 31358542).	31358542
ALK	ALK rearrange ALK G1202R	lung non-small cell carcinoma	predicted - resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK G1202R was identified in a patient with ALK-rearranged non-small cell lung carcinoma after the disease progressed while on Zykadia (ceritinib) followed by Alecensa (alectinib) therapy (PMID: 28285684).	28285684
ALK	ALK rearrange ALK G1202R	lung non-small cell carcinoma	predicted - resistant	Alectinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK G1202R was identified in 37% (17/46) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received Alecensa (alectinib) treatment (PMID: 31358542).	31358542
ALK	ALK rearrange ALK G1202R	lung non-small cell carcinoma	predicted - resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK G1202R was identified in a patient with ALK-rearranged non-small cell lung carcinoma after the disease progressed while on Xalkori (crizotinib) followed by Alecensa (alectinib) therapy (PMID: 27130468).	27130468
ALK	EML4-ALK ALK F1174V ALK G1202R	lung non-small cell carcinoma	sensitive	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK who was previously treated with Xalkori (crizotinib) and subsequently developed the resistance mutation, ALK G1269A, was treated with Zykadia (ceritinib), later progressed, and was found to have lost ALK G1269A, but gained ALK F1174V and ALK G1202R (PMID: 24675041).	24675041
ALK	ALK fusion ALK G1202R KIT amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, an ALK G1202R secondary mutation as well as KIT amplification were identified in a patient with ALK fusion-positive non-small cell lung cancer with resistance to Xalkori (crizotinib) (PMID: 22277784).	22277784
ALK	NPM1-ALK ALK G1202R	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1202R demonstrated resistance to ASP3026 in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK G1202R	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1202R demonstrated resistance to Alunbrig (brigatinib) in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK G1202R	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1202R demonstrated resistance to Alecensa (alectinib) in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK G1202R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1202R demonstrated resistance to Zykadia (ceritinib) in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK G1202R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1202R demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK S1206Y	Advanced Solid Tumor	conflicting	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing S1206Y in the context of EML4-ALK in culture (PMID: 27780853).	27780853
ALK	EML4-ALK ALK S1206Y	Advanced Solid Tumor	conflicting	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK S1206Y demonstrated moderate resistance to Alunbrig (brigatinib) in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK S1206Y	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated moderate resistance to Alecensa (alectinib) in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK S1206Y	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK S1206Y in culture and in xenograft models (PMID: 24887559).	24887559
ALK	EML4-ALK ALK S1206Y	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK S1206Y demonstrated moderate resistance to ASP3026 in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK S1206Y demonstrated growth inhibition with Zykadia (ceritinib) treatment in culture (PMID: 24675041).	24675041
ALK	EML4-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK S1206Y in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK S1206Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK S1206Y demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK S1206Y in the context of EML4-ALK in culture (PMID: 26144315).	26144315
ALK	ALK fusion ALK S1206Y	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, an ALK S1206Y secondary mutation in the context of an ALK fusion was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer (PMID: 22277784).	22277784
ALK	ALK rearrange ALK S1206Y	lung non-small cell carcinoma	resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung cancer patient harboring an ALK rearrangement responded to Xalkori (crizotinib) therapy, but then progressed after 32 months, and was found to have acquired ALK S1206Y (PMID: 25724526).	25724526
ALK	ALK rearrange ALK S1206Y	lung non-small cell carcinoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK S1206Y in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).	22277784
ALK	NPM1-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK S1206Y in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK S1206Y in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK S1206Y in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK S1206Y in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK S1206Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206Y demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
ALK	ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical	Actionable	In a preclinical study, ALK C1156Y was sensitive to Alecensa (alectinib) in an in vitro enzyme assay (PMID: 21575866).	21575866
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK ALK C1156Y were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and lack of kinase inhibition in culture (PMID: 21613408).	21613408
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y demonstrated moderate resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited proliferation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK C1156Y	lung non-small cell carcinoma	no benefit	Luminespib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer with an ALK C1156Y secondary Xalkori (crizotinib) resistance mutation did not respond to Luminespib (AUY922) therapy (PMID: 26698910).	26698910
ALK	EML4-ALK ALK C1156Y	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer developed resistance to Xalkori (crizotinib) with the emergence of ALK C1156Y, a secondary resistance mutation (PMID: 26698910).	26698910
ALK	EML4-ALK ALK C1156Y	lung non-small cell carcinoma	conflicting	Ceritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Zykadia (ceritinib) demonstrated tumor growth inhibition in xenograft models of a human non-small cell lung cancer cell line harboring EML4-ALK with ALK C1156Y when compared to Xalkori (crizotinib) (PMID: 24675041).	24675041
ALK	EML4-ALK ALK C1156Y	lung non-small cell carcinoma	conflicting	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation C1156Y, did not respond to Zykadia (ceritinib) therapy (PMID: 26698910).	26698910
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	WX-0593	Preclinical - Cell culture	Actionable	In a preclinical study, WX-0593 inhibited growth of transformed cells expressing ALK C1156Y in the context of EML4-ALK in culture (Cancer Res 2018;78(13 Suppl):Abstract nr 4794).	detail...
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing ALK C1156Y in the context of EML4-ALK demonstrated minimal sensitivity to Zykadia (ceritinib) in culture (PMID: 24675041).	24675041
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 24887559).	24887559
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing EML4-ALK with ALK C1156Y were sensitive to Alecensa (alectinib) in culture (PMID: 21575866).	21575866
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Ensartinib	Preclinical	Actionable	In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK C1156Y (PMID: 21613408).	21613408
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth and ALK phosphorylation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK C1156Y	lung non-small cell carcinoma	sensitive	Lorlatinib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation ALK C1156Y, was treated with Lorlatinib (PF-06463922) and displayed a 41% reduction in tumor growth after 5 weeks of treatment (PMID: 26698910; NCT01970865).	26698910
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
ALK	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were sensitive to Rozlytrek (entrectinib), resulting in anti-proliferative activity (PMID: 26939704).	26939704
ALK	NPM1-ALK ALK C1156Y	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156Y demonstrated moderate resistance to ASP3026 in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK C1156Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156Y demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK C1156Y	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156Y demonstrated moderate resistance to Zykadia (ceritinib) in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK C1156Y	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156Y were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
ALK	NPM1-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
ALK	ALK rearrange ALK C1156Y	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung cancer patient harboring an ALK rearrangement responded to Xalkori (crizotinib) therapy, but then progressed after 18.2 months, and was found to have acquired ALK C1156Y (PMID: 25724526).	25724526
ALK	ALK rearrange ALK C1156Y ALK L1198F	lung non-small cell carcinoma	resistant	Lorlatinib	Case Reports/Case Series	Actionable	In a clinical study, an ALK-positive non-small cell lung cancer patient harboring ALK C1156Y ALK L1198F developed resistance to Lorlatinib (PF-06463922) after initial response (PMID: 29650534).	29650534
ALK	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK C1156Y ALK L1198F	lung non-small cell carcinoma	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small lung cancer initially responded to Xalkori (crizotinib) but developed resistance with the emergence of a secondary ALK mutation C1156Y, and subsequently redeveloped sensitivity to Xalkori (crizotinib) upon the emergence of a second ALK mutation, L1198F arising from resistance to Lorlatinib (PF-06463922) (PMID: 26698910).	26698910
ALK	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK C1156Y ALK L1198F	lung non-small cell carcinoma	resistant	Lorlatinib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with EML4-ALK positive non-small lung cancer with a secondary Xalkori (critzotinib) resistance mutation C1156Y, responded to Lorlatinib (PF-06463922) but subsequently developed resistance upon the emergence of a second ALK mutation, L1198F (PMID: 26698910; NCT01970865).	26698910
ALK	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK C1156Y and ALK L1198F in the context of EML4-ALK were resistant to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK C1156Y ALK I1171T	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1171T was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	EML4-ALK ALK C1156Y ALK F1174C	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174C was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	EML4-ALK ALK C1156Y ALK F1174I	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174I was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	EML4-ALK ALK C1156Y ALK F1174V	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174V was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	EML4-ALK ALK C1156Y ALK D1203N	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK D1203N was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	EML4-ALK ALK C1156Y ALK L1256F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1256F was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
ALK	ALK R1275Q	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in human neuroblastoma cell line xenograft models harboring ALK R1275Q and wild-type TP53 (PMID: 26438783).	26438783
ALK	ALK R1275Q	neuroblastoma	conflicting	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited proliferation of neuroblastoma cells harboring ALK R1275Q in culture (PMID: 29907598).	29907598
ALK	ALK R1275Q	neuroblastoma	conflicting	Crizotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK R1275Q in culture, and only delayed tumor growth in cell line xenograft models (PMID: 26554404).	26554404
ALK	ALK R1275Q	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK R1275Q in culture (PMID: 26554404).	26554404
ALK	ALK R1275Q	neuroblastoma	sensitive	CEP-28122	Preclinical - Cell culture	Actionable	In a preclinical study, CEP-28122 inhibited growth of neuroblastoma cells harboring ALK R1275Q in culture (PMID: 22203728).	22203728
ALK	ALK R1275Q	neuroblastoma	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited proliferation of neuroblastoma cells harboring ALK R1275Q in culture (PMID: 29907598).	29907598
ALK	ALK R1275Q	neuroblastoma	sensitive	Lorlatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Lorbrena (lorlatinib) inhibited Alk phosphorylation, resulted in growth inhibition of neuroblastoma cells over expressing ALK R1275Q in culture and irapid and sustained complete tumor regression in cell line xenograft models (PMID: 26554404).	26554404
ALK	ALK R1275Q	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a transformed cell line expressing ALK R1275Q was sensitive to Alunbrig (brigatinib) in culture and in cell line xenograft models, resulting in cell growth inhibition (PMID: 27049722).	27049722
ALK	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK F1174I	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174I were resistant to ASP3026 relative to wild type NPM1-ALK in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK F1174I	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK F1174I were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Alecensa (alectinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with E1210K were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK E1210K in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK E1210K	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK E1210K were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to ASP3026 in culture (PMID: 25749034).	25749034
ALK	EML4-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alunbrig (brigatinib) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK E1210K	lung non-small cell carcinoma	resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a patient with non-small cell lung carcinoma harboring EML4-ALK progressed on treatment with Xalkori (crizotinib) and was subsequently found to harbor a secondary resistance mutation, ALK E1210K (PMID: 29636358).	29636358
ALK	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Alunbrig (brigatinib) when compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K did not response to treatment with Alecensa (alectinib) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Zykadia (ceritinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK E1210K ALK S1206C	lung non-small cell carcinoma	resistant	Brigatinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK and ALK E1210K eventually progressed on treatment with Alunbrig (brigatinib) and was subsequently found to have acquired another resistance mutation, ALK S1206C in cis (PMID: 29636358).	29636358
ALK	ALK rearrange ALK E1210K	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with ALK-rearranged non-small cell lung cancer demonstrated disease progression when treated with Xalkori (crizotinib) due to a secondary acquired resistance mutation, ALK E1210K (PMID: 27432227).	27432227
ALK	ALK F1174V	neuroblastoma	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, neuroblastoma cells harboring ALK F1174V were sensitive to Alunbrig (brigatinib) in culture and in vivo, resulting in inhibition of both Alk activity and cell proliferation (PMID: 27049722).	27049722
ALK	NPM1-ALK ALK F1174V	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK F1174V	Advanced Solid Tumor	decreased response	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK F1174V	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK F1174V	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK F1174V	Advanced Solid Tumor	predicted - sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical trial, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V, but to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK F1174V ALK L1198F	anaplastic large cell lymphoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK1198F were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F in culture (PMID: 25421750).	25421750
ALK	EML4-ALK ALK F1174V	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK F1174V in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).	27780853
ALK	EML4-ALK ALK F1174V	lung non-small cell carcinoma	predicted - sensitive	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK initially responded to Xalkori (crizotinib), but then progressed due to acquisition of the secondary resistance mutation, ALK F1174V, and then responded to treatment with Alecensa (alectinib), demonstrating a complete response in one lung nodule and a 44% decrease in size in a second lung nodule (PMID: 26464158).	26464158
ALK	EML4-ALK ALK F1174V	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK F1174V in the context of EML4-ALK in culture (PMID: 27780853).	27780853
ALK	EML4-ALK ALK F1174V	lung non-small cell carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated a partial response to Xalkori (crizotinib) treatment after 3 months, but then progressed, and was found to harbor the secondary resistance mutation, ALK F1174V (PMID: 24736079).	24736079
ALK	ALK amp ALK F1174V	neuroblastoma	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited proliferation of neuroblastoma cells harboring ALK amplification and ALK F1174V in culture (PMID: 29907598).	29907598
ALK	ALK amp ALK F1174V	neuroblastoma	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited proliferation of neuroblastoma cells harboring ALK amplification and ALK F1174V in culture (PMID: 29907598).	29907598
ALK	ALK I1171N	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing ALK I1171N was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).	27049722
ALK	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to ASP3026 in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK I1171N	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).	25749034
ALK	EML4-ALK ALK I1171N	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated resistance to treatment with Alecensa (alectinib) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK I1171N	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK I1171N	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK I1171N	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Alunbrig (brigatinib) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK I1171N	lung non-small cell carcinoma	predicted - resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated tumor regression when treated with Alecensa (alectinib), but progressed seven months later, and was found to harbor a secondary resistance mutation, ALK I1171N (PMID: 25393798).	25393798
ALK	EML4-ALK ALK I1171N	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).	27432227
ALK	ALK rearrange ALK I1171N	lung non-small cell carcinoma	predicted - resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a de novo ALK I1171N mutation was identified in the liver metastasis site and circulating DNA of a non-small cell lung cancer patient harboring an ALK rearrangement after disease progression on Alecensa (alectinib) treatment (PMID: 27565911).	27565911
ALK	ALK rearrange ALK I1171N	lung non-small cell carcinoma	predicted - sensitive	Brigatinib	Case Reports/Case Series	Actionable	In a clinical study, Alunbrig (brigatinib) treatment resulted in stable disease in 2 patients with Alecensa (alectinib)-refractory, ALK-rearranged non-small cell lung cancer with an acquired ALK I1171N (PMID: 29935304).	29935304
ALK	ALK rearrange ALK I1171N ALK L1198F	lung non-small cell carcinoma	resistant	Lorlatinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung cancer patient harboring ALK I1171N and L1198F in cis in the context of EML4-ALK demonstrated primary resistance to Lorlatinib (PF-06463922) (PMID: 29650534).	29650534
ALK	ALK rearrange ALK I1171N ALK D1203N	lung non-small cell carcinoma	resistant	Lorlatinib	Case Reports/Case Series	Actionable	In a clinical study, an ALK-positive non-small cell lung cancer patient harboring ALK I1171N and D1203N developed resistance to Lorlatinib (PF-06463922) after initial response (PMID: 29650534).	29650534
ALK	ALK rearrange ALK I1171N MET amp	lung non-small cell carcinoma	predicted - resistant	Brigatinib	Case Reports/Case Series	Actionable	In a clinical case study, MET amplification was identified together with a pre-existing ALK I1171N at disease progression while on Alunbrig (brigatinib) treatment in a patient with ALK-positive non-small cell lung cancer (PMID: 29935304).	29935304
ALK	NPM1-ALK ALK S1206C	anaplastic large cell lymphoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK ALK S1206C were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK S1206C	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK S1206C	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK S1206C	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK S1206C	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK S1206C	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK and ALK S1206C were resistant to ASP3026 treatment in culture (PMID: 25421750).	25421750
ALK	ALK F1174L	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK F1174L in culture (PMID: 26554404).	26554404
ALK	ALK F1174L	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing ALK F1174L was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).	27049722
ALK	ALK F1174L	neuroblastoma	conflicting	Lorlatinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Lorbrena (lorlatinib) inhibited growth of neuroblastoma cells over expressing ALK F1174L in culture, and induced rapid and sustained complete tumor regression in both patient-derived and cell line xenograft models harboring ALK F1174L (PMID: 26554404).	26554404
ALK	ALK F1174L	neuroblastoma	conflicting	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, neuroblastoma cells harboring ALK F1174L were resistant to Lorbrena (lorlatinib) in culture (PMID: 30322862).	30322862
ALK	ALK F1174L	neuroblastoma	sensitive	CEP-28122	Preclinical - Cell culture	Actionable	In a preclinical study, CEP-28122 inhibited growth of neuroblastoma cells harboring ALK F1174L in culture (PMID: 22203728).	22203728
ALK	ALK F1174L	neuroblastoma	sensitive	AZD3463	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD3463 inhibited growth of neuroblastoma cells harboring ALK F1174L in culture, resulted in near complete tumor regression in cell line xenograft models (PMID: 26786851).	26786851
ALK	ALK F1174L	neuroblastoma	resistant	Crizotinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK F1174L in culture, and only delayed tumor growth in patient-derived and cell line xenograft models harboring ALK F1174L (PMID: 26554404).	26554404
ALK	ALK F1174L TP53 wild-type	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in xenograft models of a crizotinib-resistant human neuroblastoma cell line harboring ALK F1174L and wild-type TP53 (PMID: 26438783).	26438783
ALK	EML4-ALK ALK F1174L	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Zykadia (ceritinib)-mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK F1174L	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK F1174L in the context of EML4-ALK in culture (PMID: 26144315).	26144315
ALK	EML4-ALK ALK F1174L	Advanced Solid Tumor	conflicting	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK F1174L in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).	27780853
ALK	EML4-ALK ALK F1174L	Advanced Solid Tumor	conflicting	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK F1174L	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK F1174L	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK F1174L	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK F1174L	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture and in xenograft models (PMID: 24887559).	24887559
ALK	EML4-ALK ALK F1174L	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Alunbrig (brigatinib)-mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK F1174L	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK F1174L in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK F1174L	anaplastic large cell lymphoma	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	ALK F1174L ALK L1198P	neuroblastoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of ALK L1198P in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to Xalkori (crizotinib) in culture (PMID: 21948233).	21948233
ALK	ALK F1174L ALK L1198P	neuroblastoma	resistant	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, expression of ALK L1198P in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to TAE684 in culture (PMID: 21948233).	21948233
ALK	ALK F1174L ALK G1123S	neuroblastoma	resistant	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, expression of ALK G1123S in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to TAE684 in culture (PMID: 21948233).	21948233
ALK	ALK F1174L ALK G1123D	neuroblastoma	resistant	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, expression of ALK G1123D in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to TAE684 in culture (PMID: 21948233).	21948233
ALK	ALK amp ALK F1174L	neuroblastoma	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited proliferation of neuroblastoma cells harboring ALK amplification and ALK F1174L in culture (PMID: 29907598).	29907598
ALK	ALK amp ALK F1174L	neuroblastoma	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited proliferation of neuroblastoma cells harboring ALK amplification and ALK F1174L in culture (PMID: 29907598).	29907598
ALK	EML4-ALK ALK F1174L ALK L1198V	lung non-small cell carcinoma	resistant	Brigatinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK progressed while being treated with Alunbrig (brigatinib) and was subsequently found to harbor two resistance mutations, ALK F1174L and ALK L1198V, which were both in cis (PMID: 29636358).	29636358
ALK	ALK rearrange ALK F1174L	lung non-small cell carcinoma	predicted - resistant	Lorlatinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK F1174C/L was identified in 14% (4/29) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received Lorbrena (lorlatinib) treatment (PMID: 31358542).	31358542
ALK	ALK rearrange	anaplastic large cell lymphoma	not applicable	N/A	Guideline	Diagnostic	ALK rearrangement aids in the diagnosis of anaplastic large cell lymphoma (NCCN.org).	detail...
ALK	ALK rearrange	anaplastic large cell lymphoma	not applicable	N/A	Guideline	Prognostic	The presence of ALK rearrangement is associated with a favorable prognosis in patients with anaplastic large cell lymphoma (NCCN.org).	detail...
ALK	ALK rearrange	lung non-small cell carcinoma	no benefit	Osimertinib	Guideline	Actionable	EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ALK rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org).	detail...
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Crizotinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (PROFILE 1014) that supported FDA approval, Xalkori (crizotinib) treatment resulted in improved progression-free survival (10.9 vs 7.0 months, HR=0.45, p<0.001) and objective response rate (74% vs 45%) relative to chemotherapy in NSCLC patients with ALK rearrangements (PMID: 25470694; NCT01154140).	detail... 25470694 detail...
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Crizotinib	Phase III	Actionable	In a Phase III trial (PROFILE 1014), Xalkori (crizotinib) treatment resulted in improved progression-free survival (PFS) (PFS=10.9 months, n=172) relative to chemotherapy (PFS=7.0 months, n=171) in NSCLC patients with ALK rearrangements, including patients with and without brain metastases at baseline, and improved intracranial disease rate in patients with brain metastases at baseline (PMID: 27022118; NCT01154140).	27022118
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Crizotinib	Guideline	Actionable	Xalkori (crizotinib) is included in guidelines as first-line and subsequent therapy for ALK rearranged non-small cell lung cancer (NCCN.org).	detail...
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Crizotinib	Phase III	Actionable	In a Phase III trial, Xalkori (crizotinib) treatment resulted in improved objective response (87.5%, 90/103 vs 45.6%, 47/103) and median progression free survival (11.1 vs 6.8 mo) compared to pemetrexed, cisplatin and carboplatinin combination treatment in treatment-naive ALK positive advanced non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9058); NCT01639001).	detail...
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Crizotinib	Guideline	Actionable	Xalkori (crizotinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring an ALK rearrangement, or as a next-line therapy in patients with ALK-rearranged non-small cell lung cancer who have not received prior (PMID: 30715168, PMID: 30285222; ESMO guidelines).	30715168 30285222 detail...
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Ceritinib	Phase II	Actionable	In a Phase II trial (ASCEND-2), non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement and previously treated with Xalkori (crizotinib) and chemotherapy demonstrated an overall response rate of 38.6% (54/140), a disease control rate of 77.1%, a median time to response of 1.8 months, a median duration of response of 9.7 months, and a median progression-free survival of 5.7 months when treated with Zykadia (ceritinib) (PMID: 27432917; NCT01685060).	27432917
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Ceritinib	Guideline	Actionable	Zykadia (ceritinib) is included in guidelines as first-line and as subsequent therapy for patients with advanced or metastatic ALK-rearranged non-small cell lung cancer (NCCN.org).	detail...
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Ceritinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I trial that supported FDA approval, Zykadia (ceritinib) resulted in a blinded independent review committee (BIRC)-assessed objective response rate of 44% (72/163) and a duration of response of 7.1 months in ALK-rearranged non-small cell lung cancer patients (PMID: 25754348; NCT01283516).	25754348 detail... detail...
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Ceritinib	Guideline	Actionable	Zykadia (ceritinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring an ALK rearrangement (PMID: 30715168, PMID: 30285222; ESMO.org).	30715168 detail... 30285222
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Ceritinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement demonstrated a median overall survival of 49.5 months following treatment with the combination of an ALK-targeted tyrosine kinase inhibitor, including Zykadia (ceritinib), and radiotherapy (PMID: 26438117).	26438117
ALK	ALK rearrange	lung non-small cell carcinoma	no benefit	Durvalumab	Guideline	Actionable	Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org).	detail...
ALK	ALK rearrange	lung non-small cell carcinoma	no benefit	Durvalumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Imfinzi (durvalumab), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).	27225694
ALK	ALK rearrange	lung non-small cell carcinoma	no benefit	Atezolizumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).	27225694
ALK	ALK rearrange	lung non-small cell carcinoma	no benefit	Atezolizumab	Guideline	Actionable	Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org).	detail...
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Ceritinib + Crizotinib	Clinical Study - Cohort	Actionable	In a retrospective analysis of patients with ALK-rearrangement positive non-small cell lung cancer, the combined median progression-free survival for sequential treatment with Xalkori (crizotinib) and Zykadia (ceritinib) without intervening treatments was 17.0 months, and overall survival was 49.4 months (PMID: 25724526).	25724526
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Ensartinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement demonstrated prolonged survival following treatment with the combination of an ALK-targeted tyrosine kinase inhibitor, including Ensartinib (X-396), and radiotherapy (PMID: 26438117).	26438117
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Ensartinib	Phase Ib/II	Actionable	In a Phase I/II trial, Ensartinib (X-396) treatment resulted in partial response in 60% (36/60) and stable disease in 21.7 % (13/60) of patients with ALK-positive non-small cell lung cancer, with a median progression-free survival of 9.2 months (PMID: 29563138; NCT01625234).	29563138
ALK	ALK rearrange	lung non-small cell carcinoma	no benefit	Gefitinib	Guideline	Actionable	EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ALK rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org).	detail...
ALK	ALK rearrange	lung non-small cell carcinoma	no benefit	Erlotinib	Guideline	Actionable	EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ALK rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org).	detail...
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Alectinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement demonstrated prolonged survival following treatment with the combination of an ALK-targeted tyrosine kinase inhibitor, including Alecensa (alectinib), and radiotherapy (PMID: 26438117).	26438117
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Alectinib	Guideline	Actionable	Alecensa (alectinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring an ALK rearrangement (PMID: 30715168, PMID: 30285222; ESMO.org).	30715168 30285222 detail...
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Alectinib	Phase II	Actionable	In a Phase II trial, Alecensa (alectinib) treatment was effective in treating non-small cell lung cancer patients with ALK rearrangement, resulting in a 50% (61/122) objective response rate (ORR) in all patients, a 45% (43/96) ORR in Crizotinib-refractory patients, and an 83% (70/84) CNS disease control rate (PMID: 26598747).	26598747
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Alectinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial supporting FDA approval (ALEX), Alecensa (alectinib) treatment resulted in improved rate of progression-free survival compared to Xalkori (crizotinib) (68.4% vs 48.7%, HR=0.47), and median progression-free survival (25.7 vs 10.4 months) in non-small cell lung cancer patients harboring ALK rearrangement (PMID: 28586279; NCT02075840).	28586279 detail... detail...
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Alectinib	Guideline	Actionable	Alecensa (alectinib) is included in guidelines as the preferred first-line therapy and as subsequent therapy for patients with ALK-rearranged advanced or metastatic non-small cell lung cancer (NCCN.org).	detail...
ALK	ALK rearrange	Advanced Solid Tumor	sensitive	ASP3026	Phase I	Actionable	In a Phase I trial, ASP3026 treatment resulted in a partial response in 50% (8/16) and stable disease in 44% (7/16) of patients with an advanced solid tumor harboring an ALK rearrangement or ALK F1174L (PMID: 26966027; NCT01284192).	26966027
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Brigatinib	FDA approved	Actionable	In a Phase II trial (ALTA) that supported FDA approval, Alunbrig (brigatinib) treatment resulted in an overall response rate of 45% (51/112) in the 90mg arm and 54% (59/110) in the 180mg arm, and median progression-free survival of 9.2 and 11.0 months respectively, in ALK-rearranged (fusion) non-small cell lung carcinoma patients who progressed on Xalkori (crizotinib) (PMID: 28475456; NCT02094573).	detail... 28475456
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Brigatinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement demonstrated prolonged survival following treatment with the combination of an ALK-targeted tyrosine kinase inhibitor, including Alunbrig (brigatinib), and radiotherapy (PMID: 26438117).	26438117
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Brigatinib	Guideline	Actionable	Alunbrig (brigatinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring an ALK rearrangement (PMID: 30715168, PMID: 30285222; ESMO.org).	30715168 detail... 30285222
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Brigatinib	Phase Ib/II	Actionable	In a Phase I/II trial, Alunbrig (brigatinib) treatment resulted in an objective response rate of 100% (8/8) in ALK inhibitor-naive, ALK-rearranged non-small cell lung cancer (NSCLC) patients, 72% (51/71) in Xalkori (crizotinib) treated ALK-rearranged NSCLC patients, and 83% (5/6) in ALK-rearranged NSCLC patients with CNS metastases (PMID: 27836716; NCT01449461).	27836716
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Brigatinib	Clinical Study	Actionable	In a retrospective analysis, Alunbrig (brigatinib) demonstrated limited efficacy, resulting in an objective response rate of 17% (3/18) and stable disease in 50% (9/18) of patients with Alecensa (alectinib) refractory, ALK-positive non-small cell lung cancer, with a median progression-free survival of 4.4 months (PMID: 29935304).	29935304
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Brigatinib	Guideline	Actionable	Alunbrig (brigatinib) is included in guidelines as first-line and subsequent therapy for patients with advanced or metastatic ALK-rearranged non-small cell lung cancer (NCCN.org).	detail...
ALK	ALK rearrange	lung non-squamous non-small cell carcinoma	sensitive	Ceritinib	Phase III	Actionable	In a Phase III trial, first-line treatment with Zykadia (ceritinib) resulted in an improved median progression-free survival of 16.6 months, compared to 8.1 months with chemotherapy, in patients with ALK-rearranged non-squamous non-small cell lung cancer (PMID: 28126333; NCT01828099).	28126333
ALK	ALK rearrange	lung non-small cell carcinoma	no benefit	Pembrolizumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).	27225694
ALK	ALK rearrange	lung non-small cell carcinoma	no benefit	Pembrolizumab	Guideline	Actionable	Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org).	detail...
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Lorlatinib	Phase II	Actionable	In a Phase II trial, Lorbrena (lorlatinib treatment resulted in an objective response (OR) rate of 90% (27/30; 1 complete response (CR) and 26 partial responses (PR)) and an intracranial response rate of 66.7% (2/3) in treatment-naive non-small cell lung cancer (NSCLC) patients harboring an ALK rearrangement, and an OR rate of 47% (93/198; 4 CR, 89 PR) and an objective intracranial response rate of 63% (51/81) in ALK-rearranged NCSLC patients that had received prior therapy (PMID: 30413378; NCT01970865).	30413378
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Lorlatinib	Guideline	Actionable	Lorbrena (lorlatinib) is included in guidelines as subsequent therapy for patients with advanced or metastatic ALK-rearranged non-small cell lung cancer that have progressed on Xalkori (crizotinib) and Alecensa (alectinib), Alunbrig (brigatinib), or Zykadia (ceritinib), or on Alecensa (alectinib), Alunbrig (brigatinib), or Zykadia (ceritinib)(NCCN.org).	detail...
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Lorlatinib	Guideline	Actionable	Lorbrena (lorlatinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring an ALK rearrangement who have progressed on a second-generation ALK tyrosine kinase inhibitor (PMID: 30715168, PMID: 30285222; ESMO.org).	30285222 detail... 30715168
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Lorlatinib	FDA approved	Actionable	In a Phase II trial that supported FDA approval, Lorbrena (lorlatinib) treatment resulted in an objective response rate of 48% (103/215, 4% complete response, 44% partial response) in ALK-rearranged non-small cell lung carcinoma patients that had received more than one prior Alk kinase inhibitor therapy, with an estimated median response duration of 12.5 months (J Clin Oncol, May 2018, 36(no. 15_suppl):9032-9032; NCT01970865).	detail... detail...
ALK	ALK rearrange	lung non-small cell carcinoma	sensitive	Lorlatinib	Phase I	Actionable	In a Phase I trial, Lorbrena (lorlatinib) treatment resulted in an objective response in 46% (19/41) of patients with non-small cell lung carcinoma harboring an ALK rearrangement (PMID: 29074098; NCT03052608).	29074098
ALK	ALK rearrange	Advanced Solid Tumor	sensitive	Entrectinib	Phase I	Actionable	In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in objective response in 67% (4/6) of patients with advanced solid tumors harboring rearrangement in ALK gene (AACR Apr 2016, Abstract # CT007).	detail...
ALK	ALK rearrange	Advanced Solid Tumor	sensitive	Entrectinib	Phase I	Actionable	In a clinical study, combined analysis of 2 Phase I trials showed Rozlytrek (entrectinib) treatment resulted in an objective response rate of 57% (4/7) in patients with ALK rearranged advanced solid tumors that were treatment-naive, but no response (0/19) in patients who received prior Alk inhibitor treatments (PMID: 28183697).	28183697
ALK	ALK rearrange	lung non-small cell carcinoma	no benefit	Afatinib	Guideline	Actionable	EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ALK rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org).	detail...
ALK	ALK rearrange	lung non-small cell carcinoma	no benefit	Nivolumab	Guideline	Actionable	Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org).	detail...
ALK	ALK rearrange	lung non-small cell carcinoma	no benefit	Nivolumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).	27225694
ALK	ALK rearrange ALK I1171T	lung non-small cell carcinoma	predicted - resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK I1171T was identified in the post-progression biopsy of a non-small cell lung cancer patient harboring an ALK rearrangement after Alecensa (alectinib) treatment (PMID: 29935304).	29935304
ALK	ALK rearrange ALK I1171T	lung adenocarcinoma	resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with a lung adenocarcinoma tumor harboring an ALK rearrangement with ALK I1171T progressed on Alecensa (alectinib) therapy after 4 months and resistance was confirmed using cell culture with cells derived from the patients tumor (PMID: 25228534).	25228534
ALK	ALK rearrange ALK I1171T	lung non-small cell carcinoma	predicted - resistant	Brigatinib	Case Reports/Case Series	Actionable	In a clinical case study, Alunbrig (brigatinib) treatment resulted in progressive disease in a patient with Alecensa (alectinib)-refractory, ALK-rearranged non-small cell lung cancer with an acquired ALK I1171T (PMID: 29935304).	29935304
ALK	ALK rearrange ALK I1171T	lung adenocarcinoma	resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with a lung adenocarcinoma tumor harboring an ALK rearrangement with ALK I1171T progressed on Xalkori (crizotinib) therapy after 8 months and resistance was confirmed using cell culture with cells derived from the patient's tumor (PMID: 25228534).	25228534
ALK	ALK rearrange MAP2K1 K57N	lung non-small cell carcinoma	sensitive	Ceritinib + Selumetinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, NSCLC patient derived cells harboring an ALK rearrangement demonstrated resistance to Zykadia (ceritinib) due to the acquired mutation MAP2K1 K57N, however, sensitivity was restored to Zykadia (ceritinib) with the addition of AZD6244, resulting in decreased cell survival in culture and reduced tumor volume in xenograft models (PMID: 25394791).	25394791
ALK	ALK rearrange SRC pos	lung non-small cell carcinoma	sensitive	Ceritinib + Saracatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of Saracatinib (AZD0530) and Zykadia (ceritinib) demonstrated efficacy in non-small cell lung cancer patient derived cells harboring an ALK fusion and upregulation of SRC in culture (PMID: 25394791).	25394791
ALK	ALK rearrange RB1 C706F TP53 loss	lung small cell carcinoma	predicted - resistant	Lorlatinib	Case Reports/Case Series	Actionable	In a clinical case study, RB1 C706F and loss of exons 1-11 in TP53 were identified in the pericardium infiltrating small cell lung cancer that developed while on Lorlatinib (PF-06463922) treatment in a patient with ALK-rearranged non-small cell lung carcinoma (PMID: 28285684).	28285684
ALK	ALK G1123S ALK rearrange	lung adenocarcinoma	predicted - resistant	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK G1123S was identified as an acquired mutation in a patient with ALK-rearranged lung adenocarcinoma whose disease relapsed 2 years after initial response to Zykadia (ceritinib) (PMID: 26134233).	26134233
ALK	ALK G1123S ALK rearrange	lung adenocarcinoma	predicted - sensitive	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, Alecensa (alectinib) treatment resulted in rapid response in a patient with ALK-rearranged lung adenocarcinoma with an acquired ALK G1123S mutation, whose disease had relapsed 2 years after initial response to Zykadia (ceritinib) (PMID: 26134233).	26134233
ALK	ALK amp ALK rearrange	lung non-small cell carcinoma	resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, three patients with non-small cell lung carcinoma co-harboring an ALK rearrangement and ALK amplification demonstrated resistance to Xalkori (crizotinib) treatment (PMID: 27432227).	27432227
ALK	ALK amp ALK rearrange	lung non-small cell carcinoma	resistant	Crizotinib	Case Reports/Case Series	Actionable	In a retrospective analysis, two non-small cell lung cancer patients harboring an ALK rearrangement responded to Xalkori (crizotinib) therapy, but then progressed, and were found to have acquired ALK amplification (PMID: 25724526).	25724526
ALK	ALK rearrange MET amp	lung adenocarcinoma	sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring an ALK rearrangement who developed resistance to Alecensa (alectinib) likely due to acquisition of MET amplification, responded well to treatment with Xalkori (crizotinib), demonstrating a radiological response after 12 days (PMID: 24128725, PMID: 24518097).	24128725 24518097
ALK	ALK rearrange MET amp	lung adenocarcinoma	resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring an ALK rearrangement developed resistance to Alecensa (alectinib) treatment, and subsequently was found to harbor amplification of MET (PMID: 24128725, PMID: 24518097).	24518097 24128725
ALK	ALK rearrange ALK V1180L	lung non-small cell carcinoma	predicted - resistant	Alectinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK V1180L was identified in 11% (5/46) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received Alecensa (alectinib) treatment (PMID: 31358542).	31358542
ALK	ALK rearrange ALK V1180L	lung non-small cell carcinoma	predicted - resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical study, ALK V1180L was identified in post-progression biopsies of 2 non-small cell lung cancer patients harboring an ALK rearrangement after Alecensa (alectinib) treatment (PMID: 29935304).	29935304
ALK	ALK rearrange ALK V1180L	lung non-small cell carcinoma	predicted - sensitive	Brigatinib	Case Reports/Case Series	Actionable	In a clinical study, Alunbrig (brigatinib) treatment resulted in 1 partial response and 1 stable disease in a total of 2 patients with Alecensa (alectinib)-refractory, ALK-rearranged non-small cell lung cancer with an acquired ALK V1180L (PMID: 29935304).	29935304
ALK	ALK rearrange ALK D1203N	lung non-small cell carcinoma	predicted - resistant	Lorlatinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK D1203N was identified in 24% (7/29) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received Lorbrena (lorlatinib) treatment (PMID: 31358542).	31358542
ALK	ALK rearrange ALK D1203N	lung non-small cell carcinoma	predicted - resistant	Brigatinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK D1203N was identified at disease progression while on Alunbrig (brigatinib) treatment in a patient with ALK-positive non-small cell lung cancer (PMID: 29935304).	29935304
ALK	ALK rearrange TP53 mut	lung non-small cell carcinoma	decreased response	Ceritinib	Clinical Study - Cohort	Actionable	In a clinical study, TP53 mutant ALK-rearranged non-small cell lung cancer patients demonstrated a lower median progression-free survival following treatment with Zykadia (ceritinib), Alecensa (alectinib), or Alunbrig (brigatinib) after Xalkori (crizotinib) vs. patients with wild-type TP53 (5.4 mo. vs. 9.9 mo.; p=0.039), and a lower median overall survival with treatment with Zykadia (ceritinib) after Xalkori (crizotinib) of 7.0 mo. vs. 50.0 mo. in patients with wild-type TP53 (p=0.001) (PMID: 30165392).	30165392
ALK	ALK rearrange TP53 mut	lung non-small cell carcinoma	decreased response	Crizotinib	Clinical Study - Cohort	Actionable	In a clinical study, TP53 mutant ALK-rearranged non-small cell lung cancer patients demonstrated a lower median progression-free survival following treatment with Xalkori (crizotinib) as a first line therapy or after chemotherapy vs. patients with wild-type TP53 (5.0 mo., n=22 vs. 14.0 mo., n=71; p<0.001), and a lower median overall survival (17.0 mo., n=13 vs. not reached n=50; p=0.049) (PMID: 30165392).	30165392
ALK	ALK rearrange TP53 mut	lung non-small cell carcinoma	decreased response	Alectinib	Clinical Study - Cohort	Actionable	In a clinical study, TP53 mutant ALK-rearranged non-small cell lung cancer patients demonstrated a lower median progression-free survival following treatment with Zykadia (ceritinib), Alecensa (alectinib), or Alunbrig (brigatinib) after Xalkori (crizotinib) vs. patients with wild-type TP53 (5.4 mo. vs. 9.9 mo.; p=0.039) (PMID: 30165392).	30165392
ALK	ALK rearrange TP53 mut	lung non-small cell carcinoma	decreased response	Brigatinib	Clinical Study - Cohort	Actionable	In a clinical study, TP53 mutant ALK-rearranged non-small cell lung cancer patients demonstrated a lower median progression-free survival following treatment with Zykadia (ceritinib), Alecensa (alectinib), or Alunbrig (brigatinib) after Xalkori (crizotinib) vs. patients with wild-type TP53 (5.4 mo. vs. 9.9 mo.; p=0.039) (PMID: 30165392).	30165392
ALK	ALK rearrange ALK F1174C	lung non-small cell carcinoma	predicted - resistant	Lorlatinib	Clinical Study - Cohort	Actionable	In a retrospective study, ALK F1174C/L was identified in 14% (4/29) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received Lorbrena (lorlatinib) treatment (PMID: 31358542).	31358542
ALK	ALK fusion	lung non-small cell carcinoma	sensitive	Brigatinib	FDA approved	Actionable	In a Phase II trial (ALTA) that supported FDA approval, Alunbrig (brigatinib) treatment resulted in an overall response rate of 45% (51/112) in the 90mg arm and 54% (59/110) in the 180mg arm, and median progression-free survival of 9.2 and 11.0 months respectively, in ALK-rearranged (fusion) non-small cell lung carcinoma patients who progressed on Xalkori (crizotinib) (PMID: 28475456; NCT02094573).	28475456 detail...
ALK	ALK fusion	lung non-small cell carcinoma	sensitive	Brigatinib	Phase Ib/II	Actionable	In a phase I/II clinical trial, Alunbrig (brigatinib) was determined to be safe and efficacious in patients with advanced, ALK-fusion positive NSCLC (PMID: 24091716).	24091716
ALK	ALK fusion	anaplastic large cell lymphoma	sensitive	Crizotinib	Phase Ib/II	Actionable	In a Phase Ib/II trial, treatment with Xalkori (crizotinib) resulted in an objective response rate of 83% (5/6, all complete responses), at the 165 mg dose, and 90% (18/20, with complete response in 80% (16/20), at the recommended phase 2 dose of 280 mg, in patients with anaplastic large cell lymphoma harboring an ALK fusion, with 72% of tested patients harboring NPM1-ALK (PMID: 28787259; NCT00939770).	28787259
ALK	ALK fusion	lung non-small cell carcinoma	sensitive	Ceritinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I trial that supported FDA approval, Zykadia (ceritinib) resulted in a blinded independent review committee (BIRC)-assessed objective response rate of 44% (72/163) and a duration of response of 7.1 months in ALK-rearranged non-small cell lung cancer patients (PMID: 25754348; NCT01283516).	detail... detail... 25754348
ALK	ALK fusion	lung non-small cell carcinoma	sensitive	Crizotinib	Guideline	Actionable	Xalkori (crizotinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring an ALK fusion (PMID: 30715168, PMID: 30285222; ESMO.org).	30285222 30715168 detail...
ALK	ALK fusion	lung non-small cell carcinoma	sensitive	Crizotinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (PROFILE 1014) that supported FDA approval, Xalkori (crizotinib) treatment resulted in improved progression-free survival (10.9 vs 7.0 months, HR=0.45, p<0.001) and objective response rate (74% vs 45%) relative to chemotherapy in NSCLC patients with ALK rearrangements (PMID: 25470694; NCT01154140).	25470694 detail... detail...
ALK	ALK fusion	lung non-small cell carcinoma	sensitive	Alectinib	Phase II	Actionable	In a Phase II trial, treatment with Alecensa (alectinib) resulted in a 49% (60/122) overall response rate in non-small cell lung cancer patients positive for an ALK fusion who had previously progressed on Xalkori (crizotinib) therapy (J Clin Oncol 33, 2015 (suppl; abstr 8008))	detail...
ALK	ALK fusion	lung non-small cell carcinoma	sensitive	Alectinib	Phase III	Actionable	In a Phase III trial, treatment with Alecensa (alectinib) resulted in improved progression-free survival compared to treatment with Xalkori (crizotinib) (HR=0.34) in ALK-positive non-small cell lung cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 9008)).	detail...
ALK	ALK fusion	lung non-small cell carcinoma	sensitive	Alectinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial supporting FDA approval (ALEX), Alecensa (alectinib) treatment resulted in improved rate of progression-free survival compared to Xalkori (crizotinib) (68.4% vs 48.7%, HR=0.47), and median progression-free survival (25.7 vs 10.4 months) in non-small cell lung cancer patients harboring ALK rearrangements (PMID: 28586279; NCT02075840).	detail... 28586279 detail...
ALK	ALK fusion	inflammatory myofibroblastic tumor	sensitive	Crizotinib	Guideline	Actionable	Xalkori (crizotinib) is included in guidelines for inflammatory myofibroblastic tumor patients with ALK translocations (NCCN.org).	detail...
ALK	ALK fusion	inflammatory myofibroblastic tumor	sensitive	Crizotinib	Phase Ib/II	Actionable	In a Phase Ib/II trial, treatment with Xalkori (crizotinib) resulted in an objective response rate of 86% (12/14), with complete response in 36% (5/14), in patients with inflammatory myofibroblastic tumor harboring an ALK fusion (PMID: 28787259; NCT00939770).	28787259
ALK	ALK fusion	Advanced Solid Tumor	predicted - sensitive	Repotrectinib	Phase I	Actionable	In a Phase I (TRIDENT-1) trial, Repotrectinib (TPX-0005) treatment resulted in stable disease in 25% (4/16) of patient with advanced solid tumor harboring ALK fusions who completed 2 cycles of treatment (J Clin Oncol 36, 2018 (suppl; abstr 2513); NCT03093116).	detail...
ALK	ALK fusion	colorectal cancer	sensitive	Entrectinib	Phase I	Actionable	In a Phase I clinical trial, Rozlytrek (entrectinib) treatment resulted in partial response for more than 3 months in a colorectal cancer patient harboring a CAD-ALK gene fusion (PMID: 26633560).	26633560
ALK	ALK fusion	lung non-small cell carcinoma	sensitive	Lorlatinib	FDA approved	Actionable	In a Phase II trial that supported FDA approval, Lorbrena (lorlatinib) treatment resulted in an objective response rate of 48% (97/198, 4% complete response, 44% partial response) in ALK positive (Alk rearrangements and fusions) non-small cell lung carcinoma patients received more than one prior Alk kinase inhibitor therapy, with an estimated median response duration of 12.5 months (J Clin Oncol, May 2018, 36(no. 15_suppl):9032-9032; NCT01970865).	detail... detail...
ALK	ALK fusion	lung non-small cell carcinoma	sensitive	Lorlatinib	Phase I	Actionable	In a Phase I trial, Lorlatinib (PF-06463922) demonstrated safety and resulted in a 50% (26/52) overall response rate in patients with ALK-positive or ROS1-positive non-small cell lung cancer, including intracranial responses in patients with CNS metastasis (J Clin Oncol 34, 2016 (suppl; abstr 9009)).	detail...
ALK	ALK fusion	inflammatory myofibroblastic tumor	sensitive	Ceritinib	Guideline	Actionable	Zykadia (ceritinib) is included in guidelines for inflammatory myofibroblastic tumor patients with ALK translocations (NCCN.org).	detail...
ALK	EML4-ALK ALK E1303K	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a patient with non-small cell lung cancer harboring EML4-ALK and ALK E1303K developed progressive disease 7 days after Xalkori (crizotinib) treatment (PMID: 29978950).	29978950
ALK	EML4-ALK ALK L1152P	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).	27780853
ALK	EML4-ALK ALK L1152P	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).	27780853
ALK	EML4-ALK ALK L1152P	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK L1152P in the context of EML4-ALK in culture (PMID: 27780853).	27780853
ALK	ALK R1192P	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing ALK R1192P was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).	27049722
ALK	EML4-ALK ALK R1192P	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK R1192P	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK R1192P	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells overexpressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK R1192P	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK R1192P	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK R1192P	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK R1192P	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK R1192P were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK R1192P	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK R1192P in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK R1192P	Advanced Solid Tumor	decreased response	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P had a reduced response to AZD3463 mediated growth inhibition in culture compared to cells expressing wild-type NPM1-ALK (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK R1192P	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Xalkori (Crizotinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK R1192P	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK R1192P	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK R1192P	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK L1198P	Advanced Solid Tumor	resistant	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing ALK L1198P in the context of EML4-ALK were resistant to TAE684 in culture (PMID: 21948233).	21948233
ALK	EML4-ALK ALK L1198P	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing ALK L1198P in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 21948233).	21948233
ALK	ALK Y1278S	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing ALK Y1278S was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).	27049722
ALK	ALK positive	neuroblastoma	sensitive	Entrectinib	Case Reports/Case Series	Actionable	In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in partial response in a patient with ALK-positive neuroblastoma (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)).	detail...
ALK	ALK positive	lung non-small cell carcinoma	sensitive	Ensartinib	Phase Ib/II	Actionable	Error	detail...
ALK	ALK positive	lung non-small cell carcinoma	sensitive	Entrectinib	Case Reports/Case Series	Actionable	In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in stable disease in a patient with ALK-positive non-small cell lung carcinoma (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)).	detail...
ALK	ALK positive	Advanced Solid Tumor	sensitive	Belizatinib	Phase Ib/II	Actionable	In a Phase I trial, Belizatinib (TSR-011) treatment resulted in a response in 100% (3/3) of patients with ALK positive advanced solid tumors when administered at higher doses, and stable disease for 7 months or longer in 56% (5/9) of patients at lower dose (J Clin Oncol 33, 2015 (suppl; abstr 8063)).	detail...
ALK	ALK positive	lung non-small cell carcinoma	sensitive	Belizatinib	Phase I	Actionable	In a Phase I clinical trial, Belizatinib (TSR-011) treatment resulted in a partial response in 60% (3/5) of non-small cell lung cancer patients positive for Alk (J Clin Oncol 32, 2014 (suppl; abstr e19005)).	detail...
ALK	ALK positive	lung non-small cell carcinoma	no benefit	Crizotinib + Onalespib	Phase II	Actionable	In a Phase II trial, Onalespib (AT13387) and Xalkori (crizotinib) combination treatment did not significantly improve median progression free survival (269 vs 266 days) or objective response rate (55.4%, 38/68 vs 45.3%, 31/68) compared to Xalkori (crizotinib) single treatment in ALK positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9059); NCT01712217).	detail...
ALK	NPM1-ALK ALK L1196Q	anaplastic large cell lymphoma	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing the crizotinib-resistant mutation ALK L1196Q in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK L1196Q	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing ALK L1196Q were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK C1156F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK C1156F in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to ASP3026 in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Alecensa (alectinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK C1156F	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156F were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to ASP3026 in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK C1156F ALK D1203N	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK C1156F and D1203N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with C1156F and D1203N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).	25749034
ALK	EML4-ALK ALK V1180L	lung non-small cell carcinoma	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis of non-small cell lung carcinoma cells harboring ALK V1180L in the context of EML4-ALK in culture (PMID: 26144315).	26144315
ALK	EML4-ALK ALK V1180L	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of a transformed cell line expressing EML4-ALK ALK V1180L in culture (PMID: 25228534).	25228534
ALK	EML4-ALK ALK V1180L	Advanced Solid Tumor	sensitive	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing ALK V1180L in the context of EML4-ALK in culture (PMID: 25228534).	25228534
ALK	EML4-ALK ALK V1180L	lung non-small cell carcinoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human non-small cell lung cancer cell line harboring ALK V1180L in the context of EML4-ALK was resistant to Xalkori (crizotinib) treatment in culture (PMID: 25228534).	25228534
ALK	EML4-ALK ALK V1180L	lung non-small cell carcinoma	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).	25228534
ALK	EML4-ALK ALK V1180L	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).	25228534
ALK	EML4-ALK ALK V1180L	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).	25228534
ALK	EML4-ALK ALK V1180L	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).	25228534
ALK	EML4-ALK ALK L1256F	lung adenocarcinoma	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorbrena (lorlatinib) did not inhibit Alk kinase activity or proliferation of lung adenocarcinoma cells expressing ALK L1256F in the context of EML4-ALK in cell culture (PMID: 30662002).	30662002
ALK	EML4-ALK ALK L1256F	lung adenocarcinoma	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited Alk kinase activity and proliferation of lung adenocarcinoma cells expressing ALK L1256F in the context of EML4-ALK in cell culture (PMID: 30662002).	30662002
ALK	ALK F1245V	neuroblastoma	predicted - sensitive	Entrectinib	Case Reports/Case Series	Actionable	In a clinical study, combined analysis of 2 Phase I trials showed Rozlytrek (entrectinib) treatment to result in a partial response that lasted 8.3 months in a patient with neuroblastoma harboring ALK F1245V, who remained on treatment for over 3.5 years due to clinical benefit (PMID: 28183697).	28183697
ALK	ALK amp	neuroblastoma	sensitive	CEP-28122	Preclinical - Cell culture	Actionable	In a preclinical study, CEP-28122 inhibited growth of ALK-amplified neuroblastoma cells in culture (PMID: 22203728).	22203728
ALK	ALK amp	neuroblastoma	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of ALK amplified neuroblastoma cells in culture (PMID: 26554404).	26554404
ALK	ALK amp	neuroblastoma	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) was less efficient than Lorlatinib (PF-06463922) to induced growth inhibition in ALK-amplified neuroblastoma cells in culture (PMID: 26554404).	26554404
ALK	NPM1-ALK amp	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to ASP3026 treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK amp	anaplastic large cell lymphoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK amp	anaplastic large cell lymphoma	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK amp	anaplastic large cell lymphoma	decreased response	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK demonstrated a decreased response compared to parental cell lines harboring NPM1-ALK when treated with Alecensa (alectinib) in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK amp	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).	25421750
ALK	ALK amp Tp53 wild-type	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in neuroblastoma cell lines harboring Alk amplification and functional TP53, resulting in growth inhibition in culture (PMID: 26438783).	26438783
ALK	ALK amp EML4-ALK EGFR L858R	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung cancer patient harboring EML4-ALK had a partial response to Xalkori (crizotinib) therapy, but progressed after four months, and was found to have acquired ALK amplification and EGFR L858R (PMID: 23344087).	23344087
ALK	EML4-ALK ALK F1174C	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).	27432227 26698910
ALK	EML4-ALK ALK F1174C	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C demonstrated decreased sensitivity to Alecensa (alectinib) in culture compared to cells expressing EML4-ALK with wild-type ALK (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).	27432227 26698910
ALK	EML4-ALK ALK F1174C	lung non-small cell carcinoma	resistant	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK who developed resistance to Xalkori (crizotinib) treatment was subsequently treated with Zykadia (ceritinib), eventually progressed, and was found to have acquired ALK F1174C (PMID: 24675041).	24675041
ALK	EML4-ALK ALK F1174C	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK F1174C	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) modestly inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK F1174C	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition by Alecensa (alectinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C did not response to treatment with Alecensa (alectinib) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Alunbrig (brigatinib) when compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	decreased response	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Lorlatinib (PF-06463922) in culture compared to cells expressing wild-type EML4-ALK (PMID: 27432227).	27432227
ALK	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).	27432227
ALK	NPM1-ALK ALK P1139S	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK P1139S in the context of NPM1-ALK in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK P1139S	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK P1139S	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK P1139S	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK P1139S	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).	25421750
ALK	EML4-ALK ALK T1151M	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK T1151M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to ASP3026 in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK T1151M	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK T1151M	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK T1151M	lung adenocarcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK T1151M was identified in the post-progression biopsy of a patient with lung adenocarcinoma harboring EML4-ALK after Xalkori (crizotinib) and Zykadia (ceritinib) therapies (PMID: 28676215).	28676215
ALK	EML4-ALK ALK T1151M	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK T1151M	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK T1151M	lung adenocarcinoma	predicted - resistant	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK T1151M was identified in the post-progression biopsy of a patient with lung adenocarcinoma harboring EML4-ALK after Xalkori (crizotinib) and Zykadia (ceritinib) therapies (PMID: 28676215).	28676215
ALK	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Alunbrig (brigatinib)-mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).	27009859
ALK	NPM1-ALK ALK T1151M	anaplastic large cell lymphoma	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).	27009859
ALK	EML4-ALK ALK D1203N	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK D1203N	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alunbrig (brigatinib) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK D1203N	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK D1203N	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK D1203N	Advanced Solid Tumor	resistant	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing ALK D1203N in the context of EML4-ALK were resistant to TAE684 in culture (PMID: 21948233).	21948233
ALK	EML4-ALK ALK D1203N	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).	27432227
ALK	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Alecensa (alectinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK G1128S	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK G1128S in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK G1128S	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1128S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to ASP3026 in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).	25749034
ALK	ALK act mut TP53 wild-type	neuroblastoma	predicted - sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to delay tumor growth in xenograft models of a human neuroblastoma cell line harboring constitutively phosphorylated wild-type Alk and wild-type TP53 (PMID: 26438783).	26438783
ALK	NPM1-ALK ALK L1122V	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1122V	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1122V	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1122V	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to ASP3026 treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK N1178H	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK N1178H were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK N1178H	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK N1178H	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK N1178H	Advanced Solid Tumor	decreased response	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to ASP3026 in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK N1178H	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK N1178H	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK N1178H	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034).	25749034
ALK	ALK I1171T	ganglioneuroblastoma	predicted - sensitive	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, Zykadia (ceritinib) treatment resulted in a 43.6% decrease of the primary tumor after 6.5 months of treatment, and complete resolution of metastases at 21 months after initiation of treatment in a pediatric patient with ganglioneuroblastoma (PMID: 29907598).	29907598
ALK	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK I1171T	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, an anaplastic large-cell lymphoma cell line expressing ALK I1171T in the context of NPM1-ALK demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 24509625).	24509625
ALK	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Alecensa (alectinib) in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK I1171T	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171T were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
ALK	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to ASP3026 in culture (PMID: 25749034).	25749034
ALK	EML4-ALK ALK I1171T	Advanced Solid Tumor	sensitive	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK I1171T in culture (PMID: 25228534).	25228534
ALK	EML4-ALK ALK I1171T	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to ASP3026 treatment in culture (PMID: 25228534).	25228534
ALK	EML4-ALK ALK I1171T	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated a partial response with Xalkori (crizotinib) treatment, but after eight months showed progression, and was found to harbor a secondary resistance mutation, ALK I1171T (PMID: 25393798).	25393798
ALK	EML4-ALK ALK I1171T	lung non-small cell carcinoma	sensitive	Lorlatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell growth in patient derived non-small cell lung cancer cells harboring ALK I1171T in the context of EML4-ALK in culture (PMID: 26144315).	26144315
ALK	EML4-ALK ALK I1171T	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK I1171T in culture (PMID: 25228534).	25228534
ALK	EML4-ALK ALK I1171T	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK I1171T	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of a transformed cell line expressing ALK I1171T in the context of EML4-ALK but to a lesser degree than cells expressing EML4-ALK in culture (PMID: 25228534).	25228534
ALK	EML4-ALK ALK I1171T	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534), however, another study with comparable cells demonstrated sensitivity in culture (PMID: 27432227).	25228534 27432227
ALK	EML4-ALK ALK I1171T	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
ALK	EML4-ALK ALK T1151dup	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK T1151dup (referred to as 1151insT) in culture and in xenograft models (PMID: 24887559).	24887559
ALK	EML4-ALK ALK T1151dup	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK T1151dup in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).	22277784
ALK	EML4-ALK ALK T1151dup	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK T1151dup in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).	27780853
ALK	EML4-ALK ALK T1151dup	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK T1151dup in the context of EML4-ALK in culture (PMID: 27780853).	27780853
ALK	NPM1-ALK ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1198F	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1198F in culture (PMID: 25421750).	25421750
ALK	NPM1-ALK ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).	25421750
ALK	EML4-ALK ALK L1198F	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1198F	Advanced Solid Tumor	decreased response	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with L1198F had reduced sensitivity to growth inhibition mediated by Lorlatinib (PF-06463922) in comparison to EML4-ALK wild type in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).	26698910
ALK	EML4-ALK ALK L1198F	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).	27432227 26698910
ALK	EML4-ALK ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing L1198F in the context of EML4-ALK in culture (PMID: 26698910).	26698910
APC	APC L852*	colorectal cancer	predicted - resistant	G007-LK	Preclinical	Actionable	In a preclinical study, G007-LK treatment did not alter gene expression pattern or affect growth in intestinal organoids established from mouse models of colorectal cancer driven by APC L850* (corresponding to L852* in human), and had no effect on tumor cell growth and differentiation in APC L850* mouse models (PMID: 31337618).	31337618
APC	APC wild-type	colorectal cancer	resistant	TASIN-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TASIN-1 did not inhibit survival of APC wild-type colorectal cancer cells in culture or in cell line xenograft models (PMID: 27798265).	27798265
APC	APC wild-type CTNNB1 wild-type	colon cancer	predicted - sensitive	Vantictumab	Preclinical - Pdx	Actionable	In a preclinical study, Vantictumab (OMP-18R5) inhibited tumor growth in patient-derived xenograft models of colon cancer with wild-type CTNNB1 (beta-catenin) and APC (PMID: 22753465).	22753465
APC	APC N1819fs APC wild-type	colorectal cancer	resistant	XAV939	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481).	28179481
APC	APC N1819fs APC wild-type	colorectal cancer	resistant	G007-LK	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481).	28179481
APC	APC Q1131* APC Q1303*	colorectal cancer	sensitive	TASIN-1	Preclinical - Cell culture	Actionable	In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cells harboring APC Q1131* and Q1303* in culture (PMID: 27798265).	27798265
APC	APC mutant	medulloblastoma	not applicable	N/A	Guideline	Prognostic	WNT-driven medulloblastomas, characterized by CTNNB1 or APC mutations, are associated with favorable prognosis (NCCN.org).	detail...
APC	APC mutant	colorectal cancer	no benefit	G-631	Preclinical - Cell line xenograft	Actionable	In a preclinical study, G-631 inhibited Wnt pathway signaling in colorectal cancer cell line xenograft models harboring an APC mutation, but demonstrated little anti-tumor activity and led to intestinal toxicity (PMID: 26692561).	26692561
APC	APC mutant	colorectal cancer	sensitive	JW74	Preclinical	Actionable	In a preclinical study, JW74 reduced tumor formation and growth in a mouse model of colorectal cancer harboring an APC mutation (PMID: 21199802).	21199802
APC	APC mutant	small intestine adenocarcinoma	not applicable	N/A	Guideline	Actionable	Familial adenomatous polyposis results from germline mutations in the APC gene, and is associated with increased risk of developing small bowel adenocarcinoma (NCCN.org).	detail...
APC	APC mutant	colon adenoma	predicted - sensitive	TetMYB	Preclinical	Actionable	In a preclinical study, TetMYB treatment resulted in improved median survival compared to control (356 vs 183 days) in APC-driven mouse models of colon adenoma (Gastroenterology, Volume 154, Issue 6, Supplement 1, May 2018, Pages S-1269).	detail...
APC	APC mutant	colorectal cancer	predicted - sensitive	K-756	Preclinical	Actionable	In a preclinical study, K-756 inhibited Wnt signaling and reduced growth of 2/3 tested APC-mutant colorectal cancer cell lines in culture (PMID: 27196752).	27196752
APC	APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut	colorectal cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369).	25261369
APC	APC L665* APC R1450*	colorectal cancer	sensitive	IWR-1	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481).	28179481
APC	APC L665* APC R1450*	colorectal cancer	sensitive	XAV939	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481).	28179481
APC	APC L665* APC R1450*	colorectal cancer	resistant	G007-LK	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481).	28179481
APC	APC E853* APC T1556fs	colorectal cancer	resistant	XAV939	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs (reported as APC T1556fs*3) demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481).	28179481
APC	APC E853* APC T1556fs	colorectal cancer	resistant	G007-LK	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs (reported as APC T1556fs*3) demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481).	28179481
APC	APC E853* APC T1556fs	colorectal cancer	resistant	IWR-1	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs (reported as APC T1556fs*3) demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481).	28179481
APC	APC S811*	colorectal cancer	sensitive	G007-LK	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with G007-LK decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481).	28179481
APC	APC S811*	colorectal cancer	sensitive	IWR-1	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with IWR-1 decreased active beta-catenin levels and reduced growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481).	28179481
APC	APC S811*	colorectal cancer	sensitive	XAV939	Preclinical - Cell culture	Actionable	In a preclinical study, XAV939 inhibited growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481).	28179481
APC	APC N1819fs	colorectal cancer	resistant	IWR-1	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line harboring APC N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481).	28179481
APC	APC Q1406*	colorectal cancer	predicted - sensitive	NVP-TNKS656	Preclinical	Actionable	In a preclinical study, NVP-TNKS656 treatment inhibited growth of mouse intestinal organoids expressing APC Q1045* (corresponding to Q1046* in human) in culture (PMID: 31337618).	31337618
APC	APC Q1406*	colorectal cancer	predicted - sensitive	XAV939	Preclinical	Actionable	In a preclinical study, XAV939 treatment inhibited growth of mouse intestinal organoids expressing APC Q1045* (corresponding to Q1046* in human) in culture (PMID: 31337618).	31337618
APC	APC Q1406*	colorectal cancer	predicted - sensitive	G007-LK	Preclinical	Actionable	In a preclinical study, G007-LK treatment altered gene expression pattern and inhibited growth of mouse intestinal organoids expressing APC Q1045* (corresponding to Q1046* in human) in culture (PMID: 31337618).	31337618
APC	APC W553*	colorectal cancer	sensitive	IWR-1	Preclinical - Cell culture	Actionable	In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC W553* in culture (PMID: 28179481).	28179481
APC	APC W553*	colorectal cancer	sensitive	G007-LK	Preclinical - Cell culture	Actionable	In a preclinical study, G007-LK inhibited growth of a patient-derived colorectal cancer cell line harboring APC W553* in culture (PMID: 28179481).	28179481
APC	APC Q1338*	colorectal cancer	sensitive	TASIN-1	Preclinical - Cell culture	Actionable	In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cell lines harboring APC Q1338* in culture (PMID: 27798265).	27798265
APC	APC Q1338*	colorectal cancer	sensitive	JW67	Preclinical	Actionable	In a preclinical study, JW67 inhibited Wnt signaling and decreased proliferation of colorectal cancer cells harboring APC Q1338* in culture (PMID: 21199802).	21199802
APC	APC Q1338*	colorectal cancer	sensitive	JW74	Preclinical	Actionable	In a preclinical study, JW74 inhibited Wnt signaling and decreased growth of colorectal cancer cells harboring APC Q1338* in culture and in xenograft models (PMID: 21199802).	21199802
APC	APC E582fs	colorectal cancer	predicted - resistant	G007-LK	Preclinical	Actionable	In a preclinical study, G007-LK treatment did not inhibited growth of mouse intestinal organoids expressing APC E580fs (corresponding to E582fs in human) in culture (PMID: 31337618).	31337618
APC	APC Q886*	colorectal cancer	predicted - resistant	XAV939	Preclinical	Actionable	In a preclinical study, XAV939 treatment did not affect growth of mouse intestinal organoids expressing APC Q884* (corresponding to Q886* in human) in culture (PMID: 31337618).	31337618
APC	APC Q886*	colorectal cancer	predicted - resistant	NVP-TNKS656	Preclinical	Actionable	In a preclinical study, NVP-TNKS656 treatment did not affect growth of mouse intestinal organoids expressing APC Q884* (corresponding to Q886* in human) in culture (PMID: 31337618).	31337618
APC	APC Q886*	colorectal cancer	predicted - resistant	G007-LK	Preclinical	Actionable	In a preclinical study, G007-LK treatment did not alter gene expression pattern or affect growth in mouse intestinal organoids expressing APC Q884* (corresponding to Q886* in human) in culture (PMID: 31337618).	31337618
APC	APC E1309*	colorectal cancer	sensitive	TASIN-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cells harboring APC E1309* in culture and in cell line xenograft models (PMID: 27798265).	27798265
APC	APC inact mut	colon cancer	sensitive	iCRT-5	Preclinical	Actionable	In a preclinical study, iCRT-5 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571).	21393571
APC	APC inact mut	colon carcinoma	sensitive	FH535	Preclinical	Actionable	In a preclinical study, FH535 inhibited beta-catenin/TCF-dependent transactivation and demonstrated toxicity in colon carcinoma cells harboring an APC mutation in culture (PMID: 18347139).	18347139
APC	APC inact mut	colon cancer	sensitive	StAx-35	Preclinical	Actionable	In a preclinical study, StAx-35 inhibited proliferation of colon cancer cell lines carrying APC deletions in culture (PMID: 23071338).	23071338
APC	APC inact mut	colon cancer	sensitive	JW55	Preclinical	Actionable	In a preclinical study, JW55 inhibited proliferation of colorectal cancer cells with an APC truncation mutation in culture and decreased tumor development in a mouse model expressing a conditional APC truncation mutation (PMID: 22440753).	22440753
APC	APC inact mut	colorectal cancer	sensitive	Pyrvinium	Preclinical	Actionable	In a preclinical study, Pyrvinium inhibited Wnt signaling and decreased viability of colon cancer cells harboring APC mutations in culture (PMID: 20890287).	20890287
APC	APC inact mut	colorectal cancer	sensitive	Sulindac	Preclinical	Actionable	In a preclinical study, colorectal cancer mouse models carrying APC inactivating mutations had reduced intestinal tumor burden after treatment with Clinoril (sulindac) (PMID: 19755659).	19755659
APC	APC inact mut	colorectal cancer	sensitive	NC043	Preclinical - Cell line xenograft	Actionable	In a preclinical study, NC043 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 21321609).	21321609
APC	APC inact mut	colorectal cancer	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, the combination of Sprycel (dasatinib) and curcumin inhibited tumor growth in a mouse model of colorectal cancer harboring an Apc mutation (PMID: 20473900).	20473900
APC	APC inact mut	colon cancer	sensitive	MF tricyclic	Preclinical	Actionable	In a preclinical study, mouse models of colon cancer carrying an APC 716del mutation had reduced polyp formation after treatment with MF tricyclic (PMID: 23843721).	23843721
APC	APC inact mut	colorectal cancer	sensitive	TASIN-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 27798265).	27798265
APC	APC inact mut	colorectal cancer	sensitive	CCT036477	Preclinical	Actionable	In a preclinical study, CCT036477 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).	20610623
APC	APC inact mut	colon cancer	sensitive	iCRT-14	Preclinical - Cell line xenograft	Actionable	In a preclinical study, iCRT-14 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture and decreased initial tumor growth in APC-mutant colon cancer cell line xenograft models (PMID: 21393571).	21393571
APC	APC inact mut	colorectal cancer	sensitive	CCT070535	Preclinical	Actionable	In a preclinical study, CCT070535 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).	20610623
APC	APC inact mut	colorectal cancer	sensitive	Erlotinib + Ibuprofen	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ibuprofen, in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in cell line xenograft models of colorectal cancer (PMID: 17909047).	17909047
APC	APC inact mut	colorectal cancer	sensitive	CCT031374	Preclinical	Actionable	In a preclinical study, CCT031374 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).	20610623
APC	APC inact mut	prostate cancer	decreased response	Abiraterone	Clinical Study	Actionable	In a clinical study, metastatic castrate-resistant prostate cancer patients harboring a Wnt pathway activating alteration (CTNNB1 activating mutation, or APC or RNF43 inactivating mutation) demonstrated shorter median overall survival (23.6 mo vs 27.7 mo) and median time to PSA progression (6.5 mo vs 9.6 mo) compared to patients without Wnt pathway alterations, and APC or RNF43 inactivating mutations were independently associated with increased hazard of PSA progression (aHR 1.83; p=0.004) (PMID: 31176623).	31176623
APC	APC inact mut	colorectal cancer	sensitive	Celecoxib + Erlotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Celebra (celecoxib), in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in human colorectal cancer cell line xenograft models (PMID: 17909047).	17909047
APC	APC inact mut	colon cancer	sensitive	G007-LK	Preclinical - Cell line xenograft	Actionable	In a preclinical study, G007-LK inhibited growth of APC-mutant colorectal cancer cell lines in culture and in xenograft models (PMID: 23539443).	23539443
APC	APC inact mut	colon cancer	sensitive	ICG-001	Preclinical	Actionable	In a preclinical study, ICG-001 decreased cell proliferation in colon cancer cell lines and in mouse models carrying APC inactivating mutations (PMID: 15314234).	15314234
APC	APC inact mut	colorectal cancer	sensitive	PKF118-310	Preclinical	Actionable	In a preclinical study, PKF118-310 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).	14749129
APC	APC inact mut	colorectal cancer	sensitive	XAV939	Preclinical	Actionable	In a preclinical study, XAV939 inhibited growth of colorectal cancer cells harboring APC inactivating mutations in culture (PMID: 19759537).	19759537
APC	APC inact mut	colon cancer	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) reduced the number of dextran sodium sulfate-induced tumors in an APC-deficient mouse model for colon cancer (PMID: 20811697).	20811697
APC	APC inact mut	colon cancer	sensitive	Sirolimus	Preclinical	Actionable	In preclinical trials, Sirolimus (rapamycin) was shown effective in reducing tumors in mouse models of familial adenomatous polyposis and colon cancer with APC deficient tumors (PMID: 18768809, PMID: 20080688).	18768809 20080688
APC	APC inact mut	prostate cancer	decreased response	Enzalutamide	Clinical Study	Actionable	In a clinical study, metastatic castrate-resistant prostate cancer patients harboring a Wnt pathway activating alteration (CTNNB1 activating mutation, or APC or RNF43 inactivating mutation) demonstrated shorter median overall survival (23.6 mo vs 27.7 mo) and median time to PSA progression (6.5 mo vs 9.6 mo) compared to patients without Wnt pathway alterations, and APC or RNF43 inactivating mutations were independently associated with increased hazard of PSA progression (aHR 1.83; p=0.004) (PMID: 31176623).	31176623
APC	APC inact mut	colon cancer	sensitive	CGP049090	Preclinical	Actionable	In a preclinical study, CGP049090 inhibited proliferation of a colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).	14749129
APC	APC inact mut	colon cancer	sensitive	Vinorelbine	Preclinical	Actionable	In preclinical studies, cells deficient in Apc protein had increased sensitivity to Navelbine (vinorelbine) compared to wild-type cells, and Navelbine (vinorelbine) treament decreased adenoma size in an Apc-deficient mouse model (PMID: 22399804).	22399804
APC	APC inact mut	colon cancer	sensitive	iCRT-3	Preclinical	Actionable	In a preclinical study, iCRT-3 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571).	21393571
APC	APC inact mut	colorectal cancer	sensitive	Celecoxib	Preclinical	Actionable	In a preclinical study, APC inactivating mutant mouse models of colon cancer had reduced polyp formation after treatment with Celebra (celecoxib) (PMID: 17909047).	17909047
APC	APC inact mut	colorectal cancer	sensitive	Niclosamide	Preclinical	Actionable	In a preclinical study, Niclosamide inhibited proliferation of colorectal cancer cells harboring APC mutations in culture (PMID: 21531761).	21531761
APC	APC inact mut	colon cancer	sensitive	PKF115-584	Preclinical	Actionable	In a preclinical study, PKF115-584 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).	14749129
APC	APC inact mut PTEN inact mut	colorectal cancer	no benefit	BEZ235 + Binimetinib	Preclinical	Actionable	In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) did not improve survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).	26206338
APC	APC inact mut PTEN inact mut	colorectal cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).	26206338
APC	APC inact mut PTEN inact mut	colorectal cancer	no benefit	Binimetinib	Preclinical	Actionable	In a preclinical study, Binimetinib (MEK162) reduced proliferation in tumors acutely but did not improve survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).	26206338
APC	APC E853* APC K1555*	colorectal cancer	sensitive	TASIN-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cells harboring APC E853* and K1555* in culture and in cell line xenograft models (PMID: 27798265).	27798265
APC	APC dec exp	colorectal cancer	predicted - sensitive	G007-LK	Preclinical	Actionable	In a preclinical study, G007-LK treatment altered gene expression pattern and induced growth arrest in intestinal organoids established from mouse models of colorectal cancer driven by APC knockdown, decreased proliferation and promoted differentiation in APC knockdown mouse models (PMID: 31337618).	31337618
APC	APC Q1429fs BRAF N581S ERBB2 L755S	rectum adenocarcinoma	no benefit	Fluorouracil + Leucovorin + Trastuzumab	Case Reports/Case Series	Actionable	In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067).	27626067
APC	APC S1197* APC S1278*	colorectal cancer	sensitive	IWR-1	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with IWR-1 decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481).	28179481
APC	APC S1197* APC S1278*	colorectal cancer	sensitive	XAV939	Preclinical - Cell culture	Actionable	In a preclinical study, XAV939 inhibited growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481).	28179481
APC	APC S1197* APC S1278*	colorectal cancer	sensitive	G007-LK	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with G007-LK decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481).	28179481
APC	APC L1488*	colorectal cancer	sensitive	TASIN-1	Preclinical - Cell culture	Actionable	In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cells harboring APC L1488* in culture (PMID: 27798265).	27798265
APC	APC I1164fs	colorectal cancer	sensitive	IWR-1	Preclinical - Cell culture	Actionable	In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC I1164fs in culture (PMID: 28179481).	28179481
APC	APC I1164fs	colorectal cancer	sensitive	G007-LK	Preclinical - Patient cell culture	Actionable	In a preclinical study, G007-LK inhibited growth of a patient-derived colorectal cancer cell line harboring APC I1164fs in culture (PMID: 28179481).	28179481
APC	APC R216*	colorectal cancer	sensitive	IWR-1	Preclinical - Cell culture	Actionable	In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC R216* in culture (PMID: 28179481).	28179481
APC	APC R216*	colorectal cancer	sensitive	G007-LK	Preclinical - Cell culture	Actionable	In a preclinical study, a patient-derived colorectal cancer cell line harboring APC R216* demonstrated sensitivity to G007-LK in culture (PMID: 28179481).	28179481
APC	APC G1416*	colorectal cancer	sensitive	TASIN-1	Preclinical - Cell culture	Actionable	In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cell lines harboring APC G11416* in culture (PMID: 27798265).	27798265
ARID1A	ARID1A Q456*	colorectal cancer	sensitive	Talazoparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Talazoparib (BMN-673) inhibited colony formation and proliferation of a human colorectal cancer cell line harboring ARID1A Q456* in culture and inhibited tumor formation in colorectal cancer xenografts harboring ARID1A Q456* (PMID: 26069190).	26069190
ARID1A	ARID1A Q456*	colorectal cancer	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a colorectal cancer cell line homozygously expressing ARID1A Q456* demonstrated sensitivity to treatment with Sprycel (dasatinib) in culture (PMID: 27364904).	27364904
ARID1A	ARID1A Q456*	colorectal cancer	sensitive	Olaparib	Preclinical	Actionable	In a preclinical study, Lynparza (olaparib) inhibited proliferation and colony formation of a colorectal cancer cell line harboring ARID1A Q456* in culture (PMID: 26069190).	26069190
ARID1A	ARID1A Q456*	colorectal cancer	sensitive	VE-821	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells homozygous for ARID1A Q456* were sensitive to VE-821 in in vitro assays, demonstrating decrease cell survival (PMID: 27958275).	27958275
ARID1A	ARID1A Q456*	colorectal cancer	sensitive	VX-970	Preclinical - Cell line xenograft	Actionable	In a preclinical study, VX-970 treatment in colorectal cancer cells homozygous for ARID1A Q456* resulted in decreased cell survival in culture, and tumor growth inhibition in cell line xenograft models (PMID: 27958275).	27958275
ARID1A	ARID1A Q456*	colorectal cancer	sensitive	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Rubraca (rucaparib) treatment resulted in increased apoptosis of colorectal cancer cells harboring ARID1A Q456* in culture (PMID: 26069190).	26069190
ARID1A	ARID1A loss	ovarian clear cell carcinoma	predicted - sensitive	JQ1	Preclinical - Cell culture	Actionable	In a preclinical study, knockout of ARID1A in ovarian clear cell carcinoma cell lines resulted in increased sensitivity to growth inhibition by JQ1 compared to cells with wild-type ARID1A in culture (PMID: 29760405).	29760405
ARID1A	ARID1A loss	ovarian cancer	predicted - sensitive	unspecified PD-L1 antibody	Preclinical	Actionable	In a preclinical study, an ARID1A-deficient orthotopic ovarian cancer mouse model treated with a PD-L1 antibody demonstrated improved survival and greater decreased tumor volume compared to those treated with control (PMID: 29736026).	29736026
ARID1A	ARID1A loss	colon cancer	predicted - sensitive	unspecified PD-L1 antibody	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ARID1A-deficient colon cancer xenograft models demonstrated an increased response to treatment with an anti-PD-L1 antibody compared to controls (PMID: 29736026).	29736026
ARID1A	ARID1A loss	Her2-receptor positive breast cancer	resistant	AZD8055	Preclinical - Cell culture	Actionable	In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to AZD8055 in culture (PMID: 27172896).	27172896
ARID1A	ARID1A loss	Her2-receptor positive breast cancer	resistant	Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to Herceptin (trastuzumab) in culture (PMID: 27172896).	27172896
ARID1A	ARID1A loss	breast cancer	sensitive	AZD8055 + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells with loss of ARID1A demonstrated restored sensitivity to AZD8055 when additionally treated with MK2206 in culture (PMID: 27172896).	27172896
ARID1A	ARID1A loss ERBB2 amp	breast cancer	sensitive	MK2206 + Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line with ARID1A loss and harboring ERBB2 (HER2) amplification demonstrated restored sensitivity to Herceptin (trastuzumab) when additionally treated with MK2206 in culture (PMID: 27172896).	27172896
ARID1A	ARID1A dec exp	breast cancer	sensitive	Veliparib	Preclinical - Cell culture	Actionable	In a preclinical study, Veliparib (ABT-888) inhibited colony formation of human mammary epithelial cells and inhibited proliferation of a human breast cancer cell line after knockdown of ARID1A in culture (PMID: 26069190).	26069190
ARID1A	ARID1A dec exp	ovarian cancer	predicted - sensitive	Buthionine sulfoximine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ovarian cancer cells with ARID1A-deficiency via knockdown were sensitive to treatment with Buthionine sulfoximine (BSO), demonstrating decreased cell survival and reduced colony formation in culture and tumor growth suppression in cell-line xenograft models (PMID: 30686770).	30686770
ARID1A	ARID1A dec exp	breast cancer	sensitive	Olaparib	Preclinical	Actionable	In a preclinical study, Lynparza (olaparib) inhibited colony formation of human mammary epithelial cells and inhibited proliferation of a human breast cancer cell line after knockdown of ARID1A in culture (PMID: 26069190).	26069190
ARID1A	ARID1A dec exp	ovarian cancer	sensitive	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 inhibited growth of ovarian cancer cells with knockdown of ARID1A expression in culture (PMID: 25686104).	25686104
ARID1A	ARID1A dec exp	breast cancer	sensitive	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Rubraca (rucaparib) inhibited colony formation of human mammary epithelial cells and inhibited proliferation of a human breast cancer cell line after knockdown of ARID1A in culture (PMID: 26069190).	26069190
ARID1A	ARID1A dec exp	breast cancer	conflicting	Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, human mammary epithelial cells with knockdown of ARID1A demonstrated resistance to Talazoparib (BMN673) when compared to parental cells in culture (PMID: 29669295).	29669295
ARID1A	ARID1A dec exp	breast cancer	conflicting	Talazoparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Talazoparib (BMN-673) selectively inhibited growth and induced apoptosis in breast cancer cells with knock-down of ARID1A in culture, and inhibited tumor growth in ARID1A-deficient breast cancer cell line xenograft models (PMID: 26069190).	26069190
ARID1A	ARID1A dec exp	ovarian cancer	sensitive	Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, knockdown of ARID1A resulted in increased sensitivity to Talazoparib (BMN-673) in ovarian cancer cells in culture (PMID: 26069190).	26069190
ARID1A	ARID1A dec exp	ovarian clear cell carcinoma	predicted - sensitive	GSK525762	Preclinical - Cell culture	Actionable	In a preclinical study, knockdown of ARID1A resulted in increased sensitivity to Molibresib (GSK525762) in ovarian clear cell carcinoma cell lines in culture (PMID: 29760405).	29760405
ARID1A	ARID1A dec exp	ovarian cancer	predicted - sensitive	APR-246	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ovarian cancer cells with ARID1A-deficiency via knockdown were sensitive to treatment with APR-246, demonstrating decreased cell survival and reduced colony formation in culture and tumor growth suppression in cell-line xenograft models (PMID: 30686770).	30686770
ARID1A	ARID1A wild-type	ovarian cancer	no benefit	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 had no significant effect on the growth of ovarian cancer cells with wild-type ARID1A in culture (PMID: 25686104).	25686104
ARID1A	ARID1A Q1148*	ovarian clear cell carcinoma	predicted - sensitive	JQ1	Preclinical - Pdx	Actionable	In a preclinical study, JQ1 inhibited tumor growth in an ovarian clear cell carcinoma patient-derived xenograft (PDX) model harboring ARID1A Q1148*, but did not inhibit growth in a model with wild-type ARID1A (PMID: 29760405).	29760405
ARID1A	ARID1A mutant	ovarian clear cell carcinoma	sensitive	Dasatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sprycel (dasatinib) resulted in decreased cell growth of ovarian clear cell carcinoma (OCCC) cells harboring an ARID1A mutation in culture and anti-tumor activity in cell line xenograft models of OCCC (PMID: 27364904).	27364904
ARID1A	ARID1A mutant	ovarian cancer	sensitive	UNC1999	Preclinical - Cell culture	Actionable	In a preclinical study, UNC1999 inhibited growth of ovarian cancer cell lines harboring ARID1A mutations in culture (PMID: 25686104).	25686104
ARID1A	ARID1A mutant	ovarian cancer	sensitive	GSK126	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GSK126 selectively inhibited growth of ARID1A-mutant ovarian cancer cells in culture, and induced tumor regression in ARID1A-mutant ovarian cancer xenograft models (PMID: 25686104).	25686104
ARID1A	ARID1A mutant	renal cell carcinoma	predicted - sensitive	Bevacizumab + Everolimus	Phase II	Actionable	In a Phase II trial, 100% (5/5) of renal cell carcinoma patients harboring ARID1A mutations achieved the primary endpoint of 6 month PFS when treated with the combination therapy Afinitor (everolimus) and Avastin (bevacizumab) (PMID: 27601542).	27601542
ARID1A	ARID1A mutant	ovarian clear cell carcinoma	sensitive	VE-821	Preclinical - Cell culture	Actionable	In a preclinical study, ovarian clear cell carcinoma cells harboring an ARID1A mutation were sensitive to VE-821 in in vitro assays, demonstrating decreased cell survival (PMID: 27958275).	27958275
ARID1A	ARID1A mutant	ovarian clear cell carcinoma	sensitive	VX-970	Preclinical - Cell line xenograft	Actionable	In a preclinical study, VX-970 treatment in ovarian clear cell carcinoma cells harboring an ARID1A mutation resulted in decreased cell survival and induction of DNA damage and apoptosis in culture, and tumor growth inhibition in cell line xenograft models (PMID: 27958275).	27958275
ARID1A	ARID1A mut PIK3CA act mut	ovarian cancer	sensitive	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, expression of a constitutively active PIK3CA mutation in ARID1A-mutant ovarian cancer cell lines enhanced growth inhibition by GSK126 in culture (PMID: 25686104).	25686104
ARID1A	ARID1A negative	ovarian clear cell carcinoma	predicted - sensitive	ENMD-2076	Phase II	Actionable	In a Phase II trial, ENMD-2076 treatment resulted a median progression-free survival (PFS) of 4.4 months in patients with ARIDA1A-negative recurrent ovarian clear cell carcinoma and a median PFS of 3.6 months in ARID1A-positive patients, with a statistically significant difference in estimated 6-month PFS rate (0.33 vs 0.12, p=0.023) (PMID: 30108107).	30108107
ASXL1	ASXL1 mutant	myelofibrosis	not applicable	N/A	Guideline	Prognostic	ASXL1 mutations are associated with inferior overall survival and leukemia-free survival in patients with myelofibrosis (NCCN.org).	detail...
ASXL1	ASXL1 mutant	acute myeloid leukemia	predicted - sensitive	CG-806	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived acute myeloid leukemia cells harboring ASXL1 mutations were sensitive to CG-806 in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1323).	detail...
ASXL1	ASXL1 mutant	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	ASXL1 mutations are associated with a poor/adverse prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).	detail...
ASXL1	ASXL1 mutant	chronic myelomonocytic leukemia	not applicable	N/A	Guideline	Prognostic	ASXL1 mutations are associated with a poor prognosis in patients with chronic myelomonocytic leukemia (NCCN.org).	detail...
ASXL1	ASXL1 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	ASXL1 mutations are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
ASXL1	ASXL1 mutant	myelodysplastic syndrome	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, mutations in ASXL1 were associated with poor prognosis in patients with myelodysplastic syndrome (PMID: 24220272, PMID: 21714648).	24220272 21714648
ASXL1	ASXL1 mutant	acute myeloid leukemia	predicted - resistant	Sunitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived acute myeloid leukemia cells harboring ASXL1 mutations were resistant to Sutent (sunitinib) in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1323).	detail...
ASXL1	ASXL1 mutant	polycythemia vera	not applicable	N/A	Guideline	Prognostic	ASXL1 mutations are associated with inferior overall survival in patients with polycythemia vera (NCCN.org).	detail...
ASXL1	ASXL1 mut CALR wild-type	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of an ASXL1 mutation combined with wild-type CALR is associated with shorter survival in patients with myelofibrosis (NCCN.org).	detail...
ASXL1	ASXL1 mut CALR mut	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of a CALR mutation combined with an ASXL1 mutation is associated with intermediate survival in patients with myelofibrosis (NCCN.org).	detail...
ASXL1	ASXL1 wild-type TET2 mutant	myelodysplastic/myeloproliferative neoplasm	sensitive	Azacitidine	Clinical Study - Cohort	Actionable	In a clinical study, myelodysplastic syndrome patients carrying TET2 mutations and wild-type ASXL1 demonstrated an increased response to treatment with the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) compared to patients with other mutational profiles (65% vs. 44%; OR 2.37, P=0.49) (PMID: 25224413).	25224413
ASXL1	ASXL1 wild-type TET2 mutant	myelodysplastic/myeloproliferative neoplasm	sensitive	Decitabine	Clinical Study - Cohort	Actionable	In a clinical study, myelodysplastic syndrome patients carrying TET2 mutations and wild-type ASXL1 demonstrated an increased response to treatment with the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) compared to patients with other mutational profiles (65% vs. 44%; OR 2.37, P=0.49) (PMID: 25224413).	25224413
ASXL1	ASXL1 wild-type CALR mut	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of a CALR mutation combined with wild-type ASXL1 is associated with longer survival in patients with myelofibrosis (NCCN.org).	detail...
ASXL1	ASXL1 inact mut	myelodysplastic/myeloproliferative neoplasm	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, nonsense and frameshift mutations in ASXL1 were associated with decreased overall survival in patients with chronic myelomonocytic leukemia (PMID: 26849014, PMID: 23690417, PMID: 20880116).	20880116 26849014 23690417
ATM	ATM P604S	neuroblastoma	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm P604S, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).	29059438
ATM	ATM L1449*	prostate adenocarcinoma	predicted - sensitive	Olaparib	Case Reports/Case Series	Actionable	In a clinical case study, Lynparza (olaparib) treatment resulted in stable disease for more than 6 months in a patient with prostate adenocarcinoma harboring ATM L1449*, amplification of AR, MYC, BCL9, MCL1, MDM4, RPS6KB1, APEX1, PNP, ATP11B, and DCUN1D1, and a TMPRSS2-ERG fusion (PMID: 29304353).	29304353
ATM	ATM H2038Y	neuroblastoma	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm H2038Y, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).	29059438
ATM	ATM V519I	neuroblastoma	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm V519I, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).	29059438
ATM	ATM A59S	neuroblastoma	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm A59S, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).	29059438
ATM	ATM V410A	lung small cell carcinoma	predicted - sensitive	Temozolomide + Veliparib	Case Reports/Case Series	Actionable	In a Phase II trial, Temodar (temozolomide) and Veliparib (ABT-888) combination treatment resulted stable disease in a patient with small cell lung cancer harboring ATM V410A, with a progression-free survival of 6.3 months and an overall survival of 6.3 months (PMID: 29906251; NCT01638546).	29906251
ATM	ATM loss	colorectal cancer	sensitive	VX-970	Phase I	Actionable	In a Phase I trial, VX-970 treatment resulted in complete response for more than 19 months in a colorectal cancer patient harboring ATM loss (J Clin Oncol 34, 2016 (suppl; abstr 2504)).	detail...
ATM	ATM loss	Advanced Solid Tumor	sensitive	YU238259	Preclinical	Actionable	In a preclinical study, YU238259 demonstrated increased cytotoxicity in ATM-deficient transformed human cell lines in culture (PMID: 26116172).	26116172
ATM	ATM loss	lung non-small cell carcinoma	sensitive	AZD6738 + Cisplatin	Preclinical	Actionable	In a preclinical study, AZD6738 and Platinol (cisplatin) synergistically induced cell death in ATM-deficient non-small cell lung carcinoma cell lines in culture, and caused rapid tumor regression in xenograft models (PMID: 26517239).	26517239
ATM	ATM loss	head and neck cancer	predicted - sensitive	AZD6738 + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of AZD6738 and Lynparza (olaparib) resulted in a synergistic effect, demonstrating cell death in head and neck cancer cells harboring ATM loss in culture (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C60).	detail...
ATM	ATM loss	chronic lymphocytic leukemia	sensitive	AZD6482	Preclinical	Actionable	In a preclinical study, AZD6482 induced cell death in ATM-deficient chronic lymphocytic leukemia cells in culture and inhibited tumor growth in xenograft models (PMID: 26563132).	26563132
ATM	ATM loss	chronic lymphocytic leukemia	sensitive	AZD6738 + Ibrutinib	Preclinical	Actionable	In a preclinical study, AZD6738 sensitized ATM-deficient chronic lymphocytic leukemia cells to Imbruvica (Ibrutinib) treatment in culture (PMID: 26563132).	26563132
ATM	ATM K2749I	neuroblastoma	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm K2749I, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).	29059438
ATM	ATM negative	Advanced Solid Tumor	predicted - sensitive	BAY1895344	Phase I	Actionable	In a Phase I trial, BAY 1895344 treatment resulted in an objective response rate of 30.7% (4/13) in patients with advanced solid tumors, all responders harbored ATM protein expression loss and/or ATM mutations (J Clin Oncol 37, 2019 (suppl; abstr 3007); NCT03188965).	detail...
ATM	ATM negative	stomach cancer	no benefit	Olaparib + Paclitaxel	Phase III	Actionable	In a Phase III trial (GOLD), addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve overall survival (12.0 vs 10.0 months, HR=0.73, p=0.25) compared to Taxol (paclitaxel) alone in Asian patients with ATM-negative gastric cancer (PMID: 29103871; NCT01924533).	29103871
ATM	ATM mutant	Advanced Solid Tumor	predicted - sensitive	BAY1895344	Phase I	Actionable	In a Phase I trial, BAY 1895344 treatment resulted in an objective response rate of 30.7% (4/13) in patients with advanced solid tumors, all responders harbored ATM protein expression loss and/or ATM mutations (J Clin Oncol 37, 2019 (suppl; abstr 3007); NCT03188965).	detail...
ATM	ATM mutant	prostate cancer	sensitive	Olaparib	Phase II	Actionable	In a Phase II clinical trial, 80% (4/5) of metastatic castration-resistant prostate cancer patients with ATM truncation mutations demonstrated response to Lynparza (olaparib) treatment (Cancer Res August 1, 2015 75:CT322).	detail...
ATM	ATM mutant	mantle cell lymphoma	predicted - sensitive	Ibrutinib + Venetoclax	Phase II	Actionable	In a Phase II trial (AIM), distinct molecular profiles were identified in mantle cell lymphoma patients responded to Imbruvica (ibrutinib) and Venclexta (venetoclax) combination therapy compared to those did not respond, with all patients harboring mutations in NSD2 (n=4), UBR5 (n=3), KMT2D (n=3), and 12 of 13 patients harboring mutations in ATM responded to the therapy, while SMARCA4 (n=4), CCND1 (n=2), and NOTCH1 (n=3) alterations were exclusively observed in nonresponders (PMID: 30455436; NCT02471391).	30455436
ATM	ATM mutant	prostate cancer	not applicable	N/A	Guideline	Risk Factor	Germline ATM mutations are associated with increased risk of developing prostate cancer (NCCN.org).	detail...
ATM	ATM mut NRAS Q61R	melanoma	predicted - sensitive	Binimetinib	Case Reports/Case Series	Actionable	In a clinical case study, a melanoma patient harboring an ATM mutation and NRAS Q61R demonstrated a partial response and 16 month progression free survival when treated with Binimetinib (MEK162) (PMID: 28514312).	28514312
ATM	ATM S824F	neuroblastoma	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm S824F, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).	29059438
ATM	ATM L1874F	neuroblastoma	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm L1874F, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).	29059438
ATM	ATM over exp	stomach cancer	sensitive	Irinotecan + Veliparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Camptosar (irinotecan) and Veliparib (ABT-888) demonstrated synergy in gastric cancer cell lines with high ATM expression, resulting in increased apoptosis in culture, and enhanced tumor growth inhibition in cell line xenograft models (PMID: 27638859).	27638859
ATM	ATM over exp	stomach cancer	decreased response	Veliparib	Preclinical - Cell culture	Actionable	In a preclinical study, high ATM expression was associated with decreased response to Veliparib (ABT-888) in gastric cancer cell lines in culture (PMID: 27638859).	27638859
ATM	ATM over exp	stomach cancer	decreased response	Irinotecan	Preclinical - Cell culture	Actionable	In a preclinical study, high ATM expression was associated with decreased response to Camptosaur (irinotecan) in gastric cancer cell lines in culture (PMID: 27638859).	27638859
ATM	ATM L1956H	neuroblastoma	no benefit	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm L1956H, resulted in similar cell viability levels as cells carrying wild-type Atm (PMID: 29059438).	29059438
ATM	ATM S333F	lung small cell carcinoma	predicted - sensitive	Temozolomide + Veliparib	Case Reports/Case Series	Actionable	In a Phase II trial, Temodar (temozolomide) and Veliparib (ABT-888) combination treatment resulted stable disease in a patient with small cell lung cancer harboring ATM S333F, with a progression-free survival of 4.2 months and an overall survival of 4.2 months (PMID: 29906251; NCT01638546).	29906251
ATM	ATM P960H	neuroblastoma	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm P960H, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).	29059438
ATM	ATM T1200Lfs*7 NRAS Q61K TP53 R213*	sarcoma	predicted - resistant	Olaparib	Case Reports/Case Series	Actionable	In a clinical case study, Lynparza (olaparib) treatment resulted in rapid disease progression in a patient with high-grade sarcoma harboring ATM T1200Lfs*7, NRAS Q61K, and TP53 R213* (PMID: 29304353).	29304353
ATM	ATM inact mut	lymphocytic leukemia	sensitive	Olaparib	Preclinical - Patient cell culture	Actionable	In a preclinical study, lymphoblastoid cell lines with ATM inactivation derived from ataxia-telangiectasia patients demonstrated increased sensitivity to Lynparza (olaparib) in culture, compared to ATM wild-type cell lines (PMID: 20739657).	20739657
ATM	ATM inact mut	Advanced Solid Tumor	sensitive	Veliparib	Preclinical - Cell culture	Actionable	In a preclinical study, an ATM-deficient cell line demonstrated increased sensitivity to Veliparib (ABT-888) compared to an ATM-reconstituted cell line, in culture (PMID: 21300883).	21300883
ATM	ATM inact mut	mantle cell lymphoma	sensitive	Bendamustine + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) sensitized a mantle cell lymphoma cell line harboring an ATM inactivating mutation to Treanda (bendamustine) in cell culture, resulting in growth inhibition (PMID: 20739657).	20739657
ATM	ATM inact mut	mantle cell lymphoma	sensitive	Olaparib + Valproic acid	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Lynparza (olaparib) and valproic acid worked synergistically to inhibit growth of a mantle cell lymphoma cell line harboring an ATM inactivating mutation in culture (PMID: 20739657).	20739657
ATM	ATM inact mut	prostate cancer	sensitive	Olaparib	Phase II	Actionable	In a Phase II clinical trial, 80% (4/5) of metastatic, castration-resistant prostate cancer patients harboring an ATM inactivating mutation responded to Lynparza (olaparib) (PMID: 26510020).	26510020
ATM	ATM inact mut	chronic lymphocytic leukemia	sensitive	Olaparib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived chronic lymphocytic leukemia cells with inactivating mutations in ATM, that had been induced to proliferate in culture, demonstrated increased sensitivity to growth inhibition by Lynparza (olaparib) compared to ATM wild-type cells (PMID: 20739657).	20739657
ATM	ATM inact mut	mantle cell lymphoma	sensitive	Fludarabine + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) sensitized a mantle cell lymphoma cell line harboring an ATM inactivating mutation to Fludara (fludarabine) in cell culture, resulting in decreased cell survival (PMID: 20739657).	20739657
ATM	ATM inact mut	mantle cell lymphoma	sensitive	Olaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a mantle cell lymphoma cell line with ATM inactivation demonstrated sensitivity to Lynparza (olaparib) in culture and in xenograft models (PMID: 20739657).	20739657
ATM	ATM inact mut	Advanced Solid Tumor	sensitive	E7449	Preclinical	Actionable	In a preclinical study, E7449 inhibited proliferation of a ATM-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298).	26513298
ATM	ATM D2725G	lung small cell carcinoma	predicted - sensitive	Temozolomide + Veliparib	Case Reports/Case Series	Actionable	In a Phase II trial, Temodar (temozolomide) and Veliparib (ABT-888) combination treatment resulted partial response in a patient with small cell lung cancer harboring ATM D2725G, with a progression-free survival of 9 months and an overall survival of 16 months (PMID: 29906251; NCT01638546).	29906251
ATM	ATM R2691C	neuroblastoma	no benefit	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm R2691C, resulted in similar cell viability levels as cells carrying wild-type Atm (PMID: 29059438).	29059438
ATM	ATM S1455R	neuroblastoma	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm S1455R, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).	29059438
ATM	ATM dec exp	stomach cancer	sensitive	Veliparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, knockdown of ATM in a gastric cancer cell line resulted in increased sensitivity to Veliparib (ABT-888) in culture and in xenograft models (PMID: 27638859).	27638859
ATM	ATM dec exp	breast cancer	sensitive	Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, knockdown of ATM expression sensitized breast cancer cells to treatment with Talzenna (talazoparib) in culture (PMID: 23881923).	23881923
ATM	ATM dec exp	stomach cancer	predicted - sensitive	Olaparib + Paclitaxel	Phase II	Actionable	In a Phase II trial, addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve progression free survival (5.29 vs 3.68 months) compared to Taxol alone, but did significantly prolong overall survival (HR = 0.35) in metastatic gastric cancer patients with decreased Atm expression (PMID: 26282658; NCT01063517).	26282658
ATM	ATM del	head and neck cancer	predicted - sensitive	AZD7648 + Olaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD7648 and Lynparza (olaparib) combination treatment enhanced cell cycle arrest and induced tumor regression in a xenograft model of isogenic ATM knock-out head and neck cancer cells (Cancer Res 2019;79(13 Suppl):Abstract nr 3506).	detail...
ATM	ATM L804fs ATM S978fs RET M918T	thyroid medullary carcinoma	predicted - sensitive	Everolimus + Vandetanib	Case Reports/Case Series	Actionable	In a clinical case study, addition of Afinitor (everolimus) to Caprelsa (vandetanib) treatment resulted in significant tumor reduction in a medullary thyroid carcinoma patient harboring ATM L804fs*4, ATM S978fs*12, and RET M918T, that achieved prolonged stable disease on Caprelsa (vandetanib) treatment alone (PMID: 27683183).	27683183
ATM	ATM positive	lung cancer	sensitive	AZD1390	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD1390 inhibited Atm activity, sensitized lung cancer cells to radiotherapy in culture, and demonstrated efficacy in cell line xenograft models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104).	detail...
ATM	ATM positive	glioblastoma multiforme	sensitive	AZD1390	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD1390 inhibited Atm activity, sensitized glioblastoma cell lines to radiotherapy in culture, and demonstrated efficacy in mouse models of glioblastoma (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104).	detail...
ATM	ATM V1841I	neuroblastoma	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm V1841I, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438).	29059438
ATRX	ATRX mutant	malignant glioma	not applicable	N/A	Guideline	Diagnostic	ATRX mutations aid in the diagnosis of gliomas (NCCN.org).	detail...
ATRX	ATRX loss	glioblastoma multiforme	sensitive	Irinotecan	Preclinical	Actionable	In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).	26936505
ATRX	ATRX loss	glioblastoma multiforme	sensitive	Topotecan	Preclinical	Actionable	In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).	26936505
ATRX	ATRX loss	glioblastoma multiforme	sensitive	Doxorubicin	Preclinical	Actionable	In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).	26936505
ATRX	ATRX loss IDH1 mut	malignant glioma	predicted - sensitive	Gemcitabine + Radiotherapy	Phase I	Actionable	In a Phase I trial, Gemzar (gemcitabine) plus radiation therapy resulted in median overall survival of 73.5 months in 7 high-grade glioma patients with IDH mutated, non-codeleted tumors with ATRX loss (PMID: 26853339).	26853339
ATRX	ATRX loss IDH1 mut	astrocytoma	not applicable	N/A	Guideline	Diagnostic	ATRX deficiency in combination with IDH mutation aids in the diagnosis of astrocytoma (NCCN.org).	detail...
ATRX	ATRX loss IDH2 mut	astrocytoma	not applicable	N/A	Guideline	Diagnostic	ATRX deficiency in combination with IDH mutation aids in the diagnosis of astrocytoma (NCCN.org).	detail...
ATRX	ATRX inact mut	Advanced Solid Tumor	sensitive	E7449	Preclinical	Actionable	In a preclinical study, E7449 inhibited proliferation of a ATRX-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298).	26513298
ATRX	ATRX fusion	neuroblastoma	predicted - sensitive	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with GSK126 resulted in reduced proliferation and increased apoptosis of neuroblastoma cell lines harboring in-frame ATRX fusions in culture (PMID: 31631027).	31631027
ATRX	ATRX fusion	neuroblastoma	predicted - sensitive	UNC1999	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with UNC1999 resulted in reduced proliferation and increased apoptosis of neuroblastoma cell lines harboring in-frame ATRX fusions in culture, and decreased tumor growth in a neuroblastoma cell line xenograft model harboring an ATRX fusion (PMID: 31631027).	31631027
ATRX	ATRX fusion	neuroblastoma	predicted - sensitive	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tazemetostat (EPZ-6438) resulted in reduced proliferation and increased apoptosis of neuroblastoma cell lines harboring in-frame ATRX fusions in culture (PMID: 31631027).	31631027
BCOR	BCOR mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	BCOR mutations, including those at codon N1425, are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
BCOR	BCOR mutant	kidney clear cell sarcoma	not applicable	N/A	Clinical Study	Emerging	In multiple clinical analyses, internal tandem duplications of the BCOR gene were consistently found in clear cell sarcoma of the kidney (PMID: 26098867, PMID: 26516930, PMID: 26573325, PMID: 26150234), suggesting that this may serve as a future diagnostic biomarker.	26150234 26098867 26516930 26573325
BCOR	BCOR mut RUNX1 mut	acute myeloid leukemia	predicted - sensitive	Tofacitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of BCOR and RUNX1 mutations correlated with sensitivity to Xeljanz (tofacitinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
BCOR	BCOR mut RUNX1 mut	acute myeloid leukemia	predicted - sensitive	Ruxolitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of BCOR and RUNX1 mutations correlated with sensitivity to Jakafi (ruxolitinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
BCOR	BCOR mut RUNX1 mut	acute myeloid leukemia	predicted - sensitive	Momelotinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of BCOR and RUNX1 mutations correlated with sensitivity to Momelotinib (CYT387) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
BCOR	BCOR mut RUNX1 mut	acute myeloid leukemia	predicted - sensitive	Pyridone 6	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of BCOR and RUNX1 mutations correlated with sensitivity to Pyridone 6 (CMP6) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
BCOR	BCOR-RARA	acute promyelocytic leukemia	predicted - sensitive	Tretinoin	Case Reports/Case Series	Actionable	In a clinical case study, a patient with acute promyelocytic leukemia harboring BCOR-RARA demonstrated sensitivity to treatment with Vesanoid (tretinoin) and achieved a complete response (PMID: 25790901).	25790901
BCORL1	BCORL1 over exp	hepatocellular carcinoma	not applicable	N/A	Clinical Study	Emerging	In a clinical study, BCORL1 over expression was associated with decreased overall survival and recurrence-free survival in patients with hepatocellular carcinoma (PMID: 26879601), suggesting that this may serve as a future prognostic biomarker.	26879601
BRAF	BRAF amp BRAF V600X NRAS Q61K	melanoma	resistant	Vemurafenib	Clinical Study - Cohort	Actionable	In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, BRAF amplification and NRAS Q61K, during treatment with Zelboraf (vemurafenib) (PMID: 24265153).	24265153
BRAF	BRAF amp BRAF V600E	lung adenocarcinoma	sensitive	Dabrafenib + SCH772984 + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, combination of Tafinlar (dabrafenib), SCH772984, and Mekinist (trametinib) resulted in durable tumor inhibition in cell line xenograft models of BRAF V600E mutated lung adenocarcinoma cells that acquired resistance to Erk inhibitors through BRAF amplification (PMID: 28714990).	28714990
BRAF	BRAF amp BRAF V600E	colorectal cancer	predicted - resistant	Panitumumab + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 24 weeks to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, amplification of BRAF V600E was identified as an acquired alteration at the time of progression (PMID: 28951457).	28951457
BRAF	BRAF amp BRAF V600E	lung adenocarcinoma	decreased response	SCH772984	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived BRAF V600E mutant lung adenocarcinoma cells that acquired resistance to Erk inhibitor through BRAF amplification were less sensitive to SCH772984 in culture (PMID: 28714990).	28714990
BRAF	BRAF amp BRAF V600E	colorectal cancer	resistant	Cetuximab + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 16 weeks to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment, amplification of BRAF V600E was identified as an acquired alteration at the time of progression (PMID: 28951457).	28951457
BRAF	BRAF amp BRAF V600E	colorectal cancer	resistant	Cetuximab + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired BRAF V600E amplification and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).	27312529
BRAF	BRAF amp BRAF V600E	colorectal cancer	resistant	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired BRAF V600E amplification and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).	27312529
BRAF	BRAF amp BRAF V600E	colorectal cancer	resistant	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired BRAF V600E amplification (PMID: 27312529).	27312529
BRAF	BRAF act mut	lung non-small cell carcinoma	sensitive	RAF709	Preclinical - Pdx	Actionable	In a preclinical study, RAF709 inhibited tumor growth in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring BRAF activating mutations (PMID: 29343524).	29343524
BRAF	BRAF act mut	melanoma	no benefit	Sorafenib	Phase II	Actionable	In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF mutations (PMID: 16880785, PMID: 22394203).	22394203 16880785
BRAF	BRAF act mut	thyroid cancer	sensitive	Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib) therapy is included in guidelines for differentiated thyroid carcinoma patients with recurrent, advanced, or metastatic disease harboring BRAF activating mutations, in cases that are not surgically resectable or amenable to radioactive iodine (NCCN.org).	detail...
BRAF	BRAF act mut	thyroid cancer	sensitive	Vemurafenib	Phase I	Actionable	In a Phase I trial, Zelboraf (vemurafenib) demonstrated safety and efficacy in metastatic papillary thyroid cancer patients carrying BRAF activating mutations (PMID: 23489023).	23489023
BRAF	BRAF act mut	thyroid cancer	sensitive	Dabrafenib	Guideline	Actionable	Tafinlar (dabrafenib) therapy is included in guidelines for differentiated thyroid carcinoma patients with recurrent, advanced, or metastatic disease harboring BRAF activating mutations, in cases that are not surgically resectable or amenable to radioactive iodine (NCCN.org).	detail...
BRAF	BRAF act mut	melanoma	sensitive	Cobimetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Cobimetinib (GDC-0973) induced cell death in human melanoma cell lines harboring BRAF activating mutations in culture and inhibited tumor growth in xenograft models (PMID: 22084396).	22084396
BRAF	BRAF act mut	Advanced Solid Tumor	sensitive	PLX8394	Preclinical	Actionable	In a preclinical study, PLX8394 had been shown to block survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAF activating mutations (PMID: 24422853).	24422853
BRAF	BRAF act mut	colorectal cancer	predicted - sensitive	VX-11e + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Erk signaling by VX-11e sensitized colorectal cancer cell lines harboring KRAS or BRAF activating mutations to WEHI-539 in culture (PMID: 27974663).	27974663
BRAF	BRAF act mut	colorectal cancer	no benefit	Venetoclax + VX-11e	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Erk signaling by VX-11e did not sensitize colorectal cancer cell lines harboring KRAS or BRAF activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663).	27974663
BRAF	BRAF act mut	papillary thyroid carcinoma	sensitive	Vemurafenib	Phase I	Actionable	In a Phase I trial, Zelboraf (vemurafenib) demonstrated safety and efficacy in metastatic papillary thyroid cancer patients carrying BRAF activating mutations (PMID: 23489023).	23489023
BRAF	BRAF act mut	Advanced Solid Tumor	sensitive	Binimetinib + Encorafenib	Phase Ib/II	Actionable	In a Phase Ib/II trial, Binimetinib (MEK162), in combination with Encorafenib (LGX818), demonstrated safety and efficacy in patients with BRAF mutant advanced solid tumors (J Clin Oncol 31, 2013 (suppl; abstr 9029)).	detail...
BRAF	BRAF V600D	melanoma	sensitive	CCT196969	Preclinical	Actionable	In a preclinical study, CCT196969 inhibited MEK and ERK phosphorylation and growth of melanoma cells harboring BRAF V600D in culture (PMID: 25500121, PMID: 17210691).	25500121 17210691
BRAF	BRAF V600D	melanoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).	27523909
BRAF	BRAF V600D	pilocytic astrocytoma	predicted - sensitive	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, single Tafinlar (dabrafenib) and subsequent Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in disease stablization in a patient with pilocytic astrocytoma harboring BRAF V600D (PMID: 28784858).	28784858
BRAF	BRAF V600D	melanoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).	27523909
BRAF	BRAF V600D	melanoma	sensitive	CCT241161	Preclinical	Actionable	In a preclinical study, CCT241161 inhibited MEK and ERK phosphorylation and growth of melanoma cells harboring BRAF V600D in culture (PMID: 25500121, PMID: 17210691).	25500121 17210691
BRAF	BRAF V600D	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited proliferation of melanoma cells harboring BRAF V600D in culture (PMID: 27523909).	27523909
BRAF	BRAF V600D	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600D in culture (PMID: 27523909).	27523909
BRAF	BRAF V600D	melanoma	sensitive	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, PLX7904 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).	27523909
BRAF	BRAF V600D PTEN loss	melanoma	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600D (PMID: 25637314).	25637314
BRAF	BRAF V600D NRAS dec exp	melanoma	no benefit	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600D and knockdown of NRAS demonstrated a decreased response to Mektovi (binimetinib) relative to cells without NRAS knockdown in culture (PMID: 29245078).	29245078
BRAF	BRAF G606E	Advanced Solid Tumor	no benefit	Vemurafenib	Clinical Study - Cohort	Actionable	In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 1 of the non-responding patients harbored BRAF G606E (PMID: 29320312; NCT02091141).	29320312
BRAF	BRAF G469V	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G469V (PMID: 26343582).	26343582
BRAF	BRAF G469V	melanoma	no benefit	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) did not inhibit ERK phosphorylation or proliferation of a melanoma cell line harboring BRAF G469V (PMID: 29903896).	29903896
BRAF	BRAF G469V	lung non-small cell carcinoma	predicted - sensitive	Sorafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with synchronous BRAF wild-type hepatocellular carcinoma (HCC) and non-small cell lung cancer harboring BRAF G469V demonstrated a partial response in primary lung lesions, complete response in the lung metastasis, and stability of the HCC following treatment with Nexavar (sorafenib) (PMID: 27388325).	27388325
BRAF	BRAF G469V NRAS Q61K	melanoma	no benefit	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) treatment did not result in significant growth inhibition in a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).	29903896
BRAF	BRAF G469V NRAS Q61K	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mektovi (binimetinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).	29903896
BRAF	BRAF G469V NRAS Q61K	melanoma	predicted - resistant	Trametinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Zelboraf (vemurafenib) to treatment with Mekinist (trametinib) resulted in increased proliferation compared to Mekinist (trametinib) alone in a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).	29903896
BRAF	BRAF G469V NRAS Q61K	melanoma	sensitive	Encorafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).	29903896
BRAF	BRAF G469V NRAS Q61K	melanoma	sensitive	LY3009120	Preclinical - Cell culture	Actionable	In a preclinical study, LY3009120 inhibited growth of a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).	29903896
BRAF	BRAF V600E BRAF T529M	Advanced Solid Tumor	predicted - resistant	SB590885	Preclinical	Actionable	In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529M were insensitive to SB590885-mediated inhibition of ERK signaling in culture (PMID: 20538618).	20538618
BRAF	BRAF V600E BRAF T529M	Advanced Solid Tumor	predicted - resistant	PLX4720	Preclinical	Actionable	In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529M were insensitive to PLX4720-mediated inhibition of ERK signaling in culture (PMID: 20538618).	20538618
BRAF	BRAF V600E BRAF T529M	Advanced Solid Tumor	predicted - sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).	20538618
BRAF	BRAF V600E BRAF T529M	Advanced Solid Tumor	predicted - sensitive	CI-1040	Preclinical	Actionable	In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation in transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M in culture (PMID: 20538618).	20538618
BRAF	BRAF V600E BRAF T529M	Advanced Solid Tumor	predicted - sensitive	RAF265	Preclinical	Actionable	In a preclinical study, RAF265 inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).	20538618
BRAF	BRAF mutant	lung non-small cell carcinoma	predicted - sensitive	unspecified PD-L1 antibody	Clinical Study - Cohort	Actionable	In a clinical study, mutant BRAF correlated with prolonged duration on immune checkpoint inhibitor therapy compared to wild-type BRAF in non-small cell lung cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #1138PD).	detail...
BRAF	BRAF mutant	colorectal cancer	sensitive	AZ628 + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in BRAF mutant colorectal cancer cell lines in culture (PMID: 26351322).	26351322
BRAF	BRAF mutant	thyroid cancer	sensitive	Selumetinib	Phase I	Actionable	In a Phase I study, selumetinib demonstrated an increase in iodine uptake and retention in a subgroup of patients with thyroid cancer that was refractory to radioiodine; including patients with BRAF and NRAS mutations disease (PMID: 23406027).	23406027
BRAF	BRAF mutant	colorectal cancer	predicted - sensitive	Dabrafenib + Panitumumab + Trametinib	Phase Ib/II	Actionable	In a Phase I/II trial, treatment with the triple combination of Tafinlar (dabrafenib), Mekinist (trametinib), and Vectibix (panitumumab) resulted in an objective response rate (ORR) of 21% and median progression-free survival (mPFS) of 4.2 mo, compared with 0% ORR and mPFS of 2.6 mo with Mekinist (trametinib) plus Vectibix (panitumumab), and 10% ORR and mPFS of 3.5 mo with Tafinlar (dabrafenib) plus Vectibix (panitumumab) in patients with BRAF-mutant colorectal cancer (PMID: 27770002; NCT01750918).	27770002
BRAF	BRAF mutant	melanoma	sensitive	Binimetinib + Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring a BRAF mutation in culture (PMID: 27307593).	27307593
BRAF	BRAF mutant	colorectal cancer	predicted - sensitive	LSN3074753	Preclinical - Pdx	Actionable	In a preclinical study, LSN3074753 resulted in a disease control rate of 8.3% (1/12) in BRAF mutant patient-derived xenograft models of colorectal cancer (PMID: 28611205).	28611205
BRAF	BRAF mutant	lung adenocarcinoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of lung adenocarcinoma cells harboring mutant BRAF in culture (PMID: 26343583).	26343583
BRAF	BRAF mutant	colorectal cancer	sensitive	MLN2480	Preclinical	Actionable	In a preclinical study, MLN2480 demonstrated efficacy in BRAF mutant xenograft models of melanoma and colorectal cancer (J Clin Oncol 31, 2013 (suppl; abstr e13529)).	detail...
BRAF	BRAF mutant	melanoma	sensitive	Buparlisib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Buparlisib (BKM120) and Encorafenib (LGX818) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring a BRAF mutation in culture (PMID: 27307593).	27307593
BRAF	BRAF mutant	melanoma	sensitive	PET-16 + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PET-16 and Zelboraf (vemurafenib) synergistically inhibited growth of melanoma cell lines in culture, resulted in enhanced tumor growth inhibition in cell ine xenograft models (PMID: 26984758).	26984758
BRAF	BRAF mutant	colorectal cancer	sensitive	Cetuximab + Encorafenib	Phase Ib/II	Actionable	In a Phase Ib/II trial, the combination therapy of Erbitux (cetuximab) and Encorafenib (LGX818) in colorectal cancer patients harboring a BRAF mutation resulted in an overall response rate of 19% (5/26), including 1 patient with a complete response and 4 patients with a partial response, and led to a median progression free survival of 3.7 months and response duration of 46 weeks (PMID: 28363909).	28363909
BRAF	BRAF mutant	melanoma	sensitive	Encorafenib	Phase I	Actionable	Error	28611198
BRAF	BRAF mutant	melanoma	sensitive	Tubastatin A	Preclinical	Actionable	In a preclinical study, Tubastatin A inhibited proliferation of BRAF mutant melanoma cell lines in culture (PMID: 25957812).	25957812
BRAF	BRAF mutant	colorectal cancer	predicted - sensitive	Binimetinib	Phase I	Actionable	In a Phase I trial, Binimetinib (MEK162) treatment resulted in an estimated progression free survival of 1.4 months and overall survival of 7.1 months in colorectal cancer patients harboring BRAF mutations (PMID: 28152546).	28152546
BRAF	BRAF mutant	melanoma	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with BRAF mutations (PMID: 23039341).	23039341
BRAF	BRAF mutant	colon cancer	predicted - sensitive	PF-00477736 + PF3644022	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of BRAF mutant colon cancer (PMID: 26140595).	26140595
BRAF	BRAF mutant	colorectal cancer	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).	detail...
BRAF	BRAF mutant	Advanced Solid Tumor	no benefit	CC-90003	Phase I	Actionable	In a Phase Ia trial, CC-90003 treatment did not result in any objective responses and demonstrated toxicity in advanced solid tumor patients harboring KRAS, NRAS, or BRAF mutations (AJ Clin Oncol 35, 2017 (suppl; abstr 2577)).	detail...
BRAF	BRAF mutant	lung non-small cell carcinoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant non-small cell lung cancer harboring (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).	detail...
BRAF	BRAF mutant	melanoma	predicted - sensitive	Belvarafenib	Phase I	Actionable	In Phase I trials, Belvarafenib (HM95573) treatment resulted in partial response in a patients with BRAF-mutant melanoma in a dose escalation study, and partial response in 33% (2/6) of BRAF-mutant melanoma patients in a dose expansion study (J Clin Oncol 37, 2019 (suppl; abstr 3000); NCT02405065, NCT03118817).	detail...
BRAF	BRAF mutant	Advanced Solid Tumor	predicted - sensitive	PF-00477736 + PF3644022	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of various cancer cell lines harboring BRAF mutations in culture and in cell line xenograft models (PMID: 26140595).	26140595
BRAF	BRAF mutant	Advanced Solid Tumor	sensitive	Dabrafenib	Phase I	Actionable	In a Phase I clinical trial, Tafinlar (dabrafenib) demonstrated safety and efficacy in patients with BRAF V600E positive solid tumors (PMID: 22608338).	22608338
BRAF	BRAF mutant	melanoma	sensitive	MLN2480	Phase I	Actionable	In a Phase I trial, MLN2480 resulted in a median progression free survival of 4.6 months and a partial response in 50% (8/16) of melanoma patients harboring a BRAF mutation (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 410P; NCT01425008).	detail...
BRAF	BRAF mutant	melanoma	sensitive	MLN2480	Preclinical	Actionable	In a preclinical study, MLN2480 demonstrated efficacy in BRAF mutant xenograft models of melanoma and colorectal cancer (J Clin Oncol 31, 2013 (suppl; abstr e13529)).	detail...
BRAF	BRAF mutant	melanoma	sensitive	S63845 + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination of S63845 and Zelboraf (vemurafenib) resulted in potent cytotoxic effects in BRAF-mutated melanoma cells in culture compared to the cytostatic effect of Zelboraf (vemurafenib) alone (PMID: 27760111).	27760111
BRAF	BRAF mutant	lung non-small cell carcinoma	predicted - sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis and enhanced ERK inhibition compared to either agent alone in non-small cell lung cancer cell lines harboring non-BRAF V600 mutations in culture (PMID: 28947956).	28947956
BRAF	BRAF mutant	melanoma	sensitive	S63845 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination of S63845 and Mekinist (trametinib) resulted in potent cytotoxic effects in BRAF-mutated melanoma cells in culture compared to the cytostatic effect of Mekinist (trametinib) alone (PMID: 27760111).	27760111
BRAF	BRAF mutant	pancreatic adenocarcinoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of human pancreatic adenocarcinoma cells harboring mutant BRAF in culture (PMID: 26343583).	26343583
BRAF	BRAF mutant	Advanced Solid Tumor	predicted - sensitive	LXH 254	Case Reports/Case Series	Actionable	In a Phase I trial, LXH 254 treatment resulted in partial response in 2.6% (2/75) and stable disease in 33% (25/75) of patients with advanced solid tumors harboring MAPK pathway alterations, one of the patient achieved partial response harbored a BRAF mutation (J Clin Oncol 36, no. 15_suppl (May 20 2018) 2586-2586; NCT02607813).	detail...
BRAF	BRAF mutant	colorectal cancer	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, a majority of human colorectal cancer cell lines (4/7) harboring mutant BRAF were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).	26343583
BRAF	BRAF mutant	Advanced Solid Tumor	sensitive	RAF709	Phase I	Actionable	In a preclinical study, cancer cell lines harboring BRAF mutations demonstrated increased sensitivity to RAF709 compared to BRAF wild-type cells in culture (PMID: 29343524).	29343524
BRAF	BRAF mutant	stomach carcinoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).	detail...
BRAF	BRAF mutant	melanoma	sensitive	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring a BRAF mutation demonstrated greater sensitivity to the combination treatment of Mekinist (trametinib) and Ibrance (palbociclib) in culture when compared to either agent alone (PMID: 27488531).	27488531
BRAF	BRAF mutant	Advanced Solid Tumor	predicted - sensitive	MLN2480	Preclinical - Cell culture	Actionable	In a preclinical study, MLN2480 inhibited downstream signaling and proliferation of several BRAF mutant solid tumor cell lines in culture (EJC Supp, Nov 2010, Vol 8(7), p40-41).	detail...
BRAF	BRAF mutant	melanoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).	detail...
BRAF	BRAF mutant	multiple myeloma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of human multiple myeloma cells harboring mutant BRAF in culture (PMID: 26343583).	26343583
BRAF	BRAF mutant	thyroid cancer	sensitive	Belvarafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Belvarafenib (HM95573) inhibited growth of BRAF mutant thyroid cancer cells in culture (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).	detail...
BRAF	BRAF mutant	melanoma	sensitive	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Buparlisib (BKM120) treatment in human melanoma cell line xenograft models with brain metastases and harboring a BRAF mutation resulted in inhibition of brain tumor growth (PMID: 27307593).	27307593
BRAF	BRAF mutant	colon cancer	predicted - sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) resulted in some reduced cell growth in colon cancer cells harboring a BRAF mutation in culture (PMID: 27655129).	27655129
BRAF	BRAF mutant	cervix carcinoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant cervical carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).	detail...
BRAF	BRAF mutant	Advanced Solid Tumor	sensitive	BGB-283	Phase I	Actionable	In a Phase I trial, BGB-283 demonstrated safety and preliminary efficacy, resulted in partial response in 14% (4/29), and prolonged stable disease in 48% (14/29) of advanced solid tumor patients harboring mutations in KRAS, NRAS, and/or BRAF (AACR Annual Meeting, Apr 2016, abstract # CT005).	detail...
BRAF	BRAF mutant	colorectal cancer	sensitive	Cetuximab + LSN3074753	Preclinical - Pdx	Actionable	In a preclinical study, LSN3074753 and Erbitux (cetuximab) synergistically inhibited tumor growth in patient-derived xenograft models of colorectal cancer harboring BRAF mutations, resulted in a disease control rate of 41.7% (5/12) (PMID: 28611205).	28611205
BRAF	BRAF mutant	colorectal cancer	predicted - resistant	SYM004	Preclinical - Pdx	Actionable	In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521).	29423521
BRAF	BRAF mutant	melanoma	sensitive	E6201 + LY294002	Preclinical	Actionable	In a preclinical study, E6201 and LY294002 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations in culture, regardless of PTEN mutation status (PMID: 23039341).	23039341
BRAF	BRAF mutant	colorectal cancer	no benefit	Regorafenib	Phase II	Actionable	In a Phase II clinical trial (PREVIUM), Stivarga (regorafenib) treatment resulted in 0% (0/15) 6-month progression free survival (PFS), a 2.2-month median PFS, and a median overall survival of 3.3 months in metastatic colorectal cancer patients with KRAS (n=9), NRAS (n=3) or BRAF (n=2) mutations who failed first line therapy; however, the trial was terminated early due to poor accrual (PMID: 30120161; NCT02175654).	30120161
BRAF	BRAF mutant	Advanced Solid Tumor	sensitive	Obatoclax	Preclinical	Actionable	In a preclinical study, obatoclax decreased proliferation in human tumor cell lines with BRAF mutation in culture (PMID: 22460902).	22460902
BRAF	BRAF mutant	melanoma	sensitive	Selumetinib	Phase II	Actionable	In a Phase II trial in patients with advanced melanoma, 5/6 patients exhibiting a response to selumetinib had BRAF-mutant tumors (PMID: 22048237).	22048237
BRAF	BRAF mutant	colorectal cancer	sensitive	Alpelisib + Cetuximab + Encorafenib	Phase Ib/II	Actionable	In a Phase Ib/II trial, the triple combination therapy of Encorafenib (LGX818), Erbitux (cetuximab), and Alpelisib (BYL719) resulted in an overall response rate of 18% (5/28), including 5 patients with a partial response, and led to a median progression free survival of 4.2 months and response duration of 12 weeks (PMID: 28363909).	detail... 28363909
BRAF	BRAF mutant	splenic marginal zone lymphoma	not applicable	N/A	Guideline	Diagnostic	BRAF mutations aid in the diagnosis of splenic marginal zone lymphoma (NCCN.org).	detail...
BRAF	BRAF mutant	melanoma	predicted - sensitive	Ulixertinib	Phase I	Actionable	In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a best response of stable disease in six melanoma patients and a partial response in three melanoma patients all harboring a BRAF mutation (PMID: 29247021).	29247021
BRAF	BRAF mutant	colorectal cancer	decreased response	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, BRAF mutant colorectal cancer cell lines demonstrated reduced sensitivity to PLX4720 in culture (PMID: 26351322).	26351322
BRAF	BRAF mutant	melanoma	predicted - sensitive	ST-162	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ST-162 treatment resulted in tumor regression in BRAF mutant-melanoma cell line xenograft models (PMID: 28775144).	28775144
BRAF	BRAF mutant	colorectal cancer	sensitive	Belvarafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Belvarafenib (HM95573) inhibited growth of BRAF mutant colorectal cancer cell lines in culture and in cell line xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).	detail...
BRAF	BRAF mutant	pancreatic cancer	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant pancreatic cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).	detail...
BRAF	BRAF mutant	melanoma	sensitive	PLX8394	Preclinical	Actionable	In a preclinical study, PLX8394 blocked survival and growth of vemurafenib/PLX4720-resistant melanoma cells harboring BRAF V600E splice variants in culture (PMID: 24422853).	24422853
BRAF	BRAF mutant	Advanced Solid Tumor	decreased response	XL147	Preclinical	Actionable	In a preclinical study, tumor cell lines harboring BRAF mutations demonstrated limited sensitivity to XL147 treatment in culture (PMID: 25637314).	25637314
BRAF	BRAF mutant	melanoma	predicted - sensitive	BI-847325	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with BI-847325 resulted in decreased expression of Mcl-1 and Mek, and inhibited growth of BRAF-mutant melanoma cell lines in culture, and inhibited tumor growth melanoma cell line xenograft models harboring BRAF mutations, including models with BRAF inhibitor resistance (PMID: 25873592).	25873592
BRAF	BRAF mutant	melanoma	sensitive	Vemurafenib + Voruciclib	Phase I	Actionable	Error	detail...
BRAF	BRAF mutant	Advanced Solid Tumor	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 resulted in tumor regression in patient derived xenograft (PDX) models harboring either a BRAF mutation, NRAS mutation, or KRAS mutation (EJC Dec 2016, 69:1; S126).	detail...
BRAF	BRAF mutant	lung non-small cell carcinoma	predicted - sensitive	unspecified PD-1 antibody	Clinical Study - Cohort	Actionable	In a clinical study, mutant BRAF correlated with prolonged duration on immune checkpoint inhibitor therapy compared to wild-type BRAF in non-small cell lung cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #1138PD).	detail...
BRAF	BRAF mut TP53 wild-type	colorectal cancer	sensitive	CGM097 + Dabrafenib + Navitoclax + PF-04217903	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Navitoclax (ABT-263), CGM097, Tafinlar (dabrafenib), and PF04217903 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046).	27659046
BRAF	BRAF mut TP53 wild-type	melanoma	sensitive	AMG 232	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 inhibited growth of a melanoma cell line with wild-type TP53, that also harbored a BRAF mutation, in culture and inhibited tumor growth in a TP53 wild-type BRAF-mutant melanoma cell line xenograft model (PMID: 25567130).	25567130
BRAF	BRAF mut TP53 wild-type	Advanced Solid Tumor	predicted - sensitive	Pimasertib + SAR405838	Phase I	Actionable	In a Phase I trial, SAR405838 and Pimasertib (MSC1936369B) combination therapy demonstrated safety and preliminary efficacy, resulted in partial response in 4% (1/24) and stable disease in 63% (15/24) of patients with TP53 wild-type advanced solid tumors harboring RAS/RAF mutations (KRAS, n=24; BRAF, n=1; NRAS, n=1) (PMID: 30585255; NCT01985191).	30585255
BRAF	BRAF mut TP53 wild-type	melanoma	sensitive	CGM097 + Encorafenib	Preclinical	Actionable	In a preclinical study, the combination of CGM097 and Encorafenib (LGX818) synergized to inhibit cell growth of a human melanoma cell line harboring mutant BRAF and wild-type TP53 in culture, and promoted tumor regression in xenograft models (Cancer Res October 1, 2014 74; 5466).	detail...
BRAF	APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut	colorectal cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369).	25261369
BRAF	BRAF mut NRAS mut	melanoma	predicted - sensitive	BI-847325	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to an NRAS mutation in culture (PMID: 25873592).	25873592
BRAF	BRAF mut NRAS mut	melanoma	sensitive	Lenvatinib	Phase I	Actionable	In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 50% (1/2) of melanoma patients harboring both BRAF and NRAS mutations (PMID: 26169970).	26169970
BRAF	BRAF mut NRAS wild-type	melanoma	sensitive	Lenvatinib	Phase I	Actionable	In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 100% (5/5) of melanoma patients harboring BRAF mutations and wild-type NRAS (PMID: 26169970).	26169970
BRAF	BRAF mut PTEN loss	melanoma	sensitive	SAR260301 + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR260301 and Zelboraf (vemurafenib) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).	27196754
BRAF	BRAF mut PTEN loss	melanoma	sensitive	SAR260301	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR260301 inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).	27196754
BRAF	BRAF mut PTEN loss	melanoma	no benefit	Pembrolizumab	Preclinical	Actionable	In a preclinical study, Keytruda (pembrolizumab) resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196).	26645196
BRAF	BRAF mut PTEN loss	melanoma	sensitive	SAR260301 + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR260301 and Selumetinib (AZD6244) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).	27196754
BRAF	BRAF mut PTEN loss	melanoma	sensitive	GSK2636771 + Pembrolizumab	Preclinical	Actionable	In a preclinical study, a melanoma mouse model harboring a BRAF mutation and PTEN loss was sensitive to the combination of GSK2636771 and Keytruda (pembrolizumab), demonstrating greater tumor growth inhibition and improved survival when compared to either therapy alone (PMID: 26645196).	26645196
BRAF	BRAF mut PTEN loss	melanoma	no benefit	GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196).	26645196
BRAF	BRAF mut PTEN mut	melanoma	decreased response	E6201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, E6201 resulted in a cytostatic response in melanoma cell lines harboring both BRAF and PTEN mutations in culture and only inhibited tumor growth at very high doses in cell line xenograft models (PMID: 23039341).	23039341
BRAF	BRAF mut PTEN mut	melanoma	predicted - sensitive	ST-162	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ST-162 resulted in tumor regression in a melanoma cell line xenograft model co-harboring mutations in BRAF and PTEN (PMID: 28775144).	28775144
BRAF	BRAF mut PTEN wild-type	melanoma	no benefit	Encorafenib + GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN wild-type	melanoma	no benefit	Binimetinib + GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN wild-type	melanoma	no benefit	GSK2636771 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, GSK2636771 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN wild-type	melanoma	sensitive	E6201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, E6201 resulted in a cytocidal response in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture and inhibited tumor growth in cell line xenograft models (PMID: 23039341).	23039341
BRAF	BRAF mut PTEN wild-type	melanoma	no benefit	AZD6482 + Binimetinib	Preclinical	Actionable	In a preclinical study, AZD6482 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN wild-type	melanoma	no benefit	AZD6482 + Encorafenib	Preclinical	Actionable	In a preclinical study, AZD6482 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN wild-type	melanoma	no benefit	AZD6482 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, AZD6482 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib + NVP-AEW541	Preclinical	Actionable	In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + AZD6482 + Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	no benefit	Alpelisib + Encorafenib	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) and Encorafenib (LGX818) combination treatment did not enhance growth inhibition in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	Encorafenib + Pictilisib	Preclinical	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + GSK2636771	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of GSK2636771 and Alpelisib (BYL719) synergized to inhibit proliferation of human melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture, and inhibited tumor growth in xenograft models of one cell line harboring these mutations (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	TGX-221	Preclinical	Actionable	In a preclincal study, TGX-221 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	Encorafenib + GSK2636771 + unspecified IGF-1R antibody	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination treatment consisting of GSK2636771, Encorafenib (LGX818), and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + AZD6482 + Encorafenib	Preclinical	Actionable	In a preclinical study, combination treatment consisting of AZD6482, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	Encorafenib + unspecified IGF-1R antibody	Preclinical	Actionable	In a preclinical study, combination treatment consists of Encorafenib (LGX818) and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	no benefit	Alpelisib + Binimetinib	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Encorafenib + NVP-AEW541	Preclinical	Actionable	In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482	Preclinical	Actionable	In a preclincal study, AZD6482 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	GSK2636771 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, GSK2636771 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + AZD6482	Preclinical	Actionable	In a preclinical study, AZD6482 and Alpelisib (BYL719) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	Pictilisib	Preclinical	Actionable	In a preclincal study, Pictilisib (GDC-0941) inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + AZD6482 + Binimetinib + Encorafenib	Preclinical	Actionable	In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib + Encorafenib + NVP-AEW541	Preclinical	Actionable	In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	NVP-AEW541 + Pictilisib	Preclinical	Actionable	In a preclinical study, Pictilisib (GDC-0941) and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	Binimetinib + GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	Binimetinib + Pictilisib	Preclinical	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	Encorafenib + GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + Encorafenib + GSK2636771	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of GSK2636771, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently inhibited tumor growth in xenograft models of a human melanoma cell line harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib	Preclinical	Actionable	In a preclinical study, AZD6482 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	no benefit	Alpelisib + NVP-AEW541	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, AZD6482 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Encorafenib	Preclinical	Actionable	In a preclinical study, AZD6482 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	sensitive	GSK2636771 + unspecified IGF-1R antibody	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination treatment consisting of GSK2636771 and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).	26577700
BRAF	BRAF mut PTEN inact mut	melanoma	decreased response	Alpelisib	Preclinical	Actionable	In a preclincal study, melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations were less sensitive to Alpelisib (BYL719)-induced growth inhibition in culture (PMID: 26577700).	26577700
BRAF	BRAF mut STAG2 dec exp	melanoma	decreased response	Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) both in culture and in cell line xenograft models (PMID: 27500726).	27500726
BRAF	BRAF mut STAG2 dec exp	melanoma	decreased response	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment in culture (PMID: 27500726).	27500726
BRAF	BRAF mut STAG2 dec exp	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726).	27500726
BRAF	BRAF mut STAG2 dec exp	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).	27500726
BRAF	BRAF mut RB1 loss	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring a BRAF mutation and RB1 loss demonstrated reduced sensitivity when treated with Mekinist (trametinib) in culture (PMID: 27488531).	27488531
BRAF	BRAF mut RB1 loss	melanoma	decreased response	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring a BRAF mutation and loss of RB1 demonstrated a decreased response to Ibrance (palbociclib) treatment in culture when compared to treatment of melanoma cell lines wild-type for BRAF (PMID: 27488531).	27488531
BRAF	BRAF mut RB1 loss	melanoma	decreased response	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line with a BRAF mutation and loss of RB1 demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531).	27488531
BRAF	BRAF mut PTPN11 dec exp	colorectal cancer	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, knocking down of Ptpn11 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322).	26351322
BRAF	BRAF mut TP53 mut	colorectal cancer	sensitive	Alpelisib + Dabrafenib + Erlotinib + Navitoclax	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Tafinlar (dabrafenib), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and TP53 mutation in culture compared to the double or triple combinations of the therapies (PMID: 27659046).	27659046
BRAF	BRAF mut PIK3CA wild-type	colorectal cancer	predicted - sensitive	TAK-733	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, mutations in BRAF, KRAS, or NRAS were associated with sensitivity to TAK-733 in colorectal cancer cell lines in culture, and patient-derived xenograft models harboring KRAS or BRAF mutations with wild-type PIK3CA demonstrated a trend toward higher tumor growth inhibition following TAK-733 treatment (PMID: 26439693).	26439693
BRAF	BRAF mutant IDH1 wild-type	glioblastoma multiforme	predicted - sensitive	Pembrolizumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).	30742119
BRAF	BRAF mutant IDH1 wild-type	glioblastoma multiforme	predicted - sensitive	Nivolumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).	30742119
BRAF	BRAF V600E BRAF T529N	Advanced Solid Tumor	sensitive	CI-1040	Preclinical	Actionable	In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation and growth of transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529N in culture (PMID: 20538618).	20538618
BRAF	BRAF V600E BRAF T529N	Advanced Solid Tumor	resistant	PLX4720	Preclinical	Actionable	In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to PLX4720 in culture (PMID: 20538618).	20538618
BRAF	BRAF V600E BRAF T529N	Advanced Solid Tumor	resistant	RAF265	Preclinical	Actionable	In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to RAF265 in culture (PMID: 20538618).	20538618
BRAF	BRAF V600E BRAF T529N	Advanced Solid Tumor	conflicting	Sorafenib	Preclinical	Actionable	In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to Nexavar (sorafenib)-mediated inhibition of Erk phosphorylation but were equally as sensitive to Nexavar (sorafenib)-mediated growth inhibition as transformed cells expressing BRAF V600E in culture (PMID: 20538618).	20538618
BRAF	BRAF V600E BRAF T529N	Advanced Solid Tumor	resistant	SB590885	Preclinical	Actionable	In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to SB590885 in culture (PMID: 20538618).	20538618
BRAF	BRAF K601T	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601T (PMID: 26343582).	26343582
BRAF	BRAF V47_D380del	melanoma	predicted - resistant	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a melanoma patient developed progressive disease after initial response to Tafinlar (dabrafinib) and Mekinist (trametinib) combination treatment, BRAF V47_D380del was identified as an acquired mutation in the progressing lesion along with mutations presented in both primary and progressing lesions, including BRAF V600E, PTEN G129E, CDKN2A/B loss, and TERT promoter mutations (PMID: 29171936).	29171936
BRAF	BRAF V47_D380del BRAF V600E	colorectal cancer	predicted - resistant	Alpelisib + Cetuximab + Encorafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 24 weeks to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment, BRAF V47_D380del (reported as deletion of exons 2-8) was identified as an acquired mutation in peritoneal metastasis at the time of progression (PMID: 28951457).	28951457
BRAF	BRAF V504_R506dup	Advanced Solid Tumor	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human embryonic kidney cells overexpressing Braf V504_R506dup were resistant to Mekinist (trametinib) in culture (PMID: 30575814).	30575814
BRAF	BRAF V504_R506dup	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human embryonic kidney cells overexpressing Braf V504_R506dup were resistant to Zelboraf (vemurafenib) in culture (PMID: 30575814).	30575814
BRAF	BRAF V504_R506dup	Advanced Solid Tumor	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human embryonic kidney cells overexpressing Braf V504_R506dup were resistant to Nexavar (sorafenib) in culture (PMID: 30575814).	30575814
BRAF	BRAF G596V NRAS G13R	colorectal cancer	sensitive	Cetuximab + LSN3074753	Preclinical - Pdx	Actionable	In a preclinical study, LSN3074753 and Erbitux (cetuximab) worked synergistically, resulting in tumor regression in a patient-derived xenograft model of colorectal cancer harboring BRAF G596V and NRAS G13R (PMID: 28611205).	28611205
BRAF	BRAF N486_T491delinsK	lymphatic system cancer	predicted - sensitive	Cobimetinib	Case Reports/Case Series	Actionable	In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including a complete response in a patient with Langerhans cell histiocytosis harboring BRAF N486_T491delinsK (PMID: 30867592; NCT01953926).	30867592
BRAF	BRAF N486_T491delinsK	Advanced Solid Tumor	predicted - sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited viability of transformed cells expressing BRAF N486_T491delinsK in culture (PMID: 30867592).	30867592
BRAF	BRAF P731T	Advanced Solid Tumor	no benefit	Vemurafenib	Clinical Study - Cohort	Actionable	In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 1 of the non-responding patients harbored BRAF P731T (PMID: 29320312; NCT02091141).	29320312
BRAF	BRAF V600X	melanoma	sensitive	Buparlisib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Buparlisib (BKM120) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).	24265152
BRAF	BRAF V600X	melanoma	sensitive	MK2206 + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).	24265152
BRAF	BRAF V600X	melanoma	sensitive	Cobimetinib + Vemurafenib	Phase III	Actionable	In a Phase III trial, combination treatment with Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months compared to 7.2 months with Zelboraf (vemurafenib) alone among patients with BRAF V600-mutated metastatic melanoma (PMID: 27480103; NCT01689519).	27480103
BRAF	BRAF V600X	melanoma	sensitive	Cobimetinib + Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination therapy is included in guidelines for patients with metastatic or unresectable melanoma harboring a BRAF V600 activating mutation (NCCN.org).	detail...
BRAF	BRAF V600X	melanoma	sensitive	Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).	detail...
BRAF	BRAF V600X	thyroid cancer	predicted - sensitive	Vemurafenib	Phase II	Actionable	In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) resulted in an overall response rate of 29% (2/7), with 1 complete response and 1 partial response, in patients with anaplastic thyroid cancer patients with BRAF V600 mutations (PMID: 26287849).	26287849
BRAF	BRAF V600X	melanoma	sensitive	ASN003	Preclinical - Pdx	Actionable	In a preclinical study, melanoma patient derived xenograft (PDX) model harboring a BRAF V600 mutation demonstrated antitumor activity when treated with ASN003 (J Clin Oncol 35, 2017 (suppl; abstr e14102)).	detail...
BRAF	BRAF V600X	melanoma	sensitive	Atezolizumab + Vemurafenib	Phase Ib/II	Actionable	In a Phase Ib trial, the combination therapy of Tecentriq (atezolizumab) and Zelboraf (vemurafenib) in patients with metastatic melanoma harboring a BRAF V600 mutation resulted in a best objective response rate of 76.5% (13/17), with a complete response in 17.6% (3/17), a median progression-free survival of 10.9 months, a median overall survival of 46.2 months, and median duration of confirmed response of 10.6 months (PMID: 31171876; NCT01656642).	31171876
BRAF	BRAF V600X	colorectal cancer	no benefit	Vemurafenib	Phase II	Actionable	In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) in colorectal cancer patients with BRAF V600 mutations did not result in clinical benefit, with no patients achieving response, and 50% (5/10) demonstrating progressive disease (PMID: 26287849).	26287849
BRAF	BRAF V600X	melanoma	sensitive	Selumetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Selumetinib (AZD6244) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).	24265152
BRAF	BRAF V600X	colorectal cancer	sensitive	Cetuximab + Irinotecan + Vemurafenib	Phase Ib/II	Actionable	In a Phase Ib trial, the addition of Zelboraf (vemurafenib) to Camptosar (irinotecan) plus Erbitux (cetuximab) improved progression-free survival (4.4 mo vs. 2.0 mo), and disease control rate (67% vs. 22%), compared to Camptosar (irinotecan) plus Erbitux (cetuximab) without Zelboraf (vemurafenib), in patients with BRAF V600-mutant colorectal cancer (J Clin Oncol 35, 2017 (suppl 4S; abstract 520)).	detail...
BRAF	BRAF V600X	melanoma	sensitive	Dabrafenib + Trametinib	Guideline	Actionable	Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for melanoma patients harboring a BRAF V600 activating mutation, as adjuvant treatment for patients with Stage III disease, or as systemic therapy for patients with unresectable or metastatic disease (NCCN.org).	detail...
BRAF	BRAF V600X	melanoma	sensitive	Dabrafenib + Trametinib	Phase Ib/II	Actionable	In a Phase I/II clinical trial, patients with BRAF V600 mutant melanoma (n=78) treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) had a median overall survival of greater than 2 years (PMID: 26811525).	26811525
BRAF	BRAF V600X	melanoma	sensitive	AMG 232 + Dabrafenib + Trametinib	Phase I	Actionable	In a Phase I trial, the combination therapy of AMG 232, Mekinist (trametinib), and Tafinlar (dabrafenib) in 6 patients with metastatic cutaneous melanoma harboring a BRAF V600 mutation resulted in 4 patients with a partial response and 2 patients with stable disease, and of the 6 patients, all experienced tumor reduction (J Clin Oncol 35, 2017 (suppl; abstr 2575)).	detail...
BRAF	BRAF V600X	cholangiocarcinoma	sensitive	Vemurafenib	Phase II	Actionable	In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) resulted in partial response in 12% (1/8) and stable disease in 50% (4/8) of cholangiocarcinoma patients with BRAF V600 mutations (PMID: 26287849).	26287849
BRAF	BRAF V600X	melanoma	sensitive	Binimetinib	Phase II	Actionable	In a Phase II trial, 20% (8/41) of melanoma patients with BRAF V600 mutations had a partial response to Binimetinib (MEK162) (PMID: 23414587).	23414587
BRAF	BRAF V600X	melanoma	sensitive	Trametinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).	24265152
BRAF	BRAF V600X	melanoma	sensitive	Dabrafenib	Guideline	Actionable	Tafinlar (dabrafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).	detail...
BRAF	BRAF V600X	colorectal cancer	sensitive	Cetuximab + Vemurafenib	Phase II	Actionable	In a Phase II clinical trial, treatment with the combination of Zelboraf (vemurafenib) and Erbitux (cetuximab) resulted in an overall response rate of 4% (1/26), stable disease in 69% (18/26), and a median progression-free survival of 3.7 months in patients with BRAF V600-mutant colorectal cancer (PMID: 26287849).	26287849
BRAF	BRAF V600X	melanoma	sensitive	MK2206 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of MK2206 and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).	24265152
BRAF	BRAF V600X	melanoma	sensitive	Atezolizumab + Cobimetinib + Vemurafenib	Phase Ib/II	Actionable	In a Phase Ib trial, the combination therapy of Tecentriq (atezolizumab), Zelboraf (vemurafenib), and Cotellic (cobimetinib) in patients with metastatic melanoma harboring a BRAF V600 mutation resulted in a best objective response rate of 71.8% (28/39), with a complete response in 20.5% (8/39), a median progression-free survival of 12.9 months, a median overall survival not yet reached, and median duration of confirmed response of 17.4 months (PMID: 31171876; NCT01656642).	detail... 31171876
BRAF	BRAF V600X	colorectal cancer	sensitive	Dabrafenib + Trametinib	Phase Ib/II	Actionable	In a Phase Ib/II trial, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in partial response or better in 12% (5/43), including 1 complete response, and stable disease in 51% (22/43) of patients with BRAF V600-mutant colorectal cancer (PMID: 26392102).	detail... 26392102
BRAF	BRAF V600X	melanoma	sensitive	Buparlisib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Buparlisib (BKM120) and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).	24265152
BRAF	BRAF V600X	lung non-small cell carcinoma	sensitive	Dabrafenib + Trametinib	Guideline	Actionable	The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) is included in guidelines as first or second-line therapy in patients with metastatic non-small cell lung cancer harboring a BRAF V600 mutation (PMID: 30715168, PMID: 30285222; ESMO.org).	30715168 detail... 30285222
BRAF	BRAF V600X	melanoma	sensitive	Buparlisib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Buparlisib (BKM120) and Selumetinib (AZD6244) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).	24265152
BRAF	PIK3CA H1047X BRAF V600X	ovarian carcinoma	predicted - sensitive	Bevacizumab + Pegylated liposomal-doxorubicin + Temsirolimus	Case Reports/Case Series	Actionable	In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian clear cell carcinoma harboring PIK3CA H1047 and BRAF V600 mutations (PMID: 21216929).	21216929
BRAF	BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R	melanoma	predicted - resistant	Vemurafenib	Clinical Study - Cohort	Actionable	In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistance-associated mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).	24265153
BRAF	BRAF V600X PIK3CA H1047R PTEN Y86fs	melanoma	resistant	Vemurafenib	Clinical Study - Cohort	Actionable	In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance-associated mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153).	24265153
BRAF	BRAF V600X PTEN H93D	melanoma	predicted - sensitive	Vemurafenib	Clinical Study - Cohort	Actionable	In a clinical study, a melanoma patient harboring a BRAF V600 mutation and PTEN H93D treated with Zelboraf (vemurafenib) for 66 weeks demonstrated a partial response (PMID: 24265153).	24265153
BRAF	AKT1 E17K BRAF V600X PTEN pos	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).	24265152
BRAF	AKT1 Q79K BRAF V600X PTEN pos	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).	24265152
BRAF	AKT1 Q79K BRAF V600X PTEN pos	melanoma	sensitive	MK2206 + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited AKT activation and growth of PTEN-expressing BRAF V600-mutant melanoma cells expressing AKT1 Q79K in culture, with increased efficacy over either agent alone (PMID: 24265152).	24265152
BRAF	BRAF V600X PTEN neg	melanoma	sensitive	Uprosertib	Preclinical - Cell culture	Actionable	In a preclinical study, lack of PTEN expression was associated with increased sensitivity to GSK2141795 in BRAF V600-mutant melanoma cell lines in culture (PMID: 24265152).	24265152
BRAF	BRAF L597Q	lung cancer	sensitive	Ulixertinib	Phase I	Actionable	In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in a lung cancer patient harboring BRAF L597Q (PMID: 29247021).	29247021
BRAF	BRAF L597Q	Advanced Solid Tumor	resistant	Vemurafenib	Clinical Study - Cohort	Actionable	In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 1 of the non-responding patients harbored BRAF L597Q (PMID: 29320312; NCT02091141).	29320312
BRAF	BRAF L597Q	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF L597Q (PMID: 26343582).	26343582
BRAF	BRAF N581Y	colon cancer	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, colon cancer cells harboring BRAF N581Y were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).	19276360
BRAF	BRAF G464R	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464R (PMID: 26343582).	26343582
BRAF	BRAF L597S	melanoma	predicted - sensitive	Trametinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of melanoma cell lines harboring BRAF L597S in culture, and resulted in tumor shrinkage in 75% (8/12) subcutaneous tumors in one patient-derived xenograft (PDX) model harboring BRAF L597S that also harbored a BRAF variant of unknown significance, BRAF R239Q, however, was not sufficient to induce tumor shrinkage in a second PDX model with BRAF L597S, resulting only in tumor growth delay (PMID: 29903896).	29903896
BRAF	BRAF L597S	Advanced Solid Tumor	sensitive	Vemurafenib	Preclinical	Actionable	In a preclinical study, treatment of cells expressing BRAF L597S with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288).	22798288
BRAF	BRAF L597S	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited growth of melanoma cell lines harboring BRAF L597S in culture (PMID: 29903896).	29903896
BRAF	BRAF L597S	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited growth of melanoma cell lines harboring BRAF L597S in culture (PMID: 29903896).	29903896
BRAF	BRAF L597S	Advanced Solid Tumor	sensitive	Trametinib	Preclinical	Actionable	Preclinical studies demonstrated the MEK inhibitor, Mekinist (trametinib) caused decreased activation of MEK and ERK in cells expressing BRAF L597S (PMID: 22798288).	22798288
BRAF	BRAF L597S	melanoma	sensitive	TAK-733	Phase I	Actionable	In a Phase I trial, one metastatic melanoma patient carrying a BRAF L597S mutation, had a partial response to the MEK inhibitor, TAK-733 (PMID: 22798288).	22798288
BRAF	BRAF L597S	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mektovi (binimetinib) resulted in increased growth inhibition in melanoma cell lines harboring BRAF L597S in culture (PMID: 29903896).	29903896
BRAF	BRAF L597S	melanoma	predicted - sensitive	Dabrafenib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) treatment inhibited ERK activation and proliferation of melanoma cell lines harboring BRAF L597S in culture, but did not result in tumor shrinkage as a single agent in a melanoma patient-derived xenograft (PDX) model harboring BRAF L597S (PMID: 29903896).	29903896
BRAF	BRAF L597S	melanoma	sensitive	Encorafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in melanoma cell lines harboring BRAF L597S in culture (PMID: 29903896).	29903896
BRAF	BRAF L597S	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited ERK activation and proliferation of melanoma cell lines harboring BRAF L597S in culture (PMID: 29903896).	29903896
BRAF	BRAF L597S	melanoma	sensitive	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in increased growth inhibition in melanoma cell lines harboring BRAF L597S in culture, and resulted in tumor shrinkage in 89% (17/19) of tumors in a patient-derived xenograft (PDX) model harboring BRAF L597S, and treatment with Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in a objective response with 34% tumor shrinkage in the patient from which the PDX model was derived from (PMID: 29903896).	29903896
BRAF	BRAF L597S	melanoma	sensitive	LY3009120	Preclinical - Cell culture	Actionable	In a preclinical study, LY3009120 inhibited growth of melanoma cells harboring BRAF L597S in culture (PMID: 29903896).	29903896
BRAF	BRAF L597S BRAF R239Q	melanoma	sensitive	Encorafenib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited ERK activation and proliferation of patient-derived melanoma cells harboring BRAF L597S, as well as BRAF R239Q, in culture, and delayed tumor growth and induced shrinkage in 8% (1/12) of tumors in a melanoma patient-derived xenograft (PDX) model (PMID: 29903896).	29903896
BRAF	BRAF L597S BRAF R239Q	melanoma	sensitive	Binimetinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited growth of patient-derived melanoma cells harboring BRAF L597S, as well as BRAF R239Q, in culture, and induced tumor shrinkage in 25% (3/12) of tumors and delayed tumor growth in a patient-derived xenograft (PDX) model (PMID: 29903896).	29903896
BRAF	BRAF L597S BRAF R239Q	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mektovi (binimetinib) increased growth inhibition in patient-derived melanoma cells harboring BRAF L597S, as well as BRAF R239Q, in culture, and resulted in tumor shrinkage in 67% of tumors, increased inhibition of ERK phosphorylation, and increased tumor growth delay compared to either agent alone in a patient-derived xenograft (PDX) model (PMID: 29903896).	29903896
BRAF	BRAF L597S BRAF R239Q	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, the addition of Tafinlar (dabrafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a patient-derived melanoma cell line harboring BRAF L597S, as well as well as BRAF R239Q, in culture, and resulted in tumor shrinkage in 100% (13/13) of subcutaneous tumors, and decreased growth of intracranial tumors in a patient-derived xenograft (PDX) model (PMID: 29903896).	29903896
BRAF	BRAF L514V	breast cancer	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) did not inhibit Erk and Mek signaling in breast cancer cells expressing BRAF L514V in culture (PMID: 29880583).	29880583
BRAF	BRAF L514V BRAF V600E	ganglioglioma	resistant	Dabrafenib	Case Reports/Case Series	Actionable	In a clinical case study, a pediatric patient with anaplastic ganglioglioma harboring BRAF V600E progressed after initial response to Tafinlar (dabrafenib) treatment, and was found to have acquired a BRAF L514V in cis with BRAF V600E, which conferred dabrafenib resistance in culture (PMID: 29880583).	29880583
BRAF	BRAF L514V BRAF V600E	melanoma	decreased response	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to TAK-632-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).	29880583
BRAF	BRAF L514V BRAF V600E	melanoma	predicted - sensitive	BGB3245	Preclinical - Cell culture	Actionable	In a preclinical study, BGB3245 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583).	29880583
BRAF	BRAF L514V BRAF V600E	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to Mekinist (trametinib)-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).	29880583
BRAF	BRAF L514V BRAF V600E	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to Tafinlar (dabrafenib)-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).	29880583
BRAF	BRAF L514V BRAF V600E	melanoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to Zelboraf (vemurafenib)-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).	29880583
BRAF	BRAF L514V BRAF V600E	melanoma	predicted - sensitive	BGB3290	Preclinical - Cell culture	Actionable	In a preclinical study, BGB3290 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583).	29880583
BRAF	BRAF L514V BRAF V600E	melanoma	decreased response	PLX8394	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to PLX8394-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).	29880583
BRAF	BRAF L514V BRAF V600E	melanoma	predicted - sensitive	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, SCH772984 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583).	29880583
BRAF	BRAF N581D	lung non-small cell carcinoma	predicted - sensitive	RMC-4550	Preclinical - Pdx	Actionable	In a preclinical study, RMC-4550 treatment resulted in decreased Erk phosphorylation and dose-dependent tumor growth inhibition in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring BRAF D594N (PMID: 30104724).	30104724
BRAF	BRAF G464V	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464V (PMID: 26343582).	26343582
BRAF	BRAF G464V	Advanced Solid Tumor	resistant	Vemurafenib	Clinical Study - Cohort	Actionable	In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 2 of the non-responding patients harbored BRAF G464V (PMID: 29320312; NCT02091141).	29320312
BRAF	BRAF K601E	Advanced Solid Tumor	conflicting	Vemurafenib	Clinical Study - Cohort	Actionable	In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 6 of the non-responding patients harbored BRAF K601E (PMID: 29320312; NCT02091141).	29320312
BRAF	BRAF K601E	Advanced Solid Tumor	conflicting	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601E (PMID: 26343582).	26343582
BRAF	BRAF K601E	Advanced Solid Tumor	conflicting	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment of cells expressing BRAF K601E with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288).	22798288
BRAF	BRAF K601E	pancreatic endocrine carcinoma	predicted - resistant	Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with a pancreatic neuroendocrine tumor harboring BRAF K601E demonstrated progressive disease when treated with Mekinist (trametinib) (PMID: 31158244).	31158244
BRAF	BRAF K601E	pancreatic endocrine carcinoma	predicted - resistant	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with a pancreatic neuroendocrine tumor harboring BRAF K601E demonstrated progressive disease when treated with a combination of Tafinlar (dabrafenib) and Mekinist (trametinib) (PMID: 31158244).	31158244
BRAF	BRAF K601E	melanoma	predicted - sensitive	Trametinib	Case Reports/Case Series	Actionable	In a Phase II trial, a melanoma patient harboring BRAF K601E demonstrated a partial response and a progression free survival of 32 weeks when treated with Mekinist (trametinib) (PMID: 23248257; NCT01037127).	23248257
BRAF	BRAF K601E	melanoma	predicted - sensitive	Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a melanoma patient harboring BRAF K601E demonstrated a 48% reduction in lymphadenopathy when treated with Mekinist (trametinib) and after more than 36 months of treatment showed a complete response (PMID: 28344857).	28344857
BRAF	BRAF K601E	melanoma	no benefit	Dabrafenib	Phase I	Actionable	In a Phase I trial, no responses were demonstrated among three melanoma patients with non-V600 BRAF mutations, including two patients harboring BRAF K601E, following treatment with Tafinlar (dabrafenib), compared to a confirmed response rate of 50% in patients harboring BRAF V600 mutations (PMID: 22608338).	22608338
BRAF	BRAF K601E	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the MEK inhibitor, Mekinist (trametinib) decreased activation of MEK and ERK in cells expressing BRAF K601E in culture (PMID: 22798288).	22798288
BRAF	BRAF K601E BRAF S363F	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).	29903896
BRAF	BRAF K601E BRAF S363F	melanoma	sensitive	Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Braftovi (encorafenib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).	29903896
BRAF	BRAF K601E BRAF S363F	melanoma	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).	29903896
BRAF	BRAF K601E BRAF S363F	melanoma	sensitive	Cobimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cotellic (cobimetinib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).	29903896
BRAF	BRAF K601E BRAF S363F	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Tafinlar (dabrafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).	29903896
BRAF	BRAF K601E BRAF S363F	melanoma	sensitive	Trametinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Zelboraf (vemurafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).	29903896
BRAF	BRAF K601E BRAF S363F	melanoma	sensitive	Encorafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).	29903896
BRAF	BRAF K601E MAP2K1 V211D	colon cancer	sensitive	MAP855	Preclinical - Pdx	Actionable	In a preclinical study, MAP955 inhibited Rsk and Erk phosphorylation, and resulted in 30% tumor regression in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).	31227518
BRAF	BRAF K601E MAP2K1 V211D	colon cancer	predicted - resistant	Binimetinib + Panitumumab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with metastatic colon cancer harboring BRAF K601E developed progressive disease after 6 weeks of Mektovi (binimetinib) and Vectibix (panitumumab) combination treatment, MAP2K1 V211D was identified as a co-occuring mutation in the biopsy from the new metastasis site (PMID: 31227518).	31227518
BRAF	BRAF K601E MAP2K1 V211D	colon cancer	resistant	Binimetinib	Preclinical - Pdx	Actionable	In a preclinical study, Mektovi (binimetinib) did not inhibit Rsk and Erk phosphorylation, and had no effect on tumor growth in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).	31227518
BRAF	BRAF K601E MAP2K1 V211D	colon cancer	resistant	Binimetinib + Cetuximab	Preclinical - Pdx	Actionable	In a preclinical study, Mektovi (binimetinib) and Erbitux (cetuximab) combination did not inhibit Rsk and Erk phosphorylation, and had no effect on tumor growth in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).	31227518
BRAF	BRAF Y472C	lung non-small cell carcinoma	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) induced apoptosis in non-small cell lung carcinoma cells harboring BRAF Y472C in culture (PMID: 22649091).	22649091
BRAF	BRAF L597V	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF L597V (PMID: 26343582).	26343582
BRAF	BRAF L597V NRAS Q61K	lung non-small cell carcinoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).	27523909
BRAF	BRAF L597V NRAS Q61K	lung non-small cell carcinoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).	27523909
BRAF	BRAF L597V NRAS Q61K	lung non-small cell carcinoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).	27523909
BRAF	BRAF L597V NRAS Q61K	lung non-small cell carcinoma	decreased response	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61L demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).	27523909
BRAF	BRAF L597V NRAS Q61K	lung non-small cell carcinoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).	27523909
BRAF	BRAF L485Y	lung non-small cell carcinoma	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring BRAF L485Y were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).	19276360
BRAF	BRAF V600K	lung non-small cell carcinoma	sensitive	Dabrafenib + Trametinib	Guideline	Actionable	The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) is included in guidelines as first or second-line therapy in patients with metastatic non-small cell lung cancer harboring a BRAF V600 mutation (PMID: 30715168, PMID: 30285222; ESMO.org).	30715168 detail... 30285222
BRAF	BRAF V600K	melanoma	sensitive	Cobimetinib + Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination therapy is included in melanoma guidelines for patients with metastatic or unresectable disease harboring a BRAF V600 activating mutation (NCCN.org).	detail...
BRAF	BRAF V600K	melanoma	sensitive	Cobimetinib + Vemurafenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (coBRIM) that supported FDA approval, treatment with the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months, compared to 7.2 months with Zelboraf (vemurafenib) plus placebo, among patients with BRAF V600-mutated metastatic melanoma, and BRAF V600E and BRAF V600K are on the companion diagnostic (PMID: 27480103; NCT01689519).	detail... 27480103 detail...
BRAF	BRAF V600K	melanoma	predicted - sensitive	Pembrolizumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, patients with melanoma harboring BRAF V600K (n=19) had increased tumor mutational burden and greater response rates (53% vs. 29%, p=0.059), progression-free survival (19 vs. 2.7 months, p=0.049), and overall survival (20.4 vs. 11.7 months, p=0.081) relative to patients with BRAF V600E (n=84) when treated with Keytruda (pembrolizumab) (n=17 and 62 for BRAF V600K and V600E, respectively) or Opdivo (nivolumab) (n=2 and 22 for BRAF V600K and V600E, respectively) (PMID: 30630828).	30630828
BRAF	BRAF V600K	melanoma	sensitive	Trametinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (METRIC) that supported FDA approval, Mekinist (trametinib) treatment, as compared to Deticine (dacarbazine) or Taxol (paclitaxel) treatment, resulted in improved progression-free survival of 4.8 months versus 1.5 months and an overall six month survival rate of 81% versus 67% in patients with BRAF V600E/K-positive metastatic melanoma (PMID: 22663011; NCT01245062).	22663011 detail... detail...
BRAF	BRAF V600K	melanoma	sensitive	Dabrafenib	Guideline	Actionable	Tafinlar (dabrafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, such as BRAF V600K, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).	detail...
BRAF	BRAF V600K	melanoma	sensitive	Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, such as BRAF V600K, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).	detail...
BRAF	BRAF V600K	melanoma	sensitive	GSK2126458	Preclinical	Actionable	In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).	22389471
BRAF	BRAF V600K	melanoma	sensitive	Binimetinib + Encorafenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) resulted in a median overall survival (OS) of 33.6 months, a 1-year OS rate of 77.5%, and a 2-year OS rate of 57.7% in patients with advanced melanoma harboring BRAF V600E/K mutations compared to a median OS of 16.9 months and 1- and 2-year OS rates of 63.1% and 43.2%, respectively, in the Zelboraf (vemurafenib) treated group (PMID: 30219628; NCT01909453).	detail... 30219628 detail... detail...
BRAF	BRAF V600K	melanoma	sensitive	Binimetinib + Encorafenib	Guideline	Actionable	Braftovi (encorafenib) in combination with Mektovi (binimetinib) is included in guidelines as first-line and second-line therapy for patients with metastatic or unresectable melanoma harboring BRAF V600E or V600K mutations (PMID: 30959471; NCCN.org).	30959471 detail...
BRAF	BRAF V600K	melanoma	sensitive	Binimetinib + Encorafenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) demonstrated improved tolerability profile and efficacy, resulted in a progression-free survival of 14.9 months in patients with advanced melanoma harboring BRAF V600E/K mutations, comparing to 7.3 months in the Zelboraf (vemurafenib) group (HR=0.54, p<0.0001) (PMID: 29573941; NCT01909453) and both BRAF V600E and BRAF V600K are on the companion diagnostic.	29573941 detail... detail... detail...
BRAF	BRAF V600K	melanoma	sensitive	Dabrafenib + Trametinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (COMBI-v) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved overall survival rate at 12 months (72% vs 65%, HR=0.69, p=0.005), median progression-free survival (11.4 vs 7.3 months, HR=0.56, p<0.001), and objective response rate (64% vs 51%, p<0.001) compared to Zelboraf (vemurafenib) in melanoma patients harboring BRAF V600E or V600K (PMID: 25399551; NCT01597908).	detail... 25399551 detail...
BRAF	BRAF V600K	melanoma	sensitive	Dabrafenib + Trametinib	Guideline	Actionable	Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for melanoma patients harboring a BRAF V600 activating mutation, such as BRAF V600K, as adjuvant therapy for stage III disease and as systemic therapy for patients with unresectable or metastatic disease (NCCN.org).	detail...
BRAF	BRAF V600K	melanoma	predicted - sensitive	Nivolumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, patients with melanoma harboring BRAF V600K (n=19) had increased tumor mutational burden and greater response rates (53% vs. 29%, p=0.059), progression-free survival (19 vs. 2.7 months, p=0.049), and overall survival (20.4 vs. 11.7 months, p=0.081) relative to patients with BRAF V600E (n=84) when treated with Keytruda (pembrolizumab) (n=17 and 62 for BRAF V600K and V600E, respectively) or Opdivo (nivolumab) (n=2 and 22 for BRAF V600K and V600E, respectively) (PMID: 30630828).	30630828
BRAF	BRAF V600K NRAS Q61K	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).	22389471
BRAF	BRAF V600K NRAS Q61K	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were 3-7 fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600K in culture (PMID: 22389471).	22389471
BRAF	BRAF V600K NRAS Q61K	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).	22389471
BRAF	BRAF V600K NRAS Q61K	melanoma	sensitive	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).	22389471
BRAF	BRAF V600K NRAS Q61K	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).	22389471
BRAF	BRAF V600K NRAS Q61K	melanoma	sensitive	GSK2126458	Preclinical	Actionable	In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).	22389471
BRAF	BRAF V600K MAP2K1 P124Q	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).	25370473
BRAF	BRAF V600K MAP2K1 P124Q	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).	25370473
BRAF	BRAF V600K MAP2K1 P124Q	melanoma	sensitive	VX-11e	Preclinical - Cell culture	Actionable	In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).	25370473
BRAF	BRAF V600K MAP2K1 P124L	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).	25370473
BRAF	BRAF V600K MAP2K1 P124L	melanoma	sensitive	VX-11e	Preclinical	Actionable	In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).	25370473
BRAF	BRAF V600K MAP2K1 P124L	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124L demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).	25370473
BRAF	BRAF N486_P490del	pancreatic cancer	predicted - sensitive	Dabrafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with pancreatic cancer harboring BRAF N486_P490del had a partial response when treated with Tafinlar (dabrafenib), demonstrating a decrease in the size of both the primary and metastatic lesions and response duration of 6 months (PMID: 31519698).	31519698
BRAF	BRAF N486_P490del	ovarian cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, an ovarian cancer cell line harboring BRAF N486_P490del was sensitive to Mekinist (trametinib), resulting in inhibition of cell growth in culture (PMID: 26732095).	26732095
BRAF	BRAF N486_P490del	ovarian cancer	predicted - resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) resulted in minimal growth inhibitory activity of an ovarian cancer cell line harboring BRAF N486_P490del (PMID: 26732095).	26732095
BRAF	BRAF N486_P490del	ovarian cancer	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, an ovarian cancer cell line harboring BRAF N486_P490del was sensitive to LY3009120, resulting in inhibition of cell growth and decreased phosphorylation of MEK and ERK in culture (PMID: 26732095).	26732095
BRAF	BRAF N486_P490del	pancreatic ductal adenocarcinoma	predicted - sensitive	Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, Mekinist (trametinib) treatment resulted in partial response in a patient with pancreatic ductal adenocarcinoma harboring BRAF N486_P490del 8 weeks after initiation of treatment and lasted for 6 months (PMID: 29903880).	29903880
BRAF	BRAF N486_P490del	ovarian cancer	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, an ovarian cancer cell line harboring BRAF N486_P490del was resistant to Zelboraf (vemurafenib), resulting in minimal inhibition of both cell growth and phosphorylation of MEK and ERK in culture (PMID: 26732095).	26732095
BRAF	BRAF G469A	lung non-small cell carcinoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a non-small cell lung cancer cell line harboring BRAF G469A demonstrated resistance to induction of apoptosis by Zelboraf (vemurafenib,) and treatment with Zelboraf (vemurafenib) was not effective in inhibiting growth in culture (PMID: 25706985).	25706985
BRAF	BRAF G469A	lung non-small cell carcinoma	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G469A mutation in culture (PMID: 26090892).	26090892
BRAF	BRAF G469A	lung non-small cell carcinoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) treatment did not result in significant growth inhibition in a non-small lung cancer cell line harboring BRAF G469A in culture (PMID: 29903896).	29903896
BRAF	BRAF G469A	head and neck cancer	sensitive	Ulixertinib	Phase I	Actionable	In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in two patients harboring BRAF G469A, including one patient with head and neck cancer and one patient with small bowel cancer (PMID: 29247021).	29247021
BRAF	BRAF G469A	lung non-small cell carcinoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased viability and enhanced ERK inhibition compared to either agent alone, in a non-small cell lung cancer cell line harboring BRAF G469A in culture (PMID: 28947956).	28947956
BRAF	BRAF G469A	lung non-small cell carcinoma	sensitive	Encorafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a non-small cell lung cancer cell line harboring BRAF G469A in culture (PMID: 29903896).	29903896
BRAF	BRAF G469A	small intestine carcinoma	sensitive	Ulixertinib	Phase I	Actionable	In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in two patients harboring BRAF G469A, including one patient with head and neck cancer and one patient with small bowel cancer (PMID: 29247021).	29247021
BRAF	BRAF G469A	lung adenocarcinoma	sensitive	PLX8394	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX8394 decreased growth of lung adenocarcinoma cell lines harboring BRAF G469A in culture, and reduced tumor growth in xenograft models (PMID: 27834212).	27834212
BRAF	BRAF G469A	lung non-small cell carcinoma	conflicting	Trametinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Zelboraf (vemurafenib) to treatment with Mekinist (trametinib) resulted in increased proliferation compared to Mekinist (trametinib) alone in a non-small cell lung cancer cell line harboring BRAF G469A in culture (PMID: 29903896).	29903896
BRAF	BRAF G469A	lung non-small cell carcinoma	conflicting	Trametinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Zelboraf (vemurafenib) inhibited growth of a non-small cell lung cancer cell line harboring BRAF G469A in culture, and prevented Mekinist (trametinib)-related activation of AKT and resulted in increased induction of apoptosis compared to either agent alone (PMID: 25706985).	25706985
BRAF	BRAF G469A	lung non-small cell carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) induced apoptosis and inhibited growth of a non-small cell lung cancer cell line harboring BRAF G469A in culture (PMID: 25706985).	25706985
BRAF	BRAF G469A	Advanced Solid Tumor	resistant	Vemurafenib	Clinical Study - Cohort	Actionable	In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 2 of the non-responding patients harbored BRAF G469A (PMID: 29320312; NCT02091141).	29320312
BRAF	BRAF G469A	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G469A (PMID: 26343582).	26343582
BRAF	BRAF G469A	lung cancer	resistant	RMC-4550	Preclinical - Cell culture	Actionable	In a preclinical study, RMC-4550 did not inhibit Erk phosphorylation or proliferation of lung cancer cells harboring BRAF G469A in culture (PMID: 30104724).	30104724
BRAF	BRAF V487_P492delinsA	pancreatic cancer	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA were sensitive to LY3009120 in culture and in xenograft models, resulting in inhibition of tumor growth and partial tumor regression (PMID: 26732095).	26732095
BRAF	BRAF V487_P492delinsA	pancreatic cancer	resistant	Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a human pancreatic cancer cell line harboring BRAF V487_P492delinsA was resistant to treatment with Zelboraf (vemurafenib) in both culture and xenograft models (PMID: 26732095).	26732095
BRAF	BRAF V487_P492delinsA	pancreatic cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA was sensitive to Mekinist (trametinib) in culture, resulting in cell growth inhibition (PMID: 26732095).	26732095
BRAF	BRAF V487_P492delinsA	pancreatic cancer	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA was resistant to Tafinlar (dabrafenib) (PMID: 26732095).	26732095
BRAF	BRAF F247L	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing BRAF F247L demonstrated sensitivity to Mekinist (trametinib) in culture (PMID: 28512244).	28512244
BRAF	BRAF F247L	Advanced Solid Tumor	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing BRAF F247L demonstrated sensitivity to Tafinlar (dabrafenib) in culture (PMID: 28512244).	28512244
BRAF	BRAF G469L	lung adenocarcinoma	no benefit	Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring BRAF G469L did not respond to Zelboraf (vemurafenib) therapy (PMID: 24035431).	24035431
BRAF	BRAF G466E	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).	27523909
BRAF	BRAF G466E	melanoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).	27523909
BRAF	BRAF G466E	melanoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF G466E in culture (PMID: 27523909).	27523909
BRAF	BRAF G466E	melanoma	decreased response	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).	27523909
BRAF	BRAF G466E	melanoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF G466E in culture (PMID: 27523909).	27523909
BRAF	BRAF G466E HRAS Q61K	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF G466E and HRAS Q61K in culture (PMID: 28783719).	28783719
BRAF	BRAF V600E BRAF T529I	Advanced Solid Tumor	predicted - resistant	SB590885	Preclinical	Actionable	In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529I were insensitive to SB590885-mediated inhibition of ERK signaling in culture (PMID: 20538618).	20538618
BRAF	BRAF V600E BRAF T529I	Advanced Solid Tumor	predicted - sensitive	RAF265	Preclinical	Actionable	In a preclinical study, RAF265 inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).	20538618
BRAF	BRAF V600E BRAF T529I	Advanced Solid Tumor	sensitive	CI-1040	Preclinical	Actionable	In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation in transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I in culture (PMID: 20538618).	20538618
BRAF	BRAF V600E BRAF T529I	Advanced Solid Tumor	predicted - sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).	20538618
BRAF	BRAF V600E BRAF T529I	Advanced Solid Tumor	predicted - resistant	PLX4720	Preclinical	Actionable	In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529I were insensitive to PLX4720-mediated inhibition of ERK signaling in culture (PMID: 20538618).	20538618
BRAF	BRAF L485W	gallbladder cancer	sensitive	Ulixertinib	Phase I	Actionable	In a Phase I trial, treatment with BVD-523 (Ulixertinib) resulted in a complete response lasting almost 1 year in a gallbladder cancer patient harboring BRAF L485W (PMID: 29247016, PMID: 29247021).	29247021 29247016
BRAF	BRAF V600E	colorectal cancer	sensitive	Panitumumab + Vemurafenib	Phase I	Actionable	In a Phase I trial, 83% (10/12) of patients with colorectal cancer carrying a BRAF V600E mutation demonstrated tumor regression when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 25589621).	25589621
BRAF	BRAF V600E	melanoma	decreased response	Nivolumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, patients with melanoma harboring BRAF V600E (n=84) had decreased response rates (29% vs. 53%, p=0.059), progression-free survival (2.7 vs. 19 months, p=0.049), and overall survival (11.7 vs. 20.4 months, p=0.081) relative to patients with BRAF V600K (n=19) when treated with Keytruda (pembrolizumab) (n=62 and 17 for BRAF V600E and V600K, respectively) or Opdivo (nivolumab) (n=22 and 2 for BRAF V600E and V600K, respectively) (PMID: 30630828).	30630828
BRAF	BRAF V600E	melanoma	sensitive	BGB-283	Preclinical - Cell culture	Actionable	In a preclinical study, BGB-283 inhibited Braf phosphorylation and cell proliferation in melanoma cell lines harboring BRAF V600E in culture (PMID: 26208524).	26208524
BRAF	BRAF V600E	melanoma	sensitive	BGB-283	Phase I	Actionable	In a Phase I trial, BGB-283 resulted in partial response in 1 of 2 melanoma patients harboring BRAF V600E, who remained on treatment for over 249 days (AACR Annual Meeting, Apr 2016, abstract # CT005).	detail...
BRAF	BRAF V600E	malignant glioma	predicted - sensitive	Everolimus + PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Afinitor (everolimus) and PLX4720 synergistically inhibited growth and induced apoptosis in glioma cell lines in culture (PMID: 27217440).	27217440
BRAF	BRAF V600E	melanoma	sensitive	BI-847325	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with BI-847325 resulted in decreased expression of Mcl-1 and Mek, and inhibited growth of melanoma cell lines harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models of BRAF V600E-positive melanoma, including models with BRAF-inhibitor resistance (PMID: 25873592).	25873592
BRAF	BRAF V600E	colorectal cancer	no benefit	Panitumumab + Trametinib	Phase I	Actionable	In a Phase I trial, combination therapy consisting of Vectibix (panitumumab) and Mekinist (trametinib) resulted in an overall response rate of 0% (0/31), stable disease in 55% (17/31), and a median progression-free survival of 2.6 months in patients with BRAF V600E colorectal cancer (PMID: 29431699; NCT01750918).	29431699
BRAF	BRAF V600E	melanoma	sensitive	INU-152	Preclinical - Cell line xenograft	Actionable	In a preclinical study, INU-152 reduced MEK and ERK phosphorylation and growth of a melanona cell line harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models (PMID: 28645859).	28645859
BRAF	BRAF V600E	colorectal cancer	sensitive	Erlotinib + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Tarceva (erlotinib) resulted in improved inhibition of tumor growth in BRAF V600E mutant human colon cancer cell line xenograft models compared to either drug as monotherapy (PMID: 22448344).	22448344
BRAF	BRAF V600E	colorectal cancer	sensitive	Cetuximab + PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of PLX4720 and Erbitux (cetuximab) inhibited tumor growth in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 22281684).	22281684
BRAF	BRAF V600E	melanoma	sensitive	SCH772984	Preclinical	Actionable	In a preclinical study, SCH772984 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534).	26267534
BRAF	BRAF V600E	colorectal cancer	sensitive	Dabrafenib + Panitumumab	Phase I	Actionable	In a Phase I trial, combination therapy consisting of Tafinlar (dabrafenib) and Vectibix (panitumumab) resulted in an overall response rate of 10% (2/20, 1 complete response, 1 partial response), stable disease in 80% (16/20), and a median progression-free survival of 3.5 months in patients with BRAF V600E colorectal cancer (PMID: 29431699; NCT01750918).	29431699
BRAF	BRAF V600E	colorectal cancer	sensitive	Dabrafenib + Panitumumab	Phase Ib/II	Actionable	In a Phase Ib/II trial, treatment with the combination of Vectibix (panitumumab) and Tafinlar (dabrafenib) resulted in stable disease in 7/8 colorectal cancer patients harboring a BRAF V600E mutation (J Clin Oncol 32:5s, 2014 (suppl; abstr 3515)).	detail...
BRAF	BRAF V600E	Advanced Solid Tumor	sensitive	PLX4720	Preclinical	Actionable	In a preclinical study, PLX4720 inhibited Erk phosphorylation and cell proliferation of transformed cells expression BRAF V600E in culture (PMID: 20538618).	20538618
BRAF	BRAF V600E	colorectal cancer	sensitive	SCH772984	Preclinical	Actionable	In a preclinical study, SCH772984 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534).	26267534
BRAF	BRAF V600E	colorectal cancer	sensitive	PLX4720 + TAK-632	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX4720 and TAK-632 combination treatment resulted in durable inhibition of Erk signaling and tumor growth in xenograft models of colorectal cancer cells harboring BRAF V600E (PMID: 27523909).	27523909
BRAF	BRAF V600E	melanoma	sensitive	SBI-0640756	Preclinical	Actionable	In a preclinical study, SBI-0640756 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).	20531415 26603897
BRAF	BRAF V600E	thyroid cancer	sensitive	Dasatinib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).	27222538
BRAF	BRAF V600E	lung non-small cell carcinoma	sensitive	TW-37 + Vemurafenib	Preclinical	Actionable	In a preclinical study, TW-37 enhanced the inhibitory effect of Zelboraf (vemurafenib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).	25665005
BRAF	BRAF V600E	melanoma	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell lines harboring BRAF V600E mutation in culture (PMID: 24448821).	24448821
BRAF	BRAF V600E	ovarian cancer	sensitive	CI-1040	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CI-1040 inhibited growth of a human ovarian cancer cell line harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models (PMID: 19018267).	19018267
BRAF	BRAF V600E	melanoma	sensitive	PAC-1 + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of PAC-1 and Zelboraf (vemurafenib) resulted in a synergistic effect when treating melanoma cells harboring BRAF V600E in culture and xenograft models, demonstrating increased apoptosis and decreased tumor volume (PMID: 27297867).	27297867
BRAF	BRAF V600E	colorectal cancer	sensitive	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E	lung cancer	sensitive	Ulixertinib	Phase I	Actionable	In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in two patients with lung cancer each harboring BRAF V600E (PMID: 29247021).	29247021
BRAF	BRAF V600E	colorectal cancer	sensitive	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).	23629727
BRAF	BRAF V600E	melanoma	sensitive	PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX4720 inhibited growth of melanoma cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 18287029).	18287029
BRAF	BRAF V600E	melanoma	sensitive	Imatinib + PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Gleevec (imatinib) and PLX4720 enhanced antitumor efficacy of melanoma cells harboring BRAF V600E, demonstrating decreased cell survival in xenograft models, and decreased phosphorylation of Mapk1 in culture (PMID: 27924459).	27924459
BRAF	BRAF V600E	malignant glioma	predicted - sensitive	Vemurafenib	Phase II	Actionable	In a Phase II clinical trial (VE-BASKET), treatment of patients with gliomas harboring BRAF V600E mutations with Zelboraf (vemurafenib) resulted in a 25% (6/24) objective response rate, 5.5-month median progression free survival, 28.2 month median overall survival, and best overall response rates of 4.2% (1/24) for complete response, 20.8% (5/24) for partial response, and 41.7% (10/24) for stable disease (PMID: 30351999; NCT01524978).	30351999
BRAF	BRAF V600E	melanoma	sensitive	Binimetinib	Phase II	Actionable	In a Phase II trial, 20% (8/41) of melanoma patients with BRAF V600 mutations had a partial response to Binimetinib (MEK162) (PMID: 23414587).	23414587
BRAF	BRAF V600E	melanoma	sensitive	Gefitinib + PLX4720	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) in combination with PLX4720 inhibited proliferation and tumorigenicity in human melanoma cell line harboring BRAF V600E and resistant to Braf inhibition in culture and in animal models (PMID: 23242808).	23242808
BRAF	BRAF V600E	colorectal cancer	sensitive	CCT196969	Preclinical - Cell culture	Actionable	In a preclinical study, CCT196969 inhibited growth of BRAF-mutant colorectal cancer cell lines in culture (PMID: 25500121), which have been reported to harbor BRAF V600E (PMID: 15294323).	25500121 15294323
BRAF	BRAF V600E	melanoma	sensitive	GSK2126458	Preclinical	Actionable	In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E	Advanced Solid Tumor	sensitive	Vemurafenib	Phase II	Actionable	In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response of 46% (12/26, 2 complete response, 10 partial response) in patients with advanced solid tumors harboring BRAF V600E, but only 4% (1/23, 1 partial response) in patients harboring non-V600 BRAF mutations (PMID: 29320312; NCT02091141).	29320312
BRAF	BRAF V600E	colorectal cancer	sensitive	Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E	colorectal cancer	sensitive	Cetuximab + Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E	colorectal cancer	sensitive	BGB-283	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, BGB-283 inhibited Braf phosphorylation and cell proliferation in colorectal cancer cell lines harboring BRAF V600E in culture, and resulted in partial tumor regression in both cell line and patient-derived xenograft models (PMID: 26208524).	26208524
BRAF	BRAF V600E	colon cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab), as a monotherapy, is not indicated for use in colon cancer patients with BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	childhood pilocytic astrocytoma	predicted - sensitive	Selumetinib	Phase I	Actionable	In a Phase I trial, Selumetinib (AZD6244) treatment resulted in a sustained partial response (PR) in 36% (9/25) and stable disease in 36% (9/25) of pediatric patients with pilocytic astrocytoma harboring KIAA1549-BRAF (n=18) or BRAF V600E (n=7), with a 2-year progression-free survival of 70%, and 29% (2/7) of the patients harboring BRAF V600E achieved PR (PMID: 31151904; NCT01089101).	31151904
BRAF	BRAF V600E	colorectal cancer	sensitive	Afatinib + BI 882370	Preclinical	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Gilotrif (afatinib) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115).	26916115
BRAF	BRAF V600E	melanoma	sensitive	Binimetinib + Encorafenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) demonstrated improved tolerability profile and efficacy, resulted in a progression-free survival of 14.9 months in patients with advanced melanoma harboring BRAF V600E/K mutations, comparing to 7.3 months in the Zelboraf (vemurafenib) group (HR=0.54, p<0.0001) (PMID: 29573941; NCT01909453), and both BRAF V600E and V600K are on the companion diagnostic.	29573941 detail... detail... detail...
BRAF	BRAF V600E	melanoma	sensitive	Binimetinib + Encorafenib	Guideline	Actionable	Braftovi (encorafenib) in combination with Mektovi (binimetinib) is included in guidelines as first-line and second-line therapy for patients with metastatic or unresectable melanoma harboring BRAF V600E or V600K mutations (PMID: 30959471; NCCN.org).	30959471 detail...
BRAF	BRAF V600E	melanoma	sensitive	Binimetinib + Encorafenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) resulted in a median overall survival (OS) of 33.6 months, a 1-year OS rate of 77.5%, and a 2-year OS rate of 57.7% in patients with advanced melanoma harboring BRAF V600E/K mutations compared to a median OS of 16.9 months and 1- and 2-year OS rates of 63.1% and 43.2%, respectively, in the Zelboraf (vemurafenib) treated group (PMID: 30219628; NCT01909453).	detail... 30219628 detail... detail...
BRAF	BRAF V600E	melanoma	sensitive	Cobimetinib + Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination therapy is included in melanoma guidelines for patients with metastatic or unresectable disease harboring a BRAF V600 activating mutation (NCCN.org).	detail...
BRAF	BRAF V600E	melanoma	sensitive	Cobimetinib + Vemurafenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (coBRIM) that supported FDA approval, treatment with the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months, compared to 7.2 months with Zelboraf (vemurafenib) plus placebo, among patients with BRAF V600-mutated metastatic melanoma, and BRAF V600E and BRAF V600K are on the companion diagnostic (PMID: 27480103; NCT01689519).	27480103 detail... detail...
BRAF	BRAF V600E	colorectal cancer	sensitive	Cetuximab + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) and Erbitux (cetuximab) combination treatment inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E	colorectal cancer	sensitive	Cetuximab + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, the combination of Zelboraf (vemurafenib) and Erbitux (cetuximab) was tolerated and showed clinical benefit in a patient with BRAF V600E mutant colorectal cancer (PMID: 24523613).	24523613
BRAF	BRAF V600E	melanoma	sensitive	Navitoclax + PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX4720 and navitoclax (ABT-263) worked synergistically to inhibit growth and increase apoptosis of BRAF V600E mutant melanoma cells in culture and in xenografts (PMID: 24983357).	24983357
BRAF	BRAF V600E	colon cancer	sensitive	PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PD-0325901 demonstrated antitumor activity against BRAF V600E colon cancer cell line xenografts (PMID: 16273091).	16273091
BRAF	BRAF V600E	colon cancer	sensitive	Dabrafenib + Panitumumab + Trametinib	Guideline	Actionable	Tafinlar (dabrafenib), Mekinist (trametinib), Vectibix (panitumumab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	melanoma	sensitive	Ganetespib + TAK-733	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the Hsp90 inhibitor, Ganetespib, in combination with the MEK1/2 inhibitor TAK-733, caused the regression of tumors in vemurafenib-resistant cell line xenograft models of melanoma (PMID: 24398428).	24398428
BRAF	BRAF V600E	melanoma	decreased response	Dabrafenib + SCH772984 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination of Tafinlar (dabrafenib), SCH772984, and Mekinist (trametinib) resulted in durable inhibition of Erk signaling and proliferation of melanoma cells overexpressing BRAF V600E in culture (PMID: 28714990).	28714990
BRAF	BRAF V600E	rectum cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab), as a monotherapy, is not indicated for use in rectum cancer patients with BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	melanoma	sensitive	SBI-755199	Preclinical	Actionable	In a preclinical study, SBI-755199 induced cell death in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897).	26603897
BRAF	BRAF V600E	colon cancer	sensitive	Navitoclax + Vemurafenib	Preclinical	Actionable	In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human colon cancer cells harboring BRAF V600E in culture (PMID: 25665005).	25665005
BRAF	BRAF V600E	thyroid gland anaplastic carcinoma	sensitive	Dabrafenib + Trametinib	Guideline	Actionable	Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for metastatic thyroid gland anaplastic carcinoma patients harboring BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	thyroid gland anaplastic carcinoma	sensitive	Dabrafenib + Trametinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase II trial (ROAR) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an overall response rate of 69% (11/16; 1 complete response and 10 partial responses) in patients with anaplastic thyroid cancer harboring BRAF V600E (PMID: 29072975; NCT02034110).	29072975 detail... detail...
BRAF	BRAF V600E	thyroid gland anaplastic carcinoma	sensitive	Dabrafenib + Trametinib	Clinical Study	Actionable	In a clinical case report, Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in a clinical and radiologic response that lasted for 9 months in an anaplastic thyroid cancer patient harboring BRAF V600E (PMID: 27697975).	27697975
BRAF	BRAF V600E	melanoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited cell invasion, cell signaling, and proliferation in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture and in animal models (PMID: 23242808).	23242808
BRAF	BRAF V600E	malignant glioma	predicted - sensitive	Everolimus + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) and Afinitor (everolimus) synergistically inhibited growth and induced apoptosis in glioma cell lines in culture, resulted in prolonged survival in cell line xenograft models (PMID: 27217440).	27217440
BRAF	BRAF V600E	melanoma	sensitive	Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, such as BRAF V600E, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).	detail...
BRAF	BRAF V600E	melanoma	sensitive	Vemurafenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (BRIM-3) that supported FDA approval, Zelboraf (vemurafenib), as compared to Deticene (dacarbazine), resulted in an improved overall survival (OS) (13.6 vs 9.7 months, HR=0.81, p=0.03) in patients with BRAF V600E-positive metastatic melanoma, with estimated OS rates of 56%, 30%, 21%, and 17% at 1, 2, 3, and 4 years, respectively (PMID: 28961848, PMID: 21639808; NCT01006980), and BRAF V600E is included on the companion diagnostic (FDA.gov).	28961848 detail... detail... 21639808
BRAF	BRAF V600E	lung non-small cell carcinoma	sensitive	Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung cancer patient harboring a BRAF V600E mutation had a complete response after treatment with Zelboraf (vemurafenib) (PMID: 23733758).	23733758
BRAF	BRAF V600E	lung non-small cell carcinoma	sensitive	Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib) is in guidelines for metastatic non-small cell lung cancer patients with BRAF V600E mutations who can not tolerate the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) (NCCN.org).	detail...
BRAF	BRAF V600E	lung non-small cell carcinoma	sensitive	Vemurafenib	Phase II	Actionable	In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response of 43% (6/14, 1 complete response, 5 partial response) in patients with non-small cell lung cancer harboring BRAF V600E, and stable disease lasting more than 120 days in 2 patients (PMID: 29320312; NCT02091141).	29320312
BRAF	BRAF V600E	Advanced Solid Tumor	sensitive	PLX8394	Preclinical	Actionable	In a preclinical study, PLX8394 had been shown to block survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAF V600E splice variants (PMID: 24422853).	24422853
BRAF	BRAF V600E	hairy cell leukemia	sensitive	Vemurafenib	Phase II	Actionable	In two Phase II clinical studies, patients with refractory hairy cell leukemia harboring BRAF V600E responded to Zelboraf (vemurafenib) with overall response rates of 96% (25/26) and 100% (24/24) as well as complete response rates of 35% (9/26) and 42% (10/24) with median follow up times of 8 and 12 weeks, respectively (PMID: 26352686).	26352686
BRAF	BRAF V600E	colorectal cancer	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).	23629727
BRAF	BRAF V600E	melanoma	decreased response	Pembrolizumab	Clinical Study	Actionable	In a retrospective analysis, patients with melanoma harboring BRAF V600E (n=84) had decreased response rates (29% vs. 53%, p=0.059), progression-free survival (2.7 vs. 19 months, p=0.049), and overall survival (11.7 vs. 20.4 months, p=0.081) relative to patients with BRAF V600K (n=19) when treated with Keytruda (pembrolizumab) (n=62 and 17 for BRAF V600E and V600K, respectively) or Opdivo (nivolumab) (n=22 and 2 for BRAF V600E and V600K, respectively) (PMID: 30630828).	30630828
BRAF	BRAF V600E	ovarian cancer	predicted - sensitive	Vemurafenib	Phase II	Actionable	In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response of 50% (2/4, 2 partial response) in patients with ovarian cancer harboring BRAF V600E, and stable disease lasting more than 120 days in 1 patient (PMID: 29320312; NCT02091141).	29320312
BRAF	BRAF V600E	colorectal cancer	sensitive	Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) decreased tumor growth in a cell line xenograft model of colorectal cancer harboring BRAF V600E (PMID: 23942066).	23942066
BRAF	BRAF V600E	colon cancer	sensitive	GDC0879	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GDC0879 inhibited survival of colon cancer cell lines harboring BRAF V600E in cell culture and cell line xenograft models (PMID: 19276360).	19276360
BRAF	BRAF V600E	colorectal cancer	sensitive	BI 882370 + Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Erbitux (cetuximab) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115).	26916115
BRAF	BRAF V600E	glioblastoma multiforme	decreased response	PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated a decreased response to treatment with PD-0325901, demonstrating increased viability of CD133 positive cells in culture (PMID: 26573800).	26573800
BRAF	BRAF V600E	melanoma	sensitive	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, RO5126766 inhibited proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 26438159).	26438159
BRAF	BRAF V600E	Advanced Solid Tumor	sensitive	CI-1040	Preclinical	Actionable	In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation and growth of transformed cells expressing BRAF V600E in culture (PMID: 20538618).	20538618
BRAF	BRAF V600E	melanoma	sensitive	Trametinib + TW-37	Preclinical	Actionable	In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).	25665005
BRAF	BRAF V600E	glioblastoma multiforme	decreased response	PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated a decreased response to treatment with PLX4720, demonstrating increased viability of CD133 positive cells in culture and in xenograft models (PMID: 26573800).	26573800
BRAF	BRAF V600E	melanoma	sensitive	Cediranib + PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX4720 and Cediranib (AZD-2171) worked synergistically to inhibit cell growth and induce apoptosis in PLX4720-resistant human melanoma cell lines harboring BRAF V600E in culture and to suppress tumor growth in xenograft models (PMID: 26461489).	26461489
BRAF	BRAF V600E	rectum cancer	sensitive	Dabrafenib + Panitumumab + Trametinib	Guideline	Actionable	Tafinlar (dabrafenib), Mekinist (trametinib), Vectibix (panitumumab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	colorectal cancer	sensitive	Pimasertib + Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).	23629727
BRAF	BRAF V600E	colorectal cancer	sensitive	INU-152	Preclinical - Cell line xenograft	Actionable	In a preclinical study, INU-152 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture, and reduced tumor growth in BRAF V600E-mutant colorectal cancer cell line xenograft models (PMID: 28645859).	28645859
BRAF	BRAF V600E	Advanced Solid Tumor	sensitive	SB590885	Preclinical	Actionable	In a preclinical study, SB590885 inhibited inhibited Erk phosphorylation and cell proliferation of transformed cells expression BRAF V600E in culture (PMID: 20538618).	20538618
BRAF	BRAF V600E	melanoma	sensitive	RXDX-105	Preclinical - Cell line xenograft	Actionable	In preclinical studies, CEP-32496 (RXDX-105) reduced tumor volume and promoted tumor regression in xenograft models of a BRAF V600E mutant human melanoma cell line (PMID: 22319199).	22319199
BRAF	BRAF V600E	glioblastoma multiforme	predicted - sensitive	Cobimetinib + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with epithelioid glioblastoma harboring BRAF V600E continued to response as Cotellic (cobimetinib) was added to Zelboraf (vemurafenib) treatment (PMID: 31217909).	31217909
BRAF	BRAF V600E	colon cancer	sensitive	Binimetinib + Encorafenib + Panitumumab	Guideline	Actionable	Braftovi (encorafenib), Mektovi (binimetinib), Vectibix (panitumumab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	melanoma	sensitive	Encorafenib	Preclinical - Cell line xenograft	Actionable	In preclinical studies, Encorafenib (LGX818) treatment of human melanoma xenograft models with BRAF V600E significantly decreased Mek activation and resulted in tumor regression (Cancer Res: 72(8) Suppl 1, Abstract #3790).	detail...
BRAF	BRAF V600E	thyroid cancer	sensitive	Dasatinib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).	27222538
BRAF	BRAF V600E	rectum cancer	sensitive	Irinotecan + Panitumumab + Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib), Vectibix (panitumumab), and Irinotecan combination therapy is included in guidelines for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	lung carcinoma	resistant	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) failed to induce apoptosis in lung carcinoma cells expressing BRAF V600E (PMID: 22649091).	22649091
BRAF	BRAF V600E	colorectal cancer	sensitive	Alpelisib + Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E	melanoma	sensitive	Alpelisib + PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Alpelisib (BYL719) and PLX4720 enhanced antitumor activity in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and decreased Akt signaling in culture (PMID: 27924459).	27924459
BRAF	BRAF V600E	colorectal cancer	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E	neuroendocrine tumor	predicted - sensitive	Trametinib + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, Mekinist (trametinib) and Zelboraf (vemurafenib) combination treatment resulted in a rapid and sustained clinical response in a patient with a rectal neuroendocrine tumor harboring a BRAF V600E mutation (PMID: 27048246).	27048246
BRAF	BRAF V600E	papillary thyroid carcinoma	sensitive	RO5126766	Preclinical	Actionable	In a preclinical study, RO5126766 inhibited Mek signaling and increased radioiodide uptake and response in transgenic animal models of papillary thyroid carcinoma driven by BRAF V600E (PMID: 27669459).	27669459
BRAF	BRAF V600E	colon cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab), as a monotherapy, is not indicated for use in colon cancer patients with BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	salivary gland carcinoma	predicted - sensitive	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case report, combined Tafinlar (dabrafenib) and Mekinist (trametinib) treatment of a patient with salivary duct carcinoma harboring BRAF V600E resulted in a reduction of metastatic lesions and stable disease lasting 13 months followed by disease progression (PMID: 30323086).	30323086
BRAF	BRAF V600E	colon cancer	sensitive	Irinotecan + Panitumumab + Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib), Vectibix (panitumumab), and Irinotecan combination therapy is included in guidelines for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	melanoma	sensitive	SBI-0640726	Preclinical	Actionable	In a preclinical study, SBI-0640726 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).	20531415 26603897
BRAF	BRAF V600E	melanoma	sensitive	Navitoclax + Vemurafenib	Preclinical	Actionable	In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).	25665005
BRAF	BRAF V600E	lymphatic system cancer	predicted - sensitive	Cobimetinib	Case Reports/Case Series	Actionable	In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including 1 partial response and 3 complete responses in 4 patients with Erdheim-Chester disease harboring BRAF V600E (PMID: 30867592; NCT01953926).	30867592
BRAF	BRAF V600E	melanoma	sensitive	ASN003	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a melanoma xenograft model harboring BRAF V600E demonstrated tumor regression when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).	detail...
BRAF	BRAF V600E	rectum cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab), as a monotherapy, is not indicated for use in rectum cancer patients with BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	melanoma	sensitive	GDC0879	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, GDC0879 inhibited survival of melanoma cell lines harboring BRAF V600E in cell culture, cell line xenograft and patient-derived xenograft (PDX) models (PMID: 19276360).	19276360
BRAF	BRAF V600E	melanoma	sensitive	Palbociclib + PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination treatment of PD-0325901 and Ibrance (palbociclib) resulted in significant tumor regression in melanoma cell line xenograft models harboring BRAF V600E and demonstrated a 56% (5/9) complete response rate (PMID: 27488531).	27488531
BRAF	BRAF V600E	colorectal cancer	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).	23629727
BRAF	BRAF V600E	melanoma	sensitive	EBI-907	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EBI-907 inhibited BRAF and ERK signaling, resulted in growth inhibition of melanoma cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 26810733).	26810733
BRAF	BRAF V600E	melanoma	sensitive	PAC-1 + Trametinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of PAC-1 to Mekinist (trametinib) and Zelboraf (vemurafenib) led to greater levels of caspase-3 activity and apoptosis in melanoma cells harboring BRAF V600E when compared to Zelboraf (vemurafenib) and Mekinist (trametinib) treatment without PAC-1 (PMID: 27297867).	27297867
BRAF	BRAF V600E	malignant glioma	predicted - sensitive	PLX4720 + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) and PLX4720 synergistically inhibited growth and induced apoptosis in glioma cell lines in culture, resulted in prolonged survival in cell line xenograft models (PMID: 27217440).	27217440
BRAF	BRAF V600E	pleomorphic xanthoastrocytoma	predicted - sensitive	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in clinical benefit that lasted for more than 14 months in a patient with pleomorphic xanthoastrocytoma harboring BRAF V600E (PMID: 29632053).	29632053
BRAF	BRAF V600E	colon neuroendocrine neoplasm	predicted - sensitive	Dabrafenib	Case Reports/Case Series	Actionable	In a clinical case study, Tafinlar (dabrafinib) treatment of a patient with recurrent neuroendocrine carcinoma of the colon harboring a BRAF V600E mutation resulted in stable disease for 6 months before disease progression (PMID: 30181415).	30181415
BRAF	BRAF V600E	melanoma	no benefit	SHP099	Preclinical	Actionable	In a preclinical study, SHP099 did not inhibit proliferation or ERK activation in a melanoma cell line harboring BRAF V600E in culture (PMID: 27362227).	27362227
BRAF	BRAF V600E	colorectal cancer	sensitive	PD-0325901	Preclinical	Actionable	In a preclinical study, PD-0325901 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534).	26267534
BRAF	BRAF V600E	colorectal cancer	sensitive	Refametinib	Preclinical	Actionable	In a preclinical study, Refametinib (BAY86-9766) inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture and suppressed tumor growth in cell line xenograft models (PMID: 19706763).	19706763
BRAF	BRAF V600E	melanoma	sensitive	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, RO4987655 inhibited proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 26438159).	26438159
BRAF	BRAF V600E	glioblastoma multiforme	predicted - sensitive	Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, Zelboraf (vemurafenib) treatment resulted in tumor regression as confirmed by MRI after 3-weeks of treatment in a patient with epithelioid glioblastoma harboring BRAF V600E (PMID: 31217909).	31217909
BRAF	BRAF V600E	glioblastoma multiforme	predicted - sensitive	Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, Zelboraf (vemurafenib) treatment resulted in a partial response 1 week after treatment in a patient with epithelioid type glioblastoma harboring BRAF V600E, although the patient soon passed due to complications (PMID: 31386052).	31386052
BRAF	BRAF V600E	melanoma	sensitive	DETD-35	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DETD-35 inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951).	27048951
BRAF	BRAF V600E	pilocytic astrocytoma	predicted - sensitive	Dabrafenib	Case Reports/Case Series	Actionable	In a clinical case study, Tafinlar (dabrafenib) treatment resulted in a near complete response and resolution of leptomeningeal dissemination in a patient with pilocytic astrocytoma harboring BRAF V600E (PMID: 28784858).	28784858
BRAF	BRAF V600E	colorectal cancer	sensitive	Lapatinib + Panobinostat	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) and Faridak (panobinostat) worked synergistically to inhibit growth of BRAF V600E mutant colorectal cancer cells in culture (PMID: 21464044).	21464044
BRAF	BRAF V600E	colon adenocarcinoma	not applicable	N/A	Phase III	Emerging	In a post-hoc analysis of a Phase III trial, BRAF V600E mutations in colon adenocarcinoma patients with microsatellite stable tumors were associated with a shorter disease-free survival and overall survival compared to those patients with microsatellite instability tumors, suggesting that BRAF V600E may serve as a future prognostic biomarker in this patient population (PMID: 26768652).	26768652
BRAF	BRAF V600E	melanoma	no benefit	Palbociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with Ibrance (palbociclib) in a melanoma cell line xenograft model harboring BRAF V600E resulted in no benefit, demonstrating low but continuous growth (PMID: 27488531).	27488531
BRAF	BRAF V600E	colorectal cancer	sensitive	Cobimetinib + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Cotellic (cobimetinib) and Zelboraf (vemurafenib) inhibited tumor growth in a cell line xenograft model of colorectal cancer harboring BRAF V600E (PMID: 28649441).	28649441
BRAF	BRAF V600E	thyroid cancer	sensitive	Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited growth of both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).	27222538
BRAF	BRAF V600E	melanoma	sensitive	DETD-35 + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DETD-35 and Zelboraf (vemurafenib) synergistically inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951).	27048951
BRAF	BRAF V600E	melanoma	sensitive	PLX4720 + Tivozanib	Preclinical	Actionable	In a preclinical study, PLX4720 and Tivozanib (AV-951) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).	26461489
BRAF	BRAF V600E	larynx cancer	predicted - sensitive	Vemurafenib	Case Reports/Case Series	Actionable	In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in complete response in a patient with larynx cancer harboring BRAF V600E (PMID: 29320312; NCT02091141).	29320312
BRAF	BRAF V600E	lung non-small cell carcinoma	sensitive	Dabrafenib + Trametinib	Guideline	Actionable	Combination of Mekinist (trametinib) and Tafinlar (dabrafenib) is in guidelines for metastatic non-small cell lung cancer patients with BRAF V600E mutations (NCCN.org).	detail...
BRAF	BRAF V600E	lung non-small cell carcinoma	sensitive	Dabrafenib + Trametinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase II trial that supported FDA approval, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in patients with non-small cell lung cancer harboring BRAF V600E resulted in an overall response rate of 66.7% (38/57) in previously treated patients and 64% (23/36) in untreated patients, versus 33% (26/78) treated with Tafinlar (dabrafenib) alone (PMID: 27080216, PMID: 27283860, PMID: 28919011; NCT01336634).	27283860 detail... 27080216 detail... detail... 28919011
BRAF	BRAF V600E	lung non-small cell carcinoma	sensitive	Navitoclax + Trametinib	Preclinical	Actionable	In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).	25665005
BRAF	BRAF V600E	Advanced Solid Tumor	predicted - sensitive	PF-00477736 + PF3644022	Preclinical - Cell culture	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of transformed cells over expressing BRAF V600E in culture, while single agent inhibition had no effect (PMID: 26140595).	26140595
BRAF	BRAF V600E	colorectal cancer	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 27523909).	27523909
BRAF	BRAF V600E	melanoma	sensitive	SBI-0640756 + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Zelboraf (vemurafenib) in combination with SBI-0640756 inhibited the association of eIF4G1 and eIF4E in Zelboraf (vemurafenib) resistant human melanoma cell lines harboring BRAF V600E in culture and reduced tumor growth in xenograft models (PMID: 26603897).	26603897
BRAF	BRAF V600E	melanoma	sensitive	TW-37 + Vemurafenib	Preclinical	Actionable	In a preclinical study, TW-37 enhanced the inhibitory effect of Zelboraf (vemurafenib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).	25665005
BRAF	BRAF V600E	thyroid cancer	sensitive	Dasatinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).	27222538
BRAF	BRAF V600E	melanoma	sensitive	Saracatinib	Preclinical	Actionable	In a preclinical study, saracatinib inhibited proliferation of human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture (PMID: 23242808).	23242808
BRAF	BRAF V600E	melanoma	sensitive	Navitoclax + Trametinib	Preclinical	Actionable	In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).	25665005
BRAF	BRAF V600E	colorectal cancer	sensitive	Cetuximab + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E	colorectal cancer	sensitive	PLX7904	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX7904 inhibited survival of colorectal cancer cells harboring BRAF V600E in culture and demonstrated anti-tumor activity in cell line xenograft models (PMID: 26466569).	26466569
BRAF	BRAF V600E	colon cancer	sensitive	Cetuximab + Dabrafenib + Trametinib	Guideline	Actionable	Tafinlar (dabrafenib), Mekinist (trametinib), Erbitux (cetuximab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	rectum cancer	sensitive	Cetuximab + Dabrafenib + Trametinib	Guideline	Actionable	Tafinlar (dabrafenib), Mekinist (trametinib), Erbitux (cetuximab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	glioblastoma multiforme	predicted - sensitive	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, an epithelioid glioblastoma patient harboring BRAF V600E treated with Mekinist (trametinib) and Tafinlar (dabrafenib) combination therapy resulted in stable disease, and the patient continued to demonstrate stable disease at least 16 months after initiation of therapy (PMID: 29632053).	29632053
BRAF	BRAF V600E	glioblastoma multiforme	predicted - sensitive	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in significant clinical improvement in a patient with epithelioid glioblastoma harboring BRAF V600E, however, her disease progressed after 3 months of therapy (PMID: 31217909).	31217909
BRAF	BRAF V600E	colorectal cancer	sensitive	Regorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture and suppressed angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960).	21170960
BRAF	BRAF V600E	melanoma	sensitive	BI-69A11	Preclinical	Actionable	In a preclinical study, BI-69A11 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).	20531415 26603897
BRAF	BRAF V600E	colorectal cancer	sensitive	Cetuximab + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E	colon cancer	sensitive	Cetuximab + Irinotecan + Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib), Erbitux (cetuximab), and Camptosar (irinotecan) combination therapy is included in guidelines for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	thyroid cancer	sensitive	Lapatinib + Vemurafenib	Preclinical	Actionable	In a preclinical study, the combination of Tykerb (lapatinib) and Zelboraf (vemurafenib) inhibited growth of thyroid cancer cells harboring a BRAF V600E mutation in culture and in BRAF-mutant mouse models of thyroid cancer (PMID: 23365119).	23365119
BRAF	BRAF V600E	thyroid cancer	sensitive	CLM3	Preclinical	Actionable	In a preclinical study, CLM3 inhibited growth, Egfr signaling, and CCND1 expression in thyroid cancer cells harboring BRAF V600E in culture (PMID: 24423321).	24423321
BRAF	BRAF V600E	colon carcinoma	sensitive	RXDX-105	Preclinical - Cell line xenograft	Actionable	In preclinical studies, CEP-32496 (RXDX-105) reduced tumor volume and promoted tumor regression in xenograft models of a BRAF V600E mutant human colon carcinoma cell line (PMID: 22319199).	22319199
BRAF	BRAF V600E	colorectal cancer	sensitive	EBI-907	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EBI-907 inhibited BRAF and ERK signaling, resulted in growth inhibition of colorectal cancer cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 26810733).	26810733
BRAF	BRAF V600E	colon cancer	sensitive	Navitoclax + Trametinib	Preclinical	Actionable	In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human colon cancer cells harboring BRAF V600E in culture (PMID: 25665005).	25665005
BRAF	BRAF V600E	melanoma	sensitive	CCT196969	Preclinical - Pdx	Actionable	In a preclinical study, CCT196969 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121).	25500121
BRAF	BRAF V600E	colorectal cancer	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation were sensitive to Nexavar (sorafenib) in culture (PMID: 24885690).	24885690
BRAF	BRAF V600E	colorectal cancer	resistant	SHP099	Preclinical - Cell culture	Actionable	In a preclincial study, colorectal cancer cell lines harboring BRAF V600E demonstrated resistance to SHP099 in culture (PMID: 27362227).	27362227
BRAF	BRAF V600E	melanoma	predicted - sensitive	RAF265	Phase I	Actionable	In a Phase I trial, treatment with RAF265 in melanoma patients resulted in an objective response rate of 12.1% (8/66), including a partial response in four patients harboring BRAF V600E, two partial responses and one complete response in patients with wild-type BRAF, and one complete response in a patient with unknown mutational status (PMID: 28719152).	28719152
BRAF	BRAF V600E	rectum cancer	sensitive	Cetuximab + Irinotecan + Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib), Erbitux (cetuximab), and Camptosar (irinotecan) combination therapy is included in guidelines for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	lung non-small cell carcinoma	sensitive	Dabrafenib	Guideline	Actionable	Tafinlar (dabrafenib) is in guidelines for metastatic non-small cell lung cancer patients with BRAF V600E mutations who can not tolerate the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) (NCCN.org).	detail...
BRAF	BRAF V600E	lung non-small cell carcinoma	sensitive	Dabrafenib	Phase II	Actionable	In a Phase II trial, 33% (26/78) of previously treated non-small cell lung carcinoma patients harboring BRAF V600E demonstrated an overall response, which included all partial responses, when treated with Tafinlar (dabrafenib) while 67% (4/6) receiving Tafinlar (dabrafenib) as a first-line treatment achieved partial responses (PMID: 27080216; NCT01336634).	27080216
BRAF	BRAF V600E	Advanced Solid Tumor	sensitive	RAF265	Preclinical	Actionable	In a preclinical study, RAF265 inhibited Erk phosphorylation and cell proliferation in BRAF V600E expressing cells in culture (PMID: 20538618).	20538618
BRAF	BRAF V600E	melanoma	sensitive	SB590885	Preclinical - Cell culture	Actionable	In a preclinical study, SB590885 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).	27523909
BRAF	BRAF V600E	papillary thyroid carcinoma	predicted - sensitive	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a papillary thyroid carcinoma patient who progressed on Lenvima (lenvatinib) was found to harbor BRAF V600E and was treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) on a clinical trial, resulting in partial response in the thyroid bed, cervical and intrathoracic lymph nodes, and pulmonary lesions, with a decrease in target lesion size of 67%, and the patient remained on treatment for 18 months before stopping due to progression (PMID: 31085763).	31085763
BRAF	BRAF V600E	melanoma	sensitive	RAF709	Preclinical - Cell culture	Actionable	In a preclinical study, RAF709 inhibited Erk signaling and proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 29343524).	29343524
BRAF	BRAF V600E	melanoma	sensitive	Trametinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (METRIC) that supported FDA approval, Mekinist (trametinib) treatment, as compared to Deticine (dacarbazine) or Taxol (paclitaxel) treatment, resulted in improved progression-free survival of 4.8 months versus 1.5 months and an overall six month survival rate of 81% versus 67% in patients with BRAF V600E/K-positive metastatic melanoma (PMID: 22663011; NCT01245062).	22663011 detail... detail...
BRAF	BRAF V600E	thyroid cancer	predicted - sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).	27222538
BRAF	BRAF V600E	glioblastoma multiforme	sensitive	Ulixertinib	Phase I	Actionable	In a Phase I trial, treatment with BVD-523 (Ulixertinib) resulted in a partial response in a patient with glioblastoma harboring BRAF V600E (PMID: 29247021).	29247021
BRAF	BRAF V600E	colorectal cancer	sensitive	CCT241161	Preclinical	Actionable	In a preclinical study, CCT241161 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 25500121, PMID: 15294323).	25500121 15294323
BRAF	BRAF V600E	colorectal cancer	sensitive	BGB-283 + Cetuximab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BGB-283 in combination with Erbitux (cetuximab) demonstrated enhanced tumor suppression in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 26208524).	26208524
BRAF	BRAF V600E	colorectal cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, colorectal cancer cells harboring a BRAF V600E mutation had increased sensitivity to Mekinist (trametinib) compared to other colorectal cancer lines in culture (PMID: 25309914).	25309914
BRAF	BRAF V600E	colorectal cancer	no benefit	Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, colorectal cancer cell lines were not sensitive to growth inhibition by Zelboraf (vemurafenib) in culture or xenograft models, due to feedback activation of EGFR signaling (PMID: 22281684).	22281684
BRAF	BRAF V600E	colorectal cancer	no benefit	Vemurafenib	Phase II	Actionable	In a Phase II trial, Zelboraf (vemurafenib) did not demonstrate meaningful clinical activity as a single agent, resulted in partial response in 5% (1/21) and stable disease in 33% (7/21) of patients with metastatic colorectal cancer harboring BRAF V600E (PMID: 26460303; NCT00405587).	26460303
BRAF	BRAF V600E	colorectal cancer	no benefit	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cell lines harboring BRAF V600E demonstrated decreased response to Zelboraf (vemurafenib) in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E	melanoma	no benefit	Sorafenib	Phase II	Actionable	In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF V600E mutations (PMID: 16880785, PMID: 22394203).	22394203 16880785
BRAF	BRAF V600E	renal cell carcinoma	predicted - sensitive	Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with metastatic renal cell carcinoma harboring BRAF V600E demonstrated a partial response following treatment with Zelboraf (vemurafenib) (PMID: 26918217).	26918217
BRAF	BRAF V600E	neuroendocrine tumor	predicted - sensitive	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in a rapid and sustained clinical response in a patient with a rectal neuroendocrine tumor harboring a BRAF V600E mutation (PMID: 27048246).	27048246
BRAF	BRAF V600E	colon cancer	sensitive	PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX4720 inhibited growth of colon cancer cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 18287029).	18287029
BRAF	BRAF V600E	melanoma	sensitive	Encorafenib + Ribociclib	Phase Ib/II	Actionable	In a Phase Ib/II trial, Encorafenib (LGX818) and Kisqali (ribociclib) combination treatment resulted in confirmed partial response in 7.1% (2/28), unconfirmed partial response in 10.7% (3/28), and stable disease in 35.7% (10/28) of patients with melanoma harboring BRAF V600E (PMID: 28351928).	28351928
BRAF	BRAF V600E	melanoma	sensitive	Refametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Refametinib (BAY86-9766) inhibited growth of melanoma cell lines harboring BRAF V600E in culture and suppressed tumor growth in cell line xenograft models (PMID: 19706763).	19706763
BRAF	BRAF V600E	ganglioglioma	predicted - sensitive	Dabrafenib	Case Reports/Case Series	Actionable	In a clinical case study, Tafinlar (dabrafenib) treatment resulted in partial response 8 weeks after therapy initiation in a pediatric patient with anaplastic ganglioglioma harboring BRAF V600E, but disease progression occurred at 40 weeks due to acquired resistance (PMID: 29880583).	29880583
BRAF	BRAF V600E	melanoma	sensitive	Cobimetinib	Phase I	Actionable	In a Phase I trial, Cotellic (cobimetinib) treatment resulted in a confirmed partial response in six melanoma patients harboring BRAF V600E (PMID: 27424159).	27424159
BRAF	BRAF V600E	colon cancer	predicted - sensitive	Cetuximab + Sorafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with metastatic colon cancer harboring BRAF V600E demonstrated mixed radiographic response with slight progression in some locations and stable disease in other locations for 7 months following treatment with the combination of Nexavar (sorafenib) and Erbitux (cetuximab) (PMID: 23792568).	23792568
BRAF	BRAF V600E	rectum cancer	sensitive	Binimetinib + Cetuximab + Encorafenib	Guideline	Actionable	Braftovi (encorafenib), Mektovi (binimetinib), Erbitux (cetuximab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	melanoma	sensitive	PLX4720 + Selumetinib	Preclinical	Actionable	In a preclinical study, PLX4720 and Selumetinib (AZD6244) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).	26461489
BRAF	BRAF V600E	pleomorphic xanthoastrocytoma	predicted - sensitive	Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, Zelboraf (vemurafenib) treatment resulted in a complete intracranial response 2 months after treatment in a patient with anaplastic pleomorphic xanthoastrocytoma harboring BRAF V600E, although the disease progressed 1 month later (PMID: 31386052).	31386052
BRAF	BRAF V600E	pleomorphic xanthoastrocytoma	predicted - sensitive	Vemurafenib	Phase II	Actionable	In a Phase II clinical trial (VE-BASKET), Zelboraf (vemurafenib) treatment of BRAF V600E mutant pleomorphic xanthoastrocytomas resulted in a 42.9% (3/7) objective response rate, a 5.7-month median progression-free survival, and best overall response rates of 14.3% (1/7) for complete response, 28.6% (2/7) for partial response, and 42.9% (3/7) for stable disease (PMID: 30351999; NCT01524978).	30351999
BRAF	BRAF V600E	melanoma	sensitive	Cediranib + PLX4720 + Selumetinib	Preclinical	Actionable	In a preclinical study, PLX4720, Cediranib (AZD-2171) and Selumetinib (AZD6244) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).	26461489
BRAF	BRAF V600E	melanoma	conflicting	PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a melanoma cell line xenograft model harboring BRAF V600E treated with PD-0325901 demonstrated stable tumor growth, but by day 44, growth ensued and thus, demonstrated no benefit (PMID: 27488531).	27488531
BRAF	BRAF V600E	melanoma	conflicting	PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, PD-0325901 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534).	26267534
BRAF	BRAF V600E	thyroid cancer	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of thyroid cancer cells harboring BRAF V600E in culture (PMID: 27523909).	27523909
BRAF	BRAF V600E	rectum cancer	sensitive	Binimetinib + Encorafenib + Panitumumab	Guideline	Actionable	Braftovi (encorafenib), Mektovi (binimetinib), Vectibix (panitumumab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	melanoma	sensitive	CCT241161	Preclinical - Pdx	Actionable	In a preclinical study, CCT241161 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121).	25500121
BRAF	BRAF V600E	melanoma	sensitive	Erlotinib + PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of PLX4720 and Tarceva (erlotinib) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models and culture (PMID: 27924459).	27924459
BRAF	BRAF V600E	lung non-small cell carcinoma	sensitive	Trametinib + TW-37	Preclinical	Actionable	In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).	25665005
BRAF	BRAF V600E	melanoma	sensitive	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, PLX7904 inhibited survival of melanoma cell lines harboring monomeric BRAF V600E as well as cells harboring the Zelboraf (vemurafenib)-resistant dimeric BRAF V600E in culture (PMID: 26466569).	26466569
BRAF	BRAF V600E	melanoma	sensitive	DEL-22379	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DEL-22379 inhibited growth of melanoma cells harboring BRAF V600E with high levels of ERK dimerization in culture and inhibited tumor progression in melanoma xenograft models harboring BRAF V600E (PMID: 26267534).	26267534
BRAF	BRAF V600E	skin melanoma	sensitive	Ganetespib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the Hsp90 inhibitor Ganetespib destabilized BRAF, especially BRAF V600E, resulted in loss of cell viability in culture and antitumor effects in cell line xenograft models of melanoma (PMID: 24398428).	24398428
BRAF	BRAF V600E	colorectal cancer	sensitive	Encorafenib	Phase I	Actionable	In a Phase I trial, Encorafenib (LGX818) showed activity in patients with advanced metastatic colorectal cancer harboring a BRAF V600E mutation, resulting in a median progression-free survival of 4 months and a best response of stable disease in 66.7% (12/18) (Ann Oncol (2014) 25 (suppl 4): iv182-iv183).	detail...
BRAF	BRAF V600E	colorectal cancer	sensitive	BI 882370 + Trametinib	Preclinical	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Mekinist (trametinib) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115).	26916115
BRAF	BRAF V600E	melanoma	sensitive	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E	colorectal cancer	predicted - sensitive	LSN3074753	Preclinical - Pdx	Actionable	In a preclinical study, LSN3074753 demonstrated modest efficacy in patient-derived xenograft models of colorectal cancer harboring BRAF V600E, resulted in tumor growth inhibition or regression, but relapse upon discontinuation of treatment (PMID: 28611205).	28611205
BRAF	BRAF V600E	colon cancer	sensitive	Binimetinib + Cetuximab + Encorafenib	Guideline	Actionable	Braftovi (encorafenib), Mektovi (binimetinib), Erbitux (cetuximab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).	detail...
BRAF	BRAF V600E	colorectal cancer	predicted - sensitive	Binimetinib + Cetuximab + Encorafenib	Phase III	Actionable	In a Phase III (BEACON CRC) trial, Braftovi (encorafenib), Mektovi (binimetinib), and Erbitux (cetuximab) combination treatment (n=111) resulted in improved median overall survival (9.0 vs 5.4 months, HR=0.52, p<0.001), confirmed response rate (26% vs 2%, p<0.001), and median progression-free survival (4.3 vs 1.5 months, HR=0.38, p<0.001) compared to control (n=107) in patients with metastatic colorectal cancer harboring BRAF V600E (PMID: 31566309; NCT02928224).	31566309
BRAF	BRAF V600E	glioblastoma multiforme	sensitive	BI2536	Preclinical - Cell culture	Actionable	In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated sensitivity to BI2536 in culture (PMID: 26573800).	26573800
BRAF	BRAF V600E	colorectal cancer	sensitive	Ulixertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ulixertinib (BVD-523) inhibited Erk signaling in colorectal cancer cells harboring BRAF V600E, resulted in cell cycle arrest in culture and tumor growth inhibition in cell line xenograft models (PMID: 28939558).	28939558
BRAF	BRAF V600E	colorectal cancer	sensitive	DT01 + Fluorouracil + Oxaliplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DT01 increased sensitivity of human colorectal cancer (CRC) cells harboring BRAF V600E to Eloxatin (oxaliplatin) and Adrucil (5-fluorouracil), and the combination resulted in decreased liver tumor growth in CRC cell line xenograft metastasis models (PMID: 26637369).	26637369
BRAF	BRAF V600E	melanoma	sensitive	PLX4720 + Vorinostat	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of PLX4720 and Zolinza (vorinostat) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and decreased Rb phosphorylation in culture (PMID: 27924459).	27924459
BRAF	BRAF V600E	thyroid cancer	sensitive	BGB-283	Phase I	Actionable	In a Phase I trial, BGB-283 resulted in partial response in 1 thyroid cancer patient harboring BRAF V600E, who remained on treatment for over 481 days (AACR Annual Meeting, Apr 2016, abstract # CT005).	detail...
BRAF	BRAF V600E	melanoma	sensitive	Selumetinib	Phase II	Actionable	In a Phase II trial, a favorable response rate to selumetinib (AZD6244) was observed in mutant BRAF but not BRAF wild-type melanoma patients (PMID: 22048237).	22048237
BRAF	BRAF V600E	hairy cell leukemia	not applicable	N/A	Guideline	Diagnostic	BRAF V600E is diagnostic and aids in distinguishing classic hairy cell leukemia (cHCL) from variant hairy cell leukemia (HCLv) and other B-cell lymphomas and leukemias (PMID: 29118233, NCCN.org).	detail... 29118233
BRAF	BRAF V600E	melanoma	sensitive	Dabrafenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III clinical trial (BREAK-3) that supported FDA approval, Tafinlar (dabrafenib) improved median progression-free survival compared to Deticene (dacarbazine) (5.1 vs 2.7 months, HR=0.3, p<0.0001) in patients with BRAF V600E positive melanoma (PMID: 22735384; NCT01227889).	detail... detail... 22735384
BRAF	BRAF V600E	melanoma	sensitive	Dabrafenib	Guideline	Actionable	Tafinlar (dabrafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, such as BRAF V600E, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).	detail...
BRAF	BRAF V600E	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E	Advanced Solid Tumor	sensitive	BGB-283	Preclinical - Cell culture	Actionable	In a preclinical study, BGB-283 inhibited viability of a variety of cancer cell lines harboring BRAF V600E in culture (PMID: 26208524).	26208524
BRAF	BRAF V600E	pancreatic endocrine carcinoma	predicted - sensitive	Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with pancreatic endocrine carcinoma found to harbor BRAF V600E demonstrated stable disease and some tumor shrinkage when treated with Zelboraf (vemurafenib) (PMID: 31158244).	31158244
BRAF	BRAF V600E	melanoma	sensitive	S3I-201	Preclinical	Actionable	In a preclinical study, S3I-201 inhibited cell invasion and Stat3 signaling in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture (PMID: 23242808).	23242808
BRAF	BRAF V600E	colorectal cancer	sensitive	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E	melanoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).	27523909
BRAF	BRAF V600E	colon neuroendocrine neoplasm	no benefit	Binimetinib	Case Reports/Case Series	Actionable	In Phase II trial, Mektovi (binimetinib) therapy in a patient with recurrent neuroendocrine carcinoma of the colon harboring a BRAF V600E mutation who had previously progressed on Tafinlar (dabrafinib) resulted in disease progression after two cycles (PMID: 30181415; NCT01885195).	30181415
BRAF	BRAF V600E	melanoma	resistant	RMC-4550	Preclinical - Cell culture	Actionable	In a preclinical study, RMC-4550 did not inhibit Erk phosphorylation or proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 30104724).	30104724
BRAF	BRAF V600E	lung non-small cell carcinoma	sensitive	Navitoclax + Vemurafenib	Preclinical	Actionable	In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).	25665005
BRAF	BRAF V600E	colorectal adenocarcinoma	sensitive	DEL-22379	Preclinical - Pdx	Actionable	In a preclinical study, DEL-22379 inhibited tumor growth in a colorectal adenocarcinoma patient-derived xenograft model harboring BRAF V600E (PMID: 26267534).	26267534
BRAF	BRAF V600E	colorectal cancer	sensitive	Gefitinib + Vemurafenib	Preclinical	Actionable	In a preclinical study, the combination of Zelboraf (vemurafenib) and Iressa (gefitinib) decreased the number of viable colorectal cancer cells harboring a BRAF V600E mutation in cell culture (PMID: 22448344).	22448344
BRAF	BRAF V600E	melanoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).	27523909
BRAF	BRAF V600E	melanoma	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 inhibited growth, downstream MAPK signaling and soft agar growth in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26343583).	26343583
BRAF	BRAF V600E	colorectal cancer	predicted - sensitive	Dabrafenib + Panitumumab + Trametinib	Phase I	Actionable	In a Phase I trial, combination therapy consisting of Tafinlar (dabrafenib), Vectibix (panitumumab), and Mekinist (trametinib) resulted in an overall response rate of 21% (19/91, 1 complete response, 18 partial response), stable disease in 65% (59/91), and a median progression-free survival of 4.2 months in patients with BRAF V600E colorectal cancer (PMID: 29431699; NCT01750918).	29431699
BRAF	BRAF V600E	melanoma	sensitive	Doxorubicin + PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of PLX4720 and Adriamycin (doxorubicin) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and inhibition of cell growth in culture (PMID: 27924459).	27924459
BRAF	BRAF V600E	thyroid cancer	conflicting	Vemurafenib	Case Reports/Case Series	Actionable	In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in complete response in a patient with anaplastic thyroid cancer harboring BRAF V600E (PMID: 29320312; NCT02091141).	29320312
BRAF	BRAF V600E	thyroid cancer	conflicting	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, thyroid cancer cells harboring BRAF V600E demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).	27523909
BRAF	BRAF V600E	glioblastoma multiforme	sensitive	BI2536 + PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of BI 2536 and PLX4720 resulted in suppression of downstream signaling, increased apoptotic activity, inhibition of cell proliferation, and tumor growth suppression in glioblastoma cell line xenograft models harboring BRAF V600E (PMID: 26573800).	26573800
BRAF	BRAF V600E	melanoma	sensitive	BI 882370 + Trametinib	Preclinical	Actionable	In a preclinical study, xenograft models of melanoma harboring BRAF V600E treated with the combination of BI 882370 and Mekinist (trametinib) demonstrated tumor regression with no regrowth during the 5 weeks of treatment (PMID: 26916115).	26916115
BRAF	BRAF V600E	melanoma	sensitive	Dabrafenib + Trametinib	Guideline	Actionable	Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for melanoma patients harboring a BRAF V600 activating mutation, such as BRAF V600E, as adjuvant therapy for stage III disease and as systemic therapy for patients with unresectable or metastatic disease (NCCN.org).	detail...
BRAF	BRAF V600E	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E	melanoma	sensitive	Dabrafenib + Trametinib	Phase II	Actionable	In a Phase II trial, BRAF V600E positive melanoma patients who progressed on treatment with BRAF inhibitors or the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) were treated again with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) after 12 weeks off treatment, which resulted in a partial response in 35% (8/25) and stable disease in 40% (10/25) (PMID: 28268064).	28268064
BRAF	BRAF V600E	melanoma	sensitive	Dabrafenib + Trametinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (COMBI-v) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved overall survival rate at 12 months (72% vs 65%, HR=0.69, p=0.005), median progression-free survival (11.4 vs 7.3 months, HR=0.56, p<0.001), and objective response rate (64% vs 51%, p<0.001) compared to Zelboraf (vemurafenib) in melanoma patients harboring BRAF V600E or V600K (PMID: 25399551; NCT01597908).	detail... detail... 25399551
BRAF	BRAF V600E	colorectal cancer	sensitive	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E	colorectal cancer	sensitive	Cetuximab + Encorafenib	Phase III	Actionable	In a Phase III (BEACON CRC) trial, Braftovi (encorafenib) and Erbitux (cetuximab) combination treatment (n=113) resulted in improved median overall survival (8.4 vs 5.4 months, HR=0.60, p<0.001), confirmed response rate (20% vs 2%, p<0.001), and median progression-free survival (4.2 vs 1.5 months, HR=0.40, p<0.001) compared to control (n=107) in patients with metastatic colorectal cancer harboring BRAF V600E (PMID: 31566309; NCT02928224).	31566309
BRAF	BRAF V600E	melanoma	sensitive	Ulixertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ulixertinib (BVD-523) inhibited Erk signaling in melanoma cells harboring BRAF V600E, resulted in cell cycle arrest in culture and tumor growth inhibition in cell line xenograft models (PMID: 28939558).	28939558
BRAF	BRAF V600E	colon cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited Braf V600E in vitro and inhibited growth of human colon cancer cells harboring BRAF V600E in culture (PMID: 21325073, PMID: 24042735).	24042735 21325073
BRAF	BRAF V600E	colorectal cancer	sensitive	Dabrafenib	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation had increased sensitivity to Tafinlar (dabrafenib) in culture compared to cell lines with wild-type BRAF (PMID: 24885690).	24885690
BRAF	MAP2K1 Q56P BRAF V600E	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the MEK inhibitor, selumetinib (AZD6244), in cell culture (PMID: 19915144).	19915144
BRAF	MAP2K1 Q56P BRAF V600E	melanoma	resistant	PLX4720	Preclinical	Actionable	In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the B-RAF inhibitor PLX4720 in culture (PMID: 19915144).	19915144
BRAF	MAP2K1 Q56P BRAF V600E	melanoma	sensitive	PLX4720 + Selumetinib	Preclinical	Actionable	In a preclinical study, combined treatment with selumetinib and PLX4720 strongly suppressed the emergence of resistant MAP2K1 mutations in BRAF V600E cells in culture (PMID: 19915144).	19915144
BRAF	BRAF V600E NRAS Q61K	colorectal cancer	predicted - resistant	Panitumumab + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 40 weeks to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, NRAS Q61K was identified as an acquired mutation at the time of progression (PMID: 28951457).	28951457
BRAF	BRAF V600E NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, a NRAS Q61K mutation conferred resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323).	21107323
BRAF	BRAF V600E NRAS Q61K	lung adenocarcinoma	predicted - resistant	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a breast cancer patient with metastatic lung adenocarcinoma harboring BRAF V600E developed progressive disease after initial response to Talfinlar (dabrafenib) and Mekinist (trametinib) combination therapy, NRAS Q61K was identified as an acquired mutation after disease progression (PMID: 29631033).	29631033
BRAF	BRAF V600E NRAS Q61K	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS Q61K	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing NRAS Q61K were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS Q61K	melanoma	sensitive	XL888	Preclinical	Actionable	In a preclinical study, treatment with XL888 resulted in increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant melanoma cells harboring BRAF V600E along with NRAS Q61K in cell culture (PMID: 22351686).	22351686
BRAF	EGFR amp EGFR S492R BRAF V600E	colorectal cancer	resistant	Cetuximab	Case Reports/Case Series	Actionable	In a clinical study, EGFR S492R was detected in the post-Erbitux (cetuximab) sample from a colorectal cancer patient harboring EGFR amplification and BRAF V600E who progressed on an Erbitux (cetuximab) regimen (PMID: 22270724).	22270724
BRAF	BRAF V600E BRAF L505H	melanoma	predicted - resistant	Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a melanoma patient harboring BRAF V600E treated with Zelboraf (vemurafenib) subsequently demonstrated resistance likely due to the secondary resistance mutation, BRAF L505H (PMID: 25515853).	25515853
BRAF	BRAF V600E MAP2K1 C121S	melanoma	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell line harboring BRAF V600E mutation and overexpressing MAP2K1 C121S in culture (PMID: 24448821).	24448821
BRAF	BRAF V600E MAP2K1 C121S	melanoma	resistant	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, MAP2K1 C121S conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).	24265154
BRAF	BRAF V600E MAP2K1 C121S	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
BRAF	BRAF V600E MAP2K1 C121S	melanoma	sensitive	VRT11E	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).	24265153
BRAF	BRAF V600E MAP2K1 C121S	melanoma	resistant	PLX4720	Preclinical	Actionable	In a preclinical study, expression of MAP2K1 C121S conferred resistance to PLX4720 in melanoma cells harboring BRAF V600E in culture (PMID: 21383288).	21383288
BRAF	BRAF V600E MAP2K1 C121S	melanoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Selumetinib (AZD6244)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).	24448821
BRAF	BRAF V600E MAP2K1 C121S	melanoma	resistant	Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient harboring BRAF V600E demonstrated an initial response to treatment with Zelboraf (vemurafenib), but progressed following emergence of a MAP2K1 C121S mutation (PMID: 21383288).	21383288
BRAF	BRAF V600E MAP2K1 C121S	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 C121S conferred resistance to Zelboraf (vemurafenib) in melanoma cell lines harboring BRAF V600, resulting in decreased sensitivity to Zelboraf (vemurafenib)-induced inhibition of MAPK pathway activation and cell proliferation in culture (PMID: 24448821).	24448821
BRAF	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).	23629727
BRAF	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).	23629727
BRAF	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Cetuximab + Regorafenib	Preclinical	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring BRAF V600E and PIK3CA P449T in culture (PMID: 25838391).	25838391
BRAF	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).	23629727
BRAF	BRAF V600E PIK3CA P449T	colorectal cancer	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).	25838391
BRAF	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Pimasertib + Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).	23629727
BRAF	BRAF V600E PIK3CA P449T	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).	25838391
BRAF	BRAF V600E NRAS G12V	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, expression of NRAS G12V in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 26267534).	26267534
BRAF	BRAF V600E NRAS G12V	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and over expressing NRAS G12V in culture (PMID: 26267534).	26267534
BRAF	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Alpelisib + Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E MAP2K1 L115P	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
BRAF	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E MAP2K1 L115P	colorectal cancer	resistant	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture, likely due to the acquired secondary resistance mutation MAP2K1 L115P (PMID: 27312529).	27312529
BRAF	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E MAP2K1 L115P	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 28655712).	28655712
BRAF	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E MAP2K1 L115P	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 26267534).	26267534
BRAF	BRAF V600E MAP2K1 L115P	melanoma	resistant	PD-0325901	Preclinical	Actionable	In a preclinical study, over expression of MAPK21 L115P in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).	26267534
BRAF	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E MAP2K1 I103N	melanoma	resistant	PD-0325901	Preclinical	Actionable	In a preclinical study, over expression of MAPK21 I103N in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).	26267534
BRAF	BRAF V600E MAP2K1 I103N	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 26267534).	26267534
BRAF	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired secondary resistant mutation of MAP2K1 V211D (PMID: 27312529).	27312529
BRAF	BRAF V600E MAP2K1 V211D	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
BRAF	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E MAP2K1 V211D	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).	28655712
BRAF	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E MAP2K1 V211D	melanoma	resistant	CI-1040	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by CI-1040 in cell culture (PMID: 19915144).	19915144
BRAF	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E MAP2K1 V211D	melanoma	sensitive	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, BVD-523 (Ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).	28655712
BRAF	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E MAP2K1 V211D	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by Selumetinib (AZD6244) in cell culture (PMID: 19915144).	19915144
BRAF	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E and also had reduced sensitivity in comparison to cell lines harboring BRAF V600E and NRAS A146T in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	no benefit	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS A146T	melanoma	sensitive	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS A146T	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS A146T	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS A146T	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS A146T	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS A146T	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS A146T	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were >10-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	conflicting	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, the response of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S to Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) was conflicting as one cell line with this mutation profile responded to the combination and another cell line with the mutation profile did not (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 K59del	melanoma	sensitive	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 K59del	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 K59del	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 K59del	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 K59del	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 K59del	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E harboring MAP2K1 K59del in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 K59del	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 Q56P	melanoma	sensitive	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 28655712).	28655712
BRAF	BRAF V600E MAP2K1 Q56P	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P displayed reduced sensitivity to Mekinist (trametinib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 Q56P	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, the combination of Talfinlar (dabrafenib) and Mekinist (trametinib) resulted in improved growth inhibition in melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 Q56P	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E MAP2K1 Q56P	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).	28655712
BRAF	BRAF V600E NRAS Q61K NRAS A146T	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cells harboring BRAF V600E and NRAS A146T and NRAS Q61K in culture (PMID: 22389471).	22389471
BRAF	BRAF V600E CSF1R positive	melanoma	sensitive	Pexidartinib + Vemurafenib	Preclinical	Actionable	In a preclinical study, a melanoma mouse model harboring BRAF V600E treated with Zelboraf (vemurafenib) demonstrated a greater drug induced sensitivity when treatment was combined with PLX3397, resulting in increased infiltration of lymphocytes via Csf1r inhibition and elevated antitumor activity (PMID: 25939769).	25939769
BRAF	BRAF V600E PTEN loss	melanoma	predicted - resistant	Everolimus	Case Reports/Case Series	Actionable	In a retrospective analysis, a melanoma patient harboring PTEN loss and BRAF V600E demonstrated resistance to Afinitor (everolimus) treatment, resulting in progressive disease (PMID: 20664172).	20664172
BRAF	BRAF V600E PTEN loss	melanoma	sensitive	GDC0879 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, GDC0879 and Pictilisib (GDC-0941) synergistically inhibited survival of melanoma cell lines harboring BFAF V600E and PTEN loss in cell culture (PMID: 19276360).	19276360
BRAF	BRAF V600E PTEN loss	melanoma	sensitive	GSK2636771 + unspecified PD-1 antibody	Preclinical	Actionable	In a preclinical study, treatment with the combination of GSK2636771 and a PD-1 antibody resulted in greater tumor infiltration of T-cells and tumor growth inhibition in mouse melanoma models expressing BRAF V600E with PTEN loss compared to either agent alone (PMID: 26645196).	26645196
BRAF	BRAF V600E PTEN loss	melanoma	sensitive	Pictilisib + PLX4720	Preclinical	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and PTEN loss demonstrated sensitivity when treated with a combination of Pictilisib (GDC-0941) and PLX4720, resulting in decreased cell proliferation in culture (PMID: 24265153).	24265153
BRAF	BRAF V600E PTEN loss	melanoma	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600E (PMID: 25637314).	25637314
BRAF	BRAF V600E MAP2K1 H119P	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E treated with Selumetinib (AZD6244) in culture demonstrated resistance, which was a result of the resistance mutation, MAP2K1 H119P (PMID: 19915144).	19915144
BRAF	BRAF V600E MAP2K1 V60E	melanoma	sensitive	VRT11E	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).	24265153
BRAF	BRAF V600E MAP2K1 V60E	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).	24265153
BRAF	BRAF V600E MAP2K1 P124S	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 24265153).	24265153
BRAF	BRAF V600E MAP2K1 P124S	melanoma	sensitive	VRT11E	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).	24265153
BRAF	BRAF V600E MAP2K1 P124S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture (PMID: 24265153).	24265153
BRAF	BRAF V600E MAP2K1 P124S	melanoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Selumetinib (AZD6244) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931).	22197931
BRAF	BRAF V600E MAP2K1 G128V	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).	24265153
BRAF	BRAF V600E MAP2K1 G128V	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).	24265153
BRAF	BRAF V600E MAP2K1 G128V	melanoma	sensitive	VRT11E	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).	24265153
BRAF	BRAF V600E MAP2K1 G128V	melanoma	resistant	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, MAP2K1 G128V conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).	24265154
BRAF	BRAF V600E MAP2K1 P162S	melanoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).	24265154
BRAF	BRAF V600E MAP2K1 P162S	melanoma	sensitive	Dabrafenib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).	24265154
BRAF	BRAF V600E MAP2K1 P162S	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).	24265154
BRAF	BRAF V600E MAP2K1 K57E	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 K57E in a melanoma cell line harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) in culture (PMID: 25370473).	25370473
BRAF	BRAF V600E MAP2K1 P124Q	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in cell culture (PMID: 25370473).	25370473
BRAF	BRAF V600E EGFR amp	colorectal cancer	resistant	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Selumetinib (AZD6244) in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR amp	colorectal cancer	sensitive	Cetuximab + Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR amp	colorectal cancer	resistant	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR amp	colorectal cancer	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR amp	colorectal cancer	resistant	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR amp	colorectal cancer	sensitive	Cetuximab + Selumetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Selumetinib (AZD6244), and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR amp	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR amp	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR amp	colorectal cancer	resistant	Cetuximab + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR amp	colorectal cancer	resistant	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR amp	colorectal cancer	resistant	Selumetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired EGFR amplification (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR G465R	colorectal cancer	resistant	Cetuximab + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation of EGFR G465R (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR G465R	colorectal cancer	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Iressa (gefitinib) in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR G465R	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR G465R	colorectal cancer	resistant	Panitumumab + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR G465R	colorectal cancer	sensitive	Cetuximab + Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR G465R	colorectal cancer	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR G465R	colorectal cancer	resistant	Panitumumab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR G465R	colorectal cancer	sensitive	Gefitinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Iressa (gefitinib) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR G465R	colorectal cancer	sensitive	Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR over exp	colorectal cancer	resistant	Selumetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, over expression of wild type EGFR in colorectal cancer cells harboring BRAF V600E resulted in sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).	27312529
BRAF	BRAF V600E EGFR over exp	colorectal cancer	sensitive	EBI-907	Preclinical - Cell culture	Actionable	In a preclinical study, EBI-907 inhibited growth of colorectal cancer cells harboring BRAF V600E and EGFR overexpression in culture (PMID: 26810733).	26810733
BRAF	BRAF V600E PIK3CA H1047R	thyroid carcinoma	resistant	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to the combination therapy, Mekinist (trametinib) and Tafinlar (dabrafenib) (PMID: 27797976).	27797976
BRAF	BRAF V600E PIK3CA H1047R	thyroid carcinoma	predicted - sensitive	Dabrafenib + Everolimus + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated tumor regression when treated with the triple combination, Tafinlar (dabrafenib), Mekinist (trametinib), and Afinitor (everolimus) (PMID: 27797976).	27797976
BRAF	BRAF V600E PIK3CA H1047R	thyroid carcinoma	resistant	Everolimus	Case Reports/Case Series	Actionable	In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to treatment with Afinitor (everolimus) (PMID: 27797976).	27797976
BRAF	BRAF V600E PIK3CA P449T TP53 R273H	colorectal cancer	sensitive	PD-0325901 + Sapanisertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and growth of colorectal cancer cells harboring BRAF V600E, PIK3CA P449T, and TP53 R273H in culture and in cell line xenograft models, but did not have synergistic effect on apoptosis (PMID: 26272063).	26272063
BRAF	BRAF V600E PIK3CA H1047R TP53 wild-type	colorectal cancer	sensitive	PD-0325901 + Sapanisertib	Preclinical - Cell culture	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).	26272063
BRAF	BRAF V600E PTEN loss TP53 wild-type	colorectal cancer	sensitive	PD-0325901 + Sapanisertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).	26272063
BRAF	BRAF V600E PIK3CA H1047K	melanoma	sensitive	ARQ092 + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring BRAF V600E and PIK3CA H1047K was sensitive to the combination treatment of Miransertib (ARQ092) and Mekinist (trametinib), demonstrating a greater inhibition of tumor growth when compared to either agent alone (PMID: 26469692).	26469692
BRAF	BRAF V600E PIK3CA mut	colorectal cancer	sensitive	ASN003	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a colorectal cancer cell line xenograft model co-harboring BRAF V600E and a PIK3CA mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).	detail...
BRAF	BRAF V600E PTEN mut	melanoma	sensitive	ASN003	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a melanoma cell line xenograft model co-harboring BRAF V600E and a PTEN mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).	detail...
BRAF	BRAF V600E TP53 Q192K	colon cancer	predicted - sensitive	Panitumumab + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a colon cancer patient harboring BRAF V600E and TP53 Q192K demonstrated a partial response when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 28514312).	28514312
BRAF	BRAF V600E MAP2K1 I111N	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N in culture (PMID: 28655712).	28655712
BRAF	BRAF V600E MAP2K1 I111N	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
BRAF	BRAF V600E MAP2K1 E203K	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
BRAF	BRAF V600E MAP2K1 E203K	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).	28655712
BRAF	BRAF V600E MAP2K1 E203K	melanoma	sensitive	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 28655712).	28655712
BRAF	BRAF V600E MAP2K1 P124L	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
BRAF	BRAF V600E MAP2K1 P124L	melanoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).	28655712
BRAF	BRAF V600E EGFR exon 19 del MET amp	lung adenocarcinoma	resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR exon 19 deletion treated with Tagrisso (osimertinib) showed progression after 16 months, and was subsequently found to have acquired BRAF V600E and MET amplification (PMID: 29596911).	29596911
BRAF	BRAF V600E MAP2K1 K57T	hairy cell leukemia	predicted - resistant	Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a single patient with hairy cell leukemia harboring BRAF V600E, who relapsed after a 38 week remission in response to Zelboraf (vemurafenib) treatment, was found to have acquired multiple clones with Mek/Erk activating mutations, of which the MAP2K1 K57T clone became dominant (PMID: 30341394).	30341394
BRAF	BRAF V600E MAP2K1 K57T	refractory hairy cell leukemia	predicted - sensitive	Cobimetinib + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a single patient with hairy cell leukemia who relapsed after initial response to Zelboraf (vemurafenib) was found to have acquired multiple clones with Mek/Erk activating mutations, of which the MAP2K1 K57T clone became dominant, and demonstrated a sustained response greater than 12 months to combined Zelboraf (vemurafenib) and Cotellic (cobimetinib) treatment (PMID: 30341394).	30341394
BRAF	EGFR exon 19 del BRAF V600E	lung adenocarcinoma	predicted - resistant	Nazartinib	Case Reports/Case Series	Actionable	In a Phase I trial, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M demonstrated a partial response to treatment with Nazartinib (CO-1686), but developed progression in the liver after 11 months, and a post-progression biopsy identified the EGFR exon 19 deletion without EGFR T790M, and emergence of BRAF V600E (PMID: 30123863; NCT02108964).	30123863
BRAF	BRAF V600E NRAS G13R	colorectal cancer	predicted - resistant	Alpelisib + Cetuximab + Encorafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 24 weeks to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment, NRAS G13R was identified as an acquired mutation in liver metastasis at the time of progression (PMID: 28951457).	28951457
BRAF	BRAF V600E NRAS G13R	colorectal cancer	predicted - sensitive	BGB659 + Cetuximab	Preclinical - Pdx	Actionable	In a preclinical study, BGB659 and Erbitux (cetuximab) combination treatment resulted in sustained inhibition of Mek and Erk phosphorylation, lead to tumor regression in patient-derived xenograft models of colorectal cancer harboring BRAF V600E and NRAS G13R (PMID: 28951457).	28951457
BRAF	BRAF V600E NRAS amp	colorectal cancer	predicted - resistant	Panitumumab + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after achieving stable disease for 16 weeks with Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, NRAS amplification was identified as an acquired alteration at the time of progression (PMID: 28951457).	28951457
BRAF	BRAF V600E NRAS over exp	colorectal cancer	sensitive	BGB659 + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, BGB659 and Erbitux (cetuximab) combination treatment demonstrated enhanced inhibition of Erk phosphorylation and growth in BRAF V600E colorectal cancer cell lines overexpressing Nras in culture (PMID: 28951457).	28951457
BRAF	BRAF V600E NRAS over exp	colorectal cancer	resistant	Cetuximab + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, overexpression of wild-type NRAS in colorectal cancer cell lines harboring BRAF V600E induced Ras activation and Braf/Craf dimerization, conferred resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture and in cell line xenograft models (PMID: 28951457).	28951457
BRAF	BRAF V600E MET amp	rectum mucinous adenocarcinoma	predicted - sensitive	Crizotinib + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with microsatellite-stable mucinous rectal cancer harboring BRAF V600E and acquired MET amplification responded to the combination treatment of Xalkori (crizotinib) and Zelboraf (vemurafenib), resulting in a rapid clinical and metabolic response (PMID: 27325282).	27325282
BRAF	BRAF V600E MET amp	rectum mucinous adenocarcinoma	predicted - resistant	Panitumumab + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with microsatellite-stable mucinous rectal cancer harboring BRAF V600E eventually developed resistance to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination therapy, potentially due to acquiring amplification of MET (PMID: 27325282).	27325282
BRAF	BRAF V600E MET amp	colorectal cancer	predicted - resistant	Alpelisib + Cetuximab + Encorafenib	Case Reports/Case Series	Actionable	In a preclinical study, emergence of MET amplification was detected in colorectal cancer cells harboring BRAF V600E that acquired resistance to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment in culture (PMID: 27325282).	27325282
BRAF	BRAF V600E MET over exp	colorectal cancer	predicted - sensitive	Crizotinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) and Zelboraf (vemurafenib) combination treatment inhibited growth of colorectal cancer cells harboring BRAF V600E and overexpressing Met in culture (PMID: 27325282).	27325282
BRAF	BRAF V600E MET over exp	colorectal cancer	resistant	Panitumumab + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpressing Met in colorectal cancer cells harboring BRAF V600E conferred resistance to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27325282).	27325282
BRAF	BRAF V600E EGFR E746_A750del	lung non-small cell carcinoma	predicted - resistant	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with advanced non-small cell lung cancer who lost EGFR T790M, but still harbors EGFR E746_A750del and acquired BRAF V600E demonstrated continued progression while being treated with the combination therapy of Sprycel (dabrafenib) and Mekinist (trametinib) (Journal of Clinical Oncology, 2019, 37, no. 15_suppl).	detail...
BRAF	BRAF V600E EGFR E746_A750del	lung non-small cell carcinoma	predicted - sensitive	Dabrafenib + Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with advanced non-small cell lung cancer who lost EGFR T790M, but still harbors EGFR E746_A750del and acquired BRAF V600E demonstrated an improved metabolic response when treated with the combination therapy of Sprycel (dabrafenib) and Tagrisso (osimertinib) (Journal of Clinical Oncology, 2019, 37, no. 15_suppl).	detail...
BRAF	BRAF K601N	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601N (PMID: 26343582).	26343582
BRAF	BRAF K601N	hematologic cancer	sensitive	LY3009120	Preclinical - Cell culture	Actionable	In a preclinical study, a hematological tumor cell line harboring BRAF K601N demonstrated sensitivity to LY3009120 in culture (PMID: 26732095).	26732095
BRAF	BRAF F595L	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Zelboraf (vemurafenib) did not reduce activation of Mek and Erk by BRAF F595L in transformed cells in culture (PMID: 26582644).	26582644
BRAF	BRAF G466V	lung adenocarcinoma	sensitive	PLX8394	Preclinical - Cell culture	Actionable	In a preclinical study, PLX8394 decreased growth of lung adenocarcinoma cell lines harboring BRAF G466V in culture (PMID: 27834212).	27834212
BRAF	BRAF G466V	colorectal cancer	predicted - sensitive	Irinotecan + Panitumumab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with metastatic colorectal cancer harboring BRAF G466V, and with wild-type RAS and NF1, demonstrated tumor regression following treatment with Vectibix (panitumumab) plus Camptosar (irinotecan) (PMID: 28783719).	28783719
BRAF	BRAF G466V	colorectal cancer	sensitive	Cetuximab	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Erbitux (cetuximab) reduced ERK signaling and resulted in tumor regression in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).	28783719
BRAF	BRAF G466V	lung non-small cell carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of non-small cell lung cancer cell lines harboring BRAF G466V in culture (PMID: 28783719).	28783719
BRAF	BRAF G466V	lung non-small cell carcinoma	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) induced apoptosis in non-small cell lung cancer cells expressing BRAF G466V in culture (PMID: 22649091).	22649091
BRAF	BRAF G466V	lung non-small cell carcinoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring BRAF G466V demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).	27523909
BRAF	BRAF G466V	lung cancer	predicted - sensitive	RMC-4550	Preclinical - Cell culture	Actionable	In a preclinical study, RMC-4550 inhibited Erk phosphorylation and proliferation of lung cancer cells harboring BRAF G466V in culture (PMID: 30104724).	30104724
BRAF	BRAF G466V	lung non-small cell carcinoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring BRAF G466V in culture (PMID: 27523909).	27523909
BRAF	BRAF G466V	lung non-small cell carcinoma	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G466V mutation in culture (PMID: 26090892).	26090892
BRAF	BRAF G466V	colorectal cancer	no benefit	Vemurafenib	Preclinical - Pdx	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit ERK signaling or tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).	28783719
BRAF	BRAF G466V	Advanced Solid Tumor	no benefit	Vemurafenib	Clinical Study - Cohort	Actionable	In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 1 of the non-responding patients harbored BRAF G466V (PMID: 29320312; NCT02091141).	29320312
BRAF	BRAF G466V	lung non-small cell carcinoma	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis, and enhanced ERK inhibition compared to either agent alone in a non-small cell lung cancer cell line harboring BRAF G466V in culture (PMID: 28947956).	28947956
BRAF	BRAF G466V	colorectal cancer	sensitive	Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Mekinist (trametinib) delayed tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).	28783719
BRAF	BRAF G466V EGFR wild-type	lung non-small cell carcinoma	sensitive	Ganetespib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ganetespib treatment resulted in decreased activation of MEK, AKT, and ERK and inhibited growth of a non-small cell lung cancer cell line with wild-type EGFR and BRAF G466V in culture, and inhibited tumor growth in xenograft models (PMID: 25077897).	25077897
BRAF	BRAF G466V NRAS Q61K	lung non-small cell carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) growth of a non-small cell lung cancer cell line harboring BRAF G466V and expressing NRAS Q61K in culture (PMID: 28783719).	28783719
BRAF	BRAF G596R	colorectal cancer	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) reduced Erk signaling and inhibited proliferation of a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28783719).	28783719
BRAF	BRAF G596R	colorectal cancer	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not reduce activation of Erk and Mek in a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28783719).	28783719
BRAF	BRAF G596R	colorectal cancer	predicted - sensitive	RMC-4550	Preclinical - Cell culture	Actionable	In a preclinical study, RMC-4550 inhibited Erk phosphorylation and proliferation of colorectal cancer cells harboring BRAF G596R in culture (PMID: 30104724).	30104724
BRAF	BRAF G596R	Advanced Solid Tumor	no benefit	Vemurafenib	Clinical Study - Cohort	Actionable	In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 1 of the non-responding patients harbored BRAF G596R (PMID: 29320312; NCT02091141).	29320312
BRAF	BRAF G596R	colorectal cancer	sensitive	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis, and enhanced ERK inhibition compared to either agent alone in a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28947956).	28947956
BRAF	BRAF G596R PIK3CA E545K	colorectal cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells harboring both BRAF G596R and PIK3CA E545K in culture (PMID: 26243863).	26243863
BRAF	BRAF G596R PTPN11 E76K	colorectal cancer	resistant	RMC-4550	Preclinical - Cell culture	Actionable	In a preclinical study, expression of PTPN11 E76K in colorectal cancer cells harboring BRAF G596R abolished their sensitivity to RMC-4550-induced inhibition of Erk phosphorylation and proliferation in culture (PMID: 30104724).	30104724
BRAF	BRAF N581S	lung adenocarcinoma	predicted - sensitive	PF-00477736 + PF3644022	Preclinical - Patient cell culture	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment resulted in significant apoptosis in primary tumor cells isolated from a lung adenocarcinoma patient harboring BRAF N581S in culture (PMID: 26140595).	26140595
BRAF	BRAF N581S	Advanced Solid Tumor	no benefit	Vemurafenib	Clinical Study - Cohort	Actionable	In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response in only 4% (1/23) of patient with advanced solid tumors harboring non-V600 BRAF mutations, 2 of the non-responding patients harbored BRAF N581S (PMID: 29320312; NCT02091141).	29320312
BRAF	APC Q1429fs BRAF N581S ERBB2 L755S	rectum adenocarcinoma	no benefit	Fluorouracil + Leucovorin + Trastuzumab	Case Reports/Case Series	Actionable	In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067).	27626067
BRAF	BRAF D594G	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF D594G in culture (PMID: 28783719).	28783719
BRAF	BRAF D594G NRAS G12D	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).	27523909
BRAF	BRAF D594G NRAS G12D	melanoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).	27523909
BRAF	BRAF D594G NRAS G12D	melanoma	decreased response	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).	27523909
BRAF	BRAF D594G NRAS G12D	melanoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).	27523909
BRAF	BRAF D594G NRAS G12D	melanoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).	27523909
BRAF	BRAF G469R NRAS Q61K	melanoma	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).	26343583
BRAF	BRAF G469R NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cells harboring BRAF G469R and NRAS G61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).	26343583
BRAF	BRAF G469R NRAS Q61K	melanoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).	26343583
BRAF	BRAF L597R	Advanced Solid Tumor	sensitive	Trametinib	Preclinical	Actionable	Preclinical studies demonstrated the MEK inhibitor, Mekinist (trametinib) caused decreased activation of MEK and ERK in cells expressing BRAF L597R (PMID: 22798288).	22798288
BRAF	BRAF L597R	Advanced Solid Tumor	sensitive	Vemurafenib	Preclinical	Actionable	In a preclinical study, treatment of cells expressing BRAF L597R with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288).	22798288
BRAF	BRAF fusion	pilocytic astrocytoma	not applicable	N/A	Guideline	Prognostic	BRAF fusions are associated with indolent disease in patients with pilocytic astrocytoma (NCCN.org).	detail...
BRAF	BRAF fusion	pilocytic astrocytoma	not applicable	N/A	Guideline	Diagnostic	BRAF fusions aid in the diagnosis of pilocytic astrocytoma (NCCN.org).	detail...
BRAF	BRAF D594N	Advanced Solid Tumor	predicted - resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not reduce activation of Mek in transformed cells expressing BRAF D594N in culture (PMID: 28783719).	28783719
BRAF	BRAF D594N	lung non-small cell carcinoma	predicted - sensitive	RMC-4550	Preclinical - Pdx	Actionable	In a preclinical study, RMC-4550 treatment resulted in decreased Erk phosphorylation and dose-dependent tumor growth inhibition in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring BRAF D594N (PMID: 30104724).	30104724
BRAF	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	Capmatinib + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Capmatinib (INC280) induced tumor regression in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).	28783719
BRAF	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	Capmatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Capmatinib (INC280) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).	28783719
BRAF	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Mekinist (trametinib) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).	28783719
BRAF	BRAF V600R	melanoma	sensitive	Dabrafenib	Case Reports/Case Series	Actionable	In a clinical case study, a melanoma patient harboring BRAF V600R treated with Tafinlar (dabrafenib) demonstrated a reduction in lesion size after 2.5 months and at 5 months, stable disease, however, after 7 months progression ensued (PMID: 27255157).	27255157
BRAF	BRAF V600R	melanoma	sensitive	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).	27523909
BRAF	BRAF V600R	melanoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF V600R in culture (PMID: 27523909).	27523909
BRAF	BRAF V600R	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).	27523909
BRAF	BRAF V600R	melanoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF V600R in culture (PMID: 27523909).	27523909
BRAF	BRAF V600R	melanoma	sensitive	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, PLX7904 inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).	27523909
BRAF	BRAF L485_P490delinsY	lung non-small cell carcinoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was sensitive to Mekinist (trametinib), resulting in cell growth inhibition (PMID: 26732095).	26732095
BRAF	BRAF L485_P490delinsY	lung non-small cell carcinoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was resistant to Tafinlar (dabrafenib) (PMID: 26732095).	26732095
BRAF	BRAF L485_P490delinsY	lung non-small cell carcinoma	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was sensitive to LY3009120 in both culture and xenograft models, resulting in significant tumor regression and inhibition of MEK and ERK phosphorylation (PMID: 26732095).	26732095
BRAF	BRAF G464E	Advanced Solid Tumor	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464E (PMID: 26343582).	26343582
BRAF	BRAF L505H	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cells expressing BRAF L505H were resistant to Zelboraf (vemurafenib) (PMID: 24283590).	24283590
BRAF	BRAF V600E/K	lung non-small cell carcinoma	sensitive	Dabrafenib + Trametinib	Guideline	Actionable	The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) is included in guidelines as first or second-line therapy in patients with metastatic non-small cell lung cancer harboring a BRAF V600 mutation (PMID: 30715168, PMID: 30285222; ESMO.org).	30715168 30285222 detail...
BRAF	BRAF V600E/K	melanoma	sensitive	Binimetinib + Encorafenib	Guideline	Actionable	Braftovi (encorafenib) in combination with Mektovi (binimetinib) is included in guidelines as first-line and second-line therapy for patients with metastatic or unresectable melanoma harboring BRAF V600E or V600K mutations (PMID: 30959471; NCCN.org).	30959471 detail...
BRAF	BRAF V600E/K	melanoma	sensitive	Binimetinib + Encorafenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) resulted in a median overall survival (OS) of 33.6 months, a 1-year OS rate of 77.5%, and a 2-year OS rate of 57.7% in patients with advanced melanoma harboring BRAF V600E/K mutations compared to a median OS of 16.9 months and 1- and 2-year OS rates of 63.1% and 43.2%, respectively, in the Zelboraf (vemurafenib) treated group (PMID: 30219628; NCT01909453).	detail... detail... detail... 30219628
BRAF	BRAF V600E/K	melanoma	sensitive	Binimetinib + Encorafenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) demonstrated improved tolerability profile and efficacy, resulted in a progression-free survival of 14.9 months in patients with advanced melanoma harboring BRAF V600E/K mutations, comparing to 7.3 months in the Zelboraf (vemurafenib) group (HR=0.54, p<0.0001) (PMID: 29573941; NCT01909453) and both BRAF V600E and V600K are on the companion diagnostic.	29573941 detail... detail... detail...
BRAF	BRAF V600E/K	melanoma	predicted - sensitive	Vemurafenib + XL888	Phase I	Actionable	In a Phase I trial, combined Zelboraf (vemurafenib) and XL888 treatment in patients with unresectable, BRAF inhibitor naive, metastatic melanoma harboring BRAF V600E (n=20) or V600K (n=1) resulted in complete and partial responses in 15% (3/20) and 60% (12/20) of evaluable patients, respectively, a 9.2-month median progression free survival, and a 34.6-month overall survival (PMID: 29674508).	29674508
BRAF	BRAF V600E/K	melanoma	sensitive	Cobimetinib + Vemurafenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (coBRIM) that supported FDA approval, treatment with the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months, compared to 7.2 months with Zelboraf (vemurafenib) plus placebo, among patients with BRAF V600-mutated metastatic melanoma, and BRAF V600E and BRAF V600K are on the companion diagnostic (PMID: 27480103; NCT01689519).	detail... detail... 27480103
BRAF	BRAF V600E/K	melanoma	sensitive	Cobimetinib + Vemurafenib	Guideline	Actionable	Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination therapy is included in melanoma guidelines for patients with metastatic or unresectable disease harboring a BRAF V600 activating mutation (NCCN.org).	detail...
BRAF	BRAF V600E/K	melanoma	sensitive	Trametinib	Phase I	Actionable	In a Phase I trial, Mekinist (trametinib) resulted in complete response in 7% (2/30), partial response in 33% (10/30), and stable disease in 37% (11/30) of BRAF-mutant melanoma patients (PMID: 22805292; NCT00687622).	22805292
BRAF	BRAF V600E/K	melanoma	sensitive	Trametinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (METRIC) that supported FDA approval, Mekinist (trametinib) treatment, as compared to Deticine (dacarbazine) or Taxol (paclitaxel) treatment, resulted in improved progression-free survival of 4.8 months versus 1.5 months and an overall six month survival rate of 81% versus 67% in patients with BRAF V600E/K positive metastatic melanoma (PMID: 22663011; NCT01245062).	22663011 detail... detail...
BRAF	BRAF V600E/K	melanoma	sensitive	Dabrafenib + Trametinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (COMBI-AD) that supported FDA approval, adjuvant treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved estimated 3-year relapse-free survival rate (58% vs 39%, HR=0.47, P<0.001) and 3-year overall survival rate (86% vs 77%, HR=0.57; 95% CI, 0.42 to 0.79, P=0.0006) compared to placebo in stage III melanoma patients harboring BRAF V600E or V600K mutations (PMID: 28891408; NCT01682083).	detail... 28891408 detail...
BRAF	BRAF V600E/K	melanoma	sensitive	Dabrafenib + Trametinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (COMBI-v) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved overall survival rate at 12 months (72% vs 65%, HR=0.69, p=0.005), median progression-free survival (11.4 vs 7.3 months, HR=0.56, p<0.001), and objective response rate (64% vs 51%, p<0.001) compared to Zelboraf (vemurafenib) in melanoma patients harboring BRAF V600E or V600K (PMID: 25399551; NCT01597908).	detail... detail... 25399551
BRAF	BRAF V600E/K PIK3CA wild-type	melanoma	no benefit	TGX-221	Preclinical	Actionable	In a preclinical study, TGX-221 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).	26137449
BRAF	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	Vemurafenib + ZSTK474	Preclinical	Actionable	In a preclinical study, ZSTK474 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).	26137449
BRAF	BRAF V600E/K PIK3CA wild-type	melanoma	no benefit	Idelalisib	Preclinical	Actionable	In a preclinical study, Zydelig (idelalisib) did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).	26137449
BRAF	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	Selumetinib + Vemurafenib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).	26137449
BRAF	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	Selumetinib + ZSTK474	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) and ZSTK474 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergistically inhibited tumor growth in cell line xenograft models (PMID: 26137449).	26137449
BRAF	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	BEZ235 + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergitically inhibited tumor growth in cell line xenograft models (PMID: 26137449).	26137449
BRAF	BRAF V600E/K PIK3CA wild-type	melanoma	no benefit	A66	Preclinical	Actionable	In a preclinical study, A66 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).	26137449
BRAF	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	BEZ235 + Vemurafenib	Preclinical	Actionable	In a preclinical study, BEZ235 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).	26137449
BRAF	BRAF V600E/K PTEN loss	Advanced Solid Tumor	predicted - sensitive	PX-866 + Vemurafenib	Phase I	Actionable	In a Phase I trial, the combination therapy of PX-866 and Zelboraf (vemurafenib) demonstrated safety and resulted in an objective response in 28% (5/18) of advanced solid tumor patients harboring BRAF V600E or K, and of those five patients, 80% (4/5) also demonstrated loss of PTEN (PMID: 29051322).	29051322
BRAF	BRAF wild-type	Advanced Solid Tumor	resistant	BGB-283	Preclinical - Cell culture	Actionable	In a preclinical study, a variety of BRAF wild-type tumor cell lines were insensitive to BGB-283 in culture (PMID: 26208524).	26208524
BRAF	BRAF wild-type	melanoma	no benefit	Selumetinib	Phase II	Actionable	In a Phase II trial, a favorable response rate to Selumetinib (AZD6244) was observed in mutant BRAF, but not BRAF wild-type, melanoma patients (PMID: 22048237).	22048237
BRAF	BRAF wild-type	melanoma	decreased response	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a BRAF wild-type melanoma cell line demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531).	27488531
BRAF	BRAF wild-type	thyroid cancer	sensitive	CLM3	Preclinical	Actionable	In a preclinical study, CLM3 inhibited growth, Egfr signaling, and CCND1 expression, in BRAF wild-type thyroid cancer cells in culture (PMID: 24423321).	24423321
BRAF	BRAF wild-type	melanoma	sensitive	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, BRAF wild-type melanoma cells demonstrated decreased cell viability when treated with Ibrance (palbociclib) in culture (PMID: 27488531).	27488531
BRAF	BRAF wild-type	melanoma	resistant	GDC0879	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells in cell culture, cell line xenograft models, and patient-derived xenograft models (PMID: 19276360).	19276360
BRAF	BRAF wild-type	malignant glioma	predicted - sensitive	Everolimus + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Afinitor (everolimus) and Selumetinib (AZD6244) synergistically inhibited growth and induced apoptosis in glioma cell lines in culture (PMID: 27217440).	27217440
BRAF	BRAF wild-type	melanoma	predicted - sensitive	RAF265	Preclinical	Actionable	In a preclinical study, RAF265 inhibited the growth of melanoma tumors orthotopically implanted in mice, including tumors wild-type for BRAF (PMID: 22351689).	22351689
BRAF	BRAF wild-type	melanoma	predicted - sensitive	RAF265	Phase I	Actionable	In a Phase I trial, treatment with RAF265 in melanoma patients resulted in an objective response rate of 12.1% (8/66), including a partial response in four patients harboring BRAF V600E, two partial responses and one complete response in patients with wild-type BRAF, and one complete response in a patient with unknown mutational status (PMID: 28719152).	28719152
BRAF	BRAF wild-type	melanoma	predicted - sensitive	Nivolumab	Phase III	Actionable	In a Phase III trial (CheckMate-066), Opdivo (nivolumab) treatment resulted in improved overall survival and response compared to treatment with Deticene (dacarbazine) in melanoma patients with wild-type BRAF, including a 3-year overall survival (OS) rate of 51.2% vs. 21.6%, a median OS of 37.5 months vs. 11.2 months, a complete response in 19% (40/210) vs. 1.4% (3/208), and a partial response in 23.8% (50/210) vs. 13% (27/208), respectively (PMID: 30422243; NCT01721772).	30422243
BRAF	BRAF wild-type	lung non-small cell carcinoma	resistant	GDC0879	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells in culture and in patient-derived xenograft models (PMID: 19276360).	19276360
BRAF	BRAF wild-type	melanoma	sensitive	Trametinib	Phase I	Actionable	In a Phase I study, 10% (4/39) of wild-type BRAF melanoma patients had a partial response to Mekinist (trametinib) (PMID: 22805292; NCT00687622).	22805292
BRAF	BRAF wild-type	melanoma	resistant	PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX4720 did not inhibit growth of BRAF wild-type melanoma cells in culture or in cell line xenograft models (PMID: 18287029).	18287029
BRAF	BRAF wild-type NRAS mutant	melanoma	sensitive	Lenvatinib	Phase I	Actionable	In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 83% (5/6) of melanoma patients harboring NRAS mutations and wild-type BRAF (PMID: 26169970).	26169970
BRAF	BRAF wild-type NRAS wild-type	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to Zelboraf (vemurafenib) in culture (PMID: 27523909).	27523909
BRAF	BRAF wild-type NRAS wild-type	melanoma	sensitive	Lenvatinib	Phase I	Actionable	In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 44% (4/9) and partial response in 22% (2/9) of melanoma patients carrying wild-type BRAF and NRAS (PMID: 26169970).	26169970
BRAF	BRAF wild-type NRAS wild-type	melanoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).	27523909
BRAF	BRAF wild-type NRAS wild-type	melanoma	sensitive	Binimetinib + Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line with wild-type BRAF and wild-type NRAS in culture (PMID: 27307593).	27307593
BRAF	BRAF wild-type NRAS wild-type	melanoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).	27523909
BRAF	BRAF wild-type NRAS wild-type	melanoma	resistant	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to PLX7904 in culture (PMID: 27523909).	27523909
BRAF	BRAF wild-type NRAS Q61K	melanoma	resistant	GDC0879	Preclinical - Pdx	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells harboring NRAS Q61K in patient-derived xenograft models (PMID: 19276360).	19276360
CALR	CALR K385fs	hematologic cancer	sensitive	Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Jakafi (ruxolitinib) inhibited growth of transformed cells expressing CALR L385fs in culture (PMID: 26668133).	26668133
CALR	CALR wild-type JAK2 wild-type MPL wild-type	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of concurrent wild-type JAK2, MPL, and CALR in myelofibrosis patients is associated with inferior leukemia-free survival compared to patients with JAK2 and/or CALR mutations, and is associated with inferior overall survival when compared to patients with CALR mutations (NCCN.org).	detail...
CALR	ASXL1 mut CALR wild-type	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of an ASXL1 mutation combined with wild-type CALR is associated with shorter survival in patients with myelofibrosis (NCCN.org).	detail...
CALR	CALR mutant	bone marrow cancer	predicted - sensitive	Alpha 2 Interferon	Clinical Study - Cohort	Actionable	In a clinical study, Roferon-A (Alpha 2 Interferon) treatment resulted in hematologic response in 100% (31/31) and complete molecular response in 6% (2/31) of essential thrombocythemia (ET) patients harboring CALR mutations (PMID: 26486786).	26486786
CALR	CALR mutant	myelofibrosis	not applicable	N/A	Guideline	Prognostic	CALR mutations are associated with improved survival when compared to JAK2 mutations or concurrent wild-type CALR, MPL, and JAK2 in patients with primary myelofibrosis (NCCN.org).	detail...
CALR	CALR mutant	bone marrow cancer	not applicable	N/A	Clinical Study	Diagnostic	CALR mutations are used in the diagnosis of myeloproliferative neoplasms, especially of essential thrombocythemia and primary myelofibrosis (PMID: 26697989, PMID: 26449662, PMID: 26071474, PMID: 25873496).	26697989 25873496 26449662 26071474
CALR	ASXL1 wild-type CALR mut	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of a CALR mutation combined with wild-type ASXL1 is associated with longer survival in patients with myelofibrosis (NCCN.org).	detail...
CALR	ASXL1 mut CALR mut	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of a CALR mutation combined with an ASXL1 mutation is associated with intermediate survival in patients with myelofibrosis (NCCN.org).	detail...
CALR	CALR L367fs	myelofibrosis	predicted - sensitive	Fedratinib	Case Reports/Case Series	Actionable	In a clinical study, two myelofibrosis patients harboring CALR L367fs (reported as L367fs*46 for patient 1 and L367fs*48 for patient 2) and wild-type JAK2 demonstrated a greater than 50% reduction in spleen size following treatment with Inrebic (fedratinib) (PMID: 24645956).	24645956
CALR	CALR L367fs	hematologic cancer	sensitive	Ruxolitinib + Temsirolimus	Preclinical - Cell culture	Actionable	In a preclinical study, Jakafi (ruxolitinib) and Torisel (temsirolimus) acted synergistically to inhibit growth of transformed cells expressing CALR L367fs in culture (PMID: 26668133).	26668133
CALR	CALR L367fs	hematologic cancer	sensitive	Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Jakafi (ruxolitinib) inhibited growth of transformed cells expressing CALR L367fs in culture (PMID: 26668133).	26668133
CALR	CALR L367fs	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of the CALR type 1 mutation, L367fs, or a type 1-like mutation is associated with improved overall survival compared to a CALR type 2 (K385fs) or CALR type 2-like mutation and JAK2 V617F in patients with myelofibrosis (NCCN.org).	detail...
CBL	CBL Y371H FLT3 wild-type	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543).	31309543
CBL	CBL Y371H FLT3 wild-type	hematologic cancer	sensitive	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543).	31309543
CBL	CBL Y371H FLT3 wild-type	hematologic cancer	decreased response	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Avapritinib (BLU-285) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture with reduced potency compared to other kinase inhibitors (PMID: 31309543).	31309543
CBL	CBL Y371H FLT3 wild-type	hematologic cancer	sensitive	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543).	31309543
CBL	CBL Y371H FLT3 wild-type	hematologic cancer	sensitive	Midostaurin	Preclinical	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture, reduced leukemia burden and prolonged survival in animal models (PMID: 31309543).	31309543
CBL	CBL Y371H FLT3 wild-type	hematologic cancer	sensitive	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Quizartinib (AC220) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543).	31309543
CBL	CBL dec exp	pancreatic ductal carcinoma	predicted - sensitive	Erlotinib + Gemcitabine	Preclinical - Cell line xenograft	Emerging	In a preclinical study, addition of Tarceva (erlotinib) overcame Gemzar (gemcitabine)-resistance in pancreatic ductal carcinoma cell lines with reduced Cbl expression via shRNA, resulted in decreased viability in cell culture and reduced tumor growth in cell line xenograft models (PMID: 25348515).	25348515
CBL	CBL del CBLB del	bone marrow cancer	predicted - sensitive	Fasudil	Preclinical	Actionable	In a preclinical study, Fasudil (HA-1077) selectively inhibited proliferation of CBL and CBLB double knockout hematopoietic stem/progenitor cells in a mouse model of myeloproliferative disorder (PMID: 26177294).	26177294
CBL	CBL Q365_E366insSK FLT3 wild-type	hematologic cancer	sensitive	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).	31309543
CBL	CBL Q365_E366insSK FLT3 wild-type	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).	31309543
CBL	CBL Q365_E366insSK FLT3 wild-type	hematologic cancer	sensitive	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).	31309543
CBL	CBL Q365_E366insSK FLT3 wild-type	hematologic cancer	decreased response	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Avapritinib (BLU-285) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture with reduced potency compared to other kinase inhibitors (PMID: 31309543).	31309543
CBL	CBL Q365_E366insSK FLT3 wild-type	hematologic cancer	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).	31309543
CBL	CBL Q365_E366insSK FLT3 wild-type	hematologic cancer	sensitive	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Quizartinib (AC220) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).	31309543
CBL	CBL mutant	bone marrow cancer	sensitive	Quizartinib	Preclinical	Actionable	In a preclinical study, Quizartinib (AC220) reduced white blood cell counts and decreased myeloid cell invasion in a CBL mutant mouse model with myeloproliferative disorder (PMID: 22990016).	22990016
CBL	CBL mutant	myelodysplastic/myeloproliferative neoplasm	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, mutations in CBL were associated with adverse prognosis in patients with chronic myelomonocytic leukemia (PMID: 26230957, PMID: 23690417, PMID: 19901108).	26230957 19901108 23690417
CBLB	CBLB dec exp	stomach cancer	decreased response	Fluorouracil	Preclinical	Actionable	In a preclinical study, gastric cancer cell lines with decreased Cblb expression level via shRNA knockdown demonstrated reduced sensitivity to Adrucil (fluorouracil) in cell culture (PMID: 24351824).	24351824
CBLB	CBL del CBLB del	bone marrow cancer	predicted - sensitive	Fasudil	Preclinical	Actionable	In a preclinical study, Fasudil (HA-1077) selectively inhibited proliferation of CBL and CBLB double knockout hematopoietic stem/progenitor cells in a mouse model of myeloproliferative disorder (PMID: 26177294).	26177294
CBLC	CBLC over exp	lung non-small cell carcinoma	not applicable	N/A	Clinical Study	Emerging	In a clinical study, over expression of Cblc was identified as a promising diagnostic biomarker for non-small cell lung cancer (PMID: 17671213).	17671213
CBLC	CBLC dec exp	breast cancer	predicted - sensitive	Olaparib	Preclinical	Actionable	In a preclinical study, decreased Cblc expression through siRNA knockdown enhanced sensitivity to Lynparza (olaparib) in cultured breast cancer cell lines (PMID: 25883215).	25883215
CBLC	CBLC dec exp	osteosarcoma	predicted - sensitive	Olaparib	Preclinical	Actionable	In a preclinical study, decreased Cblc expression through siRNA knockdown enhanced sensitivity to Lynparza (olaparib) in cultured osterosarcoma cell lines (PMID: 25883215).	25883215
CDH1	CDH1 mutant	stomach cancer	not applicable	N/A	Clinical Study	Diagnostic	Pathogenic germline CDH1 mutations are used in the diagnosis of hereditary diffuse gastric cancer (PMID: 26380059, PMID: 26182300).	26380059 26182300
CDH1	CDH1 mutant	stomach cancer	not applicable	N/A	Guideline	Risk Factor	Germline truncating mutations in CDH1 are associated with hereditary diffuse gastric cancer, which is characterized by increased risk of developing gastric cancer (NCCN.org).	detail...
CDH1	CDH1 R63* ERBB2 L869Q	breast cancer	predicted - sensitive	Capecitabine + Lapatinib	Case Reports/Case Series	Actionable	In a clinical case study, treatment with the combination of Tykerb (lapatinib) and Xeloda (capecitabine) resulted in prolonged response and reduction in liver metastasis in a metastatic breast cancer patient harboring ERBB2 L869Q and CDH1 R63* mutations (PMID: 26487584).	26487584
CDH1	CDH1 over exp	lung non-small cell carcinoma	resistant	Volasertib	Preclinical	Actionable	In a preclinical study, non-small cell lung carcinoma cells over expressing CDH1 were resistant to volasertib in culture (PMID: 26597303).	26597303
CDH1	CDH1 over exp	lung non-small cell carcinoma	resistant	BI2536	Preclinical	Actionable	In a preclinical study, non-small cell lung carcinoma cells over expressing CDH1 were resistant to BI2536 in culture (PMID: 26597303).	26597303
CDH1	CDH1 over exp	pancreatic ductal adenocarcinoma	sensitive	Erlotinib + Selumetinib	Phase II	Actionable	In a Phase II clinical trial, patients with pancreatic ductal adenocarcinoma tumors expressing high levels of Cdh1 were more likely to respond to a combination therapy of Tarceva (erlotinib) and Selumetinib (AZD6244) (PMID: 26251290).	26251290
CDKN2A	CDKN2A over exp SMARCB1 negative	rhabdoid cancer	decreased response	Palbociclib	Preclinical	Actionable	In a preclinical study, CDKN2A (p16) over expression was associated with decreased sensitivity to Ibrance (palbociclib) in a SMARCB1-negative malignant rhabdoid tumor cell line in culture (PMID: 21871868).	21871868
CDKN2A	CDKN2A pos RB1 inact mut	glioblastoma multiforme	resistant	Palbociclib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived glioblastoma cells harboring RB1 truncation mutation and expressing Cdkn2a were resistant to Ibrance (palbociclib) in culture (PMID: 22711607).	22711607
CDKN2A	CDKN2A loss	melanoma	resistant	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line deficient for CDKN2A demonstrated resistance to treatment with Ibrance (palbociclib) in culture (PMID: 27488531).	27488531
CDKN2A	CDKN2A loss	pancreatic cancer	decreased response	HMN-214 + Palbociclib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) antagonized the activity of HMN-214 in pancreatic cancer cell lines with CDKN2A loss in culture (PMID: 25156567).	25156567
CDKN2A	CDKN2A loss	chordoma	sensitive	Abemaciclib	Preclinical - Cell culture	Actionable	In a preclinical study, Abemaciclib (LY2835219) inhibited growth of chordoma cell lines with CDKN2A loss and loss of p16 protein expression in culture (PMID: 26183925).	26183925
CDKN2A	CDKN2A loss	pancreatic cancer	decreased response	GSK461364 + Palbociclib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of GSK461364 in pancreatic cancer cells with CDKN2A loss in culture (PMID: 25156567).	25156567
CDKN2A	CDKN2A loss	neuroendocrine tumor	sensitive	ZK 304709	Preclinical	Actionable	In a preclinical study, an orthotopic mouse model treated with ZK 304709 demonstrated an 80% tumor growth reduction in neuroendocrine tumor cells with CDKN2A loss (PMID: 18829975).	18829975
CDKN2A	CDKN2A loss	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line with CDKN2A loss demonstrated sensitivity to Mekinist (trametinib) in culture, resulting in inhibition of cell growth (PMID: 27488531).	27488531
CDKN2A	CDKN2A loss	Advanced Solid Tumor	predicted - sensitive	PF-00477736 + PF3644022	Preclinical - Cell culture	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of multiple cancer cell lines harboring CDKN2A loss and in Cdkn2a-depleted transformed cells in culture (PMID: 26140595).	26140595
CDKN2A	CDKN2A loss	renal cell carcinoma	sensitive	Palbociclib	Preclinical	Actionable	In a preclinical study, renal cell carcinoma cell lines with CDKN2A loss were sensitive to Palbociclib (PD-0332991) (PMID: 23898052).	23898052
CDKN2A	CDKN2A loss	biliary tract cancer	no benefit	Palbociclib	Phase II	Actionable	In a Phase II trial (TAPUR), patients with biliary cancer harboring a CDKN2A mutation or loss of CDKN2A (n=10) did not demonstrate an objective response or stable disease at 16 weeks when treated with single therapy, Ibrance (palbociclib), demonstrating a median progression-free survival of 7.3 weeks and an overall survival of 11.1 weeks (JCO Precision Oncology, Aug 14, 2019; NCT02693535).	detail...
CDKN2A	CDKN2A loss	pancreatic cancer	no benefit	Palbociclib	Phase II	Actionable	In a Phase II trial (TAPUR), patients with pancreatic cancer harboring a CDKN2A mutation or loss of CDKN2A (n=10) did not demonstrate an objective response or stable disease at 16 weeks when treated with single therapy, Ibrance (palbociclib), demonstrating a median progression-free survival of 7.2 weeks and an overall survival of 12.4 weeks (JCO Precision Oncology, Aug 14, 2019; NCT02693535).	detail...
CDKN2A	CDKN2A loss	chordoma	sensitive	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, Ibrance (palbociclib) inhibited expression of phosphorylated Rb and growth of chordoma cell lines with CDKN2A loss and loss of p16 protein expression in culture (PMID: 26183925).	26183925
CDKN2A	CDKN2A loss	pancreatic cancer	decreased response	Gemcitabine + Palbociclib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of Gemzar (gemcitabine) in pancreatic cancer cells with CDKN2A loss in culture (PMID: 25156567).	25156567
CDKN2A	CDKN2A loss	lung non-small cell carcinoma	sensitive	Palbociclib	Phase II	Actionable	In a Phase II trial, treatment with Ibrance (palbociclib) resulted in and stable disease in 50% (8/16) of non-small cell lung cancer patients with CDKN2A loss (J Clin Oncol 32:5s, 2014 (suppl; abstr 8077)).	detail...
CDKN2A	CDKN2A loss	lung non-small cell carcinoma	sensitive	Palbociclib	Phase II	Actionable	In a Phase II trial (TAPUR), Ibrance (palbociclib) treatment resulted in a disease control rate of 29% (7/28, 1 partial response, 6 stable disease at 16 weeks) in patients with non-small cell lung cancer harboring CDKN2A loss or mutations, with a median progression-free survival of 9.7 weeks and a median overall survival of 20.6 months (J Clin Oncol 37, 2019 (suppl; abstr 9041); NCT02693535).	detail...
CDKN2A	CDKN2A loss	melanoma	sensitive	Alvocidib	Preclinical	Actionable	In a preclinical study, melanoma cell lines with CDKN2A loss demonstrated a greater sensitivity to Alvocidib (flavopiridol) as compared to melanoma cell lines positive for CDKN2A (PMID: 12777976).	12777976
CDKN2A	CDKN2A loss	pancreatic cancer	decreased response	Palbociclib + Rigosertib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of ON-01910 in pancreatic cancer cell lines with CDKN2A loss in culture (PMID: 25156567).	25156567
CDKN2A	CDKN2A loss	brain glioblastoma multiforme	sensitive	Milciclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Milciclib (PHA-848125AC) resulted in tumor regression in glioma cell line xenograft models with CDKN2A loss (PMID: 23347136).	23347136
CDKN2A	CDKN2A loss NRAS mutant	melanoma	sensitive	Abemaciclib	Phase I	Actionable	In a Phase I trial, Abemaciclib (LY2835219) resulted in a partial response in a melanoma patient with CDKN2A loss and NRAS mutation (PMID: 27217383).	detail... 27217383
CDKN2A	NRAS Q61K CDKN2A loss	melanoma	sensitive	Palbociclib + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Mekinist (trametinib) induced tumor regression in a mouse melanoma model expressing NRAS Q61K and harboring CDKN2A loss (PMID: 22983396).	22983396
CDKN2A	NRAS Q61K CDKN2A loss	melanoma	sensitive	SBI-0640756	Preclinical	Actionable	In a preclinical study, SBI-0640726 delayed tumor growth of melanomas in mice with a genetic background of NRAS Q61K and CDKN2A loss (PMID: 26603897).	26603897
CDKN2A	CDKN2A loss PIK3CA act mut	lung squamous cell carcinoma	predicted - sensitive	Buparlisib + Palbociclib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with the combination of Buparlisib (BYL719) and Ibrance (palbociclib) resulted in increased tumor growth inhibition compared to either agent alone in patient-derived xenograft (PDX) models of lung squamous cell carcinoma harboring PIK3CA E542K or E545K mutations with p16 (CDKN2A) loss, including models that also had either PIK3CA amplification or PTEN loss (PMID: 30093452).	30093452
CDKN2A	CDKN2A loss PIK3CA E542K PTEN loss	lung squamous cell carcinoma	sensitive	Buparlisib + Palbociclib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with the combination of Buparlisib (BYL719) and Ibrance (palbociclib) resulted in increased tumor growth inhibition compared to either agent alone in a patient-derived xenograft (PDX) model of lung squamous cell carcinoma harboring PIK3CA E542K and PTEN loss, with p16 (CDKN2A) loss (PMID: 30093452).	30093452
CDKN2A	CDKN2A loss PIK3CA amp PIK3CA E545K	lung squamous cell carcinoma	sensitive	Buparlisib + Palbociclib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with the combination of Buparlisib (BYL719) and Ibrance (palbociclib) resulted in increased tumor growth inhibition compared to either agent alone in patient-derived xenograft (PDX) models of lung squamous cell carcinoma harboring PIK3CA E545K and PIK3CA amplification, with p16 (CDKN2A) loss (PMID: 30093452).	30093452
CDKN2A	CDKN2A loss PIK3CA amp PIK3CA E542K	lung squamous cell carcinoma	sensitive	Buparlisib + Palbociclib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with the combination of Buparlisib (BYL719) and Ibrance (palbociclib) resulted in increased tumor growth inhibition compared to either agent alone in a patient-derived xenograft (PDX) model of lung squamous cell carcinoma harboring PIK3CA E542K and PIK3CA amplification, with p16 (CDKN2A) loss (PMID: 30093452).	30093452
CDKN2A	CDKN2A R80*	stomach carcinoma	sensitive	Palbociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a gastric carcinoma cell line harboring CDKN2A R80* was sensitive to Ibrance (palbociclib) both in culture and in cell line xenograft models (PMID: 26380006, PMID: 20952405).	26380006 20952405
CDKN2A	CDKN2A del	glioblastoma multiforme	sensitive	Palbociclib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Ibrance (palbociclib) inhibited proliferation of patient-derived glioblastoma cells harboring homozygous deletion of CDKN2A in culture and prolonged survival in patient-derived xenograft models (PMID: 22711607).	22711607
CDKN2A	CDKN2A del	gastrointestinal stromal tumor	no benefit	Palbociclib	Phase II	Actionable	In a Phase II trial, Ibrance (palbociclib) treatment did not demonstrated clinical efficacy in heavily pre-treated gastrointestinal stromal tumor patients harboring CDKN2A homozygous or heterozygous deletion, with 86.4% (19/22) of patients demonstrated progressive disease at 4 months (PMID: 30979737; NCT01907607).	30979737
CDKN2A	CDKN2A del	lung cancer	predicted - sensitive	PF-00477736 + PF3644022	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of CDKN2A-deleted lung cancer (PMID: 26140595).	26140595
CDKN2A	EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*	pancreatic ductal adenocarcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).	28476735
CDKN2A	EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*	pancreatic ductal adenocarcinoma	predicted - sensitive	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).	28476735
CDKN2A	CDKN2A mutant	pancreatic cancer	no benefit	Palbociclib	Phase II	Actionable	In a Phase II trial (TAPUR), patients with pancreatic cancer harboring a CDKN2A mutation or loss of CDKN2A (n=10) did not demonstrate an objective response or stable disease at 16 weeks when treated with single therapy, Ibrance (palbociclib), demonstrating a median progression-free survival of 7.2 weeks and an overall survival of 12.4 weeks (JCO Precision Oncology, Aug 14, 2019; NCT02693535).	detail...
CDKN2A	CDKN2A mutant	pancreatic cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in CDKN2A results in familial malignant melanoma syndrome, which is associated with increased risk of developing pancreatic cancer (NCCN.org).	detail...
CDKN2A	CDKN2A mutant	lung non-small cell carcinoma	sensitive	Palbociclib	Phase II	Actionable	In a Phase II trial (TAPUR), Ibrance (palbociclib) treatment resulted in a disease control rate of 29% (7/28, 1 partial response, 6 stable disease at 16 weeks) in patients with non-small cell lung cancer harboring CDKN2A loss or mutations, with a median progression-free survival of 9.7 weeks and a median overall survival of 20.6 months (J Clin Oncol 37, 2019 (suppl; abstr 9041); NCT02693535).	detail...
CDKN2A	CDKN2A mutant	biliary tract cancer	no benefit	Palbociclib	Phase II	Actionable	In a Phase II trial (TAPUR), patients with biliary cancer harboring a CDKN2A mutation or loss of CDKN2A (n=10) did not demonstrate an objective response or stable disease at 16 weeks when treated with single therapy, Ibrance (palbociclib), demonstrating a median progression-free survival of 7.3 weeks and an overall survival of 11.1 weeks (JCO Precision Oncology, Aug 14, 2019; NCT02693535).	detail...
CDKN2A	PIK3CA mutant CDKN2A mutant	breast cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a breast cancer cell line harboring mutations in PIK3CA and CDKN2A demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).	25261369
CDKN2A	NRAS mut CDKN2A mut	acute lymphocytic leukemia	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human acute lymphoblastic leukemia cells harboring NRAS and CDKN2A mutations were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).	26343583
CDKN2A	CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H	melanoma	predicted - sensitive	Carboplatin + Imatinib + Paclitaxel	Case Reports/Case Series	Actionable	In a clinical case study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).	28514312
CDKN2A	CDKN2A negative	lung non-small cell carcinoma	sensitive	Palbociclib + PF-04691502	Preclinical - Cell culture	Actionable	In a preclinical study, Ibrance (palbociclib) and PF-04691502 synergisticaly inhibited growth of Cdkn2a-null non-small cell lung cancer cell lines in culture (PMID: 30647837).	30647837
CDKN2A	CDKN2A negative	lung non-small cell carcinoma	sensitive	Palbociclib + Sirolimus	Preclinical - Cell culture	Actionable	In a preclinical study, Ibrance (palbociclib) and Rapamune (sirolimus) synergisticaly inhibited growth of Cdkn2a-null non-small cell lung cancer cell lines in culture (PMID: 30647837).	30647837
CDKN2A	CDKN2A negative	lung non-small cell carcinoma	sensitive	Everolimus + Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, Ibrance (palbociclib) and Afinitor (everolimus) synergisticaly inhibited growth of Cdkn2a-null non-small cell lung cancer cell lines in culture (PMID: 30647837).	30647837
CDKN2A	CDKN2A negative	lung non-small cell carcinoma	predicted - sensitive	Palbociclib	Phase II	Actionable	In a Phase II trial, Ibrance (palbociclib) treatment resulted in no objective response (0/16) and stable disease in 50% (8/16) of patients with advanced Cdkn2a-null (by IHC) non-small cell lung cancer, with a median overall survival (mOS) of 5.1 months for all patients and a mOS of 16.6 months in patients achieved stable disease (PMID: 30647837; NCT01291017).	30647837
CEBPA	CEBPA mutant	acute myeloid leukemia	predicted - sensitive	Tofacitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived acute myeloid leukemia (AML) cells harboring biallelic CEBPA mutations demonstrated increased sensitivity to Xeljanz (tofacitinib) compared to control AML cells in culture (PMID: 27034432).	27034432
CEBPA	CEBPA mutant	acute myeloid leukemia	predicted - sensitive	Ruxolitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived acute myeloid leukemia (AML) cells harboring biallelic CEBPA mutations demonstrated increased sensitivity to Jakafi (ruxolitinib) compared to control AML cells in culture (PMID: 27034432).	27034432
CEBPA	CEBPA mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, biallelic CEBPA mutations were associated with favorable clinical outcome in patients with cytogenetically normal acute myeloid leukemia (PMID: 26601784, PMID: 19171880, PMID: 20038735, PMID: 22915647).	22915647 26601784 19171880 20038735
CEBPA	CEBPA mutant	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	CEBPA biallelic mutations are associated with a favorable prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).	detail...
CEBPA	CEBPA mutant	acute myeloid leukemia	predicted - sensitive	Momelotinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived acute myeloid leukemia (AML) cells harboring biallelic CEBPA mutations demonstrated increased sensitivity to Momelotinib (CYT387) compared to control AML cells in culture (PMID: 27034432).	27034432
CEBPA	CEBPA mutant	acute myeloid leukemia	predicted - sensitive	AZD1480	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived acute myeloid leukemia (AML) cells harboring biallelic CEBPA mutations demonstrated increased sensitivity to AZD1480 compared to control AML cells in culture (PMID: 27034432).	27034432
CEBPA	CEBPA mutant GATA2 mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, mutations in GATA2 were associated with better overall survival in patients with cytogenetically normal acute myeloid leukemia (CN-AML) harboring biallelic CEBPA gene mutations (PMID: 22814295, PMID: 23521373, PMID: 25241285).	25241285 22814295 23521373
CSF1R	CSF1R over exp	tenosynovial giant cell tumor	sensitive	Pexidartinib	Phase I	Actionable	In a Phase I trial, PLX3397 reduced tenosynovial giant cell tumor volume in patients with overexpression of Csf1r (PMID: 26222558).	26222558
CSF1R	CSF1R Y571D	myeloid leukemia	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, CSFR1 Y571D conferred sensitivity to Gleevec (imatinib) in myeloid cell lines in culture (PMID: 18971950).	18971950
CSF1R	CSF1R positive	Hodgkin's lymphoma	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, elevated levels of CSF1R expression were associated with a worse survival in patients with Hodgkin's lymphoma (PMID: 24619759, PMID: 26066800, PMID: 22955918).	24619759 26066800 22955918
CSF1R	CSF1R positive	chronic myelomonocytic leukemia	predicted - sensitive	NMS-P088	Preclinical - Patient cell culture	Actionable	In a preclinical study, NMS-P088 inhibited proliferation of Csf1r-expressing blasts derived from chronic myelomonocytic leukemia patients (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1324).	detail...
CSF1R	CSF1R positive	Hodgkin's lymphoma	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited CSF1R phosphorylation and induced apoptosis in Hodgkin's lymphoma cells in culture (PMID: 21517818)	21517818
CSF1R	BRAF V600E CSF1R positive	melanoma	sensitive	Pexidartinib + Vemurafenib	Preclinical	Actionable	In a preclinical study, a melanoma mouse model harboring BRAF V600E treated with Zelboraf (vemurafenib) demonstrated a greater drug induced sensitivity when treatment was combined with PLX3397, resulting in increased infiltration of lymphocytes via Csf1r inhibition and elevated antitumor activity (PMID: 25939769).	25939769
CSF3R	CSF3R Q741*	Advanced Solid Tumor	sensitive	Ibrutinib + Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Imbruvica (ibrutinib) and Jakafi (ruxolitinib) resulted in a synergistic effect in cells expressing CSF3R Q741*, demonstrating greater decreased cell viability as compared to either agent alone (PMID: 29977015).	29977015
CSF3R	CSF3R Q741*	Advanced Solid Tumor	sensitive	Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing CSF3R Q741* were sensitive to treatment with Jakafi (ruxolitinib) in culture, demonstrating decreased total colony formation (PMID: 29977015).	29977015
CSF3R	CSF3R Q741*	Advanced Solid Tumor	sensitive	Ibrutinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing CSF3R Q741* were sensitive to treatment with Imbruvica (ibrutinib) in culture, demonstrating a reduced cell proliferation (PMID: 29977015).	29977015
CSF3R	CSF3R T618I	Advanced Solid Tumor	sensitive	Ibrutinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing CSF3R T618I were sensitive to treatment with Imbruvica (ibrutinib) in culture, demonstrating a reduced cell proliferation (PMID: 29977015).	29977015
CSF3R	CSF3R T618I	Advanced Solid Tumor	sensitive	Ibrutinib + Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Imbruvica (ibrutinib) and Jakafi (ruxolitinib) resulted in a synergistic effect in cells expressing CSF3R T618I, demonstrating greater decreased cell viability as compared to either agent alone (PMID: 29977015).	29977015
CSF3R	CSF3R T618I	Advanced Solid Tumor	sensitive	Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Jakafi (ruxolitinib) reduced colony formation of cells expressing CSF3R T618I in culture (PMID: 26475333, PMID: 29977015).	26475333 29977015
CSF3R	CSF3R T640N	Advanced Solid Tumor	sensitive	Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) reduces colony formation of cells expressing CSF3R T640N in culture (PMID: 26475333).	26475333
CSF3R	CSF3R mutant	bone marrow cancer	not applicable	N/A	Clinical Study	Emerging	In clinical studies, high frequency of CSF3R mutations was identified in patients with chronic neutrophilic leukemia (PMID: 23656643, PMID: 24081659), suggesting that this may serve as a future diagnostic biomarker (PMID: 24441292).	24081659 23656643 24441292
CSF3R	CSF3R N610H	Advanced Solid Tumor	predicted - sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of transformed cells expressing CSF3R N610H in culture (PMID: 30348809).	30348809
CSF3R	CSF3R N610H	Advanced Solid Tumor	sensitive	Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Jakafi (ruxolitinib) inhibited growth of transformed cells expressing CSF3R N610H in culture (PMID: 30348809).	30348809
CSF3R	CSF3R N610S	Advanced Solid Tumor	sensitive	Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Jakafi (ruxolitinib) inhibited growth of transformed cells exxpressing CSF3R N610S in culture (PMID: 30348809).	30348809
CSF3R	CSF3R N610S	Advanced Solid Tumor	predicted - sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of transformed cells expressing CSF3R N610S in culture (PMID: 30348809).	30348809
CTNNB1	CTNNB1 mutant	endometrial cancer	predicted - sensitive	Temsirolimus	Phase II	Actionable	In a retrospective study of a Phase II trial, Torisel (temsirolimus) treatment resulted in an increased progression-free survival (HR 0.46) but not response rate (response difference 0.00) in advanced endometrial cancer patients harboring CTNNB1 mutations (PMID: 27016228).	27016228
CTNNB1	CTNNB1 mutant	hepatocellular carcinoma	sensitive	PMED-1	Preclinical	Actionable	In a preclinical study, PMED-1 decreased Wnt expression and decreased proliferation of hepatocellular carcinoma cells with Ctnnb1 mutations (PMID: 24819961).	24819961
CTNNB1	CTNNB1 mutant	colorectal cancer	sensitive	BC21	Preclinical	Actionable	In a preclinical study, BC21 inhibited growth and viability of a colorectal cancer cell line with a CTNNB1 mutation and increased beta-catenin expression in culture (PMID: 22224445).	22224445
CTNNB1	CTNNB1 mutant	medulloblastoma	not applicable	N/A	Guideline	Prognostic	WNT-driven medulloblastomas, characterized by CTNNB1 or APC mutations, are associated with favorable prognosis (NCCN.org).	detail...
CTNNB1	CTNNB1 mut NRAS mut	liver cancer	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human liver cancer cells harboring mutant NRAS and mutant CTNNB1 were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).	26343583
CTNNB1	CTNNB1 amp	acute myeloid leukemia	predicted - sensitive	CWP232291	Phase I	Actionable	In a Phase I trial, CWP232291 reduced beta-catenin expression and demonstrated safety and preliminary efficacy in acute myeloid leukemia (J Clin Oncol (Meeting Abstracts) 2015 33: 7044)).	detail...
CTNNB1	CTNNB1 S33F	colorectal cancer	predicted - resistant	G007-LK	Preclinical	Actionable	In a preclinical study, G007-LK treatment did not alter gene expression pattern or affect growth in mouse intestinal organoids expressing CTNNB1 S33F (corresponding to S33F in human) in culture (PMID: 31337618).	31337618
CTNNB1	CTNNB1 S45del	colon carcinoma	predicted - sensitive	NTRC 0066-0	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to NTRC 0066-0 compared to cell lines with wild-type CTNNB1 or an isogenic cell line lacking the CTNNB1 mutation, in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S45del	colon carcinoma	predicted - sensitive	NMS-P715	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to NMS-P715 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S45del	colon carcinoma	predicted - sensitive	BAY1217389	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to BAY1217389 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S45del	colon carcinoma	predicted - sensitive	MPI-0479605	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del demonstrated increased sensitivity to MPI-0479605 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S45del	colon carcinoma	predicted - sensitive	Mps1-IN-1	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to Mps1-IN-1 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S45del	colon carcinoma	predicted - sensitive	BAY1161909	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to BAY1161909 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S45del	colorectal adenocarcinoma	predicted - sensitive	BAY1161909	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to BAY1161909 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S45del	colon carcinoma	predicted - sensitive	Mps-BAY2b	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to Mps-BAY2b compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 T41A	lung cancer	predicted - sensitive	NMS-P715	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to NMS-P715 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 T41A	lung cancer	predicted - sensitive	BAY1217389	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to BAY1217389 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 T41A	lung cancer	predicted - sensitive	BAY1161909	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to BAY1161909 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 T41A	lung cancer	predicted - sensitive	Mps-BAY2b	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to Mps-BAY2b compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 T41A	lung cancer	predicted - sensitive	MPI-0479605	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A demonstrated increased sensitivity to MPI-0479605 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 T41A	desmoid tumor	sensitive	Imatinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, patients with desmoid fibromatosis harboring CTNNB1 T41A demonstrated a greater progression arrest rate at 6 months (70%) compared to patients with CTNNB1 wild-type (45%) when treated with Gleevec (imatinib) (PMID: 26861905).	26861905
CTNNB1	CTNNB1 T41A	lung cancer	predicted - sensitive	NTRC 0066-0	Preclinical - Cell line xenograft	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to NTRC 0066-0 compared to cell lines with wild-type CTNNB1, in culture and in xenograft models (PMID: 28751540).	28751540
CTNNB1	CTNNB1 T41A	lung cancer	predicted - sensitive	Mps1-IN-1	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to Mps1-IN-1 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 act mut	hepatocellular carcinoma	decreased response	unspecified CTLA4 antibody	Clinical Study - Cohort	Actionable	In a clinical study, treatment with immune checkpoint antibodies, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy or combinations of anti-PD-1 with anti-CTLA-4, anti-LAG3, or anti-KIR, was less effective in patients with Wnt pathway mutations in CTNNB1 or AXIN1 compared to patients without mutations in this pathway, with 0% (0/10) vs. 53% (9/17) achieving disease control, respectively, and shorter progression-free survival (2.0 months vs. 7.4 months) (PMID: 30373752; NCT01775072).	30373752
CTNNB1	CTNNB1 act mut	desmoid tumor	sensitive	Imatinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, patients with desmoid fibromatosis harboring CTNNB1 activating exon 3 mutations demonstrated a greater progression arrest rate at 6 months compared to patients with CTNNB1 wild-type tumor when treated with Gleevec (imatinib) (PMID: 26861905).	26861905
CTNNB1	CTNNB1 act mut	hepatocellular carcinoma	decreased response	unspecified CTLA4 antibody + unspecified PD-1 antibody	Clinical Study - Cohort	Actionable	In a clinical study, treatment with immune checkpoint antibodies, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy or combinations of anti-PD-1 with anti-CTLA-4, anti-LAG3, or anti-KIR, was less effective in patients with Wnt pathway mutations in CTNNB1 or AXIN1 compared to patients without mutations in this pathway, with 0% (0/10) vs. 53% (9/17) achieving disease control, respectively, and shorter progression-free survival (2.0 months vs. 7.4 months) (PMID: 30373752; NCT01775072).	30373752
CTNNB1	CTNNB1 act mut	hepatocellular carcinoma	decreased response	unspecified PD-L1 antibody	Clinical Study - Cohort	Actionable	In a clinical study, treatment with immune checkpoint antibodies, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy or combinations of anti-PD-1 with anti-CTLA-4, anti-LAG3, or anti-KIR, was less effective in patients with Wnt pathway mutations in CTNNB1 or AXIN1 compared to patients without mutations in this pathway, with 0% (0/10) vs. 53% (9/17) achieving disease control, respectively, and shorter progression-free survival (2.0 months vs. 7.4 months) (PMID: 30373752; NCT01775072).	30373752
CTNNB1	CTNNB1 act mut	hepatocellular carcinoma	decreased response	unspecified PD-1 antibody	Clinical Study - Cohort	Actionable	In a clinical study, treatment with immune checkpoint antibodies, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy or combinations of anti-PD-1 with anti-CTLA-4, anti-LAG3, or anti-KIR, was less effective in patients with Wnt pathway mutations in CTNNB1 or AXIN1 compared to patients without mutations in this pathway, with 0% (0/10) vs. 53% (9/17) achieving disease control, respectively, and shorter progression-free survival (2.0 months vs. 7.4 months) (PMID: 30373752; NCT01775072).	30373752
CTNNB1	CTNNB1 S33Y	colorectal adenocarcinoma	predicted - sensitive	NMS-P715	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y, demonstrated increased sensitivity to NMS-P715 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S33Y	colorectal adenocarcinoma	predicted - sensitive	Mps-BAY2b	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y, demonstrated increased sensitivity to Mps-BAY2b compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S33Y	colorectal adenocarcinoma	predicted - sensitive	Mps1-IN-1	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y demonstrated increased sensitivity to Mps1-IN-1 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S33Y	colorectal adenocarcinoma	predicted - sensitive	NTRC 0066-0	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal carcinoma cell line harboring CTNNB1 S33Y, demonstrated increased sensitivity to NTRC 0066-0 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S33Y	colorectal adenocarcinoma	predicted - sensitive	MPI-0479605	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y demonstrated increased sensitivity to MPI-0479605 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S33Y	colorectal adenocarcinoma	predicted - sensitive	BAY1217389	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y, demonstrated increased sensitivity to BAY1217389 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S33Y	colorectal adenocarcinoma	predicted - sensitive	BAY1161909	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y, demonstrated increased sensitivity to BAY1161909 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	APC wild-type CTNNB1 wild-type	colon cancer	predicted - sensitive	Vantictumab	Preclinical - Pdx	Actionable	In a preclinical study, Vantictumab (OMP-18R5) inhibited tumor growth in patient-derived xenograft models of colon cancer with wild-type CTNNB1 (beta-catenin) and APC (PMID: 22753465).	22753465
CTNNB1	CTNNB1 S45F	colorectal adenocarcinoma	predicted - sensitive	BAY1217389	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S45F, demonstrated increased sensitivity to BAY1217389 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S45F	colorectal adenocarcinoma	predicted - sensitive	NTRC 0066-0	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal carcinoma cell line harboring CTNNB1 S45F, demonstrated increased sensitivity to NTRC 0066-0 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S45F	desmoid tumor	sensitive	Imatinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, patients with desmoid fibromatosis harboring CTNNB1 S45F demonstrated a greater progression arrest rate at 6 months compared to CTNNB1 wild-type patients (85% vs 43%, p=0.05) when treated with Gleevec (imatinib) (PMID: 26861905).	26861905
CTNNB1	CTNNB1 S45F	colorectal adenocarcinoma	predicted - sensitive	MPI-0479605	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S45F demonstrated increased sensitivity to MPI-0479605 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S45F	colorectal adenocarcinoma	predicted - sensitive	Mps-BAY2b	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S45F, demonstrated increased sensitivity to Mps-BAY2b compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S45F	colorectal adenocarcinoma	predicted - sensitive	NMS-P715	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S45F, demonstrated increased sensitivity to NMS-P715 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 S45F	colorectal adenocarcinoma	predicted - sensitive	Mps1-IN-1	Preclinical - Cell culture	Actionable	In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S45F demonstrated increased sensitivity to Mps1-IN-1 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).	28751540
CTNNB1	CTNNB1 over exp	colon cancer	predicted - sensitive	NVP-TNKS656 + Triciribine	Preclinical - Pdx	Actionable	In a preclinical study, the combination of NVP-TNKS656 and Triciribine (API-2) inhibited tumor growth in Triciribine (API-2)-resistant patient-derived xenograft (PDX) models of colon cancer with high nuclear CTNNB1 (Beta-catenin) levels (PMID: 26224873).	26224873
DDR2	DDR2 over exp	head and neck squamous cell carcinoma	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited cell migration and invasion of head and neck squamous cell carcinoma cells overexpressing Ddr2, in culture (PMID: 27434411).	27434411
DDR2	DDR2 L239R DDR2 T654I	lung squamous cell carcinoma	predicted - resistant	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, DDR2 T654I was identified as an acquired mutation in lung squamous cell carcinoma cells harboring DDR2 L239R that became resistant to Sprycel (dasatinib) in culture (PMID: 24296828).	24296828
DDR2	DDR2 G253C	Advanced Solid Tumor	sensitive	Nilotinib + Saracatinib	Preclinical	Actionable	In a preclinical study, the combination of Saracatinib (AZD0530) and Tasigna (nilotinib) reduced proliferation of transformed cells expressing DDR2 G253C in culture, with increased potency over either agent alone (PMID: 22328973).	22328973
DDR2	DDR2 G253C	Advanced Solid Tumor	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 G253C in culture (PMID: 22328973).	22328973
DDR2	DDR2 G253C	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 G253C in culture (PMID: 22328973).	22328973
DDR2	DDR2 act mut	lung non-small cell carcinoma	sensitive	Lucitanib	Preclinical	Actionable	In a preclinical study, Lucitanib (E-3810) decreased DDR2 phosphorylation, and inhibited proliferation and induced apoptosis in lung squamous cell carcinoma cells harboring a DDR2 activating mutation in culture (PMID: 24696502).	24696502
DDR2	DDR2 L239R	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 L239R in culture (PMID: 22328973).	22328973
DDR2	DDR2 L239R	lung squamous cell carcinoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited proliferation of lung squamous cell carcinoma cells harboring a DDR2 L239R mutation in culture (PMID: 22328973).	22328973
DDR2	DDR2 L239R	lung squamous cell carcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of lung squamous cell cancer cells harboring DDR2 L239R in culture (PMID: 22328973).	22328973
DDR2	DDR2 L239R	Advanced Solid Tumor	sensitive	Nilotinib + Saracatinib	Preclinical	Actionable	In a preclinical study, the combination of Saracatinib (AZD0530) and Tasigna (nilotinib) reduced proliferation of transformed cells expressing DDR2 L239R in culture, with increased potency over either agent alone (PMID: 22328973).	22328973
DDR2	DDR2 L239R	Advanced Solid Tumor	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 L239R in culture (PMID: 22328973).	22328973
DDR2	DDR2 L239R DDR2 T654M	lung squamous cell carcinoma	decreased response	Dasatinib	Preclinical	Actionable	In a preclinical study, expression of DDR2 T654M in lung squamous cell cancer cells harboring DDR2 L239R resulted in decreased sensitivity to Sprycel (dasatinib) in culture (PMID: 22328973).	22328973
DDR2	DDR2 I638F DDR2 T654M	lung squamous cell carcinoma	decreased response	Dasatinib	Preclinical	Actionable	In a preclinical study, expression of DDR2 T654M in lung squamous cell cancer cells harboring DDR2 I638F resulted in decreased sensitivity to Sprycel (dasatinib) in culture (PMID: 22328973).	22328973
DDR2	DDR2 I638F	lung squamous cell carcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of lung squamous cell carcinoma cells harboring a DDR2 I638F mutation in cell culture (PMID: 22328973).	22328973
DDR2	DDR2 I638F	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 I638F in culture (PMID: 22328973).	22328973
DDR2	DDR2 I638F	Advanced Solid Tumor	sensitive	Nilotinib + Saracatinib	Preclinical	Actionable	In a preclinical study, the combination of Saracatinib (AZD0530) and Tasigna (nilotinib) reduced proliferation of transformed cells expressing DDR2 I638F in culture, with increased potency over either agent alone (PMID: 22328973).	22328973
DDR2	DDR2 I638F	Advanced Solid Tumor	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 I638F in culture (PMID: 22328973).	22328973
DDR2	DDR2 I638F	lung squamous cell carcinoma	sensitive	Dasatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited growth of a lung squamous cell carcinoma cell line harboring a DDR2 I638F mutation in culture and in xenograft models (PMID: 22328973).	22328973
DDR2	DDR2 amp EML4-ALK	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, DDR2 amplification (PMID: 29636358).	29636358
DDR2	DDR2 S768R	lung squamous cell carcinoma	predicted - sensitive	Dasatinib + Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, a squamous cell lung cancer patient that demonstrated a radiographic response following Sprycel (dasatinib) and Tarceva (erlotinib) combination treatment was found to carry a DDR2 S768R mutation (PMID: 22328973).	22328973
DDR2	DDR2 S768R	lung squamous cell carcinoma	predicted - sensitive	Dasatinib	Case Reports/Case Series	Actionable	In a clinical case study, patient with lung squamous cell carcinoma harboring a DDR2 S768R mutation had a positive response to (Sprycel) dasatinib treatment (PMID: 23932362).	23932362
DDR2	DDR2 G774V	Advanced Solid Tumor	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 G774V in culture (PMID: 22328973).	22328973
DDR2	DDR2 G774V	Advanced Solid Tumor	sensitive	Nilotinib + Saracatinib	Preclinical	Actionable	In a preclinical study, the combination of Saracatinib (AZD0530) and Tasigna (nilotinib) reduced proliferation of transformed cells expressing DDR2 G774V in culture, with increased potency over either agent alone (PMID: 22328973).	22328973
DDR2	DDR2 G774V	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 G774V in culture (PMID: 22328973).	22328973
DDR2	DDR2 mutant	lung squamous cell carcinoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, lung squamous cell cancer cells harboring DDR2 mutations demonstrated sensitivity to Sprycel (dasatinib) in culture (PMID: 22328973).	22328973
DDR2	DDR2 L63V	Advanced Solid Tumor	sensitive	Nilotinib + Saracatinib	Preclinical	Actionable	In a preclinical study, the combination of Saracatinib (AZD0530) with Tasigna (nilotinib) reduced Src and Stat5 activation and inhibited proliferation of transformed cells expressing DDR2 L63V in culture, with increased potency over either agent alone (PMID: 22328973).	22328973
DDR2	DDR2 L63V	lung squamous cell carcinoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) prevented colony formation and induced cell death in lung squamous cell carcinoma cells expressing DDR2 L63V in culture (PMID: 22328973).	22328973
DDR2	DDR2 L63V	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 L63V in culture (PMID: 22328973).	22328973
DDR2	DDR2 L63V	Advanced Solid Tumor	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 L63V in culture (PMID: 22328973).	22328973
DDR2	DDR2 G505S	Advanced Solid Tumor	sensitive	Nilotinib + Saracatinib	Preclinical	Actionable	In a preclinical study, the combination of Saracatinib (AZD0530) and Tasigna (nilotinib) reduced proliferation of transformed cells expressing DDR2 G505S in culture, with increased potency over either agent alone (PMID: 22328973).	22328973
DDR2	DDR2 G505S	Advanced Solid Tumor	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 G505S in culture (PMID: 22328973).	22328973
DDR2	DDR2 G505S	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing DDR2 G505S in culture (PMID: 22328973).	22328973
DNMT3A	DNMT3A R882H NRAS G12D	acute myeloid leukemia	sensitive	Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an acute myeloid leukemia cell line xenograft model harboring DNMT3A R882H and NRAS G12D was sensitive to Mekinist (trametinib), demonstrating impaired disease progression and improved survival (PMID: 31164355).	31164355
DNMT3A	DNMT3A R882H NRAS G12D	acute myeloid leukemia	sensitive	I-BET151 + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an acute myeloid leukemia cell line xenograft model harboring DNMT3A R882H and NRAS G12D treated with combined I-BET151 and Mekinist (trametinib) demonstrated impaired disease progression and improved survival superior to either therapy alone (PMID: 31164355).	31164355
DNMT3A	DNMT3A R882H NRAS G12D	acute myeloid leukemia	sensitive	I-BET151	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an acute myeloid leukemia cell line harboring DNMT3A R882H and NRAS G12D mutations demonstrated reduced proliferation and downregulation of a DNMT3A R882H associated gene expression profile upon I-BET151 treatment in culture, and I-BET151 treatment delayed the onset of leukemia symptoms and improved survival in xenograft mouse models derived from these cells (PMID: 31164355).	31164355
DNMT3A	DNMT3A wild-type FLT3 mut NPM1 mut	acute myeloid leukemia	predicted - sensitive	KO-539	Preclinical - Pdx	Actionable	In a preclinical study, KO-539 treatment prevented disease progression in patient-derived xenograft (PDX) models of DNMT3A wild-type acute myeloid leukemia harboring mutations in NPM1 and FLT3 (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27).	detail...
DNMT3A	DNMT3A mutant	acute myeloid leukemia	predicted - sensitive	Decitabine	Clinical Study - Cohort	Actionable	In a clinical study, acute myeloid leukemia patients harboring DNMT3A mutations demonstrated a greater complete response rate (60% vs 33%) compared to patients with wild-type DNMT3A when treated with frontline hypomethylating agents such as Dacogen (decitabine) (PMID: 27418649).	27418649
DNMT3A	DNMT3A mutant	acute myeloid leukemia	sensitive	Pinometostat	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pinometostat (EPZ-5676) treatment of acute myeloid leukemia cell lines and xenografts resulted in apoptosis, cell-cycle arrest, and terminal differentiation (PMID: 27335278).	27335278
DNMT3A	DNMT3A mutant	angioimmunoblastic T-cell lymphoma	not applicable	N/A	Guideline	Diagnostic	DNMT3A mutations aid in the diagnosis of angioimmunoblastic T-cell lymphoma (NCCN.org).	detail...
DNMT3A	DNMT3A mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, mutations in DNMT3A were associated with poor prognosis and shorter overall survival in patients with acute myeloid leukemia (PMID: 22490330, PMID: 21881046, PMID: 21670448).	22490330 21881046 21670448
DNMT3A	DNMT3A mut FLT3 mut NPM1 mut	acute myeloid leukemia	not applicable	N/A	Clinical Study	Emerging	In a retrospective analysis, the combination of DNMT3A, FLT3, and NPM1 mutations in patients with acute myeloid leukemia was highly associated with decreased event-free survival and overall survival, suggesting that this combination profile may serve as a future prognostic biomarker (PMID: 25281355).	25281355
DNMT3A	DNMT3A mut FLT3 exon 14 ins NPM1 mut	acute myeloid leukemia	predicted - sensitive	Entospletinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of FLT3-ITD, DNMT3A, and NPM1 mutations correlated with sensitivity to Entospletinib in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
DNMT3A	DNMT3A mut FLT3 exon 14 ins NPM1 mut	acute myeloid leukemia	predicted - sensitive	Ibrutinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of FLT3-ITD , DNMT3A, and NPM1 mutations correlated with sensitivity to Imbruvica (ibrutinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
DNMT3A	DNMT3A mut FLT3 exon 14 ins NPM1 mut	acute myeloid leukemia	predicted - sensitive	KO-539	Preclinical - Pdx	Actionable	In a preclinical study, KO-539 treatment resulted in clearance of leukemia cells in patient-derived xenograft (PDX) models of acute myeloid leukemia harboring mutations in NPM1, DNMT3, and FLT3 exon 14 (ITD) (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27).	detail...
DNMT3A	DNMT3A mut NPM1 mut	acute myeloid leukemia	predicted - sensitive	Entospletinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of DNMT3A and NPM1 mutations correlated with sensitivity to Entospletinib in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
DNMT3A	DNMT3A mut NPM1 mut	acute myeloid leukemia	predicted - sensitive	Ibrutinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of DNMT3A and NPM1 mutations correlated with sensitivity to Imbruvica (ibrutinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
EGFR	EGFR D770_N771insG	lung non-small cell carcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, treatment with Poziotinib (HM781-36B) resulted in objective partial responses in 64% (7/11) of patients with non-small cell lung cancer harboring EGFR exon 20 mutations, including a patient with EGFR D770delinsGY (PMID: 29686424; NCT03066206).	29686424
EGFR	EGFR D770_N771insG	lung non-small cell carcinoma	predicted - sensitive	Osimertinib	Case Reports/Case Series	Actionable	In a clinical study, Tagrisso (osimertinib) treatment resulted in a partial response with a progression-free survival of 6.4 months in a patient with non-small cell lung cancer harboring EGFR D770_N771insG (PMID: 31208370).	31208370
EGFR	EGFR D770_N771insG	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited EGFR phosphorylation and proliferation of cells expressing EGFR exon 20 insertion mutations, including EGFR D770_N771insG, in culture (PMID: 29748209).	29748209
EGFR	EGFR N771delinsFH	lung adenocarcinoma	sensitive	Poziotinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) growth of a lung adenocarcinoma patient-derived cell line harboring EGFR N771delinsFH in culture, and decreased tumor burden in xenograft models (PMID: 29686424).	29686424
EGFR	EGFR L747_T751delinsP	lung adenocarcinoma	predicted - sensitive	Gefitinib	Clinical Study	Actionable	In a retrospective analysis, 3 patients with lung adenocarcinoma harboring EGFR L747_T751delinsP demonstrated partial responses when treated with Iressa (gefitinib) therapy (PMID: 18981003).	18981003
EGFR	EGFR L747_T751delinsP	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsP were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_T751delinsP	Advanced Solid Tumor	sensitive	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsP were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_T751delinsP	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsP were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_T751delinsP	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsP were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L747_T751delinsP	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsP were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_T751delinsP EGFR T790M	lung adenocarcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_T751delinsP, who was found to have acquired an EGFR T790M mutation upon disease progression on Iressa (gefitinib), had rapid disease progress in response Tarceva (erlotinib) therapy (PMID: 18981003).	18981003
EGFR	EGFR L747_T751delinsP EGFR T790M	lung adenocarcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_T751delinsP that developed resistance to Iressa (gefitinib) was found to have acquired an EGFR T790M mutation (PMID: 18981003).	18981003
EGFR	EGFR L747_T751delinsP EML4-ALK	lung non-small cell carcinoma	predicted - resistant	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, EML4-ALK was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR L747_T751delinsP, whose disease progressed after initial response to Gilotrif (afatinib) (PMID: 29883838).	29883838
EGFR	EGFR K745_E746insVPVAIK	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR K745_E746insVPVAIK were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR K745_E746insVPVAIK	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR K745_E746insVPVAIK were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR K745_E746insVPVAIK	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR K745_E746insVPVAIK were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR Y764_V765insHH	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR Y764_V765insHH were resistant to Gilotrif (afatinib) in culture (PMID: 29467275).	29467275
EGFR	EGFR Y764_V765insHH	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR Y764_V765insHH were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).	29467275
EGFR	EGFR Y764_V765insHH	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR Y764_V765insHH were resistant to Tagrisso (osimertinib) in culture (PMID: 29467275).	29467275
EGFR	EGFR Y764_V765insHH	Advanced Solid Tumor	sensitive	Luminespib	Preclinical - Cell culture	Actionable	In a preclinical study, Luminespib (AUY922) decreased viability of cells expressing EGFR Y764_V765insHH in culture (PMID: 30154228).	30154228
EGFR	EGFR Y764_V765insHH	Advanced Solid Tumor	resistant	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR Y764_V765insHH were resistant to Naquotinib (ASP8273) in culture (PMID: 29467275).	29467275
EGFR	EGFR Y764_V765insHH	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR Y764_V765insHH demonstrated resistance to Vizimpro (dacomitinib) in culture (PMID: 28363995).	28363995
EGFR	EGFR A767_V769dup	lung non-small cell carcinoma	resistant	Erlotinib	Phase I	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR A767_V769dup (reported as V769_D770insASV), displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).	24353160
EGFR	EGFR A767_V769dup	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A767_V769dup (reported as V769_D770insASV) were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR A767_V769dup	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited growth of transformed cell lines expressing EGFR A767_V769dup (reported as V769insASV) in culture (PMID: 29686424).	29686424
EGFR	EGFR A767_V769dup	lung adenocarcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, Iressa (gefitinib) treatment resulted in disease progression after 3 months of treatment in a patient with metastatic lung adenocarcinoma harboring EGFR A767_V769dup (PMID: 21841502).	21841502
EGFR	EGFR A767_V769dup	lung cancer	sensitive	TAS6417	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, TAS6417 inhibited growth and induced apoptotic markers in a lung cancer patient-derived xenograft (PDX) model-derived cell line harboring EGFR A767_V769dup (reported as V769_D770insASV) in culture, and inhibited tumor growth and induced tumor regression in PDX models (PMID: 29748209).	29748209
EGFR	EGFR A767_V769dup	lung non-small cell carcinoma	resistant	Gefitinib	Case Reports/Case Series	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR A767_V769dup (reported as V769_D770insASV), displayed progressive disease following treatment with Iressa (gefitinib), and resistance to Iressa (gefitinib) was replicated in cell culture studies (PMID: 24353160).	24353160
EGFR	EGFR A767_V769dup	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A767_V769dup (reported as V769_D770insASV) were insensitive to Tarceva (erlotinib)-mediated inhibition of Egfr phosphorylation in culture (PMID: 29483211).	29483211
EGFR	EGFR A767_V769dup	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A767_V769dup (reported as V769_D770insASV) were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR A767_V769dup	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A767_V769dup were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).	29467275
EGFR	EGFR A767_V769dup	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A767_V769dup (reported as V769_D770insASV) were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR A767_V769dup	lung adenocarcinoma	sensitive	Poziotinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited EGFR phosphorylation and growth of a lung adenocarcinoma patient cell line harboring EGFR A767_V769dup in culture (PMID: 29686424).	29686424
EGFR	EGFR A767_V769dup	Advanced Solid Tumor	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR A767_V769dup in culture (PMID: 29467275).	29467275
EGFR	EGFR A767_V769dup	Advanced Solid Tumor	sensitive	Nazartinib	Preclinical - Cell culture	Actionable	In a preclinical study, EGF816 inhibited growth of transformed cells expressing EGFR A767_V769dup (reported as V769_D770insASV) in culture (PMID: 26825170).	26825170
EGFR	EGFR A767_V769dup	lung cancer	predicted - resistant	Afatinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) decreased Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR A767_V769dup in culture, bud did not affect tumor growth in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).	detail...
EGFR	EGFR A767_V769dup	lung non-small cell carcinoma	predicted - sensitive	Luminespib	Phase II	Actionable	In a Phase II trial, Luminespib (AUY922) treatment demonstrated safety and efficacy in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, with 1 of 3 patient harboring EGFR A767_V769dup achieved stable disease (PMID: 30351341; NCT01854034).	30351341
EGFR	EGFR A767_V769dup	Advanced Solid Tumor	conflicting	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR exon 20 insertions, including EGFR A767_V769dup (reported as V769_D770insASV), demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160, PMID: 29141884).	29141884 24353160
EGFR	EGFR A767_V769dup	Advanced Solid Tumor	conflicting	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR A767_V769dup in culture (PMID: 29467275).	29467275
EGFR	EGFR A767_V769dup	lung non-small cell carcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, treatment with Poziotinib (HM781-36B) resulted in objective partial responses in 64% (7/11) of patients with non-small cell lung cancer harboring EGFR exon 20 mutations, including a patient with EGFR A767_V769dup (PMID: 29686424; NCT03066206).	29686424
EGFR	EGFR A767_V769dup	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A767_V769dup (also referred to as V769_D770insASV) demonstrated resistance to Vizimpro (dacomitinib) in culture (PMID: 28363995).	28363995
EGFR	EGFR A767_V769dup	lung cancer	sensitive	Tarloxotinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR A767_V769dup in culture, and the prodrug Tarloxotinib (TRLX) resulted in tumor regression in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).	detail...
EGFR	EGFR A767_V769dup	lung non-small cell carcinoma	conflicting	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung cancer harboring EGFR A767_V769dup demonstrated a partial response when treated with Gilotrif (afatinib) (PMID: 31043566).	31043566
EGFR	EGFR A767_V769dup	lung non-small cell carcinoma	conflicting	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells expressing EGFR A767_V769dup (reported as V769_D770insASV) were resistant to Gilotrif (afatinib)-mediated growth inhibition in culture and in cell line xenograft models (PMID: 29483211).	29483211
EGFR	EGFR A767_V769dup	lung non-small cell carcinoma	conflicting	Afatinib	Preclinical - Pdx	Actionable	In a preclinicl study, patient-derived xenograft (PDX) models of non-small cell lung cancer harboring EGFR A767_V769dup (reported as M766_A767insASV) were resistant to Gilotrif (afatinib) (PMID: 29483211).	29483211
EGFR	EGFR A767_V769dup	lung non-small cell carcinoma	sensitive	Osimertinib	Preclinical - Pdx	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited tumor growth in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring EGFR A767_V769dup (reported as M766_A767insASV) (PMID: 29483211).	29483211
EGFR	EGFR A767_V769dup	lung non-small cell carcinoma	sensitive	Osimertinib	Case Reports/Case Series	Actionable	In a clinical study, Tagrisso (osimertinib) treatment resulted in a partial response with a progression-free survival of 6.0 months in a patient with non-small cell lung cancer harboring EGFR A767_V769dup (PMID: 31208370).	31208370
EGFR	EGFR A767_V769dup	lung non-small cell carcinoma	sensitive	Osimertinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited Egfr phosphorylation, resulted in growth inhibition of non-small cell lung carcinoma cells expressing EGFR A767_V769dup (reported as V769_D770insASV) in culture, and tumor regression in cell line and patient-derived xenograft (PDX) models (PMID: 29483211).	29483211
EGFR	EGFR A767_V769dup	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited Egfr phosphorylation in transformed cells expressing EGFR A767_V769dup (reported as V769_D770insASV) in culture (PMID: 29483211).	29483211
EGFR	EGFR A767_V769dup	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR A767_V769dup in culture (PMID: 29467275).	29467275
EGFR	EGFR A767_V769dup	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A767_V769dup (reported as V769_D770insASV) were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A767_V769dup	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited EGFR phosphorylation and proliferation of cells expressing EGFR exon 20 insertion mutations, including EGFR A767_V769dup (reported as V769_D770insASV), in culture (PMID: 29748209).	29748209
EGFR	EGFR R222C	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R222C were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR R222C	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R222C were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR V769_D770insASV	lung non-small cell carcinoma	predicted - sensitive	Luminespib	Phase II	Actionable	In a Phase II trial, Luminespib (AUY922) treatment demonstrated safety and efficacy in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, with 1 patient harboring EGFR V769_D770insASV achieved stable disease (PMID: 30351341; NCT01854034).	30351341
EGFR	EGFR L718Q	Advanced Solid Tumor	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L718Q in culture (PMID: 25948633).	25948633
EGFR	EGFR L718Q	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L718Q were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR L718Q	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L718Q were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L718Q	Advanced Solid Tumor	sensitive	EKI-285	Preclinical	Actionable	In a preclinical study, EKI-285 inhibited EGFR phosphorylation and growth of cells expressing EGFR L718Q in culture (PMID: 25948633).	25948633
EGFR	EGFR L718Q	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L718Q were resistant to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR L718Q	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L718Q in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR T790M EGFR L718Q	Advanced Solid Tumor	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR T790M EGFR L718Q	lung non-small cell carcinoma	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M and ectopically expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR T790M EGFR L718Q	Advanced Solid Tumor	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR T790M EGFR L718Q	lung non-small cell carcinoma	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, expression of an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation conferred resistance to Rociletinib (CO-1686) in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR L718Q	Advanced Solid Tumor	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR L718Q double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR L718Q	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L718Q double mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR L718Q	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L718Q double mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR L858R EGFR L718Q	Advanced Solid Tumor	conflicting	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L718Q and EGFR L858R in trans were sensitive to treatment with Iressa (gefitinib), but when expressed in cis, demonstrated resistance in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR L718Q	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L718Q and EGFR L858R in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR L718Q	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L718Q and EGFR L858R in cis and trans were resistant to Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR L718Q	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR L718Q double mutation demonstrated resistance to Tagrisso (osimertinib) in culture (PMID: 25948633).	25948633
EGFR	EGFR L858R EGFR L718Q	Advanced Solid Tumor	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR L718Q double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).	25948633
EGFR	EGFR L858R EGFR L718Q	Advanced Solid Tumor	conflicting	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L718Q and EGFR L858R in trans were sensitive to treatment with Tarceva (erlotinib), but when expressed in cis, demonstrated resistance in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR L718Q	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR E709A and EGFR G719C in trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR L718Q	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR L858R/EGFR L718Q double mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR L858R EGFR L718Q EGFR T790M	Advanced Solid Tumor	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).	25948633
EGFR	EGFR L858R EGFR L718Q EGFR T790M	Advanced Solid Tumor	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).	25948633
EGFR	EGFR S768_D770dup	lung non-small cell carcinoma	resistant	Erlotinib	Case Reports/Case Series	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR S768_D770dup (reported as D770_N771insSVD), displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).	24353160
EGFR	EGFR S768_D770dup	lung non-small cell carcinoma	resistant	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, non-small cell lung cancer cells expressing EGFR S768_D770dup (reported as D770_N771insSVD) were resistant to Gilotrif (afatinib)-mediated growth inhibition in culture and in cell line xenograft models (PMID: 29483211).	29483211
EGFR	EGFR S768_D770dup	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited growth of transformed cell lines expressing EGFR S768_D770dup (also reported as EGFR D770insSVD) in culture (PMID: 29686424).	29686424
EGFR	EGFR S768_D770dup	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768_D770dup (reported as D770_N771insSVD) were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR S768_D770dup	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768_D770dup (reported as D770_N771insSVD) were insensitive to Tarceva (erlotinib)-mediated inhibition of Egfr phosphorylation in culture (PMID: 29483211).	29483211
EGFR	EGFR S768_D770dup	head and neck squamous cell carcinoma	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited EGFR signaling and reduced growth of sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup in culture (PMID: 25931286).	25931286
EGFR	EGFR S768_D770dup	Advanced Solid Tumor	sensitive	Nazartinib	Preclinical - Cell culture	Actionable	In a preclinical study, EGF816 inhibited growth of transformed cells expressing EGFR S768_D770dup (reported as D770_N771insSVD) in culture (PMID: 26825170).	26825170
EGFR	EGFR S768_D770dup	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768_D770dup (also referred to as D770_N771insSVD) demonstrated resistance to Vizimpro (dacomitinib) in culture (PMID: 28363995).	28363995
EGFR	EGFR S768_D770dup	lung non-small cell carcinoma	predicted - sensitive	Luminespib	Phase II	Actionable	In a Phase II trial, Luminespib (AUY922) treatment demonstrated safety and efficacy in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, with 1 patient harboring EGFR S768_D770dup achieved stable disease (PMID: 30351341; NCT01854034).	30351341
EGFR	EGFR S768_D770dup	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768_D770dup (reported as D770_N771insSVD) were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR S768_D770dup	Advanced Solid Tumor	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR S768_D770dup (reported as D770_N771insSVD), demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160, PMID: 29141884).	24353160 29141884
EGFR	EGFR S768_D770dup	lung non-small cell carcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, treatment with Poziotinib (HM781-36B) resulted in objective partial responses in 64% (7/11) of patients with non-small cell lung cancer harboring EGFR exon 20 mutations, including a patient with EGFR S768_D770dup (PMID: 29686424; NCT03066206).	29686424
EGFR	EGFR S768_D770dup	head and neck squamous cell carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup demonstrated resistance to Iressa (gefinitib) in culture (PMID: 25931286).	25931286
EGFR	EGFR S768_D770dup	lung non-small cell carcinoma	sensitive	Osimertinib	Case Reports/Case Series	Actionable	In a clinical study, Tagrisso (osimertinib) treatment resulted in a partial response with a progression-free survival (PFS) of 14.6 months in a patient with non-small cell lung cancer harboring EGFR S768_D770dup, and stable disease with a PFS of 11.2 months in another patient (PMID: 31208370).	31208370
EGFR	EGFR S768_D770dup	lung non-small cell carcinoma	sensitive	Osimertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited Egfr phosphorylation, resulted in growth inhibition of non-small cell lung carcinoma cells expressing EGFR S768_D770dup (reported as D770_N771insSVD) in culture and tumor growth inhibition in cell line xenograft models (PMID: 29483211).	29483211
EGFR	EGFR S768_D770dup	lung cancer	sensitive	TAS6417	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAS6417 inhibited growth and induced apoptotic markers in a lung cancer cell line expressing EGFR S768_D770dup (reported as D770_N771insSVD) in culture, inhibited tumor growth and induced tumor regression in subcutaneous xenograft models, and prolonged survival in intrapulmonary xenograft models (PMID: 29748209).	29748209
EGFR	EGFR S768_D770dup	lung cancer	sensitive	Tarloxotinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR S768_D770dup in culture (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).	detail...
EGFR	EGFR S768_D770dup	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited Egfr phosphorylation in transformed cells expressing EGFR S768_D770dup (reported as D770_N771insSVD) in culture (PMID: 29483211).	29483211
EGFR	EGFR S768_D770dup	Advanced Solid Tumor	sensitive	Luminespib	Preclinical - Cell culture	Actionable	In a preclinical study, Luminespib (AUY922) decreased viability of cells expressing EGFR S768_D770dup (referred to as D770_N771insSVD) in culture (PMID: 30154228).	30154228
EGFR	EGFR S768_D770dup	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768_D770dup (reported as D770_N771insSVD) were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR S768_D770dup	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited EGFR phosphorylation and proliferation of cells expressing EGFR exon 20 insertion mutations, including EGFR S768_D770dup (reported as D770_N771insSVD), in culture (PMID: 29748209).	29748209
EGFR	EGFR S768_D770dup	head and neck squamous cell carcinoma	resistant	Erlotinib	Preclinical	Actionable	In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup demonstrated resistance to Tarceva (erlotinib) in culture (PMID: 25931286).	25931286
EGFR	EGFR S768_D770dup	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768_D770dup (reported as D770_N771insSVD) were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR V765M	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V765M were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V765M	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V765M were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V765M	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V765M were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V765M	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V765M were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR H835L	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H835L were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR H835L	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H835L were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR H835L	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H835L were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR H835L	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H835L were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR H835L	Advanced Solid Tumor	sensitive	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H835L were sensitive to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR L833V EGFR H835L	lung adenocarcinoma	predicted - sensitive	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring a compound EGFR L833V/H835L mutation responded to treatment with Iressa (gefitinib), with disease progression after 34 weeks of treatment (PMID: 21422421).	21422421
EGFR	EGFR V851I	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V851I were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V851I	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V851I were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR V851I	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V851I were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR V851I	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V851I were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR S1153I	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S1153I were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR S1153I	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S1153I were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR S1153I	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S1153I were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR T790M EGFR G796R EGFR L858R	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR G796R in culture (PMID: 29857056).	29857056
EGFR	EGFR T790M EGFR G796R EGFR L858R	Advanced Solid Tumor	resistant	EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR G796R in culture (PMID: 29857056).	29857056
EGFR	EGFR T790M EGFR G796R EGFR L858R	Advanced Solid Tumor	resistant	Cetuximab + EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, combination of EAI045 and Erbitux (cetuximab) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR G796R in culture (PMID: 29857056).	29857056
EGFR	EGFR T790M EGFR G796R EGFR L858R	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR G796R in culture (PMID: 29857056).	29857056
EGFR	EGFR T790M EGFR G796R EGFR L858R	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) did not inhibit Egfr phosphorylation and proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR G796R in culture (PMID: 29857056).	29857056
EGFR	EGFR T790M EGFR G796R EGFR L858R	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792HG796R in culture (PMID: 29857056).	29857056
EGFR	EGFR T790M EGFR G796R	lung adenocarcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a retrospective analysis, EGFR G796R was identified in 0.59% (2/340) of lung adenocarcinoma patients receiving Tagrisso (osimertinib), and 1 of the 2 patients also had EGFR T790M in cis, consistent with cell culture study and structural modeling that supports a role of EGFR G796R in cis with T790M in conferring resistance to Tagrisso (osimertinib) (PMID: 29857056).	29857056
EGFR	EGFR A871T	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A871T were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A871T	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A871T were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A871T	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A871T were resistant to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR A871T	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A871T were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR Q791R EGFR T790M	Advanced Solid Tumor	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR Q791R triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).	25948633
EGFR	EGFR L858R EGFR Q791R EGFR T790M	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR T790M/EGFR Q791R triple mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR T790M EGFR Q791R	Advanced Solid Tumor	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR Q791R triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR T790M EGFR Q791R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR Q791R triple mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR P753S	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P753S were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR P753S	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P753S were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR P753S	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P753S were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L62R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L62R were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR L62R	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L62R were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR L62R	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L62R were sensitive to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR L62R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L62R were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719S EGFR L62R	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L62R and EGFR G719S in trans were resistant to Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719S EGFR L62R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR L62R and EGFR G719S in trans in culture (PMID: 29141884).	29141884
EGFR	EGFR G719S EGFR L62R	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L62R and EGFR G719S in trans were resistant to Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR P772_H773insGNP	Advanced Solid Tumor	sensitive	Luminespib	Preclinical - Cell culture	Actionable	In a preclinical study, Luminespib (AUY922) decreased viability of cells expressing EGFR P772_H773insGNP (referred to as D770_N771insNPG) in culture (PMID: 30154228).	30154228
EGFR	EGFR P772_H773insGNP	lung non-small cell carcinoma	sensitive	Poziotinib	Preclinical	Actionable	In a preclinical study, treatment with Poziotinib (HM781-36B) decreased tumor burden by greater than 85% in a mouse model of non-small cell lung cancer expressing EGFR D770_N771insNPG (WCLC 2017, Abstract OA 12.01).	detail...
EGFR	EGFR P772_H773insGNP	Advanced Solid Tumor	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR P772_H773insGNP (referred to as D770_N771insNPG) in culture (PMID: 29467275).	29467275
EGFR	EGFR P772_H773insGNP	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR P772_H773insGNP (referred to as D770_N771insNPG) in culture (PMID: 29467275).	29467275
EGFR	EGFR P772_H773insGNP	lung cancer	sensitive	Poziotinib	Preclinical	Actionable	In a preclinical study, Poziotinib (HM781-36B) induced regression of lung tumors in mouse models harboring EGFR P772_H773insGNP (referred to as D770_N771insNPG), with no signs of progression at 12 weeks (PMID: 29686424).	29686424
EGFR	EGFR P772_H773insGNP	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited EGFR phosphorylation and growth of a transformed cell line expressing EGFR P772_H773insGNP (referred to as D770_N771insNPG) in culture (PMID: 29686424).	29686424
EGFR	EGFR P772_H773insGNP	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P772_H773insGNP (referred to as D770_N771insNPG) were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).	29467275
EGFR	EGFR P772_H773insGNP	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR P772_H773insGNP (referred to as D770_N771insNPG) in culture (PMID: 29467275).	29467275
EGFR	EGFR P772_H773insGNP	Advanced Solid Tumor	predicted - resistant	OBX1-012	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P772_H773insGNP (referred to as D770_N771insNPG) did not respond to treatment with OBX1-012 in culture (PMID: 29754184).	29754184
EGFR	EGFR C797S EGFR P772_H773insGNP EGFR T790M	Advanced Solid Tumor	predicted - resistant	OBX1-012	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR P772_H773insGNP (referred to as D770_N771insNPG), and EGFR T790M did not respond to treatment with OBX1-012 in culture (PMID: 29754184).	29754184
EGFR	EGFR H870R	lung non-small cell carcinoma	predicted - resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, EGFR H870R was insensitive to inhibition of Egfr phosphorylation by Iressa (gefitinib) in non-small cell lung cancer cells in culture (PMID: 19671738).	19671738
EGFR	EGFR L858R EGFR H870R	lung adenocarcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, Tarceva (erlotinib) treatment resulted in rapid disease progression within 3 months of treatment in a patient with metastatic lung adenocarcinoma harboring both EGFR L858R and EGFR H870R (PMID: 21841502).	21841502
EGFR	EGFR G598V	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G598V were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR G598V	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G598V were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR G598V	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G598V were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G598V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G598V were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR P699L	lung non-small cell carcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical study, Tarceva (erlotinib) treatment resulted in massive disease progression in a patient with non-small cell lung cancer harboring EGFR P699L (PMID: 31175009).	31175009
EGFR	EGFR E804G EGFR P699L	lung adenocarcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, Iressa (gefitinib) treatment resulted in rapid disease progression in a patient with lung adenocarcinoma harboring EGFR E804G and P699L (PMID: 22722798).	22722798
EGFR	EGFR G719C	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Clinical Study	Actionable	In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, D, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Tarceva (erlotinib) (PMID: 23344264).	23344264
EGFR	EGFR G719C	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719C were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719C	lung non-small cell carcinoma	sensitive	Afatinib	Phase III	Actionable	In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411).	24790411
EGFR	EGFR G719C	lung non-small cell carcinoma	sensitive	Dacomitinib	Phase III	Actionable	In Phase III clinical trials, patients with NSCLC tumors harboring an EGFR G719X (X=A, C, or S) mutation responded to EGFR tyrosine kinase inhibitors including Vizimpro (dacomitinib) (PMID: 24857124).	24857124
EGFR	EGFR G719C	lung non-small cell carcinoma	predicted - sensitive	Gefitinib	Clinical Study	Actionable	In a clinical study, analysis of published studies demonstrated that 78% (14/18) of non-small cell lung cancer patients harboring an EGFR G719 mutation, resulting in G719A, C, D, or S, were found to achieve disease control following treatment Tarceva (erlotinib) or Iressa (gefitinib) (PMID: 23344264).	23344264
EGFR	EGFR G719C	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E719C were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E709A EGFR G719C	Advanced Solid Tumor	conflicting	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A and EGFR G719C in trans were sensitive to treatment with Iressa (gefitinib), but when expressed in cis, demonstrated resistance in culture (PMID: 29141884).	29141884
EGFR	EGFR E709A EGFR G719C	lung adenocarcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, Tarceva (erlotinib) treatment resulted in a partial response lasting over 10 months in a patient with lung adenocarcinoma harboring both EGFR E709A and EGFR G719C (PMID: 21841502).	21841502
EGFR	EGFR E709A EGFR G719C	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR E709A and EGFR G719C in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR E709A EGFR G719C	Advanced Solid Tumor	conflicting	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A and EGFR G719C in trans were sensitive to treatment with Tarceva (erlotinib), but when expressed in cis, demonstrated resistance in culture (PMID: 29141884).	29141884
EGFR	EGFR E709A EGFR G719C	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tagrisso (osimertinib) resulted in decreased growth of transformed cells expressing EGFR E709A and EGFR G719C in trans in culture (PMID: 29141884).	29141884
EGFR	EGFR E709A EGFR G719C	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A and EGFR G719C in trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719C EGFR L861Q	lung non-small cell carcinoma	predicted - sensitive	Gefitinib	Case Reports/Case Series	Actionable	In a clinical study, Iressa (gefitinib) treatment resulted in a partial response with a progression-free survival of 10 months and an overall survival of 24 months in a patient with non-small cell lung cancer harboring both EGFR G719C and EGFR L861Q (PMID: 31175009).	31175009
EGFR	EGFR G719C EGFR S768I	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719C and EGFR S768I in cis were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR G719C EGFR S768I	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719C and EGFR S768I in cis and trans were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR G719C EGFR S768I	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719C and EGFR S768I in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719C EGFR S768I	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719C and EGFR S768I in cis were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR G719C EGFR S768I	lung non-small cell carcinoma	predicted - sensitive	Lazertinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Lazertinib (YH25448) demonstrated moderate inhibition of viability of patient-derived non-small cell lung cancer cells harboring both EGFR G719C and EGFR S768I (PMID: 30670498).	30670498
EGFR	EGFR G719C EGFR S768I	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719C and EGFR S768I in cis were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR L861Q	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L861Q were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L861Q	esophagus squamous cell carcinoma	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, esophageal squamous cell carcinoma cells harboring EGFR L861Q demonstrated resistance to treatment with Erbitux (cetuximab) in a cell viability assay (PMID: 27207775).	27207775
EGFR	EGFR L861Q	lung non-small cell carcinoma	sensitive	Gefitinib	Guideline	Actionable	Iressa (gefinitib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as L861Q (NCCN.org).	detail...
EGFR	EGFR L861Q	lung non-small cell carcinoma	sensitive	Gefitinib	Clinical Study	Actionable	In a retrospective analysis, a catalog of tyrosine kinase inhibitor responses of NSCLC patients harboring EGFR mutations determined that EGFR L861Q responded to Iressa (gefitinib), but possibly not as favorably as EGFR L858R, exon 19 deletion, and G719X mutations (PMID: 23344264).	23344264
EGFR	EGFR L861Q	lung non-small cell carcinoma	sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, Gilotrif (afatinib) treatment resulted in partial response in 33% (2/6), stable disease in 50% (3/6), and progressive disease in 17% (1/6) of non-small cell lung carcinoma patients harboring EGFR L861Q (PMID: 26354527).	26354527
EGFR	EGFR L861Q	lung non-small cell carcinoma	sensitive	Afatinib	FDA approved - On Companion Diagnostic	Actionable	In a post-hoc analysis of Phase II and Phase III trials that supported FDA approval (LUX-Lung2, LUX-Lung 3, LUX-Lung 6), Gilotrif (afatinib) treatment resulted in an objective rate of 56.3% (9/16) in non-small cell lung cancer patients harboring EGFR L861Q (alone or in combination with EGFR L719X or exon 19 deletion), with a mean progression-free survival of 8.2 months, and an overall survival of 17.1 months (PMID: 26051236; NCT00525148, NCT00949650, and NCT01121393).	detail... detail... 26051236
EGFR	EGFR L861Q	lung non-small cell carcinoma	sensitive	Afatinib	Guideline	Actionable	Gilotrif (afatinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as L861Q (NCCN.org).	detail...
EGFR	EGFR L861Q	esophagus squamous cell carcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR L861Q demonstrated resistance to treatment with Tarceva (erlotinib) in a cell viability assay (PMID: 27207775).	27207775
EGFR	EGFR L861Q	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L861Q were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L861Q	lung non-small cell carcinoma	sensitive	Dacomitinib	Guideline	Actionable	Vizimpro (dacomitinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as L861Q (NCCN.org).	detail...
EGFR	EGFR L861Q	lung adenocarcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, Tarceva (erlotinib) treatment resulted in disease progression after 3 months of treatment in a patient with metastatic lung adenocarcinoma harboring EGFR L861Q (PMID: 21841502).	21841502
EGFR	EGFR L861Q	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L861Q were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L861Q	lung non-small cell carcinoma	predicted - sensitive	Osimertinib	Guideline	Actionable	Tagrisso (osimertinib) is included in guidelines as preferred first-line or as subsequent therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as L861Q (NCCN.org).	detail...
EGFR	EGFR L861Q	lung non-small cell carcinoma	sensitive	Erlotinib	Clinical Study	Actionable	In an analysis of published clinical data, non-small cell cancer patients harboring EGFR L861Q were demonstrated to respond to treatment with Tarceva (erlotinib), but possibly not as favorably as EGFR L858R, exon 19 deletion, and G719X mutations (PMID: 23344264).	23344264
EGFR	EGFR L861Q	lung non-small cell carcinoma	sensitive	Erlotinib	Guideline	Actionable	Tarceva (erlotinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as L861Q (NCCN.org).	detail...
EGFR	EGFR L861Q	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited growth of transformed cells expressing EGFR L861Q in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1329).	detail...
EGFR	EGFR L861Q	lung non-small cell carcinoma	predicted - sensitive	Lazertinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Lazertinib (YH25448) inhibited viability of patient-derived non-small cell lung cancer cells harboring EGFR L861Q (PMID: 30670498).	30670498
EGFR	EGFR L861Q	lung non-small cell carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR L861Q demonstrated a response rate of 23.53% and disease control rate of 64.71%, and a median progression-free survival of 2.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).	detail...
EGFR	EGFR L861Q	esophagus squamous cell carcinoma	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) treatment resulted in apoptotic induction in esophagus squamous carcinoma cells harboring EGFR L861Q in culture and inhibited tumor growth in cell line xenograft models (PMID: 27207775).	27207775
EGFR	EGFR G719A EGFR L861Q	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR G719A and EGFR L861Q in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR L861Q	lung adenocarcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, Tarceva (erlotinib) treatment resulted in partial response lasting for 18 months in a patient with lung adenocarcinoma harboring EGFR G719A and L861Q (PMID: 28343545).	28343545
EGFR	EGFR G719A EGFR L861Q	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719A and EGFR L861Q in cis were resistant to Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR L861Q	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719A and EGFR L861Q in cis were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR L861Q	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719A and EGFR L861Q in cis were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR L861Q	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719A and EGFR L861Q in cis and trans in culture demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR L861Q EGFR T790M	lung adenocarcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, EGFR T790M was detected at the time of progression in a patient with lung adenocarcinoma harboring EGFR G719A and L861Q that was treated with Tarceva (erlotinib) (PMID: 28343545).	28343545
EGFR	EGFR G719A EGFR L861Q EGFR T790M	lung adenocarcinoma	predicted - sensitive	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, Tagrisso (osimertinib) treatment resulted in partial response for over 8 months in a patient with lung adenocarcinoma harboring EGFR G719A, L861Q, and T790M that has progressed while on Tarceva (erlotinib) treatment (PMID: 28343545).	28343545
EGFR	EGFR G719S EGFR L861Q	lung non-small cell carcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical study, Iressa (gefitinib) treatment resulted in disease progression within 2 months of treatment in a patient with non-small cell lung carcinoma harboring EGFR G719S and L861Q (PMID: 15897572).	15897572
EGFR	EGFR G719S EGFR L861Q	Advanced Solid Tumor	sensitive	DZD9008	Preclinical - Pdx	Actionable	In a preclinical study, DZD9008 resulted in tumor growth inhibition and regression in patient-derived xenograft models of tumor harboring EGFR G719S and L861Q (PDX) (AACR Annual Meeting 2019, Abstract 3081).	detail...
EGFR	EGFR G719X EGFR S768I EGFR T790M EGFR L858R EGFR L861Q	lung non-small cell carcinoma	predicted - sensitive	Icotinib	Case Reports/Case Series	Actionable	In a clinical case study, Conmana (Icotinib) treatment resulted in initial response in a patient with metastatic non-small cell lung cancer harboring EGFR G719X, S768I, T790M, L858R, and L861Q, but resistance developed after 4 months of treatment (PMID: 31045832).	31045832
EGFR	EGFR L858R EGFR L861Q	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tarceva (erlotinib) resulted in decreased growth of transformed cells expressing EGFR L861Q and EGFR L858R in cis in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR L861Q	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tagrisso (osimertinib) resulted in decreased growth of transformed cells expressing EGFR L858R and EGFR L861Q in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR L861Q	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR L858R and EGFR L861Q in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR L861Q	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L861Q and EGFR L858R in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR L861Q	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Iressa (gefitinib) resulted in decreased growth of transformed cells expressing EGFR L861Q and EGFR L858R in cis in culture (PMID: 29141884).	29141884
EGFR	EGFR-SEPTIN14	glioblastoma multiforme	sensitive	Lapatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited cell survival of a human glioblastoma multiforme cell line harboring an EGFR-SEPT14 fusion, and inhibited tumor growth in xenograft models (PMID: 23917401).	23917401
EGFR	EGFR-SEPTIN14	glioblastoma multiforme	sensitive	Erlotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited cell survival of a human glioblastoma multiforme cell line harboring an EGFR-SEPT14 fusion, and inhibited tumor growth in xenograft models (PMID: 23917401).	23917401
EGFR	EGFR G465R	colorectal cancer	sensitive	SYM004	Case Reports/Case Series	Actionable	In a clinical study, a patient with Erbitux (cetuximab)-resistant metastatic colorectal cancer harboring EGFR G465R demonstrated stable disease for 15 weeks following treatment with SYM004 (PMID: 26888827).	26888827
EGFR	EGFR G465R	colorectal cancer	sensitive	SYM004	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SYM004 inhibited EGFR downstream signaling and proliferation of a colorectal cancer cell line harboring EGFR G465R in culture, and induced tumor regression in xenograft models (PMID: 26888827).	26888827
EGFR	EGFR G465R	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR G465R were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).	26843189
EGFR	EGFR G465R	colorectal cancer	sensitive	MM-151	Preclinical	Actionable	In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR G465R in culture (PMID: 26843189).	26843189
EGFR	EGFR G465R	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR G465R were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).	26843189
EGFR	EGFR G465R EGFR S464L	colorectal cancer	sensitive	MM-151	Phase I	Actionable	In a Phase I trial, MM-151 treatment resulted in reduction of EGFR S464L and stabilization of EGFR G465R in circulating cell-free tumor DNA and prolonged stable disease in a colorectal cancer patient harboring both EGFR G465R and EGFR S464L (PMID: 26843189).	26843189
EGFR	EGFR G465E EGFR G465R	colorectal cancer	sensitive	MM-151	Phase I	Actionable	In a Phase I trial, MM-151 treatment resulted in marked reduction of EGFR G465E in circulating cell-free tumor DNA and reduced tumor size in a colorectal cancer patient harboring both EGFR G465E and EGFR G465R (PMID: 26843189).	26843189
EGFR	BRAF V600E EGFR G465R	colorectal cancer	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR G465R	colorectal cancer	resistant	Panitumumab + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR G465R	colorectal cancer	sensitive	Cetuximab + Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR G465R	colorectal cancer	resistant	Cetuximab + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation of EGFR G465R (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR G465R	colorectal cancer	resistant	Panitumumab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) in culture (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR G465R	colorectal cancer	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Iressa (gefitinib) in culture (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR G465R	colorectal cancer	sensitive	Gefitinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Iressa (gefitinib) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR G465R	colorectal cancer	sensitive	Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR G465R	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).	27312529
EGFR	EGFR A763_Y764insFQEA	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR A763_Y764insFQEA in culture (PMID: 29467275).	29467275
EGFR	EGFR A763_Y764insFQEA	lung non-small cell carcinoma	sensitive	Gefitinib	Case Reports/Case Series	Actionable	In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR A763_Y764insFQEA demonstrated a partial response when treated with Iressa (gefitinib) (PMID: 28089594).	28089594
EGFR	EGFR A763_Y764insFQEA	lung non-small cell carcinoma	sensitive	Gefitinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR A763_Y764insFQEA mutations demonstrated sensitivity to Iressa (gefitinib) in culture, in contrast to other Egfr exon 20 insertions, and consistent with clinical observations (PMID: 24353160).	24353160
EGFR	EGFR A763_Y764insFQEA	lung non-small cell carcinoma	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring EGFR A763_Y764insFQEA in culture (PMID: 29467275).	29467275
EGFR	EGFR A763_Y764insFQEA	lung non-small cell carcinoma	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR A763_Y764insFQEA mutations demonstrated sensitivity to Gilotrif (afatinib) in cell culture, in contrast to other EGFR exon 20 insertion mutations (PMID: 24353160).	24353160
EGFR	EGFR A763_Y764insFQEA	Advanced Solid Tumor	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR A763_Y764insFQEA in culture (PMID: 29467275).	29467275
EGFR	EGFR A763_Y764insFQEA	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR A763_Y764insFQEA demonstrated a partial response after treatment with Tarceva (erlotinib), however, another patient with the same mutation and tumor type demonstrated progressive disease when treated with Tarceva (erlotinib) (PMID: 28089594).	28089594
EGFR	EGFR A763_Y764insFQEA	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A763_Y764insFQEA were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 24353160).	24353160
EGFR	EGFR A763_Y764insFQEA	lung non-small cell carcinoma	predicted - sensitive	Luminespib	Preclinical - Cell culture	Actionable	In a preclinical study, Luminespib (AUY922) treatment increased EGFR degradation and apoptosis and decreased viability of a non-small cell lung cancer cell line harboring A763_Y764insFQEA in culture (PMID: 30154228).	30154228
EGFR	EGFR A763_Y764insFQEA	lung non-small cell carcinoma	predicted - sensitive	Luminespib	Phase II	Actionable	In a Phase II trial, Luminespib (AUY922) treatment demonstrated safety and efficacy in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, with a patient harboring EGFR A763_Y764insFQEA achieving stable disease (PMID: 30351341; NCT01854034).	30351341
EGFR	EGFR A763_Y764insFQEA	Advanced Solid Tumor	sensitive	Luminespib	Preclinical - Cell culture	Actionable	In a preclinical study, Luminespib (AUY922) decreased viability of cells expressing EGFR A763_Y764insFQEA in culture (PMID: 30154228).	30154228
EGFR	EGFR A763_Y764insFQEA	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited EGFR phosphorylation and growth of a transformed cell line expressing EGFR A763_Y764insFQEA in culture (PMID: 29686424).	29686424
EGFR	EGFR A763_Y764insFQEA	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited EGFR phosphorylation and proliferation of cells expressing EGFR exon 20 insertion mutations, including EGFR A763_Y764insFQEA, in culture (PMID: 29748209).	29748209
EGFR	EGFR A763_Y764insFQEA	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR A763_Y764insFQEA in culture (PMID: 29467275, PMID: 29483211).	29483211 29467275
EGFR	EGFR A763_Y764insFQEA	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR A763_Y764insFQEA in culture (PMID: 29467275, PMID: 29483211).	29483211 29467275
EGFR	EGFR A763_Y764insFQEA	lung non-small cell carcinoma	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited growth of non-small cell lung cancer cells expressing EGFR A763_Y764insFQEA in culture (PMID: 29483211).	29483211
EGFR	EGFR A763_Y764insFQEA	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A763_Y764insFQEA were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR A763_Y764insFQEA	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A763_Y764insFQEA were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR A763_Y764insFQEA EGFR T790M	lung non-small cell carcinoma	predicted - sensitive	Osimertinib	Case Reports/Case Series	Actionable	In a clinical study, Tagrisso (osimertinib) treatment resulted in a partial response with a progression-free survival of 6.4 months in a patient with non-small cell lung cancer harboring EGFR A763_Y764insFQEA and EGFR T790M (PMID: 31208370).	31208370
EGFR	EGFR act mut	lung non-small cell carcinoma	predicted - sensitive	MTI-31	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MTI-31 inhibited proliferation and migration of non-small cell lung cancer cell lines harboring oncogenic EGFR mutations in culture, and inhibited tumor growth in xenograft models (PMID: 30796032).	30796032
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Erlotinib	Guideline	Actionable	Tarceva (erlotinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring sensitizing EGFR activating mutations (PMID: 30715168, PMID: 30285222; ESMO.org).	30285222 detail... 30715168
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Erlotinib	Phase II	Actionable	In a Phase II trial, non-small cell lung cancer patients with EGFR mutations demonstrated a median progression-free survival of 10.8 months, overall survival of 31.0 months, an overall response rate of 66.2% (137/207), and a disease control rate of 82.6% (2 complete responses; 135 partial responses, and 34 stable disease) following treatment with Tarceva (erlotinib) (PMID: 26720423).	26720423
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Erlotinib	Phase III	Actionable	In a Phase III trial, a trend toward disease free survival was observed in non-small cell lung cancer patients harboring EGFR activating mutations when treated with Tarceva (erlotinib) vs placebo in the adjuvant setting, but significance was not demonstrated due to study design (PMID: 26324372).	26324372
EGFR	EGFR act mut	Advanced Solid Tumor	sensitive	AP32788	Preclinical - Cell culture	Actionable	In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing EGFR activating mutations in culture, regardless of the presence or absence of EGFR T790M (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).	detail...
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Carboplatin + Gefitinib + Pemetrexed	Guideline	Actionable	Iressa (gefitinib) in combination with Paraplatin (carboplatin) and Alimta (pemetrexed) is included in guidelines at a first-line option for patients with metastatic non-small cell lung cancer harboring sensitizing EGFR activating mutations (PMID: 30715168, PMID: 30285222; ESMO.org).	30715168 detail... 30285222
EGFR	EGFR act mut	glioblastoma multiforme	sensitive	Gefitinib + Linsitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFRvIII in culture (PMID: 26561558).	26561558
EGFR	EGFR act mut	Advanced Solid Tumor	predicted - sensitive	ABT-806	Phase I	Actionable	In a Phase I trial, ABT-806 treatment in patients with advanced solid tumors that often express EGFR amplification or EGFR vIII was well-tolerated, demonstrated safety, and resulted in stable disease in two patients (PMID: 25895099).	25895099
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Afatinib	Guideline	Actionable	Gilotrif (afatinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring sensitizing EGFR activating mutations (PMID: 30715168, PMID: 30285222; ESMO.org).	detail... 30285222 30715168
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Afatinib	Phase II	Actionable	In a Phase II trial, Gilotrif (afatinib) treatment, when compared to Iressa (gefitinib), resulted in statistically significant improvement of progression free survival (11.0 vs 10.9 months, HR 0.74, p=0.0178), time-to-treatment failure (13.7 vs 11.5 months, HR 0.75, p=0.0136), and objective response rate (72.5% vs 56%, odd ratio 2.121, p=0.0018) in patients harboring EGFR L858R or exon 19 deletion activating mutations (PMID: 28169392).	28169392
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Osimertinib	Guideline	Actionable	Tagrisso (osimertinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring sensitizing EGFR activating mutations (PMID: 30715168, PMID: 30285222; ESMO.org).	30285222 detail... 30715168
EGFR	EGFR act mut	lung non-small cell carcinoma	no benefit	Brigatinib	Guideline	Actionable	Alunbrig (brigatinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).	detail...
EGFR	EGFR act mut	lung non-small cell carcinoma	decreased response	Atezolizumab	Clinical Study - Cohort	Actionable	In a clinical study, immunotherapies including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) resulted in significantly shorter median progression-free survival (51.0 vs 70.5 days, HR=2.47, p=0.0037) in non-small cell lung cancer patients harboring EGFR (n=7) or ERBB2 (HER2) (n=7) activating mutations compared to wild-type patients (PMID: 31085721).	31085721
EGFR	EGFR act mut	head and neck squamous cell carcinoma	predicted - sensitive	WSD0922	Preclinical - Pdx	Actionable	In a preclinical study, WSD0922 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of cetuximab-resistant head and neck squamous cell carcinoma harboring EGFR activating mutations (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1326).	detail...
EGFR	EGFR act mut	glioblastoma multiforme	sensitive	BMS-754807 + Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFRvIII in culture (PMID: 26561558).	26561558
EGFR	EGFR act mut	lung non-small cell carcinoma	predicted - sensitive	WSD0922	Preclinical - Cell line xenograft	Actionable	In a preclinical study, WSD0922 treatment prolonged survival in cell line xenograft models of intracranial metastasis of non-small cell lung cancer harboring EGFR activating mutations (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1326).	detail...
EGFR	EGFR act mut	lung non-small cell carcinoma	predicted - sensitive	Erlotinib + Glesatinib	Phase I	Actionable	In a Phase I trial, Glesatinib (MGCD265) and Tarceva (erlotinib) combination treatment resulted in partial response in a non-small cell lung carcinoma patient harboring an EGFR activating mutation (J Clin Oncol 30, 2012 (suppl; abstr e13602)).	detail...
EGFR	EGFR act mut	lung non-small cell carcinoma	decreased response	Camrelizumab	Clinical Study - Cohort	Actionable	In a clinical study, immunotherapies including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) resulted in significantly shorter median progression-free survival (51.0 vs 70.5 days, HR=2.47, p=0.0037) in non-small cell lung cancer patients harboring EGFR (n=7) or ERBB2 (HER2) (n=7) activating mutations compared to wild-type patients (PMID: 31085721).	31085721
EGFR	EGFR act mut	lung non-small cell carcinoma	no benefit	Alectinib	Guideline	Actionable	Alecensa (alectinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).	detail...
EGFR	EGFR act mut	lung non-small cell carcinoma	decreased response	Nivolumab	Clinical Study - Cohort	Actionable	In a clinical study, immunotherapies including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) resulted in significantly shorter median progression-free survival (51.0 vs 70.5 days, HR=2.47, p=0.0037) in non-small cell lung cancer patients harboring EGFR (n=7) or ERBB2 (HER2) (n=7) activating mutations compared to wild-type patients (PMID: 31085721).	31085721
EGFR	EGFR act mut	lung non-small cell carcinoma	no benefit	Erlotinib + Luminespib	Phase Ib/II	Actionable	In a Phase Ib/II clinical trial, the combination of Luminespib (AUY922) and Tarceva (erlotinib) demonstrated limited clinical benefit in patients with EGFR-mutant non-small cell carcinoma with acquired resistance to EGFR tyrosine kinase inhibitors, with 16% (4/25) patients achieving partial response (PMID: 25870087).	25870087
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Dacomitinib	Guideline	Actionable	Vizimpro (dacomitinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring sensitizing EGFR activating mutations (PMID: 30715168, PMID: 30285222; ESMO.org).	detail... 30285222 30715168
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Dacomitinib	Phase II	Actionable	In a Phase II clinical trial, progression-free survival at 4 months was 95.5% in patients with EGFR-mutant non-small cell lung cancer following treatment with Vizimpro (dacomitinib), compared to 76.8% in the overall treatment population (PMID: 25456362).	25456362
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Dacomitinib	Phase III	Actionable	In a Phase III (ARCHER 1050) trial, Vizimpro (dacomitinib) demonstrated superior efficacy compared to Iressa (gefitinib) as first-line therapy in non-small cell lung cancer patients harboring EGFR activating mutations (exon 19 deletion or L858R), resulting in prolonged overall survival (34.1 vs 26.8 months, HR=0.76, p=0.0438) (PMID: 29864379; NCT01774721).	detail... 29864379
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Bevacizumab + Erlotinib	Guideline	Actionable	Tarceva (erlotinib) in combination with (bevacizumab) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring sensitizing EGFR activating mutations (PMID: 30715168, PMID: 30285222; ESMO.org).	30715168 detail... 30285222
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Amlexanox + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, non-small cell lung cancer cell lines harboring activating EGFR mutations demonstrated sensitivity to the combination of amlexanox and Selumetinib (AZD6244), resulting in synergistic growth inhibition in culture and reduced tumor growth in xenograft models (PMID: 27287717).	27287717
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Sapitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapitinib (AZD8931) inhibited EGFR, ERBB2, and ERBB3 kinase activity, and inhibited growth in several non-small cell lung cancer cell lines and xenograft models, including those with EGFR activating mutations (PMID: 20145185).	20145185
EGFR	EGFR act mut	lung non-small cell carcinoma	predicted - sensitive	Naquotinib	Phase I	Actionable	In a Phase I trial, Naquotinib (ASP8273) demonstrated preliminary antitumor activity in non-small cell lung patients harboring EGFR activating mutations (J Clin Oncol 33, 2015 (suppl; abstr 8014).	detail...
EGFR	EGFR act mut	lung non-small cell carcinoma	predicted - sensitive	Naquotinib	Phase III	Actionable	In a Phase III trial, Naquotinib (ASP8273) treatment did not result in improved efficacy compared to Tarceva (erlotinib)/Iressa (gefitinib) in patients with non-small cell lung cancer harboring an EGFR activating mutation, demonstrating a median progression-free survival of 9.3 mo vs 9.6 mo, an overall response rate of 33% (166/267) vs 47.9% (126/263), a disease control rate of 62.2% (166/267) vs 66.2% (174/263), and a duration of response of 9.17 mo vs 9.03 mo, respectively (PMID: 31070709; NCT02588261).	31070709
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	XL647	Phase II	Actionable	In a Phase II study, XL647 demonstrated antitumor activity and increased progression-free survival in non-small cell lung cancer patients harboring EGFR activating mutations (PMID: 22722787).	22722787
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Gefitinib + Pemetrexed	Phase II	Actionable	In a Phase II trial, Iressa (gefitinib) and pemetrexed combination therapy resulted in a median progression-free survival (PFS) of 6.7 months, an objective response rate of 22.9% (8/35), and an overall survival of 24.3 months in EGFR mutant non-small cell lung cancer patients who progressed on first-line Iressa (gefitinib), with no difference in PFS between exon 19 deletion and L858R groups (5.6 vs 7.0 months), or T790M positive and negative groups (5.9 vs 7.0 months) (PMID: 30268482).	30268482
EGFR	EGFR act mut	lung non-small cell carcinoma	no benefit	Ceritinib	Guideline	Actionable	Zykadia (ceritinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).	detail...
EGFR	EGFR act mut	glioblastoma multiforme	predicted - sensitive	WSD0922	Preclinical - Cell line xenograft	Actionable	In a preclinical study, WSD0922 treatment resulted in dose-dependent inhibition of EGFRvIII phosphorylation and downstream signaling in patient-derived xenograft (PDX) models of glioblastoma multiforme, and growth inhibition in ex-vivo PDX (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1326).	detail...
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Rociletinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Rociletinib (CO-1686) inhibited tumor growth in xenograft models of human non-small cell lung cancer cell lines harboring EGFR activating mutations (PMID: 24065731).	24065731
EGFR	EGFR act mut	lung squamous cell carcinoma	predicted - sensitive	WSD0922	Preclinical - Pdx	Actionable	In a preclinical study, WSD0922 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of squamous lung cancer harboring EGFR activating mutations (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1326).	detail...
EGFR	EGFR act mut	lung non-small cell carcinoma	decreased response	Neratinib	Phase I	Actionable	In a Phase I trial, Nerlynx (neratinib) demonstrated limited clinical activity in EGFR-mutant non-small cell lung cancer patients with prior EGFR TKI therapy, with a response rate of 3.4% (3/88), stable disease as best response in 50% (44/88), and prolonged stable disease in 10%, (9/88) (PMID: 20479403).	20479403
EGFR	EGFR act mut	lung non-small cell carcinoma	no benefit	Erlotinib + MK2206	Phase II	Actionable	In a Phase II trial, non-small cell lung cancer patients harboring EGFR activating mutations treated with Tarceva (erlotinib), in combination with MK-2206, demonstrated a 9% (4/45) response rate, which did not reach the primary endpoint rate of 20% or more, therefore, indicating no benefit (PMID: 26106072).	26106072
EGFR	EGFR act mut	lung non-small cell carcinoma	decreased response	Pembrolizumab	Clinical Study - Cohort	Actionable	In a clinical study, immunotherapies including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) resulted in significantly shorter median progression-free survival (51.0 vs 70.5 days, HR=2.47, p=0.0037) in non-small cell lung cancer patients harboring EGFR (n=7) or ERBB2 (HER2) (n=7) activating mutations compared to wild-type patients (PMID: 31085721).	31085721
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Gefitinib	Phase III	Actionable	In a Phase III trial, adjuvant Iressa (gefitinib) treatment resulted in prolonged disease-free survival (28.7 vs 18.0 months) compared to Navelbine (vinorelbine) and Platinol (cisplatin) combination in completely resected non-small cell lung cancer patients harboring EGFR-activating mutations (J Clin Oncol 35, 2017 (suppl; abstr 8500)).	detail...
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Gefitinib	Guideline	Actionable	Iressa (gefitinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring sensitizing EGFR activating mutations (PMID: 30715168, PMID: 30285222; ESMO.org).	30285222 30715168 detail...
EGFR	EGFR act mut	lung non-small cell carcinoma	sensitive	Gefitinib	Phase III	Actionable	In a Phase III clinical trial, Iressa (gefitinib) treatment resulted in an objective response rate of 71.2% (94/132) and increased progression-free survival in non-small cell lung cancer patients harboring EGFR activating mutations (PMID: 19692680).	19692680
EGFR	EGFR act mut EGFR T790M	lung non-small cell carcinoma	predicted - sensitive	MTI-31	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MTI-31 inhibited proliferation and migration and increased PD-L1 degradation in a non-small cell lung cancer cell line harboring an oncogenic EGFR mutation and secondary EGFR T790M mutation in culture, and inhibited tumor growth in xenograft models (PMID: 30796032).	30796032
EGFR	EGFR act mut EGFR T790M	lung non-small cell carcinoma	no benefit	Erlotinib + Luminespib	Phase Ib/II	Actionable	In a Phase Ib/II clinical trial, the combination of Luminespib (AUY922) and Tarceva (erlotinib) demonstrated limited clinical benefit in patients with EGFR-mutant non-small cell carcinoma with acquired resistance to EGFR tyrosine kinase inhibitors, including patients with EGFR T790M, with 16% (4/25) patients achieving partial response (PMID: 25870087).	25870087
EGFR	EGFR act mut EGFR T790M	lung non-small cell carcinoma	sensitive	Naquotinib	Phase I	Actionable	In a Phase I trial, treatment with ASP8273 resulted in a partial response in 41% (19/46) of non-small cell lung carcinoma patients co-harboring EGFR T790M and an EGFR activating mutation, demonstrating almost undetectable levels of the mutations in cell-free DNA (PMID: 28954786; NCT02113813).	28954786
EGFR	EGFR act mut EGFR T790M	lung non-small cell carcinoma	predicted - resistant	Gefitinib	Phase II	Actionable	In a Phase II trial, EGFR T790M was identified at disease progression in 54% (19/35) of non-small cell lung cancer patients harboring sensitizing EGFR mutations (15 exon 19 deletion, 20 L858R) who received Iressa (gefitinib) as first-line treatment (PMID: 30268482).	30268482
EGFR	EGFR amp EGFR act mut PTEN R308C	glioblastoma multiforme	sensitive	Gefitinib + Linsitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).	26561558
EGFR	EGFR amp EGFR act mut PTEN R308C	glioblastoma multiforme	sensitive	BMS-754807 + Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).	26561558
EGFR	EGFR act mut EGFR A289T PTEN I253N PTEN N69D	glioblastoma multiforme	sensitive	Gefitinib + Linsitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring mutations in EGFR (EGFRvIII, A289T) and PTEN (I253N, N69D) in culture (PMID: 26561558).	26561558
EGFR	EGFR act mut EGFR A289T PTEN I253N PTEN N69D	glioblastoma multiforme	sensitive	BMS-754807 + Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR (A289T, EGFRvIII) and PTEN (N69D, I253N) mutations in culture (PMID: 26561558).	26561558
EGFR	EGFR act mut EGFR amp	glioblastoma multiforme	predicted - sensitive	Depatuxizumab mafodotin + Radiotherapy + Temozolomide	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-414 in combination with Temodar (temozolomide) and radiotherapy inhibited tumor growth and resulted in tumor growth delay in a glioblastoma multiforme cell line xenograft model harboring amplified EGFR vIII (exon 2-7 deletion), with increased efficacy compared to the combination of Temodar (temozolomide) and radiotherapy (PMID: 26846818).	26846818
EGFR	EGFR act mut EGFR amp	glioblastoma multiforme	predicted - sensitive	Depatuxizumab mafodotin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-414 induced cytoxicity in a glioblastoma cell line harboring amplified EGFR vIII (exon 2-7 deletion) in culture, and induced complete tumor regression in cell line xenograft models of glioblastoma harboring amplified EGFR vIII (PMID: 26846818).	26846818
EGFR	EGFR amp EGFR wild-type EGFR act mut	glioblastoma multiforme	predicted - sensitive	Depatuxizumab mafodotin	Preclinical - Pdx	Actionable	In a preclinical study, ABT-414 induced tumor regression in a patient-derived xenograft model of glioblastoma multiforme harboring amplified wild-type EGFR and EGFR vIII (exon 2-7 deletion) (PMID: 26846818).	26846818
EGFR	EGFR act mut MET amp	lung cancer	sensitive	SYM015	Preclinical - Pdx	Actionable	In a preclinical study, SYM015 treatment resulted in tumor growth inhibition in patient-derived xenograft (PDX) models of MET-amplified lung cancer harboring EGFR activating mutations (PMID: 28679766).	28679766
EGFR	EGFR C797S EGFR act mut	lung non-small cell carcinoma	resistant	Naquotinib	Phase I	Actionable	In a Phase I trial, three non-small cell lung carcinoma patients initially harboring EGFR T790M and/or an EGFR activating mutation demonstrated a partial response to ASP8273 treatment, but later progressed, demonstrating in cell-free DNA, a reemergence of EGFR T790M and/or the EGFR activating mutation and EGFR C797S (PMID: 28954786; NCT02113813).	28954786
EGFR	EGFR C797S EGFR act mut	Advanced Solid Tumor	resistant	Nazartinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Nazartinib (EGF816) in transformed cells in culture (PMID: 29285266).	29285266
EGFR	EGFR C797S EGFR act mut	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Gilotrif (afatinib) in transformed cells in culture (PMID: 29285266).	29285266
EGFR	EGFR C797S EGFR act mut	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Tagrisso (osimertinib) in transformed cells in culture (PMID: 29285266).	29285266
EGFR	EGFR C797S EGFR act mut	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Tarceva (erlotinib) in transformed cells in culture (PMID: 29285266).	29285266
EGFR	EGFR act mut EGFR C797S EGFR T790M	lung non-small cell carcinoma	resistant	Naquotinib	Phase I	Actionable	In a Phase I trial, three non-small cell lung carcinoma patients initially harboring EGFR T790M and/or an EGFR activating mutation demonstrated a partial response to ASP8273 treatment, but later progressed, demonstrating in cell-free DNA, a reemergence of EGFR T790M and/or the EGFR activating mutation and EGFR C797S (PMID: 28954786; NCT02113813).	28954786
EGFR	EGFR act mut EGFR T790M MET amp	lung non-small cell carcinoma	predicted - resistant	Rociletinib	Clinical Study - Cohort	Actionable	In a retrospective analysis of a Phase I and a Phase II trial, MET amplification was identified at disease progression in 26% (11/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, 70%; L858R, 28%) treated with Rociletinib (CO-1686), conversely, preexisting MET, ERBB2 (HER2), or EGFR amplification were more common in patients with primary resistance to Rociletinib (CO-1686) (PMID: 27283993; NCT01526928, NCT02147990).	27283993
EGFR	EGFR T790M EGFR act mut ERBB2 amp	lung non-small cell carcinoma	predicted - resistant	Rociletinib	Clinical Study - Cohort	Actionable	In a retrospective analysis of a Phase I and a Phase II trial, ERBB2 (HER2) amplification was identified at disease progression in 9% (4/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, 70%; L858R, 28%) treated with Rociletinib (CO-1686), conversely, preexisting MET, ERBB2 (HER2), or EGFR amplification were more common in patients with primary resistance to Rociletinib (CO-1686) (PMID: 27283993; NCT01526928, NCT02147990).	27283993
EGFR	EGFR T790M EGFR act mut EGFR amp	lung non-small cell carcinoma	predicted - resistant	Rociletinib	Clinical Study - Cohort	Actionable	In a retrospective analysis of a Phase I and a Phase II trial, EGFR amplification was identified at disease progression in 9% (4/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, 70%; L858R, 28%) treated with Rociletinib (CO-1686), conversely, preexisting MET, ERBB2 (HER2), or EGFR amplification were more common in patients with primary resistance to Rociletinib (CO-1686) (PMID: 27283993; NCT01526928, NCT02147990).	27283993
EGFR	EGFR T790M EGFR act mut PIK3CA E542K	lung non-small cell carcinoma	predicted - resistant	Rociletinib	Clinical Study - Cohort	Actionable	In a retrospective analysis of a Phase I and a Phase II trial, PIK3CA activating mutations were identified at disease progression in 12% (5/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, n=3; L858R, n=2) treated with Rociletinib (CO-1686), PIK3CA E542K was identified in 3 of the 5 patients (PMID: 27283993; NCT01526928, NCT02147990).	27283993
EGFR	EGFR T790M EGFR act mut PIK3CA E545K	lung non-small cell carcinoma	predicted - resistant	Rociletinib	Clinical Study - Cohort	Actionable	In a retrospective analysis of a Phase I and a Phase II trial, PIK3CA activating mutations were identified at disease progression in 12% (5/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, n=3; L858R, n=2) treated with Rociletinib (CO-1686), PIK3CA E545K was identified in 4 of the 5 patients (PMID: 27283993; NCT01526928, NCT02147990).	27283993
EGFR	EGFR R108K	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R108K were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR R108K	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) treatment resulted in decreased cell viability in transformed cells expressing EGFR R108K in culture and led to tumor growth inhibition in mouse models (PMID: 29141884).	29141884
EGFR	EGFR R108K	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R108K were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR R108K	Advanced Solid Tumor	conflicting	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) decreased viability of transformed cells expressing EGFR R108K in culture (PMID: 17177598).	17177598
EGFR	EGFR R108K	Advanced Solid Tumor	conflicting	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) treatment resulted in minimal inhibition of colony formation and Egfr autophosphorylation in transformed cells expressing EGFR R108K in culture (PMID: 18408761).	18408761
EGFR	EGFR L858R EGFR R108K	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tagrisso (osimertinib) resulted in decreased growth of transformed cells expressing EGFR L858R and EGFR R108K in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR R108K	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR L858R and EGFR R108K in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR R108K	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tarceva (erlotinib) resulted in decreased growth of transformed cells expressing EGFR L858R and EGFR R108K in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR R108K	Advanced Solid Tumor	conflicting	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR R108K in cis demonstrated sensitivity to treatment with Iressa (gefitinib), but when expressed in trans, demonstrated resistance to treatment in culture (PMID: 29141884).	29141884
EGFR	EGFR E865K	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E865K were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E865K	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E865K were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR E865K	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E865K were resistant to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR E746_A750del EGFR T790M EGFR L844V	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR T790M EGFR L844V	lung non-small cell carcinoma	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M and ectopically expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR T790M EGFR L844V	lung non-small cell carcinoma	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, expression of an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation conferred resistance to Rociletinib (CO-1686) in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR T790M EGFR L844V	Advanced Solid Tumor	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR L844V	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L844V double mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR L844V	Advanced Solid Tumor	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR L844V double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR L844V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L844V double mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR L858R EGFR L844V	Advanced Solid Tumor	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR L844V double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).	25948633
EGFR	EGFR L858R EGFR L844V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR L858R/EGFR L844V double mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR L858R EGFR L844V	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR L844V double mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR L844V	Advanced Solid Tumor	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L844V in culture (PMID: 25948633).	25948633
EGFR	EGFR L844V	Advanced Solid Tumor	sensitive	EKI-285	Preclinical	Actionable	In a preclinical study, EKI-285 inhibited EGFR phosphorylation and growth of cells expressing EGFR L844V in culture (PMID: 25948633).	25948633
EGFR	EGFR L844V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L844V in culture (PMID: 25948633).	25948633
EGFR	EGFR L858R EGFR L844V EGFR T790M	Advanced Solid Tumor	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L844V triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).	25948633
EGFR	EGFR L858R EGFR L844V EGFR T790M	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L844V triple-mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR K860I	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR K860I were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR K860I	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR K860I were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V834M	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V834M were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V834M	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V834M were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR V834M	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V834M were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_T751del EGFR S752I	lung non-small cell carcinoma	sensitive	Trametinib + WZ4002	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Mekinist (trametinib) to WZ4002 treatment did not significantly impact cell viability compared to WZ4002 alone, but delayed onset of drug resistance in a non-small cell lung cancer cell line harboring EGFR L747_T751del and EGFR S752I in culture (PMID: 26036643).	26036643
EGFR	EGFR T34_A289del	neuroblastoma	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and cell proliferation in neuroblastoma cells over expressing EGFR T34_A289del in culture (PMID: 27216155).	27216155
EGFR	EGFR T34_A289del	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and cell proliferation in transformed cells over expressing EGFR T34_A289del in culture (PMID: 27216155).	27216155
EGFR	EGFR T34_A289del	neuroblastoma	resistant	Etoposide	Preclinical - Cell culture	Actionable	In a preclinical study, neuroblastoma cells over expressing EGFR T34_A289del were resistant to Eposin (etoposide) in culture (PMID: 27216155).	27216155
EGFR	EGFR T34_A289del	Advanced Solid Tumor	decreased response	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, Erbitux (cetuximab) did not efficiently inhibit Egfr phosphorylation in transformed cells over expressing T34_A289del in culture (PMID: 27216155).	27216155
EGFR	EGFR S768_V769delinsIL	lung adenocarcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, EGFR S768_V769delinsIL was detected in the pre-treatment biopsy of the brain metastasis from a patient with lung adenocarcinoma, who did not respond to Iressa (gefitinib) treatment (PMID: 17045698).	17045698
EGFR	EGFR G874D	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical study, Tarceva (erlotinib) treatment resulted in a complete response with an ongoing progression-free survival of over 5 years in a patient with non-small cell lung cancer harboring EGFR G874D (PMID: 31175009).	31175009
EGFR	EGFR exon 20 ins	lung non-small cell carcinoma	resistant	Gefitinib	Case Reports/Case Series	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions displayed progressive disease following treatment with Iressa (gefitinib), and resistance to Iressa (gefitinib) was replicated in cell culture studies (PMID: 24353160).	24353160
EGFR	EGFR exon 20 ins	lung non-small cell carcinoma	resistant	Gefitinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, non-small cell lung cancer patients with EGFR exon 20 insertions (n=29) demonstrated inferior progression-free survival following treatment with first-generation EGFR tyrosine kinase inhibitors such as Iressa (gefitinib), Tarceva (erlotinib), or Icotinib (1.9 months vs. 10.8 months) compared to patients with EGFR L858R and exon 19 deletion mutations (n=592)(PMID: 27468240).	27468240
EGFR	EGFR exon 20 ins	Advanced Solid Tumor	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, cells expressing an EGFR exon 20 insertion mutation were resistant to AZD9291 in culture (PMID: 24893891).	24893891
EGFR	EGFR exon 20 ins	Advanced Solid Tumor	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, cells expressing an EGFR exon 20 insertion demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 24065731).	24065731
EGFR	EGFR exon 20 ins	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited growth of transformed cells expressing EGFR exon 20 insertions in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1329).	detail...
EGFR	EGFR exon 20 ins	lung non-small cell carcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in an overall response rate of 73% (8/11) in non-small cell lung carcinoma patients harboring EGFR exon 20 insertions (PMID: 29162564).	29162564 detail...
EGFR	EGFR exon 20 ins	lung non-small cell carcinoma	resistant	Erlotinib	Case Reports/Case Series	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).	24353160
EGFR	EGFR exon 20 ins	lung non-small cell carcinoma	resistant	Erlotinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, non-small cell lung cancer patients with EGFR exon 20 insertions (n=29) demonstrated inferior progression-free survival following treatment with first-generation EGFR tyrosine kinase inhibitors such as Iressa (gefitinib), Tarceva (erlotinib), or Icotinib (1.9 months vs. 10.8 months) compared to patients with EGFR L858R and exon 19 deletion mutations (n=592)(PMID: 27468240).	27468240
EGFR	EGFR exon 20 ins	lung non-small cell carcinoma	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, non-small cell carcinoma cell lines harboring EGFR exon 20 insertions demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160).	24353160
EGFR	EGFR exon 20 ins	lung non-small cell carcinoma	resistant	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, Gilotrif (afatinib) treatment resulted in partial response in 33% (1/3), stable disease in 33% (1/3), and progressive disease in 337% (1/3) in non-small cell lung carcinoma patients harboring an EGFR exon 20 insertion mutation (PMID: 26354527).	26354527
EGFR	EGFR exon 20 ins	lung non-small cell carcinoma	resistant	Afatinib	Phase II	Actionable	In a post-hoc analysis of Phase II and Phase III trials (LUX-Lung2, LUX-Lung 3, LUX-Lung 6), Gilotrif (afatinib) treatment resulted in an objective response rate of 8.7% (2/23) in non-small cell lung cancer patients harboring EGFR exon 20 insertions, with a mean progression-free survival of 2.7 months, and an overall survival of 9.2 months (PMID: 26051236; NCT00525148, NCT00949650, and NCT01121393).	26051236
EGFR	EGFR exon 20 ins	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR exon 20 insertion mutation had decreased response to Vizimpro (dacomitinib) compared to other EGFR activating mutations, with inhibitory doses exceeding clinically attainable levels (PMID: 18089823, PMID: 21764376).	18089823 21764376
EGFR	EGFR exon 20 ins	Advanced Solid Tumor	predicted - sensitive	Nazartinib	Preclinical - Cell culture	Actionable	In a preclinical study, EGF816 inhibited growth of transformed cell lines expressing three different EGFR exon 20 insertions in culture (PMID: 26825170).	26825170
EGFR	EGFR exon 20 ins	Advanced Solid Tumor	sensitive	AP32788	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing EGFR exon 20 insertions in culture, and induced tumor regression in PDX models (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).	detail...
EGFR	EGFR exon 20 ins	lung non-small cell carcinoma	predicted - sensitive	Luminespib	Phase II	Actionable	In a Phase II trial, Luminespib (AUY922) demonstrated safety and preliminary efficacy in EGFR TKI-resistant non-small cell lung cancer patients harboring EGFR exon 20 insertions, with 10% (1/10) of patients achieving partial response and 30% of (3/10) patients achieving stable disease, and a median progression-free survival of 6.1 months (J Clin Oncol 33, 2015 (suppl; abstr 8015)).	detail...
EGFR	EGFR exon 20 ins	lung non-small cell carcinoma	predicted - sensitive	Luminespib	Case Reports/Case Series	Actionable	In a clinical case study, treatment with Luminespib (AUY922) on a clinical trial resulted in a partial response in a non-small cell lung cancer patient harboring an EGFR exon 20 insertion (PMID: 30154228; NCT01124864).	30154228
EGFR	EGFR exon 20 ins	lung non-small cell carcinoma	predicted - sensitive	Luminespib	Phase II	Actionable	In a Phase II trial, Luminespib (AUY922) treatment resulted in partial response or stable disease over 3 months in 38% (11/29) of patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, with an objective response rate of 17% (5/29), a median progression-free survival of 2.9 months, and a medial overall survival of 13 months (PMID: 30351341; NCT01854034).	30351341
EGFR	EGFR exon 20 ins	Advanced Solid Tumor	sensitive	DZD9008	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, DZD9008 inhibited proliferation of tumor cells expressing EGFR exon 20 insertions in culture, resulted in tumor growth inhibition and regression in patient-derived xenograft (PDX) models (AACR Annual Meeting 2019, Abstract 3081).	detail...
EGFR	EGFR exon 20 ins	lung non-small cell carcinoma	decreased response	Icotinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, non-small cell lung cancer patients with EGFR exon 20 insertions (n=29) demonstrated inferior progression-free survival following treatment with first-generation EGFR tyrosine kinase inhibitors such as Iressa (gefitinib), Tarceva (erlotinib), or Icotinib (1.9 months vs. 10.8 months) compared to patients with EGFR L858R and exon 19 deletion mutations (n=592)(PMID: 27468240).	27468240
EGFR	EGFR exon 20 ins	lung non-small cell carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions demonstrated a response rate of 11.11% and disease control rate of 44.44%, and a median progression-free survival of 1.9 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).	detail...
EGFR	EGFR exon 20 ins	lung cancer	predicted - sensitive	Tarloxotinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR exon 20 insertions in culture, and the prodrug Tarloxotinib (TRLX) resulted in tumor regression in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).	detail...
EGFR	EGFR pos EGFR exon 20 ins PIK3CA Y1021H	lung non-small cell carcinoma	predicted - sensitive	SHR-A1307	Preclinical - Pdx	Actionable	In a preclinical study, SHR-A1307 did not result in tumor regression, however, demonstrated a trend towards inhibition of tumor growth in Erbitux (cetuximab)-resistant patient-derived xenograft (PDX) models of EGFR-positive, and EGFR exon 20 insertion and PIK3CA Y1201H mutated non-small cell lung cancer (PMID: 30962319).	30962319
EGFR	EGFR wild-type	lung non-small cell carcinoma	sensitive	ER2	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ER2 inhibited EGFR signaling and proliferation and induced apoptosis of EGFR wild-type non-small cell lung cancer cells in culture and delayed tumor growth in non-small cell lung cancer cell line xenograft models with wild-type EGFR (PMID: 27040853).	27040853
EGFR	EGFR wild-type	Advanced Solid Tumor	decreased response	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) demonstrated decreased potency in inhibition of Egfr phosphorylation and resulted in decreased inhibition of downstream targets, including Stat5, in transformed cells expressing wild-type EGFR, compared to EGFR L858R expressing cells in culture (PMID: 25573954).	25573954
EGFR	EGFR wild-type	glioblastoma multiforme	no benefit	Dacomitinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Vizimpro (dacomitinib) did not inhibit Egfr signaling or survival of patient-derived EGFR wild-type glioblastoma cells in culture and in intracranial xenograft models (PMID: 25939761).	25939761
EGFR	EGFR wild-type	lung non-small cell carcinoma	no benefit	Gefitinib	Phase III	Actionable	In a Phase III trial, postoperative adjuvant Iressa (gefitinib) did not provide prolonged disease-free survival nor increased overall survival in NSCLC patients with wild-type EGFR (PMID: 23980091).	23980091
EGFR	EGFR wild-type	colon cancer	sensitive	Decitabine + Gefitinib	Preclinical	Actionable	In a preclinical study, the combined treatment of DNA methyltransferase inhibitor decitabine and EGFR inhibitor gefitinib on EGFR wild-type colon cancer cell lines resulted in synergistic effects in inhibiting cell growth and migration (PMID: 24874286).	24874286
EGFR	EGFR wild-type	Advanced Solid Tumor	resistant	EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 did not inhibit proliferation of transformed cells harboring wild type EGFR in culture (PMID: 27251290).	27251290
EGFR	EGFR wild-type	lung non-small cell carcinoma	predicted - sensitive	Atezolizumab	Clinical Study - Meta-analysis	Actionable	In a meta-analysis, compared to Taxotere (docetaxel), treatment with check point inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in EGFR wild-type (HR=0.67, P<0.001) but not EGFR mutant (HR=1.11, P=0.54) non-small cell lung carcinoma patients (PMID: 29270615).	29270615
EGFR	EGFR wild-type	lung non-small cell carcinoma	sensitive	Sorafenib	Phase II	Actionable	In a Phase II clinical trial, Nexavar (sorafenib) demonstrated efficacy in NSCLC patients with wild-type EGFR (PMID: 24166906).	24166906
EGFR	EGFR wild-type	lung non-small cell carcinoma	sensitive	Gefitinib + K-756	Preclinical	Actionable	In a preclinical study, the combination of K-756 and Iressa (gefitinib) worked synergistically to inhibit growth of non-small cell lung cancer cells with wild-type EGFR or EGFR exon 19 deletion in culture (PMID: 27196752).	27196752
EGFR	EGFR wild-type	lung non-small cell carcinoma	sensitive	Erlotinib + MK2206	Phase II	Actionable	In a Phase II trial, EGFR wild-type non-small cell lung cancer patients treated with Tarceva (erlotinib), in combination with MK-2206, demonstrated a clinical benefit as indicated by a disease control rate of 43% (15/43), thus, exceeding the primary endpoint rate of 20% (PMID: 26106072).	26106072
EGFR	EGFR wild-type	lung non-small cell carcinoma	sensitive	Icotinib	Phase III	Actionable	In Phase II and III clinical trials, Chinese patients with advanced NSCLC have shown Conmana (icotinib) to be safe and effective, with indication that patients with EGFR wild-type may receive some benefit (PMID: 23372346, PMID: 2394835, PMID: 24438614, PMID: 25261231).	23372346 24438614 25261231 2394835
EGFR	EGFR wild-type	Advanced Solid Tumor	resistant	JBJ-04-125-02	Preclinical - Cell culture	Actionable	In a preclinical study, JBJ-04-125-02 did not inhibit cell proliferation in a transformed murine cell line expressing wild-type EGFR in culture (PMID: 31092401).	31092401
EGFR	EGFR wild-type	lung non-small cell carcinoma	predicted - sensitive	Docetaxel	Guideline	Actionable	Taxotere (docetaxel) is included in guidelines for EGFR wild-type non-small cell lung cancer patients (NCCN.org).	detail...
EGFR	EGFR wild-type	lung non-small cell carcinoma	decreased response	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment demonstrated reduced potency inhibiting proliferation of non-small cell lung carcinoma cell lines harboring wild-type EGFR in culture (PMID: 26090892).	26090892
EGFR	EGFR wild-type	lung non-small cell carcinoma	predicted - sensitive	Nivolumab	Clinical Study - Meta-analysis	Actionable	In a meta-analysis, compared to Taxotere (docetaxel), treatment with check point inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in EGFR wild-type (HR=0.67, P<0.001) but not EGFR mutant (HR=1.11, P=0.54) non-small cell lung carcinoma patients (PMID: 29270615).	29270615
EGFR	EGFR wild-type	lung non-small cell carcinoma	unknown	Cabozantinib + Erlotinib	Phase II	Actionable	In a Phase II trial, the combination of Cometriq (cabozantinib) and Tarceva (erlotinib) resulted in an improved median progression-free survival of 4.7 mo vs. 1.8 mo with Tarceva (erlotinib) alone, and an improved median overall survival of 13.3 months vs 5.1 mo with Tarceva (erlotinib) in patients with EGFR wild-type non-small cell lung cancer (PMID: 27825638).	27825638
EGFR	EGFR wild-type	Advanced Solid Tumor	decreased response	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iressa (gefitinib) demonstrated decreased potency in inhibition of Egfr phosphorylation and inhibition of downstream targets, including Cbl, in EGFR wild-type expressing compared to EGFR L858R expressing transformed cells in culture (PMID: 25573954).	25573954
EGFR	EGFR wild-type	lung non-small cell carcinoma	sensitive	Cisplatin + ER2	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in non-small cell lung cancer cell line xenograft models with wild-type EGFR (PMID: 27040853).	27040853
EGFR	EGFR wild-type	lung non-small cell carcinoma	sensitive	Erlotinib + Ganetespib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Tarceva (erlotinib) and Ganetespib led to tumor regression in cell line xenograft models of EGFR wild-type non-small cell lung cancer, and demonstrated improved efficacy over either agent alone (PMID: 25077897).	25077897
EGFR	EGFR wild-type	squamous cell carcinoma	no benefit	Abivertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Abivertinib (AC0010) resulted in no antitumor activity when treating a squamous cell carcinoma cell line xenograft model harboring wild-type EGFR (PMID: 27573423).	27573423
EGFR	EGFR wild-type	lung non-small cell carcinoma	predicted - sensitive	Pembrolizumab	Clinical Study - Meta-analysis	Actionable	In a meta-analysis, compared to Taxotere (docetaxel), treatment with check point inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in EGFR wild-type (HR=0.67, P<0.001) but not EGFR mutant (HR=1.11, P=0.54) non-small cell lung carcinoma patients (PMID: 29270615).	29270615
EGFR	EGFR wild-type	lung non-small cell carcinoma	unknown	Cabozantinib	Phase II	Actionable	In a Phase II trial, treatment with Cometriq (cabozantinib) resulted in an improved median progression-free survival of 4.3 months, compared to 1.8 months with Tarceva (erlotinib), and an improved median overall survival of 9.2 months, versus 5.1 with Tarceva (erlotinib), in patients with EGFR wild-type non-small cell lung cancer (PMID: 27825638).	27825638
EGFR	EGFR wild-type	lung carcinoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) did not inhibit growth of lung carcinoma cells with activated wild-type EGFR signaling via EGF stimulation in culture (PMID: 27780853).	27780853
EGFR	EGFR wild-type MET over exp	lung non-small cell carcinoma	sensitive	Capmatinib	Phase I	Actionable	In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 29% (5/17) of EGFR wild-type, MET over-expressing non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).	detail...
EGFR	BRAF G466V EGFR wild-type	lung non-small cell carcinoma	sensitive	Ganetespib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ganetespib treatment resulted in decreased activation of MEK, AKT, and ERK and inhibited growth of a non-small cell lung cancer cell line with wild-type EGFR and BRAF G466V in culture, and inhibited tumor growth in xenograft models (PMID: 25077897).	25077897
EGFR	ALK wild-type EGFR wild-type	lung non-squamous non-small cell carcinoma	sensitive	Cisplatin + Pembrolizumab + Pemetrexed	FDA approved	Actionable	In a Phase III trial (KEYNOTE-189) that supported FDA approval, Keytruda (pembrolizumab) in combination with Alimta (pemetrexed), and a platinum therapy (cisplatin or carboplatin), resulted in improved overall survival rate at 12 months (69.2% vs 49.4%, HR=0.49, p<0.001) and median progression-free survival (8.8 vs 4.9 months, HR=0.52, p<0.001) compared to placebo in previously untreated metastatic nonsquamous non-small cell lung cancer patients without EGFR or ALK mutations (PMID: 29658856; NCT02578680).	detail... 29658856
EGFR	ALK wild-type EGFR wild-type	lung non-squamous non-small cell carcinoma	sensitive	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel	FDA approved	Actionable	In a Phase III trial (IMpower150) that supported FDA approval, Tecentriq (atezolizumab) in combination with bevacizumab, paclitaxel, and carboplatin resulted in significantly improved median progression-free survival (8.3 vs 6.8 months, HR=0.62, p<0.001) and median overall survival (19.2 vs 14.7 months, HR=0.78, p=0.02) compared to control in patients with metastatic nonsquamous non-small cell lung cancer, regardless of PD-L1 expression and EGFR or ALK mutation status (PMID: 29863955; NCT02366143).	29863955 detail...
EGFR	ALK wild-type EGFR wild-type	lung non-squamous non-small cell carcinoma	sensitive	Carboplatin + Pembrolizumab + Pemetrexed	FDA approved	Actionable	In a Phase III trial (KEYNOTE-189) that supported FDA approval, Keytruda (pembrolizumab) in combination with Alimta (pemetrexed), and a platinum therapy (cisplatin or carboplatin), resulted in improved overall survival rate at 12 months (69.2% vs 49.4%, HR=0.49, p<0.001) and median progression-free survival (8.8 vs 4.9 months, HR=0.52, p<0.001) compared to placebo in previously untreated metastatic nonsquamous non-small-cell lung cancer patients without EGFR or ALK mutations (PMID: 29658856; NCT02578680).	detail... 29658856
EGFR	EGFR wild-type STK11 wild-type TP53 mut	lung non-small cell carcinoma	predicted - sensitive	Nivolumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, a genomic profile consisted of mutant TP53, wild-type STK11 and EGFR is associated with increased PD-L1 expression and improved progression-free survival in Opdivo (nivolumab)-treated non-small cell lung cancer patients compared to STK11 or EGFR-mutant cohorts (p=0.03) (PMID: 29764856).	29764856
EGFR	EGFR wild-type STK11 wild-type TP53 mut	lung non-small cell carcinoma	predicted - sensitive	Pembrolizumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, a genomic profile consisted of mutant TP53, wild-type STK11 and EGFR is associated with increased PD-L1 expression and improved progression-free survival in Keytruda (pembrolizumab)-treated non-small cell lung cancer patients (PMID: 29764856).	29764856
EGFR	EGFR G874S	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G874S were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR G874S	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G874S were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR G874S	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G874S were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747P	lung adenocarcinoma	no benefit	Bevacizumab + Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, Tarceva (erlotinib) and Avastin (bevacizumab) combination treatment resulted in stable disease for 7 months until disease progression in a patient with lung adenocarcinoma harboring EGFR L747P (PMID: 29673089).	29673089
EGFR	EGFR L747P	lung non-small cell carcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical study, Tarceva (erlotinib) treatment resulted in disease progression in a patient with non-small cell lung cancer harboring EGFR L747P (PMID: 31175009).	31175009
EGFR	EGFR L747P	lung adenocarcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring EGFR L747P demonstrated stable disease in the right upper lobe lung lesion and brain metastases following treatment with Gilotrif (afatinib) and maintained progression-free survival for more than 24 months (PMID: 30746257).	30746257
EGFR	EGFR L747P	lung adenocarcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, EGFR L747P was identified as a primary resistance mutation in a patient with lung adenocarcinoma who did not respond to Tarceva (erlotinib) treatment (PMID: 27499993).	27499993
EGFR	EGFR L747P	lung adenocarcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, Iressa (gefitinib) treatment resulted in disease progression in a patient with lung adenocarcinoma harboring EGFR L747P (PMID: 29673089).	29673089
EGFR	EGFR L747P	lung adenocarcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, Tagrisso (osimertinib) treatment resulted in disease progression in a patient with lung adenocarcinoma harboring EGFR L747P (PMID: 29673089).	29673089
EGFR	EGFR E709_T710delinsD EGFR L792F	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, acquisition of EGFR L792F was associated with resistance to Gilotrif in transformed cells expressing EGFR E709_T710delinsD in culture (PMID: 27913578).	27913578
EGFR	EGFR E709_T710delinsD EGFR L792F	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vizimpro (dacomitinib) inhibited growth of transformed cells expressing EGFR E709_T710delinsD and EGFR L792F in culture (PMID: 27913578).	27913578
EGFR	EGFR E746_A750del EGFR L792F	Advanced Solid Tumor	decreased response	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_A750del and EGFR L792F demonstrated decreased sensitivity to Gilotrif (afatinib) in culture compared to cells expressing E746_A750del alone (PMID: 27913578).	27913578
EGFR	EGFR L792F EGFR L858R	Advanced Solid Tumor	decreased response	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR L792F demonstrated decreased sensitivity to Gilotrif (afatinib) in culture compared to cells expressing EGFR L858R alone (PMID: 27913578).	27913578
EGFR	EGFR K745_E746insTPVAIK	lung adenocarcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical study, a lung adenocarcinoma patient harboring EGFR K745_E746insTPVAIK demonstrated a partial response when treated with Tarceva (erlotinib) (PMID: 22190593).	22190593
EGFR	EGFR T751I	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T751I were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E709X	lung non-small cell carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR E709 mutations demonstrated a response rate of 66.66% and a median progression-free survival of 3.1 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).	detail...
EGFR	EGFR E709X	lung non-small cell carcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, Gilotrif (afatinib) treatment resulted in partial response in 50% (2/4) and stable disease in 50% (2/4) of non-small cell lung carcinoma patients harboring an EGFR E709 mutation (PMID: 26354527).	26354527
EGFR	EGFR L858R EGFR M766Q	lung adenocarcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma initially harboring EGFR L858R and EGFR T790M was treated with Tagrisso (osimertinib), progressed, and via cell-free DNA testing, was found to have lost EGFR T790M, but acquired EGFR M766Q and preclinical analysis of transformed cells co-expressing L858R and M766Q also demonstrated resistance to Tagrisso (osimertinib) in culture (PMID: 31254668).	31254668
EGFR	EGFR L858R EGFR M766Q	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR M766Q demonstrated resistance to treatment with Gilotrif (afatinib) in culture (PMID: 31254668).	31254668
EGFR	EGFR L858R EGFR M766Q	Advanced Solid Tumor	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR M766Q were sensitive to treatment with Nerlynx (neratinib) in culture (PMID: 31254668).	31254668
EGFR	EGFR L858R EGFR M766Q	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Poziotinib (HM781-36B) resulted in growth inhibition of transformed cells co-expressing EGFR L858R and EGFR M766Q in culture at clinically achievable concentrations (PMID: 31254668).	31254668
EGFR	EGFR L858R EGFR M766Q	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR M766Q demonstrated resistance to treatment with Tarceva (erlotinib) in culture (PMID: 31254668).	31254668
EGFR	EGFR I744M	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR I744M were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR I744M	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR I744M were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR I744M EGFR L858R	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR I744M and EGFR L858R in cis were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR I744M EGFR L858R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tagrisso (osimertinib) resulted in decreased growth of transformed cells expressing EGFR I744M and EGFR L858R in cis in culture (PMID: 29141884).	29141884
EGFR	EGFR I744M EGFR L858R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR I744M and EGFR L858R in cis in culture (PMID: 29141884).	29141884
EGFR	EGFR P772_H773dup	lung non-small cell carcinoma	predicted - sensitive	Luminespib	Phase II	Actionable	In a Phase II trial, Luminespib (AUY922) treatment demonstrated safety and efficacy in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, resulted in 1 partial response and 3 stable disease in 4 patient harboring EGFR P772_H773dup (PMID: 30351341; NCT01854034).	30351341
EGFR	EGFR P772_H773dup	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited EGFR phosphorylation and proliferation of cells expressing EGFR exon 20 insertion mutations, including EGFR P772_H773dup (reported as H773_V774insPH), in culture (PMID: 29748209).	29748209
EGFR	EGFR G719A EGFR I706T	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR I706T and EGFR G719A in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR I706T	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing EGFR I706T and EGFR G719A in cis were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR I706T	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing EGFR I706T and EGFR G719A in cis were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR I706T	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR I706T and EGFR G719A in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A	lung non-small cell carcinoma	sensitive	Afatinib	Phase III	Actionable	In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411).	24790411
EGFR	EGFR G719A	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR G719A demonstrated increased sensitivity to second-generation EGFR inhibitors including Gilotrif (afatinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR G719A	Advanced Solid Tumor	decreased response	Erlotinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to first-generation EGFR inhibitors including Tarceva (erlotinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR G719A	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR G719A demonstrated increased sensitivity to second-generation EGFR inhibitors including Vizimpro (dacomitinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR G719A	Advanced Solid Tumor	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR G719A demonstrated increased sensitivity to second-generation EGFR inhibitors including Nerlynx (neratinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR G719A	Advanced Solid Tumor	decreased response	Osimertinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to third-generation EGFR inhibitors including Tagrisso (AZD9291) in culture, when compared to second-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR G719A	Advanced Solid Tumor	decreased response	Rociletinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to third-generation EGFR inhibitors including Rociletinib (CO-1686) in culture, when compared to second-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR G719A	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719A were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A	lung non-small cell carcinoma	sensitive	Dacomitinib	Phase III	Actionable	In Phase III clinical trials, patients with NSCLC tumors harboring an EGFR G719X (X=A, C, or S) mutation responded to EGFR tyrosine kinase inhibitors including Vizimpro (dacomitinib) (PMID: 24857124).	24857124
EGFR	EGFR G719A	Advanced Solid Tumor	decreased response	Gefitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to first-generation EGFR inhibitors including Iressa (gefitinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR G719A	lung non-small cell carcinoma	predicted - sensitive	Gefitinib	Clinical Study	Actionable	In a clinical study, analysis of published data demonstrated that 7/11 non-small cell lung cancer patients harboring EGFR G719A were found to achieve disease control following EGFR tyrosine kinase inhibitor treatment with either Tarceva (erlotinib) or Iressa (gefitinib) (PMID: 23344264).	23344264
EGFR	EGFR G719A	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Clinical Study	Actionable	In an analysis of published clinical data, 7/11 non-small cell lung cancer patients harboring EGFR G719A were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Tarceva (erlotinib) (PMID: 23344264).	23344264
EGFR	EGFR G719A	Advanced Solid Tumor	sensitive	AP32788	Preclinical - Cell culture	Actionable	In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing EGFR G719A in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).	detail...
EGFR	EGFR amp EGFR G719A	glioblastoma multiforme	sensitive	BMS-754807 + Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification and EGFR G719A in culture (PMID: 26561558).	26561558
EGFR	EGFR amp EGFR G719A	glioblastoma multiforme	sensitive	Gefitinib + Linsitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification and EGFR G719A in culture (PMID: 26561558).	26561558
EGFR	EGFR G719A EGFR T790M	Advanced Solid Tumor	conflicting	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719A and EGFR T790M demonstrated resistance to Tagrisso (osimertinib) when expressed in cis, but was sensitive when expressed in trans in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR T790M	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719A and EGFR T790M were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR T790M	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719A and EGFR T790M in cis and trans in culture demonstrated resistance to treatment with Iressa (gefitinib) (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR T790M	Advanced Solid Tumor	conflicting	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719A and EGFR T790M demonstrated resistance to Gilotrif (afatinib) when expressed in cis, but was sensitive when expressed in trans in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR T790M	Advanced Solid Tumor	conflicting	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, acquisition of EGFR T790M was associated with resistance to Gilotrif (afatinib) in transformed cells expressing EGFR G719A in culture (PMID: 27913578).	27913578
EGFR	EGFR G719A EGFR L861R	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR G719A and EGFR L861R in cis demonstrated resistance to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR L861R	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical study, Tarceva (erlotinib) treatment resulted in a partial response with a progression-free survival of 6 months in a patient with non-small cell lung cancer harboring both EGFR G719A and EGFR L861R (PMID: 31175009).	31175009
EGFR	EGFR G719A EGFR L861R	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR C797S and EGFR T790M in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR L861R	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR G719A and EGFR L861R in cis demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR L861R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR G719A and EGFR L861R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR A840G EGFR G719A EGFR L704M	lung non-small cell carcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung cancer co-harboring EGFR A804G, G719A, and L704M demonstrated a partial response when treated with Gilotrif (afatinib) (PMID: 31043566).	31043566
EGFR	EGFR G719A EGFR S768I	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719A and EGFR S768I in cis were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR S768I	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719A and EGFR S768I in cis were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR S768I	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768I and EGFR G719A in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR S768I	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768I and EGFR G719A in cis were resistant to Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719A EGFR S768I	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR G719A and EGFR S768I in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L833V	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L833V were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L833V	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L833V were sensitive to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L833V	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L833V were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR L833V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L833V were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L833V	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L833V were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR L833V EGFR L858R	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L833V and EGFR L858R in cis and trans were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L833V EGFR L858R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L833V and EGFR L858R in cis and trans were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L833V EGFR L858R	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L833V and EGFR L858R in cis were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L833V EGFR L858R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L838V and EGFR L858R in trans were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR K714R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR K714R were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR K714R	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR K714R were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR K714R EGFR L858R	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR K714R and EGFR L858R in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR K714R EGFR L858R	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Iressa (gefitinib) resulted in decreased growth of transformed cells expressing EGFR K714R and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR K714R EGFR L858R	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tarceva (erlotinib) resulted in decreased growth of transformed cells expressing EGFR K714R and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR K714R EGFR L858R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tagrisso (osimertinib) resulted in decreased growth of transformed cells expressing EGFR K714R and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR R776C	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R776C were sensitive to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR R776C	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R776C were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR R776C	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R776C were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR R776C	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R776C were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR R776C	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR R776C in cis and trans were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR R776C	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR R776C in cis and trans were sensitive to treatment with Iressa (geftinib) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR R776C	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR R776C in cis and trans were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR R776C	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR R776C in cis and trans were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR R776C	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR R776C in cis and trans were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR A702T	lung non-small cell carcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical study, Iressa (gefitinib) treatment resulted in massive disease progression in a patient with non-small cell lung cancer harboring EGFR A702T (PMID: 31175009).	31175009
EGFR	EGFR G873E	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G873E were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR G873E	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G873E were resistant to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G873E	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G873E were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G873E	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G873E were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR D770_N771insVDSVDNP	lung adenocarcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, Iressa (gefitinib) treatment resulted in immediate disease progression after 4 weeks of treatment in a patient with metastatic lung adenocarcinoma harboring EGFR D770_N771insVDSVDNP (PMID: 21841502).	21841502
EGFR	EGFR A289T	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289T were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR A289T	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289T were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR A289T	lung non-small cell carcinoma	predicted - sensitive	Icotinib	Case Reports/Case Series	Actionable	In a clinical case study, Conmana (icotinib) treatment resulted in a 6-month partial response in a single East Asian patient with non-small cell lung cancer harboring the mutation, EGFR A289T (J Clin Oncol 37, 2019 (suppl; abstr e13000)).	detail...
EGFR	EGFR A289T	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289T were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR A289T EGFR L858R	Advanced Solid Tumor	conflicting	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289T and EGFR L858R in cis demonstrated sensitivity to treatment with Iressa (gefitinib), but when expressed in trans, demonstrated resistance to treatment in culture (PMID: 29141884).	29141884
EGFR	EGFR A289T EGFR L858R	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289T and EGFR L858R in cis were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR A289T EGFR L858R	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tarceva (erlotinib) resulted in decreased growth of transformed cells expressing EGFR A289T and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR A289T EGFR L858R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR A289T and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR A289T EGFR L858R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tagrisso (osimertinib) resulted in decreased growth of transformed cells expressing EGFR A289T and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR D770_N771insGV	lung non-small cell carcinoma	predicted - sensitive	Luminespib	Phase II	Actionable	In a Phase II trial, Luminespib (AUY922) treatment demonstrated safety and efficacy in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, with 1 patient harboring EGFR D770_N771insGV achieved stable disease (PMID: 30351341; NCT01854034).	30351341
EGFR	EGFR N771_H773dup	lung cancer	predicted - sensitive	TAS6417	Preclinical - Pdx	Actionable	In a preclinical study, TAS6417 inhibited tumor growth in lung cancer patient-derived xenograft (PDX) models harboring EGFR N771_H773dup (reported as H773_V774insNPH) (PMID: 29748209).	29748209
EGFR	EGFR N771_H773dup	lung adenocarcinoma	sensitive	Dacomitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Vizimpro (dacomitinib) inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR N771_H773dup (also referred to as H773_V774insNPH) in culture (PMID: 28363995).	28363995
EGFR	EGFR N771_H773dup	Advanced Solid Tumor	sensitive	TAS6417	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAS6417 inhibited EGFR phosphorylation and proliferation of cells expressing EGFR exon 20 insertion mutations, including EGFR N771_H773dup (reported as H773_V774insNPH), in culture, and inhibited tumor growth in cell line xenograft models (PMID: 29748209).	29748209
EGFR	EGFR N771_H773dup	lung non-small cell carcinoma	sensitive	Poziotinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Poziotinib (HM781-36B) decreased tumor burden by greater than 85% in 8/9 mice in a patient-derived xenograft (PDX) model of non-small cell lung cancer harboring EGFR N771_H773dup (reported as EGFR H773insNPH) (PMID: 29686424).	29686424
EGFR	EGFR N771_H773dup	lung non-small cell carcinoma	sensitive	Nazartinib	Preclinical - Pdx	Actionable	In a preclinical study, EGF816 inhibited tumor growth in patient-derived xenograft models of non-small cell lung cancer harboring EGFR N771_H773dup (reported as H773_V774insNPH) (PMID: 26825170).	26825170
EGFR	EGFR N771_H773dup	head and neck squamous cell carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup demonstrated resistance to Iressa (gefinitib) in culture (PMID: 25931286).	25931286
EGFR	EGFR N771_H773dup	lung adenocarcinoma	sensitive	Afatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR N771_H773dup (also referred to as H773_V774insNPH) in culture (PMID: 28363995).	28363995
EGFR	EGFR N771_H773dup	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited EGFR phosphorylation and growth of a transformed cell line expressing EGFR N771_H773dup (reported as H773insNPH) in culture (PMID: 29686424).	29686424
EGFR	EGFR N771_H773dup	head and neck squamous cell carcinoma	resistant	Erlotinib	Preclinical	Actionable	In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup demonstrated resistance to Tarceva (erlotinib) in culture (PMID: 25931286).	25931286
EGFR	EGFR N771_H773dup	Advanced Solid Tumor	sensitive	Nazartinib	Preclinical - Cell culture	Actionable	In a preclinical study, EGF816 inhibited growth of transformed cells expressing EGFR N771_H773dup (reported as H773_V774insNPH) in culture (PMID: 26825170).	26825170
EGFR	EGFR N771_H773dup	head and neck squamous cell carcinoma	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup in culture (PMID: 25931286).	25931286
EGFR	EGFR N771_H773dup	lung cancer	predicted - resistant	Afatinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) decreased Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR N771_H773dup in culture, bud did not affect tumor growth in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).	detail...
EGFR	EGFR N771_H773dup	lung cancer	sensitive	Tarloxotinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR N771_H773dup in culture, and the prodrug Tarloxotinib (TRLX) resulted in tumor regression in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).	detail...
EGFR	EGFR N771_H773dup	lung non-small cell carcinoma	sensitive	Osimertinib	Preclinical - Pdx	Actionable	In a preclinical study, Tagrisso (osimertinib) treatment resulted in tumor regression in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring EGFR N771_H773dup (reported as H773_V774insNPH) (PMID: 29483211).	29483211
EGFR	EGFR G696_P1033dup	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing the kinase domain duplication mutant EGFR G696_P1033dup in culture (PMID: 26286086).	26286086
EGFR	EGFR G696_P1033dup	lung adenocarcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR G696_P1033dup had a partial response after two cycles of Gilotrif (afatinib) after failing first line chemotherapy (PMID: 26286086).	26286086
EGFR	EGFR G696_P1033dup	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing kinase domain duplication mutant EGFR G696_P1033dup in culture (PMID: 26286086).	26286086
EGFR	EGFR G696_P1033dup	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing kinase domain duplication mutant EGFR G696_P1033dup in culture (PMID: 26286086).	26286086
EGFR	EGFR amp EGFR G696_P1033dup	lung adenocarcinoma	predicted - resistant	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR G696_P1033dup had a partial response after two cycles of Gilotrif (afatinib), but subsequently developed resistance to the therapy after amplification of EGFR (PMID: 26286086).	26286086
EGFR	EGFR P741L	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P741L were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR P741L	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P741L were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR P741L	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P741L were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR exon 19 del EGFR T790M EGFR L798I	lung non-small cell carcinoma	predicted - resistant	Rociletinib	Case Reports/Case Series	Actionable	In clinical study, EGFR L798I was identified at disease progression in a patients with non-small cell lung cancer harboring both EGFR T790M and EGFR exon 19 deletion treated with Rociletinib (CO-1686), consistent with structural modeling prediction in which EGFR L798I in cis with T790M interfered with Rociletinib (CO-1686) binding (PMID: 27283993).	27283993
EGFR	EGFR L833F	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L833F were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L833F	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L833F were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L833F	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L833F were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L833F	lung non-small cell carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR L833F demonstrated a response rate of 0% and disease control rate of 100%, and a median progression-free survival of 4.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).	detail...
EGFR	EGFR L833F EGFR L858R	lung non-small cell carcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung cancer co-harboring EGFR L833F and EGFR L858R demonstrated a partial response when treated with Gilotrif (afatinib) (PMID: 31043566).	31043566
EGFR	EGFR L858R	lung adenocarcinoma	no benefit	Icotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R developed progressive disease 2 months after Conmana (Icotinib) treatment (PMID: 31301016).	31301016
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Dacomitinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (ARCHER 1050) that supported FDA approval, treatment with Vizimpro (dacomitinib) as first-line therapy in patients with non-small cell lung cancer harboring an EGFR exon 19 deletion or EGFR L858R resulted in an improved median progression-free survival (mPFS) of 14.7 months compared to 9.2 months with Iressa (gefitinib), with a mPFS of 16.5 months with dacomitnib vs. 9.2 months with Iressa (gefitinib) among patients with EGFR L858R (PMID: 28958502; NCT01777421).	detail... 28958502 detail...
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Dacomitinib	Phase II	Actionable	In a Phase II clinical trial, 74% (34/46) of patients with EGFR exon 19 or 21 mutant lung cancers had partial response (PFS average= 17 months) to first line treatment with Vizimpro (dacomitinib) (J Clin Oncol 30, 2012 (suppl; abstr 7530); NCT00818441).	detail...
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Dacomitinib	Guideline	Actionable	Vizimpro (dacomitinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as L858R (NCCN.org).	detail...
EGFR	EGFR L858R	Advanced Solid Tumor	sensitive	EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 inhibited proliferation of transformed cells over expressing EGFR L858R in culture, although at a concentration much higher than the biochemical IC50 of the compound (PMID: 27251290).	27251290
EGFR	EGFR L858R	lung adenocarcinoma	sensitive	Cetuximab	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) inhibited tumor growth in mouse lung adenocarcinoma models expressing EGFR L858R (PMID: 24063894).	24063894
EGFR	EGFR L858R	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iressa (gefitinib) inhibited Egfr phosphorylation and inhibited phosphorylation of downstream signaling molecules Cbl, Erk, Akt, phospholipase C gamma, and Stat5 in EGFR L858R expressing transformed cells to a greater degree than EGFR wild-type expressing transformed cells in culture (PMID: 25573954).	25573954
EGFR	EGFR L858R	Advanced Solid Tumor	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of transformed human cell lines harboring EGFR L858R mutation in culture (PMID: 26090892).	26090892
EGFR	EGFR L858R	Advanced Solid Tumor	sensitive	EKI-285	Preclinical	Actionable	In a preclinical study, EKI-285 (CL-387,785) inhibited growth of transformed cells expressing EGFR L858R in culture (PMID: 17085664).	17085664
EGFR	EGFR L858R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR L858R in culture (PMID: 29467275).	29467275
EGFR	EGFR L858R	lung non-squamous non-small cell carcinoma	sensitive	Erlotinib	Guideline	Actionable	Tarceva (erlotinib) is included in guidelines as first-line therapy for advanced, recurrent, or metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).	detail...
EGFR	EGFR L858R	Advanced Solid Tumor	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR L858R in culture (PMID: 29467275).	29467275
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Lazertinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Lazertinib (YH25448) inhibited Egfr signaling and viability of patient-derived non-small cell lung cancer cells harboring EGFR L858R (PMID: 30670498).	30670498
EGFR	EGFR L858R	Advanced Solid Tumor	no benefit	PF-00477736 + PF3644022	Preclinical - Cell culture	Actionable	In a preclinical study, neither single agent or combination of Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 inhibited growth of transformed cells over expressing EGFR L858R in culture (PMID: 26140595).	26140595
EGFR	EGFR L858R	lung adenocarcinoma	sensitive	Bevacizumab + Erlotinib	Phase II	Actionable	In a Phase II trial (BELIEF), Avastin (bevacizumab) and Tarceva (erlotinib) combination treatment resulted in a median progression-free survival of 13.2 months and a 12 month progression-free survival of 55% (60/109) in treatment-naive lung adenocarcinoma patients harboring activating EGFR mutations (exon 19 deletion or L858R) (PMID: 28408243; NCT01562028).	28408243
EGFR	EGFR L858R	lung non-small cell carcinoma	decreased response	unspecified PD-L1 antibody	Clinical Study - Cohort	Actionable	In a retrospective analysis, treatment with immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, or anti-CTLA with anti-PD-1) resulted in comparable overall response rate (16%, 7/44 vs 22%, 47/212, p=0.42) and overall survival (HR=0.917, p=0.69), but significantly reduced progression-free survival (wild-type vs L858R, HR=0.578, p=0.001) in non-small cell lung cancer patients harboring EGFR L858R compared to EGFR wild-type patients (PMID: 31086949).	31086949
EGFR	EGFR L858R	Advanced Solid Tumor	sensitive	BGB-283	Preclinical - Cell culture	Actionable	In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing EGFR L858R in culture (PMID: 26208524).	26208524
EGFR	EGFR L858R	Advanced Solid Tumor	sensitive	Lazertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lazertinib (YH25448) inhibited Egfr phosphorylation and viability of transformed cells expressing EGFR L858R (PMID: 30670498).	30670498
EGFR	EGFR L858R	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EGFR L858R in culture (PMID: 27780853).	27780853
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Osimertinib	Phase I	Actionable	In a Phase I trial, treatment with Tagrisso (osimertinib) resulted in a response rate of 11% (2/19) in NSCLC patients harboring EGFR L858R without EGFR T790M (PMID: 25923549; NCT01802632).	25923549
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Osimertinib	Guideline	Actionable	Tagrisso (osimertinib) is included in guidelines as first-line therapy for locally advanced or metastatic non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).	detail...
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Osimertinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III (FLAURA) trial that supported FDA approval, treatment with Tagrisso (osimertinib) resulted in a longer median progression-free survival compared to treatment with either Tarceva (erlotinib) or Iressa (gefitinib) (18.9 mo vs 10.2 mo) in non-small cell lung carcinoma patients harboring either EGFR L858R or EGFR exon 19 deletion (PMID: 29151359; NCT02296125).	29151359 detail... detail...
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Osimertinib	Phase III	Actionable	In a Phase III (FLAURA) trial, treatment with Tagrisso (osimertinib) resulted in a longer median time to discontinuation of treatment (23.0 vs 16.0 months) and second progression-free survival (not reached vs 20.0 months, HR=0.58, p=0.0004) compared to treatment with either Tarceva (erlotinib) or Iressa (gefitinib) in non-small cell lung carcinoma patients harboring either EGFR L858R or EGFR exon 19 deletion (PMID: 30659024; NCT02296125).	30659024
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	TAS-121	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung cancer patient harboring EGFR L858R demonstrated 59% tumor shrinkage following treatment with TAS-121 (PMID: 30872380).	30872380
EGFR	EGFR L858R	lung cancer	sensitive	Buparlisib + Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Buparlisib (BKM-120) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).	28416483
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Nazartinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EGF816 inhibited tumor growth and induced tumor regression in cell line xenograft models of non-small cell lung cancer harboring EGFR L858R (Cancer Res 2014;74(19 Suppl):Abstract nr 1733).	detail...
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Icotinib	Clinical Study - Cohort	Actionable	In a clinical study, EGFR tyrosine kinase inhibitor treatment including Conmana (Icotinib) (n=5) resulted in partial response in 77.8% (14/18) and stable disease in 22.2% (4/18) of non-small cell lung cancer patients harboring EGFR L858R (n=16) or exon 19 deletion mutations (n=2), with a median progression-free survival of 10.5 months (PMID: 30791921).	30791921
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Icotinib	Clinical Study - Meta-analysis	Actionable	In a meta-analysis, 12 phase III trials investigating EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer patients with EFGR mutations (primarily exon 19 deletions or L858R) indicated TKIs, including icotinib, were superior to standard chemotherapy (PMID: 24533047).	24533047
EGFR	EGFR L858R	lung adenocarcinoma	sensitive	Osimertinib + Selumetinib	Preclinical	Actionable	In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib inhibited growth of lung adenocarcinoma tumors driven by EGFR L858R that had developed resistance through continued exposure to Tagrisso (osimertinib) (PMID: 25870145).	25870145
EGFR	EGFR L858R	lung cancer	sensitive	Osimertinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).	28416483
EGFR	EGFR L858R	lung non-small cell carcinoma	no benefit	Brigatinib	Guideline	Actionable	Alunbrig (brigatinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).	detail...
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring EGFR L858R mutation in culture (PMID: 26090892).	26090892
EGFR	EGFR L858R	lung non-small cell carcinoma	no benefit	EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 inhibited Egfr activation but not proliferation of non-small cell lung cancer cells harboring EGFR L858R in culture (PMID: 27251290).	27251290
EGFR	EGFR L858R	lung non-small cell carcinoma	decreased response	unspecified CTLA4 antibody + unspecified PD-1 antibody	Clinical Study - Cohort	Actionable	In a retrospective analysis, treatment with immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, or anti-CTLA with anti-PD-1) resulted in comparable overall response rate (16%, 7/44 vs 22%, 47/212, p=0.42) and overall survival (HR=0.917, p=0.69), but significantly reduced progression-free survival (wild-type vs L858R, HR=0.578, p=0.001) in non-small cell lung cancer patients harboring EGFR L858R compared to EGFR wild-type patients (PMID: 31086949).	31086949
EGFR	EGFR L858R	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited growth of transformed cells expressing EGFR L858R in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1329).	detail...
EGFR	EGFR L858R	lung adenocarcinoma	sensitive	Rociletinib	Preclinical	Actionable	In a preclinical study, CO-1686 demonstrated efficacy in treating transgenic mouse models of lung adenocarcinoma expressing EGFR L858R (PMID: 24065731).	24065731
EGFR	EGFR L858R	lung non-small cell carcinoma	no benefit	Alectinib	Guideline	Actionable	Alecensa (alectinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).	detail...
EGFR	EGFR L858R	lung non-small cell carcinoma	no benefit	Ceritinib	Guideline	Actionable	Zykadia (ceritinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).	detail...
EGFR	EGFR L858R	lung cancer	sensitive	Dasatinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).	28416483
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Ibrutinib	Preclinical - Cell culture	Actionable	In a preclinical study, Imbruvica (ibrutinib) inhibited Egfr activity and down stream signaling, resulting in cell cycle arrest in non-small cell lung cancer cells harboring EGFR L858R in culture (PMID: 26375053).	26375053
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Erlotinib	Phase II	Actionable	In a Phase II clinical trial, treatment with Tarceva (erlotinib) resulted in a median progression-free survival (PFS) of 10.8 months for the intent-to-treat population of non-small cell lung cancer patients with EGFR mutations, with a PFS of 9.2 months for patients harboring EGFR L858R (PMID: 26720423).	26720423
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Erlotinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (EURTAC) that supported FDA approval, treatment with Tarceva (erlotinib) resulted in improved progression-free survival compared to treatment with platinum-based chemotherapy in non-small cell lung cancer patients harboring EGFR L858R (HR= 0.52) (PMID: 24868098).	24868098 detail... detail...
EGFR	EGFR L858R	Advanced Solid Tumor	sensitive	Cetuximab + JBJ-04-125-02	Preclinical - Cell culture	Actionable	In a preclinical study, JBJ-04-125-02 and Erbitux (cetuximab) combination treatment inhibited cell proliferation in a transformed murine cell line expressing EGFR L858R in culture (PMID: 31092401).	31092401
EGFR	EGFR L858R	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and inhibited phosphorylation of downstream signaling molecules Cbl, Erk, Akt, phospholipase C gamma, Stat3, and Stat5 in EGFR L858R expressing transformed cells to a greater degree than EGFR wild-type expressing transformed cells in culture (PMID: 25573954).	25573954
EGFR	EGFR L858R	Advanced Solid Tumor	sensitive	DZD9008	Preclinical - Cell culture	Actionable	In a preclinical study, DZD9008 inhibited proliferation of tumor cells expressing EGFR L858R in culture (AACR Annual Meeting 2019, Abstract 3081).	detail...
EGFR	EGFR L858R	lung adenocarcinoma	sensitive	Afatinib + Cetuximab	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) and Erbitux (cetuximab) combination treatment resulted in the least tumor recurrence after treatment cessation, and delayed development of treatment resistance compared to single drug treatment in animal models of EGFR L858R-induced lung adenocarcinoma (PMID: 26341921).	26341921
EGFR	EGFR L858R	lung adenocarcinoma	predicted - sensitive	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, Tagrisso (osimertinib) treatment resulted in a progression-free survival of 10.4 months in a patient with lung adenocarcinoma harboring EGFR L858R who developed resistance to Conmana (Icotinib) (PMID: 31301016).	31301016
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring EGFR L858R in culture (PMID: 29467275).	29467275
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Gefitinib + Pemetrexed	Phase II	Actionable	In a Phase II trial, Iressa (gefitinib) and Alimta (pemetrexed) combination treatment resulted in a median progression-free survival (PFS) of 6.7 months, an objective response rate of 22.9% (8/35), and an overall survival of 24.3 months in non-small cell lung cancer patients harboring sensitizing EGFR mutations (15 exon 19 deletion, 20 L858R) who progressed on first-line Iressa (gefitinib) treatment, with no difference in PFS between exon 19 deletion and L858R groups (5.6 vs 7.0 months) (PMID: 30268482).	30268482
EGFR	EGFR L858R	Advanced Solid Tumor	sensitive	AV-412	Preclinical	Actionable	In a preclinical study, AV-412 inhibited the kinase activity of EGFR L858R (PMID: 17888033).	17888033
EGFR	EGFR L858R	Advanced Solid Tumor	decreased response	Cetuximab + EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 and Erbitux (cetuximab) combination therapy inhibited cell proliferation in a transformed murine cell line expressing EGFR L858R, however, with decreased response compared to cells treated with JBJ-04-125-02 and Erbitux (cetuximab) in culture (PMID: 31092401).	31092401
EGFR	EGFR L858R	lung non-squamous non-small cell carcinoma	sensitive	Gefitinib	Guideline	Actionable	Iressa (gefitinib) is included in guidelines as first-line therapy for advanced, recurrent, or metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).	detail...
EGFR	EGFR L858R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR L858R in culture (PMID: 29467275).	29467275
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Gefitinib	Clinical Study - Meta-analysis	Actionable	In a meta-analysis, 12 Phase III trials investigating EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer patients with EGFR mutations (primarily exon 19 deletions or L858R) indicated TKIs, including Iressa (gefitinib), were superior to standard chemotherapy (PMID: 24533047).	24533047
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Gefitinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial that supported FDA approval, Iressa (gefitinib) treatment resulted in an objective response rate of 71.2% (94/132) compared to 47.3% (61/129) with Paraplatin (carboplatin) plus Taxol (paclitaxel) and prolonged progression-free survival (HR=0.48) in non-small cell lung cancer patients harboring EGFR activating mutations, including EGFR L858R (PMID: 19692680, NCT00322452).	19692680 detail... detail...
EGFR	EGFR L858R	lung non-squamous non-small cell carcinoma	sensitive	Afatinib	Guideline	Actionable	Gilotrif (afatinib) is included in guidelines as first-line, but not subsequent therapy for metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).	detail...
EGFR	EGFR L858R	lung non-small cell carcinoma	predicted - sensitive	Cabozantinib + Erlotinib	Phase II	Actionable	In a Phase II trial (NCI 9303), Cometriq (cabozantinib) and Tarceva (erlotinib) combination treatment resulted in an objective response rate of 10.8% (4/37, 4 partial response) and an 8-week disease control rate of 67.0% (25/37) in heavily pretreated non-small cell lung cancer patients harboring EGFR mutations, progression-free survival and overall survival were not different among patients harboring EGFR L858R, exon 19 deletion, or T790M (PMID: 30915273; NCT01866410).	30915273
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Afatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial supporting FDA approval (LUX-Lung 3), Gilotrif (afatinib) treatment resulted in improved median progression-free survival compared to chemotherapy (HR=0.73) in non-small cell lung carcinoma patients harboring EGFR L858R (PMID: 23816960; NCT00949650) and EGFR L858R is on the companion diagnostic.	23816960 detail... detail...
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Afatinib	Phase II	Actionable	In a Phase II trial, Gilotrif (afatinib) treatment resulted in improved progression-free survival (11.0 vs 10.9 months) and time-to-treatment failure (13.7 vs 11.5 months) compared to Iressa (gefitinib) in treatment-naive non-small cell lung carcinoma patients harboring EGFR exon 19 deletion or L858R (PMID: 27083334).	27083334
EGFR	EGFR L858R	Advanced Solid Tumor	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing EGFR L858R in culture (PMID: 17085664).	17085664
EGFR	EGFR L858R	lung cancer	sensitive	AZD3759	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD3759 inhibited EGFR activation and growth of a lung cancer cell line harboring EGFR L858R in culture, and inhibited tumor growth in xenograft models (PMID: 27928026).	27928026
EGFR	EGFR L858R	lung cancer	sensitive	AZD3759	Case Reports/Case Series	Actionable	In a clinical case study, treatment with AZD3759 inhibited EGFR activity and demonstrated antitumor activity in two patients with non-small cell lung cancer harboring EGFR L858R, resulting in decreased CSF tumor cell number in the patient with leptomeningeal metastasis, and decreased brain tumor growth in the patient with brain metastasis (PMID: 27928026).	27928026
EGFR	EGFR L858R	lung non-small cell carcinoma	decreased response	unspecified PD-1 antibody	Clinical Study - Cohort	Actionable	In a retrospective analysis, treatment with immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, or anti-CTLA with anti-PD-1) resulted in comparable overall response rate (16%, 7/44 vs 22%, 47/212, p=0.42) and overall survival (HR=0.917, p=0.69), but significantly reduced progression-free survival (wild-type vs L858R, HR=0.578, p=0.001) in non-small cell lung cancer patients harboring EGFR L858R compared to EGFR wild-type patients (PMID: 31086949).	31086949
EGFR	EGFR L858R	lung non-small cell carcinoma	sensitive	Vandetanib	Preclinical - Cell culture	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Egfr activation, resulting in growth inhibition of non-small cell lung cancer cells harboring EGFR L858R in culture (PMID: 19447865).	19447865
EGFR	EGFR L858R	Advanced Solid Tumor	sensitive	JBJ-04-125-02	Preclinical - Cell culture	Actionable	In a preclinical study, JBJ-04-125-02 inhibited cell proliferation in a transformed murine cell line expressing EGFR L858R in culture (PMID: 31092401).	31092401
EGFR	EGFR L858R EGFR T790M	lung non-squamous non-small cell carcinoma	sensitive	Osimertinib	Phase III	Actionable	In a Phase III trial, third-line treatment with Tagrisso (osimertinib) resulted in improved median progression-free survival compared to treatment with the combination of Taxotere (docetaxel) and Avastin (bevacizumab) (10.2 mo vs. 2.95 mo., HR=0.23), and a an overall response rate of 61.6% (45/73) compared to 8.3% (6/72), in patients with non-squamous non-small cell lung cancer harboring EGFR T790M with either EGFR L858R or an EGFR exon 19 deletion (PMID: 29858027, NCT02959749).	29858027
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	decreased response	Neratinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and T790M demonstrated decreased sensitivity to Nerlynx (neratinib) in culture (PMID: 17085664).	17085664
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	AV-412	Preclinical	Actionable	In a preclinical study, AV-412 inhibited EGFR signaling in a NSCLC cell line carrying the double EGFR mutant, L858R and T790M (PMID: 17888033).	17888033
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	predicted - resistant	Vandetanib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Caprelsa (vandetanib) did not inhibit Egfr activation and growth of non-small cell lung cancer cells harboring EGFR L858R and T790M in culture, but delayed the emergence of resistance in cell line xenograft models compared to EGFR tyrosine kinase inhibitors (PMID: 19447865).	19447865
EGFR	EGFR L858R EGFR T790M	lung cancer	decreased response	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Gilotrif (afatinib) in a lung cancer cell line harboring EGFR L858R and T790M in culture (PMID: 28145866).	28145866
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T790M in cis and trans were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR T790M	lung adenocarcinoma	sensitive	Osimertinib + Selumetinib	Preclinical	Actionable	In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib inhibited growth of lung adenocarcinoma tumors driven by EGFR L858R and EGFR T790M that had developed resistance through continued exposure to Tagrisso (osimertinib) (PMID: 25870145).	25870145
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring both EGFR L858R and EGFR T790M mutations in culture (PMID: 26090892).	26090892
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	predicted - sensitive	Ibrutinib + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Imbruvica (ibrutinib) and Mekinist (trametinib) combination treatment enhanced growth inhibition of non-small cell lung cancer cells harboring EGFR L858R and T790M compared to monotherapy in culture, but did not improve tumor suppression in cell line xenograft models (PMID: 26375053).	26375053
EGFR	EGFR L858R EGFR T790M	lung cancer	resistant	AZD3759	Preclinical - Cell culture	Actionable	In a preclinical study, a lung cancer cell line harboring EGFR L858R and T790M did not demonstrate sensitivity to AZD3759 in culture (PMID: 27928026).	27928026
EGFR	EGFR L858R EGFR T790M	lung adenocarcinoma	predicted - sensitive	Lazertinib	Case Reports/Case Series	Actionable	In a Phase I/II trial, Lazertinib (YH25448) treatment resulted in 51% tumor reduction after 6 weeks of treatment in a patient with non-small cell lung cancer harboring both EGFR L858R and EGFR T790M (PMID: 30670498).	30670498
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T790M in cis and trans demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Cetuximab + EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 and Erbitux (cetuximab) synergistically inhibited proliferation of transformed cells over expressing EGFR that harbors both L858R and T790M in culture (PMID: 27251290).	27251290
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Cetuximab + EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 and Erbitux (cetuximab) combination therapy inhibited cell proliferation in a transformed murine cell line expressing EGFR L858R and T790M in culture (PMID: 31092401).	31092401
EGFR	EGFR L858R EGFR T790M	lung adenocarcinoma	resistant	Afatinib + Cetuximab	Preclinical	Actionable	In a preclinical study, EGFR T790M was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).	26341921
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	JNJ-61186372 + Osimertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Tagrisso (osimertinib) and JNJ-61186372 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring EGFR L858R and EGFR T790M, and resulted in durable response following treatment cessation (PMID: 27216193).	27216193
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	TAS-121	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung cancer (NSCLC) patient harboring EGFR L858R and T790M that had failed prior EGFR tyrosine kinase inhibitor therapy demonstrated 49% tumor shrinkage following treatment with TAS-121, and in preclinical experiments, TAS-121 inhibited EGFR signaling and proliferation of a NSCLC cell line harboring EGFR L858R and T790M in culture and inhibited tumor growth and improved survival in xenograft models (PMID: 30872380).	30872380
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Trametinib + WZ4002	Preclinical	Actionable	In a preclinical study, treatment with the combination of WZ4002 and Mekinist (trametinib) resulted in tumor regression, and decreased tumor rebound and increased survival compared to WZ4002 alone in non-small cell lung cancer mouse models expressing EGFR L858R and EGFR T790M (PMID: 26036643).	26036643
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	OBX1-012	Preclinical - Cell line xenograft	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR L858R and EGFR T790M were sensitive to treatment with OBX1-012, demonstrating decreased cell viability and apoptosis in vitro and inhibition of tumor growth in cell line xenograft models (PMID: 29754184).	29754184
EGFR	EGFR L858R EGFR T790M	lung adenocarcinoma	resistant	Afatinib	Clinical Study - Cohort	Actionable	In a clinical study, acquired EGFR T790M mutations were detected in 47.6% (20/42) of lung adenocarcinoma patients with acquired resistance to Gilotrif (afatinib), with 10 of those patients harboring EGFR L858R as their primary EGFR mutation (PMID: 26862733).	26862733
EGFR	EGFR L858R EGFR T790M	lung adenocarcinoma	sensitive	Afatinib + Cetuximab + Sirolimus	Preclinical	Actionable	In a preclinical study, addition of Rapamune (sirolimus) to Gilotrif (afatinib) and Erbitux (cetuximab) combination treatment restored sensitivity in transgenic animal models of lung adenocarcinoma driven by EGFR L858R and T790M that acquired resistance to the combination treatment, resulted in tumor shrinkage (PMID: 24813888).	24813888
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Gedatolisib + Neratinib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) and Nerlynx (neratinib) in combination worked syngerstically to inhibit Akt phosphorylation in a human non-small cell lung cancer cell line harboring EGFR L858R and T790M in culture (PMID: 21325073).	21325073
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, non-small cell carcinoma cancer cell lines harboring EGFR L858R and T790M mutations demonstrated resistance to growth inhibition by Tykerb (lapatinib) in culture (PMID: 18199554).	18199554
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Abivertinib	Phase I	Actionable	In a Phase I trial, Abivertinib (AC0010) treatment resulted in an overall response rate of 36.5% (19/52) and a disease control rate of 75% (39/52) in non-small cell lung carcinoma patients harboring EGFR exon 19 deletions (33/52) or L858R (19/52) with acquired resistance to first generation Egfr tyrosine kinase inhibitors, 87% (45/52) of the patients also harbored EGFR T790M (PMID: 29626621).	29626621
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Abivertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, non-small cell lung cancer cells harboring the double mutation, EGFR L858R and EGFR T790M, demonstrated sensitivity to treatment with Abivertinib (AC0010), resulting in inhibition of both cell growth and Egfr phosphorylation in culture, and tumor regression in xenograft models (PMID: 27573423).	27573423
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring both EGFR L858R and EGFR T790M in culture (PMID: 29467275).	29467275
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring both EGFR L858R and EGFR T790M were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).	29467275
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R and EGFR T790M were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 30962319).	30962319
EGFR	EGFR L858R EGFR T790M	lung adenocarcinoma	resistant	Erlotinib	Preclinical	Actionable	In a preclinical study, EGFR T790M was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which occurred after repeated treatments with Tarceva (erlotinib) and resulted in drug resistance (PMID: 26341921).	26341921
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring both EGFR L858R and EGFR T790M in culture (PMID: 29467275).	29467275
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	conflicting	JBJ-04-125-02	Preclinical - Cell line xenograft	Actionable	In a preclinical study, JBJ-04-125-02 did not inhibit cell proliferation in non-small cell lung carcinoma (NSCLC) cell lines harboring EGFR L858R and variable relative allelic fractions (RAF) of EGFR T790M (3% and 45%), however, inhibited cell proliferation in a NSCLC cell line harboring EGFR L858R and high RAF of EGFR T790M (50%) in culture, and inhibited tumor growth and reduced tumor volume in a cell line xenograft model (PMID: 31092401).	31092401
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L858R and EGFR T790M in culture (PMID: 29467275).	29467275
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T790M in cis and trans were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 inhibited proliferation of transformed cells over expressing EGFR that harbors both L858R and T790M in culture, although at a concentration much higher than the biochemical IC50 of the compound (PMID: 27251290).	27251290
EGFR	EGFR L858R EGFR T790M	lung cancer	sensitive	Osimertinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).	28416483
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Cetuximab + JBJ-04-125-02	Preclinical - Cell culture	Actionable	In a preclinical study, JBJ-04-125-02 and Erbitux (cetuximab) combination treatment inhibited cell proliferation in a non-small cell lung carcinoma cell line harboring EGFR T790M and L858R in culture (PMID: 31092401).	31092401
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Rociletinib	Preclinical - Pdx	Actionable	In a preclinical study, Rociletinib (CO-1686) inhibited tumor growth in human non-small cell lung cancer cell line and patient-derived xenograft models of non-small cell lung cancer harboring both EGFR L858R and EGFR T790M (PMID: 24065731).	24065731
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Rociletinib	Phase Ib/II	Actionable	In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in an objective response rate of 53.3% (8/15) in non-small cell lung cancer patients harboring both EGFR L858R and EGFR T790M (PMID: 25923550).	25923550
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Erlotinib + Ganetespib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the addition of Ganetespib overcame resistance to Tarceva (erlotinib) in cell line xenograft models of non-small cell lung cancer harboring EGFR L858R and EGFR T790M (PMID: 25077897).	25077897
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Lazertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Lazertinib (YH25448) inhibited Egfr signaling and viability of patient-derived cells and a cell line of non-small cell lung cancer harboring both EGFR T790M and EGFR L858R in culture, resulted in tumor shrinkage and inhibition of intracranial tumor growth in cell line xenograft models (PMID: 30670498).	30670498
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	predicted - sensitive	Afatinib + Dasatinib	Phase I	Actionable	In a Phase I trial, the combination of Sprycel (dasatinib) and Gilotrif (afatinib) demonstrated manageable toxicity, reduced allele frequencies of EGFR T790M and EGFR activating mutations (exon 19 deletion and L858R) in ctDNA, but only resulted in stable disease as best response in 26% of non-small cell lung cancer patients acquired resistance to tyrosine kinase inhibitors (PMID: 30880334; NCT01999985).	30880334
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	decreased response	EKI-285	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and T790M demonstrated decreased sensitivity to EKI-285 (CL-387,785) in culture (PMID: 17085664).	17085664
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R and EGFR T790M treated with Tagrisso (osimertinib) demonstrated inhibition of cell growth in culture (PMID: 30962319).	30962319
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Osimertinib	Phase I	Actionable	In a Phase I trial, Tagrisso (osimertinib) treatment resulted in a response rate of 57% (24/42) in patients harboring both EGFR L858R and T790M mutations (PMID: 25923549; NCT01802632).	25923549
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, Tagrisso (osimertinib) obtained through a Phase I/II trial (AURA) resulted in a partial response and stable disease of brain metastases in a non-small cell lung cancer patient harboring EGFR L858R and a secondary resistance mutation, EGFR T790M, which occurred post Tarceva (erlotinib) therapy (PMID: 27435396; NCT01802632).	27435396
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	no benefit	EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 inhibited Egfr activation but not proliferation of non-small cell lung cancer cells harboring EGFR with both L858R and T790M mutations in culture (PMID: 27251290).	27251290
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	DZD9008	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, DZD9008 inhibited proliferation of tumor cells expressing EGFR L858R and T790M in culture, resulted in tumor growth inhibition and regression in cell line xenograft and patient-derived xenograft (PDX) models (AACR Annual Meeting 2019, Abstract 3081).	detail...
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	conflicting	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L858R and EGFR T790M in culture (PMID: 29467275).	29467275
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	conflicting	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T790M in cis and trans demonstrated resistance to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring EGFR L858R EGFR T790M in culture (PMID: 21325073, PMID: 19238632).	21325073 19238632
EGFR	EGFR L858R EGFR T790M	lung cancer	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited growth of a lung cancer cell line harboring EGFR L858R and EGFR T790M in culture (PMID: 29748209).	29748209
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing both EGFR L858R and EGFR T790M were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).	29467275
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T790M in cis and trans demonstrated resistance to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EGFR L858R and T790M in culture (PMID: 27780853).	27780853
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Cetuximab + JBJ-04-125-02	Preclinical - Cell culture	Actionable	In a preclinical study, JBJ-04-125-02 and Erbitux (cetuximab) combination treatment inhibited cell proliferation in a transformed murine cell line expressing EGFR L858R and T790M in culture (PMID: 31092401).	31092401
EGFR	EGFR L858R EGFR T790M	lung cancer	sensitive	Dasatinib + Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).	28416483
EGFR	EGFR L858R EGFR T790M	lung cancer	sensitive	Buparlisib + Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Buparlisib (BKM-120) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).	28416483
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L858R and EGFR T790M in culture (PMID: 29467275).	29467275
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Afatinib + Ganetespib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Ganetespib and Gilotrif (afatinib) demonstrated improved antitumor activity compared to either agent alone in cell line xenograft models of non-small cell lung cancer harboring EGFR L858R and EGFR T790M (PMID: 25077897).	25077897
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	predicted - sensitive	Osimertinib + Ramucirumab	Phase I	Actionable	In a Phase I trial, Cyramza (ramucirumab) and Tagrisso (osimertinib) combination treatment resulted in an objective response rate of 76% (19/25, 1 complete response, 18 partial response), and stable disease in 16% (4/25) of EGFR-mutant (exon 19 deletion or L858R) non-small cell lung cancer patients harboring EGFR T790M, who progressed on first-line EGFR TKI therapy (J Clin Oncol 36, 2018 (suppl; abstr 9053); NCT02789345).	detail...
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Ibrutinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Imbruvica (ibrutinib) inhibited Egfr activity and down stream signaling, resulting in cell cycle arrest in culture and delayed tumor progression in cell line xenograft models of non-small cell lung cancer harboring both EGFR L858R and T790M (PMID: 26375053).	26375053
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	decreased response	EAI045 + Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 and Tagrisso (osimertinib) combination treatment inhibited cell proliferation and induced apoptosis in a non-small cell lung carcinoma cell line harboring EGFR T790M and EGFR L858R in culture, however, with decreased response compared to cells treated with Tagrisso (osimertinib) (PMID: 31092401).	31092401
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	JBJ-04-125-02	Preclinical - Cell culture	Actionable	In a preclinical study, JBJ-04-125-02 inhibited cell proliferation in a transformed murine cell line expressing EGFR L858R and T790M in culture (PMID: 31092401).	31092401
EGFR	EGFR L858R EGFR T790M	lung adenocarcinoma	sensitive	Bevacizumab + Erlotinib	Phase II	Actionable	In a Phase II trial (BELIEF), Avastin (bevacizumab) and Tarceva (erlotinib) combination treatment resulted in a median progression-free survival of 16.0 months and a 12 month progression-free survival of 68% (25/37) in treatment-naive lung adenocarcinoma patients harboring activating EGFR mutations (exon 19 deletion or L858R) and EGFR T790M (PMID: 28408243; NCT01562028).	28408243
EGFR	EGFR L858R EGFR T790M	lung cancer	sensitive	Cetuximab + EAI045	Preclinical	Actionable	In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M-mutant-driven lung cancer mouse model (PMID: 27251290).	27251290
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	predicted - sensitive	SHR-A1307	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R and EGFR T790M treated with SHR-A1307 demonstrated inhibition of cell growth in culture (PMID: 30962319).	30962319
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	Nazartinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, EGF816 inhibited proliferation of non-small cell lung cancer (NSCLC) cells harboring both EGFR L858R and EGFR T790M in culture, and induced tumor regression in NSCLC patient derived xenograft (PDX) models harboring both EGFR L858R and EGFR T790M (PMID: 26825170).	26825170
EGFR	EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Lazertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lazertinib (YH25448) inhibited Egfr phosphorylation and viability of transformed cells expressing both EGFR L858R and EGFR T790M (PMID: 30670498).	30670498
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	sensitive	JBJ-04-125-02 + Osimertinib	Preclinical - Pdx	Actionable	In a preclinical study, JBJ-04-125-02 and Tagrisso (osimertinib) combination treatment inhibited cell proliferation and induced apoptosis in a non-small cell lung carcinoma cell line harboring EGFR T790M and L858R in culture, and induced tumor regression and reduced residual tumor size in cell line xenograft models, and reduced tumor volume in a Tarceva (erlotinib)-resistant patient-derived xenograft (PDX) model (PMID: 31092401).	31092401
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, Erbitux (cetuximab) did not inhibit cell proliferation in a non-small cell lung carcinoma cell line harboring EGFR T790M and L858R in culture (PMID: 31092401).	31092401
EGFR	EGFR L858R EGFR T790M	lung adenocarcinoma	sensitive	JNJ-61186372	Preclinical - Pdx	Actionable	In a preclinical study, JNJ-61186372 induced tumor regression in lung adenocaricnoma patient-derived xenograft (PDX) models harboring EGFR L858R and EGFR T790M, with response continuing up to 2 months post-treatment cessation (PMID: 27216193).	27216193
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	resistant	Gefitinib	Clinical Study	Actionable	In a clinical study, EGFR T790M mutations were associated with acquired resistance to Iressa (gefitinib) in non-small cell lung cancer patients harboring EGFR L858R (PMID: 22263058).	22263058
EGFR	EGFR L858R EGFR T790M	lung non-small cell carcinoma	resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case report, a non-small cell lung cancer patient that progressed on Iressa (gefitinib) was demonstrated to harbor EGFR L858R and a secondary EGFR T790M mutation (PMID: 15737014).	15737014
EGFR	EGFR D761Y EGFR L858R	Advanced Solid Tumor	decreased response	Neratinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and D761Y demonstrated decreased sensitivity to Nerlynx (neratinib) in culture (PMID: 17085664).	17085664
EGFR	EGFR D761Y EGFR L858R	Advanced Solid Tumor	decreased response	Gefitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR D761Y demonstrated decreased sensitivity to Iressa (gefitinib) in culture (PMID: 17085664).	17085664
EGFR	EGFR D761Y EGFR L858R	lung non-small cell carcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EGFR L858R-mutant non-small lung cancer that developed resistance to Iressa (gefitinib) was demonstrated to have acquired a secondary EGFR D761Y mutation (PMID: 17085664).	17085664
EGFR	EGFR D761Y EGFR L858R	Advanced Solid Tumor	sensitive	EKI-285	Preclinical	Actionable	In a preclinical study, EKI-285 (CL-387,785) inhibited growth of transformed cells expressing EGFR L858R and EGFR D716Y in culture (PMID: 17085664).	17085664
EGFR	EGFR L858R EGFR T854A	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T854A were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating decreased cell growth (PMID: 29702287).	29702287
EGFR	EGFR L858R EGFR T854A	Advanced Solid Tumor	predicted - resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T854A were mildly resistant to Iressa (gefitinib) in culture (PMID: 29702287).	29702287
EGFR	EGFR L858R EGFR T854A	Advanced Solid Tumor	decreased response	Erlotinib	Preclinical	Actionable	In a preclinical study, expression of EGFR T854A decreased sensitivity of transformed cells expressing EGFR L858R to Tarceva (erlotinib) in culture (PMID: 19010870).	19010870
EGFR	EGFR L858R EGFR T854A	lung adenocarcinoma	resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, EGFR T854A was identified as an acquired mutation conferring resistance to Iressa (gefitinib) in a patient with lung adenocarcinoma harboring EGFR L858R, which was supported by decreased response to Iressa (gefitinib) in cells expressing EGFR L858R and T854A in culture (PMID: 19010870).	19010870
EGFR	EGFR L858R EGFR T854A	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T854A were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating decreased cell growth (PMID: 29702287).	29702287
EGFR	EGFR L858R EGFR T854A	Advanced Solid Tumor	predicted - sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR T854A were moderately sensitive to Alunbrig (brigatinib) in culture, demonstrating reduced cell growth (PMID: 29702287).	29702287
EGFR	EGFR L858R EGFR L747S	lung adenocarcinoma	decreased response	Erlotinib	Case Reports/Case Series	Actionable	In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR L747S had an initial partial response to Tarceva (erlotinib), but was found to progress after 6 months (PMID: 18981003).	18981003
EGFR	EGFR L858R EGFR L747S	lung adenocarcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L858R that had developed Iressa (gefitinib) resistance after an initial response was demonstrated to have acquired an EGFR L747S mutation (PMID: 18981003).	18981003
EGFR	EGFR L858R EGFR C797S	Advanced Solid Tumor	resistant	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R with EGFR C797S demonstrated resistance to inhibition by Poziotinib (HM781-36B) in culture (PMID: 29686424).	29686424
EGFR	EGFR L858R EGFR C797S	Advanced Solid Tumor	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR C797S double mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).	25948633
EGFR	EGFR L858R EGFR C797S	Advanced Solid Tumor	decreased response	JBJ-04-125-02	Preclinical - Cell culture	Actionable	In a preclinical study, JBJ-04-125-02 inhibited cell proliferation in a transformed murine cell line expressing EGFR C797S and L858R in culture, however, with decreased response compared to cells treated with Iressa (gefitinib) (PMID: 31092401).	31092401
EGFR	EGFR L858R EGFR C797S	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR L858R/EGFR C797S double mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR L858R EGFR C797S	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR C797S demonstrated sensitivity to Tarceva (erlotinib) in culture (PMID: 27913578).	27913578
EGFR	EGFR L858R EGFR C797S	Advanced Solid Tumor	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR L858R/EGFR C797S double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).	25948633
EGFR	EGFR C797S EGFR L858R EGFR T790M	lung non-small cell carcinoma	predicted - sensitive	SHR-A1307	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR C797S, EGFR L858R and EGFR exon 19 deletion mutations in-cis demonstrated inhibition of cell growth in culture following treatment with SHR-A1307 (PMID: 30962319).	30962319
EGFR	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Nazartinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to EGFR L858R and T790M conferred resistance to Nazartinib (EGF816) in transformed cells in culture (PMID: 29285266)	29285266
EGFR	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	JBJ-04-125-02	Preclinical - Cell culture	Actionable	In a preclinical study, JBJ-04-125-02 inhibited cell proliferation in a transformed murine cell line expressing EGFR L858R, C797S and T790M in culture (PMID: 31092401).	31092401
EGFR	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, Erbitux (cetuximab) inhibited growth of transformed cells expressing a EGFR L858R/T790M/C797S triple mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR C797S EGFR L858R EGFR T790M	lung cancer	sensitive	Cetuximab + EAI045	Preclinical	Actionable	In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M/C797S-mutant-driven lung cancer mouse model (PMID: 27251290).	27251290
EGFR	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing a combination of EGFR C797S, EGFR L858R, and EGFR T790M were resistant to Naquotinib (ASP8273) in culture (PMID: 29467275).	29467275
EGFR	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Cetuximab + EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 and Erbitux (cetuximab) synergistically inhibited proliferation of transformed cells over expressing EGFR that harbors concomitant C797S, L858R and T790M mutations in culture (PMID: 27251290).	27251290
EGFR	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Cetuximab + EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment inhibited cell proliferation in a transformed murine cell line expressing EGFR L858R, C797S and T790M in culture (PMID: 31092401).	31092401
EGFR	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	predicted - resistant	OBX1-012	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T790M did not respond to treatment with OBX1-012 in culture (PMID: 29754184).	29754184
EGFR	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, expression of EGFR C797S on the same allele as both EGFR L858R and T790M in transformed cell lines resulted in resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25939061).	25939061
EGFR	EGFR C797S EGFR L858R EGFR T790M	lung cancer	sensitive	JBJ-04-125-02	Preclinical	Actionable	In a preclinical study, JBJ-04-125-02 induced tumor regression in a transgenic mouse model of lung cancer harboring EGFR L858R, T790M and C797S (PMID: 31092401).	31092401
EGFR	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to EGFR L858R and T790M conferred resistance to Tarceva (erlotinib) in transformed cells in culture (PMID: 29285266)	29285266
EGFR	EGFR C797S EGFR L858R EGFR T790M	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR C797S, EGFR L858R and EGFR exon 19 deletion mutations in-cis were resistant to Tagrisso (osimertinib) in culture (PMID: 30962319).	30962319
EGFR	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	predicted - resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR C797S in culture demonstrated resistance to treatment with Iressa (gefitinib) after 3 weeks of exposure, and subsequently, were found to have acquired EGFR T790M (PMID: 31377341).	31377341
EGFR	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to EGFR L858R and T790M conferred resistance to Gilotrif (afatinib) in transformed cells in culture (PMID: 29285266).	29285266
EGFR	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	Cetuximab + JBJ-04-125-02	Preclinical - Cell culture	Actionable	In a preclinical study, JBJ-04-125-02 and Erbitux (cetuximab) combination treatment inhibited cell proliferation in a transformed murine cell line expressing EGFR L858R, C797S and T790M in culture (PMID: 31092401).	31092401
EGFR	EGFR C797S EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, EGFR C797S conferred resistance to growth inhibition by Rociletinib (CO-1686) when expressed on the same allele as EGFR L858R and T790M in transformed cells in culture (PMID: 25939061).	25939061
EGFR	EGFR L858R EGFR T790M NRAS Q61K	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).	25870145
EGFR	EGFR L858R EGFR E884K	Advanced Solid Tumor	decreased response	Erlotinib	Preclinical	Actionable	In a preclinical study, cells expressing the double EGFR L858R/E844K mutation demonstrated decreased sensitivity to Tarceva (erlotinib) in culture compared to cells expressing EGFR L858R alone (PMID: 19015641).	19015641
EGFR	EGFR L858R EGFR E884K	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical	Actionable	In a preclinical study, cells expressing the double EGFR L858R/E884K mutation demonstrated increased sensitivity to inhibition by Iressa (gefitinib) compared to cells expressing EGFR L858R alone (PMID: 20942962).	20942962
EGFR	EGFR L858R EGFR E884K	Advanced Solid Tumor	sensitive	EKI-285	Preclinical	Actionable	In a preclinical study, cells expressing the double EGFR L858R/E884K mutation demonstrated increased sensitivity to inhibition of Egfr phosphorylation by EKI-285 compared to cells expressing EGFR L858R alone (PMID: 20942962).	20942962
EGFR	EGFR I941R EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing EGFR that harbors concomitant L858R, T790M and I941R mutations demonstrated increased sensitivity to EAI045 induced growth inhibition in culture (PMID: 27251290).	27251290
EGFR	EGFR I941R EGFR L858R EGFR T790M	Advanced Solid Tumor	sensitive	JBJ-04-125-02	Preclinical - Cell culture	Actionable	In a preclinical study, JBJ-04-125-02 02 inhibited Egfr activation in a transformed murine cell line expressing EGFR L858R and T790M in culture (PMID: 31092401).	31092401
EGFR	EGFR L858R EGFR T790M PIK3CA G118D	lung non-small cell carcinoma	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).	23629727
EGFR	EGFR L858R EGFR T790M PIK3CA G118D	lung non-small cell carcinoma	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).	23629727
EGFR	EGFR L858R EGFR T790M PIK3CA G118D	lung non-small cell carcinoma	sensitive	Pimasertib + Sorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited Mapk and Akt signaling, resulted in growth inhibition of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture and in cell line xenograft models (PMID: 23629727).	23629727
EGFR	EGFR L858R EGFR T790M PIK3CA G118D	lung non-small cell carcinoma	sensitive	BEZ235 + Pimasertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).	23629727
EGFR	EGFR L858R EGFR T790M PIK3CA G118D	lung non-small cell carcinoma	decreased response	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, T790M, and PIK3CA G118D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).	23629727
EGFR	EGFR L858R MET amp	lung non-small cell carcinoma	sensitive	Crizotinib + Rociletinib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in a patient-derived xenograft model of non-small cell lung cancer harboring EGFR L858R and MET amplification, resulting in tumor growth inhibition (PMID: 27283993).	27283993
EGFR	EGFR L858R MET amp	lung non-small cell carcinoma	predicted - sensitive	Crizotinib	Clinical Study - Cohort	Actionable	In a clinical study, Xalkori (crizotinib) alone (n=8) or in combination with EGFR TKIs (n=6) resulted in an objective response rate (ORR) of 50% (7/14, 7 partial response) and a disease control rate (DCR) of 85.7% (12/14) in patients with EGFR-mutant (L858R n=12, exon 19 deletion n=2) non-small cell lung cancer who acquired resistance to EGFR TKI through MET amplification, ORR and DCR were not significantly different between patients treated with or without EGFR TKI (PMID: 30791921).	30791921
EGFR	EGFR L858R MET amp	lung adenocarcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring EGFR L858R and MET amplification demonstrated primary resistance to second line treatment with Iressa (gefitinib) (PMID: 30797494).	30797494
EGFR	EGFR L858R MET amp	lung adenocarcinoma	predicted - sensitive	Crizotinib + Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring EGFR L858R and MET amplification and primary resistance to Iressa (gefitinib) demonstrated 73% reduction in the right lung lesion after 4 weeks and almost complete reduction by 8 weeks, and maintained progression-free survival for 16.8 months following treatment with the combination of Xalkori (crizotinib) and Iressa (gefitinib) (PMID: 30797494).	30797494
EGFR	EGFR L858R MET amp	lung non-small cell carcinoma	predicted - resistant	Erlotinib	Clinical Study - Cohort	Actionable	In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).	30791921
EGFR	EGFR L858R MET amp	lung non-small cell carcinoma	predicted - resistant	Gefitinib	Clinical Study - Cohort	Actionable	In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).	30791921
EGFR	EGFR L858R MET amp	lung non-small cell carcinoma	predicted - resistant	Icotinib	Clinical Study - Cohort	Actionable	In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).	30791921
EGFR	ALK amp EML4-ALK EGFR L858R	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung cancer patient harboring EML4-ALK had a partial response to Xalkori (crizotinib) therapy, but progressed after four months, and was found to have acquired ALK amplification and EGFR L858R (PMID: 23344087).	23344087
EGFR	EGFR L858R EGFR V765_M766delinsHH	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing both EGFR L858R and EGFR V765_M766delinsHH were resistant to Gilotrif (afatinib) in culture (PMID: 29467275).	29467275
EGFR	EGFR L858R EGFR V765_M766delinsHH	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing both EGFR L858R and EGFR V765_M766delinsHH were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).	29467275
EGFR	EGFR C797S EGFR L792H EGFR L858R	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L792H, and EGFR L858R were resistant to treatment with Alunbrig (brigatinib) in culture (PMID: 29702287).	29702287
EGFR	EGFR C797S EGFR L792H EGFR L858R	Advanced Solid Tumor	predicted - sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L792H, and EGFR L858R demonstrated some efficacy to treatment with Iressa (gefitinib) in culture (PMID: 29702287).	29702287
EGFR	EGFR C797S EGFR L792H EGFR L858R	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L792H, and EGFR L858R were resistant to treatment with Gilotrif (afatinib) in culture (PMID: 29702287).	29702287
EGFR	EGFR C797S EGFR L792H EGFR L858R	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L792H, and EGFR L858R were resistant to treatment with Tagrisso (osimertinib) in culture (PMID: 29702287).	29702287
EGFR	EGFR C797S EGFR L858R EGFR T854A	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T854A demonstrated resistance to treatment with Tagrisso (osimertinib) (PMID: 29702287).	29702287
EGFR	EGFR C797S EGFR L858R EGFR T854A	Advanced Solid Tumor	predicted - resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T854A demonstrated some resistance to Iressa (gefitinib) in culture (PMID: 29702287).	29702287
EGFR	EGFR C797S EGFR L858R EGFR T854A	Advanced Solid Tumor	predicted - resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T854A demonstrated some resistance to Gilotrif (afatinib) in culture (PMID: 29702287).	29702287
EGFR	EGFR C797S EGFR L858R EGFR T854A	Advanced Solid Tumor	predicted - resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR L858R, and EGFR T854A demonstrated some resistance to Alunbrig (brigatinib) in culture (PMID: 29702287).	29702287
EGFR	EGFR L858R EGFR T790M MET amp	lung adenocarcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M progressed after 19 months on Tagrisso (osimertinib), and was found to have acquired MET amplification (PMID: 29128427).	29128427
EGFR	EGFR L858R EGFR T790M MET amp	lung adenocarcinoma	predicted - sensitive	Crizotinib + Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient with EGFR L858R, EGFR T790M, and MET amplification demonstrated a partial response in her lung lesions and an approximately 90% reduction in the retroperitoneal lymph node and right adrenal gland, and progression-free survival lasting 3 months following treatment with the combination of Tagrisso (osimertinib) and Xalkori (crizotinib) (PMID: 29128427).	29128427
EGFR	EGFR L858R EGFR T790M MET amp MET D1228H D1228N D1231Y Y1230H	lung adenocarcinoma	unknown	Cabozantinib + Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M, MET amplification and MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y demonstrated initial symptomatic improvement, decreased pleural effusion, and lung nodule shrinkage following treatment with the combination of Cometriq (Cabometyx, cabozantinib) and Tagrisso (osimertinib) (PMID: 29128427).	29128427
EGFR	EGFR L858R EGFR T790M MET amp MET D1228H D1228N D1231Y Y1230H	lung adenocarcinoma	predicted - resistant	Crizotinib + Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M and MET amplification demonstrated progressive disease after 3 months of treatment with the combination of Tagrisso (osimertinib) and Xalkori (crizotinib) and was found to have acquired 4 MET mutations: MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y (PMID: 29128427).	29128427
EGFR	EGFR L858R EGFR T790M MET amp MET D1231Y	lung adenocarcinoma	predicted - resistant	Cabozantinib + Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R, EGFR T790M, MET amplification, MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y demonstrated initial symptomatic improvement and lung nodule shrinkage following treatment Cometriq (Cabometyx, cabozantinib) and Tagrisso (osimertinib) in combination, but progressed after 1 month and was found to have lost MET D1228H, MET D1228N, and MET Y1230H, and to have an increased allele fraction of MET D1231Y (PMID: 29128427).	29128427
EGFR	EGFR L858R FGFR3-TACC3	lung non-small cell carcinoma	predicted - resistant	Afatinib + Cetuximab	Case Reports/Case Series	Actionable	In a clinical study, FGFR3-TACC3 was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR L858R, whose disease progressed after initial response to Gilotrif (afatinib) and Erbitux (cetuximab) combination therapy (PMID: 29883838).	29883838
EGFR	EGFR L858R EML4-ALK	lung non-small cell carcinoma	predicted - resistant	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, EML4-ALK was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR L858R, whose disease progressed after initial response to Tarceva (erlotinib), followed by Gilotrif (afatinib) (PMID: 29883838).	29883838
EGFR	EGFR-FGFR1 EGFR L858R	lung non-small cell carcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical study, a patient with non-small cell lung cancer initially responded to Tarceva (erlotinib) followed by Tagrisso (osimertinib), EGFR L858R and EGFR-FGFR1 were identified in post-progression tumor samples (PMID: 29883838).	29883838
EGFR	EGFR L858R PTEN mut	lung adenocarcinoma	decreased response	Erlotinib	Clinical Study - Cohort	Actionable	In a clinical study, PTEN mutations were associated with a lower overall response rate of 7.3% in lung adenocarcinoma patients harboring EGFR exon 19 deletions or L858R, compared to 70.9% (p=0.061) in patients with wild-type PTEN, following treatment with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib)(PMID: 24468202).	24468202
EGFR	EGFR L858R PTEN mut	lung adenocarcinoma	decreased response	Gefitinib	Clinical Study - Cohort	Actionable	In a clinical study, PTEN mutations were associated with a lower overall response rate of 7.3% in lung adenocarcinoma patients harboring EGFR exon 19 deletions or L858R, compared to 70.9% (p=0.061) in patients with wild-type PTEN, following treatment with EGFR tyrosine kinase inhibitors including Iressa (gefitinib) (PMID: 24468202).	24468202
EGFR	EGFR T790M EGFR L858R EGFR L792H	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).	29857056
EGFR	EGFR T790M EGFR L858R EGFR L792H	Advanced Solid Tumor	resistant	Cetuximab + EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, combination of EAI045 and Erbitux (cetuximab) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).	29857056
EGFR	EGFR T790M EGFR L858R EGFR L792H	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).	29857056
EGFR	EGFR T790M EGFR L858R EGFR L792H	Advanced Solid Tumor	resistant	EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).	29857056
EGFR	EGFR T790M EGFR L858R EGFR L792H	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) did not inhibit Egfr phosphorylation and proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).	29857056
EGFR	EGFR T790M EGFR L858R EGFR L792H	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture (PMID: 29857056).	29857056
EGFR	EGFR T790M EGFR L858R EGFR L792H	Advanced Solid Tumor	predicted - sensitive	Cetuximab + Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination of Tagrisso (osimertinib) and Erbitux (cetuximab) improved growth inhibition of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792H in culture compared to Tagrisso (osimertinib) alone (PMID: 29857056).	29857056
EGFR	EGFR T790M EGFR L858R EGFR over exp	lung non-small cell carcinoma	decreased response	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of Egfr in non-small cell lung cancer cells harboring both EGFR T790M and L858R resulted in decreased sensitivity to Rociletinib (CO-1686) in culture (PMID: 27283993).	27283993
EGFR	EGFR T790M EGFR L858R ERBB2 over exp	lung non-small cell carcinoma	decreased response	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of Ebrr2 (Her2) in non-small cell lung cancer cells harboring both EGFR T790M and L858R resulted in decreased sensitivity to Rociletinib (CO-1686) in culture (PMID: 27283993).	27283993
EGFR	EGFR L858R EGFR V292L	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tarceva (erlotinib) resulted in decreased growth of transformed cells expressing EGFR L858R and EGFR V292L in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR V292L	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR L858R and EGFR V292L in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR V292L	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR V292L in cis were sensitive to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR V292L	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tagrisso (osimertinib) resulted in decreased growth of transformed cells expressing EGFR L858R and EGFR V292L in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR V292L	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Iressa (gefitinib) resulted in decreased growth of transformed cells expressing EGFR L858R and EGFR V292L in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR S306L	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tarceva (erlotinib) resulted in decreased growth of transformed cells expressing EGFR L858R and EGFR S306L in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR S306L	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR S306L in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR S306L	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Iressa (gefitinib) resulted in decreased growth of transformed cells expressing EGFR L858R and EGFR S306L in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR S306L	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR L858R and EGFR S306L in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR S306L	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tagrisso (osimertinib) resulted in decreased growth of transformed cells expressing EGFR L858R and EGFR S306L in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R NRAS mut	melanoma	predicted - resistant	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, two of two NRAS-mutant melanoma cell lines expressing EGFR L858R were resistant to treatment with Ibrance (palbociclib) in culture (PMID: 30819666).	30819666
EGFR	EGFR L858R NRAS mut	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, one of two NRAS-mutant melanoma cell lines expressing EGFR L858R demonstrated a decreased response to Mekinist (trametinib) when compared to control in culture (PMID: 30819666).	30819666
EGFR	EGFR L858R NRAS mut	melanoma	predicted - resistant	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, two of four NRAS-mutant melanoma cell lines expressing EGFR L858R were resistant to the combination treatment of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 30819666).	30819666
EGFR	EGFR T790M EGFR L858R EGFR A871G TP53 R248W RB1 K844S	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, Tarceva (erlotinib) treatment resulted in gradual tumor reduction and improved quality of life lasted for 1.5 years in a patient with metastatic non-small cell lung cancer harboring EGFR T790M, L858R, and A871G, TP53 R248W, and RB1 K844S (PMID: 31045832).	31045832
EGFR	EGFR L703I EGFR L858R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR L703I and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L703I EGFR L858R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tagrisso (osimertinib) resulted in decreased growth of transformed cells expressing EGFR L703I and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L703I EGFR L858R	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Iressa (gefitinib) resulted in decreased growth of transformed cells expressing EGFR L703I and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L703I EGFR L858R	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tarceva (erlotinib) resulted in decreased growth of transformed cells expressing EGFR L703I and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L703I EGFR L858R	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L703I and EGFR L858R in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR E709A EGFR L858R	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A and EGFR L858R in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR E709A EGFR L858R	Advanced Solid Tumor	conflicting	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A and EGFR L858R in trans were sensitive to treatment with Tagrisso (osimertinib), but when expressed in cis, demonstrated resistance in culture (PMID: 29141884).	29141884
EGFR	EGFR E709A EGFR L858R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR E709A and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR E709G EGFR L858R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR E709G and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR E709G EGFR L858R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tagrisso (osimertinib) resulted in decreased growth of transformed cells expressing EGFR E709G and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR E709G EGFR L858R	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709G and EGFR L858R in trans were resistant to Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR E709G EGFR L858R	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tarceva (erlotinib) resulted in decreased growth of transformed cells expressing EGFR E709G and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR E709K EGFR L858R	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tarceva (erlotinib) resulted in decreased growth of transformed cells expressing EGFR E709K and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR E709K EGFR L858R	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709K and EGFR L858R in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR E709K EGFR L858R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR E709K and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR E709K EGFR L858R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tagrisso (osimertinib) resulted in decreased growth of transformed cells expressing EGFR E709K and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR E709V EGFR L858R	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709V and EGFR L858R in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR E709V EGFR L858R	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Iressa (gefitinib) resulted in decreased growth of transformed cells expressing EGFR E709V and EGFR L858R in cis in culture (PMID: 29141884).	29141884
EGFR	EGFR E709V EGFR L858R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR E709V and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR E709V EGFR L858R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tagrisso (osimertinib) resulted in decreased growth of transformed cells expressing EGFR E709V and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR E709V EGFR L858R	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tarceva (erlotinib) resulted in decreased growth of transformed cells expressing EGFR E709V and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR V738F EGFR L858R	lung non-small cell carcinoma	predicted - sensitive	Gefitinib	Case Reports/Case Series	Actionable	In a clinical study, Iressa (gefitinib) treatment resulted in a partial response with a progression-free survival of 16 months in a patient with non-small cell lung cancer harboring both EGFR V738F and EGFR L858R (PMID: 31175009).	31175009
EGFR	EGFR L833_V834delinsFL EGFR L858R	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical study, Tarceva (erlotinib) treatment resulted in a partial response with an ongoing progression-free survival of 29 months in a patient with non-small cell lung cancer harboring both EGFR V834L and EGFR L858R (PMID: 31175009).	31175009
EGFR	EGFR V834L EGFR L858R	lung non-small cell carcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, Gilotrif (afatinib) treatment resulted in a partial response with a progression-free survival of 10 months in a patient with non-small cell lung cancer harboring both EGFR V834L and EGFR L858R (PMID: 31175009).	31175009
EGFR	EGFR L718V EGFR L858R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L718V and EGFR L858R were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29571986).	29571986
EGFR	EGFR L718V EGFR L858R	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L718V and EGFR L858R demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 29571986).	29571986
EGFR	EGFR L718V EGFR L858R	lung adenocarcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, EGFR L718V was identified as an acquired mutation at disease progression in a patient with lung adenocarcinoma harboring EGFR L858R who developed resistance to Tagrisso (osimertinib) (PMID: 31301016).	31301016
EGFR	EGFR L718V EGFR L858R	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L718V and EGFR L858R demonstrated resistance to treatment with Tarceva (erlotinib) in culture (PMID: 29571986).	29571986
EGFR	EGFR L718V EGFR L858R	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L718V and EGFR L858R demonstrated resistance to treatment with Tagrisso (osimertinib) in culture (PMID: 29571986).	29571986
EGFR	EGFR L718V EGFR L858R EGFR T790M	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L718V, EGFR L858R, and EGFR T790M demonstrated resistance to treatment with Tagrisso (osimertinib) in culture (PMID: 29571986).	29571986
EGFR	EGFR L858R EGFR S720F	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR S720F and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR S720F	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tarceva (erlotinib) resulted in decreased growth of transformed cells expressing EGFR S720F and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR S720F	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tagrisso (osimertinib) resulted in decreased growth of transformed cells expressing EGFR S720F and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR S720F	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR ES720F and EGFR L858R in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR S720F	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Iressa (gefitinib) resulted in decreased growth of transformed cells expressing EGFR S720F and EGFR L858R in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R MET pos	lung non-small cell carcinoma	unknown	Erlotinib + Onartuzumab	Phase II	Actionable	In a Phase II trial, patients with MET-positive non-small lung cancer harboring either EGFR L858R or an EGFR exon 19 deletion demonstrated a median progression-free survival of 8.9 mo., median overall survival of 15.6 mo., and an overall response rate of 68.9% (all partial responses) following first-line therapy with Tarceva (erlotinib) and Onartuzumab; however, the trial was terminated early due to lack of efficacy with the therapy in another trial and thus, the results are not conclusive (PMID: 30472556).	30472556
EGFR	EGFR L858R EGFR S768I	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR L858R and EGFR S768I in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR S768I	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tagrisso (osimertinib) resulted in decreased growth of transformed cells expressing EGFR L858R and EGFR S768I in cis in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR S768I	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR S768I in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR S768I	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tarceva (erlotinib) resulted in decreased growth of transformed cells expressing EGFR L858R and EGFR S768I in cis in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR R776G	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR R776G in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR R776G	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR R776G in cis and trans were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR R776G	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR R776G in cis and trans were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR R776G	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR R776G in cis and trans were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR R776G	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L858R and EGFR R776G in cis and trans were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR L838V EGFR L858R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L838V and EGFR L858R in cis and trans were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L838V EGFR L858R	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L838V and EGFR L858R in cis and trans were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L838V EGFR L858R	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L838V and EGFR L858R in cis were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L838V EGFR L858R	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L838V and EGFR L858R in cis were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L838V EGFR L858R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L838V and EGFR L858R in cis and trans were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR V843I	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR V843I in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR V843I	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR V843I in cis and trans were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR V843I	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR V843I in cis and trans were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR V843I	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR V843I in cis and trans were sensitive to treatment with Gilotrif (afatinib), demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L858R EGFR V843I	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR V843I in cis and trans were sensitive to treatment with Iressa (gefinitib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A871G EGFR L858R	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR A871G in cis and trans were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A871G EGFR L858R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR A871G in cis and trans were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A871G EGFR L858R	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR A871G in cis and trans were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A871G EGFR L858R	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR A871G and EGFR T790M in cis and trans demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 29141884).	29141884
EGFR	EGFR A871G EGFR L858R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR L858R and EGFR A871G in cis and trans were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR T790M EGFR L792H	lung adenocarcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a retrospective analysis, EGFR L792H was identified in 1.76% (6/340) of lung adenocarcinoma patients receiving Tagrisso (osimertinib), and 5 of the 6 patients also had EGFR T790M in cis, consistent with cell culture study and structural modeling that supports a role of EGFR L792H in cis with T790M in conferring resistance to Tagrisso (osimertinib) (PMID: 29857056).	29857056
EGFR	EGFR G779S	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G779S were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_T751del	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751del were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_T751del	Advanced Solid Tumor	sensitive	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751del were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_T751del	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751del were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_T751del	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751del were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L747_T751del	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751del were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_A750delinsIP	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_A750delinsIP were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_A750delinsIP	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_A750delinsIP were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR E746_A750delinsIP	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_A750delinsIP were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_A750delinsIP	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_A750delinsIP were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_A750delinsIP	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_A750delinsIP were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_A750delinsIP	Advanced Solid Tumor	sensitive	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_A750delinsIP were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_S752del EGFR T790M EGFR P794L	lung non-small cell carcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, Gilotrif (afatinib) treatment resulted in rapid clinical response in a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion (E746_S752del), EGFR T790M and EGFR P794L (PMID: 29704676).	29704676
EGFR	EGFR E746_S752del EGFR T790M EGFR P794L	lung non-small cell carcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, Tagrisso (osimertinib) treatment resulted in initial response in a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion (E746_S752del) and T790M, however, the disease progressed 20 months after treatment started, and EGFR P794L was identified by liquid biopsy at the time of progression (PMID: 29704676).	29704676
EGFR	EGFR C797S	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR C797S were sensitive to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR C797S	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR C797S were resistant to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR C797S	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR C797S were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR C797S	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR C797S were resistant to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR E746_A750del EGFR T790M EGFR C797S	lung non-small cell carcinoma	predicted - sensitive	TQB3804	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, TQB3804 inhibited Egfr downstream signaling, resulted in growth inhibition of non-small cell lung cancer cell lines harboring EGFR E746_A750del, T790M, and C797S triple mutations in culture and in cell line xenograft models, and inhibited tumor growth in a patient-derived xenograft (PDX) model (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1320).	detail...
EGFR	EGFR E746_A750del EGFR T790M EGFR C797S	Advanced Solid Tumor	no benefit	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, Erbitux (cetuximab) did not inhibit growth of transformed cells expressing a EGFR E746_A750del/T790M/C797S triple mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR T790M EGFR C797S	Advanced Solid Tumor	predicted - sensitive	TQB3804	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TQB3804 inhibited Egfr downstream signaling, resulted in growth inhibition of transformed cells expressing EGFR E746_A750del, T790M, and C797S triple mutations in culture and in cell line xenograft models (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1320).	detail...
EGFR	EGFR E746_A750del EGFR T790M EGFR C797S	Advanced Solid Tumor	resistant	JBJ-04-125-02	Preclinical - Cell culture	Actionable	In a preclinical study, JBJ-04-125-02 did not inhibit cell proliferation in a transformed murine cell line expressing EGFR E746_A750del, C797S and T790M in culture (PMID: 31092401).	31092401
EGFR	EGFR E746_A750del EGFR C797S	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR C797S double mutation in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR C797S	lung non-small cell carcinoma	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iressa (gefitinib) inhibited growth of a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR C797S	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S demonstrated resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR C797S	lung non-small cell carcinoma	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, a non-small cell lung cancer cell line harboring EGFR DelE746_A750 and expressing EGFR DelE746_A750/C797S demonstrated resistance to growth inhibition by Rociletinib (CO1686) in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR C797S	Advanced Solid Tumor	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, cells expressing an EGFR E746_A750del/EGFR C797S double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR C797S	lung non-small cell carcinoma	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR C797S	lung non-small cell carcinoma	resistant	WZ4002	Preclinical - Cell culture	Actionable	In a preclinical study, a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S demonstrated resistance to growth inhibition by WZ4002 in culture (PMID: 25948633).	25948633
EGFR	EGFR E746_A750del EGFR C797S	Advanced Solid Tumor	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR C797S double mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).	25948633
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	Advanced Solid Tumor	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling in culture (PMID: 25964297).	25964297
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	Advanced Solid Tumor	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, expression of EGFR C797S on the same allele as an EGFR exon 19 deletion and EGFR T790M in transformed cell lines resulted in resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25939061).	25939061
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	Advanced Solid Tumor	conflicting	Gefitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) treatment resulted in partial inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).	25964297
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	resistant	WZ4002	Preclinical	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture, regardless of the allelic context of EGFR T790M and EGFR C797S (PMID: 25964297).	25964297
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).	25964297
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	Advanced Solid Tumor	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, EGFR C797S conferred resistance to growth inhibition by Rociletinib (CO-1686) when expressed on the same allele as an EGFR exon 19 deletion mutation and T790M in transformed cells in culture (PMID: 25939061).	25939061
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	lung adenocarcinoma	predicted - resistant	Nazartinib	Case Reports/Case Series	Actionable	In a Phase I trial, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M demonstrated an initial partial response to treatment with Nazartinib (CO-1686), however, demonstrated progression in the liver followed by the thorax, and progression in the thorax was coincident with emergence of an EGFR C797S mutation (PMID: 30123863; NCT02108964).	30123863
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	conflicting	Gefitinib + WZ4002	Preclinical	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to the combination of Iressa (gefitinib) and WZ4002 when T790M and C797S were in cis, but were sensitive when EGFR T790M and EGFR C797S were in trans (PMID: 25964297).	25964297
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	Advanced Solid Tumor	conflicting	Gefitinib + WZ4002	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) and WZ4002 combination treatment resulted in complete inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).	25964297
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR C797S, EGFR T790M and EGFR exon 19 deletion mutations in-cis were resistant to Tagrisso (osimertinib) in culture (PMID: 30962319).	30962319
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	resistant	Osimertinib	Phase I	Actionable	In a Phase I clinical trial, 40% (6/15) of non-small cell lung cancer patients harboring an EGFR exon 19 deletion and EGFR T790M developed resistance to Tagrisso (osimertinib) due to acquired EGFR C797S mutations (PMID: 25939061).	25939061
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical study, acquired EGFR C797S mutations were identified in post-treatment samples of 6 non-small cell lung cancer patients harboring EGFR exon 19 deletions and EGFR T790M who progressed on Tagrisso (osimertinib) (PMID: 30228210).	30228210
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	lung adenocarcinoma	predicted - resistant	Olmutinib	Case Reports/Case Series	Actionable	In a clinical case study, EGFR C797S was identified as an acquired mutation in a patient with lung adenocarcinoma harboring EGFR exon 19 deletion and T790M at disease progression while on Olmutinib (HM61713) treatment (PMID: 26749488).	26749488
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	lung adenocarcinoma	resistant	WZ4002	Preclinical	Actionable	In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).	25964297
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR C797S, EGFR T790M and EGFR exon 19 deletion mutations in-cis demonstrated inhibition of cell growth in culture following treatment with Tarceva (erlotinib) (PMID: 30962319).	30962319
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	Advanced Solid Tumor	conflicting	WZ4002	Preclinical	Actionable	In a preclinical study, WZ4002 treatment resulted in partial inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).	25964297
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	sensitive	SHR-A1307	Preclinical - Cell line xenograft	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR C797S, EGFR T790M and EGFR exon 19 deletion mutations in-cis demonstrated inhibition of cell growth in culture, and reduction of tumor volume and remission in xenograft models following treatment with SHR-A1307 (PMID: 30962319).	30962319
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture, regardless of the allelic context of EGFR T790M and EGFR C797S (PMID: 25964297).	25964297
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	lung adenocarcinoma	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).	25964297
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	lung adenocarcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).	25964297
EGFR	EGFR C797S EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	resistant	Lazertinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Lazertinib (YH25448) did not inhibit viability of patient-derived non-small cell lung cancer cells harboring EGFR C797S, EGFR exon 19 deletion, and EGFR T790M (PMID: 30670498).	30670498
EGFR	EGFR C797S EGFR exon 19 del	Advanced Solid Tumor	resistant	WZ4002	Preclinical	Actionable	In a preclinical study, transformed human cells harboring EGFR exon 19 deletion and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling in culture (PMID: 25964297).	25964297
EGFR	EGFR C797S EGFR exon 19 del	Advanced Solid Tumor	resistant	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing an EGFR exon 19 deletion with EGFR C797S demonstrated resistance to inhibition by Poziotinib (HM781-36B) in culture (PMID: 29686424).	29686424
EGFR	EGFR C797S EGFR exon 19 del	lung adenocarcinoma	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling and cell growth in lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).	25964297
EGFR	EGFR C797S EGFR exon 19 del	lung adenocarcinoma	sensitive	Gefitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling and cell growth in lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).	25964297
EGFR	EGFR C797S EGFR exon 19 del	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).	25964297
EGFR	EGFR C797S EGFR exon 19 del	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).	25964297
EGFR	EGFR C797S EGFR exon 19 del	lung adenocarcinoma	resistant	WZ4002	Preclinical	Actionable	In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).	25964297
EGFR	EGFR D770delinsGY EGFR C797S	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing an EGFR D770delinsGY/EGFR C797S double mutation demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).	28363995
EGFR	EGFR D770delinsGY EGFR C797S	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing an EGFR D770delinsGY and EGFR C797S double mutation demonstrated resistance to Vizimpro (dacomitinib) in culture (PMID: 28363995).	28363995
EGFR	EGFR C797S EGFR L747_P753delinsS EGFR T790M	Advanced Solid Tumor	resistant	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing a combination of EGFR C797S, EGFR L747_P753delinsS, and EGFR T790M were resistant to Naquotinib (ASP8273) in culture (PMID: 29467275).	29467275
EGFR	EGFR C797S EGFR L747_P753delinsS EGFR T790M	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to EGFR L747_P753delinsS and T790M conferred resistance to Gilotrif (afatinib) in transformed cells in culture (PMID: 29285266).	29285266
EGFR	EGFR C797S EGFR L747_P753delinsS EGFR T790M	Advanced Solid Tumor	resistant	Nazartinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to EGFR L747_P753delinsS and T790M conferred resistance to Nazartinib (EGF816) in transformed cells in culture (PMID: 29285266).	29285266
EGFR	EGFR C797S EGFR L747_P753delinsS EGFR T790M	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to EGFR L747_P753delinsS and T790M conferred resistance to Tagrisso (osimertinib) in transformed cells in culture (PMID: 29285266).	29285266
EGFR	EGFR C797S EGFR L747_P753delinsS EGFR T790M	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of EGFR C797S in addition to EGFR L747_P753delinsS and T790M conferred resistance to Tarceva (erlotinib) in transformed cells in culture (PMID: 29285266).	29285266
EGFR	EGFR C797S EGFR exon 19 del EGFR T854A	Advanced Solid Tumor	decreased response	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon 19 del, and EGFR T854A demonstrated a decreased response to Gilotrif (afatinib) in culture when compared to Alunbrig (brigatinib) (PMID: 29702287).	29702287
EGFR	EGFR C797S EGFR exon 19 del EGFR T854A	Advanced Solid Tumor	decreased response	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon 19 del, and EGFR T854A demonstrated a decreased response to Iressa (gefitinib) in culture when compared to Alunbrig (brigatinib) (PMID: 29702287).	29702287
EGFR	EGFR C797S EGFR exon 19 del EGFR T854A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon19 del, and EGFR T854A were sensitive to treatment with Alunbrig (brigatinib) in culture, demonstrating reduced cell growth (PMID: 29702287).	29702287
EGFR	EGFR C797S EGFR exon 19 del EGFR T854A	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon 19 del, and EGFR T854A were resistant to treatment with Tagrisso (osimertinib) (PMID: 29702287).	29702287
EGFR	EGFR C797S EGFR T790M	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR C797S and EGFR T790M in cis were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR C797S EGFR T790M	Advanced Solid Tumor	sensitive	OBX1-012	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR C797S and EGFR T790M were sensitive to treatment with OBX1-012 in culture, demonstrating decreased cell viability (PMID: 29754184).	29754184
EGFR	EGFR C797S EGFR T790M	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR C797S and EGFR T790M in cis were resistant to Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR C797S EGFR T790M	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR C797S and EGFR T790M in cis were resistant to Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR C797S EGFR T790M	lung non-small cell carcinoma	predicted - resistant	Abivertinib	Phase I	Actionable	In a Phase I trial, tertiary EGFR mutations including C797S (n=3) and L718V (n=1) were identified as a potential acquired resistance mechanism in 13% (4/30) of patients with non-small cell lung cancer harboring EGFR T790M whose disease progressed while on Abivertinib (AC0010) treatment (PMID: 31027916; NCT02330367).	31027916
EGFR	EGFR C797S EGFR T790M	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR C797S and EGFR T790M in cis were resistant to Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR C797S EGFR T790M	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR C797S and EGFR T790M in cis were resistant to Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR C797S EGFR E746_T751delinsV	lung non-small cell carcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung cancer harboring EGFR E746_T751delinsV developed resistance after 10 months of treatment, demonstrating systemic progression, and via cell-free DNA testing, was subsequently found to have acquired EGFR C797S (PMID: 31377341).	31377341
EGFR	EGFR C797S EGFR E746_T751delinsV EGFR T790M	lung non-small cell carcinoma	predicted - resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a clinical case study, a patient with non-small cell lung cancer co-harboring EGFR C797S and EGFR E746_T751delinsV treated with Tarceva (erlotinib) demonstrated disease control for four months, but at five months developed progression, and cell-free DNA testing one month before progression revealed acquisition of EGFR T790M (PMID: 31377341).	31377341
EGFR	EGFR T751_I759delinsN	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR T751_I759delinsN	Advanced Solid Tumor	sensitive	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR T751_I759delinsN	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR T751_I759delinsN	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR T751_I759delinsN	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR T751_I759delinsN	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T751_I759delinsN were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	no benefit	Brigatinib	Guideline	Actionable	Alunbrig (brigatinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).	detail...
EGFR	EGFR exon 19 del	lung cancer	sensitive	Dasatinib + Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 28416483).	28416483
EGFR	EGFR exon 19 del	Advanced Solid Tumor	sensitive	DZD9008	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, DZD9008 inhibited proliferation of tumor cells expressing EGFR exon 19 deletion mutation in culture, resulted in tumor growth inhibition and regression in cell line xenograft and patient-derived xenograft (PDX) models (AACR Annual Meeting 2019, Abstract 3081).	detail...
EGFR	EGFR exon 19 del	lung non-squamous non-small cell carcinoma	sensitive	Gefitinib	Guideline	Actionable	Iressa (gefitinib) is included in guidelines as first-line therapy for advanced, recurrent, or metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).	detail...
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	predicted - sensitive	Cabozantinib + Erlotinib	Phase II	Actionable	In a Phase II trial (NCI 9303), Cometriq (cabozantinib) and Tarceva (erlotinib) combination treatment resulted in an objective response rate of 10.8% (4/37, 4 partial response) and an 8-week disease control rate of 67.0% (25/37) in heavily pretreated non-small cell lung cancer patients harboring EGFR mutations, progression-free survival and overall survival were not different among patients harboring EGFR L858R, exon 19 deletion, or T790M (PMID: 30915273; NCT01866410).	30915273
EGFR	EGFR exon 19 del	lung adenocarcinoma	sensitive	Bevacizumab + Erlotinib	Phase II	Actionable	In a Phase II trial (BELIEF), Avastin (bevacizumab) and Tarceva (erlotinib) combination treatment resulted in a median progression-free survival of 13.2 months and a 12 month progression-free survival of 55% (60/109) in treatment-naive lung adenocarcinoma patients harboring activating EGFR mutations (exon 19 deletion or L858R) (PMID: 28408243; NCT01562028).	28408243
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Osimertinib	Phase III	Actionable	In a Phase III (FLAURA) trial, treatment with Tagrisso (osimertinib) resulted in a longer median time to discontinuation of treatment (23.0 vs 16.0 months) and second progression-free survival (not reached vs 20.0 months, HR=0.58, p=0.0004) compared to treatment with either Tarceva (erlotinib) or Iressa (gefitinib) in non-small cell lung carcinoma patients harboring either EGFR L858R or EGFR exon 19 deletion (PMID: 30659024; NCT02296125).	30659024
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Osimertinib	Guideline	Actionable	Tagrisso (osimertinib) is included in guidelines as first-line therapy for locally advanced or metastatic non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).	detail...
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Osimertinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III (FLAURA) trial that supported FDA approval, treatment with Tagrisso (osimertinib) resulted in a longer median progression-free survival compared to treatment with either Tarceva (erlotinib) or Iressa (gefitinib) (18.9 mo vs 10.2 mo) in non-small cell lung carcinoma patients harboring either EGFR L858R or EGFR exon 19 deletion (PMID: 29151359; NCT02296125).	29151359 detail... detail...
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Osimertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a human NSCLC cell line xenograft model with brain metastases harboring an EGFR exon 19 deletion demonstrated tumor regression and improved survival benefit when treated with Tagrisso (osimertinib) (PMID: 27435396).	27435396
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Osimertinib	Phase I	Actionable	In a Phase I trial, non-small cell lung cancer patients harboring EGFR exon 19 deletions demonstrated a response rate of 30% (8/27) following treatment with Tagrisso (osimertinib) (PMID: 25923549; NCT01802632).	25923549
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring an EGFR exon 19 deletion treated with Tagrisso (osimertinib) demonstrated inhibition of cell growth in culture (PMID: 30962319).	30962319
EGFR	EGFR exon 19 del	lung cancer	sensitive	Osimertinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in a lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 28416483).	28416483
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Ibrutinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Imbruvica (ibrutinib) inhibited Egfr activity and downstream signaling, resulting in cell cycle arrest in culture and delayed tumor progression in cell line xenograft models of non-small cell lung cancer harboring EGFR exon 19 deletions (PMID: 26375053).	26375053
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	predicted - sensitive	Nimotuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring an EGFR exon 19 deletion treated with Nimotuzumab demonstrated inhibition of cell growth in culture (PMID: 30962319).	30962319
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring an EGFR exon 19 deletion treated with Tarceva (erlotinib) demonstrated inhibition of cell growth in culture (PMID: 30962319).	30962319
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Erlotinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (EURTAC) that supported FDA approval, treatment with Tarceva (erlotinib) resulted in improved progression-free survival compared to treatment with platinum-based chemotherapy in non-small cell lung cancer patients harboring EGFR exon 19 deletions (HR= 0.27) (PMID: 24868098).	24868098 detail... detail...
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Erlotinib	Phase II	Actionable	In a Phase II clinical trial, treatment with Tarceva (erlotinib) resulted in a median progression-free survival (PFS) of 10.8 months for the intent-to-treat population of non-small cell lung cancer patients with EGFR mutations, with a PFS of 11.0 months for patients harboring EGFR exon 19 deletions (PMID: 26720423).	26720423
EGFR	EGFR exon 19 del	lung cancer	sensitive	AZD3759	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD3759 inhibited EGFR activation and growth of a lung cancer cell line harboring an EGFR exon 19 deletion in culture and induced tumor regression in subcutaneous xenograft models, and inhibited tumor growth in brain and leptomeningeal xenograft models (PMID: 27928026).	27928026
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	predicted - sensitive	TUL-001	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TUL-001 inhibited Egfr downstream signaling, resulted in tumor growth inhibition and prolonged overall survival in cell line xenograft models of non-small cell lung cancer brain metastasis harboring EGFR exon 19 deletion mutations (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1316).	detail...
EGFR	EGFR exon 19 del	Advanced Solid Tumor	sensitive	BGB-283	Preclinical - Cell culture	Actionable	In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing EGFR exon 19 deletion mutation in culture (PMID: 26208524).	26208524
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	decreased response	unspecified CTLA4 antibody + unspecified PD-1 antibody	Clinical Study - Cohort	Actionable	In a retrospective analysis, treatment with immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, or anti-CTLA with anti-PD-1) resulted in significantly reduced overall response rate (7%, 5/76 vs 22%, 47/212, p=0.002), progression-free survival (wild-type vs exon 19 deletion, HR=0.449, p<0.001), and overall survival (HR=0.69, p=0.03) in non-small cell lung cancer patients harboring EGFR exon 19 deletions compared to EGFR wild-type patients (PMID: 31086949).	31086949
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	TAE226	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAE226 treatment inhibited cell proliferation and decreased xenograft tumor size of non-small cell lung carcinoma cell lines harboring EGFR Exon 19 deletion mutation (PMID: 26090892).	26090892
EGFR	EGFR exon 19 del	spindle cell carcinoma	no benefit	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, a single patient diagnosed with lung spindle cell carcinoma harboring an EGFR exon 19 deletion was treated with Iressa (gefitinib), but no benefit was observed and therapy was discontinued after 14 days (PMID: 30555702).	30555702
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Nazartinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, EGF816 inhibited proliferation of non-small cell lung cancer (NSCLC) cells harboring an exon 19 deletion in culture, and induced tumor regression in NSCLC patient derived xenograft (PDX) models harboring an exon 19 deletion (PMID: 26825170).	26825170
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	JNJ-61186372	Preclinical - Cell line xenograft	Actionable	In a preclinical study, JNJ-61186372 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion, with increased efficacy following treatment cessation compared to Tarceva (erlotinib) (PMID: 27216193).	27216193
EGFR	EGFR exon 19 del	lung adenocarcinoma	sensitive	JNJ-61186372	Preclinical - Pdx	Actionable	In a preclinical study, JNJ-61186372 induced tumor regression in lung adenocaricnoma patient-derived xenograft (PDX) models harboring an EGFR exon 19 deletion, with continued response following treatment cessation (PMID: 27216193).	27216193
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	no benefit	Ceritinib	Guideline	Actionable	Zykadia (ceritinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).	detail...
EGFR	EGFR exon 19 del	Advanced Solid Tumor	sensitive	Lazertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lazertinib (YH25448) inhibited Egfr phosphorylation and viability of transformed cells expressing an EGFR exon 19 deletion mutation (PMID: 30670498).	30670498
EGFR	EGFR exon 19 del	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited growth of transformed cells expressing EGFR exon 19 deletion in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1329).	detail...
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Icotinib	Clinical Study - Cohort	Actionable	In a clinical study, EGFR tyrosine kinase inhibitor treatment including Conmana (Icotinib) (n=5) resulted in partial response in 77.8% (14/18) and stable disease in 22.2% (4/18) of non-small cell lung cancer patients harboring EGFR L858R (n=16) or exon 19 deletion mutations (n=2), with a median progression-free survival of 10.5 months (PMID: 30791921).	30791921
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Icotinib	Clinical Study - Meta-analysis	Actionable	In a meta-analysis, 12 Phase III trials investigating EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer patients with EFGR mutations (primarily exon 19 deletions or L858R) indicated TKIs, including icotinib, were superior to standard chemotherapy (PMID: 24533047).	24533047
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Gefitinib + K-756	Preclinical	Actionable	In a preclinical study, the combination of K-756 and Iressa (gefitinib) worked synergistically to inhibit growth of non-small cell lung cancer cells with wild-type EGFR or EGFR exon 19 deletion in culture (PMID: 27196752).	27196752
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Vandetanib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Egfr activation, resulting in growth inhibition of non-small cell lung cancer cells harboring EGFR exon 19 deletions in culture and in cell line xenograft models (PMID: 19447865).	19447865
EGFR	EGFR exon 19 del	lung adenocarcinoma	sensitive	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR exon 19 deletion demonstrated a partial response when treated with Tagrisso (osimertinib), which lasted for nearly 16 months (PMID: 29596911).	29596911
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Afatinib	Phase II	Actionable	In a Phase II trial, Gilotrif (afatinib) treatment resulted in improved progression-free survival (11.0 vs 10.9 months) and time-to-treatment failure (13.7 vs 11.5 months) compared to Iressa (gefitinib) in treatment-naive non-small cell lung carcinoma patients harboring EGFR exon 19 deletion or L858R (PMID: 27083334).	27083334
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Afatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial supporting FDA approval (LUX-Lung 3), Gilotrif (afatinib) treatment resulted in improved median progression-free survival compared to chemotherapy (HR=0.28) in non-small cell lung carcinoma patients harboring EGFR exon 19 deletions (PMID: 23816960; NCT00949650).	detail... detail... 23816960
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	predicted - sensitive	Panitumumab	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring an EGFR exon 19 deletion treated with Vectibix (panitumumab) demonstrated inhibition of cell growth in culture (PMID: 30962319).	30962319
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	TAS-121	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung cancer (NSCLC) patient harboring an EGFR exon 19 deletion demonstrated 82% tumor shrinkage following treatment with TAS-121, and in preclinical experiments, TAS-121 inhibited proliferation of a NSCLC cell line harboring an EGFR exon 19 deletion in culture and inhibited tumor growth in xenograft models (PMID: 30872380).	30872380
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Lazertinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Lazertinib (YH25448) inhibited Egfr signaling and viability of patient-derived cells and a cell line of non-small cell lung cancer harboring an EGFR exon 19 deletion mutation, resulted in tumor regression in patient-derived xenograft models (PMID: 30670498).	30670498
EGFR	EGFR exon 19 del	lung non-squamous non-small cell carcinoma	sensitive	Afatinib	Guideline	Actionable	Gilotrif (afatinib) is included in guidelines as first-line, but not subsequent therapy for metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).	detail...
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Gefitinib + Pemetrexed	Phase II	Actionable	In a Phase II trial, Iressa (gefitinib) and Alimta (pemetrexed) combination treatment resulted in a median progression-free survival (PFS) of 6.7 months, an objective response rate of 22.9% (8/35), and an overall survival of 24.3 months in non-small cell lung cancer patients harboring sensitizing EGFR mutations (15 exon 19 deletion, 20 L858R) who progressed on first-line Iressa (gefitinib) treatment, with no difference in PFS between exon 19 deletion and L858R groups (5.6 vs 7.0 months) (PMID: 30268482).	30268482
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	decreased response	unspecified PD-1 antibody	Clinical Study - Cohort	Actionable	In a retrospective analysis, treatment with immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, or anti-CTLA with anti-PD-1) resulted in significantly reduced overall response rate (7%, 5/76 vs 22%, 47/212, p=0.002), progression-free survival (wild-type vs exon 19 deletion, HR=0.449, p<0.001), and overall survival (HR=0.69, p=0.03) in non-small cell lung cancer patients harboring EGFR exon 19 deletions compared to EGFR wild-type patients (PMID: 31086949).	31086949
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	TH-4000	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TH-4000 induced tumor regression in erlotinib-resistant human cell line xenograft models of non-small cell lung cancer harboring EGFR exon 19 deletion mutations (J Clin Oncol 33, 2015 (suppl; abstr e13548)).	detail...
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Gefitinib	Clinical Study - Cohort	Actionable	In a clinical study, a comparison of the clinical outcomes of non-small cell lung cancer patients harboring either EGFR exon 19 deletion or L858R demonstrated similar responses to treatment with Iressa (gefitinib) or Tarceva (erlotinib), with overall response rates of 76.9% with Iressa (gefitinib) and 74.4% with Tarceva (erlotinib) (PMID: 24736073).	24736073
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Gefitinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial that supported FDA approval, Iressa (gefitinib) treatment resulted in an objective response rate of 71.2% (94/132) compared to 47.3% (61/129) with Paraplatin (carboplatin) plus Taxol (paclitaxel) and prolonged progression-free survival (HR=0.48) in non-small cell lung cancer patients harboring EGFR activating mutations, including EGFR exon 19 deletions (PMID: 19692680, NCT00322452).	detail... detail... 19692680
EGFR	EGFR exon 19 del	lung adenocarcinoma	sensitive	Gefitinib + Golvatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, addition of Golvatinib (E7050) overcame Hgf-induced Iressa (gefitinib)-resistance in lung adenocarcinoma cell lines harboring EGFR exon 19 deletions in culture and in cell line xenograft models (PMID: 22789825).	22789825
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	predicted - sensitive	Erlotinib + GLPG0634	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion in culture that had, over time, acquired resistance to Tarceva (erlotinib) showed decreased drug resistance when treatment was combined with Filgotinib (GLPG0634), demonstrating reduced expression of Osmr and phosphorylated-Stat3, and decreased cell viability (PMID: 28729401).	28729401
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	SHR-A1307	Preclinical - Cell line xenograft	Actionable	In a preclinical study, non-small cell lung cancer cells harboring an EGFR exon 19 deletion treated with SHR-A1307 demonstrated inhibition of cell growth in culture, and reduction of tumor volume and remission in xenograft models (PMID: 30962319).	30962319
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Dacomitinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (ARCHER 1050) that supported FDA approval, treatment with Vizimpro (dacomitinib) as first-line therapy in patients with non-small cell lung cancer harboring an EGFR exon 19 deletion or EGFR L858R resulted in an improved median progression-free survival (mPFS) of 14.7 months compared to 9.2 months with Iressa (gefitinib), with a mPFS of 12.3 months with dacomitnib vs. 9.8 months with Iressa (gefitinib) among patients with EGFR exon 19 deletions (PMID: 28958502; NCT01777421).	detail... 28958502 detail...
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Dacomitinib	Guideline	Actionable	Vizimpro (dacomitinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as EGFR exon 19 deletions (NCCN.org).	detail...
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	Dacomitinib	Phase II	Actionable	In a Phase II clinical trial, 74% (34/46) of patients with EGFR exon 19 or 21 mutant lung cancers had partial response (PFS average= 17 months) to first line treatment with Vizimpro (dacomitinib) (J Clin Oncol 30, 2012 (suppl; abstr 7530); NCT00818441).	detail...
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	sensitive	OBX1-012	Preclinical - Cell line xenograft	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 del were sensitive to treatment with OBX1-012, demonstrating decreased cell viability and apoptosis in vitro and inhibition of tumor growth in cell line xenograft models (PMID: 29754184).	29754184
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	decreased response	unspecified PD-L1 antibody	Clinical Study - Cohort	Actionable	In a retrospective analysis, treatment with immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, or anti-CTLA with anti-PD-1) resulted in significantly reduced overall response rate (7%, 5/76 vs 22%, 47/212, p=0.002), progression-free survival (wild-type vs exon 19 deletion, HR=0.449, p<0.001), and overall survival (HR=0.69, p=0.03) in non-small cell lung cancer patients harboring EGFR exon 19 deletions compared to EGFR wild-type patients (PMID: 31086949).	31086949
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	no benefit	Alectinib	Guideline	Actionable	Alecensa (alectinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).	detail...
EGFR	EGFR exon 19 del	lung non-small cell carcinoma	no benefit	Rociletinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Rociletinib (CO-1686) did not result in tumor regression or a survival benefit when treating a NSCLC cell line xenograft model harboring an EGFR exon 19 deletion (PMID: 27435396).	27435396
EGFR	EGFR exon 19 del	lung non-squamous non-small cell carcinoma	sensitive	Erlotinib	Guideline	Actionable	Tarceva (erlotinib) is included in guidelines as first-line therapy for advanced, recurrent, or metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).	detail...
EGFR	EGFR exon 19 del NRAS E63K	lung non-small cell carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K in culture (PMID: 25870145).	25870145
EGFR	EGFR exon 19 del NRAS E63K	lung non-small cell carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of NRAS E63K in culture (PMID: 25870145).	25870145
EGFR	EGFR exon 19 del NRAS E63K	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K were resistant to Tagrisso (osimertinib) AZD9291 treatment in culture (PMID: 25870145).	25870145
EGFR	EGFR exon 19 del NRAS amp	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).	25870145
EGFR	EGFR exon 19 del NRAS amp	lung non-small cell carcinoma	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified NRAS in culture (PMID: 25870145).	25870145
EGFR	EGFR exon 19 del NRAS amp	lung non-small cell carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS in culture (PMID: 25870145).	25870145
EGFR	EGFR exon 19 del NRAS Q61K	lung non-small cell carcinoma	resistant	WZ4002	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to WZ4002 after the emergence of NRAS Q61K in culture (PMID: 25870145).	25870145
EGFR	EGFR exon 19 del NRAS Q61K	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).	25870145
EGFR	EGFR exon 19 del NRAS Q61K	lung non-small cell carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K in culture (PMID: 25870145).	25870145
EGFR	EGFR exon 19 del NRAS G12V	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12V were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).	25870145
EGFR	EGFR exon 19 del NRAS G12R	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).	25870145
EGFR	EGFR exon 19 del NRAS G12R	lung non-small cell carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R in culture (PMID: 25870145).	25870145
EGFR	EGFR exon 19 del EGFR T790M NRAS Q61K	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).	25870145
EGFR	EGFR exon 19 del EGFR T790M MET amp	lung adenocarcinoma	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M and resistance to Tagrisso (osimertinib) following acquired MET amplification, demonstrated some improvement in symptoms with Xalkori (crizotinib) treatment (PMID: 27393507).	27393507
EGFR	EGFR exon 19 del EGFR T790M MET amp	lung adenocarcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M developed resistance to Tagrisso (osimertinib), and was found to have acquired high level amplification of MET (PMID: 27393507).	27393507
EGFR	EGFR exon 19 del MET amp	lung non-small cell carcinoma	resistant	Gefitinib	Clinical Study - Cohort	Actionable	In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).	30791921
EGFR	EGFR exon 19 del MET amp	lung non-small cell carcinoma	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, amplification of MET conferred resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring an EGFR exon 19 deletion mutation in culture (PMID: 17463250).	17463250
EGFR	EGFR exon 19 del MET amp	lung non-small cell carcinoma	sensitive	JNJ-61186372	Preclinical - Cell line xenograft	Actionable	In a preclinical study, JNJ-61186372 inhibited tumor growth in Tarceva (erlotinib)-resistant non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion and MET amplification (PMID: 27216193).	27216193
EGFR	EGFR exon 19 del MET amp	lung non-small cell carcinoma	predicted - sensitive	Crizotinib	Clinical Study - Cohort	Actionable	In a clinical study, Xalkori (crizotinib) alone (n=8) or in combination with EGFR TKIs (n=6) resulted in an objective response rate (ORR) of 50% (7/14, 7 partial response) and a disease control rate (DCR) of 85.7% (12/14) in patients with EGFR-mutant (L858R n=12, exon 19 deletion n=2) non-small cell lung cancer who acquired resistance to EGFR TKI through MET amplification, ORR and DCR were not significantly different between patients treated with or without EGFR TKI (PMID: 30791921).	30791921
EGFR	EGFR exon 19 del MET amp	lung non-small cell carcinoma	predicted - resistant	Icotinib	Clinical Study - Cohort	Actionable	In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).	30791921
EGFR	EGFR exon 19 del MET amp	lung adenocarcinoma	predicted - sensitive	Osimertinib + Savolitinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated a near complete response when treated with the combination of Savolitinib (AZD6094) and Tagrisso (osimertinib) obtained through a Phase I trial, however, after 36 weeks presented with progression (PMID: 27694386; NCT02143466).	27694386
EGFR	EGFR exon 19 del MET amp	lung adenocarcinoma	resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Tarceva (erlotinib) (PMID: 27694386).	27694386
EGFR	EGFR exon 19 del MET amp	lung adenocarcinoma	predicted - resistant	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Gilotrif (afatinib) (PMID: 27694386).	27694386
EGFR	EGFR exon 19 del MET amp	lung adenocarcinoma	predicted - sensitive	Bevacizumab + Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with Iressa (gefitinib)-resistant lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated improvement in symptoms and decrease in tumor size following treatment with Tarceva (erlotinib) and Avastin (bevacizumab) (PMID: 30792648).	30792648
EGFR	EGFR exon 19 del MET amp	lung non-small cell carcinoma	predicted - resistant	Erlotinib	Clinical Study - Cohort	Actionable	In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).	30791921
EGFR	EGFR exon 19 del MET amp MET D1228V	lung adenocarcinoma	predicted - resistant	Osimertinib + Savolitinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated a near complete response when treated with the combination of Savolitinib (AZD6094) and Tagrisso (osimertinib) obtained through a Phase I trial, however, after 36 weeks presented with progression and MET D1228V was identified as an acquired mutation (PMID: 27694386; NCT02143466).	27694386
EGFR	EGFR exon 19 del MET amp MET D1228V	lung adenocarcinoma	predicted - sensitive	Cabozantinib + Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion, MET amplification, and MET D1228V demonstrated a strong response to the combination of Tarceva (erlotinib) and Cometriq (Cabometyx, cabozantinib), resulting in reduced tumor size and continued clinical benefit 5 months after the start of therapy (PMID: 27694386).	27694386
EGFR	EGFR exon 19 del EGFR T790M	lung adenocarcinoma	resistant	Afatinib	Clinical Study - Cohort	Actionable	In a clinical study, second-site EGFR T790M mutations were detected in 47.6% (20/42) of lung adenocarcinoma patients treated with Gilotrif (afatinib) that acquired resistance, with 9 of those patients harboring primary EGFR exon 19 deletion mutations (PMID: 26862733).	26862733
EGFR	EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of EGFR T790M in culture (PMID: 25870145).	25870145
EGFR	EGFR exon 19 del EGFR T790M	Advanced Solid Tumor	sensitive	WZ4002	Preclinical - Cell culture	Actionable	In a preclinical study, WZ4002 inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).	25964297
EGFR	EGFR exon 19 del EGFR T790M	lung cancer	sensitive	GSK2334470 + Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of GSK2334470 and Tagrisso (osimertinib) resulted in increased inhibition of AKT phosphorylation and proliferation compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).	28416483
EGFR	EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	sensitive	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, Tagrisso (osimertinib) obtained through a Phase I/II trial (AURA) resulted in a partial response and stable disease of brain metastases in a non-small cell lung cancer patient harboring EGFR exon 19 deletion and a secondary resistance mutation, EGFR T790M, which occurred post Iressa (gefitinib) therapy (PMID: 27435396; NCT01802632).	27435396
EGFR	EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	sensitive	Osimertinib	Phase I	Actionable	In a Phase I trial, Tagrisso (osimertinib) treatment resulted in a response rate of 64% (49/77) in non-small cell lung cancer patients that harbored both EGFR exon 19 deletions and T790M mutations (PMID: 25923549; NCT01802632).	25923549
EGFR	EGFR exon 19 del EGFR T790M	lung adenocarcinoma	predicted - sensitive	Nazartinib	Case Reports/Case Series	Actionable	In a Phase I trial, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M demonstrated a partial response to treatment with Nazartinib (CO-1686) (PMID: 30123863; NCT02108964).	30123863
EGFR	EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	predicted - sensitive	Abivertinib	Phase I	Actionable	In a Phase I trial, Abivertinib (AC0010) treatment resulted in an overall response rate of 36.5% (19/52) and a disease control rate of 75% (39/52) in non-small cell lung carcinoma patients harboring EGFR exon 19 deletions (33/52) or L858R (19/52) with acquired resistance to first generation Egfr tyrosine kinase inhibitors, 87% (45/52) of the patients also harbored EGFR T790M (PMID: 29626621).	29626621
EGFR	EGFR exon 19 del EGFR T790M	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M were resistant to Iressa (gefitinib) induced suppression of EGFR signaling in culture (PMID: 25964297).	25964297
EGFR	EGFR exon 19 del EGFR T790M	lung adenocarcinoma	sensitive	Bevacizumab + Erlotinib	Phase II	Actionable	In a Phase II trial (BELIEF), Avastin (bevacizumab) and Tarceva (erlotinib) combination treatment resulted in a median progression-free survival of 16.0 months and a 12 month progression-free survival of 68% (25/37) in treatment-naive lung adenocarcinoma patients harboring activating EGFR mutations (exon 19 deletion or L858R) and EGFR T790M (PMID: 28408243; NCT01562028).	28408243
EGFR	EGFR exon 19 del EGFR T790M	Advanced Solid Tumor	resistant	EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, EAI045 did not inhibit proliferation of transformed cells over expressing EGFR harboring both exon 19 deletion and T790M in culture (PMID: 27251290).	27251290
EGFR	EGFR exon 19 del EGFR T790M	lung cancer	sensitive	Dasatinib + Osimertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tagrisso (osimertinib) and Sprycel (dasatinib) in combination resulted in increased PARP cleavage and inhibition of proliferation in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M compared to Tagrisso (osimertinib) alone, and inhibited tumor growth in xenograft models, with 3 out of 7 models demonstrating no tumor rebound after cessation of therapy (PMID: 28416483).	28416483
EGFR	EGFR exon 19 del EGFR T790M	lung cancer	sensitive	Osimertinib + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and Tagrisso (osimertinib) resulted in increased inhibition of ERK phosphorylation and proliferation compared to either agent alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).	28416483
EGFR	EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	predicted - sensitive	unspecified EGFR tyrosine kinase inhibitor	Clinical Study - Cohort	Actionable	In a clinical study, treatment-naive non-small cell lung cancer patients harboring both EGFR exon 19 deletion mutations and ultra-low level EGFR T790M as detected by ddPCR demonstrated improved progression-free survival (39.5 vs 11.7 months, p=0.001) after first-generation tyrosine kinase inhibitor therapy compared to patients who did not harbor both mutations (PMID: 30936123).	30936123
EGFR	EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, Iressa (gefitinib) treatment resulted in initial response in a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion, however, the disease progressed 3 years after initial treatment and EGFR T790M was identified at the time of progression (PMID: 29704676).	29704676
EGFR	EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion and EGFR T790M were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).	25964297
EGFR	EGFR exon 19 del EGFR T790M	lung non-squamous non-small cell carcinoma	sensitive	Osimertinib	Phase III	Actionable	In a Phase III trial, third-line treatment with Tagrisso (osimertinib) resulted in improved median progression-free survival compared to treatment with the combination of Taxotere (docetaxel) and Avastin (bevacizumab) (10.2 mo vs. 2.95 mo., HR=0.23), and a an overall response rate of 61.6% (45/73) compared to 8.3% (6/72), in patients with non-squamous non-small cell lung cancer harboring EGFR T790M with either EGFR L858R or an EGFR exon 19 deletion (PMID: 29858027, NCT02959749).	29858027
EGFR	EGFR exon 19 del EGFR T790M	lung adenocarcinoma	predicted - sensitive	Olmutinib	Case Reports/Case Series	Actionable	In a clinical case study, Olmutinib (HM61713) resulted in partial response after 2 cycles of treatment and was continued for 17 months until disease progression in a patient with lung adenocarcinoma harboring EGFR exon 19 deletion and T790M (PMID: 26749488).	26749488
EGFR	EGFR exon 19 del EGFR T790M	lung adenocarcinoma	predicted - sensitive	Lazertinib	Phase I	Actionable	In a Phase I/II trial, Lazertinib (YH25448) treatment resulted in a 49.3% reduction of intracranial tumor and a 12.7% reduction of the extracranial tumor in a patient with non-small cell lung cancer harboring both EGFR exon 19 deletion mation and EGFR T790M (PMID: 30670498).	30670498
EGFR	EGFR exon 19 del EGFR T790M	Advanced Solid Tumor	resistant	Cetuximab + EAI045	Preclinical - Cell culture	Actionable	In a preclinical study, combination of EAI045 and Erbitux (cetuximab) did not inhibit proliferation of transformed cells over expressing EGFR that harbors both exon 19 deletion and T790M in culture (PMID: 27251290).	27251290
EGFR	EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	sensitive	Rociletinib	Phase Ib/II	Actionable	In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in an objective response rate of 64.3% (18/28) in non-small cell lung cancer patients harboring both EGFR exon 19 deletions and EGFR T790M (PMID: 25923550).	25923550
EGFR	EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	sensitive	TAE226	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung cancer cell lines harboring both EGFR T790M and EGFR exon 19 deletion mutations, and decreased tumor size in xenograft models (PMID: 26090892).	26090892
EGFR	EGFR exon 19 del EGFR T790M	lung cancer	sensitive	Buparlisib + Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of Buparlisib (BKM120) and Tagrisso (osimertinib) resulted in increased inhibition of AKT phosphorylation and proliferation compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).	28416483
EGFR	EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	sensitive	Lazertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Lazertinib (YH25448) inhibited viability of patient-derived cells and a cell line of non-small cell lung cancer harboring both EGFR T790M and an EGFR exon 19 deletion mutation, resulted in tumor growth inhibition in cell line xenograft models (PMID: 30670498).	30670498
EGFR	EGFR exon 19 del EGFR T790M	lung cancer	sensitive	Osimertinib + PF-573228 + Saracatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tagrisso (osimertinib) with PF-573328 and Saracatinib (AZD0530) resulted in increased inhibition of AKT, FAK, and SFK phosphorylation and growth compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).	28416483
EGFR	EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	predicted - sensitive	Osimertinib + Ramucirumab	Phase I	Actionable	In a Phase I trial, Cyramza (ramucirumab) and Tagrisso (osimertinib) combination treatment resulted in an objective response rate of 76% (19/25, 1 complete response, 18 partial response), and stable disease in 16% (4/25) of EGFR-mutant (exon 19 deletion or L858R) non-small cell lung cancer patients harboring EGFR T790M, who progressed on first-line EGFR TKI therapy (J Clin Oncol 36, 2018 (suppl; abstr 9053); NCT02789345).	detail...
EGFR	EGFR exon 19 del EGFR T790M	Advanced Solid Tumor	sensitive	Lazertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lazertinib (YH25448) inhibited Egfr phosphorylation and viability of transformed cells expressing both EGFR T790M and an EGFR exon 19 deletion mutation (PMID: 30670498).	30670498
EGFR	EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	resistant	Erlotinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, 83% (5/6) of non-small cell lung cancer patients harboring EGFR exon 19 deletions that had progressed on prior treatment with Iressa (gefinitib) with secondary EGFR T790M mutations had progressive disease as best response to treatment with Tarceva (erlotinib) (PMID: 18981003).	18981003
EGFR	EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	predicted - sensitive	Afatinib + Dasatinib	Phase I	Actionable	In a Phase I trial, the combination of Sprycel (dasatinib) and Gilotrif (afatinib) demonstrated manageable toxicity, reduced allele frequencies of EGFR T790M and EGFR activating mutations (exon 19 deletion and L858R) in ctDNA, but only resulted in stable disease as best response in 26% of non-small cell lung cancer patients acquired resistance to tyrosine kinase inhibitors (PMID: 30880334; NCT01999985).	30880334
EGFR	EGFR exon 19 del EGFR T790M	lung cancer	sensitive	Osimertinib + TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of TAK-632 and Tagrisso (osimertinib) resulted in increased inhibition of ERK phosphorylation and proliferation compared to either agent alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).	28416483
EGFR	EGFR exon 19 del EGFR T790M	lung cancer	sensitive	Bosutinib + Osimertinib + PF-573228	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tagrisso (osimertinib) with PF-573328 and Bosulif (bosutinib) resulted in increased inhibition of AKT, FAK, and SFK phosphorylation and growth compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).	28416483
EGFR	EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	sensitive	WZ4002	Preclinical - Cell culture	Actionable	In a preclinical study, WZ4002 inhibited EGFR signaling and cell growth in 1st generation TKI-resistant non-small cell lung cancer cells harboring EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).	25964297
EGFR	EGFR exon 19 del EGFR T790M	lung cancer	resistant	Cetuximab + EAI045	Preclinical	Actionable	In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment did not induced response in an EGFR exon 19 deletion/T790M-driven lung cancer mouse model (PMID: 27251290).	27251290
EGFR	EGFR exon 19 del EGFR T790M	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).	25964297
EGFR	EGFR exon 19 del EGFR T790M	Advanced Solid Tumor	sensitive	BGB-283	Preclinical - Cell culture	Actionable	In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing both EGFR exon 19 deletion mutation and T790M in culture (PMID: 26208524).	26208524
EGFR	EGFR exon 19 del EGFR T790M	lung non-small cell carcinoma	sensitive	OBX1-012	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 del and EGFR T790M , resistant to Iressa (gefitinib) and Tarceva (erlotinib), were sensitive to treatment with OBX1-012, demonstrating decreased cell viability and apoptosis in vitro (PMID: 29754184).	29754184
EGFR	BRAF V600E EGFR exon 19 del MET amp	lung adenocarcinoma	resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR exon 19 deletion treated with Tagrisso (osimertinib) showed progression after 16 months, and was subsequently found to have acquired BRAF V600E and MET amplification (PMID: 29596911).	29596911
EGFR	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - sensitive	Osimertinib + Saracatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, demonstrated sensitivity to the combination of Tagrisso (osimertinib) and Saracatinib (AZD0530) in culture, resulting in decreased Akt and Erk phosphorylation and reduced cell viability (PMID: 29875142).	29875142
EGFR	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transposon insertions in MET, leading to increased phosphorylation of Met, were associated with resistance to Gilotrif (afatinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).	29875142
EGFR	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - sensitive	Afatinib + Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in MET, leading to increased Met phosphorylation, demonstrated sensitivity to the combination of Gilotrif (afatinib) and Xalkori (crizotinib) in culture, resulting in decreased Akt and Erk phosphorylation and reduced cell viability (PMID: 29875142).	29875142
EGFR	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transposon insertions in MET, leading to increased expression and phosphorylation of Met, were associated with resistance to Tarceva (erlotinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).	29875142
EGFR	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transposon insertions in MET, leading to increased phosphorylation of Met, were associated with resistance to Tagrisso (osimertinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).	29875142
EGFR	EGFR exon 19 del ERBB2 wild-type	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, transgenic mouse models with ERBB2 (HER2)-wild-type cells expressing EGFR exon 19 deletion demonstrated tumor growth inhibition and an improved progression-free survival when treated with Tagrisso (osimertinib) compared to treatment with Tarceva (erlotinib) (PMID: 29298799).	29298799
EGFR	EGFR exon 19 del EGFR T854A	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR exon 19 del and EGFR T854A were sensitive to treatment with Gilotrif (afatinib), demonstrating reduced cell growth (PMID: 29702287).	29702287
EGFR	EGFR exon 19 del EGFR T854A	Advanced Solid Tumor	predicted - sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR exon 19 del and EGFR T854A were moderately resistant to Alunbrig (brigatinib) in culture (PMID: 29702287).	29702287
EGFR	EGFR exon 19 del EGFR T854A	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR exon 19 del and EGFR T854A were sensitive to treatment with Tagrisso (osimertinib), demonstrating reduced cell growth (PMID: 29702287).	29702287
EGFR	EGFR exon 19 del EGFR T854A	Advanced Solid Tumor	predicted - resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR exon 19 del and EGFR T854A were moderately resistant to Iressa (gefitinib) in culture (PMID: 29702287).	29702287
EGFR	EGFR exon 19 del EGFR K754E	lung adenocarcinoma	decreased response	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of EGFR K754E in lung adenocarcinoma cells harboring EGFR exon 19 deletion mutations led to decreased response to Tarceva (erlotinib) compared to control cells in culture (PMID: 27478040).	27478040
EGFR	EGFR exon 19 del EGFR S645C	lung adenocarcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of EGFR S645C in lung adenocarcinoma cells harboring EGFR exon 19 deletion mutations led to resistance to Tarceva (erlotinib) in culture (PMID: 27478040).	27478040
EGFR	EGFR exon 19 del PIK3CA E418K PIK3CA E542K	lung non-small cell carcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, loss of EGFR T790M and acquired PIK3CA E418K and E542K mutations were identified in a post-treatment sample from a patient harboring an EGFR exon 19 deletion who progressed on Tagrisso (osimertinib) treatment (PMID: 30228210).	30228210
EGFR	EGFR exon 19 del PTEN mut	lung adenocarcinoma	decreased response	Erlotinib	Clinical Study - Cohort	Actionable	In a clinical study, PTEN mutations were associated with a lower overall response rate of 7.3% in lung adenocarcinoma patients harboring EGFR exon 19 deletions or L858R, compared to 70.9% (p=0.061) in patients with wild-type PTEN, following treatment with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib) (PMID: 24468202).	24468202
EGFR	EGFR exon 19 del PTEN mut	lung adenocarcinoma	decreased response	Gefitinib	Clinical Study - Cohort	Actionable	In a clinical study, PTEN mutations were associated with a lower overall response rate of 7.3% in lung adenocarcinoma patients harboring EGFR exon 19 deletions or L858R, compared to 70.9% (p=0.061) in patients with wild-type PTEN, following treatment with EGFR tyrosine kinase inhibitors including Iressa (gefitinib) (PMID: 24468202).	24468202
EGFR	EGFR exon 19 del BRAF V600E	lung adenocarcinoma	predicted - resistant	Nazartinib	Case Reports/Case Series	Actionable	In a Phase I trial, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M demonstrated a partial response to treatment with Nazartinib (CO-1686), but developed progression in the liver after 11 months, and a post-progression biopsy identified the EGFR exon 19 deletion without EGFR T790M, and emergence of BRAF V600E (PMID: 30123863; NCT02108964).	30123863
EGFR	EGFR exon 19 del EGFR L718V EGFR T790M	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing an EGFR exon 19 deletion, EGFR L718V, and EGFR T790M demonstrated resistance to treatment with Tagrisso (osimertinib) in culture (PMID: 29571986).	29571986
EGFR	EGFR exon 19 del MET pos	lung non-small cell carcinoma	unknown	Erlotinib + Onartuzumab	Phase II	Actionable	In a Phase II trial, patients with MET-positive non-small lung cancer harboring either EGFR L858R or an EGFR exon 19 deletion demonstrated a median progression-free survival of 8.9 mo., median overall survival of 15.6 mo., and an overall response rate of 68.9% (all partial responses) following first-line therapy with Tarceva (erlotinib) and Onartuzumab; however, the trial was terminated early due to lack of efficacy with the therapy in another trial and thus, the results are not conclusive (PMID: 30472556).	30472556
EGFR	EGFR A763V	lung non-small cell carcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical study, Iressa (gefitinib) treatment resulted in disease progression within 2 months of treatment in a patient with non-small cell lung carcinoma harboring EGFR A763V (PMID: 15897572).	15897572
EGFR	EGFR-PURB	lung adenocarcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR-PURB demonstrated a partial response when treated with Tarceva (erlotinib), resulting in a 48% decrease in lesion size and ongoing therapy for 20 months without indication of progression (PMID: 27102076).	27102076
EGFR	EGFR V30_R297delinsG	malignant glioma	sensitive	hEGFRvIII-CD3 bi-scFv	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, hEGFRvIII-CD3 bi-scFv induced tumor cell lysis in malignant glioma cell lines expressing EGFRvIII, induced cytotoxicity in patient-derived cells harboring EGFRvIII in culture, increased survival in a glioma cell line xenograft model, and decreased tumor burden and increased survival in both syngeneic mouse and patient-derived xenograft (PDX) malignant glioma models (PMID: 29703821).	29703821
EGFR	EGFR E746_A750del	lung non-small cell carcinoma	sensitive	ER2	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with ER2 resulted in decreased proliferation and increased apoptosis of non-small cell lung cancer (NSCLC) cells harboring EGFR E746_A750del in culture, and delayed tumor growth in NSCLC cell line xenograft models with EGFR E746_A750del (PMID: 27040853).	27040853
EGFR	EGFR E746_A750del	Advanced Solid Tumor	resistant	JBJ-04-125-02	Preclinical - Cell culture	Actionable	In a preclinical study, JBJ-04-125-02 did not inhibit cell proliferation in a transformed murine cell line expressing EGFR E746_A750del in culture (PMID: 31092401).	31092401
EGFR	EGFR E746_A750del	lung non-small cell carcinoma	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 29467275).	29467275
EGFR	EGFR E746_A750del	lung non-small cell carcinoma	sensitive	Erlotinib + Ganetespib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Ganetespib and Tarceva (erlotinib) demonstrated improved antitumor activity compared to either agent alone in cell line xenograft models of non-small cell lung cancer harboring EGFR E746_A750del (PMID: 25077897).	25077897
EGFR	EGFR E746_A750del	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_A750del demonstrated increased sensitivity to Caprelsa (vandetanib) in culture (PMID: 15604279).	15604279
EGFR	EGFR E746_A750del	lung non-small cell carcinoma	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 29467275).	29467275
EGFR	EGFR E746_A750del	lung non-small cell carcinoma	sensitive	Cisplatin + ER2	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in a non-small cell lung cancer cell line xenograft model harboring EGFR E746_A750del (PMID: 27040853).	27040853
EGFR	EGFR E746_A750del	lung non-small cell carcinoma	sensitive	Trametinib + WZ4002	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of WZ4002 and Mekinist (trametinib) inhibited tumor growth, and resulted in reduced tumor rebound compared to WZ4002 alone in non-small cell lung cancer cell line xenograft models harboring EGFR E746_A750del (PMID: 26036643).	26036643
EGFR	EGFR E746_A750del	lung non-small cell carcinoma	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring EGFR E746_A750del in culture (PMID: 21325073, PMID: 16731747).	21325073 16731747
EGFR	EGFR E746_A750del	lung carcinoma	sensitive	BGB-283	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BGB-283 inhibited Egfr phosphorylation and cell proliferation in lung carcinoma cells harboring EGFR E746_A750del in culture, and resulted in tumor regression in cell line xenograft models (PMID: 26208524).	26208524
EGFR	EGFR E746_A750del	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EGFR E746_A750del in culture (PMID: 27780853).	27780853
EGFR	EGFR E746_A750del	lung non-small cell carcinoma	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 29467275).	29467275
EGFR	EGFR E746_A750del	lung non-small cell carcinoma	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EGFR E746_A750del demonstrated resistance to growth inhibition by Tykerb (lapatinib) in cell culture (PMID: 18199554).	18199554
EGFR	EGFR E746_A750del	lung non-small cell carcinoma	sensitive	Vandetanib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR E746_A750del demonstrated increased sensitivity to Caprelsa (vandetanib) in culture (PMID: 15604279).	15604279
EGFR	EGFR E746_A750del	lung non-small cell carcinoma	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 29467275).	29467275
EGFR	EGFR E746_A750del	lung adenocarcinoma	sensitive	Abivertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, lung adenocarcinoma cells harboring EGFR E746_A750del demonstrated sensitivity to treatment with Abivertinib (AC0010), which resulted in inhibition of both cell growth and Egfr phosphorylation in culture, and tumor regression in xenograft models (PMID: 27573423).	27573423
EGFR	EGFR E746_A750del	lung cancer	sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited growth of lung cancer cell lines harboring EGFR E746_A750del in culture (PMID: 29748209).	29748209
EGFR	EGFR E746_A750del	lung adenocarcinoma	predicted - sensitive	Gefitinib	Clinical Study	Actionable	In a retrospective analysis, treatment with Iressa (gefitinib) was found to result in partial response in 7 patients, stable disease in 1 patient, and progressive disease in 1 patient with lung adenocarcinoma harboring EGFR E746_A750del (PMID: 18981003).	18981003
EGFR	EGFR E746_A750del SMO amp	lung non-small cell carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, amplification of SMO conferred acquired resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 26124204).	26124204
EGFR	EGFR E746_A750del SMO amp	lung non-small cell carcinoma	sensitive	PHA-665752 + Sonidegib	Preclinical	Actionable	In a preclinical study, the combination of Odomzo (sonidegib) and PHA-665752 decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring EGFR E746_A750del and SMO amplification in culture, and resulted in complete response in 100% (8/8) of NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).	26124204
EGFR	EGFR E746_A750del SMO amp	lung non-small cell carcinoma	no benefit	Sonidegib	Preclinical	Actionable	In a preclinical study, Odomzo (sonidegib) did not decrease viability or migration of non-small cell lung cancer cells harboring EGFR E746_A750del and amplification of SMO in culture (PMID: 26124204).	26124204
EGFR	EGFR E746_A750del SMO amp	lung non-small cell carcinoma	sensitive	Gefitinib + Sonidegib	Preclinical	Actionable	In a preclinical study, the combination of Odomzo (sonidegib) and Iressa (gefitinib) decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring an EGFR E746_A750del mutation and SMO amplification in culture and inhibited tumor growth in NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).	26124204
EGFR	EGFR E746_A750del EGFR T790M	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR E746_A750del and EGFR T790M in cis and trans were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR E746_A750del EGFR T790M	lung non-small cell carcinoma	conflicting	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) treatment did not reduce proliferation and EGFR pathway signaling in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 30322949).	30322949
EGFR	EGFR E746_A750del EGFR T790M	lung non-small cell carcinoma	conflicting	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring both EGFR E746_A750del and EGFR T790M in culture (PMID: 29467275).	29467275
EGFR	EGFR E746_A750del EGFR T790M	lung non-small cell carcinoma	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring both EGFR E746_A750del and EGFR T790M in culture (PMID: 29467275).	29467275
EGFR	EGFR E746_A750del EGFR T790M	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EGFR E746_A750del and T790M in culture (PMID: 27780853).	27780853
EGFR	EGFR E746_A750del EGFR T790M	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR E746_A750del and EGFR T790M in cis and trans demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 29141884).	29141884
EGFR	EGFR E746_A750del EGFR T790M	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR E746_A750del and EGFR T790M were sensitive to treatment with Tagrisso (osimertinib) when expressed in cis in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_A750del EGFR T790M	lung non-small cell carcinoma	sensitive	Osimertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tagrisso (osimertinib) treatment reduced proliferation and EGFR pathway signaling in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture, and reduced tumor growth in cell line xenograft mouse models (PMID: 30322949).	30322949
EGFR	EGFR E746_A750del EGFR T790M	lung non-small cell carcinoma	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of non-small cell lung cancer cells harboring both EGFR E746_A750del and EGFR T790M in culture (PMID: 29467275).	29467275
EGFR	EGFR E746_A750del EGFR T790M	lung non-small cell carcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring both EGFR E746_A750del and EGFR T790M were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).	29467275
EGFR	EGFR E746_A750del EGFR T790M	lung adenocarcinoma	predicted - resistant	Erlotinib	Clinical Study	Actionable	In a retrospective analysis, 3 of 4 patients with lung adenocarcinoma harboring EGFR E746_A750del, who were found to have acquired EGFR T790M upon disease progression on Iressa (gefitinib) therapy, had rapid disease progression in response to Tarceva (erlotinib) therapy (PMID: 18981003).	18981003
EGFR	EGFR E746_A750del EGFR T790M	lung non-small cell carcinoma	sensitive	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, Rociletinib (CO-1686) treatment reduced proliferation and EGFR pathway signaling in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 30322949).	30322949
EGFR	EGFR E746_A750del EGFR T790M	lung adenocarcinoma	predicted - resistant	Gefitinib	Clinical Study	Actionable	In a retrospective analysis, 4 patients with lung adenocarcinoma harboring EGFR E746_A750del that had developed Iressa (gefitinib) resistance were found to have acquired EGFR T790M mutations (PMID: 18981003).	18981003
EGFR	EGFR E746_A750del EGFR T790M	lung adenocarcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, EGFR T790M was identified in a patient with lung adenocarcinoma harboring EGFR E746_A750del with resistance to Iressa (gefitinib) (PMID: 15737014).	15737014
EGFR	EGFR E746_A750del EGFR T790M	Advanced Solid Tumor	resistant	JBJ-04-125-02	Preclinical - Cell culture	Actionable	In a preclinical study, JBJ-04-125-02 did not inhibit cell proliferation in a transformed murine cell line expressing EGFR E746_A750del and T790M in culture (PMID: 31092401).	31092401
EGFR	EGFR E746_A750del EGFR T790M	lung non-small cell carcinoma	sensitive	Trametinib + WZ4002	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with the combination of WZ4002 and Mekinist (trametinib) inhibited tumor growth, and resulted in increased ERK inhibition and reduced tumor rebound compared to WZ4002 alone in non-small cell lung cancer cell line xenograft models harboring both EGFR E746_A750del and EGFR T790M (PMID: 26036643).	26036643
EGFR	EGFR E746_A750del EGFR T790M	Advanced Solid Tumor	conflicting	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR E746_A750del and EGFR T790M were resistant to treatment with Tarceva (erlotinib) when expressed in cis, but sensitive to treatment when expressed in trans in culture (PMID: 29141884).	29141884
EGFR	EGFR E746_A750del EGFR T790M	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EGFR E746_A750del and EGFR T790M in cis and trans were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR amp EGFR E746_A750del	lung adenocarcinoma	sensitive	Depatuxizumab mafodotin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-414 demonstrated cytotoxicity against a lung adenocarcinoma cell line that harbored EGFR amplification and EGFR E746_A750del in culture and induced tumor regression in cell line xenograft models (PMID: 26846818).	26846818
EGFR	EGFR E746_A750del MET amp	lung adenocarcinoma	sensitive	Capmatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Capmatinib (INC280) resulted in improved survival in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).	28961841
EGFR	EGFR E746_A750del MET amp	lung non-small cell carcinoma	sensitive	Crizotinib + Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in non-small cell lung cancer cell line harboring EGFR E746_A750del and MET amplification in culture (PMID: 27283993).	27283993
EGFR	EGFR E746_A750del MET amp	lung non-small cell carcinoma	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, acquired amplification of MET conferred resistance to Iressa (gefitinib) in a non-small cell lung cancer cell line harboring EGFR E746_A750del in culture (PMID: 27612490).	27612490
EGFR	EGFR E746_A750del MET amp	lung non-small cell carcinoma	sensitive	Gefitinib + PHA-665752	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of PHA-665752 and Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).	24165158 23542356
EGFR	EGFR E746_A750del MET amp	lung non-small cell carcinoma	sensitive	Gefitinib + NPS-1034	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the addition of NPS-1034 to treatment with Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).	24165158 23542356
EGFR	EGFR E746_A750del MET amp	lung adenocarcinoma	no benefit	Afatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) did not demonstrate benefit in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification, with all treated mice demonstrating progression (PMID: 28961841).	28961841
EGFR	EGFR E746_A750del MET amp	lung non-small cell carcinoma	resistant	Rociletinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, emergence of MET amplification was associated with resistance to Rociletinib (CO1686) in non-small cell lung cancer cell line xenograft models harboring EGFR E746_A750del (PMID: 27283993).	27283993
EGFR	EGFR E746_A750del MET amp	lung adenocarcinoma	resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with metastatic lung adenocarcinoma harboring EGFR E746_A750del (referred to as K745_A750delinsK) and T790M demonstrated an initial response, but subsequent progression, of the brain metastasis following Tagrisso (osimertinib) treatment, and analysis of the brain metastasis showed loss of EGFR T790M as well as acquisition of high-level MET amplification, and resistance to Tagrisso (osimertinib) was recapitulated in a patient-derived xenograft (PDX) model (PMID: 28961841).	28961841
EGFR	EGFR E746_A750del MET amp	lung adenocarcinoma	sensitive	Afatinib + Capmatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Capmatinib (INC280) plus Gilotrif (afatinib) resulted in improved survival with no evidence of tumor 300 days post-transplantation in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).	28961841
EGFR	EGFR E746_A750del FGFR3-TACC3	lung non-small cell carcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical study, FGFR3-TACC3 was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR E746_A750del, whose disease progressed after initial response to Tarceva (erlotinib), followed by Tagrisso (osimertinib) (PMID: 29883838).	29883838
EGFR	EGFR E746_A750del FGFR3-TACC3	lung non-small cell carcinoma	predicted - resistant	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, FGFR3-TACC3 was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR E746_A750del, whose disease progressed after initial response to Gilotrif (afatinib) (PMID: 29883838).	29883838
EGFR	EGFR E746_A750del FGFR3-TACC3	lung non-small cell carcinoma	predicted - resistant	Naquotinib	Case Reports/Case Series	Actionable	In a clinical study, FGFR3-TACC3 was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR E746_A750del, whose disease progressed after initial response to Tarceva (erlotinib) followed by Naquotinib (ASP8273) (PMID: 29883838).	29883838
EGFR	EGFR E746_A750del EML4-ALK	lung non-small cell carcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical study, EML4-ALK was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR E746_A750del, whose disease progressed after initial response to Tarceva (erlotinib) followed by Tagrisso (osimertinib) (PMID: 29883838).	29883838
EGFR	EGFR amp EGFR E746_A750del EGFR T790M	lung non-small cell carcinoma	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, acquired resistance to Rociletinib (CO-1686) treatment in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture was associated with EGFR amplification and reduced expression of EGFR E746_A750del and EGFR T790M, and proliferation and EGFR pathway signaling were maintained upon Rociletinib (CO-1686) treatment in culture (PMID: 30322949).	30322949
EGFR	EGFR amp EGFR E746_A750del EGFR T790M	lung non-small cell carcinoma	sensitive	Afatinib + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, a Rociletinib (CO-1686)-resistant non-small cell lung cancer cell line harboring EGFR E746_A750del and EGFR T790M with EGFR amplification, which demonstrated reduced expression of EGFR E746_A750del and EGFR T790M relative to the parental cell line, exhibited reduced proliferation and increased apoptosis in response to combined Gilotrif (afatinib) and Erbitux (cetuximab) treatment relative to Gilotrif (afatinib) alone in culture (PMID: 30322949).	30322949
EGFR	BRAF V600E EGFR E746_A750del	lung non-small cell carcinoma	predicted - resistant	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with advanced non-small cell lung cancer who lost EGFR T790M, but still harbors EGFR E746_A750del and acquired BRAF V600E demonstrated continued progression while being treated with the combination therapy of Sprycel (dabrafenib) and Mekinist (trametinib) (Journal of Clinical Oncology, 2019, 37, no. 15_suppl).	detail...
EGFR	BRAF V600E EGFR E746_A750del	lung non-small cell carcinoma	predicted - sensitive	Dabrafenib + Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with advanced non-small cell lung cancer who lost EGFR T790M, but still harbors EGFR E746_A750del and acquired BRAF V600E demonstrated an improved metabolic response when treated with the combination therapy of Sprycel (dabrafenib) and Tagrisso (osimertinib) (Journal of Clinical Oncology, 2019, 37, no. 15_suppl).	detail...
EGFR	EGFR G721D EGFR E746_A750del	lung non-small cell carcinoma	predicted - sensitive	Gefitinib	Case Reports/Case Series	Actionable	In a clinical study, Iressa (gefitinib) treatment resulted in a partial response with a progression-free survival of 13 months in a patient with non-small cell lung cancer harboring both EGFR G721D and EGFR E746_A750del (PMID: 31175009).	31175009
EGFR	EGFR A1118T EGFR E746_A750del	Advanced Solid Tumor	conflicting	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A1118T and EGFR E746_A750del in cis demonstrated sensitivity to treatment with Iressa (gefitinib), but when expressed in trans, demonstrated resistance to treatment in culture (PMID: 29141884).	29141884
EGFR	EGFR A1118T EGFR E746_A750del	Advanced Solid Tumor	conflicting	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A1118T and EGFR E746_A750del in cis demonstrated sensitivity to treatment with Tarceva (erlotinib), but when expressed in trans, demonstrated resistance to treatment in culture (PMID: 29141884).	29141884
EGFR	EGFR A1118T EGFR E746_A750del	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR A1118T and EGFR E746_A750del in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR A1118T EGFR E746_A750del	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A1118T and EGFR E746_A750del in cis and trans in culture demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 29141884).	29141884
EGFR	EGFR A1118T EGFR E746_A750del	Advanced Solid Tumor	conflicting	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A1118T and EGFR E746_A750del in cis demonstrated sensitivity to treatment with Tagrisso (osimertinib), but when expressed in trans, demonstrated resistance to treatment in culture (PMID: 29141884).	29141884
EGFR	EGFR R252C	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R252C were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR K739_I744dup	lung adenocarcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical study, a patient with lung adenocarcinoma harboring EGFR K739_I744dup (reported as I744_K745insKIPVAI) demonstrated a partial response when treated with Tarceva (erlotinib) (PMID: 22190593).	22190593
EGFR	EGFR K739_I744dup	lung non-small cell carcinoma	predicted - sensitive	Gefitinib	Case Reports/Case Series	Actionable	In a clinical study, Iressa (gefitinib) demonstrated some efficacy in two patients with non-small cell lung cancer each harboring EGFR K739_I744dup (reported as I744_K745insKIPVAI), including a partial response in one patient and stable disease in the other patient (PMID: 28089594).	28089594
EGFR	EGFR neg FGFR1 over exp	head and neck squamous cell carcinoma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 treatment of head and neck squamous cell carcinoma cells over expressing FGFR1 and negative for EGFR resulted in decreased cell growth and reduced downstream signaling of Erk1/2 (PMID: 26936917).	26936917
EGFR	EGFR A1118T	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A1118T were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR A1118T	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A1118T were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A1118T	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A1118T were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A1118T	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A1118T were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A1118T	Advanced Solid Tumor	sensitive	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A1118T were sensitive to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR A1118T	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A1118T were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR over exp	lung squamous cell carcinoma	sensitive	Depatuxizumab mafodotin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-414 demonstrated cytoxicity against a lung squamous cell carcinoma cell line with EGFR over expression in culture and induced tumor regression in EGFR over expressing lung squamous cell carcinoma cell line xenograft models (PMID: 26846818).	26846818
EGFR	EGFR over exp	stomach cancer	predicted - sensitive	GC1118	Phase I	Actionable	In a Phase I clinical trial, treatment with GC1118 resulted in an overall response rate of 8% (1/12; partial response), stable disease in 17% (2/12), and a median progression-free survival of 6.7 weeks in patients with EGFR-overexpressing gastric cancer (PMID: 31164456; NCT02352571).	31164456
EGFR	EGFR over exp	squamous cell carcinoma	sensitive	GA201	Preclinical	Actionable	In a preclinical study, treatment with GA201 resulted in inhibition of EGFR signaling and induced antibody-dependent cell-mediated cytotoxicity towards EGFR-over expressing squamous cell carcinoma cells in culture (PMID: 23209031).	23209031
EGFR	EGFR over exp	lung cancer	sensitive	BGB-283	Preclinical - Cell culture	Actionable	In a preclinical study, BGB-283 inhibited proliferation of Egfr over expressing lung cancer cells in culture (PMID: 26208524).	26208524
EGFR	EGFR over exp	squamous cell carcinoma	sensitive	BGB-283	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BGB-283 inhibited Egfr phosphorylation in Egfr over expressing squamous cell carcinoma cells in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26208524).	26208524
EGFR	EGFR over exp	Advanced Solid Tumor	predicted - sensitive	Depatuxizumab mafodotin	Phase Ib/II	Actionable	In a Phase I/II trial, Depatuxizumab mafodotin (ABT-414) treatment resulted in partial response in 1.8% (1/56) and stable disease in 23% (13/56) of patients with advanced solid tumor harboring EGFR amplification, overexpression, or mutated EGFR variant III (PMID: 29533458; NCT01741727).	29533458
EGFR	EGFR over exp	squamous cell carcinoma	sensitive	TAK-285	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAK-285 inhibited growth of squamous cell carcinoma cells harboring EGFR over expression in culture and in cell line xenograft models (PMID: 23983820).	23983820
EGFR	EGFR over exp	esophageal cancer	sensitive	Theliatinib	Preclinical - Pdx	Actionable	In a preclinical study, Theliatinib treatment resulted in significant tumor growth inhibition in patient-derived xenograft (PDX) models of esophageal cancer with Egfr overexpression (PMID: 28881608)	28881608
EGFR	EGFR over exp ERBB2 dec exp	inflammatory breast carcinoma	sensitive	Paclitaxel + Sapitinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, combination of Sapatinib (AZD8931) and Taxol (paclitaxel) demonstrated enhanced antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erbb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).	24886365
EGFR	EGFR over exp ERBB2 dec exp	inflammatory breast carcinoma	sensitive	Sapitinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Sapitinib (AZD8931) demonstrated antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).	24886365
EGFR	BRAF V600E EGFR over exp	colorectal cancer	sensitive	EBI-907	Preclinical - Cell culture	Actionable	In a preclinical study, EBI-907 inhibited growth of colorectal cancer cells harboring BRAF V600E and EGFR overexpression in culture (PMID: 26810733).	26810733
EGFR	BRAF V600E EGFR over exp	colorectal cancer	resistant	Selumetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, over expression of wild type EGFR in colorectal cancer cells harboring BRAF V600E resulted in sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).	27312529
EGFR	EGFR over exp FGFR1 amp	head and neck squamous cell carcinoma	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells with EGFR over expression and FGFR1 amplification demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917).	26936917
EGFR	EGFR over exp FGFR1 amp	head and neck squamous cell carcinoma	sensitive	AZD4547 + Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR1 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a synergistic effect (PMID: 26936917).	26936917
EGFR	EGFR over exp FGFR2 amp	head and neck squamous cell carcinoma	sensitive	AZD4547 + Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a moderate synergistic effect (PMID: 26936917).	26936917
EGFR	EGFR over exp FGFR2 amp	head and neck squamous cell carcinoma	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917).	26936917
EGFR	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	Capmatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Capmatinib (INC280) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).	28783719
EGFR	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Mekinist (trametinib) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).	28783719
EGFR	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	Capmatinib + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Capmatinib (INC280) induced tumor regression in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).	28783719
EGFR	EGFR amp EGFR over exp	esophageal cancer	sensitive	Theliatinib	Preclinical - Pdx	Actionable	In a preclinical study, Theliatinib treatment resulted in tumor regression in patient-derived xenograft (PDX) models of esophageal cancer with both EGFR amplification and Egfr overexpression (PMID: 28881608)	28881608
EGFR	EGFR over exp PIK3CA E542K	esophageal cancer	sensitive	Theliatinib	Preclinical - Pdx	Actionable	In a preclinical study, Theliatinib treatment demonstrated decreased efficcacy in patient-derived xenograft (PDX) models of esophageal cancer with Egfr overexpression and PIK3CA E542K compared to models with only Egfr overexpression (PMID: 28881608).	28881608
EGFR	EGFR over exp FGFR1 over exp	esophageal cancer	sensitive	AZD4547	Preclinical - Pdx	Actionable	In a preclinical study, AZD4547 treatment resulted in tumor regression in patient-derived xenograft (PDX) models, with both Egfr and Fgfr1 overexpression (PMID: 28881608),	28881608
EGFR	EGFR over exp FGFR1 over exp	esophageal cancer	sensitive	Theliatinib	Preclinical - Pdx	Actionable	In a preclinical study, Theliatinib treatment demonstrated decreased efficacy in patient-derived xenograft (PDX) models of esophageal cancer with both Egfr and Fgfr1 overexpression compared to models with only Egfr overexpression (PMID: 28881608).	28881608
EGFR	EGFR over exp MET amp	lung non-small cell carcinoma	sensitive	SHR-A1307	Preclinical - Pdx	Actionable	In a preclinical study, SHR-A1307 resulted in the inhibition of tumor growth in the EGFR overexpressing and MET amplified patient-derived xenograft models (PDX) of non-small cell lung cancer (PMID: 30962319).	30962319
EGFR	EGFR L747_S752del	lung adenocarcinoma	predicted - sensitive	Gefitinib	Case Reports/Case Series	Actionable	In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del had a complete response with a 24-month progression-free survival in response to Iressa (gefitinib) therapy (PMID: 18981003).	18981003
EGFR	EGFR L747_S752del EGFR T790M	lung adenocarcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del and EGFR T790M, who was found to have acquired an EGFR T790M mutation upon disease progression on Iressa (gefitinib), had rapid disease progression in response to Tarceva (erlotinib) therapy (PMID: 18981003).	18981003
EGFR	EGFR L747_S752del EGFR T790M	lung adenocarcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del that developed Iressa (gefitinib) resistance after an initial response was demonstrated to have acquired an EGFR T790M mutation (PMID: 18981003).	18981003
EGFR	EGFR A289V	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289V were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR A289V	lung non-small cell carcinoma	predicted - sensitive	Icotinib	Case Reports/Case Series	Actionable	In a clinical case study, Conmana (icotinib) treatment resulted in a 4-month partial response in a single East Asian patient with non-small cell lung cancer harboring the mutation, EGFR A289V (J Clin Oncol 37, 2019 (suppl; abstr e13000)).	detail...
EGFR	EGFR A289V	lung non-small cell carcinoma	predicted - sensitive	Icotinib	Case Reports/Case Series	Actionable	In a clinical case study, Conmana (icotinib) treatment resulted in a 5-month partial response in a single Chinese patient with metastatic non-small cell lung cancer harboring the mutation, EGFR A289V, which was identified in circulating DNA (PMID: 30572543).	30572543
EGFR	EGFR A289V	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289V were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR A289V	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical	Actionable	In a preclinical study, Tarceva (erlotinib) decreased viability of transformed cells expressing EGFR A289V in culture (PMID: 17177598).	17177598
EGFR	EGFR A289V	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289V were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR A289V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289V were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR S752_I759del	Advanced Solid Tumor	sensitive	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S752_I759del were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR S752_I759del	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S752_I759del were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR S752_I759del	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S752_I759del were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR S752_I759del	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S752_I759del were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR S752_I759del	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S752_I759del were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR S752_I759del	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S752_I759del were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR R831L	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R831L were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR R831L	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R831L were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR R831L	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R831L were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR R831L	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R831L were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR R831L	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R831L were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR V292L	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V292L were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR V292L	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V292L were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR V292L	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V292L were sensitive to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR S464L	colorectal cancer	sensitive	MM-151	Preclinical	Actionable	In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR S464L in culture (PMID: 26843189).	26843189
EGFR	EGFR S464L	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR S464L were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).	26843189
EGFR	EGFR S464L	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR S464L were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).	26843189
EGFR	EGFR T854A	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T854A were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR T854A	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T854A were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR T854A	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T854A were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR T854A	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T854A were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR T854A	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR T854A were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR L862V	lung adenocarcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, Iressa (gefitinib) treatment resulted in disease progression after 2 months of treatment in a patient with metastatic lung adenocarcinoma harboring EGFR L862V (PMID: 21841502).	21841502
EGFR	EGFR R831H	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R831H were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR R831H	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation in cells expressing EGFR R831H in culture (PMID: 20942962).	20942962
EGFR	EGFR R831H	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R831H were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR mutant	lung non-small cell carcinoma	no benefit	Lapatinib	Phase II	Actionable	In a Phase II trial, Tykerb (lapatinib) demonstrated safety in patients with non-small cell lung cancer, but demonstrated minimal antitumor activity with no responses in patients harboring EGFR mutations (PMID: 20215545).	20215545
EGFR	EGFR mutant	lung non-small cell carcinoma	predicted - sensitive	BMS-690514	Phase II	Actionable	In a Phase IIa clinical trial, BMS-690514 demonstrated safety and preliminary anti-tumor activity in patients with non-small cell lung cancer, with patients harboring EGFR mutations achieving a disease control rate (DCR) of 70% (7/10), compared to a DCR of 29% (6/21) in EGFR-wild type patients (PMID: 23490650).	23490650
EGFR	EGFR mutant	lung non-small cell carcinoma	sensitive	Sorafenib	Phase III	Actionable	In a Phase III trial, treatment with Nexavar (sorafenib) in non-small cell lung cancer patients harboring an EGFR mutation resulted in a greater overall survival and progression free survival when compared to placebo (PMID: 26743856).	26743856
EGFR	EGFR mutant	lung non-small cell carcinoma	predicted - sensitive	DS-1205b + Erlotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with the combination of DS-1205b and Tarceva (erlotinib) delayed the onset of therapeutic resistance compared to Tarceva (erlotinib) alone in an EGFR-mutant non-small cell lung cancer cell line xenograft model, and overcame resistance to Tarceva (erlotinib) in a Tarceva (erlotinib)-resistant xenograft model (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #395P).	detail...
EGFR	EGFR mutant	lung non-small cell carcinoma	sensitive	Naquotinib	Phase I	Actionable	In a Phase I trial, ASP8273 treatment resulted in partial response in 36% (16/45) and stable disease in 27% (12/45) of non-small cell lung carcinoma patients harboring EGFR mutations, with a median progression free survival of 6.7 months (J Clin Oncol 34, 2016 (suppl; abstr 9050)).	detail...
EGFR	EGFR mutant	lung adenocarcinoma	not applicable	N/A	Clinical Study	Emerging	In a clinical study, lung adenocarcinoma patients with compound EGFR mutations had inferior overall survival when compared to patients with single EGFR mutations (PMID: 26785607), suggesting that the presence of compound EGFR mutations may be have prognostic significance in lung adenocarcinoma.	26785607
EGFR	EGFR mutant	lung non-small cell carcinoma	decreased response	Pembrolizumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).	27225694
EGFR	EGFR mutant	lung non-small cell carcinoma	predicted - sensitive	Docetaxel + Vandetanib	Phase III	Actionable	In a Phase III trial (ZODIAC), Caprelsa (vandetanib) and Taxotere (docetaxel) combination treatment resulted in improved progression-free survival (HR=0.51), overall survival (HR=0.46), and objective response (odd ratio=3.34) in non-small cell lung cancer patients harboring EGFR mutations compared to the overall study population (PMID: 25057173; NCT00312377).	25057173
EGFR	EGFR mutant	lung non-small cell carcinoma	predicted - sensitive	Cabozantinib + Erlotinib	Phase II	Actionable	In a Phase II trial (NCI 9303), Cometriq (cabozantinib) and Tarceva (erlotinib) combination treatment resulted in an objective response rate of 10.8% (4/37, 4 partial response) and an 8-week disease control rate of 67.0% (25/37) in heavily pretreated non-small cell lung cancer patients harboring EGFR mutations, progression-free survival and overall survival were not different among patients harboring EGFR L858R, exon 19 deletion, or T790M (PMID: 30915273; NCT01866410).	30915273
EGFR	EGFR mutant	lung non-small cell carcinoma	predicted - sensitive	Afatinib + Bevacizumab	Phase II	Actionable	In a Phase II trial (ABC), treatment with Gilotrif (afatinib) plus Avastin (bevacizumab) resulted in an overall response rate (ORR) of 18.8% (6/32) and stable disease in 71.9% (23/32), a median progression-free survival (mPFS) of 6.3 mo, and median overall survival was not reached in non-small cell lung cancer patients with acquired resistance to EGFR inhibitor therapy, with an ORR of 14.3% and mPFS of 6.3 mo. in patients with EGFR T790M, and 22.2% and 7.1 mo. in patients without T790M (PMID: 30192383).	30192383
EGFR	EGFR mutant	lung non-small cell carcinoma	predicted - sensitive	DS-1205b + Osimertinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with the combination of DS-1205b and Tagrisso (osimertinib) delayed the onset of therapeutic resistance compared to Tagrisso (osimertinib) alone in an EGFR-mutant non-small cell lung cancer cell line xenograft model (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #395P).	detail...
EGFR	EGFR mutant	lung non-small cell carcinoma	sensitive	Osimertinib	Guideline	Actionable	Tagrisso (osimertinib) is included in guidelines for patients with EGFR mutant non-small cell lung cancer who have progressive leptomeningeal disease (NCCN.org).	detail...
EGFR	EGFR mutant	lung non-small cell carcinoma	predicted - sensitive	Osimertinib + Selumetinib	Phase I	Actionable	In a Phase Ib trial (TATTON), Tagrisso (osimertinib) and Selumetinib (AZD6244) combination therapy resulted in partial response in 42% (15/36) and stable disease in 39% (14/36) of patients with EGFR-mutant non-small cell lung cancer in the dose-finding arm, and partial response in 34% (16/47) and stable disease in 23% (11/47) of patients in the dose expansion arm (AACR Annual Meeting 2019, Abstract CT034).	detail...
EGFR	EGFR mutant	lung non-small cell carcinoma	sensitive	Pelitinib	Phase I	Actionable	In a Phase I study, Pelitinib (EKB-569) demonstrated efficacy in 2 patients with non-small cell lung cancer with EGFR mutations and acquired resistance to gefitinib (PMID: 16364494).	16364494
EGFR	EGFR mutant	Advanced Solid Tumor	no benefit	N/A	Clinical Study	Emerging	In a clinical study, 87.5% (7/8) of solid tumor patients harboring EGFR alterations experienced disease progression within 2 months of anti-PD1/PD-L1 monotherapy, indicating a risk for hyperprogression on immunotherapy (PMID: 28351930).	28351930
EGFR	EGFR mutant	lung non-small cell carcinoma	decreased response	Atezolizumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).	27225694
EGFR	EGFR mutant	urethra adenocarcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a Phase II trial (MyPathway), Tarceva (erlotinib) treatment resulted in partial response in a patient with urethral adenocarcinoma harboring an EGFR mutation (PMID: 29320312; NCT02091141).	29320312
EGFR	EGFR mutant	lung non-small cell carcinoma	sensitive	Erlotinib + S63845	Preclinical - Cell culture	Actionable	In a preclinical study, combination of S63845 and Tarceva (erlotinib) resulted in potent cytotoxic effects in EGFR mutated non-small cell lung cancer cells in culture compared to the cytostatic effect of Tarceva (erlotinib) alone (PMID: 27760111).	27760111
EGFR	EGFR mutant	lung non-small cell carcinoma	predicted - sensitive	Afatinib	Clinical Study	Actionable	In a clinical study, Gilotrif (afatinib) treatment resulted in partial response in 22% (22/58), stable disease in 47% (27/58), and progressive disease in 31% (18/58) of non-small cell lung carcinoma patients harboring uncommon EGFR mutations (PMID: 26354527).	26354527
EGFR	EGFR mutant	lung adenocarcinoma	sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, Poziotinib (HM781-36B) displayed modest efficacy in lung adenocarcinoma patients with mutant EGFR (J Clin Oncol 33, 2015 (suppl; abstr 8085).	detail...
EGFR	EGFR mutant	lung non-small cell carcinoma	predicted - sensitive	NGI-1	Preclinical - Cell culture	Actionable	In a preclinical study, NGI-1 inhibited EGFR phosphorylation and proliferation and induced cell cycle arrest in non-small cell lung cancer cell lines harboring kinase domain mutations in EGFR in culture (PMID: 27694802).	27694802
EGFR	EGFR mutant	lung cancer	sensitive	Rociletinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Rociletinib (CO-1686) induced tumor regression in EGFR-mutant human non-small cell lung cancer cell line xenograft models, while slightly inhibiting tumor growth in xenograft models of a wild-type EGFR human squamous carcinoma cell line (PMID: 24065731).	24065731
EGFR	EGFR mutant	lung non-small cell carcinoma	decreased response	Nivolumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).	27225694
EGFR	EGFR mutant	lung non-small cell carcinoma	decreased response	Durvalumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Imfinzi (durvalumab), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).	27225694
EGFR	EGFR mutant	lung non-small cell carcinoma	sensitive	Brigatinib	Phase I	Actionable	In a Phase I trial, Alunbrig (brigatinib) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including NSCLC patients harboring EGFR mutations (J Clin Oncol 31, 2013 (suppl; abstr 8031)).	detail...
EGFR	EGFR mutant FGFR1 wild-type	lung non-small cell carcinoma	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring mutant EGFR and wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).	22238366
EGFR	EGFR mut TP53 mut	lung non-small cell carcinoma	decreased response	unspecified EGFR tyrosine kinase inhibitor	Clinical Study - Cohort	Actionable	In a clinical study, non-small cell lung cancer patients harboring both EGFR and TP53 mutations demonstrated a disease control rate (DCR) of 70.3% (26/37) following first-line treatment with an EGFR inhibitor such as Iressa (gefitinib), Tarceva (erlotinib), Gilotrif (afatinib), or Vizimpro (dacomitinib), compared to a DCR of 88.2% (75/85) in TP53 wild-type, EGFR-mutant patients (PMID: 27780855).	27780855
EGFR	EGFR mut TP53 exon 8	lung non-small cell carcinoma	decreased response	unspecified EGFR tyrosine kinase inhibitor	Clinical Study - Cohort	Actionable	In a clinical study, EGFR-mutant non-small cell lung cancer patients with TP53 exon 8 mutations demonstrated decreased disease control rate (42%, 5/12 vs 87%, 97/111), shorter median progression-free survival (4.2 vs 12.5 mo) and median overall survival (16.2 vs 32.3 mo) with first-line EGFR tyrosine kinase inhibitor treatment (such as Iressa (gefitinib), Tarceva (erlotinib), Gilotrif (afatinib), or Vizimpro (dacomitinib)), compared to TP53 exon 8 wild-type patients (PMID: 27780855).	27780855
EGFR	EGFR T790M EGFR mut	lung non-small cell carcinoma	decreased response	Nivolumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, Opdivo (nivolumab) treatment after disease progression during EGFR tyrosine kinase inhibitors resulted in longer median progression-free survival (2.1 vs 1.3 months, HR=0.48, p=0.099) in T790M-negative, EGFR mutant non-small cell lung cancer patients compared to T790M-positive patients (PMID: 28407039).	28407039
EGFR	EGFR mut MET amp	lung adenocarcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, amplification of MET was identified in a lung adenocarcinoma cell line harboring EGFR mutation that acquired resistance to Tarceva (erlotinib) in culture (PMID: 28630215).	28630215
EGFR	EGFR mut MET amp	lung non-small cell carcinoma	sensitive	Capmatinib + Gefitinib	Phase Ib/II	Actionable	In a Phase Ib/II trial, Capmatinib (INC280) and Iressa (gefitinib) combination treatment resulted in an objective response rate of 27% (43/161) in non-small cell lung cancer patients harboring EGFR mutations and MET dysregulation (amplification or overexpression), with an objective response rate of 47% in Phase II patients with a MET gene copy number greater than 6 (PMID: 30156984).	30156984
EGFR	EGFR mut MET amp	lung non-small cell carcinoma	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, Xalkori (crizotinib) treatment resulted in partial response (PR) in 50% (4/8) of patients with EGFR mutant non-small cell lung cancer that acquired MET amplification after EGFR TKI therapy, although the response was short-lived, with a median progression-free survival of 3.5 months in patients achieved PR (PMID: 30268451).	30268451
EGFR	EGFR mut MET amp	lung adenocarcinoma	sensitive	EMD 1214063 + Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) and EMD 1214063 synergistically inhibited growth of lung carcinoma cells harboring EGFR mutation and Met amplification in culture (PMID: 28630215).	28630215
EGFR	EGFR mut MET amp	lung non-small cell carcinoma	predicted - sensitive	Osimertinib + Savolitinib	Phase I	Actionable	In a Phase I trial (TATTON), Tagrisso (osimertinib) and Savolitinib (AZD6094) combination therapy resulted in an objective response rate of 52% (24/46, 24 partial response) with a median duration of response of 7.1 months in patients with EGFR-mutant, EGFR T790M negative, and MET-amplified non-small cell lung cancer, after progression on prior first/second generation EGFR inhibitors (AACR Annual Meeting 2019, Abstract CT032; NCT02143466).	detail...
EGFR	EGFR mut MET mut	lung cancer	predicted - sensitive	ABX9xx	Preclinical - Cell culture	Actionable	In a preclinical study, ABX9xx inhibited Egfr and Met downstream signaling in several lung cancer cell lines harboring both EGFR and MET mutations in culture (AACR Annual Meeting 2019, Abstract 4830).	detail...
EGFR	EGFR positive	kidney cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited tumor growth of human kidney cancer cells expressing EGFR in cell line xenograft models (PMID: 24837299).	24837299
EGFR	EGFR positive	Advanced Solid Tumor	predicted - sensitive	S-222611	Phase I	Actionable	In a Phase I clinical trial, S-222611 demonstrated safety and some efficacy in patients with advanced solid tumors expressing EGFR or ERBB2 (HER2), with an overall clinical benefit rate of 27% (7/33) (PMID: 25434923).	25434923
EGFR	EGFR positive	lung non-small cell carcinoma	conflicting	Erlotinib	Preclinical - Pdx	Actionable	In a preclinical study, Tarceva (erlotinib) treatment did not result in the inhibition of tumor growth in patient-derived xenograft (PDX) models of EGFR-positive non-small cell lung cancer (PMID: 30962319).	30962319
EGFR	EGFR positive	lung non-small cell carcinoma	conflicting	Erlotinib	Phase III	Actionable	In a Phase III trial, no difference in disease free survival was observed in non-small cell lung cancer patients positive for Egfr treated with Tarceva (erlotinib) vs placebo in the adjuvant setting (PMID: 26324372).	26324372
EGFR	EGFR positive	Advanced Solid Tumor	sensitive	AFM24	Preclinical - Cell culture	Actionable	In a preclinical study, tumor cell lines expressing EGFR demonstrated efficacy in culture when treated with the bispecific antibody, AFM24 (J Clin Oncol 35, 2017 (suppl; abstr e14001)).	detail...
EGFR	EGFR positive	lung non-small cell carcinoma	sensitive	SHR-A1307	Preclinical - Pdx	Actionable	In a preclinical study, SHR-A1307 resulted in the inhibition of tumor growth and partial tumor regression (4/5; all partial) in patient-derived xenograft (PDX) models of EGFR-positive non-small cell lung cancer (PMID: 30962319).	30962319
EGFR	EGFR positive	colorectal cancer	predicted - sensitive	MM-151	Phase I	Actionable	In a Phase I clinical trial in patients with advanced solid tumors, MM-151 demonstrated safety and preliminary antitumor activity in patients with colorectal cancer (CRC), with 2 partial responses and 30% (8/26) of CRC patients demonstrating stable disease for greater than 4 months (J Clin Oncol 32:5s, 2014 (suppl; abstr 2518)).	detail...
EGFR	EGFR positive	Advanced Solid Tumor	predicted - sensitive	AC480	Phase I	Actionable	In a Phase I clinical trial, AC480 (BMS-599626) treatment demonstrated preliminary clinical activity, resulting in stable disease as best response in 25% (11/44) of patients with advanced solid tumors, including patients expressing EGFR and/or ERBB2, with 2 patients achieving stable disease for greater than 6 months (PMID: 21576284).	21576284
EGFR	EGFR positive	Advanced Solid Tumor	sensitive	EGFRBi-armed autologous activated T cells	Preclinical - Cell culture	Actionable	In a preclinical study, EGFRBi-armed autologous activated T cells demonstrated efficacy in cultured cells of a variety of EGFR positive tumor types (PMID: 16397041).	16397041
EGFR	EGFR positive	lung non-small cell carcinoma	predicted - sensitive	SYM004	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SYM004 demonstrated efficacy in cell line xenograft models of Erbitux (cetuximab)-resistant non-small cell lung cancer (PMID: 24204198).	24204198
EGFR	EGFR positive	stomach cancer	predicted - sensitive	Irinotecan + Nimotuzumab	Phase II	Actionable	In a Phase II trial, addition of Nimotuzumab to Camptosar (irinotecan) improved median progression-free survival (118.5 vs 59.0 days), median overall survival (358.5 vs 229.5 days) and response rate (33.3% vs 0.0 %) compared to Camptosar alone in EGFR positive gastric cancer patients (PMID: 25185971).	25185971
EGFR	EGFR positive	esophageal cancer	sensitive	Theliatinib	Preclinical - Pdx	Actionable	In a preclinical study, Theliatinib demonstrated efficacy associated with Egfr expression level in patient-derived xenograft (PDX) models, with highest anti-tumor activity in models harboring both EGFR amplification and overexpression, and low to moderate efficacy in models with low or medium Egfr expression (PMID: 28881608),	28881608
EGFR	EGFR positive	Advanced Solid Tumor	no benefit	Pelitinib	Phase I	Actionable	In a Phase I study, patients with advanced solid tumors that were positive for EGFR expression demonstrated no complete or partial responses when treated with Pelitinib (EKB-569) (PMID: 16710023).	16710023
EGFR	EGFR positive	head and neck cancer	predicted - sensitive	ABBV-221	Phase I	Actionable	In a Phase I trial, ABBV-221 demonstrated safety and preliminary efficacy, resulting in unconfirmed partial response in a patient with head and neck cancer that expressed high level of Egfr and its ligand (Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 2510-2510; NCT02365662).	detail...
EGFR	EGFR positive	colorectal cancer	sensitive	SYM004	Phase I	Actionable	In a Phase I study, 13% (5/39) of patients with metastatic colorectal cancer resistant to EGFR therapy had a partial response to SYM004 while 44% (17/39) demonstrated tumor regression (PMID: 25962717).	25962717
EGFR	EGFR positive	lung non-small cell carcinoma	sensitive	ABBV-221	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EGFR-positive non-small cell lung carcinoma cell line xenograft models were sensitive to ABBV-221 treatment, demonstrating tumor regression (PMID: 29483208).	29483208
EGFR	EGFR positive	lung non-small cell carcinoma	predicted - sensitive	Radiotherapy + SYM004	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SYM004 enhanced sensitivity to radiation therapy in non-small cell lung cancer cells in culture and in cell line xenografts (PMID: 24130052).	24130052
EGFR	EGFR positive	Advanced Solid Tumor	predicted - sensitive	AVID100	Preclinical - Cell culture	Actionable	In a preclinical study, AVID100 demonstrated activity against several EGFR-positive tumor cell lines in culture (Eur J Cancer, Dec 2016, Vol 69, S147).	detail...
EGFR	EGFR positive	colorectal cancer	predicted - sensitive	GC1118	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GC1118 inhibited EGFR ligand binding and reduced ligand-induced downstream signaling and proliferation of colorectal cancer cell lines exposed to a variety of EGFR ligands in culture, and inhibited tumor growth in colorectal cancer cell line xenograft models expressing high-affinity EGFR ligands (PMID: 26586721).	26586721
EGFR	EGFR positive	biliary tract cancer	predicted - sensitive	anti-EGFR CAR T	Phase I	Actionable	In a Phase I trial, treatment with EGFR-specific CAR T cells demonstrated safety and preliminary efficacy, resulted in complete response in 6% (1/17) and stable disease in 59% (10/17) of patients with Egfr-positive biliary tract cancer (PMID: 29138340; NCT01869166).	29138340
EGFR	EGFR positive	Advanced Solid Tumor	predicted - sensitive	ABBV-221	Phase I	Actionable	In a Phase I trial, ABBV-221 demonstrated safety and preliminary efficacy, resulting in stable disease in 38% (16/42) of patients with EGFR-dependent solid tumors (Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 2510-2510; NCT02365662).	detail...
EGFR	EGFR positive	chordoma	sensitive	Lapatinib	Guideline	Actionable	Tykerb (lapatinib) is included in guidelines for recurrent chordoma patients that are EGFR positive (NCCN.org).	detail...
EGFR	EGFR positive	pancreatic adenocarcinoma	sensitive	EGFRBi-armed autologous activated T cells	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EGFRBi-armed autologous activated T cells demonstrated efficacy in cultured cells and cell line mouse xenograft models of a variety of EGFR positive tumor types including pancreatic adenocarcinoma (PMID: 16397041).	16397041
EGFR	EGFR pos ERBB2 pos	lung cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human lung cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).	24837299
EGFR	EGFR pos ERBB2 pos	colon cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human colon cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).	24837299
EGFR	EGFR pos ERBB2 pos	stomach cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited cell growth, decreased phosphorylation of Egfr and Erbb2, and resulted in anti-tumor activity of human gastric cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).	24837299
EGFR	EGFR pos ERBB2 pos	breast cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human breast cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).	24837299
EGFR	EGFR pos ERBB2 pos	urinary bladder cancer	predicted - sensitive	Afatinib + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) pre-treatment inhibited radiotherapy-induced activation of EGFR and ERBB2 (HER2) and downstream AKT and radiosensitized bladder cancer cell lines in culture, and Gilotrif (afatinib) in combination with radiotherapy led to improved tumor growth inhibition in bladder cancer cell line xenograft models compared to radiotherapy alone (PMID: 25589492).	25589492
EGFR	EGFR pos ERBB2 pos	colorectal cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, colorectal cancer cells positive for EGFR and ERBB2 (HER2) had decreased growth upon Gilotrif (afatinib) treatment (PMID: 21617858).	21617858
EGFR	EGFR H304Y	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H304Y were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR H304Y	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H304Y were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR H304Y	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H304Y were sensitive to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR D770_N771insGF	lung non-small cell carcinoma	predicted - sensitive	Luminespib	Phase II	Actionable	In a Phase II trial, Luminespib (AUY922) treatment demonstrated safety and efficacy in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, with 1 patient harboring EGFR D770_N771insGF achieved partial response (PMID: 30351341; NCT01854034).	30351341
EGFR	EGFR L747_P753delinsQ	Advanced Solid Tumor	sensitive	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsQ were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_P753delinsQ	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsQ were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_P753delinsQ	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsQ were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_P753delinsQ	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsQ were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L747_P753delinsQ	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsQ were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_P753delinsQ	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsQ were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_T751delinsV	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_T751delinsV were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_T751delinsV	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_T751delinsV were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR E746_T751delinsV	lung non-small cell carcinoma	predicted - sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a clinical case study, a patient with non-small cell lung cancer harboring EGFR E746_T751delinsV was sensitive to treatment with Tagrisso (osimertinib), demonstrating a partial response according to RECIST criteria and a near complete intracranial metastases response (PMID: 31377341).	31377341
EGFR	EGFR E746_T751delinsV	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_T751delinsV were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_T751delinsV	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_T751delinsV were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_T751delinsV	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_T751delinsV were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR G735S	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G735S were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR G735S	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G735S were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR G735S	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G735S were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR T751_I759del EGFR L798F	lung non-small cell carcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, Gilotrif (afatinib) treatment resulted in a partial response with an ongoing progression-free survival of 24 months in a patient with non-small cell lung cancer harboring both EGFR T751_I759del and EGFR L798F (PMID: 31175009).	31175009
EGFR	EGFR T790M	lung non-small cell carcinoma	decreased response	Gefitinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, non-small lung cancer patients harboring EGFR T790M (n=23) demonstrated a median progression-free survival of 2.4 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or Icotinib, compared to 10.8 months in patients with EGFR L858R and EGFR exon 19 deletions (n=592) (PMID: 27468240).	27468240
EGFR	EGFR T790M	lung non-small cell carcinoma	predicted - sensitive	Epitinib	Phase I	Actionable	In a Phase I clinical trial, HMPL-813 (Epitinib) demonstrated safety and preliminary efficacy in patients with NSCLC, including a patient with EGFR T790M (J Clin Oncol 31, 2013 (suppl; abstr e19042).	detail...
EGFR	EGFR T790M	lung non-small cell carcinoma	resistant	Erlotinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, non-small lung cancer patients harboring EGFR T790M (n=23) demonstrated a median progression-free survival of 2.4 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or Icotinib, compared to 10.8 months in patients with EGFR L858R and EGFR exon 19 deletions (n=592) (PMID: 27468240).	27468240
EGFR	EGFR T790M	lung non-small cell carcinoma	no benefit	Brigatinib	Phase Ib/II	Actionable	In a Phase I/II trial, Alunbrig (brigatinib) treatment did not result in objective response in EGFRT790M-positive non-small cell lung cancer patients resistant to one previous EGFR tyrosine kinase inhibitor (PMID: 27836716).	27836716
EGFR	EGFR T790M	lung non-small cell carcinoma	predicted - sensitive	Cabozantinib + Erlotinib	Phase II	Actionable	In a Phase II trial (NCI 9303), Cometriq (cabozantinib) and Tarceva (erlotinib) combination treatment resulted in an objective response rate of 10.8% (4/37, 4 partial response) and an 8-week disease control rate of 67.0% (25/37) in heavily pretreated non-small cell lung cancer patients harboring EGFR mutations, progression-free survival and overall survival were not different among patients harboring EGFR L858R, exon 19 deletion, or T790M (PMID: 30915273; NCT01866410).	30915273
EGFR	EGFR T790M	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited growth of transformed cells expressing EGFR T790M in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1329).	detail...
EGFR	EGFR T790M	lung non-small cell carcinoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) mildly inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with an EGFR T790M mutation (PMID: 24939055).	24939055
EGFR	EGFR T790M	Advanced Solid Tumor	sensitive	AV-412	Preclinical	Actionable	In a preclinical study, AV-412 inhibited the kinase activity of EGFR T790M (PMID: 17888033).	17888033
EGFR	EGFR T790M	lung cancer	sensitive	CUDC-101	Preclinical	Actionable	In a preclinical study, CUDC-101 inhibited the growth of lung cancer cells expressing EGFR T790M (PMID: 20388807).	20388807
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	Naquotinib	Phase I	Actionable	In a Phase I trial, ASP8273 treatment resulted in partial response in 38% (15/40) and stable disease in 28% (11/40) of non-small cell lung carcinoma patients harboring EGFR T790M, with a median progression free survival of 6.7 months (J Clin Oncol 34, 2016 (suppl; abstr 9050)).	detail...
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	Olmutinib	Phase II	Actionable	In a Phase II trial, BI 1482694 (HM61713) treatment resulted in a disease control rate of 90% (64/71), and objective response with a median duration of 8.3 months in 56% (40/71) of patients with EGFR tyrosine kinase inhibitor-resistant non-small cell lung carcinoma harboring EGFR T790M (J Clin Oncol 34, 2016 (suppl; abstr 9055)).	detail...
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	Nazartinib	Phase I	Actionable	In a Phase I study, EGF816 treatment resulted in an objective response rate of 44% (56/127), disease control rate of 91% (115/127), and an estimated progression-free survival of 9.2 months in non-small cell lung carcinoma patients harboring EGFR T790M (J Clin Oncol 34, 2016 (suppl; abstr 9044); NCT02108964).	detail...
EGFR	EGFR T790M	lung non-small cell carcinoma	decreased response	Icotinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, non-small lung cancer patients harboring EGFR T790M (n=23) demonstrated a median progression-free survival of 2.4 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or Icotinib, compared to 10.8 months in patients with EGFR L858R and EGFR exon 19 deletions (n=592) (PMID: 27468240).	27468240
EGFR	EGFR T790M	lung non-small cell carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR T790M demonstrated a response rate of 4.76% and disease control rate of 47.62%, and a median progression-free survival of 1.6 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).	detail...
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	Rociletinib	Phase I	Actionable	In a Phase I trial, CO-1686 has demonstrated safety and efficacy in NSCLC patients carrying EGFR T790M mutations (J Clin Oncol 31, 2013 (suppl; abstr 2524)).	detail...
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	Rociletinib	Phase Ib/II	Actionable	In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in a response rate of 59% (27/46) and a disease control rate of 93% (43/46) in non-small cell lung cancer patients harboring EGFR T790M (PMID: 25923550).	25923550
EGFR	EGFR T790M	lung non-small cell carcinoma	predicted - sensitive	Alflutinib	Phase I	Actionable	In a Phase I trial, Alflutinib (AST2818) treatment resulted in an objective response rate of 58.3% (7/12) and a disease control rate of 91.7% (11/12) in patents with non-small cell lung cancer harboring EGFR T790M whose disease progressed on EGFR tyrosine kinase inhibitor therapy (J Thorac Oncol. Nov 2017, Vol 12, Issue 11, Suppl. 2, pS2138).	detail...
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	Abivertinib	Phase I	Actionable	In a Phase I trial, Abivertinib (AC0010) treatment resulted in decreased EGFR T790M allele frequency in cell free DNA of non-small cell lung carcinoma patients with acquired resistance to first generation Egfr tyrosine kinase inhibitor, and resulted in partial response or stable disease (PMID: 29626621).	29626621
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	Abivertinib	Case Reports/Case Series	Actionable	In a Phase I trial, two patients with non-small cell lung cancer harboring EGFR T790M demonstrated tumor reductions of 31% and 36% when treated with Abivertinib (AC0010) (PMID: 27573423; NCT02274337).	27573423
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	Osimertinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I extension trial that supported FDA approval, treatment with Tagrisso (osimertinib) resulted in in an objective response rate of 58% (115/119) and disease control rate of 92% in patients with EGFR-TKI resistant non-small cell lung cancer harboring EGFR T790M mutations (World Conf on Lung Cancer 2015. Abst MINI16.06).	detail... detail... detail...
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	Osimertinib	Phase II	Actionable	In Phase II clinical trials (AURA extension and AURA2), Tagrisso (osimertinib) treatment resulted in a central nervous system (CNS) overall response rate of 54% (24/50), including 6 complete responses, and a CNS disease control rate of 92% (46/50) in non-small cell lung cancer patients with CNS metatstases harboring EGFR T790M (PMID: 29293889; NCT01802632, NCT02094261).	29293889
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	Osimertinib	Guideline	Actionable	Tagrisso (osimertinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring EGFR T790M (PMID: 30715168, PMID: 30285222; ESMO guidelines).	30715168 30285222 detail...
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	Osimertinib	Phase III	Actionable	In a Phase III trial (AURA3), treatment with Tagrisso (osimertinib) resulted in an improved median progression-free survival of 10.1 months vs. 4.4 months with platinum plus pemetrexed, and an objective response rate of 71% (95% CI, 65 to 76) compared to 31% (95% CI, 24 to 40) with platinum plus pemetrexed therapy in patients with EGFR T790M-positive non-small cell lung cancer (PMID: 27959700; NCT02151981).	27959700
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	Osimertinib	Phase I	Actionable	In a Phase I trial, Tagrisso (osimertinib) demonstrated efficacy in 50% (9/18) of NSCLC patients carrying EGFR T790M mutations (PMID: 24410791).	24410791
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	Osimertinib	Guideline	Actionable	Tagrisso (osimertinib) is included in guidelines as subsequent therapy in patients with EGFR T790M-positive, metastatic non-small cell lung cancer who have progressed on Tarceva (erlotinib), Iressa (gefitinib), or Gilotrif (afatinib), and in patients who have progression with symptomatic brain metastases (NCCN.org).	detail...
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	Osimertinib	Phase I	Actionable	In a Phase I trial, Tagrisso (osimertinib) treatment resulted in an objective response rate of 61% (78/127) and a disease control rate of 95% (121/127) in NSCLC patients harboring EGFR T790M mutations (PMID: 25923549; NCT01802632).	25923549
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	BEZ235 + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically inhibited proliferation of Iressa (gefitinib)-resistant NSCLC cells harboring EGFR T790M in culture and in cell line xenograft models (PMID: 24939055).	24939055
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	Amlexanox + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, non-small cell lung cancer cell lines harboring activating EGFR mutations, including EGFR T790M, demonstrated sensitivity to the combination of amlexanox and Selumetinib (AZD6244), resulting in synergistic growth inhibition in culture and reduced tumor growth in xenograft models (PMID: 27287717).	27287717
EGFR	EGFR T790M	lung adenocarcinoma	resistant	Afatinib	Clinical Study - Cohort	Actionable	In a clinical study, second-site EGFR T790M mutations were detected in 47.6% (20/42) of lung adenocarcinoma patients with acquired resistance to Gilotrif (afatinib) (PMID: 26862733).	26862733
EGFR	EGFR T790M	lung non-small cell carcinoma	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with an EGFR T790M mutation (PMID: 24939055).	24939055
EGFR	EGFR T790M	lung non-small cell carcinoma	predicted - resistant	Afatinib	Phase II	Actionable	In a post-hoc analysis of Phase II and Phase III trials (LUX-Lung2, LUX-Lung 3, LUX-Lung 6), Gilotrif (afatinib) treatment resulted in an objective response rate of 14.3% (2/14) in non-small cell lung cancer patients harboring EGFR T790M, with a mean progression-free survival of 2.9 months, and an overall survival of 14.9 months (PMID: 26051236; NCT00525148, NCT00949650, and NCT01121393).	26051236
EGFR	EGFR T790M	lung non-small cell carcinoma	predicted - resistant	Afatinib	Clinical Study	Actionable	In a clinical study, Gilotrif (afatinib) treatment resulted in partial response in 15% (4/27), stable disease in 56% (15/27), and progressive disease in 30% (8/27) of non-small cell lung carcinoma patients harboring an EGFR T790M mutation (PMID: 26354527).	26354527
EGFR	EGFR T790M ERBB2 over exp	lung adenocarcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Tagrisso (osimertinib) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).	27252416
EGFR	EGFR T790M ERBB2 over exp	lung adenocarcinoma	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Rociletinib (CO-1686) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).	27252416
EGFR	EGFR T790M MET amp	lung adenocarcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Tagrisso (osimertinib) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).	27252416
EGFR	EGFR T790M MET amp	lung non-small cell carcinoma	predicted - resistant	Rociletinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, emergence of MET amplification was identified in 26% (28/43) of EGFR T790M-positive non-small cell lung cancer patients with acquired resistance to Rociletinib (CO1686), and patients with MET amplification prior to Rociletinib (CO1686) treatment demonstrated a decreased response compared to patients without MET amplification (PMID: 27283993).	27283993
EGFR	EGFR T790M MET amp	lung adenocarcinoma	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Rociletinib (CO-1686) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).	27252416
EGFR	EGFR D770delinsGY EGFR T790M	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing an EGFR D770delinsGY/EGFR T790M double mutation demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).	28363995
EGFR	EGFR D770delinsGY EGFR T790M	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, acquisition of EGFR T790M was associated with resistance to Vizimpro (dacomitinib) in transformed cells expressing EGFR D770delinsGY (PMID: 28363995).	28363995
EGFR	EGFR G719S EGFR T790M	lung adenocarcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, Tagrisso (osimertinib) treatment resulted in disease progression after 3 months in a patient with lung adenocarcinoma harboring EGFR G719S and an acquired EGFR T790M, after her disease progressed while on Tarceva (erlotinib) and then on Gilotrif (afatinib) treatments (PMID: 29285266).	29285266
EGFR	EGFR G719S EGFR T790M	lung adenocarcinoma	predicted - resistant	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, EGFR T790M was identified as an acquired mutation in the tumor of a patient with lung adenocarcinoma harboring EGFR G719S, after her disease progressed while on Tarceva (erlotinib) and then on Gilotrif (afatinib) treatments (PMID: 29285266).	29285266
EGFR	EGFR L747_P753delinsS + EGFR T790M	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing both EGFR L747_P753delinsS and EGFR T790M were resistant to Tarceva (erlotinib) in culture (PMID: 29467275).	29467275
EGFR	EGFR L747_P753delinsS + EGFR T790M	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L747_P753delinsS and EGFR T790M in culture (PMID: 29467275).	29467275
EGFR	EGFR L747_P753delinsS + EGFR T790M	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L747_P753delinsS and EGFR T790M in culture (PMID: 29467275).	29467275
EGFR	EGFR L747_P753delinsS + EGFR T790M	Advanced Solid Tumor	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing both EGFR L747_P753delinsS and EGFR T790M in culture (PMID: 29467275).	29467275
EGFR	EGFR G724S EGFR E746_S752delinsV EGFR T790M	lung adenocarcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a single patient with lung adenocarcinoma harboring an EGFR exon 19 deletion (E746_S752delinsV) and EGFR T790M was found to have acquired, via cell free DNA testing, an EGFR G724S mutation upon disease progression after 1 year of Tagrisso (osimertinib) therapy (PMID: 30588029).	30588029
EGFR	EGFR L747_S752delinsQH EGFR T790M	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung cancer co-harboring EGFR L747_S752delinsQH and EGFR T790M demonstrated a partial response when treated with Tarceva (erlotinib) (PMID: 31043566).	31043566
EGFR	EGFR L718V EGFR T790M	lung non-small cell carcinoma	predicted - resistant	Abivertinib	Phase I	Actionable	In a Phase I trial, tertiary EGFR mutations including C797S (n=3) and L718V (n=1) were identified as a potential acquired resistance mechanism in 13% (4/30) of patients with non-small cell lung cancer harboring EGFR T790M whose disease progressed while on Abivertinib (AC0010) treatment (PMID: 31027916; NCT02330367).	31027916
EGFR	EGFR amp EGFR T790M	lung non-small cell carcinoma	predicted - resistant	Abivertinib	Phase I	Actionable	In a Phase I trial, EGFR amplification was identified as a potential acquired resistance mechanism in 23% (7/30) of patients with non-small cell lung cancer harboring EGFR T790M whose disease progressed while on Abivertinib (AC0010) treatment (PMID: 31027916; NCT02330367).	31027916
EGFR	EGFR E746_S752delinsV	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_S752delinsV were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_S752delinsV	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_S752delinsV were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_S752delinsV	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_S752delinsV were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_S752delinsV	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_S752delinsV were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_S752delinsV	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_S752delinsV were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR E746_S752delinsV MET-UBE2H	lung adenocarcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR E746_S752delinsV developed progressive disease after remained on Tarceva (erlotinib) treatment for 33 months, a MET-UBE2H fusion was identified by liquid biopsy at the time of pregression (PMID: 30244854).	30244854
EGFR	EGFR E746_S752delinsV MET-UBE2H	lung adenocarcinoma	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, Xalkori (crizotinib) treatment resulted in partial response and progression-free survival for more than 6.5 months in a patient with lung adenocarcinoma harboring EGFR E746_S752delinsV and MET-UBE2H fusion (PMID: 30244854).	30244854
EGFR	EGFR A216T EGFR E746_S752delinsV	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tagrisso (osimertinib) resulted in decreased growth of transformed cells expressing EGFR A216T and EGFR E746_S752delinsV in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR A216T EGFR E746_S752delinsV	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Iressa (gefitinib) resulted in decreased growth of transformed cells expressing EGFR A216T and EGFR E746_S752delinsV in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR A216T EGFR E746_S752delinsV	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR A216T and EGFR E746_S752delinsV in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR A216T EGFR E746_S752delinsV	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Tarceva (erlotinib) resulted in decreased growth of transformed cells expressing EGFR A216T and EGFR E746_S752delinsV in cis and trans in culture (PMID: 29141884).	29141884
EGFR	EGFR A216T EGFR E746_S752delinsV	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A216T and EGFR E746_S752delinsV in cis and trans in culture demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 29141884).	29141884
EGFR	EGFR H773Y	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H773Y were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR H773Y	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H773Y were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR H773Y	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H773Y were resistant to treatment with Rocelitinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR H773Y	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H773Y were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR H773Y	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H773Y were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L747_A750del	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_A750del were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_A750del	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_A750del were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L747_A750del	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_A750del were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_A750del	Advanced Solid Tumor	sensitive	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_A750del were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_A750del	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_A750del were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_A750del	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_A750del were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR amp EGFR I744_K745delinsKIPVAI	lung adenocarcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, Tarceva (erlotinib) treatment resulted in a partial response lasted for 7 months in a patient with metastatic lung adenocarcinoma harboring EGFR amplification and EGFR I744_K745delinsKIPVAI (PMID: 21841502).	21841502
EGFR	EGFR V843I	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V843I were resistant to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR V843I	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V843I were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR V843I	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V843I were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR V843I	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V843I were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V843I	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V843I were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR V834L	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V834L were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V834L	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V834L were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V834L	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V834L were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR V834L	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V834L were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR T263P	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical	Actionable	In a preclinical study, Tarceva (erlotinib) decreased viability of transformed cells expressing EGFR T263P in culture (PMID: 17177598).	17177598
EGFR	EGFR L747_A750delinsP	lung adenocarcinoma	decreased response	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring EGFR L747_A750delinsP did not achieve a durable response to Tarceva (erlotinib), and in a cell line derived from the patient's tumor, Tarceva (erlotinib) did not fully inhibit EGFR phosphorylation and demonstrated a reduced impact on viability compared to a cell line harboring another exon 19 deletion (PMID: 31182434).	31182434
EGFR	EGFR L747_A750delinsP	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_A750delinsP were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_A750delinsP	Advanced Solid Tumor	sensitive	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_A750delinsP were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_A750delinsP	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_A750delinsP were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L747_A750delinsP	bronchiolo-alveolar adenocarcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, EGFR T790M was identified in the post-progression lesions from a patient with bronchioloalveolar carcinoma harboring EGFR L747_A750delinsP (reported as EGFR L747_E749del; A750P) with acquired resistance to Tarceva (erlotinib) (PMID: 15737014).	15737014
EGFR	EGFR L747_A750delinsP	lung non-small cell carcinoma	decreased response	Afatinib	Clinical Study	Actionable	In a clinical study, EGFR L747_A750delinsP was associated with shorter median progression-free survival (4.1 months vs 11.4 months), shorter treatment duration (5.9 vs 14.8 months), and shorter median overall survival (14.1 months vs 47.0 months) compared to other EGFR exon 19 deletions in an analysis of 32 non-small cell lung cancer patients treated with Tarceva (erlotinib), and 2 of the 4 patients harboring EGFR L747_A750delinsP had demonstrated primary resistance to Tarceva (erlotinib) (PMID: 31182434).	31182434
EGFR	EGFR L747_A750delinsP	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_A750delinsP were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_A750delinsP	lung adenocarcinoma	decreased response	Osimertinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, an established lung adenocarcinoma cell line harboring EGFR L747_A750delinsP demonstrated decreased sensitivity to Tagrisso (osimertinib) compared to Gilotrif (afatinib) and to cell lines harboring another exon 19 deletion, and a lung adenocarcinoma patient-derived cell line harboring EGFR L747_A750delinsP demonstrated decreased sensitivity to inhibition of EGFR phosphorylation and cell viability by Tagrisso (osimertinib) compared to Gilotrif (afatinib) in culture (PMID: 31182434).	31182434
EGFR	EGFR L747_A750delinsP	lung adenocarcinoma	sensitive	Afatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, an established lung adenocarcinoma cell line harboring EGFR L747_A750delinsP demonstrated increased sensitivity to Gilotrif (afatinib) compared to other EGFR inhibitors and to cell lines harboring another exon 19 deletion, and Gilotrif (afatinib) was more effective in inhibiting EGFR phosphorylation and cell viability in a lung adenocarcinoma patient-derived cell line harboring EGFR L747_A750delinsP compared to other EGFR inhibitors, in culture (PMID: 31182434).	31182434
EGFR	EGFR L747_A750delinsP	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_A750delinsP were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_A750delinsP FGFR3-TACC3	lung non-small cell carcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical study, a patient with non-small cell lung cancer initially responded to Tarceva (erlotinib), EGFR L747_A750delinsP and FGFR3-TACC3 were identified in post-progression tumor samples (PMID: 29883838).	29883838
EGFR	EGFR amp	head and neck cancer	sensitive	unspecified EGFR antibody + unspecified ERBB3 antibody + unspecified IGF-1R antibody	Preclinical - Cell culture	Actionable	In a preclinical study, combination of an unspecified EGFR antibody, an unspecified Erbb3 (Her3) antibody, and an unspecified Igf-1r antibody resulted in potent inhibition of survival in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).	27196767
EGFR	EGFR amp	head and neck squamous cell carcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Tarceva (erlotinib) in a cell viability assay (PMID: 27207775).	27207775
EGFR	EGFR amp	urinary bladder cancer	no benefit	Afatinib	Phase II	Actionable	In a Phase II clinical trial, three urothelial carcinoma patients with EGFR amplification in the absence of other ERBB family member alterations, received no benefit from Gilotrif (afatinib) therapy (PMID: 27044931).	27044931
EGFR	EGFR amp	Advanced Solid Tumor	predicted - sensitive	MM-151	Preclinical	Actionable	In a preclinical study, MM-151 antagonized EGFR activity and inhibited proliferation in several tumor cell lines in culture (PMID: 25911688).	25911688
EGFR	EGFR amp	Advanced Solid Tumor	sensitive	Depatuxizumab mafodotin	Phase Ib/II	Actionable	In a Phase I/II trial, Depatuxizumab mafodotin (ABT-414) treatment resulted in partial response in 1.8% (1/56) and stable disease in 23% (13/56) of patients with advanced solid tumor harboring EGFR amplification, overexpression, or mutated EGFR variant III (PMID: 29533458; NCT01741727).	29533458
EGFR	EGFR amp	Advanced Solid Tumor	sensitive	Depatuxizumab mafodotin	Phase I	Actionable	In a Phase I trial, ABT-414 displayed safety and preliminary efficacy in advanced solid tumor patients with EGFR amplification (J Clin Oncol 33, 2015 (suppl; abstr 2510)).	detail...
EGFR	EGFR amp	colorectal cancer	sensitive	Panitumumab	Phase III	Actionable	In a Phase III study, response to Vectibix (pantitumumab) was associated with EGFR amplification in colorectal cancer patients (PMID: 17664472).	17664472
EGFR	EGFR amp	triple-receptor negative breast cancer	sensitive	Depatuxizumab mafodotin	Phase Ib/II	Actionable	In a Phase I/II trial, Depatuxizumab mafodotin (ABT-414) treatment resulted in partial response in a patient with EGFR amplified triple-receptor negative breast cancer (PMID: 29533458; NCT01741727).	29533458
EGFR	EGFR amp	triple-receptor negative breast cancer	sensitive	Depatuxizumab mafodotin	Preclinical	Actionable	In a preclinical study, ABT-414 demonstrated cytotoxicity against a EGFR-amplified triple-negative breast cancer cell line in culture (PMID: 26846818).	26846818
EGFR	EGFR amp	triple-receptor negative breast cancer	sensitive	SHP099	Preclinical - Cell culture	Actionable	In a preclinical study, SHP099 inhibited ERK activation and reduced proliferation of an EGFR-amplified triple-negative breast cancer cell line in culture (PMID: 27362227).	27362227
EGFR	EGFR amp	glioblastoma multiforme	sensitive	Dacomitinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Vizimpro (dacomitinib) inhibited Egfr signaling and survival of patient-derived EGFR amplified glioblastoma cells in culture and in intracranial xenograft models (PMID: 25939761).	25939761
EGFR	EGFR amp	lung non-small cell carcinoma	sensitive	Ganetespib	Preclinical - Cell culture	Actionable	In a preclinical study, Ganetespib inhibited growth of a non-small cell lung cancer cell line with EGFR amplification and overexpression in culture (PMID: 25077897).	25077897
EGFR	EGFR amp	gastric adenocarcinoma	predicted - sensitive	Cetuximab	Clinical Study - Cohort	Actionable	In a clinical study, anti-Egfr antibody therapies including Erbitux (cetuximab) and ABT-806, alone or in combination with chemotherapy, resulted in an objective response in 57% (4/7, 3 complete response, 1 partial response), and disease control in 43% (3/7) of patients with EGFR amplified gastric and esophagogastric junction adenocarcinoma with a mean circulating tumor DNA copy number of 2.5 in non-responders vs 33.9 in responders (p=0.049) (PMID: 29449271).	29449271
EGFR	EGFR amp	esophagus squamous cell carcinoma	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Gilotrif (afatinib) in a cell viability assay (PMID: 27207775).	27207775
EGFR	EGFR amp	triple-receptor negative breast cancer	sensitive	Erlotinib + PF-431396	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tarceva (erlotinib) and PF-431396 resulted in a synergistic effect in a triple-receptor negative breast cancer cell line harboring EGFR amplification, demonstrating inhibition of cell growth in culture (PMID: 27793840).	27793840
EGFR	EGFR amp	malignant glioma	no benefit	Erlotinib + Temsirolimus	Phase Ib/II	Actionable	In a Phase I/II clinical trial, Torisel (temsirolimus) in combination with Tarceva (erlotinib) demostrated minimal efficacy at the maximum tolerated dosage in high-grade glioma patients, with no correlation between EGFR amplification and survival (PMID: 24470557).	24470557
EGFR	EGFR amp	esophagus adenocarcinoma	predicted - resistant	AMG 337	Case Reports/Case Series	Actionable	In a clinical case study, a patient with esophageal adenocarcinoma progressed on AMG 337 therapy upon outgrowth of EGFR amplified tumor cells (PMID: 26432108).	26432108
EGFR	EGFR amp	penile cancer	sensitive	ABT-806	Phase I	Actionable	In a Phase I trial, ABT-806 treatment resulted in stable disease for more than 2.5 years in a penile cancer patient harboring EGFR amplification (PMID: 25895099).	25895099
EGFR	EGFR amp	gastric adenocarcinoma	predicted - sensitive	ABT-806	Clinical Study - Cohort	Actionable	In a clinical study, anti-Egfr antibody therapies including Erbitux (cetuximab) and ABT-806, alone or in combination with chemotherapy, resulted in an objective response in 57% (4/7, 3 complete response, 1 partial response), and disease control in 43% (3/7) of patients with EGFR amplified gastric and esophagogastric junction adenocarcinoma with a mean circulating tumor DNA copy number of 2.5 in non-responders vs 33.9 in responders (p=0.049) (PMID: 29449271).	29449271
EGFR	EGFR amp	head and neck cancer	sensitive	unspecified EGFR antibody + unspecified IGF-1R antibody	Preclinical - Cell culture	Actionable	In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Igf-1r antibody resulted in growth inhibition in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).	27196767
EGFR	EGFR amp	glioblastoma multiforme	no benefit	Temozolomide + Vandetanib	Phase II	Actionable	In a Phase II trial, Caprelsa (vandetinib), in combination with radiation therapy and Temodar (temozolomide), demonstrated no difference in PFS and OS in glioblastoma patients harboring EGFR amplification versus glioblastoma patients without EGFR amplification (PMID: 25910950).	25910950
EGFR	EGFR amp	gastrointestinal system cancer	sensitive	Cetuximab	Preclinical - Pdx	Actionable	In preclinical studies, Erbitux (cetuximab) promoted tumor growth inhibition in several patient-derived xenograft models of gastric cancers with EGFR amplification (PMID: 24141978).	24141978
EGFR	EGFR amp	head and neck cancer	sensitive	unspecified EGFR antibody + unspecified ERBB3 antibody	Preclinical - Cell culture	Actionable	In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Erbb3 (Her3) antibody resulted in inhibition of survival in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).	27196767
EGFR	EGFR amp	gastroesophageal junction adenocarcinoma	predicted - sensitive	Cetuximab	Clinical Study - Cohort	Actionable	In a clinical study, anti-Egfr antibody therapies including Erbitux (cetuximab) and ABT-806, alone or in combination with chemotherapy, resulted in an objective response in 57% (4/7, 3 complete response, 1 partial response), and disease control in 43% (3/7) of patients with EGFR amplified gastric and esophagogastric junction adenocarcinoma with a mean circulating tumor DNA copy number of 2.5 in non-responders vs 33.9 in responders (p=0.049) (PMID: 29449271).	29449271
EGFR	EGFR amp	head and neck squamous cell carcinoma	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of head and neck squamous cell carcinoma (HNSCC) cell lines in culture, and inhibited tumor growth in HNSCC cell line xenograft models, with highest efficacy against EGFR-amplified cell lines (PMID: 25559287).	25559287
EGFR	EGFR amp	head and neck squamous cell carcinoma	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Erbitux (cetuximab) in a cell viability assay (PMID: 27207775).	27207775
EGFR	EGFR amp	lung non-small cell carcinoma	predicted - sensitive	Docetaxel + Vandetanib	Phase III	Actionable	In a Phase III trial (ZODIAC), Caprelsa (vandetanib) and Taxotere (docetaxel) combination treatment resulted in improved progression-free survival (HR=0.61), overall survival (HR=0.48), and objective response (odd ratio=3.90) in non-small cell lung cancer patients harboring EGFR amplification compared to the overall study population (PMID: 25057173; NCT00312377).	25057173
EGFR	EGFR amp	glioblastoma multiforme	sensitive	Depatuxizumab mafodotin	Phase I	Actionable	In a Phase I trial, treatment with Depatuxizumab mafodotin (ABT-414) resulted in an overall response rate of 6.7% (3/59; 1 complete response and 2 partial responses), stable disease in 41% (27/66), and a progression-free survival rate of 28.8% (95% CI 18.5, 39.9%) at 6 months in patients with EGFR-amplified recurrent glioblastoma (PMID: 29075855; NCT01800695).	detail... 29075855
EGFR	EGFR amp	gastroesophageal junction adenocarcinoma	predicted - sensitive	ABT-806	Clinical Study - Cohort	Actionable	In a clinical study, anti-Egfr antibody therapies including Erbitux (cetuximab) and ABT-806, alone or in combination with chemotherapy, resulted in an objective response in 57% (4/7, 3 complete response, 1 partial response), and disease control in 43% (3/7) of patients with EGFR amplified gastric and esophagogastric junction adenocarcinoma with a mean circulating tumor DNA copy number of 2.5 in non-responders vs 33.9 in responders (p=0.049) (PMID: 29449271).	29449271
EGFR	EGFR amp	triple-receptor negative breast cancer	sensitive	Gefitinib + PF-573228	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Iressa (gefitinib) and PF-573228 resulted in a synergistic effect in a triple-receptor negative breast cancer cell line harboring EGFR amplification, demonstrating decreased colony formation in culture (PMID: 27793840).	27793840
EGFR	EGFR amp	esophagus squamous cell carcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Tarceva (erlotinib) in a cell viability assay (PMID: 27207775).	27207775
EGFR	EGFR amp	head and neck cancer	sensitive	unspecified EGFR antibody	Preclinical - Cell culture	Actionable	In a preclinical study, combination of two unspecified EGFR antibodies targeting nonoverlapping epitopes of Egfr resulted in Egfr degradation and inhibition of proliferation in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).	27196767
EGFR	EGFR amp	esophagus squamous cell carcinoma	sensitive	SHP099	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SHP099 inhibited ERK activation and reduced proliferation of EGFR-amplified esophageal squamous cell carcinoma cells in culture, and inhibited tumor growth in EGFR-amplified esophageal squamous cell carcinoma cell line xenograft models (PMID: 27362227).	27362227
EGFR	EGFR amp	triple-receptor negative breast cancer	sensitive	Gefitinib + PF-431396	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Iressa (gefitinib) and PF-431396 resulted in a synergistic effect in a triple-receptor negative breast cancer cell line harboring EGFR amplification, demonstrating a decrease in colony formation in culture (PMID: 27793840).	27793840
EGFR	EGFR amp	esophagus squamous cell carcinoma	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Erbitux (cetuximab) in a cell viability assay (PMID: 27207775).	27207775
EGFR	EGFR amp	head and neck squamous cell carcinoma	sensitive	Depatuxizumab mafodotin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-414 demonstrated cytoxicity against an EGFR-amplified head and neck squamous cell carcinoma (HNSCC) cell line in culture and induced tumor regression in EGFR-amplified HNSCC cell line xenograft models (PMID: 26846818).	26846818
EGFR	PDGFRA amp EGFR amp	glioblastoma multiforme	sensitive	Gefitinib + Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) and Iressa (gefitinib) acted synergistically to decrease downstream signaling activity and inhibit cell growth of glioblastoma cell lines with EGFR and PDGFRA coamplification (PMID: 22323597).	22323597
EGFR	EGFR amp EGFR S492R	colorectal cancer	resistant	Cetuximab	Case Reports/Case Series	Actionable	In a clinical study, EGFR S492R was detected in a colorectal cancer patient harboring EGFR amplification who progressed on an Erbitux (cetuximab) containing regimen, and resistance to Erbitux (cetuximab) was supported by lack of growth inhibition in colorectal cancer cells harboring EGFR S492R and EGFR amplification in culture (PMID: 22270724).	22270724
EGFR	EGFR amp EGFR S492R	colorectal cancer	predicted - sensitive	Panitumumab	Case Reports/Case Series	Actionable	In a clinical study, a colorectal cancer patient harboring both EGFR amplification and EGFR S492R demonstrated a greater than 50% reduction in liver lesion volume when treated with Vectibix (panitumumab) (PMID: 22270724).	22270724
EGFR	EGFR amp EGFR S492R BRAF V600E	colorectal cancer	resistant	Cetuximab	Case Reports/Case Series	Actionable	In a clinical study, EGFR S492R was detected in the post-Erbitux (cetuximab) sample from a colorectal cancer patient harboring EGFR amplification and BRAF V600E who progressed on an Erbitux (cetuximab) regimen (PMID: 22270724).	22270724
EGFR	EGFR amp MET amp	esophagus adenocarcinoma	sensitive	Crizotinib + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with EGFR and MET copy number gain in culture (PMID: 27595477).	27595477
EGFR	EGFR amp MET amp	lung non-small cell carcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung cancer harboring EGFR amplification progressed after Tarceva (erlotinib) treatment, and was found to have acquired a MET amplification (PMID: 30268451).	30268451
EGFR	EGFR amp MET amp	lung non-small cell carcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung cancer harboring EGFR amplification progressed after Iressa (gefitinib) treatment, and was found to have acquired MET amplification (PMID: 30268451).	30268451
EGFR	EGFR amp MET amp	lung non-small cell carcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, two patients with non-small cell lung cancer harboring EGFR amplification and EGFR T790M progressed after Tagrisso (osimertinib) treatment, and were found to have lost the EGFR T790M and acquired MET amplification (PMID: 30268451).	30268451
EGFR	EGFR amp ERBB2 amp	urinary bladder cancer	sensitive	Afatinib	Phase II	Actionable	In a Phase II clinical trial, two urothelial carcinoma patients with ERBB2 (HER2) and EGFR co-amplification had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931).	27044931
EGFR	EGFR amp ERBB2 amp	gastric adenocarcinoma	predicted - resistant	Fluorouracil + Oxaliplatin + Trastuzumab	Case Reports/Case Series	Actionable	In Phase II clinical trial, a patient with metastatic gastric adenocarcinoma progressed while on the combination therapy of Adrucil (fluorouracil), Eloxatin (oxaliplatin), and Herceptin (trastuzumab), and was subsequently found to have acquired co-amplification of EGFR and ERBB2 (HER2) in the liver metastasis (PMID: 30463996; NCT01522768).	30463996
EGFR	EGFR amp ERBB2 amp	stomach cancer	predicted - resistant	Fluorouracil + Oxaliplatin + Trastuzumab	Phase II	Actionable	In a Phase II clinical trial, co-amplification of EGFR and ERBB2 (HER2) was identified at the time of progression in a patient with ERBB2 (HER2)-positive gastric cancer who initially demonstrated a short response to the combination therapy of Herceptin (trastuzumab), Adrucil (fluorouracil), and Eloxatin (oxaliplatin), but then progression at 7 months (PMID: 30463996; NCT01522768).	30463996
EGFR	EGFR amp ERBB2 amp	stomach cancer	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a Phase II clinical trial, a gastric cancer patient with co-amplification of EGFR and ERBB2 (HER2) who previously progressed on a combination therapy with Herceptin (trastuzumab) demonstrated a 37% tumor regression when treated with Gilotrif (afatinib) (PMID: 30463996; NCT01522768).	30463996
EGFR	EGFR amp ERBB2 amp	gastric adenocarcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a Phase II clinical trial, a metastatic gastric adenocarcinoma patient with co-amplification of EGFR and ERBB2 (HER2) demonstrated a 43% tumor regression by RECIST when treated with Gilotrif (afatinib) (PMID: 30463996; NCT01522768).	30463996
EGFR	BRAF V600E EGFR amp	colorectal cancer	resistant	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR amp	colorectal cancer	resistant	Selumetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired EGFR amplification (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR amp	colorectal cancer	sensitive	Cetuximab + Selumetinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Selumetinib (AZD6244), and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR amp	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR amp	colorectal cancer	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR amp	colorectal cancer	sensitive	Cetuximab + Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR amp	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR amp	colorectal cancer	resistant	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Selumetinib (AZD6244) in culture (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR amp	colorectal cancer	resistant	Cetuximab + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR amp	colorectal cancer	resistant	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).	27312529
EGFR	BRAF V600E EGFR amp	colorectal cancer	resistant	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment in culture (PMID: 27312529).	27312529
EGFR	EGFR amp PTEN loss	glioblastoma multiforme	decreased response	Dacomitinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, patient-derived EGFR amplified glioblastoma cells harboring PTEN loss demonstrated reduced sensitivity to Vizimpro (dacomitinib) induced growth inhibition in culture and in xenograft models (PMID: 25939761).	25939761
EGFR	EGFR amp FGFR1 amp	lung cancer	resistant	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cell lines with co-amplification of FGFR1 and EGFR demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 28341788).	28341788
EGFR	EGFR amp ERBB2 over exp	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified EGFR amplification in 2 patients demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).	29208673
EGFR	EML4-ALK EGFR amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, EGFR amplification (PMID: 29636358).	29636358
EGFR	EGFR amp ERBB2 amp MET amp	gastric adenocarcinoma	resistant	Afatinib	Case Reports/Case Series	Actionable	In a Phase II clinical trial, a metastatic gastric adenocarcinoma patient with co-amplification of EGFR and ERBB2 (HER2) who initially responded to Gilotrif (afatinib) treatment progressed at 12 weeks and was found to have acquired amplification of MET in the progressing sites, which was subsequently confirmed to be associated with resistance via a patient-derived xenograft (PDX) model treated with Gilotrif (afatinib) (PMID: 30463996; NCT01522768).	30463996
EGFR	EGFR amp ERBB2 amp MET amp	gastric adenocarcinoma	predicted - resistant	AMG 337	Preclinical - Pdx	Actionable	In a Phase II clinical trial, a gastric adenocarcinoma patient-derived xenograft (PDX) model with amplification of EGFR, ERBB2 (HER2), and MET demonstrated resistance to treatment with AMG 337 (PMID: 30463996; NCT01522768).	30463996
EGFR	EGFR amp ERBB2 amp MET amp	gastric adenocarcinoma	predicted - sensitive	Afatinib + AMG 337	Preclinical - Pdx	Actionable	In a Phase II clinical trial, preclinical analysis of a gastric adenocarcinoma patient-derived xenograft (PDX) model with amplification of EGFR, ERBB2 (HER2), and MET demonstrated tumor regression when treated with a combination of Gilotrif (afatinib) and AMG 337 (PMID: 30463996; NCT01522768).	30463996
EGFR	EGFR S784F	lung non-small cell carcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, Tarceva (erlotinib) treatment resulted in disease progression after 10 weeks of treatment in a patient with metastatic non-small cell lung cancer harboring EGFR S784F (PMID: 21841502).	21841502
EGFR	EGFR A289D	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289D were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR A289D	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A289D were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating decreased cell viability (PMID: 29141884).	29141884
EGFR	EGFR A767V	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A767V were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR A767V	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A767V were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A767V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A767V were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR G863S	lung non-small cell carcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical study, Tarceva (erlotinib) treatment resulted in massive disease progression in a patient with non-small cell lung cancer harboring EGFR G863S (PMID: 31175009).	31175009
EGFR	EGFR A702S	lung non-small cell carcinoma	no benefit	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, Gilotrif (afatinib) treatment resulted in progressive disease in a non-small cell lung carcinoma patient baboring an EGFR A702S mutation (PMID: 26354527).	26354527
EGFR	EGFR E709_T710delinsD	lung non-small cell carcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical study, Tarceva (erlotinib) treatment resulted in disease progression in a patient with non-small cell lung cancer harboring EGFR E709_T710delinsD (PMID: 31175009).	31175009
EGFR	EGFR E709_T710delinsD	Advanced Solid Tumor	decreased response	Osimertinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to third-generation EGFR inhibitors including Tagrisso (AZD9291) in culture, when compared to second-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR E709_T710delinsD	Advanced Solid Tumor	decreased response	Gefitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to the first-generation EGFR inhibitor Iressa (gefitinib) in culture, when compared to second-generation inhibitors, with an IC90 concentration approximately two-times the estimated trough concentration at the recommended dose (PMID: 26206867).	26206867
EGFR	EGFR E709_T710delinsD	Advanced Solid Tumor	decreased response	Erlotinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to first-generation EGFR inhibitors including Tarceva (erlotinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR E709_T710delinsD	lung adenocarcinoma	sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, treatment with Gilotrif (afatinib) resulted in a partial response lasting 1 year in a patient with lung adenocarcinoma harboring EGFR E709_T710delinsD who had progressed on first line Platinol (cisplatin) plus Navelbine (vinorelbine) with radiotherapy (PMID: 30413663).	30413663
EGFR	EGFR E709_T710delinsD	lung adenocarcinoma	sensitive	Afatinib	Phase I	Actionable	In a clinical case study, treatment with Gilotrif (afatinib) in a lung adenocarcinoma patient harboring EGFR E709_T710delinsD resulted in tumor shrinkage, while prior treatment with Tarceva (erlotinib) had achieved stable disease (PMID: 26206867).	26206867
EGFR	EGFR E709_T710delinsD	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709_T710delinsD were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR E709_T710delinsD	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated increased sensitivity to second-generation EGFR inhibitors including Vizimpro (dacomitinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR E709_T710delinsD	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated increased sensitivity to second-generation EGFR inhibitors including Gilotrif (afatinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR E709_T710delinsD	Advanced Solid Tumor	decreased response	Rociletinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to third-generation EGFR inhibitors including Rociletinib (CO-1686) in culture, when compared to second-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR E709_T710delinsD	Advanced Solid Tumor	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated increased sensitivity to second-generation EGFR inhibitors including Nerlynx (neratinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR E709_T710delinsD SMAD4 R361C TP53 loss	lung small cell carcinoma	unknown	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR E709_T710delinsD who progressed after a 1 year partial response to Gilotrif (afatinib) was found to have disease that transformed to small cell lung cancer and had acquired a SMAD4 R361C mutation and did not express Tp53 protein (PMID: 30413663).	30413663
EGFR	EGFR I740_K745dup	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, Tarceva (erlotinib) treatment resulted in a partial response that lasted for 9 months in a patient with metastatic non-small cell lung cancer harboring EGFR I740_K745dup (reported as K745_E746insIPVAIK) (PMID: 25279299).	25279299
EGFR	EGFR I740_K745dup	lung adenocarcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, a lung adenocarcinoma patient harboring EGFR I740_K745dup (reported as K745_E746insIPVAIK) demonstrated a partial response when treated with Gilotrif (afatinib) (PMID: 22190593).	22190593
EGFR	EGFR L747S	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747S were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747S	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747S were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L747S	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747S were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L838V	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L838V were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L838V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L838V were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR K467T	colorectal cancer	sensitive	Panitumumab	Preclinical	Actionable	In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR K467T in culture (PMID: 26843189).	26843189
EGFR	EGFR K467T	Advanced Solid Tumor	predicted - sensitive	SYM004	Preclinical - Cell culture	Actionable	In a preclinical study, SYM004 inhibited phosphorylation of EGFR in cells expressing EGFR K467T in culture (PMID: 26888827).	26888827
EGFR	EGFR K467T	colorectal cancer	sensitive	MM-151	Preclinical	Actionable	In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR K467T in culture (PMID: 26843189).	26843189
EGFR	EGFR K467T	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR K467T were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).	26843189
EGFR	EGFR E709G	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709G were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR E709G	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709G were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E709G	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709G were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR E709G	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709G were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR A216T	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A216T were sensitive to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR A216T	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A216T were sensitive to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR A216T	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A216T were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR A216T	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A216T were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR A216T	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A216T were sensitive to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR V769M	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769M were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V769M	lung non-small cell carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR V769M demonstrated a response rate of 0% and disease control rate of 100%, and a median progression-free survival of 3.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).	detail...
EGFR	EGFR V769M	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769M were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR V769M	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769M were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V769M	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769M were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E749Q	lung adenocarcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with metastatic lung adenocarcinoma harboring EGFR E749Q did not respond to Iressa (gefitinib) treatment (PMID: 28162944).	28162944
EGFR	EGFR E749Q	lung non-small cell carcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical study, Tarceva (erlotinib) treatment resulted in disease progression in a patient with non-small cell lung cancer harboring EGFR E749Q (PMID: 31175009).	31175009
EGFR	EGFR-RAD51	lung adenocarcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, Gilotrif (afatinib) treatment resulted in progression-free survival over 6 months in a patient with lung adenocarcinoma harboring EGFR-RAD51 (PMID: 29472054).	29472054
EGFR	EGFR-RAD51	Advanced Solid Tumor	predicted - sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated some sensitivity to treatment with Tagrisso (osimertinib) in culture, resulting in decreased cell viability (PMID: 27102076).	27102076
EGFR	EGFR-RAD51	lung adenocarcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical study, three patients with lung adenocarcinoma harboring EGFR-RAD51 demonstrated partial responses as indicated by tumor regression, when treated with Tarceva (erlotinib) (PMID: 27102076).	27102076
EGFR	EGFR-RAD51	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated sensitivity to treatment with Erbitux (cetuximab) in culture, resulting in decreased cell viability (PMID: 27102076).	27102076
EGFR	EGFR-RAD51	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, Tarceva (erlotinib) treatment resulted in a partial response in a patient with non-small cell lung carcinoma harboring EGFR-RAD51, demonstrating decreased tumor size after one month of treatment and stable disease after 5 months of treatment (PMID: 29290255).	29290255
EGFR	EGFR-RAD51	lung adenocarcinoma	predicted - sensitive	Icotinib	Case Reports/Case Series	Actionable	In a clinical case study, Conmana (icotinib) treatment resulted in progression-free survival over 15 months in a patient with lung adenocarcinoma harboring EGFR-RAD51 (PMID: 31064887).	31064887
EGFR	EGFR-RAD51	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated sensitivity to treatment with Gilotrif (afatinib) in culture, resulting in decreased cell viability and inhibition of downstream MAPK and PI3K signaling (PMID: 27102076).	27102076
EGFR	EGFR D770_P772dup	lung non-small cell carcinoma	predicted - sensitive	Luminespib	Phase II	Actionable	In a Phase II trial, Luminespib (AUY922) treatment demonstrated safety and efficacy in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, with 1 patient harboring EGFR D770_P772dup achieved partial response (PMID: 30351341; NCT01854034).	30351341
EGFR	EGFR D770_P772dup	lung non-small cell carcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, treatment with Poziotinib (HM781-36B) resulted in objective partial responses in 64% (7/11) of patients with non-small cell lung cancer harboring EGFR exon 20 mutations, including a patient with EGFR D770_P772dup (reported as P772_H773insDNP) (PMID: 29686424; NCT03066206).	29686424
EGFR	EGFR P848L	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P848L were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR P848L	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P848L were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR P848L	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P848L were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR P848L	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P848L were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR P848L	lung non-small cell carcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical study, Tarceva (erlotinib) treatment resulted in disease progression in a patient with non-small cell lung cancer harboring EGFR P848L (PMID: 31175009).	31175009
EGFR	EGFR S720F	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S720F were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR S720F	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S720F were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR S720F	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S720F were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR S720F	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S720F were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR S720F	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S720F were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR S720F	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S720F were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_P753delinsVS	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_P753delinsVS were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_P753delinsVS	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_P753delinsVS were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR E746_P753delinsVS	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_P753delinsVS were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_P753delinsVS	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_P753delinsVS were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_P753delinsVS	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_P753delinsVS were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E746_P753delinsVS	Advanced Solid Tumor	sensitive	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E746_P753delinsVS were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR D770_N771insNPY	lung non-small cell carcinoma	predicted - sensitive	Luminespib	Phase II	Actionable	In a Phase II trial, Luminespib (AUY922) treatment demonstrated safety and efficacy in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, with 1 patient harboring EGFR D770_N771insNPY achieved stable disease (PMID: 30351341; NCT01854034).	30351341
EGFR	EGFR E709K	Advanced Solid Tumor	decreased response	Erlotinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to first-generation EGFR inhibitors including Tarceva (erlotinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR E709K	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709K were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E709K	Advanced Solid Tumor	decreased response	Osimertinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to third-generation EGFR inhibitors including Tagrisso (AZD9291) in culture, when compared to second-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR E709K	Advanced Solid Tumor	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709K demonstrated increased sensitivity to second-generation EGFR inhibitors including Nerlynx (neratinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR E709K	Advanced Solid Tumor	decreased response	Rociletinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to third-generation EGFR inhibitors including Rociletinib (CO-1686) in culture, when compared to second-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR E709K	Advanced Solid Tumor	decreased response	Gefitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to first-generation EGFR inhibitors including Iressa (gefitinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR E709K	Advanced Solid Tumor	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709K demonstrated increased sensitivity to second-generation EGFR inhibitors including Gilotrif (afatinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR E709K	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EGFR E709K demonstrated increased sensitivity to second-generation EGFR inhibitors including Vizimpro (dacomitinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).	26206867
EGFR	EGFR S492R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S492R were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR S492R	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S492R were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR S492R	colorectal cancer	sensitive	Panitumumab	Preclinical	Actionable	In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR S492R in culture (PMID: 26843189).	26843189
EGFR	EGFR S492R	lung squamous cell carcinoma	predicted - sensitive	Necitumumab	Preclinical - Cell culture	Actionable	In a preclinical study, Portrazza (necitumumab) bound EGFR S492R, and reduced ligand-induced EGFR phosphorylation in lung squamous cell carcinoma cells expressing EGFR S492R (referred to as S468R) in cell culture (PMID: 29158469).	29158469
EGFR	EGFR S492R	colorectal cancer	sensitive	SYM004	Phase I	Actionable	In a Phase I study, a colorectal cancer patient harboring EGFR S492R demonstrated a partial response when treated with SYM004 (PMID: 25962717).	25962717
EGFR	EGFR S492R	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR S492R were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).	26843189
EGFR	EGFR S492R	colorectal cancer	sensitive	MM-151	Preclinical	Actionable	In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR S492R in culture (PMID: 26843189).	26843189
EGFR	EGFR S492R	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S492R were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR P772_H773insPNP	lung adenocarcinoma	sensitive	Afatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR P772_H773insPNP in culture (PMID: 28363995).	28363995
EGFR	EGFR P772_H773insPNP	lung adenocarcinoma	sensitive	Dacomitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Vizimpro (dacomitinib) inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR P772_H773insPNP in culture (PMID: 28363995).	28363995
EGFR	EGFR P596L	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P596L were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR P596L	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P596L were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR P596L	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR P596L were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR D761_E762insEAFQ	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR D761_E762insEAFQ were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR D761_E762insEAFQ	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR D761_E762insEAFQ were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR D761_E762insEAFQ	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR D761_E762insEAFQ were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L703I	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L703I were resistant to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR L703I	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L703I were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR L703I	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L703I were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR R451C	Advanced Solid Tumor	predicted - sensitive	SYM004	Preclinical - Cell culture	Actionable	In a preclinical study, SYM004 inhibited phosphorylation of EGFR in cells expressing EGFR R451C in culture (PMID: 26888827).	26888827
EGFR	EGFR R451C	colorectal cancer	sensitive	Cetuximab	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).	26843189
EGFR	EGFR R451C	colorectal cancer	sensitive	Panitumumab	Preclinical	Actionable	In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).	26843189
EGFR	EGFR R451C	colorectal cancer	sensitive	MM-151	Preclinical	Actionable	In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).	26843189
EGFR	EGFR H773L	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H773L were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR H773L	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H773L were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR H773L	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H773L were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR H773L	lung non-small cell carcinoma	resistant	EKI-285	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells expressing EGFR H773L were resistant to EKI-285 (CL-387,785) induced Egfr signaling inhibition and apoptosis in culture (PMID: 17974985).	17974985
EGFR	EGFR H773L	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H773L were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR H773L EGFR V774M	lung adenocarcinoma	predicted - resistant	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR H773L and EGFR V774M demonstrated rapid progression following first-line treatment with Gilotrif (afatinib) (PMID: 31007929).	31007929
EGFR	EGFR L747_P753delinsS	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsS were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_P753delinsS	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) inhibited the growth of cultured cells expressing the EGFR exon 19 variant, L747_P753delinsS (PMID: 19147750).	19147750
EGFR	EGFR L747_P753delinsS	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsS were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_P753delinsS	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsS were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L747_P753delinsS	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsS were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_P753delinsS	Advanced Solid Tumor	sensitive	Naquotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of transformed cells expressing EGFR L747_P753delinsS in culture (PMID: 29467275).	29467275
EGFR	EGFR L747_P753delinsS	Advanced Solid Tumor	sensitive	AEE788	Preclinical	Actionable	In a preclinical study, AEE788 inhibited the growth of cultured cells expressing the EGFR exon 19 variant, L747_P753delinsS (PMID: 19147750).	19147750
EGFR	EGFR L747_P753delinsS	Advanced Solid Tumor	sensitive	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_P753delinsS were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_P753delinsS EML4-ALK	lung non-small cell carcinoma	predicted - resistant	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, a patient with non-small cell lung cancer initially responded to Gilotrif (afatinib), EGFR L747_P753delinsS and EML4-ALK were identified in post-progression tumor samples (PMID: 29883838).	29883838
EGFR	EGFR A864T	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A864T were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR A864T	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A864T were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A864T	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A864T were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A864T	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A864T were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR A864T	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A864T were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L858M	lung non-small cell carcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, Gilotrif (afatinib) treatment resulted in partial response in 100% (2 of 2) of non-small cell lung carcinoma patients harboring EGFR L858M mutation (PMID: 26354527).	26354527
EGFR	EGFR A859T	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A859T were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR A859T	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A859T were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR A859T	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A859T were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V774M	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V774M were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR V774M	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V774M were sensitive to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR V774M	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V774M were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR V774M	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V774M were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR A750P EGFR L747_E749del	lung non-small cell carcinoma	sensitive	Trametinib + WZ4002	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Mekinist (trametinib) to WZ4002 treatment did not significantly impact cell viability compared to WZ4002 alone, but delayed onset of drug resistance in a non-small cell lung cancer cell line harboring EGFR A750P and EGFR L747_E749del in culture (PMID: 26036643).	26036643
EGFR	EGFR A750P EGFR L747_E749del PIK3CA E545K	lung non-small cell carcinoma	decreased response	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of PIK3CA E545K in a non-small cell lung cancer cell line harboring EGFR L747_E749del and EGFR A750P resulted in decreased sensitivity to Tagrisso (osimertinib) in culture (PMID: 30228210).	30228210
EGFR	EGFR A702V	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) treatment of transformed mouse cells expressing Egfr A702V did not prevent increased cell viability, indicating resistance of Egfr A702V (PMID: 30952700).	30952700
EGFR	EGFR A702V	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, Erbitux (cetuximab) treatment of transformed mouse cells expressing Egfr A702V resulted in decreased cell viability (PMID: 30952700).	30952700
EGFR	EGFR A702V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) treatment of transformed mouse cells expressing Egfr A702V resulted in decreased cell viability (PMID: 30952700).	30952700
EGFR	EGFR E709A	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR E709A	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E709A	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E709A	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR E709A	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR E709A EGFR G719S	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A and EGFR G719S in cis and trans were resistant to Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR E709A EGFR G719S	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased growth of transformed cells expressing EGFR E709A and EGFR G719S in cis in culture (PMID: 29141884).	29141884
EGFR	EGFR E709A EGFR G719S	Advanced Solid Tumor	conflicting	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A and EGFR G719C in trans were sensitive to treatment with Tagrisso (osimertinib), but when expressed in cis, demonstrated resistance in culture (PMID: 29141884).	29141884
EGFR	EGFR E709A EGFR G719S	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A and EGFR G719S in cis and trans were resistant to Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR E709A EGFR G719S	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709A and EGFR G719C in trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719S	lung adenocarcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, Tarceva (erlotinib) treatment resulted in tumor reduction after 2 months of treatment in a patient with metastatic lung adenocarcinoma harboring EGFR G719S, and the patient stayed on treatment after 4 months (PMID: 21841502).	21841502
EGFR	EGFR G719S	lung non-small cell carcinoma	sensitive	Afatinib	Phase III	Actionable	In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411, PMID: 23344264).	23344264 24790411
EGFR	EGFR G719S	lung non-small cell carcinoma	sensitive	Dacomitinib	Phase III	Actionable	In Phase III clinical trials, patients with NSCLC tumors harboring an EGFR G719X (X=A, C, or S) mutation responded to EGFR tyrosine kinase inhibitors including Vizimpro (dacomitinib) (PMID: 24857124).	24857124
EGFR	EGFR G719S	colorectal cancer	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) reduced tumor growth in a colorectal cancer cell line xenograft model harboring EGFR G719S (PMID: 30872380).	30872380
EGFR	EGFR G719S	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719S were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719S	lung non-small cell carcinoma	sensitive	Gefitinib	Clinical Study	Actionable	In a clinical study, analysis of published studies demonstrated that 78% (14/18) of non-small cell lung cancer patients harboring an EGFR G719 mutation, resulting in G719A, C, D, or S were found to achieve disease control following treatment Tarceva (erlotinib) or Iressa (gefitinib) (PMID: 23344264).	23344264
EGFR	EGFR G719S	lung non-small cell carcinoma	sensitive	Gefitinib	Preclinical	Actionable	In a preclinical study, EGFR G719S was demonstrated to stabilize the active conformation of Egfr and result in increased sensitivity of Egfr to Iressa (gefitinib) in in vitro assays compared to wild-type Egfr (PMID: 17349580).	17349580
EGFR	EGFR G719S	lung non-small cell carcinoma	sensitive	TAS-121	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung cancer patient harboring EGFR G719S demonstrated 55% tumor shrinkage following treatment with TAS-121 (PMID: 30872380).	30872380
EGFR	EGFR G719S	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Clinical Study	Actionable	In a clinical study, analysis of published studies demonstrated that 78% (14/18) of non-small cell lung cancer patients harboring an EGFR G719 mutation, resulting in G719A, C, D, or S, were found to achieve disease control following treatment Tarceva (erlotinib) or Iressa (gefitinib) (PMID: 23344264).	23344264
EGFR	EGFR G719S	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719S were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR G719S	colorectal cancer	sensitive	TAS-121	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAS-121 reduced tumor growth in a colorectal cancer cell line xenograft model harboring EGFR G719S (PMID: 30872380).	30872380
EGFR	MAP2K1 Q56P MAP2K1 H119Y MAP2K1 D351G EGFR G719S	colorectal cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a colorectal cancer cell line harboring MAP2K1 mutations Q56P, H119Y, and D351G and an EGFR G719S mutation demonstrated some sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713).	26582713
EGFR	EGFR G719S EGFR S768I	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719S and EGFR S768I in cis and trans were resistant to Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719S EGFR S768I	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719S and EGFR S768I in cis and trans were resistant to Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719S EGFR S768I	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719S and EGFR S768I in trans were resistant to Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR G719S EGFR S768I	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR G719S and EGFR S768I in cis and trans were sensitive to Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR L861R	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L861R were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L861R	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L861R were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L861R	lung adenocarcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, Tarceva (erlotinib) treatment resulted in disease progression after 2 months of treatment in a patient with metastatic lung adenocarcinoma harboring EGFR L861R (PMID: 21841502).	21841502
EGFR	EGFR A750V	lung non-small cell carcinoma	no benefit	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, Gilotrif (afatinib) treatment resulted in progressive disease in a non-small cell lung carcinoma patient harboring an EGFR A750V mutation (PMID: 26354527).	26354527
EGFR	EGFR V786M	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V786M were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V786M	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V786M were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR G719X	lung non-small cell carcinoma	decreased response	Osimertinib	Phase Ib/II	Actionable	In a Phase I/II trial (AURA), Tagrisso (osimertinib) demonstrated limited clinical efficacy, resulted in partial response in 14% (1/7) and stable disease in 43% (3/7) of non-small cell lung cancer patients harboring EGFR G719 mutations, with 3 patients also harboring EGFR T790M (PMID: 29285266; NCT01802632).	29285266
EGFR	EGFR G719X	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited growth of transformed cells expressing EGFR G719X in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1329).	detail...
EGFR	EGFR G719X	lung non-small cell carcinoma	sensitive	Afatinib	Phase III	Actionable	In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411).	24790411
EGFR	EGFR G719X	lung non-small cell carcinoma	sensitive	Afatinib	Guideline	Actionable	Gilotrif (afatinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as G719 mutations (NCCN.org).	detail...
EGFR	EGFR G719X	lung non-small cell carcinoma	sensitive	Afatinib	FDA approved - On Companion Diagnostic	Actionable	In a post-hoc analysis of Phase II and Phase III trials that supported FDA approval (LUX-Lung2, LUX-Lung 3, LUX-Lung 6), Gilotrif (afatinib) treatment resulted in an objective response rate of 77.8% (14/18) in non-small cell lung cancer patients harboring EGFR G719X (alone or in combination with other EGFR mutations), with a mean progression-free survival of 13.8 months, and an overall survival of 26.9 months (PMID: 26051236; NCT00525148, NCT00949650, and NCT01121393).	detail... detail... 26051236
EGFR	EGFR G719X	lung non-small cell carcinoma	sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, Gilotrif (afatinib) treatment resulted in partial response in 14% (1/7), stable disease in 43% (3/7), and progressive disease in 43% (3/7) of non-small cell lung carcinoma patients carrying an EGFR G719 mutation (PMID: 26354527).	26354527
EGFR	EGFR G719X	lung non-small cell carcinoma	sensitive	Gefitinib	Guideline	Actionable	Iressa (gefinitib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as G719 mutations (NCCN.org).	detail...
EGFR	EGFR G719X	lung non-small cell carcinoma	sensitive	Gefitinib	Clinical Study	Actionable	In a clinical study, analysis of published studies demonstrated that 78% (14/18) of non-small cell lung cancer patients harboring an EGFR G719 mutation, resulting in G719A, C, D, or S, were found to achieve disease control following treatment Tarceva (erlotinib) or Iressa (gefitinib) (PMID: 23344264).	23344264
EGFR	EGFR G719X	lung non-small cell carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR G719 mutations demonstrated a response rate of 58% and disease control rate of 73.68%, and a median progression-free survival of 2.8 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).	detail...
EGFR	EGFR G719X	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Clinical Study	Actionable	In a clinical study, analysis of published studies demonstrated that 78% (14/18) of non-small cell lung cancer patients harboring an EGFR G719 mutation, resulting in G719A, C, D, or S were found to achieve disease control following treatment Tarceva (erlotinib) or Iressa (gefitinib) (PMID: 23344264).	23344264
EGFR	EGFR G719X	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Guideline	Actionable	Tarceva (erlotinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as G719 mutations (NCCN.org).	detail...
EGFR	EGFR G719X	lung non-small cell carcinoma	sensitive	Neratinib	Phase II	Actionable	In a Phase II clinical trial, treatment with Nerlynx (neratinib) resulted in partial response in 75% (3/4) and stable disease in 25% (1/4) of non-small cell lung cancer patients harboring EGFR G719 mutations (PMID: 20479403).	20479403
EGFR	EGFR G719X	lung non-small cell carcinoma	sensitive	Dacomitinib	Guideline	Actionable	Vizimpro (dacomitinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as G719 mutations (NCCN.org).	detail...
EGFR	EGFR A871G	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A871G were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A871G	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A871G were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A871G	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A871G were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR A871G	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A871G were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A871G	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A871G were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR A871G	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR A871G were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR H773_V774insAH	lung non-small cell carcinoma	predicted - sensitive	Luminespib	Phase II	Actionable	In a Phase II trial, Luminespib (AUY922) treatment demonstrated safety and efficacy in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, resulted in stable disease in a patient harboring EGFR H773_V774insAH (PMID: 30351341; NCT01854034).	30351341
EGFR	EGFR R776G	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R776G were sensitive to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR R776G	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R776G were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR R776G	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R776G were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR V802I	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V802I were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V802I	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V802I were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR V802I	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V802I were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR V802I	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V802I were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V802I	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V802I were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR D770_N771insSVD	lung non-small cell carcinoma	predicted - sensitive	Luminespib	Phase II	Actionable	In a Phase II trial, Luminespib (AUY922) treatment demonstrated safety and efficacy in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, resulted in 1 partial response and 1 stable disease in 3 patients harboring EGFR D770_N771insSVD (PMID: 30351341; NCT01854034).	30351341
EGFR	EGFR H773dup	lung non-small cell carcinoma	resistant	Erlotinib	Case Reports/Case Series	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR H773dup (reported as H773_V774insH), displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).	24353160
EGFR	EGFR H773dup	lung non-small cell carcinoma	resistant	Gefitinib	Case Reports/Case Series	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR H773dup (reported as H773_V774insH), displayed progressive disease following treatment with Iressa (gefitinib) (PMID: 24353160).	24353160
EGFR	EGFR H773dup	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H773dup (reported as H773_V774insH) were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR H773dup	Advanced Solid Tumor	sensitive	Luminespib	Preclinical - Cell culture	Actionable	In a preclinical study, Luminespib (AUY922) decreased viability of cells expressing EGFR H773dup (referred to as H773_V774insH) in culture (PMID: 30154228).	30154228
EGFR	EGFR H773dup	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H773dup (reported as H773_V774insH) were resistant to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR H773dup	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR H773dup (reported as H773_V774insH) were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR H773dup	lung non-small cell carcinoma	predicted - sensitive	Luminespib	Phase II	Actionable	In a Phase II trial, Luminespib (AUY922) treatment demonstrated safety and efficacy in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions, resulted in partial response in a patient harboring EGFR H773dup (PMID: 30351341; NCT01854034).	30351341
EGFR	EGFR H773dup	lung non-small cell carcinoma	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, non-small cell carcinoma cell lines harboring EGFR exon 20 insertions, including EGFR H773dup (reported as H773_V774insH), demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160).	24353160
EGFR	EGFR S306L	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S306L were resistant to treatment with Tagrisso (osimertinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR S306L	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S306L were sensitive to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR S306L	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S306L were sensitive to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR S306L	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S306L were sensitive to treatment with Gilotrif (afatinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR S306L	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S306L were sensitive to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR M277E	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tarceva (erlotinib) treatment of cell line xenograft models expressing EGFR M277E were sensitive to treatment, as demonstrated by decreased tumor growth (PMID: 28979142).	28979142
EGFR	EGFR L703P	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L703P were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L703P	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L703P were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability in culture (PMID: 29141884).	29141884
EGFR	EGFR L703P	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L703P were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR G465E	colorectal cancer	sensitive	MM-151	Preclinical	Actionable	In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR G465E in culture (PMID: 26843189).	26843189
EGFR	EGFR G465E	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR G465E were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).	26843189
EGFR	EGFR G465E	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR G465E were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).	26843189
EGFR	EGFR I491M	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR I491M were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).	26843189
EGFR	EGFR I491M	colorectal cancer	sensitive	MM-151	Preclinical	Actionable	In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR I491M in culture (PMID: 26843189).	26843189
EGFR	EGFR I491M	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing EGFR I491M were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).	26843189
EGFR	EGFR N771dup	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR N771dup (reported as N771_P772insN) were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR N771dup	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR N771dup (reported as N771_P772insN) were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR N771dup	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR N771dup (reported as N771_P772insN) were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR N771dup	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR N771dup (reported as N771_P772insN) were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR N771dup	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR N771dup (reported as N771_P772insN) were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR L747_T751delinsS	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsS were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR L747_T751delinsS	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsS were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_T751delinsS	Advanced Solid Tumor	sensitive	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsS were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_T751delinsS	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsS were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_T751delinsS	Advanced Solid Tumor	sensitive	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsS were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR L747_T751delinsS	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR L747_T751delinsS were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V769L	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769L were resistant to treatment with Tarceva (erlotinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR V769L	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769L were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR V769L	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769L were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR V769L	lung non-small cell carcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, Gilotrif (afatinib) treatment resulted in stable disease in a non-small cell lung carcinoma patient harboring EGFR V769L (PMID: 26354527).	26354527
EGFR	EGFR V769L	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769L were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR V769L	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR V769L were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR H773_V774delinsLM	lung adenocarcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case report, Iressa (gefitinib) treatment resulted in disease progression in a patient with lung adenocarcinoma harboring EGFR H773_V774delinsLM (reported as H773L/V774M in cis) 12 weeks after treatment (PMID: 29858019).	29858019
EGFR	EGFR H773_V774delinsLM	lung adenocarcinoma	predicted - sensitive	Bevacizumab + Gefitinib	Case Reports/Case Series	Actionable	In a clinical case report, Iressa (gefitinib) in combination with Avastin (bevacizumab) resulted in stable disease in a patient with lung adenocarcinoma harboring EGFR H773_V774delinsLM (reported as H773L/V774M in cis), until disease progression after 7 months (PMID: 29858019).	29858019
EGFR	EGFR H773_V774delinsLM	lung adenocarcinoma	predicted - sensitive	Bevacizumab + Osimertinib	Case Reports/Case Series	Actionable	In a clinical case report, Tagrisso (osimertinib) in combination with Avastin (bevacizumab) resulted in clinical improvement in tumor lesions and metastasis sites in a patient with lung adenocarcinoma harboring EGFR H773_V774delinsLM (reported as H773L/V774M in cis), until disease progression after 12 months (PMID: 29858019).	29858019
EGFR	EGFR E734Q	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical	Actionable	In a preclinical study, cells expressing EGFR E734Q demonstrated sensitivity to Tarceva (erlotinib) in culture (PMID: 20942962).	20942962
EGFR	EGFR D770delinsGY	Advanced Solid Tumor	resistant	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR D770delinsGY demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 28363995).	28363995
EGFR	EGFR D770delinsGY	lung non-small cell carcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, treatment with Poziotinib (HM781-36B) resulted in objective partial responses in 64% (7/11) of patients with non-small cell lung cancer harboring EGFR exon 20 mutations, including a patient with EGFR D770delinsGY (PMID: 29686424; NCT03066206).	29686424
EGFR	EGFR D770delinsGY	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vizimpro (dacomitinib) inhibited EGFR phosphorylation and growth of transformed cells expressing EGFR D770delinsGY in culture (PMID: 28363995).	28363995
EGFR	EGFR E868G	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical	Actionable	In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation in cells expressing EGFR E868G in culture (PMID: 20942962).	20942962
EGFR	EGFR exon 19 ins	lung non-small cell carcinoma	sensitive	Osimertinib	Guideline	Actionable	Tagrisso (osimertinib) is included in guidelines as preferred first-line or as subsequent therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as exon 19 insertions (NCCN.org).	detail...
EGFR	EGFR exon 19 ins	lung non-small cell carcinoma	sensitive	Dacomitinib	Guideline	Actionable	Vizimpro (dacomitinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as exon 19 insertions (NCCN.org).	detail...
EGFR	EGFR exon 19 ins	lung non-small cell carcinoma	sensitive	Erlotinib	Guideline	Actionable	Tarceva (erlotinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as exon 19 insertions (NCCN.org).	detail...
EGFR	EGFR exon 19 ins	lung non-small cell carcinoma	sensitive	Afatinib	Guideline	Actionable	Gilotrif (afatinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as exon 19 insertions (NCCN.org).	detail...
EGFR	EGFR exon 19 ins	lung non-small cell carcinoma	sensitive	Gefitinib	Guideline	Actionable	Iressa (gefitinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as exon 19 insertions (NCCN.org).	detail...
EGFR	EGFR R776H	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R776H were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR R776H	lung non-small cell carcinoma	no benefit	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, Gilotrif (afatinib) treatment resulted in progressive disease in a non-small cell lung carcinoma patient harboring an EGFR R776H mutation (PMID: 26354527).	26354527
EGFR	EGFR R776H	Advanced Solid Tumor	sensitive	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R776H were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR R776H	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R776H were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR R776H	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R776H were sensitive to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR R776H	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR R776H were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR S768I	Advanced Solid Tumor	decreased response	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768I had decreased sensitivity to Tarceva (erlotinib) in cell culture (PMID: 19147750).	19147750
EGFR	EGFR S768I	Advanced Solid Tumor	predicted - sensitive	TAS6417	Preclinical - Cell culture	Actionable	In a preclinical study, TAS6417 inhibited growth of transformed cells expressing EGFR S768I in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1329).	detail...
EGFR	EGFR S768I	Advanced Solid Tumor	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768I were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).	29141884
EGFR	EGFR S768I	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768I were resistant to treatment with Iressa (gefitinib) in culture (PMID: 29141884).	29141884
EGFR	EGFR S768I	lung non-small cell carcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, treatment with Poziotinib (HM781-36B) resulted in objective partial responses in 64% (7/11) of patients with non-small cell lung cancer harboring EGFR exon 20 mutations, including a patient with EGFR S768I (PMID: 29686424; NCT03066206).	29686424
EGFR	EGFR S768I	lung non-small cell carcinoma	decreased response	Icotinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR S768I (n=10) demonstrated a median progression-free survival of 2.7 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or icotinib, compared to 10.8 months in patients with EGFR L858R and EGFR exon 19 deletions (n=592) (PMID: 27468240).	27468240
EGFR	EGFR S768I	lung non-small cell carcinoma	decreased response	Icotinib	Clinical Study	Actionable	In a retrospective analysis, non-small cell lung cancer patients harboring EGFR S768I demonstrated a response rate of 25% and disease control rate of 80%, and a median progression-free survival of 3.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).	detail...
EGFR	EGFR S768I	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR S768I were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR S768I	lung non-small cell carcinoma	decreased response	Gefitinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, non-small lung cancer patients harboring EGFR S768I (n=10) demonstrated a median progression-free survival of 2.7 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or Icotinib, compared to 10.8 months in patients with EGFR L858R and EGFR exon 19 deletions (n=592) (PMID: 27468240).	27468240
EGFR	EGFR S768I	lung non-small cell carcinoma	sensitive	Dacomitinib	Guideline	Actionable	Vizimpro (dacomitinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as S768I (NCCN.org).	detail...
EGFR	EGFR S768I	lung non-small cell carcinoma	decreased response	Erlotinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, non-small lung cancer patients harboring EGFR S768I (n=10) demonstrated a median progression-free survival of 2.7 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or Icotinib, compared to 10.8 months in patients with EGFR L858R and EGFR exon 19 deletions (n=592) (PMID: 27468240).	27468240
EGFR	EGFR S768I	lung non-small cell carcinoma	sensitive	Afatinib	Guideline	Actionable	Gilotrif (afatinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as S768I (NCCN.org).	detail...
EGFR	EGFR S768I	lung non-small cell carcinoma	sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, Gilotrif (afatinib) treatment resulted in stable disease in a non-small cell lung carcinoma patient harboring EGFR S768I (PMID: 26354527).	26354527
EGFR	EGFR S768I	lung non-small cell carcinoma	sensitive	Afatinib	FDA approved - On Companion Diagnostic	Actionable	In a post-hoc analysis of Phase II and Phase III trials that supported FDA approval (LUX-Lung 2, LUX-Lung 3, LUX-Lung 6), Gilotrif (afatinib) treatment resulted in partial response in 100% (8/8) of non-small cell lung cancer patients harboring EGFR S768I (alone or in combination with EGFR L719X or L858R), with a mean progression-free survival of 14.7 months (PMID: 26051236; NCT00525148, NCT00949650, and NCT01121393).	detail... detail... 26051236
EGFR	EGFR N826S	Advanced Solid Tumor	resistant	AEE788	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR N826S demonstrated resistance to AEE788 in cell culture (PMID: 19147750).	19147750
EGFR	EGFR N826S	Advanced Solid Tumor	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR N826S demonstrated resistance to Iressa (gefitinib) in cell culture (PMID: 19147750).	19147750
EGFR	EGFR N826S	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR N826S demonstrated resistance to Tarceva (erlotinib) in cell culture (PMID: 19147750).	19147750
EGFR	EGFR N771_P772insL	lung non-small cell carcinoma	predicted - sensitive	Osimertinib	Case Reports/Case Series	Actionable	In a clinical study, Tagrisso (osimertinib) treatment resulted in stable disease with a progression-free survival of 4.9 months in a patient with non-small cell lung cancer harboring EGFR N771_P772insL (PMID: 31208370).	31208370
EGFR	EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T	olfactory neuroblastoma	predicted - sensitive	Cetuximab + Sunitinib	Case Reports/Case Series	Actionable	In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).	27149458
EGFR	EGFR E709V	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709V were sensitive to treatment with Tagrisso (osimertinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E709V	Advanced Solid Tumor	resistant	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709V were resistant to treatment with Rociletinib (CO-1686) in culture (PMID: 29141884).	29141884
EGFR	EGFR E709V	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709V were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR E709V	Advanced Solid Tumor	sensitive	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EGFR E709V were sensitive to treatment with Erbitux (cetuximab) in culture, demonstrating reduced cell viability (PMID: 29141884).	29141884
EGFR	EGFR exon19	lung non-small cell carcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, Gilotrif (afatinib) treatment resulted in partial response in 50% (1/2) and stable disease in 50% (1/2) of non-small cell lung carcinoma patients carrying an EGFR exon 19 deletion and/or insertion (PMID: 26354527).	26354527
EML4	EML4-ALK	neuroblastoma	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of neuroblastoma cells harboring EML4-ALK in culture (PMID: 26554404).	26554404
EML4	EML4-ALK	lung non-small cell carcinoma	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited phosphorylation of Alk and inhibited growth of human non-small cell lung cancer cell lines harboring EML4-ALK in culture (PMID: 25173427).	25173427
EML4	EML4-ALK	lung non-small cell carcinoma	sensitive	Brigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited Alk phosphorylation and growth in non-small cell lung cancer cell lines harboring EML4-ALK in culture, and induced near complete tumor regression in cell line xenograft models (PMID: 27780853).	27780853
EML4	EML4-ALK	lung non-small cell carcinoma	predicted - sensitive	Crizotinib + GLPG0634	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EML4-ALK in culture that had, over time, acquired resistance to Xalkori (crizotinib) showed decreased drug resistance when treatment was combined with Filgotinib (GLPG0634), demonstrating reduced expression of Osmr and phosphorylated-Stat3, and decreased cell viability (PMID: 28729401).	28729401
EML4	EML4-ALK	lung non-small cell carcinoma	sensitive	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited Alk phosphorylation and growth of a human non-small cell lung cancer cell line harboring EML4-ALK in culture and in cell line xenograft models (PMID: 21575866).	21575866
EML4	EML4-ALK	lung non-small cell carcinoma	sensitive	WX-0593	Preclinical - Pdx	Actionable	In a preclinical study, WX-0593 inhibited Alk downstream signaling and tumor growth in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring EML4-ALK (Cancer Res 2018;78(13 Suppl):Abstract nr 4794).	detail...
EML4	EML4-ALK	lung non-small cell carcinoma	sensitive	Crizotinib	Clinical Study - Cohort	Actionable	In a clinical study, non-small cell lung carcinoma patients harboring an EML4-ALK variant 1 (E13; A20, n=19) demonstrated a significantly longer progression-free survival (11.0 vs 4.2 months, p<0.05) compared to patients with a non-variant 1 EML4-ALK fusion (n=16) when treated with Xalkori (crizotinib) (PMID: 27354483).	27354483
EML4	EML4-ALK	lung non-small cell carcinoma	sensitive	Crizotinib	Phase I	Actionable	In a Phase I trial, Xalkori (crizotinib) inhibited tumor growth by at least 30% from baseline in 90% (18/20) of patients with EML4-ALK positive non-small cell lung carcinoma (PMID: 20979469; NCT00585195; NCT00585195).	20979469
EML4	EML4-ALK	lung non-small cell carcinoma	sensitive	Afatinib + Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination of Gilotrif (afatinib) and Alecensa (alectinib) restored sensitivity to Alecensa (alectinib) in non-small cell lung cancer cells harboring EML4-ALK fusion that acquired resistance to Alecensa (alectinib) through up-regulating Egfr signaling in culture, inhibited tumor progression in cell line xenograft models (PMID: 26682573).	26682573
EML4	EML4-ALK	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK in culture (PMID: 25228534).	25228534
EML4	EML4-ALK	lung non-small cell carcinoma	sensitive	Entrectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring EML4-ALK were sensitive to Rozlytrek (entrectinib), resulting in inhibition of cell proliferation and complete tumor regression in cell line xenograft models (PMID: 26939704).	26939704
EML4	EML4-ALK	lung non-small cell carcinoma	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring EML4-ALK fusion in culture (PMID: 26090892).	26090892
EML4	EML4-ALK	inflammatory myofibroblastic tumor	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with inflammatory myofibroblastic tumor harboring EML4-ALK achieved complete remission three years after starting Xalkori (crizotinib) treatment (PMID: 26808369).	26808369
EML4	EML4-ALK	lung non-small cell carcinoma	sensitive	Lorlatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and proliferation of non-small cell lung carcinoma cells harboring EML4-ALK fusion, and reduced intracranial tumor size in cell line xenograft models (PMID: 26144315).	26144315
EML4	EML4-ALK	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK in culture (PMID: 26698910).	26698910
EML4	EML4-ALK	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK in culture (PMID: 25228534).	25228534
EML4	EML4-ALK	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK in culture (PMID: 30002191).	30002191
EML4	EML4-ALK	Advanced Solid Tumor	sensitive	Ensartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ensartinib (X-396) inhibited growth of transformed cells expressing EML4-ALK in culture (PMID: 30002191).	30002191
EML4	EML4-ALK	lung non-small cell carcinoma	sensitive	CEP-28122	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CEP-28122 inhibited growth of non-small cell lung carcinoma cell lines harboring EML4-ALK in culture, and resulted in tumor regression in cell line xenograft models (PMID: 22203728).	22203728
EML4	EML4-ALK	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK in culture (PMID: 26698910).	26698910
EML4	EML4-ALK	lung non-small cell carcinoma	sensitive	MTI-31	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MTI-31 inhibited proliferation and migration and increased PD-L1 degradation in a non-small cell lung cancer cell line harboring EML4-ALK in culture, and inhibited tumor growth in xenograft models (PMID: 30796032).	30796032
EML4	EML4-ALK	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of a transformed cell line expressing EML4-ALK in culture (PMID: 25228534).	25228534
EML4	EML4-ALK	lung cancer	sensitive	X-376	Preclinical - Cell line xenograft	Actionable	In a preclinical study, X-376 inhibited Alk signaling, resulted in growth inhibition in lung cancer cells harboring EML4-ALK fusion in culture and in cell line xenograft models (PMID: 21613408).	21613408
EML4	EML4-ALK	neuroblastoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing EML4-ALK in culture (PMID: 26554404).	26554404
EML4	EML4-ALK	Advanced Solid Tumor	sensitive	WX-0593	Preclinical - Cell culture	Actionable	In a preclinical study, WX-0593 inhibited growth of transformed cells expressing EML4-ALK in culture (Cancer Res 2018;78(13 Suppl):Abstract nr 4794).	detail...
EML4	EML4-ALK	Advanced Solid Tumor	sensitive	Repotrectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Repotrectinib (TPX-0005) inhibited growth of transformed cells expressing EML4-ALK in culture, led to tumor growth inhibition in cell line xenograft models (PMID: 30093503).	30093503
EML4	EML4-ALK	lung non-small cell carcinoma	sensitive	Ensartinib + Sirolimus	Preclinical	Actionable	In a preclinical study, transformed non-small cell lung cancer cells harboring EML4-ALK demonstrated enhanced growth inhibition to a combination treatment with Afinitor (sirolimus) and Ensartinib (X-396) (PMID: 21613408).	21613408
EML4	EML4-ALK ALK G1269A	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated moderate resistance to ASP3026 in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK G1269A	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK G1269A	lung non-small cell carcinoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human lung cancer cell lines expressing ALK G1269A in the context of EML4-ALK demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 24675041).	24675041
EML4	EML4-ALK ALK G1269A	lung non-small cell carcinoma	resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK demonstrated stable disease when treated with Xalkori (crizotinib), but then progressed, and was found to harbor a secondary resistance mutation, ALK G1269A (PMID: 22235099).	22235099
EML4	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK G1269A	lung non-small cell carcinoma	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, human lung cancer cell lines harboring EML4-ALK with ALK G1269A demonstrated sensitivity to Zykadia (ceritinib) in culture (PMID: 24675041).	24675041
EML4	EML4-ALK ALK G1269A	Advanced Solid Tumor	decreased response	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated a decreased response when treated with Rozlytrek (entrectinib) compared to cells expressing wild-type EML4-ALK (PMID: 26939704).	26939704
EML4	EML4-ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated resistance to Alecensa (alectinib) in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture, and inhibited tumor growth in xenograft models (PMID: 24887559).	24887559
EML4	EML4-ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) modestly inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK G1269A	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK G1269A	lung non-small cell carcinoma	sensitive	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited proliferation of a Xalkori (crizotinib)-resistant human non-small cell lung cancer cell line harboring an EML-ALK fusion with ALK G1269A in culture and induced tumor regression in cell line xenograft models (PMID: 26849637, PMID: 23344087).	26849637 23344087
EML4	EML4-ALK ALK G1269A	lung non-small cell carcinoma	sensitive	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK fusion positive non-small cell lung cancer with ALK G1269A had a partial response to Alecensa (alectinib) treatment (PMID: 26849637).	26849637
EML4	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK G1269A	lung non-small cell carcinoma	sensitive	Lorlatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and growth of non-small cell lung cancer (NSCLC) cells over expressing ALK G1269A in the context of EML4-ALK in culture and in cell line xenograft models, as well as inhibited growth of patient derived NSCLC cells harboring EML4-ALK ALK G1269A in culture (PMID: 26144315).	26144315
EML4	EML4-ALK ALK G1269A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1269A in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22235099).	22235099
EML4	EML4-ALK ALK G1269A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK in the context of EML4-ALK were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK G1269A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In preclinical studies, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859, PMID: 26698910).	26698910 27009859
EML4	EML4-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).	26698910 27432227
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	WX-0593	Preclinical - Cell culture	Actionable	In a preclinical study, WX-0593 inhibited growth of transformed cells expressing ALK L1196M in the context of EML4-ALK in culture (Cancer Res 2018;78(13 Suppl):Abstract nr 4794).	detail...
EML4	EML4-ALK ALK L1196M	lung non-small cell carcinoma	sensitive	Ceritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited cell survival and PI3K/AKT, MEK/ERK, and mTOR signaling in two human non-small cell lung carcinoma cell lines harboring the Xalkori (crizotinib) resistance mutation EML4-ALK ALK L1196M in culture and inhibited tumor growth in xenograft models of one of those cell lines (PMID: 24675041).	24675041
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1196M in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).	22277784
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1196M in the context of EML4-ALK were insensitive to Xalkori (crizotinib) as demonstrated by a lack of growth inhibition and Alk phosphorylation in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1196M	lung non-small cell carcinoma	sensitive	Lorlatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and proliferation of non-small cell lung carcinoma cells over expressing ALK L1196M in the context of EML4-ALK in culture, and resulted in tumor regression in cell line xenograft models (PMID: 26144315).	26144315
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Repotrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Repotrectinib (TPX-0005) inhibited Alk activity and proliferation of transformed cells over expressing ALK L1196M in the context of EML4-ALK in culture (European Journal of Cancer , Volume 69, S32).	detail...
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 26698910)	26698910
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK L1196M demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Ensartinib	Preclinical	Actionable	In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK ALK L1196M (PMID: 21613408).	21613408
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were sensitive to Rozlytrek (entrectinib), resulting in anti-proliferative activity in culture (PMID: 26939704).	26939704
EML4	EML4-ALK ALK L1196M	lung adenocarcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, EML4-ALK and ALK L1196M were identified as acquired mutations in the pleural effusion from a patient with lung adenocarcinoma after his disease progressed on Xalkori (crizotinib) treatment (PMID: 28434515).	28434515
EML4	EML4-ALK ALK L1196M	lung non-small cell carcinoma	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of non-small cell lung cancer cells expressing ALK L1196M in the context of EML4-ALK in culture (PMID: 21502504).	21502504
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK L196M in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).	27780853
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated moderate resistance to ASP3026 in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 24887559).	24887559
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated decreased sensitivity to Alecensa (alectinib) compared to cells expressing EML4-ALK with wild-type ALK, in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing an EML4-ALK fusion and ALK L1196M in culture and in cell line xenograft models (PMID: 21575866).	21575866
EML4	EML4-ALK ALK C1156Y	lung non-small cell carcinoma	no benefit	Luminespib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer with an ALK C1156Y secondary Xalkori (crizotinib) resistance mutation did not respond to Luminespib (AUY922) therapy (PMID: 26698910).	26698910
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 24887559).	24887559
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing EML4-ALK with ALK C1156Y were sensitive to Alecensa (alectinib) in culture (PMID: 21575866).	21575866
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited proliferation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Ensartinib	Preclinical	Actionable	In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK C1156Y (PMID: 21613408).	21613408
EML4	EML4-ALK ALK C1156Y	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer developed resistance to Xalkori (crizotinib) with the emergence of ALK C1156Y, a secondary resistance mutation (PMID: 26698910).	26698910
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing ALK C1156Y in the context of EML4-ALK demonstrated minimal sensitivity to Zykadia (ceritinib) in culture (PMID: 24675041).	24675041
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK C1156Y	lung non-small cell carcinoma	sensitive	Lorlatinib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation ALK C1156Y, was treated with Lorlatinib (PF-06463922) and displayed a 41% reduction in tumor growth after 5 weeks of treatment (PMID: 26698910; NCT01970865).	26698910
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	WX-0593	Preclinical - Cell culture	Actionable	In a preclinical study, WX-0593 inhibited growth of transformed cells expressing ALK C1156Y in the context of EML4-ALK in culture (Cancer Res 2018;78(13 Suppl):Abstract nr 4794).	detail...
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth and ALK phosphorylation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y demonstrated moderate resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK ALK C1156Y were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and lack of kinase inhibition in culture (PMID: 21613408).	21613408
EML4	EML4-ALK ALK C1156Y	lung non-small cell carcinoma	conflicting	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation C1156Y, did not respond to Zykadia (ceritinib) therapy (PMID: 26698910).	26698910
EML4	EML4-ALK ALK C1156Y	lung non-small cell carcinoma	conflicting	Ceritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Zykadia (ceritinib) demonstrated tumor growth inhibition in xenograft models of a human non-small cell lung cancer cell line harboring EML4-ALK with ALK C1156Y when compared to Xalkori (crizotinib) (PMID: 24675041).	24675041
EML4	EML4-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were sensitive to Rozlytrek (entrectinib), resulting in anti-proliferative activity (PMID: 26939704).	26939704
EML4	EML4-ALK ALK S1206Y	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated moderate resistance to Alecensa (alectinib) in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK S1206Y	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK S1206Y in culture and in xenograft models (PMID: 24887559).	24887559
EML4	EML4-ALK ALK S1206Y	Advanced Solid Tumor	conflicting	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing S1206Y in the context of EML4-ALK in culture (PMID: 27780853).	27780853
EML4	EML4-ALK ALK S1206Y	Advanced Solid Tumor	conflicting	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK S1206Y demonstrated moderate resistance to Alunbrig (brigatinib) in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK S1206Y demonstrated growth inhibition with Zykadia (ceritinib) treatment in culture (PMID: 24675041).	24675041
EML4	EML4-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK S1206Y in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK S1206Y	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK S1206Y demonstrated moderate resistance to ASP3026 in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK S1206Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK S1206Y demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK S1206Y in the context of EML4-ALK in culture (PMID: 26144315).	26144315
EML4	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to Rozlytrek (entrectinib) in culture (PMID: 26939704).	26939704
EML4	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R demonstrated resistance to Alecensa (alectinib) in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) did not effectively inhibit growth of transformed cells expressing EML4-ALK with ALK G1202R in culture, and did not inhibit tumor growth in xenograft models (PMID: 24887559).	24887559
EML4	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK G1202R	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202R demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK G1202R	Advanced Solid Tumor	sensitive	Repotrectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Repotrectinib (TPX-0005) inhibited Alk activity and proliferation of transformed cells expressing ALK G1201R in the context of EML4-ALK in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 30093503).	30093503 detail...
EML4	EML4-ALK ALK G1202R	lung non-small cell carcinoma	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were insensitive to Zykadia (ceritinib) in culture (PMID: 24675041).	24675041
EML4	EML4-ALK ALK G1202R	lung non-small cell carcinoma	resistant	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK who acquired the secondary drug resistance mutation, ALK S1206Y, when treated with Xalkori (crizotinib) was subsequently treated with Zykadia (ceritinib), developed drug resistance, and was then found to have lost the ALK S1206Y mutation, but gained ALK G1202R (PMID: 24675041).	24675041
EML4	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R demonstrated resistance to Zykadia (ceritinib) in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1202R in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).	22277784
EML4	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK G1202R	Advanced Solid Tumor	conflicting	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R demonstrated resistance to Alunbrig (brigatinib) in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK G1202R	Advanced Solid Tumor	conflicting	Brigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK G1202R in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).	27780853
EML4	EML4-ALK ALK G1202R	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R demonstrated resistance to ASP3026 in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK G1202R	lung non-small cell carcinoma	predicted - resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK, who had developed resistance to Xalkori (crizotinib), was found to harbor ALK G1202R following treatment with Alecensa (alectinib) (PMID: 24736079).	24736079
EML4	EML4-ALK ALK G1202R	lung cancer	conflicting	Lorlatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis in transformed cells over expressing ALK G1202R in the context of EML4-ALK in culture and in cell line xenograft models (PMID: 26144315).	26144315
EML4	EML4-ALK ALK G1202R	lung cancer	conflicting	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK I1171T	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK I1171T	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated a partial response with Xalkori (crizotinib) treatment, but after eight months showed progression, and was found to harbor a secondary resistance mutation, ALK I1171T (PMID: 25393798).	25393798
EML4	EML4-ALK ALK I1171T	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK I1171T in culture (PMID: 25228534).	25228534
EML4	EML4-ALK ALK I1171T	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to ASP3026 treatment in culture (PMID: 25228534).	25228534
EML4	EML4-ALK ALK I1171T	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of a transformed cell line expressing ALK I1171T in the context of EML4-ALK but to a lesser degree than cells expressing EML4-ALK in culture (PMID: 25228534).	25228534
EML4	EML4-ALK ALK I1171T	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK I1171T	Advanced Solid Tumor	sensitive	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK I1171T in culture (PMID: 25228534).	25228534
EML4	EML4-ALK ALK I1171T	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534), however, another study with comparable cells demonstrated sensitivity in culture (PMID: 27432227).	25228534 27432227
EML4	EML4-ALK ALK I1171T	lung non-small cell carcinoma	sensitive	Lorlatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell growth in patient derived non-small cell lung cancer cells harboring ALK I1171T in the context of EML4-ALK in culture (PMID: 26144315).	26144315
EML4	EML4-ALK ALK L1152R	lung non-small cell carcinoma	resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated a brief response to Xalkori (crizotinib) treatment, but after 3 months showed tumor progression, and was found to harbor the secondary resistance mutation, ALK L1152R (PMID: 21791641).	21791641
EML4	EML4-ALK ALK L1152R	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK L1152R in the context of EML4-ALK in culture (PMID: 27780853).	27780853
EML4	EML4-ALK ALK L1152R	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK L1152R in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK L1152R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1152R demonstrated resistance to Zykadia (ceritinib) in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK L1152R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1152R in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).	27780853
EML4	EML4-ALK ALK L1152R	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK L1152R in the context of EML4-ALK in culture (PMID: 26144315).	26144315
EML4	EML4-ALK ALK L1152R	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1152R demonstrated resistance to ASP3026 in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK L1152R	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK L1152R in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK L1152R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1152R in the context of EML4-ALK demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 21791641).	21791641
EML4	EML4-ALK ALK L1152R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1152R demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
EML4	EML4-ALK ALK V1180L	lung non-small cell carcinoma	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).	25228534
EML4	EML4-ALK ALK V1180L	lung non-small cell carcinoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human non-small cell lung cancer cell line harboring ALK V1180L in the context of EML4-ALK was resistant to Xalkori (crizotinib) treatment in culture (PMID: 25228534).	25228534
EML4	EML4-ALK ALK V1180L	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).	25228534
EML4	EML4-ALK ALK V1180L	lung non-small cell carcinoma	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis of non-small cell lung carcinoma cells harboring ALK V1180L in the context of EML4-ALK in culture (PMID: 26144315).	26144315
EML4	EML4-ALK ALK V1180L	Advanced Solid Tumor	sensitive	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing ALK V1180L in the context of EML4-ALK in culture (PMID: 25228534).	25228534
EML4	EML4-ALK ALK V1180L	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, a transformed cell line expressing EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).	25228534
EML4	EML4-ALK ALK V1180L	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of a transformed cell line expressing EML4-ALK ALK V1180L in culture (PMID: 25228534).	25228534
EML4	EML4-ALK ALK V1180L	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).	25228534
EML4	EML4-ALK ALK I1171S	Advanced Solid Tumor	conflicting	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alunbrig (brigatinib)-mediated growth inhibition in culture (PMID: 27009859), however, another study with comparable cells demonstrated sensitivity (PMID: 27432227).	27432227 27009859
EML4	EML4-ALK ALK I1171S	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK I1171S	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859), however, in another study comparable cells demonstrated sensitivity (PMID: 27432227).	27009859 27432227
EML4	EML4-ALK ALK I1171S	lung non-small cell carcinoma	predicted - resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer initially responded to Alecensa (alectinib), but progressed with the emergence of a secondary ALK I1171S mutation (PMID: 25393796).	25393796
EML4	EML4-ALK ALK I1171S	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK I1171S	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK I1171S	Advanced Solid Tumor	resistant	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK I1171S	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171S demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK T1151M	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK T1151M	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK T1151M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to ASP3026 in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK T1151M	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK T1151M	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK T1151M	lung adenocarcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK T1151M was identified in the post-progression biopsy of a patient with lung adenocarcinoma harboring EML4-ALK after Xalkori (crizotinib) and Zykadia (ceritinib) therapies (PMID: 28676215).	28676215
EML4	EML4-ALK ALK T1151M	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK T1151M	lung adenocarcinoma	predicted - resistant	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK T1151M was identified in the post-progression biopsy of a patient with lung adenocarcinoma harboring EML4-ALK after Xalkori (crizotinib) and Zykadia (ceritinib) therapies (PMID: 28676215).	28676215
EML4	EML4-ALK ALK F1174L	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Alunbrig (brigatinib)-mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK F1174L	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK F1174L in the context of EML4-ALK in culture (PMID: 26144315).	26144315
EML4	EML4-ALK ALK F1174L	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture and in xenograft models (PMID: 24887559).	24887559
EML4	EML4-ALK ALK F1174L	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK F1174L	Advanced Solid Tumor	conflicting	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK F1174L in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).	27780853
EML4	EML4-ALK ALK F1174L	Advanced Solid Tumor	conflicting	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK F1174L	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK F1174L	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK F1174L	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Zykadia (ceritinib)-mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK R1192P	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK R1192P	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK R1192P	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK R1192P	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK R1192P	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells overexpressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK R1192P	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).	27009859
EML4	EML4-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK E1210K	lung non-small cell carcinoma	resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a patient with non-small cell lung carcinoma harboring EML4-ALK progressed on treatment with Xalkori (crizotinib) and was subsequently found to harbor a secondary resistance mutation, ALK E1210K (PMID: 29636358).	29636358
EML4	EML4-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alunbrig (brigatinib) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK C1156Y ALK L1198F	lung non-small cell carcinoma	resistant	Lorlatinib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with EML4-ALK positive non-small lung cancer with a secondary Xalkori (critzotinib) resistance mutation C1156Y, responded to Lorlatinib (PF-06463922) but subsequently developed resistance upon the emergence of a second ALK mutation, L1198F (PMID: 26698910; NCT01970865).	26698910
EML4	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK C1156Y ALK L1198F	lung non-small cell carcinoma	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small lung cancer initially responded to Xalkori (crizotinib) but developed resistance with the emergence of a secondary ALK mutation C1156Y, and subsequently redeveloped sensitivity to Xalkori (crizotinib) upon the emergence of a second ALK mutation, L1198F arising from resistance to Lorlatinib (PF-06463922) (PMID: 26698910).	26698910
EML4	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK C1156Y and ALK L1198F in the context of EML4-ALK were resistant to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK C1156Y ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1198F	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1198F	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).	27432227 26698910
EML4	EML4-ALK ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing L1198F in the context of EML4-ALK in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1198F	Advanced Solid Tumor	decreased response	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with L1198F had reduced sensitivity to growth inhibition mediated by Lorlatinib (PF-06463922) in comparison to EML4-ALK wild type in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK F1174C	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C demonstrated decreased sensitivity to Alecensa (alectinib) in culture compared to cells expressing EML4-ALK with wild-type ALK (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).	27432227 26698910
EML4	EML4-ALK ALK F1174C	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK F1174C	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) modestly inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK F1174C	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK F1174C	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).	27432227 26698910
EML4	EML4-ALK ALK F1174C	lung non-small cell carcinoma	resistant	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK who developed resistance to Xalkori (crizotinib) treatment was subsequently treated with Zykadia (ceritinib), eventually progressed, and was found to have acquired ALK F1174C (PMID: 24675041).	24675041
EML4	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition by Alecensa (alectinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK F1174C ALK L1198F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, introduction of an additional ALK mutation L1198F in transformed cells expressing ALK L1196M in the context of EML4-ALK reduced resistance to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1196M ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F were resistant to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1202R in the context of EML4-ALK were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1198F ALK G1202R	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK G1269A in the context of EML4-ALK were re-sensitized and became modestly sensitive to Xalkori (crizotinib) with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).	26698910
EML4	EML4-ALK ALK L1198F ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A and L1198F in culture (PMID: 26698910).	26698910
EML4	EML4-ALK SRC pos	lung cancer	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Xalkori (crizotinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).	detail...
EML4	EML4-ALK SRC pos	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Zykadia (ceritinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).	detail...
EML4	EML4-ALK SRC pos	lung cancer	sensitive	Repotrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, TPX-0005 inhibited Alk and Src signaling, and cell proliferation in lung cancer cell lines harboring EML4-ALK and elevated Src activity in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).	detail...
EML4	EML4-ALK ALK I1171N	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK I1171N	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Alunbrig (brigatinib) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK I1171N	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated resistance to treatment with Alecensa (alectinib) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK I1171N	lung non-small cell carcinoma	predicted - resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated tumor regression when treated with Alecensa (alectinib), but progressed seven months later, and was found to harbor a secondary resistance mutation, ALK I1171N (PMID: 25393798).	25393798
EML4	EML4-ALK ALK I1171N	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK I1171N	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK G1202del	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated moderate resistance to treatment with Alecensa (alectinib) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK G1202del	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK G1202del	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK G1202del	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK G1202del	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Alunbrig (brigatinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK D1203N	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alunbrig (brigatinib) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK D1203N	Advanced Solid Tumor	resistant	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing ALK D1203N in the context of EML4-ALK were resistant to TAE684 in culture (PMID: 21948233).	21948233
EML4	EML4-ALK ALK D1203N	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK D1203N	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK D1203N	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK D1203N	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Alunbrig (brigatinib) when compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C did not response to treatment with Alecensa (alectinib) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK D1203N ALK F1174C	Advanced Solid Tumor	decreased response	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Lorlatinib (PF-06463922) in culture compared to cells expressing wild-type EML4-ALK (PMID: 27432227).	27432227
EML4	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Alunbrig (brigatinib) when compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K did not response to treatment with Alecensa (alectinib) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Zykadia (ceritinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK D1203N ALK E1210K	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).	27432227
EML4	EML4-ALK ALK S1206F	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK S1206F in the context of EML4-ALK in culture (PMID: 27780853).	27780853
EML4	EML4-ALK ALK L1152P	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).	27780853
EML4	EML4-ALK ALK L1152P	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).	27780853
EML4	EML4-ALK ALK L1152P	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK L1152P in the context of EML4-ALK in culture (PMID: 27780853).	27780853
EML4	EML4-ALK ALK T1151dup	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK T1151dup (referred to as 1151insT) in culture and in xenograft models (PMID: 24887559).	24887559
EML4	EML4-ALK ALK T1151dup	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK T1151dup in the context of EML4-ALK in culture (PMID: 27780853).	27780853
EML4	EML4-ALK ALK T1151dup	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK T1151dup in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).	27780853
EML4	EML4-ALK ALK T1151dup	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK T1151dup in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).	22277784
EML4	EML4-ALK ALK F1174V	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK F1174V in the context of EML4-ALK in culture (PMID: 27780853).	27780853
EML4	EML4-ALK ALK F1174V	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK F1174V in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).	27780853
EML4	EML4-ALK ALK F1174V	lung non-small cell carcinoma	predicted - sensitive	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK initially responded to Xalkori (crizotinib), but then progressed due to acquisition of the secondary resistance mutation, ALK F1174V, and then responded to treatment with Alecensa (alectinib), demonstrating a complete response in one lung nodule and a 44% decrease in size in a second lung nodule (PMID: 26464158).	26464158
EML4	EML4-ALK ALK F1174V	lung non-small cell carcinoma	resistant	Crizotinib	Clinical Study	Actionable	In a clinical case study, a patient with non-small cell lung carcinoma harboring EML4-ALK demonstrated a partial response to Xalkori (crizotinib) treatment after 3 months, but then progressed, and was found to harbor the secondary resistance mutation, ALK F1174V (PMID: 24736079).	24736079
EML4	EML4-ALK ALK F1245C	lung non-small cell carcinoma	sensitive	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 that demonstrated resistance to treatment with Xalkori (crizotinib) after acquisition of ALK F1245C, achieved a complete radiographic response with no evidence of progression at 6 months following treatment with Zykadia (ceritinib) (PMID: 26775591).	26775591
EML4	EML4-ALK ALK F1245C	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 demonstrated an initial response to treatment with Xalkori (crizotinib), but progressed after 27 months and was found to have acquired ALK F1245C (PMID: 26775591).	26775591
EML4	EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*	pancreatic ductal adenocarcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).	28476735
EML4	EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*	pancreatic ductal adenocarcinoma	predicted - sensitive	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).	28476735
EML4	EML4-ALK ALK F1174V ALK I1171S	lung non-small cell carcinoma	predicted - resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK and ALK F1174V initially responded to Alecensa (alectinib), but then demonstrated progression in one of two lung nodules, which was found to harbor a secondary resistance mutation, ALK I1171S, and upon resection of the nodule the patient continued Alecensa (alectinib) treatment and achieved complete remission (PMID: 26464158).	26464158
EML4	EML4-ALK ALK G1269A ALK L1196M	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1196M was identified as a compound mutation in transformed cells expressing ALK G1269A in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK G1269A ALK L1196M	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a patient with non-small cell lung cancer harboring EML4-ALK demonstrated a partial response when treated with Xalkori (crizotinib), however, after 6 months the patient progressed and was found to harbor two secondary resistance mutations, ALK G1269A and ALK L1196M (PMID: 23344087).	23344087
EML4	EML4-ALK ALK C1156Y ALK L1196M	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1196M was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK C1156Y ALK L1196M	lung adenocarcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EML4-ALK treated on a clinical trial achieved a partial response when treated with Xalkori (crizotinib), however, after 5 months, the patient progressed and was found to harbor secondary resistance mutations, ALK C1156Y and ALK L1196M (PMID: 20979473; NCT00585195).	20979473
EML4	EML4-ALK ALK L1198P	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing ALK L1198P in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 21948233).	21948233
EML4	EML4-ALK ALK L1198P	Advanced Solid Tumor	resistant	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing ALK L1198P in the context of EML4-ALK were resistant to TAE684 in culture (PMID: 21948233).	21948233
EML4	ALK amp EML4-ALK EGFR L858R	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung cancer patient harboring EML4-ALK had a partial response to Xalkori (crizotinib) therapy, but progressed after four months, and was found to have acquired ALK amplification and EGFR L858R (PMID: 23344087).	23344087
EML4	EML4-ALK ALK F1174V ALK G1202R	lung non-small cell carcinoma	sensitive	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK who was previously treated with Xalkori (crizotinib) and subsequently developed the resistance mutation, ALK G1269A, was treated with Zykadia (ceritinib), later progressed, and was found to have lost ALK G1269A, but gained ALK F1174V and ALK G1202R (PMID: 24675041).	24675041
EML4	EML4-ALK ALK C1156Y ALK I1171T	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1171T was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK C1156Y ALK F1174C	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174C was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK C1156Y ALK F1174I	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174I was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK C1156Y ALK F1174V	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174V was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK C1156Y ALK D1203N	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK D1203N was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK C1156Y ALK L1256F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1256F was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK C1156Y ALK G1269A	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK G1269A was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK L1196M ALK I1171S	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1171S was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK L1196M ALK F1174C	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174C was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK L1196M ALK F1174L	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174L was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK L1196M ALK F1174V	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK F1174V was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK L1196M ALK I1179V	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1179V was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK L1196M ALK L1256F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1256F was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK F1174C ALK G1269A	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK G1269A was identified as a compound mutation in transformed cells expressing ALK F1174C in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK L1196M ALK G1202R	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK L1196M was identified as a compound mutation in transformed cells expressing ALK G1202R in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK G1269A ALK I1171T	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1171T was identified as a compound mutation in transformed cells expressing ALK G1269A in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK G1269A ALK I1171N	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ALK I1171N was identified as a compound mutation in transformed cells expressing ALK G1269A in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).	29650534
EML4	EML4-ALK ALK E1210K ALK S1206C	lung non-small cell carcinoma	resistant	Brigatinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK and ALK E1210K eventually progressed on treatment with Alunbrig (brigatinib) and was subsequently found to have acquired another resistance mutation, ALK S1206C in cis (PMID: 29636358).	29636358
EML4	EML4-ALK ALK F1174L ALK L1198V	lung non-small cell carcinoma	resistant	Brigatinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK progressed while being treated with Alunbrig (brigatinib) and was subsequently found to harbor two resistance mutations, ALK F1174L and ALK L1198V, which were both in cis (PMID: 29636358).	29636358
EML4	EML4-ALK NOTCH1 D1533A	lung non-small cell carcinoma	predicted - resistant	Ceritinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK demonstrated resistance to treatment with Zykadia (ceritinib), and was subsequently found to have acquired NOTCH1 D1533A (PMID: 29636358).	29636358
EML4	EML4-ALK NOTCH1 D1538A	lung non-small cell carcinoma	predicted - resistant	Brigatinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK demonstrated resistance to treatment with Alunbrig (brigatinib), and was subsequently found to have acquired NOTCH1 D1538A (PMID: 29636358).	29636358
EML4	EML4-ALK EGFR amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, EGFR amplification (PMID: 29636358).	29636358
EML4	EML4-ALK FGFR1 amp	lung non-small cell carcinoma	predicted - resistant	Brigatinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Alunbrig (brigatinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, FGFR1 amplification (PMID: 29636358).	29636358
EML4	EML4-ALK GNAS amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, GNAS amplification (PMID: 29636358).	29636358
EML4	EML4-ALK HRAS amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, HRAS amplification (PMID: 29636358).	29636358
EML4	DDR2 amp EML4-ALK	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, DDR2 amplification (PMID: 29636358).	29636358
EML4	EGFR E746_A750del EML4-ALK	lung non-small cell carcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical study, EML4-ALK was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR E746_A750del, whose disease progressed after initial response to Tarceva (erlotinib) followed by Tagrisso (osimertinib) (PMID: 29883838).	29883838
EML4	EGFR L747_T751delinsP EML4-ALK	lung non-small cell carcinoma	predicted - resistant	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, EML4-ALK was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR L747_T751delinsP, whose disease progressed after initial response to Gilotrif (afatinib) (PMID: 29883838).	29883838
EML4	EGFR L858R EML4-ALK	lung non-small cell carcinoma	predicted - resistant	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, EML4-ALK was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR L858R, whose disease progressed after initial response to Tarceva (erlotinib), followed by Gilotrif (afatinib) (PMID: 29883838).	29883838
EML4	EGFR L747_P753delinsS EML4-ALK	lung non-small cell carcinoma	predicted - resistant	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, a patient with non-small cell lung cancer initially responded to Gilotrif (afatinib), EGFR L747_P753delinsS and EML4-ALK were identified in post-progression tumor samples (PMID: 29883838).	29883838
EML4	EML4-ALK ALK F1174L ALK G1269A	lung adenocarcinoma	predicted - resistant	Belizatinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK F1174L and ALK G1269A were identified as newly acquired mutations in the pleural effusion from a patient with lung adenocarcinoma harboring an acquired EML4-ALK after his disease progressed on Belizatinib (TSR-011) treatment (PMID: 28434515).	28434515
EML4	EML4-ALK ALK F1174L ALK D1203N ALK G1269A	lung adenocarcinoma	predicted - resistant	Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK D1203N were identified as a newly acquired mutation in the pleural effusion from a patient with lung adenocarcinoma after his disease progressed on Zykadia (ceritinib) treatment, in addition to the EML4-ALK, ALK F1174L, and ALK G1269A acquired after disease progression on Xalkori (crizotinib) and Belizatinib (TSR-011) sequentially (PMID: 28434515).	28434515
EML4	EML4-ALK ALK E1303K	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a patient with non-small cell lung cancer harboring EML4-ALK and ALK E1303K developed progressive disease 7 days after Xalkori (crizotinib) treatment (PMID: 29978950).	29978950
EML4	EML4-ALK ALK L1256F	lung adenocarcinoma	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorbrena (lorlatinib) did not inhibit Alk kinase activity or proliferation of lung adenocarcinoma cells expressing ALK L1256F in the context of EML4-ALK in cell culture (PMID: 30662002).	30662002
EML4	EML4-ALK ALK L1256F	lung adenocarcinoma	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited Alk kinase activity and proliferation of lung adenocarcinoma cells expressing ALK L1256F in the context of EML4-ALK in cell culture (PMID: 30662002).	30662002
EML4	EML4-NTRK3	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Rozlytrek (entrectinib) inhibited growth of transformed cells expressing EML4-NTRK3 in culture (PMID: 30279230).	30279230
ERBB2	ERBB2 L663P	Advanced Solid Tumor	predicted - sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L663P demonstrated decreased cell proliferation and reduced survival when treated with Gilotrif (afatinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 L663P	Advanced Solid Tumor	predicted - sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L663P demonstrated decreased cell proliferation and reduced survival when treated with Tykerb (lapatinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 L663P	Advanced Solid Tumor	no benefit	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L663P did not benefit from treatment with Tarceva (erlotinib) in culture when compared to Erbb2 (Her2) inhibitors (PMID: 30449325).	30449325
ERBB2	ERBB2 L663P	Advanced Solid Tumor	no benefit	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L663P did not benefit from treatment with Iressa (gefitinib) in culture when compared to Erbb2 (Her2) inhibitors (PMID: 30449325).	30449325
ERBB2	ERBB2 L663P	Advanced Solid Tumor	predicted - sensitive	Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L663P demonstrated decreased cell proliferation and reduced survival when treated with Herceptin (trastuzumab) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 L663P	Advanced Solid Tumor	predicted - resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L663P demonstrated resistance to treatment with Erbitux (cetuximab) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 L663P	Advanced Solid Tumor	predicted - sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L663P demonstrated decreased cell proliferation and reduced survival when treated with Nerlynx (neratinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 L663P	Advanced Solid Tumor	predicted - sensitive	Pertuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L663P demonstrated decreased cell proliferation and reduced survival when treated with Perjeta (pertuzumab) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 P761del	endometrial cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with endometrial cancer harboring ERBB2 (HER2) P761del (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 V659E	Advanced Solid Tumor	predicted - sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) V659E demonstrated decreased cell proliferation and reduced survival when treated with Tykerb (lapatinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 V659E	Advanced Solid Tumor	predicted - sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) V659E demonstrated decreased cell proliferation and reduced survival when treated with Nerlynx (neratinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 V659E	Advanced Solid Tumor	predicted - resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) V659E demonstrated resistance to treatment with Erbitux (cetuximab) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 V659E	lung adenocarcinoma	predicted - sensitive	Ado-trastuzumab emtansine	Case Reports/Case Series	Actionable	In a Phase II trial, treatment with Kadcyla (trastuzumab emtansine) resulted in best overall responses of partial response in 44% (8/18) and stable disease in 39% (7/18), and median progression-free survival of 5 months in patients with lung adenocarcinoma harboring ERBB2 (HER2) activating mutations, and a subset of patients specifically harboring ERBB2 (HER2) V659E had a 50% (1/2) partial response rate (PMID: 29989854; NCT02675829).	29989854
ERBB2	ERBB2 V659E	Advanced Solid Tumor	predicted - sensitive	Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) V659E demonstrated decreased cell proliferation and reduced survival when treated with Herceptin (trastuzumab) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 V659E	lung non-small cell carcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in two patients with non-small cell lung cancer harboring ERBB2 (HER2) V659E (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 V659E	Advanced Solid Tumor	predicted - resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) V659E did not benefit from treatment with Iressa (gefitinib) in culture when compared to Erbb2 (Her2) inhibitors (PMID: 30449325).	30449325
ERBB2	ERBB2 V659E	biliary tract cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 11.1 months in a patient with biliary tract cancer harboring ERBB2 (HER2) V659E (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 V659E	Advanced Solid Tumor	no benefit	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) V659E did not benefit from treatment with Tarceva (erlotinib) in culture when compared to Erbb2 (Her2) inhibitors (PMID: 30449325).	30449325
ERBB2	ERBB2 V659E	lung cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) V659E in culture (PMID: 26545934).	26545934
ERBB2	ERBB2 V659E	lung cancer	no benefit	Gefitinib	Preclinical	Actionable	In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) V659E did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).	26545934
ERBB2	ERBB2 V659E	Advanced Solid Tumor	predicted - resistant	Pertuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Perjeta (pertuzumab) led to induced growth of cells expressing ERBB2 (HER2) V659E in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 V659E	breast cancer	sensitive	23814 + Tivozanib	Preclinical	Actionable	In a preclinical study, the combination of 23814 and Tivozanib (AV-951) inhibited tumor growth in several transgenic mouse models of breast cancer expressing ERBB2 (HER2) V659E, including those with resistance to VEGFR inhibitors (PMID: 25995436).	25995436
ERBB2	ERBB2 V659E	Advanced Solid Tumor	predicted - sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) V659E demonstrated decreased cell proliferation and reduced survival when treated with Gilotrif (afatinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 L915M	Advanced Solid Tumor	sensitive	XL647	Preclinical - Cell culture	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L915M in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 negative	Her2-receptor negative breast cancer	predicted - sensitive	Exemestane + Seribantumab	Phase II	Actionable	In a Phase II trial, Seribantumab (MM-12) and Aromasin (exemestane) combination treatment resulted in a 74% decrease in risk of progression (HR 0.26) and a a 59% decrease in risk of death (HR 0.436) compared to exemestane alone in ERBB2-negative, hormone receptor positive breast cancer patients (AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer, May 2016, Abstract # A14).	detail...
ERBB2	ERBB2 negative	Her2-receptor negative breast cancer	no benefit	Docetaxel + Ramucirumab	Phase III	Actionable	In a Phase III trial, Cyramze (ramucirumab) in combination with Taxotere (docetaxel) did not improve clinical outcomes in ERBB2 (HER2)-negative breast cancer patients (PMID: 25185099).	25185099
ERBB2	ERBB2 negative	Her2-receptor negative breast cancer	predicted - sensitive	Sorafenib + Vinorelbine	Phase Ib/II	Actionable	In a Phase I/II trial, combination of Navelbine (vinorelbine) and Nexavar (sorafenib) resulted in a response rate of 30% (8/27), median progression free survival of 5.7 months, and a clinical benefit rate (absence of disease progression at 6 months) of 48% (13/27) in patients with ERBB2 (HER2)-negative metastatic breast cancer (PMID: 27992451).	27992451
ERBB2	ERBB2 neg MET pos	gastroesophageal junction adenocarcinoma	no benefit	Rilotumumab	Phase III	Actionable	In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).	detail...
ERBB2	ERBB2 neg MET pos	gastric adenocarcinoma	no benefit	Onartuzumab	Phase III	Actionable	In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).	detail...
ERBB2	ERBB2 neg MET pos	gastric adenocarcinoma	no benefit	Rilotumumab	Phase III	Actionable	In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).	detail...
ERBB2	ERBB2 neg MET pos	gastroesophageal junction adenocarcinoma	no benefit	Onartuzumab	Phase III	Actionable	In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).	detail...
ERBB2	ERBB2 neg MET pos	gastric adenocarcinoma	no benefit	Fluorouracil + Leucovorin + Onartuzumab + Oxaliplatin	Phase III	Actionable	In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).	27918764
ERBB2	ERBB2 neg MET pos	esophagus adenocarcinoma	no benefit	Fluorouracil + Leucovorin + Onartuzumab + Oxaliplatin	Phase III	Actionable	In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).	27918764
ERBB2	ERBB2 neg ERBB2 pos	Her2-receptor negative breast cancer	sensitive	LY411575 + Paclitaxel	Preclinical	Actionable	In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of LY411575 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone (PMID: 27556950).	27556950
ERBB2	ERBB2 neg ERBB2 pos	Her2-receptor negative breast cancer	sensitive	Paclitaxel + RO4929097	Preclinical	Actionable	In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of RO4929097 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone (PMID: 27556950).	27556950
ERBB2	ERBB2 G660D	lung cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G660D in culture (PMID: 26545934).	26545934
ERBB2	ERBB2 G660D	lung cancer	sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, a patient with lung cancer harboring a germline mutation, ERBB2 (HER2) G660D, demonstrated improved symptoms within 30 days of Gilotrif (afatinib) treatment, as well as a 21% reduction in tumor volume in 12 weeks and a durable response that lasted for more than 15 weeks (PMID: 30449325).	30449325
ERBB2	ERBB2 G660D	lung cancer	sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, Gilotrif (afatinib) treatment resulted in partial response in the lung lesion and stable bone metastasis for over 16 months in a patient with familial lung cancer harboring germline ERBB2 G660D mutation (PMID: 29146616).	29146616
ERBB2	ERBB2 G660D	Advanced Solid Tumor	predicted - resistant	Pertuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Perjeta (pertuzumab) led to induced growth and colony formation of cells expressing ERBB2 (HER2) G660D in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 G660D	lung cancer	no benefit	Gefitinib	Preclinical	Actionable	In a preclinical study, bronchial epithelial cells cells expressing ERBB2 (HER2) G660D did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).	26545934
ERBB2	ERBB2 G660D	Advanced Solid Tumor	predicted - sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G660D demonstrated decreased cell proliferation and reduced survival when treated with Nerlynx (neratinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 G660D	Advanced Solid Tumor	predicted - sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G660D demonstrated decreased cell proliferation and reduced survival when treated with Gilotrif (afatinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 G660D	Advanced Solid Tumor	no benefit	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G660D did not benefit from treatment with Tarceva (erlotinib) in culture when compared to Erbb2 (Her2) inhibitors (PMID: 30449325).	30449325
ERBB2	ERBB2 G660D	Advanced Solid Tumor	predicted - resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G660D demonstrated resistance to treatment with Erbitux (cetuximab) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 G660D	Advanced Solid Tumor	no benefit	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G660D did not benefit from treatment with Iressa (gefitinib) in culture when compared to Erbb2 (Her2) inhibitors (PMID: 30449325).	30449325
ERBB2	ERBB2 G660D	Advanced Solid Tumor	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G660D treated with Herceptin (trastuzumab) demonstrated decreased proliferation, reduced survival, and inhibition of colony formation in culture, and in mouse models led to improved survival compared to control models with wild-type ERBB2 (HER2) (PMID: 30449325).	30449325
ERBB2	ERBB2 G660D	Advanced Solid Tumor	predicted - sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G660D demonstrated decreased cell proliferation and reduced survival when treated with Tykerb (lapatinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 S310F ERBB2 G660D	ampulla of Vater carcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, Gilotrif (afatinib) treatment resulted in stable disease with slight lymph node metastasis reduction in a patient with ampulla of Vater carcinoma harboring ERBB2 S310F and G660D, but the disease eventually progressed after 4 months (PMID: 29146616).	29146616
ERBB2	ERBB2 S310F	colon cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 S310F	colon cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 S310F	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) S310F were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 S310F	biliary tract cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response in one and progressive disease in another patient with biliary tract cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 S310F	colorectal cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 S310F	Advanced Solid Tumor	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cells expressing ERBB2 S310F in culture (PMID: 22908275).	22908275
ERBB2	ERBB2 S310F	gastroesophageal junction adenocarcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.9 months in a patient with gastroesophageal cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 S310F	urinary bladder cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 24971884).	24971884
ERBB2	ERBB2 S310F	Her2-receptor negative breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response with a progression-free survival of 14.6 months in one patient, and stable disease with a progression-free survival of 3.7 months in another patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 S310F	Advanced Solid Tumor	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) decreased cell survival of transformed human cells expressing ERBB2 (HER2) S310F (PMID: 22908275).	22908275
ERBB2	ERBB2 S310F	urinary bladder cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 24971884).	24971884
ERBB2	ERBB2 S310F	cervical cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response in 1 patient, stable disease in 1 patient, and progressive disease in 1 patient with cervical cancer harboring ERBB2 (HER2) D769N (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 S310F	colorectal cancer	conflicting	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with colorectal cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 S310F	colorectal cancer	conflicting	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 S310F	urinary bladder cancer	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, bladder cancer cells over expressing ERBB2 (HER2) S310F demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884).	24971884
ERBB2	ERBB2 S310F	endometrial cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 2.6 months in a patient with endometrial cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 S310F	urinary bladder cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 4 patients and progressive disease in 1 patient with bladder cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 S310F	lung non-small cell carcinoma	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 S310F	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) S310F were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 D277H ERBB2 S310F	urinary bladder cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F in culture (PMID: 24971884).	24971884
ERBB2	ERBB2 D277H ERBB2 S310F	urinary bladder cancer	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884).	24971884
ERBB2	ERBB2 D277H ERBB2 S310F	urinary bladder cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F in culture (PMID: 24971884).	24971884
ERBB2	ERBB2 S310F ERBB2 V842I	breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response, and 3 patients achieving stable disease for 24 weeks or more, which included a patient harboring ERBB2 (HER2) S310F and V842I (PMID: 28679771).	28679771
ERBB2	ERBB2 D277G ERBB2 S310F	urinary bladder cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with bladder cancer harboring both ERBB2 (HER2) D277G and S310F (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 amp ERBB2 S310F	lung adenocarcinoma	predicted - sensitive	Ado-trastuzumab emtansine	Case Reports/Case Series	Actionable	In a Phase II trial, treatment with Kadcyla (trastuzumab emtansine) resulted in best overall responses of partial response in 44% (8/18) and stable disease in 39% (7/18), and median progression-free survival of 5 months in patients with lung adenocarcinoma harboring ERBB2 (HER2) activating mutations; a patient harboring ERBB2 (HER2) S310F and ERBB2 (HER2) amplification had a partial response (PMID: 29989854; NCT02675829).	29989854
ERBB2	ERBB2 V697L	endometrial cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.6 months in a patient with endometrial cancer harboring ERBB2 (HER2) V697L (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 V697L	Advanced Solid Tumor	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial, a patient with cancer of unknown primary involving the head and neck that harbored ERBB2 (HER2) V697L demonstrated a response to treatment with Nerlynx (neratinib) that lasted 13 months (PMID: 29247016).	29247016
ERBB2	ERBB2 V697L	triple-receptor negative breast cancer	sensitive	Neratinib	Phase II	Actionable	In a Phase II trial, a triple-negative breast cancer patient harboring ERBB2 V697L demonstrated a response to treatment with Nerlynx (neratinib) (PMID: 29247016).	29247016
ERBB2	ERBB2 L768S	breast cancer	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Nerlynx (neratinib) in culture, resulting in decreased colony formation (PMID: 27697991).	27697991
ERBB2	ERBB2 L768S	breast cancer	sensitive	Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Herceptin (trastuzumab) in culture, resulting in decreased colony formation (PMID: 27697991).	27697991
ERBB2	ERBB2 L768S	breast cancer	sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Tykerb (lapatinib) in culture, resulting in decreased colony formation (PMID: 27697991).	27697991
ERBB2	ERBB2 G778_S779insLPS	Advanced Solid Tumor	resistant	Sapitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_S779insLPS were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 G778_S779insLPS	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_S779insLPS were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 L726I	breast cancer	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, an ERBB2 (HER2) L726I mutation was detected in a murine breast cancer cell line that acquired resistance to Iressa (gefitinib) in culture (PMID: 17638894).	17638894
ERBB2	ERBB2 V773L	breast cancer	sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Tykerb (lapatinib) in culture, resulting in decreased colony formation (PMID: 27697991).	27697991
ERBB2	ERBB2 V773L	breast cancer	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Nerlynx (nerlatinib) in culture, resulting in decreased colony formation (PMID: 27697991).	27697991
ERBB2	ERBB2 V773L	breast cancer	sensitive	Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Herceptin (trastuzumab) in culture, resulting in decreased colony formation (PMID: 27697991).	27697991
ERBB2	ERBB2 D769H	Her2-receptor negative breast cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.5 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) D769H (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 D769H	breast cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 D769H reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).	23220880
ERBB2	ERBB2 D769H	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 D769H demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).	23220880
ERBB2	ERBB2 D769H	colorectal cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with colorectal cancer harboring ERBB2 (HER2) D769H (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 D769H	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) D769H were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 D769H	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) D769H demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).	23220880
ERBB2	ERBB2 D769H	Advanced Solid Tumor	resistant	Sapitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) D769H were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 G776_V777insVGC	lung non-small cell carcinoma	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 1 patient and progressive disease in 2 patients with non-small cell lung cancer harboring ERBB2 (HER2) G776_V777insVGC (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 P780L	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) P780L in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 P780L	Advanced Solid Tumor	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) P780L demonstrated resistance to treatment with Tykerb (lapatinib) (PMID: 18413839).	18413839
ERBB2	ERBB2 Y772_A775dup	Advanced Solid Tumor	resistant	AZ5104	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) were resistant to AZ5104 in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup	urinary bladder cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patients with bladder cancer harboring ERBB2 (HER2) Y722_A775dup (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 Y772_A775dup	lung adenocarcinoma	conflicting	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, a lung adenocarcinoma patient harboring ERBB2 Y772_A775dup (also referred to as A775_G776insYVMA and E740_A741insAYVM) achieved a partial response for 5 months following treatment with pulse Gilotrif (afatinib), however, a second patient harboring ERBB2 Y772_A775dup treated with pulse Gilotrif (afatinib) demonstrated progressive disease (PMID: 26964772).	26964772
ERBB2	ERBB2 Y772_A775dup	Advanced Solid Tumor	resistant	Sapitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 Y772_A775dup	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) were resistant to Tarceva (erlotinib) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) were resistant to Tykerb (lapatinib) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 Y772_A775dup	lung non-small cell carcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 5 patients and progressive disease in 4 patients with non-small cell lung cancer harboring ERBB2 (HER2) Y772_A775dup (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 Y772_A775dup	Her2-receptor negative breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response in one patient, and stable disease in 2 patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) Y772_A775dup (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 Y772_A775dup	Advanced Solid Tumor	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as ERBB2 A775_G776insYVMA) in culture (PMID: 28363995).	28363995
ERBB2	ERBB2 Y772_A775dup	lung non-small cell carcinoma	predicted - sensitive	Poziotinib	Clinical Study	Actionable	In a retrospective analysis, Poziotinib (HM781-36B) treatment resulted in an objective response rate of 33% (1/3) in non-small cell lung cancer patients harboring ERBB2 (HER2) Y772_A775dup (reported as (A775_G776insYVMA) (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup	lung cancer	no benefit	Gefitinib	Preclinical	Actionable	In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).	26545934
ERBB2	ERBB2 Y772_A775dup	Advanced Solid Tumor	sensitive	Pyrotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Pyrotinib inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup	Advanced Solid Tumor	resistant	Tucatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) were resistant to Tucatinib (ARRY-380) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup	Advanced Solid Tumor	predicted - sensitive	Ganetespib	Preclinical - Cell culture	Actionable	In a preclinical study, Ganetespib inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as reported as A775_G776insYVMA) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup	Advanced Solid Tumor	decreased response	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) demonstrated decreased response to Vizimpro (dacomitinib) compared to Poziotinib (HM781-36B) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup	lung adenocarcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in 1 partial response, 1 stable disease, and 1 progressive disease in 3 patients with lung adenocarcinoma harboring ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) (PMID: 30149884; NCT02979821).	30149884
ERBB2	ERBB2 Y772_A775dup	Advanced Solid Tumor	predicted - sensitive	Luminespib	Preclinical - Cell culture	Actionable	In a preclinical study, Luminespib (AUY922) inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as reported as A775_G776insYVMA) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup	lung cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) in culture (PMID: 26545934).	26545934
ERBB2	ERBB2 Y772_A775dup	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) were resistant to Tagrisso (osimertinib) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup	Advanced Solid Tumor	decreased response	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) demonstrated decreased response to Gilotrif (afatinib) compared to Poziotinib (HM781-36B) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup	lung non-small cell carcinoma	no benefit	Erlotinib	Clinical Study	Actionable	In a retrospective analysis, Tarceva (erlotinib) treatment resulted in an objective response rate of 0% (0/1) in non-small cell lung cancer patients harboring ERBB2 (HER2) Y772_A775dup (reported as (A775_G776insYVMA) (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup	lung non-small cell carcinoma	predicted - sensitive	Afatinib	Clinical Study	Actionable	In a retrospective analysis, Gilotrif (afatinib) treatment resulted in an objective response rate of 16% (5/31) in non-small cell lung cancer patients harboring ERBB2 (HER2) Y772_A775dup (reported as (A775_G776insYVMA) (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup	lung non-small cell carcinoma	no benefit	Dacomitinib	Clinical Study	Actionable	In a retrospective analysis, Vizimpro (dacomitinib) treatment resulted in an objective response rate of 0% (0/13) in non-small cell lung cancer patients harboring ERBB2 (HER2) Y772_A775dup (reported as (A775_G776insYVMA) (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited ERBB2 (HER2) phosphorylation and growth of a transformed cell line expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) in culture (PMID: 29686424).	29686424
ERBB2	ERBB2 Y772_A775dup	lung cancer	sensitive	Poziotinib	Preclinical	Actionable	In a preclinical study, Poziotinib (HM781-36B) induced regression of lung tumors in mouse models harboring ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA), with no signs of progression at 12 weeks (PMID: 29686424).	29686424
ERBB2	ERBB2 Y772_A775dup ERBB2 C805S	Advanced Solid Tumor	predicted - sensitive	Ganetespib	Preclinical - Cell culture	Actionable	In a preclinical study, Ganetespib inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup ERBB2 C805S	Advanced Solid Tumor	resistant	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, ERBB2 (HER2) C805S was identified as a secondary mutation in transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) that acquired resistance to Poziotinib (HM781-36B) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup ERBB2 C805S	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S were resistant to Tagrisso (osimertinib) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup ERBB2 C805S	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing ERBB2 (HER2) C805S and ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) demonstrated resistance to Vizimpro (dacomitinib) in culture (PMID: 28363995).	28363995
ERBB2	ERBB2 Y772_A775dup ERBB2 C805S	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) and ERBB2 (HER2) C805S demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).	28363995
ERBB2	ERBB2 Y772_A775dup ERBB2 C805S	Advanced Solid Tumor	resistant	Pyrotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S were resistant to Pyrotinib in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup ERBB2 C805S	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S were resistant to Tykerb (lapatinib) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup ERBB2 C805S	Advanced Solid Tumor	resistant	AZ5104	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S were resistant to AZ5104 in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup ERBB2 C805S	Advanced Solid Tumor	predicted - sensitive	Luminespib	Preclinical - Cell culture	Actionable	In a preclinical study, Luminespib (AUY922) inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup ERBB2 C805S	Advanced Solid Tumor	resistant	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) and ERBB2 (HER2) C805S demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 28363995).	28363995
ERBB2	ERBB2 Y772_A775dup ERBB2 C805S	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S were resistant to Tarceva (erlotinib) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 Y772_A775dup ERBB2 C805S	Advanced Solid Tumor	resistant	Tucatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S were resistant to Tucatinib (ARRY-380) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 amp ERBB2 Y772_A775dup	Her2-receptor positive breast cancer	predicted - sensitive	Neratinib	Case Reports/Case Series	Actionable	In a clinical study, Nerlynx (neratinib) treatment resulted in partial response in 2 of 6 and disease stabilization in 4 of 6 breast cancer patients with ERBB2 (HER2) amplification and an ERBB2 (HER2) mutation, including stable disease in a patient harboring ERBB2 (HER2) Y772_A775dup (PMID: 30301790).	30301790
ERBB2	ERBB2 L841V	colorectal cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.8 months in a patient with colorectal cancer harboring ERBB2 (HER2) L841V (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 L841V	Her2-receptor negative breast cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 2.8 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L841V (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 G776delinsVV	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited growth of a transformed cell line expressing ERBB2 (HER2) G776delinsVV in culture (PMID: 29686424).	29686424
ERBB2	ERBB2 G776delinsVV	Advanced Solid Tumor	resistant	Sapitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVV were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 G776delinsVV	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVV were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 act mut	lung non-small cell carcinoma	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in partial response in 21% (3/14) and stable disease lasting over 120 days in 21% (3/14) of patients with non-small cell lung cancer harboring ERBB2 (HER2) activating mutations but not amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 act mut	estrogen-receptor positive breast cancer	predicted - sensitive	Vistusertib	Phase I	Actionable	In a Phase I trial, Vistusertib (AZD2014) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a patient with ER-positive breast cancer harboring an ERBB2 activating mutation (PMID: 25805799).	25805799
ERBB2	ERBB2 act mut	Advanced Solid Tumor	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 11% (4/36) of patients with advanced solid tumors harboring ERBB2 (HER2) activating mutations but not amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 act mut	lung non-small cell carcinoma	decreased response	Nivolumab	Clinical Study - Cohort	Actionable	In a clinical study, immunotherapies including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) resulted in significantly shorter median progression-free survival (51.0 vs 70.5 days, HR=2.47, p=0.0037) in non-small cell lung cancer patients harboring EGFR (n=7) or ERBB2 (HER2) (n=7) activating mutations compared to wild-type patients (PMID: 31085721).	31085721
ERBB2	ERBB2 act mut	lung non-small cell carcinoma	decreased response	Pembrolizumab	Clinical Study - Cohort	Actionable	In a clinical study, immunotherapies including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) resulted in significantly shorter median progression-free survival (51.0 vs 70.5 days, HR=2.47, p=0.0037) in non-small cell lung cancer patients harboring EGFR (n=7) or ERBB2 (HER2) (n=7) activating mutations compared to wild-type patients (PMID: 31085721).	31085721
ERBB2	ERBB2 act mut	lung adenocarcinoma	predicted - sensitive	Ado-trastuzumab emtansine	Phase II	Actionable	In a Phase II trial, treatment with Kadcyla (trastuzumab emtansine) resulted in best overall response rates of 44% (8/18) and 39% (7/18) partial response and stable disease, respectively, and median progression-free survival of 5 months in patients with lung adenocarcinoma harboring ERBB2 (HER2) activating mutations (PMID: 29989854; NCT02675829).	29989854
ERBB2	ERBB2 act mut	lung non-small cell carcinoma	decreased response	Camrelizumab	Clinical Study - Cohort	Actionable	In a clinical study, immunotherapies including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) resulted in significantly shorter median progression-free survival (51.0 vs 70.5 days, HR=2.47, p=0.0037) in non-small cell lung cancer patients harboring EGFR (n=7) or ERBB2 (HER2) (n=7) activating mutations compared to wild-type patients (PMID: 31085721).	31085721
ERBB2	ERBB2 act mut	Advanced Solid Tumor	sensitive	AEE788	Preclinical	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) activation loop mutations demonstrated sensitivity to AEE788 in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 act mut	breast cancer	sensitive	Neratinib	Phase II	Actionable	In a Phase II clinical trial, Nerlynx (neratinib) treatment resulted in clinical benefit in 36% (5/14) of metastatic breast cancer patients harboring ERBB2 (HER2) activating mutations, with 1 complete response, 1 partial response, and 2 patients achieving stable disease for greater than 6 months, and a median progression-free survival of 5 months (J Clin Oncol 34, 2016 (suppl; abstr 516)).	detail...
ERBB2	ERBB2 act mut	biliary tract cancer	predicted - sensitive	Pertuzumab + Trastuzumab	Case Reports/Case Series	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in an objective response in a patient with biliary cancer harboring an ERBB2 (HER2) activating mutation, but no amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 act mut	lung non-small cell carcinoma	decreased response	Atezolizumab	Clinical Study - Cohort	Actionable	In a clinical study, immunotherapies including Tecentriq (atezolizumab) (n=5), Opdivo (nivolumab) (n=17), Keytruda (pembrolizumab) (n=36), and Camrelizumab (SHR-1210) (n=20) resulted in significantly shorter median progression-free survival (51.0 vs 70.5 days, HR=2.47, p=0.0037) in non-small cell lung cancer patients harboring EGFR (n=7) or ERBB2 (HER2) (n=7) activating mutations compared to wild-type patients (PMID: 31085721).	31085721
ERBB2	PIK3CA act mut ERBB2 act mut	breast cancer	sensitive	VS-5584	Preclinical	Actionable	In a preclinical study, breast cancer cells with mutations in both ERBB2 (HER2) and PIK3CA were more sensitive to VS-5584 (PMID: 23270925).	23270925
ERBB2	ERBB2 act mut STK11 loss	breast cancer	sensitive	AZD8055	Preclinical	Actionable	In a preclinical study, AZD8055 inhibited tumor growth in a mouse model of spontaneous breast cancer harboring an ERBB2 (HER2) activating mutation and loss of STK11 (LKB1), which was enhanced by the addition of 2-DG (2-deoxyglucose) (PMID: 25436981).	25436981
ERBB2	ERBB2 T798M	Advanced Solid Tumor	resistant	AEE788	Preclinical	Actionable	In a preclinical study, transformed cell lines expressing ERBB2 (HER2) T798M demonstrated resistance when treated with AEE788 in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 T798M	Her2-receptor positive breast cancer	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cells expressing ERBB2 (HER2) T798M were resistant to Tykerb (lapatinib) in both culture and xenograft models (PMID: 23948973).	23948973
ERBB2	ERBB2 T798M	breast cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing the ERBB2 (HER2) T798M mutant were resistant to Erbitux (cetuximab)(PMID: 23948973).	23948973
ERBB2	ERBB2 T798M	Advanced Solid Tumor	sensitive	EKI-285	Preclinical	Actionable	In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T798M in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 T798M	breast cancer	sensitive	XL147	Preclinical	Actionable	In a preclinical study, breast cancer cell lines expressing ERBB2 (HER2) T798M demonstrated sensitivity to XL147 (SAR245408) in cell culture (PMID: 23948973).	23948973
ERBB2	ERBB2 T798M	breast cancer	sensitive	Buparlisib	Preclinical	Actionable	In a preclinical study, human breast cancer cells expressing the ERBB2 (HER2) T798M mutation demonstrated sensitivity to BKM120 (PMID: 23948973).	23948973
ERBB2	ERBB2 T798M	breast cancer	sensitive	Lapatinib + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, human breast cancer cell lines and cell line xenografts expressing ERBB2 T798M demonstrated sensitivity to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23948973).	23948973
ERBB2	ERBB2 T798M	breast cancer	sensitive	Trastuzumab + XL147	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing ERBB2 (HER2) T798M were sensitive to the combination of Herceptin (trastuzumab) and XL147 (PMID: 23948973).	23948973
ERBB2	ERBB2 T798M	breast cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing ERBB2(HER2) T798M were sensitive to Gilotrif (afatinib) (PMID: 23948973).	23948973
ERBB2	ERBB2 T798M	breast cancer	sensitive	Cetuximab + Lapatinib	Preclinical - Cell line xenograft	Actionable	In preclinical studies, the combination of Erbitux (cetuximab) and Tykerb (lapatinib) inhibited cell growth of a human breast cancer cell line harboring ERBB2 T798M and synergized to inhibit tumor growth in xenograft models (PMID: 23948973).	23948973
ERBB2	ERBB2 T798M	breast cancer	resistant	CI-1040	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing ERBB2 T798M demonstrated resistance to CI-1040 (PMID: 23948973).	23948973
ERBB2	ERBB2 T798M	Advanced Solid Tumor	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cell lines expressing ERBB2 (HER2) T798M demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 T798M	Advanced Solid Tumor	sensitive	WZ4002	Preclinical	Actionable	In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T798M in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 amp ERBB2 T798M	breast cancer	resistant	Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a human ERBB2-amplified breast cancer cell line expressing ERBB2 (HER2) T798M was resistant to Herceptin (trastuzumab) in culture and in xenograft models (PMID: 23948973).	23948973
ERBB2	ERBB2 R896C	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 R896C reverted to normal morphology in culture upon Tykerb (lapatinib) treatment (PMID: 23220880).	23220880
ERBB2	ERBB2 R896C	breast cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 R896C reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).	23220880
ERBB2	ERBB2 R896C	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) R896C reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880).	23220880
ERBB2	ERBB2 V777L	Advanced Solid Tumor	sensitive	AEE788	Preclinical	Actionable	In a preclinical study, transformed cell lines expressing ERBB2 (HER2) V777L demonstrated growth inhibition when treated with AEE788 in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 V777L	gastroesophageal junction adenocarcinoma	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.1 months in a patient with gastroesophageal cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 V777L	colon cancer	resistant	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 V777L	Advanced Solid Tumor	resistant	Sapitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) V777L were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 V777L	urinary bladder cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 6.9 months in a patients with bladder cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 V777L	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) V777L demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).	23220880
ERBB2	ERBB2 V777L	colon cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 V777L	Advanced Solid Tumor	conflicting	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V777L in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 V777L	Advanced Solid Tumor	conflicting	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) V777L were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 V777L	breast cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).	23220880
ERBB2	ERBB2 V777L	biliary tract cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 3.6 months in one patient, and progressive disease with a progression-free survival of 0.8 months in another patient with biliary tract cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 V777L	colorectal cancer	sensitive	Neratinib + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture and suppressed tumor growth in cell line xenograft models (PMID: 26243863).	26243863
ERBB2	ERBB2 V777L	colorectal cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 V777L	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 V777L	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).	23220880
ERBB2	ERBB2 V777L	colorectal cancer	conflicting	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.4 months in a patient with colorectal cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 V777L	colorectal cancer	conflicting	Neratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture and suppressed tumor growth in cell line xenograft models (PMID: 26243863).	26243863
ERBB2	ERBB2 V777L	Her2-receptor negative breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response in one patient, and progressive disease in 4 patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 V777L	colorectal cancer	resistant	Cetuximab	Preclinical - Pdx	Actionable	In a preclinical study, human colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Erbitux (cetuximab) in culture and in patient-derived xenograft models (PMID: 26243863).	26243863
ERBB2	ERBB2 V777L	endometrial cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 6.9 months in a patient with endometrial cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 L755S ERBB2 R1153* ERBB2 V777L	urinary bladder cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patients with bladder cancer harboring ERBB2 (HER2) L755S, R1153*, and V777L (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 V777L ERBB2 V842I	colorectal cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.8 months in a patient with colorectal cancer harboring ERBB2 (HER2) V777L and V842I (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 amp ERBB2 V777L	Her2-receptor positive breast cancer	predicted - sensitive	Neratinib	Case Reports/Case Series	Actionable	In a clinical study, Nerlynx (neratinib) treatment resulted in partial response in 2 of 6 and disease stabilization in 4 of 6 breast cancer patients with ERBB2 (HER2) amplification and an ERBB2 (HER2) mutation, including partial response in a patient harboring ERBB2 (HER2) V777L (PMID: 30301790).	30301790
ERBB2	ERBB2 L755P	lung non-small cell carcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 14.8 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) L755P (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 L755P	Advanced Solid Tumor	resistant	AEE788	Preclinical	Actionable	In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755P demonstrated resistance when treated with AEE788 in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 L755P	Advanced Solid Tumor	sensitive	EKI-285	Preclinical	Actionable	In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755P in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 L755P	Advanced Solid Tumor	resistant	Sapitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L755P were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 L755P	Advanced Solid Tumor	sensitive	WZ4002	Preclinical	Actionable	In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755P in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 L755P	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755P demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 L755P	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L755P were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 K753E	breast cancer	resistant	Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753E were resistant to Herceptin (trastuzumab) in culture (PMID: 27697991).	27697991
ERBB2	ERBB2 K753E	breast cancer	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753 were sensitive to Nerlynx (neratinib) in culture, resulting in decreased colony formation (PMID: 27697991).	27697991
ERBB2	ERBB2 K753E	breast cancer	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753E were resistant to Tykerb (lapatinib) in culture (PMID: 27697991).	27697991
ERBB2	ERBB2 L866M	colorectal cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 L866M	colorectal cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 L866M	colon cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 L866M	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L866M were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 L866M	colon cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 L866M	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L866M were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 amp ERBB2 L866M	colorectal cancer	sensitive	Neratinib + Trastuzumab	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in sustained tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863).	26243863
ERBB2	ERBB2 amp ERBB2 L866M	colorectal cancer	resistant	Trastuzumab	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) had no effect on tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863).	26243863
ERBB2	ERBB2 amp ERBB2 L866M	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification were resistant to Erbitux (cetuximab) (PMID: 26243863).	26243863
ERBB2	ERBB2 amp ERBB2 L866M	colorectal cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) treatment resulted in stable tumor size in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863).	26243863
ERBB2	ERBB2 G778_P780dup	lung non-small cell carcinoma	predicted - sensitive	Afatinib	Clinical Study	Actionable	In a retrospective analysis, Gilotrif (afatinib) treatment resulted in an objective response rate of 25% (1/4) in non-small cell lung cancer patients harboring ERBB2 (HER2) G778_P780dup (reported as P780_Y781insGSP) (PMID: 30527195).	30527195
ERBB2	ERBB2 G778_P780dup	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) P780_Y781insGSP reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880).	23220880
ERBB2	ERBB2 G778_P780dup	breast cancer	sensitive	Neratinib	Phase II	Actionable	In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), which included patients with ERBB2 G778_P780dup (1 complete response (referred to as V777_G778insGSP) and 1 patient with stable disease for more than 24 weeks (referred to as P780_Y781insGSP) (PMID: 28679771).	28679771
ERBB2	ERBB2 G778_P780dup	Her2-receptor negative breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 3.5 months in one patient, and stable disease with a progression-free survival of 20.0 months in another patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) G778_P780dup (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 G778_P780dup	lung cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 26545934).	26545934
ERBB2	ERBB2 G778_P780dup	Advanced Solid Tumor	resistant	Sapitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_P780dup were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 G778_P780dup	Advanced Solid Tumor	decreased response	Tucatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_P780dup (reported as P780_Y781insGSP) demonstrated decreased response to Tucatinib (ARRY-380) compared to Poziotinib (HM781-36B) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G778_P780dup	breast cancer	resistant	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 P780_Y781insGSP demonstrated resistance when treated with Herceptin (trastuzumab) (PMID: 23220880).	23220880
ERBB2	ERBB2 G778_P780dup	Advanced Solid Tumor	conflicting	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 28363995).	28363995
ERBB2	ERBB2 G778_P780dup	Advanced Solid Tumor	conflicting	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) P780_Y781insGSP demonstrated decreased response to Nerlynx (neratinib) compared to Poziotinib (HM781-36B) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G778_P780dup	lung adenocarcinoma	sensitive	Dacomitinib	Phase II	Actionable	In a Phase II trial, two lung adenocarcinoma patients harboring ERBB2 (HER2) G778_780dup (reported as P780_Y781insGSP) demonstrated partial response to treatment with Vizimpro (dacomitinib) (PMID: 25899785; NCT00818441).	25899785
ERBB2	ERBB2 G778_P780dup	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited growth of a transformed cell line expressing ERBB2 (HER2) G778_P780dup (reported P780insGSP) in culture (PMID: 29686424).	29686424
ERBB2	ERBB2 G778_P780dup	lung adenocarcinoma	predicted - sensitive	Ado-trastuzumab emtansine	Case Reports/Case Series	Actionable	In a Phase II trial, treatment with Kadcyla (trastuzumab emtansine) resulted in best overall responses of partial response in 44% (8/18) and stable disease in 39% (7/18), and median progression-free survival of 5 months in patients with lung adenocarcinoma harboring ERBB2 (HER2) activating mutations, and a subset of patients specifically harboring ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) had a 33% (1/3) partial response rate (PMID: 29989854; NCT02675829).	29989854
ERBB2	ERBB2 G778_P780dup	Advanced Solid Tumor	decreased response	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_P780dup (reported as P780_Y781insGSP) demonstrated decreased response to Gilotrif (afatinib) compared to Poziotinib (HM781-36B) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G778_P780dup	lung adenocarcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with metastatic lung adenocarcinoma harboring ERBB2 (HER2) G778_P780dup (also referred to as V777_G778insGSP) demonstrated tumor shrinkage and clinical response for 7 months following treatment with Gilotrif (afatinib) (PMID: 28363995).	28363995
ERBB2	ERBB2 G778_P780dup	lung adenocarcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, a lung adenocarcinoma patient harboring ERBB2 (HER2) G778_P780dup (also referred to as V747_G748insGSP and G748_P750dup), demonstrated a 13% regression of target lesions and stable disease for 11 months following treatment with pulse Gilotrif (afatinib) (PMID: 26964772).	26964772
ERBB2	ERBB2 G778_P780dup	lung cancer	no benefit	Gefitinib	Preclinical	Actionable	In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).	26545934
ERBB2	ERBB2 G778_P780dup	breast cancer	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 P780_Y781insGSP demonstrated resistance when treated with Tykerb (lapatinib) (PMID: 23220880).	23220880
ERBB2	ERBB2 G778_P780dup	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_P780dup (reported as P780_Y781insGSP) were resistant to Tykerb (lapatinib) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G778_P780dup	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_P80dup were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 G778_P780dup	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_P780dup (reported as P780_Y781insGSP) were resistant to Tarceva (erlotinib) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G778_P780dup	lung non-small cell carcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival over 17 months in 2 patient with non-small cell lung cancer harboring ERBB2 (HER2) G778_P780dup (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 G778_P780dup	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vizimpro (dacomitinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 28363995).	28363995
ERBB2	ERBB2 G778_P780dup	Advanced Solid Tumor	resistant	AZ5104	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_P780dup (reported as P780_Y781insGSP) were resistant to AZ5104 in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G778_P780dup	Advanced Solid Tumor	decreased response	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_P780dup (reported as P780_Y781insGSP) demonstrated decreased response to Tagrisso (osimertinib) compared to Poziotinib (HM781-36B) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsLC	lung cancer	no benefit	Gefitinib	Preclinical	Actionable	In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsLC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).	26545934
ERBB2	ERBB2 G776delinsLC	Advanced Solid Tumor	resistant	Sapitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsLC were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 G776delinsLC	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsLC were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 G776delinsLC	lung cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsLC in culture (PMID: 26545934).	26545934
ERBB2	ERBB2 amp	colorectal cancer	decreased response	Panitumumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, patients with metastatic KRAS exon 2 wild-type colorectal cancer harboring ERBB2 (HER2) amplification or overexpression (n=79) demonstrated poorer objective response rate (31.2 vs 46.9, p=0.031) and progression-free survival (5.7 vs 7 months, p=0.087) to anti-EGFR treatment (Vectibix (panitumumab) or Erbitux (cetuximab), as monotherapy or combined with chemotherapy) when compared to ERBB2 (HER2)-negative patients (n=113) (PMID: 30952821).	30952821
ERBB2	ERBB2 amp	colorectal cancer	resistant	Trastuzumab	Preclinical	Actionable	In a preclinical study, colorectal cancer tumorgrafts with ERBB2 (HER2) amplification demonstrated resistance to Herceptin (trastuzumab) treatment in animal models (PMID: 26296355).	26296355
ERBB2	ERBB2 amp	breast cancer	sensitive	Lapatinib + Torkinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination therapy of Tykerb (lapatinib) and Torkinib (PP242) in ERBB2 (HER2) amplified breast cancer cells in culture blocked cell growth, inhibited phosphorylation of Akt and S6, and led to greater caspase activity when compared to each agent alone (PMID: 27197158).	27197158
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	trastuzumab and hyaluronidase-oysk injection	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (HannaH) that supported FDA approval, Herceptin Hylecta (trastuzumab and hyaluronidase-oysk injection) treatment demonstrated safety and efficacy profile comparable to intravenous trastuzumab treatment, resulted in pathologic complete response in 45.4% (118/260) of patients with ERBB2 (HER2)-positive (IHC 3+ or ISH positive) breast cancer (PMID: 22884505; NCT00950300).	detail... detail... 22884505
ERBB2	ERBB2 amp	breast cancer	predicted - sensitive	Neratinib + Temsirolimus	Phase I	Actionable	In a Phase I clinical trial, Nerlynx (neratinib) administered with Torisel (temsirolimus) was tolerable and demonstrated antitumor activity in ERBB2 (HER2)-amplified breast cancer resistant to (Herceptin) trastuzumab (PMID: 24323026).	24323026
ERBB2	ERBB2 amp	stomach cancer	sensitive	Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Herceptin (trastuzumab) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification (PMID: 26296355).	26296355
ERBB2	ERBB2 amp	stomach cancer	predicted - sensitive	Afatinib + Trastuzumab	Case Reports/Case Series	Actionable	In a Phase II clinical trial, a gastric cancer patient with ERBB2 (HER2) amplification who progressed on previous therapy demonstrated a 22% regression in a metastatic site when treated with a combination of Gilotrif (afatinib) and Herceptin (trastuzumab) (PMID: 30463996; NCT01522768).	30463996
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	Neratinib	FDA approved	Actionable	In a Phase III trial that supported FDA approval, ERBB2 (HER2)-positive (overexpressing and/or amplification) breast cancer patients previously treated with Herceptin (trastuzumab) demonstrated a significantly greater two year invasive disease-free survival rate (93.9%) when treated with Nerlynx (neratinib) compared to the rate (91.6%) in those patients treated with placebo (PMID: 26874901; NCT00878709).	26874901 detail...
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	Neratinib	Guideline	Actionable	Nerlynx (neratinib) is included in guidelines for ERBB2 (HER2)-positive patients with high-risk early breast cancer (PMID: 31236598; ESMO.org).	detail... 31236598
ERBB2	ERBB2 amp	colorectal cancer	sensitive	Cetuximab + Lapatinib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Tykerb (lapatinib) induced tumor regression in patient-derived xenograft (PDX) models of colorectal cancer with ERBB2 (HER2) amplification (PMID: 22586653).	22586653
ERBB2	ERBB2 amp	stomach cancer	sensitive	Lapatinib + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) treatment induced tumor regression in ERBB2 (HER2)-amplified cell line xenograft models of gastric cancer (PMID: 26296355).	26296355
ERBB2	ERBB2 amp	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells with ERBB2 (HER2) amplification in culture (PMID: 21558396).	21558396
ERBB2	ERBB2 amp	uterine corpus serous adenocarcinoma	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification demonstrated sensitivity to treatment with Nerlynx (neratinib) in culture, resulting in inhibition of cell growth (PMID: 26333383).	26333383
ERBB2	ERBB2 amp	lung non-small cell carcinoma	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited proliferation and induced cell-cycle arrest and apoptosis of non-small cell lung cancer (NSCLC) cell lines with ERBB2 (HER2) amplification in culture, and inhibited tumor growth in ERBB2 (HER2)-amplified NSCLC cell line xenograft models (PMID: 26545934).	26545934
ERBB2	ERBB2 amp	uterine corpus serous adenocarcinoma	sensitive	SYD985	Preclinical	Actionable	In a preclinical study, SYD895 induced cell death in ERBB2 (HER2)-amplified primary uterine serous carcinoma (USC) cell lines in culture and inhibited tumor growth and improved survival in ERBB2 (HER2)-amplified USC primary cell line xenografts (PMID: 27256376).	27256376
ERBB2	ERBB2 amp	stomach cancer	sensitive	BMS-690514	Preclinical	Actionable	In a preclinical study, BMS-690514 inhibited tumor growth in a gastric cancer xenograft model with ERBB2 (HER2) amplification and overexpression (PMID: 21531814).	21531814
ERBB2	ERBB2 amp	uterine corpus serous adenocarcinoma	sensitive	Taselisib	Preclinical - Cell culture	Actionable	In a preclinical study, a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification demonstrated sensitivity to treatment with Taselisib (GDC-0032) in culture, resulting in inhibition of cell growth (PMID: 26333383).	26333383
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	CDX-3379	Preclinical	Actionable	In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-amplified breast cancer (PMID: 26880266).	26880266
ERBB2	ERBB2 amp	Advanced Solid Tumor	sensitive	Afatinib	Phase II	Actionable	In a Phase II trial, Gilotrif (afatinib), demonstrated safety and efficacy in various advanced solid tumor patients with ERBB2 (HER2) amplification (PMID: 23775486).	23775486
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	predicted - sensitive	BGB-283	Preclinical - Cell culture	Actionable	In a preclinical study, BGB-283 inhibited proliferation of ERBB2 (HER2) amplified breast cancer cells in culture (PMID: 26208524).	26208524
ERBB2	ERBB2 amp	stomach cancer	sensitive	TAS0728	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAS0728 inhibited Erbb2 downstream signaling and proliferation of ERBB2 (HER2) amplified gastric cancer cells in culture, and induced tumor regression in cell line xenograft models (PMID: 30787176).	30787176
ERBB2	ERBB2 amp	gastroesophageal junction adenocarcinoma	sensitive	Trastuzumab	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (ToGA) that supported FDA approval, patients with either gastric cancer or gastroesophageal junction adenocarcinoma with ERBB2 (HER2) overexpression or ERBB2 (HER2) amplification had increased overall survival (13.8 mo vs 11.1 mo) when treated with Herceptin (trastuzumab) in combination with chemotherapy compared to chemotherapy alone (PMID: 20728210; NCT01041404).	20728210 detail... detail...
ERBB2	ERBB2 amp	stomach carcinoma	no benefit	Debio 1347	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of ERBB2 (HER2) amplified gastric carcinoma (PMID: 26438159).	26438159
ERBB2	ERBB2 amp	acral lentiginous melanoma	sensitive	Ado-trastuzumab emtansine	Case Reports/Case Series	Actionable	In a clinical case study, Kadcyla (trastuzumab emtansine) treatment resulted in complete radiographic response that lasted over 28 months in a patient with acral melanoma harboring ERBB2 (HER2) amplification (26-fold) that was resistant to check-point inhibition (PMID: 30093446).	30093446
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	TAS0728	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAS0728 inhibited Erbb2 downstream signaling and proliferation of ERBB2 (HER2) amplified breast cancer cell lines in culture, and induced tumor regression in cell line xenograft models (PMID: 30787176).	30787176
ERBB2	ERBB2 amp	breast cancer	sensitive	Dacomitinib	Preclinical	Actionable	In a preclinical study, Vizimpro (dacomitinib) was more effective in preventing proliferation in ERBB2 (HER2) amplified breast cancer cells than in wild-type ERBB2 (HER2) breast cancer cells (PMID: 22761403).	22761403
ERBB2	ERBB2 amp	gastrointestinal system cancer	sensitive	Dacomitinib	Preclinical	Actionable	In a preclinical study, Vizimpro (dacomitinib) demonstrated significant growth-inhibitory effects in HER2- amplified gastric cancer cells (PMID: 18606718).	18606718
ERBB2	ERBB2 amp	breast cancer	decreased response	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, ERBB2 (HER2) amplified breast cancer cells treated with Tykerb (lapatinib) demonstrated decreased phosphorylation of Erbb2 (her2) and Akt, however, after 4-8 hours, Akt-driven Rictor showed upregulation, thereby resulting in a decreased treatment response (PMID: 27197158).	27197158
ERBB2	ERBB2 amp	lung cancer	predicted - sensitive	TAS0728	Preclinical - Cell culture	Actionable	In a preclinical study, TAS0728 inhibited Erbb2 downstream signaling and proliferation of ERBB2 (HER2) amplified lung cancer cells in culture (PMID: 30787176).	30787176
ERBB2	ERBB2 amp	Advanced Solid Tumor	predicted - sensitive	Ado-trastuzumab emtansine	Phase II	Actionable	In a Phase II (MATCH) trial, Kadcyla (trastuzumab emtansine) treatment resulted in partial response in 8.1% (3/37) and stable disease in 43% (16/37) of patients with ERBB2 (HER2) amplified non-breast, non-gastric advanced solid tumors, with a 6-month progression-free survival rate of 24.8% (J Clin Oncol 36, 2018 (suppl; abstr 100); NCT02465060).	detail...
ERBB2	ERBB2 amp	stomach cancer	sensitive	Poziotinib	Preclinical	Actionable	In a preclinical study, Poziotinib suppressed cell growth, decreased phosphorylation of downstream signaling molecules, and induced apoptosis of human gastric cancer cells harboring ERBB2 (HER2) amplification (PMID: 21306821).	21306821
ERBB2	ERBB2 amp	ovarian cancer	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 13% (1/8, all partial response) of patients with ovarian cancer harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 amp	Advanced Solid Tumor	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 26% (30/114, 2 complete response, 28 partial response) and stable disease lasting over 120 days in 14% (16/114) of patients with advanced solid tumors harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 amp	breast cancer	sensitive	Pertuzumab + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of Herceptin (trastuzumab) and Perjeta (pertuzumab), resulting in a delay of brain lesion growth and improved survival (PMID: 28539475).	28539475
ERBB2	ERBB2 amp	scrotum Paget's disease	predicted - sensitive	Ado-trastuzumab emtansine	Phase II	Actionable	In a Phase II (MATCH) trial, Kadcyla (trastuzumab emtansine) treatment resulted in partial response in a patient with ERBB2 (HER2) amplified Pagets disease of the scrotum (J Clin Oncol 36, 2018 (suppl; abstr 100); NCT02465060).	detail...
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	predicted - sensitive	KRIBB11 + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, MK-2206 and KRIBB11 synergistically inhibited growth of ERBB2 (HER2)-amplified breast cancer cell lines in culture (PMID: 28598816).	28598816
ERBB2	ERBB2 amp	colorectal cancer	sensitive	Lapatinib + Pertuzumab	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Perjeta (pertuzumab) and Tykerb (lapatinib) induced tumor regression in patient-derived xenograft (PDX) models of colorectal cancer with ERBB2 (HER2) amplification (PMID: 22586653).	22586653
ERBB2	ERBB2 amp	colorectal cancer	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 38% (14/37, all partial response) and stable disease lasting over 120 days in 11% (4/37) of patients with colorectal cancer harboring ERBB2 (HER2) amplification or overexpression, with a median duration of response of 11 months (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 amp	colorectal adenocarcinoma	predicted - sensitive	Ado-trastuzumab emtansine	Case Reports/Case Series	Actionable	In a clinical case study, a patient with metastatic colorectal adenocarcinoma harboring ERBB2 (HER2) amplification demonstrated clinical benefit with stable disease in the primary tumor for 7 months following treatment with Kadcyla (trastuzumab emtansine) (PMID: 28040715).	28040715
ERBB2	ERBB2 amp	lung squamous cell carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, a lung squamous cell carcinoma cell line with ERBB2 (HER2) amplification demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 26545934).	26545934
ERBB2	ERBB2 amp	biliary tract cancer	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 29% (2/7, all partial response) and stable disease lasting over 120 days in 38% (3/7) of patients with biliary cancer harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	Pertuzumab + Trastuzumab	Guideline	Actionable	The combination of Herceptin (trastuzumab) and Perjeta (pertuzumab) with a taxane, such as Taxotere (docetaxel) or Taxol (palictaxel), is included in guidelines for ERBB2 (HER2)-positive patients with early breast cancer patients or advanced breast cancer (PMID: 31236598, PMID: 30032243; ESMO.org).	detail... 31236598 30032243
ERBB2	ERBB2 amp	parotid gland cancer	predicted - sensitive	Ado-trastuzumab emtansine	Phase II	Actionable	In a Phase II (MATCH) trial, Kadcyla (trastuzumab emtansine) treatment resulted in partial response in a patient with ERBB2 (HER2) amplified salivary duct carcinoma of the parotid gland and a patient with ERBB2 (HER2) amplified squamous cell carcinoma of the parotid gland (J Clin Oncol 36, 2018 (suppl; abstr 100); NCT02465060).	detail...
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	Lapatinib + S63845	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tykerb (lapatinib) and S63845 demonstrated synergy in an ERBB2 (HER2)-amplified breast cancer cell line in culture, resulting in decreased cell viability (PMID: 28768804).	28768804
ERBB2	ERBB2 amp	breast cancer	sensitive	Torkinib	Preclinical - Cell culture	Actionable	In a preclinical study, ERBB2 (HER2) amplified breast cancer cells treated with Torkinib (PP242) demonstrated some efficacy in culture including reduced phosphorylation of S6 and Akt, apoptosis, and decreased cell growth (PMID: 27197158).	27197158
ERBB2	ERBB2 amp	uterine corpus serous adenocarcinoma	sensitive	Neratinib + Taselisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Taselisib (GDC-0032) and Nerlynx (neratinib) resulted in a synergistic effect, demonstrating greater cell growth inhibitory activity in uterine serous carcinoma cells harboring ERBB2 (HER2) amplification compared to either agent alone (PMID: 26333383).	26333383
ERBB2	ERBB2 amp	breast cancer	sensitive	LJM716 + Neratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of LJM716 and Nerlynx (neratinib), resulting in a delay of brain lesion growth and improved survival (PMID: 28539475).	28539475
ERBB2	ERBB2 amp	stomach cancer	predicted - sensitive	Fluorouracil + Oxaliplatin + Trastuzumab	Case Reports/Case Series	Actionable	In a Phase II clinical trial, a gastric cancer patient with ERBB2 (HER2) amplification demonstrated a response for 24 months when treated with the combination of Adrucil (fluorouracil), Eloxatin (oxaliplatin), and Herceptin (trastuzumab) (PMID: 30463996; NCT01522768).	30463996
ERBB2	ERBB2 amp	esophagus adenocarcinoma	no benefit	Lapatinib	Phase III	Actionable	In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in esophagus adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478).	26628478
ERBB2	ERBB2 amp	salivary gland cancer	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 80% (4/5, all partial response) of patients with salivary gland cancer harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 amp	breast cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited proliferation of breast cancer cell lines with ERBB2 (HER2) amplification in culture (PMID: 26545934).	26545934
ERBB2	ERBB2 amp	breast cancer	sensitive	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cell lines harboring ERBB2 (HER2) amplification demonstrated increased sensitivity to CYH33 compared to cells with normal ERBB2 (HER2) expression in culture (p<0.05) (PMID: 30003928).	30003928
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	S63845 + Trastuzumab	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, S63845 and Herceptin (trastuzumab) demonstrated synergy in ERBB2 (HER2)-amplified breast cancer cells in culture and in ERBB2 (HER2)-amplified breast cancer patient-derived xenograft (PDX) models, resulting in enhanced tumor growth inhibition and overall survival compared to either agent alone (PMID: 28768804).	28768804
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	CDX-3379 + Trastuzumab	Preclinical	Actionable	In a preclinical study, the combination of Herceptin (trastuzumab) and CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-amplified breast cancer, with increased efficacy compared to KTN3379 alone (PMID: 26880266).	26880266
ERBB2	ERBB2 amp	breast cancer	sensitive	Lapatinib + S63845	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of S63845 and Tykerb (lapatinib) resulted in potent cytotoxic effects in ERBB2 (HER2)-amplified breast cancer cells in culture compared to the cytostatic effect of Tykerb (lapatinib) alone (PMID: 27760111).	27760111
ERBB2	ERBB2 amp	gastric adenocarcinoma	sensitive	Trastuzumab	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (ToGA) that supported FDA approval, patients with either gastric or gastroesophageal junction adenocarcinoma with ERBB2 (HER2) overexpression or ERBB2 (HER2) amplification had increased overall survival (13.8 mo vs 11.1 mo) when treated with Herceptin (trastuzumab) in combination with chemotherapy compared to chemotherapy alone (PMID: 20728210; NCT01041404).	detail... 20728210 detail...
ERBB2	ERBB2 amp	urinary bladder cancer	sensitive	Afatinib	Phase II	Actionable	In a Phase II clinical trial, patients with ERBB2 (HER2) amplified urothelial carcinoma had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931).	27044931
ERBB2	ERBB2 amp	breast cancer	sensitive	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer cell line xenograft model harboring ERBB2 (HER2) amplification demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475).	28539475
ERBB2	ERBB2 amp	gastric adenocarcinoma	predicted - sensitive	Capecitabine + Lapatinib + Oxaliplatin	Phase II	Actionable	In a Phase II trial, Tykerb (lapatinib), Xeloda (capecitabine), and Eloxatin (oxaliplatin) combination treatment resulted in a disease control rate of 81.3% (26/32, 7 complete response, 15 partial response, 4 stable disease) in patients with Erbb2 (Her2)-positive (defined as IHC3+ or IHC 2+ with ERBB2 amplification) gastric adenocarcinoma (PMID: 29409051; NCT02015169).	29409051
ERBB2	ERBB2 amp	gastric adenocarcinoma	no benefit	Lapatinib	Phase III	Actionable	In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in gastric adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478).	26628478
ERBB2	ERBB2 amp	colorectal cancer	decreased response	Lapatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Tykerb (lapatinib) resulted in initial disease stabilization with subsequent progression, in patient-derived colorectal cancer tumorgraft models with ERBB2 (HER2) amplification (PMID: 26296355).	26296355
ERBB2	ERBB2 amp	pancreatic cancer	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 22% (2/9, all partial response) and stable disease lasting over 120 days in 11% (1/9) of patients with pancreatic cancer harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 amp	lung adenocarcinoma	no benefit	Dacomitinib	Phase II	Actionable	In a Phase II trial, Vizimpro (dacomitinib) treatment resulted in an overall response rate of 0% (0/4) in patients with lung adenocarcinoma harboring ERBB2 (HER2) amplification (PMID: 25899785; NCT00818441).	25899785
ERBB2	ERBB2 amp	urinary bladder cancer	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 33% (3/9, 1 complete response, 1 partial response) and stable disease lasting over 120 days in 22% (2/9) of patients with bladder cancer harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 amp	esophageal cancer	sensitive	Ibrutinib	Preclinical - Cell culture	Actionable	In a preclinical study, esophageal cancer cells with ERBB2 (HER2) amplification demonstrated sensitivity to Imbruvica (ibrutinib), resulting in decreased survival in culture (PMID: 28830912).	28830912
ERBB2	ERBB2 amp	stomach cancer	sensitive	Lapatinib	Preclinical	Actionable	In preclinical studies, Tykerb (lapatinib) demonstrated antiproliferative activity in HER2-amplified gastric cancer in cell assays and in xenograft models (PMID: 20179222).	20179222
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	Palbociclib + Trastuzumab	Preclinical	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Herceptin (trastuzumab) worked synergistically to inhibit growth of ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 19874578).	19874578
ERBB2	ERBB2 amp	breast cancer	sensitive	Neratinib + Pertuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of Perjeta (pertuzumab) and Nerlynx (neratinib), resulting in a delay of brain lesion growth and improved survival (PMID: 28539475).	28539475
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	Trastuzumab	FDA approved - On Companion Diagnostic	Actionable	Herceptin (trastuzumab) is FDA approved as an adjuvant treatment for ERBB2 (HER2)-overexpressing (or amplification) breast cancer patients and for metastatic ERBB2 (HER2)-overexpressing (or amplification) breast cancer patients as indicated by an FDA approved companion diagnostic (FDA.gov).	detail... detail...
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	Trastuzumab	Clinical Study - Meta-analysis	Actionable	In a meta-analysis, breast cancer patients with >12 copies of ERBB2 (HER2) had a better response to Herceptin (trastuzumab) than patients with 6-12 copies of ERBB2 (HER2) (PMID: 24691421).	24691421
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab) combined with a taxane, such as Taxotere (docetaxel) or Taxol (paclitaxel), is included in guidelines as neoadjuvant therapy for ERBB2 (HER2)-positive patients with early breast cancer or as first-line therapy for ERBB2 (HER2)-positive patients with advanced breast cancer (PMID: 31236598, PMID: 30032243; ESMO.org).	31236598 detail... 30032243
ERBB2	ERBB2 amp	vulva squamous cell carcinoma	sensitive	Depatuxizumab mafodotin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-414 demonstrated cytoxicity against a EGFR-amplified vulvar epidermoid carcinoma cell line in culture and induced tumor regression in EGFR-amplified vulvar epidermoid carcinoma cell line xenograft models (PMID: 26846818).	26846818
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	Docetaxel + Pertuzumab + Trastuzumab	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (CLEOPATRA) that supported FDA approval, treatment with Perjeta (pertuzumab), combined with Herceptin (trastuzumab) and Taxotere (docetaxel), improved median progression free survival to 18.5 months compared to 12.4 months with placebo plus Herceptin (trastuzumab) and Taxotere (docetaxel) in patients with ERBB2 (HER2)-positive (overexpression and amplification) metastatic breast cancer (PMID: 23801166).	23801166 detail... detail...
ERBB2	ERBB2 amp	uterine cancer	no benefit	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in no objective response (0/7) in patients with uterine cancer harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 amp	breast cancer	sensitive	LJM716 + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of Herceptin (trastuzumab) and LJM716, resulting in a delay of brain lesion growth and improved survival (PMID: 28539475).	28539475
ERBB2	ERBB2 amp	colorectal cancer	no benefit	Pertuzumab	Preclinical - Pdx	Actionable	In a preclinical study, Perjeta (pertuzumab) did not inhibit tumor growth in patient-derived xenograft (PDX) models of ERBB2 (HER2)-amplified colorectal cancer (PMID: 22586653).	22586653
ERBB2	ERBB2 amp	colorectal cancer	sensitive	Lapatinib + Trastuzumab	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) treatment induced tumor regression in patient-derived colorectal cancer tumorgraft models harboring ERBB2 (HER2) amplification (PMID: 26296355).	26296355
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	Trastuzumab + Vinorelbine	Guideline	Actionable	The combination of Herceptin (trastuzumab) and Navelbine (vinorelbine) is included in guidelines as first-line therapy for ERBB2 (HER2)-positive patients with advanced breast cancer (PMID: 30032243; ESMO.org).	30032243 detail...
ERBB2	ERBB2 amp	gastroesophageal junction adenocarcinoma	no benefit	Lapatinib	Phase III	Actionable	In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in gastroesophageal junction adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478).	26628478
ERBB2	ERBB2 amp	colorectal cancer	resistant	Cetuximab	Clinical Study - Cohort	Actionable	In a clinical study, ERBB2 (HER2) amplification was associated with resistance to Erbitux (cetuximab) in colorectal cancer patients (PMID: 21900593).	21900593
ERBB2	ERBB2 amp	colorectal cancer	resistant	Cetuximab	Clinical Study - Cohort	Actionable	In a retrospective analysis, patients with metastatic KRAS exon 2 wild-type colorectal cancer harboring ERBB2 (HER2) amplification or overexpression (n=79) demonstrated poorer objective response rate (31.2 vs 46.9, p=0.031) and progression-free survival (5.7 vs 7 months, p=0.087) to anti-EGFR treatment (Vectibix (panitumumab) or Erbitux (cetuximab), as monotherapy or combined with chemotherapy) when compared to ERBB2 (HER2)-negative patients (n=113) (PMID: 30952821).	30952821
ERBB2	ERBB2 amp	lung non-small cell carcinoma	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 13% (2/16, all partial response) and stable disease lasting over 120 days in 13% (2/16) of patients with non-small cell lung cancer harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (EMILIA) that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) improved median progression free survival (9.6 mo vs 6.4 mo) and overall survival (30.9 mo vs 25.1 mo) compared to Tykerb (lapatinib) combined with Xeloda (capecitabine) in patients with metastatic ERBB2 (HER2)-positive breast cancer (PMID: 24879797, PMID: 23020162; NCT00829166).	24879797 23020162 detail... detail...
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (KATHERINE) that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) resulted in improved invasive disease-free survival (HR=0.50, p<0.001) compared to Herceptin (trastuzumab) in patients with ERBB2 (HER2)-positive early breast cancer who had residual invasive disease after taxane and trastuzumab-based neoadjuvant therapy (PMID: 30516102; NCT01772472).	detail... detail... 30516102
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	Guideline	Actionable	Kadcyla (ado-trastuzumab emtansine) is included in the guidelines for ERBB2 (HER2)-positive patients with advanced breast cancer who progressed through one line of Herceptin (trastuzumab)-based therapy or ERBB2 (HER2)-positive patients with early breast cancer (PMID: 31236598, PMID: 30032243; ESMO.org).	detail... 31236598 30032243
ERBB2	ERBB2 amp	duodenum adenocarcinoma	predicted - sensitive	Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with duodenal adenocarcinoma harboring ERBB2 (HER2) amplification demonstrated a complete pathologic response after treatment with a combination of Herceptin (trastuzumab), Adrucil (fluorouracil), Wellcovorin (leucovorin), and Eloxatin (oxaliplatin) (PMID: 28784859).	28784859
ERBB2	ERBB2 amp	Her2-receptor positive breast cancer	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, increased copy number (CN) of ERBB2 (HER2) was associated with improved response to Poziotinib (HM781-36B) treatment in patients with Erbb2 (Her2)-positive breast cancer, with a median progression-free survival of 4.86 months in patients with CN over 8 and 2.99 months in patients with CN equal to or less than 8 (HR=0.61, p=0.037) (PMID: 30720867, NCT02418689).	30720867
ERBB2	FGFR2 wild-type ERBB2 amp	stomach cancer	resistant	AZD4547	Preclinical	Actionable	In a preclinical study, gastric cancer cells with wild-type FGFR2 and ERBB2 (HER2) amplification were resistant to treatment with AZD4547 in culture (PMID: 22869148).	22869148
ERBB2	ERBB2 amp PIK3CA C420R	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA C420R and ERBB2 (HER2) amplification (PMID: 21558396).	21558396
ERBB2	ERBB2 amp PIK3CA C420R	breast cancer	sensitive	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, CYH33 inhibited proliferation of breast cancer cell lines harboring PIK3CA C420R and ERBB2 (HER2) amplification in culture (PMID: 30003928).	30003928
ERBB2	ERBB2 amp PIK3CA N345K	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA N345K and ERBB2 (HER2) amplification in culture (PMID: 21558396).	21558396
ERBB2	ERBB2 amp PIK3CA H1047R	breast cancer	sensitive	CH5132799 + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of CH5132799 and Herceptin (trastuzumab) inhibited tumor growth and overcame Herceptin (trastuzumab) insensitivity in xenograft models of a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification (PMID: 21558396).	21558396
ERBB2	ERBB2 amp PIK3CA H1047R	breast cancer	sensitive	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, CYH33 inhibited proliferation of breast cancer cell lines harboring PIK3CA H1047R and ERBB2 (HER2) amplification in culture (PMID: 30003928).	30003928
ERBB2	ERBB2 amp PIK3CA H1047R	breast cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring ERBB2 (HER2) amplification and PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276).	17314276 21325073
ERBB2	ERBB2 amp PIK3CA H1047R	breast cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).	21558396
ERBB2	ERBB2 amp PIK3CA H1047R	ovarian cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited cell growth in a human ovarian cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).	21558396
ERBB2	ERBB2 amp PIK3CA K111N	breast cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA K111N and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).	21558396
ERBB2	ERBB2 amp PIK3CA K111N	breast cancer	predicted - sensitive	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N and ERBB2 (HER2) amplification in culture (PMID: 30003928).	30003928
ERBB2	ERBB2 amp PIK3CA E545K	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K and ERBB2 (HER2) amplification in culture (PMID: 21558396).	21558396
ERBB2	ERBB2 amp PIK3CA E545K	breast cancer	sensitive	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer cell line xenograft model co-harboring ERBB2 (HER2) amplification and PIK3CA E545K demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475).	28539475
ERBB2	ERBB2 amp PIK3CA E545K	breast cancer	predicted - sensitive	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K and ERBB2 (HER2) amplification in culture (PMID: 30003928).	30003928
ERBB2	ERBB2 amp PIK3CA E545K PIK3CA K567R	Her2-receptor positive breast cancer	sensitive	Gedatolisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited PI3K signaling, cell growth and induced apoptosis in human breast cancer cells harboring ERBB2 (HER2) amplification, PIK3CA E545K, and PIK3CA K567R in culture and in cell line xenografts (PMID: 21325073, PMID: 17314276).	17314276 21325073
ERBB2	ERBB2 amp MET amp	esophageal carcinoma	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Tykerb (lapatinib) in culture (PMID: 26432108).	26432108
ERBB2	ERBB2 amp MET amp	gastroesophageal junction adenocarcinoma	sensitive	Crizotinib + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) inhibited the growth of gastroesophageal adenocarcinoma cells with ERBB2 (HER2) and MET amplification in culture (PMID: 25350844).	25350844
ERBB2	ERBB2 amp MET amp	esophageal carcinoma	sensitive	Crizotinib + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was sensitive to inhibition by Tykerb (lapatinib) and Xalkori (crizotinib) in culture (PMID: 26432108).	26432108
ERBB2	ERBB2 amp MET amp	esophageal carcinoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was resistant to Xalkori (crizotinib) in culture (PMID: 26432108).	26432108
ERBB2	ERBB2 amp MET amp	gastric adenocarcinoma	predicted - resistant	Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with ERBB2 (HER2) amplified gastric adenocarcinoma progressed rapidly when treated with Herceptin (trastuzumab) with Xeloda (capecitabine), Eloxatin (oxaliplatin), and Avastin (bevacizumab), and reprofiling of the tumor revealed co-amplification of MET (PMID: 26432108).	26432108
ERBB2	ERBB2 amp MET amp	esophagus adenocarcinoma	sensitive	Crizotinib + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and MET amplification in culture (PMID: 27595477).	27595477
ERBB2	ERBB2 amp MET amp	gastric adenocarcinoma	predicted - resistant	Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma was insensitive to Herceptin (trastuzumab) and FOLFOX combination treatment (PMID: 26432108).	26432108
ERBB2	ERBB2 amp MET amp	gastric adenocarcinoma	predicted - sensitive	Crizotinib + Paclitaxel + Trastuzumab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma had near complete regression of the disease after 2 months of treatment with Herceptin (trastuzumab), Xalkori (crizotinib) and weekly Taxol (paclitaxel) (PMID: 26432108).	26432108
ERBB2	ERBB2 amp MET amp	gastric adenocarcinoma	predicted - resistant	AMG 337	Case Reports/Case Series	Actionable	In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma did not respond to AMG 337 therapy (PMID: 26432108).	26432108
ERBB2	ERBB2 amp TP53 R158H	gastric adenocarcinoma	predicted - resistant	AMG 337	Clinical Study	Actionable	In a clinical case study, a patient with gastric adenocarcinoma containing amplification of ERBB2 (HER2) and a TP53 R158H mutation progressed and developed metastases while being treated with AMG 337 (PMID: 26432108).	26432108
ERBB2	ERBB2 amp PIK3CA mut	Her2-receptor positive breast cancer	sensitive	Ipatasertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cell line xenograft models harboring amplification of ERBB2 (HER2) and a PIK3CA mutation demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624).	24141624
ERBB2	ERBB2 amp PIK3CA mut	breast cancer	sensitive	CUDC-907	Preclinical	Actionable	In a preclinical study, CUDC-907 inhibited downstream signaling and growth of PIK3CA-mutant breast cancer cells with ERBB2 amplification in culture (PMID: 22693356).	22693356
ERBB2	ERBB2 amp PIK3CA mut	Her2-receptor positive breast cancer	sensitive	Copanlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Aliqopa (copanlisib) promoted tumor regression in xenograft models of a human ERBB2 (HER2)-amplified breast cancer cell line harboring a PIK3CA activating mutation (PMID: 24170767).	24170767
ERBB2	ERBB2 amp PIK3CA mut	uterine corpus serous adenocarcinoma	sensitive	Neratinib + Taselisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Nerlynx (neratinib) and Taselisib (GDC-0032), compared to either agent alone, resulted in greater inhibition of cell cycle activity in a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification and a PIK3CA mutation in culture, and in xenograft models, showed increased tumor growth inhibition and tumor regression (PMID: 26333383).	26333383
ERBB2	EGFR amp ERBB2 amp	gastric adenocarcinoma	predicted - resistant	Fluorouracil + Oxaliplatin + Trastuzumab	Case Reports/Case Series	Actionable	In Phase II clinical trial, a patient with metastatic gastric adenocarcinoma progressed while on the combination therapy of Adrucil (fluorouracil), Eloxatin (oxaliplatin), and Herceptin (trastuzumab), and was subsequently found to have acquired co-amplification of EGFR and ERBB2 (HER2) in the liver metastasis (PMID: 30463996; NCT01522768).	30463996
ERBB2	EGFR amp ERBB2 amp	stomach cancer	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a Phase II clinical trial, a gastric cancer patient with co-amplification of EGFR and ERBB2 (HER2) who previously progressed on a combination therapy with Herceptin (trastuzumab) demonstrated a 37% tumor regression when treated with Gilotrif (afatinib) (PMID: 30463996; NCT01522768).	30463996
ERBB2	EGFR amp ERBB2 amp	gastric adenocarcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a Phase II clinical trial, a metastatic gastric adenocarcinoma patient with co-amplification of EGFR and ERBB2 (HER2) demonstrated a 43% tumor regression by RECIST when treated with Gilotrif (afatinib) (PMID: 30463996; NCT01522768).	30463996
ERBB2	EGFR amp ERBB2 amp	stomach cancer	predicted - resistant	Fluorouracil + Oxaliplatin + Trastuzumab	Phase II	Actionable	In a Phase II clinical trial, co-amplification of EGFR and ERBB2 (HER2) was identified at the time of progression in a patient with ERBB2 (HER2)-positive gastric cancer who initially demonstrated a short response to the combination therapy of Herceptin (trastuzumab), Adrucil (fluorouracil), and Eloxatin (oxaliplatin), but then progression at 7 months (PMID: 30463996; NCT01522768).	30463996
ERBB2	EGFR amp ERBB2 amp	urinary bladder cancer	sensitive	Afatinib	Phase II	Actionable	In a Phase II clinical trial, two urothelial carcinoma patients with ERBB2 (HER2) and EGFR co-amplification had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931).	27044931
ERBB2	ERBB2 amp PTEN dec exp	Her2-receptor positive breast cancer	decreased response	CDX-3379	Preclinical	Actionable	In a preclinical study, knockdown of PTEN expression resulted in a decreased response to treatment with CDX-3379 (KTN3379) in ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 26880266).	26880266
ERBB2	ERBB2 amp ERBB2 over exp	stomach cancer	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) induced tumor regression in a gastric cancer cell line xenograft model with HER2 (ERBB2) amplification and over expression (PMID: 23578997).	23578997
ERBB2	ERBB2 amp ERBB2 over exp	stomach cancer	sensitive	Ado-trastuzumab emtansine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification and over expression (PMID: 21458915).	21458915
ERBB2	ERBB2 amp PIK3CA wild-type	uterine corpus serous adenocarcinoma	sensitive	Neratinib + Taselisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Taselisib (GDC-0032) and Nerlynx (neratinib) delayed cell cycle activity in a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture (PMID: 26333383).	26333383
ERBB2	ERBB2 amp PIK3CA wild-type	Her2-receptor positive breast cancer	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of high ERBB2 (HER2) copy number and wild-type PIK3CA correlated with improved progression-free survival (HR=0.45, p=0.024) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
ERBB2	ERBB2 amp PIK3CA wild-type	uterine corpus serous adenocarcinoma	sensitive	Neratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Nerlynx (neratinib) delayed cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, and inhibited tumor growth in xenograft models (PMID: 26333383).	26333383
ERBB2	ERBB2 amp PIK3CA wild-type	uterine corpus serous adenocarcinoma	sensitive	Taselisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Taselisib (GDC-0032) did not result in delay of cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, however, did result in tumor growth inhibition in xenograft models (PMID: 26333383).	26333383
ERBB2	ARID1A loss ERBB2 amp	breast cancer	sensitive	MK2206 + Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line with ARID1A loss and harboring ERBB2 (HER2) amplification demonstrated restored sensitivity to Herceptin (trastuzumab) when additionally treated with MK2206 in culture (PMID: 27172896).	27172896
ERBB2	ERBB2 amp FGFR2 amp	esophagus adenocarcinoma	sensitive	AZD4547 + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of AZD-4547 and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and FGFR2 amplification in culture (PMID: 27595477).	27595477
ERBB2	ERBB2 amp ERBB2 L755S	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cell lines with ERBB2 (HER2) amplification and expressing ERBB2 L755S demonstrated decreased inhibition proliferation compared to cells expressing wild-type ERBB2 (HER2) following treatment with Herceptin (trastuzumab) (PMID: 30301790).	30301790
ERBB2	ERBB2 amp ERBB2 L755S	Her2-receptor positive breast cancer	resistant	Lapatinib + Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cell lines with ERBB2 (HER2) amplification and expressing ERBB2 L755S demonstrated decreased inhibition proliferation compared to cells expressing wild-type ERBB2 (HER2) following treatment with Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 30301790).	30301790
ERBB2	ERBB2 amp ERBB2 L755S	Her2-receptor positive breast cancer	resistant	Lapatinib + Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Tykerb (lapatinib) plus Herceptin (trastuzumab) combination therapy in ESR1-positive/ERBB2 (HER2)-positive breast cancer cells with ERBB2 amplification in culture (PMID: 28487443).	28487443
ERBB2	ERBB2 amp ERBB2 L755S	Her2-receptor positive breast cancer	decreased response	Ado-trastuzumab emtansine	Preclinical - Cell culture	Actionable	In a preclinical study, expression of ERBB2 (HER2) L755S resulted in decreased sensitivity to treatment with Kadcyla (trastuzumab emtansine) in ESR1-positive/ERBB2 (HER2)-positive breast cancer cells with ERBB2 amplification in culture (PMID: 28487443).	28487443
ERBB2	ERBB2 amp ERBB2 L755S	Her2-receptor positive breast cancer	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cell lines with ERBB2 (HER2) amplification and expressing ERBB2 L755S demonstrated decreased inhibition of ERBB2 (HER2) signaling and proliferation compared to cells expressing wild-type ERBB2 (HER2) following treatment with Tykerb (lapatinib) (PMID: 30301790).	30301790
ERBB2	ERBB2 amp ERBB2 L755S	Her2-receptor positive breast cancer	resistant	Lapatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ERBB2 (HER2) L755S was associated with reactivation of ERBB2 (HER2) signaling and acquired resistance to Tykerb (lapatinib) in ESR1-positive/ERBB2 (HER2)-positive breast cancer cell lines with ERBB2 amplification in culture and in xenograft models (PMID: 28487443).	28487443
ERBB2	ERBB2 amp ERBB2 L755S	Her2-receptor positive breast cancer	sensitive	Neratinib	Case Reports/Case Series	Actionable	In a clinical study, Nerlynx (neratinib) treatment resulted in partial response in 2 of 6 and disease stabilization in 4 of 6 breast cancer patients with ERBB2 (HER2) amplification and an ERBB2 (HER2) mutation, including stable disease in a patient harboring ERBB2 (HER2) L755S, and breast cancer cell lines with ERBB2 (HER2) amplification and expressing ERBB2 (HER2) L755S demonstrated sensitivity to Nerlynx (neratinib) in culture (PMID: 30301790).	30301790
ERBB2	ERBB2 amp ERBB2 L755S	Her2-receptor positive breast cancer	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of ESR1-positive/ERBB2 (HER2)-positive breast cancer cell lines with ERBB2 amplification and harboring ERBB2 L755S in culture (PMID: 28487443).	28487443
ERBB2	ERBB2 amp ERBB2 L755S	Her2-receptor positive breast cancer	resistant	Pertuzumab + Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Perjeta (pertuzumab) plus Herceptin (trastuzumab) combination therapy in ESR1-positive/ERBB2 (HER2)-positive breast cancer cells with ERBB2 amplification in culture (PMID: 28487443).	28487443
ERBB2	ERBB2 amp ERBB2 L755S	Her2-receptor positive breast cancer	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of ESR1-positive/ERBB2 (HER2)-positive breast cancer cell lines with ERBB2 amplification and harboring ERBB2 L755S in culture, and inhibited tumor growth in xenograft models (PMID: 28487443).	28487443
ERBB2	ERBB2 amp SRC E527K	gastroesophageal junction adenocarcinoma	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, an ERBB2 (HER2)-amplified gastroesophageal cancer cell line initially sensitive to treatment with Tykerb (lapatinib) in culture developed resistance and was subsequently found to have acquired a secondary drug resistant mutation, SRC E527K (PMID: 25350844).	25350844
ERBB2	ERBB2 amp SRC E527K	gastroesophageal junction adenocarcinoma	sensitive	Lapatinib + Saracatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tykerb (lapatinib) and Saracatinib (AZD0530) inhibited growth of ERBB2 (HER2)-amplified gastroesophageal adenocarcinoma cells harboring SRC E527K in culture (PMID: 25350844).	25350844
ERBB2	ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of SRC, ERBB2 (HER2), STK11, and NOTCH1 (PMID: 29636358).	29636358
ERBB2	ROS1 fusion ERBB2 amp FGFR3 amp RET amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of ERBB2 (HER2), FGFR3, and RET (PMID: 29636358).	29636358
ERBB2	EGFR T790M EGFR act mut ERBB2 amp	lung non-small cell carcinoma	predicted - resistant	Rociletinib	Clinical Study - Cohort	Actionable	In a retrospective analysis of a Phase I and a Phase II trial, ERBB2 (HER2) amplification was identified at disease progression in 9% (4/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, 70%; L858R, 28%) treated with Rociletinib (CO-1686), conversely, preexisting MET, ERBB2 (HER2), or EGFR amplification were more common in patients with primary resistance to Rociletinib (CO-1686) (PMID: 27283993; NCT01526928, NCT02147990).	27283993
ERBB2	ERBB2 amp ERBB2 D769Y	Her2-receptor positive breast cancer	resistant	Lapatinib	Preclinical - Pdx	Actionable	In a preclinical study, a breast cancer patient-derived xenograft (PDX) model with ERBB2 (HER2) amplification and ERBB2 D769Y was refractory to treatment with Tykerb (lapatinib) (PMID: 30301790).	30301790
ERBB2	ERBB2 amp ERBB2 D769Y	Her2-receptor positive breast cancer	resistant	Trastuzumab	Preclinical - Pdx	Actionable	In a preclinical study, a breast cancer patient-derived xenograft (PDX) model with ERBB2 (HER2) amplification and ERBB2 D769Y was refractory to treatment with Herceptin (trastuzumab) (PMID: 30301790).	30301790
ERBB2	ERBB2 amp ERBB2 D769Y	Her2-receptor positive breast cancer	sensitive	Neratinib	Case Reports/Case Series	Actionable	In a clinical study, Nerlynx (neratinib) treatment resulted in partial response in 2 of 6 and disease stabilization in 4 of 6 breast cancer patients with ERBB2 (HER2) amplification and an ERBB2 (HER2) mutation, including stable disease in a patient harboring ERBB2 (HER2) D769Y, and Nerlynx (neratinib) inhibited tumor growth in a breast cancer patient-derived xenograft (PDX) model with ERBB2 (HER2) amplification and ERBB2 (HER2) D769Y (PMID: 30301790).	30301790
ERBB2	ERBB2 amp ERBB2 L313I	Her2-receptor positive breast cancer	predicted - sensitive	Neratinib	Case Reports/Case Series	Actionable	In a clinical study, Nerlynx (neratinib) treatment resulted in partial response in 2 of 6 and disease stabilization in 4 of 6 breast cancer patients with ERBB2 (HER2) amplification and an ERBB2 (HER2) mutation, including partial response in a patient harboring ERBB2 (HER2) L313I (PMID: 30301790).	30301790
ERBB2	ERBB2 amp ERBB2 R456C	Her2-receptor positive breast cancer	predicted - sensitive	Neratinib	Case Reports/Case Series	Actionable	In a clinical study, Nerlynx (neratinib) treatment resulted in partial response in 2 of 6 and disease stabilization in 4 of 6 breast cancer patients with ERBB2 (HER2) amplification and an ERBB2 (HER2) mutation, including stable disease in a patient harboring ERBB2 (HER2) R456C (PMID: 30301790).	30301790
ERBB2	EGFR amp ERBB2 amp MET amp	gastric adenocarcinoma	predicted - resistant	AMG 337	Preclinical - Pdx	Actionable	In a Phase II clinical trial, a gastric adenocarcinoma patient-derived xenograft (PDX) model with amplification of EGFR, ERBB2 (HER2), and MET demonstrated resistance to treatment with AMG 337 (PMID: 30463996; NCT01522768).	30463996
ERBB2	EGFR amp ERBB2 amp MET amp	gastric adenocarcinoma	predicted - sensitive	Afatinib + AMG 337	Preclinical - Pdx	Actionable	In a Phase II clinical trial, preclinical analysis of a gastric adenocarcinoma patient-derived xenograft (PDX) model with amplification of EGFR, ERBB2 (HER2), and MET demonstrated tumor regression when treated with a combination of Gilotrif (afatinib) and AMG 337 (PMID: 30463996; NCT01522768).	30463996
ERBB2	EGFR amp ERBB2 amp MET amp	gastric adenocarcinoma	resistant	Afatinib	Case Reports/Case Series	Actionable	In a Phase II clinical trial, a metastatic gastric adenocarcinoma patient with co-amplification of EGFR and ERBB2 (HER2) who initially responded to Gilotrif (afatinib) treatment progressed at 12 weeks and was found to have acquired amplification of MET in the progressing sites, which was subsequently confirmed to be associated with resistance via a patient-derived xenograft (PDX) model treated with Gilotrif (afatinib) (PMID: 30463996; NCT01522768).	30463996
ERBB2	ERBB2 amp NRAS wild-type	colon cancer	sensitive	Lapatinib + Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab) in combination with Tykerb (lapatinib) is included in guidelines as second-line therapy for advanced or metastatic colon cancer patients with ERBB2 amplification and NRAS wild-type (NCCN.org).	detail...
ERBB2	ERBB2 amp NRAS wild-type	rectum cancer	sensitive	Lapatinib + Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab) in combination with Tykerb (lapatinib) is included in guidelines as second-line therapy for advanced or metastatic rectum cancer patients with ERBB2 amplification and NRAS wild-type (NCCN.org).	detail...
ERBB2	ERBB2 amp NRAS wild-type	rectum cancer	sensitive	Pertuzumab + Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab) in combination with Perjeta (pertuzumab) is included in guidelines as second-line therapy for advanced or metastatic rectum cancer patients with ERBB2 amplification and NRAS wild-type (NCCN.org).	detail...
ERBB2	ERBB2 amp NRAS wild-type	colon cancer	sensitive	Pertuzumab + Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab) in combination with Perjeta (pertuzumab) is included in guidelines as second-line therapy for advanced or metastatic colon cancer patients with ERBB2 amplification and NRAS wild-type (NCCN.org).	detail...
ERBB2	ERBB2 amp PIK3CA act mut	Her2-receptor positive breast cancer	decreased response	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
ERBB2	ERBB2 amp PIK3CA E542X	Her2-receptor positive breast cancer	decreased response	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
ERBB2	ERBB2 amp PIK3CA H1047X	Her2-receptor positive breast cancer	decreased response	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
ERBB2	ERBB2 amp PIK3CA E545X	Her2-receptor positive breast cancer	decreased response	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
ERBB2	ERBB2 L786V	lung non-small cell carcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.7 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) L786V (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 L786V	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L786V were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 L786V	Advanced Solid Tumor	resistant	Sapitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L786V were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 Q709L	Advanced Solid Tumor	predicted - resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Q709L demonstrated resistance to treatment with Erbitux (cetuximab) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 Q709L	Advanced Solid Tumor	predicted - sensitive	Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Q709L demonstrated decreased cell proliferation and reduced survival when treated with Herceptin (trastuzumab) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 Q709L	Advanced Solid Tumor	no benefit	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Q709L did not benefit from treatment with Iressa (gefitinib) in culture when compared to Erbb2 (Her2) inhibitors (PMID: 30449325).	30449325
ERBB2	ERBB2 Q709L	Advanced Solid Tumor	no benefit	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Q709L did not benefit from treatment with Tarceva (erlotinib) in culture when compared to Erbb2 (Her2) inhibitors (PMID: 30449325).	30449325
ERBB2	ERBB2 Q709L	Advanced Solid Tumor	predicted - sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Q709L demonstrated decreased cell proliferation and reduced survival when treated with Tykerb (lapatinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 Q709L	Advanced Solid Tumor	predicted - sensitive	Pertuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Q709L demonstrated decreased cell proliferation and reduced survival when treated with Perjeta (pertuzumab) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 Q709L	Advanced Solid Tumor	predicted - sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) Q709L demonstrated decreased cell proliferation and reduced survival when treated with Gilotrif (afatinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 L726F	Advanced Solid Tumor	sensitive	XL647	Preclinical - Cell culture	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L726F in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 L726F	breast cancer	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L726F demonstrated resistance to Tykerb (lapatinib) in both culture and xenograft models (PMID: 25435280).	25435280
ERBB2	ERBB2 L726F	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells over expressing ERBB2 (HER2) L726F demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 over exp	gastroesophageal junction adenocarcinoma	sensitive	S-222611	Phase I	Actionable	In a Phase I trial, S-222611 resulted in a complete response in a gastric-esophageal junction cancer patient over expressing ERBB2 (HER2) and a partial response in a gastric cancer patient also over expressing ERBB2 (HER2) (J Clin Oncol 33, 2015 (suppl; abstr 2511)).	detail...
ERBB2	ERBB2 over exp	lung non-small cell carcinoma	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 13% (2/16, all partial response) and stable disease lasting over 120 days in 13% (2/16) of patients with non-small cell lung cancer harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 over exp	stomach cancer	sensitive	S-222611	Phase I	Actionable	In a Phase I trial, S-222611 resulted in a complete response in a gastric-esophageal junction cancer patient overexpressing ERBB2 (HER2) and a partial response in a gastric cancer patient also overexpressing ERBB2 (HER2) (J Clin Oncol 33, 2015 (suppl; abstr 2511)).	detail...
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	Pertuzumab + Trastuzumab	Guideline	Actionable	The combination of Herceptin (trastuzumab) and Perjeta (pertuzumab) with a taxane, such as Taxotere (docetaxel) or Taxol (palictaxel), is included in guidelines for patients with ERBB2 (HER2)-positive early breast cancer patients or advanced breast cancer (PMID: 31236598, PMID: 30032243; ESMO.org).	31236598 detail... 30032243
ERBB2	ERBB2 over exp	ovarian cancer	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 13% (1/8, all partial response) of patients with ovarian cancer harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	ADXS31-164	Preclinical	Actionable	In a preclinical study, ADXS31-164 prevented development of spontaneous mammary tumors in Erbb2 (Her2)-over expressing transgenic animal models (PMID: 20725099).	20725099
ERBB2	ERBB2 over exp	carcinoma	predicted - sensitive	MGAH22	Phase I	Actionable	In a Phase I trial, Margetuximab (MGAH22) treatment resulted in partial responses in 12% (7/60) and stable disease in 50% (30/60) of patients with ERBB2 (HER2)-positive breast or gastric cancer, or other carcinomas that overexpress Erbb2 (Her2) (PMID: 28119295).	28119295
ERBB2	ERBB2 over exp	stomach cancer	sensitive	MM-111 + Paclitaxel + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MM-111, in combination with Herceptin (trastuzumab) and Taxol (paclitaxel), resulted in a synergistic effect thereby inhibiting ErbB2 in ERBB2 (HER2) over expressing gastric cancer cell line xenograft models (J Clin Oncol 31, 2013 (suppl 4; abstr 48)).	detail...
ERBB2	ERBB2 over exp	stomach cancer	sensitive	Varlitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Varlitinib (ARRY-334543) resulted in a 74% tumor growth inhibition and tumor regression in 88% (7/8) of human cell line xenograft models of gastric cancer overexpressing ERBB2 (HER2) (Cancer Res January 15, 2009 69; 2150).	detail...
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	PF-05280014	Preclinical	Actionable	In a preclinical study, PF-05280014 inhibited growth of ERBB2 (HER2)-over expressing breast cancer cells with activity comparable to Herceptin (trastuzumab) in culture (PMID: 25001079).	25001079
ERBB2	ERBB2 over exp	stomach cancer	sensitive	Dacomitinib	Preclinical	Actionable	In a preclinical study, ERBB2 (HER2) over expressing gastric cancer cells were sensitive to Vizimpro (dacomitinib), resulting in inhibition of ERBB2 (HER2)/ERBB3 (HER3) heterodimers (PMID: 22135232).	22135232
ERBB2	ERBB2 over exp	stomach cancer	sensitive	Dacomitinib	Phase II	Actionable	In a Phase II trial, Vizimpro (dacomitinib) resulted in a 7.4% (2/27) response rate and 40.7% (11/27) disease control rate when treating advanced gastric cancer patients with ERBB2 (HER2) over expression (J Clin Oncol 30, 2012 (suppl 4; abstr 54)).	detail...
ERBB2	ERBB2 over exp	stomach cancer	sensitive	Trastuzumab + Varlitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Varlitinib (ARRY-334543), in combination with Herceptin (trastuzumab), resulted in a 91% tumor growth inhibition and tumor regression in human cell line xenograft models of gastric cancer overexpressing ERBB2 (HER2) (Cancer Res January 15, 2009 69; 2150).	detail...
ERBB2	ERBB2 over exp	stomach cancer	sensitive	KU004	Preclinical	Actionable	In a preclinical study, KU004 inhibited growth and induced apoptosis in gastric cancer cell lines over expressing ERBB2 in culture and suppressed growth in a dose dependent manner in xenograft models (PMID: 26437915).	26437915
ERBB2	ERBB2 over exp	urinary bladder cancer	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 33% (3/9, 1 complete response, 1 partial response) and stable disease lasting over 120 days in 22% (2/9) of patients with bladder cancer harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited growth of HER2-over expressing breast carcinoma cell lines in culture (PMID: 27450453).	27450453
ERBB2	ERBB2 over exp	esophagus adenocarcinoma	sensitive	Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab), in combination with fluoropyrimidine and cisplatin, or other chemotherapy agents, but not anthracyclines, is included in guidelines for Erbb2 (Her2)-overexpressing metastatic esophageal adenocarcinoma patients (NCCN.org)	detail...
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	Trastuzumab	FDA approved - On Companion Diagnostic	Actionable	Herceptin (trastuzumab) is FDA approved as an adjuvant treatment for ERBB2 (HER2)-overexpressing (or amplification) breast cancer patients and for metastatic ERBB2 (HER2)-overexpressing (or amplification) breast cancer patients as indicated by an FDA approved companion diagnostic (FDA.gov).	detail... detail...
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab) combined with a taxane, such as Taxotere (docetaxel) or Taxol (paclitaxel), is included in guidelines as neoadjuvant therapy for patients with ERBB2 (HER2)-positive early breast cancer or as first-line therapy for patients with ERBB2 (HER2)-positive advanced breast cancer (PMID: 31236598, PMID: 30032243; ESMO.org).	detail... 31236598 30032243
ERBB2	ERBB2 over exp	breast cancer	sensitive	KU004	Preclinical	Actionable	In a preclinical study, KU004 inhibited growth and induced apoptosis in breast cancer cell lines over expressing ERBB2 in culture (PMID: 26437915).	26437915
ERBB2	ERBB2 over exp	stomach cancer	sensitive	MM-302 + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination of MM-302 and Herceptin (trastuzumab) resulted in improved tumor growth inhibition in cell line xenograft models of Erbb2 (Her2)-over expressing gastric cancer (PMID: 26759238).	26759238
ERBB2	ERBB2 over exp	gastroesophageal junction adenocarcinoma	sensitive	Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab), in combination with fluoropyrimidine and cisplatin, or other chemotherapy agents, but not anthracyclines, is included in guidelines for Erbb2 (Her2)-overexpressing metastatic esophagogastric junction adenocarcinoma patients (NCCN.org)	detail...
ERBB2	ERBB2 over exp	gastroesophageal junction adenocarcinoma	sensitive	Trastuzumab	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (ToGA) that supported FDA approval, patients with either gastric cancer or gastroesophageal junction adenocarcinoma with ERBB2 (HER2) overexpression or ERBB2 (HER2) amplification had increased overall survival (13.8 mo vs 11.1 mo) when treated with Herceptin (trastuzumab) in combination with chemotherapy compared to chemotherapy alone (PMID: 20728210; NCT01041404).	20728210 detail... detail...
ERBB2	ERBB2 over exp	stomach cancer	sensitive	CDX-3379	Preclinical	Actionable	In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth by 43% in N87 gastric cancer xenograft model, which has been demonstrated to have ERBB2 (HER2) amplification and overexpression (AACR; 2015. Abstract nr 1558, PMID: 18441328).	detail... 18441328
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	Trastuzumab + Vinorelbine	Guideline	Actionable	The combination of Herceptin (trastuzumab) and Navelbine (vinorelbine) is included in guidelines as first-line therapy for patients with ERBB2 (HER2)-positive advanced breast cancer (PMID: 30032243; ESMO.org).	30032243 detail...
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	Neratinib	FDA approved	Actionable	In a Phase III trial that supported FDA approval, ERBB2 (HER2)-positive (overexpressing and/or amplification) breast cancer patients previously treated with Herceptin (trastuzumab) demonstrated a significantly greater two year invasive disease-free survival rate (93.9%) when treated with Nerlynx (neratinib) compared to the rate (91.6%) in those patients treated with placebo (PMID: 26874901; NCT00878709).	26874901 detail...
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	Neratinib	Guideline	Actionable	Nerlynx (neratinib) is included in guidelines for patients with high-risk ERBB2 (HER2)-positive early breast cancer (PMID: 31236598; ESMO.org).	31236598 detail...
ERBB2	ERBB2 over exp	pancreatic cancer	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 22% (2/9, all partial response) and stable disease lasting over 120 days in 11% (1/9) of patients with pancreatic cancer harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 over exp	colorectal cancer	resistant	Cetuximab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ERBB2 (HER2) over expression was associated with resistance to Erbitux (cetuximab) treatment in a human cell line xenograft model of colorectal cancer (PMID: 26296355).	26296355
ERBB2	ERBB2 over exp	colorectal cancer	resistant	Cetuximab	Clinical Study - Cohort	Actionable	In a retrospective analysis, patients with metastatic KRAS exon 2 wild-type colorectal cancer harboring ERBB2 (HER2) amplification or overexpression (n=79) demonstrated poorer objective response rate (31.2 vs 46.9, p=0.031) and progression-free survival (5.7 vs 7 months, p=0.087) to anti-EGFR treatment (Vectibix (panitumumab) or Erbitux (cetuximab), as monotherapy or combined with chemotherapy) when compared to ERBB2 (HER2)-negative patients (n=113) (PMID: 30952821).	30952821
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	predicted - sensitive	MGAH22	Phase Ib/II	Actionable	In Phase I clinical trial, Margetuximab (MGAH22) displayed safety and had initial efficacy in patients with ERBB2 (HER2) positive breast cancer (J Clin Oncol 31, 2013 (suppl; abstr 3004)).	detail...
ERBB2	ERBB2 over exp	pancreatic carcinoma	predicted - sensitive	HER2 CAR-T cells	Phase I	Actionable	In a Phase I trial, treatment with ERBB2 (HER2)-specific CAR-T cells demonstrated safety and preliminary activity in patients with biliary tract or pancreatic carcinoma with ERBB2 (HER2) over expression, resulting in partial response in one of 11 patients and stable disease in 5, and a median progression free survival of 4.8 months (PMID: 28710747; NCT01935843).	28710747
ERBB2	ERBB2 over exp	stomach cancer	sensitive	BMS-690514	Preclinical	Actionable	In a preclinical study, BMS-690514 inhibited tumor growth in a gastric cancer xenograft model with ERBB2 (HER2) amplification and overexpression (PMID: 21531814).	21531814
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	Guideline	Actionable	Kadcyla (ado-trastuzumab emtansine) is included in the guidelines for patients with ERBB2 (HER2)-positive advanced breast cancer who progressed through one line of Herceptin (trastuzumab)-based therapy or ERBB2 (HER2)-positive patients with early breast cancer (PMID: 31236598, PMID: 30032243; ESMO.org).	31236598 detail... 30032243
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (KATHERINE) that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) resulted in improved invasive disease-free survival (HR=0.50, p<0.001) compared to Herceptin (trastuzumab) in patients with ERBB2 (HER2)-positive early breast cancer who had residual invasive disease after taxane and trastuzumab-based neoadjuvant therapy (PMID: 30516102; NCT01772472).	detail... detail... 30516102
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (EMILIA) that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) improved median progression free survival (9.6 mo vs 6.4 mo) and overall survival (30.9 mo vs 25.1 mo) compared to Tykerb (lapatinib) combined with Xeloda (capecitabine) in patients with metastatic ERBB2 (HER2)-positive breast cancer (PMID: 24879797, PMID: 23020162; NCT00829166).	24879797 detail... detail... 23020162
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	TAK-285	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAK-285 inhibited growth of breast cancer cell line harboring ERBB2 (HER2) over expression in culture and in cell line xenograft models (PMID: 23983820).	23983820
ERBB2	ERBB2 over exp	colorectal cancer	decreased response	Panitumumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, patients with metastatic KRAS exon 2 wild-type colorectal cancer harboring ERBB2 (HER2) amplification or overexpression (n=79) demonstrated poorer objective response rate (31.2 vs 46.9, p=0.031) and progression-free survival (5.7 vs 7 months, p=0.087) to anti-EGFR treatment (Vectibix (panitumumab) or Erbitux (cetuximab), as monotherapy or combined with chemotherapy) when compared to ERBB2 (HER2)-negative patients (n=113) (PMID: 30952821).	30952821
ERBB2	ERBB2 over exp	stomach cancer	sensitive	Ado-trastuzumab emtansine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification and over expression (PMID: 21458915).	21458915
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	Lapatinib + Trastuzumab	Guideline	Actionable	The combination of Herceptin (trastuzumab) and Tykerb (lapatinib) is included in guidelines for patients with ERBB2 (HER2)-positive advanced breast cancer who progressed on Herceptin (trastuzumab)-based therapy, however, the combination therapy is not recommended as neoadjuvant therapy for ERBB2 (HER2)-positive patients with early breast cancer (PMID: 31236598, PMID: 30032243; ESMO.org).	detail... 30032243 31236598
ERBB2	ERBB2 over exp	gastric adenocarcinoma	sensitive	Trastuzumab	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (ToGA) that supported FDA approval, patients with either gastric or gastroesophageal junction adenocarcinoma with ERBB2 (HER2) overexpression or ERBB2 (HER2) amplification had increased overall survival (13.8 mo vs 11.1 mo) when treated with Herceptin (trastuzumab) in combination with chemotherapy compared to chemotherapy alone (PMID: 20728210; NCT01041404).	20728210 detail... detail...
ERBB2	ERBB2 over exp	gastric adenocarcinoma	sensitive	Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab), in combination with fluoropyrimidine and cisplatin, or other chemotherapy agents, but not anthracyclines, is included in guidelines as first-line therapy for Erbb2 (Her2)-overexpressing metastatic gastric adenocarcinoma patients (NCCN.org)	detail...
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	CUDC-101	Phase I	Actionable	In a Phase I clinical trial, a breast cancer patient with ERBB2 (HER2) over expression that had progressed on Herceptin (trastuzumab) demonstrated stable disease for more than 12 weeks following treatment with CUDC-101 (PMID: 25107918).	25107918
ERBB2	ERBB2 over exp	breast cancer	sensitive	AV-412	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AV-412 inhibited growth of ERBB2 (HER2)-over expressing breast cancer cell lines in culture, and inhibited tumor growth in a ERBB2 (HER2)-over expressing breast cancer cell line xenograft model (PMID: 17888033).	17888033
ERBB2	ERBB2 over exp	stomach cancer	sensitive	TAK-285	Preclinical	Actionable	In a preclinical study, the N87 gastric cancer cell line, which has been demonstrated to have ERBB2 (HER2) amplification and over expression, was sensitive to TAK-285, inhibiting phosphorylation of ERBB2 (HER2) and ERBB3 (HER3) (PMID: 25594012, PMID: 18441328).	18441328 25594012
ERBB2	ERBB2 over exp	stomach cancer	sensitive	TAK-285	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAK-285 inhibited tumor growth in gastric cancer cell line xenograft models over expressing ERBB2 (HER2) (PMID: 23983820).	23983820
ERBB2	ERBB2 over exp	uterine cancer	no benefit	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in no objective response (0/7) in patients with uterine cancer harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 over exp	stomach cancer	predicted - sensitive	MM-302	Preclinical	Actionable	In a preclinical study, ERBB2 (HER2) over expressing gastric cancer xenograft models demonstrated anti-tumor activity when treated with MM-302 (Cancer Res December 15, 2010 70; P3-14-09).	detail...
ERBB2	ERBB2 over exp	salivary gland cancer	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 80% (4/5, all partial response) of patients with salivary gland cancer harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	NAX014	Preclinical	Actionable	In a preclinical study, NAX014 induced cellular senescence, prevented tumor growth, and decreased tumor volume in a Her2 positive breast cancer mouse model (PMID: 26168818).	26168818
ERBB2	ERBB2 over exp	biliary tract cancer	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 29% (2/7, all partial response) and stable disease lasting over 120 days in 38% (3/7) of patients with biliary cancer harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 over exp	breast cancer	sensitive	MM-302 + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination of MM-302 and Herceptin (trastuzumab) synergistically inhibited tumor growth in cell line xenograft models of Erbb2 (Her2)-over expressing breast cancer (PMID: 26759238).	26759238
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	Docetaxel + Pertuzumab + Trastuzumab	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (CLEOPATRA) that supported FDA approval, treatment with Perjeta (pertuzumab), combined with Herceptin (trastuzumab) and Taxotere (docetaxel), improved median progression free survival to 18.5 months compared to 12.4 months with placebo plus Herceptin (trastuzumab) and Taxotere (docetaxel) in patients with ERBB2 (HER2)-positive (overexpression and amplification) metastatic breast cancer (PMID: 23801166).	detail... 23801166 detail...
ERBB2	ERBB2 over exp	gastric adenocarcinoma	predicted - sensitive	Capecitabine + Lapatinib + Oxaliplatin	Phase II	Actionable	In a Phase II trial, Tykerb (lapatinib), Xeloda (capecitabine), and Eloxatin (oxaliplatin) combination treatment resulted in a disease control rate of 81.3% (26/32, 7 complete response, 15 partial response, 4 stable disease) in patients with Erbb2 (Her2)-positive (defined as IHC3+ or IHC 2+ with ERBB2 amplification) gastric adenocarcinoma (PMID: 29409051; NCT02015169).	29409051
ERBB2	ERBB2 over exp	stomach cancer	sensitive	HER2 CAR-T cells	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ERBB2 (HER2)-specific CAR-T cells induced cell death in ERBB2 (HER2)-over expressing gastric cancer cell lines in culture, and inhibited tumor growth and improved survival in a ERBB2 (HER2)-over expressing gastric cancer cell line xenograft model (PMID: 28284008).	28284008
ERBB2	ERBB2 over exp	stomach cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited growth of HER2-amplified and HER2-over expressing gastric cancer cell lines in culture (PMID: 18774637).	18774637
ERBB2	ERBB2 over exp	cholangiocarcinoma	predicted - sensitive	HER2 CAR-T cells	Phase I	Actionable	In a Phase I trial, a patient with perihilar cholangiocarcinoma over expressing ERBB2 achieved a partial response and progression-free survival for 4.5 months following treatment with ERBB2 (HER2)-specific CAR-T cells (PMID: 28710747, NCT01935843).	28710747
ERBB2	ERBB2 over exp	Her2-receptor positive breast cancer	sensitive	trastuzumab and hyaluronidase-oysk injection	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (HannaH) that supported FDA approval, Herceptin Hylecta (trastuzumab and hyaluronidase-oysk injection) treatment demonstrated safety and efficacy profile comparable to intravenous trastuzumab treatment, resulted in pathologic complete response in 45.4% (118/260) of patients with ERBB2 (HER2)-positive (IHC 3+ or ISH positive) breast cancer (PMID: 22884505; NCT00950300).	detail... detail... 22884505
ERBB2	ERBB2 over exp	gastric adenocarcinoma	sensitive	VS-5584	Preclinical - Cell line xenograft	Actionable	In a preclinical study, VS-5584 inhibited tumor growth in human gastric cancer cell line xenograft models overexpressing ERBB2 (HER2) (PMID: 23270925).	23270925
ERBB2	ERBB2 over exp	Advanced Solid Tumor	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 26% (30/114, 2 complete response, 28 partial response) and stable disease lasting over 120 days in 14% (16/114) of patients with advanced solid tumors harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 over exp	biliary tract cancer	predicted - sensitive	HER2 CAR-T cells	Phase I	Actionable	In a Phase I trial, treatment with ERBB2 (HER2)-specific CAR-T cells demonstrated safety and preliminary activity in patients with biliary tract or pancreatic carcinoma with ERBB2 (HER2) over expression, resulting in partial response in one of 11 patients and stable disease in 5, and a median progression free survival of 4.8 months (PMID: 28710747; NCT01935843).	28710747
ERBB2	ERBB2 over exp	colorectal cancer	predicted - sensitive	Pertuzumab + Trastuzumab	Phase II	Actionable	In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 38% (14/37, all partial response) and stable disease lasting over 120 days in 11% (4/37) of patients with colorectal cancer harboring ERBB2 (HER2) amplification or overexpression, with a median duration of response of 11 months (PMID: 29320312; NCT02091141).	29320312
ERBB2	ERBB2 over exp	stomach cancer	sensitive	Tucatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tucatinib (ARRY-380) inhibited proliferation of an ERBB2 (HER2) over expressing gastric cancer cell line in culture (Cancer Res April 15, 2010 70:3610).	detail...
ERBB2	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	sensitive	Bevacizumab + Buparlisib	Preclinical	Actionable	In a preclinical study, treatment with Buparlisib (BKM120) resulted in decreased tumor growth, but not tumor regression, in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R (PMID: 23940356).	23940356
ERBB2	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	resistant	Pertuzumab + Trastuzumab	Preclinical	Actionable	In a preclinical study, a mouse breast cancer model with ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Heceptin (trastuzumab) and Perjeta (pertuzumab) (PMID: 23940356).	23940356
ERBB2	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	sensitive	Buparlisib + Pertuzumab + Trastuzumab	Preclinical	Actionable	In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Perjeta (pertuzumab) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, with improved efficacy over Buparlisib (BKM120) alone (PMID: 23940356).	23940356
ERBB2	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	resistant	Lapatinib + Trastuzumab	Preclinical	Actionable	In a preclinical study, a mouse breast cancer model with mammary ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23940356).	23940356
ERBB2	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	sensitive	Buparlisib + Trastuzumab	Preclinical	Actionable	In a preclinical study, the combination of Herceptin (trastuzumab) and Buparlisib (BKM120) inhibited tumor growth in mouse ERBB2 (HER2)-over expressing breast cancer models expressing PIK3CA H1047R, with moderate efficacy over Buparlisib (BKM120) alone (PMID: 23940356).	23940356
ERBB2	ERBB2 over exp PIK3CA H1047R	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047R (PMID: 29208673).	29208673
ERBB2	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	no benefit	Buparlisib + Lapatinib + Trastuzumab	Preclinical	Actionable	In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Tykerb (lapatinib) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, but efficacy was not significantly improved over Buparlisib (BKM120) alone (PMID: 23940356).	23940356
ERBB2	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	resistant	Trastuzumab	Preclinical	Actionable	In a preclinical study, mouse breast cancer models over expressing ERBB2 (HER2) and expressing PIK3CA H1047R were resistant to Herceptin (trastuzumab) (PMID: 23940356).	23940356
ERBB2	ERBB2 over exp PIK3CA H1047R SRC over exp	urinary bladder cancer	no benefit	Lapatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481).	26270481
ERBB2	ERBB2 over exp PIK3CA H1047R SRC over exp	urinary bladder cancer	no benefit	Ponatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Iclusig (ponatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with SRC over expression, which also over expressed ERBB2 (HER2) and harbored PIK3CA H1047R (PMID: 26270481).	26270481
ERBB2	ERBB2 over exp PIK3CA mut	breast cancer	sensitive	ARQ092 + Paclitaxel	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of Miransertib (ARQ092) and Taxol (paclitaxel), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692).	26469692
ERBB2	ERBB2 over exp PIK3CA mut	breast cancer	sensitive	ARQ092 + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of Miransertib (ARQ092) and Herceptin (trastuzumab), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692).	26469692
ERBB2	ERBB2 over exp PIK3CA mut	Her2-receptor positive breast cancer	sensitive	PKI-179	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PKI-179 inhibited growth of breast cancer cells harboring PIK3CA mutations and ERBB2 (HER2) over expression in culture and cell line xenograft models (PMID: 20797855).	20797855
ERBB2	EGFR T790M ERBB2 over exp	lung adenocarcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Tagrisso (osimertinib) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).	27252416
ERBB2	EGFR T790M ERBB2 over exp	lung adenocarcinoma	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Rociletinib (CO-1686) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).	27252416
ERBB2	ERBB2 over exp PIK3CA N345T	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA N345T (PMID: 29208673).	29208673
ERBB2	ERBB2 over exp PIK3CA H1047L	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047L (PMID: 29208673).	29208673
ERBB2	EGFR amp ERBB2 over exp	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified EGFR amplification in 2 patients demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).	29208673
ERBB2	ERBB2 over exp MET amp MET R988C	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study - Cohort	Actionable	n a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) gastric or gastroesophageal cancer patients identified MET R988C and amplification of MET in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).	29208673
ERBB2	ERBB2 over exp MET amp	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tissue from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified MET amplification in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).	29208673
ERBB2	EGFR T790M EGFR L858R ERBB2 over exp	lung non-small cell carcinoma	decreased response	Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of Ebrr2 (Her2) in non-small cell lung cancer cells harboring both EGFR T790M and L858R resulted in decreased sensitivity to Rociletinib (CO-1686) in culture (PMID: 27283993).	27283993
ERBB2	ERBB2 over exp PIK3CA act mut	Her2-receptor positive breast cancer	decreased response	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
ERBB2	ERBB2 over exp PIK3CA E542X	Her2-receptor positive breast cancer	decreased response	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
ERBB2	ERBB2 over exp PIK3CA E545X	Her2-receptor positive breast cancer	decreased response	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
ERBB2	ERBB2 over exp PIK3CA H1047X	Her2-receptor positive breast cancer	decreased response	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
ERBB2	ERBB2 T862A	Advanced Solid Tumor	sensitive	AEE788	Preclinical	Actionable	In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T862A in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 T862A	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) N862A in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 L755_E757delinsS	Her2-receptor negative breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 9.0 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L755_E757delinsS (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 mutant	lung cancer	sensitive	Neratinib	Phase I	Actionable	In a Phase I clinical trial, Nerlynx (neratinib) administered with Torisel (temsirolimus) was tolerable and demonstrated antitumor activity in ERBB2 (HER2)-mutant non-small-cell lung cancer (PMID: 24323026).	24323026
ERBB2	ERBB2 mutant	cervical cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in an objective response rate of 20% (1/5), a clinical benefit rate of 60% (3/5), and a median progression-free survival of 20.1 months in patients with cervical cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 mutant	Her2-receptor positive breast cancer	sensitive	Neratinib	Phase II	Actionable	In a Phase II trial, Nerlynx (neratinib) treatment resulted in complete response in 12.5% (3/24) and partial response in 20.8% (5/24) of ERBB2 (HER2) mutant but not amplified breast cancer patients (Cancer Res 2017;77(4 Suppl):Abstract nr PD2-08).	detail...
ERBB2	ERBB2 mutant	lung non-small cell carcinoma	sensitive	AV-412	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring an ERBB2 (HER2) mutation demonstrated sensitivity to AV-412, resulting in decreased phosphorylation of Erbb2, Akt, and Erk (PMID: 19459856).	19459856
ERBB2	ERBB2 mutant	biliary tract cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in an objective response rate at 8 weeks of 22.2% (2/9), a clinical benefit rate of 33.3% (3/9), and a median progression-free survival of 2.8 months in patients with biliary tract cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 mutant	lung non-small cell carcinoma	predicted - sensitive	Trastuzumab + Vinorelbine	Case Reports/Case Series	Actionable	In a clinical study, treatment with Herceptin (trastuzumab) in combination with chemotherapy resulted in an objective response rate of 67% (4/6) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies (PMID: 28167203).	28167203
ERBB2	ERBB2 mutant	lung adenocarcinoma	sensitive	Afatinib	Phase II	Actionable	In a Phase II trial, treatment with Gilotrif (afatinib) resulted in objective response in 3 lung adenocarcinoma patients harboring ERBB2 (HER2) mutations (PMID: 22325357).	22325357
ERBB2	ERBB2 mutant	breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, with treatment resulting in a clinical benefit rate of 31% (5/16; 1 complete response, 1 partial response, and 3 patients achieving stable disease for 24 weeks or more) and a median progression-free survival of 16 weeks (PMID: 28679771).	28679771
ERBB2	ERBB2 mutant	ovarian cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, no clinical benefit, and a median progression-free survival of 2.1 months in patients with ovarian cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 mutant	lung non-small cell carcinoma	no benefit	Afatinib	Guideline	Actionable	Gilotrif (afatinib) is not recommended as a monotherapy in guidelines for non-small cell lung cancer patients with ERBB2 mutations (NCCN.org).	detail...
ERBB2	ERBB2 mutant	Her2-receptor negative breast cancer	sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in an object response rate of 24% (6/25), a clinical benefit rate of 40% (10/25), and a median progression-free survival of 3.5 months in patients with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 mutant	gastroesophageal junction adenocarcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, a clinical benefit rate of 20% (1/5), and a median progression-free survival of 1.7 months in patients with gastroesophageal cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 mutant	lung non-small cell carcinoma	sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in an objective response rate of 3.8% (1/26), a clinical benefit rate of 42.3% (11/26), and a median progression-free survival of 5.5 months in patients with non-small cell lung cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 mutant	lung non-small cell carcinoma	sensitive	Neratinib	Phase I	Actionable	In a Phase I study, Nerlynx (neratinib) administered with temsirolimus was tolerable and demonstrated antitumor activity in ERBB2-mutant non-small-cell lung cancer (PMID: 24323026).	24323026
ERBB2	ERBB2 mutant	lung non-small cell carcinoma	no benefit	Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab) is not recommended as a monotherapy in guidelines for non-small cell lung cancer patients with ERBB2 mutations (NCCN.org).	detail...
ERBB2	ERBB2 mutant	lung squamous cell carcinoma	predicted - sensitive	Afatinib	Phase III	Actionable	In a Phase III trial (LUX-Lung 8), secondary analysis demonstrated favorable outcomes with Gilotrif (afatinib) treatment compared to Tarceva (erlotinib) in lung squamous cell carcinoma patients with ERBB (HER) family mutations, and ERBB2 (HER2) mutations predicted an OS (HR=0.06, p=0.02) and PFS (HR=0.06, p=0.02) benefit for Gilotrif (afatinib) over Tarceva (erlotinib) treatment (PMID: 29902295; NCT01523587).	29902295
ERBB2	ERBB2 mutant	colorectal cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, a clinical benefit rate of 8.3% (1/12), and a median progression-free survival of 1.8 months in patients with colorectal cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 mutant	lung non-small cell carcinoma	sensitive	Ado-trastuzumab emtansine	Guideline	Actionable	Kadcyla (trastuzumab emtansine) is included in guidelines for non-small cell lung cancer patients with ERBB2 (HER2) mutations (NCCN.org).	detail...
ERBB2	ERBB2 mutant	urinary bladder cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, a clinical benefit rate of 18.8% (3/16), and a median progression-free survival of 1.8 months in patients with bladder cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 mutant	invasive bladder transitional cell carcinoma	predicted - sensitive	Cisplatin + Gemcitabine + Sorafenib	Phase II	Actionable	In a Phase II trial, ERBB2 (HER2) mutations were only detected in patients with muscle-invasive urothelial bladder cancer that responded to Nexavar (sorafenib), Platinol (cisplatin) and Gemzar (gemcitabine) combination therapy (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).	detail...
ERBB2	ERBB2 mutant	endometrial cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, a clinical benefit rate of 28.6% (2/7), and a median progression-free survival of 2.6 months in patients with endometrial cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 mutant	lung non-small cell carcinoma	sensitive	Pyrotinib	Phase II	Actionable	In a Phase II trial, Pyrotinib treatment in non-small cell lung cancer patients harboring an ERBB2 (HER2) mutation resulted in a partial response in 54.5% (6/11) of patients and stable disease in 27.3% (3/11) of patients, and a PFS of 6.2 months (Journal of Thoracic Oncology, Vol. 12, Issue 1, S359).	detail...
ERBB2	ERBB2 R678Q	Advanced Solid Tumor	no benefit	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) R678Q did not benefit from treatment with Tarceva (erlotinib) in culture when compared to Erbb2 (Her2) inhibitors (PMID: 30449325).	30449325
ERBB2	ERBB2 R678Q	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 R678Q demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).	23220880
ERBB2	ERBB2 R678Q	endometrial cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 5.5 months in a patient with endometrial cancer harboring ERBB2 (HER2) R678Q (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 R678Q	Advanced Solid Tumor	no benefit	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) R678Q did not benefit from treatment with Iressa (gefitinib) in culture when compared to Erbb2 (Her2) inhibitors (PMID: 30449325).	30449325
ERBB2	ERBB2 R678Q	Advanced Solid Tumor	predicted - sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) R678Q demonstrated decreased cell proliferation and reduced survival when treated with Tykerb (lapatinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 R678Q	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) R678Q demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).	23220880
ERBB2	ERBB2 R678Q	Advanced Solid Tumor	predicted - resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) R678Q demonstrated resistance to treatment with Erbitux (cetuximab) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 R678Q	colorectal cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.6 months in a patient with colorectal cancer harboring ERBB2 (HER2) R678Q (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 R678Q	Advanced Solid Tumor	predicted - sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) R678Q demonstrated decreased cell proliferation and reduced survival when treated with Nerlynx (neratinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 R678Q	Advanced Solid Tumor	predicted - sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) R678Q demonstrated decreased cell proliferation and reduced survival when treated with Gilotrif (afatinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 R678Q	gastroesophageal junction adenocarcinoma	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with gastroesophageal cancer harboring ERBB2 (HER2) R678Q (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 R678Q	Advanced Solid Tumor	predicted - sensitive	Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) R678Q demonstrated decreased cell proliferation and reduced survival when treated with Herceptin (trastuzumab) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 S653C	urinary bladder cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S653C in culture (PMID: 24971884).	24971884
ERBB2	ERBB2 S653C	urinary bladder cancer	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, bladder cancer cells over expressing ERBB2 (HER2) S653C demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884).	24971884
ERBB2	ERBB2 S653C	urinary bladder cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S653C in culture (PMID: 24971884).	24971884
ERBB2	ERBB2 wild-type	Advanced Solid Tumor	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing wild-type ERBB2 (HER2) in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 wild-type	Advanced Solid Tumor	sensitive	AEE788	Preclinical	Actionable	In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing wild-type ERBB2 (HER2) in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 wild-type	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, Tagrisso (osimertinib) treatment resulted in antitumor efficacy in cells overexpressing wild-type ERBB2 (HER2), demonstrating inhibition of ERBB2 (HER2) phosphorylation and cell growth in culture and tumor regression in mouse models overexpressing wild-type ERBB2, with an 80% reduction in tumor volume (PMID: 29298799).	29298799
ERBB2	EGFR exon 19 del ERBB2 wild-type	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical	Actionable	In a preclinical study, transgenic mouse models with ERBB2 (HER2)-wild-type cells expressing EGFR exon 19 deletion demonstrated tumor growth inhibition and an improved progression-free survival when treated with Tagrisso (osimertinib) compared to treatment with Tarceva (erlotinib) (PMID: 29298799).	29298799
ERBB2	ERBB2 A775_G776insYVMA	Advanced Solid Tumor	sensitive	JQ1 + Osimertinib	Preclinical	Actionable	In a preclinical study, transgenic mouse models expressing ERBB2 (HER2) A775_G776insYVMA demonstrated greater tumor regression when treated with the combination of JQ1 and Tagrisso (osimertinib) compared to treatment with either agent alone, which resulted in little to no regression (PMID: 29298799).	29298799
ERBB2	ERBB2 A775_G776insYVMA	lung adenocarcinoma	predicted - sensitive	Ado-trastuzumab emtansine	Case Reports/Case Series	Actionable	In a Phase II trial, treatment with Kadcyla (trastuzumab emtansine) resulted in best overall responses of partial response in 44% (8/18) and stable disease in 39% (7/18), and median progression-free survival of 5 months in patients with lung adenocarcinoma harboring ERBB2 (HER2) activating mutations, and a subset of patients specifically harboring ERBB2 (HER2) A775_G776insYVMA mutation had a 60% (3/5) partial response rate (PMID: 29989854; NCT02675829).	29989854
ERBB2	ERBB2 A775_G776insYVMA PIK3CA R425L	lung non-small cell carcinoma	predicted - resistant	Trastuzumab	Case Reports/Case Series	Actionable	In a clinical study, the PIK3CA R425L mutation was identified as a potential resistance mechanism in a non-small cell lung carcinoma patient harboring ERBB2 (HER2) A775_G776insYVMA, that progressed during Herceptin (trastuzumab) treatment (PMID: 28167203).	28167203
ERBB2	ERBB2 exon20	lung non-small cell carcinoma	predicted - sensitive	Pyrotinib	Phase I	Actionable	In a Phase II trial, Pyrotinib treatment resulted in an objective response rate of 31.7% (19/60) in non-small cell lung cancer patients harboring ERBB2 (HER2) exon 20 mutations, with a median duration of response of 7.0 months and a median progression-free survival of 6.8 months (J Clin Oncol 37, 2019 (suppl; abstr 9089); NCT02834936).	detail...
ERBB2	ERBB2 N813D	lung adenocarcinoma	predicted - sensitive	Afatinib	Phase II	Actionable	In a Phase II trial, Gilotrif (afatinib) treatment resulted in partial response in a patient with lung adenocarcinoma harboring ERBB2 (HER2) N813D (PMID: 30149884; NCT02979821).	30149884
ERBB2	ERBB2 D769Y	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Tykerb (lapatinib) treatment (PMID: 23220880).	23220880
ERBB2	ERBB2 D769Y	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) D769Y reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880).	23220880
ERBB2	ERBB2 D769Y	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) D769Y were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 D769Y	gastroesophageal junction adenocarcinoma	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with gastroesophageal cancer harboring ERBB2 (HER2) D769Y (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 D769Y	urinary bladder cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.4 months in a patient with bladder cancer harboring both ERBB2 (HER2) D769Y (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 D769Y	breast cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).	23220880
ERBB2	ERBB2 D769Y	Advanced Solid Tumor	resistant	Sapitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) D769Y were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 L869R	breast cancer	resistant	Lapatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed breast cancer cells over expressing ERBB2 (HER2) L869R were resistant to Tykerb (lapatinib) in culture, formed tumors and metastasized readily in xenograft animal models (PMID: 27900369).	27900369
ERBB2	ERBB2 L869R	Her2-receptor negative breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 3.6 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L869R (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 L869R	colorectal adenocarcinoma	predicted - resistant	Lapatinib + Trastuzumab	Case Reports/Case Series	Actionable	In a clinical case study, a colorectal carcinoma patient who initially achieved stable disease following treatment with Tykerb (lapatinib) and Herceptin (trastuzumab) developed secondary resistance, presenting with a brain metastasis, and ERBB2 (HER2) L869R was identified in the brain lesion (PMID: 29941010).	29941010
ERBB2	ERBB2 L869R	breast cancer	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited ERBB2 (HER2) phosphorylation and growth of transformed breast epithelial cells expressing ERBB2 (HER2) L869R in culture (PMID: 28274957).	28274957
ERBB2	ERBB2 L869R	lung adenocarcinoma	predicted - resistant	Lapatinib	Case Reports/Case Series	Actionable	In a clinical case study, ERBB2 (HER2) L869R was identified in the lymph node metastasis from a lung adenocarcinoma patient that progressed on Tykerb (lapatinib) therapy (PMID: 27900369).	27900369
ERBB2	ERBB2 L869R	breast cancer	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited ERBB2 (HER2) phosphorylation and growth of transformed breast epithelial cells expressing ERBB2 (HER2) L869R in culture (PMID: 28274957).	28274957
ERBB2	ERBB2 L869R	breast cancer	sensitive	Neratinib	Phase II	Actionable	In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response, and 3 patients achieving stable disease for 24 weeks or more, which included a patient harboring ERBB2 (HER2) L869R (PMID: 28679771).	28679771
ERBB2	ERBB2 L869R	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L869R were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 L869R	Advanced Solid Tumor	resistant	Sapitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L869R were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 E717K	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E717K in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 E717K	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells over expressing ERBB2 (HER2) E717K demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 K831N	colorectal cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with colorectal cancer harboring ERBB2 (HER2) K831N (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 T733I	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) T733I in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 T733I	Advanced Solid Tumor	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) T733I demonstrated resistance to treatment with Tykerb (lapatinib) (PMID: 18413839).	18413839
ERBB2	ERBB2 T733I	biliary tract cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.7 months in a patient with biliary tract cancer harboring ERBB2 (HER2) T733I (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 D769N	Advanced Solid Tumor	sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited growth of transformed cells expressing ERBB2 (HER2) D769H in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 D769N	cervical cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.5 months in a patient with cervical cancer harboring ERBB2 (HER2) D769N (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 D769N	Advanced Solid Tumor	resistant	Sapitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) D769N were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 V839G	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) V839G in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 G776delinsVC	lung non-small cell carcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 8.5 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) G776delinsVC (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 G776delinsVC	Advanced Solid Tumor	sensitive	AZ5104	Preclinical - Cell culture	Actionable	In a preclinical study, AZ5104 inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC	Advanced Solid Tumor	decreased response	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC demonstrated decreased response to Tarceva (erlotinib) compared to Poziotinib (HM781-36B) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC	Advanced Solid Tumor	resistant	Tucatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC were resistant to Tucatinib (ARRY-380) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC	lung adenocarcinoma	predicted - sensitive	Ado-trastuzumab emtansine	Case Reports/Case Series	Actionable	In a Phase II trial, treatment with Kadcyla (trastuzumab emtansine) resulted in best overall responses of partial response in 44% (8/18) and stable disease in 39% (7/18), and median progression-free survival of 5 months in patients with lung adenocarcinoma harboring ERBB2 (HER2) activating mutations, and a subset of patients specifically harboring ERBB2 (HER2) G776delinsVC had a 100% (2/2) partial response rate (PMID: 29989854; NCT02675829).	29989854
ERBB2	ERBB2 G776delinsVC	Advanced Solid Tumor	sensitive	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Poziotinib (HM781-36B) inhibited growth of a transformed cell line expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 29686424).	29686424
ERBB2	ERBB2 G776delinsVC	Advanced Solid Tumor	sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC	Advanced Solid Tumor	predicted - sensitive	Luminespib	Preclinical - Cell culture	Actionable	In a preclinical study, Luminespib (AUY922) inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC were resistant to Tykerb (lapatinib) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 G776delinsVC	lung cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 26545934).	26545934
ERBB2	ERBB2 G776delinsVC	lung non-small cell carcinoma	no benefit	Lapatinib	Clinical Study	Actionable	In a retrospective analysis, Tykerb (lapatinib) treatment resulted in an objective response rate of 0% (0/1) in non-small cell lung cancer patients harboring ERBB2 (HER2) G776delinsVC (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vizimpro (dacomitinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC	Advanced Solid Tumor	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC	Advanced Solid Tumor	resistant	Sapitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 G776delinsVC	Advanced Solid Tumor	predicted - sensitive	Ganetespib	Preclinical - Cell culture	Actionable	In a preclinical study, Ganetespib inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC	lung adenocarcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in 1 partial response and 1 stable disease in 2 patients with lung adenocarcinoma harboring ERBB2 (HER2) G776delinsVC (PMID: 30149884; NCT02979821).	30149884
ERBB2	ERBB2 G776delinsVC	lung non-small cell carcinoma	predicted - sensitive	Poziotinib	Clinical Study	Actionable	In a retrospective analysis, Poziotinib (HM781-36B) treatment resulted in an objective response rate of 50% (1/2) in non-small cell lung cancer patients harboring ERBB2 (HER2) G776delinsVC (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC	Advanced Solid Tumor	sensitive	Pyrotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Pyrotinib inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC	lung cancer	no benefit	Gefitinib	Preclinical	Actionable	In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).	26545934
ERBB2	ERBB2 G776delinsVC	lung non-small cell carcinoma	conflicting	Afatinib	Clinical Study	Actionable	In a retrospective analysis, Gilotrif (afatinib) treatment resulted in an objective response rate of 0% (0/3) in non-small cell lung cancer patients harboring ERBB2 (HER2) G776delinsVC (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC	lung non-small cell carcinoma	conflicting	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited proliferation and induced cell-cycle arrest and apoptosis of a non-small cell lung cancer (NSCLC) cell line harboring ERBB2 (HER2) G776delinsVC in culture and inhibited tumor growth in NSCLC cell line xenografts carrying ERBB2 (HER2) G776delinsVC (PMID: 26545934).	26545934
ERBB2	ERBB2 G776delinsVC	lung non-small cell carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring ERBB2 (HER2) G776delinsVC demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 26545934).	26545934
ERBB2	ERBB2 G776delinsVC	Advanced Solid Tumor	sensitive	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tagrisso (osimertinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC	lung non-small cell carcinoma	no benefit	Erlotinib	Clinical Study	Actionable	In a retrospective analysis, Tarceva (erlotinib) treatment resulted in an objective response rate of 0% (0/1) in non-small cell lung cancer patients harboring ERBB2 (HER2) G776delinsVC (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC	lung non-small cell carcinoma	no benefit	Dacomitinib	Clinical Study	Actionable	In a retrospective analysis, Vizimpro (dacomitinib) treatment resulted in an objective response rate of 0% (0/2) in non-small cell lung cancer patients harboring ERBB2 (HER2) G776delinsVC (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC ERBB2 C805S	Advanced Solid Tumor	predicted - sensitive	Luminespib	Preclinical - Cell culture	Actionable	In a preclinical study, Luminespib (AUY922) inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC and an acquired ERBB2 (HER2) C805S in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC ERBB2 C805S	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC and an acquired ERBB2 (HER2) C805S were resistant to Vizimpro (dacomitinib) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC ERBB2 C805S	Advanced Solid Tumor	predicted - sensitive	Ganetespib	Preclinical - Cell culture	Actionable	In a preclinical study, Ganetespib inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC and an acquired ERBB2 (HER2) C805S in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC ERBB2 C805S	Advanced Solid Tumor	resistant	Poziotinib	Preclinical - Cell culture	Actionable	In a preclinical study, ERBB2 (HER2) C805S was identified as a secondary mutation in transformed cells expressing ERBB2 (HER2) G776delinsVC that acquired resistance to Poziotinib (HM781-36B) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC ERBB2 C805S	Advanced Solid Tumor	resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC and an acquired ERBB2 (HER2) C805S were resistant to Tagrisso (osimertinib) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC ERBB2 C805S	Advanced Solid Tumor	resistant	Pyrotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC and an acquired ERBB2 (HER2) C805S were resistant to Pyrotinib in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC ERBB2 C805S	Advanced Solid Tumor	resistant	Tucatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC and an acquired ERBB2 (HER2) C805S were resistant to Tucatinib (ARRY-380) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC ERBB2 C805S	Advanced Solid Tumor	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC and an acquired ERBB2 (HER2) C805S were resistant to Tarceva (erlotinib) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC ERBB2 C805S	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC and an acquired ERBB2 (HER2) C805S were resistant to Tykerb (lapatinib) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC ERBB2 C805S	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC and an acquired ERBB2 (HER2) C805S were resistant to Gilotrif (afatinib) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC ERBB2 C805S	Advanced Solid Tumor	resistant	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC and an acquired ERBB2 (HER2) C805S were resistant to Nerlynx (neratinib) in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 G776delinsVC ERBB2 C805S	Advanced Solid Tumor	resistant	AZ5104	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC and an acquired ERBB2 (HER2) C805S were resistant to AZ5104 in culture (PMID: 30527195).	30527195
ERBB2	ERBB2 R784G	colorectal cancer	predicted - resistant	Cetuximab	Case Reports/Case Series	Actionable	In a clinical study, ERBB2 R784G was identified in all 11 colorectal cancer patients who were resistant to Erbitux (cetuximab) treatment, and was associated with decreased survival rate (PMID: 30549033).	30549033
ERBB2	ERBB2 D821N	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) D821N in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 S783P	Advanced Solid Tumor	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells over expressing ERBB2 (HER2) S783P were resistant to Tykerb (lapatinib) in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 S783P	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) S783P in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 G776_V777insYVMA	Advanced Solid Tumor	sensitive	Canertinib	Preclinical	Actionable	In a preclinical study, Canertinib inhibited Erbb2 (Her2) phosphorylation and cell growth in transformed human cell lines expressing ERBB2 (HER2) G776_V777insYVMA (PMID: 16843263).	16843263
ERBB2	ERBB2 G660R	Advanced Solid Tumor	predicted - sensitive	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G660R demonstrated decreased cell proliferation and reduced survival when treated with Gilotrif (afatinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 G660R	Advanced Solid Tumor	predicted - sensitive	Trastuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G660R demonstrated decreased cell proliferation and reduced survival when treated with Herceptin (trastuzumab) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 G660R	Advanced Solid Tumor	predicted - sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G660R demonstrated decreased cell proliferation and reduced survival when treated with Nerlynx (neratinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 G660R	Advanced Solid Tumor	no benefit	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G660R did not benefit from treatment with Iressa (gefitinib) in culture when compared to Erbb2 (Her2) inhibitors (PMID: 30449325).	30449325
ERBB2	ERBB2 G660R	Advanced Solid Tumor	predicted - sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G660R demonstrated decreased cell proliferation and reduced survival when treated with Tykerb (lapatinib) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 G660R	Advanced Solid Tumor	predicted - resistant	Pertuzumab	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Perjeta (pertuzumab) in transformed cells expressing ERBB2 (HER2) G660R was not effective in inhibiting cell proliferation and survival as compared to other activating ERBB2 (HER2) mutations in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 G660R	Advanced Solid Tumor	no benefit	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G660R did not benefit from treatment with Tarceva (erlotinib) in culture when compared to Erbb2 (Her2) inhibitors (PMID: 30449325).	30449325
ERBB2	ERBB2 G660R	Advanced Solid Tumor	predicted - resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) G660R demonstrated resistance to treatment with Erbitux (cetuximab) in culture (PMID: 30449325).	30449325
ERBB2	ERBB2 L785F	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells over expressing ERBB2 (HER2) L785F demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 L785F	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L785F in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 L755S	biliary tract cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease in one and stable disease in another patient with biliary tract cancer harboring ERBB2 (HER2) L755S (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 L755S	Advanced Solid Tumor	sensitive	WZ4002	Preclinical	Actionable	In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 L755S	lung non-small cell carcinoma	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 12.7 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) L755S (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 L755S	colon cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 L755S	colorectal cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 L755S	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 L755S	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L755S in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 L755S	Advanced Solid Tumor	resistant	AEE788	Preclinical	Actionable	In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755S demonstrated resistance to AEE788 in culture, except at very high doses (PMID: 22046346).	22046346
ERBB2	ERBB2 L755S	colorectal cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 L755S	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 L755S	Her2-receptor positive breast cancer	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Tykerb (lapatinib) in ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 28487443).	28487443
ERBB2	ERBB2 L755S	Her2-receptor negative breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response in 1 patient, partial response in 1 patient, stable disease in 2 patients, and progressive disease in 4 patients with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L755S (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 L755S	Advanced Solid Tumor	resistant	Sapitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L755S were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 L755S	Advanced Solid Tumor	sensitive	EKI-285	Preclinical	Actionable	In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 L755S	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L755S were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 L755S	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) L755S demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 L755S	colon cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 L755S	colon cancer	sensitive	Neratinib	Phase II	Actionable	In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response in a patient with ERBB2 (HER2) L755S, and 3 patients achieving stable disease for 24 weeks or more (PMID: 28679771).	28679771
ERBB2	ERBB2 L755S	breast cancer	sensitive	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Nerlynx (neratinib) resulted in growth inhibition in transformed human breast cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 23220880).	23220880
ERBB2	APC Q1429fs BRAF N581S ERBB2 L755S	rectum adenocarcinoma	no benefit	Fluorouracil + Leucovorin + Trastuzumab	Case Reports/Case Series	Actionable	In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067).	27626067
ERBB2	ERBB2 exon 20 ins	lung non-small cell carcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, targeted therapy with Gilotrif (afatinib) or Herceptin (trastuzumab) resulted in an objective response rate of 44% (4/9) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies, all four responders harbored ERBB2 (HER2) exon 20 insertions (PMID: 28167203).	28167203
ERBB2	ERBB2 exon 20 ins	lung non-small cell carcinoma	predicted - sensitive	Trastuzumab	Case Reports/Case Series	Actionable	In a clinical study, targeted therapy with Gilotrif (afatinib) or Herceptin (trastuzumab) resulted in an objective response rate of 44% (4/9) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies, all four responders harbored ERBB2 (HER2) exon 20 insertions (PMID: 28167203).	28167203
ERBB2	ERBB2 exon 20 ins	lung adenocarcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, treatment with pulse Gilotrif (afatinib) resulted in an objective response rate of 33.3% (1/3) in lung adenocarcinoma patients with ERBB2 (HER2) exon 20 insertion mutations (PMID: 26964772).	26964772
ERBB2	ERBB2 exon 20 ins	lung adenocarcinoma	predicted - sensitive	Dacomitinib	Phase II	Actionable	In a Phase II trial, Vizimpro (dacomitinib) treatment resulted in an overall response rate of 25% (3/26) in patients with lung adenocarcinoma harboring ERBB2 (HER2) exon 20 mutations, including exon 20 insertions, indels, and missense mutations (23, 2, 1, respectively) (PMID: 25899785; NCT00818441).	25899785
ERBB2	ERBB2 exon 20 ins	Her2-receptor negative breast cancer	predicted - sensitive	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response in 1, partial response in 1, and stable disease in 3 of the 5 patients with Erbb2 (Her2)-receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) exon 20 insertion mutations (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 exon 20 ins	lung non-small cell carcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 10 and progressive disease in 5 of the 15 patients with non-small cell lung cancer harboring ERBB2 (HER2) exon 20 insertion mutations (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 exon 20 ins	Advanced Solid Tumor	sensitive	AP32788	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing ERBB2 (HER2) exon 20 insertions in culture, and induced tumor regression in PDX models (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).	detail...
ERBB2	ERBB2 V773A	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V773A in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 V773A	Advanced Solid Tumor	sensitive	AEE788	Preclinical	Actionable	In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V773A in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 H878Y	Advanced Solid Tumor	sensitive	AEE788	Preclinical	Actionable	In a preclinical study, transformed cell lines expressing ERBB2 (HER2) H878Y demonstrated growth inhibition when treated with AEE788 in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 H878Y	Advanced Solid Tumor	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) H878Y in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 G778_S779insCPG	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vizimpro (dacomitinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G778_S779insCPG in culture (PMID: 28363995).	28363995
ERBB2	ERBB2 N857S	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) N857S in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 N857S	Advanced Solid Tumor	sensitive	AEE788	Preclinical	Actionable	In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2(HER2) N857S in culture (PMID: 22046346).	22046346
ERBB2	ERBB2 E719G	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells over expressing ERBB2 (HER2) E719G demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 E719G	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E719G in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 dec exp	breast cancer	predicted - sensitive	MP0274	Preclinical - Pdx	Actionable	In a preclinical study, MP0274 induced apoptosis in breast cancer cells with low level Erbb2 (Her2) expression in culture and inhibited tumor growth in patient-derived xenograft (PDX) models (Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-30).	detail...
ERBB2	EGFR over exp ERBB2 dec exp	inflammatory breast carcinoma	sensitive	Paclitaxel + Sapitinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, combination of Sapatinib (AZD8931) and Taxol (paclitaxel) demonstrated enhanced antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erbb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).	24886365
ERBB2	EGFR over exp ERBB2 dec exp	inflammatory breast carcinoma	sensitive	Sapitinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Sapitinib (AZD8931) demonstrated antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).	24886365
ERBB2	ERBB2 V842I	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) V842I were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 V842I	colon cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 V842I	colorectal cancer	conflicting	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 2 patients and progressive disease in 1 patient with colorectal cancer harboring ERBB2 (HER2) V842I (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 V842I	colorectal cancer	conflicting	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cell lines over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 V842I	endometrial cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.8 months in a patient with endometrial cancer harboring ERBB2 (HER2) V842I (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 V842I	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing ERBB2 (HER2) V842I were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 V842I	colorectal cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cell lines over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 V842I	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines over expressing ERBB2 (HER2) V842I were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 V842I	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) V842I demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).	23220880
ERBB2	ERBB2 V842I	Advanced Solid Tumor	resistant	Sapitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) V842I were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 V842I	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 V842I demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).	23220880
ERBB2	ERBB2 V842I	colon cancer	resistant	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V842I were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863).	26243863
ERBB2	ERBB2 V842I	breast cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 V842I reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).	23220880
ERBB2	CDH1 R63* ERBB2 L869Q	breast cancer	predicted - sensitive	Capecitabine + Lapatinib	Case Reports/Case Series	Actionable	In a clinical case study, treatment with the combination of Tykerb (lapatinib) and Xeloda (capecitabine) resulted in prolonged response and reduction in liver metastasis in a metastatic breast cancer patient harboring ERBB2 L869Q and CDH1 R63* mutations (PMID: 26487584).	26487584
ERBB2	ERBB2 G309A	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) G309A demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).	23220880
ERBB2	ERBB2 G309A	breast cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 G309A reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).	23220880
ERBB2	ERBB2 G309A	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed human breast cell lines expressing ERBB2 G309A demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).	23220880
ERBB2	ERBB2 E812K	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E812K in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 E812K	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells over expressing ERBB2 (HER2) E812K demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 E812K	lung adenocarcinoma	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in stable disease in a patient with lung adenocarcinoma harboring ERBB2 (HER2) E812K (PMID: 30149884; NCT02979821).	30149884
ERBB2	ERBB2 Y803N	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) Y803N in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 Y803N	Advanced Solid Tumor	decreased response	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells over expressing ERBB2 (HER2) Y803N demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 V773M	Advanced Solid Tumor	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) V773M were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 V773M	Advanced Solid Tumor	resistant	Sapitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ERBB2 (HER2) V773M were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020).	31588020
ERBB2	ERBB2 L755_T759del	breast cancer	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were resistant to treatment with Tykerb (lapatinib), resulting in decreased growth inhibition (PMID: 23220880).	23220880
ERBB2	ERBB2 L755_T759del	breast cancer	sensitive	Gefitinib	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were sensitive to treatment with Iressa (gefitinib) (PMID: 23220880).	23220880
ERBB2	ERBB2 L755_T759del	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were sensitive to treatment with Nerlynx (neratinib) (PMID: 23220880).	23220880
ERBB2	ERBB2 T798I	lung cancer	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed lung cancer cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247).	25238247
ERBB2	ERBB2 T798I	Advanced Solid Tumor	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, transformed cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247).	25238247
ERBB2	ERBB2 T798I	Advanced Solid Tumor	sensitive	XL647	Preclinical	Actionable	In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) T798I in culture (PMID: 18413839).	18413839
ERBB2	ERBB2 G778A	colorectal cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with colorectal cancer harboring ERBB2 (HER2) G778A (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 positive	breast cancer	sensitive	MI130004	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MI130004 inhibited proliferation of ERBB2 (HER2)-receptor positive breast cancer cells in culture, and led to decreased tumor volume and improved survival in cell line xenograft models (PMID: 29440297).	29440297
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Neratinib + Paclitaxel	Phase II	Actionable	In a Phase II trial, Nerlynx (neratinib) plus Taxol (paclitaxel) demonstrated similar efficacy to Herceptin (trastuzumab) plus Taxol (paclitaxel), with an median progression-free survival of 12.9 months, however, potentially decreased CNS metastasis risk, with an incidence of 8.3% (20/242) compared to 17.3% (41/237) in the Herceptin (trastuzumab) plus Taxol (paclitaxel) group (PMID: 27078022).	27078022
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab	Guideline	Actionable	Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).	detail...
ERBB2	ERBB2 positive	gastroesophageal junction adenocarcinoma	no benefit	Ado-trastuzumab emtansine	Phase III	Actionable	In a Phase III trial (GATSBY), Kadcyla (trastuzumab emtansine) did not demonstrate efficacy benefit over Taxol (paclitaxel) in median overall survival (7.9 vs 8.6 months) in patients with previously treated ERBB2 (HER2)-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (PMID: 28343975; NCT01641939).	detail... 28343975
ERBB2	ERBB2 positive	breast adenocarcinoma	sensitive	DS-8201a	Preclinical - Cell culture	Actionable	In a preclinical study, DS-8201 inhibited growth of an ERBB2 (HER2)-positive breast adenocarcinoma cell line in culture (PMID: 27026201).	27026201
ERBB2	ERBB2 positive	gastric adenocarcinoma	no benefit	Ado-trastuzumab emtansine	Phase III	Actionable	In a Phase III trial (GATSBY), Kadcyla (trastuzumab emtansine) did not demonstrate efficacy benefit over Taxol (paclitaxel) in median overall survival (7.9 vs 8.6 months) in patients with previously treated ERBB2 (HER2)-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (PMID: 28343975; NCT01641939).	detail... 28343975
ERBB2	ERBB2 positive	colorectal cancer	predicted - sensitive	DS-8201a	Phase I	Actionable	In a Phase I trial, treatment with DS-8201a resulted in an objective response rate of 25% (3/12) and disease control rate of 83.3% (10/12) in evaluable patients with Erbbe (Her2)-expressing colorectal cancer (Annals of Oncology (2018) 29 (suppl_8): viii150-viii204; NCT02564900).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Afatinib + Trastuzumab	Phase I	Actionable	In a Phase I clinical trial, ERBB2 (HER2)-positive breast cancer patients treated with Gilotrif (afatinib), in combination with Herceptin (trastuzumab), demonstrated an overall objective response rate of 11% (2/18) while 28% (5/18) attained a best response of stable disease (PMID: 25370464).	25370464
ERBB2	ERBB2 positive	esophageal cancer	predicted - sensitive	Afatinib + Trastuzumab	Phase II	Actionable	In a Phase II clinical trial, the combination therapy of Gilotrif (afatinib) and Herceptin (trastuzumab) in ERBB2 (HER2)-positive patients with either gastroesophageal junction adenocarcinoma, metastatic esophageal cancer, or gastric adenocarcinoma resulted in a partial response in 8% (1/12) and disease control for 4 months or more in 17% (2/12) (PMID: 30463996; NCT01522768).	30463996
ERBB2	ERBB2 positive	inflammatory breast carcinoma	predicted - sensitive	Afatinib	Phase II	Actionable	In a Phase II clinical trial, treatment with Gilotrif (afatinib) resulted in a clinical benefit rate of 35% (9/26) in patients with ERBB2 (HER2)-positive inflammatory breast cancer, with 8 confirmed partial responses and 1 patient achieving stable disease for greater than 6 months (PMID: 27923043).	27923043
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	ABP 980	Phase III	Actionable	In a Phase III trial, ABP 980 treatment demonstrated safety and efficacy similar to Herceptin (trastuzumab), with pathologic complete response rates of 48% and 40.5%, respectively, in patients with Erbb2 (Her2)-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 151PD; NCT01901146).	detail...
ERBB2	ERBB2 positive	esophageal cancer	predicted - sensitive	Afatinib	Phase II	Actionable	In a Phase II clinical trial, monotherapy with Gilotrif (afatinib) resulted in a moderate clinical benefit in ERBB2 (HER2)-positive patients with either gastroesophageal junction adenocarcinoma, metastatic esophageal cancer, or gastric adenocarcinoma, demonstrating a tumor reduction in 25% (5/20) according to RECIST, an objective partial response in 10% (2/20), a median progression-free survival of 2 months, and a median overall survival of 7 months (PMID: 30463996; NCT01522768).	30463996
ERBB2	ERBB2 positive	breast cancer	sensitive	DS-8201a	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, DS-8201 inhibited growth of ERBB2 (HER2)-positive breast cancer cell lines in culture and xenograft models, and demonstrated antitumor activity in patient-derived xenograft (PDX) models of ERBB2 (HER2)-positive breast cancer, including models with low ERBB2 (HER2) expression (PMID: 27026201).	27026201
ERBB2	ERBB2 positive	ovarian cancer	sensitive	MI130004	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MI130004 inhibited proliferation of ERBB2 (HER2)-positive ovarian cancer cells in culture, and led to decreased tumor volume, reduced ERBB2 (HER2) expression, and improved survival in cell line xenograft models (PMID: 29440297).	29440297
ERBB2	ERBB2 positive	gastroesophageal junction adenocarcinoma	predicted - sensitive	Afatinib	Phase II	Actionable	In a Phase II clinical trial, monotherapy with Gilotrif (afatinib) resulted in a moderate clinical benefit in ERBB2 (HER2)-positive patients with either gastroesophageal junction adenocarcinoma, metastatic esophageal cancer, or gastric adenocarcinoma, demonstrating a tumor reduction in 25% (5/20) according to RECIST, an objective partial response in 10% (2/20), a median progression-free survival of 2 months, and a median overall survival of 7 months (PMID: 30463996; NCT01522768).	30463996
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	CDX-3379	Preclinical	Actionable	In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-positive breast cancer (PMID: 26880266).	26880266
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Neratinib	Phase II	Actionable	In a Phase II clinical trial, Nerlynx (neratinib) demonstrated safety and efficacy as a monotherapy in patients with ERBB2 (HER2)-positive breast cancer (PMID: 23953056).	23953056
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Paclitaxel + Pertuzumab + Trastuzumab	Guideline	Actionable	Perjeta (pertuzumab), Herceptin (trastuzumab), and Taxol (paclitaxel) therapy is included in the guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-negative, ERBB2 (HER2) receptor-positive breast cancer (NCCN.org).	detail...
ERBB2	ERBB2 positive	ductal carcinoma in situ	predicted - sensitive	HER2-pulsed DC1 vaccine	Phase Ib/II	Actionable	In a Phase I/Ib clinical trial, vaccination with a HER2-peptide pulsed dendritic cell vaccine was well-tolerated and resulted in immune response in patients with ERBB2 (HER2)-positive ductal carcinoma in situ (DCIS), and resulted in pathologic complete response rate of 28% (12/42), compared to 8.3% (1/12) in patients with invasive breast cancer (PMID: 27965306).	27965306
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Metformin	Phase III	Actionable	In a Phase III trial, ERBB2 (HER2) positive breast cancer patients with diabetes demonstrated a greater disease free survival and overall survival when treated with Glucophage (metformin) compared to ERBB2 (HER2) positive breast cancer patients with diabetes not treated with Glucophage (metformin) (PMID: 28375706).	28375706
ERBB2	ERBB2 positive	gastric adenocarcinoma	predicted - sensitive	Afatinib	Phase II	Actionable	In a Phase II clinical trial, monotherapy with Gilotrif (afatinib) resulted in a moderate clinical benefit in ERBB2 (HER2)-positive patients with either gastroesophageal junction adenocarcinoma, metastatic esophageal cancer, or gastric adenocarcinoma, demonstrating a tumor reduction in 25% (5/20) according to RECIST, an objective partial response in 10% (2/20), a median progression-free survival of 2 months, and a median overall survival of 7 months (PMID: 30463996; NCT01522768).	30463996
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Varlitinib	Phase I	Actionable	In a Phase I expansion trial, 36% (5/14) of metastatic breast cancer patients positive for ERBB2 (HER2) demonstrated stable disease for up to 16 weeks when treated with Varlitinib (ARRY-334543) (Cancer Res May 1, 2009 69; 3603).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Lapatinib + Palbociclib	Preclinical	Actionable	In a preclinical study, the combination of Tykerb (lapatinib) and Ibrance (palbociclib) worked additively to suppress growth of ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 25221644).	25221644
ERBB2	ERBB2 positive	stomach carcinoma	sensitive	SYD985	Preclinical - Cell culture	Actionable	In a preclinical study, SYD985 decreased survival of a ERBB2 (HER2)-positive gastric carcinoma cell line in culture (PMID: 25589493).	25589493
ERBB2	ERBB2 positive	ovarian carcinoma	sensitive	SYD985	Preclinical - Cell culture	Actionable	In a preclinical study, SYD985 decreased survival of a ERBB2 (HER2)-positive ovarian carcinoma cell line in culture (PMID: 25589493).	25589493
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	HER2 BATs	Preclinical - Cell culture	Actionable	In a preclinical study, HER2 BATs demonstrated enhanced toxicity comparing to unarmed T-cells against Erbb2 (Her2)-positive breast cancer cells in culture (PMID: 11359672).	11359672
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Entinostat + Lapatinib	Phase I	Actionable	In a Phase I trial, Entinostat and Tykerb (lapatinib) combination treatment resulted in complete response in 7% (1/15) and stable disease in 27% (4/15) of ERBB2 (HER2) positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 609)).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Capecitabine + Trastuzumab	Phase II	Actionable	In Phase II clinical trials, the combination of Xeloda (capecitabine) and Herceptin (trastuzumab) demonstrated efficacy with a manageable toxicity profile in heavily pretreated patients with ERBB2 (HER2)-positive advanced breast cancer and earlier Herceptin (trastuzumab) exposure (PMID: 17679724).	17679724
ERBB2	ERBB2 positive	colorectal cancer	no benefit	ZW25	Phase I	Actionable	In a Phase I trial, ZW25 treatment resulted in disease progression in a patient with ERBB2 (HER2)-positive colorectal cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Oxaliplatin + Trastuzumab + TS-1	Phase II	Actionable	In a Phase II clinical trial, the combination of TS-1 (S-1) and Herceptin (trastuzumab) demonstrated safety and efficacy in patients with ERBB2 (HER2)-positive metastatic breast cancer, with an overall response rate of 53.6% (15/28), and a clinical benefit rate of 75.0% (21/28) (PMID: 24982373).	24982373
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Lapatinib + Trastuzumab	Phase II	Actionable	In a Phase II trial, Tykerb (lapatinib) and Herceptin (trastuzumab) combination treatment resulted in complete response in the breast in 10.6% (7/66) and minimal residual disease in 16.7% (11/66) of ERBB2-positive breast cancer patients 11 days after receiving the treatment (European Breast Cancer Conference; Mar 2016; Abstract #6LBA).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Lapatinib + Trastuzumab	Clinical Study - Meta-analysis	Actionable	In a meta-analysis of six randomized clinical trials, Tykerb (lapatinib) and Herceptin (trastuzumab) combination treatment resulted in 13% absolute improvement in pathologic complete response rate in ERBB2 (HER2)-positive breast cancer patients compared to Herceptin (trastuzumab) single treatment (PMID: 27140927).	27140927
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Carboplatin + Docetaxel + Trastuzumab	Guideline	Actionable	Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) therapy is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Ado-trastuzumab emtansine + Tucatinib	Phase Ib/II	Actionable	In a Phase Ib clinical trial, treatment with the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) resulted in partial response in 33% (11/33) and stable disease in 48% (16/33) and a clinical benefit rate of 58% (19/33) in patients with ERBB2 (HER2)-positive metastatic breast cancer (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-20).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Ado-trastuzumab emtansine + Tucatinib	Phase Ib/II	Actionable	In a Phase Ib clinical trial, treatment with the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) resulted in an overall response rate of 47% (15/52) and median progression-free survival of 6.5 months in patients with ERBB2 (HER2)-positive metastatic breast cancer, including patients with CNS metastasis (J Clin Oncol 34, 2016 (suppl; abstr 513)).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Ado-trastuzumab emtansine + Tucatinib	Phase Ib/II	Actionable	In a Phase Ib trial, the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) demonstrated clinical activity in CNS metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 12.5% (1/8) evaluable patients achieving CNS complete response, 25% (2/8) partial CNS response, and 62.5% (5/8) CNS stable disease (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Trodusquemine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Trodusquemine (MSI-1436) inhibited tumor growth and metastasis in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model (PMID: 24845231).	24845231
ERBB2	ERBB2 positive	breast carcinoma	sensitive	SYD985	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, SYD985 decreased survival of ERBB2 (HER2)-positive breast carcinoma cell lines in culture, and inhibited tumor growth and induced tumor remission in cell line and patient-derived xenograft models of ERBB2 (HER2)-positive breast carcinoma, including models with low ERBB2 (HER2) expression (PMID: 25589493).	25589493
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	GBR1302	Case Reports/Case Series	Actionable	In a Phase I trial, GBR 1302 treatment resulted in prolonged (more than 4 months) stable disease in a patient with ERBB2 (HER2) positive (IHC 2+) breast adenocarcinoma (Annals of Oncology, Volume 29, Issue suppl_8, October 2018, mdy288.020; NCT02829372).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine + Docetaxel	Phase Ib/II	Actionable	In a Phase Ib/II trial, Kadcyla (trastuzumab emtansine) and Taxotere (docetaxel) combination treatment resulted in median progression-free survival of 13.8 months and objective response in 80.0% (20/25) of patients with ERBB2 (HER2)-positive metastatic breast cancer (PMID: 27052654).	27052654
ERBB2	ERBB2 positive	stomach cancer	sensitive	HER2 Vaccine	Preclinical - Patient cell culture	Actionable	In a preclinical study, ERBB2 (HER2)-specific cytotoxic T-cell lines generated from gastric cancer patients demonstrated activity against autologous ERBB2 (HER2)-expressing gastric cancer cells in culture (PMID: 9754653).	9754653
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab	Guideline	Actionable	Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).	detail...
ERBB2	ERBB2 positive	breast cancer	predicted - sensitive	SYD985	Phase I	Actionable	In a Phase I trial, SYD985 treatment resulted in an overall response of 33% (33/99) and a median progression-free survival of 9.4 months in patients with ERBB2 (HER2)-positive (50) or ERBB2 (HER2)-low (49) metastatic breast cancer (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 1014-1014; NCT02277717).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	HER2 Vaccine	Phase II	Actionable	In Phase II clinical trials, ERBB2 (HER2) vaccines demonstrated safety and some efficacy in the adjuvant setting in ERBB2 (HER2)-positive breast cancer patients (PMID: 23585514).	23585514
ERBB2	ERBB2 positive	Advanced Solid Tumor	predicted - sensitive	DS-8201a	Phase I	Actionable	In a Phase I trial, treatment with DS-8201a was well-tolerated and resulted in an overall response rate (ORR) of 38% (19/50) and disease control rate (DCR) of 90% (45/50) in patients with ERBB2 (HER2)-expressing solid tumors, and an ORR of 29% (4/14) and DCR of 93% (13/14) in patients with low ERBB2 (HER2) expression (J Clin Oncol 35, 2017 (suppl; abstr 108)).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Pyrotinib	Phase I	Actionable	In a Phase I trial, Pyrotinib treatment resulted in an objective response rate of 50% (18/36, all partial responses), and a clinical benefit rate of 61.1% (22/36), and a median progression-free survival of 35.4 weeks in patients with ERBB2 (HER2)-positive breast cancer (PMID: 28498781, NCT01937689).	detail... 28498781
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	ZW25	Phase I	Actionable	In a Phase I trial, ZW25 treatment resulted in partial response in 28.6% (2/7) and stable disease in 28.6% (2/7) of patients with ERBB2 (HER2)-positive breast cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Carboplatin + Docetaxel + Pertuzumab + Trastuzumab	Guideline	Actionable	Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab) therapy, is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).	detail...
ERBB2	ERBB2 positive	pancreatic cancer	sensitive	DS-8201a	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DS-8201a inhibited tumor growth in a pancreatic cancer cell line xenograft model with low ERBB2 (HER2) expression (PMID: 27026201).	27026201
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Copanlisib	Preclinical	Actionable	In a preclinical study, breast cancer cell lines with a PIK3CA activating mutation and/or ERBB2 (HER2)-over expression demonstrated increased sensitivity to inhibition of proliferation by Aliqopa (copanlisib) in culture, compared to ERBB2 (HER2)-negative and wild-type PIK3CA cell lines (PMID: 24170767).	24170767
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	MYL-1401O + Paclitaxel	Phase III	Actionable	In a Phase III trial, MYL-1401O demonstrated safety and efficacy comparable to Herceptin (trastuzumab) when given in combination with Taxol (paclitaxel), resulted in an objective response rate of 69.6% in ERBB2 (HER2)-positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr LBA503)).	detail...
ERBB2	ERBB2 positive	ovarian cancer	sensitive	PRS-343	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PRS-343 induced localized immune activation in cell line xenograft models of Erbb2 (Her2)-positive ovarian cancer, resulted in significant tumor growth inhibition (Eur J Cancer, Dec 2016, 69 (Suppl. 1): S99, abstract 301).	detail...
ERBB2	ERBB2 positive	breast cancer	sensitive	Withacnistin	Preclinical	Actionable	In a preclinical study, withacnistin induced tumor regression in transgenic mouse models of Erbb2 (Her2)-driven breast cancer (PMID: 24983364).	24983364
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Ibrutinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Imbruvica (ibrutinib) inhibited Her family receptor signaling, resulted in apoptosis and growth inhibition in ERBB2 (HER2)-positive breast cancer cell lines in culture and in cell line xenograft models (PMID: 27256378).	27256378
ERBB2	ERBB2 positive	breast cancer	sensitive	ARX-788	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an ERBB2 (HER2)-positive breast cancer xenograft model was sensitive to treatment with ARX-788, resulting in tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639).	detail...
ERBB2	ERBB2 positive	Advanced Solid Tumor	predicted - sensitive	AC480	Phase I	Actionable	In a Phase I clinical trial, AC480 (BMS-599626) treatment demonstrated preliminary clinical activity, resulting in stable disease as best response in 25% (11/44) of patients with advanced solid tumors, including patients expressing EGFR and/or ERBB2, with 2 patients achieving stable disease for greater than 6 months (PMID: 21576284).	21576284
ERBB2	ERBB2 positive	transitional cell carcinoma	no benefit	lapuleucel-T	Phase II	Actionable	In a Phase II trial, Neuvenge (lapuleucel-T) treatment did not result in statistically significant improvement of overall survival (37.0 vs 22.2 months, HR = 0.96) or disease recurrence-free survival (11.9 vs 10.1 months, HR = 0.99) compared to standard of care in ERBB2 (HER2) positive urothelial cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 4513)).	detail...
ERBB2	ERBB2 positive	breast cancer	sensitive	ADCT-502	Preclinical - Pdx	Actionable	In a preclinical study, ADCT-502 demonstrated anti-tumor activity in ERBB2 (HER2)-expressing breast cancer cell line and patient-derived xenograft (PDX) models, including PDX models expressing low levels of ERBB2 (HER2) (Eur J Cancer, 2016, Vol. 69, Supp1, S28).	detail...
ERBB2	ERBB2 positive	sarcoma	predicted - sensitive	HER2 CAR-T cells	Phase Ib/II	Actionable	In a Phase I/II trial, treatment with ERBB2 (HER2)-specific CAR-T cells resulted in stable disease for 12 weeks to 14 months in 4/17 evaluable patients with ERBB2 (HER2)-positive sarcomas and a median overall survival of 10.3 months (PMID: 25800760; NCT00902044).	25800760
ERBB2	ERBB2 positive	uterine corpus serous adenocarcinoma	sensitive	SYD985	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SYD895 induced cell death in ERBB2 (HER2)-expressing primary uterine serous carcinoma (USC) cell lines in culture, including cell lines with both high and low levels of ERBB2 (HER2) expression, and inhibited tumor growth and improved survival in ERBB2 (HER2)-expressing USC primary cell line xenografts (PMID: 27256376).	27256376
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Pertuzumab + Trastuzumab	Phase III	Actionable	In a Phase III trial, adjuvant Herceptin (trastuzumab), Perjeta (pertuzumab), plus chemotherapy resulted in improved invasive disease-free survival compared to Herceptin (trastuzumab) plus chemotherapy in patients with Erbb2 (Her2)-positive breast cancer (J Clin Oncol 35, 2017 (suppl; abstr LBA500)).	detail...
ERBB2	ERBB2 positive	glioblastoma multiforme	sensitive	HER2 CAR-T cells	Phase I	Actionable	In a Phase I trial, glioblastoma patients positive for ERBB2 (HER2) demonstrated antitumor activity when treated with ERBB2 (HER2)-CAR-T cell therapy including one patient with a partial response and seven patients with stable disease ranging from 8 weeks to 29 months (PMID: 28426845).	28426845
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Capecitabine + Pyrotinib	Phase I	Actionable	In a Phase I trial, Pyrotinib and Xeloda (capecitabine) combination treatment was well-tolerated, and resulted in an overall response rate of 78.6% (22/28) in patients with Erbb2 (Her2)-positive metastatic breast cancer, with a median progression-free survival of 22.1 months (PMID: 31138588; NCT02361112).	31138588
ERBB2	ERBB2 positive	stomach cancer	sensitive	Lapatinib + Paclitaxel	Phase III	Actionable	In a Phase III trial, second-line treatment using Tykerb (lapatinib) with paclitaxel demonstrated some efficacy in patients with HER2-positive advanced gastric cancer (PMID: 24868024).	24868024
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Everolimus + Trastuzumab + Vinorelbine	Phase III	Actionable	In a Phase III trial (BOLERO-3), the combination of Afinitor (everolimus), Herceptin (trastuzumab), and Navelbine (vinorelbine) increased progression-free survival in patients with Herceptin (trastuzumab)-resistant, ERBB2 (HER2)-positive, advanced breast cancer who had prior taxane treatment (PMID: 24742739; NCT01007942).	24742739
ERBB2	ERBB2 positive	stomach cancer	sensitive	ARX-788	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ERBB2 (HER2)-positive ovarian xenograft model was sensitive to treatment with ARX-788, resulting in tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Capecitabine + Tucatinib	Phase Ib/II	Actionable	In a Phase Ib trial, the combination of Tucatinib (ARRY-380) with other agents demonstrated clinical activity in central nervous system (CNS) metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 1/1 evaluable patient treated with Tucatinib (ARRY-380) and Capecitabine achieving CNS partial response (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	MEDI4276	Phase I	Actionable	In a Phase I trial, MEDI4276 treatment resulted in complete response in 1 patient with breast cancer, partial response in 1 patient with breast cancer, and stable disease in 12 patients with Erbb2 (Her2)-positive breast or gastric cancer (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 470; NCT02576548).	detail...
ERBB2	ERBB2 positive	stomach cancer	predicted - sensitive	MEDI4276	Phase I	Actionable	In a Phase I trial, MEDI4276 treatment resulted in complete response in 1 patient with breast cancer, partial response in 1 patient with breast cancer, and stable disease in 12 patients with Erbb2 (Her2)-positive breast or gastric cancer (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 470; NCT02576548).	detail...
ERBB2	ERBB2 positive	ovarian cancer	sensitive	ARX-788	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an ERBB2 (HER2)-positive ovarian cancer xenograft model was sensitive to treatment with ARX-788, resulting in tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639).	detail...
ERBB2	ERBB2 positive	ovarian cancer	sensitive	Hertuzumab-vc-MMAE	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with Hertuzumab-vc-MMAE decreased viability of ERBB2 (HER2)-positive ovarian cancer cell lines in culture and inhibited tumor growth in ERBB2 (HER2)-positive ovarian cancer cell line xenograft models (PMID: 27509865).	27509865
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Hertuzumab-vc-MMAE	Preclinical - Cell culture	Actionable	In a preclinical study, Hertuzumab-vc-MMAE decreased viability of ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 27509865).	27509865
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	SB3	Phase III	Actionable	In a Phase III trial, SB3 treatment demonstrated safety, immunogenicity, and survival result similar to Herceptin (trastuzumab), resulted in event-free-survival rates of 92.2% and 91.6%, respectively, in patients with Erbb2 (Her2)-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 153PD; NCT02149524).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Capecitabine + Neratinib	Phase II	Actionable	In a Phase II trial, Nerlynx (neratinib) and Xeloda (capecitabine) combination therapy resulted in an overall 12-month survival rate of 63% (23/37) in patients with Erbb2 (Her2)-positive breast cancer brain metastases (J Clin Oncol 35, 2017 (suppl; abstr 1005)).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Tucatinib	Phase I	Actionable	In a Phase I trial, treatment with Tucatinib (ARRY-380) resulted in a response rate of 14% (3/22; all partial responses (PR)) and a clinical benefit rate (PR plus stable disease for greater than or equal to 24 weeks) of 27% (6/22) in Erbb2 (Her2)-positive breast cancer patients (PMID: 28053022).	28053022
ERBB2	ERBB2 positive	stomach cancer	sensitive	MI130004	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MI130004 inhibited proliferation of ERBB2 (HER2)-positive gastric cancer cells in culture, and led to decreased tumor volume and improved survival in cell line xenograft models (PMID: 29440297).	29440297
ERBB2	ERBB2 positive	gastroesophageal adenocarcinoma	predicted - sensitive	GBR1302	Case Reports/Case Series	Actionable	In a Phase I trial, GBR 1302 treatment resulted in prolonged (more than 4 months) stable disease in a patient with ERBB2 (HER2) positive (IHC 3+) gastroesophageal adenocarcinoma (Annals of Oncology, Volume 29, Issue suppl_8, October 2018, mdy288.020; NCT02829372).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Lapatinib + MK2206	Phase I	Actionable	In a Phase I trial, Tykerb (lapatinib) and MK2206 combination treatment resulted in stable disease for more than 6 months in 40% (2/5) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 27026198).	27026198
ERBB2	ERBB2 positive	uterine corpus serous adenocarcinoma	sensitive	Carboplatin + Paclitaxel + Trastuzumab	Guideline	Actionable	Combination Paraplatin (carboplatin), Taxol (paclitaxel), and Herceptin (trastuzumab) is in guidelines for ERBB2 (HER2)-positive patients with advanced and recurrent uterine serous carcinoma (NCCN.org).	detail...
ERBB2	ERBB2 positive	gastric adenocarcinoma	predicted - sensitive	Afatinib + Trastuzumab	Phase II	Actionable	In a Phase II clinical trial, the combination therapy of Gilotrif (afatinib) and Herceptin (trastuzumab) in ERBB2 (HER2)-positive patients with either gastroesophageal junction adenocarcinoma, metastatic esophageal cancer, or gastric adenocarcinoma resulted in a partial response in 8% (1/12) and disease control for 4 months or more in 17% (2/12) (PMID: 30463996; NCT01522768).	30463996
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Buparlisib + Trastuzumab	Phase I	Actionable	In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated in patients with ERBB2 (HER2)-positive advanced or metastatic breast cancer that had progressed on Herceptin (trastuzumab) (PMID: 24470511).	24470511
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	Phase III	Actionable	In a Phase III trial, Kadclya (trastuzumab emtansine) demonstrated improved median progression free survival and overall survival compared to Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment in patients with ERBB2 (HER2) positive breast cancer, regardless of the expression level of Erbb2 (Her2), Egfr, and Her3, or PIK3CA mutation status (PMID: 26920887).	26920887
ERBB2	ERBB2 positive	Advanced Solid Tumor	predicted - sensitive	MT-5111	Preclinical - Cell culture	Actionable	In a preclinical study, MT-5111 demonstrated toxicity against Erbb2 (Her2) positive tumor cell lines in culture regardless of their sensitivity to Kadcyla (ado-trastuzumab emtansine) (Cancer Res 2018;78(13 Suppl):Abstract nr 5769).	detail...
ERBB2	ERBB2 positive	gastroesophageal junction adenocarcinoma	predicted - sensitive	Afatinib + Trastuzumab	Phase II	Actionable	In a Phase II clinical trial, the combination therapy of Gilotrif (afatinib) and Herceptin (trastuzumab) in ERBB2 (HER2)-positive patients with either gastroesophageal junction adenocarcinoma, metastatic esophageal cancer, or gastric adenocarcinoma resulted in a partial response in 8% (1/12) and disease control for 4 months or more in 17% (2/12) (PMID: 30463996; NCT01522768).	30463996
ERBB2	ERBB2 positive	Advanced Solid Tumor	predicted - sensitive	GBR1302	Phase I	Actionable	In a Phase I trial, GBR 1302 treatment resulted in no radiological response, only prolonged (more than 4 months) stable disease in 10.5% (2/19) of patients with ERBB2 (HER2) positive advanced solid tumors (Annals of Oncology, Volume 29, Issue suppl_8, October 2018, mdy288.020; NCT02829372).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Trastuzumab + Tucatinib	Phase Ib/II	Actionable	In a Phase Ib clinical trial, the combination of Tucatinib (ARRY-380) and Herceptin (trastuzumab) demonstrated clinical activity in central nervous system (CNS) metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 100% (3/3) patients achieving CNS stable disease as best response (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).	detail...
ERBB2	ERBB2 positive	Advanced Solid Tumor	predicted - sensitive	S-222611	Phase I	Actionable	In a Phase I clinical trial, S-222611 demonstrated safety and some efficacy in patients with advanced solid tumors expressing EGFR or ERBB2 (HER2), with an overall clinical benefit rate of 27% (7/33) (PMID: 25434923).	detail... 25434923
ERBB2	ERBB2 positive	breast cancer	sensitive	Ado-trastuzumab emtansine + Tucatinib	Phase Ib/II	Actionable	In a Phase Ib/II trial, ERBB2 (HER2)-positive breast cancer patients demonstrated an objective response rate of 47% (16/34), including one complete response and fifteen partial responses, and a progression-free survival of 8.2 months when treated with a combination of Tucatinib (ARRY-380) and Kadcyla (trastuzumab emtansine) compared to 6.5 months with Herceptin (trastuzumab) and Perjeta (pertuzumab) treatment (PMID: 29955792; NCT01983501).	29955792
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Capecitabine + Trastuzumab + Tucatinib	Phase Ib/II	Actionable	In a Phase Ib trial, the combination of Tucatinib (ARRY-380), Herceptin (trastuzumab), and Capecitabine demonstrated clinical activity in CNS metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 50% (1/2) of evaluable patients achieving CNS partial response and 50% (1/2) achieving CNS stable disease (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).	detail...
ERBB2	ERBB2 positive	Advanced Solid Tumor	predicted - sensitive	ZW25	Phase I	Actionable	In a Phase I trial, ZW25 treatment resulted in partial response in 14% (2/14) and stable disease in 21% (3/14) of patients with ERBB2 (HER2)-positive tumors, including breast, gastric, esophageal, colorectal, and adnexal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123).	detail...
ERBB2	ERBB2 positive	breast cancer	predicted - sensitive	MP0274	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MP0274 inhibited proliferation of Erbb2 (Her2)-positive breast cancer cells in culture and induced tumor regression in cell line xenograft models (Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-30).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in a median progression-free survival of 4.04 months, and a disease control rate of 75.49% (77/102; 20 partial responses) in heavily-treated Erbb2 (Her2)-positive breast cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 237O; NCT02418689).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Oxaliplatin + Trastuzumab	Preclinical	Actionable	In a preclinical study, the combination of Herceptin (trastuzumab) and Eloxatin (oxaliplatin) resulted in growth inhibition of ERBB2 (HER2)-positive breast cancer cells in culture (PMID: 24300914).	24300914
ERBB2	ERBB2 positive	breast cancer	sensitive	XMT-1522	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, XMT-1522 inhibited growth of Erbb2 (Her2)-positive breast cancer cells in culter, resulted in tumor regression in both cell line and patient-derived xenograft models (Cancer Res 2016;76(4 Suppl): Abstract nr P4-14-28).	detail...
ERBB2	ERBB2 positive	stomach cancer	predicted - sensitive	ZW25	Phase I	Actionable	In a Phase I trial, ZW25 treatment resulted in stable disease in 20% (1/5) of patients with ERBB2 (HER2)-positive gastric or esophageal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #255P; NCT02892123).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	MM-302	Phase I	Actionable	In a Phase I study, MM-302 demonstrated safety in patients with ERBB2 (HER2) positive breast cancer (Cancer Res 2012;72(24 Suppl):Abstract nr P5-18-09)	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Entinostat + Lapatinib + Trastuzumab	Phase I	Actionable	In a Phase I trial, combination treatment consisted of Entinostat, Tykerb (lapatinib) and Herceptin (trastuzumab) resulted in complete response in 9% (2/22), partial response in 14% (3/22), and stable disease in 27% (6/22) of ERBB2 (HER2) positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 609)).	detail...
ERBB2	ERBB2 positive	stomach carcinoma	sensitive	Tucatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tucatinib (ARRY-380) inhibited tumor growth in a ERBB2 (HER2)-positive gastric carcinoma cell line xenograft model (Cancer Res April 15, 2012 72:852).	detail...
ERBB2	ERBB2 positive	salivary gland cancer	sensitive	Trastuzumab	Guideline	Actionable	ERBB2 (HER2)-targeted therapy, including Herceptin (trastuzumab) is included in guidelines for patients with ERBB2 (HER2)-positive salivary gland tumors with distant metastases (NCCN.org).	detail...
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	CT-P6	Phase III	Actionable	In a Phase III trial, CT-P6 demonstrated equivalence to reference Herceptin (trastuzumab) in patients with ERBB2 (HER2)-positive breast cancer, with 46.8% (116/248) of patients treated with CT-P6 achieving pathologic complete response compared to 50.4% (129/256) with Herceptin (trastuzumab) treatment (PMID: 28592386).	28592386
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	predicted - sensitive	MGAH22	Phase I	Actionable	In a Phase I trial, Margetuximab (MGAH22) treatment resulted in tumor reduction in 78% (18/23) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 28119295).	28119295
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine + Docetaxel + Pertuzumab	Phase Ib/II	Actionable	In a Phase Ib/II trial, Kadcyla (trastuzumab emtansine), Taxotere (docetaxel) and Perjeta (pertuzumab) combination treatment resulted in pathologic complete response in 60.3% (44/73) of patients with ERBB2 (HER2)-positive locally advanced breast cancer (PMID: 27052654).	27052654
ERBB2	ERBB2 positive	esophageal cancer	predicted - sensitive	ZW25	Phase I	Actionable	In a Phase I trial, ZW25 treatment resulted in stable disease in 20% (1/5) of patients with ERBB2 (HER2)-positive gastric or esophageal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #255P; NCT02892123).	detail...
ERBB2	ERBB2 positive	stomach cancer	sensitive	Oxaliplatin + Trastuzumab	Preclinical	Actionable	In a preclinical study, the combination of Herceptin (trastuzumab) and Eloxatin (oxaliplatin) resulted in growth inhibition of ERBB2 (HER2)-positive gastric cancer cells in culture (PMID: 24300914).	24300914
ERBB2	ERBB2 positive	Her2-receptor positive breast cancer	sensitive	Sunitinib + Trastuzumab	Phase II	Actionable	In a Phase II trial, Sutent (sunitinib), in combination with Herceptin (trastuzumab), demonstrated safety and efficacy in ERBB2 (HER2) positive advanced breast cancer patients (PMID: 24606768).	24606768
ERBB2	ERBB2 positive	gastroesophageal junction adenocarcinoma	no benefit	MM-111 + Paclitaxel + Trastuzumab	Phase II	Actionable	In a Phase II trial, Taxol (paclitaxel) and Herceptin (trastuzumab) treatment in combination with MM-111 did not improve progression free survival (9.6 weeks) and median overall survival (32.1 weeks) compared to without MM-111 (23.3 weeks, 56.1 weeks) in ERBB2 positive gastroesophageal junction cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 4043)).	detail...
ERBB2	ERBB2 positive	salivary gland cancer	predicted - sensitive	DS-8201a	Phase I	Actionable	In a Phase I trial, treatment with DS-8201a resulted in a partial response in 50% (2/4) of evaluable patients with salivary gland cancer and ERBB2 (HER2) expression (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 409P; NCT02564900).	detail...
ERBB2	ERBB2 positive	stomach cancer	predicted - sensitive	MGAH22	Phase I	Actionable	In a Phase I trial, Margetuximab (MGAH22) treatment resulted in partial responses in 12% (7/60) and stable disease in 50% (30/60) of patients with ERBB2 (HER2)-positive breast or gastric cancer, or other carcinomas that overexpress Erbb2 (Her2) (PMID: 28119295).	28119295
ERBB2	ERBB2 positive	stomach cancer	sensitive	DS-8201a	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, DS-8201 inhibited growth of a ERBB2 (HER2)-positive gastric carcinoma cell line in culture and in xenograft models, and induced tumor regression in a patient-derived xenograft (PDX) model of ERBB2 (HER2)-positive gastric cancer (PMID: 27026201).	27026201
ERBB2	ERBB2 pos PIK3CA act mut	Her2-receptor positive breast cancer	sensitive	Palbociclib + Pictilisib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit survival of ERBB2 (HER2)-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).	27020857
ERBB2	ERBB2 pos PIK3CA act mut	uterine cancer	sensitive	Taselisib	Preclinical	Actionable	In a preclinical study, Taselisib (GDC-0032) inhibited growth of HER2 positive uterine cancer cell lines with PIK3CA mutations (PMID: 25172762).	25172762
ERBB2	ERBB2 pos PIK3CA act mut	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).	17936563
ERBB2	ERBB2 pos PIK3CA act mut	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation due to PTEN loss and/or PIK3CA activating mutation demonstrated a decreased median progression-free survival of 4.5 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).	21676217
ERBB2	ERBB2 pos PIK3CA act mut	Her2-receptor positive breast cancer	predicted - sensitive	Buparlisib + Trastuzumab	Phase I	Actionable	In a Phase I trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on trastuzumab-based therapy (PMID: 24470511).	24470511
ERBB2	ERBB2 pos PTEN loss	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Phase I	Actionable	In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PTEN loss demonstrated a decreased median progression-free survival of 6.0 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).	21676217
ERBB2	ERBB2 pos PTEN loss	Her2-receptor positive breast cancer	no benefit	Palbociclib + Pictilisib	Preclinical	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in ERBB2 (HER2)-positive breast cancer cell lines harboring PTEN loss in culture (PMID: 27020857).	27020857
ERBB2	EGFR pos ERBB2 pos	urinary bladder cancer	predicted - sensitive	Afatinib + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) pre-treatment inhibited radiotherapy-induced activation of EGFR and ERBB2 (HER2) and downstream AKT and radiosensitized bladder cancer cell lines in culture, and Gilotrif (afatinib) in combination with radiotherapy led to improved tumor growth inhibition in bladder cancer cell line xenograft models compared to radiotherapy alone (PMID: 25589492).	25589492
ERBB2	EGFR pos ERBB2 pos	colorectal cancer	sensitive	Afatinib	Preclinical	Actionable	In a preclinical study, colorectal cancer cells positive for EGFR and ERBB2 (HER2) had decreased growth upon Gilotrif (afatinib) treatment (PMID: 21617858).	21617858
ERBB2	EGFR pos ERBB2 pos	colon cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human colon cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).	24837299
ERBB2	EGFR pos ERBB2 pos	breast cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human breast cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).	24837299
ERBB2	EGFR pos ERBB2 pos	stomach cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited cell growth, decreased phosphorylation of Egfr and Erbb2, and resulted in anti-tumor activity of human gastric cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).	24837299
ERBB2	EGFR pos ERBB2 pos	lung cancer	sensitive	S-222611	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human lung cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).	24837299
ERBB2	ERBB2 pos PIK3CA E545K	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA E545K in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).	26920887
ERBB2	ERBB2 pos PIK3CA E545K	Her2-receptor positive breast cancer	predicted - sensitive	Neratinib	Phase III	Actionable	In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).	30867034
ERBB2	ERBB2 pos PTEN mut	Her2-receptor positive breast cancer	predicted - sensitive	Buparlisib + Trastuzumab	Phase I	Actionable	In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on Herceptin (trastuzumab)-based therapy (PMID: 24470511).	24470511
ERBB2	ERBB2 pos PTEN dec exp	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).	17936563
ERBB2	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study, a retrospective analysis of Herceptin (trastuzumab) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 28177460).	28177460
ERBB2	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	decreased response	Capecitabine + Lapatinib	Phase III	Actionable	In a Phase III trial, Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment resulted in decreased median progression free survival (4.3 vs. 6.4 months), median overall survival (17.3 vs. 27.8 months), and overall response rate(17.1% vs. 39.7%) in ERBB2 (HER2) positive breast cancer patients harboring PIK3CA mutations compared to PIK3CA wild type patients (PMID: 26920887).	26920887
ERBB2	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	sensitive	AT13148	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AT13148 inhibited tumor growth in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model harboring mutant PIK3CA (PMID: 22781553).	22781553
ERBB2	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	decreased response	Lapatinib + Trastuzumab	Phase II	Actionable	In a Phase II trial, ERBB2-positive breast cancer patients harboring PIK3CA mutations demonstrated lower pathologic complete remission rate (12.5%) compared to those with wild-type PIK3CA (48.4%) after Herceptin (trastuzumab) and Tykerb (lapatinib) combination therapy (PMID: 26245675).	26245675
ERBB2	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	decreased response	Lapatinib + Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study, a retrospective analysis of the combined treatment, Herceptin (trastuzumab) and Tykerb (lapatinib), in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 28177460).	28177460
ERBB2	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	decreased response	Lapatinib	Clinical Study - Cohort	Actionable	In a clinical study, a retrospective analysis of Tykerb (lapatinib) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 28177460).	28177460
ERBB2	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	predicted - sensitive	Neratinib	Phase III	Actionable	In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).	30867034
ERBB2	ERBB2 pos PIK3CA K111N	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).	26920887
ERBB2	ERBB2 pos PIK3CA I391M	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	Preclinical - Cell culture	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture (PMID: 26920887).	26920887
ERBB2	ERBB2 pos PIK3CA C420R	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	Preclinical - Cell culture	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA C420R in culture (PMID: 26920887).	26920887
ERBB2	ERBB2 pos PIK3CA H1047R	Her2-receptor positive breast cancer	predicted - sensitive	Neratinib	Phase III	Actionable	In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).	30867034
ERBB2	ERBB2 pos PIK3CA H1047R	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA H1047R in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).	26920887
ERBB2	ERBB2 pos PIK3CA amp	Her2-receptor positive breast cancer	predicted - sensitive	Neratinib	Phase III	Actionable	In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).	30867034
ERBB2	ERBB2 pos PIK3CA E542K	Her2-receptor positive breast cancer	predicted - sensitive	Neratinib	Phase III	Actionable	In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).	30867034
ERBB2	ERBB2 pos PIK3CA E545D	Her2-receptor positive breast cancer	predicted - sensitive	Neratinib	Phase III	Actionable	In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).	30867034
ERBB2	ERBB2 S310Y	colorectal cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).	26243863
ERBB2	ERBB2 S310Y	lung squamous cell carcinoma	predicted - sensitive	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, Gilotrif (afatinib) treatment resulted in stable disease over 8-months in a patient with advanced squamous cell lung carcinoma harboring ERBB2 (HER2) S310Y (PMID: 30584328).	30584328
ERBB2	ERBB2 S310Y	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y were resistant to Erbitux (cetuximab) (PMID: 26243863).	26243863
ERBB2	ERBB2 S310Y	colorectal cancer	sensitive	Neratinib + Trastuzumab	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).	26243863
ERBB2	ERBB2 S310Y	colorectal cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).	26243863
ERBB2	ERBB2 S310Y	cervical cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 0.5 month in a patient with cervical cancer harboring ERBB2 (HER2) S310Y (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 S310Y	gastroesophageal junction adenocarcinoma	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 0.8 month in a patient with gastroesophageal cancer harboring ERBB2 (HER2) S310Y (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 S310Y	endometrial cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 9.6 months in a patient with endometrial cancer harboring ERBB2 (HER2) S310Y (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 S310Y	urinary bladder cancer	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 2 patients and progressive disease in 2 patients with bladder cancer harboring ERBB2 (HER2) S310Y (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 S310Y	colorectal cancer	sensitive	Lapatinib + Trastuzumab	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) and Tykerb (lapatinib) combination treatment resulted in tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).	26243863
ERBB2	ERBB2 S310Y	colorectal cancer	sensitive	Trastuzumab	Preclinical	Actionable	In a preclinical study, Herceptin (trastuzumab) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).	26243863
ERBB2	ERBB2 M774delinsWLV	lung adenocarcinoma	sensitive	Dacomitinib	Phase II	Actionable	In a Phase II trial, a lung adenocarcinoma patient harboring ERBB2 (HER2) M774delinsWLV demonstrated a partial response to treatment with Vizimpro (dacomitinib) (PMID: 25899785; NCT00818441).	25899785
ERBB2	ERBB2 M774delinsWLV	Advanced Solid Tumor	sensitive	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vizimpro (dacomitinib) inhibited growth of transformed cells expressing ERBB2 (HER2) M774delinsWLV in culture (PMID: 28363995).	28363995
ERBB2	ERBB2 M774delinsWLV ERBB2 C805S	Advanced Solid Tumor	resistant	Neratinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing ERBB2 (HER2) M774delinsWLV and ERBB2 (HER2) C805S demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 28363995).	28363995
ERBB2	ERBB2 M774delinsWLV ERBB2 C805S	Advanced Solid Tumor	resistant	Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, acquisition of ERBB2 (HER2) C805S in transformed cells expressing ERBB2 (HER2) M774delinsWLV conferred resistance to Vizimpro (dacomitinib) in culture (PMID: 28363995).	28363995
ERBB2	ERBB2 M774delinsWLV ERBB2 C805S	Advanced Solid Tumor	resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing ERBB2 (HER2) M774delinsWLV and ERBB2 (HER2) C805S demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).	28363995
ERBB2	ERBB2 G776V	Advanced Solid Tumor	sensitive	AP32788	Preclinical - Cell culture	Actionable	In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing ERBB2 (HER2) G776V in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).	detail...
ERBB2	ERBB2 L755A	lung non-small cell carcinoma	no benefit	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.6 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) L755A (PMID: 29420467; NCT01953926).	29420467
ERBB2	ERBB2 G292R	urinary bladder cancer	predicted - resistant	Neratinib	Phase II	Actionable	In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with bladder cancer harboring both ERBB2 (HER2) G292R (PMID: 29420467; NCT01953926).	29420467
ERBB4	ERBB4 G1109C	head and neck squamous cell carcinoma	sensitive	Afatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gilotrif (afatinib) treatment induced apoptosis in head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C in culture and inhibited tumor growth in cell line xenograft models (PMID: 27207775).	27207775
ERBB4	ERBB4 G1109C	head and neck squamous cell carcinoma	no benefit	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C were insensitive to treatment with Erbitux (cetuximab) in culture (PMID: 27207775).	27207775
ERBB4	ERBB4 G1109C	head and neck squamous cell carcinoma	no benefit	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C were insensitive to treatment with Tarceva (erlotinib) in culture (PMID: 27207775).	27207775
ERBB4	ERBB4 E563K	melanoma	sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival and induced apoptosis in melanoma cells harboring ERBB4 E563K in culture (PMID: 19718025).	19718025
ERBB4	ERBB4 R393W	melanoma	sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival of melanoma cells harboring ERBB4 R393W in culture (PMID: 19718025).	19718025
ERBB4	ERBB4 R544W	melanoma	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) induced apoptosis in melanoma cells harboring ERBB4 R544W in culture (PMID: 19718025).	19718025
ERBB4	ERBB4 mutant	lung squamous cell carcinoma	predicted - sensitive	Afatinib	Phase III	Actionable	In a Phase III trial (LUX-Lung 8), secondary analysis demonstrated favorable outcomes with Gilotrif (afatinib) treatment compared to Tarceva (erlotinib) in lung squamous cell carcinoma patients with ERBB (HER) family mutations, and ERBB4 (HER4) mutations predicted an OS (HR=0.22) and PFS (HR=0.21) benefit for Gilotrif (afatinib) over Tarceva (erlotinib) treatment (PMID: 29902295; NCT01523587).	29902295
ERBB4	ERBB4 E452K	melanoma	sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited growth and induced apoptosis in melanoma cells harboring ERBB4 E452K in culture (PMID: 19718025).	19718025
ERBB4	ERBB4 E317K	melanoma	sensitive	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited growth and induced apoptosis in melanoma cells harboring ERBB4 E317K in culture (PMID: 19718025).	19718025
ETV6	ETV6-RUNX1	acute lymphocytic leukemia	not applicable	N/A	Clinical Study	Diagnostic	ETV6-RUNX1 is used in the diagnosis of acute lymphocytic leukemia (PMID: 26711002, PMID: 15704129, PMID: 8609706, Guidelines).	15704129 8609706 detail... 26711002
ETV6	ETV6-RUNX1	acute lymphocytic leukemia	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, the ETV6-RUNX1 fusion was associated with a favorable prognosis in acute lymphocytic leukemia patients (PMID: 8609706, PMID: 10086740, PMID: 11432885, Guidelines).	11432885 detail... 8609706 10086740
ETV6	ETV6-JAK2 JAK2 N909K	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the N909K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
ETV6	ETV6-JAK2 JAK2 R975G	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the R975G mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
ETV6	ETV6-JAK2 JAK2 V881A	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the V881A mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
ETV6	ETV6 - JAK2 JAK2 G831R	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the G831R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
ETV6	ETV6 - JAK2 JAK2 E864K	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the E864K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
ETV6	ETV6 - JAK2 JAK2 G935R	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the G935R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
ETV6	ETV6 - JAK2 JAK2 M929I	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the M929I mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
ETV6	ETV6 - JAK2 JAK2 P1057S	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the P1057S mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
ETV6	ETV6 - JAK2 JAK2 R1127K	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the R1127K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
ETV6	ETV6 - JAK2 JAK2 Y918H	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the Y918H mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
ETV6	ETV6-JAK2	hematologic cancer	sensitive	NS-018	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing ETV6-JAK2 were sensitive to treatment with NS-108, demonstrating inhibition of cell growth in culture (PMID: 22829185).	22829185
ETV6	ETV6 inact mut	acute lymphocytic leukemia	not applicable	N/A	Clinical Study	Risk Factor	In multiple clinical studies, ETV6 inactivating germline mutations were shown to be a risk factor for the development of acute lymphocytic leukemia (PMID: 26522332, PMID: 26102509, PMID: 25807284).	25807284 26102509 26522332
ETV6	ETV6-ABL1	chronic myeloid leukemia	predicted - resistant	Imatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with chronic myeloid leukemia harboring ETV6-ABL1 achieved a complete hematological response after 4 weeks of Gleevec (imatinib mesylate) treatment, but the disease progressed at 6 months (PMID: 24053143).	24053143
ETV6	ETV6-ABL1	chronic myeloid leukemia	predicted - sensitive	Nilotinib	Case Reports/Case Series	Actionable	In a clinical case study, Tasigna (nilotinib) treatment resulted in a complete hematological response after 4 weeks of treatment and sustained complete cytogenetic response and major molecular response at 22 months from diagnosis in a patient with chronic myeloid leukemia harboring ETV6-ABL1, whose disease progressed while on Gleevec (imatinib mesylate) at 6 months from diagnosis (PMID: 24053143).	24053143
ETV6	ETV6-FGFR1	Advanced Solid Tumor	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with AZD4547 decreased Myc expression and inhibited growth of transformed cells expressing ETV6-FGFR1 (TEL-FGFR1) in culture (PMID: 27401245).	27401245
ETV6	ETV6-FGFR4	Advanced Solid Tumor	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with AZD4547 decreased Myc expression and inhibited growth of transformed cells expressing ETV6-FGFR4 (TEL-FGFR4) in culture (PMID: 27401245).	27401245
ETV6	ETV6-SYK	Advanced Solid Tumor	sensitive	HMPL-523	Preclinical - Cell culture	Actionable	In a preclinical study, HMPL-523 decreased viability of cells expressing ETV6-SYK in culture (Blood Dec 2016, 128 (22) 3970).	detail...
ETV6	ETV6-NTRK2	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ETV6-NTRK2 were sensitive to Rozlytrek (entrectinib) as demonstrated by reduced proliferation relative to cells expressing an empty vector in culture (PMID: 26884591).	26884591
ETV6	ETV6-NTRK2	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ETV6-NTRK2 were sensitive to Rozlytrek (entrectinib), resulting in inhibition of cell proliferation in culture (PMID: 26939704).	26939704
ETV6	ETV6-NTRK2	Advanced Solid Tumor	sensitive	Repotrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Repotrectinib (TPX-0005) inhibited proliferation of transformed cells expressing ETV6-NTRK2 in culture (PMID: 30093503).	30093503
ETV6	ETV6-NTRK2	acute myeloid leukemia	sensitive	Larotrectinib	Case Reports/Case Series	Actionable	In a clinical study, a patient with secondary AML achieved a partial remission when treated with Vitrakvi (larotrectinib), showing complete elimination of the cell population harboring ETV6-NTRK2, and the patient-derived xenograft (PDX) model harboring ETV6-NTRK2 showed sensitivity to treatment with Vitrakvi (larotrectinib), demonstrating a decrease in ETV6-NTRK2-expressing cells (PMID: 29920189).	29920189
ETV6	ETV6-NTRK1	Advanced Solid Tumor	predicted - sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ETV6-NTRK1 were sensitive to Rozlytrek (entrectinib) as demonstrated by reduced proliferation relative to cells expressing an empty vector in culture (PMID: 26884591).	26884591
ETV6	ETV6-NTRK3	salivary gland cancer	predicted - sensitive	Entrectinib	Case Reports/Case Series	Actionable	In a clinical case study, treatment with Rozlytrek (entrectinib) obtained through a Phase I trial resulted in a durable partial response in a patient with mammary analogue secretory carcinoma of the salivary gland harboring ETV6-NTRK3 (PMID: 26884591; NCT02097810).	26884591
ETV6	ETV6-NTRK3	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ETV6-NTRK3 were sensitive to Rozlytrek (entrectinib), resulting in inhibition of cell proliferation in culture (PMID: 26939704).	26939704
ETV6	ETV6-NTRK3	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ETV6-NTRK3 were sensitive to Rozlytrek (entrectinib) as demonstrated by reduced proliferation relative to cells expressing an empty vector in culture (PMID: 26884591).	26884591
ETV6	ETV6-NTRK3	small intestine neuroendocrine neoplasm	predicted - sensitive	Entrectinib	Case Reports/Case Series	Actionable	In a clinical study, Rozlytrek (entrectinib) treatment resulted in rapid response and tumor necrosis in a patient with a small intestine neuroendocrine tumor harboring a ETV6-NTRK3 fusion (PMID: 29118225; NCT02568267).	29118225
ETV6	ETV6-NTRK3	melanoma	sensitive	DS-6051a	Preclinical - Cell culture	Actionable	In a preclinical study, DS-6051a inhibited MAPK, PI3K, and PLCgamma-1 signaling in transformed melanocytes expressing ETV6-NTRK3 in culture (PMID: 27477320).	27477320
ETV6	ETV6-NTRK3	Advanced Solid Tumor	sensitive	Lestaurtinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing the fusion, ETV6-NTRK3, were treated with Lestaurtinib (CEP-701), which resulted in inhibition of ETV6-NTRK3 autophosphorylation and restoration of Tgf-b1 signaling (PMID: 16258068).	16258068
ETV6	ETV6-NTRK3	Advanced Solid Tumor	sensitive	BMS-536924	Preclinical	Actionable	In a preclinical study, transformed human cells expressing ETV6-NTRK3 were sensitive to BMS-536924, demonstrating a reduction in both cell survival and transformation activity in culture (PMID: 21804605).	21804605
ETV6	ETV6-NTRK3	fibrosarcoma	predicted - sensitive	Entrectinib	Phase I	Actionable	In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in an objective response in a pediatric patient with infantile fibrosarcoma harboring ETV6-NTRK3 fusion (J Clin Oncol 36, 2018 (suppl; abstr 10536); NCT02650401).	detail...
ETV6	ETV6-NTRK3	gastrointestinal stromal tumor	predicted - sensitive	Larotrectinib	Phase I	Actionable	In a Phase I trial, Vitrakvi (larotrectinib) treatment resulted in complete response in 1 and partial response in 2 patients with gastrointestinal stromal tumor harboring ETV6-NTRK3 fusions (PMID: 29466156, Annals of Oncology, Volume 29, Issue suppl_5; NCT02122913, NCT02637687, and NCT02576431).	29466156 detail...
ETV6	ETV6-NTRK3	Advanced Solid Tumor	sensitive	Larotrectinib	Phase II	Actionable	In a combined analysis of three trials, Vitrakvi (larotrectinib) treatment resulted in complete response in 21.4% (6/28) and partial response in 67.9% (19/28) of patients with advanced solid tumors harboring an ETV6-NTRK3 fusion (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).	29466156
ETV6	ETV6-NTRK3	congenital fibrosarcoma	not applicable	N/A	Guideline	Diagnostic	ETV6-NTRK3 fusions aid the diagnosis of congenital fibrosarcoma (NCCN.org).	detail...
ETV6	ETV6-NTRK3	breast cancer	sensitive	BMS-754807	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BMS-754807 inhibited tumor growth in cell line xenograft models of breast cancer cells overexpressing ETV6-NTRK3 (PMID: 21148487).	21148487
ETV6	ETV6-NTRK3	acute myeloid leukemia	sensitive	Crizotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited ETV6-NTRK3 activity, reduced cell growth in a human acute myeloid leukemia cell line harboring ETV6-NTRK3, and had anti-tumor activity in xenograft models (PMID: 23811600).	23811600
ETV6	ETV6-NTRK3	pancreatic cancer	predicted - sensitive	PLX7486	Case Reports/Case Series	Actionable	In a clinical case study, a patient with pancreatic cancer harboring ETV6-NTRK3 demonstrated a prolonged response when treated with PLX7486 (PMID: 31406350).	31406350
ETV6	ETV6-NTRK3	salivary gland cancer	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, Xalkori (crizotinib) treatment resulted in a brief stable disease in a patient with mammary analogue secretory carcinoma of the salivary gland harboring ETV6-NTRK3, before disease progression at 18 weeks (PMID: 26884591).	26884591
ETV6	ETV6-NTRK3	cancer	sensitive	Midostaurin	Preclinical	Actionable	In a preclinical study, the broad spectrum kinase inhibitor midostaurin inhibited growth of cells dependent on the fusion protein ETV6-NTRK3, reducing ETV6-NTRK3 kinase activity and downstream signaling and inducing apoptosis (PMID: 23131561).	23131561
ETV6	ETV6-NTRK3	acute myeloid leukemia	sensitive	Larotrectinib	Preclinical	Actionable	In a preclinical study, Vitrakvi (larotrectinib) inhibited cell growth and downstream signaling in acute myeloid leukemia cells harboring ETV6-NTRK3 in culture and xenografts (PMID: 26216294).	26216294
ETV6	ETV6-NTRK3	acute myeloid leukemia	sensitive	CH7057288	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH7057288 inhibited NTRK phosphorylation and downstream signaling and reduced growth of acute myeloid leukemia cells harboring ETV6-NTRK3 in culture, and induced tumor regression in xenograft models (PMID: 30242093).	30242093
ETV6	ETV6-NTRK3	head and neck squamous cell carcinoma	sensitive	Merestinib	Preclinical - Pdx	Actionable	In a preclinical study, a head and neck squamous cell carcinoma patient-derived xenograft (PDX) model harboring ETV6-NTRK3 was sensitive to treatment with Merestinib (LY2801653) compared to vehicle, demonstrating decreased tumor growth (PMID: 29568395).	29568395
ETV6	ETV6-NTRK3	congenital fibrosarcoma	sensitive	Larotrectinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with congenital fibrosarcoma harboring ETV6-NTRK3 demonstrated tumor regression by 90% when treated with Vitrakvi (larotrectinib) (PMID: 28578312).	28578312
ETV6	ETV6-NTRK3	congenital fibrosarcoma	sensitive	Larotrectinib	Phase Ib/II	Actionable	In a Phase I/II trial, Vitrakvi (larotrectinib) treatment resulted in complete response in 33.3% (2/6) and partial response in 66.7% (4/6) of pediatric patients with congenital fibrosarcoma harboring ETV6-NTRK3 fusions (PMID: 29606586; NCT02637687).	29606586
ETV6	ETV6-NTRK3	congenital fibrosarcoma	sensitive	Larotrectinib	Phase I	Actionable	In a Phase I clinical trial, treatment with Vitrakvi (larotrectinib) resulted in a partial response in a pediatric patient with infantile fibrosarcoma harboring ETV6-NTRK3 (PMID: 27093299).	27093299
ETV6	ETV6-NTRK3	Advanced Solid Tumor	sensitive	Repotrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Repotrectinib (TPX-0005) inhibited proliferation of transformed cells expressing ETV6-NTRK3 in culture (PMID: 30093503).	30093503
ETV6	ETV6-NTRK3	Advanced Solid Tumor	sensitive	Altiratinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing ETV6-NTRK3 demonstrated sensitivity to Altiratinib (DCC-2701) in culture, resulting in inhibition of Ntrk3 phosphorylation and decreased cell proliferation (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 790).	detail...
ETV6	ETV6-NTRK3 MAP2K1 P124S	pancreatic cancer	predicted - resistant	LOXO-195	Case Reports/Case Series	Actionable	In a clinical case study, a secondary resistance mutation, MAP2K1 P124S, was identified via cell-free DNA testing after a patient with pancreatic cancer harboring ETV6-NTRK3 progressed on LOXO-195 treatment (PMID: 31406350).	31406350
ETV6	ETV6-ROS1	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells expressing ETV6-ROS1 were sensitive to Rozlytrek (entrectinib), resulting in inhibition of cell proliferation in culture and decreased tumor growth in xenograft models (PMID: 26939704).	26939704
ETV6	ETV6-ALK	Advanced Solid Tumor	sensitive	Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ETV6-ALK demonstrated sensitivity to Rozlytrek (entrectinib) in culture (PMID: 26939704).	26939704
ETV6	ETV6-JAK3	hematologic cancer	predicted - resistant	NS-018	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing ETV6-JAK3 were insensitive to treatment with NS-108 in culture (PMID: 22829185).	22829185
ETV6	ETV6-PDGFRA	chronic leukemia	predicted - sensitive	Imatinib	Case Reports/Case Series	Actionable	In a clinical case report, a patient with ETV6-PDGFRA positive chronic eosinophilic leukemia experienced complete cytogenic remission after treatment with Gleevec (imatinib) (PMID: 17555450).	17555450
ETV6	ETV6-FGFR3	Advanced Solid Tumor	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with AZD4547 decreased Myc expression and inhibited growth of transformed cells expressing ETV6-FGFR3 (TEL-FGFR3) in culture (PMID: 27401245).	27401245
ETV6	ETV6 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	ETV6 mutations are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
ETV6	ETV6 mutant	myelodysplastic syndrome	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, ETV6 mutations were associated with a shorter overall survival in patients with myelodysplastic syndrome (PMID: 21714648, PMID: 21877899, PMID: 26769228).	21877899 26769228 21714648
EZH2	EZH2 F120L EZH2 Y111N	Advanced Solid Tumor	resistant	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, a cancer cell line co-expressing EZH2 F120L and EZH2 Y111N was resistant to Tazemetostat (EPZ-6438) in culture, demonstrating no inhibition of cell proliferation (PMID: 28135235).	28135235
EZH2	EZH2 F120L EZH2 Y111N	diffuse large B-cell lymphoma	resistant	EI1	Preclinical - Cell culture	Actionable	In a preclinical study, diffuse large B-cell lymphoma cells co-expressing EZH2 F120L and EZH2 Y111N were resistant to EI1 in culture, demonstrating no inhibition of cell proliferation (PMID: 28135235).	28135235
EZH2	EZH2 F120L EZH2 Y111N	diffuse large B-cell lymphoma	sensitive	EED226	Preclinical - Cell culture	Actionable	In a preclinical study, diffuse large B-cell lymphoma cells co-expressing EZH2 F120L and EZH2 Y111N were sensitive to EED226, demonstrating inhibition of cell proliferation in culture (PMID: 28135235).	28135235
EZH2	EZH2 over exp	medulloblastoma	predicted - sensitive	MC3629	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MC3629 decreased proliferation and induced apoptosis in human and mouse primary SHH-subgroup medulloblastoma (SHH-MB) derived stem-cell like cells expressing high EZH2 levels in culture, decreased viability of a human SHH-MB cell line expressing high EZH2 in culture, and increased apoptosis and decreased growth of human SHH-MB cell line derived stem-cell like cells in culture and in xenograft models (PMID: 28978137).	28978137
EZH2	EZH2 over exp	lung non-small cell carcinoma	sensitive	JQEZ5	Preclinical	Actionable	In a preclinical study, JQEZ5 inhibited proliferation of human EZH2-overexpressing non-small cell lung cancer cells in culture and induced tumor regression in mouse models of EZH2-overexpressing lung adenocarcinoma (PMID: 27312177).	27312177
EZH2	EZH2 Y641N	diffuse large B-cell lymphoma	predicted - sensitive	DZNeP	Preclinical - Cell culture	Actionable	In a preclinical study, DZNeP treatment resulted in an increase in the number of dead or sub-G1 cells and increased DNA damage in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N in culture (PMID: 25605023).	25605023
EZH2	EZH2 Y641N	diffuse large B-cell lymphoma	no benefit	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 alone did not alter cell-cycle progression in survival in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N in culture (PMID: 25605023).	25605023
EZH2	EZH2 Y641N	diffuse large B-cell lymphoma	sensitive	Vorinostat	Preclinical	Actionable	In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023).	25605023
EZH2	EZH2 Y641N	melanoma	predicted - sensitive	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 inhibited H3K27 trimethylation and reversed transcriptional silencing in human melanoma cells harboring EZH2 Y641N in culture (PMID: 26936398).	26936398
EZH2	EZH2 Y641N	diffuse large B-cell lymphoma	sensitive	ACY-957 + GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641N in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023).	25605023
EZH2	EZH2 Y641N	diffuse large B-cell lymphoma	sensitive	ACY-957	Preclinical	Actionable	In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated sensitivity to ACY-957 in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023).	25605023
EZH2	EZH2 Y641N	diffuse large B-cell lymphoma	sensitive	ACY-957 + DZNeP	Preclinical	Actionable	In a preclinical study, DZNeP enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641N in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023).	25605023
EZH2	EZH2 Y641N	diffuse large B-cell lymphoma	sensitive	EED226	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture and delayed tumor growth and tumor regression in a cell line xenograft model (PMID: 28135235).	28135235
EZH2	EZH2 Y641N	diffuse large B-cell lymphoma	sensitive	UNC1999	Preclinical	Actionable	In a preclinical study, UNC1999 treatment reduced H3K27me3 levels, decreased proliferation, and increased cell death in diffuse large B-cell lymphoma cells harboring an EZH2 Y641N mutation in cell culture (PMID: 23614352).	23614352
EZH2	EZH2 Y641N	diffuse large B-cell lymphoma	sensitive	ACY-957 + Doxorubicin	Preclinical	Actionable	In a preclinical study, DLBCL cells harboring EZH2 Y641N treated with the combination of ACY-957 and Adriamycin (doxorubicin) resulted in a greater sensitivity to cell death compared to treatment with either agent alone (PMID: 25605023).	25605023
EZH2	EZH2 Y641N	diffuse large B-cell lymphoma	sensitive	EED226 + EI1	Preclinical - Cell culture	Actionable	In a preclinical study, EED226 and EI1 synergistically inhibited cell proliferation in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N in culture (PMID: 28135235).	28135235
EZH2	EZH2 Y641F	lymphoma	sensitive	EPZ005687	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with EPZ005687 decreased proliferation and induced cell killing in a lymphoma cell line harboring EZH2 Y641F in culture (PMID: 23023262).	23023262
EZH2	EZH2 Y111D EZH2 Y641F	Advanced Solid Tumor	predicted - resistant	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing EZH2 and carrying simultaneous Y641F and Y111D mutations demonstrated reduced sensitivity to GSK126 in culture (PMID: 26360609).	26360609
EZH2	EZH2 Y111D EZH2 Y641F	Advanced Solid Tumor	decreased response	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing EZH2 carrying simultaneous Y641F and Y111D mutations demonstrated reduced sensitivity to Tazemetostat (EPZ-6438) in culture (PMID: 26360609).	26360609
EZH2	EZH2 mutant	myelofibrosis	not applicable	N/A	Guideline	Prognostic	EZH2 mutations are associated with inferior overall survival in patients with myelofibrosis (NCCN.org).	detail...
EZH2	EZH2 mutant	myelodysplastic/myeloproliferative neoplasm	not applicable	N/A	Guideline	Prognostic	EZH2 mutations are associated with a poor prognosis in patients with myelodysplastic/myeloproliferative neoplasm (NCCN.org).	detail...
EZH2	EZH2 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	EZH2 mutations are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
EZH2	EZH2 mutant	diffuse large B-cell lymphoma	sensitive	A-395	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a diffuse large B-cell lymphoma cell line harboring an EZH2 mutation demonstrated sensitivity to A-395, showing inhibition of tumor growth, however, due to its chemical properties A-395 will not proceed to clinical development (PMID: 28135237).	28135237
EZH2	EZH2 mutant	essential thrombocythemia	not applicable	N/A	Guideline	Prognostic	The presence of at least one mutation in either SH2B3, IDH2, U2AF1, SF3B1, EZH2, or TP53 is associated with inferior overall survival in patients with essential thrombocythemia (NCCN.org).	detail...
EZH2	EZH2 Y111D	Advanced Solid Tumor	resistant	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, over expression of EZH2 Y111D in transformed cells harboring wild-type Ezh2 resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609).	26360609
EZH2	EZH2 Y111D	Advanced Solid Tumor	resistant	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, over expression of EZH2 Y111D in transformed cells harboring wild-type Ezh2 resulted in resistance to GSK126 treatment in culture (PMID: 26360609).	26360609
EZH2	EZH2 A677G EZH2 Y111D	Advanced Solid Tumor	resistant	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing EZH2 and carrying simultaneous A677G and Y111D mutations were resistant to GSK126 in culture (PMID: 26360609).	26360609
EZH2	EZH2 A677G EZH2 Y111D	B-cell lymphoma	resistant	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, EZH2 Y111D conferred resistance to Tazemetostat (EPZ-6438) when occurring in the same allele as EZH2 A677G in B-cell lymphoma cells in culture (PMID: 26360609).	26360609
EZH2	EZH2 A677G EZH2 Y111D	Advanced Solid Tumor	resistant	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing EZH2 and carrying simultaneous A677G and Y111D mutations were resistant to Tazemetostat (EPZ-6438) in culture (PMID: 26360609).	26360609
EZH2	EZH2 A677G EZH2 Y111D	B-cell lymphoma	resistant	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, EZH2 Y111D conferred resistance to GSK126 when occurred in the same allele as EZH2 A677G in B-cell lymphoma cells in culture (PMID: 26360609).	26360609
EZH2	EZH2 Y111D SMARCB1 inact mut	rhabdoid cancer	resistant	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, over expression of EZH2 Y111D in rhabdoid tumor cells harboring an SMARCB1 inactivating mutation resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609).	26360609
EZH2	EZH2 Y646H	non-Hodgkin lymphoma	sensitive	Tazemetostat	Phase I	Actionable	In a Phase I trial, Tazemetostat (EPZ-6438) treatment resulted in partial response for more than 16 weeks in a non-Hodgkin lymphoma patient harboring a EZH2 Y646H mutation (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract #473; NCT01897571).	detail...
EZH2	EZH2 Y641S	diffuse large B-cell lymphoma	decreased response	DZNeP	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with DZNeP resulted in a slight increase in number of dead or sub-G1 cells and accumulation of DNA damage in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641S in culture (PMID: 25605023).	25605023
EZH2	EZH2 Y641S	diffuse large B-cell lymphoma	sensitive	Vorinostat	Preclinical	Actionable	In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023).	25605023
EZH2	EZH2 Y641S	melanoma	predicted - sensitive	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 reversed transcriptional silencing in human melanoma cells harboring wild-type EZH2 Y641S in culture (PMID: 26936398).	26936398
EZH2	EZH2 Y641S	diffuse large B-cell lymphoma	decreased response	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with GSK126 did not alter cell-cycle progression or decrease survival in a diffuse large B-cell lymphoma cell line harboring EZH2 Y641S in culture (PMID: 25605023).	25605023
EZH2	EZH2 Y641S	diffuse large B-cell lymphoma	sensitive	ACY-957 + DZNeP	Preclinical	Actionable	In a preclinical study, DZNeP enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641S in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023).	25605023
EZH2	EZH2 Y641S	diffuse large B-cell lymphoma	sensitive	ACY-957 + GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641S in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023).	25605023
EZH2	EZH2 Y641S	diffuse large B-cell lymphoma	sensitive	ACY-957	Preclinical	Actionable	In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated sensitivity to ACY-957 in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023).	25605023
EZH2	EZH2 Y646F	diffuse large B-cell lymphoma	sensitive	EED226	Preclinical - Cell culture	Actionable	In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646F demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235).	28135235
EZH2	EZH2 Y646F	lymphoma	sensitive	Tazemetostat	Preclinical	Actionable	In a preclinical study, treatment with EPZ-6438 inhibited proliferation and promoted cell death in lymphoma cells expressing EZH2 Y646F (PMID: 24563539).	24563539
EZH2	EZH2 Y646N	diffuse large B-cell lymphoma	sensitive	EED226	Preclinical - Cell culture	Actionable	In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646N demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235).	28135235
EZH2	EZH2 Y646N	melanoma	sensitive	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 treatment inhibited cell growth via suppression of downstream tumor suppressor gene targets and induced apoptosis in melanoma cells harboring EZH2 Y646N in culture (PMID: 26304929).	26304929
EZH2	EZH2 Y641H	melanoma	predicted - sensitive	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 inhibited H3K27 trimethylation and reversed transcriptional silencing in human melanoma cells harboring EZH2 Y641H in culture (PMID: 26936398).	26936398
EZH2	EZH2 positive	non-Hodgkin lymphoma	predicted - sensitive	Tazemetostat	Phase I	Actionable	In a Phase I trial, Tazemetostat (EPZ-6438) treatment resulted in a total response rate of 60% (9/15) in non-Hodgkin lymphoma patients harboring wild-type EZH2 (n=13/14 tested) or an EZH2 Y646H mutation (n=1/14 tested) (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract #473; NCT01897571).	detail...
EZH2	EZH2 positive	follicular lymphoma	predicted - sensitive	Tazemetostat	Phase I	Actionable	In a Phase I trial, Tazemetostat (EPZ-6438) treatment in non-Hodgkin lymphoma (NHL) patients carrying wild-type EZH2 or an EZH2 Y646H mutation resulted in an objective response rate of 60% (3/5) among patients with follicular lymphoma (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract #473; NCT01897571).	detail...
EZH2	EZH2 positive	diffuse large B-cell lymphoma	predicted - sensitive	Tazemetostat	Phase I	Actionable	In a Phase I trial, Tazemetostat (EPZ-6438) treatment in non-Hodgkin lymphoma (NHL) patients carrying wild-type EZH2 or an EZH2 Y646H mutation resulted in an objective response rate of 56% (5/9) among patients with diffuse large B-cell lymphoma (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract #473; NCT01897571).	detail...
EZH2	EZH2 wild-type	melanoma	predicted - sensitive	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, GSK126 inhibited H3K27 trimethylation in human melanoma cells harboring wild-type EZH2 in culture (PMID: 26936398).	26936398
EZH2	EZH2 Y646S	diffuse large B-cell lymphoma	sensitive	EED226	Preclinical - Cell culture	Actionable	In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646S demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235).	28135235
EZH2	EZH2 T678_R679delinsKK	acute myeloid leukemia	resistant	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, a murine acute myeloid leukemia cell line expressing EZH2 T678_R679delinsKK were resistant to Tazemetostat (EPZ-6438) in culture (PMID: 28231254).	28231254
FBXW7	FBXW7 R465C	T-cell adult acute lymphocytic leukemia	resistant	MRK-003	Preclinical	Actionable	In a preclinical study, FBXW7 R465C conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).	17646409
FBXW7	FBXW7 R465H	T-cell adult acute lymphocytic leukemia	resistant	MRK-003	Preclinical	Actionable	In a preclinical study, FBXW7 R465H conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).	17646409
FBXW7	FBXW7 R465H	lung adenocarcinoma	sensitive	Temsirolimus	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring FBXW7 R465H demonstrated tumor shrinkage when treated with Torisel (temsirolimus) (PMID: 24360397).	24360397
FBXW7	FBXW7 R505C	head and neck squamous cell carcinoma	sensitive	Vorinostat	Preclinical	Actionable	In a preclinical study, Zolinza (vorinostat) inhibited growth of a head and neck squamous cell carcinoma cell line harboring FBXW7 R505C in culture (PMID: 23274910).	23274910
FBXW7	FBXW7 R505C	colorectal cancer	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cell lines with FBXW7 R505C demonstrated acquired resistance in regorafenib (PMID: 27399335).	27399335
FBXW7	FBXW7 R505C	T-cell adult acute lymphocytic leukemia	resistant	MRK-003	Preclinical	Actionable	In a preclinical study, FBXW7 R505C conferred resistance to gamma secretase inhibitor, MRK-300, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).	17646409
FBXW7	FBXW7 loss	colon cancer	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, Rapamune (sirolimus) inhibited epithelial-mesenchymal transition, motility, and invasiveness in colon cancer cells lacking FBXW7 in culture (PMID: 23558291)	23558291
FBXW7	FBXW7 E192A	fibrolamellar carcinoma	predicted - sensitive	Sirolimus	Phase I	Actionable	In a Phase I study, Rapamune (sirolimus) resulted in prolonged stable disease in a patient with hepatocellular fibrolamellar carcinoma harboring FBXW7 E192A (PMID: 24586741).	24586741
FBXW7	FBXW7 R479Q	T-cell adult acute lymphocytic leukemia	resistant	MRK-003	Preclinical	Actionable	In a preclinical study, FBXW7 R479Q conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).	17646409
FBXW7	FBXW7 mutant	Her2-receptor negative breast cancer	predicted - sensitive	LY3039478	Phase I	Actionable	In a Phase I trial, LY3039478 treatment resulted in partial response lasted 9.5 months in a patient with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring FBXW7 mutation (PMID: 30060061; NCT01695005).	30060061
FBXW7	FBXW7 del	T-cell adult acute lymphocytic leukemia	resistant	MRK-003	Preclinical	Actionable	In a preclinical study, homozygous deletion of FBXW7 is conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).	17646409
FBXW7	FBXW7 inact mut	breast cancer	sensitive	Sirolimus	Preclinical - Cell line xenograft	Actionable	In a preclinical study, breast cancer cells harboring a FBXW7 mutation demonstrated sensitivity to Rapamune (sirolimus) in culture and in cell line xenograft models (PMID: 18787170).	18787170
FBXW7	FBXW7 inact mut	Advanced Solid Tumor	sensitive	Entinostat	Preclinical	Actionable	In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910).	23274910
FBXW7	FBXW7 inact mut	Advanced Solid Tumor	resistant	Docetaxel	Preclinical	Actionable	In a preclinical study, human cancer cell lines harboring FBXW7 inactivating mutations were resistant to docetaxel in culture (PMID: 23274910).	23274910
FBXW7	FBXW7 inact mut	Advanced Solid Tumor	sensitive	AR-42	Preclinical	Actionable	In a preclinical study, AR-42 inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).	23274910
FBXW7	FBXW7 inact mut	hematologic cancer	sensitive	AR-42	Preclinical	Actionable	In a preclinical study, AR-42 inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).	23274910
FBXW7	FBXW7 inact mut	hematologic cancer	sensitive	Entinostat	Preclinical	Actionable	In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910).	23274910
FBXW7	FBXW7 inact mut	hematologic cancer	sensitive	Belinostat	Preclinical	Actionable	In a preclinical study, Beleodaq (belinostat) inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).	23274910
FBXW7	FBXW7 inact mut	Advanced Solid Tumor	sensitive	Belinostat	Preclinical	Actionable	In a preclinical study, Beleodaq (belinostat) inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).	23274910
FBXW7	FBXW7 R505L	T-cell adult acute lymphocytic leukemia	resistant	MRK-003	Preclinical	Actionable	In a preclinical study, FBXW7 R505L may conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).	17646409
FGFR1	FGFR1-TACC1	malignant glioma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited Fgfr1 kinase activity and cell growth in transformed cells expressing the FGFR1-TACC1 fusion in culture (PMID: 22837387).	22837387
FGFR1	FGFR1-TACC1	malignant glioma	sensitive	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, PD173074 inhibited Fgfr1 kinase activity and cell growth in transformed cells expressing the FGFR1-TACC1 fusion in culture (PMID: 22837387).	22837387
FGFR1	FGFR1-TACC1	malignant glioma	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BJG398 inhibited Fgfr1 kinase activity and cell growth in transformed cells expressing the FGFR1-TACC1 fusion in culture (PMID: 22837387).	22837387
FGFR1	FGFR1 act mut	Advanced Solid Tumor	decreased response	Cediranib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR1 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).	22238366
FGFR1	FGFR1 act mut	Advanced Solid Tumor	sensitive	Debio 1347	Phase I	Actionable	In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR1 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).	detail...
FGFR1	FGFR1 act mut	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).	22238366
FGFR1	FGFR1 act mut	breast cancer	sensitive	FIIN-1	Preclinical	Actionable	In a preclinical study, FIIN-01 inhibited Fgfr1 activation-induced proliferation and transformation of human breast epithelial cell lines in culture (PMID: 20338520).	20338520
FGFR1	FGFR1 act mut	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).	22238366
FGFR1	FGFR1 act mut	Advanced Solid Tumor	decreased response	Nintedanib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR1 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).	22238366
FGFR1	FGFR1 act mut	Advanced Solid Tumor	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).	22238366
FGFR1	FGFR1 act mut	Advanced Solid Tumor	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363; NCT01703481).	26324363
FGFR1	FGFR1 V561M	lung non-small cell carcinoma	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells expressing FGFR1 V561M demonstrated resistance to AZD4547 in culture (PMID: 30257990).	30257990
FGFR1	FGFR1 V561M	Advanced Solid Tumor	sensitive	FIIN-1	Preclinical	Actionable	In a preclinical study, FIIN-01 inhibited Fgfr1 autophosphorylation in a human transformed embryonic kidney cell line harboring FGFR1 V561M mutation in culture (PMID: 20338520).	20338520
FGFR1	FGFR1 V561M	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing FGFR1 V561M in culture (PMID: 28978721).	28978721
FGFR1	FGFR1 amp	lung carcinoma	sensitive	Lucitanib	Preclinical - Cell line xenograft	Actionable	in a preclinical study, Lucitanib (E-3810) preferentially inhibited growth of FGFR1-amplified lung carcinoma cell lines in culture and in cell line xenograft models (PMID: 27988457).	27988457
FGFR1	FGFR1 amp	estrogen-receptor positive breast cancer	sensitive	Lucitanib	Preclinical - Cell culture	Actionable	In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring FGFR1 amplification demonstrated sensitivity to treatment with Lucitanib (E-3810) in culture (PMID: 27126994).	27126994
FGFR1	FGFR1 amp	lung small cell carcinoma	sensitive	Debio 1347	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of small cell lung cancer cell lines harboring FGFR1 amplification in culture (PMID: 25169980).	25169980
FGFR1	FGFR1 amp	lung small cell carcinoma	sensitive	AZD4547 + Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) induced apoptosis in a small cell lung cancer cell line with amplification of FGFR1 in culture (PMID: 28108151).	28108151
FGFR1	FGFR1 amp	lung non-small cell carcinoma	predicted - sensitive	NGI-1	Preclinical - Cell culture	Actionable	In a preclinical study, NGI-1 inhibited FGFR1 phosphorylation and proliferation of a FGFR1-amplified cell line dependent on FGFR1 signaling in culture, however, did not inhibit proliferation of an FGFR1-amplified cell line not dependent on FGFR1 signaling (PMID: 27694802).	27694802
FGFR1	FGFR1 amp	lung cancer	predicted - sensitive	Erdafitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Balversa (erdafitinib) inhibited FGFR downstream signaling and proliferation of several lung cancer cell lines with FGFR1 amplification in culture, and inhibited tumor growth in an FGFR1-amplified lung cancer cell line xenograft model (PMID: 28341788).	28341788
FGFR1	FGFR1 amp	lung large cell carcinoma	sensitive	AZD4547	Preclinical	Actionable	In a preclinical study, AZD4547 inhibited proliferation of a large cell lung cancer cell line harboring FGFR1 amplification in culture and induced tumor regression in xenograft models (PMID: 23082000).	23082000
FGFR1	FGFR1 amp	lung squamous cell carcinoma	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, patients with lung squamous cell carcinoma harboring an FGFR1 amplification demonstrated a disease control rate of 50% (18/36) when treated with BGJ398, resulting in 14 patients with stable disease and 4 patients with a partial response (PMID: 27870574).	27870574
FGFR1	FGFR1 amp	lung cancer	sensitive	AZD4547	Preclinical	Actionable	In a preclinical study, AZD4547 inhibited proliferation of lung cancer cell lines harboring FGFR1 amplification in culture and induced tumor regression in xenograft models (PMID: 23082000).	23082000
FGFR1	FGFR1 amp	lung small cell carcinoma	sensitive	AZD4547	Preclinical	Actionable	In a preclinical study, AZD4547 inhibited proliferation of a small cell lung cancer cell line harboring FGFR1 amplification in culture (PMID: 23082000).	23082000
FGFR1	FGFR1 amp	synovial sarcoma	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980).	27535980
FGFR1	FGFR1 amp	lung small cell carcinoma	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).	26438159
FGFR1	FGFR1 amp	lung squamous cell carcinoma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159).	26438159
FGFR1	FGFR1 amp	lung cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of lung cancer cells with FGFR1 amplification in culture (PMID: 22238366).	22238366
FGFR1	FGFR1 amp	lung non-small cell carcinoma	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in 96.1% tumor growth inhibition in patient-derived xenograft models of FGFR1-amplified non-small cell lung cancer (PMID: 28978721).	28978721
FGFR1	FGFR1 amp	breast cancer	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in ER-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366).	22238366
FGFR1	FGFR1 amp	lung squamous cell carcinoma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159).	26438159
FGFR1	FGFR1 amp	lung squamous cell carcinoma	predicted - sensitive	Debio 1347	Case Reports/Case Series	Actionable	In a Phase I trial, Debio 1347 treatment resulted in a stable disease with 26.7% reduction of tumor size and 100% decrease of DUSP6 score in a patient with lung squamous cell carcinoma harboring FGFR1 amplification (PMID: 30745300; NCT01948297).	30745300
FGFR1	FGFR1 amp	lung small cell carcinoma	sensitive	GSK3052230	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GSK3052230 (FP-1039) treatment inhibited growth of FGFR1 amplified lung small cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 23536011).	23536011
FGFR1	FGFR1 amp	lung non-small cell carcinoma	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).	26438159
FGFR1	FGFR1 amp	lung squamous cell carcinoma	no benefit	AZD4547	Phase I	Actionable	In a Phase Ib trial, AZD4547 demonstrated limited efficacy in patients with squamous cell lung cancer with FGFR1 amplification, resulting in an overall response rate of 8% (1/15) and a median overall survival of 4.9 months (PMID: 28615371; NCT00979134).	28615371
FGFR1	FGFR1 amp	lung non-small cell carcinoma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159).	26438159
FGFR1	FGFR1 amp	lung cancer	sensitive	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cells harboring FGFR1 amplification were sensitive to PD173074 treatment in culture, demonstrating inhibition of cell growth (PMID: 30140389).	30140389
FGFR1	FGFR1 amp	Ewing sarcoma	predicted - sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of Ewings sarcoma cell lines with FGFR1 copy number gain in culture (PMID: 26179511).	26179511
FGFR1	FGFR1 amp	lung non-small cell carcinoma	sensitive	AZD4547	Preclinical - Pdx	Actionable	In a preclinical study, AZD4547 inhibited FGFR1 signaling and resulted in tumor regression in patient-derived xenograft models of non-small cell lung carcinoma harboring FGFR1 amplification, wild-type for EGFR, K-Ras and negative for EML4-ALK fusion (PMID: 23082000).	23082000
FGFR1	FGFR1 amp	lung small cell carcinoma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159).	26438159
FGFR1	FGFR1 amp	lung non-small cell carcinoma	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited Erk signaling and growth of FGFR1-amplified non-small cell lung carcinoma cells in culture (PMID: 28630215).	28630215
FGFR1	FGFR1 amp	lung small cell carcinoma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159).	26438159
FGFR1	FGFR1 amp	breast cancer	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, 28% (9/32) of breast cancer patients harboring FGFR1 amplification demonstrated stable disease when treated with BGJ398 (PMID: 27870574).	27870574
FGFR1	FGFR1 amp	lung squamous cell carcinoma	sensitive	AZD4547 + Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) induced apoptosis in a squamous cell lung cancer cell line with amplification of FGFR1 in culture (PMID: 28108151).	28108151
FGFR1	FGFR1 amp	estrogen-receptor positive breast cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of estrogen receptor (ER)-positive breast cancer cells with FGFR2 amplification in culture (PMID: 22238366).	22238366
FGFR1	FGFR1 amp	lung cancer	sensitive	GSK3052230	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GSK3052230 (FP-1039) treatment resulted in greater tumor growth inhibition (56% vs 22%) in cell line xenograft models of FGFR1 amplified lung cancer compared to FGFR1 non-amplified models (PMID: 23536011).	23536011
FGFR1	FGFR1 amp	breast cancer	no benefit	AZD4547	Phase II	Actionable	In a Phase II clinical trial, treatment with AZD4547 resulted in a response rate of 12.5% (1/8) in patients with FGFR1-amplified breast cancer, and did not meet the predetermined criteria for efficacy (PMID: 27179038).	27179038
FGFR1	FGFR1 amp	estrogen-receptor positive breast cancer	sensitive	Nintedanib	Preclinical	Actionable	In a preclinical study, Ofev (nintedanib) inhibited the growth of ER-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366).	22238366
FGFR1	FGFR1 amp	lung non-small cell carcinoma	sensitive	Debio 1347	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of non-small cell lung cancer cell lines harboring FGFR1 amplification in culture (PMID: 25169980).	25169980
FGFR1	FGFR1 amp	lung non-small cell carcinoma	sensitive	GSK3052230	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GSK3052230 (FP-1039) treatment inhibited growth of FGFR1 amplified non-small cell lung carcinoma cell lines in culture and in cell line xenograft models (PMID: 23536011).	23536011
FGFR1	FGFR1 amp	lung adenocarcinoma	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in 64.6% tumor growth inhibition in patient-derived xenograft models of FGFR1-amplified lung adenocarcinoma (PMID: 28978721).	28978721
FGFR1	FGFR1 amp	lung non-small cell carcinoma	sensitive	E7090	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a non-small cell lung cancer cell line, harboring FGFR1 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969).	27535969
FGFR1	FGFR1 amp	Her2-receptor negative breast cancer	predicted - sensitive	Pazopanib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with ERBB2 (HER2)-receptor negative breast cancer harboring FGFR1 amplification demonstrated antitumor activity when treated with Votrient (pazopanib), including a near complete loss of brain lesions and improved function of the liver (PMID: 29223982).	29223982
FGFR1	FGFR1 amp	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 59% (10/17) of patients with advanced solid tumors harboring FGFR amplification, with a 6-month progression-free survival rate of 15% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).	detail...
FGFR1	FGFR1 amp	synovial sarcoma	sensitive	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, PD173074 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980).	27535980
FGFR1	FGFR1 amp	lung squamous cell carcinoma	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).	26438159
FGFR1	FGFR1 amp	lung large cell carcinoma	sensitive	ODM-203	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ODM-203 inhibited FGFR signaling and proliferation in a large cell lung cancer cell line with amplification of chromosome 8p12 leading to increased FGFR1 copy number, and inhibited tumor growth in xenograft models (PMID: 30301864).	30301864
FGFR1	FGFR1 amp	adrenocortical carcinoma	sensitive	Derazantinib	Phase I	Actionable	In a Phase I trial, ARQ 087 treatment resulted in stable disease with a tumor reduction of 20% in an adrenocortical carcinoma patient harboring FGFR1 amplification, who remained on study for 3.5 years (PMID: 28972963; NCT01752920).	28972963
FGFR1	FGFR1 amp	Her2-receptor positive breast cancer	sensitive	Dovitinib	Phase I	Actionable	In a Phase I trial, Dovitinib (TKI258) promoted 6-month stable disease in Erbb2 (Her2)-positive breast cancer patients with FGFR1 amplification (PMID: 23658459).	23658459
FGFR1	FGFR1 amp	lung non-small cell carcinoma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159).	26438159
FGFR1	FGFR1 amp	lung small cell carcinoma	sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, a small cell lung cancer cell line harboring FGFR1 amplification demonstrated sensitivity to E7090, resulting in decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969).	27535969
FGFR1	FGFR1 amp	lung squamous cell carcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of squamous cell lung cancer cell lines harboring FGFR1 amplification (PMID: 22238366).	22238366
FGFR1	FGFR1 amp	estrogen-receptor positive breast cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of estrogen receptor (ER)-positive breast cancer cells with FGFR1 amplification in culture (PMID: 22238366).	22238366
FGFR1	FGFR1 amp	estrogen-receptor positive breast cancer	sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring FGFR1 amplification (PMID: 7506125) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969).	7506125 27535969
FGFR1	FGFR1 amp	estrogen-receptor positive breast cancer	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in estrogen receptor (ER)-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366).	22238366
FGFR1	FGFR1 amp	Advanced Solid Tumor	predicted - sensitive	Debio 1347	Phase I	Actionable	In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297).	30745300
FGFR1	FGFR1 amp	lung non-small cell carcinoma	sensitive	BGJ398 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Mekinist (trametinib) combination treatment inhibited Erk signaling and growth of FGFR1-amplified non-small cell lung carcinoma cells in culture (PMID: 28630215).	28630215
FGFR1	FGFR1 amp	lung squamous cell carcinoma	no benefit	Dovitinib	Phase II	Actionable	In a Phase II clinical trial, dovitinib treatment resulted in a objective response rate of 11.5% (3/26, all partial responses) and disease control rate of 50% (13/26), and a median progression-free survival of 2.9 months in lung squamous cell carcinoma patients with FGFR1 amplification, and FGFR1 amplification was not determined to be a predictive biomarker for sensitivity (PMID: 27315356).	27315356
FGFR1	FGFR1 amp	synovial sarcoma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980).	27535980
FGFR1	FGFR1 amp	lung small cell carcinoma	sensitive	Cisplatin + Etoposide + GSK3052230	Preclinical - Cell line xenograft	Actionable	In a preclinical study, addition of GSK3052230 (FP-1039) to Platinol (cisplatin) and Vepesid (etoposide) resulted in improved tumor growth inhibition in cell line xenograft models of FGFR1 amplified lung small cell carcinoma (PMID: 23536011).	23536011
FGFR1	FGFR1 amp	estrogen-receptor positive breast cancer	resistant	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring an FGFR1 amplification demonstrated resistance to Alpelisib (BYL719) in culture (PMID: 27126994).	27126994
FGFR1	FGFR1 amp	transitional cell carcinoma	sensitive	AZD4547 + Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) worked synergistically to induce apoptosis and inhibit growth of a urothelial cell carcinoma cell line with FGFR1 amplification in culture, with increased efficacy over either agent alone (PMID: 28108151).	28108151
FGFR1	EGFR over exp FGFR1 amp	head and neck squamous cell carcinoma	sensitive	AZD4547 + Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR1 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a synergistic effect (PMID: 26936917).	26936917
FGFR1	EGFR over exp FGFR1 amp	head and neck squamous cell carcinoma	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells with EGFR over expression and FGFR1 amplification demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917).	26936917
FGFR1	FGFR1 amp FGFR2 amp	breast cancer	sensitive	E7090	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer cell line, harboring FGFR1 amplification and FGFR2 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969).	27535969
FGFR1	EGFR amp FGFR1 amp	lung cancer	resistant	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cell lines with co-amplification of FGFR1 and EGFR demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 28341788).	28341788
FGFR1	FGFR1 amp NRAS amp	lung non-small cell carcinoma	sensitive	BGJ398 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Mekinist (trametinib) combination treatment inhibited Erk signaling, resulting in growth inhibition in non-small cell lung carcinoma cells harboring both FGFR1 and NRAS amplification in culture (PMID: 28630215).	28630215
FGFR1	FGFR1 amp NRAS amp	lung non-small cell carcinoma	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, amplification of NRAS was identified in a non-small cell lung cancer cell line harboring FGFR1 amplification that acquired resistance to BGJ398 in culture (PMID: 28630215).	28630215
FGFR1	FGFR1 amp NRAS amp	lung non-small cell carcinoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring both FGFR1 and NRAS amplification were resistant to Mekinist (trametinib) in culture (PMID: 28630215).	28630215
FGFR1	FGFR1 amp NRAS over exp	lung non-small cell carcinoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of Nras in FGFR1-amplified non-small cell lung carcinoma cells resulted in decreased response to BGJ398 in culture (PMID: 28630215).	28630215
FGFR1	FGFR1 amp NRAS over exp	lung non-small cell carcinoma	sensitive	BGJ398 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Mekinist (trametinib) combination treatment inhibited Erk signaling, resulting in growth inhibition in FGFR1-amplified non-small cell lung carcinoma cells overexpressing Nras in culture (PMID: 28630215).	28630215
FGFR1	FGFR1 amp MET over exp	lung small cell carcinoma	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression and activation of Met was identified in a small cell lung cancer cell line harboring FGFR1 amplification that acquired resistance to BGJ398 in culture (PMID: 28630215).	28630215
FGFR1	FGFR1 amp MET over exp	lung small cell carcinoma	sensitive	BGJ398 + EMD 1214063	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and EMD 1214063 synergistically inhibited growth of small cell lung carcinoma cells harboring FGFR1 amplification and Met overexpression in culture (PMID: 28630215).	28630215
FGFR1	FGFR1 amp MET over exp	lung small cell carcinoma	sensitive	BGJ398 + Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Xalkori (crizotinib) synergistically inhibited Erk signaling, resulted in growth inhibition in small cell lung carcinoma cells harboring FGFR1 amplification and Met overexpression in culture (PMID: 28630215).	28630215
FGFR1	FGFR1 amp MET over exp	lung cancer	sensitive	Crizotinib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Rogaratinib (BAY 1163877) and Xalkori (crizotinib) synergistically inhibited proliferation of FGFR1 amplified lung cancer cells that acquired resistance to Rogaratinib (BAY 1163877) through MET overexpression and activation in culture (PMID: 27429073).	27429073
FGFR1	FGFR1 amp MET over exp	lung cancer	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, MET overexpression and activation was identified as the mechanism mediating acquired Rogaratinib (BAY 1163877) resistance in a FGFR1 amplified lung cancer cell line in culture (PMID: 27429073).	27429073
FGFR1	FGFR1 amp MET amp	lung squamous cell carcinoma	predicted - resistant	BGJ398	Phase I	Actionable	In a Phase I trial, MET amplification was detected in a squamous cell lung cancer patient harboring FGFR1 amplification whose disease relapsed after 17 months of BGJ398 treatment, supporting a role of MET amplification in drug resistance in FGFR1-amplified lung cancer (PMID: 28630215).	28630215
FGFR1	FGFR1 amp MET amp	lung cancer	sensitive	AZD4547 + Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 and Xalkori (crizotinib) synergistically inhibited proliferation of FGFR1 amplified lung cancer cells that acquired resistance to AZD4547 through MET amplification in culture (PMID: 27429073).	27429073
FGFR1	FGFR1 amp MET amp	lung cancer	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, MET amplification was identified as the mechanism mediating acquired AZD4547 resistance in a FGFR1 amplified lung cancer cell line in culture (PMID: 27429073).	27429073
FGFR1	FGFR1 amp MET dec exp	lung cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited Erk signaling and proliferation of FGFR1-amplified lung cancer cell lines with undetectable Met expression in culture (PMID: 27429073).	27429073
FGFR1	FGFR1 amp MET dec exp	lung cancer	sensitive	Rogaratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Rogaratinib (BAY 1163877) inhibited Erk signaling and proliferation of FGFR1-amplified lung cancer cell lines with undetectable Met expression in culture (PMID: 27429073).	27429073
FGFR1	FGFR1 amp MET pos	lung cancer	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1-amplified lung cancer cell lines with Met expression were resistant to Rogaratinib (BAY 1163877) in culture (PMID: 27429073).	27429073
FGFR1	FGFR1 amp MET pos	lung cancer	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1-amplified lung cancer cell lines with Met expression were resistant to AZD4547 in culture (PMID: 27429073).	27429073
FGFR1	EML4-ALK FGFR1 amp	lung non-small cell carcinoma	predicted - resistant	Brigatinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Alunbrig (brigatinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, FGFR1 amplification (PMID: 29636358).	29636358
FGFR1	AKT1 S266L FGFR1 amp	lung cancer	predicted - resistant	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cells harboring FGFR1 amplification demonstrated resistance to increasing concentrations of PD173074 in culture and was subsequently, found to have acquired AKT1 S266L (PMID: 30140389).	30140389
FGFR1	AKT1 S266L FGFR1 amp	lung cancer	predicted - sensitive	Uprosertib	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cells harboring FGFR1 amplification and AKT1 S266L demonstrated sensitivity to Uprosertib (GSK2141795) in culture, showing decreased phosphorylation of Akt1 targets and reduced cell growth (PMID: 30140389).	30140389
FGFR1	FGFR1 amp FGF2 fusion	colon cancer	predicted - sensitive	Debio 1347	Case Reports/Case Series	Actionable	In a Phase I trial, Debio 1347 treatment resulted in a partial response with 49.5% reduction of tumor size and 66% decrease of DUSP6 score in a patient with colon cancer harboring FGFR1 amplification and FGFR2 fusion (PMID: 30745300; NCT01948297).	30745300
FGFR1	FGFR1 wild-type	breast cancer	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, ER-positive breast cancer cells with wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).	22238366
FGFR1	FGFR1 wild-type	lung cancer	decreased response	AZD4547	Preclinical	Actionable	In a preclinical study, FGFR1 non-amplified lung cancer cell lines demonstrated reduced sensitivity to AZD4547 induced growth inhibition in culture and in xenograft models (PMID: 23082000).	23082000
FGFR1	EGFR mutant FGFR1 wild-type	lung non-small cell carcinoma	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring mutant EGFR and wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).	22238366
FGFR1	FGFR1 fusion	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in 22% (2/9) and stable disease in 55% (5/9) of patients with advanced solid tumors harboring FGFR fusions, with a 6-month progression-free survival rate of 42% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).	detail...
FGFR1	FGFR1 fusion	hematologic cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of hematologic cancer cells harboring FGFROP2-FGFR1 fusion in culture (PMID: 27627808).	27627808
FGFR1	FGFR1 fusion	Advanced Solid Tumor	predicted - sensitive	Debio 1347	Phase I	Actionable	In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297).	30745300
FGFR1	FGFR1 fusion	acute myeloid leukemia	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) increased apoptosis and inhibited survival of acute myelogenous leukemia cell lines harboring FGFR1OP2-FGFR1 fusion in culture (PMID: 17698633).	17698633
FGFR1	FGFR1 fusion	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited Erk, Stat5 signaling and survival of transformed cell lines overexpressing FGFR1 fusion proteins (ZMYM2-FGFR1 or BCR-FGFR1) in culture (PMID: 17698633).	17698633
FGFR1	FGFR1 positive	uterus leiomyosarcoma	decreased response	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).	27535980
FGFR1	FGFR1 positive	uterus leiomyosarcoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980).	27535980
FGFR1	FGFR1 positive	leiomyosarcoma	decreased response	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).	27535980
FGFR1	FGFR1 positive	leiomyosarcoma	decreased response	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).	27535980
FGFR1	FGFR1 positive	lung large cell carcinoma	sensitive	AZD4547 + Vistusertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture and in cell line xenograft models (PMID: 26359452).	26359452
FGFR1	FGFR1 positive	synovial sarcoma	decreased response	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).	27535980
FGFR1	FGFR1 positive	salivary gland adenoid cystic carcinoma	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including a partial remission in a patient with FGFR1-positive adenoid cystic carcinoma of the tongue (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).	detail...
FGFR1	FGFR1 positive	lung adenocarcinoma	sensitive	AZD4547 + Sirolimus	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 and Rapamune (sirolimus) synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture (PMID: 26359452).	26359452
FGFR1	FGFR1 positive	synovial sarcoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980).	27535980
FGFR1	FGFR1 positive	hemangioma	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease with resolution of edema in a patient with FGFR1-positive hemangioendothelioma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).	detail...
FGFR1	FGFR1 positive	head and neck squamous cell carcinoma	sensitive	AZD4547 + Vistusertib	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent head and neck squamous cell carcinoma cells in culture (PMID: 26359452).	26359452
FGFR1	FGFR1 positive	lung adenocarcinoma	sensitive	AZD4547 + AZD8055	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 and AZD8055 synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture (PMID: 26359452).	26359452
FGFR1	FGFR1 positive	leiomyosarcoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980).	27535980
FGFR1	FGFR1 positive	lung adenocarcinoma	sensitive	AZD4547 + Vistusertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture and in cell line xenograft models (PMID: 26359452).	26359452
FGFR1	FGFR1 positive	synovial sarcoma	decreased response	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).	27535980
FGFR1	FGFR1 positive	uterus leiomyosarcoma	decreased response	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).	27535980
FGFR1	FGFR1 positive	lung large cell carcinoma	sensitive	AZD4547 + Sirolimus	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 and Rapamune (sirolimus) synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture (PMID: 26359452).	26359452
FGFR1	FGFR1 positive	lung large cell carcinoma	sensitive	AZD4547 + AZD8055	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 and AZD8055 synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture (PMID: 26359452).	26359452
FGFR1	FGFR1 pos FGFR2 pos	hepatocellular carcinoma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, hepatocellular carcinoma cell lines treated with AZD4547 demonstrated decreased phosphorylation of FGFR1 and FGFR2, reduced colony formation, and evidence of apoptotic activity in culture (PMID: 26351320).	26351320
FGFR1	FGFR1 pos FGFR2 pos	hepatocellular carcinoma	no benefit	PHA-665752	Preclinical - Cell culture	Actionable	In a preclinical study, PHA-665752 treatment did not result in decreased colony formation or reduced phosphorylation levels of FGFR1 and FGFR2 in hepatocellular carcinoma cells in culture (PMID: 26351320).	26351320
FGFR1	FGFR1 over exp	Advanced Solid Tumor	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells overexpressing Fgfr1 in culture (PMID: 27627808).	27627808
FGFR1	FGFR1 over exp	thyroid cancer	sensitive	Lenvatinib	Preclinical	Actionable	In a preclinical study, Lenvima (lenvatinib) inhibited FGFR1 phosphorylation and signaling in thyroid cancer cells overexpressing FGFR1 (PMID: 25295214).	25295214
FGFR1	FGFR1 over exp	uterus leiomyosarcoma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980).	27535980
FGFR1	FGFR1 over exp	uterus leiomyosarcoma	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, PD173074 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980).	27535980
FGFR1	FGFR1 over exp	head and neck squamous cell carcinoma	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 inhibited cell growth and induced apoptosis in HNSCC cells over expressing Fgfr1 in culture and in xenograft models (PMID: 26015511).	26015511
FGFR1	FGFR1 over exp	renal cell carcinoma	not applicable	Sorafenib	Phase II	Emerging	In a clinical analysis of a Phase II trial, high Fgfr1 expression level was associated with decreased progression free survival in renal cell carcinoma patients treated with Nexavar (sorafenib) (PMID: 25900027).	25900027
FGFR1	FGFR1 over exp	uterus leiomyosarcoma	sensitive	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, PD173074 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980).	27535980
FGFR1	FGFR1 over exp	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing wild-type FGFR1 in culture (PMID: 28978721).	28978721
FGFR1	EGFR neg FGFR1 over exp	head and neck squamous cell carcinoma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 treatment of head and neck squamous cell carcinoma cells over expressing FGFR1 and negative for EGFR resulted in decreased cell growth and reduced downstream signaling of Erk1/2 (PMID: 26936917).	26936917
FGFR1	FGFR1 over exp PIK3CA mut	estrogen-receptor positive breast cancer	sensitive	Alpelisib + Lucitanib	Preclinical - Cell culture	Actionable	In a preclinical study, an estrogen-receptor positive breast cancer cell line over expressing FGFR1 and expressing a PIK3CA mutation demonstrated sensitivity to the combination of Alpelisib (BYL719) and Lucitanib (E-3810) in culture (PMID: 27126994).	27126994
FGFR1	EGFR over exp FGFR1 over exp	esophageal cancer	sensitive	Theliatinib	Preclinical - Pdx	Actionable	In a preclinical study, Theliatinib treatment demonstrated decreased efficacy in patient-derived xenograft (PDX) models of esophageal cancer with both Egfr and Fgfr1 overexpression compared to models with only Egfr overexpression (PMID: 28881608).	28881608
FGFR1	EGFR over exp FGFR1 over exp	esophageal cancer	sensitive	AZD4547	Preclinical - Pdx	Actionable	In a preclinical study, AZD4547 treatment resulted in tumor regression in patient-derived xenograft (PDX) models, with both Egfr and Fgfr1 overexpression (PMID: 28881608),	28881608
FGFR1	FGFR1 rearrange	lung small cell carcinoma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited survival of small cell lung cancer cells harboring FGFR1 translocation in culture (PMID: 27550940).	27550940
FGFR1	FGFR1 rearrange	myeloproliferative neoplasm	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, primary cells from 8p11 myeloproliferative syndrome patients harboring FGFR1 rearrangement were sensitive to Dovitinib (TKI258)-induced growth inhibition in culture (PMID: 17698633).	17698633
FGFR1	FGFR1 rearrange	leukemia	sensitive	AZD4547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4547 inhibited survival of leukemia cells harboring FGFR1 translocation in culture and in cell line xenograft models (PMID: 27550940).	27550940
FGFR1	FGFR1 mutant	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 40% (6/16) of patients with advanced solid tumors harboring FGFR single nucleotide variants, with a 6-month progression-free survival rate of 8% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).	detail...
FGFR1	FGFR1 mutant	Advanced Solid Tumor	sensitive	Pemigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to INCB054828 in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771).	detail...
FGFR1	FGFR1 mutant	Advanced Solid Tumor	predicted - sensitive	Debio 1347	Phase I	Actionable	In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297).	30745300
FGFR1	FGFR1 mutant	transitional cell carcinoma	predicted - sensitive	Erdafitinib	Phase II	Actionable	In a Phase II trial, Balversa (erdafitinib) treatment resulted in an objective response rate of 42% (40/96, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations (J Clin Oncol 36, 2018 (suppl; abstr 4503); NCT02365597).	detail...
FGFR1	EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*	pancreatic ductal adenocarcinoma	predicted - sensitive	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).	28476735
FGFR1	EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*	pancreatic ductal adenocarcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).	28476735
FGFR2	FGFR2 over exp	endometrial cancer	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial cells with Fgfr2 overexpression were resistant to the anti-proliferative effects of AZD4547 (PMID: 26294741).	26294741
FGFR2	FGFR2 over exp	breast cancer	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, PD173074 inhibited proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148).	22869148
FGFR2	FGFR2 over exp	breast cancer	sensitive	AZD4547	Preclinical	Actionable	In a preclinical study, AZD4547 inhibited downstream Erk phosphorylation and proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148).	22869148
FGFR2	FGFR2 over exp	Advanced Solid Tumor	sensitive	Derazantinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells overexpressing Fgfr2 in culture and in cell line xenograft models (PMID: 27627808).	27627808
FGFR2	FGFR2 over exp	breast cancer	sensitive	AZ8010	Preclinical	Actionable	In a preclinical study, AZ8010 inhibited downstream Erk phosphorylation and proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148).	22869148
FGFR2	FGFR2 over exp	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing wild-type FGFR2 in culture (PMID: 28978721).	28978721
FGFR2	FGFR2 over exp	colorectal cancer	sensitive	BAY1187982	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BAY1187982 inhibited survival of colorectal cancer cells with over expressing Fgfr2 in culture, and suppressed tumor growth in cell line xenograft models (PMID: 27543601).	27543601
FGFR2	FGFR2 amp FGFR2 over exp	stomach cancer	sensitive	AZD4547	Preclinical - Pdx	Actionable	In a preclinical study, AZD4547 decreased Myc expression and inhibited tumor growth in patient-derived xenograft (PDX) models of gastric cancer with FGFR2 amplification and over expression (PMID: 27401245).	27401245
FGFR2	FGFR2 amp FGFR2 over exp	stomach cancer	sensitive	BGJ398	Preclinical - Pdx	Actionable	In a preclinical study, BGJ398 decreased Myc expression and inhibited tumor growth in patient-derived xenograft (PDX) models of gastric cancer with FGFR2 amplification and over expression (PMID: 27401245).	27401245
FGFR2	FGFR2-CCDC6	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Balversa (erdafitinib) inhibited Fgfr phosphorylation and downstream signaling, resulted in growth inhibition of transformed cells expressing FGFR2-CCDC6 in culture (PMID: 28416604).	28416604
FGFR2	FGFR2-CCDC6	liver cancer	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in tumor regression in patient-derived xenograft models of liver cancer harboring FGFR2-CCDC6 fusion (PMID: 28978721).	28978721
FGFR2	FGFR2-CCDC6 FGFR3-TACC3	adrenal carcinoma	predicted - sensitive	Erdafitinib	Case Reports/Case Series	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted tumor shrinkage and no disease progression for 10 months in an adrenal carcinoma patient harboring FGFR3-TACC3 and FGFR2-CCDC6 fusions (PMID: 26324363; NCT01703481).	26324363
FGFR2	FGFR2-INA FGFR2 H683L FGFR2 L618V FGFR2 N550H FGFR2 N550T FGFR2 M538I	intrahepatic cholangiocarcinoma	sensitive	Futibatinib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-INA fusion with FGFR2 H683L, L618V, N550H, N550T, M538I mutations, responded to TAS-120 for 5.1 months before progressing due to acquired FGFR2 V565L and E566A mutations, detected in cell-free DNA (PMID: 31109923; NCT02052778).	31109923
FGFR2	FGFR2-INA FGFR2 H683L FGFR2 L618V FGFR2 N550H FGFR2 N550T FGFR2 M538I	intrahepatic cholangiocarcinoma	resistant	Debio 1347	Case Reports/Case Series	Actionable	In a clinical case study, a patient with intrahepatic cholangiocarcinoma harboring an FGFR2-INA fusion developed progressive disease after initial response to Debio 1347 for 11.4 months and FGFR2 H683L, L618V, N550H, N550T, M538I mutations were identified post-progression (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 H683L	intrahepatic cholangiocarcinoma	sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, TAS-120 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 H683L were sensitive to treatment as demonstrated by decreased cell viability and decreased activation of downstream signaling (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 H683L	intrahepatic cholangiocarcinoma	decreased response	Debio 1347	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 H683L had weakened sensitivity, as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 H683L	intrahepatic cholangiocarcinoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, Infigratinib (BGJ398) treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 H683L had weakened sensitivity, as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2 I548V	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 I548V (PMID: 23908597).	23908597
FGFR2	FGFR2 I548V	Advanced Solid Tumor	decreased response	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 I548V demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).	23908597
FGFR2	FGFR2 I548V	Advanced Solid Tumor	decreased response	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 I548V demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).	23908597
FGFR2	FGFR2 W290C	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing FGFR2 W290C in culture (PMID: 23786770).	23786770
FGFR2	FGFR2 W290C	Advanced Solid Tumor	sensitive	Lenvatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lenvima (lenvatinib) inhibited growth of transformed cells expressing FGFR2 W290C in culture (PMID: 23786770).	23786770
FGFR2	FGFR2 W290C	Advanced Solid Tumor	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited growth of transformed cells expressing FGFR2 W290C in culture (PMID: 23786770).	23786770
FGFR2	FGFR2 W290C	Advanced Solid Tumor	sensitive	BGJ398	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BGJ398 inhibited growth of transformed cells expressing FGFR2 W290C in culture and inhibited tumor growth in xenograft models (PMID: 23786770).	23786770
FGFR2	FGFR2 W290C	Advanced Solid Tumor	sensitive	Cediranib	Preclinical - Cell culture	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of transformed cells expressing FGFR2 W290C in culture (PMID: 23786770).	23786770
FGFR2	FGFR2 W290C	Advanced Solid Tumor	sensitive	Pazopanib	Preclinical - Cell culture	Actionable	In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR2 W290C in culture (PMID: 23786770).	23786770
FGFR2	FGFR2 amp	myxoid liposarcoma	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 increased apoptosis, and inhibited cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification in culture (PMID: 26036639).	26036639
FGFR2	FGFR2 amp	colon cancer	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 amp	stomach cancer	sensitive	E7090	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a gastric cancer cell line harboring FGFR2 amplification demonstrated decreased cell viability in culture and antitumor activity in xenograft models when treated with E7090 (PMID: 27535969).	27535969
FGFR2	FGFR2 amp	colon cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified colon cancer cells in culture (PMID: 27550940).	27550940
FGFR2	FGFR2 amp	stomach cancer	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in gastric cancer cell lines harboring FGFR2 amplification in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 amp	stomach cancer	predicted - sensitive	PRN1109	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PRN1109 treatment resulted in tumor regression in gastric cancer cell line xenograft models harboring FGFR2 amplification (Eu J Cancer 2014 Vol 50, Suppl 6:157).	detail...
FGFR2	FGFR2 amp	myxoid liposarcoma	sensitive	BGJ398 + Trabectedin	Preclinical	Actionable	In a preclinical study, BGJ398 and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification in culture (PMID: 26036639).	26036639
FGFR2	FGFR2 amp	stomach cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 amp	stomach cancer	sensitive	AZD4547	Phase II	Actionable	In a Phase II clinical trial, treatment with AZD4547 resulted in a 33% (3/9) response rate in patients with FGFR2-amplified gastroesophageal cancer, and high-level amplification was associated with clinical response (PMID: 27179038).	27179038
FGFR2	FGFR2 amp	stomach cancer	sensitive	AZD4547	Preclinical	Actionable	In a preclinical study, AZD4547 inhibited FGFR signaling, and decreased proliferation and induced cell-cycle arrest in gastric cancer cells with amplification and over expression of FGFR2 in culture (PMID: 22869148).	22869148
FGFR2	FGFR2 amp	colorectal adenocarcinoma	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR2 amplified colorectal adenocarcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).	26438159
FGFR2	FGFR2 amp	colorectal adenocarcinoma	predicted - sensitive	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, RO5126766 inhibited proliferation of FGFR2 amplified colorectal adenocarcinoma cells in culture (PMID: 26438159).	26438159
FGFR2	FGFR2 amp	breast cancer	sensitive	Debio 1347	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of breast cancer cell lines harboring FGFR2 amplification in culture (PMID: 25169980).	25169980
FGFR2	FGFR2 amp	breast cancer	sensitive	Debio 1347	Case Reports/Case Series	Actionable	In a Phase I trial, Debio 1347 treatment resulted in a stable disease with 19.4% reduction of tumor size and 41% decrease of DUSP6 score in a patient with lung squamous cell carcinoma harboring FGFR2 amplification (PMID: 30745300; NCT01948297).	30745300
FGFR2	FGFR2 amp	stomach cancer	sensitive	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, PD173074 inhibited proliferation of a gastric cancer cell line harboring FGFR2 amplification in culture (PMID: 26036639).	26036639
FGFR2	FGFR2 amp	stomach cancer	sensitive	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR2-amplified gastric cancer cell lines demonstrated sensitivity to PD173074 in culture, with cell lines with high-level FGFR2 amplification displaying higher sensitivity compared to cell lines with low-level amplification (PMID: 27179038).	27179038
FGFR2	FGFR2 amp	ovarian cancer	sensitive	BAY1187982	Preclinical - Pdx	Actionable	In a preclinical study, BAY1187982 inhibited tumor growth in patient-derived xenograft models of FGFR2 amplified ovarian cancer (PMID: 27543601).	27543601
FGFR2	FGFR2 amp	colon cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 amp	stomach carcinoma	sensitive	Debio 1347	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 inhibited tumor growth in cell line xenograft models of FGFR2 amplified gastric carcinoma (PMID: 26438159).	26438159
FGFR2	FGFR2 amp	stomach cancer	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 inhibited proliferation of gastric cancer cell lines harboring FGFR2 amplification in culture (PMID: 26036639).	26036639
FGFR2	FGFR2 amp	myxoid liposarcoma	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) increased apoptosis, inhibited cell proliferation and migration of myxoid liposarcoma cell lines harbors FGFR2 amplification in culture (PMID: 26036639).	26036639
FGFR2	FGFR2 amp	stomach cancer	sensitive	FIIN-1	Preclinical	Actionable	In a preclinical study, FIIN-01 inhibited Fgfr2-dependent cell proliferation of gastric cancer cell lines harboring FGFR2 amplification (PMID: 20338520).	20338520
FGFR2	FGFR2 amp	estrogen-receptor negative breast cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of estrogen receptor (ER)-negative breast cancer cells with FGFR2 amplification in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 amp	colon cancer	sensitive	Nintedanib	Preclinical	Actionable	In a preclinical study, Ofev (nintedanib) inhibited growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 amp	endometrial cancer	sensitive	AZD4547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified endometrial cancer cells in cell line xenograft models (PMID: 27550940).	27550940
FGFR2	FGFR2 amp	stomach cancer	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of FGFR2-amplified gastric cancer cells in culture, and inhibited tumor growth in FGFR2-amplified gastric cancer cell line xenograft models (PMID: 22238366).	22238366
FGFR2	FGFR2 amp	stomach cancer	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD-6244) did not inhibit growth of gastric cancer cells with FGFR2 amplification in culture (PMID: 19755509).	19755509
FGFR2	FGFR2 amp	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 59% (10/17) of patients with advanced solid tumors harboring FGFR amplification, with a 6-month progression-free survival rate of 15% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).	detail...
FGFR2	FGFR2 amp	stomach cancer	sensitive	Debio 1347	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of FGFR-amplified gastric cancer cells in culture and inhibited tumor growth in cell line xenograft models of gastric cancer harboring FGFR2 amplification (PMID: 25169980).	25169980
FGFR2	FGFR2 amp	uterine cancer	predicted - sensitive	Debio 1347	Case Reports/Case Series	Actionable	In a Phase I trial, Debio 1347 treatment resulted in a stable disease with 3.9% change of tumor size and 60% decrease of DUSP6 score in a patient with uterine cancer harboring FGFR2 amplification (PMID: 30745300; NCT01948297).	30745300
FGFR2	FGFR2 amp	colon cancer	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 amp	lung non-small cell carcinoma	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in 67.5% tumor growth inhibition in patient-derived xenograft models of FGFR2-amplified non-small cell lung cancer (PMID: 28978721).	28978721
FGFR2	FGFR2 amp	breast cancer	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, a breast cancer patient harboring an FGFR2 amplification demonstrated stable disease when treated with BGJ398 (PMID: 27870574).	27870574
FGFR2	FGFR2 amp	colorectal cancer	sensitive	Erdafitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Balversa (erdafitinib) inhibited tumor growth in an FGFR2-amplified colorectal cancer cell line xenograft model (PMID: 28341788).	28341788
FGFR2	FGFR2 amp	gastric adenocarcinoma	no benefit	AZD4547	Phase II	Actionable	In a Phase II trial (SHINE), AZD4547 treatment did not improve progression-free survival compared to Taxol (paclitaxel) (1.8 vs 3.5 months, p=0.9581) in advanced gastric adenocarcinoma patients with FGFR2 amplification (PMID: 29177434; NCT01457846).	29177434
FGFR2	FGFR2 amp	colon cancer	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 reduced Myc expression, induced cell-cycle arrest, and inhibited growth of a colon cancer cell line with FGFR2 amplification in culture (PMID: 27401245).	27401245
FGFR2	FGFR2 amp	Advanced Solid Tumor	predicted - sensitive	Debio 1347	Phase I	Actionable	In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297).	30745300
FGFR2	FGFR2 amp	stomach carcinoma	sensitive	PRN1371	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PRN1371 inhibited proliferation of FGFR2 amplified gastric carcinoma cells in culture and tumor growth in cell line xenograft models (PMID: 28978721).	28978721
FGFR2	FGFR2 amp	stomach cancer	sensitive	ODM-203	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ODM-203 inhibited FGFR signaling and proliferation in a gastric cancer cell line with amplification of FGFR2, and inhibited tumor growth in xenograft models (PMID: 30301864).	30301864
FGFR2	FGFR2 amp	stomach carcinoma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR2 amplified gastric carcinoma cell lines were not sensitive to RO5126766 in culture (PMID: 26438159).	26438159
FGFR2	FGFR2 amp	myxoid liposarcoma	sensitive	Dovitinib + Trabectedin	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harbors FGFR2 amplification in culture (PMID: 26036639).	26036639
FGFR2	FGFR2 amp	stomach carcinoma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR2 amplified gastric carcinoma cell lines were not sensitive to RO4987655 in culture (PMID: 26438159).	26438159
FGFR2	FGFR2 amp	gastric signet ring cell adenocarcinoma	sensitive	M-COPA	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with M-COPA resulted in decreased Fgfr2 cell surface expression and phosphorylation and reduced growth of an FGFR2-amplified signet cell gastric cancer cell line in culture (PMID: 27197184).	27197184
FGFR2	FGFR2 amp	breast cancer	sensitive	Dovitinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited cell growth of an FGFR2 amplified breast cancer cell line in culture and prevented tumor growth and induced tumor regression in FGFR2 amplified breast cancer patient derived xenograft (PDX) models (PMID: 23658459).	23658459
FGFR2	FGFR2 amp	stomach cancer	sensitive	Erdafitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Balversa (erdafitinib) inhibited proliferation of a gastric cancer cell line with FGFR2 amplification in culture, and inhibited tumor growth in xenograft models (PMID: 28341788).	28341788
FGFR2	FGFR2 amp	breast cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of breast cancer cells harboring FGFR2 amplification in culture (PMID: 27627808).	27627808
FGFR2	FGFR2 amp	Her2-receptor positive breast cancer	sensitive	Dovitinib	Phase I	Actionable	In a Phase I trial, Dovitinib (TKI258) displayed safety and preliminary efficacy resulting in tumor regression of 28.2% and 18.5% in two patients with FGFR2 amplified Erbb2 (Her2)-receptor positive breast cancer (PMID: 23658459).	23658459
FGFR2	FGFR2 amp	breast cancer	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in ER-negative breast cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 amp	breast cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified breast cancer cells in culture (PMID: 27550940).	27550940
FGFR2	FGFR2 amp	colon cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 amp	stomach cancer	predicted - sensitive	Futibatinib	Phase I	Actionable	In a Phase I trial, TAS-120 treatment resulted in clinical response in a gastric cancer patient harboring FGFR2 amplification (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD).	detail...
FGFR2	FGFR2 amp	colorectal adenocarcinoma	decreased response	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR2 amplified colorectal adenocarcinoma cells demonstrated decreased response to RO4987655 in culture (PMID: 26438159).	26438159
FGFR2	FGFR2 amp	stomach cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited Fgfr signaling and growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 27627808).	27627808
FGFR2	FGFR2 amp	colorectal cancer	sensitive	Debio 1347	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of colorectal cancer cell lines harboring FGFR2 amplification in culture (PMID: 25169980).	25169980
FGFR2	FGFR2 amp	myxoid liposarcoma	sensitive	PD173074 + Trabectedin	Preclinical	Actionable	In a preclinical study, PD173034 and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification in culture (PMID: 26036639).	26036639
FGFR2	FGFR2 amp	stomach cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 amp	myxoid liposarcoma	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, PD173074 increased apoptosis, inhibited cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification in culture (PMID: 26036639).	26036639
FGFR2	EGFR over exp FGFR2 amp	head and neck squamous cell carcinoma	sensitive	AZD4547 + Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a moderate synergistic effect (PMID: 26936917).	26936917
FGFR2	EGFR over exp FGFR2 amp	head and neck squamous cell carcinoma	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917).	26936917
FGFR2	FGFR2 amp FGFR2 fusion	stomach cancer	sensitive	Derazantinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited Fgfr signaling and growth of gastric cancer cells harboring FGFR2 amplification and PDHX-FGFR2 fusion in culture, resulted in tumor regression in cell line xenograft models (PMID: 27627808).	27627808
FGFR2	FGFR2 amp FGFR2 fusion	breast cancer	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in tumor growth inhibition in patient-derived xenograft models of FGFR2-amplified breast cancer harboring FGFR2-GAB2 fusion (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).	detail...
FGFR2	FGFR1 amp FGFR2 amp	breast cancer	sensitive	E7090	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer cell line, harboring FGFR1 amplification and FGFR2 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969).	27535969
FGFR2	ERBB2 amp FGFR2 amp	esophagus adenocarcinoma	sensitive	AZD4547 + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of AZD-4547 and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and FGFR2 amplification in culture (PMID: 27595477).	27595477
FGFR2	FGFR2 amp FGFR2-COL14A1	colon cancer	sensitive	Derazantinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited Fgfr signaling and growth of colon cancer cells harboring FGFR2 amplification and FGFR2-COL14A1 fusion in culture and in cell line xenograft models (PMID: 27627808).	27627808
FGFR2	FGFR2 amp FGFR2-COL14A1	colorectal adenocarcinoma	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of colorectal adenocarcinoma cells harboring FGFR2 amplification and FGFR2-COL14A1 fusion in culture (PMID: 28978721).	28978721
FGFR2	FGFR2 amp FGFR2-GAB2	breast cancer	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in 60.6% tumor growth inhibition in patient-derived xenograft models of breast cancer harboring FGFR2 amplification and FGFR2-GAB2 fusion (PMID: 28978721).	28978721
FGFR2	FGFR2 amp FGFR2 rearrange	cholangiocarcinoma	predicted - sensitive	Futibatinib	Phase I	Actionable	In a Phase I trial, TAS-120 treatment resulted in partial response in a patient with cholangiocarcinoma harboring FGFR2 rearrangement and FGFR2 amplification (Annals of Oncology, Volume 29, Issue suppl_5).	detail...
FGFR2	FGFR2 amp FGFR2 mut	cervical adenocarcinoma	predicted - sensitive	Debio 1347	Case Reports/Case Series	Actionable	In a Phase I trial, Debio 1347 treatment resulted in a partial response with 50% reduction of tumor size and 56% decrease of DUSP6 score in a patient with cervical adenocarcinoma harboring FGFR2 amplification and FGFR2 mutation (PMID: 30745300; NCT01948297).	30745300
FGFR2	FGFR2-NRAP	intrahepatic cholangiocarcinoma	sensitive	BGJ398	Case Reports/Case Series	Actionable	In a clinical case study, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-NRAP fusion responded to Infigratinib (BGJ398) for 7.1 months before progressing (PMID: 31109923).	31109923
FGFR2	FGFR2-NRAP	intrahepatic cholangiocarcinoma	sensitive	Futibatinib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-NRAP fusion responded to TAS-120 for 17.2 months before progressing due to an acquired FGFR2 N550K mutation, detected in cell-free DNA and the tumor biopsy (PMID: 31109923; NCT02052778).	31109923
FGFR2	FGFR2-NRAP FGFR2 N550K	intrahepatic cholangiocarcinoma	resistant	Futibatinib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-NRAP fusion responded to TAS-120 for 17.2 months before progressing due to an acquired FGFR2 N550K mutation, detected in cell-free DNA and the tumor biopsy (PMID: 31109923; NCT02052778).	31109923
FGFR2	FGFR2 act mut	Advanced Solid Tumor	sensitive	Debio 1347	Phase I	Actionable	In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR2 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).	detail...
FGFR2	FGFR2 act mut	Advanced Solid Tumor	decreased response	Nintedanib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR2 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).	22238366
FGFR2	FGFR2 act mut	Advanced Solid Tumor	decreased response	Cediranib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR2 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).	22238366
FGFR2	FGFR2 act mut	endometrial cancer	sensitive	Dovitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, both cell lines and cell line xenograft models of endometrial cancer with FGFR2 activating mutations showed greater sensitivity to Dovitinib (TKI258) as compared to FGFR2 wild-type (PMID: 23443805).	23443805
FGFR2	FGFR2 act mut	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR2 in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 act mut	Advanced Solid Tumor	decreased response	Brivanib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR2 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Brivanib (BMS-540215) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).	22238366
FGFR2	FGFR2 act mut	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR2 in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 act mut	Advanced Solid Tumor	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363; NCT01703481).	26324363
FGFR2	FGFR2 act mut	stomach carcinoma	sensitive	S-49076	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-49076 inhibited Met activation, resulting in growth inhibition of gastric carcinoma cells harboring FGFR2 activating mutations in culture and in cell line xenograft models (PMID: 23804704).	23804704
FGFR2	FGFR2 N550K	Advanced Solid Tumor	resistant	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 N550K were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).	23908597
FGFR2	FGFR2 N550K	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550K (PMID: 23908597).	23908597
FGFR2	FGFR2 N550K	Advanced Solid Tumor	resistant	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 N550K were resistant to PD173074 (PMID: 23908597).	23908597
FGFR2	FGFR2 N550K	endometrial cancer	decreased response	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial cells harboring Fgfr2 N550K were less sensitive to the anti-proliferative effects of AZD4547 than the Fgfr2 double mutant, K310R, N550K (PMID: 26294741).	26294741
FGFR2	FGFR2 N550K	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing FGFR2 N550K in culture (PMID: 28978721).	28978721
FGFR2	FGFR2 K310R FGFR2 N550K	endometrial cancer	sensitive	AZD4547	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, AZD4547 inhibited proliferation of endometrial cells and delayed tumor growth in cell-line derived xenografts harboring the Fgfr2 double mutant, K310R, N550K (PMID: 26294741).	26294741
FGFR2	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs	endometrial cancer	sensitive	BGJ398 + Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).	28119489
FGFR2	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs	endometrial cancer	sensitive	BGJ398 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Pictilisib (GDC-0941) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).	28119489
FGFR2	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs	endometrial cancer	sensitive	Alpelisib + BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Alpelisib (BYL719) resulted in a synergistic effect, demonstrating inhibition of cell proliferation and induced cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).	28119489
FGFR2	FGFR2 C383R FGFR2 N550K	endometrial cancer	resistant	PD173074	Preclinical	Actionable	In a preclinical study, an endometrial cancer cell line harboring FGFR2 C383R and expressing FGFR2 N550K demonstrated resistance when treated with PD173074 (PMID: 23908597).	23908597
FGFR2	FGFR2-ZMYM4 FGFR2 V565F FGFR2 K660M FGFR2 E566A FGFR2 N550H FGFR2 N550K	intrahepatic cholangiocarcinoma	resistant	BGJ398	Case Reports/Case Series	Actionable	In a clinical case study, a patient with intrahepatic cholangiocarcinoma harboring an FGFR2-ZMYM4 fusion developed progressive disease after initial response to Infigratinib (BGJ398) for 5.6 months and FGFR2 V565F, K660M E566A, N550H, and N550K mutations were identified in the post-progression cell-free DNA (PMID: 31109923).	31109923
FGFR2	FGFR2-ZMYM4 FGFR2 V565F FGFR2 K660M FGFR2 E566A FGFR2 N550H FGFR2 N550K	intrahepatic cholangiocarcinoma	sensitive	Futibatinib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-ZMYM4 fusion with FGFR2 V565F, K660M E566A, N550H, and N550K mutations, responded to TAS-120 for 7.2 months before progressing due to an acquired FGFR2 V563L mutation, detected in cell-free DNA (PMID: 31109923; NCT02052778).	31109923
FGFR2	FGFR2 fusion FGFR2 N550K	intrahepatic cholangiocarcinoma	sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, TAS-120 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 N550K were sensitive to treatment as demonstrated by decreased cell viability and decreased activation of downstream signaling (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 N550K	intrahepatic cholangiocarcinoma	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, Infigratinib (BGJ398) treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 N550K were resistant to treatment as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 N550K	intrahepatic cholangiocarcinoma	resistant	Debio 1347	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 N550K were resistant to treatment, as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2 L618M	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 L618M were sensitive to treatment with Iclusig (ponatinib) (PMID: 23908597).	23908597
FGFR2	FGFR2 L618M	Advanced Solid Tumor	decreased response	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 L618M demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).	23908597
FGFR2	FGFR2 L618M	Advanced Solid Tumor	decreased response	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 L618M demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).	23908597
FGFR2	FGFR2 E565A FGFR2 K659M FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2-ZMYM4	cholangiocarcinoma	predicted - resistant	BGJ398	Case Reports/Case Series	Actionable	In a clinical case study, FGFR2 mutations E565A, K659M, N549H, N549K and V564F were identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-ZMYM4 fusion after the patient progressed while on Infigratinib (BGJ398) treatment (PMID: 28034880).	28034880
FGFR2	FGR2 E565A FGFR2 K641R FGFR2 L617V FGFR2 N549H FGFR2 V564F FGFR2-OPTN	cholangiocarcinoma	predicted - resistant	BGJ398	Case Reports/Case Series	Actionable	In a clinical case study, FGFR2 mutations E565A, K641R, L617V, N549H and V564F were identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-OPTN fusion after the patient progressed while on Infigratinib (BGJ398) treatment (PMID: 28034880).	28034880
FGFR2	FGFR2 M538I	Advanced Solid Tumor	decreased response	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with Iclusig (ponatinib) (PMID: 23908597).	23908597
FGFR2	FGFR2 M538I	Advanced Solid Tumor	decreased response	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).	23908597
FGFR2	FGFR2 M538I	Advanced Solid Tumor	decreased response	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).	23908597
FGFR2	FGFR2 fusion FGFR2 M538I	intrahepatic cholangiocarcinoma	sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, TAS-120 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 M538I were sensitive to treatment as demonstrated by decreased cell viability and decreased activation of downstream signaling (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 M538I	intrahepatic cholangiocarcinoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, Infigratinib (BGJ398) treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 M538I had weakened sensitivity, as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 M538I	intrahepatic cholangiocarcinoma	decreased response	Debio 1347	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 M538I had weakened sensitivity, as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2-SORBS1 FGFR2 V565F	intrahepatic cholangiocarcinoma	resistant	Futibatinib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-SORBS1 fusion, responded to TAS-120 for 15.8 months before progressing due to an acquired FGFR2 V565F mutation, detected in cell-free DNA (PMID: 31109923; NCT02052778).	31109923
FGFR2	FGFR2 fusion FGFR2 V565F	intrahepatic cholangiocarcinoma	resistant	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, TAS-120 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 V565F were resistant to treatment, as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 V565F	intrahepatic cholangiocarcinoma	decreased response	Debio 1347	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 V565F had weakened sensitivity, as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 V565F	intrahepatic cholangiocarcinoma	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, Infigratinib (BGJ398) treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 V565F were resistant to treatment as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2-ZMYM4 FGFR2 V563L	intrahepatic cholangiocarcinoma	resistant	Futibatinib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-SORBS1 fusion with FGFR2 V565F, K660M E566A, N550H, and N550K mutations, responded to TAS-120 for 7.2 months before progressing due to an acquired FGFR2 V563L mutation, detected in cell-free DNA and tumor biopsy (PMID: 31109923; NCT02052778).	31109923
FGFR2	FGFR2 F276C	intrahepatic cholangiocarcinoma	predicted - sensitive	BGJ398	Phase I	Actionable	In a Phase II trial, BGJ398 treatment resulted in partial response after 2 month of therapy and maintained the response for 4 months in a patient with advanced intrahepatic cholangiocarcinoma harboring a FGFR2 F276C mutation, which is consistent with inhibition of Erk signaling in cholangiocarcinoma cells expressing FGFR2 F274C in culture (JCO Precis Oncol 2017:1, 1-13; NCT02150967).	detail...
FGFR2	FGFR2 N549K	endometrial carcinoma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring FGFR2 N549K were not sensitive to RO4987655 in culture (PMID: 26438159).	26438159
FGFR2	FGFR2 N549K	endometrial cancer	decreased response	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) did not potently inhibit proliferation of endometrial cancer cell lines harboring FGFR2 N549K in cell culture (PMID: 22238366).	22238366
FGFR2	FGFR2 N549K	endometrial cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of endometrial cancer cells harboring FGFR2 N549K in cell culture (PMID: 22238366).	22238366
FGFR2	FGFR2 N549K	endometrial carcinoma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring FGFR2 N549K were not sensitive to RO5126766 in culture (PMID: 26438159).	26438159
FGFR2	FGFR2 N549K	endometrial cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of endometrial cancer cells harboring FGFR2 N549K in cell culture (PMID: 22238366).	22238366
FGFR2	FGFR2 N549K	endometrial cancer	resistant	Nintedanib	Preclinical	Actionable	In a preclinical study, Ofev (Nintedanib) did not inhibit growth of endometrial cancer cells harboring FGFR2 N549K in cell culture (PMID: 22238366).	22238366
FGFR2	FGFR2 N549K	endometrial cancer	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of endometrial cancer cells harboring FGFR2 N549K in culture and in cell line xenograft models (PMID: 22238366).	22238366
FGFR2	FGFR2 N549K	endometrial carcinoma	sensitive	FIIN-1	Preclinical	Actionable	In a preclinical study, FIIN-01 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K mutation in culture (PMID: 20338520).	20338520
FGFR2	FGFR2 N549K	endometrial carcinoma	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring FGFR2 N549K were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).	26438159
FGFR2	FGFR2 N549K	endometrial cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of endometrial cancer cell lines harboring FGFR2 N549K in culture (PMID: 27627808).	27627808
FGFR2	FGFR2 N549K	endometrial cancer	sensitive	Debio 1347	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 N549K mutation in culture (PMID: 25169980).	25169980
FGFR2	FGFR2 N549K	endometrial adenocarcinoma	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of endometrial adenocarcinoma cells harboring FGFR2 N549K in culture (PMID: 28978721).	28978721
FGFR2	FGFR2 K310R FGFR2 N549K	endometrial carcinoma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO4987655 in culture (PMID: 26438159).	26438159
FGFR2	FGFR2 K310R FGFR2 N549K	endometrial cancer	sensitive	Debio 1347	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 K310R and FGFR2 N549K mutations in culture (PMID: 25169980).	25169980
FGFR2	FGFR2 K310R FGFR2 N549K	endometrial carcinoma	sensitive	FIIN-1	Preclinical	Actionable	In a preclinical study, FIIN-01 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K and FGFR2 K310R mutations in culture (PMID: 20338520).	20338520
FGFR2	FGFR2 K310R FGFR2 N549K	endometrial carcinoma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO5126766 in culture (PMID: 26438159).	26438159
FGFR2	FGFR2 K310R FGFR2 N549K	endometrial carcinoma	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).	26438159
FGFR2	FGFR2 wild-type	Advanced Solid Tumor	predicted - sensitive	AZ6089	Preclinical	Actionable	In a preclinical study, AZ12576089 (AZ6089) inhibited FGF2-induced ERK1/2 phosphorylation and cell proliferation in transformed fibroblasts in culture (PMID: 22869148).	22869148
FGFR2	FGFR2 wild-type	colon cancer	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, colon cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).	22238366
FGFR2	FGFR2 wild-type	endometrial carcinoma	resistant	FIIN-1	Preclinical	Actionable	In a preclinical study, an endometrial carcinoma cell line harboring wild-type FGFR2 was resistant to FIIN-01-induced growth inhibition in culture (PMID: 20338520).	20338520
FGFR2	FGFR2 wild-type	endometrial cancer	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial cells with Fgfr2 wild-type were resistant to the anti-proliferative effects of AZD4547 (PMID: 26294741).	26294741
FGFR2	FGFR2 wild-type	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited Fgfr2 activity in transformed cells over expressing wild-type Fgfr2 in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).	detail...
FGFR2	FGFR2 wild-type	endometrial cancer	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, endometrial cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).	22238366
FGFR2	FGFR2 wild-type	breast cancer	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, ER-negative breast cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).	22238366
FGFR2	FGFR2 wild-type	stomach cancer	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, gastric cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).	22238366
FGFR2	FGFR2 wild-type ERBB2 amp	stomach cancer	resistant	AZD4547	Preclinical	Actionable	In a preclinical study, gastric cancer cells with wild-type FGFR2 and ERBB2 (HER2) amplification were resistant to treatment with AZD4547 in culture (PMID: 22869148).	22869148
FGFR2	FGFR2 N550S	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550S (PMID: 23908597).	23908597
FGFR2	FGFR2 N550S	Advanced Solid Tumor	decreased response	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 N550S demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).	23908597
FGFR2	FGFR2 N550S	Advanced Solid Tumor	decreased response	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 N550S demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).	23908597
FGFR2	FGFR2-INA FGFR2 V565L FGFR2 E566A	intrahepatic cholangiocarcinoma	resistant	Futibatinib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-INA fusion with FGFR2 H683L, L618V, N550H, N550T, M538I mutations, responded to TAS-120 for 5.1 months before progressing due to acquired FGFR2 V565L and E566A mutations, detected in cell-free DNA (PMID: 31109923; NCT02052778).	31109923
FGFR2	FGFR2 fusion FGFR2 E566A	intrahepatic cholangiocarcinoma	decreased response	Debio 1347	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 E566A had weakened sensitivity, as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 E566A	intrahepatic cholangiocarcinoma	sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, TAS-120 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 E566A were sensitive to treatment as demonstrated by decreased cell viability and decreased activation of downstream signaling (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 E566A	intrahepatic cholangiocarcinoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, Infigratinib (BGJ398) treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 E566A had weakened sensitivity, as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2 E566G	Advanced Solid Tumor	resistant	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 E566G were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).	23908597
FGFR2	FGFR2 E566G	Advanced Solid Tumor	resistant	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 E566G were resistant to treatment with PD173074 (PMID: 23908597).	23908597
FGFR2	FGFR2 E566G	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 E566G (PMID: 23908597).	23908597
FGFR2	FGFR2 P253R	head and neck squamous cell carcinoma	predicted - sensitive	Pazopanib	Case Reports/Case Series	Actionable	In a clinical case study, treatment with Votrient (pazopanib) resulted in reduced tumor size in a patient with head and neck squamous cell carcinoma harboring FGFR2 P253R (PMID: 23786770).	23786770
FGFR2	FGFR2-SORBS1	intrahepatic cholangiocarcinoma	sensitive	BGJ398	Case Reports/Case Series	Actionable	In a clinical case study, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-SORBS1 fusion responded to Infigratinib (BGJ398) for 12.6 months before progressing due to acquired FGFR2 K660M and K175R mutations, detected in cell-free DNA (PMID: 31109923).	31109923
FGFR2	FGFR2-SORBS1 FGFR2 K660M FGFR2 K715R	intrahepatic cholangiocarcinoma	resistant	BGJ398	Case Reports/Case Series	Actionable	In a clinical case study, a patient with intrahepatic cholangiocarcinoma harboring an FGFR2-SORBS1 fusion developed progressive disease after initial response to Infigratinib (BGJ398) for 12.6 months and FGFR2 K660M and FGFR2 K715R were identified in the post-progression cell-free DNA (PMID: 31109923).	31109923
FGFR2	FGFR2-SORBS1 FGFR2 K660M FGFR2 K715R	intrahepatic cholangiocarcinoma	sensitive	Futibatinib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-SORBS1 fusion with FGFR2 K660M and K175R mutations, responded to TAS-120 for 15.8 months before progressing due to an acquired FGFR2 V565F mutation, detected in cell-free DNA (PMID: 31109923; NCT02052778).	31109923
FGFR2	FGFR2-ROCK1	cholangiocarcinoma	predicted - sensitive	Debio 1347	Case Reports/Case Series	Actionable	In a Phase I trial, Debio 1347 treatment resulted in stable disease in a patient with cholangiocarcinoma harboring FGFR2-ROCK1 (PMID: 30745300; NCT01948297).	30745300
FGFR2	EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T	olfactory neuroblastoma	predicted - sensitive	Cetuximab + Sunitinib	Case Reports/Case Series	Actionable	In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).	27149458
FGFR2	FGFR2 V564I	Advanced Solid Tumor	resistant	Debio 1347	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 did not inhibit Fgfr2 phosphorylation in transformed cells over expressing FGFR2 V564I in culture (PMID: 25169980).	25169980
FGFR2	FGFR2-FAM76A	ovarian cancer	sensitive	BGJ398	Preclinical - Patient cell culture	Actionable	In a preclincal study, BGJ398 demonstrated enhanced inhibition of the survival in patient-derived ovarian cancer cells harboring FGFR2 - FAM76A in culture (PMID: 24563622).	24563622
FGFR2	FGFR2 fusion FGFR2 K715R	intrahepatic cholangiocarcinoma	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, Infigratinib (BGJ398) treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 K715R were sensitive to treatment as demonstrated by decreased cell viability and decreased activation of downstream signaling, in in vitro assays (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 K715R	intrahepatic cholangiocarcinoma	sensitive	Debio 1347	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 K715R were sensitive to treatment as demonstrated by decreased cell viability and decreased activation of downstream signaling, in in vitro assays (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 K715R	intrahepatic cholangiocarcinoma	sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, TAS-120 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 K715R were sensitive to treatment as demonstrated by decreased cell viability and decreased activation of downstream signaling (PMID: 31109923).	31109923
FGFR2	FGFR2-CASP7	Advanced Solid Tumor	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells expressing FGFR2-CASP7 in culture (PMID: 27627808).	27627808
FGFR2	FGFR2-CASP7	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Balversa (erdafitinib) inhibited Fgfr phosphorylation and downstream signaling, resulted in growth inhibition of transformed cells expressing FGFR2-CASP7 in culture (PMID: 28416604).	28416604
FGFR2	FGFR2-BICC1 FGFR2-CASP7	transitional cell carcinoma	predicted - sensitive	Erdafitinib	Case Reports/Case Series	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted in partial response for more than 12 months in a urothelial cancer patient harboring FGFR2-BICC1 and FGFR2-CASP7 fusions (PMID: 26324363; NCT01703481).	26324363
FGFR2	FGFR2-OFD1	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Balversa (erdafitinib) inhibited Fgfr phosphorylation and downstream signaling, resulted in growth inhibition of transformed cells expressing FGFR2-OFD1 in culture (PMID: 28416604).	28416604
FGFR2	FGFR2-BICC1 FGFR2-OFD1	endometrial cancer	predicted - sensitive	Erdafitinib	Case Reports/Case Series	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted in partial response in an endometrial cancer patient harboring FGFR2-BICC1 and FGFR2-OFD1 fusions (PMID: 26324363; NCT01703481).	26324363
FGFR2	FGFR2 dec exp	breast cancer	resistant	BAY1187982	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1187982 did not inhibit growth of breast cancer cells with very low Fgfr2 expression level in culture (PMID: 27543601).	27543601
FGFR2	FGFR2 W290_I291delinsC	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing Fgfr2 W290_I291delinsC (PMID: 26048680).	26048680
FGFR2	FGFR2 W290_I291delinsC	Advanced Solid Tumor	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 prevented oncogenic transformation of cells expressing FGFR2 W290_I291delinsC (PMID: 26048680).	26048680
FGFR2	FGFR2 fusion FGFR2 L618V	intrahepatic cholangiocarcinoma	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, Infigratinib (BGJ398) treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 L618V were resistant to treatment as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 L618V	intrahepatic cholangiocarcinoma	resistant	Debio 1347	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 L618V were resistant to treatment, as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 L618V	intrahepatic cholangiocarcinoma	sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, TAS-120 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 L618V were sensitive to treatment as demonstrated by decreased cell viability and decreased activation of downstream signaling (PMID: 31109923).	31109923
FGFR2	FGFR2 V565I	Advanced Solid Tumor	resistant	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).	23908597
FGFR2	FGFR2 V565I	Advanced Solid Tumor	resistant	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with PD173074 (PMID: 23908597).	23908597
FGFR2	FGFR2 V565I	Advanced Solid Tumor	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with Iclusig (ponatinib) (PMID: 23908597).	23908597
FGFR2	FGFR2 M536I	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 M536I (PMID: 23908597).	23908597
FGFR2	FGFR2 M536I	Advanced Solid Tumor	decreased response	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 M536I demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).	23908597
FGFR2	FGFR2 M536I	Advanced Solid Tumor	decreased response	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 M536I demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).	23908597
FGFR2	FGFR2-ZMYM4	intrahepatic cholangiocarcinoma	sensitive	BGJ398	Case Reports/Case Series	Actionable	In a clinical case study, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-ZMYM4 fusion responded to Infigratinib (BGJ398) for 5.6 months before progressing due to acquired FGFR2 V565F, K660M, E566A, N550H, and N550K mutations, detected in cell-free DNA (PMID: 31109923).	31109923
FGFR2	FGFR2 - TACC3	Advanced Solid Tumor	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 prevented oncogenic transformation of cells expressing FGFR2 - TACC3 (PMID: 26048680).	26048680
FGFR2	FGFR2 - TACC3	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing the fusion, FGFR2 - TACC3 (PMID: 26048680).	26048680
FGFR2	FGFR2 fusion	cholangiocarcinoma	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, two patients with cholangiocarcinoma harboring FGFR2 fusions demonstrated a decreased tumor burden when treated with BGJ398 (PMID: 27870574).	27870574
FGFR2	FGFR2 fusion	intrahepatic cholangiocarcinoma	sensitive	Derazantinib	Phase I	Actionable	In a Phase I trial, Derazantinib (ARQ 087) treatment resulted in partial response in 2 and stable disease in 1 of the 5 intrahepatic cholangiocarcinoma patients harboring FGFR2 fusions, and progressive disease in 5 patients without FGFR aberrations (PMID: 28972963; NCT01752920).	detail... 28972963
FGFR2	FGFR2 fusion	cholangiocarcinoma	predicted - sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted in an objective response rate of 27% (3/11) in patients with cholangiocarcinoma harboring FGFR genomic alterations, including 1 with FGFR2 mutation, 2 with FGFR3 mutations, and 8 with FGFR2 fusions (PMID: 31088831; NCT01703481).	31088831
FGFR2	FGFR2 fusion	Advanced Solid Tumor	predicted - sensitive	Debio 1347	Phase I	Actionable	In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297).	30745300
FGFR2	FGFR2 fusion	transitional cell carcinoma	predicted - sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted in an objective response rate of 46% (12/26) in patients with urothelial carcinoma harboring FGFR genomic alterations, including 17 with FGFR3 mutations, and 11 with FGFR2 and/or FGFR3 fusions (PMID: 31088831; NCT01703481).	31088831
FGFR2	FGFR2 fusion	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in 22% (2/9) and stable disease in 55% (5/9) of patients with advanced solid tumors harboring FGFR fusions, with a 6-month progression-free survival rate of 42% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).	detail...
FGFR2	FGFR2 fusion	cholangiocarcinoma	predicted - sensitive	Futibatinib	Phase I	Actionable	In a Phase I trial, TAS-120 treatment resulted in an objective response rate of 25% (7/28, 7 partial responses) in patients with cholangiocarcinoma harboring FGFR2 fusions, with 71% of patients experienced tumor shrinkage, 54% (15/28) achieved stable disease (Annals of Oncology, Volume 29, Issue suppl_5).	detail...
FGFR2	FGFR2 fusion	biliary tract cancer	predicted - sensitive	Futibatinib	Phase I	Actionable	In a Phase I trial, TAS-120 treatment resulted in stable disease over 24 weeks in two biliary tract cancer patients harboring FGFR2 fusions (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD).	detail...
FGFR2	FGFR2 fusion FGFR2 V564F	cholangiocarcinoma	predicted - resistant	BGJ398	Case Reports/Case Series	Actionable	In a clinical case study, FGFR2 V564F was identified in the cell-free DNA of 3 cholangiocarcinoma patients harboring FGFR2 fusion after the patients progressed while on Infigratinib (BGJ398) treatment (PMID: 28034880).	28034880
FGFR2	FGFR1 amp FGF2 fusion	colon cancer	predicted - sensitive	Debio 1347	Case Reports/Case Series	Actionable	In a Phase I trial, Debio 1347 treatment resulted in a partial response with 49.5% reduction of tumor size and 66% decrease of DUSP6 score in a patient with colon cancer harboring FGFR1 amplification and FGFR2 fusion (PMID: 30745300; NCT01948297).	30745300
FGFR2	FGFR2 fusion FGFR2 N550H	intrahepatic cholangiocarcinoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, Infigratinib (BGJ398) treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 N550H had weakened sensitivity, as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 N550H	intrahepatic cholangiocarcinoma	decreased response	Debio 1347	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 N550H had weakened sensitivity, as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 N550H	intrahepatic cholangiocarcinoma	sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, TAS-120 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 N550H were sensitive to treatment as demonstrated by decreased cell viability and decreased activation of downstream signaling (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 K660M	intrahepatic cholangiocarcinoma	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, Infigratinib (BGJ398) treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 K660M were resistant to treatment as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 K660M	intrahepatic cholangiocarcinoma	sensitive	Futibatinib	Preclinical - Cell culture	Actionable	In a preclinical study, TAS-120 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 K660M were sensitive to treatment as demonstrated by decreased cell viability and decreased activation of downstream signaling (PMID: 31109923).	31109923
FGFR2	FGFR2 fusion FGFR2 K660M	intrahepatic cholangiocarcinoma	resistant	Debio 1347	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 K660M were resistant to treatment, as demonstrated by cell viability and downstream signaling assays (PMID: 31109923).	31109923
FGFR2	FGFR2 S252W	endometrial cancer	sensitive	Nintedanib	Preclinical	Actionable	In a preclinical study, Ofev (Nintedanib) inhibited cell proliferation in endometrial cancer cells harboring FGFR2 S252W mutation in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 S252W	endometrial cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 S252W	endometrial cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 27627808).	27627808
FGFR2	FGFR2 S252W	endometrial cancer	decreased response	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) did not potently inhibit cell proliferation in endometrial cancer cells harboring FGFR2 S252W mutation in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 S252W	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 S252W were sensitive to Dovitinib (TKI258) (PMID: 23908597).	23908597
FGFR2	FGFR2 S252W	endometrial carcinoma	sensitive	GSK3052230	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GSK3052230 (FP-1039) treatment resulted in greater tumor growth inhibition (95% vs 30%) in cell line xenograft models of endometrial carcinoma harboring FGFR2 S252W compared to FGFR2 wild-type models (PMID: 23536011).	23536011
FGFR2	FGFR2 S252W	endometrial cancer	sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, an endometrial cancer cell line harboring FGFR2 S252W (PMID: 18552176) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969).	18552176 27535969
FGFR2	FGFR2 S252W	endometrial cancer	sensitive	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) inhibited growth of endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 S252W	endometrial cancer	decreased response	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial cells harboring Fgfr2 S252W were less sensitive to the anti-proliferative effects of AZD4547 than the Fgfr2 double mutant, K310R, N550K (PMID: 26294741).	26294741
FGFR2	FGFR2 S252W	endometrial carcinoma	decreased response	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring FGFR2 S252W demonstrated decreased response to RO4987655 in culture (PMID: 26438159).	26438159
FGFR2	FGFR2 S252W	endometrial cancer	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and cell proliferation in endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366).	22238366
FGFR2	FGFR2 S252W	endometrial carcinoma	decreased response	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial carcinoma cells harboring FGFR2 S252W demonstrated decreased sensitivity to Selumetinib (AZD-6244) in culture (PMID: 26438159).	26438159
FGFR2	FGFR2 S252W	endometrial cancer	sensitive	Debio 1347	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring an FGFR2 S252W mutation in culture and inhibited tumor growth in FGFR2 S252W-positive endometrial cancer cell line xenograft models (PMID: 25169980).	25169980
FGFR2	FGFR2 S252W	endometrial carcinoma	sensitive	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, RO5126766 inhibited proliferation of endometrial carcinoma cells harboring FGFR2 S252W in culture (PMID: 26438159).	26438159
FGFR2	FGFR2-AHCYL1	Advanced Solid Tumor	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, treatment with BGJ398 prevented transformation of cells expressing FGFR2-AHCYL1 in culture (PMID: 24122810).	24122810
FGFR2	FGFR2-AHCYL1	Advanced Solid Tumor	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, treatment with PD173074 prevented transformation of cells expressing FGFR2-AHCYL1 in culture (PMID: 24122810).	24122810
FGFR2	FGFR2 - CIT	Advanced Solid Tumor	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells expressing FGFR2-CIT in culture (PMID: 27627808).	27627808
FGFR2	FGFR2-KIAA1217	cholangiocarcinoma	predicted - sensitive	Debio 1347	Case Reports/Case Series	Actionable	In a Phase I trial, Debio 1347 treatment resulted in stable disease in a patient with cholangiocarcinoma harboring FGFR2-KIAA1217 (PMID: 30745300; NCT01948297).	30745300
FGFR2	FGFR2-KIAA1217	intrahepatic cholangiocarcinoma	sensitive	Futibatinib	Preclinical - Pdx	Actionable	In a preclinical study, TAS-120 treatment of an intrahepatic cholangiocarcinoma patient-derived xenograft model, harboring an FGFR2-KIAA1217 fusion, decreased tumor growth and suppressed MEK/ERK signaling (PMID: 31109923).	31109923
FGFR2	FGFR2 N550H	Advanced Solid Tumor	resistant	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 N550H were resistant to treatment with PD173074 (PMID: 23908597).	23908597
FGFR2	FGFR2 N550H	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550H (PMID: 23908597).	23908597
FGFR2	FGFR2 N550H	Advanced Solid Tumor	decreased response	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 N550H demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).	23908597
FGFR2	FGFR2-FN1	liver cancer	predicted - sensitive	BGJ398	Preclinical - Pdx	Actionable	In a preclinical study, Infigratinib (BGJ398) treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of liver cancer harboring FGFR2-FN1 (Cancer Res 2019;79(13 Suppl):Abstract nr 2206).	detail...
FGFR2	FGFR2 K660N	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing FGFR2 K660N in culture (PMID: 23786770).	23786770
FGFR2	FGFR2 K660N	Advanced Solid Tumor	sensitive	Pazopanib	Preclinical - Cell culture	Actionable	In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR2 K660N in culture (PMID: 23786770).	23786770
FGFR2	FGFR2 K660N	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing FGFR2 K660N in culture (PMID: 28978721).	28978721 detail...
FGFR2	FGFR2 K660N	Advanced Solid Tumor	sensitive	BGJ398	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BGJ398 inhibited growth of transformed cells expressing FGFR2 K660N in culture and inhibited tumor growth in xenograft models (PMID: 23786770).	23786770
FGFR2	FGFR2 K660N	Advanced Solid Tumor	sensitive	Lenvatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lenvima (lenvatinib) inhibited growth of transformed cells expressing FGFR2 K660N in culture (PMID: 23786770).	23786770
FGFR2	FGFR2 K660N	Advanced Solid Tumor	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited growth of transformed cells expressing FGFR2 K660N in culture (PMID: 23786770).	23786770
FGFR2	FGFR2 K660N	Advanced Solid Tumor	sensitive	Cediranib	Preclinical - Cell culture	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of transformed cells expressing FGFR2 K660N in culture (PMID: 23786770).	23786770
FGFR2	FGFR2 S267_D273dup	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing Fgfr2 S267_D273dup (PMID: 26048680).	26048680
FGFR2	FGFR2 S267_D273dup	Advanced Solid Tumor	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 prevented oncogenic transformation of cells expressing FGFR2 S267_D273dup (PMID: 26048680).	26048680
FGFR2	FGFR2 V564F	Advanced Solid Tumor	resistant	AZD4547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells over expressing FGFR2 V564F were resistant to AZD4547 in culture and in cell line xenograft models (PMID: 25169980).	25169980
FGFR2	FGFR2 V564F	Advanced Solid Tumor	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR2 V564F were resistant to BGJ398 in culture (PMID: 28034880).	28034880
FGFR2	FGFR2 V564F	Advanced Solid Tumor	sensitive	Debio 1347	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of transformed cells over expressing FGFR2 V564F in culture and inhibited tumor growth in cell line xenograft models (PMID: 25169980).	25169980
FGFR2	FGFR2 V564F FGFR2-BICC1	cholangiocarcinoma	predicted - resistant	BGJ398	Case Reports/Case Series	Actionable	In a clinical case study, FGFR2 V564F was identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-BICC1 fusion after the patient progressed while on Infigratinib (BGJ398) treatment (PMID: 28034880).	28034880
FGFR2	FGFR2-GAB2	breast cancer	predicted - sensitive	BGJ398	Preclinical - Pdx	Actionable	In a preclinical study, Infigratinib (BGJ398) treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of breast cancer harboring FGFR2-GAB2 (Cancer Res 2019;79(13 Suppl):Abstract nr 2206).	detail...
FGFR2	FGFR2-AFF3	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Balversa (erdafitinib) inhibited Fgfr phosphorylation and downstream signaling, resulted in growth inhibition of transformed cells expressing FGFR2-AFF3 in culture (PMID: 28416604).	28416604
FGFR2	FGFR2 mutant	endometrial cancer	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of endometrial cancer cells harboring FGFR2 mutations in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).	detail...
FGFR2	FGFR2 mutant	cholangiocarcinoma	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, a patient with cholangiocarcinoma harboring an FGFR2 mutation demonstrated a decreased tumor burden when treated with BGJ398 (PMID: 27870574).	27870574
FGFR2	FGFR2 mutant	endometrial cancer	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 inhibited the growth of FGFR2-mutated endometrial cancer cells in vitro and in xenograft models (PMID: 23443805).	23443805
FGFR2	FGFR2 mutant	transitional cell carcinoma	sensitive	Erdafitinib	Guideline	Actionable	Balversa (erdafitinib) is included in the guidelines for patients with advanced or metastatic urothelial carcinoma harboring Fgfr2 alterations after progression on platinum-based regimens (NCCN.org).	detail...
FGFR2	FGFR2 mutant	transitional cell carcinoma	sensitive	Erdafitinib	FDA approved - Has Companion Diagnostic	Actionable	In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations (PMID: 31340094; NCT02365597).	detail... 31340094 detail...
FGFR2	FGFR2 mutant	Advanced Solid Tumor	predicted - sensitive	Debio 1347	Phase I	Actionable	In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297).	30745300
FGFR2	FGFR2 mutant	cholangiocarcinoma	predicted - sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted in an objective response rate of 27% (3/11) in patients with cholangiocarcinoma harboring FGFR genomic alterations, including 1 with FGFR2 mutation, 2 with FGFR3 mutations, and 8 with FGFR2 fusions (PMID: 31088831; NCT01703481).	31088831
FGFR2	FGFR2 mutant	Advanced Solid Tumor	sensitive	Pemigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to INCB054828 in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771).	detail...
FGFR2	FGFR2 mutant	bladder urothelial carcinoma	sensitive	Erdafitinib	FDA approved - Has Companion Diagnostic	Actionable	In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations (PMID: 31340094; NCT02365597).	detail... 31340094 detail...
FGFR2	FGFR2 mutant	bladder urothelial carcinoma	sensitive	Erdafitinib	Guideline	Actionable	Balversa (erdafitinib) is included in the guidelines for patients with advanced or metastatic urothelial carcinoma harboring Fgfr2 alterations after progression on platinum-based regimens (NCCN.org).	detail...
FGFR2	FGFR2 mutant	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 40% (6/16) of patients with advanced solid tumors harboring FGFR single nucleotide variants, with a 6-month progression-free survival rate of 8% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).	detail...
FGFR2	FGFR2-DDX21	cholangiocarcinoma	predicted - sensitive	Debio 1347	Case Reports/Case Series	Actionable	In a Phase I trial, Debio 1347 treatment resulted in stable disease in a patient with cholangiocarcinoma harboring FGFR2-DDX21 (PMID: 30745300; NCT01948297).	30745300
FGFR2	FGFR2-INA	intrahepatic cholangiocarcinoma	sensitive	Debio 1347	Case Reports/Case Series	Actionable	In a clinical case study, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-INA fusion responded to Debio 1347 for 11.4 months before progressing due to acquired FGFR2 H683L, L618V, N550H, N550T, and M538I mutations (PMID: 31109923).	31109923
FGFR2	FGFR2-INA	colon cancer	predicted - sensitive	Debio 1347	Case Reports/Case Series	Actionable	In a Phase I trial, Debio 1347 treatment resulted in a partial response in 2 patient with colon cancer harboring FGFR2-INA (PMID: 30745300; NCT01948297).	30745300
FGFR2	FGFR2 V564L	Advanced Solid Tumor	resistant	Debio 1347	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 did not inhibit Fgfr2 phosphorylation in transformed cells over expressing FGFR2 V564L in culture (PMID: 25169980).	25169980
FGFR2	FGFR2-TNS1	triple-receptor negative breast cancer	sensitive	BGJ398 + Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, triple-receptor negative breast cancer xenograft models harboring FGFR2-TNS1 demonstrated rapid and complete tumor regression when treated with the combination of BGJ398 and Buparlisib (BKM120) (PMID: 29203461).	29203461
FGFR2	FGFR2-TNS1	triple-receptor negative breast cancer	no benefit	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, triple-receptor negative breast cancer xenograft models harboring FGFR2-TNS1 demonstrated stable disease upon treatment with Buparlisib (BKM120), but also exhibited general toxicity (PMID: 29203461).	29203461
FGFR2	FGFR2-TNS1	triple-receptor negative breast cancer	sensitive	BGJ398	Preclinical - Cell line xenograft	Actionable	In a preclinical study, triple-receptor negative breast cancer xenograft models harboring FGFR2-TNS1 demonstrated tumor regression when treated with BGJ398 (PMID: 29203461).	29203461
FGFR2	FGFR2 positive	breast cancer	sensitive	BAY1187982	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, BAY1187982 inhibited survival of Fgfr2 positive breast cancer cell lines in culture, and suppressed tumor growth in both cell line and patient-derived xenograft models (PMID: 27543601).	27543601
FGFR2	FGFR2 positive	stomach cancer	sensitive	BAY1187982	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, BAY1187982 inhibited survival of gastric cancer cell lines with elevated Fgfr2 expression level in culture, and suppressed tumor growth in cell line or patient-derived xenograft models (PMID: 27543601).	27543601
FGFR2	FGFR2 positive	Advanced Solid Tumor	sensitive	BAY1187982	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, sensitivity to BAY1187982 positively correlated with Fgfr2 expression level in a variety of cancer cell lines in culture, and in cell line or patient-derived xenograft models (PMID: 27543601).	27543601
FGFR2	FGFR2 positive	breast cancer	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR2-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).	detail...
FGFR2	FGFR1 pos FGFR2 pos	hepatocellular carcinoma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, hepatocellular carcinoma cell lines treated with AZD4547 demonstrated decreased phosphorylation of FGFR1 and FGFR2, reduced colony formation, and evidence of apoptotic activity in culture (PMID: 26351320).	26351320
FGFR2	FGFR1 pos FGFR2 pos	hepatocellular carcinoma	no benefit	PHA-665752	Preclinical - Cell culture	Actionable	In a preclinical study, PHA-665752 treatment did not result in decreased colony formation or reduced phosphorylation levels of FGFR1 and FGFR2 in hepatocellular carcinoma cells in culture (PMID: 26351320).	26351320
FGFR2	FGFR2 pos FGFR3 pos	breast carcinoma	sensitive	E7090	Preclinical	Actionable	In a preclinical study, a mouse breast carcinoma cell line xenograft model demonstrated inhibition of tumor growth when treated with E7090, a result of decreased FGFR2 and FGFR3 activity (PMID: 27535969).	27535969
FGFR2	FGFR2-BICC1	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Balversa (erdafitinib) inhibited Fgfr phosphorylation and downstream signaling, resulted in growth inhibition of transformed cells expressing FGFR2-BICC1 in culture (PMID: 28416604).	28416604
FGFR2	FGFR2-BICC1	Advanced Solid Tumor	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, treatment with BGJ398 prevented transformation of cells expressing FGFR2-BICC1 in culture (PMID: 24122810).	24122810
FGFR2	FGFR2-BICC1	Advanced Solid Tumor	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, treatment with PD173074 prevented transformation of cells expressing FGFR2-BICC1 in culture (PMID: 24122810).	24122810
FGFR2	FGFR2 K660E	Advanced Solid Tumor	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770).	23786770
FGFR2	FGFR2 K660E	Advanced Solid Tumor	sensitive	Cediranib	Preclinical - Cell culture	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770).	23786770
FGFR2	FGFR2 K660E	Advanced Solid Tumor	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770).	23786770
FGFR2	FGFR2 K660E	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing FGFR2 K660E in culture (PMID: 28978721).	28978721 detail...
FGFR2	FGFR2 K660E	Advanced Solid Tumor	sensitive	Lenvatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lenvima (lenvatinib) inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770).	23786770
FGFR2	FGFR2 K660E	Advanced Solid Tumor	sensitive	Pazopanib	Preclinical - Cell culture	Actionable	In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23786770).	23786770
FGFR2	FGFR2 K660E	Advanced Solid Tumor	decreased response	PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 K660E demonstrated a decreased response when treated with PD173074 (PMID: 23908597).	23908597
FGFR2	FGFR2 K660E	Advanced Solid Tumor	resistant	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 K660E were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).	23908597
FGFR2	FGFR2 K660E	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing FGFR2 K660E in culture (PMID: 23908597).	23908597
FGFR2	FGFR2 rearrange	cholangiocarcinoma	resistant	Pemigatinib	Phase II	Actionable	In a Phase II (FIGHT-202) trial, Pemigatinib (INCB054828) treatment resulted in partial response in 18% (8/45, 1 unconfirmed complete response), stable disease in 58% (26/45) of patients with cholangiocarcinoma harboring FGFR2 translocations, with a median progression-free survival of 6.8 months; and no response were observed in cohorts of patients with other FGF/FGFR genetic alterations or wild-type FGF/FGFR (Ann Oncol, Oct 2018, 29 (suppl 8), abstract 756P; NCT02924376).	detail...
FGFR2	FGFR2 rearrange	cholangiocarcinoma	predicted - sensitive	Futibatinib	Phase I	Actionable	In a Phase I trial, TAS-120 treatment resulted in partial response in 2 patients with cholangiocarcinoma harboring FGFR2 rearrangements (Annals of Oncology, Volume 29, Issue suppl_5).	detail...
FGFR3	FGFR3 G372C	Advanced Solid Tumor	sensitive	R3Mab	Preclinical - Cell culture	Actionable	In a preclinical study, R3Mab inhibited ligand-dependent proliferation in cells expressing FGFR3 G372C (PMID: 19381019).	19381019
FGFR3	FGFR3 wild-type FGFR3 dec exp HRAS G12V	transitional cell carcinoma	resistant	PD173074	Preclinical	Actionable	In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to PD173074 in culture (PMID: 22869148).	22869148
FGFR3	FGFR3 wild-type FGFR3 dec exp HRAS G12V	transitional cell carcinoma	decreased response	AZ8010	Preclinical	Actionable	In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZ8010 in culture (PMID: 22869148).	22869148
FGFR3	FGFR3 wild-type FGFR3 dec exp HRAS G12V	transitional cell carcinoma	resistant	AZD4547	Preclinical	Actionable	In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZD4547 in culture (PMID: 22869148).	22869148
FGFR3	FGFR3 G370C	transitional cell carcinoma	sensitive	Erdafitinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations and FGFR3 G370C is included in the companion diagnostic (PMID: 31340094; NCT02365597).	detail... 31340094 detail...
FGFR3	FGFR3 G370C	bladder urothelial carcinoma	sensitive	Erdafitinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations and FGFR3 G370C is included in the companion diagnostic (PMID: 31340094; NCT02365597).	detail... 31340094 detail...
FGFR3	FGFR3 amp	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 59% (10/17) of patients with advanced solid tumors harboring FGFR amplification, with a 6-month progression-free survival rate of 15% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).	detail...
FGFR3	FGFR3 amp	urinary system cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245).	27401245
FGFR3	FGFR3 amp	Advanced Solid Tumor	predicted - sensitive	Debio 1347	Phase I	Actionable	In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297).	30745300
FGFR3	FGFR3 amp	urinary system cancer	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245).	27401245
FGFR3	FGFR3 amp	Advanced Solid Tumor	predicted - sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of several tumor cell lines with FGFR alterations in culture (Cancer Res April 15, 2011 71:3560).	detail...
FGFR3	FGFR3 amp	lung non-small cell carcinoma	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in 28.2% tumor growth inhibition in patient-derived xenograft models of FGFR3-amplified non-small cell lung cancer (PMID: 28978721).	28978721
FGFR3	FGFR3 amp	Advanced Solid Tumor	predicted - sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, BGJ398 demonstrated safety and preliminary efficacy in patients with select solid tumors harboring FGFR alterations (Cancer Res October 1, 2014 74:CT326).	detail...
FGFR3	ROS1 fusion ERBB2 amp FGFR3 amp RET amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of ERBB2 (HER2), FGFR3, and RET (PMID: 29636358).	29636358
FGFR3	FGFR3 act mut	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366).	22238366
FGFR3	FGFR3 act mut	urinary bladder cancer	predicted - sensitive	S-49076	Preclinical	Actionable	In a preclinical study, S-49076 inhibited autophosphorylation of FGFR3 and downstream signaling in bladder cancer cells over expressing constitutively active FGFR3 in culture (PMID: 23804704).	23804704
FGFR3	FGFR3 act mut	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366).	22238366
FGFR3	FGFR3 act mut	Advanced Solid Tumor	decreased response	Nintedanib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR3 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).	22238366
FGFR3	FGFR3 act mut	Advanced Solid Tumor	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363; NCT01703481).	26324363
FGFR3	FGFR3 act mut	Advanced Solid Tumor	decreased response	Cediranib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR3 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).	22238366
FGFR3	FGFR3 act mut	Advanced Solid Tumor	sensitive	Debio 1347	Phase I	Actionable	In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR3 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).	detail...
FGFR3	FGFR3 act mut	Advanced Solid Tumor	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366).	22238366
FGFR3	FGFR3 Y375C	urinary bladder cancer	resistant	Cediranib	Preclinical	Actionable	In a preclinical study, bladder cancer cells harboring an FGFR3 Y375C mutation were resistant to growth inhibition by Cediranib (AZD-2171) in culture (PMID: 22238366).	22238366
FGFR3	FGFR3 Y375C	Advanced Solid Tumor	sensitive	R3Mab	Preclinical - Cell culture	Actionable	In a preclinical study, R3Mab inhibited ligand-dependent proliferation of cells expressing FGFR3 Y375C in culture (PMID: 19381019).	19381019
FGFR3	FGFR3 Y375C	urinary bladder cancer	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366).	22238366
FGFR3	FGFR3 Y375C	urinary bladder cancer	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366).	22238366
FGFR3	FGFR3 Y375C	urinary bladder cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366).	22238366
FGFR3	FGFR3 Y375C	urinary bladder cancer	resistant	Nintedanib	Preclinical	Actionable	In a preclinical study, bladder cancer cells harboring FGFR3 Y375C were resistant to growth inhibition by Ofev (Nintedanib) in culture (PMID: 22238366).	22238366
FGFR3	FGFR3 K652E	Advanced Solid Tumor	sensitive	R3Mab	Preclinical - Cell culture	Actionable	In a preclinical study, R3Mab inhibited ligand-dependent cell proliferation in cells expressing FGFR3 K652E in culture (PMID: 19381019).	19381019
FGFR3	FGFR3 K652E	urinary bladder cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of bladder cancer cells harboring FGFR3 K652E in culture (PMID: 27627808).	27627808
FGFR3	FGFR3 fusion	Advanced Solid Tumor	predicted - sensitive	Debio 1347	Phase I	Actionable	In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297).	30745300
FGFR3	FGFR3 fusion	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in 22% (2/9) and stable disease in 55% (5/9) of patients with advanced solid tumors harboring FGFR fusions, with a 6-month progression-free survival rate of 42% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).	detail...
FGFR3	FGFR3 fusion	Advanced Solid Tumor	predicted - sensitive	Futibatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAS-120 demonstrated growth inhibition and reduced FGFR phosphorylation in human cancer cell lines and xenograft models harboring FGFR mutations (Mol Cancer Ther 2013;12(11 Suppl):A270).	detail...
FGFR3	FGFR3 fusion	transitional cell carcinoma	predicted - sensitive	Docetaxel + Vofatamab	Phase Ib/II	Actionable	In a Phase I/II trial, Vofatamab (B-701) in combination with Taxotere (docetaxel) demonstrated safety and preliminary efficacy, resulted in enhanced activity in patients with locally advanced or metastatic urothelial carcinoma harboring FGFR3 mutations or fusions comparing to wild-type patients (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 4534-4534; NCT02401542).	detail...
FGFR3	FGFR3 fusion	urinary bladder cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited survival of bladder cancer cells harboring FGFR3 fusion in culture (PMID: 27550940).	27550940
FGFR3	FGFR3 fusion	transitional cell carcinoma	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, BGJ398 treatment resulted in complete response in 4% (1/25) and partial response in 32% (8/25) of urothelial carcinoma patients harboring FGFR3 mutations or fusions (J Clin Oncol 34, 2016 (suppl; abstr 4517)).	detail...
FGFR3	FGFR3 fusion	transitional cell carcinoma	predicted - sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted in an objective response rate of 46% (12/26) in patients with urothelial carcinoma harboring FGFR genomic alterations, including 17 with FGFR3 mutations, and 11 with FGFR2 and/or FGFR3 fusions (PMID: 31088831; NCT01703481).	31088831
FGFR3	FGFR3 D764H	head and neck squamous cell carcinoma	no benefit	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited proliferation of a head and neck squamous cell carcinoma cell line expressing FGFR3 D764H in culture, however, cells expressing FGFR3 D764H did not demonstrate increased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 (PMID: 27053219).	27053219
FGFR3	FGFR3 wild-type	bladder carcinoma	sensitive	R3Mab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R3Mab decreased wild-type FGFR3 activation, thereby inhibited cell proliferation of FGFR3 wild-type human bladder cancer cells in culture and in cell line xenograft models (PMID: 19381019).	19381019
FGFR3	FGFR3 wild-type	myeloid neoplasm	sensitive	SU5402	Preclinical - Cell culture	Actionable	In a preclinical study, SU5402 inhibited proliferation of myeloma cells expressing wild-type FGFR3 in culture (PMID: 23597562).	23597562
FGFR3	FGFR3 wild-type	myeloid neoplasm	sensitive	SSR128129E	Preclinical	Actionable	In a preclinical study, SSR128129E inhibited proliferation of myeloma cells expressing wild-type FGFR3 in culture (PMID: 23597562).	23597562
FGFR3	FGFR3 wild-type	urinary bladder cancer	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, bladder cancer cells with wild-type FGFR3 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).	22238366
FGFR3	FGFR3 L608V	Advanced Solid Tumor	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 L608V	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 L608V	Advanced Solid Tumor	sensitive	LY2874455	Preclinical - Cell culture	Actionable	In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 L608V	Advanced Solid Tumor	sensitive	FIIN-2	Preclinical - Cell culture	Actionable	In a preclinical study, FIIN-2 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 L608V	Advanced Solid Tumor	decreased response	Debio 1347	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 L608V	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 L608V	Advanced Solid Tumor	decreased response	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to AZD4547 in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 L608V FGFR3 V555M	transitional cell carcinoma	resistant	BGJ398	Case Reports/Case Series	Actionable	In a clinical study, a patient with metastatic urothelial carcinoma progressed while being treated with BGJ398 and subsequent cell-free DNA testing revealed FGFR3 V555M (also corresponds to V443M) and FGFR3 L608V (also corresponds to L496V) (PMID: 29848605).	29848605
FGFR3	FGFR3 V555L	transitional cell carcinoma	resistant	BGJ398	Case Reports/Case Series	Actionable	In a clinical study, two patients with metastatic urothelial carcinoma progressed while being treated with BGJ398 and subsequent cell-free DNA testing revealed FGFR3 V555L (also corresponds to V443L) (PMID: 29848605).	29848605
FGFR3	FGFR3 V555L	Advanced Solid Tumor	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 V555L demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 R248C	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited growth of transformed cells expressing FGFR3 R248C in culture (PMID: 23786770).	23786770
FGFR3	FGFR3 R248C	Advanced Solid Tumor	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited growth of transformed cells expressing FGFR3 R248C in culture (PMID: 23786770).	23786770
FGFR3	FGFR3 R248C	bladder urothelial carcinoma	sensitive	Erdafitinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations and FGFR3 R248C is included in the companion diagnostic (PMID: 31340094; NCT02365597).	detail... 31340094 detail...
FGFR3	FGFR3 R248C	Advanced Solid Tumor	sensitive	R3Mab	Preclinical - Cell culture	Actionable	In a preclinical study, R3Mab inhibited ligand-independent proliferation induced by FGFR3 R248C in cultured cells (PMID: 19381019).	19381019
FGFR3	FGFR3 R248C	transitional cell carcinoma	sensitive	Erdafitinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations and FGFR3 R248C is included in the companion diagnostic (PMID: 31340094; NCT02365597).	31340094 detail... detail...
FGFR3	FGFR3 R248C	Advanced Solid Tumor	sensitive	Pazopanib	Preclinical - Cell culture	Actionable	In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR3 R248C in culture (PMID: 23786770).	23786770
FGFR3	FGFR3 over exp	urinary bladder cancer	sensitive	Dovitinib	Phase II	Actionable	In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response for 6 months in 8% (1/13) of non-muscle invasive bladder cancer patients over expressing FGFR3 (J Clin Oncol 34, 2016 (suppl; abstr 4526)).	detail...
FGFR3	FGFR3 over exp	urinary bladder cancer	sensitive	BEZ235 + Sorafenib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of BEZ235 and Nexavar (sorafenib) resulted in improved progression-free survival in an FGFR3-over expressing patient-derived xenograft (PDX) model of bladder cancer with secondary resistance to BGJ398 due to reactivation of downstream signaling, as evidenced by increased activation of Akt and Erk (PMID: 26270481).	26270481
FGFR3	FGFR3 over exp	glioblastoma multiforme	sensitive	U0126	Preclinical	Actionable	In a preclinical study, U0126 inhibited downstream signaling and growth of glioblastoma cells over-expressing Fgfr3 in culture (PMID: 23298836).	23298836
FGFR3	FGFR3 over exp	transitional cell carcinoma	sensitive	AZD4547	Preclinical	Actionable	In a preclinical study, AZD4547 inhibited proliferation of urothelial cancer cells with over expression of FGFR3 in culture (PMID: 22869148).	22869148
FGFR3	FGFR3 over exp	head and neck squamous cell carcinoma	sensitive	Rogaratinib	Preclinical	Actionable	In a preclinical study, Rogaratinib (BAY 1163877) inhibited tumor growth in a head and neck squamous cell carcinoma xenograft model with FGFR3 overexpression (Cancer Res August 1, 2015 75:772).	detail...
FGFR3	FGFR3 over exp	urinary bladder cancer	sensitive	SU5402	Preclinical	Actionable	In a preclinical study, SU5402 inhibited growth of bladder cancer cells over expressing wild-type FGFR3 in culture (PMID: 21119661).	21119661
FGFR3	FGFR3 over exp	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation in transformed cells overexpressing wild-type FGFR3 in culture (PMID: 28978721).	28978721
FGFR3	FGFR3 over exp	multiple myeloma	sensitive	Vofatamab	Phase I	Actionable	In a Phase I trial, Vofatamab (B-701) demonstrated safety and resulted in stable disease in 42% (6/14) of multiple myeloma patients overexpressing FGFR3 (Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4029).	detail...
FGFR3	FGFR3 over exp	urinary bladder cancer	sensitive	BGJ398	Preclinical - Pdx	Actionable	In a preclinical study, treatment with BGJ398 led to improved progression-free survival in a patient-derived xenograft (PDX) model of bladder cancer with FGFR3 over expression (PMID: 26270481).	26270481
FGFR3	FGFR3 over exp	Advanced Solid Tumor	sensitive	LY2874455	Preclinical	Actionable	In a preclinical study, LY2874455 induced tumor regression in FGFR3-over expressing bladder and multiple myeloma xenograft models (PMID: 21900693).	21900693
FGFR3	FGFR3 over exp	transitional cell carcinoma	sensitive	AZ8010	Preclinical	Actionable	In a preclinical study, AZ8010 inhibited proliferation of urothelial cancer cells with over expression of FGFR3 in culture (PMID: 22869148).	22869148
FGFR3	FGFR3 Y373C FGFR3 over exp	multiple myeloma	sensitive	AZ8010	Preclinical	Actionable	In a preclinical study, AZ8010 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells over expressing FGFR3 Y373C in culture (PMID: 22869148).	22869148
FGFR3	FGFR3 Y373C FGFR3 over exp	multiple myeloma	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, PD173074 inhibited Fgfr3 signaling and decreased proliferation and survival of multiple myeloma cells over expressing FGFR3 Y373C in culture (PMID: 22869148).	22869148
FGFR3	FGFR3 K650E FGFR3 over exp HRAS K117E	multiple myeloma	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, PD173074 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells harboring HRAS H117E and over expression of FGFR3 K650E in culture (PMID: 22869148).	22869148
FGFR3	FGFR3 K650E FGFR3 over exp HRAS K117E	myeloid neoplasm	sensitive	AZ8010	Preclinical	Actionable	In a preclinical study, AZ8010 inhibited Fgfr3 signaling and decreased proliferation of myeloma cells with HRAS K117E and overexpression of FGFR3 K650E in culture (PMID: 22869148).	22869148
FGFR3	FGFR3 S249C FGFR3 over exp	transitional cell carcinoma	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, PD173074 inhibited growth of urothelial carcinoma (UC) cells expressing high levels of FGFR3 S249C, but had reduced efficacy against UC cells with low levels of FGFR3 S249C expression (PMID: 22869148).	22869148
FGFR3	FGFR3 mut FGFR3 over exp	urinary bladder cancer	sensitive	Dovitinib	Phase II	Actionable	In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response for 6 months in 33% (1/3) of non-muscle invasive bladder cancer patients harboring both FGFR3 mutations and FGFR3 over expression (J Clin Oncol 34, 2016 (suppl; abstr 4526)).	detail...
FGFR3	FGFR3 G384D FGFR3 over exp	multiple myeloma	decreased response	AZD4547	Preclinical	Actionable	In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to AZD4547 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).	22869148
FGFR3	FGFR3 G384D FGFR3 over exp	multiple myeloma	decreased response	AZ8010	Preclinical	Actionable	In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to AZ8010 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).	22869148
FGFR3	FGFR3 G384D FGFR3 over exp	multiple myeloma	decreased response	PD173074	Preclinical	Actionable	In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to PD173074 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).	22869148
FGFR3	FGFR3 S131L	head and neck squamous cell carcinoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, a head and neck squamous cell carcinoma cell line expressing FGFR3 S131L demonstrated decreased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 in culture (PMID: 27053219).	27053219
FGFR3	FGFR3 rearrange	myeloid neoplasm	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of myeloma cells harboring FGFR3 rearrangements in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).	detail...
FGFR3	FGFR3 rearrange	myeloid neoplasm	sensitive	AZD4547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4547 inhibited survival of myeloma cells harboring FGFR3 translocation in culture and in cell line xenograft models (PMID: 27550940).	27550940
FGFR3	FGFR3 N540K	Advanced Solid Tumor	decreased response	LY2874455	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to LY2874455 in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 N540K	Advanced Solid Tumor	decreased response	FIIN-2	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to FIIN-2 in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 N540K	Advanced Solid Tumor	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 N540K were reistant to growth inhibition by AZD4547 in culture (PMID: 26992226).	26992226
FGFR3	FGFR3 N540K	Advanced Solid Tumor	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 N540K were resistant to BGJ398 in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 N540K	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 N540K in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 N540K	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinicl study, Balversa (erdafitinib) inhibited proliferation of transformed cells expressing FGFR3 N540K in culture (PMID: 26992226).	26992226
FGFR3	FGFR3 N540K	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 N540K in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 N540K	Advanced Solid Tumor	decreased response	Debio 1347	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 K650E	myeloid neoplasm	sensitive	Debio 1347	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 K650E in culture (PMID: 25169980).	25169980
FGFR3	FGFR3 K650E	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Balversa (erdafitinib) inhibited proliferation of transformed cells expressing FGFR3 K560E in culture (PMID: 26992226).	26992226
FGFR3	FGFR3 K650E	Advanced Solid Tumor	sensitive	PD98059	Preclinical	Actionable	In a preclinical study, PD98059 inhibited FGFR3 K650E-induced transformation of cells in culture (PMID: 14534538).	14534538
FGFR3	FGFR3 K650E	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 K650E	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 K650E	myeloid neoplasm	no benefit	SSR128129E	Preclinical	Actionable	In a preclinical study, SSR128129E did not inhibit proliferation of myeloma cells expressing FGFR3 K650E in culture (PMID: 23597562).	23597562
FGFR3	FGFR3 K650E	Advanced Solid Tumor	sensitive	Debio 1347	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 K650E	myeloid neoplasm	sensitive	SU5402	Preclinical - Cell culture	Actionable	In a preclinical study, SU5402 inhibited proliferation of myeloma cells expressing FGFR3 K650E in culture (PMID: 23597562).	23597562
FGFR3	FGFR3 K650E	Advanced Solid Tumor	sensitive	FIIN-2	Preclinical - Cell culture	Actionable	In a preclinical study, FIIN-2 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 K650E	Advanced Solid Tumor	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 K650E demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 K650E	Advanced Solid Tumor	decreased response	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 K650E demonstrated reduced sensitivity to growth inhibition by AZD4547 in culture (PMID: 26992226).	26992226
FGFR3	FGFR3 K650E	Advanced Solid Tumor	sensitive	LY2874455	Preclinical - Cell culture	Actionable	In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 positive	head and neck squamous cell carcinoma	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including a partial remission in a patient with FGFR3-positive head and neck squamous cell carcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).	detail...
FGFR3	FGFR3 positive	stomach cancer	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive gastric cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).	detail...
FGFR3	FGFR3 positive	lung squamous cell carcinoma	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive lung squamous cell carcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).	detail...
FGFR3	FGFR3 positive	lung adenocarcinoma	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive lung adenocarcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).	detail...
FGFR3	FGFR2 pos FGFR3 pos	breast carcinoma	sensitive	E7090	Preclinical	Actionable	In a preclinical study, a mouse breast carcinoma cell line xenograft model demonstrated inhibition of tumor growth when treated with E7090, a result of decreased FGFR2 and FGFR3 activity (PMID: 27535969).	27535969
FGFR3	FGFR3 K650M	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing FGFR3 K650M in culture (PMID: 28978721).	28978721
FGFR3	FGFR3-TACC3	urinary bladder cancer	sensitive	PRN1109	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PRN1109 treatment resulted in tumor regression in bladder cancer cell line xenograft models harboring FGFR3-TACC3 fusion (Eu J Cancer 2014 Vol 50, Suppl 6:157).	detail...
FGFR3	FGFR3-TACC3	malignant glioma	sensitive	Erdafitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Balversa (erdafitinib) inhibited proliferation of glioma cells harboring FGFR3-TACC3 fusion in culture and xenograft tumor growth in animal models (PMID: 25609060).	25609060
FGFR3	FGFR3-TACC3	urinary bladder cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of bladder cancer cell lines harboring FGFR3-TACC3 fusion in culture (PMID: 27627808).	27627808
FGFR3	FGFR3-TACC3	urinary bladder cancer	sensitive	E7090	Preclinical - Cell line xenograft	Actionable	In a preclinical study, urinary bladder cancer cells harboring FGFR3-TACC3 demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability, and antitumor activity in xenograft models (PMID: 27535969).	27535969
FGFR3	FGFR3-TACC3	bladder urothelial carcinoma	sensitive	PRN1371	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PRN1371 inhibited proliferation of bladder transitional cell carcinoma cell lines harboring FGFR3-TACC3 fusion in culture and tumor growth in cell line xenograft models (PMID: 28978721).	28978721
FGFR3	FGFR3-TACC3	lung adenocarcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatanib) inhibited growth and FGFR3 phosphorylation in cells expressing FGFR3-TACC3 fusion in culture (PMID: 25294908).	25294908
FGFR3	FGFR3-TACC3	transitional cell carcinoma	sensitive	Erdafitinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations and FGFR3-TACC3 v1 and v3 fusions are included in the companion diagnostic (PMID: 31340094; NCT02365597).	detail... 31340094 detail...
FGFR3	FGFR3-TACC3	transitional cell carcinoma	sensitive	Erdafitinib	Case Reports/Case Series	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted in partial response in 2 urothelial cancer patients harboring FGFR3-TACC3 (PMID: 26324363; NCT01703481).	26324363
FGFR3	FGFR3-TACC3	transitional cell carcinoma	predicted - sensitive	Alpelisib + BGJ398	Phase I	Actionable	In a Phase Ib trial, BGJ398 and Alpelisib (BYL719) combination treatment resulted in partial response and a complete shrinkage of target lesions lasting 4 months in one urothelial carcinoma patient harboring a FGFR3-TACC3 fusion (J Clin Oncol 34, 2016 (suppl; abstr 2500)).	detail...
FGFR3	FGFR3-TACC3	cervical squamous cell carcinoma	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in a patient with squamous cell carcinoma of the cervix harboring FGFR3-TACC3 (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).	detail...
FGFR3	FGFR3-TACC3	urinary bladder cancer	no benefit	Selumetinib	Preclinical	Actionable	In a preclinical study, bladder cancer cells harboring FGFR3-TACC were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).	26438159
FGFR3	FGFR3-TACC3	lung non-small cell carcinoma	sensitive	Erdafitinib	Preclinical - Pdx	Actionable	In a preclinical study, Balversa (erdafitinib) inhibited pERK signaling and tumor growth in a patient-derived xenograft (PDX) model of non-small cell lung cancer harboring FGFR3-TACC3 (PMID: 28341788).	28341788
FGFR3	FGFR3-TACC3	urinary bladder cancer	predicted - sensitive	Erdafitinib	Case Reports/Case Series	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted in a partial response with 38% shrinkage of tumor in a patient with metastatic bladder cancer harboring FGFR3-TACC3, who stayed on treatment for 10 months (PMID: 28416604; NCT01703481).	28416604
FGFR3	FGFR3-TACC3	urinary bladder cancer	sensitive	LY2874455	Preclinical	Actionable	In a preclinical study, LY2874455 induced tumor regression in bladder cancer xenograft models that have been demonstrated to harbor an FGFR3-TACC3 fusion (PMID: 21900693, PMID: 23175443).	21900693 23175443
FGFR3	FGFR3-TACC3	urinary bladder cancer	sensitive	FIIN-1	Preclinical	Actionable	In a preclinical study, FIIN-1 inhibited growth of the RT4 bladder cancer cell line, which has been demonstrated to harbor an FGFR3-TACC3 fusion, in culture (PMID: 20338520, PMID: 23175443).	23175443 20338520
FGFR3	FGFR3-TACC3	malignant glioma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited Fgfr3 kinase activity in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture (PMID: 22837387).	22837387
FGFR3	FGFR3-TACC3	urinary bladder cancer	sensitive	Pazopanib	Preclinical	Actionable	In a preclinical study, bladder cancer cells harboring FGFR3-TACC3 demonstrated sensitivity to Votrient (pazopanib) in culture (PMID: 23558953).	23558953
FGFR3	FGFR3-TACC3	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Balversa (erdafitinib) inhibited proliferation of transformed cells FGFR3-TACC3 in culture (PMID: 26992226).	26992226
FGFR3	FGFR3-TACC3	urinary bladder cancer	sensitive	Debio 1347	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of bladder cancer cell lines harboring an FGFR3-TACC3 fusion in culture and inhibited tumor growth in FGFR3-TACC3-positive bladder cancer cell line xenograft models (PMID: 25169980).	25169980
FGFR3	FGFR3-TACC3	urinary bladder cancer	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited growth of bladder cancer cell lines that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 24325461, PMID: 23175443).	23175443 24325461
FGFR3	FGFR3-TACC3	glioblastoma multiforme	sensitive	U0126	Preclinical	Actionable	In a preclinical study, U0126 inhibited downstream signaling and growth of glioblastoma cells expressing the FGFR3-TACC3 fusion in culture (PMID: 23298836).	23298836
FGFR3	FGFR3-TACC3	urinary bladder cancer	predicted - sensitive	S-49076	Preclinical	Actionable	In a preclinical study, S-49076 inhibited autophosphorylation of FGFR3 and downstream signaling in bladder cancer cells that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 23804704, PMID: 23175443).	23175443 23804704
FGFR3	FGFR3-TACC3	bladder urothelial carcinoma	sensitive	Erdafitinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations and FGFR3-TACC3 v1 and v3 fusions are included in the companion diagnostic (PMID: 31340094; NCT02365597).	detail... 31340094 detail...
FGFR3	FGFR3-TACC3	urinary bladder cancer	sensitive	ODM-203	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ODM-203 inhibited FGFR signaling and proliferation in a bladder cancer cell line harboring FGFR3-TACC3 and inhibited tumor growth in xenograft models (PMID: 30301864).	30301864
FGFR3	FGFR3-TACC3	glioblastoma multiforme	predicted - sensitive	Erdafitinib	Case Reports/Case Series	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted in partial response in a glioblastoma patient harboring FGFR3-TACC3 fusion (PMID: 26324363; NCT01703481).	26324363
FGFR3	FGFR3-TACC3	glioblastoma multiforme	predicted - sensitive	Erdafitinib	Case Reports/Case Series	Actionable	In a clinical study, Balversa (erdafitinib) treatment resulted in tumor reduction and stable disease in 2 glioblastoma multiforme patients harboring FGFR3-TACC3 fusion (PMID: 25609060).	25609060
FGFR3	FGFR3-TACC3	urinary bladder cancer	sensitive	SU5402	Preclinical	Actionable	In a preclinical study, SU5402 induced cell-cycle arrest and inhibited proliferation of bladder cancer cells that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 21119661, PMID: 23175443).	21119661 23175443
FGFR3	FGFR3-TACC3	urinary bladder cancer	sensitive	AZ8010	Preclinical	Actionable	In a preclinical study, AZ12908010 (AZ8010) induced cell cycle arrest and inhibited proliferation of urothelial cancer cell lines that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 22869148, PMID: 23175443).	22869148 23175443
FGFR3	FGFR3-TACC3	urinary bladder cancer	predicted - sensitive	BGJ398	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Infigratinib (BGJ398) treatment inhibited tumor growth and Erk phosphorylation in a cell line xenograft model of bladder cancer harboring FGFR3-TACC3 (Cancer Res 2019;79(13 Suppl):Abstract nr 2206).	detail...
FGFR3	FGFR3-TACC3	transitional cell carcinoma	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in a patient with urothelial transitional cell carcinoma harboring FGFR3-TACC3 (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).	detail...
FGFR3	FGFR3-TACC3	bladder transitional cell papilloma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, bladder transitional cell papilloma cells harboring FGFR3-TACC3 were not sensitive to RO4987655 in culture (PMID: 26438159).	26438159
FGFR3	FGFR3-TACC3	transitional cell carcinoma	predicted - sensitive	Debio 1347	Case Reports/Case Series	Actionable	In a Phase I trial, Debio 1347 treatment resulted in partial response in two patients with urothelial cancer harboring FGFR3-TACC3 (PMID: 30745300; NCT01948297).	30745300
FGFR3	FGFR3-TACC3	urinary bladder cancer	sensitive	ASP5878	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ASP5878 treatment inhibited proliferation of bladder cancer cell lines harboring a FGFR3-TACC3 fusion in culture, and resulted in tumor regression in a FGFR3-TACC3 positive bladder cancer cell line xenograft model (Mol Cancer Ther December 2015 14; A170).	detail...
FGFR3	FGFR3-TACC3	malignant glioma	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, Infigratinib (BJG398) inhibited Fgfr3 kinase activity in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture (PMID: 22837387).	22837387
FGFR3	FGFR3-TACC3	malignant glioma	sensitive	BGJ398	Preclinical - Pdx	Actionable	In a preclinical study, Infigratinib (BGJ398) treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of glioma harboring FGFR3-TACC3 (Cancer Res 2019;79(13 Suppl):Abstract nr 2206).	detail...
FGFR3	FGFR3-TACC3	gallbladder cancer	predicted - sensitive	Debio 1347	Case Reports/Case Series	Actionable	In a Phase I trial, Debio 1347 treatment resulted in stable disease in a patient with gallbladder cancer harboring FGFR3-TACC3 (PMID: 30745300; NCT01948297).	30745300
FGFR3	FGFR3-TACC3	bladder transitional cell papilloma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, bladder transitional cell papilloma cells harboring FGFR3-TACC3 were not sensitive to RO5126766 in culture (PMID: 26438159).	26438159
FGFR3	FGFR3-TACC3	oligodendroglioma	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in tumor regression in patient-derived xenograft models of anaplastic oligodendroglioma harboring FGFR3-TACC3 fusion (PMID: 28978721).	28978721
FGFR3	FGFR3-TACC3	Advanced Solid Tumor	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited proliferation of transformed cells expressing FGFR3-TACC3 in culture (PMID: 26992226).	26992226
FGFR3	FGFR3-TACC3	lung adenocarcinoma	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 inhibited growth and FGFR3 phosphorylation in cells expressing FGFR3-TACC3 fusion in culture (PMID: 25294908).	25294908
FGFR3	FGFR3-TACC3	urinary bladder cancer	sensitive	R3Mab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R3Mab inhibited FGFR3 signaling and tumor growth in bladder cancer cell line xenograft models harboring FGFR3-TACC3 (PMID: 25326231).	25326231
FGFR3	FGFR3-TACC3	transitional cell carcinoma	sensitive	AZD4547 + Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) worked synergistically to induce apoptosis and inhibit growth of a urothelial cell carcinoma cell line harboring FGFR3-TACC3 in culture, and inhibited tumor growth in xenograft models, with increased efficacy over either agent alone (PMID: 28108151).	28108151
FGFR3	FGFR3-TACC3	malignant glioma	sensitive	PD173074	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PD173074 inhibited Fgfr3 kinase activity and growth in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture and in cell line xenograft models (PMID: 22837387).	22837387
FGFR3	EGFR E746_A750del FGFR3-TACC3	lung non-small cell carcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical study, FGFR3-TACC3 was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR E746_A750del, whose disease progressed after initial response to Tarceva (erlotinib), followed by Tagrisso (osimertinib) (PMID: 29883838).	29883838
FGFR3	EGFR E746_A750del FGFR3-TACC3	lung non-small cell carcinoma	predicted - resistant	Naquotinib	Case Reports/Case Series	Actionable	In a clinical study, FGFR3-TACC3 was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR E746_A750del, whose disease progressed after initial response to Tarceva (erlotinib) followed by Naquotinib (ASP8273) (PMID: 29883838).	29883838
FGFR3	EGFR E746_A750del FGFR3-TACC3	lung non-small cell carcinoma	predicted - resistant	Afatinib	Case Reports/Case Series	Actionable	In a clinical study, FGFR3-TACC3 was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR E746_A750del, whose disease progressed after initial response to Gilotrif (afatinib) (PMID: 29883838).	29883838
FGFR3	EGFR L858R FGFR3-TACC3	lung non-small cell carcinoma	predicted - resistant	Afatinib + Cetuximab	Case Reports/Case Series	Actionable	In a clinical study, FGFR3-TACC3 was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR L858R, whose disease progressed after initial response to Gilotrif (afatinib) and Erbitux (cetuximab) combination therapy (PMID: 29883838).	29883838
FGFR3	EGFR L747_A750delinsP FGFR3-TACC3	lung non-small cell carcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical study, a patient with non-small cell lung cancer initially responded to Tarceva (erlotinib), EGFR L747_A750delinsP and FGFR3-TACC3 were identified in post-progression tumor samples (PMID: 29883838).	29883838
FGFR3	FGFR2-CCDC6 FGFR3-TACC3	adrenal carcinoma	predicted - sensitive	Erdafitinib	Case Reports/Case Series	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted tumor shrinkage and no disease progression for 10 months in an adrenal carcinoma patient harboring FGFR3-TACC3 and FGFR2-CCDC6 fusions (PMID: 26324363; NCT01703481).	26324363
FGFR3	FGFR3 D788N	head and neck squamous cell carcinoma	no benefit	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited proliferation of a head and neck squamous cell carcinoma cell line expressing FGFR3 D788N in culture, however, cells expressing FGFR3 D788N did not demonstrate increased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 (PMID: 27053219).	27053219
FGFR3	FGFR3 F386L	myeloid neoplasm	sensitive	Debio 1347	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 F386L in culture (PMID: 25169980).	25169980
FGFR3	FGFR3 V555M	Advanced Solid Tumor	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 V555M were resistant to AZD4547 in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 V555M	Advanced Solid Tumor	sensitive	LY2874455	Preclinical - Cell culture	Actionable	In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 V555M	Advanced Solid Tumor	decreased response	Debio 1347	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 V555M demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 V555M	Advanced Solid Tumor	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 V555M were resistant to BGJ398 in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 V555M	transitional cell carcinoma	resistant	BGJ398	Case Reports/Case Series	Actionable	In a clinical study, a patient with metastatic urothelial carcinoma progressed while being treated with BGJ398 and subsequent cell-free DNA testing revealed FGFR3 V555M (also corresponds to V443M) (PMID: 29848605).	29848605
FGFR3	FGFR3 V555M	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 V555M	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 V555M	Advanced Solid Tumor	decreased response	FIIN-2	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 V555M demonstrated reduced sensitivity to FIIN-2 in culture (PMID: 28034880).	28034880
FGFR3	FGFR3 Y373C	bladder urothelial carcinoma	sensitive	Erdafitinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations and FGFR3 Y373C is included in the companion diagnostic (PMID: 31340094; NCT02365597).	detail... 31340094 detail...
FGFR3	FGFR3 Y373C	multiple myeloma	sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, a multiple myeloma cell line harboring FGFR3 Y373C (PMID: 19901323) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969).	19901323 27535969
FGFR3	FGFR3 Y373C	myeloid neoplasm	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).	26438159
FGFR3	FGFR3 Y373C	myeloid neoplasm	sensitive	Debio 1347	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 Y373C in culture (PMID: 25169980).	25169980
FGFR3	FGFR3 Y373C	myeloid neoplasm	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to RO4987655 in culture (PMID: 26438159).	26438159
FGFR3	FGFR3 Y373C	transitional cell carcinoma	sensitive	Erdafitinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations and FGFR3 Y373C is included in the companion diagnostic (PMID: 31340094; NCT02365597).	detail... 31340094 detail...
FGFR3	FGFR3 Y373C	myeloid neoplasm	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to RO5126766 in culture (PMID: 26438159).	26438159
FGFR3	AKT1 E17K FGFR3 Y373C	urinary bladder cancer	sensitive	AZD4547 + Capivasertib	Preclinical	Actionable	In a preclinical study, the combined therapy of AZD5363 and AZD4547 resulted in tumor regression in urinary bladder cancer xenograft models simultaneously harboring the mutations, AKT1 E17K and FGFR3 Y373C (PMID: 26351323).	26351323
FGFR3	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).	25589496
FGFR3	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	ASP5878	Preclinical - Cell culture	Actionable	In a preclinical study, ASP5878 treatment inhibited proliferation of a bladder cancer cell line harboring an FGFR3-BAIAP2L1 fusion in culture (Mol Cancer Ther December 2015 14; A170).	detail...
FGFR3	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).	25589496
FGFR3	FGFR3-BAIAP2L1	Advanced Solid Tumor	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells expressing FGFR3-BAIAP2L1 in culture (PMID: 27627808).	27627808
FGFR3	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, PD173074 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).	25589496
FGFR3	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	Cediranib	Preclinical - Cell culture	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).	25589496
FGFR3	FGFR3-BAIAP2L1	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Balversa (erdafitinib) inhibited Fgfr phosphorylation and downstream signaling, resulted in growth inhibition of transformed cells expressing FGFR3-BAIA2PL1 in culture (PMID: 28416604).	28416604
FGFR3	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of bladder cancer cells harboring FGFR3-BAIAP2L1 fusion in culture (PMID: 27627808).	27627808
FGFR3	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).	25589496
FGFR3	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	Debio 1347	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 decreased phosphorylation of ERK and FRS and inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture, and inhibited tumor growth in bladder cancer cell line xenograft models with FGFR3-BAIAP2L1 (PMID: 25589496)	25589496
FGFR3	FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	Debio 1347	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of a bladder cancer cell line harboring an FGFR3-BAIAP2L1 fusion in culture (PMID: 25169980).	25169980
FGFR3	FGFR3 mutant	Advanced Solid Tumor	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, tumor cell lines with FGFR3 mutations demonstrated sensitivity to BGJ398 in culture (PMID: 23002168).	23002168
FGFR3	FGFR3 mutant	bladder urothelial carcinoma	sensitive	Dovitinib	Phase II	Actionable	In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response in 33% (1/3) of patients with BCG-unresponsive, non-muscle-invasive, urothelial carcinoma of the bladder harboring FGFR3 mutations (PMID: 27932416).	27932416
FGFR3	FGFR3 mutant	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 40% (6/16) of patients with advanced solid tumors harboring FGFR single nucleotide variants, with a 6-month progression-free survival rate of 8% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).	detail...
FGFR3	FGFR3 mutant	bladder urothelial carcinoma	sensitive	Erdafitinib	Guideline	Actionable	Balversa (erdafitinib) is included in the guidelines for patients with advanced or metastatic urothelial carcinoma harboring Fgfr3 alterations after progression on platinum-based regimens (NCCN.org).	detail...
FGFR3	FGFR3 mutant	bladder urothelial carcinoma	sensitive	Erdafitinib	FDA approved - Has Companion Diagnostic	Actionable	In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations (PMID: 31340094; NCT02365597).	detail... 31340094 detail...
FGFR3	FGFR3 mutant	cholangiocarcinoma	predicted - sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted in an objective response rate of 27% (3/11) in patients with cholangiocarcinoma harboring FGFR genomic alterations, including 1 with FGFR2 mutation, 2 with FGFR3 mutations, and 8 with FGFR2 fusions (PMID: 31088831; NCT01703481).	31088831
FGFR3	FGFR3 mutant	transitional cell carcinoma	sensitive	Erdafitinib	Guideline	Actionable	Balversa (erdafitinib) is included in the guidelines for patients with advanced or metastatic urothelial carcinoma harboring Fgfr3 alterations after progression on platinum-based regimens (NCCN.org).	detail...
FGFR3	FGFR3 mutant	transitional cell carcinoma	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted in an objective response rate of 46% (12/26) in patients with urothelial carcinoma harboring FGFR genomic alterations, including 17 with FGFR3 mutations, and 11 with FGFR2 and/or FGFR3 fusions (PMID: 31088831; NCT01703481).	31088831
FGFR3	FGFR3 mutant	transitional cell carcinoma	sensitive	Erdafitinib	FDA approved - Has Companion Diagnostic	Actionable	In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations (PMID: 31340094; NCT02365597).	detail... 31340094 detail...
FGFR3	FGFR3 mutant	transitional cell carcinoma	sensitive	Erdafitinib	Case Reports/Case Series	Actionable	In a Phase I trial, Balversa (erdafitinib) treatment resulted in 25% tumor shrinkage at week 8 in an urothelial cancer patient harboring FGFR3 mutations (PMID: 26324363; NCT01703481).	26324363
FGFR3	FGFR3 mutant	urinary bladder cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited survival of bladder cancer cells harboring FGFR3 mutation in culture (PMID: 27550940).	27550940
FGFR3	FGFR3 mutant	Advanced Solid Tumor	predicted - sensitive	Debio 1347	Phase I	Actionable	In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297).	30745300
FGFR3	FGFR3 mutant	transitional cell carcinoma	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, BGJ398 treatment resulted in complete response in 4% (1/25) and partial response in 32% (8/25) of urothelial carcinoma patients harboring FGFR3 mutations or fusions (J Clin Oncol 34, 2016 (suppl; abstr 4517); NCT01004224).	detail...
FGFR3	FGFR3 mutant	transitional cell carcinoma	sensitive	BGJ398	Clinical Study	Actionable	In a clinical study, BGJ398 treatment led to 25.4% (17/67) confirmed responses and a disease control rate of 64% (43/67), which included complete responses, partial responses, and stable disease, and resulted in a median progression-free survival of 3.75 months and a median overall survival of 7.75 months (PMID: 29848605).	29848605
FGFR3	FGFR3 mutant	transitional cell carcinoma	no benefit	Atezolizumab	Phase II	Actionable	In a Phase II trial (IMVigor 210, CheckMate 275), Tecentriq (atezolizumab) (n=119) treatment resulted in similar response rate (24% vs 21%, p=0.8) in patients with FGFR3 mutant or wild-type metastatic transitional cell carcinoma (PMID: 31272788).	31272788
FGFR3	FGFR3 mutant	transitional cell carcinoma	no benefit	Nivolumab	Phase II	Actionable	In a Phase II trial (CheckMate 275), Opdivo (nivolumab) (n=270) treatment resulted in similar response rate (20% vs 21%, p=0.2) in patients with FGFR3 mutant or wild-type metastatic transitional cell carcinoma (PMID: 31272788).	31272788
FGFR3	FGFR3 mutant	bladder urothelial carcinoma	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, patients with bladder urothelial carcinoma harboring an FGFR3 mutation demonstrated a disease control rate of 75% (6/8) when treated with BGJ398, including 3 patients with a partial response and 3 with stable disease (PMID: 27870574; NCT01004224).	27870574
FGFR3	FGFR3 mutant	Advanced Solid Tumor	sensitive	Pemigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to INCB054828 in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771).	detail...
FGFR3	FGFR3 mutant	transitional cell carcinoma	predicted - sensitive	Docetaxel + Vofatamab	Phase Ib/II	Actionable	In a Phase I/II trial, Vofatamab (B-701) in combination with Taxotere (docetaxel) demonstrated safety and preliminary efficacy, resulted in enhanced activity in patients with locally advanced or metastatic urothelial carcinoma harboring FGFR3 mutations or fusions comparing to wild-type patients (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 4534-4534; NCT02401542).	detail...
FGFR3	FGFR3 S249C	urinary bladder cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of bladder cancer cells harboring FGFR3 S249C in culture (PMID: 22238366).	22238366
FGFR3	FGFR3 S249C	urinary bladder cancer	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in bladder cancer cells harboring FGFR3 S249C mutation in culture (PMID: 22238366).	22238366
FGFR3	FGFR3 S249C	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited growth of transformed cells expressing FGFR3 S249C in culture (PMID: 23786770).	23786770
FGFR3	FGFR3 S249C	renal pelvis transitional cell carcinoma	predicted - sensitive	Pazopanib	Clinical Study	Actionable	In a case study, a patient with urothelial carcinoma of the renal pelvis harboring FGFR3 S249C demonstrated a partial response lasting 9 months following treatment with Votrient (pazopanib) (PMID: 27271022).	27271022
FGFR3	FGFR3 S249C	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing FGFR3 S249C in culture (PMID: 23786770).	23786770
FGFR3	FGFR3 S249C	urinary bladder cancer	sensitive	ASP5878	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ASP5878 treatment inhibited proliferation of a bladder cancer cell line harboring FGFR3 S249C in culture, and resulted in tumor regression in xenograft models (Mol Cancer Ther December 2015 14; A170).	detail...
FGFR3	FGFR3 S249C	Advanced Solid Tumor	sensitive	R3Mab	Preclinical - Cell culture	Actionable	In a preclinical study, R3Mab inhibited proliferation of transformed cells expressing FGFR3 S249C in culture (PMID: 19381019).	19381019
FGFR3	FGFR3 S249C	bladder carcinoma	sensitive	R3Mab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R3Mab decreased dimer formation and constitutive activation of FGFR3 S249C, and inhibited growth of bladder cancer cell lines harboring FGFR3 S249C in culture and in xenograft models (PMID: 19381019).	19381019
FGFR3	FGFR3 S249C	renal pelvis transitional cell carcinoma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to RO4987655 in culture (PMID: 26438159).	26438159
FGFR3	FGFR3 S249C	renal pelvis transitional cell carcinoma	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).	26438159
FGFR3	FGFR3 S249C	bladder urothelial carcinoma	sensitive	Dovitinib	Phase II	Actionable	In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response in a patient with BCG-unresponsive, non-muscle-invasive, urothelial carcinoma of the bladder harboring FGFR3 S249C (PMID: 27932416).	27932416
FGFR3	FGFR3 S249C	urinary system cancer	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 S249C in culture (PMID: 27401245).	27401245
FGFR3	FGFR3 S249C	urinary bladder cancer	sensitive	Debio 1347	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of bladder cancer cells harboring FGFR3 S249C in culture and inhibited tumor growth in FGFR3 S249C-positive bladder cancer cell line xenograft models (PMID: 25169980).	25169980
FGFR3	FGFR3 S249C	Advanced Solid Tumor	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited growth of transformed cells expressing FGFR3 S249C in culture (PMID: 23786770).	23786770
FGFR3	FGFR3 S249C	bladder urothelial carcinoma	sensitive	Erdafitinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations and FGFR3 S249C is included in the companion diagnostic (PMID: 31340094; NCT02365597).	detail... 31340094 detail...
FGFR3	FGFR3 S249C	urinary bladder cancer	resistant	Nintedanib	Preclinical	Actionable	In a preclinical study, bladder cancer cells harboring FGFR3 S249C were resistant to Ofev (Nintedanib) induced inhibition of cell proliferation in culture (PMID: 22238366).	22238366
FGFR3	FGFR3 S249C	urinary system cancer	sensitive	AZD4547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4547 decreased Myc expression and inhibited growth of a urinary tract cancer cell line harboring FGFR3 S249C in culture and in xenograft models (PMID: 27401245).	27401245
FGFR3	FGFR3 S249C	urinary bladder cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of bladder cancer cells harboring FGFR3 S249C mutation in culture (PMID: 22238366).	22238366
FGFR3	FGFR3 S249C	transitional cell carcinoma	sensitive	Erdafitinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations and FGFR3 S249C is included in the companion diagnostic (PMID: 31340094; NCT02365597).	detail... 31340094 detail...
FGFR3	FGFR3 S249C	renal pelvis transitional cell carcinoma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to RO5126766 in culture (PMID: 26438159).	26438159
FGFR3	FGFR3 S249C	urinary bladder cancer	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of bladder cancer cells harboring FGFR3 S249C in culture and in cell line xenograft models (PMID: 22238366).	22238366
FLT3	FLT3 exon 14 ins FLT3 F621L	acute myeloid leukemia	decreased response	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication (ITD) and expressing FLT3 F621L demonstrated a decreased response to Sutent (sunitinib) in culture when compared to treated cells harboring a FLT3 ITD and expressing FLT3 Y842C (Blood 2009 114:3776).	detail...
FLT3	FLT3 exon 14 ins FLT3 F621L	acute myeloid leukemia	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication (ITD) and expressing FLT3 F621L demonstrated sensitivity to Rydapt (midostaurin) in culture (Blood 2009 114:3776).	detail...
FLT3	FLT3 exon 14 ins FLT3 F621L	acute myeloid leukemia	sensitive	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication (ITD) and expressing FLT3 F621L demonstrated sensitivity to Nexavar (sorafenib) in culture (Blood 2009 114:3776).	detail...
FLT3	FLT3 exon 14 ins FLT3 F621L	acute myeloid leukemia	sensitive	Lestaurtinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication (ITD) and expressing FLT3 F621L demonstrated sensitivity to Lestaurtinib (CEP-701) in culture (Blood 2009 114:3776).	detail...
FLT3	FLT3 exon 14 ins FLT3 F621L	acute myeloid leukemia	decreased response	AGL2043	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication (ITD) and expressing FLT3 F621L demonstrated a decreased response to AGL2043 in culture when compared to treated cells harboring a FLT3 ITD and expressing FLT3 Y842C (Blood 2009 114:3776).	detail...
FLT3	FLT3 exon 14 ins FLT3 R845G	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 R845G were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L FLT3 R845G	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/R845G mutation were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L	hematologic cancer	sensitive	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited growth of transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L in culture (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins FLT3 F691L	Advanced Solid Tumor	resistant	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and F691L were resistant to Quizartinib (AC220) in culture (PMID: 23392356).	23392356
FLT3	FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	decreased response	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 F691L demonstrated a decreased response to Lestaurtinib (CEP-701) compared to treated cells harboring a FLT3 ITD and expressing FLT3 Y842C (Blood 2009 114:3776).	detail...
FLT3	FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	sensitive	FF-10101	Preclinical - Cell line xenograft	Actionable	In a preclinical study, FF-10101 inhibited Flt3 autophosphorylation and growth of leukemic cell lines and inhibited growth of cell line xenografts with FLT3-ITD/F691L compound mutations (PMID: 29187377).	29187377
FLT3	FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	decreased response	Lestaurtinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 F691L demonstrated a decreased response to Lestaurtinib (CEP-701) compared to treated cells harboring a FLT3 ITD and expressing FLT3 Y842C (Blood 2009 114:3776).	detail...
FLT3	FLT3 exon 14 ins FLT3 F691L	hematologic cancer	decreased response	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were less sensitive to Avapritinib (BLU-285)-induced growth inhibition compared to cells expressing FLT3 ITD in culture (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins FLT3 F691L	leukemia	predicted - sensitive	CG-806	Preclinical - Cell culture	Actionable	In a preclinical study, CG'806 inhibited FLT3 downstream signaling, resulted in growth inhibition in leukemia cells expressing FLT3 exon 14 insertion (ITD) mutation and F691L in culture (Clin Cancer Res 2017; 23(24_Suppl):Abstract nr 25).	detail...
FLT3	FLT3 exon 14 ins FLT3 F691L	hematologic cancer	decreased response	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were less sensitive to Quizartinib (AC220)-induced growth inhibition compared to cells expressing FLT3 ITD in culture (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	sensitive	MRX-2843	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant acute myeloid leukemia cells harboring FLT3 internal tandem duplication (ITD) and F691L in culture, and prolonged survival in cell line xenograft models (PMID: 27158668).	27158668
FLT3	FLT3 exon 14 ins FLT3 F691L	Advanced Solid Tumor	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and F691L were resistant to Nexavar (sorafenib) in culture (PMID: 23392356).	23392356
FLT3	FLT3 exon 14 ins FLT3 F691L	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and F691L in culture (PMID: 27158668).	27158668
FLT3	FLT3 exon 14 ins FLT3 F691L	hematologic cancer	sensitive	G-749	Preclinical - Cell culture	Actionable	In a preclinical study, cells co-expressing a FLT3 internal tandem duplication and FLT3 F691L were sensitive to G-749 in culture, demonstrating inhibition of cell growth and inhibition of Flt3 autophosphorylation (PMID: 22864397).	22864397
FLT3	FLT3 exon 14 ins FLT3 F691L	hematologic cancer	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited growth of transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L in culture (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins FLT3 F691L	leukemia	sensitive	Pexidartinib	Preclinical	Actionable	In a preclinical study, PLX3397 inhibited proliferation of human leukemia cells harboring both FLT3-ITD and FLT3 F691L in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L	Advanced Solid Tumor	sensitive	Pexidartinib	Preclinical	Actionable	In a preclinical study, PLX3397 inhibited growth of transformed cells expressing a compound FLT3 F691L/FLT3-ITD mutation in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L	hematologic cancer	decreased response	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were less sensitive to Crenolanib-induced growth inhibition compared to cells expressing FLT3 ITD in culture (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins FLT3 F691L	leukemia	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 F691L in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).	26822154
FLT3	FLT3 exon 14 ins FLT3 F691L	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing FLT3 ITD and F691L in culture (PMID: 27780853).	27780853
FLT3	FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were resistant to Nexavar (sorafenib)-induced growth inhibition in culture (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins FLT3 F691L FLT3 R834Q	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691Q/R834Q mutation were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L FLT3 D835E	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3 ITD with R834Q and F691L were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L FLT3 D835H	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835H mutation were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L FLT3 D835N	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835N mutation were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L FLT3 D839G	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD /F691L/D839G mutation were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L FLT3 Y842C	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842C mutation were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L FLT3 Y842H	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842H mutation were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L FLT3 D835G	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835G mutation were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L FLT3 D698N	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D698N mutation were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L FLT3 D839A	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835A mutation were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L FLT3 D839N	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D839N were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L FLT3 G846R	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691Q/G846R mutation were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 M664I FLT3 F691L	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/M664I mutation were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 N676S FLT3 F691L	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/N676S mutation were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L FLT3 N841K	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/N841K mutation were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L FLT3 Y842S	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842S mutation were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 F691L FLT3 D835Y	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835Y mutation were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 D835Y FLT3 F691L	hematologic cancer	resistant	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib did not decrease cell proliferation of transformed mouse cells expressing Flt3 D835Y and Flt3 F691L, indicating F691L as a resistance mutation since D835Y was sensitive alone (PMID: 30651561).	30651561
FLT3	FLT3 exon 14 ins FLT3 M837G FLT3 S838R FLT3 D839H	leukemia	predicted - resistant	Pexidartinib	Case Reports/Case Series	Actionable	In a clinical case study, a leukemia patient with FLT3-ITD positive leukemia initially responded to Pexidartinib (PLX3397), but experienced relapse after emergence of a compound FLT3 M837G/S838R/D839H mutation on the FLT3-ITD allele (PMID: 25847190).	25847190
FLT3	FLT3 exon15	acute myeloid leukemia	sensitive	Gilteritinib	Guideline	Actionable	Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 exon15	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	Guideline	Actionable	Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 Y599_D600insGLYVDFREYEY	acute myeloid leukemia	sensitive	Tandutinib	Preclinical	Actionable	In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 Y599_D600insGLYVDFREYEY in culture (PMID: 12124172).	12124172
FLT3	FLT3 act mut	acute myeloid leukemia	sensitive	Palbociclib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) blocked growth, induced apoptosis, and inhibited STAT activation in human FLT3-ITD positive human acute myeloid leukemia cells in culture (PMID: 27099147).	27099147
FLT3	FLT3 act mut	leukemia	sensitive	Pexidartinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX3397 inhibited FLT3 autophosphorylation in leukemia cells overexpressing FLT3 or harboring FLT3 activating mutations, and inhibited growth of leukemia cells harboring FLT3-ITD mutations in culture and in cell line xenograft models (ASH Annual Meeting Abstracts 2011 118: 3632).	detail...
FLT3	FLT3 act mut	acute myeloid leukemia	sensitive	Palbociclib + SGI-1776	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) and SGI-1776 were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).	27099147
FLT3	FLT3 act mut	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Sunitinib	Phase Ib/II	Actionable	In a Phase Ib/II trial, 59% (13/22) of acute myeloid leukemia patients harboring FLT3 activating mutations achieved complete remission following treatment with Sutent (sunitinib) in combination with Cytarabine and Daunorubicin (PMID: 25818407).	25818407
FLT3	FLT3 act mut	acute myeloid leukemia	sensitive	Palbociclib + Quizartinib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) and Quizartinib (AC220) were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).	27099147
FLT3	FLT3 act mut	acute myeloid leukemia	sensitive	Palbociclib + TCS 359	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) following TCS-359 treatment enhanced growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).	27099147
FLT3	FLT3 act mut	acute myeloid leukemia	sensitive	Crenolanib	Phase II	Actionable	In a Phase II trial, relapsed or refractory acute myeloid leukemia patients harboring FLT3 activating mutations without a history of FLT3 therapy demonstrated a significantly greater overall survival and event free survival compared to those that had prior FLT3 therapy when treated with Crenolanib (ASH meeting, Dec 2014, abstract #389).	detail...
FLT3	FLT3 act mut	acute myeloid leukemia	sensitive	VS-5584	Preclinical - Cell line xenograft	Actionable	In a preclinical study, VS-5584 inhibited PI3K/mTOR signaling and cell proliferation in a FLT3-ITD positive human acute myeloid leukemia cell line in culture, and inhibited tumor growth in xenograft models (PMID: 23270925).	23270925
FLT3	FLT3 act mut	acute myeloid leukemia	sensitive	TCS 359	Preclinical	Actionable	In a preclinical study, TCS-359 inhibited growth of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).	27099147
FLT3	FLT3 act mut	acute myeloid leukemia	sensitive	Palbociclib + Tandutinib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) and tandutinib (MLN518) were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).	27099147
FLT3	FLT3 exon20	acute myeloid leukemia	sensitive	Gilteritinib	Guideline	Actionable	Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 exon20	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	Guideline	Actionable	Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 exon 14 ins FLT3 M664I	Advanced Solid Tumor	decreased response	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 M664I displayed reduced sensitivity to PLX3397 relative to cells expressing FLT3-ITD in culture (PMID: 25847190).	25847190
FLT3	FLT3 D835V	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing FLT3 D835V in culture (PMID: 27158668).	27158668
FLT3	FLT3 D835V	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3 D835V were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 D835V	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835V in culture (PMID: 27158668).	27158668
FLT3	FLT3 exon 14 ins FLT3 D835V	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835V were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 wild-type	acute myeloid leukemia	sensitive	Palbociclib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) inhibited growth of human FLT3 wild-type human leukemia cells in culture (PMID: 27099147).	27099147
FLT3	FLT3 wild-type	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	Phase Ib/II	Actionable	In a Phase Ib clinical trial, Rydapt (midostaurin) treatment after Daunorubicin and Cytosar-U (cytarabine) induction resulted in complete remission in 74% (20 of 27) of acute myeloid leukemia patients carrying wild-type FLT3 (PMID: 22627678).	22627678
FLT3	FLT3 wild-type	acute myeloid leukemia	sensitive	TCS 359	Preclinical	Actionable	In a preclinical study, TCS-359 inhibited growth of FLT3 wild-type acute myeloid leukemia cell lines in culture (PMID: 27099147).	27099147
FLT3	FLT3 wild-type	Advanced Solid Tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited FLT3 phosphorylation in transformed cells expressing wild-type FLT3 in culture (PMID: 12124173).	12124173
FLT3	FLT3 wild-type	acute myeloid leukemia	predicted - sensitive	CG-806	Preclinical - Cell culture	Actionable	In a preclinical study, CG'806 inhibited Btk and aurora kinase activation, induced G2/M arrest and autophagy in acute myeloid leukemia cells harboring wild-type FLT3 in culture (Blood 2017 130:4629).	detail...
FLT3	FLT3 wild-type	acute myeloid leukemia	sensitive	Palbociclib + TCS 359	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) following TCS-359 treatment enhanced growth inhibition of FLT3 wild-type acute myeloid leukemia cell lines in culture (PMID: 27099147).	27099147
FLT3	NPM1 mutant FLT3 wild-type	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	NPM1 mutations with FLT3 wild-type (no or low allelic ratio of ITD mutations) are associated with a favorable prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).	detail...
FLT3	CBL Q365_E366insSK FLT3 wild-type	hematologic cancer	sensitive	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).	31309543
FLT3	CBL Q365_E366insSK FLT3 wild-type	hematologic cancer	sensitive	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).	31309543
FLT3	CBL Q365_E366insSK FLT3 wild-type	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).	31309543
FLT3	CBL Q365_E366insSK FLT3 wild-type	hematologic cancer	sensitive	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Quizartinib (AC220) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).	31309543
FLT3	CBL Q365_E366insSK FLT3 wild-type	hematologic cancer	decreased response	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Avapritinib (BLU-285) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture with reduced potency compared to other kinase inhibitors (PMID: 31309543).	31309543
FLT3	CBL Q365_E366insSK FLT3 wild-type	hematologic cancer	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543).	31309543
FLT3	CBL Y371H FLT3 wild-type	hematologic cancer	sensitive	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Quizartinib (AC220) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543).	31309543
FLT3	CBL Y371H FLT3 wild-type	hematologic cancer	decreased response	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Avapritinib (BLU-285) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture with reduced potency compared to other kinase inhibitors (PMID: 31309543).	31309543
FLT3	CBL Y371H FLT3 wild-type	hematologic cancer	sensitive	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543).	31309543
FLT3	CBL Y371H FLT3 wild-type	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543).	31309543
FLT3	CBL Y371H FLT3 wild-type	hematologic cancer	sensitive	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543).	31309543
FLT3	CBL Y371H FLT3 wild-type	hematologic cancer	sensitive	Midostaurin	Preclinical	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture, reduced leukemia burden and prolonged survival in animal models (PMID: 31309543).	31309543
FLT3	NPM1 wild-type FLT3 wild-type	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	NPM1 wild-type with FLT3 wild-type (no or low allelic ratio of ITD mutations) is associated with an intermediate prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).	detail...
FLT3	FLT3 R595_L601dup	acute myeloid leukemia	sensitive	Tandutinib	Preclinical	Actionable	In a preclinical study, tandutinib (CT53518) inhibited cell proliferation in cell culture and in mouse models carrying FLT3 L601_K602insREYEYDL (PMID: 12124172).	12124172
FLT3	FLT3 exon 14 ins FLT3 G846R	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 G846R were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 positive	acute myeloid leukemia	not applicable	AGS62P1	Preclinical - Patient cell culture	Actionable	In a preclinical study, AGS62P1 inhibited growth of FLT3-positive acute myeloid leukemia cell lines in culture, and led to tumor growth inhibition and regression in patient-derived xenograft (PDX) models (Blood 2015 126(23):3806).	detail...
FLT3	FLT3 exon 14 ins FLT3 D835N	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835N were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 D835X	acute myeloid leukemia	sensitive	Gilteritinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (ADMIRAL) that supported FDA approval, Xospata (gilteritinib) treatment resulted in complete remission (CR) or CR with partial hematologic recovery in 21% (29/138) of patients with relapsed or refractory acute myeloid leukemia harboring a FLT3 internal tandem duplication (ITD), D835, or I836 mutation (FDA.gov; NCT02421939).	detail... detail...
FLT3	FLT3 D835X	myelodysplastic syndrome	not applicable	N/A	Guideline	Actionable	FLT3 D835 mutations are associated with poor prognosis in patients with myelodysplastic syndromes (NCCN.org).	detail...
FLT3	FLT3 D835X	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial that supported FDA approval, treatment with Rydapt (midostaurin), combined with Cytosar-U (cytarabine) and Daunorubicin, improved overall survival (74.7 mo vs 25.6 mo) in patients with FLT3-mutant (D835X and I836X) or FLT3-ITD (exon 14 insertions) acute myeloid leukemia compared to Cytosar-U (cytarabine) and Daunorubicin with placebo (PMID: 28644114).	detail... 28644114 detail...
FLT3	FLT3 D835X	acute myeloid leukemia	sensitive	Crenolanib	Phase I	Actionable	In a Phase I trial, Crenolanib treatment resulted in an overall survival (OS) of 185 days in AML patients harboring FLT3 D835X that received no prior therapy (J Clin Oncol 34, 2016 (suppl; abstr 7008)).	detail...
FLT3	FLT3 D835X	acute myeloid leukemia	sensitive	Selinexor + Sorafenib	Phase Ib/II	Actionable	In a Phase I/II trial, combination of Selinexor and Nexavar (sorafenib) treatment resulted in complete remission in 29% (4/14) and more than 50% blast reduction in 14% (2/14) of patients with acute myeloid leukemia harboring FLT3 ITD and/or D835 mutations (ASH, 59th Annual Meeting and Exposition, Dec 2017, Abstract 1344; NCT01607892).	detail...
FLT3	FLT3 D835X FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Crenolanib	Phase I	Actionable	In a Phase I trial, Crenolanib treatment resulted in an overall survival (OS) of 128 days in AML patients harboring both FLT3 D835X and exon 14 insertion (ITD) that received no prior therapy, and an OS of 63 days in those progressed on TKIs (J Clin Oncol 34, 2016 (suppl; abstr 7008)).	detail...
FLT3	FLT3 D835X FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Selinexor + Sorafenib	Phase Ib/II	Actionable	In a Phase I/II trial, combination of Selinexor and Nexavar (sorafenib) treatment resulted in complete remission in 29% (4/14) and more than 50% blast reduction in 14% (2/14) of patients with acute myeloid leukemia harboring FLT3 ITD and/or D835 mutations (ASH, 59th Annual Meeting and Exposition, Dec 2017, Abstract 1344; NCT01607892).	detail...
FLT3	FLT3 exon 14 ins FLT3 D839G	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, FLT3 D835G conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190).	25847190
FLT3	FLT3 D835Y	acute myeloid leukemia	sensitive	E6201	Preclinical - Cell culture	Actionable	In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 D835Y in culture (PMID: 26822154).	26822154
FLT3	FLT3 D835Y	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib inhibited growth of transformed hematologic cells expressing FLT3 D835Y in culture (PMID: 31309543).	31309543
FLT3	FLT3 D835Y	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib decreased cell proliferation of transformed mouse cells expressing FLT3 D835Y (PMID: 30651561).	30651561
FLT3	FLT3 D835Y	hematologic cancer	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited growth of transformed hematologic cells expressing FLT3 D835Y in culture (PMID: 31309543).	31309543
FLT3	FLT3 D835Y	Advanced Solid Tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Rydapt (midostaurin) inhibited FLT3 phosphorylation and resulted in decreased proliferation and viability of transformed cells expressing FLT3 D835Y in culture (PMID: 12124173).	12124173
FLT3	FLT3 D835Y	hematologic cancer	sensitive	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Quizartinib (AC220) inhibited growth of transformed hematologic cells expressing FLT3 D835Y in culture (PMID: 31309543).	31309543
FLT3	FLT3 D835Y	acute promyelocytic leukemia	predicted - sensitive	Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin	Case Reports/Case Series	Actionable	In a clinical case study, a patient with acute promyelocytic leukemia harboring FLT3 D835Y demonstrated a complete molecular remission after treatment with Trisenox (arsenic trioxide) and Vesanoid (tretinoin) combined with Cytosar-U (cytarabine) and Methotrexate (PMID: 27626069).	27626069
FLT3	FLT3 D835Y	leukemia	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines over expressing FLT3 D835Y in culture (PMID: 26822154).	26822154
FLT3	FLT3 D835Y	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3 D835Y were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 D835Y	hematologic cancer	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing FLT3 D835Y were resistant to Nexavar (sorafenib)-induced growth inhibition in culture (PMID: 31309543).	31309543
FLT3	FLT3 D835Y	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing FLT3 D835Y in culture (PMID: 27158668).	27158668
FLT3	FLT3 D835Y	hematologic cancer	sensitive	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited growth of transformed hematologic cells expressing FLT3 D835Y in culture (PMID: 31309543).	31309543
FLT3	FLT3 D835Y	hematologic cancer	sensitive	Crenolanib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib, in combination with Mekinist (trametinib), synergistically decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y (PMID: 30651561).	30651561
FLT3	FLT3 D835Y	leukemia	predicted - sensitive	CG-806	Preclinical - Cell culture	Actionable	In a preclinical study, CG'806 inhibited FLT3 downstream signaling, resulted in growth inhibition in leukemia cells expressing FLT3 D835Y in culture (Clin Cancer Res 2017; 23(24_Suppl):Abstract nr 25).	detail...
FLT3	FLT3 D835Y	hematologic cancer	sensitive	G-749	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing FLT3 D835Y were sensitive to G-749 in culture, demonstrating inhibition of cell growth and inhibition of Flt3 autophosphorylation (PMID: 22864397).	22864397
FLT3	FLT3 D835Y	hematologic cancer	resistant	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing FLT3 D835Y were resistant to Avapritinib (BLU-285)-induced growth inhibition in culture (PMID: 31309543).	31309543
FLT3	FLT3 D835Y	acute promyelocytic leukemia	predicted - resistant	Tretinoin	Case Reports/Case Series	Actionable	In a clinical case study, a patient with acute promyelocytic leukemia developed meningeal relapse after maintenance therapy with Vesanoid (tretinoid), which was found to be due to a FLT3 D835Y variant (PMID: 27626069).	27626069
FLT3	FLT3 exon 14 ins FLT3 D835Y	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing FLT3 ITD and D835Y in culture (PMID: 27780853).	27780853
FLT3	FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	sensitive	FF-10101	Preclinical - Cell line xenograft	Actionable	In a preclinical study, FF-10101 inhibited Flt3 autophosphorylation and growth of leukemic cell lines and inhibited growth of cell line xenografts with FLT3-ITD/D835Y compound mutations (PMID: 29187377).	29187377
FLT3	FLT3 exon 14 ins FLT3 D835Y	leukemia	predicted - resistant	Pexidartinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with FLT3-ITD positive leukemia initially responded to Pexidartinib (PLX3397) therapy, but experienced relapse after emergence of FLT3 D835Y on the same allele as the FLT3-ITD mutation (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 D835Y	leukemia	predicted - sensitive	CG-806	Preclinical - Cell culture	Actionable	In a preclinical study, CG'806 inhibited FLT3 downstream signaling, resulted in growth inhibition in leukemia cells expressing FLT3 exon 14 insertion (ITD) mutation and D835Y in culture (Clin Cancer Res 2017; 23(24_Suppl):Abstract nr 25).	detail...
FLT3	FLT3 exon 14 ins FLT3 D835Y	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, FLT3 D835Y conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 D835Y	acute myeloid leukemia	sensitive	MRX-2843	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant acute myeloid leukemia cells harboring FLT3 internal tandem duplication (ITD) and D835Y in culture, and prolonged survival in cell line xenograft models (PMID: 27158668).	27158668
FLT3	FLT3 exon 14 ins FLT3 D835Y	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835Y in culture (PMID: 27158668).	27158668
FLT3	FLT3 D835Y FLT3 N676D	hematologic cancer	sensitive	G-749	Preclinical - Cell culture	Actionable	In a preclinical study, cells co-expressing FLT3 D835Y and FLT3 N676D were sensitive to G-749 in culture, demonstrating inhibition of cell growth and inhibition of Flt3 autophosphorylation (PMID: 22864397).	22864397
FLT3	FLT3 D835Y FLT3 D200N	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y and Flt3 D200N (PMID: 30651561).	30651561
FLT3	FLT3 D835Y FLT3 L601F	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y and Flt3 L601F (PMID: 30651561).	30651561
FLT3	FLT3 D835Y PTPN11 A72D	hematologic cancer	resistant	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib, did not decrease cell proliferation of transformed mouse cells expressing Flt3 D835Y and Ptpn11 A72D, indicating Ptpn11 A72D as a resistance mutation since Flt3 D835Y was sensitive alone (PMID: 30651561).	30651561
FLT3	FLT3 D835Y PTPN11 A72D	hematologic cancer	sensitive	Crenolanib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib, in combination with Mekinist (trametinib), synergistically decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y and Ptpn11 A72D (PMID: 30651561).	30651561
FLT3	FLT3 D835Y IDH1 wild-type	hematologic cancer	resistant	AGI-5198	Preclinical - Cell culture	Actionable	In a preclinical study, AGI-5198, did not decrease cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 wild-type (PMID: 30651561).	30651561
FLT3	FLT3 D835Y IDH1 wild-type	hematologic cancer	sensitive	AGI-5198 + Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib, in combination with AGI-5198, synergistically decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 wild-type (PMID: 30651561).	30651561
FLT3	FLT3 D835Y IDH1 wild-type	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib, decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 wild-type (PMID: 30651561).	30651561
FLT3	FLT3 D835Y IDH1 R132H	hematologic cancer	sensitive	AGI-5198 + Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib, in combination with AGI-5198, synergistically decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 R132H (PMID: 30651561).	30651561
FLT3	FLT3 D835Y IDH1 R132H	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib, decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 R132H (PMID: 30651561).	30651561
FLT3	FLT3 D835Y IDH1 R132H	hematologic cancer	resistant	AGI-5198	Preclinical - Cell culture	Actionable	In a preclinical study, AGI-5198, did not decrease cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 R132H (PMID: 30651561).	30651561
FLT3	FLT3 S451F	Advanced Solid Tumor	decreased response	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3 S451F demonstrated decreased sensitivity to inhibition of FLT3 phosphorylation and growth by Rydapt (midostaurin) in culture, when compared to cells expressing other FLT3 activating mutations (PMID: 18068628).	18068628
FLT3	FLT3 exon18	acute myeloid leukemia	sensitive	Gilteritinib	Guideline	Actionable	Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 exon18	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	Guideline	Actionable	Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE	acute myeloid leukemia	sensitive	Tandutinib	Preclinical	Actionable	In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE in culture (PMID: 12124172).	12124172
FLT3	FLT3 exon 14 ins FLT3 D835F	acute myeloid leukemia	predicted - resistant	Sorafenib	Case Reports/Case Series	Actionable	In a clinical case study, FLT3 D835F was identified as an acquired resistance mutation in a patient with acute myeloid leukemia harboring a FLT3 internal tandem duplication (ITD) whose disease progressed on Nexavar (sorafenib) after initial response (PMID: 24227820).	24227820
FLT3	FLT3 exon 14 ins FLT3 D835F	acute myeloid leukemia	predicted - sensitive	Crenolanib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Crenolanib inhibited growth of blasts derived from a patient with acute myeloid leukemia harboring FLT3 internal tandem duplication (ITD) and FLT3 D835F (PMID: 24227820).	24227820
FLT3	FLT3 exon 14 ins FLT3 D835F	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835F in culture (PMID: 27158668).	27158668
FLT3	FLT3 exon 14 ins FLT3 D835F	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835F were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing FLT3 ITD in culture (PMID: 27780853).	27780853
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	ENMD-2076	Phase I	Actionable	In a Phase I trial, an acute myeloid leukemia patient with a FLT3-ITD mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088).	27406088
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Quizartinib	Phase I	Actionable	In a Phase I trial, acute myeloid leukemia (AML) pediatric patients harboring a FLT3-ITD mutation demonstrated a greater sensitivity to treatment with Quizartinib (AC220) when compared to AML patients with wild-type FLT3, resulting in three complete responses, four with stable disease, and a lower bone marrow blast cell count (PMID: 26920889).	26920889
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Quizartinib	Phase II	Actionable	Error	29859851
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Quizartinib (AC220) inhibited Flt3 phosphorylation and growth of acute myeloid leukemia cell lines harboring FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib inhibited Flt3 phosphorylation and growth of acute myeloid leukemia cell lines harboring FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Crenolanib	Preclinical - Patient cell culture	Actionable	In a preclinical study, FLT3-ITD mutations correlated with sensitivity to Crenolanib in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Crenolanib	Phase I	Actionable	In a Phase I trial, Crenolanib treatment resulted in an overall survival (OS) of 238 days in AML patients harboring FLT3 exon 14 insertions (ITD) that received no prior therapy, and an OS of 158 days in those progressed on TKIs (J Clin Oncol 34, 2016 (suppl; abstr 7008)).	detail...
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Ki23819	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication were sensitive to Ki23819 in culture, demonstrating inhibition of autophosphorylation and downstream signaling, and reduced cell proliferation (PMID: 15815726).	15815726
FLT3	FLT3 exon 14 ins	leukemia	sensitive	Pexidartinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX3397 inhibited proliferation of human leukemia cells harboring FLT3-ITD in culture and in cell line xenograft models (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins	Advanced Solid Tumor	predicted - sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing a FLT3-ITD mutation were sensitive to Cometriq (cabozantinib) in culture (PMID: 21926191).	21926191
FLT3	FLT3 exon 14 ins	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib inhibited growth of transformed hematologic cells expressing FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	predicted - sensitive	Azacitidine + Quizartinib	Phase Ib/II	Actionable	In a Phase I/II trial, Quizartinib (AC220) in combination with Vidaza (azacitidine) resulted in a median overall survival of 13.4 months and a median progression-free survival of 6.9 months in acute myeloid leukemia patients harboring FLT3 ITD mutations (ASH 59th Annual Meeting and Exposition, Dec 2017, Abstract 723).	detail...
FLT3	FLT3 exon 14 ins	leukemia	predicted - sensitive	GMI-1359 + Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination of GMI-1359 with Nexavar (sorafenib) enhanced apoptosis compared to Nexavar (sorafenib) alone (48.9% vs 36.6%) in leukemia cell lines harboring FLT3 internal tandem duplication (ITD) mutations (Blood 2015 126(23):3790).	detail...
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	predicted - sensitive	KW-2449	Preclinical - Patient cell culture	Actionable	In a preclinical study, FLT3-ITD mutations correlated with sensitivity to KW-2449 in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Ponatinib	Phase I	Actionable	In a Phase I trial, Iclusig (ponatinib) resulted in a 25% (3/12) overall response rate, indicated as partial remission or better, in acute myeloid leukemia patients harboring FLT3-ITD (PMID: 23691988).	23691988
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Ponatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited viability of patient derived acute myeloid leukemia cells harboring FLT3 ITD mutations in culture, and inhibited growth of tumors in cell line xenograft models (PMID: 21482694).	21482694
FLT3	FLT3 exon 14 ins	hematologic cancer	sensitive	GTP-14564	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing a FLT3 internal tandem duplication were sensitive to GTP-14564 treatment in culture, demonstrating decreased Stat5 activity and growth inhibition (PMID: 12815052).	12815052
FLT3	FLT3 exon 14 ins	leukemia	predicted - sensitive	GMI-1359	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GMI-1359 in combination with chemotherapy resulted in significant survival benefit compared to chemotherapy alone (67% vs 30%) in cell line xenograft models of FLT3-ITD leukemia (Blood 2015 126(23):3790).	detail...
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	predicted - sensitive	Entospletinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, FLT3-ITD mutations correlated with sensitivity to Entospletinib in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	E6201	Preclinical - Cell culture	Actionable	In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).	26822154
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	predicted - sensitive	Cytarabine + Daunorubicin + Quizartinib	Phase I	Actionable	In a Phase I trial (QuANTUM-First), the combination therapy, Quizartinib (AC220) with Cytosar-U (cytarabine) and Cerubidine (daunorubicin), resulted in 67% (6/9) of acute myeloid leukemia patients harboring a FLT3-ITD achieving a composite complete response and two patients achieving morphologic leukemia-free state (PMID: 29139135; NCT01390337).	29139135
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Cytarabine + G-749	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of G-749 and Cytosar-U (cytarabine) resulted in a synergistic effect, demonstrating greater inhibition of proliferation compared to G-749 alone in acute myeloid leukemia cells harboring a FLT3 internal tandem duplication (PMID: 24532805).	24532805
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Azacitidine + Sorafenib	Guideline	Actionable	Nexavar (sorafenib) in combination with Vidaza (azacitidine) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a FLT3 internal tandem duplication (FLT3-ITD) mutation (NCCN.org).	detail...
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	GTP-14564	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication were sensitive to GTP-14564 treatment in culture, demonstrating growth inhibition (PMID: 12815052).	12815052
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	predicted - sensitive	SHP099	Preclinical - Pdx	Actionable	In a preclinical study, treatment with SHP099 resulted in reduction of CD45-positive leukemic cells and decreased splenomegaly in a human primary tumor-derived xenograft model of acute myeloid leukemia harboring a FLT3-ITD mutation (PMID: 27362227).	27362227
FLT3	FLT3 exon 14 ins	Advanced Solid Tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) demonstrated efficacy in inhibiting proliferation and viability of transformed cells expressing a FLT3-ITD mutation in culture (PMID: 12124173).	12124173
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	predicted - sensitive	Pacritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pacritinib (SB1518) induced apoptosis and inhibited proliferation of acute myeloid leukemia cells harboring a FLT3-ITD mutation in culture, and inhibited tumor growth and induced tumor regression in cell line xenograft models (PMID: 22829080).	22829080
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	G-749	Preclinical - Cell line xenograft	Actionable	In a preclinical study, G-749 induced apoptosis in acute myeloid leukemia cells harboring a FLT3 internal tandem duplication in culture, and inhibited tumor growth and induced tumor regression in cell line xenograft models (PMID: 24532805).	24532805
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	no benefit	Rebastinib	Phase I	Actionable	In a Phase I trial, acute myeloid leukemia patients harboring a FLT3 internal tandem duplication did not benefit from treatment with Rebastinib (DCC-2036) (PMID: 27927766).	27927766
FLT3	FLT3 exon 14 ins	leukemia	sensitive	FN-1501	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with FN-1501 reduced phoshorylation of FLT3 and downstream STAT5, ERK, and AKT, induced apoptosis and cell-cycle arrest, and decreased proliferation in a human leukemia cell line harboring a FLT3-ITD mutation in culture, and induced tumor regression in xenograft models (PMID: 29357250).	29357250
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial that supported FDA approval, treatment with Rydapt (midostaurin), combined with Cytosar-U (cytarabine) and Daunorubicin, improved overall survival (74.7 mo vs 25.6 mo) in patients with FLT3-mutant (D835X and I836X) or FLT3-ITD (exon 14 insertions) acute myeloid leukemia compared to Cytosar-U (cytarabine) and Daunorubicin with placebo (PMID: 28644114).	28644114 detail... detail...
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	predicted - sensitive	Ibrutinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, FLT3-ITD mutations correlated with sensitivity to Imbruvica (ibrutinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
FLT3	FLT3 exon 14 ins	Advanced Solid Tumor	sensitive	Pexidartinib	Preclinical	Actionable	In a preclinical study, PLX3397 inhibited proliferation of transformed cells expressing FLT3-ITD in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	FLT3 internal tandem duplication (FLT3-ITD) mutations are associated with inferior prognosis in acute myeloid leukemia patients with normal karyotype (NCCN.org).	detail...
FLT3	FLT3 exon 14 ins	hematologic cancer	sensitive	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited growth of transformed hematologic cells expressing FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins	hematologic cancer	sensitive	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited growth of transformed hematologic cells expressing FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Altiratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Altiratinib (DCC-0701) inhibited proliferation of an acute myeloid leukemia cell harboring a FLT3-ITD mutation in culture (PMID: 26285778).	26285778
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	predicted - sensitive	Cytarabine + Quizartinib	Phase Ib/II	Actionable	In a Phase I/II trial, Quizartinib (AC220) in combination with Cytosar-U (cytarabine) resulted in a median overall survival of 6.7 months and a median progression-free survival of 3 months in acute myeloid leukemia patients harboring FLT3 ITD mutations (ASH 59th Annual Meeting and Exposition, Dec 2017, Abstract 723).	detail...
FLT3	FLT3 exon 14 ins	myelodysplastic syndrome	not applicable	N/A	Guideline	Actionable	FLT3 internal tandem duplication (FLT3-ITD) mutations are associated with poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Selinexor + Sorafenib	Phase Ib/II	Actionable	In a Phase I/II trial, combination of Selinexor and Nexavar (sorafenib) treatment resulted in complete remission in 29% (4/14) and more than 50% blast reduction in 14% (2/14) of patients with acute myeloid leukemia harboring FLT3 ITD and/or D835 mutations (ASH, 59th Annual Meeting and Exposition, Dec 2017, Abstract 1344; NCT01607892).	detail...
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Decitabine + Sorafenib	Guideline	Actionable	Nexavar (sorafenib) in combination with Dacogen (decitabine) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a FLT3 internal tandem duplication (FLT3-ITD) mutation (NCCN.org).	detail...
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Semaxanib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication were sensitive to Semaxanib (SU5416) in culture, demonstrating inhibition of cell proliferation and inhibition of Flt3, Mapk, and Stat5 phosphorylation (PMID: 12351406).	12351406
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited Flt3 phosphorylation and growth of acute myeloid leukemia cell lines harboring FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Sorafenib	Preclinical - Patient cell culture	Actionable	In a preclinical study, FLT3-ITD mutations correlated with sensitivity to Nexavar (sorafenib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited Flt3 phosphorylation and growth of acute myeloid leukemia cell lines harboring FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins	leukemia	sensitive	E6201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, E6201 induced growth inhibition and apoptosis in leukemia cell lines harboring FLT3 internal tandem duplications (ITD) and reduced tumor burden in xenograft models (PMID: 26822154).	26822154
FLT3	FLT3 exon 14 ins	hematologic cancer	sensitive	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Quizartinib (AC220) inhibited growth of transformed hematologic cells expressing FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	CG-806	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CG'806 inhibited FLT3 downstream signaling, resulted in growth inhibition of acute myeloid leukemia cells harboring FLT3 exon 14 insertion (ITD) in culture and tumor inhibition in cell line xenograft models (Clin Cancer Res 2017; 23(24_Suppl):Abstract nr 25).	detail... detail...
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	resistant	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Avapritinib (BLU-285) did not inhibit Flt3 phosphorylation or growth of acute myeloid leukemia cell lines harboring FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins	hematologic cancer	decreased response	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Avapritinib (BLU-285) inhibited growth of transformed hematologic cells expressing FLT3 exon 14 insertions (ITD) in culture with reduced potency compared to other kinase inhibitors (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	FF-10101	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, FF-10101 inhibited Flt3 autophosphorylation and cell growth of leukemic cells in culture and in AML-patient-derived xenograft models with FLT3-ITD mutations (PMID: 29187377).	29187377
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	UNC1666	Preclinical - Cell culture	Actionable	In a preclinical study, UNC1666 inhibited FLT3 phosphorylation and downstream signaling, induced apoptosis of acute myeloid leukemia cells harboring FLT3 exon 14 insertions (ITD) in culture (PMID: 25762638).	25762638
FLT3	FLT3 exon 14 ins	hematologic cancer	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited growth of transformed hematologic cells expressing FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543).	31309543
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Gilteritinib	Phase Ib/II	Actionable	In a Phase I/II trial, treatment with Gilteritinib (ASP2215) at a dose of 80mg/day or higher resulted in an overall response rate of 55% (77/141) in patients with relapsed or refractory acute myeloid leukemia harboring FLT3 internal tandem duplication mutations (PMID: 28645776; NCT02014558).	28645776
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Gilteritinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (ADMIRAL) that supported FDA approval, Xospata (gilteritinib) treatment resulted in complete remission (CR) or CR with partial hematologic recovery in 21% (29/138) of patients with relapsed or refractory acute myeloid leukemia harboring a FLT3 internal tandem duplication (ITD; exon 14 insertion), D835, or I836 mutation (FDA.gov; NCT02421939).	detail... detail...
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	Gilteritinib	Guideline	Actionable	Xospata (gilteritinib) is included in the guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a FLT3 internal tandem duplication (FLT3-ITD) mutation (NCCN.org).	detail...
FLT3	FLT3 exon 14 ins	acute myeloid leukemia	sensitive	MRX-2843	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 activation, resulted in growth inhibition in acute myeloid leukemia cell lines harboring FLT3 internal tandem duplication (ITD) in culture and in cell line xenograft models, and prolonged survival in patient-derived xenograft models (PMID: 27158668).	27158668
FLT3	FLT3 exon 14 ins FLT3 Y842H	hematologic cancer	sensitive	FF-10101	Preclinical - Cell culture	Actionable	In a preclinical study, FF-10101, as compared to Quizartinib, inhibited Flt3 autophosphorylation and cell proliferation of transformed 32Dcl3 murine myeloid cells expressing a human FLT3-ITD/Y842H compound mutation (PMID: 29187377).	29187377
FLT3	FLT3 exon 14 ins FLT3 Y842H	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 Y842H were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 Y842H	Advanced Solid Tumor	decreased response	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and Y842H demonstrated reduced sensitivity to Nexavar (sorafenib) in culture (PMID: 23392356).	23392356
FLT3	FLT3 exon 14 ins FLT3 Y842H	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and Y842H in culture (PMID: 27158668).	27158668
FLT3	FLT3 exon 14 ins FLT3 Y842H	Advanced Solid Tumor	decreased response	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and Y842H demonstrated reduced sensitivity to Quizartinib (AC220) in culture (PMID: 23392356).	23392356
FLT3	FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated resistance to Nexavar (sorafenib) in culture (Blood 2009 114:3776).	detail...
FLT3	FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated sensitivity to Rydapt (midostaurin) in culture (Blood 2009 114:3776).	detail...
FLT3	FLT3 exon 14 ins FLT3 Y842C	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, FLT3 Y842C conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 Y842C	leukemia	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 Y842C in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).	26822154
FLT3	FLT3 exon 14 ins FLT3 Y842C	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and Y842C in culture (PMID: 27158668).	27158668
FLT3	FLT3 exon 14 ins FLT3 Y842C	hematologic cancer	sensitive	FF-10101	Preclinical - Cell culture	Actionable	In a preclinical study, FF-10101, as compared to Quizartinib, inhibited Flt3 autophosphorylation and cell proliferation of transformed 32Dcl3 murine myeloid cells expressing a human FLT3-ITD/Y842C compound mutation (PMID: 29187377).	29187377
FLT3	FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	sensitive	Lestaurtinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated sensitivity to Lestaurtinib (CEP-701) in culture (Blood 2009 114:3776).	detail...
FLT3	FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	resistant	AGL2043	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated resistance to AGL2043 in culture (Blood 2009 114:3776).	detail...
FLT3	FLT3 exon 14 ins FLT3 Y842C	acute myeloid leukemia	resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated resistance to Sutent (sunitinib) in culture (Blood 2009 114:3776).	detail...
FLT3	FLT3 exon 14 ins FLT3 R834Q	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 R834Q were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 D835E	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835E were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 D835H	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, FLT3 D835H conferred resistance to PLX3397 in transformed cells when expressed as a compound mutation with FLT3-ITD in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 D835H	leukemia	resistant	Pexidartinib	Clinical Study	Actionable	In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397, but experienced relapse after emergence of a FLT3 D835H mutation on the same allele as the FLT3-ITD mutation (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 D835H	acute myeloid leukemia	sensitive	FF-10101	Preclinical - Pdx	Actionable	In a preclinical study, FF-10101 inhibited cell growth in AML-patient-derived xenograft models with FLT3-ITD/D835H compound mutations (PMID: 29187377).	29187377
FLT3	FLT3 exon 14 ins FLT3 D839H	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D839H were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 D835G	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835G were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 D698N	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D698N were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 D839A	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D839A were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 D839N	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D839N were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 N676S	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 N676S were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 N841K	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 N841K were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 Y842S	Advanced Solid Tumor	resistant	Pexidartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 Y842S were resistant to PLX3397 in culture (PMID: 25847190).	25847190
FLT3	FLT3 exon 14 ins FLT3 S652G	leukemia	predicted - resistant	Pexidartinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with FLT3-ITD positive leukemia initially responded to Pexidartinib (PLX3397), but experienced relapse after emergence of a FLT3 S652G mutation on the same allele as FLT3-ITD (PMID: 25847190).	25847190
FLT3	FLT3 ITD FLT3 N676D FLT3 Y842C	leukemia	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 N676D and Y842C in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).	26822154
FLT3	FLT3 exon 14 ins NPM1 mutant	leukemia	predicted - sensitive	MI-503	Preclinical	Actionable	In a preclinical study, MI-503 inhibited growth of murine leukemia cells expressing an NPM1 mutation and FLT3 internal tandem duplication in culture, and improved survival in mouse models (PMID: 27535106).	27535106
FLT3	FLT3 exon 14 ins NPM1 mutant	leukemia	predicted - sensitive	EPZ004777	Preclinical	Actionable	In a preclinical study, EPZ004777 inhibited growth and induced differentiation of murine leukemia cells expressing an NPM1 mutation and FLT3 internal tandem duplication in culture, and improved survival in mouse models (PMID: 27535106).	27535106
FLT3	FLT3 exon 14 ins NPM1 mutant	acute myeloid leukemia	predicted - sensitive	Entospletinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of FLT3-ITD and NPM1 mutations correlated with sensitivity to Entospletinib in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
FLT3	FLT3 exon 14 ins NPM1 mutant	acute myeloid leukemia	predicted - sensitive	Sunitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of FLT3-ITD and NPM1 mutations correlated with sensitivity to Sutent (sunitinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
FLT3	FLT3 exon 14 ins NPM1 mutant	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	FLT3 exon 14 insertions (high allelic ratio of ITD mutations) with NPM1 mutations are associated with an intermediate prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).	detail...
FLT3	FLT3 exon 14 ins NPM1 mutant	acute myeloid leukemia	sensitive	ENMD-2076	Phase I	Actionable	In a Phase I trial, two acute myeloid leukemia patients co-harboring a FLT3-ITD mutation and NPM1 mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088).	27406088
FLT3	FLT3 exon 14 ins NPM1 mutant	acute myeloid leukemia	predicted - sensitive	Ibrutinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of FLT3-ITD and NPM1 mutations correlated with sensitivity to Imbruvica (ibrutinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
FLT3	FLT3 exon 14 ins NPM1 mutant	acute myeloid leukemia	predicted - sensitive	Sorafenib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of FLT3-ITD and NPM1 mutations correlated with sensitivity to Nexavar (sorafenib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
FLT3	FLT3 exon 14 ins FLT3 F691I	Advanced Solid Tumor	decreased response	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and F691I demonstrated reduced response to Sutent (sunitinib) in culture (PMID: 23392356).	23392356
FLT3	FLT3 exon 14 ins FLT3 F691I	Advanced Solid Tumor	resistant	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Quizartinib (AC220) in culture (PMID: 23392356).	23392356
FLT3	FLT3 exon 14 ins FLT3 F691I	Advanced Solid Tumor	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Nexavar (sorafenib) in culture (PMID: 23392356).	23392356
FLT3	FLT3 exon 14 ins FLT3 F691I	Advanced Solid Tumor	decreased response	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3 ITD and F691I demonstrated reduced sensitivity to Alunbrig (brigatinib) compared to cells expressing FLT3 ITD in culture (PMID: 27780853).	27780853
FLT3	FLT3 exon 14 ins FLT3 F691I	Advanced Solid Tumor	resistant	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Rydapt (midostaurin) in culture (PMID: 23392356).	23392356
FLT3	FLT3 exon 14 ins FLT3 N676D	hematologic cancer	sensitive	G-749	Preclinical - Cell culture	Actionable	In a preclinical study, cells co-expressing a FLT3 internal tandem duplication and FLT3 N676D were sensitive to G-749 in culture, demonstrating inhibition of cell growth and inhibition of Flt3 autophosphorylation (PMID: 22864397).	22864397
FLT3	FLT3 exon 14 ins FLT3 N676D	Advanced Solid Tumor	decreased response	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and N676D demonstrated reduced sensitivity to Quizartinib (AC220) in culture (PMID: 23392356).	23392356
FLT3	FLT3 exon 14 ins FLT3 N676D	Advanced Solid Tumor	resistant	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and N676D were resistant to Rydapt (midostaurin) in culture (PMID: 23392356).	23392356
FLT3	FLT3 exon 14 ins FLT3 A848P	Advanced Solid Tumor	decreased response	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and A848P demonstrated reduced sensitivity to Quizartinib (AC220) in culture (PMID: 23392356).	23392356
FLT3	FLT3 exon 14 ins FLT3 A848P	Advanced Solid Tumor	decreased response	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and A848P demonstrated reduced sensitivity to Nexavar (sorafenib) in culture (PMID: 23392356).	23392356
FLT3	FLT3 exon 14 ins FLT3 A848P	Advanced Solid Tumor	resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and A848P were resistant to Sutent (sunitinib) in culture (PMID: 23392356).	23392356
FLT3	DNMT3A mut FLT3 exon 14 ins NPM1 mut	acute myeloid leukemia	predicted - sensitive	Ibrutinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of FLT3-ITD , DNMT3A, and NPM1 mutations correlated with sensitivity to Imbruvica (ibrutinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
FLT3	DNMT3A mut FLT3 exon 14 ins NPM1 mut	acute myeloid leukemia	predicted - sensitive	KO-539	Preclinical - Pdx	Actionable	In a preclinical study, KO-539 treatment resulted in clearance of leukemia cells in patient-derived xenograft (PDX) models of acute myeloid leukemia harboring mutations in NPM1, DNMT3, and FLT3 exon 14 (ITD) (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27).	detail...
FLT3	DNMT3A mut FLT3 exon 14 ins NPM1 mut	acute myeloid leukemia	predicted - sensitive	Entospletinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of FLT3-ITD, DNMT3A, and NPM1 mutations correlated with sensitivity to Entospletinib in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
FLT3	FLT3 exon 14 ins NPM1 wild-type	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	FLT3 exon 14 insertions (high allelic ratio of ITD mutations) with NPM1 wild-type are associated with a poor/adverse prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).	detail...
FLT3	FLT3 Y572C	Advanced Solid Tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited FLT3 phosphorylation of ERK1/2 and reduced cell growth in transformed cells expressing FLT3 Y572C in culture (PMID: 18068628).	18068628
FLT3	FLT3 Y572C	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib decreased cell proliferation of transformed mouse cells expressing Flt3 Y572C (PMID: 30651561).	30651561
FLT3	FLT3 exon23	acute myeloid leukemia	sensitive	Gilteritinib	Guideline	Actionable	Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 exon23	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	Guideline	Actionable	Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 mutant	acute myeloid leukemia	sensitive	Gilteritinib	FDA approved - Has Companion Diagnostic	Actionable	In a Phase III trial (ADMIRAL) that supported FDA approval, Xospata (gilteritinib) treatment resulted in complete remission (CR) or CR with partial hematologic recovery in 21% (29/138) of patients with relapsed or refractory acute myeloid leukemia harboring a FLT3 internal tandem duplication (ITD), D835, or I836 mutation (FDA.gov; NCT02421939).	detail... detail...
FLT3	FLT3 mutant	acute myeloid leukemia	sensitive	Gilteritinib	Phase Ib/II	Actionable	In a Phase I/II trial, treatment with Gilteritinib (ASP2215) resulted in an overall response rate of 49% (93/191) in patients with relapsed or refractory acute myeloid leukemia harboring FLT3 mutations, compared to 12% (7/58) in patients with wild-type FLT3 (PMID: 28645776; NCT02014558).	detail... 28645776
FLT3	FLT3 mutant	acute myeloid leukemia	sensitive	UNC2025	Preclinical	Actionable	In a preclinical study, UNC2025 inhibited FLT3 activation and growth of acute myeloid leukemia cells harboring a FLT3-ITD mutation in culture (PMID: 25068800).	25068800
FLT3	FLT3 mutant	acute myeloid leukemia	sensitive	Crenolanib	Phase I	Actionable	In a Phase I trial, Crenolanib treatment resulted in complete response (CR) in 39% (7/18), partial response (PR) in 11% (2/18), and an overall survival (OS) of 234 days in AML patients harboring FLT3 mutations (D835X, ITD, or both) that received no prior therapy, and CR in 17% (6/36), PR in 14% (5/36), and OS of 94 days in those progressed on TKIs (J Clin Oncol 34, 2016 (suppl; abstr 7008)).	detail...
FLT3	FLT3 mutant	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	Phase Ib/II	Actionable	In a Phase Ib clinical trial, Rydapt (midostaurin) treatment after Daunorubicin and Cytosar-U (cytarabine) induction resulted in complete remission in 92% (12/13) of acute myeloid leukemia patients carrying FLT3 mutations, although overall survival rate was similar to patients with wild-type FLT3 (PMID: 22627678).	22627678
FLT3	FLT3 mutant	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	FDA approved - Has Companion Diagnostic	Actionable	In a Phase III trial that supported FDA approval, treatment with Rydapt (midostaurin), combined with Cytosar-U (cytarabine) and Daunorubicin, improved overall survival (HR=0.78, p=0.009) and event-free survival (HR=0.78, p=0.002) in patients with FLT3-mutant (ITD, D835X, and I836X mutations) acute myeloid leukemia compared to Cytosar-U (cytarabine) and Daunorubicin with placebo (PMID: 28644114; NCT00651261).	28644114 detail... detail...
FLT3	FLT3 mutant	acute myeloid leukemia	predicted - sensitive	Cytarabine + Venetoclax	Phase Ib/II	Actionable	In a Phase I/II trial, Venclexta (venetoclax) in combination with low-dose cytarabine resulted in complete remission or complete remission with incomplete count recovery in 44% (7/16) of patients with acute myeloid leukemia harboring FLT3 mutations who were ineligible for intensive chemotherapy (ASH Annual Meeting, Dec 2018, Abstract 284; NCT02287233).	detail...
FLT3	FLT3 mutant	acute myeloid leukemia	sensitive	Selinexor + Sorafenib	Phase Ib/II	Actionable	In a Phase I/II trial, combination of Selinexor and Nexavar (sorafenib) treatment resulted in complete remission in 29% (4/14) and more than 50% blast reduction in 14% (2/14) of patients with acute myeloid leukemia harboring FLT3 ITD and/or D835 mutations (ASH, 59th Annual Meeting and Exposition, Dec 2017, Abstract 1344; NCT01607892).	detail...
FLT3	FLT3 mutant	acute myeloid leukemia	sensitive	TG02	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TG02 inhibited growth of FLT3-mutated acute myeloid leukemia cells in culture, resulted in complete tumor regression in cell line xenograft animal models (PMID: 21860433).	21860433
FLT3	FLT3 mutant	acute myeloid leukemia	sensitive	E6201	Preclinical	Actionable	In a preclinical study, acute myeloid leukemia cell lines harboring FLT3 mutations demonstrated increased sensitivity to E6201 induced growth inhibition and apoptosis in culture compared to FLT3 wild-type cells (PMID: 26822154).	26822154
FLT3	FLT3 mutant	acute myeloid leukemia	sensitive	Azacitidine + Midostaurin	Phase Ib/II	Actionable	In a Phase Ib/II trial, acute myeloid leukemia patients harboring a FLT3 mutation demonstrated an improved remission duration when treated with the combination therapy, Rydapt (midostaurin) and Vidaza (azacitidine) (PMID: 25530214).	25530214
FLT3	DNMT3A mut FLT3 mut NPM1 mut	acute myeloid leukemia	not applicable	N/A	Clinical Study	Emerging	In a retrospective analysis, the combination of DNMT3A, FLT3, and NPM1 mutations in patients with acute myeloid leukemia was highly associated with decreased event-free survival and overall survival, suggesting that this combination profile may serve as a future prognostic biomarker (PMID: 25281355).	25281355
FLT3	DNMT3A wild-type FLT3 mut NPM1 mut	acute myeloid leukemia	predicted - sensitive	KO-539	Preclinical - Pdx	Actionable	In a preclinical study, KO-539 treatment prevented disease progression in patient-derived xenograft (PDX) models of DNMT3A wild-type acute myeloid leukemia harboring mutations in NPM1 and FLT3 (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27).	detail...
FLT3	FLT3 exon19	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	Guideline	Actionable	Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 exon19	acute myeloid leukemia	sensitive	Gilteritinib	Guideline	Actionable	Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 Y599_D600insSTDNEYFYVDFREYEY	acute myeloid leukemia	predicted - sensitive	FLX925	Preclinical	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3-ITD secondary resistance mutation demonstrated sensitivity to FLX925 (Cancer Res, August 1, 2015 75; 787).	detail...
FLT3	FLT3 Y599_D600insSTDNEYFYVDFREYEY	acute myeloid leukemia	predicted - sensitive	Azacitidine + Sorafenib	Phase II	Actionable	In a Phase II trial, 93% (40/43) of acute myeloid leukemia patients harbored a FLT3-ITD and of the 37 patients that were evaluable, the combination therapy, Nexavar (sorafenib) and Vidaza (azacitidine), resulted in a 46% (17/37) response rate, which included 10 CRi, 6 CR, and 1 PR (PMID: 23613521).	23613521
FLT3	FLT3 Y599_D600insSTDNEYFYVDFREYEY	acute myeloid leukemia	predicted - sensitive	E6201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, E6201 induced cell death, inhibited cell growth, and decreased tumor burden in acute myeloid leukemia cells harboring FLT3-ITD mutations in culture and in cell line xenograft models (Blood Nov 2013, 122 (21) 2683).	detail...
FLT3	FLT3 Y599_D600insSTDNEYFYVDFREYEY	acute myeloid leukemia	predicted - sensitive	Quizartinib	Phase I	Actionable	In a Phase I clinical trial, patients with refractory or relapsed acute myeloid leukemia positive for FLT3-ITD demonstrated a 53% (9/17) response rate compared to a 14% (5/37) response rate in those patients negative for FLT3-ITD when treated with Quizartinib (AC220) (PMID: 24002496).	24002496
FLT3	IDH2 R140W FLT3 Y599_D600insSTDNEYFYVDFREYEY	acute myeloid leukemia	predicted - sensitive	Enasidenib + Quizartinib	Preclinical	Actionable	In a preclinical study, the combination of Enasidenib (AG-221) and Quizartinib (AC220) stimulated leukemic cell differentiation and reduced leukemic cell self-renewal in an acute myeloid leukemia mouse model simultaneously expressing IDH2 R140Q and a FLT3-ITD mutation (Blood Dec 2014, 124 (21) 437).	detail...
FLT3	FLT3 R834Q	Advanced Solid Tumor	sensitive	PD98059	Preclinical	Actionable	In a preclinical study, PD98059 inhibited ERK1/2 phosphorylation and reduced cell growth in transformed cells expressing FLT3 R834Q (PMID: 18068628).	18068628
FLT3	FLT3 R834Q	Advanced Solid Tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited FLT3-induced phosphorylation of ERK1/2 and reduced growth of transformed cells expressing FLT3 R834Q in culture (PMID: 18068628).	18068628
FLT3	FLT3 I836X	acute myeloid leukemia	sensitive	Gilteritinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (ADMIRAL) that supported FDA approval, Xospata (gilteritinib) treatment resulted in complete remission (CR) or CR with partial hematologic recovery in 21% (29/138) of patients with relapsed or refractory acute myeloid leukemia harboring a FLT3 internal tandem duplication (ITD), D835, or I836 mutation (FDA.gov; NCT02421939).	detail... detail...
FLT3	FLT3 I836X	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial that supported FDA approval, treatment with Rydapt (midostaurin), combined with Cytosar-U (cytarabine) and Daunorubicin, improved overall survival (74.7 mo vs 25.6 mo) in patients with FLT3-mutant (D835X and I836X) or FLT3-ITD (exon 14 insertions) acute myeloid leukemia compared to Cytosar-U (cytarabine) and Daunorubicin with placebo (PMID: 28644114).	detail... detail... 28644114
FLT3	FLT3 D835H	acute myeloid leukemia	sensitive	Crenolanib	Preclinical	Actionable	In a preclinical study, Crenolanib (CP-868596) inhibited Flt3 phosphorylation and induced apoptosis in leukemia cells expressing FLT3 D835H (PMID: 24623852).	24623852
FLT3	FLT3 exon21	acute myeloid leukemia	sensitive	Gilteritinib	Guideline	Actionable	Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 exon21	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	Guideline	Actionable	Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 D835G	acute myeloid leukemia	sensitive	E6201	Preclinical - Cell culture	Actionable	In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 D835G in culture (PMID: 26822154).	26822154
FLT3	FLT3 D835G	leukemia	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines over expressing FLT3 D835G in culture (PMID: 26822154).	26822154
FLT3	FLT3 exon22	acute myeloid leukemia	sensitive	Gilteritinib	Guideline	Actionable	Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 exon22	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	Guideline	Actionable	Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 L611_E612insCSSDNEYFYVDFREYEYDLKWEFPRENL	acute myeloid leukemia	sensitive	Tandutinib	Preclinical	Actionable	In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 L611_E612insCSSDNEYFYVDFREYEYDLKWEFPRENL in culture (PMID: 12124172).	12124172
FLT3	FLT3 Y842C	acute myeloid leukemia	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) induced cell death and inhibited FLT3 activation and downstream STAT5 activation in primary acute myeloid leukemic blasts harboring FLT3 Y842C in culture (PMID: 15345593).	15345593
FLT3	FLT3 Y842C	acute myeloid leukemia	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, primary AML blasts expressing FLT3 Y842C were resistant to Gleevec (imatinib) as demonstrated by constitutively phosphorylated FLT3 and STAT-5 (PMID: 15345593).	15345593
FLT3	FLT3 exon16	acute myeloid leukemia	sensitive	Gilteritinib	Guideline	Actionable	Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 exon16	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	Guideline	Actionable	Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 E612_F613insGYVDFREYEYDLKWEFRPRENLEF	acute myeloid leukemia	sensitive	Tandutinib	Preclinical	Actionable	In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 E612_F613insGYVDFREYEYDLKWEFRPRENLEF in culture (PMID: 12124172).	12124172
FLT3	FLT3 amp	colorectal cancer	predicted - sensitive	Sorafenib	Case Reports/Case Series	Actionable	In a clinical case study, Nexavar (sorafenib) treatment targeting FLT3 amplification in a rectal adenocarcinoma patient who had progressed on all standard therapies resulted in rapid clinical improvement (PMID: 25848357).	25848357
FLT3	FLT3 I836del	cancer	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited phosphorylation of FLT3, ERK, and STAT5, and growth of transformed cells expressing FLT3 I836del in culture (PMID: 17827387).	17827387
FLT3	FLT3 I836del	cancer	sensitive	Tandutinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tandutinib (CT53518) inhibited phosphorylation of FLT3 and activation of ERK and STAT5, and reduced growth of transformed cells expressing FLT3 I836del in culture (PMID: 15256420).	15256420
FLT3	FLT3 exon14	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	Guideline	Actionable	Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 exon14	acute myeloid leukemia	sensitive	Gilteritinib	Guideline	Actionable	Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 V592G	Advanced Solid Tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited FLT3-induced phosphorylation of ERK1/2 and reduced growth of transformed cells expressing FLT3 V592G in culture (PMID: 18068628).	18068628
FLT3	FLT3 exon17	acute myeloid leukemia	sensitive	Gilteritinib	Guideline	Actionable	Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 exon17	acute myeloid leukemia	sensitive	Cytarabine + Daunorubicin + Midostaurin	Guideline	Actionable	Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).	detail...
FLT3	FLT3 K429E	hematologic cancer	resistant	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib did not decrease cell proliferation of transformed mouse cells expressing Flt3 K429E (PMID: 30651561).	30651561
FOXL2	FOXL2 C134W	granulosa cell tumor	not applicable	N/A	Preclinical	Diagnostic	FOXL2 C134W mutations are used in the diagnosis of adult granulosa cell tumors of the ovary (PMID: 26791928, PMID: 22240241).	26791928 22240241
GATA1	GATA1 mutant	megakaryocytic leukemia	not applicable	N/A	Clinical Study	Diagnostic	GATA1 mutations are used in the diagnosis of Down Syndrome related acute megakaryoblastic leukemia (PMID: 25266042, PMID: 14636651, PMID: 12586620).	14636651 12586620 25266042
GATA1	GATA1 over exp	megakaryocytic leukemia	decreased response	Daunorubicin	Preclinical - Cell culture	Actionable	In a preclinical study, high expression of GATA1 was associated with decreased sensitivity to Cerubidine (daunorubicin) in a non-Down Syndrome megakaryocytic leukemia cell line in culture (PMID: 23874683).	23874683
GATA1	GATA1 over exp	megakaryocytic leukemia	decreased response	Cytarabine	Preclinical - Cell culture	Actionable	In a preclinical study, high expression of GATA1 was associated with decreased sensitivity to Cytosar-U (cytarabine) in an non-Down Syndrome megakaryocytic leukemia cell line in culture (PMID: 23874683).	23874683
GATA2	GATA2 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	GATA2 frameshift, nonsense, or splice site mutations, or missense mutations in codons 349-398 are associated with poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
GATA2	GATA2 mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, GATA2 germline mutations were shown to be a risk factor for the development of acute myeloid leukemia following myelodysplastic syndrome (PMID: 21892162, PMID: 22271902, PMID: 22147895, PMID: 22533337).	22533337 22271902 22147895 21892162
GATA2	CEBPA mutant GATA2 mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, mutations in GATA2 were associated with better overall survival in patients with cytogenetically normal acute myeloid leukemia (CN-AML) harboring biallelic CEBPA gene mutations (PMID: 22814295, PMID: 23521373, PMID: 25241285).	25241285 22814295 23521373
GNA11	GNA11 mutant	uveal melanoma	no benefit	Trametinib	Phase I	Actionable	In a Phase I trial, Mekinist (trametinib) treatment resulted in stable disease as best response in 50% (3/6) of patients with uveal melanoma harboring GNAQ or GNA11 mutations (PMID: 22805292; NCT00687622).	22805292
GNA11	GNA11 mutant	uveal melanoma	predicted - sensitive	AEB071 + CGM097	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, treatment with the combination of Sotrastaurin (AEB071) and CGM097 resulted in tumor regression or stasis in patient-derived xenograft (PDX) models of uveal melanoma harboring GNA11 mutations, and induced apoptosis and inhibited growth of GNA11-mutant uveal melanoma cell lines in culture (PMID: 27507190).	27507190
GNA11	GNA11 mutant	uveal melanoma	predicted - sensitive	AEB071 + Everolimus	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, treatment with the combination of Sotrastaurin (AEB071) and Afinitor (everolimus) inhibited tumor growth in patient-derived xenograft (PDX) models of uveal melanoma harboring GNA11 mutations, including tumor regression, and inhibited growth of GNA11-mutant uveal melanoma cell lines in culture (PMID: 27507190).	27507190
GNA11	GNA11 mutant	uveal melanoma	no benefit	Selumetinib	Phase II	Actionable	In a Phase II trial, Selumetinib (AZD6244) did not improved overall survival (10.9 vs 9.1 months, p=0.59) compared to chemotherapy in patients with uveal melanoma harboring GNAQ or GNA11 exon 5 mutations (n=83) (PMID: 24938562; NCT01143402).	24938562
GNA11	GNA11 mutant	uveal melanoma	predicted - sensitive	AEB071 + Binimetinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Sotrastaurin (AEB071) inhibited tumor growth in patient-derived xenograft (PDX) models of uveal melanoma harboring GNA11 mutations, and inhibited growth of GNA11-mutant uveal melanoma cell lines in culture (PMID: 27507190).	27507190
GNA11	GNA11 mutant	uveal melanoma	no benefit	Dacarbazine + Selumetinib	Phase III	Actionable	In a Phase III trial (SUMIT), Selumetinib (AZD6244) in combination with Deticene (dacarbazine) did not significantly improve progression-free survival (2.8 vs 1.8 months, HR=0.78, p=0.32) or overall survival (HR=0.75, p=0.40) in patients with metastatic uveal melanoma, 94% (73/78) of analyzed patients harbored mutually exclusive GNAQ or GNA11 mutations (PMID: 29528792; NCT01974752).	29528792
GNA11	GNA11 Q209L	uveal melanoma	sensitive	FR900359	Preclinical - Cell culture	Actionable	In a preclinical study, FR900359 inhibited ERK activation and proliferation, and induced cell-cycle arrest and apoptosis in a uveal melanoma cell line harboring GNA11 Q209L in culture (PMID: 30567972).	30567972
GNA11	GNA11 Q209L	uveal melanoma	predicted - sensitive	Selumetinib	Case Reports/Case Series	Actionable	In a Phase II trial, Selumetinib (AZD6244) treatment resulted in partial response in a patient with uveal melanoma harboring GNA11 Q209L (PMID: 24938562; NCT01143402).	24938562
GNA11	GNA11 Q209L	uveal melanoma	sensitive	AEB071 + Binimetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Sotrastaurin (AEB071) synergized to inhibit growth in a human uveal melanoma cancer cell line harboring a GNA11 Q209L mutation in culture and in xenograft models, and demonstrated improved efficacy over either agent alone (PMID: 24141786).	24141786
GNA11	GNA11 Q209L	uveal melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, uveal melanoma cell lines harboring GNA11 Q209L demonstrated increased sensitivity to growth inhibition by Mekinist (trametinib) in culture, compared to cells with wild-type GNA11 (PMID: 22733540).	22733540
GNA11	GNA11 Q209L	uveal melanoma	sensitive	TAK-733	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-733 inhibited growth of uveal melanoma cell lines harboring GNA11 Q209L in culture (PMID: 22515704).	22515704
GNAQ	GNAQ mutant	uveal melanoma	predicted - sensitive	AEB071 + Everolimus	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, treatment with the combination of Sotrastaurin (AEB071) and Afinitor (everolimus) inhibited tumor growth in patient-derived xenograft (PDX) models of uveal melanoma harboring GNAQ mutations, including tumor regression or stasis, and inhibited growth of GNAQ-mutant uveal melanoma cell lines in culture (PMID: 27507190).	27507190
GNAQ	GNAQ mutant	uveal melanoma	no benefit	Dacarbazine + Selumetinib	Phase III	Actionable	In a Phase III trial (SUMIT), Selumetinib (AZD6244) in combination with Deticene (dacarbazine) did not significantly improve progression-free survival (2.8 vs 1.8 months, HR=0.78, p=0.32) or overall survival (HR=0.75, p=0.40) in patients with metastatic uveal melanoma, 94% (73/78) of analyzed patients harbored mutually exclusive GNAQ or GNA11 mutations (PMID: 29528792; NCT01974752).	29528792
GNAQ	GNAQ mutant	uveal melanoma	predicted - sensitive	AEB071 + CGM097	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, treatment with the combination of Sotrastaurin (AEB071) and CGM097 resulted in tumor regression or stasis in patient-derived xenograft (PDX) models of uveal melanoma harboring GNAQ mutations, and induced apoptosis and inhibited growth of GNAQ-mutant uveal melanoma cell lines in culture (PMID: 27507190).	27507190
GNAQ	GNAQ mutant	uveal melanoma	predicted - sensitive	AEB071 + Binimetinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Sotrastaurin (AEB071) inhibited tumor growth in patient-derived xenograft (PDX) models of uveal melanoma harboring GNAQ mutations, and inhibited growth of GNAQ-mutant uveal melanoma cell lines in culture (PMID: 27507190).	27507190
GNAQ	GNAQ mutant	uveal cancer	no benefit	Trametinib	Phase I	Actionable	In a Phase I trial, Mekinist (trametinib) treatment resulted in stable disease as best response in 50% (3/6) of patients with uveal melanoma harboring GNAQ or GNA11 mutations (PMID: 22805292; NCT00687622).	22805292
GNAQ	GNAQ Q209P	uveal melanoma	sensitive	Enzastaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Enzastaurin (LY317615) increased cell-cycle arrest and apoptosis and decreased viability of a uveal melanoma cell line harboring GNAQ Q209P in culture (PMID: 22253748).	22253748
GNAQ	GNAQ Q209P	uveal melanoma	sensitive	AEB071	Preclinical - Cell culture	Actionable	In a preclinical study, Sotrastaurin (AEB071) induced cell-cycle arrest and apoptosis, and decreased viability of a uveal melanoma cell line harboring GNAQ Q209P in culture (PMID: 22653968).	22653968
GNAQ	GNAQ Q209P	uveal melanoma	sensitive	TAK-733	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-733 inhibited growth of uveal melanoma cell lines harboring GNAQ Q209P in culture (PMID: 22515704).	22515704
GNAQ	GNAQ Q209P	uveal melanoma	sensitive	FR900359	Preclinical - Cell culture	Actionable	In a preclinical study, FR900359 inhibited ERK activation and proliferation, and induced cell-cycle arrest, apoptosis and differentiation in a uveal melanoma cell line harboring GNAQ Q209P in culture (PMID: 30567972).	30567972
GNAQ	GNAQ Q209P	uveal melanoma	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) induced cell-cycle arrest and decreased viability of uveal melanoma cells harboring GNAQ Q209P in culture (PMID: 22550165).	22550165
GNAQ	GNAQ exon5	uveal melanoma	no benefit	Selumetinib	Phase II	Actionable	In a Phase II trial, Selumetinib (AZD6244) did not improved overall survival (10.9 vs 9.1 months, p=0.59) compared to chemotherapy in patients with uveal melanoma harboring GNAQ or GNA11 exon 5 mutations (n=83) (PMID: 24938562; NCT01143402).	24938562
GNAQ	GNAQ Q209L	uveal melanoma	sensitive	AEB071	Preclinical - Cell line xenograft	Actionable	In a preclinical study, human uveal melanoma cell lines harboring GNAQ Q209L demonstrated sensitivity to Sotrastaurin (AEB071) in culture, and Sotrastaurin (AEB071) decreased tumor growth in uveal melanoma cell line xenograft models harboring GNAQ Q209L (PMID: 24141786).	24141786
GNAQ	GNAQ Q209L	uveal melanoma	sensitive	TAK-733	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-733 inhibited growth of a uveal melanoma cell line harboring GNAQ Q209L in culture (PMID: 22515704).	22515704
GNAQ	GNAQ Q209L	uveal melanoma	sensitive	AEB071 + PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, Sotrastaurin (AEB071), in combination with PD-0325901, worked synergisitically to inhibit MAPK pathway activation and proliferation of a uveal melanoma cell line harboring GNAQ Q209L (PMID: 24141786).	24141786
GNAQ	GNAQ Q209L	uveal melanoma	sensitive	FR900359	Preclinical - Cell culture	Actionable	In a preclinical study, FR900359 inhibited ERK activation and proliferation, and induced cell-cycle arrest and apoptosis in a uveal melanoma cell line harboring GNAQ Q209L in culture (PMID: 30567972).	30567972
GNAQ	GNAQ Q209L	uveal melanoma	sensitive	GSK2126458 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of Mekinist (trametinib) and GSK2126458 induced apoptosis in uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 22733540).	22733540
GNAQ	GNAQ Q209L	uveal melanoma	sensitive	Enzastaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Enzastaurin (LY317615) increased cell-cycle arrest and apoptosis and decreased viability of uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 22253748).	22253748
GNAQ	GNAQ Q209L	uveal melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, uveal melanoma cell lines harboring GNAQ Q209L demonstrated increased sensitivity to growth inhibition by Mekinist (trametinib) in culture, compared to cells with wild-type GNAQ (PMID: 22733540).	22733540
GNAQ	GNAQ Q209L	uveal melanoma	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) induced cell-cycle arrest and decreased viability of uveal melanoma cells harboring GNAQ Q209L in culture (PMID: 22550165).	22550165
GNAQ	GNAQ Q209L	uveal melanoma	sensitive	NAV-2729	Preclinical - Cell line xenograft	Actionable	In a preclinical study, NAV-2729 inhibited signaling downstream of GNAQ Q209L in melanoma cells in culture, and inhibited initiation and growth of tumors in a uveal melanoma cell line xenograft model harboring GNAQ Q209L (PMID: 27265506).	27265506
GNAQ	GNAQ Q209L	uveal melanoma	sensitive	U0126	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with U0126 resulted in reduced cell numbers in uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 19078957).	19078957
GNAQ	GNAQ Q209L	uveal melanoma	sensitive	Verteporfin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Visudyne (verteporfin) inhibited tumor formation in a uveal melanoma cell line xenograft model harboring GNAQ Q209L (PMID: 27308390).	27308390
GNAQ	GNAQ Q209L PTEN R173S	ocular melanoma	predicted - sensitive	Refametinib	Phase I	Actionable	In a Phase I clinical trial, Refametinib (BAY 86-9766) demonstrated preliminary clinical activity in patients with several tumor types, including prolonged stable disease in an ocular melanoma patient harboring GNAQ Q209L and PTEN R173S (PMID: 23434733).	23434733
GNAS	EML4-ALK GNAS amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, GNAS amplification (PMID: 29636358).	29636358
HNF1A	HNF1A inact mut	hepatocellular adenoma	not applicable	N/A	Clinical Study	Diagnostic	Inactivating mutations in HNF1A (TCF1) are used in the diagnosis of the HCA-H subtype of hepatocellular adenoma (PMID: 25076298, PMID: 26961851, PMID: 25434466).	25076298 25434466 26961851
HRAS	HRAS Q61R	Advanced Solid Tumor	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing HRAS Q61R demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513).	26544513
HRAS	HRAS Q61R	Advanced Solid Tumor	sensitive	Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing HRAS Q61R demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513).	26544513
HRAS	HRAS mutant	breast cancer	decreased response	PI-273	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cell lines harboring RAS mutations, including HRAS-mutant cell lines, demonstrated decreased sensitivity to growth inhibition by PI-273, in culture (PMID: 28827373).	28827373
HRAS	HRAS mutant	Advanced Solid Tumor	predicted - sensitive	Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, human solid tumor cell lines harboring HRAS mutations demonstrated increased sensitivity to growth inhibition by Afinitor (everolimus) in culture compared to cell lines with wild-type HRAS (PMID: 26544513).	26544513
HRAS	HRAS mutant	Advanced Solid Tumor	predicted - sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, human solid tumor cell lines harboring HRAS mutations demonstrated increased sensitivity to growth inhibition by Selumetinib (AZD6244) in culture compared to cell lines with wild-type HRAS (PMID: 26544513).	26544513
HRAS	HRAS mutant	urinary bladder cancer	sensitive	Metformin	Preclinical	Actionable	In a preclinical study, mouse models of bladder cancer harboring an HRAS mutation were sensitive to Glucophage (metformin), resulting in tumor growth reduction and prevention of hyperplasia regression (PMID: 26921394).	26921394
HRAS	HRAS mutant	Advanced Solid Tumor	predicted - sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Binimetinib (MEK162) inhibited growth and induced apoptosis in human solid tumor cell lines harboring HRAS mutations in culture (PMID: 26544513).	26544513
HRAS	HRAS mutant	thyroid medullary carcinoma	sensitive	Cabozantinib	Phase III	Actionable	In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (47 vs 8 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RAS mutations (PMID: 27525386).	27525386
HRAS	HRAS mutant	transitional cell carcinoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human urinary transitional cell carcinoma cells harboring mutant HRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).	26343583
HRAS	HRAS mutant	ovarian cancer	predicted - sensitive	Alpelisib + Binimetinib	Phase Ib/II	Actionable	In a Phase Ib study, Alpelisib (BYL719) in combination with Binimetinib (MEK162) demonstrated preliminary safety and efficacy in patients with RAS-mutant advanced solid tumors, including patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 9051).	detail...
HRAS	HRAS mutant	endometrial cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of human endometrial cancer cells harboring mutant HRAS in culture (PMID: 26343583).	26343583
HRAS	HRAS G12V	Advanced Solid Tumor	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, tumor cells expressing HRAS G12V demonstrated resistance to treatment with Vectibix (panitumumab) (PMID: 22797062).	22797062
HRAS	HRAS G12V	Advanced Solid Tumor	sensitive	Pz-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pz-1 reduced tumor growth in xenograft models of transformed cells over expressing HRAS G12V in a dose-dependent manner (PMID: 26126987).	26126987
HRAS	HRAS G12V	urinary bladder cancer	sensitive	Binimetinib + Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a bladder cell line harboring HRAS G12V in culture (PMID: 26544513).	26544513
HRAS	HRAS G12V	Advanced Solid Tumor	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, tumor cells expressing HRAS G12V demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 22797062).	22797062
HRAS	HRAS G12V	Advanced Solid Tumor	sensitive	Rigosertib	Preclinical - Cell culture	Actionable	In a preclinical study, Estybon (rigosertib) inhibited oncogenic transformation in fibroblast cells over-expressing HRAS G12V in culture (PMID: 27104980).	27104980
HRAS	HRAS G12V	Advanced Solid Tumor	predicted - sensitive	SR9009	Preclinical - Cell culture	Actionable	In a preclinical study, SR9009 treatment resulted in apoptosis in HRAS G12V-induced senescent firbroblast cells in culture (PMID: 29320480).	29320480
HRAS	HRAS G12V	Advanced Solid Tumor	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing HRAS G12V demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513).	26544513
HRAS	HRAS G12V	Advanced Solid Tumor	predicted - sensitive	SR9011	Preclinical - Cell culture	Actionable	In a preclinical study, SR9011 treatment resulted in apoptosis in HRAS G12V-induced senescent firbroblast cells in culture (PMID: 29320480).	29320480
HRAS	HRAS G12V	Advanced Solid Tumor	sensitive	Binimetinib + Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) worked synergistically to inhibit growth of transformed cells expressing HRAS G12V in culture (PMID: 26544513).	26544513
HRAS	HRAS G12V	Advanced Solid Tumor	sensitive	Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing HRAS G12V demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513).	26544513
HRAS	HRAS G12V	melanoma	sensitive	CI-1040	Preclinical	Actionable	In a preclinical study CI-1040 (PD-184352) inhibited melanoma progression in a transgenic zebrafish model of melanoma expressing HRAS G12V (PMID: 26267534).	26267534
HRAS	HRAS G12V	urinary bladder cancer	sensitive	Everolimus + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Selumetinib (AZD6244) and Afinitor (everolimus) reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a bladder cancer cell line harboring HRAS G12V in culture (PMID: 26544513).	26544513
HRAS	HRAS G12V	malignant glioma	sensitive	SF1126	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SF1126 inhibited Akt activation, proliferation, and migration of transgenic mouse glioma cells expressing HRAS G12V in culture, and suppressed tumor growth in xenograft models (PMID: 25425962).	25425962
HRAS	FGFR3 wild-type FGFR3 dec exp HRAS G12V	transitional cell carcinoma	decreased response	AZ8010	Preclinical	Actionable	In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZ8010 in culture (PMID: 22869148).	22869148
HRAS	FGFR3 wild-type FGFR3 dec exp HRAS G12V	transitional cell carcinoma	resistant	PD173074	Preclinical	Actionable	In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to PD173074 in culture (PMID: 22869148).	22869148
HRAS	FGFR3 wild-type FGFR3 dec exp HRAS G12V	transitional cell carcinoma	resistant	AZD4547	Preclinical	Actionable	In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZD4547 in culture (PMID: 22869148).	22869148
HRAS	HRAS Q61L	skin squamous cell carcinoma	no benefit	PLX7904	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX7904 did not stimulate growth of Zelboraf (vemurafenib)-induced cutaneous squamous cell carcinoma cells harboring HRAS Q61L in culture or in cell line xenograft models (PMID: 26466569).	26466569
HRAS	HRAS Q61L	lung squamous cell carcinoma	sensitive	Everolimus + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Selumetinib (AZD6244) and Afinitor (everolimus) inhibited growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture, and inhibited tumor growth in xenograft models, with increased efficacy compared to either agent alone (PMID: 26544513).	26544513
HRAS	HRAS Q61L	Advanced Solid Tumor	sensitive	Binimetinib + Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) worked synergistically to inhibit growth of transformed cells expressing HRAS Q61L in culture (PMID: 26544513).	26544513
HRAS	HRAS Q61L	lung squamous cell carcinoma	sensitive	Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture, and inhibited tumor growth in xenograft models (PMID: 26544513).	26544513
HRAS	HRAS Q61L	lung squamous cell carcinoma	sensitive	AZD8055 + Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and AZD8055 reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture (PMID: 26544513).	26544513
HRAS	HRAS Q61L	Advanced Solid Tumor	sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing HRAS Q61L demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513).	26544513
HRAS	HRAS Q61L	head and neck squamous cell carcinoma	sensitive	Sirolimus + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Rapamune (sirolimus) worked synergistically with Mekinist (trametinib) to inhibit proliferation of head and neck squamous carcinoma cell lines harboring HRAS Q61L in culture and to reduce tumor growth in cell line xenograft models (PMID: 26882569).	26882569
HRAS	HRAS Q61L	lung squamous cell carcinoma	sensitive	Binimetinib + Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture (PMID: 26544513).	26544513
HRAS	HRAS Q61L	lung squamous cell carcinoma	no benefit	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, BKM120 did not inhibit growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture (PMID: 26544513)	26544513
HRAS	HRAS Q61L	Advanced Solid Tumor	sensitive	Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing HRAS Q61L demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513).	26544513
HRAS	HRAS Q61L	bladder carcinoma	sensitive	NS1	Preclinical - Cell culture	Actionable	In a preclinical study, bladder carcinoma cells expressing HRAS Q61L demonstrated sensitivity to NS1, resulting in inhibition of Mapk signaling and cell proliferation in culture (PMID: 27820802).	27820802
HRAS	FGFR3 K650E FGFR3 over exp HRAS K117E	multiple myeloma	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, PD173074 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells harboring HRAS H117E and over expression of FGFR3 K650E in culture (PMID: 22869148).	22869148
HRAS	FGFR3 K650E FGFR3 over exp HRAS K117E	myeloid neoplasm	sensitive	AZ8010	Preclinical	Actionable	In a preclinical study, AZ8010 inhibited Fgfr3 signaling and decreased proliferation of myeloma cells with HRAS K117E and overexpression of FGFR3 K650E in culture (PMID: 22869148).	22869148
HRAS	HRAS G13R	thyroid cancer	sensitive	MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring HRAS G13R (PMID: 21289267).	21289267
HRAS	EML4-ALK HRAS amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, HRAS amplification (PMID: 29636358).	29636358
HRAS	HRAS wild-type	cancer	predicted - sensitive	FTI-277	Preclinical	Actionable	In a preclinical study, the farnesyltransferase inhibitor FTI-277 sensitized Hras transformed rat fibroblasts to radiation therapy (PMID: 8620483).	8620483
HRAS	HRAS wild-type	melanoma	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with wild-type HRAS (PMID: 23039341).	23039341
HRAS	BRAF G466E HRAS Q61K	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF G466E and HRAS Q61K in culture (PMID: 28783719).	28783719
HRAS	HRAS inact mut	thyroid cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited growth of thyroid cancer cells harboring an HRAS pathway activating mutation in cell culture (PMID: 21831957).	21831957
IDH1	IDH1 R132L	acute myeloid leukemia	sensitive	BAY1436032	Preclinical - Patient cell culture	Actionable	In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels, and inhibited growth and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132L in culture (PMID: 28232670).	28232670
IDH1	IDH1 R132L	acute myeloid leukemia	sensitive	Ivosidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I trial that supported FDA approval, Tibsovo (ivosidenib) treatment resulted in complete remission (CR) in 21.6% (27/125), CR with partial hematological recovery (CRh) in 8.8% (11/125), and overall response (OR) in 41.6% (52/125) of patients with relapsed or refractory acute myeloid leukemia harboring a susceptible IDH1 mutation (R132C/G/H/L/S) as detected by an FDA-approved test (PMID: 29860938; NCT02074839).	29860938 detail... detail...
IDH1	IDH1 R132L	acute myeloid leukemia	sensitive	Ivosidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I trial that supported FDA approval, Tibsovo (ivosidenib) treatment resulted in complete remission (CR) in 28.6% (8/28), CR with partial hematological recovery (CRh) in 14.3% (4/28) of patients age 75 or older with untreated acute myeloid leukemia harboring a susceptible IDH1 mutation (R132C/G/H/L/S) as detected by an FDA-approved test, with a median treatment duration of 4.3 months (PMID: 29860938; NCT02074839).	29860938 detail... detail...
IDH1	IDH1 R132G	acute myeloid leukemia	sensitive	Ivosidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I trial that supported FDA approval, Tibsovo (ivosidenib) treatment resulted in complete remission (CR) in 21.6% (27/125), CR with partial hematological recovery (CRh) in 8.8% (11/125), and overall response (OR) in 41.6% (52/125) of patients with relapsed or refractory acute myeloid leukemia harboring a susceptible IDH1 mutation (R132C/G/H/L/S) as detected by an FDA-approved test (PMID: 29860938; NCT02074839).	detail... 29860938 detail...
IDH1	IDH1 R132G	acute myeloid leukemia	sensitive	Ivosidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I trial that supported FDA approval, Tibsovo (ivosidenib) treatment resulted in complete remission (CR) in 28.6% (8/28), CR with partial hematological recovery (CRh) in 14.3% (4/28) of patients age 75 or older with untreated acute myeloid leukemia harboring a susceptible IDH1 mutation (R132C/G/H/L/S) as detected by an FDA-approved test, with a median treatment duration of 4.3 months (PMID: 29860938; NCT02074839).	detail... 29860938 detail...
IDH1	IDH1 R132G	acute myeloid leukemia	sensitive	BAY1436032	Preclinical - Patient cell culture	Actionable	In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132G in culture (PMID: 28232670).	28232670
IDH1	IDH1 R132X	acute myeloid leukemia	predicted - sensitive	CG-806	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived acute myeloid leukemia cells harboring IDH1 R132X mutations demonstrated increased sensitivity to CG-806 compared to wild-type cells in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1323).	detail...
IDH1	IDH1 R132X	acute myeloid leukemia	sensitive	IDH305	Phase I	Actionable	In a Phase I trial, IDH305 treatment resulted in objective response in 33% (7/21) of acute myeloid leukemia patients harboring IDH1 R132 mutations, including complete remission in 3 (14%) and partial remission in 4 (19%) patients (Blood 2016 128 (22):1073).	detail...
IDH1	IDH1 R132H	Advanced Solid Tumor	sensitive	Niraparib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Zejula (niraparib)-induced growth inhibition in culture (PMID: 28148839).	28148839
IDH1	IDH1 R132H	oligodendroglioma	sensitive	Decitabine	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Dacogen (decitabine) decreased colony formation and tumor growth in patient derived xenograft (PDX) models of patient derived oligodendroglioma cells with IDH1 R132H mutations and co-deletion of 1p and 19q (PMID: 24077826).	24077826
IDH1	IDH1 R132H	acute myeloid leukemia	sensitive	BAY1436032	Preclinical - Patient cell culture	Actionable	In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels, and inhibited growth and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132H in culture (PMID: 28232670).	28232670
IDH1	IDH1 R132H	Advanced Solid Tumor	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839).	28148839
IDH1	IDH1 R132H	Advanced Solid Tumor	sensitive	VX-970	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to VX-970-induced growth inhibition in culture (PMID: 28148839).	28148839
IDH1	IDH1 R132H	malignant glioma	predicted - sensitive	AG-881	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AG-881 treatment decreased brain tumor 2HG levels in an orthotopic glioma cell line xenograft model harboring IDH1 R132H (Mol Cancer Ther Jan 1 2018 (17) (1 Supp) B126).	detail...
IDH1	IDH1 R132H	malignant glioma	not applicable	N/A	Guideline	Diagnostic	IDH1 R132H is diagnostic and aids in the diagnosis of gliomas (NCCN.org).	detail...
IDH1	IDH1 R132H	glioblastoma multiforme	sensitive	Temozolomide + Vandetanib	Phase II	Actionable	In a Phase II trial, Caprelsa (vandetanib), in combination with Temodar (temozolomide) and radiation therapy, demonstrated a significant increase in PFS and OS in glioblastoma patients harboring IDH1 R132H compared to glioblastoma patients without IDH1 R132H (PMID: 25910950).	25910950
IDH1	IDH1 R132H	Advanced Solid Tumor	sensitive	Cisplatin + Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, Talazoparib (BMN-673) and Cisplatin synergistically inhibited growth of transformed cells over expressing IDH1 R132H in culture (PMID: 28148839).	28148839
IDH1	IDH1 R132H	Advanced Solid Tumor	decreased response	AGI-5198 + Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, AGI-5198 reverted the sensitivity of transformed cells over expressing IDH1 R132H to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).	28148839
IDH1	IDH1 R132H	colorectal cancer	resistant	AGI-5198 + Metformin	Preclinical	Actionable	In a preclinical study, colorectal cancer cells harboring IDH1 R132H demonstrated increased cell proliferation when treated with a combination of Glucophage (metformin) and AGI-5198 (PMID: 26363012).	26363012
IDH1	IDH1 R132H	grade III astrocytoma	sensitive	Azacitidine	Preclinical	Actionable	In a preclinical study, long-term treatment with Vidaza (azacitidine) resulted in increased cellular differentiation, decreased proliferation, and tumor regression in a patient-derived xenograft (PDX) model of anaplastic astrocytoma harboring IDH1 R132H (PMID: 24077805).	24077805
IDH1	IDH1 R132H	colorectal cancer	resistant	AGI-5198 + Radiotherapy	Preclinical	Actionable	In a preclinical study, colorectal cancer cells expressing IDH1 R132H were resistant to radiotherapy when treated with AGI-5198 (PMID: 26363012).	26363012
IDH1	IDH1 R132H	colon carcinoma	sensitive	Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, colon carcinoma cells over expressing IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).	28148839
IDH1	IDH1 R132H	malignant glioma	sensitive	Talazoparib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived glioma cells harboring IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).	28148839
IDH1	IDH1 R132H	colorectal cancer	sensitive	Metformin	Preclinical	Actionable	In a preclinical study, colorectal carcinoma cells expressing IDH1 R132H were sensitive to Glucophage (metformin), resulting in decreased cell proliferation in culture (PMID: 26363012).	26363012
IDH1	IDH1 R132H	malignant glioma	sensitive	AGI-5198	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AGI-5198 inhibited growth of a glioma cell line harboring IDH1 R132H in culture and in xenograft models (PMID: 23558169).	23558169
IDH1	IDH1 R132H	colon carcinoma	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, colon carcinoma cells over expressing IDH1 R132H demonstrated increased sensitivity to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839).	28148839
IDH1	IDH1 R132H	acute myeloid leukemia	sensitive	Ivosidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I trial that supported FDA approval, Tibsovo (ivosidenib) treatment resulted in complete remission (CR) in 21.6% (27/125), CR with partial hematological recovery (CRh) in 8.8% (11/125), and overall response (OR) in 41.6% (52/125) of patients with relapsed or refractory acute myeloid leukemia harboring a susceptible IDH1 mutation (R132C/G/H/L/S) as detected by an FDA-approved test (PMID: 29860938; NCT02074839).	29860938 detail... detail...
IDH1	IDH1 R132H	acute myeloid leukemia	sensitive	Ivosidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I trial that supported FDA approval, Tibsovo (ivosidenib) treatment resulted in complete remission (CR) in 28.6% (8/28), CR with partial hematological recovery (CRh) in 14.3% (4/28) of patients age 75 or older with untreated acute myeloid leukemia harboring a susceptible IDH1 mutation (R132C/G/H/L/S) as detected by an FDA-approved test, with a median treatment duration of 4.3 months (PMID: 29860938; NCT02074839).	29860938 detail... detail...
IDH1	IDH1 R132H	Advanced Solid Tumor	sensitive	Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).	28148839
IDH1	IDH1 R132H	malignant glioma	sensitive	BPTES	Preclinical - Cell culture	Actionable	In a preclinical study, a glioma cell line expressing IDH1 R132H demonstrated increased sensitivity to growth inhibition by BPTES compared to a cell line expressing wild-type IDH1 in culture (PMID: 21045145).	21045145
IDH1	IDH1 R132H	Advanced Solid Tumor	sensitive	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Rubraca (rucaparib)-induced growth inhibition in culture (PMID: 28148839).	28148839
IDH1	FLT3 D835Y IDH1 R132H	hematologic cancer	resistant	AGI-5198	Preclinical - Cell culture	Actionable	In a preclinical study, AGI-5198, did not decrease cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 R132H (PMID: 30651561).	30651561
IDH1	FLT3 D835Y IDH1 R132H	hematologic cancer	sensitive	AGI-5198 + Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib, in combination with AGI-5198, synergistically decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 R132H (PMID: 30651561).	30651561
IDH1	FLT3 D835Y IDH1 R132H	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib, decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 R132H (PMID: 30651561).	30651561
IDH1	IDH1 wild-type	malignant glioma	not applicable	N/A	Guideline	Risk Factor	IDH1 wild-type is associated with increased risk of aggressive disease in patients with grade II or III infiltrative gliomas (NCCN.org).	detail...
IDH1	IDH1 wild-type PTEN mutant	glioblastoma multiforme	resistant	Pembrolizumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, PTEN mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who did not respond to anti-PD-1 therapy, with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who responded (odds ratio=0.85, p=0.0063), with 23 PTEN mutations identified in 32 non-responders and 3 in 13 responders (PMID: 30742119).	30742119
IDH1	IDH1 wild-type PTEN mutant	glioblastoma multiforme	resistant	Nivolumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, PTEN mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who did not respond to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who responded (odds ratio=0.85, p=0.0063), with 23 PTEN mutations identified in 32 non-responders and 3 in 13 responders (PMID: 30742119).	30742119
IDH1	BRAF mutant IDH1 wild-type	glioblastoma multiforme	predicted - sensitive	Pembrolizumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).	30742119
IDH1	BRAF mutant IDH1 wild-type	glioblastoma multiforme	predicted - sensitive	Nivolumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).	30742119
IDH1	IDH1 wild-type PTPN11 mutant	glioblastoma multiforme	predicted - sensitive	Pembrolizumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).	30742119
IDH1	IDH1 wild-type PTPN11 mutant	glioblastoma multiforme	predicted - sensitive	Nivolumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).	30742119
IDH1	FLT3 D835Y IDH1 wild-type	hematologic cancer	resistant	AGI-5198	Preclinical - Cell culture	Actionable	In a preclinical study, AGI-5198, did not decrease cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 wild-type (PMID: 30651561).	30651561
IDH1	FLT3 D835Y IDH1 wild-type	hematologic cancer	sensitive	AGI-5198 + Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib, in combination with AGI-5198, synergistically decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 wild-type (PMID: 30651561).	30651561
IDH1	FLT3 D835Y IDH1 wild-type	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib, decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y and Idh1 wild-type (PMID: 30651561).	30651561
IDH1	IDH1 R132C	fibrosarcoma	predicted - sensitive	AG-881	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AG-881 treatment decreased tumor 2HG levels in a fibrosarcoma cell line xenograft model harboring IDH1 R132C (Mol Cancer Ther Jan 1 2018 (17) (1 Supp) B126).	detail...
IDH1	IDH1 R132C	sarcoma	decreased response	AGI-5198 + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, AGI-5198 reverted the sensitivity of sarcoma cells harboring IDH1 R132C to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839).	28148839
IDH1	IDH1 R132C	intrahepatic cholangiocarcinoma	sensitive	Saracatinib	Preclinical	Actionable	In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132C demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123).	27231123
IDH1	IDH1 R132C	sarcoma	decreased response	AGI-5198 + Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, AGI-5198 reverted the sensitivity of sarcoma cells harboring IDH1 R132C to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).	28148839
IDH1	IDH1 R132C	acute myeloid leukemia	sensitive	Ivosidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I trial that supported FDA approval, Tibsovo (ivosidenib) treatment resulted in complete remission (CR) in 21.6% (27/125), CR with partial hematological recovery (CRh) in 8.8% (11/125), and overall response (OR) in 41.6% (52/125) of patients with relapsed or refractory acute myeloid leukemia harboring a susceptible IDH1 mutation (R132C/G/H/L/S) as detected by an FDA-approved test (PMID: 29860938; NCT02074839).	detail... detail... detail... 29860938
IDH1	IDH1 R132C	acute myeloid leukemia	sensitive	Ivosidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I trial that supported FDA approval, Tibsovo (ivosidenib) treatment resulted in complete remission (CR) in 28.6% (8/28), CR with partial hematological recovery (CRh) in 14.3% (4/28) of patients age 75 or older with untreated acute myeloid leukemia harboring a susceptible IDH1 mutation (R132C/G/H/L/S) as detected by an FDA-approved test, with a median treatment duration of 4.3 months (PMID: 29860938; NCT02074839).	detail... 29860938 detail...
IDH1	IDH1 R132C	intrahepatic cholangiocarcinoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited growth of intrahepatic cholangiocarcinoma cells harboring IDH1 R132C in culture, and suppressed tumor growth in PDX models (PMID: 27231123).	27231123
IDH1	IDH1 R132C	malignant glioma	sensitive	AGI-5198	Preclinical	Actionable	In a preclinical study, AGI-5198 inhibited growth and promoted differentiation in glioma cells expressing IDH1 R132C (PMID: 23558169).	23558169
IDH1	IDH1 R132C	malignant glioma	sensitive	Talazoparib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived glioma cells harboring IDH1 R132C demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).	28148839
IDH1	IDH1 R132C	acute myeloid leukemia	sensitive	BAY1436032	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, BAY1436032 decreased R-2HG levels and inhibited growth of primary acute myeloid leukemia (AML) cells harboring IDH1 R132C in culture, and decreased blast number and increased survival of two AML patient-derived xenograft (PDX) models, one which harbored additional alterations in FLT3, NPM1, and NRAS and one which harbored a KMT2A (MLL) alteration (PMID: 28232670).	28232670
IDH1	IDH1 R132C	sarcoma	sensitive	Olaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Lynparza (olaparib) treatment delayed tumor growth in cell line xenograft models of sarcoma harboring IDH1 R132C (PMID: 28148839).	28148839
IDH1	IDH1 R132C SRC T341I	intrahepatic cholangiocarcinoma	resistant	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S acquired resistance to Sprycel (dasatinib) after over expressing SRC T341I in culture (PMID: 27231123).	27231123
IDH1	IDH1 R132C IDH1 S280F	acute myeloid leukemia	predicted - resistant	Ivosidenib	Case Reports/Case Series	Actionable	In a clinical study, IDH1 S280F was identified as an acquired mutation in cis with the original IDH1 R132C in a patient with acute myeloid leukemia (AML), who developed resistance to Tibsovo (ivosidenib) after initial response (PMID: 29950729).	29950729
IDH1	IDH1 R132S	intrahepatic cholangiocarcinoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S demonstrated increased sensitivity to Sprycel (dasatinib) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123).	27231123
IDH1	IDH1 R132S	intrahepatic cholangiocarcinoma	sensitive	Saracatinib	Preclinical	Actionable	In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123).	27231123
IDH1	IDH1 R132S	acute myeloid leukemia	sensitive	Ivosidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I trial that supported FDA approval, Tibsovo (ivosidenib) treatment resulted in complete remission (CR) in 28.6% (8/28), CR with partial hematological recovery (CRh) in 14.3% (4/28) of patients age 75 or older with untreated acute myeloid leukemia harboring a susceptible IDH1 mutation (R132C/G/H/L/S) as detected by an FDA-approved test, with a median treatment duration of 4.3 months (PMID: 29860938; NCT02074839).	detail... 29860938 detail...
IDH1	IDH1 R132S	acute myeloid leukemia	sensitive	Ivosidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I trial that supported FDA approval, Tibsovo (ivosidenib) treatment resulted in complete remission (CR) in 21.6% (27/125), CR with partial hematological recovery (CRh) in 8.8% (11/125), and overall response (OR) in 41.6% (52/125) of patients with relapsed or refractory acute myeloid leukemia harboring a susceptible IDH1 mutation (R132C/G/H/L/S) as detected by an FDA-approved test (PMID: 29860938; NCT02074839).	detail... 29860938 detail...
IDH1	IDH1 R132S	acute myeloid leukemia	sensitive	BAY1436032	Preclinical - Patient cell culture	Actionable	In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels, and inhibited growth and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132S in culture (PMID: 28232670).	28232670
IDH1	IDH1 mutant	acute myeloid leukemia	predicted - sensitive	Cytarabine + Venetoclax	Phase Ib/II	Actionable	In a Phase I/II trial, Venclexta (venetoclax) in combination with low-dose cytarabine resulted in complete remission or complete remission with incomplete count recovery in 72% (13/18) of patients with acute myeloid leukemia harboring IDH1 or IDH2 mutations who were ineligible for intensive chemotherapy (ASH Annual Meeting, Dec 2018, Abstract 284; NCT02287233).	detail...
IDH1	IDH1 mutant	malignant glioma	not applicable	N/A	Guideline	Diagnostic	IDH1 mutations aid in the diagnosis of gliomas (PMID: 23041832, PMID: 19755387, PMID: 19915484; NCCN.org).	detail... 23041832 19755387 19915484
IDH1	IDH1 mutant	malignant glioma	not applicable	N/A	Guideline	Prognostic	IDH1 mutations are associated with a favorable prognosis in patients with glioma, and are associated with a survival benefit for patients treated with radiation or alkylator therapy (NCCN.org).	detail...
IDH1	IDH1 mutant	malignant glioma	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, including two meta-analyses, IDH1 mutations were associated with improved overall survival and progression free survival in patients with gliomas (PMID: 23817809, PMID: 26220714, PMID: 23894344).	23894344 23817809 26220714
IDH1	IDH1 mutant	acute myeloid leukemia	predicted - sensitive	LY3410738	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, LY3410738 reversed mutant IDH1-induced differentiation block in patient-derived acute myeloid leukemia (AML) cells, inhibited 2-HG production, induced differentiation, and eliminated AML cells in patient-derived orthotopic animal models of IDH1-mutant AML (AACR 2019 Annual Meeting, Abstract LB-274).	detail...
IDH1	IDH1 mutant	acute myeloid leukemia	sensitive	Azacitidine	Guideline	Actionable	Vidaza (azacitidine) is included in guidelines for adult patients with acute myeloid leukemia harboring an IDH1 mutation (NCCN.org).	detail...
IDH1	IDH1 mutant	chondrosarcoma	resistant	Dasatinib	Preclinical	Actionable	In a preclinical study, chondrosarcoma cells harboring IDH1 mutations were resistant to Sprycel (dasatinib) in culture (PMID: 27231123).	27231123
IDH1	IDH1 mutant	acute myeloid leukemia	predicted - sensitive	Venetoclax	Phase II	Actionable	In a Phase II trial, 33% (4/12) of acute myeloid leukemia patients harboring either IDH1 or IDH2 mutations responded to treatment with Venclexta (venetoclax), demonstrating a complete response or complete response with incomplete blood count recovery (PMID: 27520294).	27520294
IDH1	IDH1 mutant	astrocytoma	not applicable	N/A	Guideline	Diagnostic	IDH1 mutations aid in the diagnosis of grade II and grade III astrocytomas (NCCN.org).	detail...
IDH1	IDH1 mutant	grade III astrocytoma	not applicable	N/A	Guideline	Diagnostic	IDH1 mutations aid in the diagnosis of grade III astrocytomas (NCCN.org).	detail...
IDH1	IDH1 mutant	malignant glioma	sensitive	Ivosidenib	Phase I	Actionable	In a Phase I trial, AG-120 demonstrated safety and preliminary efficacy in IDH1-mutant glioma patients (Neuro Oncol (2016) 18 (suppl 6): vi12).	detail...
IDH1	IDH1 mutant	glioblastoma multiforme	not applicable	N/A	Guideline	Diagnostic	IDH1 mutations aid in the diagnosis of secondary grade IV glioblastomas (NCCN.org).	detail...
IDH1	IDH1 mutant	glioblastoma multiforme	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, including two meta-analyses, IDH1 mutations were associated with a greater overall survival and progression-free survival in patients with glioblastoma (PMID: 23904262, PMID: 26945349, PMID: 20560678).	20560678 23904262 26945349
IDH1	IDH1 mutant	lung adenocarcinoma	resistant	Dasatinib	Preclinical	Actionable	In a preclinical study, lung adenocarcinoma cells harboring IDH1 mutations were resistant to Sprycel (dasatinib) in culture (PMID: 27231123).	27231123
IDH1	IDH1 mutant	polycythemia vera	not applicable	N/A	Guideline	Actionable	IDH1 mutations are associated with inferior overall survival in patients with polycythemia vera (NCCN.org).	detail...
IDH1	IDH1 mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In two meta-analyses, IDH1 mutations were associated with a worse overall survival in patients with acute myeloid leukemia (PMID: 22616558, PMID: 23226625).	22616558 23226625
IDH1	IDH1 mutant	glioblastoma multiforme	predicted - sensitive	Bevacizumab + Lomustine	Phase II	Actionable	In a retrospective analysis of a Phase II trial, IDH1 mutation correlated with favorable overall survival in recurrent glioblastoma patients treated with a combination of Avastin (bevacizumab) and Lomustine (PMID: 26762204).	26762204
IDH1	IDH1 mutant	acute myeloid leukemia	sensitive	Ivosidenib	FDA approved - Has Companion Diagnostic	Actionable	In a Phase I trial that supported FDA approval, Tibsovo (ivosidenib) treatment resulted in complete remission (CR) in 21.6% (27/125), CR with partial hematological recovery (CRh) in 8.8% (11/125), and overall response (OR) in 41.6% (52/125) of patients with relapsed or refractory acute myeloid leukemia harboring a susceptible IDH1 mutation (R132C/G/H/L/S) as detected by an FDA-approved test (PMID: 29860938; NCT02074839).	detail... detail... 29860938
IDH1	IDH1 mutant	acute myeloid leukemia	sensitive	Ivosidenib	Guideline	Actionable	Tibsovo (ivosidenib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring an IDH1 mutation (NCCN.org).	detail...
IDH1	IDH1 mutant	oligodendroglioma	not applicable	N/A	Guideline	Diagnostic	IDH1 mutations aid in the diagnosis of oligodendrogliomas (NCCN.org).	detail...
IDH1	IDH1 mutant	cholangiocarcinoma	sensitive	Ivosidenib	Phase I	Actionable	In a Phase I trial, AG-120 treatment resulted in partial response in 6% (4/72) and stable disease in 56% (40/72) of cholangiocarcinoma patients harboring IDH1 mutations (Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 4015-4015; NCT02073994).	detail...
IDH1	IDH1 mutant	myelofibrosis	not applicable	N/A	Guideline	Prognostic	IDH1 mutations are associated with inferior leukemia-free survival in patients with myelofibrosis (NCCN.org).	detail...
IDH1	IDH1 mutant	angioimmunoblastic T-cell lymphoma	not applicable	N/A	Guideline	Diagnostic	IDH1 mutations aid in the diagnosis of angioimmunoblastic T-cell lymphoma (NCCN.org).	detail...
IDH1	IDH1 mutant	acute myeloid leukemia	sensitive	Decitabine	Guideline	Actionable	Dacogen (decitabine) is included in guidelines for adult patients with acute myeloid leukemia harboring an IDH1 mutation (NCCN.org).	detail...
IDH1	ATRX loss IDH1 mut	malignant glioma	predicted - sensitive	Gemcitabine + Radiotherapy	Phase I	Actionable	In a Phase I trial, Gemzar (gemcitabine) plus radiation therapy resulted in median overall survival of 73.5 months in 7 high-grade glioma patients with IDH mutated, non-codeleted tumors with ATRX loss (PMID: 26853339).	26853339
IDH1	ATRX loss IDH1 mut	astrocytoma	not applicable	N/A	Guideline	Diagnostic	ATRX deficiency in combination with IDH mutation aids in the diagnosis of astrocytoma (NCCN.org).	detail...
IDH2	IDH2 R140L	acute myeloid leukemia	sensitive	Enasidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial that supported FDA approval, Idhifa (enasidenib) treatment resulted in an overall response rate of 40.3% (71/176) with a median response duration of 5.8 months, complete remission in 19.3% (34/176), and stable disease in 48.3% (85/176) of acute myeloid leukemia patients harboring IDH2 mutations (PMID: 28588020; NCT01915498) and IDH2 R140L is on the companion diagnostic.	detail... detail... 28588020
IDH2	IDH2 wild-type	malignant glioma	not applicable	N/A	Guideline	Risk Factor	IDH2 wild-type is associated with increased risk of aggressive disease in patients with grade II or III infiltrative gliomas (NCCN.org).	detail...
IDH2	IDH2 R172W	acute myeloid leukemia	sensitive	Enasidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial that supported FDA approval, Idhifa (enasidenib) treatment resulted in an overall response rate of 40.3% (71/176) with a median response duration of 5.8 months, complete remission in 19.3% (34/176), and stable disease in 48.3% (85/176) of acute myeloid leukemia patients harboring IDH2 mutations (PMID: 28588020; NCT01915498) and IDH2 R172W is on the companion diagnostic.	28588020 detail... detail...
IDH2	IDH2 R172S	acute myeloid leukemia	sensitive	Enasidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial that supported FDA approval, Idhifa (enasidenib) treatment resulted in an overall response rate of 40.3% (71/176) with a median response duration of 5.8 months, complete remission in 19.3% (34/176), and stable disease in 48.3% (85/176) of acute myeloid leukemia patients harboring IDH2 mutations (PMID: 28588020; NCT01915498) and IDH2 R172S is on the companion diagnostic.	28588020 detail... detail...
IDH2	IDH2 R172K	colorectal cancer	predicted - sensitive	Enasidenib	Preclinical - Cell culture	Actionable	In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels in a colorectal carcinoma cell line expressing IDH2 R172K in culture (PMID: 28193778).	28193778
IDH2	IDH2 R172K	acute myeloid leukemia	sensitive	Enasidenib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels and induced differentiation of leukemic blasts from acute myeloid leukemia (AML) patients harboring IDH2 R172K in culture (PMID: 28193778).	28193778
IDH2	IDH2 R172K	acute myeloid leukemia	sensitive	Enasidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial that supported FDA approval, Idhifa (enasidenib) treatment resulted in an overall response rate of 40.3% (71/176) with a median response duration of 5.8 months, complete remission in 19.3% (34/176), and stable disease in 48.3% (85/176) of acute myeloid leukemia patients harboring IDH2 mutations (PMID: 28588020; NCT01915498) and IDH2 R172K is on the companion diagnostic.	detail... detail... 28588020
IDH2	IDH2 R172K	glioblastoma multiforme	predicted - sensitive	Enasidenib	Preclinical - Cell culture	Actionable	In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels in a glioblastoma cell line expressing IDH2 R172K in culture (PMID: 28193778).	28193778
IDH2	IDH2 R140W	acute myeloid leukemia	sensitive	Enasidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial that supported FDA approval, Idhifa (enasidenib) treatment resulted in an overall response rate of 40.3% (71/176) with a median response duration of 5.8 months, complete remission in 19.3% (34/176), and stable disease in 48.3% (85/176) of acute myeloid leukemia patients harboring IDH2 mutations (PMID: 28588020; NCT01915498) and IDH2 R140W is on the companion diagnostic.	detail... detail... 28588020
IDH2	IDH2 R140W FLT3 Y599_D600insSTDNEYFYVDFREYEY	acute myeloid leukemia	predicted - sensitive	Enasidenib + Quizartinib	Preclinical	Actionable	In a preclinical study, the combination of Enasidenib (AG-221) and Quizartinib (AC220) stimulated leukemic cell differentiation and reduced leukemic cell self-renewal in an acute myeloid leukemia mouse model simultaneously expressing IDH2 R140Q and a FLT3-ITD mutation (Blood Dec 2014, 124 (21) 437).	detail...
IDH2	IDH2 D76fs	acute myeloid leukemia	sensitive	Venetoclax	Phase II	Actionable	In a Phase II trial, an acute myeloid leukemia patient harboring IDH2 D76fs demonstrated sensitivity to treatment with Venclexta (venetoclax), achieving a complete response with incomplete blood count recovery after 24 weeks (PMID: 27520294).	27520294
IDH2	IDH2 R140G	acute myeloid leukemia	sensitive	Enasidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial that supported FDA approval, Idhifa (enasidenib) treatment resulted in an overall response rate of 40.3% (71/176) with a median response duration of 5.8 months, complete remission in 19.3% (34/176), and stable disease in 48.3% (85/176) of acute myeloid leukemia patients harboring IDH2 mutations (PMID: 28588020; NCT01915498) and IDH2 R140G is on the companion diagnostic.	detail... detail... 28588020
IDH2	IDH2 mutant	acute myeloid leukemia	predicted - sensitive	Cytarabine + Venetoclax	Phase Ib/II	Actionable	In a Phase I/II trial, Venclexta (venetoclax) in combination with low-dose cytarabine resulted in complete remission or complete remission with incomplete count recovery in 72% (13/18) of patients with acute myeloid leukemia harboring IDH1 or IDH2 mutations who were ineligible for intensive chemotherapy (ASH Annual Meeting, Dec 2018, Abstract 284; NCT02287233).	detail...
IDH2	IDH2 mutant	acute myeloid leukemia	sensitive	Enasidenib	Guideline	Actionable	Idhifa (enasidenib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring an IDH2 mutation (NCCN.org).	detail...
IDH2	IDH2 mutant	acute myeloid leukemia	sensitive	Enasidenib	FDA approved - Has Companion Diagnostic	Actionable	In a Phase I/II trial that supported FDA approval, Idhifa (enasidenib) treatment resulted in an overall response rate of 40.3% (71/176) with a median response duration of 5.8 months, complete remission in 19.3% (34/176), and stable disease in 48.3% (85/176) of acute myeloid leukemia patients harboring IDH2 mutations (R140Q/L/G/W, R172K/M/G/S/W) (PMID: 28588020; NCT01915498).	28588020 detail... detail...
IDH2	IDH2 mutant	malignant glioma	not applicable	N/A	Guideline	Diagnostic	IDH2 mutations aid in the diagnosis of gliomas (NCCN.org).	detail...
IDH2	IDH2 mutant	malignant glioma	not applicable	N/A	Guideline	Prognostic	IDH2 mutations are associated with a favorable prognosis in patients with glioma, and are associated with a survival benefit for patients treated with radiation or alkylator therapy (NCCN.org).	detail...
IDH2	IDH2 mutant	acute myeloid leukemia	sensitive	Azacitidine	Guideline	Actionable	Vidaza (azacitidine) is included in guidelines for adult patients with acute myeloid leukemia harboring an IDH2 mutation (NCCN.org).	detail...
IDH2	IDH2 mutant	polycythemia vera	not applicable	N/A	Guideline	Actionable	IDH2 mutations are associated with inferior overall survival in patients with polycythemia vera (NCCN.org).	detail...
IDH2	IDH2 mutant	angioimmunoblastic T-cell lymphoma	not applicable	N/A	Guideline	Diagnostic	IDH2 mutations aid in the diagnosis of angioimmunoblastic T-cell lymphoma (NCCN.org).	detail...
IDH2	IDH2 mutant	glioblastoma multiforme	not applicable	N/A	Guideline	Diagnostic	IDH2 mutations aid in the diagnosis of secondary grade IV glioblastomas (NCCN.org).	detail...
IDH2	IDH2 mutant	acute myeloid leukemia	sensitive	Decitabine	Guideline	Actionable	Dacogen (decitabine) is included in guidelines for adult patients with acute myeloid leukemia harboring an IDH2 mutation (NCCN.org).	detail...
IDH2	IDH2 mutant	oligodendroglioma	not applicable	N/A	Guideline	Diagnostic	IDH2 mutations aid in the diagnosis of oligodendrogliomas (NCCN.org).	detail...
IDH2	IDH2 mutant	myelofibrosis	not applicable	N/A	Guideline	Prognostic	IDH2 mutations are associated with inferior leukemia-free survival in patients with myelofibrosis (NCCN.org).	detail...
IDH2	IDH2 mutant	essential thrombocythemia	not applicable	N/A	Guideline	Prognostic	The presence of at least one mutation in either SH2B3, IDH2, U2AF1, SF3B1, EZH2, or TP53 is associated with inferior overall survival in patients with essential thrombocythemia (NCCN.org).	detail...
IDH2	IDH2 mutant	grade III astrocytoma	not applicable	N/A	Guideline	Diagnostic	IDH2 mutations aid in the diagnosis of grade III astrocytomas (NCCN.org).	detail...
IDH2	IDH2 mutant	acute myeloid leukemia	predicted - sensitive	Venetoclax	Phase II	Actionable	In a Phase II trial, 33% (4/12) of acute myeloid leukemia patients harboring either IDH1 or IDH2 mutations responded to treatment with Venclexta (venetoclax), demonstrating a complete response or complete response with incomplete blood count recovery (PMID: 27520294).	27520294
IDH2	IDH2 mutant	astrocytoma	not applicable	N/A	Guideline	Diagnostic	IDH2 mutations aid in the diagnosis of grade II and grade III astrocytomas (NCCN.org).	detail...
IDH2	IDH2 mutant	hematologic cancer	sensitive	Enasidenib	Phase I	Actionable	In a Phase I study, Enasidenib (AG-221) demonstrated safety and efficacy in patients with hematological cancer harboring IDH2 mutations and included 8 CR, 1 CRp, 3 CRi, and 8 PR (ASH Meeting, Dec 2014, abstract #115).	detail...
IDH2	ATRX loss IDH2 mut	astrocytoma	not applicable	N/A	Guideline	Diagnostic	ATRX deficiency in combination with IDH mutation aids in the diagnosis of astrocytoma (NCCN.org).	detail...
IDH2	IDH2 R140Q	acute myeloid leukemia	sensitive	Enasidenib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Enasidenib (AG-221) treatment reduced 2-hydroxyglutarate (2HG) levels and induced differentiation of leukemic blasts from acute myeloid leukemia (AML) patients harboring IDH2 R140Q in culture, and decreased 2HG levels and blast percentage and improved survival relative to Cytosar-U (cytarabine) treatment in IDH2 R140Q-mutant primary AML xenograft models (PMID: 28193778).	28193778
IDH2	IDH2 R140Q	acute myeloid leukemia	sensitive	Enasidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial that supported FDA approval, Idhifa (enasidenib) treatment resulted in an overall response rate of 40.3% (71/176) with a median response duration of 5.8 months, complete remission in 19.3% (34/176), and stable disease in 48.3% (85/176) of acute myeloid leukemia patients harboring IDH2 mutations (PMID: 28588020; NCT01915498) and IDH2 R140Q is on the companion diagnostic.	detail... detail... 28588020
IDH2	IDH2 R140Q	malignant glioma	predicted - sensitive	AG-881	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AG-881 treatment decreased tumor 2HG levels in a glioma cell line xenograft model harboring IDH2 R140Q (Mol Cancer Ther Jan 1 2018 (17) (1 Supp) B126).	detail...
IDH2	IDH2 R140Q	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	IDH2 R140Q is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
IDH2	IDH2 R140Q	acute myeloid leukemia	sensitive	AGI-6780	Preclinical	Actionable	In a preclinical study, treatment with AGI-6780 resulted in the differentiation of erythroleukemia and AML cell lines expressing IDH2 R140Q (PMID: 23558173).	23558173
IDH2	IDH2 R140Q	glioblastoma multiforme	predicted - sensitive	Enasidenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels in a glioblastoma cell line expressing IDH2 R140Q in culture and in xenograft models (PMID: 28193778).	28193778
IDH2	IDH2 R140Q IDH2 Q316E	acute myeloid leukemia	resistant	Enasidenib	Case Reports/Case Series	Actionable	In a clinical study, IDH2 Q316E was identified as an acquired mutation in trans with the original IDH2 R140Q in a patient with acute myeloid leukemia (AML), who developed resistance to Idhifa (enasidenib) after initial response, and coexpression of IDH2 Q316E in trans or in cis with IDH2 R140Q conferred resistance to Idhifa (enasidenib) in culture and in animal models of AML, supporting a mechanism of variants cooperating to confer resistance (PMID: 29950729).	29950729
IDH2	IDH2 R140Q IDH2 I319M	acute myeloid leukemia	resistant	Enasidenib	Case Reports/Case Series	Actionable	In a clinical study, IDH2 I319M was identified as an acquired mutation in trans with the original IDH2 R140Q in a patient with acute myeloid leukemia (AML), who developed resistance to Idhifa (enasidenib) after initial response, and coexpression of IDH2 I319M in trans or in cis with IDH2 R140Q conferred resistance to Idhifa (enasidenib) in culture, supporting a mechanism of variants cooperating to confer resistance (PMID: 29950729).	29950729
IDH2	IDH2 R172M	acute myeloid leukemia	sensitive	Enasidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial that supported FDA approval, Idhifa (enasidenib) treatment resulted in an overall response rate of 40.3% (71/176) with a median response duration of 5.8 months, complete remission in 19.3% (34/176), and stable disease in 48.3% (85/176) of acute myeloid leukemia patients harboring IDH2 mutations (PMID: 28588020; NCT01915498) and IDH2 R172M is on the companion diagnostic.	28588020 detail... detail...
IDH2	IDH2 R172G	acute myeloid leukemia	sensitive	Enasidenib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial that supported FDA approval, Idhifa (enasidenib) treatment resulted in an overall response rate of 40.3% (71/176) with a median response duration of 5.8 months, complete remission in 19.3% (34/176), and stable disease in 48.3% (85/176) of acute myeloid leukemia patients harboring IDH2 mutations (PMID: 28588020; NCT01915498) and IDH2 R172G is on the companion diagnostic.	28588020 detail... detail...
IDH2	IDH2 R172X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	IDH2 R172X is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
IKZF1	IKZF1 del	acute lymphocytic leukemia	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, including a meta-analysis, IKZF1 deletion was associated with a worse event-free survival and overall survival in patients with acute lymphocytic leukemia (PMID: 25335741, PMID: 26194343, PMID: 27067989).	25335741 26194343 27067989
IKZF1	IKZF1 wild-type	multiple myeloma	sensitive	Lenalidomide	Preclinical	Actionable	In a preclinical study, Revlimid (lenalidomide) treatment resulted in IKZF1 degradation and decreased proliferation of multiple myeloma cells in culture (PMID: 24292625).	24292625
JAK2	ETV6 - JAK2 JAK2 R1127K	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the R1127K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
JAK2	ETV6-JAK2 JAK2 V881A	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the V881A mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
JAK2	JAK2 R938Q	B-cell childhood acute lymphoblastic leukemia	resistant	Ruxolitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, bone marrow mononuclear cells from a pediatric B-cell acute lymphoblastic leukemia with an acquired Jak2 R938Q mutation were resistant to Jakafi (ruxolitinib) (PMID: 29025600).	29025600
JAK2	JAK2 V617F JAK2 R938L	hematologic cancer	resistant	Momelotinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to Momelotinib (CYT387) in culture (PMID: 21926964).	21926964
JAK2	JAK2 V617F JAK2 R938L	hematologic cancer	resistant	Ruxolitinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).	21926964
JAK2	JAK2 V617F JAK2 R938L	hematologic cancer	resistant	AZD1480	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964).	21926964
JAK2	JAK2 V617F JAK2 R938L	hematologic cancer	resistant	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to Inrebic (fedratinib) in culture (PMID: 21926964).	21926964
JAK2	JAK2 V617F JAK2 R938L	hematologic cancer	resistant	Lestaurtinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to lestauranib in culture (PMID: 21926964).	21926964
JAK2	CALR wild-type JAK2 wild-type MPL wild-type	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of concurrent wild-type JAK2, MPL, and CALR in myelofibrosis patients is associated with inferior leukemia-free survival compared to patients with JAK2 and/or CALR mutations, and is associated with inferior overall survival when compared to patients with CALR mutations (NCCN.org).	detail...
JAK2	JAK2 V617F JAK2 E864K	hematologic cancer	resistant	NVP-BVB808	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E864K double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).	22271575
JAK2	JAK2 V617F JAK2 E864K	hematologic cancer	resistant	NVP-BSK805	Preclinical - Cell culture	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E864K double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).	22271575
JAK2	JAK2 R683G JAK2 E864K	cancer	resistant	NVP-BSK805	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing the JAK2 R683G/E864K double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).	22271575
JAK2	JAK2 R683G JAK2 E864K	cancer	resistant	NVP-BVB808	Preclinical	Actionable	In a preclinical study, cells expressing the JAK2 R683G/E864K double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).	22271575
JAK2	ETV6 - JAK2 JAK2 E864K	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the E864K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
JAK2	JAK2 R867Q	hematologic cancer	decreased response	AZ960	Preclinical	Actionable	In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to AZ960 in culture (PMID: 24398328).	24398328
JAK2	JAK2 R867Q	hematologic cancer	decreased response	Luminespib	Preclinical	Actionable	In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Luminespib (AUY922) in culture (PMID: 24398328).	24398328
JAK2	JAK2 R867Q	hematologic cancer	decreased response	Ruxolitinib	Preclinical	Actionable	In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Jakafi (ruxolitinib) in culture (PMID: 24398328).	24398328
JAK2	JAK2 R867Q	hematologic cancer	decreased response	Momelotinib	Preclinical	Actionable	In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Momelotinib (CYT387) in culture (PMID: 24398328).	24398328
JAK2	JAK2 R867Q	hematologic cancer	decreased response	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Inrebic (fedratinib) in culture (PMID: 24398328).	24398328
JAK2	JAK2 V617F JAK2 E985K	hematologic cancer	resistant	Ruxolitinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E985K double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).	21926964
JAK2	JAK2 over exp	Advanced Solid Tumor	sensitive	Pictilisib + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790).	24251790
JAK2	JAK2 over exp	Advanced Solid Tumor	sensitive	Ruxolitinib + TGX-221	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790).	24251790
JAK2	JAK2 over exp	triple-receptor negative breast cancer	sensitive	NVP-BSK805 + Paclitaxel	Preclinical - Pdx	Actionable	In a preclinical study, NVP-BSK805 with Abraxane (paclitaxel) inhibited tumor growth in patient-derived xenograft models of triple-negative breast cancer with JAK2 overexpression (PMID: 27075627).	27075627
JAK2	JAK2 over exp	Advanced Solid Tumor	sensitive	Ruxolitinib + ZSTK474	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790).	24251790
JAK2	JAK2 over exp	Advanced Solid Tumor	sensitive	BEZ235 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790).	24251790
JAK2	JAK2 over exp MPL over exp	Advanced Solid Tumor	sensitive	Ruxolitinib + ZSTK474	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).	24251790
JAK2	JAK2 over exp MPL over exp	Advanced Solid Tumor	sensitive	Ruxolitinib + TGX-221	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).	24251790
JAK2	JAK2 over exp MPL over exp	Advanced Solid Tumor	sensitive	Pictilisib + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).	24251790
JAK2	JAK2 over exp MPL over exp	Advanced Solid Tumor	sensitive	BEZ235 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).	24251790
JAK2	ETV6-JAK2 JAK2 N909K	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the N909K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
JAK2	JAK2 V617F JAK2 M929I	hematologic cancer	resistant	Ruxolitinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 M929I double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).	21926964
JAK2	ETV6 - JAK2 JAK2 M929I	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the M929I mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
JAK2	JAK2 V617F JAK2 I960V	hematologic cancer	resistant	Fedratinib	Preclinical - Cell culture	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Inrebic (fedratinib) in culture (PMID: 21926964).	21926964
JAK2	JAK2 V617F JAK2 I960V	hematologic cancer	resistant	Lestaurtinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Lestauranib in culture (PMID: 21926964).	21926964
JAK2	JAK2 V617F JAK2 I960V	hematologic cancer	resistant	Momelotinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Momelotinib in culture (PMID: 21926964).	21926964
JAK2	JAK2 V617F JAK2 I960V	hematologic cancer	resistant	Ruxolitinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).	21926964
JAK2	JAK2 V617F JAK2 I960V	hematologic cancer	resistant	AZD1480	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964).	21926964
JAK2	JAK2 inact mut	melanoma	predicted - resistant	Pembrolizumab	Case Reports/Case Series	Actionable	In a clinical study, a melanoma patient treated with Keytruda (pembrolizumab) initially demonstrated a partial response, however, post 734 days developed disease progression due to a splice site mutation in JAK2, which resulted in an intron inclusion and an early stop codon, leading to a loss of protein expression (PMID: 27433843).	27433843
JAK2	JAK2 amp	triple-receptor negative breast cancer	sensitive	NVP-BSK805 + Paclitaxel	Preclinical - Pdx	Actionable	In a preclinical study, NVP-BSK805 with Abraxane (paclitaxel) inhibited tumor growth in triple-negative breast cancer patient-derived xenograft models with JAK2 amplification (PMID: 27075627).	27075627
JAK2	JAK2 amp	triple-receptor negative breast cancer	sensitive	NVP-BSK805	Preclinical - Pdx	Actionable	In a preclinical study, NVP-BSK805 inhibited tumor growth in triple-negative breast cancer patient-derived xenograft models harboring JAK2 amplification (PMID: 27075627).	27075627
JAK2	JAK2 V617F JAK2 G935R	hematologic cancer	resistant	NVP-BVB808	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).	22271575
JAK2	JAK2 V617F JAK2 G935R	hematologic cancer	resistant	Ruxolitinib	Preclinical	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575).	22271575
JAK2	JAK2 V617F JAK2 G935R	hematologic cancer	resistant	NVP-BSK805	Preclinical - Cell culture	Actionable	In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).	22271575
JAK2	JAK2 R683G JAK2 G935R	cancer	resistant	NVP-BSK805	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).	22271575
JAK2	JAK2 R683G JAK2 G935R	cancer	resistant	Ruxolitinib	Preclinical	Actionable	In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575).	22271575
JAK2	JAK2 R683G JAK2 G935R	cancer	resistant	NVP-BVB808	Preclinical	Actionable	In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).	22271575
JAK2	ETV6 - JAK2 JAK2 G935R	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the G935R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
JAK2	ETV6-JAK2 JAK2 R975G	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the R975G mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
JAK2	ETV6 - JAK2 JAK2 G831R	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the G831R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
JAK2	ETV6 - JAK2 JAK2 Y918H	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the Y918H mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
JAK2	ETV6 - JAK2 JAK2 P1057S	hematologic cancer	resistant	Pyridone 6	Preclinical	Actionable	In a preclinical study, immune cells expressing ETV6-JAK2 with the P1057S mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).	22916261
JAK2	JAK2 Y931C	cancer	resistant	Ruxolitinib	Preclinical	Actionable	In a preclinical study, cells harboring JAK2 Y931C displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).	21393331
JAK2	JAK2 V617F JAK2 Y931C	cancer	resistant	Ruxolitinib	Preclinical	Actionable	In a preclinical study, cells harboring the JAK2 V617F/Y931C double mutation displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).	21393331
JAK2	JAK2 V617F	acute myeloid leukemia	sensitive	RP6530 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, RP6530 worked synergistically with Jakafi (ruxolitinib) to inhibit proliferation of Jakafi (ruxolitinib)-resistant erythroleukemia cell lines carrying JAK2 V617F mutation ( Cancer Res August 1, 2015 75; 2704 ).	detail...
JAK2	JAK2 V617F	bone marrow cancer	sensitive	CHZ868	Preclinical	Actionable	In a preclinical study, CHZ868 inhibited proliferation of myeloproliferative neoplasm cells harboring JAK2 V617F , including cells with decreased response to Type I JAK inhibitors following chronic exposure, and decreased mutant allele burden in a mouse polycythemia vera model expressing JAK2 V617F (PMID: 26175413).	26175413
JAK2	JAK2 V617F	myeloproliferative neoplasm	sensitive	BMS-911543	Preclinical - Cell culture	Actionable	In a preclinical study, BMS-911543 inhibited colony growth in myeloproliferative neoplasm patient-derived hematopoetic progenitor cells harboring JAK2 V617F in culture (PMID: 22015772).	22015772
JAK2	JAK2 V617F	bone marrow cancer	sensitive	AZD1208 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) worked synergistically with AZD1208 to inhibit proliferation of myeloproliferative cancer cell lines harboring JAK2 V617F in culture (PMID: 26472029).	26472029
JAK2	JAK2 V617F	myeloproliferative neoplasm	predicted - sensitive	LY2784544	Phase I	Actionable	In a Phase I trial, treatment with Gandotinib (LY2784544) demonstrated safety in myeloproliferative neoplasm patients harboring JAK2 V617F and resulted in clinical improvement as best response in 29% (9/31) patients with myelofibrosis (PMID: 28934680).	28934680
JAK2	JAK2 V617F	Advanced Solid Tumor	sensitive	Ruxolitinib + ZSTK474	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790).	24251790
JAK2	JAK2 V617F	myeloproliferative neoplasm	sensitive	Ropeginterferon	Preclinical - Cell culture	Actionable	In a preclinical study, Ropeginterferon treatment resulted in dose-dependent inhibition of cell proliferation in myeloproliferative neoplasm cell lines harboring JAK2 V617F in culture (PMID: 30287855).	30287855
JAK2	JAK2 V617F	hematologic cancer	sensitive	SHP099	Preclinical - Cell culture	Actionable	In a preclinical study, SHP099 inhibited proliferation of a hematopoietic cancer cell line harboring JAK2 V617F in culture (PMID: 27362227).	27362227
JAK2	JAK2 V617F	polycythemia vera	sensitive	Ropeginterferon	Clinical Study - Cohort	Actionable	In a clinical study using data from a Phase III trial, polycythemia vera patients demonstrated significant reduction in the median JAK2 V617F mutational burden at 12 months following treatment with Ropeginterferon compared to Droxia (hydroxyurea) (13.8% vs. 33.2%; p<0.02) (PMID: 30287855; NCT01949805).	30287855
JAK2	JAK2 V617F	polycythemia vera	sensitive	Ropeginterferon	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived erythroid progenitors harboring JAK2 V617F demonstrated sensitivity to Ropeginterferon in culture (PMID: 30287855).	30287855
JAK2	JAK2 V617F	bone marrow cancer	sensitive	Ruxolitinib + SGI-1776	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) worked synergistically with SGI-1776 to inhibit proliferation of myeloproliferative cancer cell lines harboring JAK2 V617F in culture (PMID: 26472029).	26472029
JAK2	JAK2 V617F	megakaryocytic leukemia	sensitive	Ropeginterferon	Preclinical - Cell culture	Actionable	In a preclinical study, a megakaryoblastic leukemia cell line expressing JAK2 V617F demonstrated inhibition of cell proliferation in culture when treated with Ropeginterferon (PMID: 30287855).	30287855
JAK2	JAK2 V617F	myelofibrosis	not applicable	N/A	Guideline	Prognostic	JAK2 V617F is associated with intermediate prognosis and higher risk of thrombosis when compared to the presence of CALR mutations in patients with primary myelofibrosis (NCCN.org).	detail...
JAK2	JAK2 V617F	essential thrombocythemia	sensitive	BMS-911543	Preclinical - Cell culture	Actionable	In a preclinical study, BMS-911543 inhibited proliferation and induced apoptosis in an essential thrombocythemia cell line harboring JAK2 V617F in culture (PMID: 22015772).	22015772
JAK2	JAK2 V617F	bone marrow cancer	decreased response	AZD1208	Preclinical	Actionable	In a preclinical study, myeloproliferative cancer cell lines harboring JAK2 V617F demonstrated reduced sensitivity to AZD1208 induced growth inhibition in culture (PMID: 26472029).	26472029
JAK2	JAK2 V617F	bone marrow cancer	decreased response	SGI-1776	Preclinical	Actionable	In a preclinical study, myeloproliferative cancer cell lines harboring JAK2 V617F demonstrated reduced sensitivity to SGI-1776 induced growth inhibition in culture (PMID: 26472029).	26472029
JAK2	JAK2 V617F	hematologic cancer	sensitive	BMS-911543	Preclinical - Cell culture	Actionable	In a preclinical study, BMS-911543 inhibited proliferation of transformed cells expressing JAK2 V617F in culture (PMID: 22015772).	22015772
JAK2	JAK2 V617F	Advanced Solid Tumor	sensitive	Ruxolitinib + TGX-221	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790).	24251790
JAK2	JAK2 V617F	acute myeloid leukemia	sensitive	Go6976	Preclinical	Actionable	In a preclinical study, Go 6976 inhibited proliferation of cultured acute myeloid leukemia cells expressing the JAK2 V617F mutation (PMID: 16956345).	16956345
JAK2	JAK2 V617F	hematologic cancer	sensitive	NS-018	Preclinical	Actionable	In a preclinical study, cells expressing JAK2 V617F were sensitive to treatment with NS-108, demonstrating cell growth inhibition and increased apoptotic activity in culture and improved survival in transgenic mouse models (PMID: 22829185).	22829185
JAK2	JAK2 V617F	Advanced Solid Tumor	sensitive	BEZ235 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790).	24251790
JAK2	JAK2 V617F	acute myeloid leukemia	sensitive	A-1155463	Preclinical	Actionable	In a preclinical study, acute myeloid leukemia cells harboring JAK2 V617F demonstrated sensitivity to A-1155463 in culture (PMID: 25787766).	25787766
JAK2	JAK2 V617F	Advanced Solid Tumor	sensitive	Pictilisib + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790).	24251790
JAK2	JAK2 V617F	myeloid leukemia	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed mouse myeloid cells over expressing JAK2 V617F were resistant to Gleevec (imatinib) in culture (PMID: 21224473).	21224473
JAK2	JAK2 V617F MPL wild-type	Advanced Solid Tumor	sensitive	Ruxolitinib + TGX-221	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).	24251790
JAK2	JAK2 V617F MPL wild-type	Advanced Solid Tumor	sensitive	Pictilisib + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).	24251790
JAK2	JAK2 V617F MPL wild-type	Advanced Solid Tumor	sensitive	Ruxolitinib + ZSTK474	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).	24251790
JAK2	JAK2 V617F MPL wild-type	Advanced Solid Tumor	sensitive	BEZ235 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).	24251790
JAK3	JAK3 G589D	hematologic cancer	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xeljanz (tofacitinib, CP-690,550) decreased cell viability in transformed mouse Ba/F3 cells expressing Jak3 G589D (PMID: 28284718).	28284718
JAK3	JAK3 A572V	mature T-cell and NK-cell lymphoma	sensitive	Tofacitinib	Preclinical	Actionable	In a preclinical study, Xeljanz (tofacitinib), a pan-JAK inhibitor, reduced cell viability and increased apoptosis in a JAK3 A572V mutant natural killer/T-cell lymphoma cell line (PMID: 22705984).	22705984
JAK3	JAK3 A572V	Advanced Solid Tumor	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing JAK3 A572V in culture demonstrated decreased cell survival, increased G1 arrest, elevated apoptotic activity, and reduced phosphorylation of Stat5a when treated with Xeljanz (tofacitinib) (PMID: 21821710).	21821710
JAK3	JAK3 A572V	acute myeloid leukemia	predicted - resistant	NS-018	Preclinical - Cell culture	Actionable	In a preclinical study, an acute myeloid leukemia cell line harboring JAK3 A572V was insensitive to treatment with NS-108 in culture (PMID: 22829185).	22829185
JAK3	JAK3 H583Y	hematologic cancer	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xeljanz (tofacitinib, CP-690,550) decreased cell viability in transformed mouse Ba/F3 cells expressing Jak3 H538Y (PMID: 28284718).	28284718
JAK3	JAK3 A573V	hematologic cancer	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xeljanz (tofacitinib, CP-690,550) decreased cell viability in transformed mouse Ba/F3 cells expressing Jak3 A573V (PMID: 29046866).	29046866
JAK3	JAK3 V674A	Advanced Solid Tumor	decreased response	NIBR3049	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing JAK3 V674A demonstrated reduced sensitivity to NIBR3049 in culture (PMID: 26446793).	26446793
JAK3	JAK3 V674A	Advanced Solid Tumor	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 V674A in culture (PMID: 26446793).	26446793
JAK3	JAK3 V674A	Advanced Solid Tumor	sensitive	Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Jakafi (ruxolitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 V674A in culture (PMID: 26446793).	26446793
JAK3	JAK3 L156P	Advanced Solid Tumor	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing JAK3 L156P in culture demonstrated decreased cell survival, increased G1 arrest, and reduced phosphorylation of Stat5a when treated with Xeljanz (tofacitinib) (PMID: 21821710).	21821710
JAK3	JAK3 M511I	hematologic cancer	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xeljanz (tofacitinib, CP-690,550) decreased cell viability in transformed mouse Ba/F3 cells expressing Jak3 M511I (PMID: 29046866).	29046866
JAK3	JAK3 L857P	Advanced Solid Tumor	decreased response	Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing JAK3 L857P demonstrated reduced sensitivity to Jakafi (ruxolitinib) in culture (PMID: 26446793).	26446793
JAK3	JAK3 L857P	Advanced Solid Tumor	sensitive	NIBR3049	Preclinical - Cell culture	Actionable	In a preclinical study, NIBR3049 inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 L857P in culture (PMID: 26446793).	26446793
JAK3	JAK3 L857P	Advanced Solid Tumor	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 L857P in culture (PMID: 26446793).	26446793
JAK3	JAK3 L857P JAK3 Y100A	Advanced Solid Tumor	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing both JAK3 L857P and Y100A in culture (PMID: 26446793).	26446793
JAK3	JAK3 L857P JAK3 Y100A	Advanced Solid Tumor	sensitive	NIBR3049	Preclinical - Cell culture	Actionable	In a preclinical study, NIBR3049 inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing both JAK3 L857P and Y100A in culture (PMID: 26446793).	26446793
JAK3	JAK3 L857P JAK3 Y100A	Advanced Solid Tumor	decreased response	Ruxolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing both JAK3 L857P and JAK3 Y100A demonstrated reduced sensitivity to Jakafi (ruxolitinib) in culture (PMID: 26446793).	26446793
JAK3	JAK3 E183G	Advanced Solid Tumor	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing JAK3 E183G in culture demonstrated decreased cell survival, increased G1 arrest, elevated apoptotic activity, and reduced phosphorylation of Stat5a when treated with Xeljanz (tofacitinib) (PMID: 21821710).	21821710
JAK3	JAK3 I87T	Advanced Solid Tumor	sensitive	JANEX-1	Preclinical - Cell culture	Actionable	In a preclinical study, JANEX-1 (WHI-P131) inhibited proliferation of transformed cells expressing JAK3 I87T in culture (PMID: 18397343).	18397343
JAK3	JAK3 R172Q	Advanced Solid Tumor	sensitive	Tofacitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing JAK3 R172Q in culture demonstrated decreased cell survival, reduced phosphorylation of Stat5a, and G1 arrest when treated with Xeljanz (tofacitinib) (PMID: 21821710).	21821710
JAK3	JAK3 V722I	Advanced Solid Tumor	sensitive	Tofacitinib	Preclinical	Actionable	In a preclinical study, Xeljanz (tofacitinib) treatment converted cells expressing JAK3 V221I from factor-independent to factor-dependent growth in cell culture (PMID: 25146434).	25146434
KDM6A	KDM6A loss	multiple myeloma	sensitive	GSK343	Preclinical - Cell culture	Actionable	In a preclinical study, a multiple myeloma cell line with KDM6A loss demonstrated sensitivity to treatment with GSK343, resulting in cell-cycle arrest and increased apoptosis in culture (PMID: 29045832).	29045832
KDM6A	KDM6A loss	multiple myeloma	sensitive	GSK126	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a multiple myeloma cell line demonstrated sensitivity to treatment with GSK126, resulting in decreased viability in culture and decreased tumor growth in xenograft models (PMID: 29045832).	29045832
KDM6A	KDM6A loss	bladder urothelial carcinoma	sensitive	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, KDM6A-null urothelial bladder carcinoma cell lines demonstrated sensitivity to GSK126, resulting in decreased proliferation in culture (PMID: 28228601).	28228601
KDM6A	KDM6A loss	bladder urothelial carcinoma	sensitive	GSK503	Preclinical - Pdx	Actionable	In a preclinical study, GSK503 inhibited tumor growth in a cell line xenograft model and in a patient-derived xenograft (PDX) model of KDM6A-null urothelial bladder carcinoma (PMID: 28228601).	28228601
KDM6A	KDM6A loss	bladder urothelial carcinoma	sensitive	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, KDM6A-null urothelial bladder carcinoma cell lines demonstrated sensitivity to Tazemetostat (EPZ-6438), resulting in decreased proliferation in culture (PMID: 28228601).	28228601
KDM6A	KDM6A loss	bladder urothelial carcinoma	sensitive	GSK343	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GSK343 inhibited proliferation of KDM6A-null urothelial bladder carcinoma cell lines in culture, and delayed tumor onset, improved survival, and inhibited tumor growth in xenograft models (PMID: 28228601).	28228601
KDR	KDR R1032Q	colorectal cancer	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited reduced ERK phosphorylation and inhibited growth of a colorectal cancer cell line harboring KDR (VEGFR2) R1032Q in culture (PMID: 29588308).	29588308
KDR	KDR R1032Q	colorectal cancer	sensitive	Lenvatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of KDR (VEGFR2) R1032Q in a colorectal cancer cell line resulted in increased sensitivity to Lenvima (lenvatinib), leading to increased growth inhibition in culture (PMID: 29588308).	29588308
KDR	KDR over exp	breast cancer	predicted - resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, upregulation of Kdr (Vegfr2) was identified in tumors acquired resistance to Sutent (sunitinib) in allograft models of breast cancer (PMID: 28011623).	28011623
KDR	KDR wild-type	Advanced Solid Tumor	predicted - sensitive	Ramucirumab	Phase I	Actionable	In a Phase I trial, Cyramza (ramucirumab), an inhibitor of KDR (VEGFR2), demonstrated safety and efficacy (partial response or stable disease) in patients with advanced solid tumors (PMID: 20048182).	20048182
KDR	KDR wild-type	pancreatic cancer	sensitive	Gemcitabine + VEGFR2-169	Phase I	Actionable	In a Phase I trial, VEGFR2-169, in combination with Gemzar (gemcitabine), achieved a disease control rate of 67% (12/18) and an improved overall survival time to 8.7 months in pancreatic cancer patients expressing the HLA-A*2402 version of the KDR (VEGFR2) wild-type allele (PMID: 19930156).	19930156
KDR	KDR wild-type	Advanced Solid Tumor	predicted - sensitive	Pz-1	Preclinical	Actionable	In a preclinical study, Pz-1 inhibited Kdr2 phosphorylation in transformed cells expressing KDR wild-type (PMID: 26126987).	26126987
KDR	KDR positive	melanoma	predicted - sensitive	Anti-VEGFR2 CAR CD8 lymphocytes	Preclinical	Actionable	In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes increased survival of melanoma mouse models (PMID: 23633494).	23633494
KDR	KDR positive	Advanced Solid Tumor	predicted - sensitive	Anti-VEGFR2 CAR CD8 lymphocytes	Preclinical	Actionable	In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes, displayed efficacy in inhibiting cell and tumor growth in a variety of solid tumor cell lines and mouse tumor models (PMID: 20978347).	20978347
KDR	KDR positive	pancreatic cancer	sensitive	TAS-115	Preclinical	Actionable	In a preclinical study, pancreatic islet endothelial cells were sensitive to TAS-115, resulting in decreased phosphorylation of Vegfr2, and inhibition of cell growth and angiogenesis in culture and mouse models (PMID: 24140932).	24140932
KDR	KDR positive	Advanced Solid Tumor	predicted - sensitive	Tanibirumab	Phase I	Actionable	In a Phase I trial, Tanibirumab treatment demonstrated manageable toxicity and preliminary efficacy, resulted in increased circulating Kdr (Vegfr2), Vegf and Pigf, and stable disease in 61% (11/18) of patients with refractory solid tumors (PMID: 28391576; NCT01660360).	28391576
KDR	KDR pos RET C634W	thyroid medullary carcinoma	predicted - sensitive	Motesanib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Motesanib (AMG 706) inhibited KDR (VEGFR2) phosphorylation, but had minimal activity against RET in a medullary thyroid carcinoma (MTC) cell line harboring RET C634W in culture, however, inhibited both RET and KDR (VEGFR2) phosphorylation and decreased tumor angiogenesis and growth in MTC cell line xenograft models with RET C634W (PMID: 21422803).	21422803
KDR	KDR D717V	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing KDR D717V were sensitive to Sutent (sunitinib) in culture (PMID: 19723655).	19723655
KDR	KDR amp	lung non-small cell carcinoma	no benefit	Vandetanib	Phase III	Actionable	In a retrospective analysis of a Phase III trial, treatment with Caprelsa (vandetanib) did not correlate with an improved PFS, OS, or objective response rate in non-small cell lung carcinoma patients harboring a KDR amplification nor did it inhibit cell proliferation of the KDR amplified archived tumor cells in culture (PMID: 26578684).	26578684
KDR	ROS1 fusion KDR amp KIT amp PDGFRA amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of KIT, KDR, and PDGFRA (PMID: 29636358).	29636358
KDR	EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T	olfactory neuroblastoma	predicted - sensitive	Cetuximab + Sunitinib	Case Reports/Case Series	Actionable	In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).	27149458
KDR	KDR act mut	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, cells expressing KDR activating mutations were sensitive to Sutent (sunitinib) in cell culture (PMID: 19723655).	19723655
KDR	KDR act mut	bladder urothelial carcinoma	predicted - sensitive	Sunitinib	Phase II	Actionable	In a Phase II clinical trial of patients with metastatic urothelial cancer, Sutent (sunitinib) demonstrated limited antitumor activity, warranting further investigation of VEGF pathways as a therapeutic target (PMID: 20142593).	20142593
KDR	KDR act mut	Advanced Solid Tumor	predicted - sensitive	Lucitanib	Phase I	Actionable	In a Phase I trial, Lucitanib (E-3810) demonstrated safety and efficacy in patients with FGF-aberrant or angiogenesis-sensitive advanced solid tumors (PMID: 25193991).	25193991
KDR	KDR act mut	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) demonstrated efficacy in cells expressing KDR activating mutations (PMID: 19723655).	19723655
KDR	KDR Q472H	melanoma	sensitive	unspecified VEGFR2 antibody	Preclinical	Actionable	In a preclinical study, human melanoma cells harboring KDR (VEGFR2) Q472H demonstrated increased sensitivity to treatment with a VEGFR2 (KDR) function-blocking antibody compared to cells with wild-type KDR (VEGFR), resulting in decreased proliferation and invasion in culture (PMID: 26631613).	26631613
KDR	KDR A1065T	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, cells expressing KDR A1065T were sensitive to Sutent (sunitinib) in culture (PMID: 19723655).	19723655
KDR	KDR L840F	colorectal cancer	resistant	Regorafenib	Preclinical - Pdx	Actionable	In a preclinical study, a metastatic colorectal cancer patient-derived xenograft (PDX) model harboring KDR (VEGFR2) L840F did not respond to treatment with Stivarga (regorafenib) (PMID: 29588308).	29588308
KDR	KDR L840F	colorectal cancer	resistant	Sorafenib	Preclinical - Pdx	Actionable	In a preclinical study, a metastatic colorectal cancer patient-derived xenograft (PDX) model harboring KDR (VEGFR2) L840F did not respond to treatment with Nexavar (sorafenib) (PMID: 29588308).	29588308
KIT	KIT Y578C	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation efficiently in transformed human cells over expressing KIT Y578C in culture (PMID: 23567324).	23567324
KIT	KIT W557C KIT Y578C	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation efficiently in transformed human cells over expressing both KIT W557C and KIT Y578C in culture (PMID: 23567324).	23567324
KIT	KIT T632I	melanoma	predicted - resistant	Imatinib	Case Reports/Case Series	Actionable	In a clinical case study, Gleevec (imatinib) treatment resulted in worsened condition and continued disease progression and metastasis in a patient with metastatic melanoma harboring KIT T632I (PMID: 31043947).	31043947
KIT	KIT P577_D579del	thymic carcinoma	predicted - sensitive	Sorafenib	Case Reports/Case Series	Actionable	In a clinical case report, a patient with advanced thymic carcinoma harboring KIT P577_D579del demonstrated response to treatment with Nexavar (sorafenib), with a decrease in tumor size (PMID: 20970876).	20970876
KIT	KIT M552_V559del	Advanced Solid Tumor	sensitive	Motesanib	Preclinical - Cell culture	Actionable	In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing KIT M552_V559del in culture (PMID: 20633291).	20633291
KIT	KIT D579del	thymic carcinoma	sensitive	Imatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with thymic carcinoma harboring KIT D579del achieved disease stabilization following treatment with Gleevec (imatinib) (PMID: 24419427).	24419427
KIT	KIT V560G	mast cell neoplasm	sensitive	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited proliferation of mast cells harboring KIT V560G in culture (PMID: 31085175).	31085175
KIT	KIT V560G	mast-cell leukemia	sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation and proliferation of mast cell leukemia cells harboring KIT V560G in culture (PMID: 29093181).	29093181
KIT	KIT V560G	Advanced Solid Tumor	sensitive	Nilotinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT V560G demonstrated inhibition of cell proliferation and tumor regression both in culture and in vivo when treated with Tasigna (nilotinib) (PMID: 20442311).	20442311
KIT	KIT V560G	mast cell neoplasm	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sutent (sunitinib) inhibited proliferation of mast cells harboring KIT V560G in culture (PMID: 31085175).	31085175
KIT	KIT V560G	mast cell neoplasm	sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Avapritinib (BLU-285) inhibited proliferation of mast cells harboring KIT V560G in culture (PMID: 31085175).	31085175
KIT	KIT V560G	mast cell neoplasm	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) inhibited proliferation of mast cells harboring KIT V560G in culture (PMID: 31085175).	31085175
KIT	KIT V560G	mast cell neoplasm	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited proliferation of mast cells harboring KIT V560G in culture (PMID: 31085175).	31085175
KIT	KIT V560G	mast cell neoplasm	sensitive	Ripretinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ripretinib (DCC-2618) inhibited proliferation of mast cells harboring KIT V560G in culture (PMID: 31085175).	31085175
KIT	KIT V560G	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, cells expressing KIT V560G demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT D816V KIT V560G	mast-cell leukemia	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis in a mast-cell leukemia cell line harboring both KIT V560G and KIT D816V in culture (PMID: 18024392).	18024392
KIT	KIT D816V KIT V560G	mast-cell leukemia	sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation and proliferation of a mast cell leukemia cell line harboring KIT D816V and V560G in culture (PMID: 29093181).	29093181
KIT	KIT D816V KIT V560G	mast cell neoplasm	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, mast cells harboring both KIT D816V and KIT V560G were resistant to Gleevec (imatinib) in culture (PMID: 31085175).	31085175
KIT	KIT D816V KIT V560G	mast-cell leukemia	sensitive	BPR1J373	Preclinical - Cell culture	Actionable	In a preclinical study, a mast-cell leukemia cell line simultaneously harboring KIT D816V and KIT V560G was sensitive to BPR1J373 in culture, demonstrating inhibition of Kit phosphorylation and apoptotic activity (PMID: 27512117).	27512117
KIT	KIT D816V KIT V560G	mast cell neoplasm	resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, mast cells harboring both KIT D816V and KIT V560G were resistant to Sutent (sunitinib) in culture (PMID: 31085175).	31085175
KIT	KIT D816V KIT V560G	mast cell neoplasm	sensitive	Ripretinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ripretinib (DCC-2618) inhibited proliferation of mast cells harboring KIT D816V and KIT V560G in culture, and inhibited tumor growth in cell line xenograft models (PMID: 31085175).	31085175
KIT	KIT D816V KIT V560G	mast cell neoplasm	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited proliferation of mast cells harboring KIT D816V and KIT V560G in culture (PMID: 31085175).	31085175
KIT	KIT D816V KIT V560G	mast-cell leukemia	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of a human mast cell line harboring both KIT V560G and KIT D816V in culture (PMID: 24552773).	24552773
KIT	KIT D816V KIT V560G	mast cell neoplasm	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, mast cells harboring both KIT D816V and KIT V560G were resistant to Stivarga (regorafenib) in culture (PMID: 31085175).	31085175
KIT	KIT D816V KIT V560G	mast cell neoplasm	sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Avapritinib (BLU-285) inhibited proliferation of mast cells harboring KIT D816V and KIT V560G in culture (PMID: 31085175).	31085175
KIT	KIT D816V KIT V560G	mast cell neoplasm	resistant	Quizartinib	Preclinical	Actionable	In a preclinical study, KIT D816V conferred resistance to Quizartinib in a mast cell line harboring both KIT V560G and KIT D816V in culture (PMID: 23497317).	23497317
KIT	KIT D677N KIT D816V	Advanced Solid Tumor	resistant	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT D816V and KIT D677N demonstrated resistance to treatment with Rydapt (midostaurin) in culture compared to cells expressing KIT D816V alone (PMID: 31270078).	31270078
KIT	KIT D677N KIT D816V	Advanced Solid Tumor	predicted - sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT D816V and KIT D677N demonstrated some sensitivity to treatment with Avapritinib (BLU-285) in culture (PMID: 31270078).	31270078
KIT	KIT K558_G565delinsR	gastrointestinal stromal tumor	sensitive	Cabozantinib	Preclinical - Pdx	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) resulted in tumor regression, decreased mitotic activity, and increased apoptotic activity in a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT K558_G565delins (PMID: 27777285).	27777285
KIT	KIT K558_G565delinsR	gastrointestinal stromal tumor	sensitive	Imatinib	Preclinical - Pdx	Actionable	In a preclinical study, Gleevec (imatinib) treatment resulted in tumor regression and decreased mitotic activity in gastrointestinal stromal tumor patient derived xenograft (PDX) models harboring KIT K558_G565delinsR (PMID: 27777285).	27777285
KIT	KIT V560del	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, Sutent (sunitinib) inhibited growth of transformed cell lines over expressing KIT V560del in culture (PMID: 19861435).	19861435
KIT	KIT V560del	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) inhibited growth of transformed cell lines over expressing KIT V560del in culture (PMID: 19861435).	19861435
KIT	KIT V560del KIT over exp	thymic carcinoma	predicted - sensitive	Imatinib	Case Reports/Case Series	Actionable	In a clinical case report, a patient with metastatic thymic carcinoma harboring KIT V560del with KIT over expression initially demonstrated stable disease and reduction in metastatic lesions following treatment with Gleevec (imatinib), but progressed after 6 months (PMID: 15201427).	15201427
KIT	KIT V560del KIT V654A	Advanced Solid Tumor	sensitive	Nilotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tasigna (nilotinib) inhibited proliferation of transformed cells expressing a KIT V560del/V654A double mutation in culture (PMID: 17699867).	17699867
KIT	KIT D816V KIT Y672C	Advanced Solid Tumor	decreased response	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT D816V and KIT Y672C demonstrated a decreased response compared to cells expressing KIT D816V alone when treated with Rydapt (midostaurin) in culture (PMID: 31270078).	31270078
KIT	KIT D816V KIT Y672C	Advanced Solid Tumor	predicted - sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT D816V and KIT Y672C demonstrated some sensitivity to treatment with Avapritinib (BLU-285) in culture (PMID: 31270078).	31270078
KIT	KIT Y553N	thymic carcinoma	sensitive	Imatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with metastatic thymic carcinoma harboring KIT Y553N demonstrated improved clinical performance and reduction in metastatic lesions following treatment with Gleevec (imatinib) (PMID: 21969494).	21969494
KIT	KIT H697Y	Advanced Solid Tumor	decreased response	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cell lines overexpressing KIT H697Y demonstrated reduced sensitivity to Gleevec (imatinib mesylate)-induced growth inhibition in culture (PMID: 19861435).	19861435
KIT	KIT H697Y	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, Sutent (sunitinib) inhibited growth of transformed cell lines overexpressing KIT H697Y in culture (PMID: 19861435).	19861435
KIT	KIT K558delinsNP	Advanced Solid Tumor	sensitive	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells expressing K558delinsNP demonstrated sensitivity to treatment with Stivarga (regorafenib) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT K558delinsNP	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing K558delinsNP demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT K558delinsNP	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT K558delinsNP demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT K558delinsNP	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT K558delinsNP demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT V559G	Advanced Solid Tumor	sensitive	Axitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT V559G in culture (PMID: 31205508).	31205508
KIT	KIT L576P	Advanced Solid Tumor	sensitive	Axitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT L576P in culture (PMID: 31205508).	31205508
KIT	KIT L576P	melanoma	sensitive	Dasatinib	Case Reports/Case Series	Actionable	In a clinical study, two patients with melanoma harboring KIT L576P, one who had progressed on Gleevec (imatinib), demonstrated initial clinical benefit following treatment with Sprycel (dasatinib); however, one patient progressed after 3 months, and the other patient progressed after 4 months of treatment (PMID: 19671763).	19671763
KIT	KIT L576P	melanoma	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited MNK pathway activation and proliferation of melanoma cell lines harboring KIT L576P in culture (PMID: 29035277).	29035277
KIT	KIT L576P	melanoma	unknown	Imatinib	Case Reports/Case Series	Actionable	In a clinical case study, Gleevec (imatinib) treatment resulted in initial tumor reduction, but was followed by disease progression at all tumor sites in a patient with metastasized labial melanoma harboring KIT L576P (PMID: 20372153).	20372153
KIT	KIT L576P	melanoma	predicted - sensitive	Bevacizumab + Sorafenib	Case Reports/Case Series	Actionable	In a Phase I trial, a melanoma patient harboring KIT L576P demonstrated sensitivity to the combination treatment of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in a partial response for 8 months (PMID: 25363205).	25363205
KIT	KIT L576P	melanoma	sensitive	SEL201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SEL201 inhibited MNK pathway signaling and growth of melanoma cells harboring KIT L576P in culture, and suppressed tumor metastasis in xenograft models (PMID: 29035277).	29035277
KIT	KIT L576P	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including three melanoma patients harboring KIT L576P demonstrating a partial response (PMID: 28327988).	28327988
KIT	KIT L576P KIT W557R	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient co-harboring KIT L576P and KIT W557R demonstrating a partial response and a progression free survival of 5.3 months and overall survival of 14.7 months when treated with Tasigna (nilotinib) (PMID: 28327988).	28327988
KIT	KIT T670I	gastrointestinal stromal tumor	predicted - sensitive	Imatinib	Case Reports/Case Series	Actionable	In a clinical case report, a patient with a gastrointestinal stromal tumor developed disease progression while being treated with Gleevec (imatinib), demonstrating a KIT T670I mutation in the progressive lesion (PMID: 15236194).	15236194
KIT	KIT T670I	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, cells expressing KIT T670I demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT T670I	gastrointestinal stromal tumor	predicted - resistant	Avapritinib	Phase I	Actionable	In a Phase I trial, patients with gastrointestinal stromal tumors harboring either KIT V654A or KIT T670I compared to those without either KIT mutation demonstrated an overall response rate of 0% (n=25) vs. 26% (n=84) and a progressive disease rate of 72% vs 23%, respectively when treated with Avapritinib (BLU-285) (PMID: 31270078; NCT02508532).	31270078
KIT	KIT T670I	melanoma	resistant	Dasatinib	Preclinical	Actionable	In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Sprycel (dasatinib) (PMID: 23582185, PMID: 25594040).	23582185 25594040
KIT	KIT T670I	melanoma	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Gleevec (imatinib mesylate) (PMID: 23582185, PMID: 25594040).	23582185 25594040
KIT	KIT T670I	melanoma	resistant	Nilotinib	Preclinical	Actionable	In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Tasigna (nilotinib) (PMID: 23582185, PMID: 25594040).	23582185 25594040
KIT	KIT T670I	melanoma	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, Sutent (sunitinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT T670I (PMID: 23582185, PMID: 25594040).	23582185 25594040
KIT	KIT T670I	Advanced Solid Tumor	sensitive	Axitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT T670I in culture, however, with decreased potency compared to its potency against other KIT variants (PMID: 31205508).	31205508
KIT	KIT T670I	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sutent (sunitinib) inhibited proliferation of transformed cells expressing KIT T670I in culture (PMID: 31205508).	31205508
KIT	KIT W557_K558del KIT T670I	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and decreased tumor volume (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT T670I	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated resistance to treatment with Stivarga (regorafenib) in culture (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT T670I	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited proliferation and induced apoptosis of transformed cells expressing a KIT W557_K558del/T670I double mutation in culture (PMID: 17699867).	17699867
KIT	KIT W557_K558del KIT T670I	Advanced Solid Tumor	resistant	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing a KIT W557_K558del/T670I double mutation demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 17699867).	17699867
KIT	KIT W557_K558del KIT T670I	Advanced Solid Tumor	resistant	Nilotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing a KIT W557_K558del/T670I double mutation demonstrated resistance to Tasigna (nilotinib) in culture (PMID: 17699867).	17699867
KIT	KIT W557_K558del KIT T670I	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated sensitivity to treatment with Sutent (sunitinib) in both culture and cell line xenograft models, resulting in reduced cell viability, decreased tumor volume, and tumor regression (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT T670I	Advanced Solid Tumor	no benefit	Imatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated no response to treatment with Gleevec (imatinib) in both culture and xenograft models (PMID: 25239608).	25239608
KIT	KIT V560_Y578del KIT T670I	gastrointestinal stromal tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT T670I demonstrated sensitivity to treatment with Iclusig (ponatinib) (PMID: 25239608).	25239608
KIT	KIT V560_Y578del KIT T670I	gastrointestinal stromal tumor	sensitive	Axitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and downstream signaling, reduced proliferation, and induced cell-cycle arrest in a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del and KIT T670I in culture, and inhibited tumor growth in xenograft models (PMID: 31205508).	31205508
KIT	KIT V560_Y578del KIT T670I	gastrointestinal stromal tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, a patient-derived gastrointestinal stromal tumor (GIST) cell line co-harboring KIT V560_Y578del and KIT T670I demonstrated sensitivity to treatment with Sutent (sunitinib) (PMID: 25239608).	25239608
KIT	KIT V560_Y578del KIT T670I	gastrointestinal stromal tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sutent (sunitinib) inhibited proliferation of a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del in culture (PMID: 31205508).	31205508
KIT	KIT T670I KIT V560D	Advanced Solid Tumor	sensitive	Motesanib	Preclinical - Cell culture	Actionable	In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing a KIT V560D/T670I double mutation in culture (PMID: 20633291).	20633291
KIT	KIT T670I KIT V560D	Advanced Solid Tumor	resistant	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT V560D and KIT T670I were resistant to Flumatinib in culture (PMID: 24205792).	24205792
KIT	KIT T670I KIT V559D	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT V559D and KIT T670I were sensitive to treatment with Sutent (sunitinib) in culture, demonstrating decreased cell proliferation (PMID: 24205792).	24205792
KIT	KIT T670I KIT V559D	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sutent (sunitinib) inhibited proliferation of transformed cells expressing KIT T670I and KIT V559D in culture (PMID: 31205508).	31205508
KIT	KIT exon 11 KIT T670I	gastrointestinal stromal tumor	predicted - sensitive	Regorafenib	Preclinical - Pdx	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited Kit signaling, resulted in tumor growth inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT exon 11 mutation (K550_splice) and KIT T670I, which was established from a patient who did not respond to Gleevec (imatinib mesylate) (PMID: 29100343).	29100343
KIT	KIT exon 11 KIT T670I	gastrointestinal stromal tumor	predicted - sensitive	Sunitinib	Preclinical - Pdx	Actionable	In a preclinical study, Sutent (sunitinib) inhibited Kit signaling, resulted in 86.7% tumor growth inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT exon 11 mutation (K550_splice) and KIT T670I, which was established from a patient who did not respond to Gleevec (imatinib mesylate) (PMID: 29100343).	29100343
KIT	KIT exon 11 KIT T670I	gastrointestinal stromal tumor	resistant	Imatinib	Preclinical - Pdx	Actionable	In a preclinical study, Gleevec (imatinib mesylate) did not inhibit Kit, Erk signaling and resulted in limited (53.9%) tumor inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT exon 11 mutation (K550_splice) and KIT T670I, which was established from a patient who did not respond to Gleevec (imatinib mesylate) (PMID: 29100343).	29100343
KIT	KIT D816V KIT T670I	Advanced Solid Tumor	decreased response	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT D816V and KIT T670I demonstrated a decreased response compared to cells expressing KIT D816V alone when treated with Rydapt (midostaurin) in culture (PMID: 31270078).	31270078
KIT	KIT D816V KIT T670I	Advanced Solid Tumor	resistant	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT D816V and KIT T670I demonstrated resistance to treatment with Avapritinib (BLU-285) in culture (PMID: 31270078).	31270078
KIT	KIT exon 11 del KIT T670I	gastrointestinal stromal tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited proliferation of gastrointestinal stromal tumor cells harboring both KIT exon 11 deletion and KIT T670I in culture (PMID: 31085175).	31085175
KIT	KIT exon 11 del KIT T670I	gastrointestinal stromal tumor	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, gastrointestinal stromal tumor cells harboring both KIT exon 11 deletion and KIT T670I were resistant to Gleevec (imatinib) in culture (PMID: 31085175).	31085175
KIT	KIT exon 11 del KIT T670I	gastrointestinal stromal tumor	sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Avapritinib (BLU-285) inhibited proliferation of gastrointestinal stromal tumor cells harboring both KIT exon 11 deletion and KIT T670I in culture (PMID: 31085175).	31085175
KIT	KIT exon 11 del KIT T670I	gastrointestinal stromal tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sutent (sunitinib) inhibited proliferation of gastrointestinal stromal tumor cells harboring both KIT exon 11 deletion and KIT T670I in culture (PMID: 31085175).	31085175
KIT	KIT exon 11 del KIT T670I	gastrointestinal stromal tumor	decreased response	Ripretinib	Preclinical - Cell culture	Actionable	In a preclinical study, gastrointestinal stromal tumor cells harboring both KIT exon 11 deletion and KIT T670I demonstrated reduced response to growth inhibition by Ripretinib (DCC-2618) compared to cells harboring KIT exon 11 deletion alone in culture (PMID: 31085175).	31085175
KIT	KIT exon 11 del KIT T670I	gastrointestinal stromal tumor	sensitive	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Sutent (sunitinib) inhibited proliferation of gastrointestinal stromal tumor cells harboring both KIT exon 11 deletion and KIT T670I in culture (PMID: 31085175).	31085175
KIT	KIT W557_K558del	Advanced Solid Tumor	sensitive	Nilotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tasigna (nilotinib) inhibited growth of transformed cells expressing KIT W557_K558del in culture (PMID: 17699867).	17699867
KIT	KIT W557_K558del	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing W557_K558del demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT W557_K558del	Advanced Solid Tumor	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis of transformed cells expressing KIT W557_K558del in culture (PMID: 17699867).	17699867
KIT	KIT W557_K558del	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT W557_K558del	Advanced Solid Tumor	sensitive	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Stivarga (regorafineb) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT W557_K558del	gastrointestinal stromal tumor	sensitive	PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, PD-0325901 treatment inhibited Erk phosphorylation and decreased expression of ETV1 and CXCR4 in gastrointestinal stromal tumor cells harboring KIT W557_K558del (PMID: 26936919).	26936919
KIT	KIT W557_K558del	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and near complete tumor regression (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT V654A	Advanced Solid Tumor	no benefit	Imatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated no response to treatment with Gleevec (imatinib) in both culture and xenograft models (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT V654A	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated resistance to treatment with Stivarga (regorafenib) in culture (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT V654A	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and decreased tumor volume (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT V654A	gastrointestinal stromal tumor	sensitive	Avapritinib	Preclinical - Pdx	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation and resulted in tumor regression in patient-derived xenograft models of Gleevec (imatinib)-resistant gastrointestinal stromal tumor harboring KIT W557_K558del and V654A (PMID: 29093181).	29093181
KIT	KIT W557_K558del KIT V654A	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated sensitivity to treatment with Sutent (sunitinib) in both culture and cell line xenograft models, resulting in reduced cell viability, decreased tumor volume, and tumor regression (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT D816H	Advanced Solid Tumor	decreased response	Imatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated a decreased response to treatment with Gleevec (imatinib) in both culture and xenograft models, resulting in only a slight decrease in tumor volume (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT D816H	Advanced Solid Tumor	decreased response	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated a decreased response to treatment with Stivarga (regorafenib) in culture (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT D816H	Advanced Solid Tumor	decreased response	Sunitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated a decreased response to treatment with Sutent (sunitinib) in both culture and cell line xenograft models, resulting in only a slight decrease in tumor volume (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT D816H	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and tumor regression (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT Y823D	gastrointestinal stromal tumor	sensitive	Ponatinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, a patient derived GIST cell line co-harboring KIT W557_K558del and KIT Y823D demonstrated sensitivity to Iclusig (ponatinib) in a PDX model, resulting in complete tumor regression (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT Y823D	gastrointestinal stromal tumor	sensitive	Avapritinib	Preclinical - Pdx	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation and resulted in tumor regression in patient-derived xenograft models of Gleevec (imatinib mesylate)-resistant gastrointestinal stromal tumor harboring KIT W557_K558del and Y823D (PMID: 29093181).	29093181
KIT	KIT W557_K558del KIT Y823D	gastrointestinal stromal tumor	sensitive	Ripretinib	Preclinical - Pdx	Actionable	In a preclinical study, DCC-2618 induced tumor regression in a patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT W557_K558del and KIT Y823D (PMID: 31085175).	31085175
KIT	KIT W557_K558del KIT D816G	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT D816G	Advanced Solid Tumor	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT D816G	Advanced Solid Tumor	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT D816G	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT D820A	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820A were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT D820A	Advanced Solid Tumor	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820A were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT D820A	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing W557_K558del and KIT D820A were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT D820A	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820A were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT D820G	Advanced Solid Tumor	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT D820G	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT D820G	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT D820G	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT N822K	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT N822K	Advanced Solid Tumor	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were resistant to Sutent (sunitinb) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT N822K	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT N822K	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT A829P	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT A829P	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT A829P	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT A829P	Advanced Solid Tumor	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Sutent (sunitinb) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT W557_K558del KIT D816E KIT D820V	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Case Reports/Case Series	Actionable	In a clinical study, KIT D816E and D820V were identified as secondary mutations in a patient with gastrointestinal stromal tumor harboring KIT W557_K558del who developed resistance to Gleevec (imatinib) (PMID: 18294292).	18294292
KIT	KIT Y553S KIT V556_T574del KIT D820Y	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Case Reports/Case Series	Actionable	In a clinical study, KIT D820Y was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring primary KIT V569_L576del and KIT Y553S mutations, who developed resistance to Gleevec (imatinib) (PMID: 18488160).	18488160
KIT	KIT V555_L576del KIT D820G KIT D820Y	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Case Reports/Case Series	Actionable	In a clinical study, KIT D820G and KIT D820Y were identified as secondary mutations in a patient with gastrointestinal stromal tumor harboring a primary KIT V555_L576del mutation, who developed resistance to Gleevec (imatinib) (PMID: 18488160).	18488160
KIT	KIT W557G	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation efficiently in transformed human cells over expressing KIT W557G in culture (PMID: 23567324).	23567324
KIT	KIT D820A KIT V560D	gastrointestinal stromal tumor	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, a gastrointestinal stromal tumor cell line harboring KIT V560D and KIT D820A demonstrated resistance to Sutent (sunitinib) in culture (PMID: 18955458).	18955458
KIT	KIT D820A KIT V560D	gastrointestinal stromal tumor	resistant	Imatinib	Case Reports/Case Series	Actionable	In a clinical study, KIT D820A was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring a primary KIT V560D mutation, who developed resistance to Gleevec (imatinib mesylate) (PMID: 16954519).	16954519
KIT	KIT D820A KIT V560D	gastrointestinal stromal tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, a gastrointestinal stromal tumor cell line harboring KIT V560D and KIT D820A demonstrated resistance to Gleevec (imatinib) in culture (PMID: 16954519).	16954519
KIT	KIT V559A	melanoma	predicted - sensitive	Imatinib	Case Reports/Case Series	Actionable	In a clinical case study, Gleevec (imatinib) treatment in a patient with metastatic melanoma resulted in regression of the lung metastasis, which harbored KIT V559A; however, neither the primary tumor or lymph node metastasis responded, which had wild-type KIT (PMID: 19812602).	19812602
KIT	KIT V559A	melanoma	sensitive	Nilotinib	Case Reports/Case Series	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41), including a melanoma patient harboring KIT V559A demonstrating a partial response and progression-free survival of 19.4 months and overall survival of 32.9 months (PMID: 28327988).	28327988
KIT	KIT V559A	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Case Reports/Case Series	Actionable	In a clinical study, KIT V559A was identified as a secondary mutation in a patient with gastrointestinal stromal tumor who developed resistance to Gleevec (imatinib) (PMID: 18488160).	18488160
KIT	KIT V559A	Advanced Solid Tumor	sensitive	Axitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT V559A in culture (PMID: 31205508).	31205508
KIT	KIT wild-type	acute myeloid leukemia	sensitive	BPR1J373	Preclinical - Cell culture	Actionable	In a preclinical study, an acute myeloid leukemia cell line harboring KIT wild-type was sensitive to BPR1J373 in culture, demonstrating apoptotic induction and inhibition of cell proliferation (PMID: 27512117).	27512117
KIT	KIT wild-type	megakaryocytic leukemia	decreased response	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, KIT wild-type megakaryocytic leukemia cells were less sensitive to BLU-285 compared to cells harboring KIT mutations in culture (PMID: 29093181).	29093181
KIT	KIT S476I	mast-cell leukemia	predicted - sensitive	Midostaurin	Preclinical - Patient cell culture	Actionable	In a preclinical study, treatment with Rydapt (midostaurin) decreased proliferation of patient-derived neoplastic mast cells harboring KIT S476I in culture (PMID: 25209843).	25209843
KIT	KIT S476I	mast-cell leukemia	predicted - sensitive	Nilotinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, treatment with Tasigna (nilotinib) decreased proliferation of patient-derived neoplastic mast cells harboring KIT S476I in culture (PMID: 25209843).	25209843
KIT	KIT S476I MET R988C	gastrointestinal stromal tumor	predicted - sensitive	Bevacizumab + Sorafenib	Case Reports/Case Series	Actionable	In a Phase I trial, a GIST patient harboring KIT S476I and MET R988C demonstrated sensitivity to the combination treatment, Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for 6 months (PMID: 25363205).	25363205
KIT	KIT V569_L576del KIT V654A KIT N822K	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Case Reports/Case Series	Actionable	In a clinical study, KIT V654A and KIT N822K were identified as secondary mutations in a patient with gastrointestinal stromal tumor harboring a primary KIT V569_L576del mutation, who developed resistance to Gleevec (imatinib) (PMID: 18488160).	18488160
KIT	KIT D820N	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Case Reports/Case Series	Actionable	In a clinical study, KIT D820N was identified as a secondary mutation in the metastatic lesions from a gastrointestinal stromal tumor patient whose disease progressed on Gleevec (imatinib) (PMID: 18628470).	18628470
KIT	KIT V560_L576del	gastrointestinal stromal tumor	sensitive	Ponatinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, a patient derived GIST cell line harboring KIT V560_L576del demonstrated sensitivity to Iclusig (ponatinib) in both culture and PDX models, resulting in phosphorylation inhibition of Akt, Kit, and Erk (PMID: 25239608).	25239608
KIT	KIT V560_L576del	gastrointestinal stromal tumor	sensitive	Imatinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, a patient derived GIST cell line harboring KIT V560_L576del demonstrated sensitivity to Gleevec (imatinib) in both culture and PDX models, resulting in phosphorylation inhibition of Akt, Kit, and Erk (PMID: 25239608).	25239608
KIT	KIT V560_L576del KIT V654A	gastrointestinal stromal tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_L576del and KIT V654A demonstrated sensitivity to treatment with Sutent (sunitinib) (PMID: 25239608).	25239608
KIT	KIT D816G ROS1 fusion	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion developed resistance to treatment with Xalkori (crizotinib) and was subsequently found to have acquired KIT D816G (PMID: 29636358).	29636358
KIT	KIT P551_V555del	gastrointestinal stromal tumor	sensitive	Sorafenib	Preclinical - Pdx	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited Erk signaling, induced apoptosis, resulted in tumor growth inhibition in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT P551_V555del (PMID: 19139124).	19139124
KIT	KIT K558_V560del KIT W557C	gastrointestinal stromal tumor	predicted - sensitive	Ponatinib	Case Reports/Case Series	Actionable	In a clinical study, a GIST patient harboring KIT K558_V560del and KIT W557C, resistant to Gleevec (imatinib), Sutent (sunitinib), and Stivarga (regorafenib), demonstrated sensitivity when treated with Iclusig (ponatinib), which resulted in a radiologic response and stabilization for six months (PMID: 25239608).	25239608
KIT	KIT K558_V560del KIT V654A	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Case Reports/Case Series	Actionable	In a clinical study, KIT V654A was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring a primary KIT K558_V560del mutation, who developed resistance to Gleevec (imatinib) (PMID: 18488160).	18488160
KIT	KIT V560D	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT V560D demonstrating a partial response and progression free survival of 8.6 months and overall survival of 23.5 months (PMID: 28327988).	28327988
KIT	KIT V560D	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT V560D were sensitive to Nexavar (sorafenib) in culture (PMID: 22665524).	22665524
KIT	KIT V560D	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT V560D	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT V560D	Advanced Solid Tumor	sensitive	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Stivarga (regorafineb) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT V560D	gastrointestinal stromal tumor	predicted - sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT V560D were sensitive to treatment with Avapritinib (BLU-285) in culture, demonstrating decreased cell growth (PMID: 31270078).	31270078
KIT	KIT V560D	Advanced Solid Tumor	sensitive	Motesanib	Preclinical - Cell culture	Actionable	In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing KIT V560D in culture (PMID: 20633291).	20633291
KIT	KIT V560D	Advanced Solid Tumor	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT V560D were sensitive to Sprycel (dasatinib) in culture (PMID: 16397263).	16397263
KIT	KIT V560D	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT V560D KIT V654A	Advanced Solid Tumor	decreased response	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT V560D and KIT V654A demonstrated a decreased response to treatment with Avapritinib (BLU-285) compared to cells expressing KIT V560D alone in culture (PMID: 31270078).	31270078
KIT	KIT V560D KIT V654A	Advanced Solid Tumor	sensitive	Motesanib	Preclinical - Cell culture	Actionable	In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing a KIT V560D/V654A double mutation in culture (PMID: 20633291).	20633291
KIT	KIT V560D KIT V654A	Advanced Solid Tumor	resistant	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT V560D and KIT V654A were resistant to Flumatinib in culture (PMID: 24205792).	24205792
KIT	KIT T417_D419delinsI	Advanced Solid Tumor	sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT T417_D419delinsI were sensitive to treatment with Flumatinib, demonstrating decreased cell proliferation (PMID: 24205792).	24205792
KIT	KIT T417_D419delinsI	Advanced Solid Tumor	conflicting	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT T417_D419delinsI were resistant to treatment with Gleevec (imatinib) in culture (PMID: 24205792).	24205792
KIT	KIT T417_D419delinsI	Advanced Solid Tumor	conflicting	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation in transformed cells over expressing KIT T417_D419delinsI in culture (PMID: 16015387).	16015387
KIT	KIT T417_D419delinsI	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT T417_D419delinsI were sensitive to treatment with Sutent (sunitinib), demonstrating decreased cell proliferation (PMID: 24205792).	24205792
KIT	KIT exon 17	gastrointestinal stromal tumor	sensitive	Avapritinib	Phase I	Actionable	In a Phase I trial, BLU-285 demonstrated preliminary antitumor activity in gastrointestinal stromal tumor patients harboring KIT mutations, with reduced tumor burden in 38% (5/13) of patients, including 1 partial response and 4 stable diseases, and 3 of the 5 responding patients harbored KIT exon 17 mutations (EORTC-NCI-AACR 2016, Abs 6LBA).	detail...
KIT	KIT exon 17	gastrointestinal stromal tumor	predicted - sensitive	Pexidartinib + PLX9486	Phase I	Actionable	In a Phase I trial, PLX9486 and Pexidartinib (PLX3397) combination therapy demonstrated safety and preliminary efficacy, resulted in a partial response rate of 8.3% (1/12) and progression-free survival not yet reached in patients with advanced solid tumors, 11 of these patients had gastrointestinal stromal tumor that progressed on Gleevec (imatinib mesylate), and most harbored KIT exon 11 and exon 17 mutations (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 11509-11509; NCT02401815).	detail...
KIT	KIT exon 17	gastrointestinal stromal tumor	predicted - sensitive	PLX9486	Phase I	Actionable	In a Phase I trial, PLX9486 demonstrated safety and preliminary efficacy, resulted in a progression-free survival of more than 24 weeks and partial response in 8.3% (2/24) of patients with advanced solid tumors, 20 of these patients had gastrointestinal stromal tumor that progressed on Gleevec (imatinib mesylate), and most harbored KIT exon 11 and exon 17 mutations (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 11509-11509; NCT02401815).	detail...
KIT	KIT exon 17	Advanced Solid Tumor	sensitive	Avapritinib	Preclinical	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation and proliferation of various tumor cell lines harboring KIT exon 17 mutations in culture, and induced tumor regression in an allograft animal model (PMID: 29093181).	29093181
KIT	KIT exon 11 KIT exon 17	gastrointestinal stromal tumor	predicted - sensitive	PLX9486	Phase I	Actionable	In a Phase I trial, PLX9486 treatment resulted in partial response with 33% decrease of tumor size after 4 cycles of therapy in a patient with gastrointestinal stromal tumor harboring a primary KIT exon 11 mutation and a secondary KIT exon 17 mutation, who progressed on prior Gleevec (imatinib mesylate) and Sutent (sunitinib) therapies (CTOS Annual Meeting, Nov 2017, abstract # 2771952).	detail...
KIT	KIT P577del KIT W557Lfs*5 KIT D820G	gastrointestinal stromal tumor	resistant	Imatinib	Preclinical - Pdx	Actionable	In a preclinical study, a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT mutations, P577del, W557Lfs*5, and D820G, demonstrated resistance to treatment with Gleevec (imatinib) (PMID: 27777285).	27777285
KIT	KIT P577del KIT W557Lfs*5 KIT D820G	gastrointestinal stromal tumor	sensitive	PLX9486	Preclinical - Pdx	Actionable	In a preclinical study, PLX9486 treatment decreased Mapk and Kit downstream signaling, resulted in tumor volume stabilization in patient-derived xenograft (PDX) models of gastrointestinal stromal tumor harboring KIT P577del, W557Lfs*5, and D820G (18th Annual BSMO Meeting, Feb 2016, abstract O5).	detail...
KIT	KIT P577del KIT W557Lfs*5 KIT D820G	gastrointestinal stromal tumor	sensitive	Cabozantinib	Preclinical - Pdx	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) slowed tumor growth and decreased mitotic activity in a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT mutations, P577del, W557Lfs*5, and D820G (PMID: 27777285).	27777285
KIT	KIT D820G KIT V559D	Advanced Solid Tumor	sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT D820G and KIT V559D were sensitive to Flumatinib in culture, demonstrating decreased cell proliferation (PMID: 24205792).	24205792
KIT	KIT D820Y	melanoma	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited MNK pathway activation and proliferation of melanoma cell lines harboring KIT D820Y in culture (PMID: 29035277).	29035277
KIT	KIT D820Y	melanoma	predicted - sensitive	Sorafenib	Case Reports/Case Series	Actionable	In a clinical case study, Nexavar (sorafenib) treatment resulted in stable disease with 27% reduction in target lesions at 4 weeks in a patient with anal melanoma and pulmonary metastases harboring KIT D820Y (PMID: 20372153).	20372153
KIT	KIT D820Y	melanoma	sensitive	SEL201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SEL201 inhibited MNK pathway signaling and growth of melanoma cell lines harboring KIT D820Y in culture, and suppressed tumor metastasis in xenograft models (PMID: 29035277).	29035277
KIT	KIT D820Y	melanoma	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib mesylate) failed to inhibit MNK pathway activation and proliferation of melanoma cell lines harboring KIT D820Y in culture (PMID: 29035277).	29035277
KIT	KIT D820Y KIT V559D	Advanced Solid Tumor	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture (PMID: 17699867).	17699867
KIT	KIT D820Y KIT V559D	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture (PMID: 17699867).	17699867
KIT	KIT D820Y KIT V559D	Advanced Solid Tumor	sensitive	Nilotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tasigna (nilotinib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture, with increased potency compared to Sprycel (dasatinib) or Nexavar (sorafenib) (PMID: 17699867).	17699867
KIT	KIT Y568_L576delinsCV KIT D816E KIT D820Y	gastrointestinal stromal tumor	predicted - sensitive	Ripretinib	Case Reports/Case Series	Actionable	In a Phase I trial, treatment with Ripretinib (DCC-2618) decreased circulating tumor DNA, resulted in stable disease lasting over 21 months in a patient with gastrointestinal stromal tumor harboring a primary KIT Y568_L576delinsCV mutation and two acquired resistance mutations, KIT D816E and KIT D820Y (PMID: 31085175; NCT02571036).	31085175
KIT	KIT W557R	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT W557R demonstrating a partial response and progression free survival of 35.4 months and overall survival of 35.4 months (PMID: 28327988).	28327988
KIT	KIT D816F	Advanced Solid Tumor	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816F were resistant to Gleevec (imatinib mesylate) in culture (PMID: 16397263).	16397263
KIT	KIT D816H	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, cells expressing KIT D816H demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT D816H	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, KIT D816H demonstrated resistance to Stivarga (regorafenib) in an in vitro assay, and conferred secondary resistance to Stivarga (regorafenib) in transformed cells expressing other KIT mutations (PMID: 25239608).	25239608
KIT	KIT D816H	Advanced Solid Tumor	predicted - sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816H were more sensitive to treatment with Flumatinib in culture compared to Gleevec (imatinib) (PMID: 24205792).	24205792
KIT	KIT D816H	Advanced Solid Tumor	predicted - sensitive	AZD3229	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD3229 inhibited Kit signaling, resulted in tumor regression in cell line xenograft models of transformed cells expressing KIT D816H (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1328).	detail...
KIT	KIT D816H	Advanced Solid Tumor	predicted - sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816H were more sensitive to treatment with Sutent (sunitinib) in culture compared to Gleevec (imatinib) (PMID: 24205792).	24205792
KIT	KIT exon 11	gastrointestinal stromal tumor	predicted - sensitive	Ponatinib	Phase II	Actionable	In a Phase II trial, Iclusig (ponatinib) treatment resulted in partial response in 7% (2/27), stable disease in 59% (16/27), a median progression free survival of 4.3 months and a median overall survival of 15.0 months in gastrointestinal stromal tumor patients harboring KIT exon 11 mutations after prior tyrosine kinase inhibitor treatment failure (J Clin Oncol 33, 2015 (suppl; abstr 10535)).	detail...
KIT	KIT exon 11	gastrointestinal stromal tumor	sensitive	Imatinib + PKF118-310	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of PKF118-310 and Gleevec (imatinib) resulted in decreased viability of gastrointestinal stromal tumor (GIST) cell lines harboring KIT exon 11 mutations compared to Gleevec (imatinib) alone, in culture (PMID: 28611108).	28611108
KIT	KIT exon 11	gastrointestinal stromal tumor	decreased response	Sunitinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, GIST patients with KIT exon 11 mutations showed decreased benefit compared to patients with exon 9 mutations, with median PFS of 7.0 months with exon 11 mutations vs. 12.3 months with exon 9 mutations, and an ORR of 6% (9/143) vs. 19% (8/42) following treatment with Sutent (sunitinib) (PMID: 26772734).	26772734
KIT	KIT exon 11	gastrointestinal stromal tumor	predicted - sensitive	PLX9486	Phase I	Actionable	In a Phase I trial, PLX9486 demonstrated safety and preliminary efficacy, resulted in a progression-free survival of more than 24 weeks and partial response in 8.3% (2/24) of patients with advanced solid tumors, 20 of these patients had gastrointestinal stromal tumor that progressed on Gleevec (imatinib mesylate), and most harbored KIT exon 11 and exon 17 mutations (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 11509-11509; NCT02401815).	detail...
KIT	KIT exon 11	gastrointestinal stromal tumor	sensitive	Imatinib + XAV939	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with the combination of XAV939 and Gleevec (imatinib) resulted in decreased viability of gastrointestinal stromal tumor (GIST) cell lines harboring KIT exon 11 mutations compared to Gleevec (imatinib) alone, in culture (PMID: 28611108).	28611108
KIT	KIT exon 11	gastrointestinal stromal tumor	sensitive	Imatinib	Guideline	Actionable	Gleevec (imatinib) is included in the guidelines as first-line therapy for patients with gastrointestinal stromal tumor (GIST) with KIT exon 11 mutations (NCCN.org).	detail...
KIT	KIT exon 11	gastrointestinal stromal tumor	sensitive	Imatinib	Guideline	Actionable	Gleevec (imatinib) is included in the guidelines for patients with advanced/metastatic gastrointestinal stromal tumor (GIST) with KIT exon 11 mutations (PMID: 30188977; ESMO.org).	30188977 detail...
KIT	KIT exon 11	gastrointestinal stromal tumor	sensitive	Imatinib	Phase III	Actionable	In a Phase III trial, Gleevec (imatinib) treatment resulted in longer overall survival (OS) (66 vs 40 months) in gastrointestinal stromal tumor (GIST) patients harboring KIT exon 11 mutations compared to KIT and PDGFRA wild-type patients, while subtypes of KIT exon 11 mutations (deletion, insertation/duplication, point mutation) did not affect OS outcome (PMID: 28196207; NCT00009906).	28196207
KIT	KIT exon 11	gastrointestinal stromal tumor	sensitive	Imatinib	Phase III	Actionable	In a Phase III trial, a long-term analysis of gastrointestinal stromal tumor (GIST) patients treated with Gleevec (imatinib) demonstrated patients harboring KIT exon 11 mutations had a median progression-free survival of 39.4 months, and median overall survival was not reached, with 69.1% of patients with KIT exon 11 mutations alive at 5 years (PMID: 26687836; NCT00367861).	26687836
KIT	KIT exon 11	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 5% (1/19) and partial response in 21% (4/19) of melanoma patients harboring KIT exon 11 or exon 13 mutations (PMID: 28843487; NCT01168050).	28843487
KIT	KIT exon 11	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41), which included a partial response of 38.5% (10/26) and a progression free survival of 5.4 months in melanoma patients harboring KIT exon 11 mutations (PMID: 28327988).	28327988
KIT	KIT exon 11	gastrointestinal stromal tumor	sensitive	Nilotinib	Phase III	Actionable	In a Phase III trial, a 24 month progression free survival was observed in 69.6% of advanced GIST patients harboring KIT exon 11 mutations when treated with Tasigna (nilotinib) (J Clin Oncol May 2013 vol. 31 no. 15_suppl 10501).	detail...
KIT	KIT exon 11	gastrointestinal stromal tumor	sensitive	Regorafenib	Phase II	Actionable	In a Phase II clinical trial, treatment with Stivarga (regorafenib) resulted in a clinical benefit rate of 76% (25/33), a median progression-free survival (PFS) of 13.2 months, and a median overall survival of 25 months in patients with gastrointestinal stromal tumors, with patients with KIT exon 11 mutations demonstrating the longest PFS of 13.4 months (PMID: 27371698).	27371698
KIT	KIT exon 11	gastrointestinal stromal tumor	sensitive	Ripretinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ripretinib (DCC-2618) inhibited Kit phosphorylation and proliferation of gastrointestinal stromal tumor cells harboring a KIT exon 11 deletion mutation in culture, and resulted in tumor regression in cell line xenograft models (PMID: 31085175).	31085175
KIT	KIT exon 11	gastrointestinal stromal tumor	predicted - sensitive	Dasatinib	Phase II	Actionable	In a Phase II clinical trial, Sprycel (dasatinib) demonstrated preliminary activity in patients with Gleevec (imatinib)-resistant gastrointestinal stromal tumor (GIST), including patients harboring KIT exon 11 mutations, with a partial response rate of 32% (15/47), median progression-free survival of 2.0 months, and overall survival of 19 months (J Clin Oncol 29: 2011 (suppl; abstr 10006)).	detail...
KIT	KIT exon 11	melanoma	predicted - sensitive	Imatinib	Case Reports/Case Series	Actionable	In a clinical case study, Gleevec (imatinib) treatment resulted in a partial response in a patient with metastastic anal melanoma harboring a 21 base-pair duplication in KIT exon 11, and reduced pulmonary metastasis by 60% (PMID: 20372153).	20372153
KIT	KIT exon 11	gastrointestinal stromal tumor	predicted - sensitive	Pexidartinib + PLX9486	Phase I	Actionable	In a Phase I trial, PLX9486 and Pexidartinib (PLX3397) combination therapy demonstrated safety and preliminary efficacy, resulted in a partial response rate of 8.3% (1/12) and progression-free survival not yet reached in patients with advanced solid tumors, 11 of these patients had gastrointestinal stromal tumor that progressed on Gleevec (imatinib mesylate), and most harbored KIT exon 11 and exon 17 mutations (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 11509-11509; NCT02401815).	detail...
KIT	KIT exon 11	gastrointestinal stromal tumor	sensitive	Imatinib + MK2206	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Gleevec (imatinib) and MK2206 increased growth inhibition and decreased viability of gastrointestinal stromal tumor (GIST) cell lines harboring KIT exon 11 mutations in culture, and improved survival and inhibited tumor growth in a KIT exon 11-mutant GIST cell line xenograft model, with increased efficacy compared to either agent alone (PMID: 27370604).	27370604
KIT	KIT exon 11 KIT A829P	gastrointestinal stromal tumor	sensitive	Imatinib + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Gleevec (imatinib) and MK2206 demonstrated synergy in inhibiting growth of a Gleevec (imatinib)-resistant gastrointestinal stromal tumor cell line harboring a KIT exon 11 mutation and KIT A829P in culture (PMID: 27370604).	27370604
KIT	KIT exon 11 KIT V654A	gastrointestinal stromal tumor	sensitive	Imatinib + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Gleevec (imatinib) and MK2206 demonstrated synergy in inhibiting growth of a Gleevec (imatinib)-resistant gastrointestinal stromal tumor cell line harboring a KIT exon 11 deletion mutation and KIT V654A in culture (PMID: 27370604).	27370604
KIT	KIT D816V	hematologic cancer	resistant	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Quizartinib (AC220) did not inhibit Kit phosphorylation or growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT	KIT D816V	Advanced Solid Tumor	resistant	Cabozantinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Cometriq (cabozantinib) in culture (PMID: 24205792).	24205792
KIT	KIT D816V	acute myeloid leukemia	predicted - sensitive	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) demonstrated moderate inhibition of Kit phosphorylation and growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT	KIT D816V	hematologic cancer	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib inhibited Kit phosphorylation and growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT	KIT D816V	hematologic cancer	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Nexavar (sorafenib) did not inhibit Kit phosphorylation or growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT	KIT D816V	hematologic cancer	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematopoietic cells expressing KIT D816V demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 17229632).	17229632
KIT	KIT D816V	acute myeloid leukemia	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib inhibited Kit phosphorylation and growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT	KIT D816V	Advanced Solid Tumor	resistant	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were resistant to treatment with Flumatinib in culture (PMID: 24205792).	24205792
KIT	KIT D816V	Advanced Solid Tumor	sensitive	Ripretinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ripretinib (DCC-2618) inhibited proliferation of transformed cells expressing KIT D816V in culture (PMID: 31085175).	31085175
KIT	KIT D816V	Advanced Solid Tumor	resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were resistant to treatment with Sutent (sunitinib) in culture (PMID: 24205792).	24205792
KIT	KIT D816V	Advanced Solid Tumor	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, KIT D816V mutations demonstrated resistance to Sutent (sunitinib) in a biochemical assay (PMID: 19164557).	19164557
KIT	KIT D816V	hematologic cancer	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, a mouse myeloid cell line expressing KIT D816V demonstrated resistance to Gleevec (imatinib) in culture (PMID: 12481435).	12481435
KIT	KIT D816V	acute myeloid leukemia	sensitive	Cytarabine + Dasatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with acute myeloid leukemia harboring KIT D816V achieved long-term remission and loss of KIT D816V following treatment with the combination of Sprycel (dasatinib) and Cytosar-U (cytarabine) (PMID: 18986703).	18986703
KIT	KIT D816V	Advanced Solid Tumor	sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were sensitive to treatment with Avapritinib (BLU-285) in culture, demonstrating decreased cell proliferation (PMID: 31270078).	31270078
KIT	KIT D816V	mast cell neoplasm	predicted - sensitive	Avapritinib	Phase I	Actionable	In a Phase I trial, patients with either aggressive systemic mastocytosis, mast cell leukemia, or systemic mastocytosis with an associated hematologic neoplasm harboring KIT D816V demonstrated a reduction in mast cell burden and a decrease in KIT D816V allelic fraction when treated with BLU-285 (ASH Annual Meeting, Dec 2017, Plenary 2).	detail...
KIT	KIT D816V	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were resistant to Stivarga (regorafenib) in culture (PMID: 31085175).	31085175
KIT	KIT D816V	acute myeloid leukemia	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited Kit phosphorylation and growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT	KIT D816V	Advanced Solid Tumor	predicted - sensitive	BPR1J373	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were sensitive to BPR1J373, demonstrating inhibition of Kit phosphorylation (PMID: 27512117).	27512117
KIT	KIT D816V	acute myeloid leukemia	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Nexavar (sorafenib) did not inhibit Kit phosphorylation or growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT	KIT D816V	Advanced Solid Tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816V were sensitive to treatment with Rydapt (midostaurin) in culture, demonstrating decreased cell proliferation (PMID: 31270078).	31270078
KIT	KIT D816V	hematologic cancer	predicted - sensitive	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) demonstrated moderate inhibition of Kit phosphorylation and growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT	KIT D816V	Indication other than cancer	resistant	Imatinib	FDA contraindicated	Actionable	Gleevec (imatinib) is not indicated for patients with aggressive systemic mastocytosis harboring KIT D816V (FDA.gov).	detail... detail...
KIT	KIT D816V	acute myeloid leukemia	resistant	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Quizartinib (AC220) did not inhibit Kit phosphorylation or growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT	KIT D816V	hematologic cancer	sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Avapritinib (BLU-285) inhibited Kit phosphorylation and growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT	KIT D816V	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Gleevec (imatinib mesylate) in culture (PMID: 15790786).	15790786
KIT	KIT D816V	Advanced Solid Tumor	decreased response	Nilotinib	Preclinical	Actionable	In a preclinical study, Tasigna (nilotinib) decreased viability of cells expressing KIT D816V in culture, but did not inhibit KIT phosphorylation or growth of KIT D816V-expressing tumors in mouse models (PMID: 20442311).	20442311
KIT	KIT D816V	acute myeloid leukemia	sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Avapritinib (BLU-285) inhibited Kit phosphorylation and growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT	KIT D816V	hematologic cancer	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited Kit phosphorylation and growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543).	31309543
KIT	KIT D816V	Advanced Solid Tumor	resistant	Quizartinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Quizartinib in culture (PMID: 23497317).	23497317
KIT	KIT D816V	hematologic cancer	sensitive	FF-10101	Preclinical - Cell culture	Actionable	In a preclinical study, FF-10101, as compared to Quizartinib, inhibited cell proliferation of transformed 32Dcl3 murine myeloid cells expressing human Kit D816V (PMID: 29187377).	29187377
KIT	KIT D816V	Advanced Solid Tumor	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) did not inhibit growth of transformed cells expressing KIT D816V in culture (PMID: 22301675).	22301675
KIT	KIT D816V NRAS Q61R	melanoma	no benefit	Pembrolizumab + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a melanoma patient harboring KIT D816V and NRAS Q61R demonstrated progressive disease when treated with a combination of Mekinist (trametinib) and Keytruda (pembrolizumab) (PMID: 28514312).	28514312
KIT	KIT D816V KIT N655K	Advanced Solid Tumor	predicted - sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT D816V and KIT N655K demonstrated some sensitivity to treatment with Avapritinib (BLU-285) in culture (PMID: 31270078).	31270078
KIT	KIT D816V KIT N655K	Advanced Solid Tumor	resistant	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT D816V and KIT N655K demonstrated resistance to treatment with Rydapt (midostaurin) in culture compared to cells expressing KIT D816V alone (PMID: 31270078).	31270078
KIT	KIT D816V KIT V654A	Advanced Solid Tumor	resistant	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT D816V and KIT V654A demonstrated resistance to treatment with Rydapt (midostaurin) in culture compared to cells expressing KIT D816V alone (PMID: 31270078).	31270078
KIT	KIT D816V KIT V654A	Advanced Solid Tumor	predicted - sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT D816V and KIT V654A demonstrated some sensitivity to treatment with Avapritinib (BLU-285) in culture (PMID: 31270078).	31270078
KIT	KIT D816V KIT T670V	Advanced Solid Tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT D816V and KIT T670V were sensitive to treatment with Rydapt (midostaurin) in culture, demonstrating decreased cell proliferation (PMID: 31270078).	31270078
KIT	KIT D816V KIT T670V	Advanced Solid Tumor	predicted - resistant	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT D816V and KIT T670V demonstrated some resistance to treatment with Avapritinib (BLU-285) in culture (PMID: 31270078).	31270078
KIT	KIT D816V KIT T670A	Advanced Solid Tumor	sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT D816V and KIT T670A demonstrated sensitivity to treatment with Avapritinib (BLU-285) in culture (PMID: 31270078).	31270078
KIT	KIT D816V KIT T670A	Advanced Solid Tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT D816V and KIT T670A were sensitive to treatment with Rydapt (midostaurin) in culture, demonstrating decreased cell proliferation (PMID: 31270078).	31270078
KIT	KIT exon 13	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41), which included a partial response in 7.7% (1/13) of melanoma patients harboring KIT exon 13 mutations (PMID: 28327988).	28327988
KIT	KIT exon 13	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 5% (1/19) and partial response in 21% (4/19) of melanoma patients harboring KIT exon 11 or exon 13 mutations (PMID: 28843487; NCT01168050).	28843487
KIT	KIT exon 13	gastrointestinal stromal tumor	sensitive	Imatinib + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Gleevec (imatinib) and MK2206 demonstrated synergy in inhibiting growth of a gastrointestinal stromal tumor cell line harboring a KIT exon 13 mutation in culture (PMID: 27370604).	27370604
KIT	KIT exon 9	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, Stivarga (regorafineb) had no effect on transformed cells expressing a KIT exon 9 mutation in culture (PMID: 25239608).	25239608
KIT	KIT exon 9	gastrointestinal stromal tumor	sensitive	Imatinib	Guideline	Actionable	Gleevec (imatinib) is included in the guidelines as first-line therapy for patients with gastrointestinal stromal tumor (GIST) with KIT exon 9 mutations (NCCN.org).	detail...
KIT	KIT exon 9	gastrointestinal stromal tumor	sensitive	Imatinib	Guideline	Actionable	Gleevec (imatinib) is included in the guidelines for patients with advanced/metastatic gastrointestinal stromal tumor (GIST) with KIT exon 9 mutations (PMID: 30188977; ESMO.org).	30188977 detail...
KIT	KIT exon 9	gastrointestinal stromal tumor	predicted - sensitive	Sunitinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, GIST patients with KIT exon 9 mutations showed improved progression-free survival (PFS), overall survival, and objective response rate (ORR) compared to patients with exon 11 mutations, with a median PFS of 12.3 months vs. 7.0 months, and an ORR of 19% (8/42) vs. 6% (9/143) following treatment with Sutent (sunitinib) (PMID: 26772734).	26772734
KIT	KIT exon 9	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) had no effect on transformed cells expressing a KIT exon 9 mutation in culture (PMID: 25239608).	25239608
KIT	KIT exon 9	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a KIT exon 9 mutation demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT exon 9	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing a KIT exon 9 mutation demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT C443S	mucosal melanoma	sensitive	Imatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with mucosal melanoma harboring KIT C443S demonstrated a substantial response to Gleevec (imatinib) in the first two weeks and then developed progression at 15 weeks (PMID: 25003536).	25003536
KIT	KIT V560_Y578del	gastrointestinal stromal tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, a patient derived GIST cell line harboring KIT V560_Y578del demonstrated sensitivity to Gleevec (imatinib) in culture (PMID: 25239608).	25239608
KIT	KIT V560_Y578del	gastrointestinal stromal tumor	sensitive	Axitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and downstream signaling, reduced proliferation and induced cell-cycle arrest in a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del in culture, and inhibited tumor growth in xenograft models (PMID: 31205508).	31205508
KIT	KIT V560_Y578del	gastrointestinal stromal tumor	sensitive	Ponatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, a patient-derived gastrointestinal stromal tumor (GIST) cell line harboring KIT V560_Y578del demonstrated sensitivity to Iclusig (ponatinib) in culture (PMID: 25239608).	25239608
KIT	KIT V560_Y578del	gastrointestinal stromal tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sutent (sunitinib) inhibited proliferation of a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del in culture (PMID: 31205508).	31205508
KIT	KIT V560_Y578del	gastrointestinal stromal tumor	sensitive	BGJ398 + Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antiproliferative activity in gastrointestinal stromal tumor cells harboring KIT V560_Y578del in culture (PMID: 25673643).	25673643
KIT	KIT V560_Y578del KIT D816E	gastrointestinal stromal tumor	decreased response	Sunitinib	Preclinical	Actionable	In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT D816E demonstrated a decreased response to treatment with Sutent (sunitinib) (PMID: 25239608).	25239608
KIT	KIT V560_Y578del KIT A829P	gastrointestinal stromal tumor	decreased response	Sunitinib	Preclinical	Actionable	In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT A829P demonstrated a decreased response to treatment with Sutent (sunitinib) (PMID: 25239608).	25239608
KIT	KIT D820V	gastrointestinal stromal tumor	sensitive	Avapritinib	Phase I	Actionable	In a Phase I trial, BLU-285 treatment resulted in tumor reduction lasting through 15 cycles of treatment in a patient with gastrointestinal stromal tumor harboring KIT D820V, whose disease had progressed on previous Gleevec (imatinib), Sutent (sunitinib), and Stivarga (regorafenib) treatment (PMID: 29093181; NCT02508532).	29093181
KIT	KIT exon 11 del	gastrointestinal stromal tumor	predicted - sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Kit phosphorylation and proliferation of gastrointestinal stromal tumor cells harboring KIT exon 11 deletion in culture (PMID: 31085175).	31085175
KIT	KIT exon 11 del	gastrointestinal stromal tumor	predicted - sensitive	Imatinib	Phase III	Actionable	In a Phase III trial, gastrointestinal stromal tumor patients harboring KIT exon 11 deletions or indels demonstrated improved improved recurrence-free survival (RFS) with 3-year adjuvant Gleevec (imatinib) treatment (5-year RFS, 70%), compared to patients receiving 1-year treatment (5-year RFS, 41.3%) (PMID: 28334365).	28334365
KIT	KIT exon 11 del	gastrointestinal stromal tumor	predicted - sensitive	AZD3229	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD3229 inhibited Kit signaling, resulted in tumor regression in cell line xenograft models of gastrointestinal stromal tumor harboring KIT exon 11 deletion mutation (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1328).	detail...
KIT	KIT exon 11 del	gastrointestinal stromal tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited Kit phosphorylation and proliferation of gastrointestinal stromal tumor cells harboring KIT exon 11 deletion in culture (PMID: 31085175).	31085175
KIT	KIT exon 11 del	gastrointestinal stromal tumor	sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Avapritinib (BLU-285) inhibited Kit phosphorylation and proliferation of gastrointestinal stromal tumor cells harboring KIT exon 11 deletion in culture (PMID: 31085175).	31085175
KIT	KIT exon 11 del	gastrointestinal stromal tumor	sensitive	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited Kit phosphorylation and proliferation of gastrointestinal stromal tumor cells harboring KIT exon 11 deletion in culture (PMID: 31085175).	31085175
KIT	KIT exon 11 del	gastrointestinal stromal tumor	sensitive	Ripretinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ripretinib (DCC-2618) inhibited Kit phosphorylation and proliferation of gastrointestinal stromal tumor cells harboring KIT exon 11 deletion, resulted in tumor regression in cell line xenograft models (PMID: 31085175).	31085175
KIT	KIT exon 11 del	gastrointestinal stromal tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sutent (sunitinib) inhibited Kit phosphorylation and proliferation of gastrointestinal stromal tumor cells harboring KIT exon 11 deletion in culture (PMID: 31085175).	31085175
KIT	KIT exon 11 del KIT D816E	gastrointestinal stromal tumor	sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Avapritinib (BLU-285) inhibited proliferation of gastrointestinal stromal tumor cells harboring both KIT exon 11 deletion and KIT D816E in culture (PMID: 31085175).	31085175
KIT	KIT exon 11 del KIT D816E	gastrointestinal stromal tumor	decreased response	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, gastrointestinal stromal tumor cells harboring both KIT exon 11 deletion and KIT D816E demonstrated reduced response to growth inhibition by Sutent (sunitinib) compared to cells harboring KIT exon 11 deletion alone in culture (PMID: 31085175).	31085175
KIT	KIT exon 11 del KIT D816E	gastrointestinal stromal tumor	sensitive	Ripretinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ripretinib (DCC-2618) inhibited proliferation of gastrointestinal stromal tumor cells harboring both KIT exon 11 deletion and KIT D816E in culture (PMID: 31085175).	31085175
KIT	KIT exon 11 del KIT D816E	gastrointestinal stromal tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited proliferation of gastrointestinal stromal tumor cells harboring both KIT exon 11 deletion and KIT D816E in culture (PMID: 31085175).	31085175
KIT	KIT exon 11 del KIT D816E	gastrointestinal stromal tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) inhibited proliferation of gastrointestinal stromal tumor cells harboring both KIT exon 11 deletion and KIT D816E in culture (PMID: 31085175).	31085175
KIT	KIT exon 11 del KIT D816E	gastrointestinal stromal tumor	sensitive	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited proliferation of gastrointestinal stromal tumor cells harboring both KIT exon 11 deletion and KIT D816E in culture (PMID: 31085175).	31085175
KIT	KIT M552_K558del	gastrointestinal stromal tumor	predicted - resistant	Ponatinib	Case Reports/Case Series	Actionable	In a clinical study, a GIST patient harboring KIT M552_K558del, resistant to multiple tyrosine kinase inhibitors, demonstrated resistance to Iclusig (ponatinib) treatment as indicated by disease progression after 4 weeks of treatment (PMID: 25239608).	25239608
KIT	KIT Y823D	gastrointestinal stromal tumor	predicted - sensitive	AZD3229	Preclinical - Pdx	Actionable	In a preclinical study, AZD3229 inhibited Kit signaling, resulted in tumor regression in patient-derived xenograft (PDX) models of gastrointestinal stromal tumor harboring KIT Y823D (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1328).	detail...
KIT	KIT Y823D	Advanced Solid Tumor	sensitive	Motesanib	Preclinical - Cell culture	Actionable	In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing KIT Y823D in culture (PMID: 20633291).	20633291
KIT	KIT V559D KIT Y823D	Advanced Solid Tumor	no benefit	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT Y823D and KIT V559D were insensitive to Sutent (sunitinib) in culture and in mouse models (PMID: 24205792).	24205792
KIT	KIT V559D KIT Y823D	Advanced Solid Tumor	no benefit	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) treatment in a mouse model with cells expressing KIT V559D and KIT Y823D resulted in shortened survival (PMID: 24205792).	24205792
KIT	KIT V559D KIT Y823D	Advanced Solid Tumor	sensitive	Flumatinib	Preclinical	Actionable	In a preclinical study, Flumatinib treatment in transformed cells co-expressing KIT N822K and KIT V559D demonstrated decreased cell proliferation and inhibition of Kit, Erk 1/2, and Stat3 phosphorylation in culture, and led to improved survival in mouse models (PMID: 24205792).	24205792
KIT	KIT over exp	seminoma	sensitive	Imatinib	Case Reports/Case Series	Actionable	In a clinical case study, Gleevec (imatinib) in conjunction with third-line chemotherapy resulted in a complete response in a patient with stage IV chemoresistant pure seminoma with KIT overexpression (PMID: 18751412).	18751412
KIT	KIT over exp	Advanced Solid Tumor	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells overexpressing Kit in culture (PMID: 27627808).	27627808
KIT	KIT V654A	Advanced Solid Tumor	sensitive	Axitinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT V654A in culture, and inhibited tumor growth in xenograft models (PMID: 31205508).	31205508
KIT	KIT V654A	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sutent (sunitinib) inhibited proliferation of transformed cells expressing KIT V654A in culture (PMID: 31205508).	31205508
KIT	KIT V654A	gastrointestinal stromal tumor	predicted - sensitive	AZD3229	Preclinical - Pdx	Actionable	In a preclinical study, AZD3229 inhibited Kit signaling, resulted in tumor regression in patient-derived xenograft (PDX) models of gastrointestinal stromal tumor harboring KIT V654A (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1328).	detail...
KIT	KIT V654A	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, cells expressing KIT V654A demonstrated some sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT V654A	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, cells expressing KIT V654A demonstrated resistance to Gleevec (imatinib) in culture (PMID: 16751810).	16751810
KIT	KIT V654A	gastrointestinal stromal tumor	predicted - resistant	Avapritinib	Phase I	Actionable	In a Phase I trial, patients with gastrointestinal stromal tumors harboring either KIT V654A or KIT T670I compared to those without either KIT mutation demonstrated an overall response rate of 0% (n=25) vs. 26% (n=84) and a progressive disease rate of 72% vs 23%, respectively when treated with Avapritinib (BLU-285) (PMID: 31270078; NCT02508532).	31270078
KIT	KIT V559D KIT V654A	Advanced Solid Tumor	sensitive	Axitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT V654A and KIT V559D in culture (PMID: 31205508).	31205508
KIT	KIT V559D KIT V654A	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sutent (sunitinib) inhibited proliferation of transformed cells expressing KIT V654A and KIT V559D in culture (PMID: 31205508).	31205508
KIT	KIT V559D KIT V654A	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT V559D and KIT V654A were sensitive to treatment with Sutent (sunitinib) in culture, demonstrating decreased cell proliferation (PMID: 24205792).	24205792
KIT	KIT V559_G565del KIT V654A KIT A829P	gastrointestinal stromal tumor	predicted - sensitive	Ripretinib	Case Reports/Case Series	Actionable	In a Phase I trial, treatment with Ripretinib (DCC-2618) decreased circulating tumor DNA, resulted in stable disease lasting over 26 months in a patient with gastrointestinal stromal tumor harboring a primary KIT V559_G565del mutation and two acquired resistance mutations, KIT V654A and KIT A829P (PMID: 31085175; NCT02571036).	31085175
KIT	KIT K642E	gastrointestinal stromal tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, a patient derived GIST cell line harboring KIT K642E demonstrated sensitivity to Iclusig (ponatinib) in culture (PMID: 25239608).	25239608
KIT	KIT K642E	gastrointestinal stromal tumor	sensitive	Sunitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Sutent (sunitinib) inhibited proliferation of a gastrointestinal stromal tumor (GIST) cell line and primary GIST patient-derived cells harboring KIT K642E in culture (PMID: 31205508).	31205508
KIT	KIT K642E	gastrointestinal stromal tumor	sensitive	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited proliferation of gastrointestinal stromal tumor cells harboring KIT K642E in culture (PMID: 21170960).	21170960
KIT	KIT K642E	vulvar melanoma	predicted - sensitive	Imatinib	Case Reports/Case Series	Actionable	In a clinical case study, Gleevec (imatinib) treatment resulted in partial response in a patient with recurrent vulval melanoma harboring KIT K642E, with reduction of tumor mass by 35% at 12 weeks (PMID: 20372153).	20372153
KIT	KIT K642E	gastrointestinal stromal tumor	sensitive	Axitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Inlyta (axitinib) inhibited phosphorylation of KIT and downstream signaling, reduced proliferation, and induced cell-cycle arrest in a cultured gastrointestinal stromal tumor (GIST) cell line harboring KIT K642E, and inhibited proliferation of primary GIST cells harboring KIT K642E in culture (PMID: 31205508).	31205508
KIT	KIT K642E	gastrointestinal stromal tumor	sensitive	BGJ398 + Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antiproliferative activity in gastrointestinal stromal tumor cells harboring KIT K642E in culture (PMID: 25673643).	25673643
KIT	KIT K642E	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT K642E demonstrating a partial response and a progression free survival of 5.8 months and overall survival of 18.6 months (PMID: 28327988).	28327988
KIT	KIT D820E	thymic carcinoma	predicted - sensitive	Sorafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with metastatic thymic carcinoma harboring KIT D820E demonstrated a partial response to treatment with Nexavar (sorafenib) (PMID: 19461405).	19461405
KIT	KIT D820E	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, cells expressing KIT D820E demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT A502_Y503dup KIT D820E	gastrointestinal stromal tumor	predicted - resistant	Sunitinib	Preclinical - Pdx	Actionable	In a preclinical study, Sutent (sunitinib) did not inhibit Kit, Erk, or Mtor signaling and resulted in minimal (26.2%) tumor inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT A502_Y503dup and KIT D820E, which was established from a patient who did not respond to Gleevec (imatinib mesylate) and Sutent (sunitinib) (PMID: 29100343).	29100343
KIT	KIT A502_Y503dup KIT D820E	gastrointestinal stromal tumor	resistant	Imatinib	Preclinical - Pdx	Actionable	In a preclinical study, Gleevec (imatinib mesylate) did not inhibit Kit, Erk, or Mtor signaling and resulted in minimal (7.4%) tumor inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT A502_Y503dup and KIT D820E, which was established from a patient who did not respond to Gleevec (imatinib mesylate) and Sutent (sunitinib) (PMID: 29100343).	29100343
KIT	KIT P551_W557delinsL	gastrointestinal stromal tumor	predicted - sensitive	Ponatinib	Case Reports/Case Series	Actionable	In a clinical study, a GIST patient harboring KIT P551_W557delinsL, resistant to Gleevec (imatinib), Sutent (sunitinib), and Stivarga (regorafenib), demonstrated sensitivity to Iclusig (ponatinib) treatment, which resulted in tumor regression and stable disease (PMID: 25239608).	25239608
KIT	KIT positive	germ cell cancer	resistant	Imatinib	Phase II	Actionable	In a small Phase II study, 18 patients with KIT-positive refractory germ cell tumors treated with Gleevec (imatinib) experienced no significant antitumor activity (PMID: 16462496).	16462496
KIT	KIT positive	gastrointestinal stromal tumor	sensitive	Imatinib	FDA approved	Actionable	In a Phase II trial that supported FDA approval, treatment with Gleevec (imatinib) resulted in an overall response rate of 38% (56/147) and a median duration of response of 13 weeks in patients with metastatic or unresectable KIT-positive GIST (PMID: 12374669).	12374669 detail...
KIT	KIT positive	prostate neuroendocrine neoplasm	no benefit	Imatinib	Preclinical	Actionable	In a preclinical study, a prostate neuroendocrine tumor mouse model expressing Kit did not respond to Gleevec (imatinib), a result of impaired signaling of the Kit pathway (PMID: 27980106).	27980106
KIT	KIT positive	breast cancer	predicted - sensitive	Imatinib + Letrozole	Phase 0	Actionable	In a pilot trial, Gleevec (imatinib mesylate) and Femara (letrozole) combination treatment resulted in clinical partial response in 90% (9/10) and stable disease in 10% (1/10) of the evaluable patients with invasive hormone-sensitive breast cancer, 8 of the 13 enrolled patients had KIT-positive tumors (PMID: 18248884).	18248884
KIT	KIT D816E KIT Y570_L576del PTEN T321fs	gastrointestinal stromal tumor	resistant	Imatinib	Preclinical - Pdx	Actionable	In a preclinical study, Gleevec (imatinib mesylate) did not inhibit Kit, Erk, or Mtor signaling and resulted in minimal tumor inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT D816E, KIT Y570_L576del, and PTEN T321fs, which was established from a patient who did not respond to Gleevec (imatinib mesylate), Sutent (sunitinib), and Nexavar (sorafenib) (PMID: 29100343).	29100343
KIT	KIT D816E KIT Y570_L576del PTEN T321fs	gastrointestinal stromal tumor	sensitive	Regorafenib	Preclinical - Pdx	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited Kit, Erk, and Mtor signaling, resulted in tumor growth inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT D816E, KIT Y570_L576del, and PTEN T321fs, which was established from a patient who did not respond to Gleevec (imatinib mesylate), Sutent (sunitinib), and Nexavar (sorafenib) (PMID: 29100343).	29100343
KIT	KIT D816E KIT Y570_L576del PTEN T321fs	gastrointestinal stromal tumor	sensitive	Imatinib + LY294002	Preclinical - Pdx	Actionable	In a preclinical study, Gleevec (imatinib mesylate) in combination with LY394002 resulted in enhanced tumor growth inhibition compared to monotherapy in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT D816E, KIT Y570_L576del, and PTEN T321fs, which was established from a patient who did not respond to Gleevec (imatinib mesylate), Sutent (sunitinib), and Nexavar (sorafenib) (PMID: 29100343).	29100343
KIT	KIT D816E KIT Y570_L576del PTEN T321fs	gastrointestinal stromal tumor	resistant	Sunitinib	Preclinical - Pdx	Actionable	In a preclinical study, Sutent (sunitinib) demonstrated limited inhibition of Kit, Erk, and Mtor signaling and resulted in minimal (22.9%) tumor inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT D816E, KIT Y570_L576del, and PTEN T321fs, which was established from a patient who did not respond to Gleevec (imatinib mesylate), Sutent (sunitinib), and Nexavar (sorafenib) (PMID: 29100343).	29100343
KIT	KIT W557_K558delinsCE KIT N822K	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Case Reports/Case Series	Actionable	In a clinical study, KIT N822K was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring a primary KIT W557_K558delinsCE mutation, who developed resistance to Gleevec (imatinib mesylate) (PMID: 18488160).	18488160
KIT	KIT A502_Y503dup	Advanced Solid Tumor	sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT A502_Y503dup (Y503_F504insAY) were sensitive to Flumatinib in culture, demonstrating decreased cell proliferation (PMID: 24205792).	24205792
KIT	KIT A502_Y503dup	gastrointestinal stromal tumor	resistant	Imatinib	Preclinical - Pdx	Actionable	In a preclinical study, a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT A502_Y503dup demonstrated resistance to treatment with Gleevec (imatinib), resulting in increased tumor volume (PMID: 27777285).	27777285
KIT	KIT A502_Y503dup	gastrointestinal stromal tumor	predicted - sensitive	Regorafenib	Preclinical - Pdx	Actionable	In a preclinical study, Stivarga (regorafenib) did not significantly inhibit Kit, Erk, or Mtor signaling, but resulted in tumor growth inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT A502_Y503dup and KIT D820E, which was established from a patient who did not respond to Gleevec (imatinib mesylate) and Sutent (sunitinib) (PMID: 29100343).	29100343
KIT	KIT A502_Y503dup	gastrointestinal stromal tumor	sensitive	Cabozantinib	Preclinical - Pdx	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) resulted in decreased tumor volume and reduced mitotic activity in a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT A502_Y503dup (PMID: 27777285).	27777285
KIT	KIT A502_Y503dup	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT A502_Y503dup (Y503_F504insAY) were sensitive to Sutent (sunitinib) in culture, demonstrating decreased cell proliferation (PMID: 24205792).	24205792
KIT	KIT A502_Y503dup	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT A502_Y503dup (Y503_F504insAY) were sensitive to Gleevec (imatinib) in culture, demonstrating decreased cell proliferation (PMID: 24205792).	24205792
KIT	KIT A502_Y503dup KIT N822K	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Case Reports/Case Series	Actionable	In a clinical study, KIT N822K was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring a primary KIT A502_Y503dup mutation, who developed resistance to Gleevec (imatinib) (PMID: 18488160).	18488160
KIT	KIT A502_Y503dup PDGFRA H687Y	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Case Reports/Case Series	Actionable	In a clinical study, PDGFRA H687Y was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring primary KIT A502_Y503dup mutation, who developed resistance to Gleevec (imatinib mesylate) (PMID: 18488160).	18488160
KIT	KIT N822I	Advanced Solid Tumor	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT N822I demonstrated resistance to Gleevec (imatinib) in culture (PMID: 21689725).	21689725
KIT	KIT N822I	Advanced Solid Tumor	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis of transformed cells expressing KIT N822I in culture (PMID: 21689725).	21689725
KIT	KIT P551_V555delinsTL	gastrointestinal stromal tumor	sensitive	Sorafenib	Preclinical - Pdx	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited Erk signaling, induced apoptosis, resulted in tumor growth inhibition in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT P551_V555delinsTL (PMID: 19139124).	19139124
KIT	KIT A829P	melanoma	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, melanoma cells expressing KIT A829P demonstrated resistance to treatment with Gleevec (imatinib mesylate) (PMID: 23582185, PMID: 25594040).	23582185 25594040
KIT	KIT A829P	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, cells expressing KIT A829P demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT A829P	melanoma	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, melanoma cells expressing KIT A829P demonstrated resistance to treatment with Sutent (sunitinib) (PMID: 23582185, PMID: 25594040).	23582185 25594040
KIT	KIT A829P	melanoma	sensitive	Dasatinib	Preclinical	Actionable	In a preclinical study, Sprycel (dasatinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT A829P (PMID: 23582185, PMID: 25594040).	23582185 25594040
KIT	KIT A829P	melanoma	sensitive	Nilotinib	Preclinical	Actionable	In a preclinical study, Tasigna (nilotinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT A829P (PMID: 23582185, PMID: 25594040).	23582185 25594040
KIT	KIT A829P	Advanced Solid Tumor	sensitive	Axitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT A829P in culture, however, with decreased potency compared to its potency against other KIT variants (PMID: 31205508).	31205508
KIT	KIT A829P KIT V559D	Advanced Solid Tumor	sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT A829P and KIT V559D were sensitive to Flumatinib in culture, demonstrating decreased cell proliferation and inhibition of Kit, Erk1/2, and Stat3 phosphorylation (PMID: 24205792).	24205792
KIT	KIT A829P KIT V559D	Advanced Solid Tumor	no benefit	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT A829P and KIT V559D were insensitive to Sutent (sunitinib) in culture (PMID: 24205792).	24205792
KIT	KIT act mut	gastrointestinal stromal tumor	sensitive	Cabozantinib	Preclinical	Actionable	In a preclinical study, Cometriq (cabozantinib) decreased cell viability in imatinib-sensitive and resistant gastrointestinal stromal tumor (GIST) cell lines harboring KIT activating mutations in culture, and induced tumor regression in KIT-mutant GIST mouse models (PMID: 25836719).	25836719
KIT	KIT act mut	gastrointestinal stromal tumor	sensitive	Pexidartinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX3397 inhibited growth of gastrointestinal stromal tumor cell lines harboring KIT activating mutations in culture and in cell line xenograft models (PMID: 24583793).	24583793
KIT	KIT act mut	gastrointestinal stromal tumor	not applicable	N/A	Guideline	Diagnostic	KIT activating mutations aid the diagnosis of gastrointestinal stromal tumor (NCCN.org).	detail...
KIT	KIT act mut	Advanced Solid Tumor	sensitive	PLX9486	Preclinical	Actionable	In a preclinical study, PLX9486 inhibited KIT mutations, including exon 17 mutations, and demonstrated in vivo and in vitro activity against tumors harboring KIT exon 17 mutations (Cancer Res February 1, 2016 76; IA32).	detail...
KIT	KIT act mut	melanoma	sensitive	Imatinib	Guideline	Actionable	Gleevec (imatinib) is included in guidelines as second-line therapy for metastatic or unresectable melanoma patients with KIT activating mutations (NCCN.org).	detail...
KIT	KIT P551_E554del	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT P551_E554del were resistant to treatment with Gleevec (imatinib) in culture (PMID: 25239608).	25239608
KIT	KIT P551_E554del	Advanced Solid Tumor	resistant	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT P551_E554del were resistant to treatment with Sutent (sunitinib) in culture (PMID: 25239608).	25239608
KIT	KIT P551_E554del	Advanced Solid Tumor	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT P551_E554del were resistant to treatment with Stivarga (regorafenib) in culture (PMID: 25239608).	25239608
KIT	KIT P551_E554del	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT P551_E554del demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT V559del	gastrointestinal stromal tumor	sensitive	G007-LK + Imatinib	Preclinical	Actionable	In a preclinical study, the combination of G007-LK and Gleevec (imatinib) demonstrated increased anti-tumor activity compared to either agent alone in a mouse model of gastrointestinal stromal tumor expressing Kit V558del (corresponding to human V559del) (PMID: 28611108).	28611108
KIT	KIT W557_V559delinsF	gastrointestinal stromal tumor	sensitive	Avapritinib	Preclinical - Pdx	Actionable	In a preclinical study, BLU-285 treatment resulted in tumor regression in patient-derived xenograft models of gastrointestinal stromal tumor harboring KIT W557_V559delinsF (PMID: 29093181).	29093181
KIT	KIT mutant	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 4% (1/25), durable partial response in 16% (4/25), and stable disease in 56% (14/25) of melanoma patients harboring KIT mutations (PMID: 28843487; NCT01168050).	28843487
KIT	KIT mutant	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) treatment in patients with melanoma harboring KIT mutations resulted in an overall response rate of 26.2% (11/42), which included 11 patients with a partial response, a median duration of response of 7.1 months, and an overall survival of 18 months (PMID: 28327988; NCT01028222).	28327988
KIT	KIT mutant	gastrointestinal stromal tumor	predicted - sensitive	Ripretinib	Phase I	Actionable	In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including KIT-mutant gastrointestinal stromal tumor (GIST), with 1 patient harboring KIT exon 11 and 17 mutations demonstrating a partial response, and 7/7 KIT-mutant GIST patients demonstrating a partial metabolic response (EORTC-NCI-AACR 2016, Abs 7LBA).	detail...
KIT	KIT mutant	gastrointestinal stromal tumor	sensitive	BGJ398 + Imatinib	Preclinical - Pdx	Actionable	In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antitumor activity in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT mutations (PMID: 25673643).	25673643
KIT	KIT mutant	gastrointestinal stromal tumor	predicted - sensitive	Avapritinib	Phase I	Actionable	In a Phase I (NAVIGATOR) trial, Avapritinib (BLU-285) treatment resulted in an objective response rate of 13% (7/52, 7 partial responses) and a disease control rate of 63% (33/52) in patients with KIT-mutant gastrointestinal stromal tumor (The CTOS 2018 Annual Meeting, Nov 14-17, Rome Italy, Paper 012 3027631; NCT02508532).	detail...
KIT	KIT mutant	gastrointestinal stromal tumor	not applicable	N/A	Clinical Study	Diagnostic	KIT mutations are used in the diagnosis of gastrointestinal stromal tumors (PMID: 25193432, PMID: 26276366, PMID: 25729899).	25193432 26276366 25729899
KIT	KIT mutant	gastrointestinal stromal tumor	sensitive	HQP1351	Preclinical - Cell line xenograft	Actionable	In a preclinical study, HQP1351 demonstrated greater tumor inhibition compared to Iclusig (ponatinib) in cell line xenograft models of gastrointestinal stromal tumor harboring secondary KIT mutations (Cancer Res 2018;78(13 Suppl):Abstract nr 1979).	detail...
KIT	RUNX1-RUNX1T1 KIT mut	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, coincident KIT mutations were associated with higher relapse rate and decreased overall survival in acute myeloid leukemia patients with RUNX1-RUNX1T1 fusions (PMID: 18648004, PMID: 16384925, PMID: 25111512).	25111512 16384925 18648004
KIT	KIT M541L	chronic leukemia	sensitive	Imatinib	Phase I	Actionable	In Phase I trials, KIT M541L has been associated with response to Gleevec (imatinib) in chronic eosinophilic leukemia, NOS (PMID: 25015329) and mastocytosis (PMID: 18795925).	25015329 18795925
KIT	KIT V559D	melanoma	sensitive	Nilotinib	Phase II	Actionable	In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT V559D demonstrating a partial response and progression free survival of 28.3 months and overall survival of 28.3 months (PMID: 28327988).	28327988
KIT	KIT V559D	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, cells expressing KIT V559D demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT	KIT V559D	gastrointestinal stromal tumor	sensitive	Axitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Inlyta (axitinib) inhibited proliferation of gastrointestinal stromal tumor patient-derived primary cells harboring KIT V559D in culture (PMID: 31205508).	31205508
KIT	KIT V559D	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) decreased KIT signaling, and inhibited growth and induced apoptosis of transformed cells expressing KIT V559D in culture (PMID: 21689725).	21689725
KIT	KIT V559D	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT V559D were sensitive to Gleevec (imatinib), demonstrating decreased cell proliferation in culture and inhibition of Kit, Erk1/2, and Stat3 phosphorylation (PMID: 24205792).	24205792
KIT	KIT V559D	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT V559D were sensitive to Sutent (sunitinib), demonstrating decreased cell proliferation in culture and inhibition of Kit, Erk1/2, and Stat3 phosphorylation (PMID: 24205792).	24205792
KIT	KIT V559D	Advanced Solid Tumor	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) decreased KIT signaling, and inhibited growth and induced apoptosis of transformed cells expressing KIT V559D in culture (PMID: 21689725).	21689725
KIT	KIT V559D	Advanced Solid Tumor	sensitive	Axitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT V559D in culture (PMID: 31205508).	31205508
KIT	KIT V559D	Advanced Solid Tumor	sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT V559D were sensitive to Flumatinib, demonstrating decreased cell proliferation in culture and inhibition of Kit, Erk1/2, and Stat3 phosphorylation (PMID: 24205792).	24205792
KIT	KIT N822K KIT V559D	Advanced Solid Tumor	sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT N822K and KIT V559D were sensitive to Flumatinib in culture, demonstrating decreased cell proliferation and inhibition of Kit, Erk 1/2, and Stat3 phosphorylation (PMID: 24205792).	24205792
KIT	KIT N822K KIT V559D	Advanced Solid Tumor	no benefit	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing KIT N822K and KIT V559D were insensitive to Sutent (sunitinib) in culture (PMID: 24205792).	24205792
KIT	KIT N822K	Advanced Solid Tumor	predicted - sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT N822K were more sensitive to treatment with Sutent (sunitinib) in culture compared to Gleevec (imatinib), demonstrating decreased cell proliferation (PMID: 24205792).	24205792
KIT	KIT N822K	acute myeloid leukemia	sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation and proliferation of acute myeloid leukemia cells harboring KIT N822K in culture (PMID: 29093181).	29093181
KIT	KIT N822K	leukemia	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Kit signaling and viability in leukemia cells harboring KIT N822K in culture (PMID: 21482694).	21482694
KIT	KIT N822K	Advanced Solid Tumor	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT N822K were resistant to treatment with Gleevec (imatinib) in culture (PMID: 24205792).	24205792
KIT	KIT N822K	Advanced Solid Tumor	predicted - sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT N822K were more sensitive to treatment with Flumatinib in culture compared to Gleevec (imatinib), demonstrating decreased cell proliferation (PMID: 24205792).	24205792
KIT	KIT N822K	acute myeloid leukemia	sensitive	BPR1J373	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an acute myeloid leukemia cell line harboring KIT N822K demonstrated sensitivity to treatment with BPR1J373, showing inhibition of Kit phosphorylation and apoptotic induction in culture, and tumor regression in xenograft models (PMID: 27512117).	27512117
KIT	KIT N822K	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Case Reports/Case Series	Actionable	In a clinical case study, KIT N822K was identified in the tumor of a gastrointestinal stromal tumor patient who was resistant to Gleevec (imatinib) treatment (PMID: 26316776).	26316776
KIT	KIT N822K	acute myeloid leukemia	sensitive	Ripretinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ripretinib (DCC-2618) inhibited proliferation of acute myeloid leukemia cells harboring KIT N822K in culture (PMID: 31085175).	31085175
KIT	KIT N822K	acute myeloid leukemia	sensitive	Ripretinib	Preclinical - Pdx	Actionable	In a preclinical study, DCC-2618 induced tumor regression in a patient-derived xenograft (PDX) model of acute myeloid leukemia harboring KIT N822K (Cancer Res 2015;75(15 Suppl):Abstract nr 2690).	detail...
KIT	KIT N822K	acute myeloid leukemia	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited proliferation of acute myeloid leukemia cells harboring KIT N822K in culture (PMID: 31085175).	31085175
KIT	KIT N822K	acute myeloid leukemia	decreased response	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring KIT N822K demonstrated reduced response to growth inhibition by Gleevec (imatinib) compared to GIST cells harboring KIT exon 11 deletion in culture (PMID: 31085175).	31085175
KIT	KIT N822K	acute myeloid leukemia	sensitive	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited proliferation of acute myeloid leukemia cells harboring KIT N822K in culture (PMID: 31085175).	31085175
KIT	KIT N822K	acute myeloid leukemia	predicted - sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, an acute myeloid leukemia cell line harboring KIT N822K demonstrated increased sensitivity to Sutent (sunitinib) compared to cells with wild-type KIT, resulting in increased inhibition of colony formation, and induction of cell-cycle arrest, apoptosis, and autophagy in culture (PMID: 31217744).	31217744
KIT	KIT N822K	acute myeloid leukemia	predicted - sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sutent (sunitinib) inhibited proliferation of acute myeloid leukemia cells harboring KIT N822K in culture (PMID: 31085175).	31085175
KIT	KIT N822K RUNX1-RUNX1T1	acute myeloid leukemia	sensitive	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Quizartinib (AC220) inhibited Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture (PMID: 31309543).	31309543
KIT	KIT N822K RUNX1-RUNX1T1	acute myeloid leukemia	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib inhibited Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture (PMID: 31309543).	31309543
KIT	KIT N822K RUNX1-RUNX1T1	acute myeloid leukemia	decreased response	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) demonstrated reduced ability to inhibit Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture compared to other kinase inhibitors (PMID: 31309543).	31309543
KIT	KIT N822K RUNX1-RUNX1T1	acute myeloid leukemia	sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Avapritinib (BLU-285) inhibited Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture (PMID: 31309543).	31309543
KIT	KIT N822K RUNX1-RUNX1T1	acute myeloid leukemia	sensitive	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture (PMID: 31309543).	31309543
KIT	KIT N822K RUNX1-RUNX1T1	acute myeloid leukemia	decreased response	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) demonstrated reduced ability to inhibit Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture compared to other kinase inhibitors (PMID: 31309543).	31309543
KIT	KIT D816Y	mast cell neoplasm	predicted - sensitive	Avapritinib	Preclinical	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation and proliferation of murine mastocytoma cells harboring KIT D814Y (corresponding to human D816Y) in culture, and resulted in tumor regression in allograft animal models (PMID: 29093181).	29093181
KIT	KIT D816Y	mast cell neoplasm	predicted - resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, mouse mastocytoma cells harboring KIT D814Y (corresponds to D816Y in human) were resistant to Gleevec (imatinib) in culture (PMID: 31085175).	31085175
KIT	KIT D816Y	mast cell neoplasm	predicted - sensitive	Ripretinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ripretinib (DCC-2618) inhibited proliferation of a mouse mastocytosis cell line expressing KIT K816Y in culture (Cancer Res 2015;75(15 Suppl):Abstract nr 2690).	detail...
KIT	KIT D816Y	mast cell neoplasm	predicted - sensitive	Ripretinib	Preclinical	Actionable	In a preclinical study, Ripretinib (DCC-2618) inhibited proliferation of mouse mastocytoma cells harboring KIT D814Y (corresponds to D816Y in human) in culture, and resulted in tumor growth inhibition in allograft models (PMID: 31085175).	31085175
KIT	KIT D816Y	mast cell neoplasm	predicted - sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited proliferation of mouse mastocytoma cells harboring KIT D814Y (corresponds to D816Y in human) in culture (PMID: 31085175).	31085175
KIT	KIT D816Y	Advanced Solid Tumor	resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816Y were resistant to treatment with Sutent (sunitinib) in culture (PMID: 24205792).	24205792
KIT	KIT D816Y	Advanced Solid Tumor	resistant	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816Y were resistant to treatment with Flumatinib in culture (PMID: 24205792).	24205792
KIT	KIT D816Y	mast cell neoplasm	decreased response	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, mouse mastocytoma cells harboring KIT D814Y (corresponds to D816Y in human) demonstrated reduced response to growth inhibition by Sutent (sunitinib) compared to GIST cells harboring KIT exon 11 deletion in culture (PMID: 31085175).	31085175
KIT	KIT D816Y	mast cell neoplasm	predicted - resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, mouse mastocytoma cells harboring KIT D814Y (corresponds to D816Y in human) were resistant to Stivarga (regorafenib) in culture (PMID: 31085175).	31085175
KIT	KIT D816Y	Advanced Solid Tumor	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816Y were resistant to Gleevec (imatinib mesylate) in culture (PMID: 16397263).	16397263
KIT	KIT D816Y	Advanced Solid Tumor	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT D816Y were resistant to treatment with Gleevec (imatinib) in culture (PMID: 24205792).	24205792
KIT	KIT I571_D579dup	Advanced Solid Tumor	predicted - resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT I571_D579dup (KIT D579_H580insIDPTQLPYD) were moderately resistant to Gleevec (imatinib) in culture (PMID: 24205792).	24205792
KIT	KIT I571_D579dup	Advanced Solid Tumor	predicted - resistant	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT I571_D579dup (KIT D579_H580insIDPTQLPYD) were moderately resistant to Flumatinib in culture (PMID: 24205792).	24205792
KIT	KIT I571_D579dup	Advanced Solid Tumor	predicted - resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT I571_D579dup (KIT D579_H580insIDPTQLPYD) were moderately resistant to Sutent (sunitinib) in culture (PMID: 24205792).	24205792
KIT	KIT amp PDGFRA amp	glioblastoma multiforme	sensitive	Ripretinib	Phase I	Actionable	In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including a partial response in a glioblastoma multiforme patient harboring KIT and PDGFRA amplification (EORTC-NCI-AACR 2016, Abs 7LBA).	detail...
KIT	ROS1 fusion KDR amp KIT amp PDGFRA amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of KIT, KDR, and PDGFRA (PMID: 29636358).	29636358
KIT	ALK fusion ALK G1202R KIT amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, an ALK G1202R secondary mutation as well as KIT amplification were identified in a patient with ALK fusion-positive non-small cell lung cancer with resistance to Xalkori (crizotinib) (PMID: 22277784).	22277784
KIT	KIT N505I	melanoma	predicted - sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) decreased phosphorylation of KIT, AKT, and ERK in melanocytes expressing KIT N505I in culture (PMID: 24317392).	24317392
KIT	KIT N505I	melanoma	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, KIT N505I induced phosphorylation of KIT, ERK, and AKT, and was inhibited by Nexavar (sorafenib) in cell culture of melanocytes, demonstrating sensitivity of N505I to sorafenib (PMID: 24317392).	24317392
KIT	KIT V559_V560del	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT V559_V560del were sensitive to Gleevec (imatinib), demonstrating decreased cell proliferation in culture (PMID: 24205792).	24205792
KIT	KIT V559_V560del	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT V559_V560del were sensitive to Sutent (sunitinib), demonstrating decreased cell proliferation in culture (PMID: 24205792).	24205792
KIT	KIT V559_V560del	Advanced Solid Tumor	sensitive	Flumatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT V559_V560del were sensitive to Flumatinib, demonstrating decreased cell proliferation in culture (PMID: 24205792).	24205792
KIT	KIT K550_W557del	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT K550_W557del	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT K550_W557del	Advanced Solid Tumor	sensitive	Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Stivarga (regorafenib) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KIT	KIT K550_W557del	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608).	25239608
KMT2A	KMT2A-MLLT3	acute myeloid leukemia	sensitive	MI-503	Preclinical - Patient cell culture	Actionable	In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia (AML) cell line and primary AML samples harboring KMT2A-MLLT3 (MLL-AF9) in culture (PMID: 25817203).	25817203
KMT2A	KMT2A-MLLT3	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	KMT2A-MLLT3 fusions are associated with an intermediate prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).	detail...
KMT2A	KMT2A-MLLT3	acute myeloid leukemia	sensitive	I-BET151 + SGC0946	Preclinical - Patient cell culture	Actionable	In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-MLLT3 in culture, and prolonged survival in animal models of mouse KMT2A-MLLT3-positive leukemia (PMID: 27294782).	27294782
KMT2A	KMT2A-MLLT3	acute myeloid leukemia	sensitive	Dinaciclib	Preclinical	Actionable	In a preclinical study, treatment with Dinaciclib resulted in induced cell death of acute myeloid leukemia cells harboring KMT2A-MLLT3 in culture (PMID: 26627013).	26627013
KMT2A	KMT2A-MLLT3	leukemia	sensitive	MI-503	Preclinical	Actionable	In a preclinical study, MI-503 reduced progression and improved survival of a mouse leukemia model expressing KMT2A-MLLT3 (MLL-AF9) (PMID: 25817203).	25817203
KMT2A	KMT2A-MLLT3	leukemia	sensitive	IRAK1/4	Preclinical	Actionable	In a preclinical study, a transgenic leukemic mouse model harboring KMT2A-MLLT3 demonstrated sensitivity to IRAK1/4, resulting in delayed progression and improved survival (PMID: 28065413).	28065413
KMT2A	KMT2A-MLLT3 SRSF2 P95H	acute myeloid leukemia	sensitive	H3B-8800	Preclinical	Actionable	In a preclinical study, H3B-8800 inhibited tumor growth in transplant animal models of mouse acute myeloid leukemia cells harboring SRSF2 P95H and KMT2A-MLLT3 (MLL-AF9) while had no effect in SRSF2 wild-type controls (Blood 2016 128:966).	detail...
KMT2A	KMT2A - EP300	acute myeloid leukemia	sensitive	MI-503	Preclinical - Patient cell culture	Actionable	In a preclinical study, MI-503 inhibited growth of a primary acute myeloid sample harboring KMT2A-EP300 in culture (PMID: 25817203).	25817203
KMT2A	KMT2A-ELL	acute myeloid leukemia	sensitive	I-BET151 + SGC0946	Preclinical - Patient cell culture	Actionable	In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-ELL in culture (PMID: 27294782).	27294782
KMT2A	KMT2A-MLLT1	acute myeloid leukemia	sensitive	MI-503	Preclinical - Cell culture	Actionable	In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia cell line harboring KMT2A-MLLT1 (MLL-ENL) in culture (PMID: 25817203).	25817203
KMT2A	KMT2A-MLLT1 NRAS G12D	acute myeloid leukemia	sensitive	Dinaciclib	Preclinical	Actionable	In a preclinical study, acute myeloid leukemia cells co-harboring KMT2A-MLLT1 and NRAS G12D demonstrated a decrease in tumor burden, reduced colony formation, and an increase in cell death when treated with Dinaciclib in both culture and mouse models (PMID: 26627013).	26627013
KMT2A	KMT2A-MLLT1 NRAS G12D	acute myeloid leukemia	predicted - sensitive	AZ20	Preclinical	Actionable	In a preclinical study, AZ20 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).	27625305
KMT2A	KMT2A-MLLT1 NRAS G12D	acute myeloid leukemia	predicted - sensitive	AZD0156	Preclinical	Actionable	In a preclinical study, AZD0156 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).	27625305
KMT2A	KMT2A rearrange	acute lymphocytic leukemia	decreased response	Romidepsin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Istodax (romidepsin) resulted in minimal activity in acute lymphocytic leukemia cell lines harboring a KMT2A rearrangement in culture, and in cell line xenograft models, demonstrating decreased leukemic cells by 16% (PMID: 27443263).	27443263
KMT2A	KMT2A rearrange	acute lymphocytic leukemia	sensitive	Cytarabine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Cytosar-U (cytarabine) decreased leukemic cells by 66% in acute lymphocytic leukemia cell line xenograft models harboring a KMT2A rearrangement (PMID: 27443263).	27443263
KMT2A	KMT2A rearrange	acute lymphocytic leukemia	sensitive	Cytarabine + Dacinostat	Preclinical - Cell culture	Actionable	In a preclinical study, Dacinostat (LAQ824) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cell lines harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263).	27443263
KMT2A	KMT2A rearrange	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	KMT2A rearrangements (t(v;11q23.3)) are associated with a poor/adverse prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).	detail...
KMT2A	KMT2A rearrange	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, KMT2A rearrangements, specifically partial tandem duplications, were associated with a poor overall survival in acute myeloid leukemia patients (PMID: 24487413, PMID: 22915647, PMID: 22417203, PMID: 21881046).	21881046 24487413 22417203 22915647
KMT2A	KMT2A rearrange	acute lymphocytic leukemia	sensitive	Cytarabine + Romidepsin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Istodax (romidepsin) enhanced the effects of Cytosar-U (cytarabine) in acute lymphocytic leukemia cell lines harboring a KMT2A rearrangement in culture, and in cell line xenograft models, demonstrating decreased leukemic cells by 73% (PMID: 27443263).	27443263
KMT2A	KMT2A rearrange	acute lymphocytic leukemia	sensitive	Cytarabine + Panobinostat	Preclinical - Cell culture	Actionable	In a preclinical study, Farydak (panobinostat) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cells harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263).	27443263
KMT2A	KMT2A rearrange	acute leukemia	predicted - sensitive	Pinometostat	Case Reports/Case Series	Actionable	In a Phase I trial, Pinometostat (EPZ-5676) treatment resulted in complete remission in 2 patients with KMT2A rearranged (both with t(11;19)) acute leukemia (PMID: 29724899; NCT01684150).	29724899
KMT2A	KMT2A rearrange	leukemia	predicted - sensitive	I-CBP112 + JQ1	Preclinical	Actionable	In a preclinical study, I-CBP112 sensitized leukemia cells harboring KMT2A fusions to JQ1, resulting in decreased cell growth in culture (PMID: 26552700).	26552700
KMT2A	KMT2A rearrange	acute lymphocytic leukemia	sensitive	Cytarabine + Mocetinostat	Preclinical - Cell culture	Actionable	In a preclinical study, Mocetinostat (MGCD0103) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cell lines harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263).	27443263
KMT2A	KMT2A rearrange	acute myeloid leukemia	predicted - sensitive	KO-539	Preclinical - Cell line xenograft	Actionable	In a preclinical study, KO-539 inhibited growth of KMT2A (MLL1)-rearranged acute myeloid leukemia cells in culture, and prolonged survival in cell-line xenograft models (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27).	detail...
KMT2A	KMT2A rearrange	leukemia	predicted - sensitive	Doxorubicin + I-CBP112	Preclinical	Actionable	In a preclinical study, I-CBP112 sensitized leukemia cells harboring KMT2A fusions to Doxorubicin, leading to decreased cell growth in culture (PMID: 26552700).	26552700
KMT2A	KMT2A fusion	acute myeloid leukemia	sensitive	I-BET151 + SGC0946	Preclinical - Patient cell culture	Actionable	In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A fusions in culture (PMID: 27294782).	27294782
KMT2A	KMT2A fusion	acute myeloid leukemia	predicted - sensitive	MI-503	Preclinical - Cell culture	Actionable	In a preclinical study, MI-503 inhibited growth of several acute myeloid leukemia (AML) cell lines and primary AML samples harboring KMT2A (MLL) fusions in culture (PMID: 25817203).	25817203
KMT2A	KMT2A-MLLT10	acute myeloid leukemia	sensitive	I-BET151 + SGC0946	Preclinical - Patient cell culture	Actionable	In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-MLLT10 in culture (PMID: 27294782).	27294782
KMT2A	KMT2A-MLLT10	leukemia	sensitive	EPZ004777	Preclinical	Actionable	In a preclinical study, transformed cells expressing the fusion, KMT2A-MLLT10, demonstrated sensitivity to EPZ004777 in culture and in mouse models, resulting in cell cycle arrest, increased apoptotic activity, and inhibition of cell proliferation (PMID: 23138183).	23138183
KMT2A	KMT2A-AFF1	acute lymphocytic leukemia	predicted - sensitive	AZD5153	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD5153 inhibited proliferation of acute lymphocytic leukemia cells harboring KMT2A-AFF1 (MLL-AF4) in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426).	27573426
KMT2A	KMT2A-AFF1	leukemia	sensitive	IRAK1/4	Preclinical - Cell culture	Actionable	In a preclinical study, leukemia cells harboring KMT2A-AFF1 demonstrated sensitivity to IRAK1/4 in culture, resulting in decreased cell proliferation (PMID: 28065413).	28065413
KMT2A	KMT2A-AFF1	acute myeloid leukemia	sensitive	Dinaciclib	Preclinical	Actionable	In a preclinical study, treatment with Dinaciclib resulted in induced cell death of acute myeloid leukemia cells harboring KMT2A-AFF1 in culture (PMID: 26627013).	26627013
KMT2A	KMT2A-AFF1	acute myeloid leukemia	sensitive	MI-503	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MI-503 reduced expression of KMT2A (MLL) fusion target genes, inhibited growth of an acute myeloid leukemia (AML) cell lines harboring KMT2A-AFF1 (MLL-AF4) in culture, and inhibited tumor growth and progression in an AML cell line xenograft model harboring KMT2A-AFF1 (MLL-AF4) (PMID: 25817203).	25817203
KMT2A	KMT2A-AFF1	acute myeloid leukemia	predicted - sensitive	AZD5153	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD5153 inhibited proliferation of acute myeloid leukemia cells harboring KMT2A-AFF1 (MLL-AF4) in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426).	27573426
KMT2A	KMT2A-AFF1	leukemia	sensitive	I-BET151 + SGC0946	Preclinical - Cell culture	Actionable	In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of leukemia cells harboring KMT2A-AFF1 in culture (PMID: 27294782).	27294782
KMT2A	KMT2A-SEPTIN6	acute myeloid leukemia	sensitive	I-BET151 + SGC0946	Preclinical - Patient cell culture	Actionable	In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-SEPTIN6 in culture (PMID: 27294782).	27294782
KMT2A	KMT2A-GAS7	leukemia	sensitive	AMI-408	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with AMI-408 decreased growth of leukemia cells expressing KMT2A-GAS7 (MLL-GAS7) in culture, and increased survival in xenograft models (PMID: 26766589).	26766589
MAP2K1	MAP2K1 L115P	melanoma	resistant	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) did not inhibit proliferation of melanoma cells expressing Map2k1 L115P (PMID: 19915144).	19915144
MAP2K1	MAP2K1 L115P	Advanced Solid Tumor	resistant	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, CI-1040 (PD184352) did not inhibit kinase activity of Map2k1 L115P expressed in transformed human kidney cells (PMID: 12370306).	12370306
MAP2K1	MAP2K1 L115P	melanoma	resistant	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, CI-1040 (PD184352) did not inhibit proliferation of melanoma cells expressing Map2k1 L115P (PMID: 19915144).	19915144
MAP2K1	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
MAP2K1	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
MAP2K1	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
MAP2K1	BRAF V600E MAP2K1 L115P	melanoma	resistant	PD-0325901	Preclinical	Actionable	In a preclinical study, over expression of MAPK21 L115P in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).	26267534
MAP2K1	BRAF V600E MAP2K1 L115P	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 28655712).	28655712
MAP2K1	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
MAP2K1	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
MAP2K1	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
MAP2K1	BRAF V600E MAP2K1 L115P	colorectal cancer	resistant	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture, likely due to the acquired secondary resistance mutation MAP2K1 L115P (PMID: 27312529).	27312529
MAP2K1	BRAF V600E MAP2K1 L115P	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
MAP2K1	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Cetuximab + Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
MAP2K1	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Dabrafenib + SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
MAP2K1	BRAF V600E MAP2K1 L115P	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 26267534).	26267534
MAP2K1	BRAF V600E MAP2K1 L115P	colorectal cancer	sensitive	Alpelisib + Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).	27312529
MAP2K1	MAP2K1 P105_I107del	lymphatic system cancer	predicted - sensitive	Cobimetinib	Case Reports/Case Series	Actionable	In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including a complete response in a patient with Erdheim-Chester disease harboring MAP2K1 P105_I107del (PMID: 30867592; NCT01953926).	30867592
MAP2K1	BRAF V600E MAP2K1 P162S	melanoma	sensitive	Dabrafenib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).	24265154
MAP2K1	BRAF V600E MAP2K1 P162S	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).	24265154
MAP2K1	BRAF V600E MAP2K1 P162S	melanoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).	24265154
MAP2K1	BRAF V600E MAP2K1 E203K	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).	28655712
MAP2K1	BRAF V600E MAP2K1 E203K	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
MAP2K1	BRAF V600E MAP2K1 E203K	melanoma	sensitive	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 28655712).	28655712
MAP2K1	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E and also had reduced sensitivity in comparison to cell lines harboring BRAF V600E and NRAS A146T in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	no benefit	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).	22389471
MAP2K1	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).	22389471
MAP2K1	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	conflicting	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, the response of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S to Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) was conflicting as one cell line with this mutation profile responded to the combination and another cell line with the mutation profile did not (PMID: 22389471).	22389471
MAP2K1	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).	22389471
MAP2K1	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
MAP2K1	MAP2K1 C121S	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 C121S	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 C121S	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 C121S	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 C121S conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366).	28179366
MAP2K1	MAP2K1 C121S	colorectal cancer	sensitive	Cetuximab + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 C121S in culture (PMID: 28179366).	28179366
MAP2K1	MAP2K1 C121S	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 C121S	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 C121S	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 C121S displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	BRAF V600E MAP2K1 C121S	melanoma	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell line harboring BRAF V600E mutation and overexpressing MAP2K1 C121S in culture (PMID: 24448821).	24448821
MAP2K1	BRAF V600E MAP2K1 C121S	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
MAP2K1	BRAF V600E MAP2K1 C121S	melanoma	resistant	PLX4720	Preclinical	Actionable	In a preclinical study, expression of MAP2K1 C121S conferred resistance to PLX4720 in melanoma cells harboring BRAF V600E in culture (PMID: 21383288).	21383288
MAP2K1	BRAF V600E MAP2K1 C121S	melanoma	sensitive	VRT11E	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).	24265153
MAP2K1	BRAF V600E MAP2K1 C121S	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 C121S conferred resistance to Zelboraf (vemurafenib) in melanoma cell lines harboring BRAF V600, resulting in decreased sensitivity to Zelboraf (vemurafenib)-induced inhibition of MAPK pathway activation and cell proliferation in culture (PMID: 24448821).	24448821
MAP2K1	BRAF V600E MAP2K1 C121S	melanoma	resistant	Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient harboring BRAF V600E demonstrated an initial response to treatment with Zelboraf (vemurafenib), but progressed following emergence of a MAP2K1 C121S mutation (PMID: 21383288).	21383288
MAP2K1	BRAF V600E MAP2K1 C121S	melanoma	resistant	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, MAP2K1 C121S conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).	24265154
MAP2K1	BRAF V600E MAP2K1 C121S	melanoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Selumetinib (AZD6244)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).	24448821
MAP2K1	BRAF V600E MAP2K1 G128V	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).	24265153
MAP2K1	BRAF V600E MAP2K1 G128V	melanoma	resistant	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, MAP2K1 G128V conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).	24265154
MAP2K1	BRAF V600E MAP2K1 G128V	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).	24265153
MAP2K1	BRAF V600E MAP2K1 G128V	melanoma	sensitive	VRT11E	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).	24265153
MAP2K1	MAP2K1 Q56_V60del	ovarian serous carcinoma	predicted - sensitive	Selumetinib	Case Reports/Case Series	Actionable	In a Phase II trial, Selumetinib (AZD6244) treatment resulted in a complete response that lasted over 5 years with continuous treatment in a patient with serous ovarian cancer harboring MAP2K1 Q56_V60del (PMID: 26324360).	26324360
MAP2K1	MAP2K1 Q56P MAP2K1 H119Y MAP2K1 D351G EGFR G719S	colorectal cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a colorectal cancer cell line harboring MAP2K1 mutations Q56P, H119Y, and D351G and an EGFR G719S mutation demonstrated some sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1	MAP2K1 K57T	colorectal cancer	sensitive	Cetuximab + Trametinib	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57T in culture (PMID: 26644315).	26644315
MAP2K1	MAP2K1 K57T	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, a colorectal cancer cell line expressing MAP2K1 K57T was resistant to Vectibix (panitumumab) in culture (PMID: 26644315).	26644315
MAP2K1	MAP2K1 K57T	colorectal cancer	predicted - resistant	Cetuximab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with colorectal cancer developed liver metastases harboring MAP2K1 K57T that were insensitive to Erbitux (cetuximab) treatment and the mutation was confirmed to cause resistance in human colorectal cancer cell lines in culture (PMID: 26644315).	26644315
MAP2K1	MAP2K1 K57T	colorectal cancer	sensitive	Panitumumab + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a combination of Vectibix (panitumumab) and Mekinist (trametinib) caused tumor regression in a patients colorectal cancer metastases harboring MAP2K1 K57T after being identified pre-clinically as a combination likely to inhibit MAP2K1 K57T expressing colorectal cancer (PMID: 26644315).	26644315
MAP2K1	BRAF V600E MAP2K1 K57T	refractory hairy cell leukemia	predicted - sensitive	Cobimetinib + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a single patient with hairy cell leukemia who relapsed after initial response to Zelboraf (vemurafenib) was found to have acquired multiple clones with Mek/Erk activating mutations, of which the MAP2K1 K57T clone became dominant, and demonstrated a sustained response greater than 12 months to combined Zelboraf (vemurafenib) and Cotellic (cobimetinib) treatment (PMID: 30341394).	30341394
MAP2K1	BRAF V600E MAP2K1 K57T	hairy cell leukemia	predicted - resistant	Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a single patient with hairy cell leukemia harboring BRAF V600E, who relapsed after a 38 week remission in response to Zelboraf (vemurafenib) treatment, was found to have acquired multiple clones with Mek/Erk activating mutations, of which the MAP2K1 K57T clone became dominant (PMID: 30341394).	30341394
MAP2K1	MAP2K1 Q56P BRAF V600E	melanoma	sensitive	PLX4720 + Selumetinib	Preclinical	Actionable	In a preclinical study, combined treatment with selumetinib and PLX4720 strongly suppressed the emergence of resistant MAP2K1 mutations in BRAF V600E cells in culture (PMID: 19915144).	19915144
MAP2K1	MAP2K1 Q56P BRAF V600E	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the MEK inhibitor, selumetinib (AZD6244), in cell culture (PMID: 19915144).	19915144
MAP2K1	MAP2K1 Q56P BRAF V600E	melanoma	resistant	PLX4720	Preclinical	Actionable	In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the B-RAF inhibitor PLX4720 in culture (PMID: 19915144).	19915144
MAP2K1	MAP2K1 Q56P	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 Q56P	lung adenocarcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Selumetinib (AZD6244), resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1	MAP2K1 Q56P	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 Q56P	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 Q56P	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 Q56P	stomach cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a gastric cancer cell line harboring MAP2K1 Q56P demonstrated sensitivity to Mekinist (trametinib), resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1	MAP2K1 Q56P	lung adenocarcinoma	sensitive	Refametinib	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Refametinib (BAY86-9766), resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1	MAP2K1 Q56P	stomach cancer	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, selumetinib (AZD6244) inhibited growth of a gastric cancer cell line that requires MAP2K1 Q56P and inhibited phosphorylation of ERK in these cells (PMID: 22327936).	22327936
MAP2K1	MAP2K1 Q56P	lymphatic system cancer	predicted - sensitive	Cobimetinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with refractory Erdheim-Chester disease harboring a MAP2K1 Q56P mutation had a reduction of lymphatic infiltrates to background within a month of receiving Cotellic (cobimetinib) therapy (PMID: 26566875).	26566875
MAP2K1	MAP2K1 Q56P	lymphatic system cancer	predicted - sensitive	Cobimetinib	Case Reports/Case Series	Actionable	In a Phase II trial, treatment with Mekinist (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and stable disease in 6% (1/18) of patients, including a complete response in a patient with Erdheim-Chester disease harboring MAP2K1 Q56P (PMID: 30867592; NCT01953926).	30867592
MAP2K1	MAP2K1 Q56P	lung adenocarcinoma	sensitive	PD-0325901	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to PD-0325901, resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1	MAP2K1 Q56P	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 Q56P	lung adenocarcinoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Mekinist (trametinib), resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1	MAP2K1 Q56P	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 Q56P displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	BRAF V600E MAP2K1 Q56P	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P displayed reduced sensitivity to Mekinist (trametinib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).	22389471
MAP2K1	BRAF V600E MAP2K1 Q56P	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, the combination of Talfinlar (dabrafenib) and Mekinist (trametinib) resulted in improved growth inhibition in melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E MAP2K1 Q56P	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).	28655712
MAP2K1	BRAF V600E MAP2K1 Q56P	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E MAP2K1 Q56P	melanoma	sensitive	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 28655712).	28655712
MAP2K1	BRAF V600E MAP2K1 P124S	melanoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Selumetinib (AZD6244) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931).	22197931
MAP2K1	BRAF V600E MAP2K1 P124S	melanoma	sensitive	VRT11E	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).	24265153
MAP2K1	BRAF V600E MAP2K1 P124S	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 24265153).	24265153
MAP2K1	BRAF V600E MAP2K1 P124S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture (PMID: 24265153).	24265153
MAP2K1	ETV6-NTRK3 MAP2K1 P124S	pancreatic cancer	predicted - resistant	LOXO-195	Case Reports/Case Series	Actionable	In a clinical case study, a secondary resistance mutation, MAP2K1 P124S, was identified via cell-free DNA testing after a patient with pancreatic cancer harboring ETV6-NTRK3 progressed on LOXO-195 treatment (PMID: 31406350).	31406350
MAP2K1	MAP2K1 L115A	Advanced Solid Tumor	decreased response	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, CI-1040 (PD184352) partially inhibited kinase activity of Map2k1 L115A expressed in transformed human kidney cells (PMID: 12370306).	12370306
MAP2K1	BRAF V600E MAP2K1 K59del	melanoma	sensitive	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).	22389471
MAP2K1	BRAF V600E MAP2K1 K59del	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E MAP2K1 K59del	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E MAP2K1 K59del	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E harboring MAP2K1 K59del in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E MAP2K1 K59del	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E MAP2K1 K59del	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).	22389471
MAP2K1	BRAF V600E MAP2K1 K59del	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).	22389471
MAP2K1	BRAF V600E MAP2K1 H119P	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E treated with Selumetinib (AZD6244) in culture demonstrated resistance, which was a result of the resistance mutation, MAP2K1 H119P (PMID: 19915144).	19915144
MAP2K1	MAP2K1 V60E	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Mekinist (trametinib) in culture (PMID: 24265153).	24265153
MAP2K1	MAP2K1 V60E	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 24265153).	24265153
MAP2K1	BRAF V600E MAP2K1 V60E	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).	24265153
MAP2K1	BRAF V600E MAP2K1 V60E	melanoma	sensitive	VRT11E	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).	24265153
MAP2K1	BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R	melanoma	predicted - resistant	Vemurafenib	Clinical Study - Cohort	Actionable	In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistance-associated mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).	24265153
MAP2K1	MAP2K1 K57N	colorectal cancer	sensitive	Panitumumab + Trametinib	Preclinical	Actionable	In a preclinical study, Vectibix (panitumumab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315).	26644315
MAP2K1	MAP2K1 K57N	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 K57N	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 K57N	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 K57N	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 K57N	colorectal cancer	sensitive	Cetuximab + Trametinib	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315).	26644315
MAP2K1	MAP2K1 K57N	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 K57N	lung adenocarcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, selumetinib (AZD6244) inhibited phosphorylation of ERK in cells expressing MAP2K1 K57N and inhibited MAP2K1 K57N-dependent growth in cell culture (PMID: 18632602).	18632602
MAP2K1	MAP2K1 K57N	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Erbitux (cetuximab) in culture (PMID: 26644315).	26644315
MAP2K1	MAP2K1 K57N	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 K57N	lymphatic system cancer	sensitive	Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with refractory Erdheim-Chester disease harboring a MAP2K1 K57N mutation had a sustained clinical response to Mekinist (trametinib) for over 6 months (PMID: 26566875).	26566875
MAP2K1	MAP2K1 K57N	colorectal cancer	resistant	Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Vectibix (panitumumab) in culture (PMID: 26644315).	26644315
MAP2K1	ALK rearrange MAP2K1 K57N	lung non-small cell carcinoma	sensitive	Ceritinib + Selumetinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, NSCLC patient derived cells harboring an ALK rearrangement demonstrated resistance to Zykadia (ceritinib) due to the acquired mutation MAP2K1 K57N, however, sensitivity was restored to Zykadia (ceritinib) with the addition of AZD6244, resulting in decreased cell survival in culture and reduced tumor volume in xenograft models (PMID: 25394791).	25394791
MAP2K1	MAP2K1 I111S	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 I111S	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 I111S	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 I111S	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 I111S	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 I111S	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 I111S displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 I103N	Advanced Solid Tumor	decreased response	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, CI-1040 (PD184352) partially inhibited kinase activity of Map2k1 I103N expressed in transformed human kidney cells (PMID: 12370306).	12370306
MAP2K1	MAP2K1 I103N	melanoma	resistant	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Selumetinib (AZD6244) did not inhibit proliferation of melanoma cells expressing Map2k1 I103N (PMID: 19915144).	19915144
MAP2K1	MAP2K1 I103N	melanoma	resistant	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, CI-1040 (PD184352) did not inhibit proliferation of melanoma cells expressing Map2k1 I103N (PMID: 19915144).	19915144
MAP2K1	BRAF V600E MAP2K1 I103N	melanoma	resistant	PD-0325901	Preclinical	Actionable	In a preclinical study, over expression of MAPK21 I103N in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).	26267534
MAP2K1	BRAF V600E MAP2K1 I103N	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 26267534).	26267534
MAP2K1	MAP2K1 P124L	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, transformed human melanoma cells expressing MAP2K1 P124L demonstrated resistance to the MEK inhibitor, Selumetinib (AZD6244) (PMID: 19915144).	19915144
MAP2K1	MAP2K1 P124L	lymphatic system cancer	predicted - sensitive	Cobimetinib	Case Reports/Case Series	Actionable	In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including a complete response in a patient with mixed histiocytosis harboring MAP2K1 P124L (PMID: 30867592; NCT01953926).	30867592
MAP2K1	BRAF V600K MAP2K1 P124L	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124L demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).	25370473
MAP2K1	BRAF V600K MAP2K1 P124L	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).	25370473
MAP2K1	BRAF V600K MAP2K1 P124L	melanoma	sensitive	VX-11e	Preclinical	Actionable	In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).	25370473
MAP2K1	BRAF V600E MAP2K1 P124L	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
MAP2K1	BRAF V600E MAP2K1 P124L	melanoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).	28655712
MAP2K1	MAP2K1 V211D	Advanced Solid Tumor	predicted - resistant	Cobimetinib	Preclinical	Actionable	In a preclinical study, Cotellic (cobimetinib) did not inhibit kinase activity of MAP2K1 V211D in an in vitro assay (PMID: 31227518).	31227518
MAP2K1	MAP2K1 V211D	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 V211D displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 V211D	Advanced Solid Tumor	predicted - resistant	Binimetinib	Preclinical	Actionable	In a preclinical study, Mektovi (binimetinib) did not inhibit kinase activity of MAP2K1 V211D in an in vitro assay (PMID: 31227518).	31227518
MAP2K1	MAP2K1 V211D	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 V211D displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 V211D	Advanced Solid Tumor	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, Map2k1 V211D displayed resistance to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 V211D	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 V211D displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 V211D	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 V211D displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 V211D	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 V211D displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	SCH772984	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).	27312529
MAP2K1	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Cetuximab + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired secondary resistant mutation of MAP2K1 V211D (PMID: 27312529).	27312529
MAP2K1	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Cetuximab + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).	27312529
MAP2K1	BRAF V600E MAP2K1 V211D	melanoma	resistant	Selumetinib	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by Selumetinib (AZD6244) in cell culture (PMID: 19915144).	19915144
MAP2K1	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Cetuximab + Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).	27312529
MAP2K1	BRAF V600E MAP2K1 V211D	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).	28655712
MAP2K1	BRAF V600E MAP2K1 V211D	melanoma	resistant	CI-1040	Preclinical	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by CI-1040 in cell culture (PMID: 19915144).	19915144
MAP2K1	BRAF V600E MAP2K1 V211D	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
MAP2K1	BRAF V600E MAP2K1 V211D	colorectal cancer	resistant	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).	27312529
MAP2K1	BRAF V600E MAP2K1 V211D	melanoma	sensitive	Ulixertinib	Preclinical - Cell culture	Actionable	In a preclinical study, BVD-523 (Ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).	28655712
MAP2K1	BRAF K601E MAP2K1 V211D	colon cancer	predicted - resistant	Binimetinib + Panitumumab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with metastatic colon cancer harboring BRAF K601E developed progressive disease after 6 weeks of Mektovi (binimetinib) and Vectibix (panitumumab) combination treatment, MAP2K1 V211D was identified as a co-occuring mutation in the biopsy from the new metastasis site (PMID: 31227518).	31227518
MAP2K1	BRAF K601E MAP2K1 V211D	colon cancer	resistant	Binimetinib + Cetuximab	Preclinical - Pdx	Actionable	In a preclinical study, Mektovi (binimetinib) and Erbitux (cetuximab) combination did not inhibit Rsk and Erk phosphorylation, and had no effect on tumor growth in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).	31227518
MAP2K1	BRAF K601E MAP2K1 V211D	colon cancer	resistant	Binimetinib	Preclinical - Pdx	Actionable	In a preclinical study, Mektovi (binimetinib) did not inhibit Rsk and Erk phosphorylation, and had no effect on tumor growth in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).	31227518
MAP2K1	BRAF K601E MAP2K1 V211D	colon cancer	sensitive	MAP855	Preclinical - Pdx	Actionable	In a preclinical study, MAP955 inhibited Rsk and Erk phosphorylation, and resulted in 30% tumor regression in patient-derived xenograft (PDX) models of metastatic colon cancer harboring BRAF K601E and MAP2K1 V211D (PMID: 31227518).	31227518
MAP2K1	MAP2K1 K57E	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, MAP2K1 (MEK1) K57E mutations restored extracellular signal-regulated kinase (ERK) activation in the presence of Tafinlar (dabrafenib) in cultured melanoma cell lines (PMID: 24463458).	24463458
MAP2K1	BRAF V600E MAP2K1 K57E	melanoma	resistant	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 K57E in a melanoma cell line harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) in culture (PMID: 25370473).	25370473
MAP2K1	BRAF V600E MAP2K1 I111N	melanoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).	28655712
MAP2K1	BRAF V600E MAP2K1 I111N	melanoma	sensitive	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N in culture (PMID: 28655712).	28655712
MAP2K1	MAP2K1 P124Q	lymphatic system cancer	predicted - sensitive	Cobimetinib	Case Reports/Case Series	Actionable	In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including a complete response in a patient with Erdheim-Chester disease harboring MAP2K1 P124Q (PMID: 30867592; NCT01953926).	30867592
MAP2K1	BRAF V600K MAP2K1 P124Q	melanoma	sensitive	VX-11e	Preclinical - Cell culture	Actionable	In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).	25370473
MAP2K1	BRAF V600K MAP2K1 P124Q	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).	25370473
MAP2K1	BRAF V600K MAP2K1 P124Q	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).	25370473
MAP2K1	BRAF V600E MAP2K1 P124Q	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in cell culture (PMID: 25370473).	25370473
MAP2K1	MAP2K1 F129L	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 F129L	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 F129L	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 F129L	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 F129L	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 F129L	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F129L displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 F129L	colorectal cancer	sensitive	RO4927350	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F129L demonstrated sensitivity to treatment with RO4927350 in culture and in cell line xenograft models, demonstrating inhibition of tumor growth (PMID: 21705440).	21705440
MAP2K1	MAP2K1 F53S	Advanced Solid Tumor	sensitive	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, CI-1040 (PD184352) inhibited kinase activity of Map2k1 F53S expressed in transformed human kidney cells (PMID: 12370306).	12370306
MAP2K1	MAP2K1 F53L	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MAP2K1 F53L conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366).	28179366
MAP2K1	MAP2K1 F53L	Advanced Solid Tumor	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 F53L	Advanced Solid Tumor	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 F53L	colorectal cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F53L demonstrated sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713).	26582713
MAP2K1	MAP2K1 F53L	Advanced Solid Tumor	resistant	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 F53L	Advanced Solid Tumor	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 F53L	colorectal cancer	sensitive	Cetuximab + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 F53L in culture (PMID: 28179366).	28179366
MAP2K1	MAP2K1 F53L	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1	MAP2K1 F53L	Advanced Solid Tumor	resistant	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 F53L displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MET	MET del exon14	colorectal cancer	sensitive	Cabozantinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Cometriq (cabozantinib) inhibited growth of patient-derived colorectal cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439).	26375439
MET	MET del exon14	stomach cancer	sensitive	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of gastric cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing deletion of MET exon 14 were sensitive to Glesatinib (MGCD265) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324).	28765324
MET	MET del exon14	stomach cancer	sensitive	SYM015	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SYM015 treatment resulted in sustained tumor growth inhibition in cell line xenograft models of gastric cancer harboring MET exon 14 skipping mutations (PMID: 28679766).	28679766
MET	MET del exon14	stomach carcinoma	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (cabozantinib) inhibited growth of patient-derived gastric carcinoma cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439).	26375439
MET	MET del exon14	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14	lung adenocarcinoma	predicted - sensitive	Glesatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation demonstrated a 66% reduction in target lesion size and maintained a partial response for 7 months when treated with Glesatinib (MGCD265) (PMID: 28765324).	28765324
MET	MET del exon14	lung non-small cell carcinoma	sensitive	KTN0073-IgG1	Preclinical - Cell culture	Actionable	In a preclinical study, KTN0073-IgG1 inhibited growth of a non-small cell lung cancer cell line harboring deletion of MET exon 14 in culture (PMID: 27550450).	27550450
MET	MET del exon14	stomach carcinoma	sensitive	PHA-665752	Preclinical - Patient cell culture	Actionable	In a preclinical study, PHA-665752 inhibited growth of patient-derived gastric carcinoma cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439).	26375439
MET	MET del exon14	stomach cancer	predicted - sensitive	OMO-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, OMO-1 inhibited tumor growth in a cell line xenograft model of gastric cancer with a MET exon 14 skipping mutation (Cancer Res 2018;78(13 Suppl):Abstract nr 4791).	detail...
MET	MET del exon14	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14	lung non-small cell carcinoma	sensitive	Onartuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Onartuzumab inhibited tumor growth and decreased MET expression in a non-small cell lung cancer xenograft model harboring a deletion of MET exon 14 (PMID: 23882082).	23882082
MET	MET del exon14	lung non-small cell carcinoma	predicted - sensitive	Savolitinib	Phase II	Actionable	In a Phase II trial, Savolitinib (AZD6094) treatmetn resulted in partial response in 51.6% (16/31) and stable disease in 32.3% (10/31) of patients with pulmonary sarcomatoid carcinoma (n=14) or other types of non-small cell lung cancer (n=20) harboring MET exon 14 skipping mutations (AACR Annual Meeting 2019, Abstract CT301; NCT02897479).	detail...
MET	MET del exon14	Advanced Solid Tumor	sensitive	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of transformed cells expressing a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14	stomach cancer	decreased response	Emibetuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Emibetuzumab (LY2875358) treatment resulted in initial tumor growth inhibition followed by regrowth in cell line xenograft models of gastric cancer harboring MET exon 14 skipping mutations (PMID: 28679766).	28679766
MET	MET del exon14	lung adenocarcinoma	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, Xalkori (crizotinib) treatment resulted in stable disease for 7 months in a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation (PMID: 31312453).	31312453
MET	MET del exon14	lung adenocarcinoma	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, three patients with lung adenocarcinoma harboring a MET exon 14 skipping mutation demonstrated partial responses when treated with Xalkori (crizotinib) (PMID: 25971939).	25971939
MET	MET del exon14	stomach carcinoma	sensitive	SAIT301	Preclinical - Patient cell culture	Actionable	In a preclinical study, SAIT301 inhibited growth of patient-derived gastric carcinoma cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439).	26375439
MET	MET del exon14	stomach cancer	decreased response	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, gastric cancer cells harboring a MET exon 14 skipping mutation demonstrated decreased response to Savolitinib (AZD6094) compared to cells expressing sensitizing MET mutations in culture (PMID: 31279006).	31279006
MET	MET del exon14	stomach carcinoma	sensitive	Crizotinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of patient-derived gastric carcinoma cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439).	26375439
MET	MET del exon14	colorectal cancer	sensitive	Crizotinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of patient-derived colorectal cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439).	26375439
MET	MET del exon14	stomach cancer	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of gastric cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14	stomach cancer	decreased response	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, gastric cancer cells harboring a MET exon 14 skipping mutation demonstrated decreased response to Merestinib (LY2801653) compared to cells expressing sensitizing MET mutations in culture (PMID: 31279006).	31279006
MET	MET del exon14	stomach cancer	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of gastric cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14	Advanced Solid Tumor	resistant	Tivantinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing a MET exon 14 skipping mutation were resistant to Tivantinib (ARQ197) in culture (PMID: 31279006).	31279006
MET	MET del exon14	stomach cancer	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of gastric cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14	lung cancer	sensitive	SYM015	Preclinical - Pdx	Actionable	In a preclinical study, SYM015 treatment resulted in sustained tumor growth inhibition in patient-derived xenograft (PDX) models of lung cancer harboring MET exon 14 skipping mutations (PMID: 28679766).	28679766
MET	MET del exon14	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing a deletion of MET exon 14 were sensitive to Capmatinib (INC280) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324).	28765324
MET	MET del exon14	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14	lung cancer	decreased response	Emibetuzumab	Preclinical - Pdx	Actionable	In a preclinical study, Emibetuzumab (LY2875358) treatment resulted in initial tumor growth inhibition followed by regrowth in patient-derived xenograft (PDX) models of lung cancer harboring MET exon 14 skipping mutations (PMID: 28679766).	28679766
MET	MET del exon14	Advanced Solid Tumor	sensitive	SYM015	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Sym015 inhibited growth of cancer cell lines harboring a deletion of MET exon 14 in culture, and inhibited tumor growth in patient-derived xenograft (PDX) models with deletion of MET exon 14 (Cancer Res July 15 2016 (76) (14 Supplement) 1219).	detail...
MET	MET del exon14	colorectal cancer	sensitive	SAIT301	Preclinical - Patient cell culture	Actionable	In a preclinical study, SAIT301 inhibited growth of patient-derived colorectal cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439).	26375439
MET	MET del exon14	colorectal cancer	sensitive	PHA-665752	Preclinical - Patient cell culture	Actionable	In a preclinical study, PHA-665752 inhibited growth of patient-derived colorectal cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439).	26375439
MET	MET del exon14	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing a deletion of MET exon 14 were sensitive to Xalkori (crizotinib) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324).	28765324
MET	MET del exon14	lung cancer	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth in lung cancer cells harboring a deletion of MET exon 14 and loss of the wild-type MET allele in culture (PMID: 28765324).	28765324
MET	MET del exon14	stomach cancer	decreased response	Tivantinib	Preclinical - Cell culture	Actionable	In a preclinical study, gastric cancer cells harboring a MET exon 14 skipping mutation demonstrated decreased response to Tivantinib (ARQ197) in culture (PMID: 31279006).	31279006
MET	MET del exon14	lung squamous cell carcinoma	predicted - sensitive	Capmatinib	Case Reports/Case Series	Actionable	In a clinical case study, Capmatinib (INC280) treatment resulted in a decreased tumor volume of 61% in a patient with lung squamous cell carcinoma harboring a MET exon 14 skipping mutation (PMID: 25971938).	25971938
MET	MET del exon14	stomach cancer	conflicting	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, gastric cancer cells harboring a MET exon 14 skipping mutation were resistant to Glesatinib (MGCD265) in culture (PMID: 31279006).	31279006
MET	MET del exon14	stomach cancer	conflicting	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth in gastric cancer cells harboring a deletion of MET exon 14 and amplification of the mutant allele in culture, and resulted in tumor regression in cell line xenograft models (PMID: 28765324).	28765324
MET	MET del exon14 TP53 R175H	histiocytic and dendritic cell cancer	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, Xalkori (crizotinib) treatment resulted in a decrease in tumor volume by more than 60% in a patient with histiocytic sarcoma harboring MET exon 14 skipping and TP53 R175H (PMID: 25971938).	25971938
MET	MET del exon14 TP53 N30fs	lung large cell carcinoma	predicted - sensitive	Capmatinib	Case Reports/Case Series	Actionable	In a clinical case study, Capmatinib (INC280) treatment resulted in decreased tumor volume by 53% in a patient with large cell lung carcinoma harboring MET exon 14 skipping and TP53 N30fs*14 (PMID: 25971938).	25971938
MET	MET del exon14 MET D1228N	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET D1228N secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228N	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET D1228N secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228N	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228N secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228N	Advanced Solid Tumor	resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228N secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Savolitinib (AZD6094) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228N	Advanced Solid Tumor	resistant	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228N secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Capmatinib (INC280) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228N	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET D1228N secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228N	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells expressing MET deletion exon 14 and MET D1228N were sensitive to Glesatinib (MGCD265) treatment, demonstrating cell growth inhibition in culture and 21% tumor regression in xenograft models (PMID: 28765324).	28765324
MET	MET del exon14 MET D1228N	lung squamous cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with squamous cell lung cancer harboring a MET exon 14 skipping mutation was determined to have acquired MET D1228N after progression on Xalkori (crizotinib) therapy (PMID: 27343442).	27343442
MET	MET del exon14 MET D1228N	Advanced Solid Tumor	resistant	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228N secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Tepotinib (MSC2156119J) in culture (PMID: 31279006).	31279006
MET	CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H	melanoma	predicted - sensitive	Carboplatin + Imatinib + Paclitaxel	Case Reports/Case Series	Actionable	In a clinical case study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).	28514312
MET	MET amp MET del exon14 MET D1228N MET G1163R MET Y1230H MET Y1230S	lung adenocarcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring MET deletion exon 14 responded to Xalkori (crizotinib), demonstrating a near complete response at 3 months, however, after 9 months progression ensued and a re-biospy identified MET del exon14, MET amplification, MET D1228N, MET Y1230H, MET Y1230S, and MET G1163R (PMID: 28522754).	28522754
MET	MET amp MET del exon14 MET D1228N MET G1163R MET Y1230H MET Y1230S	lung adenocarcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring MET deletion exon 14 and MET amplification demonstrated resistance to Xalkori (crizotinib), and the patient was found to have acquired MET Y1230H, MET D1228N, MET Y1230S, and MET G1163R (PMID: 28765324).	28765324
MET	MET amp MET del exon14	lung cancer	sensitive	Glesatinib	Preclinical - Pdx	Actionable	In a preclinical study, a lung cancer patient-derived xenograft (PDX) model harboring MET amplification and MET exon 14 deletion demonstrated tumor regression when treated with Glesatinib (MGCD265) (PMID: 28765324).	28765324
MET	MET amp MET del exon14	lung adenocarcinoma	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient co-harboring MET exon 14 deletion and MET amp was sensitive to Xalkori (crizotinib), demonstrating a partial response for 8 months (PMID: 28765324).	28765324
MET	MET amp MET del exon14	lung adenocarcinoma	predicted - sensitive	Cabozantinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation and MET amplification demonstrated a complete response via PERCIST criteria when treated with Cometriq (Cabometyx, cabozantinib) (PMID: 25971939).	25971939
MET	MET amp MET del exon14	lung cancer	predicted - sensitive	TPX-0022	Preclinical - Pdx	Actionable	In a preclinical study, TPX-0022 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of lung cancer harboring MET amplification and MET exon 14 deletion (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1321).	detail...
MET	MET amp MET del exon14	lung non-small cell carcinoma	sensitive	SCC244	Preclinical - Pdx	Actionable	In a preclinical study, non-small cell lung carcinoma patient derived xenograft (PDX) models co-harboring MET amplification and MET deletion of exon 14 were sensitive to SCC244 treatment, demonstrating a complete response in four and a partial response in another four (PMID: 29237805).	29237805
MET	MET amp MET del exon14	lung non-small cell carcinoma	sensitive	Glesatinib	Preclinical - Pdx	Actionable	In a preclinical study, Glesatinib (MGCD265) treatment resulted in tumor regression in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring deletion of MET exon 14 and varying degrees of MET amplification (PMID: 28765324).	28765324
MET	MET del exon14 MET Y1230C	Advanced Solid Tumor	resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230C secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Savolitinib (AZD6094) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230C	Advanced Solid Tumor	resistant	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230C secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Tepotinib (MSC2156119J) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230C	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET Y1230C secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230C	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET Y1230C secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230C	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells expressing MET deletion exon 14 and MET Y1230C were sensitive to Glesatinib (MGCD265) treatment, demonstrating cell growth inhibition in culture and 52% tumor regression in xenograft models (PMID: 28765324).	28765324
MET	MET del exon14 MET Y1230C	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET Y1230C secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230C	Advanced Solid Tumor	resistant	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230C secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Capmatinib (INC280) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230C	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230C secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET amp MET del exon14 MET D1228N MET G1163R MET L1195V	lung adenocarcinoma	predicted - resistant	Glesatinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient previously harboring MET amp, MET deletion exon 14, MET D1228N, MET Y1230H, MET Y1230S, and MET G1163R demonstrated a decrease in lesion size when treated with Glesatinib (MGCD265), however, progression ensued and plasma testing indicated the patient lost Y1230H and Y1230S, but acquired MET L1195V (PMID: 28765324).	28765324
MET	MET del exon14 MET G1090S	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing MET G1090S secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1090S	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET G1090S secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1090S	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET G1090S secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1090S	Advanced Solid Tumor	sensitive	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of transformed cells expressing MET G1090S secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1090S	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET G1090S secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1090S	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET G1090S secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1090S	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET G1090S secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1090A	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET G1090A secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1090A	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET G1090A secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1090A	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET G1090A secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1090A	Advanced Solid Tumor	decreased response	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET G1090A secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Tepotinib (MSC2156119J) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1090A	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET G1090A secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1090A	Advanced Solid Tumor	decreased response	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET G1090A secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Savolitinib (AZD6094) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1090A	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET G1090A secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1092L	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET V1092L secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1092L	Advanced Solid Tumor	sensitive	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of transformed cells expressing MET V1092L secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1092L	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET V1092L secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1092L	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET V1092L secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1092L	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET V1092L secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1092L	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET V1092L secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1092L	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET V1092L secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1092I	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET V1092I secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1092I	Advanced Solid Tumor	sensitive	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of transformed cells expressing MET V1092I secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1092I	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET V1092I secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1092I	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET V1092I secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1092I	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET V1092I secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1092I	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET V1092I secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1092I	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET V1092I secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1133V	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET D1133V secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1133V	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET D1133V secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1133V	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing MET D1133V secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1133V	Advanced Solid Tumor	decreased response	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1133V secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1133V	Advanced Solid Tumor	decreased response	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1133V secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Glesatinib (MGCD265) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1133V	Advanced Solid Tumor	sensitive	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of transformed cells expressing MET D1133V secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1133V	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET D1133V secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1155M	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET V1155M secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1155M	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET V1155M secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1155M	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET V1155M secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1155M	Advanced Solid Tumor	sensitive	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of transformed cells expressing MET V1155M secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1155M	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET V1155M secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1155M	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET V1155M secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET V1155M	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET V1155M secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1159H	Advanced Solid Tumor	sensitive	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of transformed cells expressing MET Y1159H secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1159H	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1159H secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1159H	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET Y1159H secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1159H	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET Y1159H secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1159H	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET Y1159H secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1159H	Advanced Solid Tumor	decreased response	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1159H secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1159H	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET Y1159H secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1163R	Advanced Solid Tumor	decreased response	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET G1163R secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1163R	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET G1163R secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1163R	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET G1163R secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1163R	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET G1163R secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1163R	Advanced Solid Tumor	decreased response	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET G1163R secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Glesatinib (MGCD265) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1163R	Advanced Solid Tumor	decreased response	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET G1163R secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Tepotinib (MSC2156119J) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1163R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET G1163R secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1163E	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET G1163E secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1163E	Advanced Solid Tumor	sensitive	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of transformed cells expressing MET G1163E secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1163E	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET G1163E secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1163E	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET G1163E secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1163E	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET G1163E secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1163E	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET G1163E secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET G1163E	Advanced Solid Tumor	decreased response	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET G1163E secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Glesatinib (MGCD265) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1164G	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET D1164G secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1164G	Advanced Solid Tumor	decreased response	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1164G secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Tepotinib (MSC2156119J) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1164G	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET D1164G secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1164G	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET D1164G secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1164G	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET D1164G secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1164G	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1164G secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1164G	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET D1164G secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET L1195F	Advanced Solid Tumor	decreased response	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET L1195F secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Glesatinib (MGCD265) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET L1195F	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET L1195F secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET L1195F	Advanced Solid Tumor	resistant	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET L1195F secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET L1195F	Advanced Solid Tumor	sensitive	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of transformed cells expressing MET L1195F secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET L1195F	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET L1195F secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET L1195F	Advanced Solid Tumor	decreased response	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET L1195F secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Merestinib (LY2801653) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET L1195F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing MET L1195F secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET L1195V	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET L1195V secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET L1195V	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET L1195V secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET L1195V	Advanced Solid Tumor	decreased response	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET L1195V secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Tepotinib (MSC2156119J) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET L1195V	Advanced Solid Tumor	resistant	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET L1195V secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Glesatinib (MGCD265) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET L1195V	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET L1195V secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET L1195V	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET L1195V secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET L1195V	Advanced Solid Tumor	decreased response	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET L1195V secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET F1200L	Advanced Solid Tumor	decreased response	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET F1200L secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Merestinib (LY2801653) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET F1200L	Advanced Solid Tumor	sensitive	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of transformed cells expressing MET F1200L secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET F1200L	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing MET F1200L secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET F1200L	Advanced Solid Tumor	resistant	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET F1200L secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET F1200L	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET F1200L secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET F1200L	Advanced Solid Tumor	decreased response	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET F1200L secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Merestinib (LY2801653) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET F1200L	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET F1200L secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET F1200I	Advanced Solid Tumor	resistant	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET F1200I secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Glesatinib (MGCD265) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET F1200I	Advanced Solid Tumor	resistant	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET F1200I secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Merestinib (LY2801653) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET F1200I	Advanced Solid Tumor	sensitive	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of transformed cells expressing MET F1200I secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET F1200I	Advanced Solid Tumor	resistant	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET F1200I secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET F1200I	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET F1200I secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET F1200I	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET F1200I secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET F1200I	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET F1200I secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET M1211T	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET M1211T secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET M1211T	Advanced Solid Tumor	sensitive	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of transformed cells expressing MET M1211T secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET M1211T	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing MET M1211T secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET M1211T	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET M1211T secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET M1211T	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET M1211T secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET M1211T	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET M1211T secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET M1211T	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET M1211T secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228A	Advanced Solid Tumor	resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228A secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Savolitinib (AZD6094) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228A	Advanced Solid Tumor	resistant	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228A secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228A secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228A	Advanced Solid Tumor	resistant	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228A secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Capmatinib (INC280) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228A	Advanced Solid Tumor	resistant	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228A secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Tepotinib (MSC2156119J) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228A	Advanced Solid Tumor	decreased response	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228A secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Merestinib (LY2801653) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228A	Advanced Solid Tumor	resistant	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228A secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Glesatinib (MGCD265) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228E	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET D1228E secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228E	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET D1228E secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228E	Advanced Solid Tumor	resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228E secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Savolitinib (AZD6094) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228E	Advanced Solid Tumor	decreased response	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228E secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Capmatinib (INC280) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228E	Advanced Solid Tumor	resistant	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228E secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Tepotinib (MSC2156119J) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228E	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228E secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228E	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET D1228E secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228G	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228G secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228G	Advanced Solid Tumor	resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228G secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Savolitinib (AZD6094) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228G	Advanced Solid Tumor	decreased response	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228G secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228G	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET D1228G secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228G	Advanced Solid Tumor	resistant	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228G secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Capmatinib (INC280) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228G	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET D1228G secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228G	Advanced Solid Tumor	resistant	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228G secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Tepotinib (MSC2156119J) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228H	Advanced Solid Tumor	resistant	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228H secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Tepotinib (MSC2156119J) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228H	Advanced Solid Tumor	resistant	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228H secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Capmatinib (INC280) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228H	Advanced Solid Tumor	resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228H secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Savolitinib (AZD6094) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228H	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET D1228H secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228H	Advanced Solid Tumor	decreased response	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228H secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228H	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228H secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228H	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET D1228H secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228Y	Advanced Solid Tumor	decreased response	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228Y secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Merestinib (LY2801653) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228Y	Advanced Solid Tumor	resistant	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228Y secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Tepotinib (MSC2156119J) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228Y	Advanced Solid Tumor	decreased response	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228Y secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Glesatinib (MGCD265) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228Y secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228Y	Advanced Solid Tumor	resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228Y secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Savolitinib (AZD6094) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228Y	Advanced Solid Tumor	resistant	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228Y secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET D1228Y	Advanced Solid Tumor	resistant	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET D1228Y secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Capmatinib (INC280) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230D	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET Y1230D secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230D	Advanced Solid Tumor	resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230D secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Savolitinib (AZD6094) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230D	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230D secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230D	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET Y1230D secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230D	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET Y1230D secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230D	Advanced Solid Tumor	resistant	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230D secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Capmatinib (INC280) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230D	Advanced Solid Tumor	resistant	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230D secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Tepotinib (MSC2156119J) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230N	Advanced Solid Tumor	resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230N secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Savolitinib (AZD6094) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230N	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET Y1230N secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230N	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET Y1230N secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230N	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230N secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230N	Advanced Solid Tumor	resistant	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230N secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Tepotinib (MSC2156119J) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230N	Advanced Solid Tumor	resistant	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230N secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Capmatinib (INC280) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230N	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET Y1230N secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230S	Advanced Solid Tumor	resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230S secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Savolitinib (AZD6094) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230S	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET Y1230S secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230S	Advanced Solid Tumor	resistant	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230S secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Tepotinib (MSC2156119J) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230S	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230S secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230S	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET Y1230S secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230S	Advanced Solid Tumor	resistant	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230S secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Capmatinib (INC280) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230S	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET Y1230S secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230H	Advanced Solid Tumor	resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230H secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Savolitinib (AZD6094) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230H	Advanced Solid Tumor	resistant	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230H secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Capmatinib (INC280) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230H	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET Y1230H secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230H	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET Y1230H secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230H	Advanced Solid Tumor	resistant	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230H secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Tepotinib (MSC2156119J) in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230H	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET Y1230H secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).	31279006
MET	MET del exon14 MET Y1230H	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of MET Y1230H secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).	31279006
MET	MET N375S	Advanced Solid Tumor	decreased response	SU11274	Preclinical	Actionable	In a preclinical study, cells expressing MET N375S had decreased sensitivity to SU11274 in culture compared to cells expressing wild-type MET (PMID: 19723643).	19723643
MET	MET N375S	oral cavity cancer	no benefit	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with oral cavity cancer harboring MET N375S demonstrated progressive disease and overall survival of five weeks when treated with Xalkori (crizotinib) (PMID: 28514312).	28514312
MET	MET N375S	ovarian carcinoma	predicted - sensitive	Bevacizumab + Sorafenib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with ovarian cancer harboring MET N375S demonstrated sensitivity to the combination treatment, Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for greater than six months (PMID: 25363205).	25363205
MET	MET D1010Y	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET D1010Y in culture (PMID: 31279006).	31279006
MET	MET D1010Y	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET D1010Y in culture (PMID: 31279006).	31279006
MET	MET D1010Y	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET D1010Y in culture (PMID: 31279006).	31279006
MET	MET D1010Y	Advanced Solid Tumor	resistant	Tivantinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing MET D1010Y were resistant to Tivantinib (ARQ197) in culture (PMID: 31279006).	31279006
MET	MET D1010Y	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing MET D1010Y in culture (PMID: 31279006).	31279006
MET	MET D1010Y	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET D1010Y in culture (PMID: 31279006).	31279006
MET	MET D1010Y	Advanced Solid Tumor	sensitive	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of transformed cells expressing MET D1010Y in culture (PMID: 31279006).	31279006
MET	MET D1010Y	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET D1010Y in culture (PMID: 31279006).	31279006
MET	MET positive	clear cell sarcoma	predicted - sensitive	Crizotinib	Phase II	Actionable	In a Phase II trial (CREATE), Xalkori (crizotinib) treatment in MET-positive clear cell sarcoma patients resulted in an objective response rate of 3.8% (1/26) and a median progression-free survival of 131 days, similar to results achieved with first-line Adriamycin (doxorubicin) in non-selected metastatic soft tissue sarcomas (PMID: 28950372; NCT01524926).	28950372
MET	MET positive	glioblastoma multiforme	sensitive	Ningetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ningetinib inhibited Met phosphorylation in tumor tissue, resulted in prolonged median survival time and significantly increased life-span in cell line xenograft models of glioblastoma (Cancer Res 2014;74(19 Suppl):Abstract nr 1755).	detail...
MET	MET positive	ovarian cancer	predicted - sensitive	Altiratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited MET activation, decreased viability and migration of c-MET positive ovarian cancer cells in culture, and reduced tumor growth in ovarian cancer cell line xenograft models (PMID: 24362531).	24362531
MET	MET positive	Advanced Solid Tumor	sensitive	INCB028060	Phase I	Actionable	In a Phase I trial, INCB028060 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, as indicated by decreased whole blood Met phosphorylation level (J Clin Oncol 29: 2011 (suppl; abstr 3091)).	detail...
MET	MET positive	lung non-small cell carcinoma	conflicting	Erlotinib + Onartuzumab	Phase III	Actionable	In a Phase II clinical trial, Onartuzumab (RO5490258), in combination with Tarceva (erlotinib) demonstrated efficacy in patients with Met-positive NSCLC (PMID: 24101053). However, a subsequent Phase III clinical trial has been unable to confirm this efficacy (J Clin Oncol 32:5s, 2014 (suppl; abstr 8000)).	24101053 detail...
MET	MET positive	lung non-small cell carcinoma	sensitive	Telisotuzumab vedotin	Phase I	Actionable	In a Phase I clinical trial, ABBV-399 was well-tolerated and demonstrated preliminary efficacy in patients with MET-positive non-small cell lung cancer, with 30% (3/10) of patients demonstrating a partial response (J Clin Oncol 34, 2016 (suppl; abstr 2510)).	detail...
MET	MET positive	hepatocellular carcinoma	predicted - sensitive	Emibetuzumab + Ramucirumab	Phase Ib/II	Actionable	In a Phase Ib/II trial, Emibetuzumab (LY2875358) and Cyramza (ramucirumab) combination treatment resulted in an objective response rate of 6.7% (3/45) and a disease control rate of 60% (27/45) in patients with hepatocellular carcinoma, with a median progression-free survival (mPFS) of 5.4 months, patients with MET expression of 2+ or above in over 50% of tumor cells (n=19) demonstrated improved mPFS (8.1 vs 2.8 mo, HR=0.22) compared to patients below the cut-off (n=14) (PMID: 31142504; NCT02082210).	31142504
MET	MET positive	lung non-small cell carcinoma	sensitive	Capmatinib	Phase I	Actionable	In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 19% (5/26) of MET-positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).	detail...
MET	MET positive	myeloid neoplasm	predicted - sensitive	Amuvatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Amuvatinib (MP470) demonstrated efficacy in reducing Met phosphorylation and inducing apoptosis in cultured myeloma cells (PMID: 24326130).	24326130
MET	MET positive	multiple myeloma	predicted - sensitive	Ficlatuzumab	Phase I	Actionable	In a Phase I trial, Ficlatuzumab treatment resulted in stable disease in 57% (12/21) of patients with advanced solid tumors and a decrease in phosphorylated Met in one patient with multiple myeloma (PMID: 24901237).	24901237
MET	MET positive	triple-receptor negative breast cancer	sensitive	Cabozantinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Cometriq (cabozantinib) inhibited Met activity, cell growth, and invasive cellular characteristics in a human MET positive TNBC cell line in culture, and reduced tumor volume in xenograft models (PMID: 26432786).	26432786
MET	MET positive	glioblastoma multiforme	predicted - sensitive	Altiratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited viability of several MET-expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451).	26965451
MET	MET positive	Advanced Solid Tumor	sensitive	ARGX-111	Phase I	Actionable	In a Phase I trial, ARGX-111 demonstrated safety and resulted in some efficacy in patients with advanced solid tumors expressing MET, including a decrease in circulating tumor cells positive for MET (Journal of Clinical Oncology 33, no. 15_suppl, May 2015, 2580-2580).	detail...
MET	MET positive	glioblastoma multiforme	sensitive	Altiratinib + Bevacizumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Altiratinib (DCC-2701) and Avastin (bevacizumab) inhibited tumor growth and invasiveness, decreased blood vessel formation, and prolonged survival in cell line xenograft models of MET-expressing glioblastoma (PMID: 26965451).	26965451
MET	MET positive	cholangiocarcinoma	predicted - sensitive	Cabozantinib	Phase II	Emerging	In a Phase II trial, higher baseline soluble Met level correlated with longer overall survival in cholangiocarcinoma patients treated with Cometriq (cabozantinib) (PMID: 28192597).	28192597
MET	MET positive	Advanced Solid Tumor	predicted - sensitive	Merestinib	Preclinical - Pdx	Actionable	In a preclinical study, Merestinib (LY2801653) treatment resulted in growth inhibition correlating with Met expression level in a panel of patient-derived xenograft models of solid tumors (Cancer Res 2010;70(8 Suppl):Abstract nr 3611).	detail...
MET	MET positive	Advanced Solid Tumor	sensitive	Emibetuzumab	Phase I	Actionable	In a Phase I trial, Emibetuzumab (LY2875358) treatment resulted in durable partial response in 4% (1/23) of Met-positive patients with advanced solid tumors (J Clin Oncol 31, 2013 (suppl; abstr 8093)).	detail...
MET	MET positive	lung non-small cell carcinoma	sensitive	Emibetuzumab + Erlotinib	Phase I	Actionable	In a Phase I trial, Emibetuzumab (LY2875358) and Tarceva (erlotinib) combination treatment resulted in durable partial response in 15% (2/13) of Met-positive patients with non-small cell lung carcinoma (J Clin Oncol 31, 2013 (suppl; abstr 8093)).	detail...
MET	MET positive	lung non-small cell carcinoma	sensitive	Emibetuzumab + Erlotinib	Phase I	Actionable	In a Phase I trial, Emibetuzumab (LY2875358) and Tarceva (erlotinib) combination treatment resulted in durable partial response in 14.3% (2/14) of patients with non-small cell lung carcinoma, with both responders being Met positive (PMID: 27803065).	27803065
MET	MET positive	Advanced Solid Tumor	no benefit	AMG208	Phase I	Actionable	In a Phase I trial, Met expression and mutation status were not associated with response to AMG208 treatment in patients with advanced solid tumor (PMID: 26155941; NCT00813384).	26155941
MET	ERBB2 neg MET pos	gastric adenocarcinoma	no benefit	Rilotumumab	Phase III	Actionable	In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).	detail...
MET	ERBB2 neg MET pos	gastric adenocarcinoma	no benefit	Fluorouracil + Leucovorin + Onartuzumab + Oxaliplatin	Phase III	Actionable	In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).	27918764
MET	ERBB2 neg MET pos	esophagus adenocarcinoma	no benefit	Fluorouracil + Leucovorin + Onartuzumab + Oxaliplatin	Phase III	Actionable	In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).	27918764
MET	ERBB2 neg MET pos	gastric adenocarcinoma	no benefit	Onartuzumab	Phase III	Actionable	In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).	detail...
MET	ERBB2 neg MET pos	gastroesophageal junction adenocarcinoma	no benefit	Rilotumumab	Phase III	Actionable	In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).	detail...
MET	ERBB2 neg MET pos	gastroesophageal junction adenocarcinoma	no benefit	Onartuzumab	Phase III	Actionable	In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).	detail...
MET	FGFR1 amp MET pos	lung cancer	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1-amplified lung cancer cell lines with Met expression were resistant to Rogaratinib (BAY 1163877) in culture (PMID: 27429073).	27429073
MET	FGFR1 amp MET pos	lung cancer	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, FGFR1-amplified lung cancer cell lines with Met expression were resistant to AZD4547 in culture (PMID: 27429073).	27429073
MET	EGFR exon 19 del MET pos	lung non-small cell carcinoma	unknown	Erlotinib + Onartuzumab	Phase II	Actionable	In a Phase II trial, patients with MET-positive non-small lung cancer harboring either EGFR L858R or an EGFR exon 19 deletion demonstrated a median progression-free survival of 8.9 mo., median overall survival of 15.6 mo., and an overall response rate of 68.9% (all partial responses) following first-line therapy with Tarceva (erlotinib) and Onartuzumab; however, the trial was terminated early due to lack of efficacy with the therapy in another trial and thus, the results are not conclusive (PMID: 30472556).	30472556
MET	EGFR L858R MET pos	lung non-small cell carcinoma	unknown	Erlotinib + Onartuzumab	Phase II	Actionable	In a Phase II trial, patients with MET-positive non-small lung cancer harboring either EGFR L858R or an EGFR exon 19 deletion demonstrated a median progression-free survival of 8.9 mo., median overall survival of 15.6 mo., and an overall response rate of 68.9% (all partial responses) following first-line therapy with Tarceva (erlotinib) and Onartuzumab; however, the trial was terminated early due to lack of efficacy with the therapy in another trial and thus, the results are not conclusive (PMID: 30472556).	30472556
MET	MET exon 14	lung non-small cell carcinoma	unknown	Ipilimumab + Nivolumab	Clinical Study	Actionable	In a retrospective study, treatment with single agent PD-1/PD-L1 checkpoint inhibitors (Imfinzi (durvalumab), Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab), or combined Yervoy (ipilimumab) and Opdivo (nivolumab) resulted in a 17% (4/24) overall response rate, and a 1.9-month median progression-free survival in patients with lung cancer harboring alterations in MET exon 14, and responses were not associated with PD-L1 expression or tumor mutational burden (PMID: 30165371).	30165371
MET	MET exon 14	lung non-small cell carcinoma	sensitive	Crizotinib	Guideline	Actionable	Xalkori (crizotinib) is included in guidelines for non-small cell lung cancer patients with MET exon 14 mutations (NCCN.org).	detail...
MET	MET exon 14	lung non-small cell carcinoma	unknown	Pembrolizumab	Clinical Study	Actionable	In a retrospective study, treatment with single agent PD-1/PD-L1 checkpoint inhibitors (Imfinzi (durvalumab), Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab), or combined Yervoy (ipilimumab) and Opdivo (nivolumab) resulted in a 17% (4/24) overall response rate, and a 1.9-month median progression-free survival in patients with lung cancer harboring alterations in MET exon 14, and responses were not associated with PD-L1 expression or tumor mutational burden (PMID: 30165371).	30165371
MET	MET exon 14	lung non-small cell carcinoma	predicted - sensitive	Tepotinib	Phase II	Actionable	In a Phase II trial, Tepotinib (MSC2156119J) treatment resulted in partial response in 60.0% (9/15) and stable disease in 20% (3/15) of patients with non-small cell lung cancer harboring MET exon 14 skipping mutations (J Clin Oncol 36, 2018 (suppl; abstr 9016); NCT02864992).	detail...
MET	MET exon 14	lung non-small cell carcinoma	unknown	Durvalumab	Clinical Study	Actionable	In a retrospective study, treatment with single agent PD-1/PD-L1 checkpoint inhibitors (Imfinzi (durvalumab), Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab), or combined Yervoy (ipilimumab) and Opdivo (nivolumab) resulted in a 17% (4/24) overall response rate, and a 1.9-month median progression-free survival in patients with lung cancer harboring alterations in MET exon 14, and responses were not associated with PD-L1 expression or tumor mutational burden (PMID: 30165371).	30165371
MET	MET exon 14	lung non-small cell carcinoma	unknown	Atezolizumab	Clinical Study	Actionable	In a retrospective study, treatment with single agent PD-1/PD-L1 checkpoint inhibitors (Imfinzi (durvalumab), Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab), or combined Yervoy (ipilimumab) and Opdivo (nivolumab) resulted in a 17% (4/24) overall response rate, and a 1.9-month median progression-free survival in patients with lung cancer harboring alterations in MET exon 14, and responses were not associated with PD-L1 expression or tumor mutational burden (PMID: 30165371).	30165371
MET	MET exon 14	lung non-small cell carcinoma	sensitive	Capmatinib	Phase I	Actionable	In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 100% (2/2) of non-small cell lung carcinoma patients harboring MET exon 14 mutations (J Clin Oncol 34, 2016 (suppl; abstr 9067)).	detail...
MET	MET exon 14	lung non-small cell carcinoma	unknown	Nivolumab	Clinical Study	Actionable	In a retrospective study, treatment with single agent PD-1/PD-L1 checkpoint inhibitors (Imfinzi (durvalumab), Keytruda (pembrolizumab), Opdivo (nivolumab), or Tecentriq (atezolizumab), or combined Yervoy (ipilimumab) and Opdivo (nivolumab) resulted in a 17% (4/24) overall response rate, and a 1.9-month median progression-free survival in patients with lung cancer harboring alterations in MET exon 14, and responses were not associated with PD-L1 expression or tumor mutational burden (PMID: 30165371).	30165371
MET	MET D1228V	Advanced Solid Tumor	resistant	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing MET D1228V demonstrated resistance to treatment with Capmatinib (INC280) in culture, resulting in sustained Met phosphorylation (PMID: 27694386).	27694386
MET	MET D1228V	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing MET D1228V were sensitive to Cometriq (Cabometyx, cabozantinib) in culture, resulting in suppression of Met phosphorylation (PMID: 27694386).	27694386
MET	MET D1228V	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing MET D1228V were sensitive to Glesatinib (MGCD265) in culture, resulting in suppression of Met phosphorylation (PMID: 27694386).	27694386
MET	MET D1228V	Advanced Solid Tumor	resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing MET D1228V demonstrated resistance to treatment with Savolitinib (AZD6094) in culture, resulting in sustained Met phosphorylation (PMID: 27694386).	27694386
MET	MET D1228V	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing MET D1228V were sensitive to Merestinib (LY2801653) in culture, resulting in suppression of Met phosphorylation (PMID: 27694386).	27694386
MET	MET D1228V	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells expressing MET D1228V demonstrated resistance to treatment with Xalkori (crizotinib) in culture, resulting in sustained Met phosphorylation (PMID: 27694386).	27694386
MET	EGFR exon 19 del MET amp MET D1228V	lung adenocarcinoma	predicted - sensitive	Cabozantinib + Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion, MET amplification, and MET D1228V demonstrated a strong response to the combination of Tarceva (erlotinib) and Cometriq (Cabometyx, cabozantinib), resulting in reduced tumor size and continued clinical benefit 5 months after the start of therapy (PMID: 27694386).	27694386
MET	EGFR exon 19 del MET amp MET D1228V	lung adenocarcinoma	predicted - resistant	Osimertinib + Savolitinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated a near complete response when treated with the combination of Savolitinib (AZD6094) and Tagrisso (osimertinib) obtained through a Phase I trial, however, after 36 weeks presented with progression and MET D1228V was identified as an acquired mutation (PMID: 27694386; NCT02143466).	27694386
MET	MET L1213V	cancer	resistant	SU11274	Preclinical	Actionable	In a preclinical study, a cell line expressing MET L1213V showed resistance to SU11274 treatment (PMID: 15064724).	15064724
MET	EGFR mut MET mut	lung cancer	predicted - sensitive	ABX9xx	Preclinical - Cell culture	Actionable	In a preclinical study, ABX9xx inhibited Egfr and Met downstream signaling in several lung cancer cell lines harboring both EGFR and MET mutations in culture (AACR Annual Meeting 2019, Abstract 4830).	detail...
MET	MET Y1248H	cancer	resistant	SU11274	Preclinical	Actionable	In a preclinical study, a cell line expressing MET Y1248H showed resistance to SU11274 treatment (PMID: 15064724).	15064724
MET	MET R988C	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing MET R998C demonstrated sensitivity to Xalkori (crizotinib) in culture (PMID: 17483355).	17483355
MET	KIT S476I MET R988C	gastrointestinal stromal tumor	predicted - sensitive	Bevacizumab + Sorafenib	Case Reports/Case Series	Actionable	In a Phase I trial, a GIST patient harboring KIT S476I and MET R988C demonstrated sensitivity to the combination treatment, Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for 6 months (PMID: 25363205).	25363205
MET	ERBB2 over exp MET amp MET R988C	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study - Cohort	Actionable	n a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) gastric or gastroesophageal cancer patients identified MET R988C and amplification of MET in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).	29208673
MET	MET V1206L	cancer	sensitive	SU11274	Preclinical	Actionable	In a preclinical study, a cell line expressing MET V1206I demonstrated sensitivity to SU11274 treatment (PMID: 19783361).	19783361
MET	MET F1200I	papillary renal cell carcinoma	predicted - sensitive	Crizotinib	Phase II	Actionable	In a Phase II trial, a patient with papillary renal cell carcinoma harboring MET G1163T demonstrated a partial response with a duration of 37.3 months when treated with Xalkori (crizotinib) (PMID: 29149761; NCT01524926).	29149761
MET	MET D1228N	Advanced Solid Tumor	predicted - sensitive	Cabozantinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were sensitive to treatment with Cometriq (Cabometyx, cabozantinib), demonstrating inhibition of cell growth in culture and tumor growth inhibition in mouse models (PMID: 28396313).	28396313
MET	MET D1228N	Advanced Solid Tumor	predicted - sensitive	Altiratinib	Preclinical	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET D1228N in an in vitro kinase assay (PMID: 26285778).	26285778
MET	MET D1228N	Advanced Solid Tumor	predicted - resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were resistant to treatment with Savolitinib (AZD6094), demonstrating sustained cell growth in culture (PMID: 28396313).	28396313
MET	MET D1228N	Advanced Solid Tumor	predicted - sensitive	BMS-777607	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to D1228N in humans) were sensitive to treatment with BMS-777607 (ASLAN002), demonstrating inhibition of cell growth in culture (PMID: 28396313).	28396313
MET	MET D1228N	Advanced Solid Tumor	predicted - resistant	Crizotinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were resistant to treatment with Xalkori (crizotinib), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313).	28396313
MET	MET D1228N	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells over expressing MET D1228N in culture (PMID: 23275061).	23275061
MET	MET D1228N	Advanced Solid Tumor	predicted - resistant	Capmatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were resistant to treatment with Capmatinib (INC280), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313).	28396313
MET	EGFR L858R EGFR T790M MET amp MET D1228H D1228N D1231Y Y1230H	lung adenocarcinoma	predicted - resistant	Crizotinib + Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M and MET amplification demonstrated progressive disease after 3 months of treatment with the combination of Tagrisso (osimertinib) and Xalkori (crizotinib) and was found to have acquired 4 MET mutations: MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y (PMID: 29128427).	29128427
MET	EGFR L858R EGFR T790M MET amp MET D1228H D1228N D1231Y Y1230H	lung adenocarcinoma	unknown	Cabozantinib + Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M, MET amplification and MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y demonstrated initial symptomatic improvement, decreased pleural effusion, and lung nodule shrinkage following treatment with the combination of Cometriq (Cabometyx, cabozantinib) and Tagrisso (osimertinib) (PMID: 29128427).	29128427
MET	MET amp MET D1228N	triple-receptor negative breast cancer	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, MET D1228N was identified as an acquired mutation at disease progression in a patient with triple-receptor negative breast cancer harboring a 30-fold amplification of MET, after initial response to Xalkori (crizotinib) treatment (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1317).	detail...
MET	MET amp MET D1228N	triple-receptor negative breast cancer	predicted - sensitive	Cabozantinib	Case Reports/Case Series	Actionable	In a clinical case study, Cometriq (Cabometyx, cabozantinib) treatment resulted in stable diseases in a patient with triple-receptor negative breast cancer harboring a 30-fold amplification of MET whom developed resistance to Xalkori (crizotinib) after acquiring MET D1228N (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1317).	detail...
MET	MET act mut	Advanced Solid Tumor	sensitive	Emibetuzumab	Preclinical	Actionable	In a preclinical study, Emibetuzumab (LY2875358) treatment inhibited MET activation and proliferation of tumor cells with constitutive MET activation in culture, and inhibited tumor growth in xenograft models (PMID: 25231402).	25231402
MET	MET act mut	malignant glioma	sensitive	Merestinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Merestinib (LY2801653) demonstrated anti-tumor activity in cell line xenograft models of glioma with autocrine activation of Met signaling (PMID: 23275061).	23275061
MET	MET act mut	hepatocellular carcinoma	sensitive	Tepotinib	Preclinical	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited tumor growth in hepatocellular cancer (HCC) mouse xenograft models with MET overexpression or activation (Cancer Res April 15, 2013; 73(8 Supplement): 925)	detail...
MET	MET act mut	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical	Actionable	In a preclinical study, cells harboring MET activating mutations demonstrated sensitivity to treatment with Glesatinib (MGCD265) in cell-based assays (AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3609).	detail...
MET	MET act mut	papillary renal cell carcinoma	predicted - sensitive	Savolitinib	Phase II	Actionable	In a Phase II trial, treatment with Savolitinib (AZD6094) resulted in an overall response rate (ORR) of 18% (8/44, all partial responses) in the subgroup of patients with MET-driven papillary renal cell carcinoma (PRCC), which included patients with MET kinase domain mutations, compared to an ORR of 0% (0/46) in patients with MET-independent PRCC (PMID: 28644771; NCT02127710).	28644771
MET	MET act mut	stomach carcinoma	sensitive	S-49076	Preclinical - Cell line xenograft	Actionable	In a preclinical study, S-49076 inhibited Met activation, resulting in growth inhibition of gastric carcinoma cells harboring MET activating mutations in culture and in cell line xenograft models (PMID: 23804704).	23804704
MET	MET act mut	lung non-small cell carcinoma	predicted - sensitive	Crizotinib	Phase I	Actionable	In a Phase I clinical trial, Xalkori (crizotinib) was generally well-tolerated and demonstrated preliminary efficacy in patients with non-small cell lung cancer harboring MET exon 14 alterations, with anti-tumor activity demonstrated in 10/15 evaluable patients (J Clin Oncol 34, 2016 (suppl; abstr 108)).	detail...
MET	MET act mut	Advanced Solid Tumor	sensitive	Altiratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited MET activity, including MET activating mutations, and inhibited proliferation of MET-driven tumor cell lines in culture (PMID: 26285778).	26285778
MET	MET act mut	sarcoma	sensitive	BMS-777607	Preclinical	Actionable	In a preclinical study, BMS-777607 (ASLAN002) demonstrated efficacy in blocking Met phosphorylation and inhibiting cell proliferation and metastasis in cultured cells and murine models with activating Met mutations (PMID: 22286523).	22286523
MET	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - resistant	Afatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transposon insertions in MET, leading to increased phosphorylation of Met, were associated with resistance to Gilotrif (afatinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).	29875142
MET	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - sensitive	Afatinib + Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in MET, leading to increased Met phosphorylation, demonstrated sensitivity to the combination of Gilotrif (afatinib) and Xalkori (crizotinib) in culture, resulting in decreased Akt and Erk phosphorylation and reduced cell viability (PMID: 29875142).	29875142
MET	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - sensitive	Osimertinib + Saracatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, demonstrated sensitivity to the combination of Tagrisso (osimertinib) and Saracatinib (AZD0530) in culture, resulting in decreased Akt and Erk phosphorylation and reduced cell viability (PMID: 29875142).	29875142
MET	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transposon insertions in MET, leading to increased expression and phosphorylation of Met, were associated with resistance to Tarceva (erlotinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).	29875142
MET	EGFR exon 19 del MET act mut	lung adenocarcinoma	predicted - resistant	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, transposon insertions in MET, leading to increased phosphorylation of Met, were associated with resistance to Tagrisso (osimertinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).	29875142
MET	MET R1004G	oral squamous cell carcinoma	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, Xalkori (crizotinib) treatment resulted in rapid clinical response in a patient with oral cavity squamous cell carcinoma harboring MET R1004G (PMID: 31391294).	31391294
MET	MET M1250T	Advanced Solid Tumor	predicted - sensitive	Altiratinib	Preclinical	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET M1250T in an in vitro kinase assay (PMID: 26285778).	26285778
MET	MET Y1003F	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET Y1003F in culture (PMID: 31279006).	31279006
MET	MET Y1003F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing MET Y1003F in culture (PMID: 31279006).	31279006
MET	MET Y1003F	Advanced Solid Tumor	sensitive	Cabozantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET Y1003F in culture (PMID: 31279006).	31279006
MET	MET Y1003F	Advanced Solid Tumor	resistant	Tivantinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing MET Y1003F were resistant to Tivantinib (ARQ197) in culture (PMID: 31279006).	31279006
MET	MET Y1003F	Advanced Solid Tumor	sensitive	Tepotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of transformed cells expressing MET Y1003F in culture (PMID: 31279006).	31279006
MET	MET Y1003F	Advanced Solid Tumor	sensitive	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET Y1003F in culture (PMID: 31279006).	31279006
MET	MET Y1003F	Advanced Solid Tumor	sensitive	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET Y1003F in culture (PMID: 31279006).	31279006
MET	MET Y1003F	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET Y1003F in culture (PMID: 31279006).	31279006
MET	EGFR E746_S752delinsV MET-UBE2H	lung adenocarcinoma	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, Xalkori (crizotinib) treatment resulted in partial response and progression-free survival for more than 6.5 months in a patient with lung adenocarcinoma harboring EGFR E746_S752delinsV and MET-UBE2H fusion (PMID: 30244854).	30244854
MET	EGFR E746_S752delinsV MET-UBE2H	lung adenocarcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR E746_S752delinsV developed progressive disease after remained on Tarceva (erlotinib) treatment for 33 months, a MET-UBE2H fusion was identified by liquid biopsy at the time of pregression (PMID: 30244854).	30244854
MET	MET V1110I	cancer	sensitive	SU11274	Preclinical	Actionable	In a preclinical study, a cell line expressing MET V1110I demonstrated sensitivity to SU11274 treatment (PMID: 19783361).	19783361
MET	MET M1268T	cancer	sensitive	K252a	Preclinical	Actionable	In preclinical studies, cell lines transformed by MET M1268T were sensitive to K252a treatment in both culture and mouse model experiments (PMID: 12118367).	12118367
MET	MET M1268T	cancer	sensitive	SU11274	Preclinical	Actionable	In a preclinical study, a cell line expressing MET M1268T demonstrated sensitivity to SU11274 treatment (PMID: 15064724).	15064724
MET	MET H1112L	cancer	sensitive	SU11274	Preclinical	Actionable	In a preclinical study, a cell line expressing MET H1112L demonstrated sensitivity to SU11274 treatment (PMID: 19783361).	19783361
MET	MET V1238I	cancer	sensitive	SU11274	Preclinical	Actionable	In a preclinical study, a cell line expressing MET V1238I demonstrated sensitivity to SU11274 treatment (PMID: 19783361).	19783361
MET	MET Y1230D	Advanced Solid Tumor	predicted - sensitive	Altiratinib	Preclinical	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230D in an in vitro kinase assay (PMID: 26285778).	26285778
MET	MET D1228H	Advanced Solid Tumor	predicted - sensitive	Altiratinib	Preclinical	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET D1228H in an in vitro kinase assay (PMID: 26285778).	26285778
MET	MET D1228H	papillary renal cell carcinoma	predicted - sensitive	Crizotinib	Phase II	Actionable	In a Phase II trial, a patient with papillary renal cell carcinoma harboring MET D1228H demonstrated a partial response with a duration of 21.8 months when treated with Xalkori (crizotinib) (PMID: 29149761; NCT01524926).	29149761
MET	MET wild-type	Advanced Solid Tumor	decreased response	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in MET wild-type cell line xenograft models of various tumor types (PMID: 28765324).	28765324
MET	MET wild-type	colorectal cancer	decreased response	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in cell line xenograft models of MET wild-type colorectal cancer (PMID: 28765324).	28765324
MET	MET wild-type	prostate cancer	decreased response	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in cell line xenograft models of MET wild-type prostate caner (PMID: 28765324).	28765324
MET	MET wild-type	prostate cancer	sensitive	BMS-777607	Preclinical	Actionable	In a preclinical study, BMS-777607 (ASLAN002) demonstrated efficacy in inhibiting migration and invasion of cultured prostate cancer cells expressing wild-type Met (PMID: 20515943).	20515943
MET	MET wild-type	bladder carcinoma	decreased response	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in cell line xenograft models of MET wild-type urinary bladder carcinoma (PMID: 28765324).	28765324
MET	MET wild-type	breast cancer	decreased response	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glesatinib (MGCD265) treatment only resulted in partial growth inhibition in cell line xenograft models of MET wild-type breast cancer (PMID: 28765324).	28765324
MET	MET wild-type	pancreatic cancer	decreased response	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in cell line xenograft models of MET wild-type pancreatic cancer (PMID: 28765324).	28765324
MET	MET wild-type	cholangiocarcinoma	sensitive	Merestinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, LY2801653 inhibited phosphorylation of Met, resulting in inhibition of cholangiocarcinoma proliferation in cell culture and growth of tumors in Pdx models (PMID: 26757360).	26757360
MET	MET H1112Y	cancer	sensitive	SU11274	Preclinical	Actionable	In a preclinical study, a cell line expressing MET H1112Y demonstrated sensitivity to SU11274 treatment (PMID: 15064724).	15064724
MET	MET Y1230H	Advanced Solid Tumor	predicted - resistant	Crizotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were resistant to treatment with Xalkori (crizotinib), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in cell line xenograft mouse models (PMID: 28396313).	28396313
MET	MET Y1230H	Advanced Solid Tumor	predicted - resistant	Savolitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were resistant to treatment with Savolitinib (AZD6094), demonstrating sustained cell growth in culture (PMID: 28396313).	28396313
MET	MET Y1230H	Advanced Solid Tumor	predicted - sensitive	BMS-777607	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to Y1230H in humans) were sensitive to treatment with BMS-777607 (ASLAN002), demonstrating inhibition of cell growth in culture (PMID: 28396313).	28396313
MET	MET Y1230H	Advanced Solid Tumor	predicted - resistant	Capmatinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were resistant to treatment with Capmatinib (INC280), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313).	28396313
MET	MET Y1230H	Advanced Solid Tumor	predicted - sensitive	Altiratinib	Preclinical	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230H in an in vitro kinase assay (PMID: 26285778).	26285778
MET	MET Y1230H	Advanced Solid Tumor	predicted - sensitive	Cabozantinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were sensitive to treatment with Cometriq (Cabometyx, cabozantinib), demonstrating inhibition of cell growth in culture and tumor growth inhibition in mouse models (PMID: 28396313).	28396313
MET	MET over exp MET Y1230H	stomach cancer	resistant	PHA-665752	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MET Y1230H was associated with resistance to PHA-665752 in a gastric cancer cell line with MET over expression in culture (PMID: 21266357).	21266357
MET	MET over exp MET Y1230C MET Y1230H	stomach cancer	resistant	Crizotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, acquired MET Y1230C and MET Y1230H mutations were associated with secondary resistance to Xalkori (crizotinib) in a MET-over expressing gastric cancer cell line xenograft model, and cells derived from this model demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 21266357).	21266357
MET	MET F1200L MET Y1230H	stomach cancer	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) treated with Xalkori (crizotinib) in culture for several months developed resistance and was found to co-harbor MET Y1230H and MET F1200L(PMID: 28765324).	28765324 15494073
MET	MET F1200L MET Y1230H	stomach cancer	resistant	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) co-harboring MET Y1230H and MET F1200L demonstrated resistance when treated with Capmatinib (INC280) in culture (PMID: 28765324).	28765324 15494073
MET	MET F1200L MET Y1230H	stomach cancer	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) co-harboring MET Y1230H and MET F1200L was sensitive to treatment with Glesatinib (MGCD265), demonstrating cell growth inhibition in culture (PMID: 28765324).	28765324 15494073
MET	MET negative	triple-receptor negative breast cancer	no benefit	Cabozantinib	Preclinical	Actionable	In a preclinical study, Cometriq (cabozantinib) treatment had no effect on the cellular outgrowth or tumor volume of a TNBC cell line negative for MET expression in culture (PMID: 26432786).	26432786
MET	MET Y1230C	Advanced Solid Tumor	sensitive	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a transformed cell line expressing MET Y1230C was sensitive to Glesatinib (MGCD265), demonstrating inhibition of cell growth in culture and 88% tumor regression in xenograft models (PMID: 28765324).	28765324
MET	MET Y1230C	stomach cancer	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a Capmatinib (INC280)-resistant gastric cancer cell line (PMID: 15494073) harboring MET Y1230C also demonstrated resistance when treated with Xalkori (crizotinib) (PMID: 28765324).	15494073 28765324
MET	MET Y1230C	stomach cancer	resistant	Capmatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) treated with Capmatinib (INC280) in culture for several months developed resistance and was found to harbor MET Y1230C (PMID: 28765324).	15494073 28765324
MET	MET Y1230C	Advanced Solid Tumor	sensitive	Merestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells over expressing MET Y1230C in culture (PMID: 23275061).	23275061
MET	MET Y1230C	Advanced Solid Tumor	predicted - sensitive	Altiratinib	Preclinical	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230C in an in vitro kinase assay (PMID: 26285778).	26285778
MET	MET Y1230C	stomach cancer	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) harboring MET Y1230C was sensitive to treatment with Glesatinib (MGCD265), demonstrating cell growth inhibition in culture (PMID: 28765324).	28765324 15494073
MET	MET over exp MET Y1230C	stomach cancer	resistant	PHA-665752	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an acquired MET Y1230C mutation was associated with resistance to PHA-665752 in a MET-over expressing gastric cancer cell line xenograft model, and cells derived from this xenograft model demonstrated sustained MET activation following treatment with PHA-665752 in culture (PMID: 21266357).	21266357
MET	EGFR L858R EGFR T790M MET amp MET D1231Y	lung adenocarcinoma	predicted - resistant	Cabozantinib + Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R, EGFR T790M, MET amplification, MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y demonstrated initial symptomatic improvement and lung nodule shrinkage following treatment Cometriq (Cabometyx, cabozantinib) and Tagrisso (osimertinib) in combination, but progressed after 1 month and was found to have lost MET D1228H, MET D1228N, and MET Y1230H, and to have an increased allele fraction of MET D1231Y (PMID: 29128427).	29128427
MET	MET dec exp	triple-receptor negative breast cancer	sensitive	Veliparib	Preclinical - Cell culture	Actionable	In a preclinical study, triple-receptor negative breast cancer cell lines with decreased Met expression via shRNA knockdown demonstrated increased sensitivity to Veliparib (ABT-888) induced growth and colony formation inhibition in culture (PMID: 26779812).	26779812
MET	MET dec exp	triple-receptor negative breast cancer	sensitive	Olaparib	Preclinical	Actionable	In a preclinical study, triple-receptor negative breast cancer cell lines with decreased Met expression via shRNA knockdown demonstrated increased sensitivity to Lynparza (olaparib) induced growth and colony formation inhibition in culture (PMID: 26779812).	26779812
MET	MET dec exp	triple-receptor negative breast cancer	sensitive	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, triple-receptor negative breast cancer cell lines with decreased Met expression via shRNA knockdown demonstrated increased sensitivity to Rubraca (rucaparib) induced growth and colony formation inhibition in culture (PMID: 26779812).	26779812
MET	FGFR1 amp MET dec exp	lung cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited Erk signaling and proliferation of FGFR1-amplified lung cancer cell lines with undetectable Met expression in culture (PMID: 27429073).	27429073
MET	FGFR1 amp MET dec exp	lung cancer	sensitive	Rogaratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Rogaratinib (BAY 1163877) inhibited Erk signaling and proliferation of FGFR1-amplified lung cancer cell lines with undetectable Met expression in culture (PMID: 27429073).	27429073
MET	MET amp MET over exp	lung non-small cell carcinoma	sensitive	Altiratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited Met phosphorylation and proliferation of a non-small cell lung cancer cell line with MET amplification and overexpression in culture (PMID: 26285778).	26285778
MET	MET amp MET over exp	stomach cancer	sensitive	Altiratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Altiratinib (DCC-0701) inhibited Met phosphorylation and proliferation of a gastric cancer cell line with MET amplification and over expression in culture, and inhibited tumor growth and induced tumor regression in xenograft models (PMID: 26285778).	26285778
MET	MET amp MET over exp	lung adenocarcinoma	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, Xalkori (crizotinib) treatment resulted in gradual reduction of tumor size in a patient with lung adenocarcinoma harboring low-level MET amplification and high Met expression by IHC (3+), until disease progression at 20.7 months (PMID: 31200822).	31200822
MET	MET amp MET over exp	stomach carcinoma	sensitive	K252a	Preclinical	Actionable	In preclinical studies, a MET amplified, gastric carcinoma cell over expressing Met was sensitive to K252a treatment in both culture and mouse model experiments (PMID: 12118367).	12118367
MET	MET over exp	lung adenocarcinoma	predicted - sensitive	Telisotuzumab vedotin	Preclinical - Pdx	Actionable	In a preclinical study, ABBV-399 demonstrated efficacy in MET-expressing lung adenocarcinoma patient-derived xenograft (PDX) models, with the PDX model with higher MET expression levels showing improved tumor growth delay (PMID: 27573171).	27573171
MET	MET over exp	triple-receptor negative breast cancer	unknown	Buparlisib + Crizotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, triple-receptor negative breast cancer xenograft models overexpressing MET demonstrated stable disease when treated with the combination therapy, BKM120 and Xalkori (crizotinib) (PMID: 29203461).	29203461
MET	MET over exp	triple-receptor negative breast cancer	decreased response	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, triple-receptor negative breast cancer cell lines overexpressing Met demonstrated decreased sensitivity to Rubraca (rucaparib) induced growth and colony formation inhibition in culture (PMID: 26779812).	26779812
MET	MET over exp	lung adenocarcinoma	sensitive	Merestinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Merestinib (LY2801653) demonstrated anti-tumor activity in cell line xenograft models of lung adenocarcinoma with Met over expression (PMID: 23275061).	23275061
MET	MET over exp	breast cancer	sensitive	Crizotinib + Rucaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of a Met-over expressing human breast cancer cell line in culture, and reduced tumor growth in xenograft models (PMID: 26779812).	26779812
MET	MET over exp	glioblastoma multiforme	predicted - sensitive	Altiratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Altiratinib (DCC-2701) inhibited Met phosphorylation and viability of several Met over expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451).	26965451
MET	MET over exp	lung non-small cell carcinoma	sensitive	Erlotinib + Telisotuzumab vedotin	Phase I	Actionable	In a Phase I trial, the combination of Telisotuzumab vedotin (ABBV-399) and Tarceva (erlotinib) resulted in a partial response in 31% (4/13) of non-small cell lung carcinoma patients and disease control at 12 weeks in 61.5% (8/13) of patients (J Clin Oncol 35, 2017 (suppl; abstr 2509)).	detail...
MET	MET over exp	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, over expression of MET conferred resistance to Erbitux (cetuximab) in colorectal cancer cell lines in culture (PMID: 23729478).	23729478
MET	MET over exp	lung cancer	sensitive	SYM015	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, SYM015 treatment reduced Met expression and phosphorylation, resulted in growth inhibition in culture, and tumor elimination in both cell line xenograft and patient-derived xenograft (PDX) models of lung cancer with high Met expression (PMID: 28679766).	28679766
MET	MET over exp	stomach cancer	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of a human gastric cancer cell line with high levels of MET expression in culture (PMID: 26432108).	26432108
MET	MET over exp	triple-receptor negative breast cancer	sensitive	Crizotinib + Rucaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of Met-over expressing human triple-receptor negative breast cancer cell lines in culture, and reduced tumor growth in xenograft models (PMID: 26779812).	26779812
MET	MET over exp	stomach cancer	sensitive	KRC-00715	Preclinical	Actionable	In a preclinical study, KRC-00715 induced cell-cycle arrest and inhibited growth of Met-over expressing gastric cancer cell lines in culture and in xenograft models, and did not inhibit growth of cell lines with low Met expression (PMID: 26801760).	26801760
MET	MET over exp	triple-receptor negative breast cancer	sensitive	Foretinib + Veliparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Foretinib (GSK1363089) and Veliparib (ABT-888) worked synergistically to inhibit growth of Met-over expressing triple-receptor negative breast cancer cells in culture, and reduced tumor growth in xenograft models (PMID: 26779812).	26779812
MET	MET over exp	stomach cancer	sensitive	SYM015	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, SYM015 treatment reduced Met expression and phosphorylation, resulted in growth inhibition in culture, and tumor elimination in patient-derived xenograft (PDX) models of gastric cancer with high Met expression (PMID: 28679766).	28679766
MET	MET over exp	lung cancer	sensitive	Crizotinib + Rucaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of a Met-over expressing human lung cancer cell line in culture, and reduced tumor growth in xenograft models (PMID: 26779812).	26779812
MET	MET over exp	hepatocellular carcinoma	sensitive	Tepotinib	Preclinical - Pdx	Actionable	In a preclinical study, Tepotinib (MSC2156119J) treatment resulted in tumor regression in patient-derived xenograft models of hepatocellular cancer with high Met expression level (PMID: 25256830).	25256830
MET	MET over exp	lung non-small cell carcinoma	sensitive	Telisotuzumab vedotin	Preclinical - Cell culture	Actionable	In a preclinical study, Telisotuzumab vedotin (ABBV-399) inhibited growth of MET over expressing non-small cell lung cancer cell lines in culture (PMID: 27573171).	27573171
MET	MET over exp	lung non-small cell carcinoma	sensitive	Telisotuzumab vedotin	Phase I	Actionable	In a Phase I trial, Telisotuzumab vedotin (ABBV-399) was well-tolerated and resulted in a disease control rate of 56% (9/16) in patients with MET-overexpressing non-small cell lung cancer, with partial response in 19% (3/16) and stable disease in 38% (6/16), and resulted in reduction in target lesions in 44% (7/16) of patients (PMID: 30285518; NCT02099058).	detail... 30285518
MET	MET over exp	colorectal cancer	sensitive	JNJ 38877605 + Panitumumab	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of JNJ-38877605 to Vectibix (panitumumab) treatment overcame Vectibix (panitumumab) resistance in colorectal cancer cell lines over expressing MET in culture (PMID: 23729478).	23729478
MET	MET over exp	lung papillary adenocarcinoma	sensitive	Telisotuzumab vedotin	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with ABBV-399 resulted in complete response in a MET-over expressing papillary lung adenocarcinoma cell line xenograft model (PMID: 27573171).	27573171
MET	MET over exp	malignant mesothelioma	predicted - sensitive	AMG 337	Case Reports/Case Series	Actionable	In a Phase I trial, AMG 337 treatment resulted in a partial response in a patient with mesothelioma with MET overexpression by IHC (PMID: 30425090; NCT01253707).	30425090
MET	MET over exp	stomach cancer	sensitive	KRC-00509	Preclinical	Actionable	In a preclinical study, KRC-00509 induced cell-cycle arrest and inhibited growth of Met-over expressing gastric cancer cell lines in culture, and did not inhibit growth of cell lines with low Met expression (PMID: 26801760).	26801760
MET	MET over exp	colorectal cancer	resistant	Panitumumab	Preclinical - Cell culture	Actionable	In a preclinical study, over expression of MET conferred resistance to Vectibix (panitumumab) in colorectal cancer cell lines in culture (PMID: 23729478).	23729478
MET	MET over exp	lung small cell carcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines over-expressing MET (PMID: 25122427).	25122427
MET	MET over exp	cholangiocarcinoma	predicted - sensitive	Cabozantinib	Phase II	Actionable	In a Phase II trial, a cholangiocarcinoma patient with high Met expression in tumor stayed on Cometriq (cabozantinib) treatment for 278 days (PMID: 28192597).	28192597
MET	MET over exp	stomach carcinoma	sensitive	EMD 1214063	Preclinical - Cell culture	Actionable	In a preclinical study, EMD 1214063 inhibited Met phosphorylation and cell viability of Met over-expressing gasric carcinoma cell lines in culture, regardless of their TP53 status (PMID: 26358474).	26358474
MET	MET over exp	stomach cancer	sensitive	Merestinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, LY2801653 blocked tumor growth in a gastric cancer cell line xenograft model over expressing Met (PMID: 23275061).	23275061
MET	MET over exp	lung non-small cell carcinoma	sensitive	SCC244	Preclinical - Pdx	Actionable	In a preclinical study, non-small cell lung carcinoma patient-derived xenograft (PDX) models harboring MET overexpression were sensitive to SCC244, demonstrating inhibition of tumor growth and nine partial responses (PMID: 29237805).	29237805
MET	MET over exp	triple-receptor negative breast cancer	sensitive	Foretinib + Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Foretinib (GSK1363089) and Rubraca (rucaparib) combination treatment resulted in enhanced growth inhibition in Met-over expressing triple-receptor negative breast cancer cells in culture (PMID: 26779812).	26779812
MET	MET over exp	hepatocellular carcinoma	no benefit	Tivantinib	Phase III	Actionable	In a Phase III trial, second-line treatment with Tivantinib (ARQ197) did not result in improved overall survival over placebo in hepatocellular carcinoma patients with high MET expression (PMID: 29625879; NCT01755767).	29625879
MET	MET over exp	lung squamous cell carcinoma	sensitive	EMD 1214063	Preclinical - Cell culture	Actionable	In a preclinical study, EMD 1214063 inhibited Met phosphorylation and cell viability of Met over-expressing lung squamous cell carcinoma cells in culture (PMID: 26358474).	26358474
MET	MET over exp	colorectal cancer	sensitive	Cetuximab + JNJ 38877605	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of JNJ-38877605 to Erbitux (cetuximab) treatment overcame Erbitux (cetuximab) resistance in colorectal cancer cell lines over expressing MET in culture (PMID: 23729478).	23729478
MET	MET over exp	hepatocellular carcinoma	sensitive	SCC244	Preclinical - Pdx	Actionable	In a preclinical study, hepatocellular carcinoma patient-derived xenograft (PDX) models overexpressing MET were sensitive to SCC244, demonstrating a complete response in one and partial response in eleven (PMID: 29237805).	29237805
MET	MET over exp	melanoma	sensitive	XL147	Preclinical	Actionable	In a preclinical study, XL147 inhibited migration and growth of mouse melanoma cells with MET over expression in culture (PMID: 25637314).	25637314
MET	EGFR wild-type MET over exp	lung non-small cell carcinoma	sensitive	Capmatinib	Phase I	Actionable	In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 29% (5/17) of EGFR wild-type, MET over-expressing non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).	detail...
MET	MET over exp TP53 dec exp	stomach carcinoma	sensitive	EMD 1214063 + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, shRNA knock-down of Tp53 in Met over-expressing gastric carcinoma cells enhanced sensitivity to the combination of EMD 1214063 and radiation in culture (PMID: 26358474).	26358474
MET	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Mekinist (trametinib) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).	28783719
MET	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	Capmatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Capmatinib (INC280) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).	28783719
MET	BRAF D594N BRAF G466A EGFR over exp MET over exp	collecting duct carcinoma	sensitive	Capmatinib + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Capmatinib (INC280) induced tumor regression in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).	28783719
MET	FGFR1 amp MET over exp	lung small cell carcinoma	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression and activation of Met was identified in a small cell lung cancer cell line harboring FGFR1 amplification that acquired resistance to BGJ398 in culture (PMID: 28630215).	28630215
MET	FGFR1 amp MET over exp	lung cancer	sensitive	Crizotinib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Rogaratinib (BAY 1163877) and Xalkori (crizotinib) synergistically inhibited proliferation of FGFR1 amplified lung cancer cells that acquired resistance to Rogaratinib (BAY 1163877) through MET overexpression and activation in culture (PMID: 27429073).	27429073
MET	FGFR1 amp MET over exp	lung small cell carcinoma	sensitive	BGJ398 + EMD 1214063	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and EMD 1214063 synergistically inhibited growth of small cell lung carcinoma cells harboring FGFR1 amplification and Met overexpression in culture (PMID: 28630215).	28630215
MET	FGFR1 amp MET over exp	lung small cell carcinoma	sensitive	BGJ398 + Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Xalkori (crizotinib) synergistically inhibited Erk signaling, resulted in growth inhibition in small cell lung carcinoma cells harboring FGFR1 amplification and Met overexpression in culture (PMID: 28630215).	28630215
MET	FGFR1 amp MET over exp	lung cancer	resistant	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, MET overexpression and activation was identified as the mechanism mediating acquired Rogaratinib (BAY 1163877) resistance in a FGFR1 amplified lung cancer cell line in culture (PMID: 27429073).	27429073
MET	BRAF V600E MET over exp	colorectal cancer	resistant	Panitumumab + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpressing Met in colorectal cancer cells harboring BRAF V600E conferred resistance to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27325282).	27325282
MET	BRAF V600E MET over exp	colorectal cancer	predicted - sensitive	Crizotinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) and Zelboraf (vemurafenib) combination treatment inhibited growth of colorectal cancer cells harboring BRAF V600E and overexpressing Met in culture (PMID: 27325282).	27325282
MET	MET M1149T	papillary renal cell carcinoma	predicted - sensitive	Crizotinib	Phase II	Actionable	In a Phase II trial, a patient with papillary renal cell carcinoma harboring MET M1149T demonstrated stable disease when treated with Xalkori (crizotinib) (PMID: 29149761; NCT01524926).	29149761
MET	MET T1010I	lung carcinoma	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, lung carcinoma cell lines harboring MET T1010I showed sensitivity to Xalkori (crizotinib) in cell culture (PMID: 17483355).	17483355
MET	MET amp	lung non-small cell carcinoma	sensitive	EMD 1214063	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of non-small cell lung carcinoma harboring MET amplification (PMID: 23553846).	23553846
MET	MET amp	esophagus adenocarcinoma	predicted - sensitive	AMG 337	Case Reports/Case Series	Actionable	In a Phase I trial, AMG 337 treatment resulted in a complete response in a patient with MET amplified esophagus adenocarcinoma at week 33 (PMID: 30425090; NCT01253707).	30425090
MET	MET amp	esophagus adenocarcinoma	predicted - sensitive	AMG 337	Case Reports/Case Series	Actionable	In a clinical case study, a patient with MET amplified esophageal adenocarcinoma had a partial response to AMG 337 therapy after 2 months of treatment (PMID: 26432108).	26432108
MET	MET amp	lung non-small cell carcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung cancer harboring EGFR amplification and EGFR T790M progressed after Tagrisso (osimertinib) treatment, and was found to have lost the EGFR mutations and acquired a MET amplification (PMID: 30268451).	30268451
MET	MET amp	lung non-small cell carcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, two patients with non-small cell lung cancer harboring EGFR T790M progressed after Tagrisso (osimertinib) treatment, and were found to have lost EGFR T790M and acquired a MET amplification (PMID: 30268451).	30268451
MET	MET amp	stomach cancer	sensitive	KTN0073-IgG2	Preclinical - Cell line xenograft	Actionable	In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited growth of a MET-amplified gastric cancer cell line in culture and in xenograft models (PMID: 27550450).	27550450
MET	MET amp	colorectal cancer	sensitive	JNJ 38877605	Preclinical - Pdx	Actionable	In a preclinical study, JNJ-38877605 inhibited tumor growth in colorectal cancer patient-derived xenograft models with MET amplification (PMID: 23729478).	23729478
MET	MET amp	Advanced Solid Tumor	predicted - sensitive	Capmatinib	Phase I	Actionable	In a Phase I trial, INC280 displayed safety and preliminary efficacy in patients with MET dependent solid tumors (J Clin Oncol 32:5s, 2014 (suppl; abstr 2520)).	detail...
MET	MET amp	hepatocellular carcinoma	sensitive	AMG 337	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, AMG 337 inhibited Met phosphorylation and growth of hepatocellular carcinoma (HCC) cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified HCC patient-derived xenograft models (PMID: 27196749).	27196749
MET	MET amp	stomach cancer	sensitive	SGX523	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SGX523 inhibited Met signaling and proliferation of MET amplified gastric cancer cells in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 19934279).	19934279
MET	MET amp	stomach cancer	sensitive	AMG 337	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 337 inhibited growth of gastric cancer cell lines in culture, and inhibited growth and induced regression of tumors in MET-amplified gastric cancer cell line xenograft models (PMID: 27196782).	27196782
MET	MET amp	stomach carcinoma	sensitive	EMD 1214063	Preclinical - Cell line xenograft	Actionable	In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of gastric carcinoma harboring MET amplification (PMID: 23553846).	23553846
MET	MET amp	Advanced Solid Tumor	predicted - sensitive	SAR125844	Phase I	Actionable	In a Phase I trial, SAR125844 treatment in advanced solid tumor patients harboring a MET amplification was well-tolerated and resulted in a partial response in 17% (5/29) of patients, including patients with non-small cell lung carcinoma, and stable disease in 59% (17/29) of patients (PMID: 29145039; NCT01391533).	detail... 29145039
MET	MET amp	lung non-small cell carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with MET amplification (PMID: 24939055).	24939055
MET	MET amp	lung non-small cell carcinoma	sensitive	Capmatinib	Phase I	Actionable	In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 63% (5/8) of MET amplified non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).	detail...
MET	MET amp	stomach cancer	no benefit	Debio 1347	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of MET amplified gastric cancer (PMID: 26438159).	26438159
MET	MET amp	lung non-small cell carcinoma	sensitive	KTN0073-IgG2	Preclinical - Cell culture	Actionable	In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited proliferation of a MET-amplified non-small cell lung cancer cell line in culture (PMID: 27550450).	27550450
MET	MET amp	papillary renal cell carcinoma	sensitive	Savolitinib	Preclinical - Pdx	Actionable	In a preclinical study, Savolitinib (AZD6094) demonstrated antitumor activity in patient-derived papillary renal cell carcinoma xenograft models harboring MET amplification (PMID: 25779944).	25779944
MET	MET amp	papillary renal cell carcinoma	sensitive	Savolitinib	Case Reports/Case Series	Actionable	In a Phase I trial, treatment with Savolitinib (AZD6094) was well-tolerated and resulted in partial response in 8% (3/39) of patients with advanced solid tumors, with all 3 responses in patients with papillary renal cell carcinoma, 1 with MET amplification and 2 with chromosome 7 gain (PMID: 30952639; NCT01773018).	30952639
MET	MET amp	papillary renal cell carcinoma	sensitive	Savolitinib	Phase II	Actionable	In a Phase II trial, treatment with Savolitinib (AZD6094) resulted in an overall response rate (ORR) of 18% (8/44, all partial responses) in the subgroup of patients with MET-driven papillary renal cell carcinoma (PRCC), which included patients with MET amplification, compared to an ORR of 0% (0/46) in patients with MET-independent PRCC (PMID: 28644771; NCT02127710).	28644771
MET	MET amp	lung non-small cell carcinoma	sensitive	MTI-31	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MTI-31 inhibited proliferation a non-small cell lung cancer cell line with MET amplification in culture, and inhibited tumor growth in xenograft models (PMID: 30796032).	30796032
MET	MET amp	stomach cancer	predicted - sensitive	TPX-0022	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TPX-0022 inhibits phosphorylation of Met and downstream signaling, resulted in growth inhibition of MET amplified gastric cancer cell lines in culture and in cell line xenograft models (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1321).	detail...
MET	MET amp	lung cancer	sensitive	Glesatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth of MET-amplified lung cancer cells in culture (PMID: 28765324).	28765324
MET	MET amp	lung non-small cell carcinoma	predicted - sensitive	PP-121	Preclinical - Cell culture	Actionable	In a preclinical study, the multitarget kinase inhibitor PP-121 inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207).	26483207
MET	MET amp	triple-receptor negative breast cancer	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, Xalkori (crizotinib) treatment resulted in a completed response that sustained for 22 weeks in a patient with triple-receptor negative breast cancer harboring a 30-fold amplification of MET, with MET overexpression and hyperactivity confirmed by IHC (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1317).	detail...
MET	MET amp	stomach cancer	sensitive	Glesatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glesatinib (MGCD265) treatment resulted in tumor regression in MET-amplified gastric cancer cell line xenograft models (PMID: 28765324).	28765324
MET	MET amp	lung non-small cell carcinoma	predicted - sensitive	Ganetespib	Preclinical - Cell culture	Actionable	In a preclinical study, disruption of multiple kinases with Hsp90 inhibitor Ganetespib inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207).	26483207
MET	MET amp	Advanced Solid Tumor	sensitive	Emibetuzumab	Preclinical	Actionable	In a preclinical study, Emibetuzumab (LY2875358) treatment inhibited MET activation and proliferation of tumor cells with MET amplification in culture, and inhibited growth in MET-amplified tumor xenograft models (PMID: 25231402).	25231402
MET	MET amp	Advanced Solid Tumor	decreased response	EMD 1204831	Clinical Study - Cohort	Actionable	In a retrospective study, treatment with Met inhibitors, including AMG 337 or EMD 1204831, resulted in stable disease in 29% (2/7) of advanced solid tumor patients harboring MET amplification while 10% (14/134) of MET non-amplified patients achieved partial response (PMID: 25326232).	25326232
MET	MET amp	colorectal cancer	resistant	Cetuximab	Case Reports/Case Series	Actionable	In a clinical case study, MET amplification was associated with resistance to Erbitux (cetuximab) in 2 colorectal cancer patients, and in patient-derived xenograft (PDX) models (PMID: 23729478).	23729478
MET	MET amp	lung non-small cell carcinoma	sensitive	SGX523	Preclinical - Cell culture	Actionable	In a preclinical study, SGX523 inhibited survival of MET-amplified non-small cell lung cancer cells in culture (PMID: 26483207).	26483207
MET	MET amp	lung squamous cell carcinoma	sensitive	SCC244	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SCC244 inhibited Met activity, downstream signaling, and cell proliferation in lung squamous cell carcinoma cells harboring MET amplification in culture, and inhibited tumor growth in cell line xenograft models (PMID: 29237805).	29237805
MET	MET amp	Advanced Solid Tumor	sensitive	ABT-700	Phase I	Actionable	In a Phase I trial, ABT-700 demonstrated safety and preliminary efficacy in patients with MET-amplified advanced solid tumors, including a patient with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 2507)).	detail...
MET	MET amp	stomach cancer	sensitive	SAR125844	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR125844 inhibited Met signaling leading to growth inhibition of MET amplified gastric cancer cell lines in culture and in xenograft models (PMID: 25504634).	25504634
MET	MET amp	stomach cancer	sensitive	Golvatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of gastric cancer cell lines in culture and in cell line xenograft models (PMID: 19832844).	19832844
MET	MET amp	stomach cancer	sensitive	TAS-115	Preclinical	Actionable	In a preclinical study, MET amplified gastric cancer cell lines were sensitive to TAS-115, resulting in suppression of cell proliferation in culture (PMID: 24140932).	24140932
MET	MET amp	lung non-small cell carcinoma	predicted - sensitive	Merestinib	Preclinical - Pdx	Actionable	In a preclinical study, Merestinib (LY2801653) treatment resulted in growth inhibition in patient-derived xenograft (PDX) models of MET-amplified non-small cell lung carcinoma that were resistant to Egfr inhibitors (Cancer Res 2010;70(8 Suppl):Abstract nr 3611).	detail...
MET	MET amp	lung non-small cell carcinoma	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring MET amplification in culture (PMID: 26090892).	26090892
MET	MET amp	lung squamous cell carcinoma	predicted - sensitive	OMO-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, OMO-1 induced tumor regression in a cell line xenograft model of MET-amplified squamous non-small cell lung cancer (Cancer Res 2018;78(13 Suppl):Abstract nr 4791).	detail...
MET	MET amp	stomach cancer	predicted - sensitive	OMO-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, OMO-1 inhibited tumor growth in a cell line xenograft model of MET-amplified gastric cancer (Cancer Res 2018;78(13 Suppl):Abstract nr 4791).	detail...
MET	MET amp	Advanced Solid Tumor	sensitive	Tepotinib	Phase I	Actionable	In a Phase I study, Tepotinib (MSC2156119J) demonstrated safety and preliminary efficacy in advanced solid tumor patients with MET amplification (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2591).	detail...
MET	MET amp	lung non-small cell carcinoma	predicted - sensitive	Alvespimycin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, disruption of multiple kinases with Hsp90 inhibitor Alvespimycin inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture and in cell line xenograft models (PMID: 26483207).	26483207
MET	MET amp	lung cancer	sensitive	SAR125844	Preclinical - Cell culture	Actionable	In a preclinical study, SAR125844 inhibited Met signaling, leading to growth inhibition of MET amplified lung cancer cells in culture (PMID: 25504634).	25504634
MET	MET amp	lung non-small cell carcinoma	sensitive	Crizotinib	Preclinical - Pdx	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited tumor grow in patient-derived xenograft models of MET amplified non-small cell lung cancer (PMID: 26483207).	26483207
MET	MET amp	lung non-small cell carcinoma	sensitive	Crizotinib	Guideline	Actionable	Xalkori (crizotinib) is included in guidelines for non-small cell lung cancer patients with high level MET amplification (NCCN.org).	detail...
MET	MET amp	lung non-small cell carcinoma	sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung cancer patient with MET amplification demonstrated a partial response to first-line treatment with Xalkori (crizotinib) with improvement in performance status (PMID: 31156053).	31156053
MET	MET amp	lung non-small cell carcinoma	predicted - sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the multitarget kinase inhibitor Sprycel (dasatinib) inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207).	26483207
MET	MET amp	stomach cancer	sensitive	ARGX-111	Phase I	Actionable	In a Phase I trial, a gastric cancer patient harboring MET amplification was sensitive to treatment with ARGX-111, demonstrating stable disease, a metabolic response, and a decrease in circulating tumor cells (Journal of Clinical Oncology 33, no. 15_suppl (May 2015) 2580-2580).	detail...
MET	MET amp	gastroesophageal adenocarcinoma	predicted - sensitive	AMG 337	Phase II	Actionable	In a Phase II trial, AMG 337 treatment resulted in an objective response rate of 18% (8/45, 8 partial responses) and stable disease in 36% (16/45) of patients with MET-amplified gastroesophageal adenocarcinoma (PMID: 30366938; NCT02016534).	30366938
MET	MET amp	lung non-small cell carcinoma	sensitive	BEZ235 + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically inhibited proliferation of an Iressa (gefitinib)-resistant NSCLC cell line harboring MET amplification in culture and in cell line xenograft models (PMID: 24939055).	24939055
MET	MET amp	lung cancer	sensitive	AMG 337	Preclinical - Cell culture	Actionable	In a preclinical study, AMG 337 inhibited growth of MET-amplified lung cancer cell lines in culture (PMID: 27196782).	27196782
MET	MET amp	hepatocellular carcinoma	predicted - sensitive	TPX-0022	Preclinical - Pdx	Actionable	In a preclinical study, TPX-0022 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of hepatocellular carcinoma harboring MET amplification (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1321).	detail...
MET	MET amp	stomach cancer	sensitive	TAE226	Preclinical	Actionable	In a preclinical study, TAE226 treatment inhibited proliferation of gastric cancer cell lines harboring MET amplification in culture (PMID: 26090892).	26090892
MET	MET amp	stomach cancer	sensitive	M-COPA	Preclinical - Cell line xenograft	Actionable	In a preclinical study, M-COPA reduced Met cell surface expression and downstream signaling and decreased growth of MET-amplified gastric cancer cell lines in culture, and demonstrated antitumor activity in MET-amplified gastric cancer cell line xenograft models (PMID: 27197184).	27197184
MET	MET amp	lung non-small cell carcinoma	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with MET amplification (PMID: 24939055).	24939055
MET	MET amp	gastroesophageal cancer	predicted - sensitive	AMG 337	Phase I	Actionable	In a Phase I trial, AMG 337 treatment resulted in complete response in 10% (1/10), partial response in 40% (4/10), and stable disease in 20% (2/10) of patients with MET amplified gastroesophageal cancer (J Clin Oncol 33, no. 3_suppl (January 20 2015) 1-1; NCT01253707).	detail...
MET	MET amp	Advanced Solid Tumor	sensitive	SYM015	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Sym015 inhibited growth of cancer cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified patient-derived xenograft (PDX) models (Cancer Res July 15 2016 (76) (14 Supplement) 1219).	detail...
MET	MET amp	lung non-small cell carcinoma	predicted - sensitive	AMG 337	Case Reports/Case Series	Actionable	In a Phase I trial, AMG 337 treatment resulted in a partial response in a patient with MET amplified non-small cell lung cancer (PMID: 30425090; NCT01253707).	30425090
MET	MET amp	lung non-small cell carcinoma	predicted - sensitive	AMG 337	Case Reports/Case Series	Actionable	In a Phase II trial, AMG 337 treatment resulted in no objective response (0/3) and only stable disease in 33% (1/3) of patients with MET-amplified non-small cell lung cancer (PMID: 30366938; NCT02016534).	30366938
MET	MET amp	liver cancer	sensitive	Crizotinib	Preclinical - Pdx	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited tumor grow in patient-derived xenograft models of MET amplified liver cancer (PMID: 26483207).	26483207
MET	MET amp	lung cancer	sensitive	Golvatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of lung cancer cells in culture and tumor regression in cell line xenograft models (PMID: 19832844).	19832844
MET	MET amp	stomach cancer	sensitive	Telisotuzumab vedotin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABBV-399 inhibited growth of MET-amplified gastric cancer cell in culture, and induced tumor regression in a MET-amplified gastric cancer cell line xenograft model (PMID: 27573171).	27573171
MET	MET amp	stomach cancer	sensitive	SCC244	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SCC244 inhibited Met activity, downstream signaling, and cell proliferation in gastric cancer cells harboring MET amplification in culture, and inhibited tumor growth in cell line xenograft models (PMID: 29237805).	29237805
MET	MET amp	Advanced Solid Tumor	conflicting	AMG 337	Clinical Study - Cohort	Actionable	In a retrospective study, treatment with Met inhibitors, including AMG 337 or EMD 1204831, resulted in stable disease in 29% (2/7) of advanced solid tumor patients harboring MET amplification while 10% (14/134) of MET non-amplified patients achieved partial response (PMID: 25326232).	25326232
MET	MET amp	Advanced Solid Tumor	conflicting	AMG 337	Phase I	Actionable	In a Phase I trial, AMG 337 treatment resulted in an objective response rate (ORR) of 29.6% (8/27) and a median duration of response (mDOR) of 197 days in patients with MET amplified advanced solid tumors, compared to an ORR of 9.9% (11/111) and mDOR of 202 days in all patients (PMID: 30425090; NCT01253707).	30425090
MET	MET amp	Advanced Solid Tumor	not applicable	N/A	Clinical Study	Emerging	In a retrospective study, advanced solid tumor patients harboring MET amplification demonstrated worse overall survival (7.23 months) comparing to patients without MET amplification (8.62 months) (PMID: 25326232), suggesting that this may serve as a future prognostic biomarker.	25326232
MET	MET amp	lung non-small cell carcinoma	sensitive	SCC244	Preclinical - Pdx	Actionable	In a preclinical study, non-small cell lung carcinoma patient-derived xenograft models harboring MET amplification were sensitive to SCC244, demonstrating inhibition of tumor growth and stable disease (PMID: 29237805).	29237805
MET	ERBB2 amp MET amp	esophageal carcinoma	sensitive	Crizotinib + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was sensitive to inhibition by Tykerb (lapatinib) and Xalkori (crizotinib) in culture (PMID: 26432108).	26432108
MET	ERBB2 amp MET amp	esophageal carcinoma	resistant	Lapatinib	Preclinical	Actionable	In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Tykerb (lapatinib) in culture (PMID: 26432108).	26432108
MET	ERBB2 amp MET amp	gastric adenocarcinoma	predicted - resistant	AMG 337	Case Reports/Case Series	Actionable	In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma did not respond to AMG 337 therapy (PMID: 26432108).	26432108
MET	ERBB2 amp MET amp	gastroesophageal junction adenocarcinoma	sensitive	Crizotinib + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) inhibited the growth of gastroesophageal adenocarcinoma cells with ERBB2 (HER2) and MET amplification in culture (PMID: 25350844).	25350844
MET	ERBB2 amp MET amp	gastric adenocarcinoma	predicted - resistant	Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma was insensitive to Herceptin (trastuzumab) and FOLFOX combination treatment (PMID: 26432108).	26432108
MET	ERBB2 amp MET amp	esophagus adenocarcinoma	sensitive	Crizotinib + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and MET amplification in culture (PMID: 27595477).	27595477
MET	ERBB2 amp MET amp	gastric adenocarcinoma	predicted - resistant	Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with ERBB2 (HER2) amplified gastric adenocarcinoma progressed rapidly when treated with Herceptin (trastuzumab) with Xeloda (capecitabine), Eloxatin (oxaliplatin), and Avastin (bevacizumab), and reprofiling of the tumor revealed co-amplification of MET (PMID: 26432108).	26432108
MET	ERBB2 amp MET amp	esophageal carcinoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was resistant to Xalkori (crizotinib) in culture (PMID: 26432108).	26432108
MET	ERBB2 amp MET amp	gastric adenocarcinoma	predicted - sensitive	Crizotinib + Paclitaxel + Trastuzumab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma had near complete regression of the disease after 2 months of treatment with Herceptin (trastuzumab), Xalkori (crizotinib) and weekly Taxol (paclitaxel) (PMID: 26432108).	26432108
MET	EGFR amp MET amp	lung non-small cell carcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, two patients with non-small cell lung cancer harboring EGFR amplification and EGFR T790M progressed after Tagrisso (osimertinib) treatment, and were found to have lost the EGFR T790M and acquired MET amplification (PMID: 30268451).	30268451
MET	EGFR amp MET amp	esophagus adenocarcinoma	sensitive	Crizotinib + Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with EGFR and MET copy number gain in culture (PMID: 27595477).	27595477
MET	EGFR amp MET amp	lung non-small cell carcinoma	predicted - resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung cancer harboring EGFR amplification progressed after Tarceva (erlotinib) treatment, and was found to have acquired a MET amplification (PMID: 30268451).	30268451
MET	EGFR amp MET amp	lung non-small cell carcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung cancer harboring EGFR amplification progressed after Iressa (gefitinib) treatment, and was found to have acquired MET amplification (PMID: 30268451).	30268451
MET	EGFR exon 19 del EGFR T790M MET amp	lung adenocarcinoma	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M and resistance to Tagrisso (osimertinib) following acquired MET amplification, demonstrated some improvement in symptoms with Xalkori (crizotinib) treatment (PMID: 27393507).	27393507
MET	EGFR exon 19 del EGFR T790M MET amp	lung adenocarcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M developed resistance to Tagrisso (osimertinib), and was found to have acquired high level amplification of MET (PMID: 27393507).	27393507
MET	EGFR exon 19 del MET amp	lung non-small cell carcinoma	predicted - sensitive	Crizotinib	Clinical Study - Cohort	Actionable	In a clinical study, Xalkori (crizotinib) alone (n=8) or in combination with EGFR TKIs (n=6) resulted in an objective response rate (ORR) of 50% (7/14, 7 partial response) and a disease control rate (DCR) of 85.7% (12/14) in patients with EGFR-mutant (L858R n=12, exon 19 deletion n=2) non-small cell lung cancer who acquired resistance to EGFR TKI through MET amplification, ORR and DCR were not significantly different between patients treated with or without EGFR TKI (PMID: 30791921).	30791921
MET	EGFR exon 19 del MET amp	lung adenocarcinoma	predicted - sensitive	Osimertinib + Savolitinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated a near complete response when treated with the combination of Savolitinib (AZD6094) and Tagrisso (osimertinib) obtained through a Phase I trial, however, after 36 weeks presented with progression (PMID: 27694386; NCT02143466).	27694386
MET	EGFR exon 19 del MET amp	lung adenocarcinoma	predicted - sensitive	Bevacizumab + Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with Iressa (gefitinib)-resistant lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated improvement in symptoms and decrease in tumor size following treatment with Tarceva (erlotinib) and Avastin (bevacizumab) (PMID: 30792648).	30792648
MET	EGFR exon 19 del MET amp	lung non-small cell carcinoma	sensitive	JNJ-61186372	Preclinical - Cell line xenograft	Actionable	In a preclinical study, JNJ-61186372 inhibited tumor growth in Tarceva (erlotinib)-resistant non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion and MET amplification (PMID: 27216193).	27216193
MET	EGFR exon 19 del MET amp	lung non-small cell carcinoma	predicted - resistant	Erlotinib	Clinical Study - Cohort	Actionable	In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).	30791921
MET	EGFR exon 19 del MET amp	lung adenocarcinoma	resistant	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Tarceva (erlotinib) (PMID: 27694386).	27694386
MET	EGFR exon 19 del MET amp	lung non-small cell carcinoma	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, amplification of MET conferred resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring an EGFR exon 19 deletion mutation in culture (PMID: 17463250).	17463250
MET	EGFR exon 19 del MET amp	lung non-small cell carcinoma	resistant	Gefitinib	Clinical Study - Cohort	Actionable	In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).	30791921
MET	EGFR exon 19 del MET amp	lung adenocarcinoma	predicted - resistant	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Gilotrif (afatinib) (PMID: 27694386).	27694386
MET	EGFR exon 19 del MET amp	lung non-small cell carcinoma	predicted - resistant	Icotinib	Clinical Study - Cohort	Actionable	In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).	30791921
MET	EGFR T790M MET amp	lung adenocarcinoma	resistant	Rociletinib	Preclinical	Actionable	In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Rociletinib (CO-1686) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).	27252416
MET	EGFR T790M MET amp	lung non-small cell carcinoma	predicted - resistant	Rociletinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, emergence of MET amplification was identified in 26% (28/43) of EGFR T790M-positive non-small cell lung cancer patients with acquired resistance to Rociletinib (CO1686), and patients with MET amplification prior to Rociletinib (CO1686) treatment demonstrated a decreased response compared to patients without MET amplification (PMID: 27283993).	27283993
MET	EGFR T790M MET amp	lung adenocarcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Tagrisso (osimertinib) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).	27252416
MET	EGFR E746_A750del MET amp	lung non-small cell carcinoma	resistant	Rociletinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, emergence of MET amplification was associated with resistance to Rociletinib (CO1686) in non-small cell lung cancer cell line xenograft models harboring EGFR E746_A750del (PMID: 27283993).	27283993
MET	EGFR E746_A750del MET amp	lung non-small cell carcinoma	sensitive	Gefitinib + PHA-665752	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of PHA-665752 and Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).	24165158 23542356
MET	EGFR E746_A750del MET amp	lung adenocarcinoma	no benefit	Afatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Gilotrif (afatinib) did not demonstrate benefit in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification, with all treated mice demonstrating progression (PMID: 28961841).	28961841
MET	EGFR E746_A750del MET amp	lung adenocarcinoma	resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with metastatic lung adenocarcinoma harboring EGFR E746_A750del (referred to as K745_A750delinsK) and T790M demonstrated an initial response, but subsequent progression, of the brain metastasis following Tagrisso (osimertinib) treatment, and analysis of the brain metastasis showed loss of EGFR T790M as well as acquisition of high-level MET amplification, and resistance to Tagrisso (osimertinib) was recapitulated in a patient-derived xenograft (PDX) model (PMID: 28961841).	28961841
MET	EGFR E746_A750del MET amp	lung adenocarcinoma	sensitive	Afatinib + Capmatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Capmatinib (INC280) plus Gilotrif (afatinib) resulted in improved survival with no evidence of tumor 300 days post-transplantation in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).	28961841
MET	EGFR E746_A750del MET amp	lung adenocarcinoma	sensitive	Capmatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Capmatinib (INC280) resulted in improved survival in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).	28961841
MET	EGFR E746_A750del MET amp	lung non-small cell carcinoma	sensitive	Crizotinib + Rociletinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in non-small cell lung cancer cell line harboring EGFR E746_A750del and MET amplification in culture (PMID: 27283993).	27283993
MET	EGFR E746_A750del MET amp	lung non-small cell carcinoma	resistant	Gefitinib	Preclinical - Cell culture	Actionable	In a preclinical study, acquired amplification of MET conferred resistance to Iressa (gefitinib) in a non-small cell lung cancer cell line harboring EGFR E746_A750del in culture (PMID: 27612490).	27612490
MET	EGFR E746_A750del MET amp	lung non-small cell carcinoma	sensitive	Gefitinib + NPS-1034	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the addition of NPS-1034 to treatment with Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).	24165158 23542356
MET	EGFR L858R MET amp	lung non-small cell carcinoma	predicted - resistant	Erlotinib	Clinical Study - Cohort	Actionable	In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).	30791921
MET	EGFR L858R MET amp	lung adenocarcinoma	predicted - sensitive	Crizotinib + Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring EGFR L858R and MET amplification and primary resistance to Iressa (gefitinib) demonstrated 73% reduction in the right lung lesion after 4 weeks and almost complete reduction by 8 weeks, and maintained progression-free survival for 16.8 months following treatment with the combination of Xalkori (crizotinib) and Iressa (gefitinib) (PMID: 30797494).	30797494
MET	EGFR L858R MET amp	lung non-small cell carcinoma	predicted - resistant	Icotinib	Clinical Study - Cohort	Actionable	In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).	30791921
MET	EGFR L858R MET amp	lung non-small cell carcinoma	sensitive	Crizotinib + Rociletinib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in a patient-derived xenograft model of non-small cell lung cancer harboring EGFR L858R and MET amplification, resulting in tumor growth inhibition (PMID: 27283993).	27283993
MET	EGFR L858R MET amp	lung non-small cell carcinoma	predicted - sensitive	Crizotinib	Clinical Study - Cohort	Actionable	In a clinical study, Xalkori (crizotinib) alone (n=8) or in combination with EGFR TKIs (n=6) resulted in an objective response rate (ORR) of 50% (7/14, 7 partial response) and a disease control rate (DCR) of 85.7% (12/14) in patients with EGFR-mutant (L858R n=12, exon 19 deletion n=2) non-small cell lung cancer who acquired resistance to EGFR TKI through MET amplification, ORR and DCR were not significantly different between patients treated with or without EGFR TKI (PMID: 30791921).	30791921
MET	EGFR L858R MET amp	lung adenocarcinoma	predicted - resistant	Gefitinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring EGFR L858R and MET amplification demonstrated primary resistance to second line treatment with Iressa (gefitinib) (PMID: 30797494).	30797494
MET	EGFR L858R MET amp	lung non-small cell carcinoma	predicted - resistant	Gefitinib	Clinical Study - Cohort	Actionable	In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).	30791921
MET	MET amp TP53 del	breast cancer	sensitive	Crizotinib	Preclinical	Actionable	In a preclinical study, Xalkori (crizotinib) treatment resulted in complete tumor regression in transplant models of TP53-null-luminal breast cancer harboring MET amplification (PMID: 27149990).	27149990
MET	FGFR1 amp MET amp	lung cancer	sensitive	AZD4547 + Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 and Xalkori (crizotinib) synergistically inhibited proliferation of FGFR1 amplified lung cancer cells that acquired resistance to AZD4547 through MET amplification in culture (PMID: 27429073).	27429073
MET	FGFR1 amp MET amp	lung squamous cell carcinoma	predicted - resistant	BGJ398	Phase I	Actionable	In a Phase I trial, MET amplification was detected in a squamous cell lung cancer patient harboring FGFR1 amplification whose disease relapsed after 17 months of BGJ398 treatment, supporting a role of MET amplification in drug resistance in FGFR1-amplified lung cancer (PMID: 28630215).	28630215
MET	FGFR1 amp MET amp	lung cancer	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, MET amplification was identified as the mechanism mediating acquired AZD4547 resistance in a FGFR1 amplified lung cancer cell line in culture (PMID: 27429073).	27429073
MET	EGFR mut MET amp	lung adenocarcinoma	sensitive	EMD 1214063 + Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Tarceva (erlotinib) and EMD 1214063 synergistically inhibited growth of lung carcinoma cells harboring EGFR mutation and Met amplification in culture (PMID: 28630215).	28630215
MET	EGFR mut MET amp	lung non-small cell carcinoma	sensitive	Capmatinib + Gefitinib	Phase Ib/II	Actionable	In a Phase Ib/II trial, Capmatinib (INC280) and Iressa (gefitinib) combination treatment resulted in an objective response rate of 27% (43/161) in non-small cell lung cancer patients harboring EGFR mutations and MET dysregulation (amplification or overexpression), with an objective response rate of 47% in Phase II patients with a MET gene copy number greater than 6 (PMID: 30156984).	30156984
MET	EGFR mut MET amp	lung non-small cell carcinoma	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, Xalkori (crizotinib) treatment resulted in partial response (PR) in 50% (4/8) of patients with EGFR mutant non-small cell lung cancer that acquired MET amplification after EGFR TKI therapy, although the response was short-lived, with a median progression-free survival of 3.5 months in patients achieved PR (PMID: 30268451).	30268451
MET	EGFR mut MET amp	lung non-small cell carcinoma	predicted - sensitive	Osimertinib + Savolitinib	Phase I	Actionable	In a Phase I trial (TATTON), Tagrisso (osimertinib) and Savolitinib (AZD6094) combination therapy resulted in an objective response rate of 52% (24/46, 24 partial response) with a median duration of response of 7.1 months in patients with EGFR-mutant, EGFR T790M negative, and MET-amplified non-small cell lung cancer, after progression on prior first/second generation EGFR inhibitors (AACR Annual Meeting 2019, Abstract CT032; NCT02143466).	detail...
MET	EGFR mut MET amp	lung adenocarcinoma	resistant	Erlotinib	Preclinical - Cell culture	Actionable	In a preclinical study, amplification of MET was identified in a lung adenocarcinoma cell line harboring EGFR mutation that acquired resistance to Tarceva (erlotinib) in culture (PMID: 28630215).	28630215
MET	EGFR act mut MET amp	lung cancer	sensitive	SYM015	Preclinical - Pdx	Actionable	In a preclinical study, SYM015 treatment resulted in tumor growth inhibition in patient-derived xenograft (PDX) models of MET-amplified lung cancer harboring EGFR activating mutations (PMID: 28679766).	28679766
MET	ERBB2 over exp MET amp	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tissue from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified MET amplification in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).	29208673
MET	ALK rearrange MET amp	lung adenocarcinoma	resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring an ALK rearrangement developed resistance to Alecensa (alectinib) treatment, and subsequently was found to harbor amplification of MET (PMID: 24128725, PMID: 24518097).	24518097 24128725
MET	ALK rearrange MET amp	lung adenocarcinoma	sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient harboring an ALK rearrangement who developed resistance to Alecensa (alectinib) likely due to acquisition of MET amplification, responded well to treatment with Xalkori (crizotinib), demonstrating a radiological response after 12 days (PMID: 24128725, PMID: 24518097).	24128725 24518097
MET	BRAF V600E EGFR exon 19 del MET amp	lung adenocarcinoma	resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR exon 19 deletion treated with Tagrisso (osimertinib) showed progression after 16 months, and was subsequently found to have acquired BRAF V600E and MET amplification (PMID: 29596911).	29596911
MET	EGFR L858R EGFR T790M MET amp	lung adenocarcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M progressed after 19 months on Tagrisso (osimertinib), and was found to have acquired MET amplification (PMID: 29128427).	29128427
MET	EGFR L858R EGFR T790M MET amp	lung adenocarcinoma	predicted - sensitive	Crizotinib + Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, a lung adenocarcinoma patient with EGFR L858R, EGFR T790M, and MET amplification demonstrated a partial response in her lung lesions and an approximately 90% reduction in the retroperitoneal lymph node and right adrenal gland, and progression-free survival lasting 3 months following treatment with the combination of Tagrisso (osimertinib) and Xalkori (crizotinib) (PMID: 29128427).	29128427
MET	ALK rearrange ALK I1171N MET amp	lung non-small cell carcinoma	predicted - resistant	Brigatinib	Case Reports/Case Series	Actionable	In a clinical case study, MET amplification was identified together with a pre-existing ALK I1171N at disease progression while on Alunbrig (brigatinib) treatment in a patient with ALK-positive non-small cell lung cancer (PMID: 29935304).	29935304
MET	EGFR act mut EGFR T790M MET amp	lung non-small cell carcinoma	predicted - resistant	Rociletinib	Clinical Study - Cohort	Actionable	In a retrospective analysis of a Phase I and a Phase II trial, MET amplification was identified at disease progression in 26% (11/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, 70%; L858R, 28%) treated with Rociletinib (CO-1686), conversely, preexisting MET, ERBB2 (HER2), or EGFR amplification were more common in patients with primary resistance to Rociletinib (CO-1686) (PMID: 27283993; NCT01526928, NCT02147990).	27283993
MET	BRAF V600E MET amp	rectum mucinous adenocarcinoma	predicted - resistant	Panitumumab + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with microsatellite-stable mucinous rectal cancer harboring BRAF V600E eventually developed resistance to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination therapy, potentially due to acquiring amplification of MET (PMID: 27325282).	27325282
MET	BRAF V600E MET amp	colorectal cancer	predicted - resistant	Alpelisib + Cetuximab + Encorafenib	Case Reports/Case Series	Actionable	In a preclinical study, emergence of MET amplification was detected in colorectal cancer cells harboring BRAF V600E that acquired resistance to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment in culture (PMID: 27325282).	27325282
MET	BRAF V600E MET amp	rectum mucinous adenocarcinoma	predicted - sensitive	Crizotinib + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with microsatellite-stable mucinous rectal cancer harboring BRAF V600E and acquired MET amplification responded to the combination treatment of Xalkori (crizotinib) and Zelboraf (vemurafenib), resulting in a rapid clinical and metabolic response (PMID: 27325282).	27325282
MET	EGFR amp ERBB2 amp MET amp	gastric adenocarcinoma	predicted - sensitive	Afatinib + AMG 337	Preclinical - Pdx	Actionable	In a Phase II clinical trial, preclinical analysis of a gastric adenocarcinoma patient-derived xenograft (PDX) model with amplification of EGFR, ERBB2 (HER2), and MET demonstrated tumor regression when treated with a combination of Gilotrif (afatinib) and AMG 337 (PMID: 30463996; NCT01522768).	30463996
MET	EGFR amp ERBB2 amp MET amp	gastric adenocarcinoma	resistant	Afatinib	Case Reports/Case Series	Actionable	In a Phase II clinical trial, a metastatic gastric adenocarcinoma patient with co-amplification of EGFR and ERBB2 (HER2) who initially responded to Gilotrif (afatinib) treatment progressed at 12 weeks and was found to have acquired amplification of MET in the progressing sites, which was subsequently confirmed to be associated with resistance via a patient-derived xenograft (PDX) model treated with Gilotrif (afatinib) (PMID: 30463996; NCT01522768).	30463996
MET	EGFR amp ERBB2 amp MET amp	gastric adenocarcinoma	predicted - resistant	AMG 337	Preclinical - Pdx	Actionable	In a Phase II clinical trial, a gastric adenocarcinoma patient-derived xenograft (PDX) model with amplification of EGFR, ERBB2 (HER2), and MET demonstrated resistance to treatment with AMG 337 (PMID: 30463996; NCT01522768).	30463996
MET	EGFR over exp MET amp	lung non-small cell carcinoma	sensitive	SHR-A1307	Preclinical - Pdx	Actionable	In a preclinical study, SHR-A1307 resulted in the inhibition of tumor growth in the EGFR overexpressing and MET amplified patient-derived xenograft models (PDX) of non-small cell lung cancer (PMID: 30962319).	30962319
MET	MET E168D	Advanced Solid Tumor	sensitive	SU11274	Preclinical	Actionable	In a preclinical study, SU11274 induced apoptosis of cells expressing MET E168D, which demonstrated increased sensitivity compared to cells expressing wild-type MET (PMID: 19723643).	19723643
MLH1	MLH1 inact mut	colorectal cancer	not applicable	N/A	Preclinical	Emerging	In a preclinical study, MLH1 inactivation through hypermethylation was associated with high microsatellite instability (MSI-H) colorectal carcinoma by whole genome sequencing of tumor samples (PMID: 22810696), suggesting it may be a potential biomarker.	22810696
MLH1	MLH1 mutant	pancreatic cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in MLH1 result in Lynch syndrome, which is associated with increased risk of developing pancreatic cancer (NCCN.org).	detail...
MLH1	MLH1 mutant	small intestine adenocarcinoma	not applicable	N/A	Guideline	Risk Factor	Lynch syndrome results from germline mutations in DNA mismatch repair genes including MLH1, MSH2, MSH6, and PMS2, and is associated with increased risk of developing small bowel adenocarcinoma (NCCN.org).	detail...
MLH1	MLH1 mutant	colon cancer	not applicable	N/A	Guideline	Risk Factor	Lynch syndrome results from germline mutations in DNA mismatch repair genes including MLH1, MSH2, MSH6, and PMS2, and is associated with increased risk of developing colon cancer (NCCN.org).	detail...
MLH1	MLH1 mutant	stomach cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in MLH1 result in Lynch syndrome, which is associated with increased risk of early onset of gastric cancer (NCCN.org).	detail...
MLH1	MLH1 mutant	endometrial cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in MLH1 result in Lynch syndrome, which is associated with increased risk of developing endometrial cancer (NCCN.org).	detail...
MLH1	MLH1 mutant	rectum cancer	not applicable	N/A	Guideline	Risk Factor	Lynch syndrome results from germline mutations in DNA mismatch repair genes including MLH1, MSH2, MSH6, and PMS2, and is associated with increased risk of developing colorectal cancer (NCCN.org).	detail...
MLH1	MLH1 loss	colon cancer	sensitive	KU60648	Preclinical - Cell culture	Actionable	In a preclinical study, MLH1 deficient colon cancer cell lines were sensitive to KU60648 in culture, demonstrating decreased cell viability and reduced colony formation (PMID: 28224663).	28224663
MLH1	MLH1 M524I PDGFRA W559_R560del	gastrointestinal stromal tumor	predicted - sensitive	Imatinib	Case Reports/Case Series	Actionable	In a clinical case study, Gleevec (imatinib) treatment resulted in disease-free survival for over 10 months in a patient with epithelioid variant of gastrointestinal stromal tumor harboring PDGFRA W559_R560del and MLH1 M524I (PMID: 31273885).	31273885
MLH1	MLH1 negative	ovarian cancer	sensitive	Pembrolizumab	Guideline	Actionable	Keytruda (pembrolizumab) is included in guidelines as systemic therapy for patients with recurrent ovarian cancer with MLH1 deficiency (NCCN.org).	detail...
MPL	MPL W515L	myelofibrosis	sensitive	Everolimus	Phase II	Actionable	In a phase II study of patients with myelofibrosis, 2/2 patients with MPL W515L/K had tumor response to everolimus, with one patient displaying clinical benefit (PMID: 21725052).	21725052
MPL	MPL W515L	myeloproliferative neoplasm	sensitive	BMS-911543	Preclinical - Cell culture	Actionable	In a preclinical study, BMS-911543 inhibited colony growth in myeloproliferative neoplasm patient-derived hematopoetic progenitor cells harboring MPL W515L in culture (PMID: 22015772).	22015772
MPL	MPL W515L	Advanced Solid Tumor	sensitive	BEZ235 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).	24251790
MPL	MPL W515L	Advanced Solid Tumor	sensitive	Ruxolitinib + TGX-221	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).	24251790
MPL	MPL W515L	hematologic cancer	sensitive	CHZ868	Preclinical	Actionable	In a preclinical study, CHZ868 inhibited proliferation of bone marrow cell lines expressing MPL W515L in culture, including cells with decreased response to Type I JAK inhibitors due to chronic exposure (PMID: 26175413).	26175413
MPL	MPL W515L	myelofibrosis	sensitive	CHZ868	Preclinical	Actionable	In a preclinical study, CHZ868 demonstrated efficacy in a mouse model of MPL W515L induced myelofibrosis (PMID: 26175413).	26175413
MPL	MPL W515L	hematologic cancer	sensitive	NS-018	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing MPL W515L were sensitive to treatment with NS-108, demonstrating inhibition of cell growth in culture (PMID: 22829185).	22829185
MPL	MPL W515L	myelofibrosis	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, MK2206 treatment reduced disease burden in MPL W515L transduced mouse models of myelofibrosis (PMID: 23748344).	23748344
MPL	MPL W515L	Advanced Solid Tumor	sensitive	Ruxolitinib + ZSTK474	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).	24251790
MPL	MPL W515L	myelofibrosis	not applicable	N/A	Guideline	Prognostic	MPL W515L is associated with intermediate prognosis and higher risk of thrombosis when compared to the presence of CALR mutations in patients with primary myelofibrosis (NCCN.org).	detail...
MPL	MPL W515L	hematologic cancer	sensitive	BMS-911543	Preclinical - Cell culture	Actionable	In a preclinical study, BMS-911543 inhibited proliferation of transformed cells expressing MPL W515L in culture (PMID: 22015772).	22015772
MPL	MPL W515L	Advanced Solid Tumor	sensitive	Pictilisib + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).	24251790
MPL	MPL W515K	myelofibrosis	sensitive	Everolimus	Phase II	Actionable	In a phase II study of patients with myelofibrosis, 2/2 patients with MPL W515L/K had tumor response to everolimus, with one patient displaying clinical benefit (PMID: 21725052).	21725052
MPL	MPL W515K	myelofibrosis	not applicable	N/A	Guideline	Prognostic	MPL W515K is associated with intermediate prognosis and higher risk of thrombosis when compared to the presence of CALR mutations in patients with primary myelofibrosis (NCCN.org).	detail...
MPL	JAK2 over exp MPL over exp	Advanced Solid Tumor	sensitive	Pictilisib + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).	24251790
MPL	JAK2 over exp MPL over exp	Advanced Solid Tumor	sensitive	Ruxolitinib + TGX-221	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).	24251790
MPL	JAK2 over exp MPL over exp	Advanced Solid Tumor	sensitive	Ruxolitinib + ZSTK474	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).	24251790
MPL	JAK2 over exp MPL over exp	Advanced Solid Tumor	sensitive	BEZ235 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).	24251790
MPL	JAK2 V617F MPL wild-type	Advanced Solid Tumor	sensitive	Pictilisib + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).	24251790
MPL	JAK2 V617F MPL wild-type	Advanced Solid Tumor	sensitive	Ruxolitinib + ZSTK474	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).	24251790
MPL	JAK2 V617F MPL wild-type	Advanced Solid Tumor	sensitive	BEZ235 + Ruxolitinib	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).	24251790
MPL	JAK2 V617F MPL wild-type	Advanced Solid Tumor	sensitive	Ruxolitinib + TGX-221	Preclinical	Actionable	In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).	24251790
MPL	CALR wild-type JAK2 wild-type MPL wild-type	myelofibrosis	not applicable	N/A	Guideline	Prognostic	The presence of concurrent wild-type JAK2, MPL, and CALR in myelofibrosis patients is associated with inferior leukemia-free survival compared to patients with JAK2 and/or CALR mutations, and is associated with inferior overall survival when compared to patients with CALR mutations (NCCN.org).	detail...
MSH6	MSH6 negative	ovarian cancer	sensitive	Pembrolizumab	Guideline	Actionable	Keytruda (pembrolizumab) is included in guidelines as systemic therapy for patients with recurrent ovarian cancer with MSH6 deficiency (NCCN.org).	detail...
MSH6	MSH6 T1219I	glioblastoma multiforme	resistant	Temozolomide	Preclinical	Actionable	In a preclinical study, glioblastoma cells harboring a MSH6 T1219I mutation were resistant to Temodar (temozolomide) in cell culture (PMID: 19584161).	19584161
MSH6	MSH6 loss	colon carcinoma	not applicable	N/A	Preclinical	Emerging	Preclinical shRNA mediated-inhibition of PTEN-induced putative kinase 1 (PINK1) in colon carcinoma cells with MSH6 loss resulted in synthetic lethality, suggesting PINK1 may be a promising therapeutic target for MSH6 deficient cancer cells (PMID: 21242281).	21242281
MSH6	MSH6 loss	colon cancer	no benefit	KU60648	Preclinical - Cell culture	Actionable	In a preclinical study, MSH6 deficient colon cancer cells did not respond to treatment with KU60648 in culture (PMID: 28224663).	28224663
MSH6	MSH6 mutant	rectum cancer	not applicable	N/A	Guideline	Actionable	Lynch syndrome results from germline mutations in DNA mismatch repair genes including MLH1, MSH2, MSH6, and PMS2, and is associated with increased risk of developing colorectal cancer (NCCN.org).	detail...
MSH6	MSH6 mutant	endometrial cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in MSH6 result in Lynch syndrome, which is associated with increased risk of developing endometrial cancer (NCCN.org).	detail...
MSH6	MSH6 mutant	colon cancer	not applicable	N/A	Guideline	Actionable	Lynch syndrome results from germline mutations in DNA mismatch repair genes including MLH1, MSH2, MSH6, and PMS2, and is associated with increased risk of developing colon cancer (NCCN.org).	detail...
MSH6	MSH6 mutant	colorectal cancer	not applicable	N/A	Clinical Study	Diagnostic	Germline mutations in MSH6 are associated with microsatellite instability in colorectal cancer (CRC), and are diagnostic for Lynch syndrome (hereditary nonpolyposis colorectal cancer) in colorectal cancer patients (PMID: 26582061; PMID: 19125127).	26582061 19125127
MSH6	MSH6 mutant	pancreatic cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in MSH6 result in Lynch syndrome, which is associated with increased risk of developing pancreatic cancer (NCCN.org).	detail...
MSH6	MSH6 mutant	small intestine adenocarcinoma	not applicable	N/A	Guideline	Risk Factor	Lynch syndrome results from germline mutations in DNA mismatch repair genes including MLH1, MSH2, MSH6, and PMS2, and is associated with increased risk of developing small bowel adenocarcinoma (NCCN.org).	detail...
MYD88	MYD88 wild-type	diffuse large B-cell lymphoma	predicted - sensitive	ST2825	Preclinical	Actionable	In a preclinical study, STS2825 demonstrated effective inhibition of MYD88 homodimerization and signalling in cultured cells and is currently being evaluated in preclinical studies of B cell lymphoma (Blood Lymph Canc 2013; 3: 53-61).	detail...
MYD88	MYD88 L265P	central nervous system lymphoma	sensitive	Ibrutinib	Phase I	Actionable	In a Phase I trial, two patients with primary central nervous system lymphoma each harboring MYD88 L265P demonstrated a complete response when treated with Imbruvica (ibrutinib) (PMID: 28619981).	28619981
MYD88	MYD88 L265P	diffuse large B-cell lymphoma	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, MYD88 L265P was associated with a worse overall survival in patients with diffuse large B-cell lymphoma when compared to MYD88 wild-type (PMID: 24903481, PMID: 25055137, PMID: 26792260).	26792260 24903481 25055137
MYD88	MYD88 L265P	non-Hodgkin lymphoma	no benefit	Ibrutinib	Preclinical - Pdx	Actionable	In a preclinical study, a non-Hodgkin lymphoma (NHL) patient derived xenograft (PDX) model harboring both CD79B Y197N and MYD88 L265P demonstrated sensitivity to Ibruvica (ibrutinib) while an NHL patient derived xenograft (PDX) model harboring only MYD88 L265P did not respond to Ibruvica (ibrutinib) (ASH 57th Annual Meeting, 2015, abstract #2759).	detail...
MYD88	MYD88 L265P	Waldenstroem's macroglobulinemia	not applicable	N/A	Guideline	Diagnostic	MYD88 L265P is diagnostic and aids distinguishing Waldenstrom macroglobulinemia from IgM-secreting B-cell lymphomas and IgM plasma cell myeloma (NCCN.org).	detail...
MYD88	MYD88 L265P	B-cell lymphoma	sensitive	IMO-8400	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with IMO-8400 resulted in decreased survival of B-cell lymphoma cell lines harboring MYD88 L265P in culture, and decreased tumor growth in a MYD88 L265P-positive B-cell lymphoma cell line xenograft models (Cancer Res October 1, 2014 74:2570).	detail...
MYD88	MYD88 L265P	diffuse large B-cell lymphoma	sensitive	Vorinostat	Preclinical - Cell culture	Actionable	In a preclinical study, a diffuse large B-cell lymphoma cell line harboring MYD88 L256P demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased apoptosis (PMID: 27733371).	27733371
MYD88	MYD88 L265P	diffuse large B-cell lymphoma	resistant	Ibrutinib	Phase II	Actionable	In a Phase II trial, all of diffuse large B-cell lymphoma patients harboring MYD88 L265P (n=4) did not respond to Imbruvica (ibrutinib) treatment (Blood 2012, 120 (21): 686).	detail...
MYD88	MYD88 mutant	lymphoplasmacytic lymphoma	not applicable	N/A	Clinical Study	Diagnostic	MYD88 mutations are used in the diagnosis of lymphoplasmacytic lymphoma (Guidelines, PMID: 22944768, PMID: 26230596).	detail... 26230596 22944768
MYD88	MYD88 mutant	marginal zone B-cell lymphoma	not applicable	N/A	Guideline	Diagnostic	MYD88 mutations are used to differentiate Waldenstroem's macroglobulinemia from marginal zone B-cell lymphoma in the presence of plasmacytic differentiation (NCCN.org).	detail...
MYD88	MYD88 mutant	nodal marginal zone lymphoma	not applicable	N/A	Guideline	Diagnostic	MYD88 mutations aid in the diagnosis of nodal marginal zone lymphoma (NCCN.org).	detail...
MYD88	MYD88 mutant	splenic marginal zone lymphoma	not applicable	N/A	Guideline	Diagnostic	MYD88 mutations aid in the diagnosis of splenic marginal zone lymphoma (NCCN.org).	detail...
MYD88	MYD88 mutant	MALT lymphoma	not applicable	N/A	Guideline	Actionable	MYD88 mutations aid in the diagnosis of gastric MALT lymphoma (NCCN.org).	detail...
MYD88	MYD88 act mut	diffuse large B-cell lymphoma	predicted - sensitive	Tomivosertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, eFT508 demonstrated anti-tumor activity in two diffuse large B-cell lymphoma cell line xenograft models, both harboring MYD88 activating mutations (Blood Dec 2015, 126 (23) 1554).	detail...
NOTCH1	EML4-ALK NOTCH1 D1538A	lung non-small cell carcinoma	predicted - resistant	Brigatinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK demonstrated resistance to treatment with Alunbrig (brigatinib), and was subsequently found to have acquired NOTCH1 D1538A (PMID: 29636358).	29636358
NOTCH1	NOTCH1 A1552G	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1552G in culture (PMID: 25104330).	25104330
NOTCH1	NOTCH1 S2449fs	triple-receptor negative breast cancer	sensitive	PF-03084014	Preclinical - Pdx	Actionable	In a preclinical study, PF-03084014 treatment resulted in tumor regression in patient derived xenograft animal models of triple receptor negative breast cancer harboring NOTCH1 S2449fs (PMID: 25564152).	25564152
NOTCH1	NOTCH1 R1683W	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 R1683W in culture (PMID: 25104330).	25104330
NOTCH1	NOTCH1 rearrange	triple-receptor negative breast cancer	sensitive	MRK-003 + Paclitaxel	Preclinical	Actionable	In a preclinical study, MRK-003 and Taxol (paclitaxel) worked synergistically to inhibit tumor growth in triple receptor-negative breast cancer xenograft models harboring NOTCH1 rearrangement, resulting in tumor regression (PMID: 25104330).	25104330
NOTCH1	NOTCH1 rearrange	triple-receptor negative breast cancer	no benefit	MRK-003 + SCH772984	Preclinical	Actionable	In a preclinical study, SCH772984 did not potentiate the growth inhibition effect of MRK-003 in triple receptor-negative breast cancer cells harboring NOTCH1 rearrangement in culture (PMID: 25104330).	25104330
NOTCH1	NOTCH1 rearrange	triple-receptor negative breast cancer	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited growth of triple receptor-negative breast cancer cells harboring NOTCH1 rearrangement in culture and reduced tumor growth in xenograft models (PMID: 25104330).	25104330
NOTCH1	NOTCH1 C478F	head and neck squamous cell carcinoma	sensitive	LGK974	Preclinical	Actionable	In a preclinical study, LGK974 inhibited growth of head and neck squamous cell carcinoma cells harboring NOTCH1 C478F in culture and xenograft models (PMID: 24277854).	24277854
NOTCH1	ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of SRC, ERBB2 (HER2), STK11, and NOTCH1 (PMID: 29636358).	29636358
NOTCH1	NOTCH1 positive	breast cancer	sensitive	LY3039478	Preclinical	Actionable	In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of breast cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).	detail...
NOTCH1	NOTCH1 positive	glioblastoma multiforme	sensitive	Radiotherapy + RO4929097 + Temozolomide	Phase I	Actionable	In a Phase I trial, addition of RO4929097 to Temodar (temozolomide) and radiation therapy inhibited Notch signaling and cell proliferation in patient tumor samples, resulted in a median overall survival of 21 months and a median progression free survival of 13 months in glioblastoma patients (PMID: 27154916).	27154916
NOTCH1	NOTCH1 positive	ovarian cancer	sensitive	LY3039478	Preclinical	Actionable	In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of ovarian cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).	detail...
NOTCH1	NOTCH1 positive	colon cancer	sensitive	LY3039478	Preclinical	Actionable	In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of colon cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).	detail...
NOTCH1	NOTCH1 positive	prostate cancer	predicted - sensitive	Docetaxel + PF-03084014	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-03084014 and Taxotere (docetaxel) in combination inhibited growth of Notch1-expressing Taxotere (docetaxel)-resistant prostate cancer cell lines in culture, and inhibited both soft tissue and bony tumor growth in Taxotere (docetaxel)-resistant prostate cancer cell line xenograft models, with increased efficacy over either agent alone (PMID: 26202948).	26202948
NOTCH1	NOTCH1 positive	lung cancer	sensitive	LY3039478	Preclinical	Actionable	In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of lung cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).	detail...
NOTCH1	NOTCH1 positive	stomach cancer	sensitive	LY3039478	Preclinical	Actionable	In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of gastric cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).	detail...
NOTCH1	NOTCH1 positive	glioblastoma multiforme	sensitive	LY3039478	Preclinical	Actionable	In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of glioblastoma (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).	detail...
NOTCH1	NOTCH1 act mut	breast cancer	sensitive	Brontictuzumab	Preclinical - Pdx	Actionable	In a preclinical study, Brontictuzumab (OMP-52M51) inhibited tumor growth and reduced cancer stem cells in xenograft models of tumor derived from a breast cancer patient harboring activating NOTCH1 mutations (Cancer Res 2013;73(8 Suppl):Abstract nr 3728).	detail...
NOTCH1	NOTCH1 act mut	acute lymphocytic leukemia	sensitive	Brontictuzumab	Preclinical - Pdx	Actionable	In a preclinical study, xenograft models of patient-derived acute lymphocytic leukemia cells harboring NOTCH1 activating muatations demonstrated better response to Brontictuzumab (OMP-52M51) compared to NOTCH1 wild-type models (PMID: 23774673).	23774673
NOTCH1	NOTCH1 act mut	T-cell adult acute lymphocytic leukemia	predicted - sensitive	Dexamethasone + Ribociclib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) resulted in reduced leukemia burden and a greater survival benefit in a NOTCH1 activated T-cell acute lymphoblastic leukemia patient derived xenograft (PDX) model when compared to control or either agent alone (PMID: 28151717).	28151717
NOTCH1	NOTCH1 act mut	colorectal cancer	sensitive	PF-03084014	Preclinical - Cell culture	Actionable	In a preclinical study, the gamma secretase inhibitor PF-03084014 reduced Notch1 cleavage, decreased activation of Notch targets, and increased apoptosis in colorectal cancer cell lines exhibiting increased Notch activation (PMID: 23868008).	23868008
NOTCH1	NOTCH1 I1680S	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 I1680S in culture (PMID: 25104330).	25104330
NOTCH1	NOTCH1 V1599M	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1599M in culture (PMID: 25104330).	25104330
NOTCH1	NOTCH1 V1676I	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1676I in culture (PMID: 25104330).	25104330
NOTCH1	NOTCH1 A1707T	Advanced Solid Tumor	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, transformed cells expressing NOTCH1 A1707T demonstrated sensitivity to MRK-003 in culture (PMID: 25104330).	25104330
NOTCH1	NOTCH1 A1707T	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1707T in culture (PMID: 25104330).	25104330
NOTCH1	NOTCH1 wild-type	triple-receptor negative breast cancer	no benefit	MRK-003 + Paclitaxel	Preclinical	Actionable	In a preclinical study, the combination of MRK-003 and Taxol (paclitaxel) did not potentiate the anti-tumor effects compared to single agent therapy in triple receptor-negative breast cancer xenograft models harboring wild-type NOTCH1 (PMID: 25104330).	25104330
NOTCH1	NOTCH1 wild-type	triple-receptor negative breast cancer	decreased response	MRK-003	Preclinical	Actionable	In a preclinical study, triple receptor-negative breast cancer xenograft models harboring wild-type NOTCH1 demonstrated reduced sensitivity to MRK-003 induced tumor growth inhibition (PMID: 25104330).	25104330
NOTCH1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Asparaginase + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).	28151717
NOTCH1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Bortezomib + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).	28151717
NOTCH1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	JQ1 + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).	28151717
NOTCH1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717).	28151717
NOTCH1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Methotrexate + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).	28151717
NOTCH1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	conflicting	Dexamethasone + Ribociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and NOTCH1 resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, however, survival did not differ between xenograft models treated with the combination or Kisqali (ribociclib) alone (PMID: 28151717).	28151717
NOTCH1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Everolimus + Ribociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture, and prolonged survival in cell-line xenograft models (PMID: 28151717).	28151717
NOTCH1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Prednisolone + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).	28151717
NOTCH1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Mercaptopurine + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).	28151717
NOTCH1	NOTCH1 wild-type RB1 loss	T-cell adult acute lymphocytic leukemia	resistant	Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type NOTCH1 and loss of RB1 demonstrated resistance to Kisqali (ribociclib) in culture, resulting in limited inhibition of cell growth (PMID: 28151717).	28151717
NOTCH1	NOTCH1 over exp	Advanced Solid Tumor	sensitive	Brontictuzumab	Phase I	Actionable	In a Phase I trial, Brontictuzumab (OMP-52M51) treatment resulted in stable disease in 43% (3/7) of advanced solid tumor patients with elevated levels of Notch1 intracellular domain (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C42).	detail...
NOTCH1	NOTCH1 A1552V	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1552V in culture (PMID: 25104330).	25104330
NOTCH1	NOTCH1 V1575A	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1575A in culture (PMID: 25104330).	25104330
NOTCH1	NOTCH1 E1567K	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 E1567K in culture (PMID: 25104330).	25104330
NOTCH1	NOTCH1 mutant	mantle cell lymphoma	predicted - resistant	Ibrutinib + Venetoclax	Phase II	Actionable	In a Phase II trial (AIM), distinct molecular profiles were identified in mantle cell lymphoma patients responded to Imbruvica (ibrutinib) and Venclexta (venetoclax) combination therapy compared to those did not respond, with all patients harboring mutations in NSD2 (n=4), UBR5 (n=3), KMT2D (n=3), and 12 of 13 patients harboring mutations in ATM responded to the therapy, while SMARCA4 (n=4), CCND1 (n=2), and NOTCH1 (n=3) alterations were exclusively observed in nonresponders (PMID: 30455436; NCT02471391).	30455436
NOTCH1	NOTCH1 mutant	triple-receptor negative breast cancer	sensitive	PF-03084014	Preclinical - Pdx	Actionable	In a preclinical study, PF-03084014 treatment resulted in tumor regression in patient-derived xenograft models of triple receptor negative breast cancer harboring NOTCH1 mutations (PMID: 25564152).	25564152
NOTCH1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Everolimus + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture (PMID: 28151717).	28151717
NOTCH1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Bortezomib + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).	28151717
NOTCH1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	JQ1 + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).	28151717
NOTCH1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Mercaptopurine + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).	28151717
NOTCH1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Methotrexate + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).	28151717
NOTCH1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Dexamethasone + Ribociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, and a greater survival benefit in xenograft models when compared to Kisqali (ribociclib) alone (PMID: 28151717).	28151717
NOTCH1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Prednisolone + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).	28151717
NOTCH1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a T-cell acute lymphoblastic leukemia cell line co-harboring wild-type RB1 and a NOTCH1 mutation demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717).	28151717
NOTCH1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Asparaginase + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).	28151717
NOTCH1	EML4-ALK NOTCH1 D1533A	lung non-small cell carcinoma	predicted - resistant	Ceritinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK demonstrated resistance to treatment with Zykadia (ceritinib), and was subsequently found to have acquired NOTCH1 D1533A (PMID: 29636358).	29636358
NOTCH1	NOTCH1 A1570G	osteosarcoma	sensitive	MRK-003	Preclinical	Actionable	In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1570G in culture (PMID: 25104330).	25104330
NPM1	FLT3 exon 14 ins NPM1 wild-type	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	FLT3 exon 14 insertions (high allelic ratio of ITD mutations) with NPM1 wild-type are associated with a poor/adverse prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).	detail...
NPM1	NPM1 wild-type FLT3 wild-type	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	NPM1 wild-type with FLT3 wild-type (no or low allelic ratio of ITD mutations) is associated with an intermediate prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).	detail...
NPM1	NPM1-ALK ALK I1171T	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171T were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK I1171T	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, an anaplastic large-cell lymphoma cell line expressing ALK I1171T in the context of NPM1-ALK demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 24509625).	24509625
NPM1	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to ASP3026 in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Alecensa (alectinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK I1171T	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK	Advanced Solid Tumor	sensitive	TAE684	Preclinical - Cell culture	Actionable	In a preclinical study, TAE684 inhibited proliferation of transformed cells expressing NPM1-ALK in culture (PMID: 20207848).	20207848
NPM1	NPM1-ALK	anaplastic large cell lymphoma	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of an anaplastic large cell lymphoma cell line harboring NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK	anaplastic large cell lymphoma	sensitive	CEP-28122	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, CEP-28122 inhibited Alk activation, resulting in growth inhibition in culture, and tumor regression in both cell line and patient-derived xenograft models of NPM1-ALK positive anaplastic large cell lymphoma (PMID: 22203728).	22203728
NPM1	NPM1-ALK	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK	anaplastic large cell lymphoma	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of an anaplastic large cell lymphoma cell line harboring NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK	anaplastic large cell lymphoma	sensitive	Entrectinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, anaplastic large cell lymphoma cells harboring NPM1-ALK were sensitive to Rozlytrek (entrectinib) in culture and in cell line xenograft models, resulting in inhibition of NPM1-ALK autophosphorylation and near complete tumor regression (PMID: 26939704).	26939704
NPM1	NPM1-ALK	anaplastic large cell lymphoma	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of an anaplastic large cell lymphoma cell line harboring NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK	anaplastic large cell lymphoma	sensitive	Brigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited Alk phosphorylation and growth in anaplastic large cell lymphoma cell lines harboring NPM1-ALK in culture, and induced near complete tumor regression in cell line xenograft models (PMID: 27780853).	27780853
NPM1	NPM1-ALK	anaplastic large cell lymphoma	sensitive	Crizotinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited cell growth, Alk phosphorylation, downstream signaling and induced apoptosis in human anaplastic large cell lymphoma cell lines harboring a NPM1-ALK fusion in culture and in xenograft models (PMID: 18089725).	18089725
NPM1	NPM1-ALK	anaplastic large cell lymphoma	sensitive	Crizotinib	Phase Ib/II	Actionable	In a Phase Ib/II trial, treatment with Xalkori (crizotinib) resulted in an objective response rate of 83% (5/6, all complete responses), at the 165 mg dose, and 90% (18/20, with complete response in 80% (16/20), at the recommended phase 2 dose of 280 mg, in patients with anaplastic large cell lymphoma harboring an ALK fusion, with 72% of tested patients harboring NPM1-ALK (PMID: 28787259; NCT00939770).	28787259
NPM1	NPM1-ALK	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK amp	anaplastic large cell lymphoma	decreased response	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK demonstrated a decreased response compared to parental cell lines harboring NPM1-ALK when treated with Alecensa (alectinib) in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK amp	anaplastic large cell lymphoma	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK amp	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK amp	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to ASP3026 treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK amp	anaplastic large cell lymphoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1196M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M demonstrated resistance to ASP3026 in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK L1196M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M demonstrated moderate resistance to Zykadia (ceritinib) in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1196M	Advanced Solid Tumor	conflicting	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M demonstrated moderate resistance to Alunbrig (brigatinib) in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK F1174V	Advanced Solid Tumor	predicted - sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical trial, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V, but to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK F1174V	Advanced Solid Tumor	decreased response	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK F1174V	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK F1174V	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK F1174V	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1198F in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1198F	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1122V	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1122V	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to ASP3026 treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1122V	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1122V	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1122V ALK L1196M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1122V ALK L1196M	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1122V ALK L1196M	anaplastic large cell lymphoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1122V ALK L1196M	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1122V ALK L1196M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK P1139S	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK P1139S	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK P1139S in the context of NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK P1139S	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK P1139S	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK P1139S	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK S1206C	Advanced Solid Tumor	decreased response	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK S1206C	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK and ALK S1206C were resistant to ASP3026 treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK S1206C	anaplastic large cell lymphoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK ALK S1206C were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK S1206C	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK S1206C	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK S1206C	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK F1174V ALK L1198F	anaplastic large cell lymphoma	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK1198F were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK F1174V ALK L1198F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	decreased response	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	decreased response	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK L1196M ALK D1203N	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N in culture (PMID: 25421750).	25421750
NPM1	NPM1-ALK ALK I1171S	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK I1171S	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK I1171S	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK I1171S	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK I1171S	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1161S were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK I1171S	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK I1171S	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Alunbrig (brigatinib)-mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK T1151M	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK T1151M	anaplastic large cell lymphoma	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK F1174L	anaplastic large cell lymphoma	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK F1174L	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK F1174L	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK F1174L in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK R1192P	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK R1192P in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK R1192P	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK R1192P were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK R1192P	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Xalkori (Crizotinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK R1192P	Advanced Solid Tumor	decreased response	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P had a reduced response to AZD3463 mediated growth inhibition in culture compared to cells expressing wild-type NPM1-ALK (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK R1192P	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK R1192P	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK R1192P	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK G1269A	Advanced Solid Tumor	conflicting	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK G1269A	Advanced Solid Tumor	conflicting	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A demonstrated resistance to ASP3026 in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK G1269A	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK G1269A	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A demonstrated resistance to Alecensa (alectinib) in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK G1269A	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK G1269A	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK G1269A	Advanced Solid Tumor	conflicting	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK G1269A	Advanced Solid Tumor	sensitive	AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK G1269A	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK G1269A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK G1269A	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
NPM1	NPM1-ALK ALK I1171N	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK I1171N	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to ASP3026 in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK C1156Y	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156Y demonstrated moderate resistance to ASP3026 in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK C1156Y	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156Y were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK C1156Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK C1156Y in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK C1156Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156Y demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK C1156Y	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156Y demonstrated moderate resistance to Zykadia (ceritinib) in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK F1174I	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK F1174I were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK F1174I	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174I were resistant to ASP3026 relative to wild type NPM1-ALK in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK F1174I	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to ASP3026 in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Alecensa (alectinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK C1156F	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK C1156F in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK C1156F	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156F were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK C1156F	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to ASP3026 in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Alecensa (alectinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK E1210K	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK E1210K in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with E1210K were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK E1210K	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK E1210K	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK E1210K were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to ASP3026 in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Alecensa (alectinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK G1128S	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK G1128S	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1128S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK G1128S	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK G1128S in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK C1156F ALK D1203N	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK C1156F and D1203N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with C1156F and D1203N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to ASP3026 in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK C1156F ALK D1203N	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK N1178H	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK N1178H	Advanced Solid Tumor	sensitive	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK N1178H	Advanced Solid Tumor	resistant	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK N1178H	Advanced Solid Tumor	decreased response	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to ASP3026 in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK N1178H	anaplastic large cell lymphoma	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK N1178H were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK N1178H	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK N1178H	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK L1196Q	anaplastic large cell lymphoma	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing ALK L1196Q were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK L1196Q	anaplastic large cell lymphoma	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited growth of human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing the crizotinib-resistant mutation ALK L1196Q in culture (PMID: 25749034).	25749034
NPM1	NPM1-ALK ALK L1152R	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1152R demonstrated resistance to ASP3026 in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK L1152R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1152R demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK L1152R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1152R demonstrated resistance to Zykadia (ceritinib) in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK L1152R	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1152R demonstrated moderate resistance to Alecensa (alectinib) in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK L1152R	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK L1152R in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK G1202R	Advanced Solid Tumor	resistant	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1202R demonstrated resistance to Alecensa (alectinib) in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK G1202R	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1202R demonstrated resistance to Zykadia (ceritinib) in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK G1202R	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1202R demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK G1202R	Advanced Solid Tumor	resistant	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1202R demonstrated resistance to ASP3026 in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK G1202R	Advanced Solid Tumor	resistant	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1202R demonstrated resistance to Alunbrig (brigatinib) in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK S1206Y in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, ASP3026 inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK S1206Y in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK S1206Y	Advanced Solid Tumor	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206Y demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alecensa (alectinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK S1206Y in culture (PMID: 25727400).	25727400
NPM1	NPM1-ALK ALK S1206Y	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK S1206Y in culture (PMID: 25727400).	25727400
NPM1	NPM1 mutant	acute myeloid leukemia	predicted - sensitive	Ibrutinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, NPM1 mutations correlated with sensitivity to Imbruvica (ibrutinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
NPM1	NPM1 mutant	leukemia	predicted - sensitive	EPZ004777	Preclinical	Actionable	In preclinical study, treatment with EPZ004777 resulted in reduced proliferation and increased differentiation of murine leukemia cells expressing an NPM1 mutation, and improved survival in NPM1-mutant murine leukemia models (PMID: 27535106).	27535106
NPM1	NPM1 mutant	acute myeloid leukemia	predicted - sensitive	Cytarabine + Venetoclax	Phase Ib/II	Actionable	In a Phase I/II trial, Venclexta (venetoclax) in combination with low-dose cytarabine resulted in complete remission or complete remission with incomplete count recovery in 89% (8/9) of patients with acute myeloid leukemia harboring NPM1 mutations who were ineligible for intensive chemotherapy (ASH Annual Meeting, Dec 2018, Abstract 284; NCT02287233).	detail...
NPM1	NPM1 mutant	acute myeloid leukemia	predicted - sensitive	Entospletinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, NPM1 mutations correlated with sensitivity to Entospletinib in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
NPM1	NPM1 mutant	acute myeloid leukemia	predicted - sensitive	EPZ004777	Preclinical - Patient cell culture	Actionable	In a preclinical study, EPZ004777 decreased HOX gene expression, and reduced proliferation and increased differentiation of a human acute myeloid leukemia (AML) cell line and primary AML samples harboring NPM1 mutations in culture (PMID: 27535106).	27535106
NPM1	NPM1 mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, an NPM1 mutation without FLT3 internal tandem duplication (ITD) mutation was associated with favorable prognosis in acute myeloid leukemia (AML) patients, compared to AML patients harboring an NPM1 mutation and FLT3 ITD mutation (PMID: 19047294, PMID: 24573385, PMID: 25713434).	25713434 19047294 24573385
NPM1	NPM1 mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, mutations in NPM1, in the absence of a FLT3 ITD mutation, were associated with favorable prognosis in acute myeloid leukemia patients with normal karyotype (PMID: 26239249, PMID: 26586702, PMID: 26676635, PMID: 16109776).	26239249 26676635 16109776 26586702
NPM1	NPM1 mutant	acute myeloid leukemia	sensitive	NSC348884	Preclinical	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a NPM1 mutation were sensitive to NSC348884 as demonstrated by induced apoptosis (PMID: 21719597).	21719597
NPM1	NPM1 mutant	acute myeloid leukemia	sensitive	ENMD-2076	Phase I	Actionable	In a Phase I trial, three acute myeloid leukemia patient harboring an NPM1 mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088).	27406088
NPM1	NPM1 mutant	acute myeloid leukemia	predicted - sensitive	MI-503	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia cell line and primary AML samples harboring NPM1 mutations in culture, and reduced tumor burden and improved survival in an NPM1-mutant AML cell line xenograft model (PMID: 27535106).	27535106
NPM1	NPM1 mutant FLT3 wild-type	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	NPM1 mutations with FLT3 wild-type (no or low allelic ratio of ITD mutations) are associated with a favorable prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).	detail...
NPM1	FLT3 exon 14 ins NPM1 mutant	acute myeloid leukemia	sensitive	ENMD-2076	Phase I	Actionable	In a Phase I trial, two acute myeloid leukemia patients co-harboring a FLT3-ITD mutation and NPM1 mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088).	27406088
NPM1	FLT3 exon 14 ins NPM1 mutant	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	FLT3 exon 14 insertions (high allelic ratio of ITD mutations) with NPM1 mutations are associated with an intermediate prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).	detail...
NPM1	FLT3 exon 14 ins NPM1 mutant	acute myeloid leukemia	predicted - sensitive	Entospletinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of FLT3-ITD and NPM1 mutations correlated with sensitivity to Entospletinib in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
NPM1	FLT3 exon 14 ins NPM1 mutant	leukemia	predicted - sensitive	MI-503	Preclinical	Actionable	In a preclinical study, MI-503 inhibited growth of murine leukemia cells expressing an NPM1 mutation and FLT3 internal tandem duplication in culture, and improved survival in mouse models (PMID: 27535106).	27535106
NPM1	FLT3 exon 14 ins NPM1 mutant	acute myeloid leukemia	predicted - sensitive	Sorafenib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of FLT3-ITD and NPM1 mutations correlated with sensitivity to Nexavar (sorafenib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
NPM1	FLT3 exon 14 ins NPM1 mutant	leukemia	predicted - sensitive	EPZ004777	Preclinical	Actionable	In a preclinical study, EPZ004777 inhibited growth and induced differentiation of murine leukemia cells expressing an NPM1 mutation and FLT3 internal tandem duplication in culture, and improved survival in mouse models (PMID: 27535106).	27535106
NPM1	FLT3 exon 14 ins NPM1 mutant	acute myeloid leukemia	predicted - sensitive	Ibrutinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of FLT3-ITD and NPM1 mutations correlated with sensitivity to Imbruvica (ibrutinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
NPM1	FLT3 exon 14 ins NPM1 mutant	acute myeloid leukemia	predicted - sensitive	Sunitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of FLT3-ITD and NPM1 mutations correlated with sensitivity to Sutent (sunitinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
NPM1	DNMT3A mut FLT3 mut NPM1 mut	acute myeloid leukemia	not applicable	N/A	Clinical Study	Emerging	In a retrospective analysis, the combination of DNMT3A, FLT3, and NPM1 mutations in patients with acute myeloid leukemia was highly associated with decreased event-free survival and overall survival, suggesting that this combination profile may serve as a future prognostic biomarker (PMID: 25281355).	25281355
NPM1	DNMT3A mut FLT3 exon 14 ins NPM1 mut	acute myeloid leukemia	predicted - sensitive	Entospletinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of FLT3-ITD, DNMT3A, and NPM1 mutations correlated with sensitivity to Entospletinib in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
NPM1	DNMT3A mut FLT3 exon 14 ins NPM1 mut	acute myeloid leukemia	predicted - sensitive	Ibrutinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of FLT3-ITD , DNMT3A, and NPM1 mutations correlated with sensitivity to Imbruvica (ibrutinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
NPM1	DNMT3A mut FLT3 exon 14 ins NPM1 mut	acute myeloid leukemia	predicted - sensitive	KO-539	Preclinical - Pdx	Actionable	In a preclinical study, KO-539 treatment resulted in clearance of leukemia cells in patient-derived xenograft (PDX) models of acute myeloid leukemia harboring mutations in NPM1, DNMT3, and FLT3 exon 14 (ITD) (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27).	detail...
NPM1	DNMT3A wild-type FLT3 mut NPM1 mut	acute myeloid leukemia	predicted - sensitive	KO-539	Preclinical - Pdx	Actionable	In a preclinical study, KO-539 treatment prevented disease progression in patient-derived xenograft (PDX) models of DNMT3A wild-type acute myeloid leukemia harboring mutations in NPM1 and FLT3 (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27).	detail...
NPM1	DNMT3A mut NPM1 mut	acute myeloid leukemia	predicted - sensitive	Ibrutinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of DNMT3A and NPM1 mutations correlated with sensitivity to Imbruvica (ibrutinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
NPM1	DNMT3A mut NPM1 mut	acute myeloid leukemia	predicted - sensitive	Entospletinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of DNMT3A and NPM1 mutations correlated with sensitivity to Entospletinib in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
NPM1	NPM1 W288fs	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	NPM1 W288fs mutations are associated with poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
NPM1	NPM1 exon12	acute myeloid leukemia	sensitive	Deguelin	Preclinical	Actionable	In preclinical studies, deguelin treatment of an AML cell line harboring NPM1 exon12 mutation resulted in reduced levels of mutant Npm1 protein and induced differentiation of the cells (PMID: 25242579, PMID: 25348016).	25242579 25348016
NPM1	NPM1 exon12	acute myeloid leukemia	sensitive	Ixazomib + Vorinostat	Preclinical - Cell culture	Actionable	In a preclinical study, Ixazomib (MLN9708) and Zolinza (vorinostat) synergistically induced apoptosis in NPMc+ (due to NPM1 exon 12 mutations) acute myeloid leukemia cells in culture (PMID: 26634271).	26634271
NPM1	NPM1 exon12	acute myeloid leukemia	predicted - sensitive	Ixazomib	Case Reports/Case Series	Actionable	In a clinical study, Ixazomib (MLN9708) treatment resulted in significantly reduced peripheral blast cells in a NPMc+ (due to NPM1 exon 12 mutations) acute myeloid leukemia (AML) patient, and demonstrated selective toxicity towards NPMc+ AML cell lines in culture (PMID: 26634271).	26634271
NRAS	NRAS mutant	melanoma	predicted - sensitive	Nivolumab	Clinical Study - Cohort	Actionable	In a clinical study, NRAS mutations were associated with higher 6-month objective response rate (53.3% vs. 19.6% without NRAS mutations; p=0.019) following treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab) in patients with metastatic melanoma, however, progression-free survival and overall survival were similar between patients with and without NRAS mutations (PMID: 29973670).	29973670
NRAS	NRAS mutant	melanoma	predicted - sensitive	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cell lines harboring an NRAS mutation were sensitive to the combination therapy of Ibrance (palbociclib) and Mekinist (trametinib) in culture, demonstrating reduced cell viability, colony formation, and pathway activity, and increased cell cycle arrest (PMID: 30819666).	30819666
NRAS	NRAS mutant	lung adenocarcinoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human lung adenocarcinoma cell lines harboring mutant NRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).	26343583
NRAS	NRAS mutant	acute myeloid leukemia	predicted - resistant	Pazopanib	Preclinical - Patient cell culture	Actionable	In a preclinical study, NRAS mutations correlated with resistance to Votrient (pazopanib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
NRAS	NRAS mutant	melanoma	sensitive	CCT241161	Preclinical	Actionable	In a preclinical study, CCT241161 inhibited growth of melanoma cells harboring NRAS mutations in culture (PMID: 25500121).	25500121
NRAS	NRAS mutant	ovarian cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of ovarian cancer cells harboring mutant NRAS in culture (PMID: 26343583).	26343583
NRAS	NRAS mutant	transitional cell carcinoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, human urinary tract transitional cell carcinoma cells harboring mutant NRAS were moderately sensitive to Mekinist (trametinib) growth inhibition in culture (PMID: 26343583).	26343583
NRAS	NRAS mutant	melanoma	sensitive	SBI-0640756	Preclinical	Actionable	In a preclinical study, SBI-0640756 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897).	26603897
NRAS	NRAS mutant	autonomic nervous system neoplasm	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of human autonomic ganglia cancer cells harboring mutant NRAS in culture (PMID: 26343583).	26343583
NRAS	NRAS mutant	stomach carcinoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).	detail...
NRAS	NRAS mutant	Advanced Solid Tumor	predicted - sensitive	BGB-283	Phase I	Actionable	In a Phase I trial, BGB-283 demonstrated safety and preliminary efficacy, resulted in partial response in 14% (4/29), and prolonged stable disease in 48% (14/29) of advanced solid tumor patients harboring mutations in KRAS, NRAS, and/or BRAF (AACR Annual Meeting, Apr 2016, abstract # CT005).	detail...
NRAS	NRAS mutant	lymphoma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of human lymphoma cells harboring mutant NRAS in culture (PMID: 26343583).	26343583
NRAS	NRAS mutant	melanoma	predicted - sensitive	Belvarafenib	Case Reports/Case Series	Actionable	In a Phase I trial, Belvarafenib (HM95573) treatment resulted in an unconfirmed partial response in a patient with NRAS mutant melanoma (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2570-2570; NCT02405065).	detail...
NRAS	NRAS mutant	melanoma	predicted - sensitive	Belvarafenib	Phase I	Actionable	In Phase I trials, Belvarafenib (HM95573) treatment resulted in partial response in 44% (4/9) of patients with NRAS-mutant melanoma in a dose escalation study, and partial response in 22% (2/9) of NRAS-mutant melanoma patients in a dose expansion study (J Clin Oncol 37, 2019 (suppl; abstr 3000); NCT02405065, NCT03118817).	detail...
NRAS	NRAS mutant	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring a mutation in NRAS were resistant to Zelboraf (vemurafenib) mediated growth inhibition in culture (PMID: 26343583).	26343583
NRAS	NRAS mutant	Advanced Solid Tumor	no benefit	CC-90003	Phase I	Actionable	In a Phase Ia trial, CC-90003 treatment did not result in any objective responses and demonstrated toxicity in advanced solid tumor patients harboring KRAS, NRAS, or BRAF mutations (J Clin Oncol 35, 2017 (suppl; abstr 2577)).	detail...
NRAS	NRAS mutant	melanoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).	detail...
NRAS	NRAS mutant	multiple myeloma	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of human multiple myeloma cells harboring mutant NRAS in culture (PMID: 26343583).	26343583
NRAS	NRAS mutant	melanoma	sensitive	BI-69A11	Preclinical	Actionable	In a preclinical study, BI-69A11 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897).	26603897
NRAS	NRAS mutant	leukemia	sensitive	Belvarafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Belvarafenib (HM95573) inhibited growth of NRAS mutant leukemia cells in culture (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).	detail...
NRAS	NRAS mutant	melanoma	predicted - sensitive	Ulixertinib	Phase I	Actionable	In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a best response of stable disease in six melanoma patients and a partial response in three melanoma patients all harboring an NRAS mutation (PMID: 29247021).	29247021
NRAS	NRAS mutant	acute myeloid leukemia	predicted - resistant	Tivozanib	Preclinical - Patient cell culture	Actionable	In a preclinical study, NRAS mutations correlated with resistance to Tivozanib (AV-951) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
NRAS	NRAS mutant	melanoma	sensitive	Binimetinib + Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring an NRAS mutation (PMID: 27307593).	27307593
NRAS	NRAS mutant	colorectal cancer	predicted - resistant	SYM004	Preclinical - Pdx	Actionable	In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521).	29423521
NRAS	NRAS mutant	cervix carcinoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant cervical carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).	detail...
NRAS	NRAS mutant	melanoma	sensitive	Palbociclib + PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination treatment of PD-0325901 and Ibrance (palbociclib) resulted in tumor regression in 33% (2/6) of melanoma xenograft models harboring an NRAS mutation (PMID: 27488531).	27488531
NRAS	NRAS mutant	melanoma	sensitive	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Buparlisib (BKM120) treatment in human melanoma cell line xenograft models with brain metastases and harboring an NRAS mutation resulted in inhibition of brain tumor growth and an improved survival benefit (PMID: 27307593).	27307593
NRAS	NRAS mutant	melanoma	no benefit	PD-0325901	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PD-0325901 treatment resulted in stable tumor growth in melanoma cell line xenograft models harboring an NRAS mutation, however, growth later ensued and thus, demonstrates a lack of benefit (PMID: 27488531).	27488531
NRAS	NRAS mutant	melanoma	sensitive	CCT196969	Preclinical	Actionable	In a preclinical study, CCT196969 inhibited growth of melanoma cells harboring NRAS mutations in culture (PMID: 25500121).	25500121
NRAS	NRAS mutant	acute myeloid leukemia	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 inhibited proliferation of human NRAS mutant acute myeloid leukemia cell lines in culture (PMID: 26343583).	26343583
NRAS	NRAS mutant	melanoma	sensitive	Binimetinib + Ribociclib	Phase Ib/II	Actionable	In a Phase Ib/II trial, the combination of Binimetinib (MEK162) and Kisqali (ribociclib) resulted in a partial response in 43% (6/14) and stable disease in 43% (6/14) of NRAS mutant melanoma patients (J Clin Oncol 32:5s, 2014 (Suppl;abstr 9009)).	detail...
NRAS	NRAS mutant	melanoma	sensitive	Binimetinib + Ribociclib	Phase Ib/II	Actionable	In a Phase Ib trial, the combination of Binimetinib (MEK162) and Kisqali (ribociclib) resulted in a median progression-free survival of 6.7 months, a partial response in 25% (4/16), and stable disease in 44% (7/16) of NRAS mutant melanoma patients (J Clin Oncol 35, 2017 (suppl; abstr 9519)).	detail...
NRAS	NRAS mutant	central nervous system cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of human central nervous system cancer cells harboring mutant NRAS in culture (PMID: 26343583).	26343583
NRAS	NRAS mutant	leukemia	sensitive	Alpelisib + Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination therapy of Alpelisib (BYL719) and Binimetinib (MEK162) led to a synergistic effect in leukemia cells harboring mutant NRAS, demonstrating cell death in culture (PMID: 29437705).	29437705
NRAS	NRAS mutant	colorectal cancer	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).	detail...
NRAS	NRAS mutant	acute myeloid leukemia	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of human acute myeloid leukemia cell lines harboring mutant NRAS in culture (PMID: 26343583).	26343583
NRAS	NRAS mutant	colorectal cancer	no benefit	Cetuximab + Fluorouracil + Irinotecan + Leucovorin	Phase III	Actionable	In a retrospective analysis of a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI did not demonstrate an improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with RAS mutations (PMID: 25605843).	25605843
NRAS	NRAS mutant	thyroid cancer	sensitive	Selumetinib	Phase I	Actionable	In a Phase I study, selumetinib demonstrated an increase in iodine uptake and retention in a subgroup of patients with thyroid cancer that was refractory to radioiodine; including patients with BRAF and NRAS mutations disease (PMID: 23406027).	23406027
NRAS	NRAS mutant	melanoma	sensitive	S63845 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination of S63845 and Mekinist (trametinib) resulted in potent cytotoxic effects in NRAS-mutated melanoma cells in culture compared to the cytostatic effect of Mekinist (trametinib) alone (PMID: 27760111).	27760111
NRAS	NRAS mutant	leukemia	predicted - sensitive	Trametinib	Phase Ib/II	Actionable	In a Phase Ib/II clinical trial, treatment with Mekinist (trametinib) resulted in an overall response rate of 28% in RAS-mutant leukemia patients, with 12% (7/57) of patients achieving complete remission (ASH 2015 Annual Meeting, Abst 677).	detail...
NRAS	NRAS mutant	lung non-small cell carcinoma	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant non-small cell lung cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).	detail...
NRAS	NRAS mutant	melanoma	predicted - sensitive	Pembrolizumab	Clinical Study - Cohort	Actionable	In a clinical study, NRAS mutations were associated with higher 6-month objective response rate (53.3% vs. 19.6% without NRAS mutations; p=0.019) following treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab) in patients with metastatic melanoma, however, progression-free survival and overall survival were similar between patients with and without NRAS mutations (PMID: 29973670).	29973670
NRAS	NRAS mutant	acute myeloid leukemia	predicted - resistant	Vemurafenib	Preclinical - Patient cell culture	Actionable	In a preclinical study, NRAS mutations correlated with resistance to Zelboraf (vemurafenib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
NRAS	NRAS mutant	pancreatic cancer	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant pancreatic cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).	detail...
NRAS	NRAS mutant	Advanced Solid Tumor	sensitive	Obatoclax	Preclinical	Actionable	In a preclinical study, obatoclax decreased proliferation in human tumor cell lines with NRAS mutation in culture (PMID: 22460902).	22460902
NRAS	NRAS mutant	acute myeloid leukemia	predicted - sensitive	AZD5153	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD5153 inhibited proliferation of acute myeloid leukemia cells harboring NRAS mutation in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426).	27573426
NRAS	NRAS mutant	melanoma	sensitive	Tubastatin A	Preclinical	Actionable	In a preclinical study, Tubastatin A inhibited proliferation of NRAS mutant melanoma cell lines in culture (PMID: 25957812).	25957812
NRAS	NRAS mutant	hematologic cancer	predicted - resistant	SHP099	Preclinical	Actionable	In a preclinical study, hematopoietic cancer cell lines harboring NRAS mutations demonstrated resistance to SHP099 in cell culture (PMID: 27362227).	27362227
NRAS	NRAS mutant	colon cancer	resistant	GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, colon cancer cells harboring NRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).	19276360
NRAS	NRAS mutant	neuroblastoma	sensitive	Alpelisib + Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination therapy of Alpelisib (BYL719) and Binimetinib (MEK162) led to a synergistic effect in neuroblastoma cells harboring mutant NRAS, demonstrating cell death in culture (PMID: 29437705).	29437705
NRAS	NRAS mutant	liver cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited growth of liver cancer cell lines harboring mutant NRAS in culture (PMID: 26343583).	26343583
NRAS	NRAS mutant	melanoma	sensitive	Trametinib	Phase I	Actionable	In a Phase I trial, Mekinist (trametinib) treatment resulted in stable disease in 29% (2/7) of patients with NRAS mutated melanoma (PMID: 22805292; NCT00687622).	22805292
NRAS	NRAS mutant	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, NRAS-mutant melanoma cell lines were sensitive to treatment with Mekinist (trametinib) in culture, demonstrating decreased cell viability, colony formation, and pathway activity, and increased cell cycle arrest (PMID: 30819666).	30819666
NRAS	NRAS mutant	Advanced Solid Tumor	predicted - sensitive	KO-947	Preclinical - Pdx	Actionable	In a preclinical study, KO-947 resulted in tumor regression in patient derived xenograft (PDX) models harboring either a BRAF mutation, NRAS mutation, or KRAS mutation (EJC Dec 2016, 69:1; S126).	detail...
NRAS	NRAS mutant	Advanced Solid Tumor	no benefit	NS1	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing an NRAS mutation did not respond to treatment with NS1 in culture, resulting in sustained downstream signaling and cell transformation (PMID: 27820802).	27820802
NRAS	NRAS mutant	melanoma	sensitive	SBI-0640726	Preclinical	Actionable	In a preclinical study, SBI-0640726 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897).	26603897
NRAS	NRAS mutant	biliary tract cancer	predicted - sensitive	Binimetinib	Phase I	Actionable	In a Phase I trial, Binimetinib (MEK162) treatment resulted in partial response in a biliary tract cancer patient harboring NRAS mutation (PMID: 28152546)	28152546
NRAS	NRAS mutant	melanoma	conflicting	Palbociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ibrance (palbociclib) treatment resulted in stable tumor growth in melanoma cell line xenograft models harboring an NRAS mutation, however, growth later ensued and thus, demonstrated a lack of benefit (PMID: 27488531).	27488531
NRAS	NRAS mutant	melanoma	conflicting	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, NRAS-mutant melanoma cell lines were sensitive to treatment with Ibrance (palbociclib) in culture, demonstrating decreased cell viability, colony formation, and pathway activity, and increased cell cycle arrest (PMID: 30819666).	30819666
NRAS	NRAS mutant	melanoma	conflicting	Binimetinib	Phase III	Actionable	In a Phase III clinical trial, treatment with Binimetinib (MEK162) improved median progression-free survival compared to treatment with Deticene (dacarbazine) (2.8 mo. vs. 1.5 mo.), but did not improve overall survival in patients with NRAS-mutant melanoma (PMID: 28284557).	28284557
NRAS	NRAS mutant	melanoma	conflicting	Binimetinib	Phase II	Actionable	In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).	23414587
NRAS	NRAS mutant	melanoma	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 inhibited growth of NRAS mutant human melanoma cell lines in culture (PMID: 26343583).	26343583
NRAS	NRAS mutant	melanoma	sensitive	Adavosertib	Preclinical	Actionable	In a preclinical study, Adavosertib (MK-1775) showed efficacy in NRAS mutant melanoma and in mutant KRAS colorectal, pancreatic, and lung cancers (PMID: 24791855).	24791855
NRAS	NRAS mutant	colorectal cancer	no benefit	Regorafenib	Phase II	Actionable	In a Phase II clinical trial (PREVIUM), Stivarga (regorafenib) treatment resulted in 0% (0/15) 6-month progression free survival (PFS), a 2.2-month median PFS, and a median overall survival of 3.3 months in metastatic colorectal cancer patients with KRAS (n=9), NRAS (n=3) or BRAF (n=2) mutations who failed first line therapy; however, the trial was terminated early due to poor accrual (PMID: 30120161; NCT02175654).	30120161
NRAS	NRAS mutant	sarcoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human sarcoma cells harboring mutant NRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).	26343583
NRAS	NRAS mutant	hepatocellular carcinoma	sensitive	Refametinib + Sorafenib	Phase II	Actionable	In a Phase II trial, Refametinib (BAY86-9766) and Nexavar (sorafenib) combination treatment resulted in an objective response rate of 6.3% (1/16), a disease control rate of 43.8% (7/16), an overall survival of 12.7 months, and a progression-free survival of 1.5 months in patients unresectable or metastatic hepatocellular carcinoma harboring RAS (NRAS and KRAS) mutations (PMID: 29950351; NCT01915602).	29950351
NRAS	NRAS mutant	Advanced Solid Tumor	sensitive	RAF709	Preclinical - Cell culture	Actionable	In a preclinical study, cancer cell lines harboring NRAS mutations demonstrated increased sensitivity to RAF709 compared to NRAS wild-type cells in culture (PMID: 29343524).	29343524
NRAS	NRAS mutant	non-Hodgkin lymphoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human non-Hodgkin lymphoma cells harboring mutant NRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).	26343583
NRAS	NRAS mutant	skin melanoma	sensitive	Binimetinib	Phase III	Actionable	In a Phase III trial, Binimetinib (MEK162) treatment resulted in improved progression free survival (2.8 months), objective response rate (15%, 40/269) and disease control rate (58%, 156/269) compared to Deticene (dacarbazine) (1.5 months, 7%, 25%, respectively) in NRAS-mutant cutaneous melanoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9500)).	detail...
NRAS	BRAF wild-type NRAS mutant	melanoma	sensitive	Lenvatinib	Phase I	Actionable	In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 83% (5/6) of melanoma patients harboring NRAS mutations and wild-type BRAF (PMID: 26169970).	26169970
NRAS	CDKN2A loss NRAS mutant	melanoma	sensitive	Abemaciclib	Phase I	Actionable	In a Phase I trial, Abemaciclib (LY2835219) resulted in a partial response in a melanoma patient with CDKN2A loss and NRAS mutation (PMID: 27217383).	detail... 27217383
NRAS	BRAF mut NRAS mut	melanoma	sensitive	Lenvatinib	Phase I	Actionable	In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 50% (1/2) of melanoma patients harboring both BRAF and NRAS mutations (PMID: 26169970).	26169970
NRAS	BRAF mut NRAS mut	melanoma	predicted - sensitive	BI-847325	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to an NRAS mutation in culture (PMID: 25873592).	25873592
NRAS	CTNNB1 mut NRAS mut	liver cancer	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human liver cancer cells harboring mutant NRAS and mutant CTNNB1 were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).	26343583
NRAS	NRAS mut STAG2 dec exp	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in NRAS mutated melanoma cell lines resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).	27500726
NRAS	NRAS mut PIK3CA wild-type	colorectal cancer	predicted - sensitive	TAK-733	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS and with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture (PMID: 26439693).	26439693
NRAS	AKT1 pos NRAS mut	melanoma	predicted - resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, one of two NRAS-mutant melanoma cell lines expressing AKT1 demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).	30819666
NRAS	AKT1 pos NRAS mut	melanoma	predicted - resistant	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, two of four NRAS-mutant melanoma cell lines expressing AKT1 were resistant to the combination treatment of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 30819666).	30819666
NRAS	AKT1 pos NRAS mut	melanoma	predicted - resistant	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, two of two NRAS-mutant melanoma cell lines with AKT1 expression demonstrated resistance to treatment with Ibrance (palbociclib) in culture (PMID: 30819666).	30819666
NRAS	NRAS mut PIK3CA H1047R	melanoma	predicted - resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, one of two NRAS-mutant melanoma cell lines expressing PIK3CA H1047R demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).	30819666
NRAS	NRAS mut PIK3CA E545K	melanoma	predicted - resistant	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, four of four NRAS-mutant melanoma cell lines expressing PIK3CA E545K were resistant to the combination treatment of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 30819666).	30819666
NRAS	NRAS mut PIK3CA E545K	melanoma	predicted - resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, NRAS-mutant melanoma cell lines expressing PIK3CA E545K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).	30819666
NRAS	NRAS mut PIK3CA E545K	melanoma	predicted - resistant	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, two of two NRAS-mutant melanoma cell lines expressing PIK3CA E545K demonstrated resistance to treatment with Ibrance (palbociclib) in culture (PMID: 30819666).	30819666
NRAS	EGFR L858R NRAS mut	melanoma	predicted - resistant	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, two of two NRAS-mutant melanoma cell lines expressing EGFR L858R were resistant to treatment with Ibrance (palbociclib) in culture (PMID: 30819666).	30819666
NRAS	EGFR L858R NRAS mut	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, one of two NRAS-mutant melanoma cell lines expressing EGFR L858R demonstrated a decreased response to Mekinist (trametinib) when compared to control in culture (PMID: 30819666).	30819666
NRAS	EGFR L858R NRAS mut	melanoma	predicted - resistant	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, two of four NRAS-mutant melanoma cell lines expressing EGFR L858R were resistant to the combination treatment of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 30819666).	30819666
NRAS	NRAS mut NRAS Q61L	melanoma	predicted - resistant	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, NRAS-mutant melanoma cells expressing NRAS Q61L demonstrated resistance to the combination treatment with Mekinist (trametinib) and Ibrance (palbociclib) in culture (PMID: 30819666).	30819666
NRAS	NRAS mut NRAS Q61L	melanoma	predicted - resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, NRAS-mutant melanoma cells expressing NRAS Q61L demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).	30819666
NRAS	NRAS mut NRAS Q61L	melanoma	decreased response	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, NRAS-mutant melanoma cells expressing NRAS Q61L demonstrated a decreased response to treatment with Ibrance (palbociclib) in culture when compared to control (PMID: 30819666).	30819666
NRAS	NRAS mut NRAS Q61K	melanoma	predicted - resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, NRAS-mutant melanoma cells expressing NRAS Q61K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).	30819666
NRAS	NRAS mut NRAS Q61K	melanoma	decreased response	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, NRAS-mutant melanoma cells expressing NRAS Q61K demonstrated a decreased response to treatment with Ibrance (palbociclib) in culture compared to control (PMID: 30819666).	30819666
NRAS	NRAS mut NRAS Q61K	melanoma	predicted - resistant	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, NRAS-mutant melanoma cells expressing NRAS Q61K demonstrated resistance to the combination treatment of Mekinist (trametinib) and Ibrance (palbociclib) in culture (PMID: 30819666).	30819666
NRAS	NRAS mut TP53 wild-type	Advanced Solid Tumor	predicted - sensitive	Pimasertib + SAR405838	Phase I	Actionable	In a Phase I trial, SAR405838 and Pimasertib (MSC1936369B) combination therapy demonstrated safety and preliminary efficacy, resulted in partial response in 4% (1/24) and stable disease in 63% (15/24) of patients with TP53 wild-type advanced solid tumors harboring RAS/RAF mutations (KRAS, n=24; BRAF, n=1; NRAS, n=1) (PMID: 30585255; NCT01985191).	30585255
NRAS	NRAS G12D	Advanced Solid Tumor	sensitive	N-Arachidonoyl Dopamine	Preclinical - Cell culture	Actionable	In a preclinical study, N-Arachidonoyl Dopamine (NADA) disrupted NRAS protein membrane localization and decreased NRAS downstream signaling, and inhibited proliferation and induced cell death in transformed cells expressing NRAS G12D in culture (PMID: 27760835).	27760835
NRAS	NRAS G12D	acute myeloid leukemia	sensitive	Alpelisib + Binimetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Alpelisib (BYL719) inhibited proliferation in a human acute myeloid leukemia (AML) cell line harboring NRAS G12D in culture, and decreased disease burden in xenograft models (PMID: 24569456).	24569456
NRAS	NRAS G12D	acute myeloid leukemia	sensitive	Binimetinib	Preclinical	Actionable	In a preclinical study, Binimetinib (MEK162) inhibited growth of acute myeloid leukemia cells that have been demonstrated to harbor NRAS G12D in culture and decreased disease burden in xenograft models with NRAS G12D (PMID: 24569456, PMID: 11238126).	24569456 11238126
NRAS	KMT2A-MLLT1 NRAS G12D	acute myeloid leukemia	predicted - sensitive	AZ20	Preclinical	Actionable	In a preclinical study, AZ20 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).	27625305
NRAS	KMT2A-MLLT1 NRAS G12D	acute myeloid leukemia	predicted - sensitive	AZD0156	Preclinical	Actionable	In a preclinical study, AZD0156 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).	27625305
NRAS	KMT2A-MLLT1 NRAS G12D	acute myeloid leukemia	sensitive	Dinaciclib	Preclinical	Actionable	In a preclinical study, acute myeloid leukemia cells co-harboring KMT2A-MLLT1 and NRAS G12D demonstrated a decrease in tumor burden, reduced colony formation, and an increase in cell death when treated with Dinaciclib in both culture and mouse models (PMID: 26627013).	26627013
NRAS	BRAF D594G NRAS G12D	melanoma	decreased response	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).	27523909
NRAS	BRAF D594G NRAS G12D	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).	27523909
NRAS	BRAF D594G NRAS G12D	melanoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).	27523909
NRAS	BRAF D594G NRAS G12D	melanoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).	27523909
NRAS	BRAF D594G NRAS G12D	melanoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).	27523909
NRAS	AKT1 E17K NRAS G12D	prostate cancer	sensitive	BAY1125976	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring AKT E17K and NRAS G12D in culture, and demonstrated antitumor activity in xenograft models (PMID: 27699769).	27699769
NRAS	DNMT3A R882H NRAS G12D	acute myeloid leukemia	sensitive	Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an acute myeloid leukemia cell line xenograft model harboring DNMT3A R882H and NRAS G12D was sensitive to Mekinist (trametinib), demonstrating impaired disease progression and improved survival (PMID: 31164355).	31164355
NRAS	DNMT3A R882H NRAS G12D	acute myeloid leukemia	sensitive	I-BET151	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an acute myeloid leukemia cell line harboring DNMT3A R882H and NRAS G12D mutations demonstrated reduced proliferation and downregulation of a DNMT3A R882H associated gene expression profile upon I-BET151 treatment in culture, and I-BET151 treatment delayed the onset of leukemia symptoms and improved survival in xenograft mouse models derived from these cells (PMID: 31164355).	31164355
NRAS	DNMT3A R882H NRAS G12D	acute myeloid leukemia	sensitive	I-BET151 + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an acute myeloid leukemia cell line xenograft model harboring DNMT3A R882H and NRAS G12D treated with combined I-BET151 and Mekinist (trametinib) demonstrated impaired disease progression and improved survival superior to either therapy alone (PMID: 31164355).	31164355
NRAS	NRAS G12X	colorectal cancer	resistant	Cetuximab	FDA contraindicated	Actionable	Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 2, codon 12 mutations is contraindicated (FDA.gov).	detail...
NRAS	NRAS G12X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	NRAS G12X is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
NRAS	NRAS G12X	colorectal cancer	resistant	Panitumumab	FDA contraindicated	Actionable	Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 2, codon 12 mutations is contraindicated (FDA.gov).	detail...
NRAS	EGFR exon 19 del NRAS amp	lung non-small cell carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS in culture (PMID: 25870145).	25870145
NRAS	EGFR exon 19 del NRAS amp	lung non-small cell carcinoma	resistant	Afatinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified NRAS in culture (PMID: 25870145).	25870145
NRAS	EGFR exon 19 del NRAS amp	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).	25870145
NRAS	NRAS amp	melanoma	predicted - sensitive	Binimetinib	Preclinical - Pdx	Actionable	In a preclinical study, Mektovi (binimetinib) treatment resulted in reduced tumor growth and proliferation in two patient-derived xenograft (PDX) melanoma models with NRAS copy number gain and without BRAF or NRAS mutations (PMID: 29245078).	29245078
NRAS	FGFR1 amp NRAS amp	lung non-small cell carcinoma	sensitive	BGJ398 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Mekinist (trametinib) combination treatment inhibited Erk signaling, resulting in growth inhibition in non-small cell lung carcinoma cells harboring both FGFR1 and NRAS amplification in culture (PMID: 28630215).	28630215
NRAS	FGFR1 amp NRAS amp	lung non-small cell carcinoma	resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells harboring both FGFR1 and NRAS amplification were resistant to Mekinist (trametinib) in culture (PMID: 28630215).	28630215
NRAS	FGFR1 amp NRAS amp	lung non-small cell carcinoma	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, amplification of NRAS was identified in a non-small cell lung cancer cell line harboring FGFR1 amplification that acquired resistance to BGJ398 in culture (PMID: 28630215).	28630215
NRAS	BRAF V600E NRAS amp	colorectal cancer	predicted - resistant	Panitumumab + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after achieving stable disease for 16 weeks with Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, NRAS amplification was identified as an acquired alteration at the time of progression (PMID: 28951457).	28951457
NRAS	BRAF V600D NRAS dec exp	melanoma	no benefit	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600D and knockdown of NRAS demonstrated a decreased response to Mektovi (binimetinib) relative to cells without NRAS knockdown in culture (PMID: 29245078).	29245078
NRAS	NRAS wild-type	melanoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, an NRAS wild-type melanoma cell line demonstrated inhibition of cell growth when treated with Mekinist (trametinib) in culture (PMID: 27488531).	27488531
NRAS	NRAS wild-type	colorectal cancer	predicted - sensitive	Panitumumab	FDA approved - On Companion Diagnostic	Actionable	Vectibix (panitumumab) is FDA approved for metastatic colorectal patients that are NRAS wild-type, as detected by a companion diagnostic (FDA.gov).	detail... detail...
NRAS	NRAS wild-type	colorectal cancer	predicted - sensitive	Panitumumab	Phase III	Actionable	In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920).	26341920
NRAS	NRAS wild-type	melanoma	decreased response	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, an NRAS wild-type melanoma cell line demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531).	27488531
NRAS	NRAS wild-type	melanoma	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with wild-type NRAS (PMID: 23039341).	23039341
NRAS	NRAS wild-type	colorectal cancer	predicted - sensitive	Cetuximab + Fluorouracil + Irinotecan + Leucovorin	Phase III	Actionable	In a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI demonstrated a significant clinical benefit in OS, PFS, and objective response compared to FOLFIRI alone in colorectal cancer patients with RAS wild-type status (PMID: 25605843).	25605843
NRAS	NRAS wild-type	melanoma	sensitive	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, NRAS wild-type melanoma cells demonstrated decreased cell viability when treated with Ibrance (palbociclib) in culture (PMID: 27488531).	27488531
NRAS	BRAF mut NRAS wild-type	melanoma	sensitive	Lenvatinib	Phase I	Actionable	In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 100% (5/5) of melanoma patients harboring BRAF mutations and wild-type NRAS (PMID: 26169970).	26169970
NRAS	BRAF wild-type NRAS wild-type	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to Zelboraf (vemurafenib) in culture (PMID: 27523909).	27523909
NRAS	BRAF wild-type NRAS wild-type	melanoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).	27523909
NRAS	BRAF wild-type NRAS wild-type	melanoma	resistant	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to PLX7904 in culture (PMID: 27523909).	27523909
NRAS	BRAF wild-type NRAS wild-type	melanoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).	27523909
NRAS	BRAF wild-type NRAS wild-type	melanoma	sensitive	Lenvatinib	Phase I	Actionable	In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 44% (4/9) and partial response in 22% (2/9) of melanoma patients carrying wild-type BRAF and NRAS (PMID: 26169970).	26169970
NRAS	BRAF wild-type NRAS wild-type	melanoma	sensitive	Binimetinib + Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line with wild-type BRAF and wild-type NRAS in culture (PMID: 27307593).	27307593
NRAS	ERBB2 amp NRAS wild-type	rectum cancer	sensitive	Pertuzumab + Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab) in combination with Perjeta (pertuzumab) is included in guidelines as second-line therapy for advanced or metastatic rectum cancer patients with ERBB2 amplification and NRAS wild-type (NCCN.org).	detail...
NRAS	ERBB2 amp NRAS wild-type	colon cancer	sensitive	Lapatinib + Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab) in combination with Tykerb (lapatinib) is included in guidelines as second-line therapy for advanced or metastatic colon cancer patients with ERBB2 amplification and NRAS wild-type (NCCN.org).	detail...
NRAS	ERBB2 amp NRAS wild-type	colon cancer	sensitive	Pertuzumab + Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab) in combination with Perjeta (pertuzumab) is included in guidelines as second-line therapy for advanced or metastatic colon cancer patients with ERBB2 amplification and NRAS wild-type (NCCN.org).	detail...
NRAS	ERBB2 amp NRAS wild-type	rectum cancer	sensitive	Lapatinib + Trastuzumab	Guideline	Actionable	Herceptin (trastuzumab) in combination with Tykerb (lapatinib) is included in guidelines as second-line therapy for advanced or metastatic rectum cancer patients with ERBB2 amplification and NRAS wild-type (NCCN.org).	detail...
NRAS	NRAS G12V	colorectal cancer	sensitive	Cetuximab + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring NRAS G12V in culture (PMID: 28179366).	28179366
NRAS	NRAS G12V	colorectal cancer	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells harboring NRAS G12V demonstrated resistance to Erbitux (cetuximab) in culture (PMID: 28179366).	28179366
NRAS	EGFR exon 19 del NRAS G12V	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12V were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).	25870145
NRAS	BRAF V600E NRAS G12V	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, expression of NRAS G12V in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 26267534).	26267534
NRAS	BRAF V600E NRAS G12V	melanoma	sensitive	DEL-22379	Preclinical - Cell culture	Actionable	In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and over expressing NRAS G12V in culture (PMID: 26267534).	26267534
NRAS	NRAS exon 3	colon cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in colon cancer patients with NRAS exon 3 mutations (NCCN.org).	detail...
NRAS	NRAS exon 3	rectum cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in rectum cancer patients with NRAS exon 3 mutations (NCCN.org).	detail...
NRAS	NRAS exon 3	rectum cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in rectum cancer patients with NRAS exon 3 mutations (NCCN.org).	detail...
NRAS	NRAS exon 3	colon cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in colon cancer patients with NRAS exon 3 mutations (NCCN.org).	detail...
NRAS	NRAS G13V	adult T-cell leukemia	sensitive	3144	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, 3144 inhibited growth of patient-derived T-cell acute lymphocytic leukemia cells harboring NRAS G13V in culture, and reduced tumor burden in xenograft models (PMID: 28235199).	28235199
NRAS	NRAS mut CDKN2A mut	acute lymphocytic leukemia	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, human acute lymphoblastic leukemia cells harboring NRAS and CDKN2A mutations were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).	26343583
NRAS	BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R	melanoma	predicted - resistant	Vemurafenib	Clinical Study - Cohort	Actionable	In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistance-associated mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).	24265153
NRAS	NRAS A146X	colorectal cancer	resistant	Panitumumab	FDA contraindicated	Actionable	Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 4, codon 146 mutations is contraindicated (FDA.gov).	detail...
NRAS	NRAS A146X	colorectal cancer	resistant	Cetuximab	FDA contraindicated	Actionable	Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 4, codon 146 mutations is contraindicated (FDA.gov).	detail...
NRAS	EGFR exon 19 del NRAS E63K	lung non-small cell carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K in culture (PMID: 25870145).	25870145
NRAS	EGFR exon 19 del NRAS E63K	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K were resistant to Tagrisso (osimertinib) AZD9291 treatment in culture (PMID: 25870145).	25870145
NRAS	EGFR exon 19 del NRAS E63K	lung non-small cell carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of NRAS E63K in culture (PMID: 25870145).	25870145
NRAS	NRAS K117X	colorectal cancer	resistant	Panitumumab	FDA contraindicated	Actionable	Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 4, codon 117 mutations is contraindicated (FDA.gov).	detail...
NRAS	NRAS K117X	colorectal cancer	resistant	Cetuximab	FDA contraindicated	Actionable	Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 4, codon 117 mutations is contraindicated (FDA.gov).	detail...
NRAS	NRAS G13X	colorectal cancer	resistant	Panitumumab	FDA contraindicated	Actionable	Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 2, codon 13 mutations is contraindicated (FDA.gov).	detail...
NRAS	NRAS G13X	colorectal cancer	resistant	Cetuximab	FDA contraindicated	Actionable	Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 2, codon 13 mutations is contraindicated (FDA.gov).	detail...
NRAS	NRAS G13X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	NRAS G13X is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
NRAS	NRAS Q61H	rhabdomyosarcoma	sensitive	Alpelisib + Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination therapy of Alpelisib (BYL719) and Binimetinib (MEK162) led to a synergistic effect in rhabdomyosarcoma cells harboring NRAS Q61H, demonstrating cell death in culture (PMID: 29437705).	29437705
NRAS	NRAS Q61R	melanoma	sensitive	Binimetinib	Phase II	Actionable	In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).	23414587
NRAS	NRAS Q61R	thyroid cancer	sensitive	MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring NRAS Q61R (PMID: 21289267).	21289267
NRAS	AKT1 E17K NRAS Q61R	bladder carcinoma	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited Akt activation and downstream signaling in bladder cancer cell lines carrying both Akt1 E17K and Nras Q61R mutations (AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3685).	detail...
NRAS	KIT D816V NRAS Q61R	melanoma	no benefit	Pembrolizumab + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a melanoma patient harboring KIT D816V and NRAS Q61R demonstrated progressive disease when treated with a combination of Mekinist (trametinib) and Keytruda (pembrolizumab) (PMID: 28514312).	28514312
NRAS	ATM mut NRAS Q61R	melanoma	predicted - sensitive	Binimetinib	Case Reports/Case Series	Actionable	In a clinical case study, a melanoma patient harboring an ATM mutation and NRAS Q61R demonstrated a partial response and 16 month progression free survival when treated with Binimetinib (MEK162) (PMID: 28514312).	28514312
NRAS	NRAS Q61K	melanoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cell lines harboring NRAS Q61K in culture (PMID: 26343583).	26343583
NRAS	NRAS Q61K	melanoma	predicted - sensitive	RAF709	Preclinical - Cell culture	Actionable	In a preclinical study, RAF709 inhibited Erk signaling in melanoma cells harboring NRAS Q61K in culture (PMID: 29343524).	29343524
NRAS	NRAS Q61K	melanoma	sensitive	Binimetinib	Phase II	Actionable	In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).	23414587
NRAS	NRAS Q61K	lung non-small cell carcinoma	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).	23629727
NRAS	NRAS Q61K	lung cancer	sensitive	RAF709	Preclinical - Cell line xenograft	Actionable	In a preclinical study, RAF709 inhibited Erk signaling and proliferation of lung cancer cells harboring NRAS Q61K in culture, and resulted in tumor regression in cell line xenograft models (PMID: 29343524).	29343524
NRAS	NRAS Q61K	lung non-small cell carcinoma	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).	23629727
NRAS	NRAS Q61K	lung non-small cell carcinoma	sensitive	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).	23629727
NRAS	NRAS Q61K	lung non-small cell carcinoma	decreased response	Gedatolisib	Preclinical	Actionable	In a preclinical study, human non-small cell lung cancer cells harboring NRAS Q61K had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073, PMID: 12068308).	21325073 12068308
NRAS	NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring NRAS Q61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).	26343583
NRAS	NRAS Q61K	lung non-small cell carcinoma	sensitive	Pimasertib + Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).	23629727
NRAS	NRAS Q61K	melanoma	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring NRAS Q61K in culture (PMID: 26343583).	26343583
NRAS	BRAF V600E NRAS Q61K	lung adenocarcinoma	predicted - resistant	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a breast cancer patient with metastatic lung adenocarcinoma harboring BRAF V600E developed progressive disease after initial response to Talfinlar (dabrafenib) and Mekinist (trametinib) combination therapy, NRAS Q61K was identified as an acquired mutation after disease progression (PMID: 29631033).	29631033
NRAS	BRAF V600E NRAS Q61K	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS Q61K	melanoma	sensitive	XL888	Preclinical	Actionable	In a preclinical study, treatment with XL888 resulted in increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant melanoma cells harboring BRAF V600E along with NRAS Q61K in cell culture (PMID: 22351686).	22351686
NRAS	BRAF V600E NRAS Q61K	colorectal cancer	predicted - resistant	Panitumumab + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 40 weeks to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, NRAS Q61K was identified as an acquired mutation at the time of progression (PMID: 28951457).	28951457
NRAS	BRAF V600E NRAS Q61K	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing NRAS Q61K were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, a NRAS Q61K mutation conferred resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323).	21107323
NRAS	NRAS Q61K CDKN2A loss	melanoma	sensitive	Palbociclib + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Mekinist (trametinib) induced tumor regression in a mouse melanoma model expressing NRAS Q61K and harboring CDKN2A loss (PMID: 22983396).	22983396
NRAS	NRAS Q61K CDKN2A loss	melanoma	sensitive	SBI-0640756	Preclinical	Actionable	In a preclinical study, SBI-0640726 delayed tumor growth of melanomas in mice with a genetic background of NRAS Q61K and CDKN2A loss (PMID: 26603897).	26603897
NRAS	EGFR exon 19 del NRAS Q61K	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).	25870145
NRAS	EGFR exon 19 del NRAS Q61K	lung non-small cell carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K in culture (PMID: 25870145).	25870145
NRAS	EGFR exon 19 del NRAS Q61K	lung non-small cell carcinoma	resistant	WZ4002	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to WZ4002 after the emergence of NRAS Q61K in culture (PMID: 25870145).	25870145
NRAS	EGFR exon 19 del EGFR T790M NRAS Q61K	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).	25870145
NRAS	EGFR L858R EGFR T790M NRAS Q61K	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).	25870145
NRAS	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).	22389471
NRAS	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	conflicting	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, the response of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S to Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) was conflicting as one cell line with this mutation profile responded to the combination and another cell line with the mutation profile did not (PMID: 22389471).	22389471
NRAS	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E MAP2K1 P387S NRAS Q61K	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
NRAS	BRAF V600K NRAS Q61K	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).	22389471
NRAS	BRAF V600K NRAS Q61K	melanoma	sensitive	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).	22389471
NRAS	BRAF V600K NRAS Q61K	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were 3-7 fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600K in culture (PMID: 22389471).	22389471
NRAS	BRAF V600K NRAS Q61K	melanoma	sensitive	GSK2126458	Preclinical	Actionable	In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).	22389471
NRAS	BRAF V600K NRAS Q61K	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).	22389471
NRAS	BRAF V600K NRAS Q61K	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS Q61K NRAS A146T	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cells harboring BRAF V600E and NRAS A146T and NRAS Q61K in culture (PMID: 22389471).	22389471
NRAS	BRAF G469R NRAS Q61K	melanoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).	26343583
NRAS	BRAF G469R NRAS Q61K	melanoma	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).	26343583
NRAS	BRAF G469R NRAS Q61K	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cells harboring BRAF G469R and NRAS G61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).	26343583
NRAS	BRAF amp BRAF V600X NRAS Q61K	melanoma	resistant	Vemurafenib	Clinical Study - Cohort	Actionable	In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, BRAF amplification and NRAS Q61K, during treatment with Zelboraf (vemurafenib) (PMID: 24265153).	24265153
NRAS	BRAF wild-type NRAS Q61K	melanoma	resistant	GDC0879	Preclinical - Pdx	Actionable	In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells harboring NRAS Q61K in patient-derived xenograft models (PMID: 19276360).	19276360
NRAS	BRAF L597V NRAS Q61K	lung non-small cell carcinoma	sensitive	AZ628	Preclinical - Cell culture	Actionable	In a preclinical study, AZ628 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).	27523909
NRAS	BRAF L597V NRAS Q61K	lung non-small cell carcinoma	decreased response	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).	27523909
NRAS	BRAF L597V NRAS Q61K	lung non-small cell carcinoma	sensitive	TAK-632	Preclinical - Cell culture	Actionable	In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).	27523909
NRAS	BRAF L597V NRAS Q61K	lung non-small cell carcinoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).	27523909
NRAS	BRAF L597V NRAS Q61K	lung non-small cell carcinoma	decreased response	PLX7904	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61L demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).	27523909
NRAS	BRAF G466V NRAS Q61K	lung non-small cell carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) growth of a non-small cell lung cancer cell line harboring BRAF G466V and expressing NRAS Q61K in culture (PMID: 28783719).	28783719
NRAS	BRAF G469V NRAS Q61K	melanoma	sensitive	Encorafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).	29903896
NRAS	BRAF G469V NRAS Q61K	melanoma	sensitive	Binimetinib + Encorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mektovi (binimetinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).	29903896
NRAS	BRAF G469V NRAS Q61K	melanoma	sensitive	LY3009120	Preclinical - Cell culture	Actionable	In a preclinical study, LY3009120 inhibited growth of a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).	29903896
NRAS	BRAF G469V NRAS Q61K	melanoma	predicted - resistant	Trametinib + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Zelboraf (vemurafenib) to treatment with Mekinist (trametinib) resulted in increased proliferation compared to Mekinist (trametinib) alone in a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).	29903896
NRAS	BRAF G469V NRAS Q61K	melanoma	no benefit	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Tafinlar (dabrafenib) treatment did not result in significant growth inhibition in a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).	29903896
NRAS	ATM T1200Lfs*7 NRAS Q61K TP53 R213*	sarcoma	predicted - resistant	Olaparib	Case Reports/Case Series	Actionable	In a clinical case study, Lynparza (olaparib) treatment resulted in rapid disease progression in a patient with high-grade sarcoma harboring ATM T1200Lfs*7, NRAS Q61K, and TP53 R213* (PMID: 29304353).	29304353
NRAS	NRAS A59X	colorectal cancer	resistant	Panitumumab	FDA contraindicated	Actionable	Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 3, codon 59 mutations is contraindicated (FDA.gov).	detail...
NRAS	NRAS A59X	colorectal cancer	resistant	Cetuximab	FDA contraindicated	Actionable	Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 3, codon 59 mutations is contraindicated (FDA.gov).	detail...
NRAS	BRAF G596V NRAS G13R	colorectal cancer	sensitive	Cetuximab + LSN3074753	Preclinical - Pdx	Actionable	In a preclinical study, LSN3074753 and Erbitux (cetuximab) worked synergistically, resulting in tumor regression in a patient-derived xenograft model of colorectal cancer harboring BRAF G596V and NRAS G13R (PMID: 28611205).	28611205
NRAS	BRAF V600E NRAS G13R	colorectal cancer	predicted - sensitive	BGB659 + Cetuximab	Preclinical - Pdx	Actionable	In a preclinical study, BGB659 and Erbitux (cetuximab) combination treatment resulted in sustained inhibition of Mek and Erk phosphorylation, lead to tumor regression in patient-derived xenograft models of colorectal cancer harboring BRAF V600E and NRAS G13R (PMID: 28951457).	28951457
NRAS	BRAF V600E NRAS G13R	colorectal cancer	predicted - resistant	Alpelisib + Cetuximab + Encorafenib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 24 weeks to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment, NRAS G13R was identified as an acquired mutation in liver metastasis at the time of progression (PMID: 28951457).	28951457
NRAS	NRAS over exp	melanoma	predicted - sensitive	Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mektovi (binimetinib) treatment in melanoma cell lines with NRAS overexpression, but without NRAS or BRAF mutations, resulted in reduced downstream signaling and proliferation in cultured cells (PMID: 29245078).	29245078
NRAS	FGFR1 amp NRAS over exp	lung non-small cell carcinoma	sensitive	BGJ398 + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 and Mekinist (trametinib) combination treatment inhibited Erk signaling, resulting in growth inhibition in FGFR1-amplified non-small cell lung carcinoma cells overexpressing Nras in culture (PMID: 28630215).	28630215
NRAS	FGFR1 amp NRAS over exp	lung non-small cell carcinoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of Nras in FGFR1-amplified non-small cell lung carcinoma cells resulted in decreased response to BGJ398 in culture (PMID: 28630215).	28630215
NRAS	BRAF V600E NRAS over exp	colorectal cancer	resistant	Cetuximab + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, overexpression of wild-type NRAS in colorectal cancer cell lines harboring BRAF V600E induced Ras activation and Braf/Craf dimerization, conferred resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture and in cell line xenograft models (PMID: 28951457).	28951457
NRAS	BRAF V600E NRAS over exp	colorectal cancer	sensitive	BGB659 + Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, BGB659 and Erbitux (cetuximab) combination treatment demonstrated enhanced inhibition of Erk phosphorylation and growth in BRAF V600E colorectal cancer cell lines overexpressing Nras in culture (PMID: 28951457).	28951457
NRAS	NRAS exon 2	colon cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in colon cancer patients with NRAS exon 2 mutations (NCCN.org).	detail...
NRAS	NRAS exon 2	colon cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in colon cancer patients with NRAS exon 2 mutations (NCCN.org).	detail...
NRAS	NRAS exon 2	rectum cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in rectum cancer patients with NRAS exon 2 mutations (NCCN.org).	detail...
NRAS	NRAS exon 2	rectum cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in rectum cancer patients with NRAS exon 2 mutations (NCCN.org).	detail...
NRAS	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	no benefit	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E and also had reduced sensitivity in comparison to cell lines harboring BRAF V600E and NRAS A146T in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS A146T MAP2K1 P387S	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS A146T	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS A146T	melanoma	sensitive	GSK2126458 + Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS A146T	melanoma	resistant	Dabrafenib	Preclinical	Actionable	In a preclinical study, human melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS A146T	melanoma	sensitive	Dabrafenib + GSK2126458	Preclinical	Actionable	In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS A146T	melanoma	decreased response	GSK2126458	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS A146T	melanoma	decreased response	Trametinib	Preclinical	Actionable	In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were >10-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).	22389471
NRAS	BRAF V600E NRAS A146T	melanoma	sensitive	Dabrafenib + Trametinib	Preclinical	Actionable	In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).	22389471
NRAS	EGFR exon 19 del NRAS G12R	lung non-small cell carcinoma	resistant	Osimertinib	Preclinical	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).	25870145
NRAS	EGFR exon 19 del NRAS G12R	lung non-small cell carcinoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R in culture (PMID: 25870145).	25870145
NRAS	NRAS G13D	melanoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cells harboring NRAS G13D in culture (PMID: 26343583).	26343583
NRAS	NRAS G13D	adult T-cell leukemia	sensitive	3144	Preclinical - Cell culture	Actionable	In a preclinical study, 3144 inhibited growth of patient-derived T-cell acute lymphocytic leukemia cells harboring NRAS G13D in culture (PMID: 28235199).	28235199
NRAS	NRAS G13D	melanoma	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring NRAS G13D in culture (PMID: 26343583).	26343583
NRAS	NRAS G13D	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cells harboring NRAS G13D were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).	26343583
NRAS	NRAS Q61L	melanoma	sensitive	Binimetinib	Phase II	Actionable	In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).	23414587
NRAS	NRAS Q61L	melanoma	sensitive	RAF709	Preclinical - Cell culture	Actionable	In a preclinical study, RAF709 inhibited Erk signaling and proliferation of melanoma cells harboring NRAS Q61L in culture (PMID: 29343524).	29343524
NRAS	NRAS Q61L	melanoma	decreased response	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring NRAS Q61L in culture (PMID: 26343583).	26343583
NRAS	NRAS Q61L	melanoma	sensitive	CCT196969	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CCT196969 inhibited MEK and ERK activation and growth of a melanoma cell line harboring NRAS Q61L in culture, and inhibited tumor growth in a NRAS Q61L-mutant melanoma cell line xenograft model (PMID: 25500121, PMID: 23431193).	25500121 23431193
NRAS	NRAS Q61L	melanoma	sensitive	CCT241161	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CCT241161 inhibited MEK and ERK activation and growth of a melanoma cell line harboring NRAS Q61L in culture, and inhibited tumor growth in a NRAS Q61L-mutant melanoma cell line xenograft model (PMID: 25500121, PMID: 23431193).	25500121 23431193
NRAS	NRAS Q61L	melanoma	resistant	Vemurafenib	Preclinical	Actionable	In a preclinical study, human melanoma cells harboring NRAS Q61L were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).	26343583
NRAS	NRAS Q61L	melanoma	decreased response	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring NRAS Q61L in culture (PMID: 26343583).	26343583
NRAS	NRAS Q61L	melanoma	resistant	PLX4720	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PLX4720 did not inhibit growth of melanoma cells harboring NRAS Q61L in culture or in cell line xenograft models (PMID: 25500121, PMID: 23431193).	25500121 23431193
NRAS	NRAS exon 4	rectum cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in rectum cancer patients with NRAS exon 4 mutations (NCCN.org).	detail...
NRAS	NRAS exon 4	colon cancer	resistant	Panitumumab	Guideline	Actionable	Vectibix (panitumumab) is not indicated for use in colon cancer patients with NRAS exon 4 mutations (NCCN.org).	detail...
NRAS	NRAS exon 4	colon cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in colon cancer patients with NRAS exon 4 mutations (NCCN.org).	detail...
NRAS	NRAS exon 4	rectum cancer	resistant	Cetuximab	Guideline	Actionable	Erbitux (cetuximab) is not indicated for use in rectum cancer patients with NRAS exon 4 mutations (NCCN.org).	detail...
NRAS	NRAS Q61X	colorectal cancer	resistant	Panitumumab	FDA contraindicated	Actionable	Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 3, codon 61 mutations is contraindicated (FDA.gov).	detail...
NRAS	NRAS Q61X	colorectal cancer	resistant	Cetuximab	FDA contraindicated	Actionable	Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 3, codon 61 mutations is contraindicated (FDA.gov).	detail...
NRAS	NRAS Q61X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	NRAS Q61X is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
PDGFRA	PDGFRA H650Q	leukemia	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, mice injected with transformed cells harboring PDGFRA H650Q developed leukemia-like disease that is sensitive to Gleevec (imatinib) (PMID: 21224473).	21224473
PDGFRA	PDGFRA R748G	myeloid leukemia	sensitive	Imatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gleevec (imatinib) inhibited growth of transformed mouse myeloid cells over expressing PDGFRA R748G in culture and prolonged survival in xenograft models (PMID: 21224473).	21224473
PDGFRA	PDGFRA G853D	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA G853D in culture (PMID: 24132921).	24132921
PDGFRA	PDGFRA G853D	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical	Actionable	In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA G853D in culture (PMID: 24132921).	24132921
PDGFRA	PDGFRA L221F	gastrointestinal stromal tumor	sensitive	Imatinib	Phase I	Actionable	In a Phase I retrospective study, treatment with Gleevec (imatinib) demonstrated a prolonged response in a patient with a gastrointestinal stromal tumor harboring a PDGFRA L221F mutation (PMID: 22718859).	22718859
PDGFRA	PDGFRA R841K	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical	Actionable	In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA R841K in culture (PMID: 24132921).	24132921
PDGFRA	PDGFRA R841K	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA R841K in culture (PMID: 24132921).	24132921
PDGFRA	PDGFRA H845_N848delinsP	gastrointestinal stromal tumor	predicted - sensitive	Imatinib	Case Reports/Case Series	Actionable	In a clinical case study, Gleevec (imatinib) treatment resulted in a complete metabolic response in all lesions in a patient with gastric gastrointestinal stromal tumor harboring PDGFRA H845_N848delinsP (PMID: 30778083).	30778083
PDGFRA	PDGFRA H845_N848delinsP	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in transformed cells over expressing PDGFRA H845_N848delinsP in culture (PMID: 21224473).	21224473
PDGFRA	PDGFRA D842_I843delinsIM	Advanced Solid Tumor	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing PDGFRA D842_I843delinsIM were resistant to inhibition of Pdgfra phosphorylation by Gleevec (imatinib) in culture (PMID: 21224473).	21224473
PDGFRA	PDGFRA D842X	gastrointestinal stromal tumor	sensitive	Avapritinib	Phase I	Actionable	In a Phase I (NAVIGATOR) trial, Avapritinib (BLU-285) treatment resulted in an objective response rate of 70% (26/37, 2 complete responses, 24 partial responses) and a disease control rate of 97% (36/37) in patients with gastrointestinal stromal tumor harboring PDGFRA D842 mutations (The CTOS 2018 Annual Meeting, Nov 14-17, Rome Italy, Paper 012 3027631; NCT02508532).	detail...
PDGFRA	PDGFRA D842X	gastrointestinal stromal tumor	sensitive	Avapritinib	Phase I	Actionable	In a Phase I trial, BLU-285 demonstrated preliminary antitumor activity in gastrointestinal stromal tumor patients harboring PDGFRA D842 mutations, with partial responses in 50% (6/12) and stable disease in 50% (6/12) of patients (EORTC-NCI-AACR 2016, Abs 6LBA).	detail...
PDGFRA	PDGFRA V561_I562insER	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in transformed cells over expressing PDGFRA V561_I562insER in culture (PMID: 21224473).	21224473
PDGFRA	PDGFRA D842V	Advanced Solid Tumor	sensitive	Ripretinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ripretinib (DCC-2618) inhibited proliferation of transformed cells expressing PDGFRA D842V in culture (PMID: 31085175).	31085175
PDGFRA	PDGFRA D842V	gastrointestinal stromal tumor	resistant	Imatinib	Guideline	Actionable	Gleevec (imatinib) is not indicated for use in gastrointestinal stromal tumor (GIST) patients with PDGFRA D842V mutations (NCCN.org).	detail...
PDGFRA	PDGFRA D842V	Advanced Solid Tumor	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated resistance to Gleevec (imatinib) in culture (PMID: 30389923).	30389923
PDGFRA	PDGFRA D842V	Advanced Solid Tumor	resistant	Imatinib	Preclinical	Actionable	In a preclinical study, expression of PDGFRA D842V conferred resistance to Gleevec (imatinib) in cell culture (PMID: 15928335).	15928335
PDGFRA	PDGFRA D842V	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated sensitivity to Crenolanib in culture, resulting in decreased cell proliferation (PMID: 30389923).	30389923
PDGFRA	PDGFRA D842V	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib inhibited Pdgfra phosphorylation and proliferation of transformed cells expressing PDGFRA D842V in culture (PMID: 22745105).	22745105
PDGFRA	PDGFRA D842V	Advanced Solid Tumor	sensitive	GSK2126458	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated sensitivity to GSK2126458 (omipalisib) in culture, resulting in decreased cell proliferation (PMID: 30389923).	30389923
PDGFRA	PDGFRA D842V	gastrointestinal stromal tumor	sensitive	Dasatinib	Guideline	Actionable	Sprycel (dasatinib) is included in the guidelines for patients with gastrointestinal stromal tumor (GIST) with PDGFRA D842V mutations (NCCN.org).	detail...
PDGFRA	PDGFRA D842V	gastrointestinal stromal tumor	sensitive	Dasatinib	Phase 0	Actionable	In a clinical trial, Sprycel (dasatinib) treatment resulted in a partial response in 25% (12/48) of patients with Gleevec (imatinib)-resistant gastrointestinal stromal tumor, with decreased tumor size in 2 of those patients, 1 of which harbored PDGFRA D842V (PMID: 29710216).	29710216
PDGFRA	PDGFRA D842V	gastrointestinal stromal tumor	sensitive	Avapritinib	Phase I	Actionable	In a Phase I trial, BLU-285 treatment resulted in partial response lasted for more than 15 cycles of treatment, and sustained reduction of plasma PDGFRA D842V in a patient with gastrointestinal stromal tumor harboring PDGFRA D842V, whose disease had progressed on previous Gleevec (imatinib mesylate), Sprycel (dasatinib), and Crenolanib treatment (PMID: 29093181; NCT02508532).	29093181
PDGFRA	PDGFRA D842V	gastrointestinal stromal tumor	sensitive	Crenolanib	Phase Ib/II	Actionable	In a Phase I/II trial, treatment with Crenolanib (CP-868596) resulted in a clinical benefit rate of 31% (5/16) in gastronintestinal stromal tumor patients harboring PDGFRA D842V, with partial response in 2/16 and stable disease in 3/16 patients (J Clin Oncol 34, 2016 (suppl; abstr 11010)).	detail...
PDGFRA	PDGFRA D842V	Advanced Solid Tumor	sensitive	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) inhibited proliferation of transformed cells expressing PDGFRA D842V in culture (PMID: 31085175).	31085175
PDGFRA	PDGFRA D842V	gastrointestinal stromal tumor	predicted - sensitive	Regorafenib	Clinical Study - Cohort	Actionable	In a clinical study, Stivarga (regorafenib) treatment resulted in partial response in 11% (2/18) of patients and stable disease in 39% (7/18) of gastrointestinal stromal tumor patients, including prolonged stable disease for 12 months in a patient harboring PDGFRA D842V (PMID: 25905001).	25905001
PDGFRA	PDGFRA D842V	Advanced Solid Tumor	sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation in transformed cells overexpressing PDGFRA D842V in culture (PMID: 29093181).	29093181
PDGFRA	PDGFRA D842V	Advanced Solid Tumor	decreased response	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated reduced response to growth inhibition by Stivarga (regorafenib) compared to GIST cells harboring KIT exon 11 deletion in culture (PMID: 31085175).	31085175
PDGFRA	PDGFRA D842V	Advanced Solid Tumor	resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated resistance to Sutent (sunitinib) in culture (PMID: 30389923).	30389923
PDGFRA	PDGFRA D842V	Advanced Solid Tumor	resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing PDGFRA D842V demonstrated resistance to inhibition of PDGFRA phosphorylation by Sutent (sunitinib) in culture (PMID: 18955458).	18955458
PDGFRA	PDGFRA D842V	Advanced Solid Tumor	resistant	Nilotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated resistance to growth inhibition by Tasigna (nilotinib) in culture (PMID: 18794084).	18794084
PDGFRA	PDGFRA D842V	Advanced Solid Tumor	resistant	Nilotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated resistance to Tasigna (nilotinib) in culture (PMID: 30389923).	30389923
PDGFRA	PDGFRA D842V PDGFRA V561D	Advanced Solid Tumor	resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, PDGFRA D842V conferred resistance to inhibition of PDGFRA phosphorylation by Sutent (sunitinib) in cells expressing PDGFRA V561D in culture (PMID: 18955458).	18955458
PDGFRA	PDGFRA Y288C	Advanced Solid Tumor	resistant	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA Y288C demonstrated resistance to Crenolanib in culture (PMID: 30389923).	30389923
PDGFRA	PDGFRA Y288C	Advanced Solid Tumor	no benefit	AZD9150	Preclinical - Cell culture	Actionable	In a preclinical study, ISIS-STAT3rx (AZD9150) did not decrease viability of transformed cells expressing PDGFRA Y288C in culture (PMID: 30389923).	30389923
PDGFRA	PDGFRA Y288C	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) treatment resulted in decreased proliferation of transformed cells expressing PDGFRA Y288C in culture (PMID: 30389923).	30389923
PDGFRA	PDGFRA Y288C	Advanced Solid Tumor	sensitive	GSK2126458	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA Y288C demonstrated sensitivity to GSK2126458 (omipalisib) in culture, resulting in decreased cell proliferation (PMID: 30389923).	30389923
PDGFRA	PDGFRA Y288C	Advanced Solid Tumor	resistant	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA Y288C demonstrated resistance to Sutent (sunitinib) in culture (PMID: 30389923).	30389923
PDGFRA	PDGFRA Y288C	Advanced Solid Tumor	resistant	Nilotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA Y288C demonstrated resistance to Tasigna (nilotinib) in culture (PMID: 30389923).	30389923
PDGFRA	PDGFRA Y288C	Advanced Solid Tumor	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA Y288C demonstrated resistance to Gleevec (imatinib) in culture (PMID: 30389923).	30389923
PDGFRA	PDGFRA R841_D842delinsKI	Advanced Solid Tumor	resistant	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing PDGFRA R841_D842delinsKI were resistant to inhibition of Pdgfra phosphorylation by Gleevec (imatinib) in culture (PMID: 21224473).	21224473
PDGFRA	PDGFRA N659S	myeloid leukemia	decreased response	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed mouse myeloid cells over expressing PDGFRA N659S demonstrated reduced sensitivity to Gleevec (imatinib) in culture (PMID: 21224473).	21224473
PDGFRA	KIT A502_Y503dup PDGFRA H687Y	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Case Reports/Case Series	Actionable	In a clinical study, PDGFRA H687Y was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring primary KIT A502_Y503dup mutation, who developed resistance to Gleevec (imatinib mesylate) (PMID: 18488160).	18488160
PDGFRA	PDGFRA H845Y	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in cells expressing PDGFRA H845Y in culture (PMID: 24132921).	24132921
PDGFRA	PDGFRA H845Y	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical	Actionable	In a preclinical study, crenolanib inhibited Pdgfra phosphorylation in cells expressing PDGFRA H845Y in culture (PMID: 24132921).	24132921
PDGFRA	PDGFRA V561D	Advanced Solid Tumor	sensitive	Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA V561D demonstrated sensitivity to Sutent (sunitinib) in culture, resulting in decreased cell proliferation (PMID: 30389923).	30389923
PDGFRA	PDGFRA V561D	Advanced Solid Tumor	sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, BLU-285 inhibited Kit phosphorylation in transformed cells overexpressing PDGFRA V561D in culture (PMID: 29093181).	29093181
PDGFRA	PDGFRA V561D	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing PDGFRA V561D demonstrated sensitivity to Gleevec (imatinib) in cell culture (PMID: 15928335).	15928335
PDGFRA	PDGFRA V561D	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA V561D demonstrated sensitivity to Gleevec (imatinib) in culture, resulting in decreased cell proliferation (PMID: 30389923).	30389923
PDGFRA	PDGFRA V561D	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA V561D demonstrated sensitivity to Crenolanib in culture, resulting in decreased cell proliferation (PMID: 30389923).	30389923
PDGFRA	PDGFRA V561D	Advanced Solid Tumor	sensitive	GSK2126458	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA V561D demonstrated sensitivity to GSK2126458 (omipalisib) in culture, resulting in decreased cell proliferation (PMID: 30389923).	30389923
PDGFRA	PDGFRA V561D	Advanced Solid Tumor	sensitive	Nilotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing PDGFRA V561D demonstrated sensitivity to Tasigna (nilotinib) in culture, resulting in decreased cell proliferation (PMID: 30389923).	30389923
PDGFRA	PDGFRA mutant	gastrointestinal stromal tumor	sensitive	Imatinib	Guideline	Actionable	Gleevec (imatinib) is included in the guidelines as first-line therapy for patients with gastrointestinal stromal tumor (GIST) with PDGFRA mutations (NCCN.org).	detail...
PDGFRA	PDGFRA mutant	gastrointestinal stromal tumor	not applicable	N/A	Clinical Study	Diagnostic	PDGFRA mutations are used in the diagnosis of gastrointestinal stromal tumors (PMID: 26276366, PMID: 25729899).	25729899 26276366
PDGFRA	CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H	melanoma	predicted - sensitive	Carboplatin + Imatinib + Paclitaxel	Case Reports/Case Series	Actionable	In a clinical case study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).	28514312
PDGFRA	PDGFRA act mut	pancreatic cancer	predicted - sensitive	Vistusertib	Phase I	Actionable	In a Phase I trial, Vistusertib (AZD2014) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a patient with pancreatic cancer harboring a PDGFRA activating mutation (PMID: 25805799).	25805799
PDGFRA	PDGFRA act mut	gastrointestinal stromal tumor	not applicable	N/A	Guideline	Diagnostic	PDGFRA activating mutations aid the diagnosis of gastrointestinal stromal tumor (NCCN.org).	detail...
PDGFRA	PDGFRA D842Y	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical	Actionable	In a preclinical study, Crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA D842Y in culture (PMID: 24132921).	24132921
PDGFRA	PDGFRA D842Y	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA D842Y in culture (PMID: 24132921).	24132921
PDGFRA	PDGFRA V658A	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical	Actionable	In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA V658A in culture (PMID: 24132921).	24132921
PDGFRA	PDGFRA V658A	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA V658A in culture (PMID: 24132921).	24132921
PDGFRA	PDGFRA P577S	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical	Actionable	In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA P577S in culture (PMID: 24132921).	24132921
PDGFRA	PDGFRA P577S	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA P577S in culture (PMID: 24132921).	24132921
PDGFRA	PDGFRA N848K	lung non-small cell carcinoma	predicted - sensitive	Imatinib	Case Reports/Case Series	Actionable	In a clinical case study, a non-small cell lung cancer patient harboring PDGFRA N848K achieved a durable response to Gleevec (imatinib), lasting more than 23 months (PMID: 30268485).	30268485
PDGFRA	PDGFRA amp	lung small cell carcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of lung squamous cell cancer cells with PDGFRA amplification in culture (PMID: 22328973).	22328973
PDGFRA	PDGFRA amp	lung non-small cell carcinoma	sensitive	Sunitinib	Preclinical	Actionable	In a preclinical study, Sutent (sunitinib) decreased cell proliferation and inhibited downstream signaling in a NSCLC cell line harboring a PDGFRA amplification (PMID: 19366796).	19366796
PDGFRA	PDGFRA amp	lung squamous cell carcinoma	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) inhibited growth of lung squamous cell cancer cells with PDGFRA amplification in culture (PMID: 22328973).	22328973
PDGFRA	PDGFRA amp	lung cancer	sensitive	Ripretinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ripretinib (DCC-2618) inhibited proliferation of lung cancer cells harboring PDGFRA amplification in culture, and resulted in tumor regression in cell line xenograft models (PMID: 31085175).	31085175
PDGFRA	PDGFRA amp	malignant peripheral nerve sheath tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, a malignant peripheral nerve sheath tumor cell line harboring a PDGFRA amplification demonstrated cell growth inhibition when treated with Gleevec (imatinib) (PMID: 16357008).	16357008
PDGFRA	PDGFRA amp	lung squamous cell carcinoma	sensitive	Dasatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sprycel (dasatinib) inhibited growth of a lung squamous cell cancer (SCC) cell line with amplification of PDGFRA in culture, and inhibited tumor growth in PDGFRA-amplified lung SCC xenograft models (PMID: 22328973).	22328973
PDGFRA	PDGFRA amp EGFR amp	glioblastoma multiforme	sensitive	Gefitinib + Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) and Iressa (gefitinib) acted synergistically to decrease downstream signaling activity and inhibit cell growth of glioblastoma cell lines with EGFR and PDGFRA coamplification (PMID: 22323597).	22323597
PDGFRA	KIT amp PDGFRA amp	glioblastoma multiforme	sensitive	Ripretinib	Phase I	Actionable	In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including a partial response in a glioblastoma multiforme patient harboring KIT and PDGFRA amplification (EORTC-NCI-AACR 2016, Abs 7LBA).	detail...
PDGFRA	ROS1 fusion KDR amp KIT amp PDGFRA amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of KIT, KDR, and PDGFRA (PMID: 29636358).	29636358
PDGFRA	PDGFRA S566_E571delinsR	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in transformed cells over expressing PDGFRA S566_E571delinsR in culture (PMID: 21224473).	21224473
PDGFRA	PDGFRA Y849S	myeloid leukemia	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) inhibited growth of transformed mouse myeloid cells over expressing PDGFRA Y849S in culture (PMID: 21224473).	21224473
PDGFRA	PDGFRA Y849S	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and cell proliferation in transformed cells over expressing PDGFRA Y849S in culture (PMID: 21224473).	21224473
PDGFRA	PDGFRA N659K	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) decreased Pdgfra phosphorylation in cells expressing PDGFRA N659K in culture (PMID: 22745105).	22745105
PDGFRA	PDGFRA N659K	Advanced Solid Tumor	sensitive	Crenolanib	Preclinical	Actionable	In a preclinical study, crenolanib decreased Pdgfra phosphorylation in cells expressing PDGFRA N659K in culture (PMID: 22745105).	22745105
PDGFRA	PDGFRA D846Y	Advanced Solid Tumor	sensitive	Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and cell proliferation in transformed cells over expressing PDGFRA D846Y in culture (PMID: 21224473).	21224473
PDGFRA	MLH1 M524I PDGFRA W559_R560del	gastrointestinal stromal tumor	predicted - sensitive	Imatinib	Case Reports/Case Series	Actionable	In a clinical case study, Gleevec (imatinib) treatment resulted in disease-free survival for over 10 months in a patient with epithelioid variant of gastrointestinal stromal tumor harboring PDGFRA W559_R560del and MLH1 M524I (PMID: 31273885).	31273885
PDGFRA	PDGFRA I843del	Advanced Solid Tumor	sensitive	Imatinib	Preclinical	Actionable	In a preclinical study, Gleevec (imatinib) decreased phosphorylation of Pdgfra in cell lines expressing PDGFRA I843del mutation in culture (PMID: 14645423).	14645423
PDGFRA	PDGFRA D846V	osteosarcoma	predicted - sensitive	Sorafenib	Case Reports/Case Series	Actionable	In a clinical case study, a pediatric patient with metastatic osteosarcoma demonstrated a partial response to treatment with Nexavar (sorafenib) for 51 months prior to recurrence, and analysis of the pre-progression tumor demonstrated presence of PDGFRA D846V, which was not present in the post-progression sample, suggesting that the PDGFRA variant may have conferred sensitivity to Nexavar (sorafenib) (PMID: 30318721).	30318721
PDGFRA	PDGFRA D846V	gastrointestinal stromal tumor	predicted - resistant	Imatinib	Case Reports/Case Series	Actionable	In a clinical study, none of 4 gastrointestinal stromal tumor patients harboring PDGFRA D842V (n=3) or PDGFRA D846V (n=1) mutations treated on a Phase III clinical trial demonstrated a response to treatment with Gleevec (imatinib), compared to 5 of 6 patients harboring PDGFRA sensitizing mutations (PMID: 16624552).	16624552
PIK3CA	PIK3CA E542V	colorectal cancer	predicted - sensitive	Cetuximab	Case Reports/Case Series	Actionable	In a retrospective analysis, Erbitux (cetuximab) treatment resulted in stable disease in a colorectal carcinoma patient harboring a PIK3CA E542V mutation (PMID: 25714871).	25714871
PIK3CA	PIK3CA R38C PTEN mut	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 decreased growth of endometrial cancer cells harboring PIK3CA R38C and PTEN mutations in culture and in xenograft models (PMID: 22662154).	22662154
PIK3CA	PIK3CA R38C PTEN loss	endometrial cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of an endometrial cancer cell line harboring PIK3CA R38C and PTEN loss in culture (PMID: 21558396).	21558396
PIK3CA	PIK3CA H450_P458del	breast cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed breast epithelial cells expressing PIK3CA H450_P458del were sensitive to treatment with Alpelisib (BYL719) in culture, demonstrating growth inhibition and decreased invasiveness of acini (PMID: 29284706).	29284706
PIK3CA	PIK3CA E453K	breast cancer	resistant	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells expressing PIK3CA E453K demonstrated resistance to treatment with Buparlisib (BKM120) in culture (PMID: 29636477).	29636477
PIK3CA	PIK3CA E453K	lung squamous cell carcinoma	no benefit	Taselisib	Case Reports/Case Series	Actionable	In a Phase I (SWOG S1400B) trial, Taselisib (GDC-0032) treatment did not meet primary endpoint in patients with lung squamous cell carcinoma harboring PIK3CA mutations, a patients harboring PIK3CA E453K did not demonstrated response (PMID: 31158500; NCT02785913).	31158500
PIK3CA	ERBB2 over exp PIK3CA N345T	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA N345T (PMID: 29208673).	29208673
PIK3CA	PIK3CA V955G	colorectal cancer	resistant	Cetuximab + Fluorouracil	Case Reports/Case Series	Actionable	In a clinical study, PIK3CA V955G was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in a colorectal cancer patient, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA V955G (PMID: 28424201).	28424201
PIK3CA	PIK3CA over exp	lung squamous cell carcinoma	sensitive	BEZ235	Preclinical - Cell culture	Actionable	In a preclinical study, BEZ235 induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type Pik3ca in culture (PMID: 26013318).	26013318
PIK3CA	PIK3CA over exp	lung squamous cell carcinoma	sensitive	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, Buparlisib (BKM120) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type Pik3ca in culture (PMID: 26013318).	26013318
PIK3CA	PIK3CA over exp	head and neck squamous cell carcinoma	sensitive	Gedatolisib	Preclinical - Cell culture	Actionable	In a preclinical study, some head and neck squamous cell carcinoma cell lines over expressing PIK3CA demonstrated sensitivity to treatment with Gedatolisib (PF-05212384) (PMID: 25977343).	25977343
PIK3CA	PIK3CA over exp	glioblastoma multiforme	sensitive	YM-024	Preclinical	Actionable	In a preclinical study, YM-024 inhibited proliferation and anchorage-independent growth of glioblastoma cell lines with elevated Pik3ca protein level in culture (PMID: 24718026).	24718026
PIK3CA	PIK3CA over exp	lung squamous cell carcinoma	sensitive	Alpelisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alpelisib (BYL719) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type PIK3CA in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26013318).	26013318
PIK3CA	PIK3CA R88Q	malignant pleural mesothelioma	sensitive	GDC-0980	Phase I	Actionable	In a Phase I trial, treatment with Apitolisib (GDC-0980) resulted in a partial response in a patient with malignant pleural mesothelioma harboring PIK3CA R88Q (PMID: 26787751).	26787751
PIK3CA	PIK3CA R88Q	colorectal cancer	predicted - sensitive	Cetuximab + Floxuridine + Fluorouracil + Irinotecan	Case Reports/Case Series	Actionable	In a retrospective analysis, treatment with the combination of Erbitux (cetuximab), Adrucil (fluorouracil), Camptosar (irinotecan), and Floxuridine resulted in at least 24 months without evidence of disease in a colorectal carcinoma patient harboring a PIK3CA R88Q mutation (PMID: 25714871).	25714871
PIK3CA	PIK3CA R88Q PTEN mut	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154).	22662154
PIK3CA	PIK3CA R88Q PTEN mut	endometrial cancer	sensitive	Everolimus	Preclinical	Actionable	In a preclinical study, Afinitor (everolimus) inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154).	22662154
PIK3CA	PIK3CA V955I	colorectal cancer	resistant	Cetuximab + Fluorouracil	Case Reports/Case Series	Actionable	In a clinical study, PIK3CA V955I was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in a colorectal cancer patient, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA V955I (PMID: 28424201).	28424201
PIK3CA	PIK3CA E453del PIK3CA T1025K PIK3CA R88L PTEN mut PTEN loss	endometrial carcinoma	sensitive	Copanlisib	Phase I	Actionable	In a Phase I clinical trial, an endometrial carcinoma patient harboring PIK3CA T1052K, R88L, and E453del, as well as a PTEN mutation and loss of PTEN protein expression demonstrated a complete response to treatment with Aliqopa (copanlisib) (PMID: 27672108).	27672108
PIK3CA	PIK3CA K944N	colorectal cancer	resistant	Cetuximab + Fluorouracil	Case Reports/Case Series	Actionable	In a clinical study, PIK3CA K944N was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in two colorectal cancer patients, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA K944N (PMID: 28424201).	28424201
PIK3CA	PIK3CA E542K	breast cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA E542K	Advanced Solid Tumor	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, Rapamune (sirolimus) demonstrated efficacy in inhibiting transformation of cultured cells containing PIK3CA E542K mutations (PMID: 15647370).	15647370
PIK3CA	PIK3CA E542K	head and neck squamous cell carcinoma	sensitive	GDC-0980	Phase I	Actionable	In a Phase I trial, Apitolisib (GDC-0980) treatment resulted in a partial response in a patient with head and neck squamous cell carcinoma harboring a PIK3CA E542K mutation (PMID: 26787751).	26787751
PIK3CA	PIK3CA E542K	colon adenocarcinoma	sensitive	VS-5584	Preclinical	Actionable	In preclinical studies, VS-5584 demonstrated efficacy in a variety of cancer cell lines, particularly those harboring PIK3CA mutations (PMID: 23270925).	23270925
PIK3CA	PIK3CA E542K	Her2-receptor negative breast cancer	sensitive	Alpelisib + Fulvestrant	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib), plus Faslodex (fulvestrant), treatment of patients with advanced hormone-receptor positive (ESR1 or PGR), HER2 negative breast cancer harboring one of 11 PIK3CA mutations (n=341) versus those patients with wild-type PIK3CA (n=231) resulted in a greater median progression-free survival (11 vs 5.7 mo) and overall response rate (26.6% vs 12.8%), and PIK3CA E542K is included in the companion diagnostic (PMID: 31091374: NCT02437318).	detail... detail... 31091374
PIK3CA	PIK3CA E542K	cervical squamous cell carcinoma	sensitive	Gemcitabine + LY2780301	Phase Ib/II	Actionable	In a Phase Ib trial, a patient with cervical squamous cell carcinoma harboring PIK3CA E542K demonstrated a partial response when treated with a combination of LY2780301 and Gemzar (gemcitabine) (PMID: 28750271).	28750271
PIK3CA	PIK3CA E542K	colorectal cancer	resistant	Cetuximab + Fluorouracil	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells over expressing PIK3CA E542K were resistant to Erbitux (cetuximab) and Fluorouracil combination treatment in culture (PMID: 28424201).	28424201
PIK3CA	PIK3CA E542K	colorectal cancer	predicted - sensitive	Cetuximab + Irinotecan	Case Reports/Case Series	Actionable	In a retrospective analysis, treatment with the combination of Erbitux (cetuximab) and Camptosar (irinotecan) resulted in a partial response in 50% (1/2) and stable disease in 50% (1/2) of colorectal carcinoma patients harboring a PIK3CA E542K mutation (PMID: 25714871).	25714871
PIK3CA	PIK3CA E542K	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA E542K in culture (PMID: 21558396).	21558396
PIK3CA	PIK3CA E542K	breast cancer	resistant	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells expressing PIK3CA E542K demonstrated resistance to treatment with Buparlisib (BKM120) in culture (PMID: 29636477).	29636477
PIK3CA	PIK3CA E542K	colorectal cancer	sensitive	PD-0325901 + Pictilisib	Preclinical - Cell line xenograft	Actionable	In preclinical studies, the combination of GDC-0941 and PD-0325901 (PI3K and MEK inhibitors, respectively) inhibited tumor growth in colorectal cancer cell line xenograft models (PMID: 24339963).	24339963
PIK3CA	PIK3CA E542K	breast cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA E542K	papillary thyroid carcinoma	sensitive	MK2206 + Temsirolimus	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 suppressed activation of AKT induced by Torisel (temsirolimus), and MK2206 and Torisel (temsirolimus) demonstrated synergy in inhibiting growth of a papillary thyroid cancer cell line harboring PIK3CA E542K in culture (PMID: 21289267).	21289267
PIK3CA	PIK3CA E542K	lung squamous cell carcinoma	no benefit	Taselisib	Case Reports/Case Series	Actionable	In a Phase I (SWOG S1400B) trial, Taselisib (GDC-0032) treatment did not meet primary endpoint in patients with lung squamous cell carcinoma harboring PIK3CA mutations, none of the 6 patients harboring PIK3CA E542K demonstrated response (PMID: 31158500; NCT02785913).	31158500
PIK3CA	PIK3CA E542K	breast cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA E542K	breast cancer	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA E542K	papillary thyroid carcinoma	sensitive	MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with PI3K/AKT pathway alterations in culture, including a papillary thyroid cancer cell line harboring PIK3CA E542K (PMID: 21289267).	21289267
PIK3CA	PIK3CA E542K	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA E542K	gastrointestinal system cancer	sensitive	Capivasertib	Preclinical	Actionable	In a preclinical study, gastric cancer cells harboring PI3KCA E542K mutations were sensitive to the AKT inhibitor AZD5363 (PMID: 24088382).	24088382
PIK3CA	PIK3CA E542K	breast cancer	sensitive	Miransertib	Preclinical - Cell culture	Actionable	In a preclinical study, a hormone breast cancer cell line harboring PIK3CA E542K was sensitive to Miransertib (ARQ092) in culture, demonstrating inhibition of cell growth (PMID: 26469692).	26469692
PIK3CA	PIK3CA E542K	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA E542K PTEN loss	breast cancer	predicted - sensitive	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA E542K and PTEN loss in culture (PMID: 30003928).	30003928
PIK3CA	PIK3CA E542K PTEN loss	stomach cancer	unknown	Sirolimus	Phase 0	Actionable	In a pilot clinical trial, Rapamune (sirolumus) demonstrated modest clinical activity in patients with PIK3CA-mutant gastric cancer (n=3) or hilar cholangiocarcinoma (n=1), including a gastric cancer patient harboring PIK3CA E542K and PTEN loss, with a 0% response rate, median progression-free survival of 1.9 months, and median overall survival of 3.6 months (PMID: 28685070).	28685070
PIK3CA	PIK3CA E542K PTEN loss	lung squamous cell carcinoma	sensitive	Alpelisib	Preclinical - Pdx	Actionable	In a preclinical study, Alpelisib (BYL719) treatment resulted in response in a lung squamous cell carcinoma patient-derived xenograft (PDX) model harboring PIK3CA E542K and PTEN loss (PMID: 30093452).	30093452
PIK3CA	PIK3CA E542K PTEN loss	breast cancer	predicted - sensitive	BEZ235 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA E542K and PTEN loss to WEHI-539 in culture (PMID: 27974663).	27974663
PIK3CA	EGFR over exp PIK3CA E542K	esophageal cancer	sensitive	Theliatinib	Preclinical - Pdx	Actionable	In a preclinical study, Theliatinib treatment demonstrated decreased efficcacy in patient-derived xenograft (PDX) models of esophageal cancer with Egfr overexpression and PIK3CA E542K compared to models with only Egfr overexpression (PMID: 28881608).	28881608
PIK3CA	EGFR exon 19 del PIK3CA E418K PIK3CA E542K	lung non-small cell carcinoma	predicted - resistant	Osimertinib	Case Reports/Case Series	Actionable	In a clinical case study, loss of EGFR T790M and acquired PIK3CA E418K and E542K mutations were identified in a post-treatment sample from a patient harboring an EGFR exon 19 deletion who progressed on Tagrisso (osimertinib) treatment (PMID: 30228210).	30228210
PIK3CA	PIK3CA amp PIK3CA E542K	lung squamous cell carcinoma	sensitive	Buparlisib	Preclinical - Pdx	Actionable	In a preclinical study, Buparlisib (BKM120) treatment resulted in inhibition of AKT and S6 phosphorylation and durable response in a lung squamous cell carcinoma patient-derived xenograft (PDX) model harboring PIK3CA E542K and PIK3CA amplification (PMID: 30093452).	30093452
PIK3CA	PIK3CA amp PIK3CA E542K	lung squamous cell carcinoma	sensitive	Alpelisib	Preclinical - Pdx	Actionable	In a preclinical study, Alpelisib (BYL719) treatment resulted in response in a lung squamous cell carcinoma patient-derived xenograft (PDX) model harboring PIK3CA E542K and PIK3CA amplification (PMID: 30093452).	30093452
PIK3CA	CDKN2A loss PIK3CA E542K PTEN loss	lung squamous cell carcinoma	sensitive	Buparlisib + Palbociclib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with the combination of Buparlisib (BYL719) and Ibrance (palbociclib) resulted in increased tumor growth inhibition compared to either agent alone in a patient-derived xenograft (PDX) model of lung squamous cell carcinoma harboring PIK3CA E542K and PTEN loss, with p16 (CDKN2A) loss (PMID: 30093452).	30093452
PIK3CA	CDKN2A loss PIK3CA amp PIK3CA E542K	lung squamous cell carcinoma	sensitive	Buparlisib + Palbociclib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with the combination of Buparlisib (BYL719) and Ibrance (palbociclib) resulted in increased tumor growth inhibition compared to either agent alone in a patient-derived xenograft (PDX) model of lung squamous cell carcinoma harboring PIK3CA E542K and PIK3CA amplification, with p16 (CDKN2A) loss (PMID: 30093452).	30093452
PIK3CA	EGFR T790M EGFR act mut PIK3CA E542K	lung non-small cell carcinoma	predicted - resistant	Rociletinib	Clinical Study - Cohort	Actionable	In a retrospective analysis of a Phase I and a Phase II trial, PIK3CA activating mutations were identified at disease progression in 12% (5/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, n=3; L858R, n=2) treated with Rociletinib (CO-1686), PIK3CA E542K was identified in 3 of the 5 patients (PMID: 27283993; NCT01526928, NCT02147990).	27283993
PIK3CA	ERBB2 pos PIK3CA E542K	Her2-receptor positive breast cancer	predicted - sensitive	Neratinib	Phase III	Actionable	In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).	30867034
PIK3CA	PIK3CA G1049R	breast cancer	resistant	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells expressing PIK3CA G1049R demonstrated resistance to treatment with Buparlisib (BKM120) in culture (PMID: 29636477).	29636477
PIK3CA	PIK3CA G1049R	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA G1049R	breast cancer	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA G1049R	breast cancer	sensitive	Alpelisib	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA G1049R	breast cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA G1049R	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA G1049R	Advanced Solid Tumor	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA G1049R	breast cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA G1049R	lung squamous cell carcinoma	no benefit	Taselisib	Case Reports/Case Series	Actionable	In a Phase I (SWOG S1400B) trial, Taselisib (GDC-0032) treatment did not meet primary endpoint in patients with lung squamous cell carcinoma harboring PIK3CA mutations, a patients harboring PIK3CA G1047R did not demonstrated response (PMID: 31158500; NCT02785913).	31158500
PIK3CA	PIK3CA E545G	Her2-receptor negative breast cancer	sensitive	Alpelisib + Fulvestrant	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib), plus Faslodex (fulvestrant), treatment of patients with advanced hormone-receptor positive (ESR1 or PGR), HER2 negative breast cancer harboring one of 11 PIK3CA mutations (n=341) versus those patients with wild-type PIK3CA (n=231) resulted in a greater median progression-free survival (11 vs 5.7 mo) and overall response rate (26.6% vs 12.8%), and PIK3CA E545G is included in the companion diagnostic (PMID: 31091374: NCT02437318).	31091374 detail... detail...
PIK3CA	PIK3CA M1043V	Advanced Solid Tumor	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, Rapamune (sirolimus) inhibited proliferation in cultured cells expressing PIK3CA M1043V (PMID: 17376864).	17376864
PIK3CA	PIK3CA E545A	Her2-receptor negative breast cancer	sensitive	Alpelisib + Fulvestrant	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib), plus Faslodex (fulvestrant), treatment of patients with advanced hormone-receptor positive (ESR1 or PGR), HER2 negative breast cancer harboring one of 11 PIK3CA mutations (n=341) versus those patients with wild-type PIK3CA (n=231) resulted in a greater median progression-free survival (11 vs 5.7 mo) and overall response rate (26.6% vs 12.8%), and PIK3CA E545A is included in the companion diagnostic (PMID: 31091374: NCT02437318).	31091374 detail... detail...
PIK3CA	PIK3CA F930S	colorectal cancer	resistant	Cetuximab + Fluorouracil	Case Reports/Case Series	Actionable	In a clinical study, PIK3CA F930S was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in a colorectal cancer patient, which is consistent with cell culture studies demonstrating moderate resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA F930S (PMID: 28424201).	28424201
PIK3CA	PIK3CA P539R	breast cancer	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA P539R in culture (PMID: 27699769).	27699769
PIK3CA	PIK3CA P539R	breast cancer	predicted - sensitive	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA P539R in culture (PMID: 30003928).	30003928
PIK3CA	PIK3CA P539R PIK3CA H1047R	breast cancer	sensitive	Miransertib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA P539R and H1047R were sensitive to Miransertib (ARQ092) in culture, demonstrating inhibition of cell growth (PMID: 26469692).	26469692
PIK3CA	PIK3CA P539R PIK3CA H1047R	breast cancer	sensitive	PF-04691502	Preclinical - Cell culture	Actionable	In a preclinical study, PF-04691502 inhibited Akt phosphorylation and proliferation of breast cancer cells harboring both PIK3CA P539R and H1047R in culture (PMID: 21750219).	21750219
PIK3CA	PIK3CA P539R PIK3CA H1047R	breast cancer	sensitive	ARQ 751	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line harboring PIK3CA P539R and PH1047R was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692).	26469692
PIK3CA	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs	endometrial cancer	sensitive	BGJ398 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Pictilisib (GDC-0941) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).	28119489
PIK3CA	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs	endometrial cancer	sensitive	BGJ398 + Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).	28119489
PIK3CA	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs	endometrial cancer	sensitive	Alpelisib + BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Alpelisib (BYL719) resulted in a synergistic effect, demonstrating inhibition of cell proliferation and induced cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).	28119489
PIK3CA	PIK3CA N345K	breast cancer	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA N345K	breast cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA N345K	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA N345K	Advanced Solid Tumor	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA N345K	breast cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA N345K	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA N345K	breast cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA N345K	lung squamous cell carcinoma	no benefit	Taselisib	Case Reports/Case Series	Actionable	In a Phase I (SWOG S1400B) trial, Taselisib (GDC-0032) treatment did not meet primary endpoint in patients with lung squamous cell carcinoma harboring PIK3CA mutations, none of the 2 patients harboring PIK3CA N345K demonstrated response (PMID: 31158500; NCT02785913).	31158500
PIK3CA	ERBB2 amp PIK3CA N345K	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA N345K and ERBB2 (HER2) amplification in culture (PMID: 21558396).	21558396
PIK3CA	PIK3CA Q546K	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA Q546K	breast cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA Q546K	Advanced Solid Tumor	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA Q546K	breast cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA Q546K	breast cancer	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA Q546K	breast cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA Q546K	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA E78K PIK3CA D939G PIK3CA E726K	estrogen-receptor positive breast cancer	no benefit	Alpelisib + Letrozole	Phase Ib/II	Actionable	In a Phase Ib trial, an estrogen-receptor positive breast cancer patient harboring PIK3CA mutations, E78K, D939G, and E726K, demonstrated progressive disease when treated with a combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994).	27126994
PIK3CA	PIK3CA H1047L	breast cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA H1047L	breast cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA H1047L	breast cancer	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA H1047L	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA H1047L	Her2-receptor negative breast cancer	sensitive	Alpelisib + Fulvestrant	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib), plus Faslodex (fulvestrant) treatment of patients with advanced hormone-receptor positive (ESR1 or PGR), HER2 negative breast cancer harboring one of 11 PIK3CA mutations (n=341) versus those patients with wild-type PIK3CA (n=231) resulted in a greater median progression-free survival (11 vs 5.7 mo) and overall response rate (26.6% vs 12.8%), and PIK3CA H1047L is included in the companion diagnostic (PMID: 31091374: NCT02437318).	detail... 31091374 detail...
PIK3CA	PIK3CA H1047L	breast cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA H1047L	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).	26627007
PIK3CA	ERBB2 over exp PIK3CA H1047L	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047L (PMID: 29208673).	29208673
PIK3CA	ERBB2 amp PIK3CA E542X	Her2-receptor positive breast cancer	decreased response	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
PIK3CA	ERBB2 over exp PIK3CA E542X	Her2-receptor positive breast cancer	decreased response	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
PIK3CA	PIK3CA H1047X	colorectal cancer	predicted - resistant	Bevacizumab + Temsirolimus	Case Reports/Case Series	Actionable	In a clinical study, a colorectal cancer patient harboring a mutation at PIK3CA H1047 demonstrated progressive disease when treated with Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929).	21216929
PIK3CA	PIK3CA H1047X	small intestine adenocarcinoma	predicted - resistant	Bortezomib + Temsirolimus + Topotecan	Case Reports/Case Series	Actionable	In a clinical study, the combination of Torisel (temsirolimus) plus Velcade (bortezomib) and Hycamtin (topotecan) resulted in progressive disease in a patient with small intestine adenocarcinoma harboring a PIK3CA H1047 mutation (PMID: 21216929).	21216929
PIK3CA	PIK3CA H1047X	endometrial adenocarcinoma	predicted - sensitive	Temsirolimus	Case Reports/Case Series	Actionable	In a clinical study, a patient with endometrial adenocarcinoma harboring a PIK3CA H1047 mutation demonstrated a partial response when treated with Torisel (temsirolimus) (PMID: 21216929).	21216929
PIK3CA	PIK3CA H1047X	lung non-small cell carcinoma	sensitive	Taselisib	Phase I	Actionable	In a Phase I trial, a non-small cell lung carcinoma patient harboring a mutation at PIK3CA H1047 demonstrated a confirmed partial response when treated with Taselisib (GDC-0032) (PMID: 28331003).	28331003
PIK3CA	PIK3CA H1047X BRAF V600X	ovarian carcinoma	predicted - sensitive	Bevacizumab + Pegylated liposomal-doxorubicin + Temsirolimus	Case Reports/Case Series	Actionable	In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian clear cell carcinoma harboring PIK3CA H1047 and BRAF V600 mutations (PMID: 21216929).	21216929
PIK3CA	ERBB2 amp PIK3CA H1047X	Her2-receptor positive breast cancer	decreased response	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
PIK3CA	ERBB2 over exp PIK3CA H1047X	Her2-receptor positive breast cancer	decreased response	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
PIK3CA	ERBB2 A775_G776insYVMA PIK3CA R425L	lung non-small cell carcinoma	predicted - resistant	Trastuzumab	Case Reports/Case Series	Actionable	In a clinical study, the PIK3CA R425L mutation was identified as a potential resistance mechanism in a non-small cell lung carcinoma patient harboring ERBB2 (HER2) A775_G776insYVMA, that progressed during Herceptin (trastuzumab) treatment (PMID: 28167203).	28167203
PIK3CA	PIK3CA N345I	breast cancer	resistant	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells expressing PIK3CA N345I demonstrated resistance to treatment with Buparlisib (BKM120) in culture (PMID: 29636477).	29636477
PIK3CA	PIK3CA K966E	colorectal cancer	resistant	Cetuximab + Fluorouracil	Clinical Study - Cohort	Actionable	In a clinical study, PIK3CA K966E was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in a colorectal cancer patient, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells overexpressing PIK3CA K966E (PMID: 28424201).	28424201
PIK3CA	PIK3CA C420R	Her2-receptor negative breast cancer	sensitive	Alpelisib + Fulvestrant	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib), plus Faslodex (fulvestrant), treatment of patients with advanced hormone-receptor positive (ESR1 or PGR), HER2 negative breast cancer harboring one of 11 PIK3CA mutations (n=341) versus those patients with wild-type PIK3CA (n=231) resulted in a greater median progression-free survival (11 vs 5.7 mo) and overall response rate (26.6% vs 12.8%), and PIK3CA C420R is included in the companion diagnostic (PMID: 31091374: NCT02437318).	detail... detail... 31091374
PIK3CA	PIK3CA C420R	ovarian clear cell adenocarcinoma	sensitive	DS-7423	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA C420R was sensitive to DS-7423 in culture, demonstrating inhibition of cell proliferation (PMID: 24504419).	24504419
PIK3CA	PIK3CA C420R	Advanced Solid Tumor	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, cells expressing PIK3CA C420R were sensitive to Rapamune (sirolimus) in culture (PMID: 17376864).	17376864
PIK3CA	ERBB2 amp PIK3CA C420R	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA C420R and ERBB2 (HER2) amplification (PMID: 21558396).	21558396
PIK3CA	ERBB2 amp PIK3CA C420R	breast cancer	sensitive	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, CYH33 inhibited proliferation of breast cancer cell lines harboring PIK3CA C420R and ERBB2 (HER2) amplification in culture (PMID: 30003928).	30003928
PIK3CA	ERBB2 pos PIK3CA C420R	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	Preclinical - Cell culture	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA C420R in culture (PMID: 26920887).	26920887
PIK3CA	BRAF V600E PIK3CA H1047K	melanoma	sensitive	ARQ092 + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring BRAF V600E and PIK3CA H1047K was sensitive to the combination treatment of Miransertib (ARQ092) and Mekinist (trametinib), demonstrating a greater inhibition of tumor growth when compared to either agent alone (PMID: 26469692).	26469692
PIK3CA	EGFR pos EGFR exon 20 ins PIK3CA Y1021H	lung non-small cell carcinoma	predicted - sensitive	SHR-A1307	Preclinical - Pdx	Actionable	In a preclinical study, SHR-A1307 did not result in tumor regression, however, demonstrated a trend towards inhibition of tumor growth in Erbitux (cetuximab)-resistant patient-derived xenograft (PDX) models of EGFR-positive, and EGFR exon 20 insertion and PIK3CA Y1201H mutated non-small cell lung cancer (PMID: 30962319).	30962319
PIK3CA	PIK3CA I391M	uterine cancer	predicted - sensitive	Sirolimus	Case Reports/Case Series	Actionable	In a clinical case study, a uterine cancer patient harboring PIK3CA I391M demonstrated stable disease when treated with Rapamune (sirolimus) (PMID: 28514312).	28514312
PIK3CA	ERBB2 pos PIK3CA I391M	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	Preclinical - Cell culture	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture (PMID: 26920887).	26920887
PIK3CA	PIK3CA D350G PIK3CA R93W PTEN R130G	endometrial cancer	sensitive	Miransertib	Preclinical - Pdx	Actionable	In a preclinical study, a patient-derived xenograft (PDX) model of endometrial cancer harboring PIK3CA D350G, PIK3CA R93W, and PTEN R130G was sensitive to Miransertib (ARQ092), demonstrating greater than 90% inhibition of tumor growth (PMID: 26469692).	26469692
PIK3CA	PIK3CA Q546E	Her2-receptor negative breast cancer	sensitive	Alpelisib + Fulvestrant	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib), plus Faslodex (fulvestrant), treatment of patients with advanced hormone-receptor positive (ESR1 or PGR), HER2 negative breast cancer harboring one of 11 PIK3CA mutations (n=341) versus those patients with wild-type PIK3CA (n=231) resulted in a greater median progression-free survival (11 vs 5.7 mo) and overall response rate (26.6% vs 12.8%), and PIK3CA Q546E is included in the companion diagnostic (PMID: 31091374: NCT02437318).	detail... 31091374 detail...
PIK3CA	PIK3CA E365K PTEN mut	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154).	22662154
PIK3CA	PIK3CA E365K PTEN mut	endocervical carcinoma	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154).	22662154
PIK3CA	ERBB2 amp PIK3CA E545K PIK3CA K567R	Her2-receptor positive breast cancer	sensitive	Gedatolisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited PI3K signaling, cell growth and induced apoptosis in human breast cancer cells harboring ERBB2 (HER2) amplification, PIK3CA E545K, and PIK3CA K567R in culture and in cell line xenografts (PMID: 21325073, PMID: 17314276).	17314276 21325073
PIK3CA	PIK3CA H1047Y	glioblastoma multiforme	sensitive	YM-024	Preclinical	Actionable	In a preclinical study, glioblastoma cell lines harboring PIK3CA H1047Y demonstrated increased sensitivity to YM-204 induced growth inhibition (PMID: 24718026).	24718026
PIK3CA	PIK3CA H1047Y	endometrial cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited cell growth in a human endometrial cancer cell line harboring a PIK3CA H1047Y mutation, and inhibited tumor growth in xenograft models (PMID: 21558396).	21558396
PIK3CA	PIK3CA H1047Y	Her2-receptor negative breast cancer	sensitive	Alpelisib + Fulvestrant	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib), plus Faslodex (fulvestrant) treatment of patients with advanced hormone-receptor positive (ESR1 or PGR), HER2 negative breast cancer harboring one of 11 PIK3CA mutations (n=341) versus those patients with wild-type PIK3CA (n=231) resulted in a greater median progression-free survival (11 vs 5.7 mo) and overall response rate (26.6% vs 12.8%), and PIK3CA H1047Y is included in the companion diagnostic (PMID: 31091374; NCT02437318).	detail... 31091374 detail...
PIK3CA	PIK3CA G118D	lung non-small cell carcinoma	sensitive	LY3023414	Preclinical - Cell line xenograft	Actionable	In a preclinical study, LY3023414 inhibited proliferation of non-small cell lung cancer cells harboring PIK3CA G118D in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478).	27439478
PIK3CA	EGFR L858R EGFR T790M PIK3CA G118D	lung non-small cell carcinoma	sensitive	BEZ235 + Pimasertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).	23629727
PIK3CA	EGFR L858R EGFR T790M PIK3CA G118D	lung non-small cell carcinoma	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).	23629727
PIK3CA	EGFR L858R EGFR T790M PIK3CA G118D	lung non-small cell carcinoma	sensitive	Pimasertib + Sorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited Mapk and Akt signaling, resulted in growth inhibition of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture and in cell line xenograft models (PMID: 23629727).	23629727
PIK3CA	EGFR L858R EGFR T790M PIK3CA G118D	lung non-small cell carcinoma	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).	23629727
PIK3CA	EGFR L858R EGFR T790M PIK3CA G118D	lung non-small cell carcinoma	decreased response	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, T790M, and PIK3CA G118D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).	23629727
PIK3CA	PIK3CA P124L PTEN del	urinary bladder cancer	decreased response	Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) demonstrated limited inhibition of Akt phosphorylation and growth in bladder cancer cells harboring PIK3CA P124L and PTEN deletion in culture (PMID: 28808038).	28808038
PIK3CA	ERBB2 over exp PIK3CA E545X	Her2-receptor positive breast cancer	decreased response	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
PIK3CA	ERBB2 amp PIK3CA E545X	Her2-receptor positive breast cancer	decreased response	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
PIK3CA	PIK3CA R108H PTEN mut	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R108H and PTEN mutations in culture (PMID: 22662154).	22662154
PIK3CA	PIK3CA K111N	breast cancer	sensitive	Miransertib	Preclinical - Cell culture	Actionable	In a preclinical study, hormone receptor positive breast cancer cells harboring PIK3CA K111N were sensitive to Miransertib (ARQ092) in culture, demonstrating inhibition of cell growth (PMID: 26469692).	26469692
PIK3CA	PIK3CA K111N	breast cancer	sensitive	DHM25	Preclinical - Cell culture	Actionable	In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 26237138).	26237138
PIK3CA	PIK3CA K111N	estrogen-receptor positive breast cancer	sensitive	AZD8835	Preclinical	Actionable	In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA K111N in culture and induced tumor regression in xenograft models (PMID: 26839307).	26839307
PIK3CA	PIK3CA K111N	breast cancer	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 27699769).	27699769
PIK3CA	PIK3CA K111N	breast cancer	sensitive	ARQ 751	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line harboring PIK3CA K111N was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692).	26469692
PIK3CA	ERBB2 amp PIK3CA K111N	breast cancer	predicted - sensitive	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N and ERBB2 (HER2) amplification in culture (PMID: 30003928).	30003928
PIK3CA	ERBB2 amp PIK3CA K111N	breast cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA K111N and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).	21558396
PIK3CA	ERBB2 pos PIK3CA K111N	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).	26920887
PIK3CA	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	sensitive	Buparlisib + Trastuzumab	Preclinical	Actionable	In a preclinical study, the combination of Herceptin (trastuzumab) and Buparlisib (BKM120) inhibited tumor growth in mouse ERBB2 (HER2)-over expressing breast cancer models expressing PIK3CA H1047R, with moderate efficacy over Buparlisib (BKM120) alone (PMID: 23940356).	23940356
PIK3CA	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	resistant	Trastuzumab	Preclinical	Actionable	In a preclinical study, mouse breast cancer models over expressing ERBB2 (HER2) and expressing PIK3CA H1047R were resistant to Herceptin (trastuzumab) (PMID: 23940356).	23940356
PIK3CA	ERBB2 over exp PIK3CA H1047R	stomach cancer	predicted - resistant	Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047R (PMID: 29208673).	29208673
PIK3CA	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	sensitive	Buparlisib + Pertuzumab + Trastuzumab	Preclinical	Actionable	In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Perjeta (pertuzumab) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, with improved efficacy over Buparlisib (BKM120) alone (PMID: 23940356).	23940356
PIK3CA	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	sensitive	Bevacizumab + Buparlisib	Preclinical	Actionable	In a preclinical study, treatment with Buparlisib (BKM120) resulted in decreased tumor growth, but not tumor regression, in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R (PMID: 23940356).	23940356
PIK3CA	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	resistant	Pertuzumab + Trastuzumab	Preclinical	Actionable	In a preclinical study, a mouse breast cancer model with ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Heceptin (trastuzumab) and Perjeta (pertuzumab) (PMID: 23940356).	23940356
PIK3CA	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	no benefit	Buparlisib + Lapatinib + Trastuzumab	Preclinical	Actionable	In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Tykerb (lapatinib) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, but efficacy was not significantly improved over Buparlisib (BKM120) alone (PMID: 23940356).	23940356
PIK3CA	ERBB2 over exp PIK3CA H1047R	Her2-receptor positive breast cancer	resistant	Lapatinib + Trastuzumab	Preclinical	Actionable	In a preclinical study, a mouse breast cancer model with mammary ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23940356).	23940356
PIK3CA	PIK3CA H1047R	stomach cancer	sensitive	Capivasertib	Preclinical - Pdx	Actionable	In a preclinical study, AZD5363 inhibited growth in a patient-derived xenograft model of gastric cancer harboring a PIK3CA H1047R mutation (PMID: 24088382).	24088382
PIK3CA	PIK3CA H1047R	thyroid cancer	sensitive	MK2206 + Temsirolimus	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 and Torisel (temsirolimus) demonstrated synergy in inhibiting growth of an anaplastic thyroid cancer cell line harboring PIK3CA H1047R in culture (PMID: 21289267).	21289267
PIK3CA	PIK3CA H1047R	lung adenocarcinoma	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 promoted tumor regression in a mouse lung adenocarcinoma model expressing PIK3CA H1047R (PMID: 19029981).	19029981
PIK3CA	PIK3CA H1047R	Advanced Solid Tumor	predicted - sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Piqray (Alpelisib) decreased Akt phosphorylation and inhibited PI3K signaling, and demonstrated dose-dependent inhibition of survival in human pluripotent stem cells harboring PIK3CA H1047R in culture (PMID: 30948643).	30948643
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	Alpelisib	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA H1047R	head and neck squamous cell carcinoma	predicted - sensitive	SHR-A1307	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring PIK3CA H1047R treated with SHR-A1307 demonstrated inhibition of cell growth in culture (PMID: 30962319).	30962319
PIK3CA	PIK3CA H1047R	progesterone-receptor positive breast cancer	predicted - sensitive	Everolimus	Clinical Study - Cohort	Actionable	In a retrospective analysis, combination of Afinitor (everolimus) and hormone therapy resulted in improved median progression-free survival (8.8 vs 4.1 months, p=0.02) in patients with hormone receptor-positive metastatic breast cancer harboring PIK3CA H1047R (n=6) compared to patients without PIK3CA H1047R (n=10) (PMID: 31088410).	31088410
PIK3CA	PIK3CA H1047R	Advanced Solid Tumor	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA H1047R	colorectal cancer	sensitive	Cetuximab	Case Reports/Case Series	Actionable	In a retrospective analysis, Erbitux (cetuximab) combined with radiation therapy resulted in stable disease for 6 months in a colorectal carcinoma patient harboring a PIK3CA H1047R mutation (PMID: 25714871).	25714871
PIK3CA	PIK3CA H1047R	estrogen-receptor positive breast cancer	predicted - sensitive	Everolimus	Clinical Study - Cohort	Actionable	In a retrospective analysis, combination of Afinitor (everolimus) and hormone therapy resulted in improved median progression-free survival (8.8 vs 4.1 months, p=0.02) in patients with hormone receptor-positive metastatic breast cancer harboring PIK3CA H1047R (n=6) compared to patients without PIK3CA H1047R (n=10) (PMID: 31088410).	31088410
PIK3CA	PIK3CA H1047R	head and neck squamous cell carcinoma	resistant	Cetuximab	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells harboring PIK3CA H1047R were resistant to Erbitux (cetuximab) in culture (PMID: 30962319).	30962319
PIK3CA	PIK3CA H1047R	ovarian cancer	sensitive	AZD8835	Preclinical	Actionable	In a preclinical study, AZD8835 inhibited tumor growth in mouse xenografts of ovarian cancer with a Pik3ca H1047R mutation (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2830).	detail...
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	CYH33	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CYH33 inhibited proliferation of breast cancer cell lines harboring PIK3CA H1047R in culture, inhibited tumor progression in a transgenic mouse model, and induced cell cycle arrest, and inhibited PI3K signaling and tumor growth in cell line xenograft models (PMID: 30003928).	30003928
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	Miransertib	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line harboring PIK3CA H1047R demonstrated sensitivity to treatment with Miransertib (ARQ092) in culture, resulting in inhibition of cell proliferation (PMID: 26469692).	26469692
PIK3CA	PIK3CA H1047R	ovarian cancer	sensitive	CH5132799	Phase I	Actionable	In a Phase I trial, CH5132799 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a partial response in a patient with ovarian cancer harboring PIK3CA H1047R (PMID: 25231405).	25231405
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA H1047R	ovarian cancer	sensitive	A66	Preclinical - Cell line xenograft	Actionable	In a preclinical study, A66 delayed tumor growth in an ovarian cancer cell line xenograft model harboring PIK3CA H1047R (PMID: 21668414).	21668414
PIK3CA	PIK3CA H1047R	Advanced Solid Tumor	sensitive	Rigosertib	Preclinical - Cell culture	Actionable	In a preclinical study, Estybon (rigosertib) inhibited oncogenic transformation in fibroblast cells over-expressing PIK3CA H1047R in culture (PMID: 27104980).	27104980
PIK3CA	PIK3CA H1047R	thyroid cancer	sensitive	MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring PIK3CA H1047R (PMID: 21289267).	21289267
PIK3CA	PIK3CA H1047R	Advanced Solid Tumor	sensitive	A66	Preclinical	Actionable	In a preclinical study, A66 delayed tumor growth in human tumor xenograft models harboring PIK3CA H1047R mutations (PMID: 21668414).	21668414
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	Taselisib	Phase I	Actionable	In a Phase I trial, four patients with breast cancer harboring PIK3CA H1047R demonstrated a confirmed partial response when treated with Taselisib (GDC-0032) (PMID: 28331003).	28331003
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	ARQ 751	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line harboring PIK3CA H1047R demonstrated sensitivity to treatment with ARQ 751 in culture, resulting in inhibition of cell proliferation (PMID: 26469692).	26469692
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA H1047R	head and neck squamous cell carcinoma	sensitive	Gedatolisib	Preclinical - Cell culture	Actionable	In a preclinical study, head and neck squamous cell carcinoma cell lines harboring PIK3CA H1047R demonstrated sensitivity to treatment with Gedatolisib (PF-05212384) in culture (PMID: 25977343).	25977343
PIK3CA	PIK3CA H1047R	ovarian cancer	sensitive	PF-04691502	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-04691502 inhibited Pi3k signaling, resulted in growth inhibition of ovarian cancer cells harboring PIK3CA H1047R in culture and in cell line xenograft models (PMID: 21750219).	21750219
PIK3CA	PIK3CA H1047R	Her2-receptor negative breast cancer	sensitive	Alpelisib + Fulvestrant	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib), plus Faslodex (fulvestrant) treatment of patients with advanced hormone-receptor positive (ESR1 or PGR), HER2 negative breast cancer harboring one of 11 PIK3CA mutations (n=341) versus those patients with wild-type PIK3CA (n=231) resulted in a greater median progression-free survival (11 vs 5.7 mo) and overall response rate (26.6% vs 12.8%), and PIK3CA H1047R is included in the companion diagnostic (PMID: 31091374: NCT02437318).	detail... 31091374 detail...
PIK3CA	PIK3CA H1047R	urinary bladder cancer	sensitive	BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, BEZ235 inhibited tumor growth in a patient-derived xenograft (PDX) model of bladder cancer harboring PIK3CA H1047R (PMID: 26270481).	26270481
PIK3CA	PIK3CA H1047R	lung squamous cell carcinoma	sensitive	BEZ235	Preclinical - Cell culture	Actionable	In a preclinical study, BEZ235 induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA H1047R in culture (PMID: 26013318).	26013318
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA H1047R	lung squamous cell carcinoma	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA H1047R in culture (PMID: 26013318).	26013318
PIK3CA	PIK3CA H1047R	colorectal cancer	sensitive	Metformin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glucophage (metformin) demonstrated efficacy in treating dietary restriction-resistant human colorectal cancer cell line xenograft tumors harboring PIK3CA H1047R (PMID: 23986086).	23986086
PIK3CA	PIK3CA H1047R	colorectal cancer	resistant	Cetuximab + Fluorouracil	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells over expressing PIK3CA H1047R were resistant to Erbitux (cetuximab) and Fluorouracil combination treatment in culture (PMID: 28424201).	28424201
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA H1047R	head and neck squamous cell carcinoma	sensitive	Radiotherapy + Taselisib	Preclinical	Actionable	In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis of head and neck squamous carcinoma cells harboring PIK3CA H1047R (PMID: 26589432).	26589432
PIK3CA	PIK3CA H1047R	lung squamous cell carcinoma	sensitive	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, Buparlisib (BKM120) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type Pik3ca in culture (PMID: 26013318).	26013318
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	BAY1125976	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of breast cancer cell lines harboring PIK3CA H1047R in culture, and inhibited AKT signaling and tumor growth in a PIK3CA H1047R-mutant cell line xenograft model (PMID: 27699769).	27699769
PIK3CA	PIK3CA H1047R	head and neck squamous cell carcinoma	sensitive	Sirolimus + Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Rapamune (sirolimus) worked synergistically with Mekinist (trametinib) to inhibit proliferation of head and neck squamous carcinoma cell lines harboring PIK3CA H1047R in culture and to reduce tumor growth in cell line xenograft models (PMID: 26882569).	26882569
PIK3CA	PIK3CA H1047R	lung adenocarcinoma	no benefit	Sirolimus	Preclinical	Actionable	In a preclinical study, Sirolimus (rapamycin) failed to inhibit tumor growth in a mouse lung adenocarcinoma model expressing the PIK3CA H1047R mutation (PMID: 19029981).	19029981
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA H1047R	Advanced Solid Tumor	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, transformed cells expressing PIK3CA H1047R were sensitive to Rapamune (sirolimus), resulting in inhibition of transformation in culture (PMID: 15647370).	15647370
PIK3CA	PIK3CA H1047R	urinary bladder cancer	sensitive	Cisplatin + Pictilisib	Preclinical - Pdx	Actionable	In a preclinical study, combination of or sequential treatment with Pictilisib (GDC-0941) and Platinol (cisplatin) significantly delayed tumor growth and prolonged survival in patient-derived xenograft (PDX) models of bladder cancer harboring PIK3CA H1047R (PMID: 28808038).	28808038
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	Metformin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Glucophage (metformin) inhibited cell proliferation of a dietary restriction-resistant PIK3CA H1047R-harboring human breast cancer cell line in culture, and inhibited tumor growth in xenograft models (PMID: 23986086).	23986086
PIK3CA	PIK3CA H1047R	urinary bladder cancer	sensitive	Pictilisib	Preclinical - Pdx	Actionable	In a preclinical study, Pictilisib (GDC-0941) inhibited Akt phosphorylation and tumor growth, prolonged survival in patient-derived xenograft (PDX) models of bladder cancer harboring PIK3CA H1047R (PMID: 28808038).	28808038
PIK3CA	PIK3CA H1047R	breast metaplastic carcinoma	predicted - sensitive	Buparlisib + Paclitaxel	Case Reports/Case Series	Actionable	In a clinical case study, Buparlisib (BKM120) in combination with Taxol (paclitaxel) resulted in a durable partial response in a patient with breast metaplastic carcinoma harboring PIK3CA H1047R, with a total response period of 70 weeks and an overall survival of 42 months (PMID: 30577988).	30577988
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer cell line xenograft model harboring PIK3CA H1047R demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475).	28539475
PIK3CA	PIK3CA H1047R	lung cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 reduced tumor size in mouse models of lung cancer carrying PIK3CA H1047R (PMID: 19029981).	19029981
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276).	17314276 21325073
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	DHM25	Preclinical - Cell culture	Actionable	In a preclinical study, DHM25 increased cell death in breast cancer cell lines harboring PIK3CA H1047R in culture (PMID: 26237138).	26237138
PIK3CA	PIK3CA H1047R	lung squamous cell carcinoma	no benefit	Taselisib	Case Reports/Case Series	Actionable	In a Phase I (SWOG S1400B) trial, Taselisib (GDC-0032) treatment did not meet primary endpoint in patients with lung squamous cell carcinoma harboring PIK3CA mutations, none of the 4 patients harboring PIK3CA H1047R demonstrated response (PMID: 31158500; NCT02785913).	31158500
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	M2698	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer xenograft model harboring PIK3CA H1047R was sensitive to M2698 (MSC2363318A), demonstrating inhibition of tumor growth (PMID: 27186432).	27186432
PIK3CA	PIK3CA H1047R	lung cancer	no benefit	Sirolimus	Preclinical	Actionable	In a preclinical study, Sirolimus (rapamycin) did not induce tumor shrinkage in mouse lung cancer models carrying PIK3CA H1047R (PMID: 19029981).	19029981
PIK3CA	PIK3CA H1047R	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells harboring PIK3CA H1047R in culture (PMID: 21558396).	21558396
PIK3CA	ERBB2 amp PIK3CA H1047R	ovarian cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited cell growth in a human ovarian cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).	21558396
PIK3CA	ERBB2 amp PIK3CA H1047R	breast cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).	21558396
PIK3CA	ERBB2 amp PIK3CA H1047R	breast cancer	sensitive	CH5132799 + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of CH5132799 and Herceptin (trastuzumab) inhibited tumor growth and overcame Herceptin (trastuzumab) insensitivity in xenograft models of a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification (PMID: 21558396).	21558396
PIK3CA	ERBB2 amp PIK3CA H1047R	breast cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring ERBB2 (HER2) amplification and PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276).	17314276 21325073
PIK3CA	ERBB2 amp PIK3CA H1047R	breast cancer	sensitive	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, CYH33 inhibited proliferation of breast cancer cell lines harboring PIK3CA H1047R and ERBB2 (HER2) amplification in culture (PMID: 30003928).	30003928
PIK3CA	BRAF V600X PIK3CA H1047R PTEN Y86fs	melanoma	resistant	Vemurafenib	Clinical Study - Cohort	Actionable	In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance-associated mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153).	24265153
PIK3CA	ERBB2 over exp PIK3CA H1047R SRC over exp	urinary bladder cancer	no benefit	Ponatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Iclusig (ponatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with SRC over expression, which also over expressed ERBB2 (HER2) and harbored PIK3CA H1047R (PMID: 26270481).	26270481
PIK3CA	ERBB2 over exp PIK3CA H1047R SRC over exp	urinary bladder cancer	no benefit	Lapatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481).	26270481
PIK3CA	ERBB2 pos PIK3CA H1047R	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA H1047R in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).	26920887
PIK3CA	ERBB2 pos PIK3CA H1047R	Her2-receptor positive breast cancer	predicted - sensitive	Neratinib	Phase III	Actionable	In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).	30867034
PIK3CA	BRAF V600E PIK3CA H1047R	thyroid carcinoma	predicted - sensitive	Dabrafenib + Everolimus + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated tumor regression when treated with the triple combination, Tafinlar (dabrafenib), Mekinist (trametinib), and Afinitor (everolimus) (PMID: 27797976).	27797976
PIK3CA	BRAF V600E PIK3CA H1047R	thyroid carcinoma	resistant	Everolimus	Case Reports/Case Series	Actionable	In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to treatment with Afinitor (everolimus) (PMID: 27797976).	27797976
PIK3CA	BRAF V600E PIK3CA H1047R	thyroid carcinoma	resistant	Dabrafenib + Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to the combination therapy, Mekinist (trametinib) and Tafinlar (dabrafenib) (PMID: 27797976).	27797976
PIK3CA	BRAF V600E PIK3CA H1047R TP53 wild-type	colorectal cancer	sensitive	PD-0325901 + Sapanisertib	Preclinical - Cell culture	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).	26272063
PIK3CA	PIK3CA H1047R PTEN E307K	breast cancer	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA H1047R and PTEN E307K in culture (PMID: 27699769).	27699769
PIK3CA	AKT1 over exp PIK3CA H1047R	breast cancer	resistant	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).	27604488
PIK3CA	PIK3CA H1047R PTEN loss	breast cancer	predicted - sensitive	BEZ235 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to WEHI-539 in culture (PMID: 27974663).	27974663
PIK3CA	PIK3CA H1047R PTEN loss	triple-receptor negative breast cancer	predicted - sensitive	ABT-737 + BEZ235	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-737 and BEZ235 combination treatment resulted in tumor regression in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).	27974663
PIK3CA	PIK3CA H1047R PTEN loss	breast cancer	predicted - sensitive	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA H1047R and PTEN loss in culture (PMID: 30003928).	30003928
PIK3CA	PIK3CA H1047R PTEN loss	breast cancer	no benefit	BEZ235 + Venetoclax	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to Venclexta (venetoclax) in culture (PMID: 27974663).	27974663
PIK3CA	PIK3CA H1047R PTEN loss	triple-receptor negative breast cancer	predicted - sensitive	ABT-737 + Sapanisertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-737 and Sapanisertib (MLN0128) combination treatment resulted in inhibition of tumor growth in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).	27974663
PIK3CA	PIK3CA H1047R TP53 S90fs	ovarian clear cell adenocarcinoma	decreased response	DS-7423	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA H1047R and TP53 S90fs*33 demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419).	24504419
PIK3CA	NRAS mut PIK3CA H1047R	melanoma	predicted - resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, one of two NRAS-mutant melanoma cell lines expressing PIK3CA H1047R demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).	30819666
PIK3CA	PIK3CA amp	ovarian cancer	sensitive	SAR245409	Preclinical - Cell line xenograft	Actionable	In a preclinical study, an ovarian cancer cell line harboring PIK3CA E545K was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).	24634413
PIK3CA	PIK3CA amp	head and neck squamous cell carcinoma	predicted - sensitive	AZD8055	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with AZD8055 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PIK3CA amplification in culture (PMID: 28446642).	28446642
PIK3CA	PIK3CA amp	ovarian cancer	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited PI3K signaling and proliferation of a PIK3CA amplified human ovarian cancer cell line in culture, and inhibited tumor growth in xenograft models (PMID: 25637314).	25637314
PIK3CA	PIK3CA amp	head and neck squamous cell carcinoma	sensitive	BEZ235	Preclinical - Cell culture	Actionable	In a preclinical study, BEZ235 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PIK3CA amplification in culture (PMID: 28446642).	28446642
PIK3CA	PIK3CA amp	head and neck squamous cell carcinoma	sensitive	Radiotherapy + Taselisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis in HNSCC cell lines and cell line xenograft models with PIK3CA amplification (PMID: 26589432).	26589432
PIK3CA	PIK3CA amp	lung squamous cell carcinoma	no benefit	Buparlisib	Preclinical - Pdx	Actionable	In a preclinical study, lung squamous cell carcinoma a patient-derived xenograft (PDX) model harboring PIK3CA amplification, without additional PIK3CA mutations, did not respond to Buparlisib (BKM120) treatment (PMID: 30093452).	30093452
PIK3CA	PIK3CA amp	triple-receptor negative breast cancer	sensitive	NVP-AEW541 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, NVP-AEW541 enhanced sensitivity of PIK3CA amplified triple-receptor negative breast cancer cells to Pictilisib (GDC-0941) in culture (PMID: 27196766).	27196766
PIK3CA	PIK3CA amp	ovarian cancer	sensitive	Panulisib	Preclinical	Actionable	In a preclinical study, Panulisib (P7170) downregulated mTOR pathway signaling in ovarian cancer cells with amplified PIK3CA (PMID: 25700704).	25700704
PIK3CA	PIK3CA amp	nasopharynx carcinoma	sensitive	MK2206	Phase II	Actionable	In a Phase II study, MK2206 increased stable disease to 12 months in a nasopharyngeal carcinoma patient with Pik3ca amplification (PMID: 26084990).	26084990
PIK3CA	PIK3CA amp	triple-receptor negative breast cancer	sensitive	Linsitinib + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Linsitinib (OSI-906) enhanced sensitivity of PIK3CA amplified triple-receptor negative breast cancer cells to Pictilisib (GDC-0941) in culture (PMID: 27196766).	27196766
PIK3CA	PIK3CA amp	urinary bladder cancer	sensitive	Gemcitabine + Pictilisib	Preclinical - Pdx	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Gemzar (gemcitabine) combination treatment resulted in inhibition of Akt phosphorylation and improved tumor growth inhibition and survival compared to single agent therapy in patient-derived xenograft (PDX) models of PIK3CA amplified bladder cancer (PMID: 28808038).	28808038
PIK3CA	PIK3CA amp PIK3CA E545K	lung squamous cell carcinoma	predicted - sensitive	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Buparlisib (BKM120) treatment resulted in inhibition of AKT and S6 phosphorylation and durable responses in 2 of 3 lung squamous cell carcinoma patient-derived xenograft (PDX) models harboring PIK3CA E545K and PIK3CA amplification (PMID: 30093452).	30093452
PIK3CA	CDKN2A loss PIK3CA amp PIK3CA E545K	lung squamous cell carcinoma	sensitive	Buparlisib + Palbociclib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with the combination of Buparlisib (BYL719) and Ibrance (palbociclib) resulted in increased tumor growth inhibition compared to either agent alone in patient-derived xenograft (PDX) models of lung squamous cell carcinoma harboring PIK3CA E545K and PIK3CA amplification, with p16 (CDKN2A) loss (PMID: 30093452).	30093452
PIK3CA	ERBB2 pos PIK3CA amp	Her2-receptor positive breast cancer	predicted - sensitive	Neratinib	Phase III	Actionable	In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).	30867034
PIK3CA	PIK3CA M1043I	lung squamous cell carcinoma	no benefit	Taselisib	Case Reports/Case Series	Actionable	In a Phase I (SWOG S1400B) trial, Taselisib (GDC-0032) treatment did not meet primary endpoint in patients with lung squamous cell carcinoma harboring PIK3CA mutations, a patients harboring PIK3CA M1043I did not demonstrated response (PMID: 31158500; NCT02785913).	31158500
PIK3CA	PIK3CA E545D	Her2-receptor negative breast cancer	sensitive	Alpelisib + Fulvestrant	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib), plus Faslodex (fulvestrant), treatment of patients with advanced hormone-receptor positive (ESR1 or PGR), HER2 negative breast cancer with one of 11 PIK3CA mutations (n=341) versus patients with wild-type PIK3CA (n=231) resulted in a greater median progression-free survival (11 vs 5.7 mo) and overall response (26.6% vs 12.8%), and PIK3CA E545D (1635G>T only) is included in the companion diagnostic (PMID: 31091374: NCT02437318).	31091374 detail... detail...
PIK3CA	ERBB2 pos PIK3CA E545D	Her2-receptor positive breast cancer	predicted - sensitive	Neratinib	Phase III	Actionable	In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).	30867034
PIK3CA	PIK3CA D549Y	urinary bladder cancer	decreased response	Pictilisib	Preclinical - Pdx	Actionable	In a preclinical study, Pictilisib (GDC-0941) demonstrated limited tumor growth inhibition and survival benefit in patient-derived xenograft (PDX) models of bladder cancer harboring PIK3CA D549Y (PMID: 28808038).	28808038
PIK3CA	PIK3CA wild-type	Her2-receptor negative breast cancer	no benefit	Alpelisib	Phase I	Actionable	In a Phase I trial, Alpelisib (BYL719) treatment resulted in no clinical benefit in 4 patients with ER-positive, ERBB2 (HER2)-negative breast cancer harboring PIK3CA mutations (PMID: 29401002; NCT01219699).	29401002
PIK3CA	PIK3CA wild-type	triple-receptor negative breast cancer	no benefit	Palbociclib + Pictilisib	Preclinical	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in PIK3CA wild-type, triple-receptor negative breast cancer cell lines in culture (PMID: 27020857).	27020857
PIK3CA	PIK3CA wild-type	Her2-receptor positive breast cancer	sensitive	Lapatinib + Paclitaxel + Trastuzumab	Phase II	Actionable	In a Phase II trial, the combination of Taxol (paclitaxel) plus Herceptin (trastuzumab) and Tykerb (lapatinib) resulted in a higher pathologic complete remission rate in ERBB2 (HER2)-receptor positive breast cancer patients with PIK3CA wild-type compared to those harboring a PIK3CA mutation (PMID: 26245675).	26245675
PIK3CA	PIK3CA wild-type	breast cancer	predicted - sensitive	A-1210477 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, combination of WEHI-539 and A-1210477 resulted in enhanced apoptosis in PIK3CA wild-type breast cancer cell lines in culture (PMID: 27974663).	27974663
PIK3CA	PIK3CA wild-type	Advanced Solid Tumor	sensitive	PX-866	Phase I	Actionable	In a Phase I study, PX-866 demonstrated efficacy and was well tolerated in patients with advanced solid tumor with both PIK3CA wild-type and mutant status (PMID: 22693357).	22693357
PIK3CA	PIK3CA wild-type	breast cancer	no benefit	BEZ235 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize PIK3CA wild-type breast cancer cell lines to WEHI-539 in culture (PMID: 27974663).	27974663
PIK3CA	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	Vemurafenib + ZSTK474	Preclinical	Actionable	In a preclinical study, ZSTK474 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).	26137449
PIK3CA	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	BEZ235 + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergitically inhibited tumor growth in cell line xenograft models (PMID: 26137449).	26137449
PIK3CA	BRAF V600E/K PIK3CA wild-type	melanoma	no benefit	TGX-221	Preclinical	Actionable	In a preclinical study, TGX-221 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).	26137449
PIK3CA	BRAF V600E/K PIK3CA wild-type	melanoma	no benefit	A66	Preclinical	Actionable	In a preclinical study, A66 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).	26137449
PIK3CA	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	Selumetinib + Vemurafenib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).	26137449
PIK3CA	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	BEZ235 + Vemurafenib	Preclinical	Actionable	In a preclinical study, BEZ235 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).	26137449
PIK3CA	BRAF V600E/K PIK3CA wild-type	melanoma	no benefit	Idelalisib	Preclinical	Actionable	In a preclinical study, Zydelig (idelalisib) did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).	26137449
PIK3CA	BRAF V600E/K PIK3CA wild-type	melanoma	sensitive	Selumetinib + ZSTK474	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Selumetinib (AZD6244) and ZSTK474 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergistically inhibited tumor growth in cell line xenograft models (PMID: 26137449).	26137449
PIK3CA	PIK3CA wild-type PTEN loss	breast cancer	no benefit	Everolimus + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and Selumetinib (AZD6244) (PMID: 21358673).	21358673
PIK3CA	PIK3CA wild-type PTEN loss	breast cancer	no benefit	Everolimus + U0126	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and U0126 (PMID: 21358673).	21358673
PIK3CA	PIK3CA wild-type PTEN loss	breast cancer	sensitive	Torkinib + U0126	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and U0126 in culture (PMID: 21358673).	21358673
PIK3CA	PIK3CA wild-type PTEN loss	breast cancer	resistant	AZD8835	Preclinical	Actionable	In a preclinical study, human breast cancer cells with wild-type PIK3CA and loss of PTEN were resistant to growth inhibition by AZD8835 in culture (PMID: 26839307).	26839307
PIK3CA	PIK3CA wild-type PTEN loss	breast cancer	sensitive	Selumetinib + Torkinib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and Selumetinib (AZD6244) in culture (PMID: 21358673).	21358673
PIK3CA	ERBB2 amp PIK3CA wild-type	uterine corpus serous adenocarcinoma	sensitive	Taselisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Taselisib (GDC-0032) did not result in delay of cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, however, did result in tumor growth inhibition in xenograft models (PMID: 26333383).	26333383
PIK3CA	ERBB2 amp PIK3CA wild-type	uterine corpus serous adenocarcinoma	sensitive	Neratinib + Taselisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Taselisib (GDC-0032) and Nerlynx (neratinib) delayed cell cycle activity in a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture (PMID: 26333383).	26333383
PIK3CA	ERBB2 amp PIK3CA wild-type	Her2-receptor positive breast cancer	predicted - sensitive	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of high ERBB2 (HER2) copy number and wild-type PIK3CA correlated with improved progression-free survival (HR=0.45, p=0.024) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
PIK3CA	ERBB2 amp PIK3CA wild-type	uterine corpus serous adenocarcinoma	sensitive	Neratinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Nerlynx (neratinib) delayed cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, and inhibited tumor growth in xenograft models (PMID: 26333383).	26333383
PIK3CA	NRAS mut PIK3CA wild-type	colorectal cancer	predicted - sensitive	TAK-733	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS and with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture (PMID: 26439693).	26439693
PIK3CA	BRAF mut PIK3CA wild-type	colorectal cancer	predicted - sensitive	TAK-733	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, mutations in BRAF, KRAS, or NRAS were associated with sensitivity to TAK-733 in colorectal cancer cell lines in culture, and patient-derived xenograft models harboring KRAS or BRAF mutations with wild-type PIK3CA demonstrated a trend toward higher tumor growth inhibition following TAK-733 treatment (PMID: 26439693).	26439693
PIK3CA	PIK3CA wild-type PTEN pos	head and neck squamous cell carcinoma	predicted - sensitive	Cetuximab + Cisplatin	Clinical Study - Cohort	Actionable	In a clinical study, combination of Erbitux (cetuximab) with Platinol (cisplatin) tended to improve progression-free survival compared to placebo in PTEN-expressing, PIK3CA wild-type head and neck squamous cell carcinoma patients (HR=0.54, p=0.0502) by multivariable analysis, but not in PTEN null or PIK3CA mutated patients (HR=0.76, p=0.54) (PMID: 30926065).	30926065
PIK3CA	AKT1 wild-type PIK3CA wild-type PTEN wild-type	triple-receptor negative breast cancer	no benefit	Capivasertib + Paclitaxel	Phase II	Actionable	In a Phase II trial, Capivasertib (AZD5363) in combination with Taxol (paclitaxel) as first-line therapy resulted in improved median progression-free survival (9.3 vs 3.7 months, HR=0.30, p=0.01) compared to placebo in patients with metastatic triple-negative breast cancer harboring PIK3CA, AKT1, and/or PTEN mutations, but not in patients with wile-type PIK3CA, AKT1, and PTEN (5.3 vs 4.4 months, HR=1.13, p=0.61) (PMID: 30715161; NCT02423603).	30715161
PIK3CA	PIK3CA Q546R	Her2-receptor negative breast cancer	sensitive	Alpelisib + Fulvestrant	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib), plus Faslodex (fulvestrant), treatment of patients with advanced hormone-receptor positive (ESR1 or PGR), HER2 negative breast cancer harboring one of 11 PIK3CA mutations (n=341) versus those patients with wild-type PIK3CA (n=231) resulted in a greater median progression-free survival (11 vs 5.7 mo) and overall response rate (26.6% vs 12.8%), and PIK3CA Q546R is included in the companion diagnostic (PMID: 31091374: NCT02437318).	31091374 detail... detail...
PIK3CA	PIK3CA Q546R	prostate cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of prostate cancer cells harboring PIK3CA Q546R in culture (PMID: 21558396).	21558396
PIK3CA	PIK3CA V952A	colorectal cancer	resistant	Cetuximab + Fluorouracil	Case Reports/Case Series	Actionable	In a clinical study, PIK3CA V952A was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in a colorectal cancer patient, which is consistent with cell culture studies demonstrating moderate resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA V952A (PMID: 28424201).	28424201
PIK3CA	PIK3CA P447_L455del	estrogen-receptor positive breast cancer	predicted - sensitive	Alpelisib + Letrozole	Case Reports/Case Series	Actionable	In a clinical case study, a patient with estrogen-receptor positive breast cancer harboring PIK3CA P447_L455del demonstrated an 11 month sustained response to the combination therapy of Femara (letrozole) and Alpelisib (BYL719) (PMID: 29284706).	29284706
PIK3CA	PIK3CA act mut	estrogen-receptor positive breast cancer	predicted - sensitive	Capivasertib + Tamoxifen	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of AZD5363 and 4-hydroxytamoxifen (4-OHT) worked synergistically or additively to inhibit growth of several estrogen receptor-positive breast cancer cell lines in culture, including cell lines with PIK3CA activating mutations, and overcame tamoxifen resistance in a resistant cell line (PMID: 26116361).	26116361
PIK3CA	PIK3CA act mut	breast cancer	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, breast cancer cell lines harboring activating mutations in PIK3CA had increased sensitivity to MK2206 in cell culture (PMID: 22932669).	22932669
PIK3CA	PIK3CA act mut	breast cancer	no benefit	Buparlisib + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, Buparlisib (BKM120) did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).	27974663
PIK3CA	PIK3CA act mut	Advanced Solid Tumor	sensitive	Everolimus	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Afinitor (everolimus) demonstrated efficacy in multiple cancer cell lines in culture and xenograft models with PIK3CA activating mutations (PMID: 20664172).	20664172
PIK3CA	PIK3CA act mut	lung squamous cell carcinoma	predicted - sensitive	Alpelisib	Preclinical - Pdx	Actionable	In a preclinical study, Alpelisib (BYL719) treatment resulted in responses in multiple lung squamous cell carcinoma patient-derived xenograft (PDX) models harboring PIK3CA E545K or E542K mutations, including models with PIK3CA amplification or PTEN loss (PMID: 30093452).	30093452
PIK3CA	PIK3CA act mut	breast cancer	predicted - sensitive	Sapanisertib + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, the ATP-competitive mTORC1/2 inhibitor Sapanisertib (MLN0128) sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).	27974663
PIK3CA	PIK3CA act mut	breast cancer	predicted - sensitive	Torin 1 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, the ATP-competitive mTORC1/2 inhibitor Torin1 sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).	27974663
PIK3CA	PIK3CA act mut	breast cancer	predicted - sensitive	MK2206 + Ridaforolimus	Phase I	Actionable	In a Phase I clinical trial, Ridaforolimus in combination with MK-2206 demonstrated clinical activity in breast cancer patients expressing a PI3K pathway dependent gene expression signature, with complete response in 14.3% (2/14), partial response in 12.5% (2/16), and 2 patients achieving stable disease (PMID: 26187616).	26187616
PIK3CA	PIK3CA act mut	head and neck squamous cell carcinoma	predicted - sensitive	AZD8055 + Cetuximab	Preclinical - Pdx	Actionable	In a preclinical study, two head and neck squamous cell carcinoma patient-derived xenograft (PDX) models harboring a PIK3CA activating mutation demonstrated greater delayed tumor growth when treated with a combination of AZD8055 and Erbitux (cetuximab) compared to either agent alone (PMID: 28446642).	28446642
PIK3CA	PIK3CA act mut	Advanced Solid Tumor	sensitive	Afuresertib	Preclinical	Actionable	In a preclinical study, various tumor cell lines harboring PI3KCA activating mutations demonstrated increased sensitivity to Afuresertib (GSK2110183) in cultured cells (PMID: 24978597).	24978597
PIK3CA	PIK3CA act mut	lung non-small cell carcinoma	sensitive	Pictilisib	Preclinical - Cell line xenograft	Actionable	In preclinical studies, the PI3K inhibitor GDC-0941 demonstrated efficacy against NSCLC tumor cell lines in culture and in xenograft models harboring alterations in the PI3K pathway (PMID: 23136191).	23136191
PIK3CA	PIK3CA act mut	lung small cell carcinoma	predicted - sensitive	Navitoclax + Pictilisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Navitoclax (ABT-263) and GDC-0941 resulted in increased tumor growth delay and apoptosis in a small cell lung cancer cell line xenograft model harboring a PIK3CA activating mutation compared to either drug alone (PMID: 27197306).	27197306
PIK3CA	PIK3CA act mut	Advanced Solid Tumor	conflicting	Taselisib	Phase II	Actionable	In a Phase II (MATCH) trial, Taselisib (GDC-0032) treatment resulted in no objective response (0/65) but prolonged stable disease (estimated 6-month progression-free survival rate 27%) in patients with advanced solid tumors harboring PIK3CA activating mutations (J Clin Oncol 36, 2018 (suppl; abstr 101); NCT02465060).	detail...
PIK3CA	PIK3CA act mut	Advanced Solid Tumor	conflicting	Taselisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Taselisib (GDC-0032) effectively suppressed growth of multiple tumor types in cell line xenograft models, with greater selectivity for PIK3CA activating mutants (PMID: 23662903).	23662903
PIK3CA	PIK3CA act mut	triple-receptor negative breast cancer	predicted - sensitive	Bevacizumab + Doxorubicin + Everolimus	Phase I	Actionable	In a Phase I trial, triple-receptor negative breast cancer patients, including those with PIK3CA activating mutations, demonstrated an overall response rate of 21% (11/52) and clinical benefit rate of 40% (21/52) when treated with a combination of Avastin (bevacizumab), Adriamycin (doxorubicin), and either Afinitor (everolimus) or Torisel (temsirolimus) (PMID: 27893038).	27893038
PIK3CA	PIK3CA act mut	Advanced Solid Tumor	sensitive	Metformin	Preclinical	Actionable	In a preclinical study, Glucophage (metformin) demonstrated efficacy in treating dietary restriction-resistant human xenograft tumors harboring a PIK3CA-activating mutation (PMID: 23986086).	23986086
PIK3CA	PIK3CA act mut	Advanced Solid Tumor	sensitive	Ipatasertib + Paclitaxel	Phase Ib/II	Actionable	In a Phase Ib trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) demonstrated safety and anti-tumor activity in patients with advanced solid tumors, including patients with PIK3CA activating mutations (Annals of Oncology (2014) 25 (suppl_4): iv146-iv164. 10.1093/annonc/mdu331).	detail...
PIK3CA	PIK3CA act mut	head and neck squamous cell carcinoma	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, PF-05212384 decreased viability of head and neck squamous carcinoma cells harboring a PIK3CA activating mutation in cell culture (PMID: 24823695).	24823695
PIK3CA	PIK3CA act mut	Advanced Solid Tumor	sensitive	GSK1059615	Preclinical	Actionable	In a preclinical study, solid tumor cell lines harboring PIK3CA activating mutations demonstrated increased sensitivity to GSK1059615 in culture (Clin Cancer Res October 1, 2008 14; B37).	detail...
PIK3CA	PIK3CA act mut	breast cancer	no benefit	BEZ235 + Venetoclax	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663).	27974663
PIK3CA	PIK3CA act mut	ovarian clear cell adenocarcinoma	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 demonstrated efficacy in mouse xenograft models of ovarian clear cell adenocarcinoma with PIK3CA mutations (PMID: 24927217).	24927217
PIK3CA	PIK3CA act mut	lung squamous cell carcinoma	predicted - sensitive	Buparlisib	Preclinical - Pdx	Actionable	In a preclinical study, Buparlisib (BKM120) treatment resulted in inhibition of AKT and S6 phosphorylation and durable responses in 4/5 lung squamous cell carcinoma patient-derived xenograft (PDX) models harboring PIK3CA E545K or E542K mutations, 3 that also had PIK3CA amplification and 1 with PTEN loss (PMID: 30093452).	30093452
PIK3CA	PIK3CA act mut	Advanced Solid Tumor	sensitive	BAY1125976	Preclinical	Actionable	In a preclinical study, BAY1125976 demonstrated anti-tumor efficacy in multiple xenograft tumor models of different cancers with PIK3CA mutations or PTEN deletions and displayed synergy with other anti-cancer therapies (Cancer Res 2013;73(8 Suppl):Abstract nr 2050).	detail...
PIK3CA	PIK3CA act mut	breast cancer	no benefit	Alpelisib + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).	27974663
PIK3CA	PIK3CA act mut	triple-receptor negative breast cancer	predicted - sensitive	Bevacizumab + Doxorubicin + Temsirolimus	Phase I	Actionable	In a Phase I trial, triple-receptor negative breast cancer patients, including those with PIK3CA activating mutations, demonstrated an overall response rate of 21% (11/52) and clinical benefit rate of 40% (21/52) when treated with a combination of Avastin (bevacizumab), Adriamycin (doxorubicin), and either Afinitor (everolimus) or Torisel (temsirolimus) (PMID: 27893038).	27893038
PIK3CA	PIK3CA act mut	breast cancer	predicted - sensitive	BEZ235 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).	27974663
PIK3CA	PIK3CA act mut	breast cancer	sensitive	Copanlisib	Preclinical	Actionable	In a preclinical study, breast cancer cell lines with a PIK3CA activating mutation and/or ERBB2 (HER2) over expression demonstrated increased sensitivity to inhibition of proliferation by Aliqopa (copanlisib) in culture, compared to ERBB2 (HER2)-negative and wild-type PIK3CA cell lines (PMID: 24170767).	24170767
PIK3CA	PIK3CA act mut	breast cancer	sensitive	Copanlisib	Phase I	Actionable	In a Phase I clinical trial, treatment with Aliqopa (copanlisib) resulted in partial response in one and stable disease in another patient with breast cancer harboring activating PIK3CA mutations (PMID: 27672108; NCT00962611).	27672108
PIK3CA	PIK3CA act mut	breast cancer	predicted - sensitive	Vistusertib + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, the ATP-competitive mTORC1/2 inhibitor Vistusertib (AZD2014) sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).	27974663
PIK3CA	ERBB2 pos PIK3CA act mut	Her2-receptor positive breast cancer	predicted - sensitive	Buparlisib + Trastuzumab	Phase I	Actionable	In a Phase I trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on trastuzumab-based therapy (PMID: 24470511).	24470511
PIK3CA	ERBB2 pos PIK3CA act mut	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).	17936563
PIK3CA	ERBB2 pos PIK3CA act mut	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation due to PTEN loss and/or PIK3CA activating mutation demonstrated a decreased median progression-free survival of 4.5 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).	21676217
PIK3CA	ERBB2 pos PIK3CA act mut	Her2-receptor positive breast cancer	sensitive	Palbociclib + Pictilisib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit survival of ERBB2 (HER2)-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).	27020857
PIK3CA	ERBB2 pos PIK3CA act mut	uterine cancer	sensitive	Taselisib	Preclinical	Actionable	In a preclinical study, Taselisib (GDC-0032) inhibited growth of HER2 positive uterine cancer cell lines with PIK3CA mutations (PMID: 25172762).	25172762
PIK3CA	PIK3CA act mut ERBB2 act mut	breast cancer	sensitive	VS-5584	Preclinical	Actionable	In a preclinical study, breast cancer cells with mutations in both ERBB2 (HER2) and PIK3CA were more sensitive to VS-5584 (PMID: 23270925).	23270925
PIK3CA	PIK3CA act mut PTEN dec exp	renal cell carcinoma	no benefit	Everolimus	Phase II	Actionable	In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had no difference in progression free survival when stratified by the presence (n=21) or absence (n=17) of PIK3CA activating mutations (PMID: 26951309).	26951309
PIK3CA	PIK3CA act mut PTEN dec exp	renal cell carcinoma	no benefit	GDC-0980	Phase II	Actionable	In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by the presence (n=21) or absence (n=15) of PIK3CA activating mutation or loss of Pten expression (PMID: 26951309).	26951309
PIK3CA	PIK3CA act mut PTEN wild-type	breast cancer	sensitive	Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, 8/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Afinitor (everolimus) in culture, resulting in decreased cell viability (PMID: 21358673).	21358673
PIK3CA	PIK3CA act mut PTEN wild-type	breast cancer	sensitive	Torkinib	Preclinical - Cell culture	Actionable	In a preclinical study, 9/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Torkinib (PP242) in culture, resulting in decreased cell viability (PMID: 21358673).	21358673
PIK3CA	ARID1A mut PIK3CA act mut	ovarian cancer	sensitive	GSK126	Preclinical - Cell culture	Actionable	In a preclinical study, expression of a constitutively active PIK3CA mutation in ARID1A-mutant ovarian cancer cell lines enhanced growth inhibition by GSK126 in culture (PMID: 25686104).	25686104
PIK3CA	CDKN2A loss PIK3CA act mut	lung squamous cell carcinoma	predicted - sensitive	Buparlisib + Palbociclib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with the combination of Buparlisib (BYL719) and Ibrance (palbociclib) resulted in increased tumor growth inhibition compared to either agent alone in patient-derived xenograft (PDX) models of lung squamous cell carcinoma harboring PIK3CA E542K or E545K mutations with p16 (CDKN2A) loss, including models that also had either PIK3CA amplification or PTEN loss (PMID: 30093452).	30093452
PIK3CA	ERBB2 amp PIK3CA act mut	Her2-receptor positive breast cancer	decreased response	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
PIK3CA	ERBB2 over exp PIK3CA act mut	Her2-receptor positive breast cancer	decreased response	Poziotinib	Phase II	Actionable	In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).	30720867
PIK3CA	PIK3CA E545V	ovarian clear cell adenocarcinoma	sensitive	DS-7423	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA E545V was sensitive to DS-7423 in culture, demonstrating inhibition of cell proliferation (PMID: 24504419).	24504419
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	MLN1117	Preclinical	Actionable	In a preclinical study, MLN1117 inhibited proliferation of tumor cells harboring oncogenic PIK3CA mutations in culture and inhibited tumor growth in PIK3CA mutant xenograft models (Cancer Ther 2011;10(11 Suppl):Abstract nr A171).	detail...
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	MLN1117	Phase I	Actionable	In a Phase I trial, MLN1117 demonstrated safety and preliminary efficacy in a variety of patients with advanced solid tumors carrying PIK3CA mutations (Journal of Clinical Oncology, 2015 ASCO Annual Meeting Vol 33, No 15_suppl., 2015: 2501).	detail...
PIK3CA	PIK3CA mutant	invasive bladder transitional cell carcinoma	predicted - resistant	Cisplatin + Gemcitabine + Sorafenib	Phase II	Actionable	In a Phase II trial, PIK3CA mutations were more frequent in muscle-invasive urothelial bladder cancer patients that did not respond to Nexavar (sorafenib), Platinol (cisplatin) and Gemzar (gemcitabine) combination therapy than those who did respond (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).	detail...
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	predicted - sensitive	Uprosertib	Phase I	Actionable	In a Phase I clinical trial, GSK2141795 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, with 4 patients with PIK3CA mutations and/or PTEN loss achieving stable disease for greater than 6 months (J Clin Oncol 29: 2011 (suppl; abstr 3003)).	detail...
PIK3CA	PIK3CA mutant	Her2-receptor negative breast cancer	sensitive	Alpelisib + Fulvestrant	Phase III	Actionable	In a Phase III (SOLAR-1) trial, Alpelisib (BYL719) and Faslodex (fulvestrant) combination therapy significantly improved median progression-free survival (11.0 vs 5.7 months, HR=0.65, p=0.00065), and overall response rate (36% vs 16%, p=0.0002) compared to placebo in hormone receptor-positive, Erbb2 (Her2)-negative breast cancer patients harboring PIK3CA mutations (ESMO 2018 Congress, Oct 2018, Presidential Symposium 1, abstract LBA3; NCT02437318).	detail...
PIK3CA	PIK3CA mutant	Her2-receptor negative breast cancer	sensitive	Alpelisib + Fulvestrant	FDA approved - Has Companion Diagnostic	Actionable	In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib), plus Faslodex (fulvestrant), treatment of patients with advanced hormone-receptor positive (ESR1 or PGR), HER2 negative breast cancer harboring one of 11 PIK3CA mutations (n=341) versus those patients with wild-type PIK3CA (n=231) resulted in a greater median progression-free survival (11 vs 5.7 mo) and overall response rate (26.6% vs 12.8%) (PMID: 31091374: NCT02437318).	31091374 detail... detail...
PIK3CA	PIK3CA mutant	estrogen-receptor positive breast cancer	no benefit	Fulvestrant + Pictilisib	Phase II	Actionable	In a Phase II trial, Falsodex (fulvestrant) and Pictilisib (GDC-0941) combination treatment resulted in similar progression free survival in ER positive breast cancer patients harboring PIK3CA mutations and those who were PIK3CA wild-type (PMID: 27174596).	27174596
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	Taselisib	Phase I	Actionable	In a Phase I trial, Taselisib (GDC-0032) demonstrated activity in patients with PIK3CA-mutant advanced solid tumors, in the absence of alterations in the MAPK or PTEN pathways (Cancer Res October 1, 2014 74:915).	detail...
PIK3CA	PIK3CA mutant	Her2-receptor positive breast cancer	sensitive	CCT128930	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CCT128930 induced growth arrest and inhibited tumor growth in a xenograft model of a ERBB2 (HER2)-positive human breast cancer cell line harboring a PIK3CA mutation (PMID: 21191045).	21191045
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	A-443654	Preclinical	Actionable	In a preclinical study, cells expressing mutant PIK3CA demonstrated increased sensitivity to A-443654 compared to cells expressing wild-type PIK3CA (PMID: 19208828).	19208828
PIK3CA	PIK3CA mutant	head and neck squamous cell carcinoma	sensitive	Radiotherapy + Taselisib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis in HNSCC cell lines, cell line xenograft models, and a patient derived xenograft (PDX) model, all with PIK3CA mutations (PMID: 26589432).	26589432
PIK3CA	PIK3CA mutant	Her2-receptor negative breast cancer	sensitive	Alpelisib	Phase I	Actionable	In a Phase I trial, Alpelisib (BYL719) treatment resulted in a disease control rate of 60.9% (14/23, 0 complete response (CR), 1 partial response (PR), 13 stable disease (SD)), and a clinical benefit rate (CR+PR+SD>24 weeks) of 17.4% (4/23) in patients with ER-positive, ERBB2 (HER2)-negative breast cancer harboring PIK3CA mutations (PMID: 29401002; NCT01219699).	29401002
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	Alpelisib	Phase I	Actionable	In a Phase I trial, Alpelisib (BYL719) demonstrated safety and efficacy in patients with advanced solid tumor harboring PIK3CA mutations, resulted in a disease control rate of 58.2% (78/134, 1 complete response (CR), 7 partial response (PR), 70 stable disease (SD)), and a clinical benefit rate (CR+PR+SD>24 weeks) of 15.7% (21/134) (PMID: 29401002; NCT01219699).	29401002
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	Alpelisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PIK3CA mutations were associated with sensitivity to Alpelisib (BYL719) in human tumor cell lines in culture and in xenograft models (PMID: 24608574).	24608574
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	CUDC-907	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CUDC-907 inhibited PIK3CA, blocked downstream AKT pathway activation, and induced apoptosis and cell cycle arrest in both PIK3CA wild-type and PIK3CA mutant human cancer cell lines and xenograft models of multiple tumor types (PMID: 22693356).	22693356
PIK3CA	PIK3CA mutant	triple-receptor negative breast cancer	sensitive	Palbociclib + Pictilisib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit the survival of triple-receptor negative breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).	27020857
PIK3CA	PIK3CA mutant	hematologic cancer	sensitive	CUDC-907	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CUDC-907 inhibited PIK3CA, blocked downstream AKT pathway activation, and induced apoptosis and cell cycle arrest in both PIK3CA wild-type and PIK3CA mutant human cancer cell lines and xenograft models of multiple solid and hematologic cancers (PMID: 22693356).	22693356
PIK3CA	PIK3CA mutant	female reproductive organ cancer	predicted - sensitive	Capivasertib	Phase I	Actionable	In a Phase I trial, treatment with AZD5363 was well-tolerated and resulted in tumor shrinkage in 56% (14/25) patients with PIK3CA-mutant gynecological cancers, however, the response rate was modest with confirmed RECIST responses in 8% (2/26) of patients (PMID: 29066505; NCT01226316).	29066505
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	Carboxyamidotriazole Orotate	Phase I	Actionable	In a Phase I clinical trial, carboxyamidotriazole orotate treatment demonstrated some efficacy in patients with various solid tumors, including patients harboring PIK3CA mutations (J Clin Oncol 31, 2013 (suppl; abstr 2518)).	detail...
PIK3CA	PIK3CA mutant	breast cancer	sensitive	Alpelisib + GSK2334470	Preclinical - Cell line xenograft	Actionable	In a preclinical study, GSK2334470 resensitized Alpelisib (BYL719)-resistant breast cancer cell lines harboring PIK3CA mutations to Alpelisib (BYL719) in culture and in cell line xenograft models (PMID: 27451907).	27451907
PIK3CA	PIK3CA mutant	breast cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, Sapanisertib (MLN0128) demonstrated efficacy in PIK3CA mutant breast cancer xenograft models (PMID: 23085766).	23085766
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	no benefit	Alpelisib + BGJ398	Phase Ib/II	Actionable	In a Phase Ib trial, treatment with the combination of Piqray (alpelisib) and Infigratinib (BGJ398) resulted in partial response (PR) in 9.7% (6/62) and disease control (PR or stable disease) in 61.3% (34/62) of patients with advanced solid tumors harboring a PIK3CA mutation with or without an FGFR alteration, however, the efficacy was not deemed great enough to pursue further development (JCO Precision Oncology 2019 :3, 1-13).	detail...
PIK3CA	PIK3CA mutant	breast cancer	sensitive	Pictilisib	Preclinical	Actionable	In a preclinical study, GDC-0941 inhibited growth and induced apoptosis in breast cancer cells expressing PIK3CA mutations (PMID: 24601221).	24601221
PIK3CA	PIK3CA mutant	estrogen-receptor positive breast cancer	sensitive	AZD8835	Preclinical	Actionable	In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA mutations in culture and suppressed tumor growth in xenograft models (PMID: 26839307).	26839307
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	PX-866	Phase I	Actionable	In a Phase I trial, PX-866 demonstrated efficacy and was well tolerated in patients with advanced solid tumor with both PIK3CA wild-type and mutant status (PMID: 22693357).	22693357
PIK3CA	PIK3CA mutant	triple-receptor negative breast cancer	predicted - sensitive	Capivasertib + Paclitaxel	Phase II	Actionable	In a Phase II trial, Capivasertib (AZD5363) in combination with Taxol (paclitaxel) as first-line therapy resulted in improved median progression-free survival (9.3 vs 3.7 months, HR=0.30, p=0.01) compared to placebo in patients with metastatic triple-negative breast cancer harboring PIK3CA, AKT1, and/or PTEN mutations, but not in patients with wile-type PIK3CA, AKT1, and PTEN (5.3 vs 4.4 months, HR=1.13, p=0.61) (PMID: 30715161; NCT02423603).	30715161
PIK3CA	PIK3CA mutant	estrogen-receptor positive breast cancer	predicted - sensitive	Letrozole	Phase III	Actionable	In a Phase III trial, estrogen-receptor positive breast cancer patients harboring a PIK3CA mutation demonstrated a greater benefit when treated with Femara (letrozole) compared to Nolvadex (tamoxifen) (PMID: 29902286; NCT00004205).	29902286
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	XL147	Preclinical	Actionable	In a preclinical study, tumor cell lines with PIK3CA mutations demonstrated sensitivity to XL147 in culture (PMID: 25637314).	25637314
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	XL147	Phase I	Actionable	In a Phase I clinical trial, XL147 (SAR24508) was shown to be safe and potentially efficacious, with clinical activity seen irrespective of tumor PI3K pathway molecular alterations (PMID: 24166903).	24166903
PIK3CA	PIK3CA mutant	cervical cancer	predicted - sensitive	Alpelisib	Phase I	Actionable	In a Phase I trial, Alpelisib (BYL719) treatment resulted in partial response in 3 patients with cervical cancer harboring PIK3CA mutations (PMID: 29401002; NCT01219699).	29401002
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	GDC-0980	Phase I	Actionable	In a Phase I trial, Apitolisib (GDC-0980) treatment resulted in partial response in 21% (3/14) and stable disease in 57% (8/14) of patients with advanced solid tumors harboring PIK3CA mutations (PMID: 26787751).	26787751
PIK3CA	PIK3CA mutant	ovarian cancer	sensitive	OSI-027	Preclinical - Cell line xenograft	Actionable	In a preclinical study, OSI-027 inhibited tumor growth in ovarian cancer cell line xenograft models harboring PIK3CA mutations (PMID: 21673091).	21673091
PIK3CA	PIK3CA mutant	endometrial cancer	sensitive	GDC-0980	Phase II	Actionable	In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)).	detail...
PIK3CA	PIK3CA mutant	breast cancer	sensitive	VS-5584	Preclinical	Actionable	In a preclinical study, PIK3CA mutant breast cancer cells showed increased sensitivity to VS-5584 compared to PIK3CA wild-type cells in culture (PMID: 23270925).	23270925
PIK3CA	PIK3CA mutant	squamous cell carcinoma	sensitive	Carboxyamidotriazole Orotate	Phase I	Actionable	In a Phase I clinical trial, carboxyamidotriazole orotate treatment demonstrated some efficacy in patients with various solid tumors including squamous cell carcinomas (tonsil) with PI3KCA and NRAS mutations (J Clin Oncol 31, 2013 (suppl; abstr 2518)).	detail...
PIK3CA	PIK3CA mutant	colorectal cancer	sensitive	Alpelisib	Phase I	Actionable	In a Phase I trial, Alpelisib (BYL719) treatment resulted in a disease control rate of 34.3% (12/35, 0 complete response (CR), 2 partial response (PR), 10 stable disease (SD)), and a clinical benefit rate (CR+PR+SD>24 weeks) of 8.6% (3/35) in patients with colorectal cancer harboring PIK3CA mutations (PMID: 29401002; NCT01219699).	29401002
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	VS-5584	Preclinical	Actionable	In preclinical studies, VS-5584 demonstrated efficacy in a variety of cancer cell lines, particularly those harboring PIK3CA mutations (PMID: 23270925).	23270925
PIK3CA	PIK3CA mutant	breast cancer	no benefit	Temsirolimus	Phase II	Actionable	In a Phase II trial, Torisel (temsirolimus) treatment resulted in stable disease in 9.7% (3/31) of breast cancer patients positive for ER, PR or ERBB2 (HER2), however there was no association between PIK3CA mutational status and clinical benefits (PMID: 22245973).	22245973
PIK3CA	PIK3CA mutant	ovarian cancer	sensitive	Temsirolimus	Case Reports/Case Series	Actionable	In a clinical study, an ovarian cancer patient harboring a PIK3CA E542 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929).	21216929
PIK3CA	PIK3CA mutant	ovarian cancer	sensitive	Temsirolimus	Phase I	Actionable	In a Phase I clinical trial, Torisel (temsirolimus) demonstrated limited efficacy in ovarian cancer patients with PIK3CA mutations (PMID: 22271473).	22271473
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	Bevacizumab + Pegylated liposomal-doxorubicin + Temsirolimus	Clinical Study	Actionable	In a clinical study, the combination of Torisel (temisirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxirubicin) resulted in stable disease in patients with advanced solid tumors harboring PIK3CA mutations (PMID: 21216929).	21216929
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	Bevacizumab + Pegylated liposomal-doxorubicin + Temsirolimus	Clinical Study	Actionable	In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in patients with advanced solid tumors harboring PIK3CA mutations (PMID: 21216929).	21216929
PIK3CA	PIK3CA mutant	breast cancer	predicted - sensitive	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cell lines harboring PIK3CA mutations demonstrated increased sensitivity to CYH33 compared to cell lines with wild-type PIK3CA in culture (p<0.01) (PMID: 30003928).	30003928
PIK3CA	PIK3CA mutant	breast cancer	sensitive	OSI-027	Preclinical - Cell line xenograft	Actionable	In a preclinical study, OSI-027 induced tumor regression in breast cancer cell line xenograft models harboring PIK3CA mutations (PMID: 21673091).	21673091
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	BAY1082439	Preclinical	Actionable	In a preclinical study, BAY1082439 induced regression in xenograft models of advanced solid tumors with PIK3CA mutations (Cancer Res April 15, 2012 72; 2799).	detail...
PIK3CA	PIK3CA mutant	breast adenocarcinoma	sensitive	GS-9820	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Acalisib (GS-9820) resulted in tumor growth inhibition in xenograft models of breast adenocarcinoma harboring a PIK3CA mutation (Mol Cancer Ther 2009;8(12 Suppl):B136).	detail...
PIK3CA	PIK3CA mutant	stomach cancer	predicted - sensitive	MLN1117	Case Reports/Case Series	Actionable	In a Phase I trial, MLN1117 (INK1117) treatment resulted in a partial response in one patient with gastric cancer harboring a PIK3CA mutation (PMID: 28490463; NCT01449370).	28490463
PIK3CA	PIK3CA mutant	ovarian cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of ovarian cancer cells with PIK3CA mutations in culture (PMID: 21558396).	21558396
PIK3CA	PIK3CA mutant	ovarian cancer	sensitive	Buparlisib + Olaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Buparlisib (BKM120) and Lynparza (olaparib) worked synergistically to induce apoptosis and inhibit growth of ovarian cancer cell lines harboring PIK3CA mutations in culture, and induced apoptosis and decreased proliferation of PIK3CA-mutant ovarian cancer cell line xenograft models (PMID: 26909613).	26909613
PIK3CA	PIK3CA mutant	head and neck squamous cell carcinoma	predicted - sensitive	Carboplatin + Paclitaxel + Temsirolimus	Phase II	Actionable	In a Phase II trial, two patients with head and neck squamous cell carcinoma harboring a PIK3CA mutation who had stable disease demonstrated some tumor regression when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834).	28961834
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	CC-223	Phase I	Actionable	In a Phase I trial, CC-223 demonstrated safety and preliminary efficacy in patients with solid tumors, including stable disease for greater than 110 days in 2 patients with PIK3CA mutation or PTEN deletion (PMID: 26177599).	26177599 detail...
PIK3CA	PIK3CA mutant	lung squamous cell carcinoma	no benefit	Taselisib	Phase I	Actionable	In a Phase I (SWOG S1400B) trial, Taselisib (GDC-0032) treatment did not meet primary endpoint in patients with lung squamous cell carcinoma harboring PIK3CA mutations, with only 1 responder in the primary analysis population (n=21) (PMID: 31158500; NCT02785913).	31158500
PIK3CA	PIK3CA mutant	hepatocellular carcinoma	decreased response	Sorafenib	Clinical Study - Cohort	Actionable	In a clinical case study, Nexavar (sorafenib) treatment of patients with hepatocellular carcinoma harboring Mtor pathway mutations in PIK3CA, PTEN, TSC2, or TSC1 (n=12), resulted in a lower disease control rate (8.3% vs. 40.2%), shorter progression-free survival (1.9 months vs. 5.3 months) and shorter overall survival (10.4 months vs. 17.9 months) compared to patients without mutations in this pathway (n=67) (PMID: 30373752; NCT01775072).	30373752
PIK3CA	PIK3CA mutant	endometrial cancer	no benefit	Temsirolimus	Phase II	Actionable	In a retrospective study of a Phase II trial, mutation status of PIK3CA was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228).	27016228
PIK3CA	PIK3CA mutant	breast cancer	predicted - sensitive	Capivasertib	Preclinical	Actionable	In a preclinical study, AZD5363 inhibited growth in breast cancer cell lines and xenograft models expressing PIK3CA mutations (PMID: 22294718).	22294718
PIK3CA	PIK3CA mutant	breast cancer	predicted - sensitive	Capivasertib	Phase I	Actionable	In a Phase I trial, treatment with AZD5363 was well-tolerated and resulted in tumor shrinkage in 46% (12/26) patients with PIK3CA-mutant breast cancer, with confirmed RECIST responses in 4% (1/28) of patients (PMID: 29066505; NCT01226316).	29066505
PIK3CA	PIK3CA mutant	cervical cancer	decreased response	Cetuximab	Phase II	Actionable	In a Phase II clinical trial, Erbitux (cetuximab) treatment, in addition to radiochemotherapy, did not result in any complete responses (0/8) and demonstrated a worse disease free survival when compared to radiochemotherapy alone in cervical cancer patients harboring PIK3CA mutations (PMID: 25724520).	25724520
PIK3CA	PIK3CA mutant	colorectal cancer	predicted - sensitive	MS417 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) and MS417 in combination resulted in improved growth inhibition and increased cell death compared to either agent alone in colorectal cancer cell lines harboring PIK3CA mutations in culture (PMID: 26058079).	26058079
PIK3CA	PIK3CA mutant	lung non-small cell carcinoma	sensitive	PWT33597	Preclinical	Actionable	In a preclinical study, PWT33597 decreased signaling of mTOR and PIK3 pathways in non-small cell lung cancer cells with Pik3ca mutations (Cancer Res 2011;71(8 Suppl):Abstract nr 4485).	detail...
PIK3CA	PIK3CA mutant	endometrial cancer	sensitive	Alpelisib	Phase I	Actionable	In a Phase I trial, Alpelisib (BYL719) treatment resulted in complete response in 1 and partial response in 1patient with endometrial cancer harboring PIK3CA mutations (PMID: 29401002; NCT01219699).	29401002
PIK3CA	PIK3CA mutant	gastric adenocarcinoma	sensitive	Fluorouracil + PI-103	Preclinical	Actionable	In a preclinical study, PI-103 enhanced sensitivity to 5-FU in gastric cancer cells with mutant PIK3CA (PMID: 22336586).	22336586
PIK3CA	PIK3CA mutant	breast cancer	sensitive	AT13148	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a ERBB3 (HER3) positive breast cancer cell line xenograft model harboring a PIK3CA mutation was demonstrated decreased tumor growth when treated with AT13148 (PMID: 22781553).	22781553
PIK3CA	PIK3CA mutant	endometrial cancer	sensitive	Pictilisib	Preclinical	Actionable	In a preclinical study, endometrioid endometrial cancer cell lines harboring PIK3CA mutations demonstrated increased sensitivity to GDC-0941 (Pictilisib) induced growth inhibition comparing to PIK3CA wild-type cells in culture (PMID: 23674493).	23674493
PIK3CA	PIK3CA mutant	endometrial cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of endometrial cancer cells with PIK3CA mutations in culture (PMID: 21558396).	21558396
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	AZD8835	Preclinical	Actionable	In a preclinical study, AZD8835 inhibited growth of a variety of advanced solid tumor models with Pik3ca mutations in culture (PMID: 26839307).	26839307
PIK3CA	PIK3CA mutant	triple-receptor negative breast cancer	sensitive	Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, triple-receptor negative breast cancer cell lines harboring PIK3CA mutations demonstrated increased sensitivity to Pictilisib (GDC-0941) in culture (PMID: 27196766).	27196766
PIK3CA	PIK3CA mutant	breast cancer	predicted - sensitive	GDC-0077	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, GDC-0077 inhibited proliferation and induced apoptosis in PIK3CA-mutant breast cancer cell lines in culture, and induced apoptosis and tumor regression in PIK3CA-mutant breast cancer cell line and patient-derived xenograft models (AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 156).	detail...
PIK3CA	PIK3CA mutant	estrogen-receptor positive breast cancer	no benefit	Fulvestrant	Phase II	Actionable	In a Phase II trial, Falsodex (fulvestrant) treatment resulted in similar progression free survival in ER positive breast cancer patients harboring PIK3CA mutations and those who were PIK3CA wild-type (PMID: 27174596).	27174596
PIK3CA	PIK3CA mutant	breast cancer	sensitive	CUDC-907	Preclinical	Actionable	In a preclinical study, CUDC-907 inhibited growth of human breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 22693356).	22693356
PIK3CA	PIK3CA mutant	endometrioid ovary carcinoma	sensitive	Capivasertib	Phase I	Actionable	In a Phase I clinical trial, AZD5363 demonstrated safety and efficacy in patients with advanced solid tumors, including prolonged stable disease in one patient with a PIK3CA-mutant endometrioid ovarian cancer (American Association for Cancer Research; 06 Apr 2013-10 Apr 2013; Abstract LB-66).	detail...
PIK3CA	PIK3CA mutant	Her2-receptor negative breast cancer	no benefit	Capivasertib + Paclitaxel	Phase II	Actionable	In a Phase II trial, the addition of AZD5363 to Taxol (paclitaxel) therapy did not improve progression-free survival compared to placebo (10.9 vs 10.8 months) in patients with PIK3CA-mutant, Esr1-positive, Erbb2 (Her2)-negative breast cancer (PMID: 30860570; NCT01625286).	30860570
PIK3CA	PIK3CA mutant	colon cancer	sensitive	PWT33597	Preclinical	Actionable	In a preclinical study, PWT33597 decreased signaling of mTOR and PIK3 pathways in colon cancer cells with Pik3ca mutations (Cancer Res 2011;71(8 Suppl):Abstract nr 4485).	detail...
PIK3CA	PIK3CA mutant	triple-receptor negative breast cancer	predicted - sensitive	Ipatasertib + Paclitaxel	Phase II	Actionable	In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients harboring mutations in PIK3CA, AKT1, or PTEN (J Clin Oncol 35, 2017 (suppl; abstr 1009)).	detail...
PIK3CA	PIK3CA mutant	stomach cancer	sensitive	BAY1082439	Preclinical	Actionable	In a preclinical study, BAY1082439 inhibited growth of gastric cancer cells harboring PIK3CA mutations in culture and xenograft models (AACR; 2015. Abstract nr 2674).	detail...
PIK3CA	PIK3CA mutant	breast cancer	predicted - sensitive	MLN1117	Case Reports/Case Series	Actionable	In a Phase I trial, MLN1117 (INK1117) treatment resulted in partial response in 3 patients with breast cancer harboring PI3CA mutations (PMID: 28490463; NCT01449370).	28490463
PIK3CA	PIK3CA mutant	breast cancer	no benefit	MK2206	Phase II	Actionable	In a Phase II trial, MK2206 demonstrated limited clinical efficacy in patients with advanced breast cancer harboring mutations in PIK3CA (n=14) or AKT1 (n=4), resulted in an objective response rate of 5.6% (1/18, 1 partial response) and a 6-month progression-free survival rate of 5.6%, with no significant target inhibition in tumor biopsies (PMID: 31277699; NCT01277757).	31277699
PIK3CA	PIK3CA mutant	prostate cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of prostate cancer cells with PIK3CA mutations in culture (PMID: 21558396).	21558396
PIK3CA	PIK3CA mutant	stomach cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 demonstrated efficacy in promoting apoptosis of gastric cancer cells harboring a PIK3CA mutation in culture (PMID: 22543857).	22543857
PIK3CA	PIK3CA mutant	breast cancer	sensitive	Letrozole + Taselisib	Phase Ib/II	Actionable	In a Phase Ib trial, Taselisib (GDC-0032) and Femara (letrozole) combination therapy resulted in an overall response rate of 38% in breast cancer patients with PIK3CA mutations, compared to 9% in patients with wild-type PIK3CA (Cancer Res May 1, 2015 75; PD5-2).	detail...
PIK3CA	PIK3CA mutant	colon cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 demonstrated efficacy in promoting apoptosis of colon cancer cells harboring a PIK3CA mutation in culture (PMID: 22543857).	22543857
PIK3CA	PIK3CA mutant	lung non-small cell carcinoma	sensitive	PF-04691502	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-04691502 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring PIK3CA mutations (PMID: 21750219).	21750219
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	M2698	Preclinical	Actionable	In a preclinical study, MSC2363318A demonstrated anti-proliferative activity against many solid tumor cell lines with PI3K pathway genomic alterations, and inhibited tumor growth in several human cancer xenograft models of breast, pancreatic, glioblastoma and ovarian cancers (Mol Cancer Ther 2013;12(11 Suppl):A162).	detail...
PIK3CA	PIK3CA mutant	breast cancer	sensitive	AZD8835	Preclinical	Actionable	In a preclinical study, AZD8835 inhibited tumor growth in breast cancer xenograft models harboring PIK3CA mutations (AACR; 2015. Abstract nr 2665).	detail...
PIK3CA	PIK3CA mutant	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, breast cancer cells with PIK3CA mutations, both with and without ERBB2 (HER2) amplification, demonstrated sensitivity to CH5132799 in culture (PMID: 21558396).	21558396
PIK3CA	PIK3CA mutant	head and neck cancer	sensitive	Alpelisib	Phase I	Actionable	In a Phase I trial, Alpelisib (BYL719) treatment resulted in a disease control rate of 68.4% (13/19, 0 complete response (CR), 0 partial response (PR), 13 stable disease (SD)), and a clinical benefit rate (CR+PR+SD>24 weeks) of 10.5% (2/19) in patients with head and neck cancer harboring PIK3CA mutations (PMID: 29401002; NCT01219699).	29401002
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, human cancer cell lines harboring PIK3CA mutations were sensitive to Sapanisertib (MLN0128) as demonstrated by significant growth inhibition (PMID: 25261369).	25261369
PIK3CA	PIK3CA mutant	breast cancer	no benefit	GSK2126458	Phase I	Actionable	In a Phase I trial, GSK2126458 was well-tolerated and resulted in some efficacy in patients with breast cancer harboring a PIK3CA mutation including stable disease in 22% (2/9), however, objective response rate was not associated with PIK3CA mutations when compared to those without PIK3CA mutations (PMID: 26603258).	26603258
PIK3CA	PIK3CA mutant	Advanced Solid Tumor	sensitive	AT-7867	Preclinical	Actionable	In a preclinical study, AT-7867 inhibited proliferation in several human tumor cell lines harboring PIK3CA mutations in culture (PMID: 20423992).	20423992
PIK3CA	PIK3CA mutant CDKN2A mutant	breast cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a breast cancer cell line harboring mutations in PIK3CA and CDKN2A demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).	25261369
PIK3CA	APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut	colorectal cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369).	25261369
PIK3CA	ERBB2 amp PIK3CA mut	uterine corpus serous adenocarcinoma	sensitive	Neratinib + Taselisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Nerlynx (neratinib) and Taselisib (GDC-0032), compared to either agent alone, resulted in greater inhibition of cell cycle activity in a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification and a PIK3CA mutation in culture, and in xenograft models, showed increased tumor growth inhibition and tumor regression (PMID: 26333383).	26333383
PIK3CA	ERBB2 amp PIK3CA mut	Her2-receptor positive breast cancer	sensitive	Copanlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Aliqopa (copanlisib) promoted tumor regression in xenograft models of a human ERBB2 (HER2)-amplified breast cancer cell line harboring a PIK3CA activating mutation (PMID: 24170767).	24170767
PIK3CA	ERBB2 amp PIK3CA mut	breast cancer	sensitive	CUDC-907	Preclinical	Actionable	In a preclinical study, CUDC-907 inhibited downstream signaling and growth of PIK3CA-mutant breast cancer cells with ERBB2 amplification in culture (PMID: 22693356).	22693356
PIK3CA	ERBB2 amp PIK3CA mut	Her2-receptor positive breast cancer	sensitive	Ipatasertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cell line xenograft models harboring amplification of ERBB2 (HER2) and a PIK3CA mutation demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624).	24141624
PIK3CA	PIK3CA mutant PTEN loss	breast cancer	resistant	Alpelisib	Case Reports/Case Series	Actionable	In a clinical case study, a breast cancer patient harboring a PIK3CA mutation developed resistance to Alpelisib (BYL719) treatment and progressive disease after initial response, accompanied by a loss of PTEN, and the corrresponding patient-derived xenograft model demonstrated resistance to Alpelisib (BYL719)-induced inhibition of tumor growth (PMID: 25409150).	detail... 25409150
PIK3CA	PIK3CA mutant PTEN loss	breast cancer	sensitive	Alpelisib + AZD6482	Preclinical - Pdx	Actionable	In a preclinical study, AZD6482 and Alpelisib (BYL719) combination treatment inhibited Akt signaling and growth in a breast cancer patient-derived xenograft (PDX) model harboring a PIK3CA mutation and PTEN loss (Cancer Res October 1, 2014 74; LB-327).	detail...
PIK3CA	PIK3CA mutant PTEN loss	prostate cancer	sensitive	PKI-179	Preclinical - Cell culture	Actionable	In a preclinical study, PKI-179 inhibited growth of prostate cancer cells harboring PIK3CA mutations and PTEN loss in culture (PMID: 20797855).	20797855
PIK3CA	PIK3CA mutant PTEN loss	breast cancer	sensitive	Buparlisib	Preclinical - Pdx	Actionable	In a preclinical study, Buparlisib (BKM120) inhibited Akt signaling and growth in a PDX model of breast cancer cells harboring a PIK3CA mutation and PTEN loss ( Cancer Res October 1, 2014 74; LB-327 ).	detail...
PIK3CA	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study, a retrospective analysis of Herceptin (trastuzumab) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 28177460).	28177460
PIK3CA	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	decreased response	Capecitabine + Lapatinib	Phase III	Actionable	In a Phase III trial, Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment resulted in decreased median progression free survival (4.3 vs. 6.4 months), median overall survival (17.3 vs. 27.8 months), and overall response rate(17.1% vs. 39.7%) in ERBB2 (HER2) positive breast cancer patients harboring PIK3CA mutations compared to PIK3CA wild type patients (PMID: 26920887).	26920887
PIK3CA	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	sensitive	AT13148	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AT13148 inhibited tumor growth in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model harboring mutant PIK3CA (PMID: 22781553).	22781553
PIK3CA	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	decreased response	Lapatinib + Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study, a retrospective analysis of the combined treatment, Herceptin (trastuzumab) and Tykerb (lapatinib), in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 28177460).	28177460
PIK3CA	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	decreased response	Lapatinib + Trastuzumab	Phase II	Actionable	In a Phase II trial, ERBB2-positive breast cancer patients harboring PIK3CA mutations demonstrated lower pathologic complete remission rate (12.5%) compared to those with wild-type PIK3CA (48.4%) after Herceptin (trastuzumab) and Tykerb (lapatinib) combination therapy (PMID: 26245675).	26245675
PIK3CA	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	decreased response	Lapatinib	Clinical Study - Cohort	Actionable	In a clinical study, a retrospective analysis of Tykerb (lapatinib) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 28177460).	28177460
PIK3CA	ERBB2 pos PIK3CA mut	Her2-receptor positive breast cancer	predicted - sensitive	Neratinib	Phase III	Actionable	In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).	30867034
PIK3CA	ERBB2 over exp PIK3CA mut	breast cancer	sensitive	ARQ092 + Paclitaxel	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of Miransertib (ARQ092) and Taxol (paclitaxel), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692).	26469692
PIK3CA	ERBB2 over exp PIK3CA mut	Her2-receptor positive breast cancer	sensitive	PKI-179	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PKI-179 inhibited growth of breast cancer cells harboring PIK3CA mutations and ERBB2 (HER2) over expression in culture and cell line xenograft models (PMID: 20797855).	20797855
PIK3CA	ERBB2 over exp PIK3CA mut	breast cancer	sensitive	ARQ092 + Trastuzumab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of Miransertib (ARQ092) and Herceptin (trastuzumab), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692).	26469692
PIK3CA	FGFR1 over exp PIK3CA mut	estrogen-receptor positive breast cancer	sensitive	Alpelisib + Lucitanib	Preclinical - Cell culture	Actionable	In a preclinical study, an estrogen-receptor positive breast cancer cell line over expressing FGFR1 and expressing a PIK3CA mutation demonstrated sensitivity to the combination of Alpelisib (BYL719) and Lucitanib (E-3810) in culture (PMID: 27126994).	27126994
PIK3CA	BRAF V600E PIK3CA mut	colorectal cancer	sensitive	ASN003	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a colorectal cancer cell line xenograft model co-harboring BRAF V600E and a PIK3CA mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).	detail...
PIK3CA	PIK3CA V344G	glioblastoma multiforme	no benefit	YM-024	Preclinical	Actionable	In a preclinical study, YM-024 did not inhibit proliferation of glioblastoma cell lines harboring PIK3CA V344G in culture (PMID: 24718026).	24718026
PIK3CA	PIK3CA E39K	breast cancer	resistant	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells expressing PIK3CA E39K demonstrated resistance to treatment with Buparlisib (BKM120) in culture (PMID: 29636477).	29636477
PIK3CA	PIK3CA E545K	colorectal cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 decreased cell proliferation in colorectal cancer cells harboring a PIK3CA E545K mutation in cell culture (PMID: 21966435).	21966435
PIK3CA	PIK3CA E545K	breast cancer	sensitive	Lapatinib	Preclinical	Actionable	In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA E545K	lung squamous cell carcinoma	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA E545K in culture (PMID: 26013318).	26013318
PIK3CA	PIK3CA E545K	breast cancer	sensitive	MK2206	Preclinical	Actionable	In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA E545K	urinary bladder cancer	sensitive	Pictilisib + Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Nexavar (sorafenib) synergistically decreased Erk and Akt phosphorylation, inhibited survival of bladder cancer cells harboring PIK3CA E545K in culture (PMID: 28808038).	28808038
PIK3CA	PIK3CA E545K	breast cancer	sensitive	Everolimus	Preclinical	Actionable	In a preclinical study, breast cancer cell lines harboring a PIK3CA E545K mutation had increased sensitivity to Afinitor (everolimus) in culture (PMID: 20664172).	20664172
PIK3CA	PIK3CA E545K	Advanced Solid Tumor	resistant	A66	Preclinical	Actionable	In a preclinical study, cancer cell lines harboring PIK3CA E545K did not demonstrate sensitivity to A66 in culture, in contrast with cells harboring PIK3CA H1047R (PMID: 21668414).	21668414
PIK3CA	PIK3CA E545K	Klatskin's tumor	unknown	Sirolimus	Phase 0	Actionable	In a pilot clinical trial, Rapamune (sirolumus) demonstrated modest clinical activity in patients with PIK3CA-mutant gastric cancer (n=3) or hilar cholangiocarcinoma (n=1; harboring PIK3CA E545K), with a 0% response rate, median progression-free survival of 1.9 months, and median overall survival of 3.6 months (PMID: 28685070).	28685070
PIK3CA	PIK3CA E545K	colorectal cancer	resistant	Cetuximab + Fluorouracil	Preclinical - Cell culture	Actionable	In a preclinical study, colorectal cancer cells over expressing PIK3CA E545K were resistant to Erbitux (cetuximab) and Fluorouracil combination treatment in culture (PMID: 28424201).	28424201
PIK3CA	PIK3CA E545K	breast cancer	resistant	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells expressing PIK3CA E545K demonstrated resistance to treatment with Buparlisib (BKM120) in culture (PMID: 29636477).	29636477
PIK3CA	PIK3CA E545K	breast cancer	sensitive	Miransertib	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Miransertib (ARQ092) resulted in growth inhibition in hormone receptor positive breast cancer cells harboring PIK3CA E545K in culture (PMID: 26469692).	26469692
PIK3CA	PIK3CA E545K	Advanced Solid Tumor	sensitive	Alpelisib	Preclinical - Pdx	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited PIK3CA E545K and showed anti-tumor activity in patient-derived xenograft models harboring a PIK3CA E545K mutation (PMID: 24608574).	24608574
PIK3CA	PIK3CA E545K	breast cancer	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA E545K	urinary bladder cancer	sensitive	Cisplatin + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Platinol (cisplatin) synergistically inhibited Akt phosphorylation and growth of bladder cancer cells harboring PIK3CA E545K in culture (PMID: 28808038).	28808038
PIK3CA	PIK3CA E545K	breast cancer	predicted - sensitive	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K in culture (PMID: 30003928).	30003928
PIK3CA	PIK3CA E545K	leukemia	sensitive	LY3023414	Preclinical	Actionable	In a preclinical study, LY3023414 inhibited tumor growth in a transgenic animal model of leukemia driven by PIK3CA E545K (PMID: 27439478).	27439478
PIK3CA	PIK3CA E545K	urinary bladder cancer	sensitive	Gemcitabine + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Gemzar (gemcitabine) synergistically inhibited Akt phosphorylation and growth of bladder cancer cells harboring PIK3CA E545K in culture (PMID: 28808038).	28808038
PIK3CA	PIK3CA E545K	head and neck squamous cell carcinoma	predicted - sensitive	Carboplatin + Paclitaxel + Temsirolimus	Phase II	Actionable	In a Phase II trial, a patient with head and neck squamous cell carcinoma harboring PIK3CA E545K demonstrated a partial response when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834).	28961834
PIK3CA	PIK3CA E545K	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells expressing PIK3CA E545K (PMID: 21558396).	21558396
PIK3CA	PIK3CA E545K	lung squamous cell carcinoma	sensitive	Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, Buparlisib (BKM120) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA E545K in culture (PMID: 26013318).	26013318
PIK3CA	PIK3CA E545K	cervical cancer	sensitive	PW12	Preclinical	Actionable	In a preclinical study, PW12 inhibited proliferation of cervical cancer cells with a PIK3CA E545K mutation (PMID: 22391131).	22391131
PIK3CA	PIK3CA E545K	Her2-receptor negative breast cancer	sensitive	Alpelisib + Fulvestrant	FDA approved - On Companion Diagnostic	Actionable	In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib), plus Faslodex (fulvestrant), treatment of patients with advanced hormone-receptor positive (ESR1 or PGR), HER2 negative breast cancer harboring one of 11 PIK3CA mutations (n=341) versus those patients with wild-type PIK3CA (n=231) resulted in a greater median progression-free survival (11 vs 5.7 mo) and overall response rate (26.6% vs 12.8%), and PIK3CA E545K is included in the companion diagnostic (PMID: 31091374: NCT02437318).	31091374 detail... detail...
PIK3CA	PIK3CA E545K	breast cancer	sensitive	DHM25	Preclinical - Cell culture	Actionable	In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PIK3CA E545K in culture (PMID: 26237138).	26237138
PIK3CA	PIK3CA E545K	colon cancer	sensitive	LY2780301	Phase I	Actionable	In a Phase I trial, a colon cancer patient harboring PIK3CA E545K was sensitive to LY2780301, demonstrating stable disease for approximately 125 days (PMID: 25902900).	25902900
PIK3CA	PIK3CA E545K	thyroid cancer	sensitive	MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, expression of PIK3CA E545K in a thyroid cancer cell line resulted in increased sensitivity to MK2206 in culture (PMID: 21289267).	21289267
PIK3CA	PIK3CA E545K	Advanced Solid Tumor	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, Rapamune (sirolimus) demonstrated efficacy in inhibiting transformation of cultured cells containing PIK3CA E545K mutations (PMID: 15647370).	15647370
PIK3CA	PIK3CA E545K	breast cancer	sensitive	WYE-125132	Preclinical	Actionable	In a preclinical study, WYE-125132 inhibited proliferation of breast cancer cells with a PIK3CA E545K mutation (PMID: 20068177).	20068177
PIK3CA	PIK3CA E545K	breast cancer	sensitive	ARQ 751	Preclinical - Cell culture	Actionable	In a preclinical study, a breast cancer cell line harboring PIK3CA E545K was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692).	26469692
PIK3CA	PIK3CA E545K	Advanced Solid Tumor	sensitive	Rigosertib	Preclinical - Cell culture	Actionable	In a preclinical study, Estybon (rigosertib) inhibited oncogenic transformation in fibroblast cells over-expressing PIK3CA E545K in culture (PMID: 27104980).	27104980
PIK3CA	PIK3CA E545K	breast cancer	sensitive	SAR245409	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer cell line harboring PIK3CA E545K was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation and colony formation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).	24634413
PIK3CA	PIK3CA E545K	Advanced Solid Tumor	sensitive	Trametinib	Preclinical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA E545K	lung squamous cell carcinoma	no benefit	Taselisib	Case Reports/Case Series	Actionable	In a Phase I (SWOG S1400B) trial, Taselisib (GDC-0032) treatment did not meet primary endpoint in patients with lung squamous cell carcinoma harboring PIK3CA mutations, only 1 of the 11 patients harboring PIK3CA E545K demonstrated response (PMID: 31158500; NCT02785913).	31158500
PIK3CA	PIK3CA E545K	breast cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring PIK3CA E545K in culture (PMID: 21325073, PMID: 17314276).	17314276 21325073
PIK3CA	PIK3CA E545K	breast cancer	predicted - sensitive	BEZ235 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA E545K to WEHI-539 in culture (PMID: 27974663).	27974663
PIK3CA	PIK3CA E545K	estrogen-receptor positive breast cancer	sensitive	AZD8835	Preclinical	Actionable	In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA E545K in culture and suppressed tumor growth in xenograft models (PMID: 26839307).	26839307
PIK3CA	PIK3CA E545K	breast cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA E545K	breast cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA E545K	breast cancer	sensitive	BAY1125976	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K in culture, and inhibited AKT signaling and tumor growth in xenograft models (PMID: 27699769).	27699769
PIK3CA	PIK3CA E545K	breast carcinoma	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited PI3K signaling and proliferation of a human breast carcinoma cell line harboring PIK3CA E545K in culture and inhibited tumor growth in xenograft models (PMID: 25637314).	25637314
PIK3CA	PIK3CA E545K	breast cancer	sensitive	PKI-402	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with PKI-402 resulted in decreased Akt phosphorylation and tumor regression in ERBB2 (HER2)-positive breast cancer cell line xenograft models harboring PIK3CA E545K (PMID: 20371716).	20371716
PIK3CA	PIK3CA E545K	breast cancer	no benefit	BEZ235 + Venetoclax	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA E545K to Venclexta (venetoclax) in culture (PMID: 27974663).	27974663
PIK3CA	PIK3CA E545K	gastrointestinal system cancer	sensitive	Capivasertib	Preclinical	Actionable	In a preclinical study, gastric cancer cells harboring PI3KCA E545K mutations were sensitive to the AKT inhibitor AZD5363 (PMID: 24088382).	24088382
PIK3CA	PIK3CA E545K	urinary bladder cancer	sensitive	Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) inhibited Akt phosphorylation, resulted in growth inhibition in bladder cancer cells harboring PIK3CA E545K in culture (PMID: 28808038).	28808038
PIK3CA	PIK3CA E545K	head and neck squamous cell carcinoma	sensitive	Rigosertib	Preclinical - Pdx	Actionable	In a preclinical study, head and neck squamous cell carcinoma patient-derived xenograft models harboring a PIK3CA E545K mutation demonstrated increased sensitivity to Estybon (rigosertib) (PMID: 23873848).	23873848
PIK3CA	PIK3CA E545K	colorectal cancer	sensitive	Cetuximab + Irinotecan	Case Reports/Case Series	Actionable	In a retrospective analysis, treatment with the combination of Erbitux (cetuximab) and Camptosar (irinotecan) resulted in stable disease in 50% (1/2) and 14 months without evidence of disease in 50% (1/2) of colorectal carcinoma patients harboring a PIK3CA E545K mutation (PMID: 25714871).	25714871
PIK3CA	PIK3CA E545K	breast cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).	26627007
PIK3CA	PIK3CA E545K	Advanced Solid Tumor	sensitive	GDC-0980	Phase I	Actionable	In a Phase I trial, Apitolisib (GDC-0980) resulted in a partial response in two patients, one with head and neck squamous cell carcinoma and another with ovarian cancer, both harboring PIK3CA E545K (PMID: 26787751).	26787751
PIK3CA	PIK3CA E545K	lung non-small cell carcinoma	sensitive	Copanlisib + Paclitaxel	Preclinical - Pdx	Actionable	In a preclinical study, Aliqopa (copanlisib), in combination with Taxol (paclitaxel), induced tumor regression in PIK3CA E545K-mutant patient-derived non-small cell lung cancer xenografts (PMID: 24170767).	24170767
PIK3CA	PIK3CA E545K	esophagus squamous cell carcinoma	sensitive	LY294002	Preclinical	Actionable	In a preclinical study, LY294002 inhibited cell proliferation of esophagus squamous cell carcinoma cells expressing PIK3CA E545K (PMID: 18262558).	18262558
PIK3CA	PIK3CA E545K	lung squamous cell carcinoma	sensitive	BEZ235	Preclinical - Cell culture	Actionable	In a preclinical study, BEZ235 induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA E545K in culture (PMID: 26013318).	26013318
PIK3CA	PIK3CA E545K	ovarian cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of ovarian cancer cells harboring PIK3CA E545K in culture (PMID: 21558396).	21558396
PIK3CA	ERBB2 amp PIK3CA E545K	breast cancer	predicted - sensitive	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K and ERBB2 (HER2) amplification in culture (PMID: 30003928).	30003928
PIK3CA	ERBB2 amp PIK3CA E545K	breast cancer	sensitive	Buparlisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a breast cancer cell line xenograft model co-harboring ERBB2 (HER2) amplification and PIK3CA E545K demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475).	28539475
PIK3CA	ERBB2 amp PIK3CA E545K	breast cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K and ERBB2 (HER2) amplification in culture (PMID: 21558396).	21558396
PIK3CA	ERBB2 pos PIK3CA E545K	Her2-receptor positive breast cancer	sensitive	Ado-trastuzumab emtansine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA E545K in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).	26920887
PIK3CA	ERBB2 pos PIK3CA E545K	Her2-receptor positive breast cancer	predicted - sensitive	Neratinib	Phase III	Actionable	In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).	30867034
PIK3CA	BRAF G596R PIK3CA E545K	colorectal cancer	sensitive	Neratinib	Preclinical	Actionable	In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells harboring both BRAF G596R and PIK3CA E545K in culture (PMID: 26243863).	26243863
PIK3CA	AKT1 over exp PIK3CA E545K	breast cancer	resistant	Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA E545K resulted in resistance to Pictilisib (GDC-0941) in culture (PMID: 27604488).	27604488
PIK3CA	PIK3CA E545K PTEN loss	stomach cancer	unknown	Sirolimus	Phase 0	Actionable	In a pilot clinical trial, Rapamune (sirolumus) demonstrated modest clinical activity in patients with PIK3CA-mutant gastric cancer (n=3) or hilar cholangiocarcinoma (n=1), including 2 gastric cancer patients harboring PIK3CA E545K and PTEN loss, with a 0% response rate, median progression-free survival of 1.9 months, and median overall survival of 3.6 months (PMID: 28685070).	28685070
PIK3CA	PIK3CA E545K PTEN loss	lung squamous cell carcinoma	sensitive	Buparlisib	Preclinical - Pdx	Actionable	In a preclinical study, Buparlisib (BKM120) treatment resulted in inhibition of AKT and S6 phosphorylation and durable response in a lung squamous cell carcinoma patient-derived xenograft (PDX) model harboring PIK3CA E542K and PTEN loss (PMID: 30093452).	30093452
PIK3CA	EGFR A750P EGFR L747_E749del PIK3CA E545K	lung non-small cell carcinoma	decreased response	Osimertinib	Preclinical - Cell culture	Actionable	In a preclinical study, overexpression of PIK3CA E545K in a non-small cell lung cancer cell line harboring EGFR L747_E749del and EGFR A750P resulted in decreased sensitivity to Tagrisso (osimertinib) in culture (PMID: 30228210).	30228210
PIK3CA	EGFR T790M EGFR act mut PIK3CA E545K	lung non-small cell carcinoma	predicted - resistant	Rociletinib	Clinical Study - Cohort	Actionable	In a retrospective analysis of a Phase I and a Phase II trial, PIK3CA activating mutations were identified at disease progression in 12% (5/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, n=3; L858R, n=2) treated with Rociletinib (CO-1686), PIK3CA E545K was identified in 4 of the 5 patients (PMID: 27283993; NCT01526928, NCT02147990).	27283993
PIK3CA	NRAS mut PIK3CA E545K	melanoma	predicted - resistant	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, two of two NRAS-mutant melanoma cell lines expressing PIK3CA E545K demonstrated resistance to treatment with Ibrance (palbociclib) in culture (PMID: 30819666).	30819666
PIK3CA	NRAS mut PIK3CA E545K	melanoma	predicted - resistant	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, four of four NRAS-mutant melanoma cell lines expressing PIK3CA E545K were resistant to the combination treatment of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 30819666).	30819666
PIK3CA	NRAS mut PIK3CA E545K	melanoma	predicted - resistant	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, NRAS-mutant melanoma cell lines expressing PIK3CA E545K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).	30819666
PIK3CA	PIK3CA E545K ROS1 rearrange	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a Phase II clinical trial, a patient with non-small cell lung cancer harboring a ROS1 rearrangement demonstrated progression while being treated with Xalkori (crizotinib), and was found to have acquired a PIK3CA E545K mutation (PMID: 30978502; NCT02183870).	30978502
PIK3CA	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Pimasertib + Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).	23629727
PIK3CA	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).	23629727
PIK3CA	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Pimasertib + Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).	23629727
PIK3CA	BRAF V600E PIK3CA P449T	colorectal cancer	resistant	Regorafenib	Preclinical	Actionable	In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).	25838391
PIK3CA	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Everolimus + Pimasertib	Preclinical - Cell culture	Actionable	In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).	23629727
PIK3CA	BRAF V600E PIK3CA P449T	colorectal cancer	sensitive	Cetuximab + Regorafenib	Preclinical	Actionable	In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring BRAF V600E and PIK3CA P449T in culture (PMID: 25838391).	25838391
PIK3CA	BRAF V600E PIK3CA P449T	colorectal cancer	resistant	Cetuximab	Preclinical	Actionable	In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).	25838391
PIK3CA	BRAF V600E PIK3CA P449T TP53 R273H	colorectal cancer	sensitive	PD-0325901 + Sapanisertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and growth of colorectal cancer cells harboring BRAF V600E, PIK3CA P449T, and TP53 R273H in culture and in cell line xenograft models, but did not have synergistic effect on apoptosis (PMID: 26272063).	26272063
PTEN	PTEN mutant	endometrial cancer	resistant	AZD6482	Preclinical	Actionable	In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to AZD6482 induced growth inhibition in culture (PMID: 23674493).	23674493
PTEN	PTEN mutant	hepatocellular carcinoma	decreased response	Sorafenib	Clinical Study - Cohort	Actionable	In a clinical case study, Nexavar (sorafenib) treatment of patients with hepatocellular carcinoma harboring Mtor pathway mutations in PIK3CA, PTEN, TSC2, or TSC1 (n=12), resulted in a lower disease control rate (8.3% vs. 40.2%), shorter progression-free survival (1.9 months vs. 5.3 months) and shorter overall survival (10.4 months vs. 17.9 months) compared to patients without mutations in this pathway (n=67) (PMID: 30373752; NCT01775072).	30373752
PTEN	PTEN mutant	head and neck squamous cell carcinoma	resistant	Taselisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, head and neck squamous cell carcinoma cell lines and cell line xenograft models with PTEN alterations were resistant to the apoptotic effects of Taselisib (GDC-0032) (PMID: 26589432).	26589432
PTEN	PTEN mutant	endometrial cancer	resistant	TGX-221	Preclinical	Actionable	In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to TGX-221 induced growth inhibition in culture (PMID: 23674493).	23674493
PTEN	PTEN mutant	endometrial cancer	resistant	A66	Preclinical	Actionable	In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to A66 induced growth inhibition in culture (PMID: 23674493).	23674493
PTEN	PTEN mutant	breast cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, Sapanisertib (MLN0128) induced apoptosis and inhibited MTORC1 signaling in breast cancer cells harboring a PTEN mutation (PMID: 25261369).	25261369
PTEN	PTEN mutant	uterine cancer	sensitive	GSK2256098	Preclinical	Actionable	In a preclinical study, uterine cancer cells harboring a PTEN mutation demonstrated sensitivity to GSK2256098, resulting in inhibition of Ptk2 (Fak) phosphorylation, decreased tumor growth, and apoptosis both in culture and in mouse models (PMID: 25833835).	25833835
PTEN	PTEN mutant	triple-receptor negative breast cancer	predicted - sensitive	Ipatasertib + Paclitaxel	Phase II	Actionable	In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients harboring mutations in PIK3CA, AKT1, or PTEN (J Clin Oncol 35, 2017 (suppl; abstr 1009)).	detail...
PTEN	PTEN mutant	endometrial cancer	no benefit	Temsirolimus	Phase II	Actionable	In a retrospective study of a Phase II trial, mutation status of PTEN was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228).	27016228
PTEN	PTEN mutant	uterine cancer	sensitive	GSK2256098 + Topotecan	Preclinical	Actionable	In a preclinical study, uterine cancer cells harboring a PTEN mutation were more sensitive to the combination of GSK2256098 and Hycamtin (topotecan) than uterine cancer cells wild-type for PTEN, resulting in decreased tumor growth in culture and in mouse models (PMID: 25833835).	25833835
PTEN	PTEN mutant	endometrial cancer	sensitive	A66 + GSK2636771	Preclinical	Actionable	In a preclinical study, A66 and GSK2636771 combination treatment inhibited viability of endometrioid endometrial cancer cell lines harboring PTEN mutations in culture (PMID: 23674493).	23674493
PTEN	PTEN mutant	endometrial cancer	sensitive	A66 + AZD6482	Preclinical	Actionable	In a preclinical study, A66 and AZD6482 combination treatment inhibited viability of endometrioid endometrial cancer cell lines harboring PTEN mutations in culture (PMID: 23674493).	23674493
PTEN	PTEN mutant	endometrial cancer	resistant	GSK2636771	Preclinical	Actionable	In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to GSK2636771 induced growth inhibition in culture (PMID: 23674493).	23674493
PTEN	PTEN mutant	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 decreased growth of endometrial cancer cells harboring a PTEN nonsense mutation in culture and in xenograft models (PMID: 22662154).	22662154
PTEN	PTEN mutant	triple-receptor negative breast cancer	predicted - sensitive	Capivasertib + Paclitaxel	Phase II	Actionable	In a Phase II trial, Capivasertib (AZD5363) in combination with Taxol (paclitaxel) as first-line therapy resulted in improved median progression-free survival (9.3 vs 3.7 months, HR=0.30, p=0.01) compared to placebo in patients with metastatic triple-negative breast cancer harboring PIK3CA, AKT1, and/or PTEN mutations, but not in patients with wile-type PIK3CA, AKT1, and PTEN (5.3 vs 4.4 months, HR=1.13, p=0.61) (PMID: 30715161; NCT02423603).	30715161
PTEN	PTEN mutant	endometrial cancer	sensitive	Everolimus	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Afinitor (everolimus) inhibited growth of endometrial cancer cells harboring a PTEN nonsense mutation in culture and in xenograft models (PMID: 22662154).	22662154
PTEN	PTEN mutant	endometrial cancer	sensitive	GDC-0980	Phase II	Actionable	In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)).	detail...
PTEN	PTEN mutant	breast cancer	sensitive	CUDC-907	Preclinical - Cell culture	Actionable	In a preclinical study, CUDC-907 inhibited growth of breast cancer cells lines harboring Pten mutations and/or deletions (PMID: 22693356).	22693356
PTEN	PTEN mutant	breast cancer	predicted - sensitive	MS417 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) and MS417 in combination resulted in improved growth inhibition and increased cell death compared to either agent alone in a PTEN-mutant breast cancer cell line in culture (PMID: 26058079).	26058079
PTEN	PTEN mutant	melanoma	sensitive	BI-69A11	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BI-69A11 resulted in antitumor activity in a melanoma cell line harboring a PTEN mutation, including induction of cell death in culture, and in xenograft models, tumor growth inhibition and tumor regression (PMID: 19175524).	19175524
PTEN	PTEN mutant	uterine cancer	sensitive	GSK2256098 + Paclitaxel	Preclinical	Actionable	In a preclinical study, uterine cancer cells harboring a PTEN mutation were more sensitive to the combination of GSK2256098 and Taxol (paclitaxel) than uterine cancer cells wild-type for PTEN, resulting in decreased tumor growth in culture and in mouse models (PMID: 25833835).	25833835
PTEN	PTEN mutant TP53 mutant	glioblastoma multiforme	sensitive	Navitoclax + ONC201	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of ONC201 (TIC10) and Navitoclax (ABT-263) increased apoptosis and worked synergistically to inhibit proliferation of a glioblastoma cell line harboring mutations in PTEN and TP53 in culture (PMID: 26474387).	26474387
PTEN	PTEN mutant TP53 mutant	skin cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a skin cancer cell line harboring mutations in PTEN and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).	25261369
PTEN	PTEN mut RB1 mut SMAD4 mut TP53 mut	skin cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).	25261369
PTEN	PIK3CA R88Q PTEN mut	endometrial cancer	sensitive	Everolimus	Preclinical	Actionable	In a preclinical study, Afinitor (everolimus) inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154).	22662154
PTEN	PIK3CA R88Q PTEN mut	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154).	22662154
PTEN	PIK3CA R108H PTEN mut	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R108H and PTEN mutations in culture (PMID: 22662154).	22662154
PTEN	PIK3CA R38C PTEN mut	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 decreased growth of endometrial cancer cells harboring PIK3CA R38C and PTEN mutations in culture and in xenograft models (PMID: 22662154).	22662154
PTEN	PIK3CA E365K PTEN mut	endocervical carcinoma	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154).	22662154
PTEN	PIK3CA E365K PTEN mut	endometrial cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154).	22662154
PTEN	BRAF mut PTEN mut	melanoma	predicted - sensitive	ST-162	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ST-162 resulted in tumor regression in a melanoma cell line xenograft model co-harboring mutations in BRAF and PTEN (PMID: 28775144).	28775144
PTEN	BRAF mut PTEN mut	melanoma	decreased response	E6201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, E6201 resulted in a cytostatic response in melanoma cell lines harboring both BRAF and PTEN mutations in culture and only inhibited tumor growth at very high doses in cell line xenograft models (PMID: 23039341).	23039341
PTEN	ERBB2 pos PTEN mut	Her2-receptor positive breast cancer	predicted - sensitive	Buparlisib + Trastuzumab	Phase I	Actionable	In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on Herceptin (trastuzumab)-based therapy (PMID: 24470511).	24470511
PTEN	PIK3CA E453del PIK3CA T1025K PIK3CA R88L PTEN mut PTEN loss	endometrial carcinoma	sensitive	Copanlisib	Phase I	Actionable	In a Phase I clinical trial, an endometrial carcinoma patient harboring PIK3CA T1052K, R88L, and E453del, as well as a PTEN mutation and loss of PTEN protein expression demonstrated a complete response to treatment with Aliqopa (copanlisib) (PMID: 27672108).	27672108
PTEN	BRAF V600E PTEN mut	melanoma	sensitive	ASN003	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a melanoma cell line xenograft model co-harboring BRAF V600E and a PTEN mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).	detail...
PTEN	EGFR exon 19 del PTEN mut	lung adenocarcinoma	decreased response	Gefitinib	Clinical Study - Cohort	Actionable	In a clinical study, PTEN mutations were associated with a lower overall response rate of 7.3% in lung adenocarcinoma patients harboring EGFR exon 19 deletions or L858R, compared to 70.9% (p=0.061) in patients with wild-type PTEN, following treatment with EGFR tyrosine kinase inhibitors including Iressa (gefitinib) (PMID: 24468202).	24468202
PTEN	EGFR exon 19 del PTEN mut	lung adenocarcinoma	decreased response	Erlotinib	Clinical Study - Cohort	Actionable	In a clinical study, PTEN mutations were associated with a lower overall response rate of 7.3% in lung adenocarcinoma patients harboring EGFR exon 19 deletions or L858R, compared to 70.9% (p=0.061) in patients with wild-type PTEN, following treatment with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib) (PMID: 24468202).	24468202
PTEN	EGFR L858R PTEN mut	lung adenocarcinoma	decreased response	Erlotinib	Clinical Study - Cohort	Actionable	In a clinical study, PTEN mutations were associated with a lower overall response rate of 7.3% in lung adenocarcinoma patients harboring EGFR exon 19 deletions or L858R, compared to 70.9% (p=0.061) in patients with wild-type PTEN, following treatment with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib)(PMID: 24468202).	24468202
PTEN	EGFR L858R PTEN mut	lung adenocarcinoma	decreased response	Gefitinib	Clinical Study - Cohort	Actionable	In a clinical study, PTEN mutations were associated with a lower overall response rate of 7.3% in lung adenocarcinoma patients harboring EGFR exon 19 deletions or L858R, compared to 70.9% (p=0.061) in patients with wild-type PTEN, following treatment with EGFR tyrosine kinase inhibitors including Iressa (gefitinib) (PMID: 24468202).	24468202
PTEN	IDH1 wild-type PTEN mutant	glioblastoma multiforme	resistant	Pembrolizumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, PTEN mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who did not respond to anti-PD-1 therapy, with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who responded (odds ratio=0.85, p=0.0063), with 23 PTEN mutations identified in 32 non-responders and 3 in 13 responders (PMID: 30742119).	30742119
PTEN	IDH1 wild-type PTEN mutant	glioblastoma multiforme	resistant	Nivolumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, PTEN mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who did not respond to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who responded (odds ratio=0.85, p=0.0063), with 23 PTEN mutations identified in 32 non-responders and 3 in 13 responders (PMID: 30742119).	30742119
PTEN	PTEN N48I	urinary bladder cancer	decreased response	Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) demonstrated limited inhibition of Akt phosphorylation and growth in bladder cancer cells harboring PTEN N48I in culture (PMID: 28808038).	28808038
PTEN	BRAF V600X PTEN H93D	melanoma	predicted - sensitive	Vemurafenib	Clinical Study - Cohort	Actionable	In a clinical study, a melanoma patient harboring a BRAF V600 mutation and PTEN H93D treated with Zelboraf (vemurafenib) for 66 weeks demonstrated a partial response (PMID: 24265153).	24265153
PTEN	PTEN negative	glioblastoma multiforme	no benefit	Temozolomide + Vandetanib	Phase II	Actionable	In a Phase II trial, Caprelsa (vandetinib), in combination with radiation therapy and Temodar (temozolomide), demonstrated no difference in PFS and OS when compared between glioblastoma patients negative for PTEN versus those positive for PTEN (PMID: 25910950).	25910950
PTEN	PTEN negative	lung squamous cell carcinoma	sensitive	Buparlisib	Phase II	Actionable	In a Phase II trial, one patient with Pten negative squamous NSCLC had a partial response to Buparlisib (BKM120) however, stage 2 of the study was not initiated due to failure of meeting overall stage 1 response endpoints (PMID: 26098748).	26098748
PTEN	PTEN negative	Advanced Solid Tumor	sensitive	Talazoparib	Preclinical - Cell culture	Actionable	In a preclinical study, PTEN-deficient cancer cell lines with DNA repair deficiency demonstrated high sensitivity to the PARP inhibitor, Talazoparib (BMN-673) (PMID: 23881923).	23881923
PTEN	BRAF V600X PTEN neg	melanoma	sensitive	Uprosertib	Preclinical - Cell culture	Actionable	In a preclinical study, lack of PTEN expression was associated with increased sensitivity to GSK2141795 in BRAF V600-mutant melanoma cell lines in culture (PMID: 24265152).	24265152
PTEN	PIK3CA D350G PIK3CA R93W PTEN R130G	endometrial cancer	sensitive	Miransertib	Preclinical - Pdx	Actionable	In a preclinical study, a patient-derived xenograft (PDX) model of endometrial cancer harboring PIK3CA D350G, PIK3CA R93W, and PTEN R130G was sensitive to Miransertib (ARQ092), demonstrating greater than 90% inhibition of tumor growth (PMID: 26469692).	26469692
PTEN	PTEN loss	prostate cancer	sensitive	Capivasertib	Preclinical	Actionable	In a preclinical study, treatment with AZD5363 decreased AKT phosphorylation and downstream signaling and reduced tumor burden in mouse models of PTEN-deficient prostate cancer, including both castration-naive and castration resistant models (PMID: 26910118).	26910118
PTEN	PTEN loss	renal carcinoma	decreased response	Gedatolisib	Preclinical	Actionable	In a preclinical study, human renal carcinoma cells with PTEN loss had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073).	21325073
PTEN	PTEN loss	glioblastoma multiforme	sensitive	PF-04691502	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-04691502 inhibited Akt phosphorylation, resulted in growth inhibition of PTEN-null glioblastoma cells in culture and in cell line xenograft models (PMID: 21750219).	21750219
PTEN	PTEN loss	Advanced Solid Tumor	no benefit	SAR260301	Phase I	Actionable	In a Phase I trial, SAR260301 demonstrated acceptable safety but undesirable pharmacokinetics, and resulted in no response in patients with advanced solid tumors harboring PTEN loss (J Clin Oncol 33, 2015 (suppl; abstr 2564)).	detail...
PTEN	PTEN loss	glioblastoma multiforme	no benefit	BLZ945	Preclinical	Actionable	In a preclinical study, BLZ945 resulted in limited benefit in transgenic mouse models of glioblastoma harboring a loss of PTEN (PMID: 27199435).	27199435
PTEN	PTEN loss	prostate cancer	sensitive	Ipatasertib	Phase I	Actionable	In a Phase I trial, a patient with castration resistant prostate cancer harboring a loss of PTEN demonstrated an improved prostate specific antigen when treated with Ipatasertib (GDC-0068) (PMID: 27872130).	27872130
PTEN	PTEN loss	diffuse large B-cell lymphoma	predicted - sensitive	Idelalisib + MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 partially restored sensitivity to Zydelig (idelalisib) in diffuse large B-cell lymphoma cells harboring PTEN loss with acquired resistance to Zydelig (idelalisib), resulting in increased apoptosis in culture (PMID: 28178345).	28178345
PTEN	PTEN loss	acute lymphocytic leukemia	sensitive	BGT226	Preclinical - Cell culture	Actionable	In a preclinical study, BGT226 treatment in PTEN-deficient acute lymphoblastic leukemia cells resulted in inhibition of PI3K/Akt signaling and apoptotic activity in culture (PMID: 23705826).	23705826
PTEN	PTEN loss	prostate cancer	sensitive	OP449	Preclinical	Actionable	In a preclinical study, prostate cancer mouse models deficient for Pten demonstrated inhibition of the PI3K/Akt signaling pathway and a decrease in both tumor size and cell proliferation when treated with OP449 (PMID: 26563471).	26563471
PTEN	PTEN loss	ovarian mucinous neoplasm	no benefit	KX2-391 + Oxaliplatin	Preclinical	Actionable	In a preclinical study, KX2-391 and Eloxatin (oxaliplatin) combination treatment did not show improved tumor suppression in xenograft models of ovarian mucinous carcinoma harboring PTEN loss when compared to single agent treatment (PMID: 24100628).	24100628
PTEN	PTEN loss	melanoma	sensitive	DETD-35 + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DETD-35 and Zelboraf (vemurafenib) combination treatment resulted in further reduction of tumor size in cell line xenograft models of Zelboraf (vemurafenib)-resistant melanoma harboring PTEN loss when compared to single agent treatment (PMID: 27048951).	27048951
PTEN	PTEN loss	colorectal cancer	sensitive	AZD8186 + Vistusertib	Phase I	Actionable	In a Phase I trial, the combination of AZD8186 and Vistusertib (AZD2014) resulted in a partial response in a patient with PTEN-deficient colorectal cancer (J Clin Oncol 35, 2017 (suppl; abstr 2570)).	detail...
PTEN	PTEN loss	breast cancer	sensitive	OSI-027	Preclinical - Cell line xenograft	Actionable	In a preclinical study, OSI-027 induced tumor regression in PTEN-null breast cancer cell line xenograft models (PMID: 21673091).	21673091
PTEN	PTEN loss	diffuse large B-cell lymphoma	predicted - sensitive	GSK2334470 + Idelalisib	Preclinical - Cell culture	Actionable	In a preclinical study, GSK2334470 partially restored sensitivity to Zydelig (idelalisib) in diffuse large B-cell lymphoma cells harboring PTEN loss that acquired resistance to Zydelig (idelalisib), resulting in increased apoptosis in culture (PMID: 28178345).	28178345
PTEN	PTEN loss	prostate cancer	sensitive	Panulisib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Panulisib (P7170) inhibited tumor growth in PTEN null prostate cancer cell xenograft models (PMID: 25700704).	25700704
PTEN	PTEN loss	head and neck squamous cell carcinoma	predicted - sensitive	AZD8055	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with AZD8055 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PTEN loss in culture (PMID: 28446642).	28446642
PTEN	PTEN loss	prostate cancer	sensitive	GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 inhibited viability of prostate cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).	23674493
PTEN	PTEN loss	prostate cancer	predicted - sensitive	CX-5461 + CX-6258	Preclinical	Actionable	In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in decreased tumor burden in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174).	27486174
PTEN	PTEN loss	prostate cancer	no benefit	CX-5461	Preclinical	Actionable	In a preclinical study, CX-5461 treatment did not result in histological change in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174).	27486174
PTEN	PTEN loss	lung squamous cell carcinoma	predicted - sensitive	AZD8186	Phase I	Actionable	In a Phase I trial, AZD8186 demonstrated preliminary efficacy in patients with tumor types with prevalent PTEN-deficiency, including squamous non-small cell lung cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT329).	detail...
PTEN	PTEN loss	Advanced Solid Tumor	sensitive	BAY1125976	Preclinical	Actionable	In a preclinical study, BAY1125976 demonstrated anti-tumor efficacy in multiple xenograft tumor models of different cancers with PIK3CA mutations or PTEN deletions and displayed synergy with other anti-cancer therapies (Cancer Res 2013;73(8 Suppl):Abstract nr 2050).	detail...
PTEN	PTEN loss	sarcoma	sensitive	YU238259	Preclinical	Actionable	In a preclinical study, YU238259 demonstrated increased cytotoxicity in PTEN-deficient sarcoma cell lines in culture (PMID: 26116172).	26116172
PTEN	PTEN loss	brain glioma	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human glioma cells with PTEN loss in culture (PMID: 21325073).	21325073
PTEN	PTEN loss	uterine corpus sarcoma	sensitive	AT13148	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AT13148 inhibited tumor growth in a PTEN-deficient human uterine sarcoma cell line xenograft model (PMID: 22781553).	22781553
PTEN	PTEN loss	Advanced Solid Tumor	no benefit	Everolimus	Phase II	Actionable	In a Phase II trial, Afinitor (everolimus) treatment in patients with advanced solid tumors harboring PTEN loss did not reach its primary endpoint, resulting in only stable disease or progressive disease (PMID: 28330462).	28330462
PTEN	PTEN loss	prostate cancer	sensitive	AT13148	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AT13148 inhibited tumor growth in a PTEN-deficient human prostate cancer cell line xenograft model (PMID: 22781553).	22781553
PTEN	PTEN loss	prostate carcinoma	decreased response	SAR260301	Preclinical - Cell line xenograft	Actionable	In a precliinical study, PTEN deficient prostate carcinoma cells demonstrated reduced response to SAR260301 in cell culture and in cell line xenograft models (PMID: 27196754).	27196754
PTEN	PTEN loss	transitional cell carcinoma	resistant	Everolimus	Phase II	Actionable	In a Phase II trial, 57% (8/14) of transitional cell carcinoma patients that demonstrated uncontrolled disease after treatment with Afinitor (everolimus) harbored PTEN loss compared to 0% of patients with controlled disease demonstrating no evidence of PTEN loss (PMID: 22473592).	22473592
PTEN	PTEN loss	triple-receptor negative breast cancer	sensitive	AZD6482 + Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Rubraca (rucaparib) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).	detail...
PTEN	PTEN loss	prostate cancer	sensitive	Abiraterone + Ipatasertib	Phase II	Actionable	In a Phase II trial, the combination of Ipatasertib (GDC-0068) and Zytiga (abiraterone) resulted in a better progression-free survival in metastatic castration resistant prostate cancer patients with PTEN loss when compared to placebo combined with Zytiga (PMID: 30037818; NCT01485861).	30037818 detail...
PTEN	PTEN loss	triple-receptor negative breast cancer	sensitive	AZD6482 + Talazoparib	Preclinical	Actionable	In a preclinical study, the combination of Talazoparib (BMN-673) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res, Feb 2016 14; B12).	detail...
PTEN	PTEN loss	prostate cancer	predicted - sensitive	AR-mTOR-26	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AR-mTOR-26 treatment resulted in antitumor activity in prostate cancer xenograft models with PTEN loss (Cancer Res 2010;70(8 Suppl):Abstract nr 4484).	detail...
PTEN	PTEN loss	ovarian mucinous neoplasm	decreased response	KX2-391	Preclinical	Actionable	In a preclincal study, mucinous ovarian carcinoma cell lines harboring PTEN loss were less sensitive to KX2-391 induced growth inhibition in culture and tumor suppression in xenograft models (PMID: 24100628).	24100628
PTEN	PTEN loss	head and neck squamous cell carcinoma	predicted - sensitive	Rigosertib	Phase I	Actionable	In a Phase I trial in patients with advanced solid tumors, Estybon (rigosertib) treatment resulted in responses in 2 patients with head and neck squamous cell carcinoma (1 complete response and 1 partial response), 1 harboring PIK3CA amplification and the other harboring PTEN loss (Cancer Res April 15 2013 (73) (8 Supplement) LB-198).	detail...
PTEN	PTEN loss	prostate cancer	sensitive	KU-60019	Preclinical	Actionable	In a preclinical study, KU-60019 blocked tumor growth in PTEN-deficient human prostate cancer xenograft models (PMID: 25870146).	25870146
PTEN	PTEN loss	triple-receptor negative breast cancer	predicted - sensitive	AZD8186	Phase I	Actionable	In a Phase I trial, AZD8186 demonstrated preliminary efficacy in patients with tumor types with prevalent PTEN-deficiency, including triple negative breast cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT329).	detail...
PTEN	PTEN loss	triple-receptor negative breast cancer	sensitive	AZD6482 + Niraparib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Zejula (niraparib) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).	detail...
PTEN	PTEN loss	breast adenocarcinoma	sensitive	Gemcitabine + LY2780301	Phase Ib/II	Actionable	In a Phase Ib trial, a breast adenocarcinoma patient harboring PTEN loss demonstrated a partial response when treated with a combination of LY2780301 and Gemzar (gemcitabine) (PMID: 28750271).	28750271
PTEN	PTEN loss	prostate cancer	sensitive	AZD6482	Preclinical	Actionable	In a preclinical study, AZD6482 inhibited viability of prostate cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).	23674493
PTEN	PTEN loss	head and neck squamous cell carcinoma	predicted - sensitive	BEZ235	Preclinical - Cell culture	Actionable	In a preclinical study, BEZ235 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PTEN loss in culture (PMID: 28446642).	28446642
PTEN	PTEN loss	prostate cancer	predicted - sensitive	CX-6258	Preclinical	Actionable	In a preclinical study, CX-6258 treatment resulted in decreased carcinoma in situ in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174).	27486174
PTEN	PTEN loss	colon cancer	sensitive	KU-55933	Preclinical	Actionable	In a preclinical study, KU-55933 induced cell cycle arrest and caspase activation in PTEN deficient human colon cancer cells in culture (PMID: 25870146).	25870146
PTEN	PTEN loss	breast cancer	resistant	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PTEN loss demonstrated resistance to Alpelisib (BYL719) in culture (PMID: 27604488).	27604488
PTEN	PTEN loss	Advanced Solid Tumor	sensitive	Capivasertib	Preclinical - Cell culture	Actionable	In a preclinical study, AZD5363 inhibited growth of various solid tumor cell culture models with loss of Pten (PMID: 22294718).	22294718
PTEN	PTEN loss	prostate cancer	sensitive	AZD8186	Preclinical	Actionable	In a preclinical study, AZD8186 inhibited tumor growth of PTEN deficient prostate xenografts models (PMID: 25514658).	25514658
PTEN	PTEN loss	glioblastoma multiforme	sensitive	GDC-0084	Preclinical - Cell line xenograft	Actionable	In a preclinical study, two PTEN-deficient glioblastoma cell line xenograft models were sensitive to GDC-0084 treatment, resulting in decreased tumor volumes by 70% and 40%, and inhibition of PI3K pathway signaling (PMID: 27638506).	27638506
PTEN	PTEN loss	breast cancer	sensitive	AZD6482	Preclinical	Actionable	In a preclinical study, AZD6482 inhibited viability of breast cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).	23674493
PTEN	PTEN loss	glioblastoma multiforme	sensitive	CCT128930	Preclinical - Cell line xenograft	Actionable	In preclinical studies, CCT128930 prevented tumor growth in a PTEN-null human glioblastoma cell line xenograft model (PMID: 21191045).	21191045
PTEN	PTEN loss	breast cancer	resistant	Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, 10/12 breast cancer cell lines with PTEN loss demonstrated resistance to Afinitor (everolimus) in culture (PMID: 21358673).	21358673
PTEN	PTEN loss	renal carcinoma	sensitive	Capivasertib	Preclinical - Pdx	Actionable	In a preclinical study, AZD5363 inhibited growth of renal cancer Pdx models with Pten loss (PMID: 22294718).	22294718
PTEN	PTEN loss	prostate cancer	no benefit	MK2206	Phase I	Actionable	In a Phase I clinical trial, 8 patients with metastatic, castration-resistant prostate cancer harboring a loss of PTEN did not respond to MK-2206 therapy, but prolonged stable disease was observed in 2 patients (PMID: 26187616).	26187616
PTEN	PTEN loss	glioblastoma multiforme	sensitive	LY3023414	Preclinical - Cell line xenograft	Actionable	In a preclinical study, LY3023414 inhibited Pi3k/mTor signaling and proliferation in PTEN deficient glioblastoma cells in culture, and resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478).	27439478
PTEN	PTEN loss	breast cancer	no benefit	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, PTEN loss was not associated with sensitivity to CYH33 in breast cancer cell lines in culture (PMID: 30003928).	30003928
PTEN	PTEN loss	breast cancer	sensitive	GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 inhibited viability of breast cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).	23674493
PTEN	PTEN loss	triple-receptor negative breast cancer	sensitive	AZD6482 + Veliparib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Veliparib (ABT-888) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).	detail...
PTEN	PTEN loss	melanoma	sensitive	DETD-35	Preclinical - Cell line xenograft	Actionable	In a preclinical study, DETD-35 treatment resulted in reduced tumor size in cell line xenograft models of Zelboraf (vemurafenib)-resistant melanoma harboring PTEN loss (PMID: 27048951).	27048951
PTEN	PTEN loss	breast cancer	no benefit	MK2206	Phase II	Actionable	In a Phase II trial, MK2206 treatment resulted in no objective response and 1 stable disease in 7 patients with advanced breast cancer harboring PTEN loss (PMID: 31277699; NCT01277757).	31277699
PTEN	PTEN loss	prostate cancer	sensitive	SAR245409	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a prostate cancer cell line with PTEN loss was sensitive to XL765 (SAR245409) treatment, demonstrating inhibition of the PI3K pathway and decreased colony formation in culture, and inhibition of tumor growth and reduced tumor vascularization in cell line xenograft models (PMID: 24634413).	24634413
PTEN	PTEN loss	renal cell carcinoma	predicted - sensitive	Everolimus	Clinical Study - Cohort	Actionable	In a retrospective analysis, loss of PTEN expression was associated with improved progression-free survival compared to PTEN positive (10.5 vs 5.3 months) in renal cell carcinoma patients treated with Afinitor (everolimus) (PMID: 30327302).	30327302
PTEN	PTEN loss	prostate cancer	sensitive	SF1126	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a glioblastoma cell line harboring PTEN loss (PMID: 24634413) was sensitive to SF1126, demonstrating a 76% decrease in tumor growth in cell line xenograft models (PMID: 18172313).	18172313 24634413
PTEN	PTEN loss	breast adenocarcinoma	sensitive	SAR245409	Preclinical - Cell culture	Actionable	In a preclinical study, a breast adenocarcinoma cell line harboring PTEN loss was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture (PMID: 24634413).	24634413
PTEN	PTEN loss	triple-receptor negative breast cancer	sensitive	AZD6482 + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Lynparza (olaparib) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).	detail...
PTEN	PTEN loss	ovarian cancer	sensitive	OSI-027	Preclinical - Cell line xenograft	Actionable	In a preclinical study, OSI-027 inhibited tumor growth in PTEN-null ovarian cancer cell line xenograft models (PMID: 21673091).	21673091
PTEN	PTEN loss	glioblastoma multiforme	sensitive	PKI-402	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PKI-402 inhibited tumor growth in PTEN-negative glioblastoma multiforme cell line xenograft models (PMID: 20371716).	20371716
PTEN	PTEN loss	breast cancer	resistant	Torkinib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cell lines with PTEN loss demonstrated resistance to Torkinib (PP242) in culture (PMID: 21358673).	21358673
PTEN	PTEN loss	prostate cancer	sensitive	GS-9820	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Acalisib (GS-9820) resulted in tumor growth inhibition in xenograft models of prostate cancer with PTEN deficiency (Mol Cancer Ther 2009;8(12 Suppl):B136).	detail...
PTEN	PTEN loss	melanoma	sensitive	GSK2636771	Preclinical	Actionable	In a preclinical study, human melanoma cells with PTEN loss were sensitive to GSK2636771, resulting in decreased activation of Akt and some inhibition of tumor growth (PMID: 26645196).	26645196
PTEN	PTEN loss	triple-receptor negative breast cancer	sensitive	M2698	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a triple-receptor negative breast cancer xenograft model harboring PTEN loss was sensitive to M2698 (MSC2363318A), demonstrating inhibition of tumor growth and tumor regression (PMID: 27186432).	27186432
PTEN	PTEN loss	lung squamous cell carcinoma	no benefit	Buparlisib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, lung squamous cell carcinoma patient-derived xenograft (PDX) models harboring PTEN loss did not respond to Buparlisib (BKM120) treatment (PMID: 30093452).	30093452
PTEN	PTEN loss	lung non-small cell carcinoma	sensitive	Pictilisib	Preclinical - Cell line xenograft	Actionable	In preclinical studies, the PI3K inhibitor GDC-0941 demonstrated efficacy against NSCLC tumor cell lines in both culture and xenograft models harboring alterations in the PI3K pathway (PMID: 23136191).	23136191
PTEN	PTEN loss	glioblastoma multiforme	resistant	A66	Preclinical - Cell line xenograft	Actionable	In a preclinical study, A66 did not inhibit tumor growth in a PTEN-null cell line xenograft model of glioblastoma (PMID: 21668414).	21668414
PTEN	ERBB2 pos PTEN loss	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Phase I	Actionable	In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PTEN loss demonstrated a decreased median progression-free survival of 6.0 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).	21676217
PTEN	ERBB2 pos PTEN loss	Her2-receptor positive breast cancer	no benefit	Palbociclib + Pictilisib	Preclinical	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in ERBB2 (HER2)-positive breast cancer cell lines harboring PTEN loss in culture (PMID: 27020857).	27020857
PTEN	PIK3CA R38C PTEN loss	endometrial cancer	sensitive	CH5132799	Preclinical	Actionable	In a preclinical study, CH5132799 inhibited proliferation of an endometrial cancer cell line harboring PIK3CA R38C and PTEN loss in culture (PMID: 21558396).	21558396
PTEN	PTEN loss VHL loss	renal carcinoma	decreased response	Gedatolisib	Preclinical	Actionable	In a preclinical study, human renal carcinoma cells with PTEN loss and VHL loss had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073).	21325073
PTEN	BRAF mut PTEN loss	melanoma	sensitive	SAR260301	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR260301 inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).	27196754
PTEN	BRAF mut PTEN loss	melanoma	sensitive	SAR260301 + Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR260301 and Zelboraf (vemurafenib) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).	27196754
PTEN	BRAF mut PTEN loss	melanoma	sensitive	SAR260301 + Selumetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR260301 and Selumetinib (AZD6244) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).	27196754
PTEN	BRAF mut PTEN loss	melanoma	sensitive	GSK2636771 + Pembrolizumab	Preclinical	Actionable	In a preclinical study, a melanoma mouse model harboring a BRAF mutation and PTEN loss was sensitive to the combination of GSK2636771 and Keytruda (pembrolizumab), demonstrating greater tumor growth inhibition and improved survival when compared to either therapy alone (PMID: 26645196).	26645196
PTEN	BRAF mut PTEN loss	melanoma	no benefit	GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196).	26645196
PTEN	BRAF mut PTEN loss	melanoma	no benefit	Pembrolizumab	Preclinical	Actionable	In a preclinical study, Keytruda (pembrolizumab) resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196).	26645196
PTEN	PTEN loss STK11 loss	endometrial cancer	sensitive	Pictilisib	Preclinical	Actionable	In a preclinical study, the PI3K inhibitor GDC-0941 reduced tumor growth rate in immunodeficient mice engrafted with endometrial tumors from PTEN/STK11 (LKB1) deficient mice (PMID: 24322983).	24322983
PTEN	PIK3CA mutant PTEN loss	breast cancer	sensitive	Alpelisib + AZD6482	Preclinical - Pdx	Actionable	In a preclinical study, AZD6482 and Alpelisib (BYL719) combination treatment inhibited Akt signaling and growth in a breast cancer patient-derived xenograft (PDX) model harboring a PIK3CA mutation and PTEN loss (Cancer Res October 1, 2014 74; LB-327).	detail...
PTEN	PIK3CA mutant PTEN loss	breast cancer	resistant	Alpelisib	Case Reports/Case Series	Actionable	In a clinical case study, a breast cancer patient harboring a PIK3CA mutation developed resistance to Alpelisib (BYL719) treatment and progressive disease after initial response, accompanied by a loss of PTEN, and the corrresponding patient-derived xenograft model demonstrated resistance to Alpelisib (BYL719)-induced inhibition of tumor growth (PMID: 25409150).	detail... 25409150
PTEN	PIK3CA mutant PTEN loss	prostate cancer	sensitive	PKI-179	Preclinical - Cell culture	Actionable	In a preclinical study, PKI-179 inhibited growth of prostate cancer cells harboring PIK3CA mutations and PTEN loss in culture (PMID: 20797855).	20797855
PTEN	PIK3CA mutant PTEN loss	breast cancer	sensitive	Buparlisib	Preclinical - Pdx	Actionable	In a preclinical study, Buparlisib (BKM120) inhibited Akt signaling and growth in a PDX model of breast cancer cells harboring a PIK3CA mutation and PTEN loss ( Cancer Res October 1, 2014 74; LB-327 ).	detail...
PTEN	PIK3CA wild-type PTEN loss	breast cancer	no benefit	Everolimus + U0126	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and U0126 (PMID: 21358673).	21358673
PTEN	PIK3CA wild-type PTEN loss	breast cancer	resistant	AZD8835	Preclinical	Actionable	In a preclinical study, human breast cancer cells with wild-type PIK3CA and loss of PTEN were resistant to growth inhibition by AZD8835 in culture (PMID: 26839307).	26839307
PTEN	PIK3CA wild-type PTEN loss	breast cancer	no benefit	Everolimus + Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and Selumetinib (AZD6244) (PMID: 21358673).	21358673
PTEN	PIK3CA wild-type PTEN loss	breast cancer	sensitive	Torkinib + U0126	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and U0126 in culture (PMID: 21358673).	21358673
PTEN	PIK3CA wild-type PTEN loss	breast cancer	sensitive	Selumetinib + Torkinib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and Selumetinib (AZD6244) in culture (PMID: 21358673).	21358673
PTEN	PTEN loss RB1 loss	triple-receptor negative breast cancer	resistant	Pictilisib	Preclinical	Actionable	In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Pictilisib (GDC-0941) induced growth inhibition in culture (PMID: 27020857).	27020857
PTEN	PTEN loss RB1 loss	triple-receptor negative breast cancer	resistant	Palbociclib	Preclinical	Actionable	In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Ibrance (palbociclib) induced growth inhibition in culture (PMID: 27020857).	27020857
PTEN	PTEN loss RB1 loss	triple-receptor negative breast cancer	no benefit	Palbociclib + Pictilisib	Preclinical	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in triple-receptor negative breast cancer cell lines harboring PTEN and RB1 loss in culture (PMID: 27020857).	27020857
PTEN	BRAF V600E PTEN loss	melanoma	sensitive	Pictilisib + PLX4720	Preclinical	Actionable	In a preclinical study, a melanoma cell line harboring BRAF V600E and PTEN loss demonstrated sensitivity when treated with a combination of Pictilisib (GDC-0941) and PLX4720, resulting in decreased cell proliferation in culture (PMID: 24265153).	24265153
PTEN	BRAF V600E PTEN loss	melanoma	sensitive	GDC0879 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, GDC0879 and Pictilisib (GDC-0941) synergistically inhibited survival of melanoma cell lines harboring BFAF V600E and PTEN loss in cell culture (PMID: 19276360).	19276360
PTEN	BRAF V600E PTEN loss	melanoma	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600E (PMID: 25637314).	25637314
PTEN	BRAF V600E PTEN loss	melanoma	predicted - resistant	Everolimus	Case Reports/Case Series	Actionable	In a retrospective analysis, a melanoma patient harboring PTEN loss and BRAF V600E demonstrated resistance to Afinitor (everolimus) treatment, resulting in progressive disease (PMID: 20664172).	20664172
PTEN	BRAF V600E PTEN loss	melanoma	sensitive	GSK2636771 + unspecified PD-1 antibody	Preclinical	Actionable	In a preclinical study, treatment with the combination of GSK2636771 and a PD-1 antibody resulted in greater tumor infiltration of T-cells and tumor growth inhibition in mouse melanoma models expressing BRAF V600E with PTEN loss compared to either agent alone (PMID: 26645196).	26645196
PTEN	BRAF V600D PTEN loss	melanoma	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600D (PMID: 25637314).	25637314
PTEN	EGFR amp PTEN loss	glioblastoma multiforme	decreased response	Dacomitinib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, patient-derived EGFR amplified glioblastoma cells harboring PTEN loss demonstrated reduced sensitivity to Vizimpro (dacomitinib) induced growth inhibition in culture and in xenograft models (PMID: 25939761).	25939761
PTEN	BRAF V600E PTEN loss TP53 wild-type	colorectal cancer	sensitive	PD-0325901 + Sapanisertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).	26272063
PTEN	PIK3CA H1047R PTEN loss	breast cancer	no benefit	BEZ235 + Venetoclax	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to Venclexta (venetoclax) in culture (PMID: 27974663).	27974663
PTEN	PIK3CA H1047R PTEN loss	triple-receptor negative breast cancer	predicted - sensitive	ABT-737 + Sapanisertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-737 and Sapanisertib (MLN0128) combination treatment resulted in inhibition of tumor growth in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).	27974663
PTEN	PIK3CA H1047R PTEN loss	triple-receptor negative breast cancer	predicted - sensitive	ABT-737 + BEZ235	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ABT-737 and BEZ235 combination treatment resulted in tumor regression in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).	27974663
PTEN	PIK3CA H1047R PTEN loss	breast cancer	predicted - sensitive	BEZ235 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to WEHI-539 in culture (PMID: 27974663).	27974663
PTEN	PIK3CA H1047R PTEN loss	breast cancer	predicted - sensitive	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA H1047R and PTEN loss in culture (PMID: 30003928).	30003928
PTEN	PIK3CA E542K PTEN loss	breast cancer	predicted - sensitive	BEZ235 + WEHI-539	Preclinical - Cell culture	Actionable	In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA E542K and PTEN loss to WEHI-539 in culture (PMID: 27974663).	27974663
PTEN	PIK3CA E542K PTEN loss	lung squamous cell carcinoma	sensitive	Alpelisib	Preclinical - Pdx	Actionable	In a preclinical study, Alpelisib (BYL719) treatment resulted in response in a lung squamous cell carcinoma patient-derived xenograft (PDX) model harboring PIK3CA E542K and PTEN loss (PMID: 30093452).	30093452
PTEN	PIK3CA E542K PTEN loss	breast cancer	predicted - sensitive	CYH33	Preclinical - Cell culture	Actionable	In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA E542K and PTEN loss in culture (PMID: 30003928).	30003928
PTEN	PIK3CA E542K PTEN loss	stomach cancer	unknown	Sirolimus	Phase 0	Actionable	In a pilot clinical trial, Rapamune (sirolumus) demonstrated modest clinical activity in patients with PIK3CA-mutant gastric cancer (n=3) or hilar cholangiocarcinoma (n=1), including a gastric cancer patient harboring PIK3CA E542K and PTEN loss, with a 0% response rate, median progression-free survival of 1.9 months, and median overall survival of 3.6 months (PMID: 28685070).	28685070
PTEN	PTEN loss TP53 loss	prostate cancer	sensitive	Capivasertib	Preclinical	Actionable	In a preclinical study, treatment with AZD5363 improved overall survival and progression-free survival in mouse models of prostate cancer with inactivated PTEN and TP53 (PMID: 26910118).	26910118
PTEN	PIK3CA E545K PTEN loss	stomach cancer	unknown	Sirolimus	Phase 0	Actionable	In a pilot clinical trial, Rapamune (sirolumus) demonstrated modest clinical activity in patients with PIK3CA-mutant gastric cancer (n=3) or hilar cholangiocarcinoma (n=1), including 2 gastric cancer patients harboring PIK3CA E545K and PTEN loss, with a 0% response rate, median progression-free survival of 1.9 months, and median overall survival of 3.6 months (PMID: 28685070).	28685070
PTEN	PIK3CA E545K PTEN loss	lung squamous cell carcinoma	sensitive	Buparlisib	Preclinical - Pdx	Actionable	In a preclinical study, Buparlisib (BKM120) treatment resulted in inhibition of AKT and S6 phosphorylation and durable response in a lung squamous cell carcinoma patient-derived xenograft (PDX) model harboring PIK3CA E542K and PTEN loss (PMID: 30093452).	30093452
PTEN	BRAF V600E/K PTEN loss	Advanced Solid Tumor	predicted - sensitive	PX-866 + Vemurafenib	Phase I	Actionable	In a Phase I trial, the combination therapy of PX-866 and Zelboraf (vemurafenib) demonstrated safety and resulted in an objective response in 28% (5/18) of advanced solid tumor patients harboring BRAF V600E or K, and of those five patients, 80% (4/5) also demonstrated loss of PTEN (PMID: 29051322).	29051322
PTEN	CDKN2A loss PIK3CA E542K PTEN loss	lung squamous cell carcinoma	sensitive	Buparlisib + Palbociclib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with the combination of Buparlisib (BYL719) and Ibrance (palbociclib) resulted in increased tumor growth inhibition compared to either agent alone in a patient-derived xenograft (PDX) model of lung squamous cell carcinoma harboring PIK3CA E542K and PTEN loss, with p16 (CDKN2A) loss (PMID: 30093452).	30093452
PTEN	PTEN dec exp	Advanced Solid Tumor	sensitive	GSK2636771	Phase Ib/II	Actionable	In a Phase I/II trial, GSK2636771 treatment inhibited Akt signaling, and resulted in partial response in 2% (1/53) and stable disease in 25% (13/53) of patients with PTEN-deficient advanced solid tumors (J Clin Oncol 32:5s, 2014 (suppl; abstr 2514)).	detail...
PTEN	PTEN dec exp	renal cell carcinoma	no benefit	GDC-0980	Phase II	Actionable	In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by high expression (n=17) and low expression (n=19) of Pten (PMID: 26951309).	26951309
PTEN	PTEN dec exp	melanoma	decreased response	Nivolumab	Clinical Study - Cohort	Actionable	In a clinical study, melanoma patients with PTEN expression in less than 10% of tumor cells demonstrated decreased response to anti-PD-1 antibodies, including Opdivo (nivolumab), as compared to patients in which PTEN is present in over 10% of tumor cells (PMID: 26645196).	26645196
PTEN	PTEN dec exp	Advanced Solid Tumor	predicted - sensitive	Pemetrexed + Sorafenib	Phase I	Actionable	In a Phase I clinical trial, low Pten expression or lack of Pten expression was associated with better response to treatment with the combination of Alimta (pemetrexed) and Nexavar (sorafenib) in patients with advanced solid tumors (PMID: 27213589).	27213589
PTEN	PTEN dec exp	triple-receptor negative breast cancer	predicted - sensitive	Ipatasertib + Paclitaxel	Phase II	Actionable	In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients with low Pten expression (J Clin Oncol 35, 2017 (suppl; abstr 1009)).	detail...
PTEN	PTEN dec exp	melanoma	decreased response	Pembrolizumab	Clinical Study - Cohort	Actionable	In a clinical study, melanoma patients with PTEN expression in less than 10% of tumor cells demonstrated decreased response to anti-PD-1 antibodies, including Keytruda (pembrolizumab), compared to patients in which PTEN is present in over 10% of tumor cells (PMID: 26645196).	26645196
PTEN	PTEN dec exp	renal cell carcinoma	no benefit	Everolimus	Phase II	Actionable	In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had no difference in progression free survival when stratified by high expression (n=17) and low expression (n=21) of Pten (PMID: 26951309).	26951309
PTEN	PTEN dec exp	melanoma	sensitive	SAR260301	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR260301 inhibited tumor growth in xenograft models of melanoma cell lines harboring PTEN deficiency (PMID: 24387221).	24387221
PTEN	PIK3CA act mut PTEN dec exp	renal cell carcinoma	no benefit	GDC-0980	Phase II	Actionable	In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by the presence (n=21) or absence (n=15) of PIK3CA activating mutation or loss of Pten expression (PMID: 26951309).	26951309
PTEN	PIK3CA act mut PTEN dec exp	renal cell carcinoma	no benefit	Everolimus	Phase II	Actionable	In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had no difference in progression free survival when stratified by the presence (n=21) or absence (n=17) of PIK3CA activating mutations (PMID: 26951309).	26951309
PTEN	ERBB2 amp PTEN dec exp	Her2-receptor positive breast cancer	decreased response	CDX-3379	Preclinical	Actionable	In a preclinical study, knockdown of PTEN expression resulted in a decreased response to treatment with CDX-3379 (KTN3379) in ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 26880266).	26880266
PTEN	ERBB2 pos PTEN dec exp	Her2-receptor positive breast cancer	decreased response	Trastuzumab	Clinical Study - Cohort	Actionable	In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).	17936563
PTEN	PTEN R130Q	head and neck squamous cell carcinoma	predicted - sensitive	Carboplatin + Paclitaxel + Temsirolimus	Phase II	Actionable	In a Phase II trial, a patient with head and neck squamous cell carcinoma harboring PTEN R130Q demonstrated a partial response when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834).	28961834
PTEN	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs	endometrial cancer	sensitive	Alpelisib + BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Alpelisib (BYL719) resulted in a synergistic effect, demonstrating inhibition of cell proliferation and induced cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).	28119489
PTEN	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs	endometrial cancer	sensitive	BGJ398 + Buparlisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).	28119489
PTEN	FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs	endometrial cancer	sensitive	BGJ398 + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BGJ398 and Pictilisib (GDC-0941) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489).	28119489
PTEN	PTEN A126G	prostate cancer	sensitive	AZD6482	Preclinical	Actionable	In a preclinical study, AZD6482 inhibited Akt signaling and cell migration in prostate cancer cell lines overexpressing PTEN A126G (PMID: 26504226).	26504226
PTEN	PTEN A126G	prostate cancer	sensitive	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, Alpelisib (BYL719) inhibited Akt signaling and cell migration in prostate cancer cells expressing PTEN A126G in culture (PMID: 26504226).	26504226
PTEN	PTEN positive	melanoma	sensitive	Nivolumab	Clinical Study - Cohort	Actionable	In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Opdivo (nivolumab) (PMID: 26645196).	26645196
PTEN	PTEN positive	head and neck squamous cell carcinoma	predicted - sensitive	Cetuximab	Clinical Study - Cohort	Actionable	In a clinical study, high PTEN expression was associated with improved progression-free survival (HR=0.35, p=0.008) in head and neck squamous cell carcinoma patients treated with Erbitux (cetuximab) with or without Nexavar (sorafenib) (PMID: 30926065).	30926065
PTEN	PTEN positive	melanoma	sensitive	Pembrolizumab	Clinical Study - Cohort	Actionable	In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Keytruda (pembrolizumab) (PMID: 26645196).	26645196
PTEN	AKT1 E17K BRAF V600X PTEN pos	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).	24265152
PTEN	AKT1 Q79K BRAF V600X PTEN pos	melanoma	resistant	Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).	24265152
PTEN	AKT1 Q79K BRAF V600X PTEN pos	melanoma	sensitive	MK2206 + Vemurafenib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited AKT activation and growth of PTEN-expressing BRAF V600-mutant melanoma cells expressing AKT1 Q79K in culture, with increased efficacy over either agent alone (PMID: 24265152).	24265152
PTEN	PIK3CA wild-type PTEN pos	head and neck squamous cell carcinoma	predicted - sensitive	Cetuximab + Cisplatin	Clinical Study - Cohort	Actionable	In a clinical study, combination of Erbitux (cetuximab) with Platinol (cisplatin) tended to improve progression-free survival compared to placebo in PTEN-expressing, PIK3CA wild-type head and neck squamous cell carcinoma patients (HR=0.54, p=0.0502) by multivariable analysis, but not in PTEN null or PIK3CA mutated patients (HR=0.76, p=0.54) (PMID: 30926065).	30926065
PTEN	PTEN inact mut	prostate adenocarcinoma	sensitive	Paclitaxel + XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of XL147 and Taxol (paclitaxel) inhibited tumor growth and angiogenesis in xenograft models of a human prostate adenocarcinoma cell line harboring an inactivating mutation in PTEN, with increased efficacy compared to either agent alone (PMID: 25637314).	25637314
PTEN	PTEN inact mut	estrogen-receptor positive breast cancer	sensitive	Fulvestrant + Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Faslodex (fulvestrant) and PIctilisib (GDC-0941) resulted in decreased cell viability and increased apoptotic activity in PTEN deficient estrogen-receptor (ER) positive breast cancer cells in culture (PMID: 26733612).	26733612
PTEN	PTEN inact mut	estrogen-receptor positive breast cancer	sensitive	Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, a PTEN deficient estrogen-receptor (ER) positive breast cancer cell line demonstrated increased sensitivity to treatment in culture when Pictilisib (GDC-0941) was given at a higher dose for a shorter duration, resulting in inhibition of cell growth (PMID: 26733612).	26733612
PTEN	PTEN inact mut	prostate adenocarcinoma	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited PI3K signaling, growth, and migration of a human prostate adenocarcinoma cell line harboring a PTEN inactivating mutation in culture, and inhibited tumor growth and vascularization in xenograft models (PMID: 25637314).	25637314
PTEN	PTEN inact mut	Advanced Solid Tumor	sensitive	Capivasertib	Preclinical - Cell culture	Actionable	In a preclinical study, AZD5363 inhibited growth of various solid tumor cell culture models with inactivating Pten mutations (PMID: 22294718).	22294718
PTEN	PTEN inact mut	glioblastoma multiforme	sensitive	SAR245409	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a glioblastoma cell line harboring a PTEN inactivating mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).	24634413
PTEN	PTEN inact mut	kidney cancer	sensitive	LY3023414	Preclinical - Cell line xenograft	Actionable	In a preclinical study, LY3023414 inhibited proliferation of renal cancer cells harboring PTEN inactivating mutation in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478).	27439478
PTEN	PTEN inact mut	glioblastoma multiforme	sensitive	SF1126	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a glioblastoma cell line harboring a PTEN inactivating mutation (PMID: 24634413) was sensitive to SF1126, demonstrating inhibition of tumor growth in cell line xenograft models (PMID: 18172313).	18172313 24634413
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + AZD6482 + Encorafenib	Preclinical	Actionable	In a preclinical study, combination treatment consisting of AZD6482, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	no benefit	Alpelisib + Encorafenib	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) and Encorafenib (LGX818) combination treatment did not enhance growth inhibition in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Encorafenib + NVP-AEW541	Preclinical	Actionable	In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	no benefit	Alpelisib + Binimetinib	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	Encorafenib + GSK2636771 + unspecified IGF-1R antibody	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination treatment consisting of GSK2636771, Encorafenib (LGX818), and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482	Preclinical	Actionable	In a preclincal study, AZD6482 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	no benefit	Alpelisib + NVP-AEW541	Preclinical	Actionable	In a preclinical study, Alpelisib (BYL719) and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + Encorafenib + GSK2636771	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of GSK2636771, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently inhibited tumor growth in xenograft models of a human melanoma cell line harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	decreased response	Alpelisib	Preclinical	Actionable	In a preclincal study, melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations were less sensitive to Alpelisib (BYL719)-induced growth inhibition in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + AZD6482 + Binimetinib	Preclinical - Cell culture	Actionable	In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	Pictilisib	Preclinical	Actionable	In a preclincal study, Pictilisib (GDC-0941) inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	Encorafenib + GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	GSK2636771 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, GSK2636771 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	Binimetinib + Pictilisib	Preclinical	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	Binimetinib + GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	NVP-AEW541 + Pictilisib	Preclinical	Actionable	In a preclinical study, Pictilisib (GDC-0941) and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + GSK2636771	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of GSK2636771 and Alpelisib (BYL719) synergized to inhibit proliferation of human melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture, and inhibited tumor growth in xenograft models of one cell line harboring these mutations (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib + Encorafenib + NVP-AEW541	Preclinical	Actionable	In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib	Preclinical	Actionable	In a preclinical study, AZD6482 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	Encorafenib + Pictilisib	Preclinical	Actionable	In a preclinical study, Pictilisib (GDC-0941) and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Binimetinib + NVP-AEW541	Preclinical	Actionable	In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + Encorafenib	Preclinical	Actionable	In a preclinical study, AZD6482 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	Encorafenib + unspecified IGF-1R antibody	Preclinical	Actionable	In a preclinical study, combination treatment consists of Encorafenib (LGX818) and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + AZD6482	Preclinical	Actionable	In a preclinical study, AZD6482 and Alpelisib (BYL719) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	Alpelisib + AZD6482 + Binimetinib + Encorafenib	Preclinical	Actionable	In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	GSK2636771 + unspecified IGF-1R antibody	Preclinical - Cell line xenograft	Actionable	In a preclinical study, combination treatment consisting of GSK2636771 and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	TGX-221	Preclinical	Actionable	In a preclincal study, TGX-221 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN inact mut	melanoma	sensitive	AZD6482 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, AZD6482 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).	26577700
PTEN	APC inact mut PTEN inact mut	colorectal cancer	sensitive	BEZ235	Preclinical	Actionable	In a preclinical study, BEZ235 inhibited PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).	26206338
PTEN	APC inact mut PTEN inact mut	colorectal cancer	no benefit	BEZ235 + Binimetinib	Preclinical	Actionable	In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) did not improve survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).	26206338
PTEN	APC inact mut PTEN inact mut	colorectal cancer	no benefit	Binimetinib	Preclinical	Actionable	In a preclinical study, Binimetinib (MEK162) reduced proliferation in tumors acutely but did not improve survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).	26206338
PTEN	PTEN T319fs	breast cancer	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PTEN T319fs*1 in culture (PMID: 27699769).	27699769
PTEN	EGFR amp EGFR act mut PTEN R308C	glioblastoma multiforme	sensitive	BMS-754807 + Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).	26561558
PTEN	EGFR amp EGFR act mut PTEN R308C	glioblastoma multiforme	sensitive	Gefitinib + Linsitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).	26561558
PTEN	PTEN del	prostate cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human prostate cancer cell line with deletion of PTEN (PMID: 21558396).	21558396
PTEN	PTEN del	prostate cancer	predicted - sensitive	AZD8186	Phase I	Actionable	In a Phase I trial, AZD8186 demonstrated preliminary efficacy in patients with tumor types with prevalent PTEN-deficiency, including prostate cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT329).	detail...
PTEN	PTEN del	prostate cancer	sensitive	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, Rubraca (rucaparib) induced senescence and increased radiosensitivity in PTEN null prostate cancer cells in culture (PMID: 23565244).	23565244
PTEN	PTEN del	prostate cancer	sensitive	Pictilisib + Vorinostat	Preclinical	Actionable	In a preclinical study, GDC-0941 and Zolinza (vorinostat) acted synergistically to inhibit growth of a human prostate cancer cell line harboring a PTEN deletion in culture (PMID: 9661880, PMID: 22693356).	22693356 9661880
PTEN	PTEN del	Advanced Solid Tumor	no benefit	GSK2636771	Phase I	Actionable	In a Phase I trial, patients with advanced solid tumors deficient in PTEN lacked benefit from GSK2636771 (PMID: 26117819).	26117819
PTEN	PTEN del	prostate cancer	sensitive	Ipatasertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, prostate cancer cell line xenograft models with PTEN deletion demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624).	24141624
PTEN	PTEN del	head and neck squamous cell carcinoma	resistant	Taselisib	Preclinical	Actionable	In a preclinical study, head and neck squamous cell carcinoma cells homozygous for PTEN deletion were resistant to Taselisib (GDC-0032) in culture (PMID: 26589432).	26589432
PTEN	PTEN del	prostate cancer	sensitive	Alpelisib + AZD8186	Preclinical	Actionable	In a preclinical study, AZD8186 and Alpelisib (BYL719) combination treatment resulted in minor inhibition of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).	25544636
PTEN	PTEN del	prostate cancer	sensitive	Alpelisib + AZD8186 + Enzalutamide	Preclinical	Actionable	In a preclinical study, AZD8186, Alpelisib (BYL719), and Xtandi (enzalutamide) combination treatment resulted in near-complete suppression of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).	25544636
PTEN	PTEN del	prostate cancer	sensitive	AZD8186 + Enzalutamide	Preclinical	Actionable	In a preclinical study, AZD8186 and Xtandi (enzalutamide) combination treatment resulted in suppression of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).	25544636
PTEN	PTEN del	Advanced Solid Tumor	sensitive	CC-223	Phase I	Actionable	In a Phase I trial, CC-223 demonstrated safety and preliminary efficacy in patients with solid tumors, including stable disease for greater than 110 days in 2 patients with PIK3CA mutation or PTEN deletion (PMID: 26177599).	26177599
PTEN	PTEN del	prostate cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human prostate cancer cells harboring PTEN deletion in culture (PMID: 21325073, PMID: 14737113).	14737113 21325073
PTEN	PTEN del	lung non-small cell carcinoma	predicted - sensitive	PF-04691502	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PF-04691502 inhibited tumor growth in PTEN-deleted non-small cell lung cancer cell line xenograft models (PMID: 21750219).	21750219
PTEN	PTEN del	prostate cancer	sensitive	VS-5584	Preclinical - Cell line xenograft	Actionable	In a preclinical study, VS-5584 inhibited PI3K/mTOR signaling and cell proliferation in a human prostate cancer cell line harboring a PTEN deletion in culture, and inhibited PI3K/MTOR signaling and tumor growth in xenograft models (PMID: 23270925).	23270925
PTEN	PTEN del	stomach cancer	sensitive	CH5132799	Preclinical - Cell line xenograft	Actionable	In a preclinical study, CH5132799 induced tumor regression in xenograft models of a human stomach cancer cell line with deletion of PTEN (PMID: 21558396).	21558396
PTEN	PTEN del	breast cancer	sensitive	CUDC-907	Preclinical - Cell culture	Actionable	In a preclinical study, CUDC-907 inhibited growth of breast cancer cells lines harboring Pten mutations and/or deletions (PMID: 22693356).	22693356
PTEN	PTEN del	urinary bladder cancer	sensitive	Metformin	Preclinical	Actionable	In a preclinical study, bladder cancer cells with PTEN deletion were sensitive to Glucophage (metformin) in culture, resulting in inhibition of cell growth (PMID: 26921394).	26921394
PTEN	PIK3CA P124L PTEN del	urinary bladder cancer	decreased response	Pictilisib	Preclinical - Cell culture	Actionable	In a preclinical study, Pictilisib (GDC-0941) demonstrated limited inhibition of Akt phosphorylation and growth in bladder cancer cells harboring PIK3CA P124L and PTEN deletion in culture (PMID: 28808038).	28808038
PTEN	PTEN G129R	ovarian mucinous neoplasm	decreased response	KX2-391	Preclinical	Actionable	In a preclincal study, mucinous ovarian carcinoma cell lines over-expressing PTEN G129R were less sensitive to KX2-391 induced growth inhibition in culture and tumor suppression in xenograft models (PMID: 24100628).	24100628
PTEN	PTEN V275*	triple-receptor negative breast cancer	sensitive	DHM25	Preclinical - Cell culture	Actionable	In a preclinical study, DHM25 increased cell death and decreased migration of a triple-negative breast cancer cell line harboring PTEN V275* in culture (PMID: 26237138).	26237138
PTEN	KIT D816E KIT Y570_L576del PTEN T321fs	gastrointestinal stromal tumor	sensitive	Regorafenib	Preclinical - Pdx	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited Kit, Erk, and Mtor signaling, resulted in tumor growth inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT D816E, KIT Y570_L576del, and PTEN T321fs, which was established from a patient who did not respond to Gleevec (imatinib mesylate), Sutent (sunitinib), and Nexavar (sorafenib) (PMID: 29100343).	29100343
PTEN	KIT D816E KIT Y570_L576del PTEN T321fs	gastrointestinal stromal tumor	sensitive	Imatinib + LY294002	Preclinical - Pdx	Actionable	In a preclinical study, Gleevec (imatinib mesylate) in combination with LY394002 resulted in enhanced tumor growth inhibition compared to monotherapy in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT D816E, KIT Y570_L576del, and PTEN T321fs, which was established from a patient who did not respond to Gleevec (imatinib mesylate), Sutent (sunitinib), and Nexavar (sorafenib) (PMID: 29100343).	29100343
PTEN	KIT D816E KIT Y570_L576del PTEN T321fs	gastrointestinal stromal tumor	resistant	Imatinib	Preclinical - Pdx	Actionable	In a preclinical study, Gleevec (imatinib mesylate) did not inhibit Kit, Erk, or Mtor signaling and resulted in minimal tumor inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT D816E, KIT Y570_L576del, and PTEN T321fs, which was established from a patient who did not respond to Gleevec (imatinib mesylate), Sutent (sunitinib), and Nexavar (sorafenib) (PMID: 29100343).	29100343
PTEN	KIT D816E KIT Y570_L576del PTEN T321fs	gastrointestinal stromal tumor	resistant	Sunitinib	Preclinical - Pdx	Actionable	In a preclinical study, Sutent (sunitinib) demonstrated limited inhibition of Kit, Erk, and Mtor signaling and resulted in minimal (22.9%) tumor inhibition in patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT D816E, KIT Y570_L576del, and PTEN T321fs, which was established from a patient who did not respond to Gleevec (imatinib mesylate), Sutent (sunitinib), and Nexavar (sorafenib) (PMID: 29100343).	29100343
PTEN	PTEN A72fs	breast cancer	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring PTEN A72fs*5 in culture (PMID: 21325073, PMID: 17314276).	17314276 21325073
PTEN	PTEN A72fs	triple-receptor negative breast cancer	sensitive	DHM25	Preclinical - Cell culture	Actionable	In a preclinical study, DHM25 increased cell death in a triple-negative breast cancer cell line harboring PTEN A72fs*5 in culture (PMID: 26237138).	26237138
PTEN	GNAQ Q209L PTEN R173S	ocular melanoma	predicted - sensitive	Refametinib	Phase I	Actionable	In a Phase I clinical trial, Refametinib (BAY 86-9766) demonstrated preliminary clinical activity in patients with several tumor types, including prolonged stable disease in an ocular melanoma patient harboring GNAQ Q209L and PTEN R173S (PMID: 23434733).	23434733
PTEN	BRAF V600X PIK3CA H1047R PTEN Y86fs	melanoma	resistant	Vemurafenib	Clinical Study - Cohort	Actionable	In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance-associated mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153).	24265153
PTEN	PTEN C136Y	breast cancer	resistant	Alpelisib	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring PTEN C136Y demonstrated resistance to Alpelisib (BYL719) in culture (PMID: 27604488).	27604488
PTEN	PTEN L108R	breast cancer	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PTEN L108R in culture (PMID: 27699769).	27699769
PTEN	PTEN L108R	breast cancer	sensitive	DHM25	Preclinical - Cell culture	Actionable	In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PTEN L108R in culture (PMID: 26237138).	26237138
PTEN	EGFR act mut EGFR A289T PTEN I253N PTEN N69D	glioblastoma multiforme	sensitive	BMS-754807 + Dacomitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vizimpro (dacomitinib) and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR (A289T, EGFRvIII) and PTEN (N69D, I253N) mutations in culture (PMID: 26561558).	26561558
PTEN	EGFR act mut EGFR A289T PTEN I253N PTEN N69D	glioblastoma multiforme	sensitive	Gefitinib + Linsitinib	Preclinical	Actionable	In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring mutations in EGFR (EGFRvIII, A289T) and PTEN (I253N, N69D) in culture (PMID: 26561558).	26561558
PTEN	PTEN wild-type	uterine cancer	decreased response	GSK2256098	Preclinical	Actionable	In a preclinical study, GSK2256098 treatment resulted in a decreased response in uterine cancer cells with PTEN wild-type versus uterine cancer cells harboring a PTEN mutation (PMID: 25833835).	25833835
PTEN	PTEN wild-type	glioblastoma multiforme	sensitive	2-Methoxyestradiol	Preclinical	Actionable	In a preclinical study, 2-Methoxyestradiol (2ME2) inhibited tumor-induced angiogenesis and reduced tumor growth in PTEN reconstituted GBM cell lines and mouse models (PMID: 24162827).	24162827
PTEN	PTEN wild-type	melanoma	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and sensitivity was associated with wild-type PTEN (PMID: 23039341).	23039341
PTEN	PTEN wild-type	ovarian mucinous neoplasm	sensitive	KX2-391	Preclinical	Actionable	In a preclinical study, KX2-391 inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628).	24100628
PTEN	PTEN wild-type	ovarian mucinous neoplasm	sensitive	KX2-391 + Oxaliplatin	Preclinical	Actionable	In a preclinical study, KX2-391 and Eloxatin (oxaliplatin) synergistically inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628).	24100628
PTEN	BRAF mut PTEN wild-type	melanoma	sensitive	E6201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, E6201 resulted in a cytocidal response in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture and inhibited tumor growth in cell line xenograft models (PMID: 23039341).	23039341
PTEN	BRAF mut PTEN wild-type	melanoma	no benefit	AZD6482 + Encorafenib	Preclinical	Actionable	In a preclinical study, AZD6482 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN wild-type	melanoma	no benefit	GSK2636771 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, GSK2636771 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN wild-type	melanoma	no benefit	Encorafenib + GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN wild-type	melanoma	no benefit	AZD6482 + Binimetinib	Preclinical	Actionable	In a preclinical study, AZD6482 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN wild-type	melanoma	no benefit	AZD6482 + NVP-AEW541	Preclinical	Actionable	In a preclinical study, AZD6482 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
PTEN	BRAF mut PTEN wild-type	melanoma	no benefit	Binimetinib + GSK2636771	Preclinical	Actionable	In a preclinical study, GSK2636771 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).	26577700
PTEN	PIK3CA act mut PTEN wild-type	breast cancer	sensitive	Torkinib	Preclinical - Cell culture	Actionable	In a preclinical study, 9/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Torkinib (PP242) in culture, resulting in decreased cell viability (PMID: 21358673).	21358673
PTEN	PIK3CA act mut PTEN wild-type	breast cancer	sensitive	Everolimus	Preclinical - Cell culture	Actionable	In a preclinical study, 8/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Afinitor (everolimus) in culture, resulting in decreased cell viability (PMID: 21358673).	21358673
PTEN	AKT1 wild-type PIK3CA wild-type PTEN wild-type	triple-receptor negative breast cancer	no benefit	Capivasertib + Paclitaxel	Phase II	Actionable	In a Phase II trial, Capivasertib (AZD5363) in combination with Taxol (paclitaxel) as first-line therapy resulted in improved median progression-free survival (9.3 vs 3.7 months, HR=0.30, p=0.01) compared to placebo in patients with metastatic triple-negative breast cancer harboring PIK3CA, AKT1, and/or PTEN mutations, but not in patients with wile-type PIK3CA, AKT1, and PTEN (5.3 vs 4.4 months, HR=1.13, p=0.61) (PMID: 30715161; NCT02423603).	30715161
PTEN	PTEN R130*	follicular thyroid carcinoma	sensitive	MK2206	Preclinical - Cell culture	Actionable	In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with PI3K/AKT pathway alterations in culture, including an follicular thyroid cancer cell line harboring PTEN R130* and loss of one PTEN allele (PMID: 21289267).	21289267
PTEN	PIK3CA H1047R PTEN E307K	breast cancer	sensitive	BAY1125976	Preclinical - Cell culture	Actionable	In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA H1047R and PTEN E307K in culture (PMID: 27699769).	27699769
PTEN	PTEN V54fs	glioblastoma multiforme	sensitive	XL147	Preclinical - Cell line xenograft	Actionable	In a preclinical study, XL147 inhibited tumor growth in xenograft models of a human glioblastoma cell line harboring PTEN V54fs (PMID: 25637314).	25637314
PTPN11	FLT3 D835Y PTPN11 A72D	hematologic cancer	resistant	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib, did not decrease cell proliferation of transformed mouse cells expressing Flt3 D835Y and Ptpn11 A72D, indicating Ptpn11 A72D as a resistance mutation since Flt3 D835Y was sensitive alone (PMID: 30651561).	30651561
PTPN11	FLT3 D835Y PTPN11 A72D	hematologic cancer	sensitive	Crenolanib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib, in combination with Mekinist (trametinib), synergistically decreased cell proliferation of transformed mouse cells expressing Flt3 D835Y and Ptpn11 A72D (PMID: 30651561).	30651561
PTPN11	PTPN11 dec exp	myeloid leukemia	resistant	SHP099	Preclinical - Cell culture	Actionable	In a preclinical study, SHP099 had no effect on Erk1/2 phosphorylation, Bcl-xl expression, Parp cleavage, and growth of PTPN11 knock-out myeloid cells in culture (PMID: 29568093).	29568093
PTPN11	BRAF mut PTPN11 dec exp	colorectal cancer	sensitive	PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, knocking down of Ptpn11 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322).	26351322
PTPN11	PTPN11 D61Y	myeloid leukemia	resistant	SHP099	Preclinical - Cell culture	Actionable	In a preclinical study, SHP099 had no effect on Erk1/2 phosphorylation, Bcl-xl expression, Parp cleavage, and growth of myeloid cells expressing PTPN11 D61Y in culture (PMID: 29568093).	29568093
PTPN11	PTPN11 T253M PTPN11 Q257L	lung non-small cell carcinoma	resistant	Selumetinib + SHP099	Preclinical - Cell culture	Actionable	In a preclinical study, pancreatic ductal adenocarcinoma cells co-expressing PTPN11 T253M and PTPN11 Q257L were resistant to the combination therapy, Selumetinib (AZD6244) and SHP099, in culture (PMID: 30045908).	30045908
PTPN11	PTPN11 E69K	myeloid leukemia	sensitive	SHP099	Preclinical - Cell culture	Actionable	In a preclinical study, SHP099 inhibited Erk1/2 phosphorylation, Bcl-xl expression, Parp cleavage, and growth of myeloid cells expressing PTPN11 A72V in culture (PMID: 29568093).	29568093
PTPN11	PTPN11 A72V	myeloid leukemia	resistant	SHP099	Preclinical - Cell culture	Actionable	In a preclinical study, SHP099 had no effect on Erk1/2 phosphorylation, Bcl-xl expression, Parp cleavage, and growth of myeloid cells expressing PTPN11 A72V in culture (PMID: 29568093).	29568093
PTPN11	PTPN11 E76K	juvenile myelomonocytic leukemia	sensitive	Cryptotanshinone	Preclinical	Actionable	In a preclinical study, myeloid cells harboring PTPN11 E76K were sensitive to cryptotanshinone in culture, resulting in decreased cell growth (PMID: 23957426).	23957426
PTPN11	PTPN11 E76K	leukemia	sensitive	U0126	Preclinical	Actionable	In a preclinical study, U0126 induced apoptotic activity of leukemia cells expressing PTPN11 E76K in culture (PMID: 17942397).	17942397
PTPN11	PTPN11 E76K	leukemia	sensitive	PD98059	Preclinical	Actionable	In a preclinical study, PD98059 induced apoptotic activity of leukemia cells expressing PTPN11 E76K in culture (PMID: 17942397).	17942397
PTPN11	PTPN11 E76K	myeloid leukemia	resistant	SHP099	Preclinical - Cell culture	Actionable	In a preclinical study, SHP099 had no effect on Erk1/2 phosphorylation, Bcl-xl expression, Parp cleavage, and growth of myeloid cells expressing PTPN11 E76K in culture (PMID: 29568093).	29568093
PTPN11	PTPN11 E76K	hematologic cancer	sensitive	II-B08	Preclinical	Actionable	In a preclinical study, hematopoietic progenitor cells expressing PTPN11 E76K were sensitive to II-B08, resulting in decreased cell proliferation (PMID: 20170098).	20170098
PTPN11	BRAF G596R PTPN11 E76K	colorectal cancer	resistant	RMC-4550	Preclinical - Cell culture	Actionable	In a preclinical study, expression of PTPN11 E76K in colorectal cancer cells harboring BRAF G596R abolished their sensitivity to RMC-4550-induced inhibition of Erk phosphorylation and proliferation in culture (PMID: 30104724).	30104724
PTPN11	PTPN11 mutant	juvenile myelomonocytic leukemia	not applicable	N/A	Clinical Study	Emerging	In two clinical studies, PTPN11 mutations were frequently identified in patients with juvenile myelomonocytic leukemia and were found to be associated with poor survival (PMID: 19047918, PMID: 21901340), suggesting that this may serve as a future prognostic biomarker.	21901340 19047918
PTPN11	IDH1 wild-type PTPN11 mutant	glioblastoma multiforme	predicted - sensitive	Nivolumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).	30742119
PTPN11	IDH1 wild-type PTPN11 mutant	glioblastoma multiforme	predicted - sensitive	Pembrolizumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, MAPK pathway mutations were significantly enriched in patients with IDH1 wild-type glioblastoma who responded to anti-PD-1 therapy with either Keytruda (pembrolizumab) or Opdivo (nivolumab), compared to those who did not respond (odds ratio=12.8, p=0.019), with 4 MAPK pathway mutations (2 in BRAF, 2 in PTPN11) identified in 13 responders and 1 (BRAF) in 32 non-responders (PMID: 30742119).	30742119
PTPN11	PTPN11 act mut	lung non-small cell carcinoma	sensitive	Refametinib	Preclinical	Actionable	In a preclinical study, Refemetinib (BAY86-9766) inhibited growth of NSCLC cells harboring activating PTPN11 mutations in culture (J Clin Oncol 33, 2015(Suppl; abstr 11077)).	detail...
RAD21	RAD21 wild-type	breast cancer	not applicable	N/A	Preclinical	Emerging	In a preclinical study, siRNA inhibition of RAD21 in breast cancer cells resulted in increased sensitivity to Toposaur (etoposide) in culture, suggesting RAD21 may be a potential therapeutic target for enhanced sensitivity to chemotherapeutics (PMID: 15767545).	15767545
RB1	ALK rearrange RB1 C706F TP53 loss	lung small cell carcinoma	predicted - resistant	Lorlatinib	Case Reports/Case Series	Actionable	In a clinical case study, RB1 C706F and loss of exons 1-11 in TP53 were identified in the pericardium infiltrating small cell lung cancer that developed while on Lorlatinib (PF-06463922) treatment in a patient with ALK-rearranged non-small cell lung carcinoma (PMID: 28285684).	28285684
RB1	PTEN mut RB1 mut SMAD4 mut TP53 mut	skin cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).	25261369
RB1	RB1 mut TP53 mut	breast carcinoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring TP53 and RB1 mutations in culture (PMID: 17121911).	17121911
RB1	RB1 mut TP53 mut	prostate carcinoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of prostate carcinoma cell lines harboring Tp53 and Rb1 mutations in culture and reduced tumor growth in xenograft models (PMID: 17121911).	17121911
RB1	RB1 mut TP53 mut	cervical cancer	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of cervical carcinoma cell lines harboring Tp53 and Rb1 mutations (PMID: 17121911).	17121911
RB1	RB1 mutant	estrogen-receptor positive breast cancer	predicted - resistant	Palbociclib	Phase III	Actionable	In a Phase III trial (PALOMA-3), acquired RB1 mutations were identified in patents with ER-positive, ERBB2 (HER2)-negative breast cancer at the end of treatment in the Faslodex (fulvestrant) plus Ibrance (palbociclib) but not the Faslodex (fulvestrant) plus placebo arm, suggesting a role in conferring resistance to Ibrance (palbociclib) (PMID: 30206110; NCT01942135).	30206110
RB1	RB1 mutant	osteosarcoma	sensitive	VCN-01	Preclinical - Cell line xenograft	Actionable	In a preclinical study, VCN-01 decreased viability of a human RB1-mutant primary osteosarcoma cell line in culture, and inhibited tumor growth and decreased lung metastases in xenograft models (PMID: 26603261).	26603261
RB1	RB1 K240Sfs*22 TP53 R248W	Her2-receptor negative breast cancer	predicted - resistant	Fulvestrant + Palbociclib	Case Reports/Case Series	Actionable	In a clinical case study, RB1 K240Sfs*22 and TP53 R248W were identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 5 months of Ibrance (palbociclib) and Faslodex (fulvestrant) combination treatment (PMID: 29236940).	29236940
RB1	EGFR T790M EGFR L858R EGFR A871G TP53 R248W RB1 K844S	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, Tarceva (erlotinib) treatment resulted in gradual tumor reduction and improved quality of life lasted for 1.5 years in a patient with metastatic non-small cell lung cancer harboring EGFR T790M, L858R, and A871G, TP53 R248W, and RB1 K844S (PMID: 31045832).	31045832
RB1	RB1 E268* RB1 I101fs RB1 T738_R775del RB1 V654fs	Her2-receptor negative breast cancer	predicted - resistant	Fulvestrant + Palbociclib	Case Reports/Case Series	Actionable	In a clinical case study, RB1 mutations including E268*, I101fs, T738_R775del, and V654fs were identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 8 months of Ibrance (palbociclib) and Faslodex (fulvestrant) combination treatment (PMID: 29236940).	29236940
RB1	RB1 H483Y	Her2-receptor negative breast cancer	predicted - resistant	Letrozole + Ribociclib	Case Reports/Case Series	Actionable	In a clinical case study, RB1 H48Y was identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 13 months of Kisqali (ribociclib) and Femara (letrozole) combination treatment (PMID: 29236940).	29236940
RB1	RB1 inact mut	retinoblastoma	sensitive	Nutlin-3	Preclinical	Actionable	In a preclinical study, Nutlin-3a induced p53 pathway signaling in MDMX mouse models with retinoblastoma and 69% (70/102) of the eyes harvested from the mouse models demonstrated complete response or stable disease after 18 weeks of therapy (PMID: 21515735).	21515735
RB1	RB1 inact mut	retinoblastoma	sensitive	BAY 61-3606	Preclinical	Actionable	In a preclinical study, a retinoblastoma cell line was sensitive to BAY 61-3606 in cell culture and in xenograft models, demonstrating increased apoptosis (PMID: 22237022).	22237022
RB1	RB1 inact mut	glioblastoma multiforme	resistant	Palbociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ibrance (palbociclib) failed to inhibit growth of RB1-deficient glioblastoma cell lines in culture and in intracranial cell line xenograft models (PMID: 20354191).	20354191
RB1	RB1 inact mut	retinoblastoma	sensitive	Fostamatinib	Preclinical	Actionable	In a preclinical study, retinoblastoma cell lines demonstrated sensitivity to Fostamatinib resulting in cell death (PMID: 22237022).	22237022
RB1	CDKN2A pos RB1 inact mut	glioblastoma multiforme	resistant	Palbociclib	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived glioblastoma cells harboring RB1 truncation mutation and expressing Cdkn2a were resistant to Ibrance (palbociclib) in culture (PMID: 22711607).	22711607
RB1	RB1 loss	lung small cell carcinoma	resistant	Trilaciclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, RB1-deficient small cell lung cancer cell lines were resistant to Trilaciclib (G1T28) in culture and in xenograft models (PMID: 26826116).	26826116
RB1	RB1 loss	retinoblastoma	sensitive	Vorinostat	Preclinical - Cell culture	Actionable	In a preclinical study, Zolinza (vorinostat) inhibited growth of retinoblastoma cell lines in culture (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).	23498719 18483379
RB1	RB1 loss	lung small cell carcinoma	sensitive	Topotecan + Trilaciclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Trilaciclib (G1T28) and Hycamtin (topotecan) inhibited tumor growth in RB1-deficient small cell lung cancer cell line xenograft models, with greater efficacy than Hycamtin (topotecan) alone (PMID: 26826116).	26826116
RB1	RB1 loss	Advanced Solid Tumor	no benefit	Palbociclib	Preclinical	Actionable	In preclinical studies, the CDK4/6 inhibitor, Ibrance (palbociclib), was not effective in a variety of solid tumors with Rb1-deficiency (PMID: 26649278).	26649278
RB1	RB1 loss	retinoblastoma	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, Sirolimus (rapamycin) decreased tumor occurrence, tumor hypoxia and tumor vascularization in a retinoblastoma mouse model with functionally inactivated Rb protein (PMID: 21468343, PMID: 1689463).	21468343 1689463
RB1	RB1 loss	estrogen-receptor positive breast cancer	resistant	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, RB1 loss was associated with acquired resistance to Ibrance (palbociclib) in an estrogen-receptor positive breast cancer cell line in culture (PMID: 27020857).	27020857
RB1	RB1 loss	retinoblastoma	sensitive	Entinostat	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Entinostat (MS-275) inhibited growth of retinoblastoma cell lines in culture and inhibited tumor growth in a retinoblastoma cell line xenograft model (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).	23498719 18483379
RB1	RB1 loss	retinoblastoma	sensitive	Trichostatin A	Preclinical - Cell culture	Actionable	In a preclinical study, Trichostatin A (TSA) inhibited growth of retinoblastoma cell lines in culture (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).	23498719 18483379
RB1	RB1 loss	neuroendocrine tumor	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, Sirolimus (rapamycin) slowed pituitary tumors and decreased the occurrence of thyroid tumors in Rb1+/- mice (PMID: 23454836).	23454836
RB1	PTEN loss RB1 loss	triple-receptor negative breast cancer	resistant	Palbociclib	Preclinical	Actionable	In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Ibrance (palbociclib) induced growth inhibition in culture (PMID: 27020857).	27020857
RB1	PTEN loss RB1 loss	triple-receptor negative breast cancer	no benefit	Palbociclib + Pictilisib	Preclinical	Actionable	In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in triple-receptor negative breast cancer cell lines harboring PTEN and RB1 loss in culture (PMID: 27020857).	27020857
RB1	PTEN loss RB1 loss	triple-receptor negative breast cancer	resistant	Pictilisib	Preclinical	Actionable	In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Pictilisib (GDC-0941) induced growth inhibition in culture (PMID: 27020857).	27020857
RB1	BRAF mut RB1 loss	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring a BRAF mutation and RB1 loss demonstrated reduced sensitivity when treated with Mekinist (trametinib) in culture (PMID: 27488531).	27488531
RB1	BRAF mut RB1 loss	melanoma	decreased response	Palbociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line harboring a BRAF mutation and loss of RB1 demonstrated a decreased response to Ibrance (palbociclib) treatment in culture when compared to treatment of melanoma cell lines wild-type for BRAF (PMID: 27488531).	27488531
RB1	BRAF mut RB1 loss	melanoma	decreased response	Palbociclib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, a melanoma cell line with a BRAF mutation and loss of RB1 demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531).	27488531
RB1	NOTCH1 wild-type RB1 loss	T-cell adult acute lymphocytic leukemia	resistant	Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type NOTCH1 and loss of RB1 demonstrated resistance to Kisqali (ribociclib) in culture, resulting in limited inhibition of cell growth (PMID: 28151717).	28151717
RB1	RB1 positive	breast cancer	predicted - sensitive	Paclitaxel + Palbociclib	Phase I	Actionable	In a Phase I trial, alternating sequential treatment with Ibrance (palbociclib) and Taxol (paclitaxel) resulted in a median progression-free survival (mPFS) of 209 days in patients with Rb1-positive breast cancer, with a mPFS of 802 days and a clinical benefit rate of 55.6% (5/9) at the recommended phase II dose (PMID: 30635336; NCT01320592).	30635336
RB1	RB1 positive	medulloblastoma	sensitive	Palbociclib	Preclinical - Pdx	Actionable	In a preclinical study, Ibrance (palbociclib) inhibited Rb1 phosphorylation in tumor tissues and improved survival in patient-derived intracranial xenograft models of medulloblastoma (PMID: 27012813).	27012813
RB1	RB1 positive	glioblastoma multiforme	predicted - sensitive	Palbociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ibrance (palbociclib) inhibited proliferation of RB1-proficient glioblastoma cell lines in culture and inhibited tumor growth in intracranial cell line xenograft models (PMID: 20354191).	20354191
RB1	RB1 positive	Advanced Solid Tumor	predicted - sensitive	Ribociclib	Phase I	Actionable	In a Phase I clinical trial, Kisqali (ribociclib) demonstrated safety and preliminary efficacy in patients with RB1-positive solid tumors and lymphomas, resulting in partial responses in 2.3% (3/132) of patients and stable disease in 32.6% (41/132) of patients, including 8 patients demonstrating stable disease for greater than 6 months (PMID: 27542767, PMID: 24795392).	detail... 24795392 27542767
RB1	TP53 mutant RB1 wild-type	osteosarcoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of osteosarcoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).	17121911
RB1	TP53 mutant RB1 wild-type	colon carcinoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).	17121911
RB1	TP53 mutant RB1 wild-type	breast carcinoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).	17121911
RB1	TP53 mutant RB1 wild-type	mantle cell lymphoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).	17121911
RB1	TP53 wild-type RB1 wild-type	breast carcinoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).	17121911
RB1	TP53 wild-type RB1 wild-type	colon carcinoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).	17121911
RB1	TP53 wild-type RB1 wild-type	melanoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of melanoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).	17121911
RB1	TP53 wild-type RB1 wild-type	mantle cell lymphoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).	17121911
RB1	TP53 wild-type RB1 wild-type	lung carcinoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of lung carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).	17121911
RB1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Bortezomib + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).	28151717
RB1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a T-cell acute lymphoblastic leukemia cell line co-harboring wild-type RB1 and a NOTCH1 mutation demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717).	28151717
RB1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Asparaginase + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).	28151717
RB1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Prednisolone + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).	28151717
RB1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Everolimus + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture (PMID: 28151717).	28151717
RB1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Dexamethasone + Ribociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, and a greater survival benefit in xenograft models when compared to Kisqali (ribociclib) alone (PMID: 28151717).	28151717
RB1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Methotrexate + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).	28151717
RB1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Mercaptopurine + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).	28151717
RB1	NOTCH1 mut RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	JQ1 + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).	28151717
RB1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Methotrexate + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).	28151717
RB1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Everolimus + Ribociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture, and prolonged survival in cell-line xenograft models (PMID: 28151717).	28151717
RB1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717).	28151717
RB1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Asparaginase + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).	28151717
RB1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Prednisolone + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).	28151717
RB1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	JQ1 + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).	28151717
RB1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	sensitive	Bortezomib + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).	28151717
RB1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	decreased response	Mercaptopurine + Ribociclib	Preclinical - Cell culture	Actionable	In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717).	28151717
RB1	NOTCH1 wild-type RB1 wild-type	T-cell adult acute lymphocytic leukemia	conflicting	Dexamethasone + Ribociclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and NOTCH1 resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, however, survival did not differ between xenograft models treated with the combination or Kisqali (ribociclib) alone (PMID: 28151717).	28151717
RET	RET C634F	thyroid medullary carcinoma	predicted - sensitive	Sorafenib	Phase II	Actionable	In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C634F (PMID: 20368568).	20368568
RET	RET M918X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET M918X mutations result in multiple endocrine neoplasia, type 2B (MEN 2B), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).	detail...
RET	RET Y791X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET Y791X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with increased risk of developing thyroid medullary carcinoma (NCCN.org).	detail...
RET	RET C620R	thyroid medullary carcinoma	sensitive	Everolimus	Phase II	Actionable	In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease of 116 weeks in a MEN2A patient with medullary thyroid cancer carrying a RET C620R mutation (PMID: 26294908).	26294908
RET	RET S891A	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation in cells expressing RET S891A in culture (PMID: 17664273).	17664273
RET	RET S891A	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET S891A in culture (PMID: 23526464).	23526464
RET	RET S891A	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET S891A in culture (PMID: 15184865).	15184865
RET	RET G691S	Advanced Solid Tumor	sensitive	Dovitinib	Phase I	Actionable	In a Phase I clinical trial, two patients with germline RET G691S mutations demonstrated sensitivity to Dovitinib (TKI258) treatment (PMID: 25103625).	25103625
RET	RET Y806C	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET Y806C in culture (PMID: 23526464).	23526464
RET	RET C634R RET Y806C	Advanced Solid Tumor	resistant	Vandetanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806C were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224).	19029224
RET	RET V804M + RET Y806C	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Compound germline RET V840M and Y806C mutations result in multiple endocrine neoplasia, type 2B (MEN 2B), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).	detail...
RET	RET C620X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET C620X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).	detail...
RET	RET V804M + RET S904C	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Compound germline RET V840M and S904C mutations result in multiple endocrine neoplasia, type 2B (MEN 2B), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).	detail...
RET	RET over exp	breast cancer	sensitive	Y078-DM1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Y078-DM1 induced cytotoxicity in a human breast cancer cell line with high levels of RET expression in culture and inhibited tumor growth in xenograft models (PMID: 26240273).	26240273
RET	RET C634R RET Y806F	Advanced Solid Tumor	predicted - sensitive	Vandetanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806F in culture demonstrated inhibition of Ret phosphorylation and activity in kinase assays when treated with Caprelsa (vandetanib) (PMID: 19029224).	19029224
RET	EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T	olfactory neuroblastoma	predicted - sensitive	Cetuximab + Sunitinib	Case Reports/Case Series	Actionable	In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).	27149458
RET	RET C630X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET C630X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).	detail...
RET	RET act mut	lung non-small cell carcinoma	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited RET phosphorylation and reduced viability of non-small cell lung cancer cells with RET activating mutations (Cancer Res April 15, 2013 73; 2084).	detail...
RET	RET L790X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET L790X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with increased risk of developing thyroid medullary carcinoma (NCCN.org).	detail...
RET	RET C609X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET C609X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with increased risk of developing thyroid medullary carcinoma (NCCN.org).	detail...
RET	RET C634Y	Advanced Solid Tumor	sensitive	ALW-II-41-27	Preclinical - Cell culture	Actionable	In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling, reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350).	26046350
RET	RET C634Y	Advanced Solid Tumor	sensitive	HG-6-63-01	Preclinical	Actionable	In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350).	26046350
RET	RET C634Y	thyroid medullary carcinoma	predicted - sensitive	Sorafenib	Phase II	Actionable	In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C634Y (PMID: 20368568).	20368568
RET	RET C634Y	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells harboring RET C634Y in culture (PMID: 23526464).	23526464
RET	RET C634Y	Advanced Solid Tumor	sensitive	XMD15-44	Preclinical	Actionable	In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350).	26046350
RET	RET L790F	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET L790F in culture (PMID: 15184865).	15184865
RET	RET L790F	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET L790F in culture (PMID: 23526464).	23526464
RET	RET A883X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET A883X mutations result in multiple endocrine neoplasia, type 2B (MEN 2B), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).	detail...
RET	RET C634X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET C634X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).	detail...
RET	RET C611X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET C611X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).	detail...
RET	RET D631_R635delinsG RET L629P RET V637R	thyroid medullary carcinoma	predicted - sensitive	BLU-667	Phase I	Actionable	In a Phase I trial, a patient with medullary thryoid cancer harboring RET D631_R635delinsG, L629P, and V637R demonstrated a partial response, with maximal tumor reduction of 47% at 10 months, following treatment with BLU-667 (PMID: 29657135; NCT03037385).	29657135
RET	RET M918T	thyroid medullary carcinoma	sensitive	Selpercatinib	Preclinical - Cell culture	Actionable	In a preclinical study, thyroid medullary carcinoma cells harboring RET M918T were sensitive to treatment with Selpercatinib (LOXO-292) in culture, demonstrating decreased cell proliferation (PMID: 29912274).	29912274
RET	RET M918T	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased proliferation of cells expressing RET M918T in culture (PMID: 17664273).	17664273
RET	RET M918T	thyroid medullary carcinoma	sensitive	HG-6-63-01	Preclinical	Actionable	In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET M918T in culture (PMID: 26046350).	26046350
RET	RET M918T	lung small cell carcinoma	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited growth of small cell lung carcinoma lines expressing RET M918T (PMID: 25122427).	25122427
RET	RET M918T	Advanced Solid Tumor	predicted - sensitive	Pz-1	Preclinical	Actionable	In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET M918T (PMID: 26126987).	26126987
RET	RET M918T	Advanced Solid Tumor	sensitive	HG-6-63-01	Preclinical	Actionable	In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350).	26046350
RET	RET M918T	Advanced Solid Tumor	sensitive	XMD15-44	Preclinical	Actionable	In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350).	26046350
RET	RET M918T	thyroid medullary carcinoma	sensitive	XMD15-44	Preclinical	Actionable	In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET M918T in culture (PMID: 26046350).	26046350
RET	RET M918T	thyroid medullary carcinoma	predicted - sensitive	BLU-667	Phase I	Actionable	In a Phase I trial, a patient with sporadic medullary thryoid cancer harboring RET M918T demonstrated a partial response, with maximal tumor reduction of 47% following treatment with BLU-667 (PMID: 29657135; NCT03037385).	29657135
RET	RET M918T	thyroid medullary carcinoma	sensitive	Cabozantinib	Phase III	Actionable	In a Phase III trial, Cometriq (cabozantinib) increased overall survival to 25.4 months in medullary thyroid carcinoma patients with RET M918T (J Clin Oncol 33, 2015, suppl; abstr 6012).	detail...
RET	RET M918T	thyroid medullary carcinoma	sensitive	Cabozantinib	Phase III	Actionable	In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (61 vs 17 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RET M918T (PMID: 27525386).	27525386
RET	RET M918T	thyroid carcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited RET signaling and decreased proliferation of thyroid carcinoma cells harboring a RET M918T mutation in culture (PMID: 23526464).	23526464
RET	RET M918T	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation and transforming activity in cells expressing RET M918T in culture (PMID: 15184865).	15184865
RET	RET M918T	thyroid medullary carcinoma	sensitive	ALW-II-41-27	Preclinical - Cell culture	Actionable	In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thryoid carcinoma cells harboring RET M918T in culture (PMID: 26046350).	26046350
RET	RET M918T	thyroid medullary carcinoma	sensitive	Everolimus	Phase II	Actionable	In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease in 71% (5/7) of medullary thyroid cancer patients, and 4 of the 7 patients carried a RET M918T mutation (PMID: 26294908).	26294908
RET	RET M918T	lung small cell carcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines expressing RET M918T (PMID: 25122427).	25122427
RET	RET M918T	Advanced Solid Tumor	sensitive	ALW-II-41-27	Preclinical - Cell culture	Actionable	In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling, reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350).	26046350
RET	RET M918T	thyroid medullary carcinoma	predicted - sensitive	Sorafenib	Phase II	Actionable	In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 10% (1/10) and stable disease in 90% (9/10) of patients with medullary thyroid carcinoma harboring RET M918T (PMID: 20368568).	20368568
RET	RET M918T	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET M918T in culture (PMID: 23526464).	23526464
RET	RET M918T	Advanced Solid Tumor	sensitive	Selpercatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing RET M918T were sensitive to treatment with Selpercatinib (LOXO-292) in culture, demonstrating decreased cell proliferation (PMID: 29912274).	29912274
RET	RET M918T	thyroid medullary carcinoma	sensitive	AZD1480	Preclinical - Cell culture	Actionable	In a preclinical study, AZD1480 reduced phosphorylation of RET and downstream effectors, and inhibited growth and increased apoptosis of a medullary thyroid cancer cell line harboring RET M918T in culture (PMID: 23056499).	23056499
RET	RET M918T	colorectal cancer	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of colorectal cancer cells harboring a RET M918T mutation in culture (PMID: 17664273).	17664273
RET	ATM L804fs ATM S978fs RET M918T	thyroid medullary carcinoma	predicted - sensitive	Everolimus + Vandetanib	Case Reports/Case Series	Actionable	In a clinical case study, addition of Afinitor (everolimus) to Caprelsa (vandetanib) treatment resulted in significant tumor reduction in a medullary thyroid carcinoma patient harboring ATM L804fs*4, ATM S978fs*12, and RET M918T, that achieved prolonged stable disease on Caprelsa (vandetanib) treatment alone (PMID: 27683183).	27683183
RET	RET M918T RET V804M	thyroid medullary carcinoma	resistant	Everolimus + Vandetanib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with thyroid medullary carcinoma harboring RET M918T progressed on multiple therapies, including Nexavar (sorafenib), Caprelsa (vandetanib), Cometriq (cabozantinib), MGCD-516 (sitravatinib), and RXDX-105 (CEP-32496), and upon progression with the combination therapy, Caprelsa (vandetanib) and Afinitor (everolimus), cell-free DNA testing revealed RET M918T and acquisition of a secondary drug resistant mutation, RET V804M (PMID: 29912274; NCT03157128).	29912274
RET	RET M918T RET V804M	thyroid medullary carcinoma	sensitive	Selpercatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with thyroid medullary cancer harboring RET M918T and RET V804M demonstrated an initial response to Selpercatinib (LOXO-292), which included a decrease in allelic fraction of RET M918T and RET V804M over 8 weeks and a radiographic response of nearly 54% post 6.9 months of treatment (PMID: 29912274; NCT03157128).	29912274
RET	RET M918T RET V804M	lung adenocarcinoma	resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma initially treated with chemotherapy and immunotherapy was found to harbor KIF5B-RET, and was then treated with Alecensa (alectinib), which resulted in an intracranial response, but eventually led to further progression (PMID: 29912274; NCT03157128).	29912274
RET	RET Y791F	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET Y791F in culture (PMID: 15184865).	15184865
RET	RET Y791F	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET Y971F in culture (PMID: 23526464).	23526464
RET	RET fusion	lung non-small cell carcinoma	predicted - sensitive	Selpercatinib	Phase Ib/II	Actionable	In a Phase I/II trial (LIBRETTO-001), Selpercatinib (LOXO-292) treatment resulted in an objective response rate of 68% (71/105) in RET fusion-positive non-small cell lung cancer patients (IASLC 2019 World Conference on Lung Cancer, Sep 2019, abstract# PL02.08; NCT03157128).	detail... detail...
RET	RET fusion	lung non-small cell carcinoma	sensitive	Vandetanib	Phase II	Actionable	In a Phase II trial, Caprelsa (vandetanib) treatment resulted in a disease control rate of 88% (15/17), median progression-free survival (PFS) of 4.7 months, and partial response in 53% (9/17) of non-small cell lung adenocarcinoma patients harboring RET fusions (J Clin Oncol 34, 2016 (suppl; abstr 9012)).	detail...
RET	RET fusion	lung non-small cell carcinoma	sensitive	Vandetanib	Phase II	Actionable	In a Phase II trial, Caprelsa (vandetanib) treatment resulted in partial remission in 17% (3/18) and stable disease in 44% (8/18) of non-small cell lung adenocarcinoma patients harboring RET fusions (J Clin Oncol 34, 2016 (suppl; abstr 9013)).	detail...
RET	RET fusion	papillary thyroid carcinoma	sensitive	Selpercatinib	Phase I	Actionable	In a Phase I trial, Selpercatinib (LOXO-292) treatment resulted in an objective response rate of 83% (5/6) in RET fusion-positive papillary thyroid cancer patients (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128).	detail...
RET	RET C618X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET C618X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).	detail...
RET	RET E884K	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET E884K in culture (PMID: 23526464).	23526464
RET	RET E768X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET E768X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with increased risk of developing thyroid medullary carcinoma (NCCN.org).	detail...
RET	RET S891X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET S891X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with increased risk of developing thyroid medullary carcinoma (NCCN.org).	detail...
RET	RET C634R RET Y806E	Advanced Solid Tumor	resistant	Vandetanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806E were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224).	19029224
RET	RET A883F	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET A883F in culture (PMID: 15184865).	15184865
RET	RET A883F	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET A883F in culture (PMID: 23526464).	23526464
RET	RET C634W	thyroid medullary carcinoma	sensitive	BLU-667	Preclinical - Cell line xenograft	Actionable	In a preclinical study, BLU-667 inhibited Ret signaling and proliferation of a medullary thyroid cancer cell line harboring RET C634W in culture, and inhibited tumor growth in xenograft models (PMID: 29657135).	detail... 29657135
RET	RET C634W	thyroid medullary carcinoma	sensitive	Selpercatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, thyroid medullary carcinoma cells harboring RET C634W were sensitive to treatment with Selpercatinib (LOXO-292), demonstrating decreased cell proliferation in culture and inhibition of tumor growth in cell line xenograft models (PMID: 29912274).	29912274
RET	RET C634W	thyroid cancer	sensitive	Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited proliferation of thyroid cancer cells harboring RET C634W in culture (PMID: 21170960).	21170960
RET	RET C634W	thyroid medullary carcinoma	sensitive	RXDX-105	Preclinical - Cell culture	Actionable	In a preclinical study, RXDX-105 (CEP-32496) reduced phosphorylation of RET and downstream signaling and inhibited proliferation of a medullary thyroid cancer cell line harboring RET C634W in culture (PMID: 28011461).	28011461
RET	RET C634W	thyroid carcinoma	sensitive	Cabozantinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Cometriq (cabozantinib) inhibited phosphorylation of RET C634W and decreased tumor growth in xenograft models of a human thyroid carcinoma cell line harboring RET C634W mutation (PMID: 23705946).	23705946
RET	RET C634W	thyroid medullary carcinoma	sensitive	Sorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and inhibited tumor growth in cell line xenograft models of medullary thyroid carcinoma harboring RET C634W (PMID: 16507829).	16507829
RET	RET C634W	thyroid cancer	sensitive	AZD1480	Preclinical - Cell culture	Actionable	In a preclinical study, AZD1480 reduced phosphorylation of RET and downstream effectors, and inhibited growth and increased apoptosis of a thyroid cancer cell line harboring RET C634W in culture (PMID: 23056499).	23056499
RET	RET C634W	thyroid cancer	sensitive	Lenvatinib	Preclinical	Actionable	In a preclinical study, Lenvima (lenvatinib) inhibited RET phosphorylation and signaling in thyroid cancer cells expressing RET C634W (PMID: 25295214).	25295214
RET	RET C634W	thyroid medullary carcinoma	sensitive	ALW-II-41-27	Preclinical - Cell culture	Actionable	In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350).	26046350
RET	RET C634W	thyroid medullary carcinoma	sensitive	XMD15-44	Preclinical	Actionable	In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350).	26046350
RET	RET C634W	thyroid carcinoma	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of thyroid carcinoma cells harboring a RET C634W mutation in culture (PMID: 17664273).	17664273
RET	RET C634W	thyroid medullary carcinoma	sensitive	HG-6-63-01	Preclinical	Actionable	In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350).	26046350
RET	RET C634W	thyroid carcinoma	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited RET signaling and decreased growth of thyroid carcinoma cells harboring a RET C634W mutation in culture and in cell line xenograft models (PMID: 23526464).	23526464
RET	KDR pos RET C634W	thyroid medullary carcinoma	predicted - sensitive	Motesanib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Motesanib (AMG 706) inhibited KDR (VEGFR2) phosphorylation, but had minimal activity against RET in a medullary thyroid carcinoma (MTC) cell line harboring RET C634W in culture, however, inhibited both RET and KDR (VEGFR2) phosphorylation and decreased tumor angiogenesis and growth in MTC cell line xenograft models with RET C634W (PMID: 21422803).	21422803
RET	RET E768D	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET E768D in culture (PMID: 15184865).	15184865
RET	RET E768D	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET E768D in culture (PMID: 23526464).	23526464
RET	RET rearrange	papillary thyroid carcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) decreased proliferation of papillary thyroid carcinoma cells harboring the RET/PTC1 rearrangement in culture (PMID: 23526464).	23526464
RET	RET rearrange	papillary thyroid carcinoma	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and activation of downstream signaling, and decreased growth of papillary thyroid carcinoma cells harboring the RET/PTC1 oncogene in culture (PMID: 17664273).	17664273
RET	RET rearrange	lung non-small cell carcinoma	predicted - sensitive	RXDX-105	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-small cell lung cancer harboring a RET rearrangement demonstrated a sustained partial response following treatment with RXDX-105 (CEP-32496) on a Phase Ib clinical trial (PMID: 28011461; NCT01877811).	28011461
RET	RET rearrange	lung non-small cell carcinoma	predicted - sensitive	RXDX-105	Phase I	Actionable	In a Phase Ib trial, treatment with RXDX-105 (CEP-32496) resulted in an overall response rate of 19% (6/31) and stable disease in 39% (12/31) of patients with treatment-naive non-small cell lung cancer harboring a RET fusion (PMID: 30487236; NCT01877811)	30487236
RET	RET rearrange	lung cancer	no benefit	Ponatinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, multikinase inhibitor treatment demonstrated suboptimal clinical efficacy in RET-rearranged lung cancer patients with measurable baseline brain metastasis, resulted in confirmed intracranial response in 18% (2/11) of the patients; Iclusig (ponatinib) treatment resulted in no intracranial response in 3 patients (PMID: 30017832).	30017832
RET	RET rearrange	lung non-small cell carcinoma	predicted - sensitive	Alectinib	Case Reports/Case Series	Actionable	In a clinical study, Alecensa (alectinib) treatment resulted in objective radiographic response in 50% (2/4) and stable disease in 25% (1/4) of non-small cell lung carcinoma patients harboring RET rearrangement (PMID: 27544060).	27544060
RET	RET rearrange	lung cancer	predicted - sensitive	Alectinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, multikinase inhibitor treatment demonstrated suboptimal clinical efficacy in RET-rearranged lung cancer patients with measurable baseline brain metastasis, resulted in confirmed intracranial response in 18% (2/11) of the patients; Alecensa (alectinib) treatment resulted an intracranial response in 1 of 2 patients (PMID: 30017832).	30017832
RET	RET rearrange	lung non-small cell carcinoma	sensitive	Vandetanib	Clinical Study	Actionable	In a clinical study, analysis of patients with RET-rearranged non-small cell lung cancer treated with RET inhibitors demonstrated a response rate of 18% (2/11, all partial responses) and stable disease in 27% (3/11) of patients following Caprelsa (vandetanib) treatment (PMID: 28447912).	28447912
RET	RET rearrange	lung non-small cell carcinoma	sensitive	Vandetanib	Guideline	Actionable	Caprelsa (vandetanib) is in guidelines for non-small cell lung cancer patients with RET rearrangements (NCCN.org).	detail...
RET	RET rearrange	lung cancer	conflicting	Cabozantinib	Clinical Study - Cohort	Actionable	In a retrospective analysis, multikinase inhibitor treatment demonstrated suboptimal clinical efficacy in RET-rearranged lung cancer patients with measurable baseline brain metastasis, resulted in confirmed intracranial response in 18% (2/11) of the patients; Cometriq (cabozantinib) treatment resulted in no intracranial response in 3 patients (PMID: 30017832).	30017832
RET	RET rearrange	lung cancer	conflicting	Cabozantinib	Phase II	Actionable	In a Phase II clinical trial, treatment with Cometriq (cabozantinib) resulted in an overall response rate of 28% (7/25) in patients with RET-rearranged lung cancer (PMID: 27825636).	27825636
RET	RET rearrange	Advanced Solid Tumor	sensitive	RXDX-105	Preclinical - Pdx	Actionable	In a preclinical study, CEP-32496 (RXDX-105) induced tumor regression in patient-derived xenograft models of several advanced solid tumor type with RET rearrangements (2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Abstract A174).	detail...
RET	RET rearrange	lung non-small cell carcinoma	sensitive	Cabozantinib	Clinical Study	Actionable	In a clinical study, analysis of patients with RET-rearranged non-small cell lung cancer treated with RET inhibitors demonstrated a response rate of 37% (7/19), with complete response in 5% (1/19) and partial response in 32% (6/19) of patients, and stable disease in 26% (5/19) of patients following Cometriq (cabozantinib) treatment (PMID: 28447912).	28447912
RET	RET rearrange	lung non-small cell carcinoma	sensitive	Cabozantinib	Guideline	Actionable	Cometriq (cabozantinib) is in guidelines for non-small cell lung cancer patients with RET rearrangements (NCCN.org).	detail...
RET	RET rearrange	lung non-small cell carcinoma	predicted - sensitive	Sunitinib	Clinical Study	Actionable	In a clinical study, analysis of patients with RET-rearranged non-small cell lung cancer treated with RET inhibitors demonstrated a response rate of 18% (2/9, all partial responses), and stable disease in 33% (3/9) of patients following Sutent (sunitinib) treatment (PMID: 28447912).	28447912
RET	RET V804L	Advanced Solid Tumor	predicted - sensitive	Pz-1	Preclinical	Actionable	In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET V804L (PMID: 26126987).	26126987
RET	RET V804L	Advanced Solid Tumor	resistant	Vandetanib	Preclinical	Actionable	In a preclinical study, transformed cells expressing RET V804L demonstrated resistance to growth inhibition by Caprelsa (vandetanib) in culture (PMID: 15184865).	15184865
RET	RET V804L	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed human cell lines expressing RET V804L demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235).	23811235
RET	RET C634R	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed human cell lines expressing RET C634R demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235).	23811235
RET	RET C634R	thyroid medullary carcinoma	predicted - sensitive	Sorafenib	Phase II	Actionable	In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 50% (1/2) and stable disease in 50% (1/2) of patients with medullary thyroid carcinoma harboring RET C634R (PMID: 20368568).	20368568
RET	RET C634R	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of cells expressing RET C634R in culture (PMID: 17664273).	17664273
RET	RET C634R	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET kinase activity and proliferation in transformed cells expressing RET C634R in culture (PMID: 16507829).	16507829
RET	RET C634R	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited RET phosphorylation and decreased growth of transformed cells expressing RET C634R in culture (PMID: 15184865).	15184865
RET	RET C634R	Advanced Solid Tumor	sensitive	Pz-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pz-1 inhibited Ret signaling in transformed cells over expressing RET C634R and inhibited tumor growth in cell line xenografts models (PMID: 26126987).	26126987
RET	RET C634R RET V804G	Advanced Solid Tumor	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, transformed cell lines expressing Ret protein carrying both C634R and V804G mutations were more sensitive to Vandetanib induced inhibition of Ret activity than cells expressing Ret C634R alone in culture (PMID: 15184865).	15184865
RET	RET C634R RET V804M	Advanced Solid Tumor	resistant	Vandetanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed human cells co-expressing RET C634R and RET V804M were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224).	19029224
RET	RET wild-type	lung small cell carcinoma	sensitive	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited growth of small cell lung carcinoma lines expressing wild-type RET (PMID: 25122427).	25122427
RET	RET wild-type	lung small cell carcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines expressing wild-type RET (PMID: 25122427).	25122427
RET	RET mutant	cancer	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited wild-type RET and RET mutations to prevent cell proliferation in cell culture (PMID: 17664273).	17664273
RET	RET mutant	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of cancer cell lines harboring RET mutations in cultured and in cell line xenograft models (PMID: 23526464).	23526464
RET	RET mutant	thyroid medullary carcinoma	sensitive	Cabozantinib	Phase III	Actionable	In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (60 vs 20 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RET mutations (PMID: 27525386).	27525386
RET	RET mutant	thyroid medullary carcinoma	sensitive	Selpercatinib	Phase I	Actionable	In a Phase I trial, Selpercatinib (LOXO-292) treatment resulted in partial response in 14% (2/14) and tumor reduction in 79% (11/14) of RET mutant thyroid medullary cancer patients (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128).	detail...
RET	RET mutant	thyroid medullary carcinoma	sensitive	Everolimus	Phase II	Actionable	In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease in 71% (5/7) of medullary thyroid cancer patients, including patients harboring RET mutations, with median progression-free survival of 33 weeks (PMID: 26294908).	26294908
RET	RET mutant	colorectal cancer	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) demonstrated efficacy in RET mutant positive colorectal cancer cell lines (PMID: 23811235).	23811235
RET	RET V804M	Advanced Solid Tumor	sensitive	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of transformed cells expressing RET V804M in culture (PMID: 16507829).	16507829
RET	RET V804M	Advanced Solid Tumor	predicted - sensitive	Pz-1	Preclinical	Actionable	In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET V804M (PMID: 26126987).	26126987
RET	RET V804M	Advanced Solid Tumor	resistant	Vandetanib	Preclinical	Actionable	In a preclinical study, transformed cells expressing RET V804M demonstrated resistance to growth inhibition by Caprelsa (vandetanib) in culture (PMID: 15184865).	15184865
RET	RET V804M	thyroid medullary carcinoma	sensitive	Selpercatinib	Phase I	Actionable	In a Phase I trial, Selpercatinib (LOXO-292) treatment resulted in partial response in a thyroid medullary cancer patientharboring RET V804M (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128).	detail...
RET	RET V804M	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, transformed human cell lines expressing RET V804M demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235).	23811235
RET	RET V804M + RET E805K	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Compound germline RET V840M and E805K mutations result in multiple endocrine neoplasia, type 2B (MEN 2B), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).	detail...
RET	ROS1 fusion ERBB2 amp FGFR3 amp RET amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of ERBB2 (HER2), FGFR3, and RET (PMID: 29636358).	29636358
RET	RET V804X	thyroid medullary carcinoma	not applicable	N/A	Guideline	Risk Factor	Germline RET V804X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with increased risk of developing thyroid medullary carcinoma (NCCN.org).	detail...
RET	RET C618R	thyroid medullary carcinoma	predicted - sensitive	Sorafenib	Phase II	Actionable	In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C618R (PMID: 20368568).	20368568
RET	RET positive	breast cancer	sensitive	Y078-DM4	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Y078-DM4 induced cytotoxicity in RET-expressing human breast cancer cell lines in culture and inhibited tumor growth in xenograft models (PMID: 26240273).	26240273
RET	RET positive	thyroid medullary carcinoma	sensitive	Y078-DM4	Preclinical	Actionable	In a preclinical study, Y078-DM4 induced cytotoxicity in a RET-expressing medullary thyroid cell line in culture (PMID: 26240273).	26240273
RET	RET D898V	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET D898V in culture (PMID: 23526464).	23526464
ROS1	ROS1 fusion ROS1 G2032R	Advanced Solid Tumor	predicted - sensitive	Repotrectinib	Phase I	Actionable	In a Phase I (TRIDENT-1) trial, Repotrectinib (TPX-0005) treatment resulted in partial response in a patient with advanced solid tumor harboring ROS1 G2032R in the context of ROS1 fusion (J Clin Oncol 36, 2018 (suppl; abstr 2513); NCT03093116).	detail...
ROS1	ROS1 fusion	lung non-small cell carcinoma	predicted - sensitive	DS6051b	Phase I	Actionable	In a Phase I clinical trial, DS-6051b was well-tolerated and demonstrated some preliminary efficacy in patients with advanced solid tumors, including a partial response in a patient with non-small cell lung cancer liver metastases harboring a ROS1 fusion (Cancer Res July 15 2016 (76) (14 Supplement) CT024).	detail...
ROS1	ROS1 fusion	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ROS1 fusion proteins in culture (PMID: 27780853).	27780853
ROS1	ROS1 fusion	Advanced Solid Tumor	predicted - sensitive	Repotrectinib	Phase I	Actionable	In a Phase I (TRIDENT-1) trial, Repotrectinib (TPX-0005) treatment resulted in partial response in 21.6% (8/37) of patients with advanced solid tumors harboring ROS1 or NTRK fusions (J Clin Oncol 36, 2018 (suppl; abstr 2513); NCT03093116).	detail...
ROS1	ROS1 fusion	lung non-small cell carcinoma	sensitive	Entrectinib	FDA approved	Actionable	In a combined analysis of 3 clinical trials (ALKA-372-001, STARTRK-1, STARTRK-2) that supported FDA approval, Rozlytrek (entrectinib) treatment resulted in an objective response rate of 77% (41/53), a median duration of response of 25 months in patients with ROS1 fusion positive non-small cell lung cancer, with median progression-free survival of 26 and 14 months for patients without (n=30) and with (n=23) CNS disease, respectively (Cancer Res 2019;79(13 Suppl):Abstract nr CT192; NCT02097810; NCT02568267).	detail... detail...
ROS1	ROS1 fusion	lung non-small cell carcinoma	sensitive	Crizotinib	FDA approved	Actionable	In a Phase I trial that supported FDA approval, non-small cell lung cancer patients with ROS1 rearrangements treated with Xalkori (crizotinib) demonstrated an objective response rate of 72% (36/50), with 3 complete responses and 33 partial responses, a median duration of response of 17.6 months, and a median progression-free survival of 19.2 months (PMID: 25264305; NCT00585195) and requires FDA-approved test.	detail... 25264305
ROS1	ROS1 fusion	lung non-small cell carcinoma	sensitive	Lorlatinib	Phase I	Actionable	In a Phase I clinical trial, Lorlatinib (PF-06463922) demonstrated safety and resulted in a 50% (26/52) overall response rate in patients with ALK-positive or ROS1-positive non-small cell lung cancer, including intracranial responses in patients with CNS metastasis (J Clin Oncol 34, 2016 (suppl; abstr 9009)).	detail...
ROS1	ROS1 fusion ROS1 L2026M ROS1 L1951R	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion progressed after 17 months of treatment with Xalkori (crizotinib), and was found to have acquired two additional mutations in trans, ROS1 L2026M and ROS1 L1951R, and cells derived from this patient showed partially decreased SHP2 and ERK1/2 signaling and ROS1 activation (PMID: 29636358).	29636358
ROS1	ROS1 fusion ROS1 L2026M ROS1 L1951R	lung non-small cell carcinoma	resistant	Ceritinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient co-harboring a ROS1 fusion, and two other mutations in trans, ROS1 L2026M, and ROS1 L1951R demonstrated resistance to treatment with Zykadia (ceritinib), and cells derived from this patient showed partially decreased SHP2 and ERK1/2 signaling and ROS1 activation (PMID: 29636358).	29636358
ROS1	KIT D816G ROS1 fusion	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion developed resistance to treatment with Xalkori (crizotinib) and was subsequently found to have acquired KIT D816G (PMID: 29636358).	29636358
ROS1	ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of SRC, ERBB2 (HER2), STK11, and NOTCH1 (PMID: 29636358).	29636358
ROS1	ROS1 fusion KDR amp KIT amp PDGFRA amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of KIT, KDR, and PDGFRA (PMID: 29636358).	29636358
ROS1	ROS1 fusion ERBB2 amp FGFR3 amp RET amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of ERBB2 (HER2), FGFR3, and RET (PMID: 29636358).	29636358
ROS1	TP53 P278H ROS1 L2026M ROS1 rearrange	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a Phase II clinical trial, a patient with non-small cell lung cancer harboring a ROS1 rearrangement demonstrated progression while being treated with Xalkori (crizotinib), and was found to have acquired two mutations, ROS1 L2026M and TP53 P278H (PMID: 30978502; NCT02183870).	30978502
ROS1	ROS1 positive	lung non-small cell carcinoma	sensitive	Lorlatinib	Guideline	Actionable	Lorbrena (lorlatinib) is included in guidelines for ROS1 positive non-small cell lung cancer for patients who have progressed on Xalkori (crizotinib) or Zykadia (ceritinib) (NCCN.org).	detail...
ROS1	ROS1 positive	pancreatic cancer	predicted - sensitive	Entrectinib	Case Reports/Case Series	Actionable	In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in stable disease in a patient with ROS1-positive pancreatic cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)).	detail...
ROS1	ROS1 positive	lung non-small cell carcinoma	sensitive	Entrectinib	FDA approved	Actionable	In a combined analysis of 3 clinical trials (ALKA-372-001, STARTRK-1, STARTRK-2) that supported FDA approval, Rozlytrek (entrectinib) treatment resulted in an objective response rate of 77% (41/53), a median duration of response of 25 months in patients with ROS1 fusion positive non-small cell lung cancer, with median progression-free survival of 26 and 14 months for patients without (n=30) and with (n=23) CNS disease, respectively (Cancer Res 2019;79(13 Suppl):Abstract nr CT192; NCT02097810; NCT02568267).	detail... detail...
ROS1	ALK neg ROS1 pos	lung non-small cell carcinoma	sensitive	Crizotinib	Phase II	Actionable	In a Phase II trial, Xalkori (crizotinib) treatment resulted in an objective response rate of 69% (89/129), and a median duration of treatment of 7.8 months in ALK negative, ROS1 positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9022); NCT01945021).	detail...
ROS1	ROS1 rearrange	lung non-small cell carcinoma	no benefit	Osimertinib	Guideline	Actionable	EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ROS1 rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org).	detail...
ROS1	ROS1 rearrange	lung non-small cell carcinoma	no benefit	Afatinib	Guideline	Actionable	EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ROS1 rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org).	detail...
ROS1	ROS1 rearrange	lung non-small cell carcinoma	no benefit	Alectinib	Guideline	Actionable	Alecensa (alectinib) is not indicated for use in ROS1 rearranged non-small cell lung cancer patients whose disease became resistant to Xalkori (crizotinib) (NCCN.org).	detail...
ROS1	ROS1 rearrange	Advanced Solid Tumor	sensitive	Entrectinib	Phase I	Actionable	In a clinical study, combined analysis of 2 Phase I trials showed Rozlytrek (entrectinib) treatment to result in an objective response rate of 86% (12/14) in patients with ROS-1 rearranged advanced solid tumors that were treatment-naive, but no response (0/6) in patients who received prior Xalkori (crizotinib) (PMID: 28183697).	28183697
ROS1	ROS1 rearrange	Advanced Solid Tumor	sensitive	Entrectinib	Phase I	Actionable	In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in complete response in 13% (1/12) and objection response in 75% (6/8) of patients with advanced solid tumors harboring rearrangement in ROS1 gene (AACR Apr 2016, Abstract # CT007).	detail...
ROS1	ROS1 rearrange	lung non-small cell carcinoma	sensitive	Entrectinib	Phase I	Actionable	In a clinical study, combined analysis of 2 Phase I trials showed Rozlytrek (entrectinib) treatment to result in complete response in 15% (2/13) and partial response in 77% (10/13) patients with ROS-1 rearranged non-small cell lung carcinoma that were treatment-naive (PMID: 28183697).	28183697
ROS1	ROS1 rearrange	lung non-small cell carcinoma	sensitive	Entrectinib	Guideline	Actionable	Rozlytrek (entrectinib) is included in guidelines as a preferred therapy for patients with advanced or metastatic ROS1 rearrangement-positive non-small cell lung cancer (NCCN.org).	detail...
ROS1	ROS1 rearrange	lung non-small cell carcinoma	sensitive	Crizotinib	FDA approved	Actionable	In a Phase I trial that supported FDA approval, non-small cell lung cancer patients with ROS1 rearrangements treated with Xalkori (crizotinib) demonstrated an objective response rate of 72% (36/50), with 3 complete responses and 33 partial responses, a median duration of response of 17.6 months, and a median progression-free survival of 19.2 months (PMID: 25264305; NCT00585195) and requires FDA-approved test.	25264305 detail...
ROS1	ROS1 rearrange	lung non-small cell carcinoma	sensitive	Crizotinib	Guideline	Actionable	Xalkori (crizotinib) is included in guidelines as the preferred first-line therapy for ROS1 rearranged non-small cell lung cancer (NCCN.org).	detail...
ROS1	ROS1 rearrange	lung non-small cell carcinoma	sensitive	Crizotinib	Phase II	Actionable	In a Phase II clinical trial, patients with non-small cell lung cancer harboring a ROS1 rearrangement demonstrated an objective response rate of 70% (21/30; all partial response), a median progression-free survival (PFS) of 20 months, a duration of response of 19 months, and a survival rate of 83% at 12 months and 63% at 24 months, when treated with Xalkori (crizotinib) (PMID: 30978502; NCT02183870).	30978502
ROS1	ROS1 rearrange	lung non-small cell carcinoma	sensitive	Crizotinib	Guideline	Actionable	Xalkori (crizotinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring a ROS1 rearrangement, or as a next-line therapy in patients with ROS1-rearranged non-small cell lung cancer who have not received prior Xalkori (crizotinib) therapy (PMID: 30715168, PMID: 30285222; ESMO.org).	detail... 30285222 30715168
ROS1	ROS1 rearrange	lung non-small cell carcinoma	no benefit	Gefitinib	Guideline	Actionable	EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ROS1 rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org).	detail...
ROS1	ROS1 rearrange	lung non-small cell carcinoma	sensitive	Lorlatinib	Guideline	Actionable	Lorbrena (lorlatinib) is included in guidelines as subsequent therapy in patients with advanced or metastatic ROS1-rearranged non-small lung cancer who have progressed on Xalkori (crizotinib) or Zykadia (ceritinib) (NCCN.org).	detail...
ROS1	ROS1 rearrange	lung non-small cell carcinoma	sensitive	Lorlatinib	Phase I	Actionable	In a Phase I trial, Lorlatinib (PF-06463922) treatment resulted in an objective response in 50% (6/12) of patients with non-small cell lung carcinoma harboring a ROS1 rearrangement (PMID: 29074098; NCT03052608).	29074098
ROS1	ROS1 rearrange	lung non-small cell carcinoma	sensitive	Ceritinib	Phase II	Actionable	In a Phase II trial, treatment with Zykadia (ceritinib) resulted in an overall response rate of 62% (20/32, including 1 complete response), a disease control rate of 81% (26/32), and a progression-free survival of 9.3 months in all patients and 19.3 months in Xalkori (crizotinib)-naive patients with non-small cell lung cancer harboring a ROS1 rearrangement (PMID: 28520527; NCT01964157).	28520527
ROS1	ROS1 rearrange	lung non-small cell carcinoma	sensitive	Ceritinib	Guideline	Actionable	Zykadia (ceritinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring a ROS1 rearrangement who have not received prior Xalkori (crizotinib) therapy (PMID: 30715168, PMID: 30285222; ESMO.org).	30285222 detail... 30715168
ROS1	ROS1 rearrange	lung non-small cell carcinoma	sensitive	Ceritinib	Guideline	Actionable	Zykadia (ceritinib) is included in guidelines as first-line therapy for ROS1-rearranged non-small cell lung cancer, but is not indicated after patients become resistant to Xalkori (crizotinib) (NCCN.org).	detail...
ROS1	ROS1 rearrange	lung non-small cell carcinoma	no benefit	Erlotinib	Guideline	Actionable	EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ROS1 rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org).	detail...
ROS1	ROS1 rearrange	lung non-small cell carcinoma	no benefit	Brigatinib	Guideline	Actionable	Alunbrig (brigatinib) is not indicated for use in ROS1 rearranged non-small cell lung cancer patients whose disease became resistant to Xalkori (crizotinib) (NCCN.org).	detail...
ROS1	ROS1 rearrange	lung non-small cell carcinoma	sensitive	NPS-1034	Preclinical - Cell culture	Actionable	In a preclinical study, NPS-1034 inhibited ROS1 activity and proliferation of a non-small cell lung cancer cell line harboring a ROS1 rearrangement in culture (PMID: 24165158).	24165158
ROS1	ROS1 rearrange	lung adenocarcinoma	sensitive	Crizotinib	Phase I	Actionable	In a retrospective analysis of Phase I clinical data, Xalkori (crizotinib) resulted in an objective response rate of 80% (24/30) and a median PFS of 9.1 months in patients with ROS1 rearranged lung adenocarcinoma (PMID: 25667280).	25667280
ROS1	TP53 mut ROS1 rearrange	lung non-small cell carcinoma	predicted - sensitive	Crizotinib	Clinical Study - Cohort	Actionable	In a Phase II clinical trial, treatment with Xalkori (crizotinib) demonstrated a shorter median progression-free survival in patients with non-small cell lung cancer co-harboring a ROS1 rearrangement and TP53 mutation compared to patients with a ROS1 rearrangement and wild-type TP53 (7 vs. 24.1 months; p=0.022) (PMID: 30978502; NCT02183870).	30978502
ROS1	PIK3CA E545K ROS1 rearrange	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a Phase II clinical trial, a patient with non-small cell lung cancer harboring a ROS1 rearrangement demonstrated progression while being treated with Xalkori (crizotinib), and was found to have acquired a PIK3CA E545K mutation (PMID: 30978502; NCT02183870).	30978502
RUNX1	RUNX1 mutant	myelodysplastic syndrome	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, RUNX1 mutations were associated with poor overall survival in patients with myelodysplastic syndrome (PMID: 21714648, PMID: 22869879).	22869879 21714648
RUNX1	RUNX1 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	RUNX1 mutations are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
RUNX1	RUNX1 mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, RUNX1 mutations were associated with adverse clinical outcome in acute myeloid leukemia patients (PMID: 21343560, PMID: 22689681, PMID: 22753902, PMID: 25652455).	21343560 25652455 22689681 22753902
RUNX1	RUNX1 mutant	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	RUNX1 mutations are associated with a poor/adverse prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).	detail...
RUNX1	BCOR mut RUNX1 mut	acute myeloid leukemia	predicted - sensitive	Pyridone 6	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of BCOR and RUNX1 mutations correlated with sensitivity to Pyridone 6 (CMP6) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
RUNX1	BCOR mut RUNX1 mut	acute myeloid leukemia	predicted - sensitive	Ruxolitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of BCOR and RUNX1 mutations correlated with sensitivity to Jakafi (ruxolitinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
RUNX1	BCOR mut RUNX1 mut	acute myeloid leukemia	predicted - sensitive	Momelotinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of BCOR and RUNX1 mutations correlated with sensitivity to Momelotinib (CYT387) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
RUNX1	BCOR mut RUNX1 mut	acute myeloid leukemia	predicted - sensitive	Tofacitinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, co-occurrence of BCOR and RUNX1 mutations correlated with sensitivity to Xeljanz (tofacitinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).	30333627
RUNX1	RUNX1-RUNX1T1	leukemia	sensitive	Doxorubicin + I-CBP112	Preclinical	Actionable	In a preclinical study, the combination of I-CBP112 and Doxorubicin worked synergistically to inhibit growth of leukemia cells harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700)	26552700
RUNX1	RUNX1-RUNX1T1	leukemia	sensitive	I-CBP112	Preclinical	Actionable	In a preclinical study, I-CBP112 inhibited clonogenic growth in a leukemia cell line harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700).	26552700
RUNX1	RUNX1-RUNX1T1	acute myeloid leukemia	sensitive	RN-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, RN-1 inhibited growth of acute myeloid leukemia cell lines harboring RUNX1-RUNX1T1 in culture, and inhibited tumor growth in xenograft models (PMID: 26837761).	26837761
RUNX1	RUNX1-RUNX1T1	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	RUNX1-RUNX1T1 fusions (t(8;21)(q22;q22.1)) are associated with a favorable prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).	detail...
RUNX1	RUNX1-RUNX1T1	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, the t(8;21) cytogenetic abnormality, which leads to the RUNX1-RUNX1T1 fusion, is associated with core-binding factor acute myeloid leukemia and favorable prognosis (PMID: 22180162, PMID: 9746770, PMID: 25111512).	9746770 25111512 22180162
RUNX1	RUNX1-RUNX1T1	leukemia	sensitive	I-CBP112 + JQ1	Preclinical	Actionable	In a preclinical study, the combination of I-CBP112 and JQ1 worked synergistically to inhibit growth of leukemia cells harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700)	26552700
RUNX1	RUNX1-RUNX1T1	acute myeloid leukemia	sensitive	GSK690	Preclinical - Cell culture	Actionable	In a preclinical study, GSK690 inhibited growth of acute myeloid leukemia cell lines harboring RUNX1-RUNX1T1 in culture (PMID: 26837761).	26837761
RUNX1	RUNX1-RUNX1T1 KIT mut	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, coincident KIT mutations were associated with higher relapse rate and decreased overall survival in acute myeloid leukemia patients with RUNX1-RUNX1T1 fusions (PMID: 18648004, PMID: 16384925, PMID: 25111512).	25111512 16384925 18648004
RUNX1	KIT N822K RUNX1-RUNX1T1	acute myeloid leukemia	sensitive	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture (PMID: 31309543).	31309543
RUNX1	KIT N822K RUNX1-RUNX1T1	acute myeloid leukemia	sensitive	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Avapritinib (BLU-285) inhibited Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture (PMID: 31309543).	31309543
RUNX1	KIT N822K RUNX1-RUNX1T1	acute myeloid leukemia	decreased response	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) demonstrated reduced ability to inhibit Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture compared to other kinase inhibitors (PMID: 31309543).	31309543
RUNX1	KIT N822K RUNX1-RUNX1T1	acute myeloid leukemia	sensitive	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib inhibited Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture (PMID: 31309543).	31309543
RUNX1	KIT N822K RUNX1-RUNX1T1	acute myeloid leukemia	decreased response	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) demonstrated reduced ability to inhibit Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture compared to other kinase inhibitors (PMID: 31309543).	31309543
RUNX1	KIT N822K RUNX1-RUNX1T1	acute myeloid leukemia	sensitive	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, Quizartinib (AC220) inhibited Kit phosphorylation and growth of acute myeloid leukemia cell lines harboring KIT N822K and RUNX1-RUNX1T1 in culture (PMID: 31309543).	31309543
SETBP1	SETBP1 mutant	chronic myelomonocytic leukemia	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, mutations in SETBP1 were associated with poor prognosis in patients with chronic myelomonocytic leukemia (PMID: 29225884, PMID: 28158286, PMID: 28209919, PMID: 23558523, PMID: 23832012).	29225884 28209919 23832012 23558523 28158286
SETBP1	SETBP1 mutant	myelodysplastic/myeloproliferative neoplasm	not applicable	N/A	Preclinical	Emerging	In a preclinical study, SETPB1 missense mutations conferred a predicted gain-of-function, resulting in transformation of murine myeloid progenitors and increased Pp2ac phosphorylation compared to wild-type SETBP1 in culture, suggesting that Setbp1 may serve as a potential therapeutic target (PMID: 23832012).	23832012
SETBP1	SETBP1 mutant	myelodysplastic syndrome	not applicable	N/A	Clinical Study	Prognostic	In clinical analyses, mutations in SETBP1 were associated with poor prognosis in patients with myelodysplastic syndrome (PMID: 28447248, PMID: 28158286, PMID: 24127063, PMID: 23889083, PMID: 23832012).	23889083 24127063 28447248 23832012 28158286
SF3B1	SF3B1 R625X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 R625X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
SF3B1	SF3B1 mutant	essential thrombocythemia	not applicable	N/A	Guideline	Prognostic	The presence of at least one mutation in either SH2B3, IDH2, U2AF1, SF3B1, EZH2, or TP53 is associated with inferior overall survival in patients with essential thrombocythemia (NCCN.org).	detail...
SF3B1	SF3B1 mutant	myelodysplastic syndrome	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, SF3B1 mutations were associated with better overall survival in patients with myelodysplastic syndrome (PMID: 21998214, PMID: 22096241, PMID: 24220272), but may not have independent prognostic significance (PMID: 22096241).	22096241 21998214 24220272
SF3B1	SF3B1 K666N	endometrial cancer	sensitive	Spliceostatin A	Preclinical	Actionable	In a preclinical study, Spliceostatin A inhibited survival of endometrial cancer cells harboring SF3B1 K666N in culture (PMID: 25424858).	25424858
SF3B1	SF3B1 E622X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 E622X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
SF3B1	SF3B1 K700E	chronic myeloid leukemia	sensitive	H3B-8800	Preclinical - Cell line xenograft	Actionable	In a preclinical study, H3B-8800 inhibited tumor growth in cell line xenograft models of chronic myeloid leukemia harboring SF3B1 K700E while had no effect in SF3B1 wild-type controls (Blood 2016 128:966).	detail...
SF3B1	SF3B1 K700E	acute myeloid leukemia	sensitive	H3B-8800	Preclinical - Cell culture	Actionable	In a preclinical study, H3B-8800 preferentially inhibited growth of mouse acute myeloid leukemia cells harboring SF3B1 K700E compared to SF3B1 wild-type cells in culture (Blood 2016 128:966).	detail...
SF3B1	SF3B1 K700E	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 K700E is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
SF3B1	SF3B1 K700E	hematologic cancer	sensitive	E7107	Preclinical - Cell culture	Actionable	In a preclinical study, mouse cells expressing SF3B1 K700E demonstrated sensitivity to E7107 in culture, resulting in decreased viability of cells (PMID: 27622333).	27622333
SF3B1	SF3B1 K700E	pancreatic cancer	sensitive	Spliceostatin A	Preclinical	Actionable	In a preclinical study, Spliceostatin A inhibited survival of pancreatic cancer cells harboring SF3B1 K700E in culture (PMID: 25424858).	25424858
SF3B1	SF3B1 K666X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 K666X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
SF3B1	SF3B1 G742X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 G742X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
SF3B1	SF3B1 N626X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 N626X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
SF3B1	SF3B1 D781X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 D781X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
SF3B1	SF3B1 R1074H	Advanced Solid Tumor	resistant	H3B-8800	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells overexpressing SF3B1 R1074H were resistant to H3B-8800 in culture (Blood 2016 128:966).	detail...
SF3B1	SF3B1 G740X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 G740X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
SF3B1	SF3B1 T663X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 T663X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
SF3B1	SF3B1 H662X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 H662X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
SF3B1	SF3B1 Y623X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 Y623X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
SF3B1	SF3B1 I704X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SF3B1 I704X is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
SMAD4	SMAD4 del	pancreatic cancer	decreased response	Gemcitabine	Preclinical	Actionable	In a preclinical study, pancreatic cancer cell lines harboring SMAD4 homozygous deletions were half as sensitive to gemcitabine in vitro as wild-type cells (PMID: 22753594).	22753594
SMAD4	SMAD4 del	pancreatic cancer	sensitive	Irinotecan	Preclinical	Actionable	In a preclinical study, pancreatic cancer cell lines harboring inactivated SMAD4 (mutations or deletion) displayed 4.5-fold greater sensitivity to irinotecan in vitro than wild-type (PMID: 22753594).	22753594
SMAD4	SMAD4 del	pancreatic cancer	sensitive	Cisplatin	Preclinical	Actionable	In a preclinical study, pancreatic cancer cell lines harboring SMAD4 homozygous deletions were twice as sensitive to cisplatin in vitro as wild-type cells (PMID: 22753594).	22753594
SMAD4	EGFR E709_T710delinsD SMAD4 R361C TP53 loss	lung small cell carcinoma	unknown	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR E709_T710delinsD who progressed after a 1 year partial response to Gilotrif (afatinib) was found to have disease that transformed to small cell lung cancer and had acquired a SMAD4 R361C mutation and did not express Tp53 protein (PMID: 30413663).	30413663
SMAD4	CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H	melanoma	predicted - sensitive	Carboplatin + Imatinib + Paclitaxel	Case Reports/Case Series	Actionable	In a clinical case study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).	28514312
SMAD4	SMAD4 loss	pancreatic carcinoma	sensitive	SD-093	Preclinical	Actionable	In a preclinical study, SD-093 reduced the migration and invasiveness of pancreatic carcinoma cell lines lacking Smad4 (PMID: 15289325).	15289325
SMAD4	EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*	pancreatic ductal adenocarcinoma	predicted - sensitive	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).	28476735
SMAD4	EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*	pancreatic ductal adenocarcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).	28476735
SMAD4	SMAD4 inact mut	pancreatic cancer	sensitive	Irinotecan	Preclinical	Actionable	In a preclinical study, pancreatic cancer cell lines harboring inactivated SMAD4 (mutations or deletion) displayed 4.5-fold greater sensitivity to irinotecan in vitro than wild-type (PMID: 22753594).	22753594
SMAD4	PTEN mut RB1 mut SMAD4 mut TP53 mut	skin cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).	25261369
SMAD4	APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut	colorectal cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369).	25261369
SMAD4	SMAD4 mutant	colorectal cancer	no benefit	Cetuximab	Clinical Study - Cohort	Actionable	In a clinical study, Chinese metastatic colorectal cancer patients harboring a SMAD4 mutation did not respond to treatment with Erbitux (cetuximab) and showed a shorter progression-free survival compared to patients with wild-type SMAD4 (median: 90 vs 250 days, p=0.0081) (PMID: 29703253).	29703253
SMAD4	SMAD4 mutant	stomach cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in SMAD4 or BMPR1A result in juvenile polyposis syndrome, which is associated with increased risk of developing gastric cancer (NCCN.org).	detail...
SMAD4	SMAD4 dec exp	colorectal cancer	not applicable	N/A	Clinical Study	Prognostic	In clinical and meta-analyses, decreased expression of Smad4 was correlated with poor prognosis in colorectal cancer (PMID: 25749173, PMID: 19478385, PMID: 25681512, PMID: 26861460).	25749173 19478385 26861460 25681512
SMAD4	SMAD4 dec exp	head and neck squamous cell carcinoma	sensitive	Cetuximab + SP600125	Preclinical - Cell culture	Actionable	In a preclinical study, addition of SP600125 to Erbitux (cetuximab) restored sensitivity to Erbitux (cetuximab) in Smad4 knocked-down head and neck squamous cell carcinoma cells in culture (PMID: 28522603).	28522603
SMAD4	SMAD4 dec exp	head and neck squamous cell carcinoma	decreased response	SP600125	Preclinical - Cell culture	Actionable	In a preclinical study, SP600125 demonstrated modest inhibition of Jnk activity and transient growth inhibition in Smad4 knocked-down head and neck squamous cell carcinoma cells in culture (PMID: 28522603).	28522603
SMAD4	SMAD4 dec exp	head and neck squamous cell carcinoma	sensitive	Cetuximab + U0126	Preclinical - Cell culture	Actionable	In a preclinical study, addition of U0126 to Erbitux (cetuximab) restored sensitivity to Erbitux (cetuximab) in Smad4 knocked-down head and neck squamous cell carcinoma cells in culture (PMID: 28522603).	28522603
SMAD4	SMAD4 dec exp	head and neck squamous cell carcinoma	resistant	Cetuximab	Clinical Study - Cohort	Actionable	In a clinical study, decreased Smad4 expression level correlated with Erbitux (cetuximab) resistance in head and neck squamous cell carcinoma (HNSCC) patients, which is consistent with cell culture studies demonstrating Erbitux (cetuximab) resistance induced by knocking-down of Smad4 expression in HNSCC cell lines (PMID: 28522603).	28522603
SMAD4	SMAD4 dec exp	head and neck squamous cell carcinoma	decreased response	U0126	Preclinical - Cell culture	Actionable	In a preclinical study, U0126 demonstrated modest inhibition of Mapk activity and transient growth inhibition in Smad4 knocked-down head and neck squamous cell carcinoma cells in culture (PMID: 28522603).	28522603
SMAD4	SMAD4 dec exp	pancreatic cancer	not applicable	N/A	Clinical Study	Prognostic	In clinical and meta-analyses, loss of Smad4 expression and SMAD4 inactivating mutations were associated with decreased survival in patients with pancreatic cancer (PMID: 26947875, PMID: 25760429, PMID: 22504380, PMID: 19584151).	22504380 19584151 25760429 26947875
SMARCB1	SMARCB1 negative	chordoma	predicted - sensitive	Tazemetostat	Phase I	Actionable	In a Phase I trial, Tazemetostat (EPZ-6438) was well-tolerated and demonstrated anti-tumor activity in pediatric patients with SMARCB1 (INI)-deficient tumors, including complete or partial responses in patients with epithelioid sarcoma (n=1), chordoma (n=2), and atypical teratoid rhaboid tumor (n=1) (AACR-NCI-EORTC Int Conference on Molecular Targets and Cancer Therapeutics 2017, A175; NCT02601937).	detail...
SMARCB1	SMARCB1 negative	epithelioid sarcoma	predicted - sensitive	Tazemetostat	Phase I	Actionable	In a Phase I trial, Tazemetostat (EPZ-6438) was well-tolerated and demonstrated anti-tumor activity in pediatric patients with SMARCB1 (INI)-deficient tumors, including complete or partial responses in patients with epithelioid sarcoma (n=1), chordoma (n=2), and atypical teratoid rhaboid tumor (n=1) (AACR-NCI-EORTC Int Conference on Molecular Targets and Cancer Therapeutics 2017, A175; NCT02601937).	detail...
SMARCB1	SMARCB1 negative	atypical teratoid rhabdoid tumor	sensitive	DZNeP + Radiotherapy	Preclinical	Actionable	In a preclinical study, DZNep increased radiosensitivity in SMARCB1-negative atypical teratoid rhabdoid tumor cell lines in culture (PMID: 23190500).	23190500
SMARCB1	SMARCB1 negative	rhabdoid cancer	sensitive	Alvocidib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Alvocidib (flavopiridol) induced cell-cycle arrest and inhibited growth of human rhabdoid tumor cell lines with SMARCB1 biallelic deficiency in culture and inhibted tumor growth in SMARCB1-deficient cell line xenograft models (PMID: 18223228).	18223228
SMARCB1	SMARCB1 negative	rhabdoid cancer	sensitive	Palbociclib	Preclinical	Actionable	In a preclinical study, Ibrance (palbociclib) inhibited growth of SMARCB1-negative malignant rhabdoid tumor cell lines in culture, and sensitivity was associated with low levels of p16 expression (PMID: 21871868).	21871868
SMARCB1	SMARCB1 negative	atypical teratoid rhabdoid tumor	sensitive	DZNeP	Preclinical	Actionable	In a preclinical study, DZNep induced apoptosis and cell-cycle arrest and inhibited growth of SMARCB1-negative atypical teratoid rhabdoid tumor cell lines in culture (PMID: 23190500).	23190500
SMARCB1	SMARCB1 negative	rhabdoid cancer	sensitive	Fenretinide + Vorinostat	Preclinical	Actionable	In a preclinical study, the combination of Zolinza (vorinostat) and fenretinide induced apoptosis and inhibited growth of rhabdoid tumor cell lines in culture (PMID: 23764045).	23764045
SMARCB1	SMARCB1 negative	atypical teratoid rhabdoid tumor	predicted - sensitive	Tazemetostat	Phase I	Actionable	In a Phase I trial, Tazemetostat (EPZ-6438) was well-tolerated and demonstrated anti-tumor activity in pediatric patients with SMARCB1 (INI)-deficient tumors, including complete or partial responses in patients with epithelioid sarcoma (n=1), chordoma (n=2), and atypical teratoid rhaboid tumor (n=1) (AACR-NCI-EORTC Int Conference on Molecular Targets and Cancer Therapeutics 2017, A175; NCT02601937).	detail...
SMARCB1	CDKN2A over exp SMARCB1 negative	rhabdoid cancer	decreased response	Palbociclib	Preclinical	Actionable	In a preclinical study, CDKN2A (p16) over expression was associated with decreased sensitivity to Ibrance (palbociclib) in a SMARCB1-negative malignant rhabdoid tumor cell line in culture (PMID: 21871868).	21871868
SMARCB1	SMARCB1 inact mut	epithelioid sarcoma	not applicable	N/A	Guideline	Diagnostic	SMARCB1 inactivating mutations aid the diagnosis of epithelioid sarcoma (NCCN.org).	detail...
SMARCB1	EZH2 Y111D SMARCB1 inact mut	rhabdoid cancer	resistant	Tazemetostat	Preclinical - Cell culture	Actionable	In a preclinical study, over expression of EZH2 Y111D in rhabdoid tumor cells harboring an SMARCB1 inactivating mutation resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609).	26360609
SMARCB1	SMARCB1 loss	rhabdoid cancer	sensitive	Tazemetostat	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tazemetostat (EPZ-6438) inhibited growth of SMARCB1-deficient malignant rhabdoid tumor cell lines in culture, and inhibited H3K27 trimethylation and induced tumor regression in a SMARCB1-deleted human malignant rhabdoid tumor cell line xenograft model (PMID: 23620515).	23620515
SMARCB1	SMARCB1 loss	atypical teratoid rhabdoid tumor	sensitive	CFI-400945	Preclinical - Cell culture	Actionable	In a preclinical study, CFI-400945 inhibited proliferation and decreased survival and migration of SMARCB1-deficient atypical teratoid rhabdoid tumor cells in culture (PMID: 28398638).	28398638
SMARCB1	SMARCB1 del	epithelioid sarcoma	not applicable	N/A	Guideline	Diagnostic	SMARCB1 deletion aids the diagnosis of epithelioid sarcoma (NCCN.org).	detail...
SMO	SMO A459V	Advanced Solid Tumor	decreased response	Taladegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO A459V	Advanced Solid Tumor	decreased response	Sonidegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO A459V	Advanced Solid Tumor	sensitive	JQ1	Preclinical	Actionable	In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).	25759019
SMO	SMO A459V	Advanced Solid Tumor	decreased response	Vismodegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO N476K	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO N476K resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO D473Y	basal cell carcinoma	predicted - resistant	Vismodegib	Case Reports/Case Series	Actionable	In a clinical case study, a de novo SMO D473Y mutation was identified in a recurrent lesion from a basal cell carcinoma patient following an initial 11-month complete clinical response to Erivedge (vismodegib) during a Phase II trial (PMID: 25306392; NCT01367665).	25306392
SMO	SMO K519R	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO K519R resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO L325F	Advanced Solid Tumor	predicted - resistant	MRT-92	Preclinical	Actionable	In a preclinical study, transformed human cells expressing SMO L325F displayed reduced binding to MRT-92 (PMID: 25636740).	25636740
SMO	SMO F460L	Advanced Solid Tumor	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, a transformed cell line expressing SMO F460L demonstrated resistance to Erivedge (vismodegib) as compared to wild-type (PMID: 25759020).	25759020
SMO	SMO L412F	Advanced Solid Tumor	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, a transformed cell line expressing SMO L412F demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020).	25759020
SMO	SMO Q477E	basal cell carcinoma	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, a transformed cell line expressing SMO Q477E was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020).	25759020
SMO	SMO Q477E	basal cell carcinoma	no benefit	Sonidegib	Phase I	Actionable	In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO Q477E with resistance to Erivedge (vismodegib) (PMID: 26546616).	26546616
SMO	SMO E181K	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO E181K resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO G453D	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO G453D resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO T349I	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO T349I resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO T241M	Advanced Solid Tumor	decreased response	Sonidegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO T241M	Advanced Solid Tumor	decreased response	Vismodegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO T241M	Advanced Solid Tumor	decreased response	Taladegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO T241M	Advanced Solid Tumor	sensitive	JQ1	Preclinical	Actionable	In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).	25759019
SMO	SMO P513L	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO P513L resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO I408V	Advanced Solid Tumor	decreased response	Sonidegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO I408V	Advanced Solid Tumor	decreased response	Taladegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO I408V	Advanced Solid Tumor	decreased response	Vismodegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO I408V	Advanced Solid Tumor	sensitive	JQ1	Preclinical	Actionable	In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).	25759019
SMO	SMO T336I	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO T336I resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO P739S	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO P739S resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO H231R	basal cell carcinoma	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, a transformed cell line expressing SMO H231R was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020).	25759020
SMO	SMO T640A	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO T640A resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO D473H	basal cell carcinoma	resistant	Sonidegib	Phase I	Actionable	In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO D473H with resistance to Erivedge (vismodegib) (PMID: 26546616).	26546616
SMO	SMO D473H	Advanced Solid Tumor	sensitive	Taladegib	Preclinical	Actionable	In a preclinical study, LY2940680, inhibited the activity of SMO D473H, which is a mutant that confers resistance to the treatment of vismodegib (Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, Abstract #2819).	detail...
SMO	SMO D473H	Advanced Solid Tumor	predicted - sensitive	TAK-441	Preclinical	Actionable	In a preclinical study, TAK-441 inhibited Gli-reporter activation in cells transfected with SMO D473H in culture (PMID: 24291104).	24291104
SMO	SMO dec exp	osteosarcoma	predicted - sensitive	SANT1	Preclinical	Actionable	In a preclinical study, SANT1 inhibited survival of osteosarcoma cell lines with reduced SMO mRNA level in culture (PMID: 26781311).	26781311
SMO	SMO wild-type	stomach cancer	predicted - sensitive	Vismodegib	Preclinical	Actionable	In a preclinical study, Vismodegib (GDC-0449) inhibited Hedgehog pathway signaling, increased apoptosis, and decreased proliferation of a gastric cancer cell line in culture (PMID: 26676867).	26676867
SMO	SMO wild-type	medulloblastoma	sensitive	Taladegib	Preclinical	Actionable	In a preclinical study, LY2940680 was demonstrated to bind to the Smo receptor and inhibit hedgehog signaling in a human medulloblastoma tumor cell line (Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, Abstract #2819).	detail...
SMO	EGFR E746_A750del SMO amp	lung non-small cell carcinoma	resistant	Gefitinib	Preclinical	Actionable	In a preclinical study, amplification of SMO conferred acquired resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 26124204).	26124204
SMO	EGFR E746_A750del SMO amp	lung non-small cell carcinoma	no benefit	Sonidegib	Preclinical	Actionable	In a preclinical study, Odomzo (sonidegib) did not decrease viability or migration of non-small cell lung cancer cells harboring EGFR E746_A750del and amplification of SMO in culture (PMID: 26124204).	26124204
SMO	EGFR E746_A750del SMO amp	lung non-small cell carcinoma	sensitive	Gefitinib + Sonidegib	Preclinical	Actionable	In a preclinical study, the combination of Odomzo (sonidegib) and Iressa (gefitinib) decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring an EGFR E746_A750del mutation and SMO amplification in culture and inhibited tumor growth in NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).	26124204
SMO	EGFR E746_A750del SMO amp	lung non-small cell carcinoma	sensitive	PHA-665752 + Sonidegib	Preclinical	Actionable	In a preclinical study, the combination of Odomzo (sonidegib) and PHA-665752 decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring EGFR E746_A750del and SMO amplification in culture, and resulted in complete response in 100% (8/8) of NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).	26124204
SMO	SMO V414A	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO V414A resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO T548I	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO T548I resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO D384A	Advanced Solid Tumor	predicted - resistant	MRT-92	Preclinical	Actionable	In a preclinical study, transformed human cells expressing SMO D384A displayed reduced binding to MRT-92 (PMID: 25636740).	25636740
SMO	SMO L221P	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO L221P resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO V321M	Advanced Solid Tumor	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, a transformed cell line expressing SMO V321M demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020).	25759020
SMO	SMO V321M	Advanced Solid Tumor	decreased response	Sonidegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO V321M	Advanced Solid Tumor	decreased response	Taladegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO V321M	Advanced Solid Tumor	sensitive	JQ1	Preclinical	Actionable	In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO V321M on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).	25759019
SMO	SMO V321M	basal cell carcinoma	predicted - resistant	Vismodegib	Case Reports/Case Series	Actionable	In a clinical case study, a de novo SMO V321M mutation was identified in a recurrent lesion from a basal cell carcinoma patient following an initial twenty week response to Erivedge (vismodegib) (PMID: 25199678).	25199678
SMO	SMO A327P	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO A327P resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO G497W	basal cell carcinoma	predicted - resistant	Vismodegib	Case Reports/Case Series	Actionable	In a clinical case study, a basal cell carcinoma patient who did not respond to Erivedge (vismodegib) during a Phase II trial was found to harbor a SMO G497W mutation in the initial and progressing lesions (PMID: 25306392; NCT01367665).	25306392
SMO	SMO R199Q	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO R199Q resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO L353F	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO L353F resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO P698T	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO P698T resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO Y394A	Advanced Solid Tumor	predicted - resistant	MRT-92	Preclinical	Actionable	In a preclinical study, transformed human cells expressing SMO Y394A displayed reduced binding to MRT-92 (PMID: 25636740).	25636740
SMO	SMO V329F	Advanced Solid Tumor	predicted - resistant	MRT-92	Preclinical	Actionable	In a preclinical study, transformed human cells expressing SMO V329F displayed reduced binding to MRT-92 (PMID: 25636740).	25636740
SMO	SMO S387N	Advanced Solid Tumor	sensitive	Arsenic trioxide + Posaconazole	Preclinical	Actionable	In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO S391N (corresponding to human SMO S387N) in culture (PMID: 26823493).	26823493
SMO	SMO S387N	Advanced Solid Tumor	resistant	Sonidegib	Preclinical	Actionable	In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO S391N (corresponding to human SMO S387N) were resistant to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).	26823493
SMO	SMO S387N	Advanced Solid Tumor	sensitive	Posaconazole	Preclinical	Actionable	In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO S391N (corresponding to human SMO S387N) in culture (PMID: 26823493).	26823493
SMO	SMO S387N	sarcoma	decreased response	Vismodegib	Preclinical	Actionable	In a preclinical study, mouse sarcoma cell lines over expressing SMO S387N demonstrated reduced response to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO S387N	Advanced Solid Tumor	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO S391N (corresponding to human SMO S387N) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).	26823493
SMO	SMO W281L	basal cell carcinoma	predicted - resistant	Vismodegib	Case Reports/Case Series	Actionable	In a clinical case study, a de novo SMO W281L mutation was identified in a recurrent lesion from a basal cell carcinoma patient following an initial twenty week response to Erivedge (vismodegib) (PMID: 25199678).	25199678
SMO	SMO E481G	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO E481G resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO M525G	Advanced Solid Tumor	predicted - resistant	MRT-92	Preclinical	Actionable	In a preclinical study, transformed human cells expressing SMO M525G displayed reduced binding to MRT-92 (PMID: 25636740).	25636740
SMO	SMO S533N	basal cell carcinoma	resistant	Sonidegib	Phase I	Actionable	In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient with resistance to Erivedge (vismodegib) harboring SMO D533N (PMID: 26546616).	26546616
SMO	SMO R400A	Advanced Solid Tumor	predicted - sensitive	MRT-92	Preclinical	Actionable	In a preclincal, transformed human cells expressing SMO R400A displayed reduced binding to MRT-92 (PMID: 25636740).	25636740
SMO	SMO C390R	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO C390R resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO T466F	Advanced Solid Tumor	predicted - resistant	MRT-92	Preclinical	Actionable	In a preclinical study, transformed human cells expressing SMO T466F displayed reduced binding to MRT-92 (PMID: 25636740).	25636740
SMO	SMO W281C	basal cell carcinoma	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, a transformed cell line expressing SMO W281C was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020).	25759020
SMO	SMO W281C	Advanced Solid Tumor	decreased response	Sonidegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO W281C	Advanced Solid Tumor	sensitive	JQ1	Preclinical	Actionable	In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).	25759019
SMO	SMO W281C	Advanced Solid Tumor	decreased response	Taladegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO V386A	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO V386A resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO C469Y	Advanced Solid Tumor	decreased response	Vismodegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO C469Y	Advanced Solid Tumor	decreased response	Sonidegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO C469Y	Advanced Solid Tumor	sensitive	JQ1	Preclinical	Actionable	In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).	25759019
SMO	SMO C469Y	Advanced Solid Tumor	decreased response	Taladegib	Preclinical	Actionable	In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO F605L	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO F605L resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO D506N	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO D506N resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO T534I	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO T534I resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO R168H	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO R168H resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO P739L	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO P739L resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO T349P	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO T349P resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO E518K	Advanced Solid Tumor	sensitive	Arsenic trioxide + Posaconazole	Preclinical	Actionable	In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO E522K (corresponding to human SMO E518K) in culture (PMID: 26823493).	26823493
SMO	SMO E518K	Advanced Solid Tumor	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO E522K (corresponding to human SMO E518K) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).	26823493
SMO	SMO E518K	Advanced Solid Tumor	decreased response	Sonidegib	Preclinical	Actionable	In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO E522K (corresponding to human SMO E518K) demonstrated decreased response to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).	26823493
SMO	SMO E518K	Advanced Solid Tumor	predicted - resistant	MRT-92	Preclinical	Actionable	In a preclinical study, transformed human cells expressing SMO E518K displayed reduced binding to MRT-92 (PMID: 25636740).	25636740
SMO	SMO E518K	Advanced Solid Tumor	sensitive	Posaconazole	Preclinical	Actionable	In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO E522K (corresponding to human SMO E518K) in culture (PMID: 26823493).	26823493
SMO	SMO W535L	Advanced Solid Tumor	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, a transformed cell line expressing SMO W535L demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020).	25759020
SMO	SMO W535L	Advanced Solid Tumor	resistant	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, mouse fibroblast cells expressing human SMO W535L were resistant to Hedgehog pathway inhibition by Erivedge (vismodegib) in culture (PMID: 25801792).	25801792
SMO	SMO W535L	Advanced Solid Tumor	resistant	Posaconazole	Preclinical	Actionable	In a preclinical study, Posaconazole did not inhibit Hedghog signaling in mouse fibroblasts over expressing murine SMO W539L (corresponding to human SMO W535L) in culture (PMID: 26823493).	26823493
SMO	SMO W535L	basal cell carcinoma	predicted - sensitive	Sonidegib	Phase I	Actionable	In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in stable disease in a basal cell carcinoma patient harboring SMO W535L with resistance to Erivedge (vismodegib) (PMID: 26546616).	26546616
SMO	SMO W535L	medulloblastoma	sensitive	Arsenic trioxide	Preclinical	Actionable	In a preclinical study, treatment with arsenic trioxide resulted in improved survival in a transgenic mouse model of medulloblastoma expressing SMO W535L (PMID: 21183792).	21183792
SMO	SMO N219D	Advanced Solid Tumor	resistant	Sonidegib	Preclinical	Actionable	In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO N223D (corresponding to human SMO N219D) were resistant to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).	26823493
SMO	SMO N219D	Advanced Solid Tumor	sensitive	Arsenic trioxide + Posaconazole	Preclinical	Actionable	In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO N223D (corresponding to human SMO N219D) in culture (PMID: 26823493).	26823493
SMO	SMO N219D	Advanced Solid Tumor	sensitive	Posaconazole	Preclinical	Actionable	In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO N223D (corresponding to human SMO N219D) in culture (PMID: 26823493).	26823493
SMO	SMO N219D	sarcoma	decreased response	Vismodegib	Preclinical	Actionable	In a preclinical study, mouse sarcoma cell lines over expressing SMO N219D demonstrated reduced response to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO D473G	Advanced Solid Tumor	sensitive	Posaconazole	Preclinical	Actionable	In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO D477G (corresponding to human SMO D473G) in culture (PMID: 26823493).	26823493
SMO	SMO D473G	basal cell carcinoma	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, a transformed cell line expressing SMO D473G was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020).	25759020
SMO	SMO D473G	basal cell carcinoma	resistant	Sonidegib	Phase I	Actionable	In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO D473G with resistance to Erivedge (vismodegib) (PMID: 26546616).	26546616
SMO	SMO D473G	Advanced Solid Tumor	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D477G (corresponding to human SMO D473G) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).	26823493
SMO	SMO D473G	Advanced Solid Tumor	resistant	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, mouse fibroblast cells expressing human SMO D473G were resistant to Hedgehog pathway inhibition by Erivedge (vismodegib) in culture (PMID: 25801792).	25801792
SMO	SMO D473G	Advanced Solid Tumor	sensitive	Arsenic trioxide + Posaconazole	Preclinical	Actionable	In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO D477G (corresponding to human SMO D473G) in culture (PMID: 26823493).	26823493
SMO	SMO D384N	Advanced Solid Tumor	resistant	Sonidegib	Preclinical	Actionable	In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D388N (corresponding to human SMO D384N) were resistant to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).	26823493
SMO	SMO D384N	Advanced Solid Tumor	sensitive	Posaconazole	Preclinical	Actionable	In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO D388N (corresponding to human SMO D384N) in culture (PMID: 26823493).	26823493
SMO	SMO D384N	Advanced Solid Tumor	resistant	Vismodegib	Preclinical	Actionable	In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D388N (corresponding to human SMO D384N) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).	26823493
SMO	SMO D384N	Advanced Solid Tumor	sensitive	Arsenic trioxide + Posaconazole	Preclinical	Actionable	In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO D388N (corresponding to human SMO D384N) in culture (PMID: 26823493).	26823493
SMO	SMO D384N	sarcoma	decreased response	Vismodegib	Preclinical	Actionable	In a preclinical study, mouse sarcoma cell lines over expressing SMO D384N demonstrated reduced response to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 25759019).	25759019
SMO	SMO K564E	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO K564E resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SMO	SMO V404M	Advanced Solid Tumor	no benefit	Vismodegib	Preclinical - Cell culture	Actionable	In a preclinical study, Erivedge (vismodegib) treatment of cells expressing SMO V404M resulted in Hedgehog pathway activity similar to that of wild-type Smo in culture (PMID: 25801792).	25801792
SRC	SRC positive	biliary tract cancer	sensitive	Bosutinib + Gemcitabine	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Bosulif (bosutinib) and Gemzar (gemcitabine) synergistically inhibited Src signaling, decreased proliferation and migration of billary tract cancer cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27196758).	27196758
SRC	SRC positive	glioblastoma multiforme	sensitive	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Sprycel (dasatinib) treatment resulted in a strong antitumoral effect in GBM cell lines with high levels of Src phosphorylation (PMID: 19098899).	19098899
SRC	SRC positive	Advanced Solid Tumor	predicted - sensitive	Bosutinib	Preclinical - Cell culture	Actionable	In a preclinical study, Bosulif (bosutinib) inhibited invasion and migration of Src-positive cells in culture (PMID: 18483306).	18483306
SRC	SRC positive	triple-receptor negative breast cancer	sensitive	KX2-391 + Paclitaxel	Preclinical - Cell line xenograft	Actionable	In a preclinical study, KX2-392 and Taxol (paclitaxel) worked synergistically to inhibit Src signaling and proliferation of triple-receptor negative breast cancer cell lines in culture, and induced tumor regression and suppressed metastasis in xenograft models (PMID: 22784709).	22784709
SRC	SRC positive	glioblastoma multiforme	sensitive	Si306	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Si306 inhibited SRC phosphorylation and proliferation of SRC-expressing glioblastoma cell lines in culture, and inhibited tumor growth and increased survival in cell line xenograft models (PMID: 27196762).	27196762
SRC	SRC positive	glioblastoma multiforme	sensitive	Radiotherapy + Si306	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Si306 in combination with radiotherapy decreased growth of radiotherapy-sensitive SRC-positive glioblastoma cells in culture and decreased tumor growth in cell line xenograft models, with increased efficacy compared to Si306 or radiotherapy alone (PMID: 27196762).	27196762
SRC	SRC positive	triple-receptor negative breast cancer	predicted - sensitive	UM-164	Preclinical - Cell line xenograft	Actionable	In a preclinical study, UM-164 inhibited proliferation and induced apoptosis in human triple-receptor negative breast cancer cell lines with elevated Src activity in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27154914).	27154914
SRC	SRC positive	biliary tract cancer	sensitive	Bosutinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Bosulif (bosutinib) inhibited Src signaling, resulted in cell cycle arrest and decreased invasion of biliary tract cancer cell lines in culture, and delayed tumor growth in cell line xenograft models (PMID: 27196758).	27196758
SRC	SRC positive	biliary tract cancer	sensitive	Bosutinib + Cisplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Bosulif (bosutinib) and Platinol (cisplatin) synergistically inhibited Src signaling, decreased proliferation and migration of billary tract cancer cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27196758).	27196758
SRC	SRC positive	triple-receptor negative breast cancer	sensitive	KX2-391	Preclinical - Cell line xenograft	Actionable	In a preclinical study, KX2-392 inhibited Src signaling and proliferation in triple-receptor negative breast cancer cell lines in culture, and suppressed tumor growth in xenograft models (PMID: 22784709).	22784709
SRC	SRC positive	triple-receptor negative breast cancer	sensitive	BIRB-796 + Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, BIRB-796 in combination with Sprycel (dasatinib) resulted in improved growth inhibition in both 2D and 3D cultures of triple-receptor negative breast cancer cell lines with elevated Src activity compared to single agent treatment (PMID: 27154914).	27154914
SRC	SRC positive	lung non-small cell carcinoma	predicted - sensitive	AC-93253 iodide	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AC-93253 iodide reduced the expression and phosphorylation of Src in non-small cell lung carcinoma cells, which led to antitumor activity, including decreased cell proliferation, cell migration, cell invasion, and colony formation in culture and inhibition of tumor growth in cell line xenograft models (PMID: 29132432).	29132432
SRC	EML4-ALK SRC pos	lung cancer	resistant	Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Xalkori (crizotinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).	detail...
SRC	EML4-ALK SRC pos	lung cancer	sensitive	Repotrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, TPX-0005 inhibited Alk and Src signaling, and cell proliferation in lung cancer cell lines harboring EML4-ALK and elevated Src activity in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).	detail...
SRC	EML4-ALK SRC pos	Advanced Solid Tumor	resistant	Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Zykadia (ceritinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).	detail...
SRC	ALK rearrange SRC pos	lung non-small cell carcinoma	sensitive	Ceritinib + Saracatinib	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of Saracatinib (AZD0530) and Zykadia (ceritinib) demonstrated efficacy in non-small cell lung cancer patient derived cells harboring an ALK fusion and upregulation of SRC in culture (PMID: 25394791).	25394791
SRC	IDH1 R132C SRC T341I	intrahepatic cholangiocarcinoma	resistant	Dasatinib	Preclinical - Cell culture	Actionable	In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S acquired resistance to Sprycel (dasatinib) after over expressing SRC T341I in culture (PMID: 27231123).	27231123
SRC	ERBB2 amp SRC E527K	gastroesophageal junction adenocarcinoma	sensitive	Lapatinib + Saracatinib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Tykerb (lapatinib) and Saracatinib (AZD0530) inhibited growth of ERBB2 (HER2)-amplified gastroesophageal adenocarcinoma cells harboring SRC E527K in culture (PMID: 25350844).	25350844
SRC	ERBB2 amp SRC E527K	gastroesophageal junction adenocarcinoma	resistant	Lapatinib	Preclinical - Cell culture	Actionable	In a preclinical study, an ERBB2 (HER2)-amplified gastroesophageal cancer cell line initially sensitive to treatment with Tykerb (lapatinib) in culture developed resistance and was subsequently found to have acquired a secondary drug resistant mutation, SRC E527K (PMID: 25350844).	25350844
SRC	SRC over exp	clear cell renal cell carcinoma	no benefit	Cediranib + Saracatinib	Phase II	Actionable	In a Phase II clinical trial, baseline expression of SRC was not predictive for response to Saracatinib (AZD0530) and Recentin (cediranib) relative to Recentin (cediranib) in patients with metastatic clear-cell renal cell carcinoma (PMID: 26802156).	26802156
SRC	ERBB2 over exp PIK3CA H1047R SRC over exp	urinary bladder cancer	no benefit	Ponatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Iclusig (ponatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with SRC over expression, which also over expressed ERBB2 (HER2) and harbored PIK3CA H1047R (PMID: 26270481).	26270481
SRC	ERBB2 over exp PIK3CA H1047R SRC over exp	urinary bladder cancer	no benefit	Lapatinib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481).	26270481
SRC	SRC amp	lung non-small cell carcinoma	sensitive	Derazantinib	Case Reports/Case Series	Actionable	In a Phase I trial, Derazantinib (ARQ 087) treatment resulted in 25% tumor reduction and stable disease for 36 weeks in a squamous non-small cell lung carcinoma patient harboring SRC amplification (PMID: 28972963; NCT01752920).	28972963 detail...
SRC	ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of SRC, ERBB2 (HER2), STK11, and NOTCH1 (PMID: 29636358).	29636358
SRSF2	SRSF2 mutant	acute myeloid leukemia	predicted - sensitive	CG-806	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived acute myeloid leukemia cells harboring SRSF2 mutations were sensitive to CG-806 in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1323).	detail...
SRSF2	SRSF2 mutant	polycythemia vera	not applicable	N/A	Guideline	Prognostic	SRSF2 mutations are associated with inferior overall survival in patients with polycythemia vera (NCCN.org).	detail...
SRSF2	SRSF2 mutant	myelodysplastic syndrome	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, SRSF2 mutations were associated with shortened survival in patients with myelodysplastic syndrome (PMID: 26769228, PMID: 26508027).	26508027 26769228
SRSF2	SRSF2 mutant	myelofibrosis	not applicable	N/A	Guideline	Prognostic	SRSF2 mutations are associated with inferior overall survival and leukemia-free survival in patients with myelofibrosis (NCCN.org).	detail...
SRSF2	KMT2A-MLLT3 SRSF2 P95H	acute myeloid leukemia	sensitive	H3B-8800	Preclinical	Actionable	In a preclinical study, H3B-8800 inhibited tumor growth in transplant animal models of mouse acute myeloid leukemia cells harboring SRSF2 P95H and KMT2A-MLLT3 (MLL-AF9) while had no effect in SRSF2 wild-type controls (Blood 2016 128:966).	detail...
SRSF2	SRSF2 P95X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	SRSF2 P95X is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
STAG2	STAG2 negative	osteosarcoma	predicted - resistant	Cisplatin	Preclinical - Cell culture	Actionable	In a preclinical study, osteosarcoma cells with Stag2 deficiency were resistant to treatment with Platinol (cisplatin) in culture, demonstrating decreased apoptotic activity and increased cell viability compared to wild-type Stag2 (PMID: 31157248).	31157248
STAG2	STAG2 S653*	glioblastoma multiforme	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 S653*, PMID: 21852505) demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817).	21852505 24356817
STAG2	STAG2 S653*	glioblastoma multiforme	sensitive	Camptothecin	Preclinical - Cell culture	Actionable	In a preclinical study, glioblastoma cells harboring a STAG2 mutation (reported as STAG2 S653*, PMID: 21852505) demonstrated increased sensitivity to the combination of Lynparza (olaparib) and camptothecin compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817).	24356817 21852505
STAG2	STAG2 dec exp	colorectal cancer	sensitive	Olaparib	Preclinical	Actionable	In a preclinical study, colorectal cancer cells with knockdown of STAG2 expression demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture (PMID: 24356817).	24356817
STAG2	BRAF mut STAG2 dec exp	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).	27500726
STAG2	BRAF mut STAG2 dec exp	melanoma	decreased response	Dabrafenib + Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment in culture (PMID: 27500726).	27500726
STAG2	BRAF mut STAG2 dec exp	melanoma	decreased response	Dabrafenib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726).	27500726
STAG2	BRAF mut STAG2 dec exp	melanoma	decreased response	Vemurafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) both in culture and in cell line xenograft models (PMID: 27500726).	27500726
STAG2	NRAS mut STAG2 dec exp	melanoma	decreased response	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in NRAS mutated melanoma cell lines resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).	27500726
STAG2	STAG2 N357fs	glioblastoma multiforme	sensitive	Rucaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505), demonstrated increased sensitivity to treatment with Rubraca (rucaparib) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817).	21852505 24356817
STAG2	STAG2 N357fs	glioblastoma multiforme	sensitive	Olaparib + Temozolomide	Preclinical - Cell culture	Actionable	In a preclinical study, glioblastoma cells harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to the combination of Lynparza (olaparib) and Temodar (temozolomide) compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817).	21852505 24356817
STAG2	STAG2 N357fs	glioblastoma multiforme	sensitive	Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture, resulting in decreased proliferation and colony formation, and increased DNA damage compared to isogenic cells with wild-type STAG2 (PMID: 24356817).	21852505 24356817
STAG2	STAG2 N357fs	glioblastoma multiforme	sensitive	Camptothecin + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, glioblastoma cells harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to the combination of Lynparza (olaparib) and camptothecin compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817).	21852505 24356817
STAG2	STAG2 N357fs	glioblastoma multiforme	sensitive	Veliparib	Preclinical - Cell culture	Actionable	In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to treatment with Veliparib (ABT-888) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817).	21852505 24356817
STAG2	STAG2 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	STAG2 mutations are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
STK11	STK11 F298L	pituitary carcinoma	predicted - sensitive	Everolimus + Radiotherapy	Case Reports/Case Series	Actionable	In a clinical case study, a patient with adenocorticotropic pituitary carcinoma harboring an STK11 inactivating mutation demonstrated clinical efficacy for greater than 6 months when treated with a combination of Afinitor (everolimus) and radiotherapy (PMID: 27615706).	27615706
STK11	STK11 E57fs	lung non-small cell carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 E57fs, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).	27821489
STK11	STK11 wild-type	Advanced Solid Tumor	sensitive	Metformin	Preclinical - Cell culture	Actionable	In a preclinical studies, Glucophage (metformin) inhibited cancer cell growth by activating the AMP kinase pathway in a variety of cancer cell lines that retained one functional allele of STK11 (PMID: 17062558, PMID: 18006825).	18006825 17062558
STK11	EGFR wild-type STK11 wild-type TP53 mut	lung non-small cell carcinoma	predicted - sensitive	Pembrolizumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, a genomic profile consisted of mutant TP53, wild-type STK11 and EGFR is associated with increased PD-L1 expression and improved progression-free survival in Keytruda (pembrolizumab)-treated non-small cell lung cancer patients (PMID: 29764856).	29764856
STK11	EGFR wild-type STK11 wild-type TP53 mut	lung non-small cell carcinoma	predicted - sensitive	Nivolumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, a genomic profile consisted of mutant TP53, wild-type STK11 and EGFR is associated with increased PD-L1 expression and improved progression-free survival in Opdivo (nivolumab)-treated non-small cell lung cancer patients compared to STK11 or EGFR-mutant cohorts (p=0.03) (PMID: 29764856).	29764856
STK11	STK11 inact mut	endometrial cancer	sensitive	Sirolimus	Preclinical	Actionable	In a preclinical study, Rapamune (sirolimus) reduced S6K phosphorylation and inhibited tumor growth in mouse models of STK11 (LKB1)-deficient endometrial cancer, including models with advanced tumors (PMID: 20142330).	20142330
STK11	STK11 inact mut	Advanced Solid Tumor	sensitive	CI-1040	Preclinical - Cell culture	Actionable	In a preclinical study, the presence an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to CI-1040 (PD184352) in human tumor cell lines in culture (PMID: 27821489).	27821489
STK11	STK11 inact mut	lung non-small cell carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).	27821489
STK11	STK11 inact mut	Advanced Solid Tumor	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, the presence of an STK11 loss expression signature, which correlated to STK11 inactivating mutations, was associated with increased sensitivity to Mekinist (trametinib) in human tumor cell lines in culture (PMID: 27821489).	27821489
STK11	STK11 inact mut	Advanced Solid Tumor	sensitive	RDEA119	Preclinical - Cell culture	Actionable	In a preclinical study, the presence of an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to RDEA119 in human tumor cell lines in culture (PMID: 27821489).	27821489
STK11	STK11 inact mut	Advanced Solid Tumor	sensitive	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, the presence of an STK11 inactivating mutation and STK11 loss expression signature was associated with increased sensitivity to Selumetinib (AZD6244) in human tumor cell lines in culture (PMID: 27821489).	27821489
STK11	STK11 inact mut	Advanced Solid Tumor	sensitive	PD-0325901	Preclinical - Cell culture	Actionable	In a preclinical study, the presence of an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to PD-0325901 in human tumor cell lines in culture (PMID: 27821489).	27821489
STK11	STK11 K48fs	lung non-small cell carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 K48fs, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).	27821489
STK11	STK11 loss	Advanced Solid Tumor	no benefit	Metformin	Preclinical - Cell culture	Actionable	In a preclinical study, Glucophage (metformin) was unable to inhibit cancer cell growth in cancer cell lines with biallelic loss of STK11 (PMID: 17062558, PMID: 18006825).	18006825 17062558
STK11	STK11 loss	lung cancer	resistant	unspecified PD-1 antibody	Preclinical	Actionable	In a preclinical study, PD-1 antibodies were ineffective in treating Stk11 (also known as Lkb1) deficient lung tumors in mice (PMID: 26833127).	26833127
STK11	PTEN loss STK11 loss	endometrial cancer	sensitive	Pictilisib	Preclinical	Actionable	In a preclinical study, the PI3K inhibitor GDC-0941 reduced tumor growth rate in immunodeficient mice engrafted with endometrial tumors from PTEN/STK11 (LKB1) deficient mice (PMID: 24322983).	24322983
STK11	ERBB2 act mut STK11 loss	breast cancer	sensitive	AZD8055	Preclinical	Actionable	In a preclinical study, AZD8055 inhibited tumor growth in a mouse model of spontaneous breast cancer harboring an ERBB2 (HER2) activating mutation and loss of STK11 (LKB1), which was enhanced by the addition of 2-DG (2-deoxyglucose) (PMID: 25436981).	25436981
STK11	STK11 D194E STK11 loss	pancreatic cancer	predicted - sensitive	Everolimus	Case Reports/Case Series	Actionable	In a clinical case study, a pancreatic cancer patient with Peutz-Jeghers syndrome harboring STK11 D194E and loss of heterozygosity of the other STK11 allele in the tumor achieved a partial response following treatment with Afinitor (everolimus), but progressed after 9 months (PMID: 21189378).	21189378
STK11	ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of SRC, ERBB2 (HER2), STK11, and NOTCH1 (PMID: 29636358).	29636358
STK11	STK11 W332*	lung non-small cell carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 W332*, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).	27821489
STK11	STK11 dec exp	lung non-small cell carcinoma	sensitive	Trametinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, knockdown of STK11 increased sensitivity to Mekinist (trametinib) in non-small cell lung cancer cell lines in culture and in xenograft models (PMID: 27821489).	27821489
STK11	STK11 Q37*	lung non-small cell carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 Q37*, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).	27821489
STK11	STK11 F354L	triple-receptor negative breast cancer	predicted - sensitive	Everolimus + Exemestane	Case Reports/Case Series	Actionable	In a clinical case study, Afinitor (everolimus) in combination with Aromasin (exemestane) resulted in complete response ongoing for 14 months in a patient with metastatic triple-receptor negative breast cancer harboring STK11 F354L (PMID: 28550065).	28550065
STK11	STK11 E199*	lung non-small cell carcinoma	sensitive	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 E199*, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).	27821489
STK11	STK11 mutant	stomach cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in STK11 result in Peutz Jeghers syndrome, which is associated with increased risk of developing gastric cancer (NCCN.org).	detail...
STK11	STK11 mutant	lung non-small cell carcinoma	decreased response	unspecified PD-L1 antibody	Clinical Study - Cohort	Actionable	In a clinical study, mutant STK11 correlated with a worse outcome with immune checkpoint inhibitor treatment compared to wild-type STK11 in non-small cell lung cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #1138PD).	detail...
STK11	STK11 mutant	pancreatic cancer	not applicable	N/A	Guideline	Risk Factor	Germline mutations in STK11 result in Peutz Jeghers syndrome, which is associated with increased risk of developing pancreatic cancer (NCCN.org).	detail...
STK11	STK11 mutant	lung non-small cell carcinoma	decreased response	unspecified PD-1 antibody	Clinical Study - Cohort	Actionable	In a clinical study, mutant STK11 correlated with a worse outcome with immune checkpoint inhibitor treatment compared to wild-type STK11 in non-small cell lung cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #1138PD).	detail...
STK11	STK11 mutant	small intestine adenocarcinoma	sensitive	N/A	Guideline	Actionable	Peutz-Jeghers syndrome often results from mutations in the STK11 gene, and is associated with increased risk of developing small bowel adenocarcinoma (NCCN.org).	detail...
STK11	STK11 mutant	lung non-small cell carcinoma	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PF-05212384) inhibited growth of human non-small cell lung carcinoma cells harboring an STK11 mutation in culture (PMID: 21325073).	21325073
TET2	TET2 mutant	acute myeloid leukemia	not applicable	N/A	Clinical Study	Prognostic	In multiple clinical studies, including a meta-analysis, TET2 mutations were associated with shorter overall survival in patients with acute myeloid leukemia (PMID: 24524305, PMID: 25412851, PMID: 24994606).	24524305 25412851 24994606
TET2	TET2 mutant	acute myeloid leukemia	predicted - sensitive	Azacitidine	Phase I	Actionable	In a retrospective analysis, presence of a TET2 mutation correlated with higher overall response rate (ORR) in patients with myelodysplastic syndrome and acute myeloid leukemia following treatment with Vidaza (azacitidine), with an ORR of 85% (11/3) in TET2-mutated patients, compared to 47% (34/47) in patients with wild-type TET2, but did not correlate with overall survival (PMID: 21494260).	21494260
TET2	TET2 mutant	angioimmunoblastic T-cell lymphoma	not applicable	N/A	Guideline	Diagnostic	TET2 mutations aid in the diagnosis of angioimmunoblastic T-cell lymphoma (NCCN.org).	detail...
TET2	ASXL1 wild-type TET2 mutant	myelodysplastic/myeloproliferative neoplasm	sensitive	Azacitidine	Clinical Study - Cohort	Actionable	In a clinical study, myelodysplastic syndrome patients carrying TET2 mutations and wild-type ASXL1 demonstrated an increased response to treatment with the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) compared to patients with other mutational profiles (65% vs. 44%; OR 2.37, P=0.49) (PMID: 25224413).	25224413
TET2	ASXL1 wild-type TET2 mutant	myelodysplastic/myeloproliferative neoplasm	sensitive	Decitabine	Clinical Study - Cohort	Actionable	In a clinical study, myelodysplastic syndrome patients carrying TET2 mutations and wild-type ASXL1 demonstrated an increased response to treatment with the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) compared to patients with other mutational profiles (65% vs. 44%; OR 2.37, P=0.49) (PMID: 25224413).	25224413
TP53	TP53 R249S	hepatocellular carcinoma	sensitive	CP-31398	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with CP-31398 resulted in decreased proliferation, increased apoptosis, and cell-cycle arrest in a hepatocellular carcinoma cell line harboring TP53 R249S in culture, and inhibited tumor growth in xenograft models (PMID: 26250460).	26250460
TP53	TP53 V173M	acute myeloid leukemia	predicted - sensitive	APR-246	Phase I	Actionable	In a Phase I clinical trial, APR-246 demonstrated safety and preliminary clinical activity in patients with hematological cancers, including an acute myeloid leukemia patient harboring TP53 V173M that achieved a decrease in bone marrow blast percentage from 46% to 26% (PMID: 22965953).	22965953
TP53	ERBB2 amp TP53 R158H	gastric adenocarcinoma	predicted - resistant	AMG 337	Clinical Study	Actionable	In a clinical case study, a patient with gastric adenocarcinoma containing amplification of ERBB2 (HER2) and a TP53 R158H mutation progressed and developed metastases while being treated with AMG 337 (PMID: 26432108).	26432108
TP53	TP53 P223L TP53 V274F	prostate cancer	resistant	Ganetespib	Preclinical	Actionable	In a preclinical study, Ganetespib inhibited growth of human prostate cancer cells harboring TP53 P223L and V274F in culture (PMID: 26009011).	26009011
TP53	TP53 del	ovarian cancer	no benefit	Nutlin-3	Preclinical	Actionable	In a preclinical study, treatment with Nutlin-3 had little effect on growth of ovarian cancer cells with deletion of TP53 in culture (PMID: 25964101).	25964101
TP53	TP53 del	colorectal cancer	decreased response	Tanespimycin	Preclinical	Actionable	In a preclincal study, Tanespimycin (17-AAG) treatment of mutagen induced colorectal cancer in a genetic mouse model with biallelic loss of TP53 was less effective than treatment of mice bearing a single allele with a TP53 R248Q mutation (PMID: 30107178).	30107178
TP53	TP53 del	ovarian cancer	sensitive	Cisplatin + Nutlin-3	Preclinical	Actionable	In a preclinical study, Nutlin-3 and cisplatin worked cooperatively to induce apoptosis and decrease growth of ovarian cancer cells with TP53 deletion in culture (PMID: 25964101).	25964101
TP53	TP53 del	ovarian clear cell carcinoma	predicted - sensitive	thioureidobutyronitrile	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment resulted in Tp53-independent increase of Cdkn1a expression and apoptosis of ovarian clear cell carcinoma cells harboring TP53 deletion in culture and in cell line xenograft models (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221).	detail...
TP53	TP53 del	colorectal cancer	predicted - sensitive	Doxorubicin + Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, sequential administration of Roscovotine (seliciclib) followed by Adriamycin (doxorubicin) synergistically induced apoptosis in TP53-null colorectal cancer cells in culture (PMID: 26826118).	26826118
TP53	TP53 del	colorectal cancer	predicted - sensitive	TC-A2317	Preclinical - Cell culture	Actionable	In a preclinical study, MK-8745 treatment resulted in polyploidy in TP53-null colorectal cancer cells in culture (PMID: 22293494).	22293494
TP53	TP53 del	ovarian cancer	sensitive	Etoposide + Nutlin-3	Preclinical	Actionable	In a preclinical study, Nutlin-3 and etoposide worked cooperatively to induce apoptosis and decrease growth of ovarian cancer cells with TP53 deletion in culture (PMID: 25964101).	25964101
TP53	MET amp TP53 del	breast cancer	sensitive	Crizotinib	Preclinical	Actionable	In a preclinical study, Xalkori (crizotinib) treatment resulted in complete tumor regression in transplant models of TP53-null-luminal breast cancer harboring MET amplification (PMID: 27149990).	27149990
TP53	TP53 R248W	lung non-small cell carcinoma	sensitive	APR-246 + Cisplatin	Preclinical	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of non-small lung cancer cells harboring TP53 R248W in culture (PMID: 26086967).	26086967
TP53	TP53 R248W VHL inact mut	clear cell renal cell carcinoma	resistant	PT2399	Preclinical - Cell culture	Actionable	In a preclinical study, TP53 R248W was associated with resistance to PT2399 in VHL-defective clear cell renal cell carcinoma cell lines in culture (PMID: 27595393).	27595393
TP53	RB1 K240Sfs*22 TP53 R248W	Her2-receptor negative breast cancer	predicted - resistant	Fulvestrant + Palbociclib	Case Reports/Case Series	Actionable	In a clinical case study, RB1 K240Sfs*22 and TP53 R248W were identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 5 months of Ibrance (palbociclib) and Faslodex (fulvestrant) combination treatment (PMID: 29236940).	29236940
TP53	EGFR T790M EGFR L858R EGFR A871G TP53 R248W RB1 K844S	lung non-small cell carcinoma	predicted - sensitive	Erlotinib	Case Reports/Case Series	Actionable	In a clinical case study, Tarceva (erlotinib) treatment resulted in gradual tumor reduction and improved quality of life lasted for 1.5 years in a patient with metastatic non-small cell lung cancer harboring EGFR T790M, L858R, and A871G, TP53 R248W, and RB1 K844S (PMID: 31045832).	31045832
TP53	TP53 P72R	lung non-small cell carcinoma	sensitive	Cisplatin + Irinotecan	Phase I	Actionable	In phase I clinical studies, NSCLC patients with TP53 P72R mutations had a longer progression-free survival than wild-type TP53 patients, after combined treatment with Camptosar (irinotecan) and Platinol (cisplatin) (PMID: 18618574).	18618574
TP53	TP53 P72R	breast cancer	predicted - sensitive	Daunoxome	Phase I	Actionable	In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804).	16243804
TP53	TP53 P72R	estrogen-receptor negative breast cancer	sensitive	Cyclophosphamide + Doxorubicin + Fluorouracil	Phase I	Actionable	In a Phase I clinical trial, breast cancer patients harboring TP53 P72R who were estrogen receptor negative had a more favorable response to Doxil (doxorubicin) in combination with Adrucil (fluorouracil) and Cytoxan (cyclophosphamide) (PMID: 16243804).	16243804
TP53	TP53 P72R	breast cancer	sensitive	Epirubicin	Phase I	Actionable	In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations, who were also hormone receptor negative, demonstrated a favorable response to Ellence (epirubicin) in combination with other chemotherapeutic agents (PMID: 22903472).	22903472
TP53	TP53 P72R	sarcoma	sensitive	Doxorubicin + Ifosfamide	Phase I	Actionable	In a Phase I clinical trial, sarcoma patients harboring TP53 P72R mutations had longer progression-free survival after treatment with Cyfos (ifosfamide) and Adriamycin (doxorubicin) (PMID: 23165797).	23165797
TP53	TP53 P72R	breast cancer	predicted - sensitive	Daunorubicin	Phase I	Actionable	In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804).	16243804
TP53	TP53 P72R	breast cancer	predicted - sensitive	Pegylated liposomal-doxorubicin	Phase I	Actionable	In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804).	16243804
TP53	TP53 P72R TP53 Y220C	breast cancer	no benefit	Cyclophosphamide + Epirubicin	Phase I	Actionable	In a Phase I clinical trial, a breast cancer patient carrying TP53 P72R and Y220C mutations demonstrated incomplete response to treatment with an Ellence (epirubicin)-Cytoxan (cyclophosphamide) combination regimen (PMID: 17388661).	17388661
TP53	MET del exon14 TP53 N30fs	lung large cell carcinoma	predicted - sensitive	Capmatinib	Case Reports/Case Series	Actionable	In a clinical case study, Capmatinib (INC280) treatment resulted in decreased tumor volume by 53% in a patient with large cell lung carcinoma harboring MET exon 14 skipping and TP53 N30fs*14 (PMID: 25971938).	25971938
TP53	TP53 E258Q	osteosarcoma	resistant	Nutlin-3	Preclinical	Actionable	In a preclinical study, TP53 E258Q resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).	21643018
TP53	TP53 Y163H	ovarian cancer	sensitive	APR-246 + Cisplatin	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 Y163H in culture (PMID: 27179933).	27179933
TP53	TP53 P177T	osteosarcoma	resistant	Nutlin-3	Preclinical	Actionable	In a preclinical study, TP53 P177T resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).	21643018
TP53	ALK wild-type TP53 P177T	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 P177T in culture (PMID: 26438783).	26438783
TP53	PIK3CA H1047R TP53 S90fs	ovarian clear cell adenocarcinoma	decreased response	DS-7423	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA H1047R and TP53 S90fs*33 demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419).	24504419
TP53	TP53 C135Y	peritoneum cancer	sensitive	APR-246 + Cisplatin	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived peritoneum cancer cells harboring TP53 C135Y in culture (PMID: 27179933).	27179933
TP53	TP53 P98fs TP53 R175C TP53 S215G	ovarian cancer	predicted - resistant	Adavosertib + Carboplatin	Phase II	Actionable	In a Phase II trial, Paraplatin (carboplatin) and Adavosertib (MK-1775) combination treatment resulted in disease progression in an ovarian cancer patient harboring TP53 P98fs, R175C, and S215G (PMID: 27998224).	27998224
TP53	TP53 R248Q	colorectal cancer	sensitive	Tanespimycin	Preclinical	Actionable	In a preclincal study, Tanespimycin (17-AAG) treatment reduced p-Stat3 expression, induced apoptosis, and inhibited tumor growth of mutagen induced colorectal cancer in a genetic mouse model expressing TP53 R248Q (PMID: 30107178).	30107178
TP53	TP53 R248Q	ovarian cancer	sensitive	ReACp53	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, ReACp53 rescued p53 activity and decreased viability of ovarian cancer cells harboring TP53 R248Q in culture, and induced tumor regression in patient-derived ovarian cancer xenograft models harboring TP53 R248Q (PMID: 26748848).	26748848
TP53	TP53 R248Q	ovarian cancer	sensitive	APR-246 + Cisplatin	Preclinical	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of a Platinol (cisplatin)-resistant ovarian cancer cell line harboring TP53 R248Q in culture and inhibited tumor growth in TP53 R248Q-carrying ovarian cancer cell line xenograft models (PMID: 26086967).	26086967
TP53	TP53 R248Q	colorectal cancer	predicted - sensitive	Napabucasin	Preclinical - Cell culture	Actionable	In a preclinical study, Napabucasin (BBI608) treatment reduced Stat3 phosphorylation and impaired wound healing in colorectal cancer cell lines expressing TP53 R248Q in culture (PMID: 30107178).	30107178
TP53	TP53 R248Q	Advanced Solid Tumor	sensitive	Ganetespib	Preclinical	Actionable	In a preclinical study, Ganetespib extended survival by 48% in mice with tumors expressing TP53 R248Q (PMID: 26009011).	26009011
TP53	TP53 R248Q	acute myeloid leukemia	resistant	ALRN-6924	Preclinical - Cell culture	Actionable	In a preclinical study, ALRN-6924 did not inhibit the growth of acute myeloid leukemia cells harboring TP53 R248Q in culture (PMID: 29643228).	29643228
TP53	TP53 I195* TP53 R248Q	ovarian carcinoma	sensitive	ReACp53	Preclinical	Actionable	In a preclinical study, ReACp53 induced cell death and decreased proliferation of human primary ovarian carcinoma cells harboring both TP53 I195* and TP53 R248Q in culture (PMID: 26748848).	26748848
TP53	ALK wild-type TP53 C176F	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 C176F in culture (PMID: 26438783).	26438783
TP53	TP53 R175H	colorectal cancer	sensitive	NSC59984	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with NSC59984 resulted in increased degradation of mutant Tp53 and cell death in a colorectal cancer cell line harboring TP53 R175H in culture (PMID: 26294215).	26294215
TP53	TP53 R175H	head and neck cancer	sensitive	ReACp53	Preclinical	Actionable	In a preclinical study, ReACp53 induced cell death and decreased proliferation of head and neck carcinoma cells harboring TP53 R175H in culture (PMID: 26748848).	26748848
TP53	TP53 R175H	breast cancer	sensitive	NSC319726	Preclinical - Cell culture	Actionable	In a preclinical study, breast cancer cells harboring TP53 R175H demonstrated increased sensitivity to NSC319726 in culture (PMID: 22624712).	22624712
TP53	TP53 R175H	breast cancer	sensitive	Ganetespib	Preclinical - Cell culture	Actionable	In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 R175H in culture (PMID: 26009011).	26009011
TP53	TP53 R175H	Advanced Solid Tumor	sensitive	ReACp53	Preclinical	Actionable	In a preclinical study, treatment with ReACp53 induced cell death in primary human uterine fibroblasts expressing TP53 R175H in culture (PMID: 26748848).	26748848
TP53	TP53 R175H	ovarian clear cell adenocarcinoma	decreased response	DS-7423	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring TP53 S241F demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419).	24504419
TP53	TP53 R175H	lung non-small cell carcinoma	resistant	Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 R175H were resistant to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).	22862161
TP53	TP53 R175H	ovarian cancer	sensitive	NSC319726	Preclinical - Cell culture	Actionable	In a preclinical study, ovarian cancer cells harboring TP53 R175H demonstrated increased sensitivity to NSC319726-induced growth inhibition in culture and in cell line xenograft models (PMID: 22624712).	22624712
TP53	TP53 R175H	Advanced Solid Tumor	sensitive	Alvespimycin + Vorinostat	Preclinical	Actionable	In a preclinical study, Alvespimycin (17-DMAG) and Zolinza (vorinostat) extended survival by 59% in mice with tumors expressing Tp53 R172H (which corresponds to R175H in the human Tp53 protein) (PMID: 26009011).	26009011
TP53	MET del exon14 TP53 R175H	histiocytic and dendritic cell cancer	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, Xalkori (crizotinib) treatment resulted in a decrease in tumor volume by more than 60% in a patient with histiocytic sarcoma harboring MET exon 14 skipping and TP53 R175H (PMID: 25971938).	25971938
TP53	EGFR mut TP53 exon 8	lung non-small cell carcinoma	decreased response	unspecified EGFR tyrosine kinase inhibitor	Clinical Study - Cohort	Actionable	In a clinical study, EGFR-mutant non-small cell lung cancer patients with TP53 exon 8 mutations demonstrated decreased disease control rate (42%, 5/12 vs 87%, 97/111), shorter median progression-free survival (4.2 vs 12.5 mo) and median overall survival (16.2 vs 32.3 mo) with first-line EGFR tyrosine kinase inhibitor treatment (such as Iressa (gefitinib), Tarceva (erlotinib), Gilotrif (afatinib), or Vizimpro (dacomitinib)), compared to TP53 exon 8 wild-type patients (PMID: 27780855).	27780855
TP53	TP53 A159V	lung non-small cell carcinoma	decreased response	Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 A159V demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).	22862161
TP53	TP53 R280K	ovarian cancer	sensitive	APR-246 + Cisplatin	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically in culture, resulting in reduced cell viability in patient derived ovarian cancer cells harboring TP53 R280K (PMID: 27179933).	27179933
TP53	TP53 R280K	breast cancer	sensitive	Ganetespib	Preclinical	Actionable	In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 R280K in culture (PMID: 26009011).	26009011
TP53	TP53 R280K	triple-receptor negative breast cancer	sensitive	YW3-56	Preclinical - Cell line xenograft	Actionable	In a preclinical study, YW3-56 inhibited proliferation of a human triple-negative breast cancer (TNBC) cell line harboring TP53 R280K in culture and inhibited tumor growth in TP53 R280K-mutant TNBC cell line xenograft models (PMID: 25612620).	25612620
TP53	TP53 Y163C	lung small cell carcinoma	sensitive	APR-246 + Cisplatin	Preclinical	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of small lung cancer cells harboring TP53 Y163C in culture (PMID: 26086967).	26086967
TP53	TP53 mutant	acute myeloid leukemia	predicted - sensitive	CG-806	Preclinical - Patient cell culture	Actionable	In a preclinical study, patient-derived acute myeloid leukemia cells harboring TP53 mutations were sensitive to CG-806 in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1323).	detail...
TP53	TP53 mutant	CLL/SLL	sensitive	Rituximab + Venetoclax	Guideline	Actionable	Venclexta (venetoclax) combined with Rituxan (rituximab) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).	detail...
TP53	TP53 mutant	head and neck squamous cell carcinoma	sensitive	AZD7762 + Cisplatin	Preclinical	Actionable	In a preclinical study, the treatment of a head and neck squamous cell carcinoma cell line with mutant TP53 (C176F and A161S) with AZD7762, a pan Chk1/2 inhibitor, sensitizes the cells to Platinol (cisplatin) (PMID: 23839309).	23839309
TP53	TP53 mutant	ovarian clear cell adenocarcinoma	decreased response	DS-7423	Preclinical	Actionable	In a preclinical study, ovarian clear cell adenocarcinoma cell lines harboring TP53 mutations demonstrated reduced sensitivity to DS-7423 induced apoptosis in culture compared to TP53 wild-type cells (PMID: 24504419).	24504419
TP53	TP53 mutant	neuroblastoma	resistant	Nutlin-3	Preclinical	Actionable	In a preclinical study, neuroblastoma cell lines harboring TP53 mutant were resistant to nutlin-3 mediated growth inhibition (PMID: 21725357).	21725357
TP53	TP53 mutant	colorectal cancer	sensitive	Pazopanib + Vorinostat	Phase I	Actionable	In a Phase I trial, the combination of Votrient (pazopanib) and Zolinza (vorinostat) resulted in improved progression-free survival and overall survival in metastatic sarcoma and colorectal cancer patients harboring TP53 hotspot mutations, and resulted in a stable disease rate of 83% (5/6), compared to a stable disease rate of 9% (1/11) in patients without detected TP53 mutations (PMID: 25669829).	25669829
TP53	TP53 mutant	Advanced Solid Tumor	sensitive	Adavosertib	Phase I	Actionable	In a retrospective analysis of a Phase I trial, Adavosertib (MK-1775) combined with a chemotherapy resulted in a 21% (4/19) response rate in advanced solid tumor patients harboring a TP53 mutation and in those without a TP53 mutation, a 12% (4/33) response rate was observed (PMID: 27601554).	27601554
TP53	TP53 mutant	hypopharynx cancer	predicted - sensitive	unspecified EGFR antibody + unspecified ERBB3 antibody + unspecified IGF-1R antibody	Preclinical - Cell culture	Actionable	In a preclinical study, combination of an unspecified EGFR antibody, an unspecified Erbb3 (Her3) antibody, and an unspecified Igf-1r antibody resulted in potent inhibition of survival in TP53 mutated hypopharyngeal carcinoma cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).	27196767
TP53	TP53 mutant	ovarian cancer	no benefit	Nutlin-3	Preclinical	Actionable	In a preclinical study, treatment with Nutlin-3 had little effect on growth of ovarian cancer cells with TP53 mutations in culture (PMID: 25964101).	25964101
TP53	TP53 mutant	hypopharynx cancer	predicted - sensitive	unspecified EGFR antibody + unspecified ERBB3 antibody	Preclinical - Cell culture	Actionable	In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Erbb3 (Her3) antibody resulted in inhibition of survival in TP53 mutated hypopharyngeal carcinoma cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).	27196767
TP53	TP53 mutant	colorectal cancer	predicted - sensitive	NSC59984	Preclinical - Cell line xenograft	Actionable	In a preclinical study, NSC59984 treatment resulted in increased Tp53 signaling and cell death in colorectal cancer cell lines harboring TP53 mutations, and inhibited tumor growth in TP53-mutant cell line colorectal cancer xenograft models (PMID: 26294215).	26294215
TP53	TP53 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	TP53 mutations except P47S and P72R are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
TP53	TP53 mutant	acute myeloid leukemia	predicted - sensitive	Cytarabine + Venetoclax	Phase Ib/II	Actionable	In a Phase I/II trial, Venclexta (venetoclax) in combination with low-dose cytarabine resulted in complete remission or complete remission with incomplete count recovery in 30% (3/10) of patients with acute myeloid leukemia harboring TP53 mutations who were ineligible for intensive chemotherapy (ASH Annual Meeting, Dec 2018, Abstract 284; NCT02287233).	detail...
TP53	TP53 mutant	acute myeloid leukemia	sensitive	Decitabine	Guideline	Actionable	Dacogen (decitabine) is included in guidelines for adult patients with acute myeloid leukemia harboring a TP53 mutation (NCCN.org).	detail...
TP53	TP53 mutant	hypopharynx cancer	resistant	unspecified EGFR antibody	Preclinical - Cell culture	Actionable	In a preclinical study, combination of two unspecified EGFR antibodies targeting nonoverlapping epitopes of Egfr did not inhibit proliferation of Tp53 mutated hypopharyngeal carcinoma cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).	27196767
TP53	TP53 mutant	tongue squamous cell carcinoma	sensitive	AZD6738 + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a tongue squamous cell carcinoma cell line harboring a TP53 mutation in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704).	28062704
TP53	TP53 mutant	Advanced Solid Tumor	sensitive	Bevacizumab	Clinical Study - Cohort	Actionable	In a retrospective study, Avastin (bevacizumab) treatment was associated with increased progression-free survival in cancer patients carrying TP53 mutations (PMID: 23670029).	23670029
TP53	TP53 mutant	CLL/SLL	sensitive	Ibrutinib	Guideline	Actionable	Imbruvica (ibrutinib) is indicated in the guidelines as first line therapy and relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).	detail...
TP53	TP53 mutant	medulloblastoma	decreased response	JQ1	Preclinical	Actionable	In a preclinical study, medulloblastoma cell lines with TP53 mutations had significantly less sensitivity to the BET inhibitor, JQ1, than cell lines carrying wild-type TP53 (PMID: 24231268).	24231268
TP53	TP53 mutant	lung non-small cell carcinoma	predicted - sensitive	Pembrolizumab	Phase I	Actionable	In a clinical study, a retrospective analysis of a Phase I trial demonstrated non-small cell lung carcinoma (NSCLC) patients harboring either a TP53 mutation (n=15) or KRAS mutation (n=8) had greater progression free survival compared to NSCLC patients harboring wild-type TP53 or KRAS (n=15) (14.5mo vs 14.7mo vs 3.5mo, respectively) when treated with Keytruda (pembrolizumab) (PMID: 28039262).	28039262
TP53	TP53 mutant	lung non-small cell carcinoma	predicted - sensitive	Pembrolizumab	Clinical Study - Cohort	Actionable	In a clinical study, immune checkpoint inhibitor treatment including Keytruda (pembrolizumab) (n=1), Opdivo (nivolumab) with (n=8) or without (n=63) Yervoy (ipilimumab) resulted in improved median overall survival (18.1 vs 8.1 months, HR=0.48, p=0.04), median progression-free survival (4.5 vs 1.4 months, p=0.03), and objective response rate (51.2% vs 20.7%, p=0.01) in TP53 mutant (n=41) non-small cell lung cancer patients compared to TP53 wild-type (n=31) patients (PMID: 31097096).	31097096
TP53	TP53 mutant	lung non-small cell carcinoma	predicted - sensitive	Ipilimumab + Nivolumab	Clinical Study - Cohort	Actionable	In a clinical study, immune checkpoint inhibitor treatment including Keytruda (pembrolizumab) (n=1), Opdivo (nivolumab) with (n=8) or without (n=63) Yervoy (ipilimumab) resulted in improved median overall survival (18.1 vs 8.1 months, HR=0.48, p=0.04), median progression-free survival (4.5 vs 1.4 months, p=0.03), and objective response rate (51.2% vs 20.7%, p=0.01) in TP53 mutant (n=41) non-small cell lung cancer patients compared to TP53 wild-type (n=31) patients (PMID: 31097096).	31097096
TP53	TP53 mutant	leukemia	decreased response	RG7112	Phase I	Actionable	In a Phase I clinical trial, the majority of 19 leukemia patients with identified TP53 mutations did not demonstrate response to treatment with RG7112, with 2 acute myeloid leukemia patients harboring TP53 mutations showing clinical activity, but not improvement, and 1 sCLL/CLL patient achieving stable disease (PMID: 26459177).	26459177
TP53	TP53 mutant	neuroblastoma	resistant	MI-63	Preclinical	Actionable	In a preclinical study, neuroblastoma cell lines harboring TP53 mutant were resistant to MI-63 mediated growth inhibition (PMID: 21725357).	21725357
TP53	TP53 mutant	CLL/SLL	sensitive	Duvelisib	Guideline	Actionable	Copiktra (duvelisib) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).	detail...
TP53	TP53 mutant	glioblastoma multiforme	sensitive	Adavosertib + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Adavosertib (MK-1775) and radiation therapy synergized to inhibit tumor growth in a human glioblastoma multiforme cell line xenograft model harboring mutant TP53 (PMID: 21992793).	21992793
TP53	TP53 mutant	Advanced Solid Tumor	resistant	AMG 232	Preclinical - Cell culture	Actionable	In a preclinical study, AMG 232 did not inhibit growth of human tumor cell lines harboring TP53 mutations in culture (PMID: 25567130).	25567130
TP53	TP53 mutant	triple-receptor negative breast cancer	predicted - sensitive	Carboplatin + Nutlin-3	Preclinical - Cell culture	Actionable	In a preclinical study, Nutlin-3 and Paraplatin (carboplatin) synergistically inhibited growth in TP53 mutated triple-receptor negative breast cancer cell lines in culture and in cell line xenograft models (PMID: 26494859).	26494859
TP53	TP53 mutant	triple-receptor negative breast cancer	predicted - sensitive	Doxorubicin + Seliciclib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, sequential administration of Roscovotine (seliciclib) followed by Adriamycin (doxorubicin) synergistically induced apoptosis in TP53-mutant triple-receptor negative breast cancer cell lines in culture, and inhibited tumor growth, prolonged survival in cell line xenograft models (PMID: 26826118).	26826118
TP53	TP53 mutant	lung non-small cell carcinoma	predicted - sensitive	Nivolumab	Clinical Study - Cohort	Actionable	In a clinical study, immune checkpoint inhibitor treatment including Keytruda (pembrolizumab) (n=1), Opdivo (nivolumab) with (n=8) or without (n=63) Yervoy (ipilimumab) resulted in improved median overall survival (18.1 vs 8.1 months, HR=0.48, p=0.04), median progression-free survival (4.5 vs 1.4 months, p=0.03), and objective response rate (51.2% vs 20.7%, p=0.01) in TP53 mutant (n=41) non-small cell lung cancer patients compared to TP53 wild-type (n=31) patients (PMID: 31097096).	31097096
TP53	TP53 mutant	CLL/SLL	sensitive	Venetoclax	Guideline	Actionable	Venclexta (venetoclax) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).	detail...
TP53	TP53 mutant	ovarian cancer	predicted - sensitive	Adavosertib + Carboplatin	Phase II	Actionable	In a Phase II trial, Paraplatin (carboplatin) and Adavosertib (MK-1775) combination treatment resulted in an overall response rate of 43% (9/21), a median progression-free survival of 5.3 months and a median overall survival of 12.6 months in ovarian cancer patients harboring TP53 mutations (PMID: 27998224).	27998224
TP53	TP53 mutant	sarcoma	predicted - sensitive	GDC-0575 + Gemcitabine	Phase I	Actionable	In a Phase I trial, GDC-0575 and Gemzar (gemcitabine) combination treatment resulted in a prolonged tumor response in 2 soft tissue sarcoma patients harboring TP53 mutations, and no response in a patient with TP53 wild-type tumor (PMID: 29409053; NCT01564251).	29409053
TP53	TP53 mutant	chronic lymphocytic leukemia	predicted - sensitive	Duvelisib	Phase I	Actionable	In a Phase I trial, Copiktra (duvelisib) treatment inhibited Akt phosphorylation, resulted in complete response in 2% (1/49), partial response in 53% (26/49), and stable disease in 43% (21/49) of chronic lymphocytic leukemia patients, of which 49% (23/47) carried TP53 mutations (Blood 124 (21): 3334).	detail...
TP53	TP53 mutant	CLL/SLL	not applicable	N/A	Guideline	Prognostic	TP53 mutations are associated with a poor prognosis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (NCCN.org).	detail...
TP53	TP53 mutant	colorectal cancer	sensitive	Bevacizumab	Phase III	Actionable	In a Phase III trial, Avastin (bevacizumab), in combination with chemotherapy, provided a significant survival benefit in patients with colorectal cancers regardless of mutational status in KRAS, BRAF, and TP53 (PMID: 17145525).	17145525
TP53	TP53 mutant	colorectal cancer	sensitive	Prodigiosin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Prodigiosin inhibited self-renewal of colorectal cancer cell lines harboring TP53 mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 26759239).	26759239
TP53	TP53 mutant	neuroblastoma	resistant	GSK2830371	Preclinical	Actionable	In a preclinical study, neuroblastoma cell lines harboring TP53 mutations were resistant to GSK2830371 induced growth inhibition in culture (PMID: 25658463).	25658463
TP53	TP53 mutant	breast carcinoma	predicted - sensitive	Camptothecin + CHIR-124	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Camptothecin and CHIR-124 demonstrated synergy in TP53-mutant breast carcinoma cell lines in culture, resulting in increased growth inhibition (PMID: 17255282).	17255282
TP53	TP53 mutant	triple-receptor negative breast cancer	predicted - sensitive	GDC-0425 + Gemcitabine	Phase I	Actionable	In a Phase I trial, treatment with GDC-0425 followed by Gemzar (gemcitabine) resulted in a partial response in a patient with triple-receptor negative breast cancer harboring a TP53 mutation (PMID: 27815358).	27815358
TP53	TP53 mutant	sarcoma	sensitive	Pazopanib	Clinical Study - Cohort	Actionable	In a retrospective analysis, advanced sarcoma patients with TP53 mutations displayed improved progression-free survival (208 vs 136 days, p=0.036) relative to patients with wild-type TP53 when treated with Votrient (pazopanib) (PMID: 26646755).	26646755
TP53	TP53 mutant	head and neck squamous cell carcinoma	predicted - sensitive	Buparlisib + Paclitaxel	Phase II	Actionable	In a Phase II (BERIL-1) trial, Buparlisib (BKM120) and Taxol (paclitaxel) combination treatment resulted in improved overall survival (HR=0.52) and prolonged progression-free survival (HR=0.45) in head and neck squamous cell carcinoma patients harboring TP53 mutations compared to TP53 wild-type patients (PMID: 29490986; NCT01852292).	29490986
TP53	TP53 mutant	Advanced Solid Tumor	sensitive	Pazopanib + Vorinostat	Phase I	Actionable	In a Phase I trial, the combination of Votrient (pazopanib) and Zolinza (vorinostat) improved progression-free survival and overall survival in advanced solid tumor patients harboring TP53 hotspot mutations, and resulted in an increased stable disease rate of 45% (5/11), compared to a stable disease rate of 16% (4/25) in patients without detected TP53 mutations (PMID: 25669829).	25669829
TP53	TP53 mutant	Advanced Solid Tumor	sensitive	CTX-1	Preclinical	Actionable	In a preclinical study, CTX-1 induced increased Tp53 protein levels and cell death in human tumor cell lines with mutant Tp53 in culture (PMID: 26883273).	26883273
TP53	TP53 mutant	hypopharynx cancer	predicted - sensitive	unspecified EGFR antibody + unspecified IGF-1R antibody	Preclinical - Cell culture	Actionable	In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Igf-1r antibody resulted in inhibition of survival in TP53 mutated hypopharyngeal carcinoma cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).	27196767
TP53	TP53 mutant	osteosarcoma	not applicable	N/A	Guideline	Risk Factor	Germline mutations in TP53 result in Li-Fraumeni syndrome, which is associated with increased risk of developing osteosarcoma (NCCN.org).	detail...
TP53	TP53 mutant	ovarian cancer	sensitive	Etoposide + Nutlin-3	Preclinical	Actionable	In a preclinical study, Nutlin-3 and etoposide worked cooperatively to induce apoptosis in ovarian cancer cell lines with TP53 inactivating mutations in culture (PMID: 25964101).	25964101
TP53	TP53 mutant	chronic lymphocytic leukemia	predicted - sensitive	Ibrutinib + Venetoclax	Phase II	Actionable	In a Phase II trial, Imbruvica (ibrutinib) and Venclexta (venetoclax) combination therapy resulted in a response rate of 100% (14/14, 9 complete response, 5 partial response) in relapsed or refractory chronic lymphocytic leukemia (CLL) patients, and a response rate of 100% (16/16, 9 complete response, 7 partial response) in untreated patients with high-risk features including del 17p, TP53 mutations, and del 11q (ASH, 59th Annual Meeting and Exposition, Dec 2017, Abstract 429; NCT02756897).	detail...
TP53	TP53 mutant	ovarian serous carcinoma	sensitive	thioureidobutyronitrile	Preclinical - Cell culture	Actionable	In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment decreased mutant Tp53 level, resulted in apoptosis of ovarian serous carcinoma cells harboring TP53 mutations in culture (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221).	detail...
TP53	TP53 mutant	CLL/SLL	sensitive	Acalabrutinib	Guideline	Actionable	Calquence (acalabrutinib) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).	detail...
TP53	TP53 mutant	essential thrombocythemia	not applicable	N/A	Guideline	Prognostic	The presence of at least one mutation in either SH2B3, IDH2, U2AF1, SF3B1, EZH2, or TP53 is associated with inferior overall survival in patients with essential thrombocythemia (NCCN.org).	detail...
TP53	TP53 mutant	essential thrombocythemia	not applicable	N/A	Guideline	Prognostic	TP53 mutations are associated with inferior leukemia-free survival in patients with essential thrombocythemia (NCCN.org).	detail...
TP53	TP53 mutant	Advanced Solid Tumor	sensitive	Unspecified VEGFR inhibitor	Clinical Study - Cohort	Actionable	In a clinical study, VEGF/VEGFR inhibitor treatment resulted in improved rates of response (stable disease over 6 months/partial/complete response, 31% vs 7%), time-to-treatment failure, and overall survival (both p<0.01) compared to control in patients with TP53 mutant advanced solid tumors (n=106), but not in patients with TP53 wild-type tumors (n=82) (PMID: 27466356).	27466356
TP53	TP53 mutant	colorectal cancer	sensitive	PD0166285	Preclinical	Actionable	In a preclinical study, PD0166285 sensitizes colorectal cancer cells with TP53 mutation to radiation induced cell death (PMID: 11719452).	11719452
TP53	TP53 mutant	pharynx squamous cell carcinoma	sensitive	AZD6738 + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a pharynx squamous cell carcinoma cell line harboring a TP53 mutation in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704).	28062704
TP53	TP53 mutant	sarcoma	sensitive	Pazopanib + Vorinostat	Phase I	Actionable	In a Phase I trial, the combination of Votrient (pazopanib) and Zolinza (vorinostat) resulted in improved progression-free survival and overall survival in metastatic sarcoma and colorectal cancer patients harboring TP53 hotspot mutations, and resulted in a stable disease rate of 83% (5/6), compared to a stable disease rate of 9% (1/11) in patients without detected TP53 mutations (PMID: 25669829).	25669829
TP53	TP53 mutant	glioblastoma multiforme	sensitive	AZD1390	Preclinical - Cell culture	Actionable	In a preclinical study, TP53 mutant glioblastoma cells demonstrated increased sensitivity to radiosensitization by AZD1390 treatment compared to TP53 wild-type cells in culture (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104).	detail...
TP53	TP53 mutant	CLL/SLL	sensitive	Obinutuzumab + Venetoclax	Guideline	Actionable	The combination of Venclexta (venetoclax) and Gazyva (obinutuzumab) is indicated in the guidelines as first line therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).	detail...
TP53	TP53 mutant	fibrous histiocytoma	predicted - sensitive	GDC-0575 + Gemcitabine	Preclinical - Pdx	Actionable	In a preclinical study, GDC-0575 and Gemzar (gemcitabine) combination treatment inhibited tumor growth, prolonged progression-free survival in patient-derived xenogrft (PDX) models of undifferentiated pleomorphic sarcoma (fibrous histiocytoma) (PMID: 29409053).	29409053
TP53	TP53 mutant	breast cancer	sensitive	PK11007	Preclinical - Cell culture	Actionable	In a preclinical study, TP53-mutated breast cancer cell lines demonstrated increased sensitivity to PK11007 compared to TP53-wild type cells in culture, regardless of Esr1 and Erbb2 (Her2) status (J Clin Oncol 35, 2017 (suppl; abstr e14099)).	detail...
TP53	TP53 mutant	colon carcinoma	predicted - sensitive	Camptothecin + CHIR-124	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Camptothecin and CHIR-124 demonstrated synergy in TP53-mutant colon carcinoma cell lines in culture, resulting in increased growth inhibition (PMID: 17255282).	17255282
TP53	TP53 mutant	acute myeloid leukemia	not applicable	N/A	Guideline	Prognostic	TP53 mutations are associated with a poor/adverse prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).	detail...
TP53	TP53 mutant	lung non-small cell carcinoma	sensitive	CEP-8983 + Cisplatin	Preclinical	Actionable	In a preclinical study, the combination of CEP-8983 and Platinol (cisplatin) worked synergistically to induce cell death in non-small cell lung cancer cell lines in culture, irrespective of TP53 status (PMID: 23428903).	23428903
TP53	TP53 mutant	glioblastoma multiforme	sensitive	Adavosertib	Preclinical - Pdx	Actionable	In a preclinical study, treatment with Adavosertib (MK-1775) decreased CDK1 phosphorylation and reduced tumor growth in patient-derived xenograft models of glioblastoma multiforme that harbor TP53 mutations (PMID: 27196784).	27196784
TP53	TP53 mutant	CLL/SLL	sensitive	Idelalisib + Rituximab	Guideline	Actionable	Zydelig (idelalisib) combined with Rituxan (rituximab) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).	detail...
TP53	PTEN mutant TP53 mutant	skin cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a skin cancer cell line harboring mutations in PTEN and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).	25261369
TP53	PTEN mutant TP53 mutant	glioblastoma multiforme	sensitive	Navitoclax + ONC201	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of ONC201 (TIC10) and Navitoclax (ABT-263) increased apoptosis and worked synergistically to inhibit proliferation of a glioblastoma cell line harboring mutations in PTEN and TP53 in culture (PMID: 26474387).	26474387
TP53	PTEN mut RB1 mut SMAD4 mut TP53 mut	skin cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369).	25261369
TP53	APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut	colorectal cancer	sensitive	Sapanisertib	Preclinical	Actionable	In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369).	25261369
TP53	RB1 mut TP53 mut	cervical cancer	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of cervical carcinoma cell lines harboring Tp53 and Rb1 mutations (PMID: 17121911).	17121911
TP53	RB1 mut TP53 mut	prostate carcinoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of prostate carcinoma cell lines harboring Tp53 and Rb1 mutations in culture and reduced tumor growth in xenograft models (PMID: 17121911).	17121911
TP53	RB1 mut TP53 mut	breast carcinoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring TP53 and RB1 mutations in culture (PMID: 17121911).	17121911
TP53	TP53 mutant RB1 wild-type	colon carcinoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).	17121911
TP53	TP53 mutant RB1 wild-type	mantle cell lymphoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).	17121911
TP53	TP53 mutant RB1 wild-type	breast carcinoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).	17121911
TP53	TP53 mutant RB1 wild-type	osteosarcoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of osteosarcoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).	17121911
TP53	ALK wild-type TP53 mutant	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 mutations in culture (PMID: 26438783).	26438783
TP53	EGFR mut TP53 mut	lung non-small cell carcinoma	decreased response	unspecified EGFR tyrosine kinase inhibitor	Clinical Study - Cohort	Actionable	In a clinical study, non-small cell lung cancer patients harboring both EGFR and TP53 mutations demonstrated a disease control rate (DCR) of 70.3% (26/37) following first-line treatment with an EGFR inhibitor such as Iressa (gefitinib), Tarceva (erlotinib), Gilotrif (afatinib), or Vizimpro (dacomitinib), compared to a DCR of 88.2% (75/85) in TP53 wild-type, EGFR-mutant patients (PMID: 27780855).	27780855
TP53	BRAF mut TP53 mut	colorectal cancer	sensitive	Alpelisib + Dabrafenib + Erlotinib + Navitoclax	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Tafinlar (dabrafenib), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and TP53 mutation in culture compared to the double or triple combinations of the therapies (PMID: 27659046).	27659046
TP53	EGFR wild-type STK11 wild-type TP53 mut	lung non-small cell carcinoma	predicted - sensitive	Nivolumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, a genomic profile consisted of mutant TP53, wild-type STK11 and EGFR is associated with increased PD-L1 expression and improved progression-free survival in Opdivo (nivolumab)-treated non-small cell lung cancer patients compared to STK11 or EGFR-mutant cohorts (p=0.03) (PMID: 29764856).	29764856
TP53	EGFR wild-type STK11 wild-type TP53 mut	lung non-small cell carcinoma	predicted - sensitive	Pembrolizumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, a genomic profile consisted of mutant TP53, wild-type STK11 and EGFR is associated with increased PD-L1 expression and improved progression-free survival in Keytruda (pembrolizumab)-treated non-small cell lung cancer patients (PMID: 29764856).	29764856
TP53	ALK rearrange TP53 mut	lung non-small cell carcinoma	decreased response	Crizotinib	Clinical Study - Cohort	Actionable	In a clinical study, TP53 mutant ALK-rearranged non-small cell lung cancer patients demonstrated a lower median progression-free survival following treatment with Xalkori (crizotinib) as a first line therapy or after chemotherapy vs. patients with wild-type TP53 (5.0 mo., n=22 vs. 14.0 mo., n=71; p<0.001), and a lower median overall survival (17.0 mo., n=13 vs. not reached n=50; p=0.049) (PMID: 30165392).	30165392
TP53	ALK rearrange TP53 mut	lung non-small cell carcinoma	decreased response	Brigatinib	Clinical Study - Cohort	Actionable	In a clinical study, TP53 mutant ALK-rearranged non-small cell lung cancer patients demonstrated a lower median progression-free survival following treatment with Zykadia (ceritinib), Alecensa (alectinib), or Alunbrig (brigatinib) after Xalkori (crizotinib) vs. patients with wild-type TP53 (5.4 mo. vs. 9.9 mo.; p=0.039) (PMID: 30165392).	30165392
TP53	ALK rearrange TP53 mut	lung non-small cell carcinoma	decreased response	Ceritinib	Clinical Study - Cohort	Actionable	In a clinical study, TP53 mutant ALK-rearranged non-small cell lung cancer patients demonstrated a lower median progression-free survival following treatment with Zykadia (ceritinib), Alecensa (alectinib), or Alunbrig (brigatinib) after Xalkori (crizotinib) vs. patients with wild-type TP53 (5.4 mo. vs. 9.9 mo.; p=0.039), and a lower median overall survival with treatment with Zykadia (ceritinib) after Xalkori (crizotinib) of 7.0 mo. vs. 50.0 mo. in patients with wild-type TP53 (p=0.001) (PMID: 30165392).	30165392
TP53	ALK rearrange TP53 mut	lung non-small cell carcinoma	decreased response	Alectinib	Clinical Study - Cohort	Actionable	In a clinical study, TP53 mutant ALK-rearranged non-small cell lung cancer patients demonstrated a lower median progression-free survival following treatment with Zykadia (ceritinib), Alecensa (alectinib), or Alunbrig (brigatinib) after Xalkori (crizotinib) vs. patients with wild-type TP53 (5.4 mo. vs. 9.9 mo.; p=0.039) (PMID: 30165392).	30165392
TP53	TP53 mut ROS1 rearrange	lung non-small cell carcinoma	predicted - sensitive	Crizotinib	Clinical Study - Cohort	Actionable	In a Phase II clinical trial, treatment with Xalkori (crizotinib) demonstrated a shorter median progression-free survival in patients with non-small cell lung cancer co-harboring a ROS1 rearrangement and TP53 mutation compared to patients with a ROS1 rearrangement and wild-type TP53 (7 vs. 24.1 months; p=0.022) (PMID: 30978502; NCT02183870).	30978502
TP53	TP53 Y327L	ovarian carcinoma	sensitive	ReACp53	Preclinical	Actionable	In a preclinical study, ReACp53 induced cell death in human primary ovarian carcinoma cells harboring TP53 Y327L in culture (PMID: 26748848).	26748848
TP53	TP53 S215G	lung non-small cell carcinoma	resistant	Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 S215G were resistant to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).	22862161
TP53	TP53 Y234C	lung non-small cell carcinoma	decreased response	Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 Y234C demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).	22862161
TP53	TP53 Y234C	ovarian carcinoma	sensitive	ReACp53	Preclinical	Actionable	In a preclinical study, ReACp53 induced cell death in human primary ovarian carcinoma cells harboring TP53 Y234C in culture (PMID: 26748848).	26748848
TP53	TP53 D259Y	melanoma	sensitive	Vemurafenib	Preclinical	Actionable	In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of human melanoma cells TP53 D259Y in culture (PMID: 26343583).	26343583
TP53	TP53 D259Y	melanoma	sensitive	Selumetinib	Preclinical	Actionable	In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cells harboring TP53 D259Y in culture (PMID: 26343583).	26343583
TP53	TP53 D259Y	melanoma	sensitive	LY3009120	Preclinical	Actionable	In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring TP53 D259Y in culture (PMID: 26343583).	26343583
TP53	TP53 positive	breast cancer	sensitive	Serdemetan	Phase I	Actionable	In a Phase I trial, Serdemetan (JNJ-26854165) treatment induced a 102% increase of Tp53 expression in tumor tissue, resulted in partial response in a patient with breast cancer (PMID: 21831953).	21831953
TP53	TP53 positive	Advanced Solid Tumor	predicted - sensitive	p28	Phase I	Actionable	In a Phase I trial, treatment with p28 was well-tolerated and demonstrated preliminary efficacy in patients with Tp53-positive advanced solid tumors, with complete response in 6% (1/15), partial response in 20% (3/15), and stable disease in 46% (7/15) of patients (PMID: 23449360).	23449360
TP53	TP53 positive	Advanced Solid Tumor	sensitive	MVAp53	Phase I	Actionable	In a phase I study, Ankara (MVAp53) demonstrated safety and efficacy in patients with metastatic colon, gastric and pancreas cancer stained positive for p53 (J Clin Oncol 31, 2013 (suppl; abstr 3089)).	detail...
TP53	TP53 positive	ovarian cancer	predicted - sensitive	NU6027 + Temozolomide	Preclinical - Cell culture	Actionable	In a preclinical study, NU6027 enhanced the efficacy of Temodar (temozolomide) in ovarian cancer cells with mismatch repair activity and positive for TP53 in culture, demonstrating a 50% greater decrease in cell survival compared to Temodar (temozolomide) alone (PMID: 21730979).	21730979
TP53	TP53 positive	Advanced Solid Tumor	sensitive	Serdemetan	Phase I	Actionable	In a Phase I trial, Serdemetan (JNJ-26854165) treatment increased Tp53 expression in tumor and surrogate tissue, resulted in partial response in 1.8% (1/57) and stable disease in 38.6% (22/57) of patients with advanced solid tumors (PMID: 21831953).	21831953
TP53	TP53 Y163*	ovarian cancer	predicted - sensitive	Adavosertib + Carboplatin	Phase II	Actionable	In a Phase II trial, Paraplatin (carboplatin) and Adavosertib (MK-1775) combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 Y163* (PMID: 27998224).	27998224
TP53	TP53 inact mut	breast cancer	sensitive	Adavosertib + Radiotherapy	Preclinical	Actionable	In a preclinical study, Adavosertib (MK-1775) increased the efficacy of radiation in breast cancer cells with defective TP53 in culture (PMID: 21799033).	21799033
TP53	TP53 inact mut	prostate cancer	no benefit	Enzalutamide	Clinical Study - Cohort	Actionable	In a clinical study, treatment with either Xtandi (enzalutamide) or Zytiga (abiraterone) in patients with metastatic castration-resistant prostate cancer harboring a TP53 inactivating mutation, detected via circulating tumor cells, demonstrated a shorter progression-free survival (3.0 vs 8.7mo; P<0.0001) and overall survival (7.8 vs 26.7mo; P<0.0001) and fewer patients with a PSA response greater than or equal to 50% (15.4 vs 46.8%; P=0.008) compared to those patients with wild-type TP53 (PMID: 30209161).	30209161
TP53	TP53 inact mut	prostate cancer	no benefit	Abiraterone	Clinical Study - Cohort	Actionable	In a clinical study, treatment with either Xtandi (enzalutamide) or Zytiga (abiraterone) in patients with metastatic castration-resistant prostate cancer harboring a TP53 inactivating mutation, detected via circulating tumor cells, demonstrated a shorter progression-free survival (3.0 vs 8.7mo; P<0.0001) and overall survival (7.8 vs 26.7mo; P<0.0001) and fewer patients with a PSA response greater than or equal to 50% (15.4 vs 46.8%; P=0.008) compared to those patients with wild-type TP53 (PMID: 30209161).	30209161
TP53	TP53 inact mut	breast carcinoma	predicted - sensitive	CHIR-124 + Irinotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, sequential treatment with Camptosaur (irinotecan) and CHIR-124 enhanced tumor growth inhibition compared to either agent alone in a breast carcinoma cell line xenograft model with defective TP53 (PMID: 17255282).	17255282
TP53	TP53 inact mut	ovarian cancer	sensitive	Cisplatin + Nutlin-3	Preclinical	Actionable	In a preclinical study, Nutlin-3 and cisplatin worked cooperatively to induce apoptosis in ovarian cancer cell lines with TP53 inactivating mutations in culture (PMID: 25964101).	25964101
TP53	TP53 inact mut	chronic lymphocytic leukemia	predicted - sensitive	AZD6482	Preclinical	Actionable	In a preclinical study, AZD6482 induced cell death in TP53-deficient chronic lymphocytic leukemia cells in culture and inhibited tumor growth in xenograft models (PMID: 26563132).	26563132
TP53	TP53 inact mut	chronic lymphocytic leukemia	sensitive	AZD6738 + Ibrutinib	Preclinical	Actionable	In a preclinical study, AZD6738 sensitized TP53-deficient chronic lymphocytic leukemia cells to Imbruvica (Ibrutinib) treatment in culture (PMID: 26563132).	26563132
TP53	TP53 inact mut	breast cancer	sensitive	AMG 900	Preclinical	Actionable	In a preclinical study, breast cancer cell lines with TP53 loss of function mutations had more pronounced apoptosis after treatment with AMG 900 in culture (PMID: 24091768).	24091768
TP53	TP53 inact mut	ovarian cancer	sensitive	Cisplatin + LB-100	Preclinical	Actionable	In a preclinical study, LB100 treatment decreased PP2A activity and increased sensitivity to Platinol (cisplatin) in a cisplatin-resistant ovarian cancer cell line harboring a TP53 inactivating mutation in culture (PMID: 25376608).	25376608
TP53	TP53 inact mut	lung small cell carcinoma	sensitive	APR-246	Preclinical - Cell line xenograft	Actionable	In a preclinical study, APR-246 induced apoptosis in small-cell lung cancer (SCLC) cell lines and decreased tumor growth in SCLC cell line xenograft models harboring Tp53 inactivating mutations (PMID: 21415220).	21415220
TP53	TP53 inact mut	ovarian carcinoma	sensitive	ReACp53	Preclinical	Actionable	In a preclinical study, ReACp53 induced cell death and decreased proliferation of ovarian carcinoma cells harboring TP53 mutations in culture, but did not effect viability of ovarian carcinoma cells with wild-type TP53 (PMID: 26748848).	26748848
TP53	TP53 inact mut	breast carcinoma	predicted - sensitive	CHIR-124 + SN-38	Preclinical - Cell culture	Actionable	In a preclinical study, SN-38 and CHIR-124 demonstrated synergy in a breast carcinoma cell line with defective TP53, resulting in increased cell cycle arrest and apoptosis in culture (PMID: 17255282).	17255282
TP53	TP53 inact mut	ovarian cancer	sensitive	Adavosertib + Carboplatin + Paclitaxel	Phase I	Actionable	In a Phase I trial, ovarian patients with TP53 deficiency had a 78.6% response rate to Adavosertib (MK-1775) in combination with carboplatin and paclitaxel (J Clin Oncol 31, 2013 (suppl; abstr 5518)).	detail...
TP53	TP53 G244S	mantle cell lymphoma	predicted - sensitive	Ibrutinib + Rituximab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-nodal leukemic mantle cell lymphoma harboring TP53 G244S, as well as KMT2A V2593A and BCOR S830Cfs*6, achieved complete remission (CR) with no evident minimum residual disease after 5 months of combined Rituxan (rituximab) and Imbruvica (ibrutinib) therapy, and following subsequent autologous stem-cell transplantation remained in CR beyond 18 months (PMID: 30559058).	30559058
TP53	TP53 Y220C	lung non-small cell carcinoma	resistant	Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 Y220C were resistant to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).	22862161
TP53	TP53 Y220C	hepatocellular carcinoma	sensitive	CP-31398	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with CP-31398 resulted in decreased proliferation, increased apoptosis, and cell-cycle arrest in a hepatocellular carcinoma cell line harboring TP53 Y220C in culture (PMID: 26250460).	26250460
TP53	TP53 loss	Advanced Solid Tumor	sensitive	Adavosertib	Preclinical	Actionable	In a preclinical study, tumor cell lines carrying deficient TP53 were sensitized to DNA-damaging agents upon Adavosertib (MK-1775) administration (PMID: 19887545).	19887545
TP53	TP53 loss	CLL/SLL	sensitive	Rituximab + Venetoclax	Guideline	Actionable	Venclexta (venetoclax) combined with Rituxan (rituximab) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).	detail...
TP53	TP53 loss	glioblastoma multiforme	sensitive	BLZ945	Preclinical	Actionable	In a preclinical study, treatment with BLZ945 demonstrated some efficacy, specifically a 56% tumor reduction, in transgenic mouse models of glioblastoma with a loss of TP53 (PMID: 27199435).	27199435
TP53	TP53 loss	CLL/SLL	sensitive	Idelalisib + Rituximab	Guideline	Actionable	Zydelig (idelalisib) combined with Rituxan (rituximab) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).	detail...
TP53	TP53 loss	Advanced Solid Tumor	decreased response	CTX-1	Preclinical	Actionable	In a preclinical study, CTX-1 induced cell death in TP53-deficient human tumor cell lines in culture, but had a greater effect on cell lines with wild-type TP53 compared to isogenic cell lines with TP53 loss (PMID: 26883273).	26883273
TP53	TP53 loss	osteosarcoma	decreased response	CPUY201112	Preclinical	Actionable	In a preclinical study, an osteosarcoma cell line lacking TP53 demonstrated a decreased response to CPUY201112 in culture, when compared to osteosarcoma cells with wild-type TP53 (PMID: 26743233).	26743233
TP53	TP53 loss	thymoma	predicted - resistant	Selinexor	Preclinical - Cell culture	Actionable	In a preclinical study, a thymoma cell line with TP53 loss demonstrated primary resistance to Selinexor (KPT-330) in culture, and reconstitution of TP53 expression resulted in increased Selinexor sensitivity (PMID: 28819023).	28819023
TP53	TP53 loss	colorectal cancer	sensitive	PHA-680632 + Radiotherapy	Preclinical - Pdx	Actionable	In a preclinical study, PHA-680632 synergized with radiotherapy to decrease tumor growth in Pdx models deficient in Tp53 (PMID: 18026198).	18026198
TP53	TP53 loss	CLL/SLL	not applicable	N/A	Guideline	Prognostic	Loss of TP53 is associated with a poor prognosis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (NCCN.org).	detail...
TP53	TP53 loss	colon carcinoma	sensitive	SP600125	Preclinical	Actionable	In a preclinical study, SP600125 induced cell death in colon carcinoma cells deficient for p53 (PMID: 22438244).	22438244
TP53	TP53 loss	lung cancer	resistant	AMG 232 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 did not enhance radiation-induced cytotoxicity in TP53-null lung cancer cells in culture and in cell line xenograft models (PMID: 26162687).	26162687
TP53	TP53 loss	CLL/SLL	sensitive	Ibrutinib	Guideline	Actionable	Imbruvica (ibrutinib) is indicated in the guidelines as first line therapy and relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).	detail...
TP53	TP53 loss	CLL/SLL	sensitive	Duvelisib	Guideline	Actionable	Copiktra (duvelisib) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).	detail...
TP53	TP53 loss	mantle cell lymphoma	predicted - resistant	Bendamustine + Rituximab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-nodal leukemic mantle cell lymphoma with TP53 loss, as well as a CCND1 translocation, had no response to combined Rituxan (rituximab) and Treanda (bendamustine) therapy, and had a doubling of white blood cells during two cycles of treatment (PMID: 30559058).	30559058
TP53	TP53 loss	colon cancer	sensitive	CHIR-124 + SN-38	Preclinical - Cell culture	Actionable	In a preclinical study, a colon cancer cell line deficient in TP53 demonstrated increased sensitivity to sequential treatment with SN-38 and CHIR-124 compared to cells with wild-type TP53, resulting in increased apoptosis and micronucleation in culture (PMID: 17255282).	17255282
TP53	TP53 loss	CLL/SLL	sensitive	Acalabrutinib	Guideline	Actionable	Calquence (acalabrutinib) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).	detail...
TP53	TP53 loss	ovarian cancer	no benefit	ReACp53	Preclinical	Actionable	In a preclincial study, ReACp53 did not induce cell death in ovarian cancer cells with loss of TP53 in culture (PMID: 26748848).	26748848
TP53	TP53 loss	CLL/SLL	sensitive	Obinutuzumab + Venetoclax	Guideline	Actionable	The combination of Venclexta (venetoclax) and Gazyva (obinutuzumab) is indicated in the guidelines as first line therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).	detail...
TP53	TP53 loss	colon carcinoma	sensitive	MPI-0479605	Preclinical	Actionable	In a preclinical study the TTK (MPS1) inhibitor, MPI-0479605, inhibited cell cycle progression of colon carcinoma cells deficient for Tp53 with equivalent efficacy to cells with wild-type Tp53 (PMID: 21980130).	21980130
TP53	TP53 loss	colorectal cancer	sensitive	Prodigiosin	Preclinical	Actionable	In a preclinical study, Prodigiosin inhibited self-renewal of colorectal cancer cell lines harboring TP53 loss in culture (PMID: 26759239).	26759239
TP53	TP53 loss	pancreatic cancer	sensitive	Adavosertib + Gemcitabine	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Adavosertib (MK-1775) and Gemzar (gemcitabine) inhibited Wee1 expression, Cdc2 phosphorylation, and tumor growth in several patient-derived xenograft models of pancreatic cancer harboring TP53 mutations (PMID: 21389100).	21389100
TP53	TP53 loss	ovarian cancer	sensitive	Cisplatin + LB-100	Preclinical	Actionable	In a preclinical study, LB100 treatment decreased PP2A activity and increased sensitivity to Platinol (cisplatin) in cisplatin-resistant ovarian cancer cells with TP53 loss in culture and in xenograft models (PMID: 25376608).	25376608
TP53	TP53 loss	acute myeloid leukemia	resistant	ALRN-6924	Preclinical - Cell culture	Actionable	In a preclinical study, ALRN-6924 did not inhibit the growth of TP53-null acute myeloid leukemia cells in culture (PMID: 29643228).	29643228
TP53	TP53 loss	mantle cell lymphoma	predicted - sensitive	Ibrutinib + Rituximab	Case Reports/Case Series	Actionable	In a clinical case study, a patient with non-nodal leukemic mantle cell lymphoma with TP53 loss, as well as a CCND1 translocation, had a rapid response to combined Rituxan (rituximab) and Imbruvica (ibrutinib) therapy, achieved a complete remission (CR) within 6 months, underwent autologous stem-cell transplantation, and remained in CR 18 months thereafter (PMID: 30559058).	30559058
TP53	TP53 loss	colorectal cancer	predicted - sensitive	Ad5CMV-p53 gene	Preclinical	Actionable	In a preclinical study, Ad5CMV-p53 gene therapy suppressed growth of allograft colorectal cancer in rat models (PMID: 15608394).	15608394
TP53	TP53 loss	colon cancer	decreased response	CPUY201112	Preclinical	Actionable	In a preclinical study, colon cancer cells lacking TP53 had a decreased response to CPUY201112 in culture, when compared to colon cancer cells with wild-type TP53 (PMID: 26743233).	26743233
TP53	TP53 loss	CLL/SLL	sensitive	Venetoclax	Guideline	Actionable	Venclexta (venetoclax) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).	detail...
TP53	TP53 loss	lung cancer	resistant	AMG 232	Preclinical - Cell culture	Actionable	In a preclinical study, TP53-null lung cancer cells were resistant to AMG 232 induced growth inhibition in culture (PMID: 26162687).	26162687
TP53	TP53 loss	colorectal cancer	sensitive	AZD6738 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD6738 increased sensitivity to radiotherapy in colorectal cancer xenograft models harboring a loss of TP53, resulting in a greater delay of tumor growth compared to radiation alone and an improved survival compared to control or either agent alone (PMID: 28062704).	28062704
TP53	ALK rearrange RB1 C706F TP53 loss	lung small cell carcinoma	predicted - resistant	Lorlatinib	Case Reports/Case Series	Actionable	In a clinical case study, RB1 C706F and loss of exons 1-11 in TP53 were identified in the pericardium infiltrating small cell lung cancer that developed while on Lorlatinib (PF-06463922) treatment in a patient with ALK-rearranged non-small cell lung carcinoma (PMID: 28285684).	28285684
TP53	PTEN loss TP53 loss	prostate cancer	sensitive	Capivasertib	Preclinical	Actionable	In a preclinical study, treatment with AZD5363 improved overall survival and progression-free survival in mouse models of prostate cancer with inactivated PTEN and TP53 (PMID: 26910118).	26910118
TP53	EGFR E709_T710delinsD SMAD4 R361C TP53 loss	lung small cell carcinoma	unknown	Afatinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EGFR E709_T710delinsD who progressed after a 1 year partial response to Gilotrif (afatinib) was found to have disease that transformed to small cell lung cancer and had acquired a SMAD4 R361C mutation and did not express Tp53 protein (PMID: 30413663).	30413663
TP53	TP53 R273H	lung non-small cell carcinoma	sensitive	APR-246 + Cisplatin	Preclinical	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of non-small lung cancer cells harboring TP53 R273H in culture (PMID: 26086967).	26086967
TP53	TP53 R273H TP53 P309S	colorectal cancer	sensitive	Cisplatin + NSC59984	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Platinol (cisplatin) and NSC59984 worked synergistically to decrease viability of a colorectal cancer cell line harboring TP53 R273H and TP53 P309S in culture (PMID: 26294215).	26294215
TP53	TP53 R273H TP53 P309S	colorectal cancer	sensitive	NSC59984	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with NSC59984 induced Tp53 pathway signaling, degradation of mutant Tp53, and cell death in a colorectal cancer cell line harboring TP53 R273H and TP53 P309S in culture (PMID: 26294215).	26294215
TP53	BRAF V600E PIK3CA P449T TP53 R273H	colorectal cancer	sensitive	PD-0325901 + Sapanisertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and growth of colorectal cancer cells harboring BRAF V600E, PIK3CA P449T, and TP53 R273H in culture and in cell line xenograft models, but did not have synergistic effect on apoptosis (PMID: 26272063).	26272063
TP53	TP53 R273W	breast cancer	resistant	NSC319726	Preclinical - Cell culture	Actionable	In a preclinical study, NSC319726 did not inhibit tumor growth in xenograft models of breast cancer harboring TP53 R273W (PMID: 22624712).	22624712
TP53	TP53 P98A	lung non-small cell carcinoma	decreased response	Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 P98A demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).	22862161
TP53	TP53 P151H	ovarian cancer	sensitive	APR-246 + Cisplatin	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 P151H in culture (PMID: 27179933).	27179933
TP53	TP53 R175L	colorectal cancer	sensitive	NSC59984	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with NSC59984 resulted in increased degradation of mutant Tp53 and cell death in a colorectal cancer cell line harboring TP53 R175L in culture (PMID: 26294215).	26294215
TP53	TP53 R175L	lung large cell carcinoma	sensitive	NSC319726	Preclinical - Cell culture	Actionable	In a preclinical study, lung large cell carcinoma cells harboring TP53 R175L demonstrated increased sensitivity to NSC319726 in culture (PMID: 22624712).	22624712
TP53	TP53 R158G	lung non-small cell carcinoma	sensitive	Gedatolisib	Preclinical	Actionable	In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring TP53 R158G in culture (PMID: 21325073, PMID: 23980093).	21325073 23980093
TP53	TP53 R273L	lung small cell carcinoma	sensitive	APR-246	Preclinical - Cell line xenograft	Actionable	In a preclinical study, APR-246 demonstrated efficacy in cell line xenograft models of small cell lung cancer harboring TP53 R273L (PMID: 21415220).	21415220
TP53	TP53 L111Q	ovarian cancer	sensitive	APR-246 + Cisplatin	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 L111Q in culture (PMID: 27179933).	27179933
TP53	BRAF V600E TP53 Q192K	colon cancer	predicted - sensitive	Panitumumab + Vemurafenib	Case Reports/Case Series	Actionable	In a clinical case study, a colon cancer patient harboring BRAF V600E and TP53 Q192K demonstrated a partial response when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 28514312).	28514312
TP53	TP53 C238F	fallopian tube cancer	sensitive	APR-246 + Cisplatin	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived fallopian tube cancer cells harboring TP53 C238F in culture (PMID: 27179933).	27179933
TP53	TP53 L194F	breast cancer	sensitive	Tanespimycin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tanespimycin (17-AAG) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011).	26009011
TP53	TP53 L194F	breast cancer	sensitive	Tanespimycin + Vorinostat	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tanespimycin (17-AAG) and Zolinza (vorinostat) were synergistic towards tumor growth inhibition in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011).	26009011
TP53	TP53 L194F	breast cancer	sensitive	Ganetespib	Preclinical - Cell culture	Actionable	In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 L194F in culture (PMID: 26009011).	26009011
TP53	TP53 L194F	breast cancer	sensitive	Vorinostat	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Zolinza (vorinostat) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011).	26009011
TP53	TP53 wild-type	medulloblastoma	sensitive	JQ1	Preclinical	Actionable	In a preclinical study, medulloblastoma cell lines with TP53 mutations had significantly less sensitivity to the BET inhibitor, JQ1, than cell lines carrying wild-type TP53 (PMID: 24231268).	24231268
TP53	TP53 wild-type	breast cancer	sensitive	AMG 232	Preclinical - Cell culture	Actionable	In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type breast cancer cells in culture (PMID: 26162687).	26162687
TP53	TP53 wild-type	colon carcinoma	sensitive	MPI-0479605	Preclinical	Actionable	In a preclinical study the TTK (MPS1) inhibitor, MPI-0479605, inhibited cell cycle progression of colon carcinoma cells deficient for Tp53 with equivalent efficacy to cells with wild-type Tp53 (PMID: 21980130).	21980130
TP53	TP53 wild-type	colon cancer	sensitive	AMG 232	Preclinical - Cell culture	Actionable	In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type colon cancer cells in culture (PMID: 26162687).	26162687
TP53	TP53 wild-type	colorectal cancer	sensitive	ALRN-6924	Phase I	Actionable	In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with colorectal cancer (J Clin Oncol 35, 2017 (suppl; abstr 2505)).	detail...
TP53	TP53 wild-type	melanoma	sensitive	AMG 232 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type melanoma cells in culture and in cell line xenograft models (PMID: 26162687).	26162687
TP53	TP53 wild-type	osteosarcoma	sensitive	AMG 232	Preclinical - Cell culture	Actionable	In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type osteosarcoma cells in culture (PMID: 26162687).	26162687
TP53	TP53 wild-type	acute myeloid leukemia	sensitive	CTX-1	Preclinical	Actionable	In a preclinical study, CTX-1 improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273).	26883273
TP53	TP53 wild-type	lung non-small cell carcinoma	sensitive	AMG 232 + Carboplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of AMG 232 and Paraplatin (carboplatin) worked synergistically to inhibit tumor growth in a TP53 wild-type non-small cell lung cancer cell line xenograft model, with increased efficacy over either agent alone (PMID: 25567130).	25567130
TP53	TP53 wild-type	fibrosarcoma	sensitive	Pegylated liposomal-doxorubicin + RO6839921	Preclinical - Cell line xenograft	Actionable	In a preclinical study, RO6839921 and Doxil combination treatment demonstrated sustained survival benefit in TP53 wild-type fibrosarcoma cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).	detail...
TP53	TP53 wild-type	Advanced Solid Tumor	sensitive	CTX-1	Preclinical	Actionable	In a preclinical study, CTX-1 induced cell death in several solid tumor cell lines with wild-type TP53 in culture (PMID: 26883273).	26883273
TP53	TP53 wild-type	Advanced Solid Tumor	sensitive	HDM201	Preclinical - Cell line xenograft	Actionable	In a preclinical study, HDM201 treatment resulted in tumor regression in various cell line xenograft models of Tp53 wild-type tumors (Cancer Res 2016;76(14 Suppl):Abstract nr 4855).	detail...
TP53	TP53 wild-type	acute myeloid leukemia	sensitive	CTX-1 + Nutlin-3	Preclinical	Actionable	In a preclinical study, the combination of CTX-1 and Nutlin-3 resulting in improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273).	26883273
TP53	TP53 wild-type	Advanced Solid Tumor	sensitive	CTX-1 + Nutlin-3	Preclinical	Actionable	In a preclinical study, CTX-1 and Nutlin-3 worked cooperatively to induce cell death in several TP53 wild-type human tumor cell lines in culture (PMID: 26883273).	26883273
TP53	TP53 wild-type	colon cancer	sensitive	AMG 232 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type colon cancer cells in culture and in cell line xenograft models (PMID: 26162687).	26162687
TP53	TP53 wild-type	colon cancer	sensitive	CPUY201112	Preclinical	Actionable	In a preclinical study, CPUY201112 reduced viability and induced apoptosis in a colon cancer cell line with wild-type TP53 in culture, and had a limited effect on a colon cancer cell line lacking TP53 (PMID: 26743233).	26743233
TP53	TP53 wild-type	multiple myeloma	predicted - sensitive	AMG 232	Phase I	Actionable	In a Phase I trial, AMG 232 demonstrated acceptable safety, and resulted in stable disease in 50% (5/10) of patients with TP53 wild-type multiple myeloma (PMID: 31359240; NCT01723020).	31359240
TP53	TP53 wild-type	Advanced Solid Tumor	predicted - sensitive	ALRN-6924	Phase I	Actionable	In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 45% (25/55), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 21 patients demonstrating stable disease (J Clin Oncol 35, 2017 (suppl; abstr 2505)).	detail...
TP53	TP53 wild-type	neuroblastoma	predicted - sensitive	GSK2830371	Preclinical	Actionable	In a preclinical study, GSK2830371 inhibited proliferation of neuroblastoma cell lines carrying wild-type TP53 in culture (PMID: 25658463).	25658463
TP53	TP53 wild-type	lung carcinoma	sensitive	AZD6738 + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a lung carcinoma cell line harboring wild-type TP53 in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704).	28062704
TP53	TP53 wild-type	salivary gland adenoid cystic carcinoma	predicted - sensitive	Cisplatin + SAR405838	Preclinical - Pdx	Actionable	In a preclinical study, the combination of SAR405838 (MI-773) and Platinol (cisplatin) resulted in increased Tp53 and Mdm2 expression, and demonstrated improved efficacy over either agent alone in TP53 wild-type patient-derived xenograft (PDX) models of salivary gland adenoid cystic carcinoma, resulting in tumor regression without tumor rebound after cessation of therapy (PMID: 27550999).	27550999
TP53	TP53 wild-type	Advanced Solid Tumor	unknown	MK-8242	Phase I	Actionable	In a Phase I trial, MK-8242 demonstrated safety and some preliminary clinical activity in patients with TP53 wild-type advanced solid tumors, particularly those with liposarcoma (LPS), with an overall response rate (ORR) of 6.4% (3/41; all partial responses), all in patients with LPS (ORR in LPS 11.1% (3/27)), and 75.6% (31/41) of patients achieving stable disease (PMID: 28240971).	28240971
TP53	TP53 wild-type	ovarian cancer	predicted - sensitive	Ad.p53-DC vaccine	Phase I	Actionable	In Phase I and Phase II clinical trials, various forms of p53 gene therapy (such as adenoviral-p53) have been shown to be generally safe and have demonstrated clinical efficacy in patients with ovarian cancer (PMID: 12082455; PMID: 19621448; PMID: 21927947; PMID: 15297186; PMID: 12082456).	15297186 21927947 19621448 12082455 12082456
TP53	TP53 wild-type	acute myeloid leukemia	sensitive	ALRN-6924	Preclinical - Patient cell culture	Actionable	In a preclinical study, ALRN-6924 inhibited growth of cells derived from patients with TP53 wild-type acute myeloid leukemia in culture, and inhibited leukemia cell growth, prolonged survival in cell line xenograft models (PMID: 29643228).	29643228
TP53	TP53 wild-type	Merkel cell carcinoma	sensitive	ALRN-6924	Phase I	Actionable	In a Phase I trial, ALRN-6924 treatment in a patient with Merkel cell carcinoma resulted in a complete response (J Clin Oncol 35, 2017 (suppl; abstr 2505)).	detail...
TP53	TP53 wild-type	neuroblastoma	predicted - sensitive	Doxorubicin + GSK2830371	Preclinical	Actionable	In a preclinical study, GSK283071 and Adriamycin (doxorubicin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463).	25658463
TP53	TP53 wild-type	Advanced Solid Tumor	sensitive	AMG 232	Phase I	Actionable	In a Phase I trial, AMG 232 demonstrated acceptable safety, and resulted in stable disease in 80% (31/39) of patients with TP53 wild-type advanced solid tumors, with a median duration of 3.1 months (PMID: 31359240; NCT01723020).	31359240
TP53	TP53 wild-type	Advanced Solid Tumor	sensitive	AMG 232	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 induced activation of Tp53 target genes and inhibited growth of several human tumor cell lines with wild-type TP53 in culture and in cell line xenograft models (PMID: 25567130).	25567130
TP53	TP53 wild-type	liposarcoma	sensitive	ALRN-6924	Phase I	Actionable	In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with liposarcoma (J Clin Oncol 35, 2017 (suppl; abstr 2505)).	detail...
TP53	TP53 wild-type	liposarcoma	predicted - sensitive	AMG 232	Phase I	Actionable	In a Phase I trial, AMG 232 demonstrated acceptable safety, and resulted in stable disease in 100% (10/10) of patients with TP53 wild-type well-differentiated liposarcomas (WDLPS) and 70% (7/10) of patients with TP53 wild-type de-differentiated liposarcomas, with median duration of 3.9 and 2.0 months respectively, and one patient with WDLPS achieved unconfirmed partial response per central evaluation (PMID: 31359240; NCT01723020).	31359240
TP53	TP53 wild-type	prostate cancer	sensitive	SAR405838	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR405838 inhibited growth of TP53 wild-type prostate cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).	25145672
TP53	TP53 wild-type	papillary thyroid carcinoma	sensitive	APG-115	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a TP53 wild-type dedifferentiated papillary thyroid carcinoma cell line treated with APG-115 demonstrated decreased cell viability and induction of cell cycle arrest and apoptosis in culture, and tumor growth suppression and tumor regression in xenograft models (PMID: 28498808).	28498808
TP53	TP53 wild-type	sarcoma	sensitive	Adavosertib + Gemcitabine	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, the combination of Adavosertib (MK-1775) and Gemzar (gemcitabine) induced cell death in a variety of sarcoma cell lines and inhibited tumor growth in a patient-derived sarcoma xenograft model, independent of TP53 mutational status (PMID: 23520471).	23520471
TP53	TP53 wild-type	colorectal cancer	sensitive	Prodigiosin	Preclinical	Actionable	In a preclinical study, Prodigiosin inhibited self-renewal of Tp53 wild-type colorectal cancer cell lines in culture (PMID: 26759239).	26759239
TP53	TP53 wild-type	estrogen-receptor positive breast cancer	predicted - sensitive	AMG 232	Phase I	Actionable	In a Phase I trial, AMG 232 demonstrated acceptable safety, and resulted in stable disease in 83.3% (10/12) of patients with TP53 wild-type ER-positive breast cancer (BC), with a median duration of 2.0 months in ER-positive, PR-positive BC, 1.4 months in ER-positive, PR-negative BC, and one patient achieved unconfirmed partial response per central evaluation (PMID: 31359240; NCT01723020).	31359240
TP53	TP53 wild-type	lung non-small cell carcinoma	sensitive	AMG 232 + Cisplatin	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of AMG 232 and Platinol (cisplatin) worked synergistically to inhibit tumor growth in a TP53 wild-type non-small cell lung cancer cell line xenograft model, with increased efficacy over either agent alone, resulting in tumor stasis (PMID: 25567130).	25567130
TP53	TP53 wild-type	lung cancer	sensitive	AMG 232 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type lung cancer cell lines in culture and in cell line xenograft models (PMID: 26162687).	26162687
TP53	TP53 wild-type	colon cancer	sensitive	Adavosertib + PF-00477736	Preclinical	Actionable	In a preclinical study, Adavosertib (MK-1775), in combination with the Chk1 inhibitor, PF-00477736, showed efficacy in various human cancer cell lines (breast, ovarian, colon, prostate), independently of p53 status (PMID: 22713237).	22713237
TP53	TP53 wild-type	peripheral T-cell lymphoma	sensitive	ALRN-6924	Phase I	Actionable	In a Phase I trial, ALRN-6924 treatment in a patient with peripheral T-cell lymphoma resulted in a complete response (J Clin Oncol 35, 2017 (suppl; abstr 2505)).	detail...
TP53	TP53 wild-type	breast cancer	predicted - sensitive	SAR405838	Preclinical - Pdx	Actionable	In a preclinical study, SAR405838 (MI-77301) induced p53 signaling and inhibited tumor growth in patient-derived xenograft models of endocrine therapy-resistant breast cancer with wild-type TP53, and induced cell-cycle arrest and inhibited growth of patient-derived endocrine therapy-resistant breast cancer cells in culture (PMID: 27765850).	27765850
TP53	TP53 wild-type	osteosarcoma	sensitive	CPUY201112	Preclinical	Actionable	In a preclinical study, CPUY201112 reduced viability and induced apoptosis in an osteosarcoma cell line with wild-type TP53 in culture, and had a limited effect on an osteosarcoma cell line lacking TP53 (PMID: 26743233).	26743233
TP53	TP53 wild-type	lung non-small cell carcinoma	sensitive	Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, Roscovotine (seliciclib) induced substantial apoptosis in non-small cell lung carcinoma cells overexpressing wild-type TP53 in culture (PMID: 22862161).	22862161
TP53	TP53 wild-type	lung non-small cell carcinoma	sensitive	CEP-8983 + Cisplatin	Preclinical	Actionable	In a preclinical study, the combination of CEP-8983 and Platinol (cisplatin) worked synergistically to induce cell death in non-small cell lung cancer cell lines in culture, irrespective of TP53 status (PMID: 23428903).	23428903
TP53	TP53 wild-type	breast cancer	sensitive	AMG 232 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type breast cancer cells in culture (PMID: 26162687).	26162687
TP53	TP53 wild-type	ovarian cancer	no benefit	p53-SLP vaccine	Phase II	Actionable	In a Phase II trial, p53-SLP vaccine was demonstrated to be safe, well tolerated and to induce p53-specific T-cell responses in ovarian cancer patients; however clinical impact was lacking (PMID: 19621448, PMID: 21328579).	21328579 19621448
TP53	TP53 wild-type	salivary gland adenoid cystic carcinoma	predicted - sensitive	SAR405838	Preclinical - Pdx	Actionable	In a preclinical study, treatment with SAR405838 (MI-773) resulted in activation of Mdm2 and Tp53 in patient-derived salivary gland adenoid cystic carcinoma (ACC) cells in culture, and led to induction of apoptosis and tumor regression in ACC patient-derived xenograft (PDX) models with wild-type TP53 (PMID: 26936915).	26936915
TP53	TP53 wild-type	colon cancer	sensitive	SAR405838	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR405838 inhibited growth of TP53 wild-type colon cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).	25145672
TP53	TP53 wild-type	acute myeloid leukemia	sensitive	Cytarabine + RO6839921	Preclinical - Cell line xenograft	Actionable	In a preclinical study, RO6839921 and Cytosar-U (cytarabine) combination treatment demonstrated anti-tumor activity in TP53 wild-type disseminated acute myeloid leukemia cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).	detail...
TP53	TP53 wild-type	lymphoma	predicted - sensitive	ALRN-6924	Phase I	Actionable	In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 45% (25/55), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 21 patients demonstrating stable disease (J Clin Oncol 35, 2017 (suppl; abstr 2505)).	detail...
TP53	TP53 wild-type	melanoma	sensitive	APR-246	Preclinical - Cell line xenograft	Actionable	In a preclinical study, APR-246 inhibited growth of TP53 wild-type melanoma cells in 3D culture and in cell line xenograft models (PMID: 21239882).	21239882
TP53	TP53 wild-type	Advanced Solid Tumor	decreased response	Pazopanib + Vorinostat	Phase I	Actionable	In a Phase I study, patients with advanced solid tumor harboring TP53 mutations had increased progression-free survival and overall survival than TP53 wild-type patients after treatment with Votrient (pazopanib) in combination with Zolinza (vorinostat) (J Clin Oncol 32:5s, 2014 (suppl; abstr 2576)).	detail...
TP53	TP53 wild-type	colorectal cancer	predicted - sensitive	PD-0325901 + Sapanisertib	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically induced apoptosis in TP53 wild-type but not TP53 mutated colorectal cancer cell lines in culture, and demonstrated anti-tumor activity in TP53 wild-type but not TP53 mutated patient-derived xenograft models (PMID: 26272063).	26272063
TP53	TP53 wild-type	acute myeloid leukemia	sensitive	RO6839921	Preclinical - Cell line xenograft	Actionable	In a preclinical study, RO6839921 demonstrated anti-tumor activity in TP53 wild-type disseminated acute myeloid leukemia cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).	detail...
TP53	TP53 wild-type	neuroblastoma	predicted - sensitive	Carboplatin + GSK2830371	Preclinical	Actionable	In a preclinical study, GSK283071 and Paraplatin (carboplatin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463).	25658463
TP53	TP53 wild-type	endometrioid ovary carcinoma	sensitive	thioureidobutyronitrile	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment increased Tp53 and Cdkn1a protein levels, resulted in growth inhibition of TP53 wild-type endometrioid ovary carcinoma cells in culture and in cell line xenograft models (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221).	detail...
TP53	TP53 wild-type	lung cancer	sensitive	AMG 232	Preclinical - Cell culture	Actionable	In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type lung cancer cell lines in culture (PMID: 26162687).	26162687
TP53	TP53 wild-type	lung non-small cell carcinoma	sensitive	AMG 232	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 induced activation of Tp53 target genes and inhibited growth of a non-small cell lung cancer (NSCLC) cell line with wild-type TP53 in culture and inhibited tumor growth in a TP53 wild-type NSCLC cell line xenograft model (PMID: 25567130).	25567130
TP53	TP53 wild-type	acute leukemia	sensitive	SAR405838	Preclinical - Cell line xenograft	Actionable	In a preclinical study, SAR405838 inhibited growth of TP53 wild-type acute leukemia cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).	25145672
TP53	TP53 wild-type	osteosarcoma	sensitive	AMG 232 + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type osteosarcoma cells in culture and in cell line xenograft models (PMID: 26162687).	26162687
TP53	TP53 wild-type	colorectal cancer	predicted - sensitive	MK-8745	Preclinical - Cell culture	Actionable	In a preclinical study, MK-8745 treatment resulted in apoptosis in Tp53 wild-type colorectal cancer cells in culture (PMID: 22293494).	22293494
TP53	TP53 wild-type	colon cancer	sensitive	Trifluridine	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Trifluridine (FTD) resulted in Tp53-dependent cell-cycle arrest and decreased expression of CyclinB1 and Cdk1 in a Tp53-proficient colon cancer cancer cell line in culture (PMID: 25700705).	25700705
TP53	TP53 wild-type	lung large cell carcinoma	resistant	NSC319726	Preclinical - Cell line xenograft	Actionable	In a preclinical study, NSC319726 did not inhibit tumor growth in xenograft models of TP53 wild-type lung large cell carcinoma (PMID: 22624712).	22624712
TP53	TP53 wild-type	melanoma	sensitive	AMG 232	Preclinical - Cell culture	Actionable	In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type melanoma cells in culture (PMID: 26162687).	26162687
TP53	TP53 wild-type	liposarcoma	predicted - sensitive	MK-8242	Phase I	Actionable	In a Phase I trial, MK-8242 demonstrated safety and some preliminary clinical activity in patients with advanced solid tumors, particularly those with TP53 wild-type liposarcoma (LPS), with an overall response rate (ORR) of 6.4% (3/41; all partial responses), all in patients with LPS (ORR in LPS 11.1% (3/27)), and a median progression-free survival in LPS of 237 days (PMID: 28240971).	28240971
TP53	BRAF mut TP53 wild-type	melanoma	sensitive	CGM097 + Encorafenib	Preclinical	Actionable	In a preclinical study, the combination of CGM097 and Encorafenib (LGX818) synergized to inhibit cell growth of a human melanoma cell line harboring mutant BRAF and wild-type TP53 in culture, and promoted tumor regression in xenograft models (Cancer Res October 1, 2014 74; 5466).	detail...
TP53	BRAF mut TP53 wild-type	colorectal cancer	sensitive	CGM097 + Dabrafenib + Navitoclax + PF-04217903	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of Navitoclax (ABT-263), CGM097, Tafinlar (dabrafenib), and PF04217903 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046).	27659046
TP53	BRAF mut TP53 wild-type	melanoma	sensitive	AMG 232	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AMG 232 inhibited growth of a melanoma cell line with wild-type TP53, that also harbored a BRAF mutation, in culture and inhibited tumor growth in a TP53 wild-type BRAF-mutant melanoma cell line xenograft model (PMID: 25567130).	25567130
TP53	BRAF mut TP53 wild-type	Advanced Solid Tumor	predicted - sensitive	Pimasertib + SAR405838	Phase I	Actionable	In a Phase I trial, SAR405838 and Pimasertib (MSC1936369B) combination therapy demonstrated safety and preliminary efficacy, resulted in partial response in 4% (1/24) and stable disease in 63% (15/24) of patients with TP53 wild-type advanced solid tumors harboring RAS/RAF mutations (KRAS, n=24; BRAF, n=1; NRAS, n=1) (PMID: 30585255; NCT01985191).	30585255
TP53	TP53 wild-type RB1 wild-type	melanoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of melanoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).	17121911
TP53	TP53 wild-type RB1 wild-type	breast carcinoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).	17121911
TP53	TP53 wild-type RB1 wild-type	colon carcinoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).	17121911
TP53	TP53 wild-type RB1 wild-type	lung carcinoma	sensitive	R547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R547 inhibited proliferation of lung carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).	17121911
TP53	TP53 wild-type RB1 wild-type	mantle cell lymphoma	sensitive	R547	Preclinical	Actionable	In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).	17121911
TP53	ALK F1174L TP53 wild-type	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in xenograft models of a crizotinib-resistant human neuroblastoma cell line harboring ALK F1174L and wild-type TP53 (PMID: 26438783).	26438783
TP53	ALK F1245C TP53 wild-type	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Pdx	Actionable	In a preclinical study, Xalkori (crizotinib) worked synergistically with Topotecan and Cytoxan (cyclophosphamide), resulting in sustained tumor regression in crizotinib-resistant neuroblastoma PDX models harboring ALK F1245C and wild-type Tp53 (PMID: 26438783).	26438783
TP53	ALK act mut TP53 wild-type	neuroblastoma	predicted - sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to delay tumor growth in xenograft models of a human neuroblastoma cell line harboring constitutively phosphorylated wild-type Alk and wild-type TP53 (PMID: 26438783).	26438783
TP53	ALK mut TP53 wild-type	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Pdx & cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in patient-derived neuroblastoma cell lines harboring Alk mutations and functional TP53, resulting in growth inhibition in culture and tumor regression in animal models (PMID: 26438783).	26438783
TP53	ALK amp Tp53 wild-type	neuroblastoma	sensitive	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in neuroblastoma cell lines harboring Alk amplification and functional TP53, resulting in growth inhibition in culture (PMID: 26438783).	26438783
TP53	ALK wild-type TP53 wild-type	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and wild-type TP53 in culture (PMID: 26438783).	26438783
TP53	BRAF V600E PIK3CA H1047R TP53 wild-type	colorectal cancer	sensitive	PD-0325901 + Sapanisertib	Preclinical - Cell culture	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).	26272063
TP53	BRAF V600E PTEN loss TP53 wild-type	colorectal cancer	sensitive	PD-0325901 + Sapanisertib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).	26272063
TP53	NRAS mut TP53 wild-type	Advanced Solid Tumor	predicted - sensitive	Pimasertib + SAR405838	Phase I	Actionable	In a Phase I trial, SAR405838 and Pimasertib (MSC1936369B) combination therapy demonstrated safety and preliminary efficacy, resulted in partial response in 4% (1/24) and stable disease in 63% (15/24) of patients with TP53 wild-type advanced solid tumors harboring RAS/RAF mutations (KRAS, n=24; BRAF, n=1; NRAS, n=1) (PMID: 30585255; NCT01985191).	30585255
TP53	MET over exp TP53 dec exp	stomach carcinoma	sensitive	EMD 1214063 + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, shRNA knock-down of Tp53 in Met over-expressing gastric carcinoma cells enhanced sensitivity to the combination of EMD 1214063 and radiation in culture (PMID: 26358474).	26358474
TP53	TP53 S241F	lung small cell carcinoma	sensitive	APR-246	Preclinical - Cell line xenograft	Actionable	In a preclinical study, APR-246 demonstrated efficacy in xenograft models of small cell lung cancer harboring TP53 S241F (PMID: 21415220).	21415220
TP53	TP53 S241F	ovarian clear cell adenocarcinoma	decreased response	DS-7423	Preclinical - Cell culture	Actionable	In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring TP53 S241F demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419).	24504419
TP53	TP53 S241F	ovarian cancer	sensitive	Ganetespib	Preclinical	Actionable	In a preclinical study, Ganetespib inhibited growth of human ovarian cancer cells harboring TP53 S241F in culture (PMID: 26009011).	26009011
TP53	TP53 P278H ROS1 L2026M ROS1 rearrange	lung non-small cell carcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a Phase II clinical trial, a patient with non-small cell lung cancer harboring a ROS1 rearrangement demonstrated progression while being treated with Xalkori (crizotinib), and was found to have acquired two mutations, ROS1 L2026M and TP53 P278H (PMID: 30978502; NCT02183870).	30978502
TP53	TP53 P278R	ovarian cancer	sensitive	APR-246 + Cisplatin	Preclinical - Patient cell culture	Actionable	In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 P278R in culture (PMID: 27179933).	27179933
TP53	ATM T1200Lfs*7 NRAS Q61K TP53 R213*	sarcoma	predicted - resistant	Olaparib	Case Reports/Case Series	Actionable	In a clinical case study, Lynparza (olaparib) treatment resulted in rapid disease progression in a patient with high-grade sarcoma harboring ATM T1200Lfs*7, NRAS Q61K, and TP53 R213* (PMID: 29304353).	29304353
TP53	TP53 negative	breast cancer	sensitive	Bevacizumab + Docetaxel + Doxorubicin	Phase I	Actionable	In a pilot trial, TP53-negative breast cancer patients demonstrated increased survival following treatment with Avastin (bevacizumab) in combination with chemotherapy agents, Adriamycin (doxorubicin) and Taxotere (docetaxel), compared to patients with TP53-positive tumors (PMID: 21399868).	21399868
TP53	TP53 negative	lung non-small cell carcinoma	decreased response	Seliciclib	Preclinical - Cell culture	Actionable	In a preclinical study, TP53-null non-small cell lung carcinoma cells demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).	22862161
TP53	TP53 I232S	osteosarcoma	resistant	Nutlin-3	Preclinical	Actionable	In a preclinical study, TP53 I232S resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).	21643018
TP53	TP53 over exp	ovarian cancer	predicted - sensitive	HLA-A2 p53:264-272 vaccine	Phase I	Actionable	In a Phase I trial, the HLA-A2 p53:264-272 vaccine demonstrated safety and preliminary efficacy in patients with TP53 overexpressing ovarian cancer, resulting in a progression-free survival of 5.5 months and an overall survival of 40.4 months (PMID: 21927947).	21927947
TP53	ALK wild-type TP53 H168R	neuroblastoma	no benefit	Crizotinib + Cyclophosphamide + Topotecan	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Xalkori (crizotinib) did not improve the effect of Topotecan and Cytoxan (cyclophosphamide) on tumor growth suppression in xenograft models of a human neuroblastoma cell line harboring wild-type ALK and TP53 H168R (PMID: 26438783).	26438783
TP53	TP53 R280M	osteosarcoma	resistant	Nutlin-3	Preclinical	Actionable	In a preclinical study, TP53 R280M resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).	21643018
U2AF1	U2AF1 Q157X	myelofibrosis	not applicable	N/A	Guideline	Prognostic	U2AF1 Q157 mutations are associated with inferior overall survival compared to U2AF1 S34 mutations or wild-type U2AF1 in patients with primary myelofibrosis (NCCN.org).	detail...
U2AF1	U2AF1 Q157X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	U2AF1 Q157X is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
U2AF1	U2AF1 mutant	essential thrombocythemia	not applicable	N/A	Guideline	Prognostic	The presence of at least one mutation in either SH2B3, IDH2, U2AF1, SF3B1, EZH2, or TP53 is associated with inferior overall survival in patients with essential thrombocythemia (NCCN.org).	detail...
U2AF1	U2AF1 mutant	myelodysplastic syndrome	not applicable	N/A	Clinical Study	Emerging	In multiple clinical studies, the presence of U2AF1 mutations was associated with a trend toward risk of progression to acute myeloid leukemia, however, the prognostic significance of U2AF1 mutations is still unclear (PMID: 25465125, PMID: 22158538, PMID: 22389253).	22158538 22389253 25465125
U2AF1	U2AF1 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	U2AF1 mutations are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
U2AF1	U2AF1 S34X	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	U2AF1 S34X is associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
U2AF1	U2AF1 S34F	lung cancer	sensitive	H3B-8800	Preclinical - Cell line xenograft	Actionable	In a preclinical study, H3B-8800 preferentially inhibited growth of lung cancer cells harboring U2AF1 S34F compared to U2AF1 wild-type cells in culture and in cell line xenograft models (Cancer Res 2017;77(13 Suppl):Abstract nr 1185).	detail...
VHL	VHL V155fs	kidney cancer	predicted - sensitive	Sunitinib + Trametinib	Preclinical - Pdx	Actionable	In a preclinical study, the combination of Mekinist (trametinib) and Sutent (sunitinib) inhibited tumor growth in patient-derived xenograft models of renal cancer harboring VHL V155fs (referred to as V155fs*4) (PMID: 26487278).	26487278
VHL	VHL over exp	clear cell renal cell carcinoma	no benefit	Cediranib + Saracatinib	Phase II	Actionable	In a Phase II clinical study, baseline expression of VHL was not predictive for response to Saracatinib (AZD0530) and Recentin (cediranib) relative to Recentin (cediranib) in patients with metastatic clear-cell renal cell carcinoma (PMID: 26802156).	26802156
VHL	VHL mutant	renal cell carcinoma	predicted - sensitive	Sunitinib	Phase I	Actionable	In a Phase I trial, 33% (6/18) of renal cell carcinoma patients harboring a VHL mutation, as determined from archived patient specimens, demonstrated a partial response when treated with Sutent (sunitinib) (PMID: 22105611).	22105611
VHL	VHL mutant	renal cell carcinoma	no benefit	N/A	Clinical Study	Prognostic	In a meta-analysis of 6 clinical studies, VHL mutation status was not associated with overall response rate (relative risk=1.47, p=0.20), progression-free survival (HR=1.02, p=0.91), or overall survival (HR=0.80, p=0.21) in a total of 633 patients with renal cell carcinoma who received anti-VEGF therapy (PMID: 28103578).	28103578
VHL	VHL mutant	renal cell carcinoma	sensitive	Everolimus	Phase I	Actionable	In a Phase I study, Afinitor (everolimus), as compared to Apitolisib (GDC-0980), resulted in a greater progression free survival and overall survival in patients with renal cell carcinoma harboring VHL mutations (J Clin Oncol 32:5s, 2014 (suppl; abstr 4525)).	detail...
VHL	VHL inact mut	clear cell renal cell carcinoma	conflicting	PT2399	Preclinical - Pdx	Actionable	In a preclinical study, PT2399 had variable impact on tumor growth in clear cell renal cell carcinoma (ccRCC) cell line and patient-derived xenograft (PDX) models with defective VHL, with decreased tumor growth in a VHL-defective ccRCC PDX model and some VHL-defective ccRCC cell line xenograft models, and no tumor suppression in other cell line xenograft models (PMID: 27595393).	27595393
VHL	VHL inact mut	renal cell carcinoma	predicted - sensitive	Everolimus	Phase II	Actionable	In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had a trend towards improved in progression free survival when stratified by the presence (median PFS=8.6 months, n=15) or absence (median PFS=5.5 months, n=16) of deleterious VHL mutations (PMID: 26951309).	26951309
VHL	VHL inact mut	renal cell carcinoma	no benefit	GDC-0980	Phase II	Actionable	In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by the presence (n=5) or absence (n=17) of deleterious VHL mutations (PMID: 26951309).	26951309
VHL	VHL inact mut	renal cell carcinoma	predicted - sensitive	Alpha 2 Interferon + Bevacizumab	Clinical Study - Cohort	Actionable	In a retrospective analysis, VHL alterations did not impact overall survival or objective response in renal cell carcinoma patients treated with a VEGF-targeted therapy, including Avastin (bevacizumab) and Alpha 2 Interferon combination therapy, but were associated with a prolonged time to progression (PMID: 16827904).	16827904
VHL	TP53 R248W VHL inact mut	clear cell renal cell carcinoma	resistant	PT2399	Preclinical - Cell culture	Actionable	In a preclinical study, TP53 R248W was associated with resistance to PT2399 in VHL-defective clear cell renal cell carcinoma cell lines in culture (PMID: 27595393).	27595393
VHL	VHL del	renal cell carcinoma	predicted - sensitive	Regorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Stivarga (regorafenib) inhibited angiogenesis and tumor growth in cell line xenograft models of renal cell carcinoma harboring VHL gene deletion (PMID: 21170960).	21170960
VHL	VHL negative	renal cell carcinoma	sensitive	STF-62247	Preclinical	Actionable	In a preclinical study, STF-62247 induced selective cytotoxicity and inhibited tumor growth of renal cell carcinoma cells lacking VHL (PMID: 18769110, PMID: 18598947).	18769110 18598947
VHL	VHL loss	renal cell carcinoma	sensitive	BPTES	Preclinical - Cell culture	Actionable	In a preclinical study, VHL-deficient renal cell carcinoma cells demonstrated growth inhibition and suppression of DNA synthesis in culture when treated with BPTES (PMID: 28346230).	28346230
VHL	VHL loss	renal cell carcinoma	sensitive	CB-839 + Olaparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of CB-839 and Lynparza (olaparib) resulted in a synergistic effect, demonstrating greater reduction in tumor volume compared to either agent alone in renal carcinoma cell xenograft models deficient for VHL (PMID: 28346230).	28346230
VHL	VHL loss	renal cell carcinoma	sensitive	Bevacizumab	Preclinical	Actionable	In a preclinical study, clear cell renal cell carcinoma xenograft models with VHL loss demonstrated sensitivity to Avastin (bevacizumab) (PMID: 22931246).	22931246
VHL	VHL loss	renal cell carcinoma	sensitive	BPTES + Olaparib	Preclinical - Cell culture	Actionable	In a preclinical study, the combination of BPTES and Lynparza (olaparib) resulted in a synergistic effect, demonstrating growth inhbition of VHL-deficient renal cell carcinoma cells in culture (PMID: 28346230).	28346230
VHL	VHL loss	renal cell carcinoma	sensitive	ELR510444	Preclinical - Cell line xenograft	Actionable	In a preclinical study, renal cell carcinoma cells deficient for VHL were sensitive to ELR510444 both in culture and in cell line xenograft models (PMID: 22295124).	22295124
VHL	VHL loss	renal cell carcinoma	sensitive	CB-839	Preclinical - Cell culture	Actionable	In a preclinical study, VHL-deficient renal cell carcinoma cells demonstrated growth inhibition in culture when treated with CB-839 (PMID: 28346230).	28346230
VHL	PTEN loss VHL loss	renal carcinoma	decreased response	Gedatolisib	Preclinical	Actionable	In a preclinical study, human renal carcinoma cells with PTEN loss and VHL loss had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073).	21325073
ZRSR2	ZRSR2 mutant	myelodysplastic syndrome	not applicable	N/A	Guideline	Prognostic	ZRSR2 mutations are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org).	detail...
